22-oxacalcitriol O +
suppresses O +
secondary B-Disease +
hyperparathyroidism I-Disease +
without O +
inducing O +
low B-Disease +
bone I-Disease +
turnover I-Disease +
in O +
dogs O +
with O +
renal B-Disease +
failure I-Disease -
. O +

BACKGROUND O -
: O +
Calcitriol O +
therapy O +
suppresses O +
serum O +
levels O +
of O +
parathyroid O +
hormone O +
( O -
PTH O -
) O +
in O +
patients O +
with O +
renal B-Disease +
failure I-Disease +
but O +
has O +
several O +
drawbacks O -
, O +
including O +
hypercalcemia B-Disease +
and/or O +
marked O +
suppression B-Disease +
of I-Disease +
bone I-Disease +
turnover I-Disease -
, O +
which O +
may O +
lead O +
to O +
adynamic B-Disease +
bone I-Disease +
disease I-Disease -
. O +

A O +
new O +
vitamin O +
D O +
analogue O -
, O +
22-oxacalcitriol O +
( O -
OCT O -
) O -
, O +
has O +
been O +
shown O +
to O +
have O +
promising O +
characteristics O -
. O +

This O +
study O +
was O +
undertaken O +
to O +
determine O +
the O +
effects O +
of O +
OCT O +
on O +
serum O +
PTH O +
levels O +
and O +
bone O +
turnover O +
in O +
states O +
of O +
normal O +
or O +
impaired B-Disease +
renal I-Disease +
function I-Disease -
. O +

METHODS O -
: O +
Sixty O +
dogs O +
were O +
either O +
nephrectomized O +
( O -
Nx O -
, O +
N O +
= O +
38 O -
) O +
or O +
sham O -
- O -
operated O +
( O -
Sham O -
, O +
N O +
= O +
22 O -
) O -
. O +

The O +
animals O +
received O +
supplemental O +
phosphate O +
to O +
enhance O +
PTH O +
secretion O -
. O +

Fourteen O +
weeks O +
after O +
the O +
start O +
of O +
phosphate O +
supplementation O -
, O +
half O +
of O +
the O +
Nx O +
and O +
Sham O +
dogs O +
received O +
doses O +
of O +
OCT O +
( O -
three O +
times O +
per O +
week O -
) O -
; O +
the O +
other O +
half O +
were O +
given O +
vehicle O +
for O +
60 O +
weeks O -
. O +

Thereafter O -
, O +
the O +
treatment O +
modalities O +
for O +
a O +
subset O +
of O +
animals O +
were O +
crossed O +
over O +
for O +
an O +
additional O +
eight O +
months O -
. O +

Biochemical O +
and O +
hormonal O +
indices O +
of O +
calcium O +
and O +
bone O +
metabolism O +
were O +
measured O +
throughout O +
the O +
study O -
, O +
and O +
bone O +
biopsies O +
were O +
done O +
at O +
baseline O -
, O +
60 O +
weeks O +
after O +
OCT O +
or O +
vehicle O +
treatment O -
, O +
and O +
at O +
the O +
end O +
of O +
the O +
crossover O +
period O -
. O +

RESULTS O -
: O +
In O +
Nx O +
dogs O -
, O +
OCT O +
significantly O +
decreased O +
serum O +
PTH O +
levels O +
soon O +
after O +
the O +
induction O +
of O +
renal B-Disease +
insufficiency I-Disease -
. O +

In O +
long O -
- O -
standing O +
secondary B-Disease +
hyperparathyroidism I-Disease -
, O +
OCT O +
( O -
0.03 O +
microg O -
/ O -
kg O -
) O +
stabilized O +
serum O +
PTH O +
levels O +
during O +
the O +
first O +
months O -
. O +

Serum O +
PTH O +
levels O +
rose O +
thereafter O -
, O +
but O +
the O +
rise O +
was O +
less O +
pronounced O +
compared O +
with O +
baseline O +
than O +
the O +
rise O +
seen O +
in O +
Nx O +
control O -
. O +

These O +
effects O +
were O +
accompanied O +
by O +
episodes O +
of O +
hypercalcemia B-Disease +
and O +
hyperphosphatemia B-Disease -
. O +

In O +
animals O +
with O +
normal O +
renal O +
function O -
, O +
OCT O +
induced O +
a O +
transient O +
decrease O +
in O +
serum O +
PTH O +
levels O +
at O +
a O +
dose O +
of O +
0.1 O +
microg O -
/ O -
kg O -
, O +
which O +
was O +
not O +
sustained O +
with O +
lowering O +
of O +
the O +
doses O -
. O +

In O +
Nx O +
dogs O -
, O +
OCT O +
reversed O +
abnormal O +
bone O +
formation O -
, O +
such O +
as O +
woven B-Disease +
osteoid I-Disease +
and O +
fibrosis B-Disease -
, O +
but O +
did O +
not O +
significantly O +
alter O +
the O +
level O +
of O +
bone O +
turnover O -
. O +

In O +
addition O -
, O +
OCT O +
improved O +
mineralization O +
lag O +
time O -
, O +
( O -
that O +
is O -
, O +
the O +
rate O +
at O +
which O +
osteoid O +
mineralizes O -
) O +
in O +
both O +
Nx O +
and O +
Sham O +
dogs O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
indicate O +
that O +
even O +
though O +
OCT O +
does O +
not O +
completely O +
prevent O +
the O +
occurrence O +
of O +
hypercalcemia B-Disease +
in O +
experimental O +
dogs O +
with O +
renal B-Disease +
insufficiency I-Disease -
, O +
it O +
may O +
be O +
of O +
use O +
in O +
the O +
management O +
of O +
secondary B-Disease +
hyperparathyroidism I-Disease +
because O +
it O +
does O +
not O +
induce O +
low B-Disease +
bone I-Disease +
turnover I-Disease +
and O -
, O +
therefore O -
, O +
does O +
not O +
increase O +
the O +
risk O +
of O +
adynamic B-Disease +
bone I-Disease +
disease I-Disease -
. O +

Hypotension B-Disease -
, O +
bradycardia B-Disease -
, O +
and O +
asystole B-Disease +
after O +
high O -
- O -
dose O +
intravenous O +
methylprednisolone O +
in O +
a O +
monitored O +
patient O -
. O +

We O +
report O +
a O +
case O +
of O +
hypotension B-Disease -
, O +
bradycardia B-Disease -
, O +
and O +
asystole B-Disease +
after O +
intravenous O +
administration O +
of O +
high O -
- O -
dose O +
methylprednisolone O +
in O +
a O +
73-year O -
- O -
old O +
patient O +
who O +
underwent O +
electrocardiographic O +
( O -
ECG O -
) O +
monitoring O +
throughout O +
the O +
episode O -
. O +

There O +
was O +
a O +
history O +
of O +
ischemic B-Disease +
cardiac B-Disease +
disease I-Disease +
9 O +
years O +
earlier O -
. O +

The O +
patient O +
was O +
admitted O +
with O +
a O +
pulmonary B-Disease -
- I-Disease -
renal I-Disease +
syndrome I-Disease +
with O +
hemoptysis B-Disease -
, O +
rapidly O +
progressive O +
renal B-Disease +
failure I-Disease -
, O +
and O +
hypoxemia B-Disease +
that O +
required O +
mechanical O +
ventilation O +
in O +
the O +
intensive O +
care O +
unit O -
. O +

After O +
receiving O +
advanced O +
cardiopulmonary O +
resuscitation O -
, O +
the O +
patient O +
recovered O +
cardiac O +
rhythm O -
. O +

The O +
ECG O +
showed O +
a O +
junctional O +
rhythm O +
without O +
ventricular B-Disease +
arrhythmia I-Disease -
. O +

This O +
study O +
reviews O +
the O +
current O +
proposed O +
mechanisms O +
of O +
sudden B-Disease +
death I-Disease +
after O +
a O +
high O +
dose O +
of O +
intravenous O +
methylprednisolone O +
( O -
IVMP O -
) O -
. O +

These O +
mechanisms O +
are O +
not O +
well O +
understood O +
because O -
, O +
in O +
most O +
cases O -
, O +
the O +
patients O +
were O +
not O +
monitored O +
at O +
the O +
moment O +
of O +
the O +
event O -
. O +

Rapid O +
infusion O +
and O +
underlying O +
cardiac B-Disease +
disease I-Disease +
were O +
important O +
risk O +
factors O +
in O +
the O +
case O +
reported O +
here O -
, O +
and O +
the O +
authors O +
discount O +
ventricular B-Disease +
arrhythmia I-Disease +
as O +
the O +
main O +
mechanism O -
. O +

Worsening O +
of O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
by O +
motor O +
and O +
mental O +
tasks O -
. O +

Ten O +
patients O +
who O +
had O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
with O +
disabling O +
dyskinesia B-Disease +
were O +
included O +
in O +
this O +
study O +
to O +
evaluate O +
the O +
role O +
of O +
mental O +
( O -
mental O +
calculation O -
) O +
and O +
motor O +
( O -
flexion O -
/ O -
extension O +
of O +
right O +
fingers O -
, O +
flexion O -
/ O -
extension O +
of O +
left O +
fingers O -
, O +
flexion O -
/ O -
extension O +
of O +
the O +
neck O -
, O +
speaking O +
aloud O -
) O +
tasks O +
on O +
the O +
worsening O +
of O +
peak O -
- O -
dose O +
dyskinesia B-Disease +
following O +
administration O +
of O +
an O +
effective O +
single O +
dose O +
of O +
apomorphine O -
. O +

Compared O +
with O +
the O +
score O +
at O +
rest O +
( O -
1.3+ O -
/ O -
-0.3 O -
) O -
, O +
a O +
significant O +
aggravation O +
of O +
the O +
dyskinesia B-Disease +
score O +
was O +
observed O +
during O +
speaking O +
aloud O +
( O -
5.2+ O -
/ O -
-1.1 O -
, O +
p<0.05 O -
) O -
, O +
movements O +
of O +
right O +
( O -
4.5+ O -
/ O -
-1.0 O -
, O +
p<0.05 O -
) O +
and O +
left O +
( O -
3.7+ O -
/ O -
-0.8 O -
, O +
p<0.05 O -
) O +
fingers O -
, O +
movements O +
of O +
the O +
neck O +
( O -
5.1+ O -
/ O -
-1.0 O -
, O +
p<0.05 O -
) O -
, O +
and O +
mental O +
calculation O +
( O -
3.1+ O -
/ O -
-1.0 O -
, O +
p<0.05 O -
) O -
. O +

These O +
results O +
suggest O +
that O +
activation O +
tasks O +
such O +
as O +
" O -
speaking O +
aloud O -
" O +
could O +
be O +
used O +
for O +
objective O +
assessment O +
of O +
dyskinesia B-Disease +
severity O -
. O +

Selegiline O -
- O -
induced O +
postural B-Disease +
hypotension I-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
: O +
a O +
longitudinal O +
study O +
on O +
the O +
effects O +
of O +
drug O +
withdrawal O -
. O +

OBJECTIVES O -
: O +

The O +
United O +
Kingdom O +
Parkinson B-Disease -
's I-Disease +
Disease I-Disease +
Research O +
Group O +
( O -
UKPDRG O -
) O +
trial O +
found O +
an O +
increased O +
mortality O +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
randomized O +
to O +
receive O +
10 O +
mg O +
selegiline O +
per O +
day O +
and O +
L O -
- O -
dopa O +
compared O +
with O +
those O +
taking O +
L O -
- O -
dopa O +
alone O -
. O +

Recently O -
, O +
we O +
found O +
that O +
therapy O +
with O +
selegiline O +
and O +
L O -
- O -
dopa O +
was O +
associated O +
with O +
selective O +
systolic B-Disease +
orthostatic I-Disease +
hypotension I-Disease +
which O +
was O +
abolished O +
by O +
withdrawal O +
of O +
selegiline O -
. O +

This O +
unwanted O +
effect O +
on O +
postural O +
blood O +
pressure O +
was O +
not O +
the O +
result O +
of O +
underlying O +
autonomic O +
failure O -
. O +

The O +
aims O +
of O +
this O +
study O +
were O +
to O +
confirm O +
our O +
previous O +
findings O +
in O +
a O +
separate O +
cohort O +
of O +
patients O +
and O +
to O +
determine O +
the O +
time O +
course O +
of O +
the O +
cardiovascular O +
consequences O +
of O +
stopping O +
selegiline O +
in O +
the O +
expectation O +
that O +
this O +
might O +
shed O +
light O +
on O +
the O +
mechanisms O +
by O +
which O +
the O +
drug O +
causes O +
orthostatic B-Disease +
hypotension I-Disease -
. O +

METHODS O -
: O +
The O +
cardiovascular O +
responses O +
to O +
standing O +
and O +
head O -
- O -
up O +
tilt O +
were O +
studied O +
repeatedly O +
in O +
PD B-Disease +
patients O +
receiving O +
selegiline O +
and O +
as O +
the O +
drug O +
was O +
withdrawn O -
. O +

RESULTS O -
: O +
Head O -
- O -
up O +
tilt O +
caused O +
systolic B-Disease +
orthostatic I-Disease +
hypotension I-Disease +
which O +
was O +
marked O +
in O +
six O +
of O +
20 O +
PD B-Disease +
patients O +
on O +
selegiline O -
, O +
one O +
of O +
whom O +
lost O +
consciousness O +
with O +
unrecordable O +
blood O +
pressures O -
. O +

A O +
lesser O +
degree O +
of O +
orthostatic B-Disease +
hypotension I-Disease +
occurred O +
with O +
standing O -
. O +

Orthostatic B-Disease +
hypotension I-Disease +
was O +
ameliorated O +
4 O +
days O +
after O +
withdrawal O +
of O +
selegiline O +
and O +
totally O +
abolished O +
7 O +
days O +
after O +
discontinuation O +
of O +
the O +
drug O -
. O +

Stopping O +
selegiline O +
also O +
significantly O +
reduced B-Disease +
the I-Disease +
supine I-Disease +
systolic I-Disease +
and I-Disease +
diastolic I-Disease +
blood I-Disease +
pressures I-Disease +
consistent O +
with O +
a O +
previously O +
undescribed O +
supine O +
pressor O +
action O -
. O +

CONCLUSION O -
: O +
This O +
study O +
confirms O +
our O +
previous O +
finding O +
that O +
selegiline O +
in O +
combination O +
with O +
L O -
- O -
dopa O +
is O +
associated O +
with O +
selective O +
orthostatic B-Disease +
hypotension I-Disease -
. O +

The O +
possibilities O +
that O +
these O +
cardiovascular O +
findings O +
might O +
be O +
the O +
result O +
of O +
non O -
- O -
selective O +
inhibition O +
of O +
monoamine O +
oxidase O +
or O +
of O +
amphetamine O +
and O +
metamphetamine O +
are O +
discussed O -
. O +

Further O +
studies O +
on O +
effects O +
of O +
irrigation O +
solutions O +
on O +
rat O +
bladders O -
. O +

Further O +
studies O +
on O +
the O +
effects O +
of O +
certain O +
irrigating O +
fluids O +
on O +
the O +
rat O +
bladder O +
for O +
18 O +
hours O +
are O +
reported O -
. O +

The O +
results O +
have O +
shown O +
that O +
the O +
degradation O +
product O +
p O -
- O -
choloroaniline O +
is O +
not O +
a O +
significant O +
factor O +
in O +
chlorhexidine O -
- O -
digluconate O +
associated O +
erosive O +
cystitis B-Disease -
. O +

A O +
high O +
percentage O +
of O +
kanamycin O -
- O -
colistin O +
and O +
povidone O -
- O -
iodine O +
irrigations O +
were O +
associated O +
with O +
erosive O +
cystitis B-Disease +
and O +
suggested O +
a O +
possible O +
complication O +
with O +
human O +
usage O -
. O +

Picloxydine O +
irrigations O +
appeared O +
to O +
have O +
a O +
lower O +
incidence O +
of O +
erosive O +
cystitis B-Disease +
but O +
further O +
studies O +
would O +
have O +
to O +
be O +
performed O +
before O +
it O +
could O +
be O +
recommended O +
for O +
use O +
in O +
urological O +
procedures O -
. O +

Effects O +
of O +
tetrandrine O +
and O +
fangchinoline O +
on O +
experimental O +
thrombosis B-Disease +
in O +
mice O +
and O +
human O +
platelet B-Disease +
aggregation I-Disease -
. O +

Tetrandrine O +
( O -
TET O -
) O +
and O +
fangchinoline O +
( O -
FAN O -
) O +
are O +
two O +
naturally O +
occurring O +
analogues O +
with O +
a O +
bisbenzylisoquinoline O +
structure O -
. O +

The O +
present O +
study O +
was O +
undertaken O +
to O +
investigate O +
the O +
effects O +
of O +
TET O +
and O +
FAN O +
on O +
the O +
experimental O +
thrombosis B-Disease +
induced O +
by O +
collagen O +
plus O +
epinephrine O +
( O -
EP O -
) O +
in O +
mice O -
, O +
and O +
platelet B-Disease +
aggregation I-Disease +
and O +
blood B-Disease +
coagulation I-Disease +
in O +
vitro O -
. O +

In O +
the O +
in O +
vivo O +
study O -
, O +
the O +
administration O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
of O +
TET O +
and O +
FAN O +
in O +
mice O +
showed O +
the O +
inhibition O +
of O +
thrombosis B-Disease +
by O +
55 O -
% O +
and O +
35 O -
% O -
, O +
respectively O -
, O +
while O +
acetylsalicylic O +
acid O +
( O -
ASA O -
, O +
50 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
, O +
a O +
positive O +
control O -
, O +
showed O +
only O +
30 O -
% O +
inhibition O -
. O +

In O +
the O +
vitro O +
human O +
platelet B-Disease +
aggregations I-Disease +
induced O +
by O +
the O +
agonists O +
used O +
in O +
tests O -
, O +
TET O +
and O +
FAN O +
showed O +
the O +
inhibitions O +
dose O +
dependently O -
. O +

In O +
addition O -
, O +
neither O +
TET O +
nor O +
FAN O +
showed O +
any O +
anticoagulation O +
activities O +
in O +
the O +
measurement O +
of O +
the O +
activated O +
partial O +
thromboplastin O +
time O +
( O -
APTT O -
) O -
, O +
prothrombin O +
time O +
( O -
PT O -
) O +
and O +
thrombin O +
time O +
( O -
TT O -
) O +
using O +
human O -
- O -
citrated O +
plasma O -
. O +

These O +
results O +
suggest O +
that O +
antithrombosis O +
of O +
TET O +
and O +
FAN O +
in O +
mice O +
may O +
be O +
mainly O +
related O +
to O +
the O +
antiplatelet O +
aggregation O +
activities O -
. O +

Urine O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
D O -
- O -
glucosaminidase O -
-- O -
a O +
marker O +
of O +
tubular O +
damage O -
? O +

BACKGROUND O -
: O +
Although O +
an O +
indicator O +
of O +
renal B-Disease +
tubular I-Disease +
dysfunction I-Disease -
, O +
an O +
increased O +
urinary O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
D O -
- O -
glucosaminidase O +
( O -
NAG O -
) O +
activity O +
might O +
reflect O +
increased O +
lysosomal O +
activity O +
in O +
renal O +
tubular O +
cells O -
. O +

METHODS O -
: O +
Puromycin O +
aminonucleoside O +
( O -
PAN O -
) O +
was O +
administered O +
to O +
Sprague O +
Dawley O +
rats O +
to O +
induce O +
proteinuria B-Disease -
. O +

Total O +
protein O -
, O +
albumin O -
, O +
NAG O +
activity O +
and O +
protein O +
electrophoretic O +
pattern O +
were O +
assessed O +
in O +
daily O +
urine O +
samples O +
for O +
33 O +
days O -
. O +

The O +
morphological O +
appearance O +
of O +
the O +
kidneys O +
was O +
examined O +
on O +
days O +
three O -
, O +
four O -
, O +
six O -
, O +
eight O +
and O +
thirty O +
three O +
and O +
the O +
NAG O +
isoenzyme O +
patterns O +
on O +
days O +
zero O -
, O +
four O -
, O +
eight O +
and O +
thirty O +
three O -
. O +

RESULTS O -
: O +
Following O +
intravenous O +
PAN O +
urine O +
volume O +
and O +
urine O +
NAG O +
activity O +
increased O +
significantly O +
by O +
day O +
two O -
, O +
but O +
returned O +
to O +
normal O +
by O +
day O +
four O -
. O +

After O +
day O +
four O +
all O +
treated O +
animals O +
exhibited O +
a O +
marked O +
rise O +
in O +
urine O +
albumin O -
, O +
total O +
protein O +
excretion O +
and O +
NAG O +
activity O -
. O +

Electrophoresis O +
showed O +
a O +
generalised O +
increase O +
in O +
middle O +
and O +
high O +
molecular O +
weight O +
urine O +
proteins O +
from O +
day O +
four O +
onwards O -
. O +

Protein O +
droplets O +
first O +
appeared O +
prominent O +
in O +
tubular O +
cells O +
on O +
day O +
four O -
. O +

Peak O +
urine O +
NAG O +
activity O +
and O +
a O +
change O +
in O +
NAG O +
isoenzyme O +
pattern O +
coincided O +
with O +
both O +
the O +
peak O +
proteinuria B-Disease +
and O +
the O +
reduction O +
in O +
intracellular O +
protein O +
and O +
NAG O +
droplets O +
( O -
day O +
six O +
onwards O -
) O -
. O +

CONCLUSIONS O -
: O +
This O +
animal O +
model O +
demonstrates O +
that O +
an O +
increase O +
in O +
lysosomal O +
turnover O +
and O +
hence O +
urine O +
NAG O +
activity O -
, O +
occurs O +
when O +
increased O +
protein O +
is O +
presented O +
to O +
the O +
tubular O +
cells O -
. O +

Urine O +
NAG O +
activity O +
is O +
thus O +
a O +
measure O +
of O +
altered O +
function O +
in O +
the O +
renal O +
tubules O +
and O +
not O +
simply O +
an O +
indicator O +
of O +
damage O -
. O +

Cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
after O +
spinal O +
anaesthesia O +
with O +
hyperbaric O +
5 O -
% O +
lignocaine O -
: O +
a O +
review O +
of O +
six O +
cases O +
of O +
cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
reported O +
to O +
the O +
Swedish O +
Pharmaceutical O +
Insurance O +
1993 O -
- O -
1997 O -
. O +

Six O +
cases O +
of O +
cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
with O +
varying O +
severity O +
were O +
reported O +
to O +
the O +
Swedish O +
Pharmaceutical O +
Insurance O +
during O +
the O +
period O +
1993 O -
- O -
1997 O -
. O +

All O +
were O +
associated O +
with O +
spinal O +
anaesthesia O +
using O +
hyperbaric O +
5 O -
% O +
lignocaine O -
. O +

Five O +
cases O +
had O +
single O -
- O -
shot O +
spinal O +
anaesthesia O +
and O +
one O +
had O +
a O +
repeat O +
spinal O +
anaesthetic O +
due O +
to O +
inadequate O +
block O -
. O +

The O +
dose O +
of O +
hyperbaric O +
5 O -
% O +
lignocaine O +
administered O +
ranged O +
from O +
60 O +
to O +
120 O +
mg O -
. O +

Three O +
of O +
the O +
cases O +
were O +
most O +
likely O +
caused O +
by O +
direct O +
neurotoxicity B-Disease +
of O +
hyperbaric O +
5 O -
% O +
lignocaine O -
. O +

In O +
the O +
other O +
3 O +
cases O -
, O +
direct O +
neurotoxicity B-Disease +
was O +
also O +
probable O -
, O +
but O +
unfortunately O +
radiological O +
investigations O +
were O +
not O +
done O +
to O +
definitely O +
exclude O +
a O +
compressive O +
aetiology O -
. O +

All O +
cases O +
sustained O +
permanent O +
neurological B-Disease +
deficits I-Disease -
. O +

We O +
recommend O +
that O +
hyperbaric O +
lignocaine O +
should O +
be O +
administered O +
in O +
concentrations O +
not O +
greater O +
than O +
2 O -
% O +
and O +
at O +
a O +
total O +
dose O +
preferably O +
not O +
exceeding O +
60 O +
mg O -
. O +

Angioedema B-Disease +
due O +
to O +
ACE O +
inhibitors O -
: O +
common O +
and O +
inadequately O +
diagnosed O -
. O +

The O +
estimated O +
incidence O +
of O +
angioedema B-Disease +
during O +
angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitor O +
treatment O +
is O +
between O +
1 O +
and O +
7 O +
per O +
thousand O +
patients O -
. O +

This O +
potentially O +
serious O +
adverse O +
effect O +
is O +
often O +
preceded O +
by O +
minor O +
manifestations O +
that O +
may O +
serve O +
as O +
a O +
warning O -
. O +

Cocaine O -
- O -
induced O +
mood B-Disease +
disorder I-Disease -
: O +
prevalence O +
rates O +
and O +
psychiatric B-Disease +
symptoms O +
in O +
an O +
outpatient O +
cocaine O -
- O -
dependent O +
sample O -
. O +

This O +
paper O +
attempts O +
to O +
examine O +
and O +
compare O +
prevalence O +
rates O +
and O +
symptom O +
patterns O +
of O +
DSM O +
substance O -
- O -
induced O +
and O +
other O +
mood B-Disease +
disorders I-Disease -
. O +

243 O +
cocaine O -
- O -
dependent O +
outpatients O +
with O +
cocaine O -
- O -
induced O +
mood B-Disease +
disorder I-Disease +
( O -
CIMD B-Disease -
) O -
, O +
other O +
mood B-Disease +
disorders I-Disease -
, O +
or O +
no O +
mood B-Disease +
disorder I-Disease +
were O +
compared O +
on O +
measures O +
of O +
psychiatric B-Disease +
symptoms O -
. O +

The O +
prevalence O +
rate O +
for O +
CIMD B-Disease +
was O +
12 O -
% O +
at O +
baseline O -
. O +

Introduction O +
of O +
the O +
DSM O -
- O -
IV O +
diagnosis O +
of O +
CIMD B-Disease +
did O +
not O +
substantially O +
affect O +
rates O +
of O +
the O +
other O +
depressive B-Disease +
disorders I-Disease -
. O +

Patients O +
with O +
CIMD B-Disease +
had O +
symptom O +
severity O +
levels O +
between O +
those O +
of O +
patients O +
with O +
and O +
without O +
a O +
mood B-Disease +
disorder I-Disease -
. O +

These O +
findings O +
suggest O +
some O +
validity O +
for O +
the O +
new O +
DSM O -
- O -
IV O +
diagnosis O +
of O +
CIMD B-Disease -
, O +
but O +
also O +
suggest O +
that O +
it O +
requires O +
further O +
specification O +
and O +
replication O -
. O +

Effect O +
of O +
fucoidan O +
treatment O +
on O +
collagenase O -
- O -
induced O +
intracerebral B-Disease +
hemorrhage I-Disease +
in O +
rats O -
. O +

Inflammatory O +
cells O +
are O +
postulated O +
to O +
mediate O +
some O +
of O +
the O +
brain B-Disease +
damage I-Disease +
following O +
ischemic B-Disease +
stroke I-Disease -
. O +

Intracerebral B-Disease +
hemorrhage I-Disease +
is O +
associated O +
with O +
more O +
inflammation B-Disease +
than O +
ischemic B-Disease +
stroke I-Disease -
. O +

We O +
tested O +
the O +
sulfated O +
polysaccharide O +
fucoidan O -
, O +
which O +
has O +
been O +
reported O +
to O +
reduce O +
inflammatory O +
brain B-Disease +
damage I-Disease -
, O +
in O +
a O +
rat O +
model O +
of O +
intracerebral B-Disease +
hemorrhage I-Disease +
induced O +
by O +
injection O +
of O +
bacterial O +
collagenase O +
into O +
the O +
caudate O +
nucleus O -
. O +

Rats O +
were O +
treated O +
with O +
seven O +
day O +
intravenous O +
infusion O +
of O +
fucoidan O +
( O -
30 O +
micrograms O +
h-1 O -
) O +
or O +
vehicle O -
. O +

The O +
hematoma B-Disease +
was O +
assessed O +
in O +
vivo O +
by O +
magnetic O +
resonance O +
imaging O -
. O +

Motor O +
behavior O -
, O +
passive O +
avoidance O -
, O +
and O +
skilled O +
forelimb O +
function O +
were O +
tested O +
repeatedly O +
for O +
six O +
weeks O -
. O +

Fucoidan O -
- O -
treated O +
rats O +
exhibited O +
evidence O +
of O +
impaired B-Disease +
blood I-Disease +
clotting I-Disease +
and O +
hemodilution B-Disease -
, O +
had O +
larger O +
hematomas B-Disease -
, O +
and O +
tended O +
to O +
have O +
less O +
inflammation B-Disease +
in O +
the O +
vicinity O +
of O +
the O +
hematoma B-Disease +
after O +
three O +
days O -
. O +

They O +
showed O +
significantly O +
more O +
rapid O +
improvement O +
of O +
motor O +
function O +
in O +
the O +
first O +
week O +
following O +
hemorrhage B-Disease +
and O +
better O +
memory O +
retention O +
in O +
the O +
passive O +
avoidance O +
test O -
. O +

Acute O +
white B-Disease +
matter I-Disease +
edema I-Disease +
and O +
eventual O +
neuronal B-Disease +
loss I-Disease +
in O +
the O +
striatum O +
adjacent O +
to O +
the O +
hematoma B-Disease +
did O +
not O +
differ O +
between O +
the O +
two O +
groups O -
. O +

Investigation O +
of O +
more O +
specific O +
anti O -
- O -
inflammatory O +
agents O +
and O +
hemodiluting O +
agents O +
are O +
warranted O +
in O +
intracerebral B-Disease +
hemorrhage I-Disease -
. O +

Severe O +
immune O +
hemolytic B-Disease +
anemia I-Disease +
associated O +
with O +
prophylactic O +
use O +
of O +
cefotetan O +
in O +
obstetric O +
and O +
gynecologic O +
procedures O -
. O +

Second- O +
and O +
third O -
- O -
generation O +
cephalosporins O -
, O +
especially O +
cefotetan O -
, O +
are O +
increasingly O +
associated O +
with O +
severe O -
, O +
sometimes O +
fatal O +
immune O +
hemolytic B-Disease +
anemia I-Disease -
. O +

We O +
noticed O +
that O +
10 O +
of O +
our O +
35 O +
cases O +
of O +
cefotetan O -
- O -
induced O +
hemolytic B-Disease +
anemias I-Disease +
were O +
in O +
patients O +
who O +
had O +
received O +
cefotetan O +
prophylactically O +
for O +
obstetric O +
and O +
gynecologic O +
procedures O -
. O +

Eight O +
of O +
these O +
cases O +
of O +
severe O +
immune O +
hemolytic B-Disease +
anemia I-Disease +
are O +
described O -
. O +

Effects O +
of O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
on O +
hemostasis O +
in O +
patients O +
with O +
aneurysmal B-Disease +
subarachnoid I-Disease +
hemorrhage I-Disease -
. O +

Platelet O +
function O +
is O +
impaired O +
by O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
with O +
prominent O +
anti O -
- O -
inflammatory O +
properties O -
. O +

Their O +
safety O +
in O +
patients O +
undergoing O +
intracranial O +
surgery O +
is O +
under O +
debate O -
. O +

Patients O +
with O +
aneurysmal B-Disease +
subarachnoid I-Disease +
hemorrhage I-Disease +
( O -
SAH B-Disease -
) O +
were O +
randomized O +
to O +
receive O +
either O +
ketoprofen O -
, O +
100 O +
mg O -
, O +
three O +
times O +
a O +
day O +
( O -
ketoprofen O +
group O -
, O +
n O +
= O +
9 O -
) O +
or O +
a O +
weak O +
NSAID O -
, O +
acetaminophen O -
, O +
1 O +
g O -
, O +
three O +
times O +
a O +
day O +
( O -
acetaminophen O +
group O -
, O +
n O +
= O +
9 O -
) O +
starting O +
immediately O +
after O +
the O +
diagnosis O +
of O +
aneurysmal B-Disease +
SAH B-Disease -
. O +

Treatment O +
was O +
continued O +
for O +
3 O +
days O +
postoperatively O -
. O +

Test O +
blood O +
samples O +
were O +
taken O +
before O +
treatment O +
and O +
surgery O +
as O +
well O +
as O +
on O +
the O +
first O -
, O +
third O -
, O +
and O +
fifth O +
postoperative O +
mornings O -
. O +

Maximal O +
platelet B-Disease +
aggregation I-Disease +
induced O +
by O +
6 O +
microM O +
of O +
adenosine O +
diphosphate O +
decreased O +
after O +
administration O +
of O +
ketoprofen O -
. O +

Aggregation O +
was O +
lower O +
( O -
P O +
< O +
.05 O -
) O +
in O +
the O +
ketoprofen O +
group O +
than O +
in O +
the O +
acetaminophen O +
group O +
just O +
before O +
surgery O +
and O +
on O +
the O +
third O +
postoperative O +
day O -
. O +

In O +
contrast O -
, O +
maximal O +
platelet B-Disease +
aggregation I-Disease +
increased O +
in O +
the O +
acetaminophen O +
group O +
on O +
the O +
third O +
postoperative O +
day O +
as O +
compared O +
with O +
the O +
pretreatment O +
platelet B-Disease +
aggregation I-Disease +
results O +
( O -
P O +
< O +
.05 O -
) O -
. O +

One O +
patient O +
in O +
the O +
ketoprofen O +
group O +
developed O +
a O +
postoperative O +
intracranial O +
hematoma B-Disease -
. O +

Coagulation O +
( O -
prothrombin O +
time O +
[ O -
PT O -
] O -
, O +
activated O +
partial O +
thromboplastin O +
time O +
[ O -
APPT O -
] O -
, O +
fibrinogen O +
concentration O -
, O +
and O +
antithrombin O +
III O +
[ O -
AT O +
III O -
] O -
) O +
was O +
comparable O +
between O +
the O +
two O +
groups O -
. O +

Ketoprofen O +
but O +
not O +
acetaminophen O +
impaired O +
platelet O +
function O +
in O +
patients O +
with O +
SAH B-Disease -
. O +

If O +
ketoprofen O +
is O +
used O +
before O +
surgery O +
on O +
cerebral O +
artery B-Disease +
aneurysms I-Disease -
, O +
it O +
may O +
pose O +
an O +
additional O +
risk O +
factor O +
for O +
hemorrhage B-Disease -
. O +

Recurarization O +
in O +
the O +
recovery O +
room O -
. O +

A O +
case O +
of O +
recurarization O +
in O +
the O +
recovery O +
room O +
is O +
reported O -
. O +

Accumulation O +
of O +
atracurium O +
in O +
the O +
intravenous O +
line O +
led O +
to O +
recurarization O +
after O +
flushing O +
the O +
line O +
in O +
the O +
recovery O +
room O -
. O +

A O +
respiratory B-Disease +
arrest I-Disease +
with O +
severe O +
desaturation B-Disease +
and O +
bradycardia B-Disease +
occurred O -
. O +

Circumstances O +
leading O +
to O +
this O +
event O +
and O +
the O +
mechanisms O +
enabling O +
a O +
neuromuscular B-Disease +
blockade I-Disease +
to O +
occur O -
, O +
following O +
the O +
administration O +
of O +
a O +
small O +
dose O +
of O +
relaxant O -
, O +
are O +
discussed O -
. O +

The O +
haemodynamic O +
effects O +
of O +
propofol O +
in O +
combination O +
with O +
ephedrine O +
in O +
elderly O +
patients O +
( O -
ASA O +
groups O +
3 O +
and O +
4 O -
) O -
. O +

The O +
marked O +
vasodilator O +
and O +
negative O +
inotropic O +
effects O +
of O +
propofol O +
are O +
disadvantages O +
in O +
frail O +
elderly O +
patients O -
. O +

We O +
investigated O +
the O +
safety O +
and O +
efficacy O +
of O +
adding O +
different O +
doses O +
of O +
ephedrine O +
to O +
propofol O +
in O +
order O +
to O +
obtund O +
the O +
hypotensive B-Disease +
response O -
. O +

The O +
haemodynamic O +
effects O +
of O +
adding O +
15 O -
, O +
20 O +
or O +
25 O +
mg O +
of O +
ephedrine O +
to O +
200 O +
mg O +
of O +
propofol O +
were O +
compared O +
to O +
control O +
in O +
40 O +
ASA O +
3 O -
/ O -
4 O +
patients O +
over O +
60 O +
years O +
presenting O +
for O +
genito O -
- O -
urinary O +
surgery O -
. O +

The O +
addition O +
of O +
ephedrine O +
to O +
propofol O +
appears O +
to O +
be O +
an O +
effective O +
method O +
of O +
obtunding O +
the O +
hypotensive B-Disease +
response O +
to O +
propofol O +
at O +
all O +
doses O +
used O +
in O +
this O +
study O -
. O +

However O -
, O +
marked O +
tachycardia B-Disease +
associated O +
with O +
the O +
use O +
of O +
ephedrine O +
in O +
combination O +
with O +
propofol O +
occurred O +
in O +
the O +
majority O +
of O +
patients O -
, O +
occasionally O +
reaching O +
high O +
levels O +
in O +
individual O +
patients O -
. O +

Due O +
to O +
the O +
risk O +
of O +
this O +
tachycardia B-Disease +
inducing O +
myocardial B-Disease +
ischemia I-Disease -
, O +
we O +
would O +
not O +
recommend O +
the O +
use O +
in O +
elderly O +
patients O +
of O +
any O +
of O +
the O +
ephedrine O -
/ O -
propofol O -
/ O -
mixtures O +
studied O -
. O +

Nitric O +
oxide O +
synthase O +
expression O +
in O +
the O +
course O +
of O +
lead O -
- O -
induced O +
hypertension B-Disease -
. O +

We O +
recently O +
showed O +
elevated O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O -
, O +
reduced O +
urinary O +
excretion O +
of O +
NO O +
metabolites O +
( O -
NOx O -
) O -
, O +
and O +
increased O +
NO O +
sequestration O +
as O +
nitrotyrosine O +
in O +
various O +
tissues O +
in O +
rats O +
with O +
lead O -
- O -
induced O +
hypertension B-Disease -
. O +

This O +
study O +
was O +
designed O +
to O +
discern O +
whether O +
the O +
reduction O +
in O +
urinary O +
NOx O +
in O +
lead O -
- O -
induced O +
hypertension B-Disease +
is O -
, O +
in O +
part O -
, O +
due O +
to O +
depressed O +
NO O +
synthase O +
( O -
NOS O -
) O +
expression O -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
randomly O +
assigned O +
to O +
a O +
lead O -
- O -
treated O +
group O +
( O -
given O +
lead O +
acetate O -
, O +
100 O +
ppm O -
, O +
in O +
drinking O +
water O +
and O +
regular O +
rat O +
chow O -
) O -
, O +
a O +
group O +
given O +
lead O +
and O +
vitamin O +
E O -
- O -
fortified O +
chow O -
, O +
or O +
a O +
normal O +
control O +
group O +
given O +
either O +
regular O +
food O +
and O +
water O +
or O +
vitamin O +
E O -
- O -
fortified O +
food O +
for O +
12 O +
weeks O -
. O +

Tail O +
blood O +
pressure O -
, O +
urinary O +
NOx O +
excretion O -
, O +
plasma O +
malondialdehyde O +
( O -
MDA O -
) O -
, O +
and O +
endothelial O +
and O +
inducible O +
NOS O +
( O -
eNOS O +
and O +
iNOS O -
) O +
isotypes O +
in O +
the O +
aorta O +
and O +
kidney O +
were O +
measured O -
. O +

The O +
lead O -
- O -
treated O +
group O +
exhibited O +
a O +
rise O +
in O +
blood O +
pressure O +
and O +
plasma O +
MDA O +
concentration O -
, O +
a O +
fall O +
in O +
urinary O +
NOx O +
excretion O -
, O +
and O +
a O +
paradoxical O +
rise O +
in O +
vascular O +
and O +
renal O +
tissue O +
eNOS O +
and O +
iNOS O +
expression O -
. O +

Vitamin O +
E O +
supplementation O +
ameliorated O +
hypertension B-Disease -
, O +
lowered O +
plasma O +
MDA O +
concentration O -
, O +
and O +
raised O +
urinary O +
NOx O +
excretion O +
while O +
significantly O +
lowering O +
vascular O -
, O +
but O +
not O +
renal O -
, O +
tissue O +
eNOS O +
and O +
iNOS O +
expression O -
. O +

Vitamin O +
E O +
supplementation O +
had O +
no O +
effect O +
on O +
either O +
blood O +
pressure O -
, O +
plasma O +
MDA O -
, O +
or O +
NOS O +
expression O +
in O +
the O +
control O +
group O -
. O +

The O +
study O +
also O +
revealed O +
significant O +
inhibition O +
of O +
NOS O +
enzymatic O +
activity O +
by O +
lead O +
in O +
cell O -
- O -
free O +
preparations O -
. O +

In O +
conclusion O -
, O +
lead O -
- O -
induced O +
hypertension B-Disease +
in O +
this O +
model O +
was O +
associated O +
with O +
a O +
compensatory O +
upregulation O +
of O +
renal O +
and O +
vascular O +
eNOS O +
and O +
iNOS O +
expression O -
. O +

This O +
is O -
, O +
in O +
part O -
, O +
due O +
to O +
ROS O -
- O -
mediated O +
NO O +
inactivation O -
, O +
lead O -
- O -
associated O +
inhibition O +
of O +
NOS O +
activity O -
, O +
and O +
perhaps O +
stimulatory O +
actions O +
of O +
increased O +
shear O +
stress O +
associated O +
with O +
hypertension B-Disease -
. O +

Glyceryl O +
trinitrate O +
induces O +
attacks O +
of O +
migraine B-Disease +
without I-Disease +
aura I-Disease +
in O +
sufferers O +
of O +
migraine B-Disease +
with I-Disease +
aura I-Disease -
. O +

Migraine B-Disease +
with I-Disease +
aura I-Disease +
and O +
migraine B-Disease +
without I-Disease +
aura I-Disease +
have O +
the O +
same O +
pain B-Disease +
phase O -
, O +
thus O +
indicating O +
that O +
migraine B-Disease +
with I-Disease +
aura I-Disease +
and O +
migraine B-Disease +
without I-Disease +
aura I-Disease +
share O +
a O +
common O +
pathway O +
of O +
nociception O -
. O +

In O +
recent O +
years O -
, O +
increasing O +
evidence O +
has O +
suggested O +
that O +
the O +
messenger O +
molecule O +
nitric O +
oxide O +
( O -
NO O -
) O +
is O +
involved O +
in O +
pain B-Disease +
mechanisms O +
of O +
migraine B-Disease +
without I-Disease +
aura I-Disease -
. O +

In O +
order O +
to O +
clarify O +
whether O +
the O +
same O +
is O +
true O +
for O +
migraine B-Disease +
with I-Disease +
aura I-Disease -
, O +
in O +
the O +
present O +
study O +
we O +
examined O +
the O +
headache B-Disease +
response O +
to O +
intravenous O +
infusion O +
of O +
glyceryl O +
trinitrate O +
( O -
GTN O -
) O +
( O -
0.5 O +
microg O -
/ O -
kg O -
/ O -
min O +
for O +
20 O +
min O -
) O +
in O +
12 O +
sufferers O +
of O +
migraine B-Disease +
with I-Disease +
aura I-Disease -
. O +

The O +
specific O +
aim O +
was O +
to O +
elucidate O +
whether O +
an O +
aura O +
and/or O +
an O +
attack O +
of O +
migraine B-Disease +
without I-Disease +
aura I-Disease +
could O +
be O +
induced O -
. O +

Fourteen O +
healthy O +
subjects O +
served O +
as O +
controls O -
. O +

Aura O +
symptoms O +
were O +
not O +
elicited O +
in O +
any O +
subject O -
. O +

Headache B-Disease +
was O +
more O +
severe O +
in O +
migraineurs B-Disease +
than O +
in O +
the O +
controls O +
during O +
and O +
immediately O +
after O +
GTN O +
infusion O +
( O -
p=0.037 O -
) O +
as O +
well O +
as O +
during O +
the O +
following O +
11 O +
h O +
( O -
p O +
= O +
0.008 O -
) O -
. O +

In O +
the O +
controls O -
, O +
the O +
GTN O -
- O -
induced O +
headache B-Disease +
gradually O +
disappeared O -
, O +
whereas O +
in O +
migraineurs B-Disease +
peak O +
headache B-Disease +
intensity O +
occurred O +
at O +
a O +
mean O +
time O +
of O +
240 O +
min O +
post O -
- O -
infusion O -
. O +

At O +
this O +
time O +
the O +
induced O +
headache B-Disease +
in O +
6 O +
of O +
12 O +
migraineurs B-Disease +
fulfilled O +
the O +
diagnostic O +
criteria O +
for O +
migraine B-Disease +
without I-Disease +
aura I-Disease +
of O +
the O +
International O +
Headache B-Disease +
Society O -
. O +

The O +
results O +
therefore O +
suggest O +
that O +
NO O +
is O +
involved O +
in O +
the O +
pain B-Disease +
mechanisms O +
of O +
migraine B-Disease +
with I-Disease +
aura I-Disease -
. O +

Since O +
cortical O +
spreading O +
depression B-Disease +
has O +
been O +
shown O +
to O +
liberate O +
NO O +
in O +
animals O -
, O +
this O +
finding O +
may O +
help O +
our O +
understanding O +
of O +
the O +
coupling O +
between O +
cortical O +
spreading O +
depression B-Disease +
and O +
headache B-Disease +
in O +
migraine B-Disease +
with I-Disease +
aura I-Disease -
. O +

Gemcitabine O +
plus O +
vinorelbine O +
in O +
nonsmall B-Disease +
cell I-Disease +
lung I-Disease +
carcinoma I-Disease +
patients O +
age O +
70 O +
years O +
or O +
older O +
or O +
patients O +
who O +
can O -
not O +
receive O +
cisplatin O -
. O +

Oncopaz O +
Cooperative O +
Group O -
. O +

BACKGROUND O -
: O +
Although O +
the O +
prevalence O +
of O +
nonsmall B-Disease +
cell I-Disease +
lung I-Disease +
carcinoma I-Disease +
( O -
NSCLC B-Disease -
) O +
is O +
high O +
among O +
elderly O +
patients O -
, O +
few O +
data O +
are O +
available O +
regarding O +
the O +
efficacy O +
and O +
toxicity B-Disease +
of O +
chemotherapy O +
in O +
this O +
group O +
of O +
patients O -
. O +

Recent O +
reports O +
indicate O +
that O +
single O +
agent O +
therapy O +
with O +
vinorelbine O +
( O -
VNB O -
) O +
or O +
gemcitabine O +
( O -
GEM O -
) O +
may O +
obtain O +
a O +
response O +
rate O +
of O +
20 O -
- O -
30 O -
% O +
in O +
elderly O +
patients O -
, O +
with O +
acceptable O +
toxicity B-Disease +
and O +
improvement O +
in O +
symptoms O +
and O +
quality O +
of O +
life O -
. O +

In O +
the O +
current O +
study O +
the O +
efficacy O +
and O +
toxicity B-Disease +
of O +
the O +
combination O +
of O +
GEM O +
and O +
VNB O +
in O +
elderly O +
patients O +
with O +
advanced O +
NSCLC B-Disease +
or O +
those O +
with O +
some O +
contraindication O +
to O +
receiving O +
cisplatin O +
were O +
assessed O -
. O +

METHODS O -
: O +
Forty O -
- O -
nine O +
patients O +
with O +
advanced O +
NSCLC B-Disease +
were O +
included O -
, O +
38 O +
of O +
whom O +
were O +
age O +
> O -
/= O +
70 O +
years O +
and O +
11 O +
were O +
age O +
< O +
70 O +
years O +
but O +
who O +
had O +
some O +
contraindication O +
to O +
receiving O +
cisplatin O -
. O +

All O +
patients O +
were O +
evaluable O +
for O +
response O +
and O +
toxicity B-Disease -
. O +

Treatment O +
was O +
comprised O +
of O +
VNB O -
, O +
25 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
, O +
plus O +
GEM O -
, O +
1000 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
, O +
both O +
on O +
Days O +
1 O -
, O +
8 O -
, O +
and O +
15 O +
every O +
28 O +
days O -
. O +

Patients O +
received O +
a O +
minimum O +
of O +
three O +
courses O +
unless O +
progressive O +
disease O +
was O +
detected O -
. O +

RESULTS O -
: O +
One O +
hundred O +
sixty O -
- O -
five O +
courses O +
were O +
administered O -
, O +
with O +
a O +
median O +
of O +
3 O -
. O +
6 O +
courses O +
per O +
patient O -
. O +

The O +
overall O +
response O +
rate O +
was O +
26 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
15 O -
- O -
41 O -
% O -
) O -
. O +

Two O +
patients O +
attained O +
a O +
complete O +
response O +
( O -
4 O -
% O -
) O +
and O +
11 O +
patients O +
( O -
22 O -
% O -
) O +
achieved O +
a O +
partial O +
response O -
. O +

Eastern O +
Cooperative O +
Oncology O +
Group O +
performance O +
status O +
improved O +
in O +
35 O -
% O +
of O +
those O +
patients O +
with O +
an O +
initial O +
value O +
> O +
0 O -
, O +
whereas O +
relief O +
of O +
at O +
least O +
1 O +
symptom O +
without O +
worsening O +
of O +
other O +
symptoms O +
was O +
noted O +
in O +
27 O +
patients O +
( O -
55 O -
% O -
) O -
. O +

The O +
median O +
time O +
to O +
progression O +
was O +
16 O +
weeks O +
and O +
the O +
1-year O +
survival O +
rate O +
was O +
33 O -
% O -
. O +

Toxicity B-Disease +
was O +
mild O -
. O +

Six O +
patients O +
( O -
12 O -
% O -
) O +
had O +
World O +
Health O +
Organization O +
Grade O +
3 O -
- O -
4 O +
neutropenia B-Disease -
, O +
2 O +
patients O +
( O -
4 O -
% O -
) O +
had O +
Grade O +
3 O -
- O -
4 O +
thrombocytopenia B-Disease -
, O +
and O +
2 O +
patients O +
( O -
4 O -
% O -
) O +
had O +
Grade O +
3 O +
neurotoxicity B-Disease -
. O +

Three O +
patients O +
with O +
severe O +
neutropenia B-Disease +
( O -
6 O -
% O -
) O +
died O +
of O +
sepsis B-Disease -
. O +

The O +
median O +
age O +
of O +
those O +
patients O +
developing O +
Grade O +
3 O -
- O -
4 O +
neutropenia B-Disease +
was O +
significantly O +
higher O +
than O +
that O +
of O +
the O +
remaining O +
patients O +
( O -
75 O +
years O +
vs. O +
72 O +
years O -
; O +
P O +
= O +
0.047 O -
) O -
. O +

CONCLUSIONS O -
: O +
The O +
combination O +
of O +
GEM O +
and O +
VNB O +
is O +
moderately O +
active O +
and O +
well O +
tolerated O +
except O +
in O +
patients O +
age O +
> O -
/= O +
75 O +
years O -
. O +

This O +
age O +
group O +
had O +
an O +
increased O +
risk O +
of O +
myelosuppression B-Disease -
. O +

Therefore O +
the O +
prophylactic O +
use O +
of O +
granulocyte O -
- O -
colony O +
stimulating O +
factor O +
should O +
be O +
considered O +
with O +
this O +
treatment O -
. O +

New O +
chemotherapy O +
combinations O +
with O +
higher O +
activity O +
and O +
lower O +
toxicity B-Disease +
are O +
needed O +
for O +
elderly O +
patients O +
with O +
advanced O +
NSCLC B-Disease -
. O +

Rapid O +
reversal O +
of O +
life O -
- O -
threatening O +
diltiazem O -
- O -
induced O +
tetany B-Disease +
with O +
calcium O +
chloride O -
. O +

We O +
describe O +
a O +
patient O +
who O +
developed O +
tetany B-Disease +
with O +
sudden O +
respiratory B-Disease +
arrest I-Disease +
after O +
the O +
infusion O +
of O +
intravenous O +
diltiazem O -
. O +

The O +
administration O +
of O +
calcium O +
chloride O +
rapidly O +
resolved O +
the O +
patient O -
's O +
tetany B-Disease +
with O +
prompt O +
recovery O +
of O +
respiratory O +
function O -
, O +
averting O +
the O +
need O +
for O +
more O +
aggressive O +
airway O +
management O +
and O +
ventilatory O +
support O -
. O +

The O +
emergency O +
physician O +
should O +
be O +
aware O +
that O +
life O -
- O -
threatening O +
tetany B-Disease +
may O +
accompany O +
the O +
administration O +
of O +
intravenous O +
diltiazem O +
and O +
that O +
calcium O +
chloride O +
may O +
be O +
a O +
rapid O +
and O +
effective O +
remedy O -
. O +

Predictors O +
of O +
decreased B-Disease +
renal I-Disease +
function I-Disease +
in O +
patients O +
with O +
heart B-Disease +
failure I-Disease +
during O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
therapy O -
: O +
results O +
from O +
the O +
studies O +
of O +
left B-Disease +
ventricular I-Disease +
dysfunction I-Disease +
( O -
SOLVD O -
) O +
BACKGROUND O -
: O +
Although O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
therapy O +
reduces O +
mortality O +
rates O +
in O +
patients O +
with O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
( O -
CHF B-Disease -
) O -
, O +
it O +
may O +
also O +
cause O +
decreased B-Disease +
renal I-Disease +
function I-Disease -
. O +

Little O +
information O +
is O +
available O +
to O +
predict O +
which O +
patients O +
are O +
at O +
highest O +
risk O +
for O +
this O +
complication O -
. O +

OBJECTIVE O -
: O +
To O +
quantify O +
specific O +
clinical O +
predictors O +
of O +
reduction B-Disease +
in I-Disease +
renal I-Disease +
function I-Disease +
in O +
patients O +
with O +
CHF B-Disease +
who O +
are O +
prescribed O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
therapy O -
. O +

METHOD O -
: O +
We O +
analyzed O +
data O +
from O +
the O +
Studies O +
of O +
Left B-Disease +
Ventricular I-Disease +
Dysfunction I-Disease +
( O -
SOLVD O -
) O -
, O +
a O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
trial O +
of O +
enalapril O +
for O +
the O +
treatment O +
of O +
CHF B-Disease -
. O +

There O +
were O +
3379 O +
patients O +
randomly O +
assigned O +
to O +
enalapril O +
with O +
a O +
median O +
follow O -
- O -
up O +
of O +
974 O +
days O +
and O +
3379 O +
patients O +
randomly O +
assigned O +
to O +
placebo O +
with O +
a O +
mean O +
follow O -
- O -
up O +
of O +
967 O +
days O -
. O +

Decreased B-Disease +
renal I-Disease +
function I-Disease +
was O +
defined O +
as O +
a O +
rise O +
in O +
serum O +
creatinine O +
> O -
/=0.5 O +
mg O -
/ O -
dL O +
( O -
44 O +
micromol O -
/ O -
L O -
) O +
from O +
baseline O -
. O +

We O +
used O +
time O -
- O -
to O -
- O -
event O +
analysis O +
to O +
identify O +
potential O +
predictors O +
of O +
decrease O +
in O +
renal O +
function O +
including O +
age O -
, O +
baseline O +
ejection O +
fraction O -
, O +
baseline O +
creatinine O -
, O +
low O +
systolic O +
blood O +
pressure O +
( O -
< O -
100 O +
mm O +
Hg O -
) O -
, O +
history O +
of O +
hypertension B-Disease -
, O +
diabetes B-Disease -
, O +
and O +
use O +
of O +
antiplatelet O -
, O +
diuretic O -
, O +
and O +
beta O -
- O -
blocker O +
therapy O -
. O +

RESULTS O -
: O +
Patients O +
randomly O +
assigned O +
to O +
enalapril O +
had O +
a O +
33 O -
% O +
greater O +
likelihood O +
of O +
decreased B-Disease +
renal I-Disease +
function I-Disease +
than O +
controls O +
( O -
P O +
= O -
.003 O -
) O -
. O +

By O +
multivariate O +
analysis O -
, O +
in O +
both O +
the O +
placebo O +
and O +
enalapril O +
groups O +
older O +
age O -
, O +
diuretic O +
therapy O -
, O +
and O +
diabetes B-Disease +
were O +
associated O +
with O +
decreased B-Disease +
renal I-Disease +
function I-Disease -
, O +
whereas O +
beta O -
- O -
blocker O +
therapy O +
and O +
higher O +
ejection O +
fraction O +
were O +
renoprotective O -
. O +

Older O +
age O +
was O +
associated O +
with O +
a O +
greater O +
risk O +
of O +
developing O +
decreased B-Disease +
renal I-Disease +
function I-Disease +
in O +
both O +
groups O -
, O +
but O +
significantly O +
more O +
so O +
in O +
the O +
enalapril O +
group O +
( O -
enalapril O -
: O +
risk O +
ratio O +
[ O -
RR O -
] O +
1.42 O +
per O +
10 O +
years O -
, O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O +
1.32 O -
- O -
1.52 O +
with O +
enalapril O -
; O +
placebo O -
: O +
RR O +
1.18 O -
, O +
95 O -
% O +
CI O +
1.12 O -
- O -
1.25 O -
) O -
. O +

Diuretic O +
therapy O +
was O +
likewise O +
associated O +
with O +
a O +
greater O +
risk O +
of O +
decreased B-Disease +
renal I-Disease +
function I-Disease +
in O +
the O +
enalapril O +
group O +
( O -
RR O +
1.89 O -
, O +
95 O -
% O +
CI O +
1.70 O -
- O -
2.08 O -
) O +
than O +
in O +
the O +
placebo O +
group O +
( O -
RR O +
1.35 O -
, O +
95 O -
% O +
CI O +
1.09 O -
- O -
1.66 O -
) O -
. O +

Conversely O -
, O +
enalapril O +
had O +
a O +
relative O +
renoprotective O +
effect O +
( O -
RR O +
1.33 O -
, O +
95 O -
% O +
CI O +
1.13 O -
- O -
1.53 O -
) O +
compared O +
with O +
placebo O +
( O -
RR O +
1.96 O -
, O +
95 O -
% O +
CI O +
1.57 O -
- O -
2.44 O -
) O +
in O +
patients O +
with O +
diabetes B-Disease -
. O +

A O +
lower O +
risk O +
of O +
renal B-Disease +
impairment I-Disease +
was O +
seen O +
in O +
both O +
groups O +
with O +
beta O -
- O -
blocker O +
therapy O +
( O -
RR O +
0.70 O -
, O +
95 O -
% O +
CI O +
0.57 O -
- O -
0.85 O -
) O +
and O +
higher O +
baseline O +
ejection O +
fraction O +
( O -
RR O +
0.93 O +
per O +
5 O -
% O +
increment O -
, O +
95 O -
% O +
CI O +
0.91 O -
- O -
0 O -
. O +
96 O -
) O -
. O +

CONCLUSIONS O -
: O +
Enalapril O +
use O +
caused O +
a O +
33 O -
% O +
increase O +
in O +
the O +
risk O +
of O +
decreased B-Disease +
renal I-Disease +
function I-Disease +
in O +
patients O +
with O +
CHF B-Disease -
. O +

Diuretic O +
use O +
and O +
advanced O +
age O +
increased O +
this O +
risk O -
. O +

Diabetes B-Disease +
was O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
renal B-Disease +
impairment I-Disease +
in O +
all O +
patients O +
with O +
CHF B-Disease -
, O +
but O +
this O +
risk O +
was O +
reduced O +
in O +
the O +
enalapril O +
group O +
compared O +
with O +
the O +
placebo O +
group O -
. O +

beta O -
- O -
Blocker O +
therapy O +
and O +
higher O +
ejection O +
fraction O +
were O +
renoprotective O +
in O +
all O +
patients O +
regardless O +
of O +
therapy O -
. O +

A O +
selective O +
dopamine O +
D4 O +
receptor O +
antagonist O -
, O +
NRA0160 O -
: O +
a O +
preclinical O +
neuropharmacological O +
profile O -
. O +

NRA0160 O -
, O +
5 O +
- O +
[ O -
2- O +
( O +
4- O +
( O +
3 O +
- O +
fluorobenzylidene O -
) O +
piperidin-1-yl O -
) O +
ethyl O -
] O +
- O +
4 O +
- O -
( O -
4-fluorophenyl O -
) O +
thiazole-2-carboxamide O -
, O +
has O +
a O +
high O +
affinity O +
for O +
human O +
cloned O +
dopamine O +
D4.2 O -
, O +
D4.4 O +
and O +
D4.7 O +
receptors O -
, O +
with O +
Ki O +
values O +
of O +
0.5 O -
, O +
0.9 O +
and O +
2.7 O +
nM O -
, O +
respectively O -
. O +

NRA0160 O +
is O +
over O +
20,000fold O +
more O +
potent O +
at O +
the O +
dopamine O +
D4.2 O +
receptor O +
compared O +
with O +
the O +
human O +
cloned O +
dopamine O +
D2L O +
receptor O -
. O +

NRA0160 O +
has O +
negligible O +
affinity O +
for O +
the O +
human O +
cloned O +
dopamine O +
D3 O +
receptor O +
( O -
Ki=39 O +
nM O -
) O -
, O +
rat O +
serotonin O +
( O -
5-HT O -
) O -
2A O +
receptors O +
( O -
Ki=180 O +
nM O -
) O +
and O +
rat O +
alpha1 O +
adrenoceptor O +
( O -
Ki=237 O +
nM O -
) O -
. O +

NRA0160 O +
and O +
clozapine O +
antagonized O +
locomotor O +
hyperactivity B-Disease +
induced O +
by O +
methamphetamine O +
( O -
MAP O -
) O +
in O +
mice O -
. O +

NRA0160 O +
and O +
clozapine O +
antagonized O +
MAP O -
- O -
induced O +
stereotyped O +
behavior O +
in O +
mice O -
, O +
although O +
their O +
effects O +
did O +
not O +
exceed O +
50 O -
% O +
inhibition O -
, O +
even O +
at O +
the O +
highest O +
dose O +
given O -
. O +

NRA0160 O +
and O +
clozapine O +
significantly O +
induced O +
catalepsy B-Disease +
in O +
rats O -
, O +
although O +
their O +
effects O +
did O +
not O +
exceed O +
50 O -
% O +
induction O +
even O +
at O +
the O +
highest O +
dose O +
given O -
. O +

NRA0160 O +
and O +
clozapine O +
significantly O +
reversed O +
the O +
disruption O +
of O +
prepulse O +
inhibition O +
( O -
PPI O -
) O +
in O +
rats O +
produced O +
by O +
apomorphine O -
. O +

NRA0160 O +
and O +
clozapine O +
significantly O +
shortened O +
the O +
phencyclidine O +
( O -
PCP O -
) O -
-induced O +
prolonged O +
swimming O +
latency O +
in O +
rats O +
in O +
a O +
water O +
maze O +
task O -
. O +

These O +
findings O +
suggest O +
that O +
NRA0160 O +
may O +
have O +
unique O +
antipsychotic O +
activities O +
without O +
the O +
liability O +
of O +
motor O +
side O +
effects O +
typical O +
of O +
classical O +
antipsychotics O -
. O +

Warfarin O -
- O -
induced O +
artery B-Disease +
calcification I-Disease +
is O +
accelerated O +
by O +
growth O +
and O +
vitamin O +
D. O +
The O +
present O +
studies O +
demonstrate O +
that O +
growth O +
and O +
vitamin O +
D O +
treatment O +
enhance O +
the O +
extent O +
of O +
artery B-Disease +
calcification I-Disease +
in O +
rats O +
given O +
sufficient O +
doses O +
of O +
Warfarin O +
to O +
inhibit O +
gamma O -
- O -
carboxylation O +
of O +
matrix O +
Gla O +
protein O -
, O +
a O +
calcification B-Disease +
inhibitor O +
known O +
to O +
be O +
expressed O +
by O +
smooth O +
muscle O +
cells O +
and O +
macrophages O +
in O +
the O +
artery O +
wall O -
. O +

The O +
first O +
series O +
of O +
experiments O +
examined O +
the O +
influence O +
of O +
age O +
and O +
growth O +
status O +
on O +
artery B-Disease +
calcification I-Disease +
in O +
Warfarin O -
- O -
treated O +
rats O -
. O +

Treatment O +
for O +
2 O +
weeks O +
with O +
Warfarin O +
caused O +
massive O +
focal O +
calcification B-Disease +
of I-Disease +
the I-Disease +
artery I-Disease +
media O +
in O +
20-day O -
- O -
old O +
rats O +
and O +
less O +
extensive O +
focal O +
calcification B-Disease +
in O +
42-day O -
- O -
old O +
rats O -
. O +

In O +
contrast O -
, O +
no O +
artery B-Disease +
calcification I-Disease +
could O +
be O +
detected O +
in O +
10-month O -
- O -
old O +
adult O +
rats O +
even O +
after O +
4 O +
weeks O +
of O +
Warfarin O +
treatment O -
. O +

To O +
directly O +
examine O +
the O +
importance O +
of O +
growth O +
to O +
Warfarin O -
- O -
induced O +
artery B-Disease +
calcification I-Disease +
in O +
animals O +
of O +
the O +
same O +
age O -
, O +
20-day O -
- O -
old O +
rats O +
were O +
fed O +
for O +
2 O +
weeks O +
either O +
an O +
ad O +
libitum O +
diet O +
or O +
a O +
6-g O -
/ O -
d O +
restricted O +
diet O +
that O +
maintains O +
weight O +
but O +
prevents O +
growth O -
. O +

Concurrent O +
treatment O +
of O +
both O +
dietary O +
groups O +
with O +
Warfarin O +
produced O +
massive O +
focal O +
calcification B-Disease +
of I-Disease +
the I-Disease +
artery I-Disease +
media O +
in O +
the O +
ad O +
libitum O -
- O -
fed O +
rats O +
but O +
no O +
detectable O +
artery B-Disease +
calcification I-Disease +
in O +
the O +
restricted O -
- O -
diet O -
, O +
growth O -
- O -
inhibited O +
group O -
. O +

Although O +
the O +
explanation O +
for O +
the O +
association O +
between O +
artery B-Disease +
calcification I-Disease +
and O +
growth O +
status O +
can O -
not O +
be O +
determined O +
from O +
the O +
present O +
study O -
, O +
there O +
was O +
a O +
relationship O +
between O +
higher O +
serum O +
phosphate O +
and O +
susceptibility O +
to O +
artery B-Disease +
calcification I-Disease -
, O +
with O +
30 O -
% O +
higher O +
levels O +
of O +
serum O +
phosphate O +
in O +
young O -
, O +
ad O +
libitum O -
- O -
fed O +
rats O +
compared O +
with O +
either O +
of O +
the O +
groups O +
that O +
was O +
resistant O +
to O +
Warfarin O -
- O -
induced O +
artery B-Disease +
calcification I-Disease -
, O +
ie O -
, O +
the O +
10-month O -
- O -
old O +
rats O +
and O +
the O +
restricted O -
- O -
diet O -
, O +
growth O -
- O -
inhibited O +
young O +
rats O -
. O +

This O +
observation O +
suggests O +
that O +
increased O +
susceptibility O +
to O +
Warfarin O -
- O -
induced O +
artery B-Disease +
calcification I-Disease +
could O +
be O +
related O +
to O +
higher O +
serum O +
phosphate O +
levels O -
. O +

The O +
second O +
set O +
of O +
experiments O +
examined O +
the O +
possible O +
synergy O +
between O +
vitamin O +
D O +
and O +
Warfarin O +
in O +
artery B-Disease +
calcification I-Disease -
. O +

High O +
doses O +
of O +
vitamin O +
D O +
are O +
known O +
to O +
cause O +
calcification B-Disease +
of I-Disease +
the I-Disease +
artery I-Disease +
media O +
in O +
as O +
little O +
as O +
3 O +
to O +
4 O +
days O -
. O +

High O +
doses O +
of O +
the O +
vitamin O +
K O +
antagonist O +
Warfarin O +
are O +
also O +
known O +
to O +
cause O +
calcification B-Disease +
of I-Disease +
the I-Disease +
artery I-Disease +
media O -
, O +
but O +
at O +
treatment O +
times O +
of O +
2 O +
weeks O +
or O +
longer O +
yet O +
not O +
at O +
1 O +
week O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
investigated O +
the O +
synergy O +
between O +
these O +
2 O +
treatments O +
and O +
found O +
that O +
concurrent O +
Warfarin O +
administration O +
dramatically O +
increased O +
the O +
extent O +
of O +
calcification B-Disease +
in O +
the O +
media O +
of O +
vitamin O +
D O -
- O -
treated O +
rats O +
at O +
3 O +
and O +
4 O +
days O -
. O +

There O +
was O +
a O +
close O +
parallel O +
between O +
the O +
effect O +
of O +
vitamin O +
D O +
dose O +
on O +
artery B-Disease +
calcification I-Disease +
and O +
the O +
effect O +
of O +
vitamin O +
D O +
dose O +
on O +
the O +
elevation O +
of O +
serum O +
calcium O -
, O +
which O +
suggests O +
that O +
vitamin O +
D O +
may O +
induce O +
artery B-Disease +
calcification I-Disease +
through O +
its O +
effect O +
on O +
serum O +
calcium O -
. O +

Because O +
Warfarin O +
treatment O +
had O +
no O +
effect O +
on O +
the O +
elevation O +
in O +
serum O +
calcium O +
produced O +
by O +
vitamin O +
D O -
, O +
the O +
synergy O +
between O +
Warfarin O +
and O +
vitamin O +
D O +
is O +
probably O +
best O +
explained O +
by O +
the O +
hypothesis O +
that O +
Warfarin O +
inhibits O +
the O +
activity O +
of O +
matrix O +
Gla O +
protein O +
as O +
a O +
calcification B-Disease +
inhibitor O -
. O +

High O +
levels O +
of O +
matrix O +
Gla O +
protein O +
are O +
found O +
at O +
sites O +
of O +
artery B-Disease +
calcification I-Disease +
in O +
rats O +
treated O +
with O +
vitamin O +
D O +
plus O +
Warfarin O -
, O +
and O +
chemical O +
analysis O +
showed O +
that O +
the O +
protein O +
that O +
accumulated O +
was O +
indeed O +
not O +
gamma O -
- O -
carboxylated O -
. O +

These O +
observations O +
indicate O +
that O +
although O +
the O +
gamma O -
- O -
carboxyglutamate O +
residues O +
of O +
matrix O +
Gla O +
protein O +
are O +
apparently O +
required O +
for O +
its O +
function O +
as O +
a O +
calcification B-Disease +
inhibitor O -
, O +
they O +
are O +
not O +
required O +
for O +
its O +
accumulation O +
at O +
calcification B-Disease +
sites O -
. O +

Test O +
conditions O +
influence O +
the O +
response O +
to O +
a O +
drug O +
challenge O +
in O +
rodents O -
. O +

These O +
studies O +
were O +
conducted O +
to O +
examine O +
the O +
differential O +
response O +
to O +
a O +
drug O +
challenge O +
under O +
varied O +
experimental O +
test O +
conditions O +
routinely O +
employed O +
to O +
study O +
drug O -
- O -
induced O +
behavioral O +
and O +
neurophysiological O +
responses O +
in O +
rodents O -
. O +

Apomorphine O -
, O +
a O +
nonselective O +
dopamine O +
agonist O -
, O +
was O +
selected O +
due O +
to O +
its O +
biphasic O +
behavioral O +
effects O -
, O +
its O +
ability O +
to O +
induce O +
hypothermia B-Disease -
, O +
and O +
to O +
produce O +
distinct O +
changes O +
to O +
dopamine O +
turnover O +
in O +
the O +
rodent O +
brain O -
. O +

From O +
such O +
experiments O +
there O +
is O +
evidence O +
that O +
characterization O +
and O +
detection O +
of O +
apomorphine O -
- O -
induced O +
activity O +
in O +
rodents O +
critically O +
depends O +
upon O +
the O +
test O +
conditions O +
employed O -
. O +

In O +
rats O -
, O +
detection O +
of O +
apomorphine O -
- O -
induced O +
hyperactivity B-Disease +
was O +
facilitated O +
by O +
a O +
period O +
of O +
acclimatization O +
to O +
the O +
test O +
conditions O -
. O +

Moreover O -
, O +
test O +
conditions O +
can O +
impact O +
upon O +
other O +
physiological O +
responses O +
to O +
apomorphine O +
such O +
as O +
drug O -
- O -
induced O +
hypothermia B-Disease -
. O +

In O +
mice O -
, O +
apomorphine O +
produced O +
qualitatively O +
different O +
responses O +
under O +
novel O +
conditions O +
when O +
compared O +
to O +
those O +
behaviors O +
elicited O +
in O +
the O +
home O +
test O +
cage O -
. O +

Drug O -
- O -
induced O +
gross O +
activity O +
counts O +
were O +
increased O +
in O +
the O +
novel O +
exploratory O +
box O +
only O -
, O +
while O +
measures O +
of O +
stereotypic O +
behavior O +
were O +
similar O +
in O +
both O -
. O +

By O +
contrast O -
, O +
apomorphine O -
- O -
induced O +
locomotion O +
was O +
more O +
prominent O +
in O +
the O +
novel O +
exploratory O +
box O -
. O +

Dopamine O +
turnover O +
ratios O +
( O -
DOPAC O -
: O -
DA O +
and O +
HVA O -
: O -
DA O -
) O +
were O +
found O +
to O +
be O +
lower O +
in O +
those O +
animals O +
exposed O +
to O +
the O +
exploratory O +
box O +
when O +
compared O +
to O +
their O +
home O +
cage O +
counterparts O -
. O +

However O -
, O +
apomorphine O -
- O -
induced O +
reductions O +
in O +
striatal O +
dopamine O +
turnover O +
were O +
detected O +
in O +
both O +
novel O +
and O +
home O +
cage O +
environments O -
. O +

The O +
implications O +
of O +
these O +
findings O +
are O +
discussed O +
with O +
particular O +
emphasis O +
upon O +
conducting O +
psychopharmacological O +
challenge O +
tests O +
in O +
rodents O -
. O +

Hemolysis B-Disease +
of O +
human O +
erythrocytes O +
induced O +
by O +
tamoxifen O +
is O +
related O +
to O +
disruption O +
of O +
membrane O +
structure O -
. O +

Tamoxifen O +
( O -
TAM O -
) O -
, O +
the O +
antiestrogenic O +
drug O +
most O +
widely O +
prescribed O +
in O +
the O +
chemotherapy O +
of O +
breast B-Disease +
cancer I-Disease -
, O +
induces O +
changes O +
in O +
normal O +
discoid O +
shape O +
of O +
erythrocytes O +
and O +
hemolytic B-Disease +
anemia I-Disease -
. O +

This O +
work O +
evaluates O +
the O +
effects O +
of O +
TAM O +
on O +
isolated O +
human O +
erythrocytes O -
, O +
attempting O +
to O +
identify O +
the O +
underlying O +
mechanisms O +
on O +
TAM O -
- O -
induced O +
hemolytic B-Disease +
anemia I-Disease +
and O +
the O +
involvement O +
of O +
biomembranes O +
in O +
its O +
cytostatic O +
action O +
mechanisms O -
. O +

TAM O +
induces O +
hemolysis B-Disease +
of O +
erythrocytes O +
as O +
a O +
function O +
of O +
concentration O -
. O +

The O +
extension O +
of O +
hemolysis B-Disease +
is O +
variable O +
with O +
erythrocyte O +
samples O -
, O +
but O +
12.5 O +
microM O +
TAM O +
induces O +
total O +
hemolysis B-Disease +
of O +
all O +
tested O +
suspensions O -
. O +

Despite O +
inducing O +
extensive O +
erythrocyte O +
lysis O -
, O +
TAM O +
does O +
not O +
shift O +
the O +
osmotic O +
fragility O +
curves O +
of O +
erythrocytes O -
. O +

The O +
hemolytic B-Disease +
effect O +
of O +
TAM O +
is O +
prevented O +
by O +
low O +
concentrations O +
of O +
alpha O -
- O -
tocopherol O +
( O -
alpha O -
- O -
T O -
) O +
and O +
alpha O -
- O -
tocopherol O +
acetate O +
( O -
alpha O -
- O -
TAc O -
) O +
( O -
inactivated O +
functional O +
hydroxyl O -
) O +
indicating O +
that O +
TAM O -
- O -
induced O +
hemolysis B-Disease +
is O +
not O +
related O +
to O +
oxidative O +
membrane O +
damage O -
. O +

This O +
was O +
further O +
evidenced O +
by O +
absence O +
of O +
oxygen O +
consumption O +
and O +
hemoglobin O +
oxidation O +
both O +
determined O +
in O +
parallel O +
with O +
TAM O -
- O -
induced O +
hemolysis B-Disease -
. O +

Furthermore O -
, O +
it O +
was O +
observed O +
that O +
TAM O +
inhibits O +
the O +
peroxidation O +
of O +
human O +
erythrocytes O +
induced O +
by O +
AAPH O -
, O +
thus O +
ruling O +
out O +
TAM O -
- O -
induced O +
cell O +
oxidative O +
stress O -
. O +

Hemolysis B-Disease +
caused O +
by O +
TAM O +
was O +
not O +
preceded O +
by O +
the O +
leakage O +
of O +
K O -
( O -
+ O -
) O +
from O +
the O +
cells O -
, O +
also O +
excluding O +
a O +
colloid O -
- O -
osmotic O +
type O +
mechanism O +
of O +
hemolysis B-Disease -
, O +
according O +
to O +
the O +
effects O +
on O +
osmotic O +
fragility O +
curves O -
. O +

However O -
, O +
TAM O +
induces O +
release O +
of O +
peripheral O +
proteins O +
of O +
membrane O -
- O -
cytoskeleton O +
and O +
cytosol O +
proteins O +
essentially O +
bound O +
to O +
band O +
3 O -
. O +

Either O +
alpha O -
- O -
T O +
or O +
alpha O -
- O -
TAc O +
increases O +
membrane O +
packing O +
and O +
prevents O +
TAM O +
partition O +
into O +
model O +
membranes O -
. O +

These O +
effects O +
suggest O +
that O +
the O +
protection O +
from O +
hemolysis B-Disease +
by O +
tocopherols O +
is O +
related O +
to O +
a O +
decreased O +
TAM O +
incorporation O +
in O +
condensed O +
membranes O +
and O +
the O +
structural O +
damage O +
of O +
the O +
erythrocyte O +
membrane O +
is O +
consequently O +
avoided O -
. O +

Therefore O -
, O +
TAM O -
- O -
induced O +
hemolysis B-Disease +
results O +
from O +
a O +
structural O +
perturbation O +
of O +
red O +
cell O +
membrane O -
, O +
leading O +
to O +
changes O +
in O +
the O +
framework O +
of O +
the O +
erythrocyte O +
membrane O +
and O +
its O +
cytoskeleton O +
caused O +
by O +
its O +
high O +
partition O +
in O +
the O +
membrane O -
. O +

These O +
defects O +
explain O +
the O +
abnormal O +
erythrocyte O +
shape O +
and O +
decreased O +
mechanical O +
stability O +
promoted O +
by O +
TAM O -
, O +
resulting O +
in O +
hemolytic B-Disease +
anemia I-Disease -
. O +

Additionally O -
, O +
since O +
membrane O +
leakage O +
is O +
a O +
final O +
stage O +
of O +
cytotoxicity O -
, O +
the O +
disruption O +
of O +
the O +
structural O +
characteristics O +
of O +
biomembranes O +
by O +
TAM O +
may O +
contribute O +
to O +
the O +
multiple O +
mechanisms O +
of O +
its O +
anticancer O +
action O -
. O +

Changes O +
of O +
sodium O +
and O +
ATP O +
affinities O +
of O +
the O +
cardiac O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O +
during O +
and O +
after O +
nitric O +
oxide O +
deficient O +
hypertension B-Disease -
. O +

In O +
the O +
cardiovascular O +
system O -
, O +
NO O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
a O +
variety O +
of O +
functions O -
. O +

Inhibition O +
of O +
NO O +
synthesis O +
induces O +
sustained O +
hypertension B-Disease -
. O +

In O +
several O +
models O +
of O +
hypertension B-Disease -
, O +
elevation O +
of O +
intracellular O +
sodium O +
level O +
was O +
documented O +
in O +
cardiac O +
tissue O -
. O +

To O +
assess O +
the O +
molecular O +
basis O +
of O +
disturbances O +
in O +
transmembraneous O +
transport O +
of O +
Na+ O -
, O +
we O +
studied O +
the O +
response O +
of O +
cardiac O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O +
to O +
NO O -
- O -
deficient O +
hypertension B-Disease +
induced O +
in O +
rats O +
by O +
NO O -
- O -
synthase O +
inhibition O +
with O +
40 O +
mg O -
/ O -
kg O -
/ O -
day O +
N O -
( O -
G O -
) O -
-nitro O -
- O -
L O -
- O -
arginine O +
methyl O +
ester O +
( O -
L O -
- O -
NAME O -
) O +
for O +
4 O +
four O +
weeks O -
. O +

After O +
4-week O +
administration O +
of O +
L O -
- O -
NAME O -
, O +
the O +
systolic O +
blood O +
pressure O +
( O -
SBP O -
) O +
increased O +
by O +
36 O -
% O -
. O +

Two O +
weeks O +
after O +
terminating O +
the O +
treatment O -
, O +
the O +
SBP O +
recovered O +
to O +
control O +
value O -
. O +

When O +
activating O +
the O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O +
with O +
its O +
substrate O +
ATP O -
, O +
no O +
changes O +
in O +
Km O +
and O +
Vmax O +
values O +
were O +
observed O +
in O +
NO O -
- O -
deficient O +
rats O -
. O +

During O +
activation O +
with O +
Na+ O -
, O +
the O +
Vmax O +
remained O +
unchanged O -
, O +
however O +
the O +
K O -
( O -
Na O -
) O +
increased O +
by O +
50 O -
% O -
, O +
indicating O +
a O +
profound O +
decrease O +
in O +
the O +
affinity O +
of O +
the O +
Na+-binding O +
site O +
in O +
NO O -
- O -
deficient O +
rats O -
. O +

After O +
recovery O +
from O +
hypertension B-Disease -
, O +
the O +
activity O +
of O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O +
increased O -
, O +
due O +
to O +
higher O +
affinity O +
of O +
the O +
ATP O -
- O -
binding O +
site O -
, O +
as O +
revealed O +
from O +
the O +
lowered O +
Km O +
value O +
for O +
ATP O -
. O +

The O +
K O -
( O -
Na O -
) O +
value O +
for O +
Na+ O +
returned O +
to O +
control O +
value O -
. O +

Inhibition O +
of O +
NO O -
- O -
synthase O +
induced O +
a O +
reversible O +
hypertension B-Disease +
accompanied O +
by O +
depressed B-Disease +
Na+-extrusion O +
from O +
cardiac O +
cells O +
as O +
a O +
consequence O +
of O +
deteriorated O +
Na+-binding O +
properties O +
of O +
the O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O -
. O +

After O +
recovery O +
of O +
blood O +
pressure O +
to O +
control O +
values O -
, O +
the O +
extrusion O +
of O +
Na+ O +
from O +
cardiac O +
cells O +
was O +
normalized O -
, O +
as O +
revealed O +
by O +
restoration O +
of O +
the O +
( O -
Na O -
, O -
K O -
) O -
-ATPase O +
activity O -
. O +

Effects O +
of O +
long O -
- O -
term O +
pretreatment O +
with O +
isoproterenol O +
on O +
bromocriptine O -
- O -
induced O +
tachycardia B-Disease +
in O +
conscious O +
rats O -
. O +

It O +
has O +
been O +
shown O +
that O +
bromocriptine O -
- O -
induced O +
tachycardia B-Disease -
, O +
which O +
persisted O +
after O +
adrenalectomy O -
, O +
is O +
( O -
i O -
) O +
mediated O +
by O +
central O +
dopamine O +
D2 O +
receptor O +
activation O +
and O +
( O -
ii O -
) O +
reduced O +
by O +
5-day O +
isoproterenol O +
pretreatment O -
, O +
supporting O +
therefore O +
the O +
hypothesis O +
that O +
this O +
effect O +
is O +
dependent O +
on O +
sympathetic O +
outflow O +
to O +
the O +
heart O -
. O +

This O +
study O +
was O +
conducted O +
to O +
examine O +
whether O +
prolonged O +
pretreatment O +
with O +
isoproterenol O +
could O +
abolish O +
bromocriptine O -
- O -
induced O +
tachycardia B-Disease +
in O +
conscious O +
rats O -
. O +

Isoproterenol O +
pretreatment O +
for O +
15 O +
days O +
caused O +
cardiac B-Disease +
hypertrophy I-Disease +
without O +
affecting O +
baseline O +
blood O +
pressure O +
and O +
heart O +
rate O -
. O +

In O +
control O +
rats O -
, O +
intravenous O +
bromocriptine O +
( O -
150 O +
microg O -
/ O -
kg O -
) O +
induced O +
significant O +
hypotension B-Disease +
and O +
tachycardia B-Disease -
. O +

Bromocriptine O -
- O -
induced O +
hypotension B-Disease +
was O +
unaffected O +
by O +
isoproterenol O +
pretreatment O -
, O +
while O +
tachycardia B-Disease +
was O +
reversed O +
to O +
significant O +
bradycardia B-Disease -
, O +
an O +
effect O +
that O +
was O +
partly O +
reduced O +
by O +
i.v O -
. O +

domperidone O +
( O -
0.5 O +
mg O -
/ O -
kg O -
) O -
. O +

Neither O +
cardiac O +
vagal O +
nor O +
sympathetic O +
tone O +
was O +
altered O +
by O +
isoproterenol O +
pretreatment O -
. O +

In O +
isolated O +
perfused O +
heart O +
preparations O +
from O +
isoproterenol O -
- O -
pretreated O +
rats O -
, O +
the O +
isoproterenol O -
- O -
induced O +
maximal O +
increase O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
was O +
significantly O +
reduced O -
, O +
compared O +
with O +
saline O -
- O -
pretreated O +
rats O +
( O -
the O +
EC50 O +
of O +
the O +
isoproterenol O -
- O -
induced O +
increase O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
was O +
enhanced O +
approximately O +
22-fold O -
) O -
. O +

These O +
results O +
show O +
that O +
15-day O +
isoproterenol O +
pretreatment O +
not O +
only O +
abolished O +
but O +
reversed O +
bromocriptine O -
- O -
induced O +
tachycardia B-Disease +
to O +
bradycardia B-Disease -
, O +
an O +
effect O +
that O +
is O +
mainly O +
related O +
to O +
further O +
cardiac O +
beta O -
- O -
adrenoceptor O +
desensitization O +
rather O +
than O +
to O +
impairment O +
of O +
autonomic O +
regulation O +
of O +
the O +
heart O -
. O +

They O +
suggest O +
that O -
, O +
in O +
normal O +
conscious O +
rats O -
, O +
the O +
central O +
tachycardia B-Disease +
of O +
bromocriptine O +
appears O +
to O +
predominate O +
and O +
to O +
mask O +
the O +
bradycardia B-Disease +
of O +
this O +
agonist O +
at O +
peripheral O +
dopamine O +
D2 O +
receptors O -
. O +

Vasopressin O +
in O +
the O +
treatment O +
of O +
milrinone O -
- O -
induced O +
hypotension B-Disease +
in O +
severe O +
heart B-Disease +
failure I-Disease -
. O +

The O +
use O +
of O +
phosphodiesterase O +
inhibitors O +
such O +
as O +
milrinone O +
in O +
the O +
treatment O +
of O +
severe O +
heart B-Disease +
failure I-Disease +
is O +
frequently O +
restricted O +
because O +
they O +
cause O +
vasodilation O +
and O +
hypotension B-Disease -
. O +

In O +
patients O +
with O +
decompensated O +
heart B-Disease +
failure I-Disease +
with O +
hypotension B-Disease +
after O +
treatment O +
with O +
milrinone O -
, O +
low O +
doses O +
of O +
vasopressin O +
restored O +
blood O +
pressure O +
without O +
inhibiting O +
the O +
inotropic O +
effect O +
of O +
milrinone O -
. O +

A O +
developmental O +
analysis O +
of O +
clonidine O -
's O +
effects O +
on O +
cardiac O +
rate O +
and O +
ultrasound O +
production O +
in O +
infant O +
rats O -
. O +

Under O +
controlled O +
conditions O -
, O +
infant O +
rats O +
emit O +
ultrasonic O +
vocalizations O +
during O +
extreme O +
cold O +
exposure O +
and O +
after O +
administration O +
of O +
the O +
alpha O -
( O -
2 O -
) O +
adrenoceptor O +
agonist O -
, O +
clonidine O -
. O +

Previous O +
investigations O +
have O +
determined O +
that O -
, O +
in O +
response O +
to O +
clonidine O -
, O +
ultrasound O +
production O +
increases O +
through O +
the O +
2nd O -
- O -
week O +
postpartum O +
and O +
decreases O +
thereafter O -
. O +

Given O +
that O +
sympathetic O +
neural O +
dominance O +
exhibits O +
a O +
similar O +
developmental O +
pattern O -
, O +
and O +
given O +
that O +
clonidine O +
induces O +
sympathetic O +
withdrawal O +
and O +
bradycardia B-Disease -
, O +
we O +
hypothesized O +
that O +
clonidine O -
's O +
developmental O +
effects O +
on O +
cardiac O +
rate O +
and O +
ultrasound O +
production O +
would O +
mirror O +
each O +
other O -
. O +

Therefore O -
, O +
in O +
the O +
present O +
experiment O -
, O +
the O +
effects O +
of O +
clonidine O +
administration O +
( O -
0.5 O +
mg O -
/ O -
kg O -
) O +
on O +
cardiac O +
rate O +
and O +
ultrasound O +
production O +
were O +
examined O +
in O +
2- O -
, O +
8- O -
, O +
15- O -
, O +
and O +
20-day O -
- O -
old O +
rats O -
. O +

Age O -
- O -
related O +
changes O +
in O +
ultrasound O +
production O +
corresponded O +
with O +
changes O +
in O +
cardiovascular O +
variables O -
, O +
including O +
baseline O +
cardiac O +
rate O +
and O +
clonidine O -
- O -
induced O +
bradycardia B-Disease -
. O +

This O +
experiment O +
is O +
discussed O +
with O +
regard O +
to O +
the O +
hypothesis O +
that O +
ultrasound O +
production O +
is O +
the O +
acoustic O +
by O -
- O -
product O +
of O +
a O +
physiological O +
maneuver O +
that O +
compensates O +
for O +
clonidine O -
's O +
detrimental O +
effects O +
on O +
cardiovascular O +
function O -
. O +

Recurrent O +
use O +
of O +
newer O +
oral O +
contraceptives O +
and O +
the O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease -
. O +

The O +
epidemiological O +
studies O +
that O +
assessed O +
the O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease +
( O -
VTE B-Disease -
) O +
associated O +
with O +
newer O +
oral O +
contraceptives O +
( O -
OC O -
) O +
did O +
not O +
distinguish O +
between O +
patterns O +
of O +
OC O +
use O -
, O +
namely O +
first O -
- O -
time O +
users O -
, O +
repeaters O +
and O +
switchers O -
. O +

Data O +
from O +
a O +
Transnational O +
case O -
- O -
control O +
study O +
were O +
used O +
to O +
assess O +
the O +
risk O +
of O +
VTE B-Disease +
for O +
the O +
latter O +
patterns O +
of O +
use O -
, O +
while O +
accounting O +
for O +
duration O +
of O +
use O -
. O +

Over O +
the O +
period O +
1993 O -
- O -
1996 O -
, O +
551 O +
cases O +
of O +
VTE B-Disease +
were O +
identified O +
in O +
Germany O +
and O +
the O +
UK O +
along O +
with O +
2066 O +
controls O -
. O +

Totals O +
of O +
128 O +
cases O +
and O +
650 O +
controls O +
were O +
analysed O +
for O +
repeat O +
use O +
and O +
135 O +
cases O +
and O +
622 O +
controls O +
for O +
switching O +
patterns O -
. O +

The O +
adjusted O +
rate O +
ratio O +
of O +
VTE B-Disease +
for O +
repeat O +
users O +
of O +
third O +
generation O +
OC O +
was O +
0.6 O +
( O -
95 O -
% O +
CI:0.3 O -
- O -
1.2 O -
) O +
relative O +
to O +
repeat O +
users O +
of O +
second O +
generation O +
pills O -
, O +
whereas O +
it O +
was O +
1.3 O +
( O -
95 O -
% O +
CI:0.7 O -
- O -
2.4 O -
) O +
for O +
switchers O +
from O +
second O +
to O +
third O +
generation O +
pills O +
relative O +
to O +
switchers O +
from O +
third O +
to O +
second O +
generation O +
pills O -
. O +

We O +
conclude O +
that O +
second O +
and O +
third O +
generation O +
agents O +
are O +
associated O +
with O +
equivalent O +
risks O +
of O +
VTE B-Disease +
when O +
the O +
same O +
agent O +
is O +
used O +
repeatedly O +
after O +
interruption O +
periods O +
or O +
when O +
users O +
are O +
switched O +
between O +
the O +
two O +
generations O +
of O +
pills O -
. O +

These O +
analyses O +
suggest O +
that O +
the O +
higher O +
risk O +
observed O +
for O +
the O +
newer O +
OC O +
in O +
other O +
studies O +
may O +
be O +
the O +
result O +
of O +
inadequate O +
comparisons O +
of O +
pill O +
users O +
with O +
different O +
patterns O +
of O +
pill O +
use O -
. O +

Differential O +
effects O +
of O +
systemically O +
administered O +
ketamine O +
and O +
lidocaine O +
on O +
dynamic O +
and O +
static O +
hyperalgesia B-Disease +
induced O +
by O +
intradermal O +
capsaicin O +
in O +
humans O -
. O +

We O +
have O +
examined O +
the O +
effect O +
of O +
systemic O +
administration O +
of O +
ketamine O +
and O +
lidocaine O +
on O +
brush O -
- O -
evoked O +
( O -
dynamic O -
) O +
pain B-Disease +
and O +
punctate O -
- O -
evoked O +
( O -
static O -
) O +
hyperalgesia B-Disease +
induced O +
by O +
capsaicin O -
. O +

In O +
a O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
crossover O +
study O -
, O +
we O +
studied O +
12 O +
volunteers O +
in O +
three O +
experiments O -
. O +

Capsaicin O +
100 O +
micrograms O +
was O +
injected O +
intradermally O +
on O +
the O +
volar O +
forearm O +
followed O +
by O +
an O +
i.v O -
. O +

infusion O +
of O +
ketamine O +
( O -
bolus O +
0.1 O +
mg O +
kg-1 O +
over O +
10 O +
min O +
followed O +
by O +
infusion O +
of O +
7 O +
micrograms O +
kg-1 O +
min-1 O -
) O -
, O +
lidocaine O +
5 O +
mg O +
kg-1 O +
or O +
saline O +
for O +
50 O +
min O -
. O +

Infusion O +
started O +
15 O +
min O +
after O +
injection O +
of O +
capsaicin O -
. O +

The O +
following O +
were O +
measured O -
: O +
spontaneous O +
pain B-Disease -
, O +
pain B-Disease +
evoked O +
by O +
punctate O +
and O +
brush O +
stimuli O +
( O -
VAS O -
) O -
, O +
and O +
areas O +
of O +
brush O -
- O -
evoked O +
and O +
punctate O -
- O -
evoked O +
hyperalgesia B-Disease -
. O +

Ketamine O +
reduced O +
both O +
the O +
area O +
of O +
brush O -
- O -
evoked O +
and O +
punctate O -
- O -
evoked O +
hyperalgesia B-Disease +
significantly O +
and O +
it O +
tended O +
to O +
reduce O +
brush O -
- O -
evoked O +
pain B-Disease -
. O +

Lidocaine O +
reduced O +
the O +
area O +
of O +
punctate O -
- O -
evoked O +
hyperalgesia B-Disease +
significantly O -
. O +

It O +
tended O +
to O +
reduce O +
VAS O +
scores O +
of O +
spontaneous O +
pain B-Disease +
but O +
had O +
no O +
effect O +
on O +
evoked O +
pain B-Disease -
. O +

The O +
differential O +
effects O +
of O +
ketamine O +
and O +
lidocaine O +
on O +
static O +
and O +
dynamic O +
hyperalgesia B-Disease +
suggest O +
that O +
the O +
two O +
types O +
of O +
hyperalgesia B-Disease +
are O +
mediated O +
by O +
separate O +
mechanisms O +
and O +
have O +
a O +
distinct O +
pharmacology O -
. O +

Treatment O +
of O +
tacrolimus O -
- O -
related O +
adverse O +
effects O +
by O +
conversion O +
to O +
cyclosporine O +
in O +
liver O +
transplant O +
recipients O -
. O +

When O +
tacrolimus O +
side O +
effects O +
persist O +
despite O +
dose O +
reduction O -
, O +
conversion O +
to O +
cyclosporine O -
- O -
based O +
immunosuppression O +
( O -
CyA O -
) O +
is O +
necessary O -
. O +

We O +
characterized O +
tacrolimus O +
side O +
effects O +
that O +
warranted O +
discontinuation O +
of O +
the O +
drug O -
, O +
and O +
outcomes O +
after O +
conversion O -
. O +

Of O +
388 O +
liver O +
recipients O +
who O +
received O +
tacrolimus O +
as O +
primary O +
immunosuppression O -
, O +
70 O +
required O +
conversion O +
to O +
CyA. O +
We O +
recorded O +
indication O +
for O +
conversion O -
, O +
whether O +
conversion O +
was O +
early O +
or O +
late O +
after O +
transplantation O -
, O +
tacrolimus O +
dose O +
and O +
trough O +
blood O +
level O +
at O +
conversion O -
, O +
and O +
incidence O +
of O +
rejection O +
after O +
conversion O -
. O +

Conversion O +
was O +
early O +
in O +
29 O +
patients O +
( O -
41.4 O -
% O -
) O +
and O +
late O +
in O +
41 O +
( O -
58.6 O -
% O -
) O -
. O +

Indications O +
for O +
early O +
conversion O +
were O +
neurotoxicity B-Disease +
( O -
20 O -
) O -
, O +
( B-Disease -
insulin I-Disease -
- I-Disease -
dependent I-Disease -
) I-Disease +
diabetes I-Disease +
mellitus I-Disease +
( O -
IDDM B-Disease -
) O +
( O -
5 O -
) O -
, O +
nephrotoxicity B-Disease +
( O -
3 O -
) O -
, O +
gastrointestinal B-Disease +
( I-Disease -
GI I-Disease -
) I-Disease +
toxicity I-Disease +
( O -
6 O -
) O -
, O +
and O +
cardiomyopathy B-Disease +
( O -
1 O -
) O -
, O +
and O +
for O +
late O +
conversion O +
were O +
neurotoxicity B-Disease +
( O -
15 O -
) O -
, O +
IDDM B-Disease +
( O -
12 O -
) O -
, O +
nephrotoxicity B-Disease +
( O -
3 O -
) O -
, O +
GI B-Disease +
toxicity I-Disease +
( O -
5 O -
) O -
, O +
hepatotoxicity B-Disease +
( O -
6 O -
) O -
, O +
post B-Disease -
- I-Disease -
transplant I-Disease +
lmphoproliferate I-Disease +
disease I-Disease +
( O -
PTLD B-Disease -
) O +
( O -
2 O -
) O -
, O +
cardiomyopathy B-Disease +
( O -
1 O -
) O -
, O +
hemolytic B-Disease +
anemia I-Disease +
( O -
1 O -
) O -
, O +
and O +
pruritus B-Disease +
( O -
1 O -
) O -
. O +

All O +
early O -
- O -
conversion O +
patients O +
showed O +
improvement O -
/ O -
resolution O +
of O +
symptoms O -
. O +

Among O +
late O -
- O -
conversion O +
patients O -
, O +
37 O +
( O -
90.2 O -
% O -
) O +
had O +
improvement O -
/ O -
resolution O -
; O +
in O +
4 O +
( O -
9.8 O -
% O -
) O -
, O +
adverse O +
effects O +
persisted O -
. O +

The O +
overall O +
rejection O +
rate O +
was O +
30 O -
% O -
. O +

Sixty O -
- O -
two O +
patients O +
( O -
88.6 O -
% O -
) O +
are O +
alive O +
with O +
functioning O +
grafts O +
686 O +
+ O -
/- O +

362 O +
days O +
( O -
range O -
, O +
154 O -
- O -
1433 O +
days O -
) O +
after O +
conversion O -
. O +

When O +
tacrolimus O +
side O +
effects O +
are O +
unresponsive O +
to O +
dose O +
reduction O -
, O +
conversion O +
to O +
CyA O +
can O +
be O +
accomplished O +
safely O -
, O +
with O +
no O +
increased O +
risk O +
of O +
rejection O +
and O +
excellent O +
long O -
- O -
term O +
outcome O -
. O +

Development O +
of O +
apomorphine O -
- O -
induced O +
aggressive B-Disease +
behavior I-Disease -
: O +
comparison O +
of O +
adult O +
male O +
and O +
female O +
Wistar O +
rats O -
. O +

The O +
development O +
of O +
apomorphine O -
- O -
induced O +
( O -
1.0 O +
mg O -
/ O -
kg O +
s.c O -
. O +

once O +
daily O -
) O +
aggressive B-Disease +
behavior I-Disease +
of O +
adult O +
male O +
and O +
female O +
Wistar O +
rats O +
obtained O +
from O +
the O +
same O +
breeder O +
was O +
studied O +
in O +
two O +
consecutive O +
sets O -
. O +

In O +
male O +
animals O -
, O +
repeated O +
apomorphine O +
treatment O +
induced O +
a O +
gradual O +
development O +
of O +
aggressive B-Disease +
behavior I-Disease +
as O +
evidenced O +
by O +
the O +
increased O +
intensity O +
of O +
aggressiveness B-Disease +
and O +
shortened O +
latency O +
before O +
the O +
first O +
attack O +
toward O +
the O +
opponent O -
. O +

In O +
female O +
rats O -
, O +
only O +
a O +
weak O +
tendency O +
toward O +
aggressiveness B-Disease +
was O +
found O -
. O +

In O +
conclusion O -
, O +
the O +
present O +
study O +
demonstrates O +
gender O +
differences O +
in O +
the O +
development O +
of O +
the O +
apomorphine O -
- O -
induced O +
aggressive B-Disease +
behavior I-Disease +
and O +
indicates O +
that O +
the O +
female O +
rats O +
do O +
not O +
fill O +
the O +
validation O +
criteria O +
for O +
use O +
in O +
this O +
method O -
. O +

Intracranial B-Disease +
aneurysms I-Disease +
and O +
cocaine B-Disease +
abuse I-Disease -
: O +
analysis O +
of O +
prognostic O +
indicators O -
. O +

OBJECTIVE O -
: O +
The O +
outcome O +
of O +
subarachnoid B-Disease +
hemorrhage I-Disease +
associated O +
with O +
cocaine B-Disease +
abuse I-Disease +
is O +
reportedly O +
poor O -
. O +

However O -
, O +
no O +
study O +
in O +
the O +
literature O +
has O +
reported O +
the O +
use O +
of O +
a O +
statistical O +
model O +
to O +
analyze O +
the O +
variables O +
that O +
influence O +
outcome O -
. O +

METHODS O -
: O +
A O +
review O +
of O +
admissions O +
during O +
a O +
6-year O +
period O +
revealed O +
14 O +
patients O +
with O +
cocaine O -
- O -
related O +
aneurysms B-Disease -
. O +

This O +
group O +
was O +
compared O +
with O +
a O +
control O +
group O +
of O +
135 O +
patients O +
with O +
ruptured B-Disease +
aneurysms I-Disease +
and O +
no O +
history O +
of O +
cocaine B-Disease +
abuse I-Disease -
. O +

Age O +
at O +
presentation O -
, O +
time O +
of O +
ictus O +
after O +
intoxication O -
, O +
Hunt O +
and O +
Hess O +
grade O +
of O +
subarachnoid B-Disease +
hemorrhage I-Disease -
, O +
size O +
of O +
the O +
aneurysm B-Disease -
, O +
location O +
of O +
the O +
aneurysm B-Disease -
, O +
and O +
the O +
Glasgow O +
Outcome O +
Scale O +
score O +
were O +
assessed O +
and O +
compared O -
. O +

RESULTS O -
: O +
The O +
patients O +
in O +
the O +
study O +
group O +
were O +
significantly O +
younger O +
than O +
the O +
patients O +
in O +
the O +
control O +
group O +
( O -
P O +
< O +
0.002 O -
) O -
. O +

In O +
patients O +
in O +
the O +
study O +
group O -
, O +
all O +
aneurysms B-Disease +
were O +
located O +
in O +
the O +
anterior O +
circulation O -
. O +

The O +
majority O +
of O +
these O +
aneurysms B-Disease +
were O +
smaller O +
than O +
those O +
of O +
the O +
control O +
group O +
( O -
8 O +
+ O -
/- O +

6.08 O +
mm O +
versus O +
11 O +
+ O -
/- O +

5.4 O +
mm O -
; O +
P O +
= O +
0.05 O -
) O -
. O +

The O +
differences O +
in O +
mortality O +
and O +
morbidity O +
between O +
the O +
two O +
groups O +
were O +
not O +
significant O -
. O +

Hunt O +
and O +
Hess O +
grade O +
( O -
P O +
< O +
0.005 O -
) O +
and O +
age O +
( O -
P O +
< O +
0.007 O -
) O +
were O +
significant O +
predictors O +
of O +
outcome O +
for O +
the O +
patients O +
with O +
cocaine O -
- O -
related O +
aneurysms B-Disease -
. O +

CONCLUSION O -
: O +
Cocaine O +
use O +
predisposed O +
aneurysmal B-Disease +
rupture I-Disease +
at O +
a O +
significantly O +
earlier O +
age O +
and O +
in O +
much O +
smaller O +
aneurysms B-Disease -
. O +

Contrary O +
to O +
the O +
published O +
literature O -
, O +
this O +
group O +
did O +
reasonably O +
well O +
with O +
aggressive O +
management O -
. O +

Effect O +
of O +
intravenous O +
nimodipine O +
on O +
blood O +
pressure O +
and O +
outcome O +
after O +
acute B-Disease +
stroke I-Disease -
. O +

BACKGROUND O +
AND O +
PURPOSE O -
: O +
The O +
Intravenous O +
Nimodipine O +
West O +
European O +
Stroke B-Disease +
Trial O +
( O -
INWEST O -
) O +
found O +
a O +
correlation O +
between O +
nimodipine O -
- O -
induced O +
reduction B-Disease +
in I-Disease +
blood I-Disease +
pressure I-Disease +
( O -
BP O -
) O +
and O +
an O +
unfavorable O +
outcome O +
in O +
acute B-Disease +
stroke I-Disease -
. O +

We O +
sought O +
to O +
confirm O +
this O +
correlation O +
with O +
and O +
without O +
adjustment O +
for O +
prognostic O +
variables O +
and O +
to O +
investigate O +
outcome O +
in O +
subgroups O +
with O +
increasing O +
levels O +
of O +
BP B-Disease +
reduction I-Disease -
. O +

METHODS O -
: O +
Patients O +
with O +
a O +
clinical O +
diagnosis O +
of O +
ischemic B-Disease +
stroke I-Disease +
( O -
within O +
24 O +
hours O -
) O +
were O +
consecutively O +
allocated O +
to O +
receive O +
placebo O +
( O -
n=100 O -
) O -
, O +
1 O +
mg O -
/ O -
h O +
( O -
low O -
- O -
dose O -
) O +
nimodipine O +
( O -
n=101 O -
) O -
, O +
or O +
2 O +
mg O -
/ O -
h O +
( O -
high O -
- O -
dose O -
) O +
nimodipine O +
( O -
n=94 O -
) O -
. O +

The O +
correlation O +
between O +
average O +
BP O +
change O +
during O +
the O +
first O +
2 O +
days O +
and O +
the O +
outcome O +
at O +
day O +
21 O +
was O +
analyzed O -
. O +

RESULTS O -
: O +
Two O +
hundred O +
sixty O -
- O -
five O +
patients O +
were O +
included O +
in O +
this O +
analysis O +
( O -
n=92 O -
, O +
93 O -
, O +
and O +
80 O +
for O +
placebo O -
, O +
low O +
dose O -
, O +
and O +
high O +
dose O -
, O +
respectively O -
) O -
. O +

Nimodipine O +
treatment O +
resulted O +
in O +
a O +
statistically O +
significant O +
reduction B-Disease +
in I-Disease +
systolic I-Disease +
BP I-Disease +
( O -
SBP O -
) O +
and O +
diastolic O +
BP O +
( O -
DBP O -
) O +
from O +
baseline O +
compared O +
with O +
placebo O +
during O +
the O +
first O +
few O +
days O -
. O +

In O +
multivariate O +
analysis O -
, O +
a O +
significant O +
correlation O +
between O +
DBP B-Disease +
reduction I-Disease +
and O +
worsening O +
of O +
the O +
neurological O +
score O +
was O +
found O +
for O +
the O +
high O -
- O -
dose O +
group O +
( O -
beta=0.49 O -
, O +
P=0 O -
. O +
048 O -
) O -
. O +

Patients O +
with O +
a O +
DBP B-Disease +
reduction I-Disease +
of O +
> O +
or O +
= O -
20 O -
% O +
in O +
the O +
high O -
- O -
dose O +
group O +
had O +
a O +
significantly O +
increased O +
adjusted O +
OR O +
for O +
the O +
compound O +
outcome O +
variable O +
death B-Disease +
or O +
dependency O +
( O -
Barthel O +
Index O +
< O -
60 O -
) O +
( O -
n O -
/ O -
N=25 O -
/ O -
26 O -
, O +
OR O +
10 O -
. O +
16 O -
, O +
95 O -
% O +
CI O +
1.02 O +
to O +
101.74 O -
) O +
and O +
death B-Disease +
alone O +
( O -
n O -
/ O -
N=9 O -
/ O -
26 O -
, O +
OR O +
4.336 O -
, O +
95 O -
% O +
CI O +
1.131 O +
16.619 O -
) O +
compared O +
with O +
all O +
placebo O +
patients O +
( O -
n O -
/ O -
N=62 O -
/ O -
92 O +
and O +
14 O -
/ O -
92 O -
, O +
respectively O -
) O -
. O +

There O +
was O +
no O +
correlation O +
between O +
SBP O +
change O +
and O +
outcome O -
. O +

CONCLUSIONS O -
: O +
DBP O -
, O +
but O +
not O +
SBP O -
, O +
reduction O +
was O +
associated O +
with O +
neurological O +
worsening O +
after O +
the O +
intravenous O +
administration O +
of O +
high O -
- O -
dose O +
nimodipine O +
after O +
acute B-Disease +
stroke I-Disease -
. O +

For O +
low O -
- O -
dose O +
nimodipine O -
, O +
the O +
results O +
were O +
not O +
conclusive O -
. O +

These O +
results O +
do O +
not O +
confirm O +
or O +
exclude O +
a O +
neuroprotective O +
property O +
of O +
nimodipine O -
. O +

Neonatal O +
pyridoxine O +
responsive O +
convulsions B-Disease +
due O +
to O +
isoniazid O +
therapy O -
. O +

A O +
17-day O -
- O -
old O +
infant O +
on O +
isoniazid O +
therapy O +
13 O +
mg O -
/ O -
kg O +
daily O +
from O +
birth O +
because O +
of O +
maternal O +
tuberculosis B-Disease +
was O +
admitted O +
after O +
4 O +
days O +
of O +
clonic B-Disease +
fits I-Disease -
. O +

No O +
underlying O +
infective O +
or O +
biochemical O +
cause O +
could O +
be O +
found O -
. O +

The O +
fits B-Disease +
ceased O +
within O +
4 O +
hours O +
of O +
administering O +
intramuscular O +
pyridoxine O -
, O +
suggesting O +
an O +
aetiology O +
of O +
pyridoxine O +
deficiency O +
secondary O +
to O +
isoniazid O +
medication O -
. O +

Ketamine O +
sedation O +
for O +
the O +
reduction O +
of O +
children O -
's O +
fractures B-Disease +
in O +
the O +
emergency O +
department O -
. O +

BACKGROUND O -
: O +
There O +
recently O +
has O +
been O +
a O +
resurgence O +
in O +
the O +
utilization O +
of O +
ketamine O -
, O +
a O +
unique O +
anesthetic O -
, O +
for O +
emergency O -
- O -
department O +
procedures O +
requiring O +
sedation O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
examine O +
the O +
safety O +
and O +
efficacy O +
of O +
ketamine O +
for O +
sedation O +
in O +
the O +
treatment O +
of O +
children O -
's O +
fractures B-Disease +
in O +
the O +
emergency O +
department O -
. O +

METHODS O -
: O +
One O +
hundred O +
and O +
fourteen O +
children O +
( O -
average O +
age O -
, O +
5.3 O +
years O -
; O +
range O -
, O +
twelve O +
months O +
to O +
ten O +
years O +
and O +
ten O +
months O -
) O +
who O +
underwent O +
closed O +
reduction O +
of O +
an O +
isolated O +
fracture B-Disease +
or O +
dislocation B-Disease +
in O +
the O +
emergency O +
department O +
at O +
a O +
level O -
- O -
I O +
trauma B-Disease +
center O +
were O +
prospectively O +
evaluated O -
. O +

Ketamine O +
hydrochloride O +
was O +
administered O +
intravenously O +
( O -
at O +
a O +
dose O +
of O +
two O +
milligrams O +
per O +
kilogram O +
of O +
body O +
weight O -
) O +
in O +
ninety O -
- O -
nine O +
of O +
the O +
patients O +
and O +
intramuscularly O +
( O -
at O +
a O +
dose O +
of O +
four O +
milligrams O +
per O +
kilogram O +
of O +
body O +
weight O -
) O +
in O +
the O +
other O +
fifteen O -
. O +

A O +
board O -
- O -
certified O +
emergency O +
physician O +
skilled O +
in O +
airway O +
management O +
supervised O +
administration O +
of O +
the O +
anesthetic O -
, O +
and O +
the O +
patients O +
were O +
monitored O +
by O +
a O +
registered O +
nurse O -
. O +

Any O +
pain B-Disease +
during O +
the O +
reduction O +
was O +
rated O +
by O +
the O +
orthopaedic O +
surgeon O +
treating O +
the O +
patient O +
according O +
to O +
the O +
Children O -
's O +
Hospital O +
of O +
Eastern O +
Ontario O +
Pain B-Disease +
Scale O +
( O -
CHEOPS O -
) O -
. O +

RESULTS O -
: O +
The O +
average O +
time O +
from O +
intravenous O +
administration O +
of O +
ketamine O +
to O +
manipulation O +
of O +
the O +
fracture B-Disease +
or O +
dislocation B-Disease +
was O +
one O +
minute O +
and O +
thirty O -
- O -
six O +
seconds O +
( O -
range O -
, O +
twenty O +
seconds O +
to O +
five O +
minutes O -
) O -
, O +
and O +
the O +
average O +
time O +
from O +
intramuscular O +
administration O +
to O +
manipulation O +
was O +
four O +
minutes O +
and O +
forty O -
- O -
two O +
seconds O +
( O -
range O -
, O +
sixty O +
seconds O +
to O +
fifteen O +
minutes O -
) O -
. O +

The O +
average O +
score O +
according O +
to O +
the O +
Children O -
's O +
Hospital O +
of O +
Eastern O +
Ontario O +
Pain B-Disease +
Scale O +
was O +
6.4 O +
points O +
( O -
range O -
, O +
5 O +
to O +
10 O +
points O -
) O -
, O +
reflecting O +
minimal O +
or O +
no O +
pain B-Disease +
during O +
fracture B-Disease +
reduction O -
. O +

Adequate O +
fracture B-Disease +
reduction O +
was O +
obtained O +
in O +
111 O +
of O +
the O +
children O -
. O +

Ninety O -
- O -
nine O +
percent O +
( O -
sixty O -
- O -
eight O -
) O +
of O +
the O +
sixty O -
- O -
nine O +
parents O +
present O +
during O +
the O +
reduction O +
were O +
pleased O +
with O +
the O +
sedation O +
and O +
would O +
allow O +
it O +
to O +
be O +
used O +
again O +
in O +
a O +
similar O +
situation O -
. O +

Patency O +
of O +
the O +
airway O +
and O +
independent O +
respiration O +
were O +
maintained O +
in O +
all O +
of O +
the O +
patients O -
. O +

Blood O +
pressure O +
and O +
heart O +
rate O +
remained O +
stable O -
. O +

Minor O +
side O +
effects O +
included O +
nausea B-Disease +
( O -
thirteen O +
patients O -
) O -
, O +
emesis B-Disease +
( O -
eight O +
of O +
the O +
thirteen O +
patients O +
with O +
nausea B-Disease -
) O -
, O +
clumsiness B-Disease +
( O -
evident O +
as O +
ataxic B-Disease +
movements I-Disease +
in O +
ten O +
patients O -
) O -
, O +
and O +
dysphoric B-Disease +
reaction I-Disease +
( O -
one O +
patient O -
) O -
. O +

No O +
long O -
- O -
term O +
sequelae O +
were O +
noted O -
, O +
and O +
no O +
patients O +
had O +
hallucinations B-Disease +
or O +
nightmares O -
. O +

CONCLUSIONS O -
: O +
Ketamine O +
reliably O -
, O +
safely O -
, O +
and O +
quickly O +
provided O +
adequate O +
sedation O +
to O +
effectively O +
facilitate O +
the O +
reduction O +
of O +
children O -
's O +
fractures B-Disease +
in O +
the O +
emergency O +
department O +
at O +
our O +
institution O -
. O +

Ketamine O +
should O +
only O +
be O +
used O +
in O +
an O +
environment O +
such O +
as O +
the O +
emergency O +
department O -
, O +
where O +
proper O +
one O -
- O -
on O -
- O -
one O +
monitoring O +
is O +
used O +
and O +
board O -
- O -
certified O +
physicians O +
skilled O +
in O +
airway O +
management O +
are O +
directly O +
involved O +
in O +
the O +
care O +
of O +
the O +
patient O -
. O +

Prednisolone O -
- O -
induced O +
muscle B-Disease +
dysfunction I-Disease +
is O +
caused O +
more O +
by O +
atrophy B-Disease +
than O +
by O +
altered O +
acetylcholine O +
receptor O +
expression O -
. O +

Large O +
doses O +
of O +
glucocorticoids O +
can O +
alter O +
muscle O +
physiology O +
and O +
susceptibility O +
to O +
neuromuscular O +
blocking O +
drugs O +
by O +
mechanisms O +
not O +
clearly O +
understood O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
moderate O +
and O +
large O +
doses O +
of O +
prednisolone O +
on O +
muscle O +
function O +
and O +
pharmacology O -
, O +
and O +
their O +
relationship O +
to O +
changes O +
in O +
muscle O +
size O +
and O +
acetylcholine O +
receptor O +
( O -
AChR O -
) O +
expression O -
. O +

With O +
institutional O +
approval O -
, O +
35 O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
randomly O +
allocated O +
to O +
receive O +
daily O +
subcutaneous O +
doses O +
of O +
10 O +
mg O -
/ O -
kg O +
prednisolone O +
( O -
P10 O +
group O -
) O -
, O +
100 O +
mg O -
/ O -
kg O +
prednisolone O +
( O -
P100 O +
group O -
) O -
, O +
or O +
an O +
equal O +
volume O +
of O +
saline O +
( O -
S O +
group O -
) O +
for O +
7 O +
days O -
. O +

A O +
fourth O +
group O +
of O +
rats O +
was O +
pair O +
fed O +
( O -
food O +
restricted O -
) O +
with O +
the O +
P100 O +
rats O +
for O +
7 O +
days O +
( O -
FR O +
group O -
) O -
. O +

On O +
Day O +
8 O -
, O +
the O +
nerve O -
- O -
evoked O +
peak O +
twitch O +
tensions O -
, O +
tetanic B-Disease +
tensions O -
, O +
and O +
fatigability O -
, O +
and O +
the O +
dose O -
- O -
response O +
curves O +
of O +
d O -
- O -
tubocurarine O +
in O +
the O +
tibialis O +
cranialis O +
muscle O +
were O +
measured O +
in O +
vivo O +
and O +
related O +
to O +
muscle O +
mass O +
or O +
expression O +
of O +
AChRs O -
. O +

Rate O +
of O +
body O +
weight O +
gain O +
was O +
depressed O +
in O +
the O +
P100 O -
, O +
FR O -
, O +
and O +
P10 O +
groups O +
compared O +
with O +
the O +
S O +
group O -
. O +

Tibialis O +
muscle O +
mass O +
was O +
smaller O +
in O +
the O +
P100 O +
group O +
than O +
in O +
the O +
P10 O +
or O +
S O +
groups O -
. O +

The O +
evoked O +
peak O +
twitch O +
and O +
tetanic B-Disease +
tensions O +
were O +
less O +
in O +
the O +
P100 O +
group O +
than O +
in O +
the O +
P10 O +
or O +
S O +
groups O -
, O +
however O -
, O +
tension O +
per O +
milligram O +
of O +
muscle O +
mass O +
was O +
greater O +
in O +
the O +
P100 O +
group O +
than O +
in O +
the O +
S O +
group O -
. O +

The O +
50 O -
% O +
effective O +
dose O +
of O +
d O -
- O -
tubocurarine O +
( O -
microg O -
/ O -
kg O -
) O +
in O +
the O +
tibialis O +
muscle O +
was O +
smaller O +
in O +
the O +
P10 O +
( O -
33.6 O +
+ O -
/- O +

5.4 O -
) O +
than O +
in O +
the O +
S O +
( O -
61.9 O +
+ O -
/- O +
5.0 O -
) O +
or O +
the O +
P100 O +
( O -
71.3 O +
+ O -
/- O +

9.6 O -
) O +
groups O -
. O +

AChR O +
expression O +
was O +
less O +
in O +
the O +
P10 O +
group O +
than O +
in O +
the O +
S O +
group O -
. O +

The O +
evoked O +
tensions O +
correlated O +
with O +
muscle O +
mass O +
( O -
r O -
( O -
2 O -
) O +
= O +
0.32 O -
, O +
P O +
< O +
0.001 O -
) O -
, O +
however O -
, O +
not O +
with O +
expression O +
of O +
AChR. O +
The O +
50 O -
% O +
effective O +
dose O +
of O +
d O -
- O -
tubocurarine O +
did O +
not O +
correlate O +
with O +
muscle O +
mass O +
or O +
AChR O +
expression O -
. O +

Our O +
results O +
suggest O +
that O +
the O +
neuromuscular B-Disease +
dysfunction I-Disease +
after O +
prednisolone O +
is O +
dose O -
- O -
dependent O -
, O +
and O +
derives O +
primarily O +
from O +
muscle B-Disease +
atrophy I-Disease +
and O +
derives O +
less O +
so O +
from O +
changes O +
in O +
AChR O +
expression O -
. O +

IMPLICATIONS O -
: O +
The O +
mechanisms O +
by O +
which O +
chronic O +
glucocorticoid O +
therapy O +
alters O +
neuromuscular O +
physiology O +
and O +
pharmacology O +
are O +
unclear O -
. O +

We O +
suggest O +
that O +
the O +
observed O +
effects O +
are O +
dose O -
- O -
dependent O +
and O +
derive O +
primarily O +
from O +
muscle B-Disease +
atrophy I-Disease +
and O +
derive O +
less O +
from O +
changes O +
in O +
acetylcholine O +
receptor O +
expression O -
. O +

Cyclosporine O +
and O +
tacrolimus O -
- O -
associated O +
thrombotic B-Disease +
microangiopathy I-Disease -
. O +

The O +
development O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
( O -
TMA B-Disease -
) O +
associated O +
with O +
the O +
use O +
of O +
cyclosporine O +
has O +
been O +
well O +
documented O -
. O +

Treatments O +
have O +
included O +
discontinuation O +
or O +
reduction O +
of O +
cyclosporine O +
dose O +
with O +
or O +
without O +
concurrent O +
plasma O +
exchange O -
, O +
plasma O +
infusion O -
, O +
anticoagulation O -
, O +
and O +
intravenous O +
immunoglobulin O +
G O +
infusion O -
. O +

However O -
, O +
for O +
recipients O +
of O +
organ O +
transplantation O -
, O +
removing O +
the O +
inciting O +
agent O +
is O +
not O +
without O +
the O +
attendant O +
risk O +
of O +
precipitating O +
acute O +
rejection O +
and O +
graft O +
loss O -
. O +

The O +
last O +
decade O +
has O +
seen O +
the O +
emergence O +
of O +
tacrolimus O +
as O +
a O +
potent O +
immunosuppressive O +
agent O +
with O +
mechanisms O +
of O +
action O +
virtually O +
identical O +
to O +
those O +
of O +
cyclosporine O -
. O +

As O +
a O +
result O -
, O +
switching O +
to O +
tacrolimus O +
has O +
been O +
reported O +
to O +
be O +
a O +
viable O +
therapeutic O +
option O +
in O +
the O +
setting O +
of O +
cyclosporine O -
- O -
induced O +
TMA B-Disease -
. O +

With O +
the O +
more O +
widespread O +
application O +
of O +
tacrolimus O +
in O +
organ O +
transplantation O -
, O +
tacrolimus O -
- O -
associated O +
TMA B-Disease +
has O +
also O +
been O +
recognized O -
. O +

However O -
, O +
literature O +
regarding O +
the O +
incidence O +
of O +
the O +
recurrence O +
of O +
TMA B-Disease +
in O +
patients O +
exposed O +
sequentially O +
to O +
cyclosporine O +
and O +
tacrolimus O +
is O +
limited O -
. O +

We O +
report O +
a O +
case O +
of O +
a O +
living O +
donor O +
renal O +
transplant O +
recipient O +
who O +
developed O +
cyclosporine O -
- O -
induced O +
TMA B-Disease +
that O +
responded O +
to O +
the O +
withdrawal O +
of O +
cyclosporine O +
in O +
conjunction O +
with O +
plasmapheresis O +
and O +
fresh O +
frozen O +
plasma O +
replacement O +
therapy O -
. O +

Introduction O +
of O +
tacrolimus O +
as O +
an O +
alternative O +
immunosuppressive O +
agent O +
resulted O +
in O +
the O +
recurrence O +
of O +
TMA B-Disease +
and O +
the O +
subsequent O +
loss O +
of O +
the O +
renal O +
allograft O -
. O +

Patients O +
who O +
are O +
switched O +
from O +
cyclosporine O +
to O +
tacrolimus O +
or O +
vice O +
versa O +
should O +
be O +
closely O +
monitored O +
for O +
the O +
signs O +
and O +
symptoms O +
of O +
recurrent O +
TMA B-Disease -
. O +

Pain B-Disease +
responses O +
in O +
methadone O -
- O -
maintained O +
opioid O +
abusers O -
. O +

Providing O +
pain B-Disease +
management O +
for O +
known O +
opioid O +
abusers O +
is O +
a O +
challenging O +
clinical O +
task O -
, O +
in O +
part O +
because O +
little O +
is O +
known O +
about O +
their O +
pain B-Disease +
experience O +
and O +
analgesic O +
requirements O -
. O +

This O +
study O +
was O +
designed O +
to O +
describe O +
pain B-Disease +
tolerance O +
and O +
analgesic O +
response O +
in O +
a O +
sample O +
of O +
opioid B-Disease +
addicts I-Disease +
stabilized O +
in O +
methadone O -
- O -
maintenance O +
( O -
MM O -
) O +
treatment O +
( O -
n O +
= O +
60 O -
) O +
in O +
comparison O +
to O +
matched O +
nondependent O +
control O +
subjects O +
( O -
n O +
= O +
60 O -
) O -
. O +

By O +
using O +
a O +
placebo O -
- O -
controlled O -
, O +
two O -
- O -
way O +
factorial O +
design O -
, O +
tolerance O +
to O +
cold O -
- O -
pressor O +
( O -
CP O -
) O +
pain B-Disease +
was O +
examined O -
, O +
both O +
before O +
and O +
after O +
oral O +
administration O +
of O +
therapeutic O +
doses O +
of O +
common O +
opioid O +
( O -
hydromorphone O +
2 O +
mg O -
) O +
and O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
( O -
ketorolac O +
10 O +
mg O -
) O +
analgesic O +
agents O -
. O +

Results O +
showed O +
that O +
MM O +
individuals O +
were O +
significantly O +
less O +
tolerant O +
of O +
CP O +
pain B-Disease +
than O +
control O +
subjects O -
, O +
replicating O +
previous O +
work O -
. O +

Analgesic O +
effects O +
were O +
significant O +
neither O +
for O +
medication O +
nor O +
group O -
. O +

These O +
data O +
indicate O +
that O +
MM O +
opioid O +
abusers O +
represent O +
a O +
pain B-Disease -
- I-Disease -
intolerant I-Disease +
subset O +
of O +
clinical O +
patients O -
. O +

Their O +
complaints O +
of O +
pain B-Disease +
should O +
be O +
evaluated O +
seriously O +
and O +
managed O +
aggressively O -
. O +

Analgesic O +
effect O +
of O +
intravenous O +
ketamine O +
in O +
cancer B-Disease +
patients O +
on O +
morphine O +
therapy O -
: O +
a O +
randomized O -
, O +
controlled O -
, O +
double O -
- O -
blind O -
, O +
crossover O -
, O +
double O -
- O -
dose O +
study O -
. O +

Pain B-Disease +
not O +
responsive O +
to O +
morphine O +
is O +
often O +
problematic O -
. O +

Animal O +
and O +
clinical O +
studies O +
have O +
suggested O +
that O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
antagonists O -
, O +
such O +
as O +
ketamine O -
, O +
may O +
be O +
effective O +
in O +
improving O +
opioid O +
analgesia O +
in O +
difficult O +
pain B-Disease +
syndromes O -
, O +
such O +
as O +
neuropathic B-Disease +
pain I-Disease -
. O +

A O +
slow O +
bolus O +
of O +
subhypnotic O +
doses O +
of O +
ketamine O +
( O -
0.25 O +
mg O -
/ O -
kg O +
or O +
0.50 O +
mg O -
/ O -
kg O -
) O +
was O +
given O +
to O +
10 O +
cancer B-Disease +
patients O +
whose O +
pain B-Disease +
was O +
unrelieved O +
by O +
morphine O +
in O +
a O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
crossover O -
, O +
double O -
- O -
dose O +
study O -
. O +

Pain B-Disease +
intensity O +
on O +
a O +
0 O +
to O +
10 O +
numerical O +
scale O -
; O +
nausea B-Disease +
and O +
vomiting B-Disease -
, O +
drowsiness O -
, O +
confusion B-Disease -
, O +
and O +
dry B-Disease +
mouth I-Disease -
, O +
using O +
a O +
scale O +
from O +
0 O +
to O +
3 O +
( O -
not O +
at O +
all O -
, O +
slight O -
, O +
a O +
lot O -
, O +
awful O -
) O -
; O +
Mini O -
- O -
Mental O +
State O +
Examination O +
( O -
MMSE O -
) O +
( O -
0 O -
- O -
30 O -
) O -
; O +
and O +
arterial O +
pressure O +
were O +
recorded O +
before O +
administration O +
of O +
drugs O +
( O -
T0 O -
) O +
and O +
after O +
30 O +
minutes O +
( O -
T30 O -
) O -
, O +
60 O +
minutes O +
( O -
T60 O -
) O -
, O +
120 O +
minutes O +
( O -
T120 O -
) O -
, O +
and O +
180 O +
minutes O +
( O -
T180 O -
) O -
. O +

Ketamine O -
, O +
but O +
not O +
saline O +
solution O -
, O +
significantly O +
reduced O +
the O +
pain B-Disease +
intensity O +
in O +
almost O +
all O +
the O +
patients O +
at O +
both O +
doses O -
. O +

This O +
effect O +
was O +
more O +
relevant O +
in O +
patients O +
treated O +
with O +
higher O +
doses O -
. O +

Hallucinations B-Disease +
occurred O +
in O +
4 O +
patients O -
, O +
and O +
an O +
unpleasant O +
sensation O +
( O -
" O -
empty O +
head O -
" O -
) O +
was O +
also O +
reported O +
by O +
2 O +
patients O -
. O +

These O +
episodes O +
reversed O +
after O +
the O +
administration O +
of O +
diazepam O +
1 O +
mg O +
intravenously O -
. O +

Significant O +
increases O +
in O +
drowsiness O +
were O +
reported O +
in O +
patients O +
treated O +
with O +
ketamine O +
in O +
both O +
groups O +
and O +
were O +
more O +
marked O +
with O +
ketamine O +
0.50 O +
mg O -
/ O -
kg O -
. O +

A O +
significant O +
difference O +
in O +
MMSE O +
was O +
observed O +
at O +
T30 O +
in O +
patients O +
who O +
received O +
0.50 O +
mg O -
/ O -
kg O +
of O +
ketamine O -
. O +

Ketamine O +
can O +
improve O +
morphine O +
analgesia O +
in O +
difficult O +
pain B-Disease +
syndromes O -
, O +
such O +
as O +
neuropathic B-Disease +
pain I-Disease -
. O +

However O -
, O +
the O +
occurrence O +
of O +
central O +
adverse O +
effects O +
should O +
be O +
taken O +
into O +
account O -
, O +
especially O +
when O +
using O +
higher O +
doses O -
. O +

This O +
observation O +
should O +
be O +
tested O +
in O +
studies O +
of O +
prolonged O +
ketamine O +
administration O -
. O +

Conversion O +
to O +
rapamycin O +
immunosuppression O +
in O +
renal O +
transplant O +
recipients O -
: O +
report O +
of O +
an O +
initial O +
experience O -
. O +

BACKGROUND O -
: O +
The O +
aim O +
of O +
this O +
study O +
is O +
to O +
evaluate O +
the O +
effects O +
of O +
RAPA O +
conversion O +
in O +
patients O +
undergoing O +
cyclosporine O +
( O -
CsA O -
) O +
or O +
tacrolimus O +
( O -
Tac O -
) O +
toxicity B-Disease -
. O +

METHODS O -
: O +
Twenty O +
renal O +
transplant O +
recipients O +
were O +
switched O +
to O +
fixed O +
dose O +
rapamycin O +
( O -
RAPA O -
) O +
( O -
5 O +
mg O -
/ O -
day O -
) O +
0 O +
to O +
204 O +
months O +
posttransplant O -
. O +

Drug O +
monitoring O +
was O +
not O +
initially O +
used O +
to O +
adjust O +
doses O -
. O +

The O +
indications O +
for O +
switch O +
were O +
chronic O +
CsA O +
or O +
Tac O +
nephrotoxicity B-Disease +
( O -
12 O -
) O -
, O +
acute O +
CsA O +
or O +
Tac O +
toxicity B-Disease +
( O -
3 O -
) O -
, O +
severe O +
facial B-Disease +
dysmorphism I-Disease +
( O -
2 O -
) O -
, O +
posttransplant B-Disease +
lymphoproliferative I-Disease +
disorder I-Disease +
( O -
PTLD B-Disease -
) O +
in O +
remission O +
( O -
2 O -
) O -
, O +
and O +
hepatotoxicity B-Disease +
in O +
1 O -
. O +

Follow O -
- O -
up O +
is O +
7 O +
to O +
24 O +
months O -
. O +

RESULTS O -
: O +
In O +
the O +
12 O +
patients O +
switched O +
because O +
of O +
chronic O +
nephrotoxicity B-Disease +
there O +
was O +
a O +
significant O +
decrease O +
in O +
serum O +
creatinine O +
[ O -
233+ O -
/ O -
-34 O +
to O +
210+ O -
/ O -
-56 O +
micromol O -
/ O -
liter O +
( O -
P<0.05 O -
) O +
at O +
6 O +
months O -
] O -
. O +

Facial B-Disease +
dysmorphism I-Disease +
improved O +
in O +
two O +
patients O -
. O +

No O +
relapse O +
of O +
PTLD B-Disease +
was O +
observed O -
. O +

Five O +
patients O +
developed O +
pneumonia B-Disease +
( O -
two O +
Pneumocystis B-Disease +
carinii I-Disease +
pneumonia I-Disease -
, O +
one O +
infectious B-Disease +
mononucleosis I-Disease +
with O +
polyclonal O +
PTLD B-Disease +
lung O +
infiltrate O -
) O +
and O +
two O +
had O +
bronchiolitis B-Disease +
obliterans I-Disease -
. O +

There O +
were O +
no O +
deaths O -
. O +

RAPA O +
was O +
discontinued O +
in O +
four O +
patients O -
, O +
because O +
of O +
pneumonia B-Disease +
in O +
two O -
, O +
PTLD B-Disease +
in O +
one O -
, O +
and O +
oral O +
aphtous B-Disease +
ulcers I-Disease +
in O +
one O -
. O +

RAPA O +
levels O +
were O +
high O +
( O -
> O -
15 O +
ng O -
/ O -
ml O -
) O +
in O +
7 O +
of O +
13 O +
( O -
54 O -
% O -
) O +
patients O -
. O +

CONCLUSIONS O -
: O +
RAPA O +
conversion O +
provides O +
adequate O +
immunosuppression O +
to O +
enable O +
CsA O +
withdrawal O -
. O +

However O -
, O +
when O +
converting O +
patients O +
to O +
RAPA O +
drug O +
levels O +
should O +
be O +
monitored O +
to O +
avoid O +
over O -
- O -
immunosuppression O +
and O +
adequate O +
antiviral O +
and O +
Pneumocystis B-Disease +
carinii I-Disease +
pneumonia I-Disease +
prophylaxis O +
should O +
be O +
given O -
. O +

Electro O -
- O -
oculography O -
, O +
electroretinography O -
, O +
visual O +
evoked O +
potentials O -
, O +
and O +
multifocal O +
electroretinography O +
in O +
patients O +
with O +
vigabatrin O -
- O -
attributed O +
visual B-Disease +
field I-Disease +
constriction I-Disease -
. O +

PURPOSE O -
: O +
Symptomatic O +
visual B-Disease +
field I-Disease +
constriction I-Disease +
thought O +
to O +
be O +
associated O +
with O +
vigabatrin O +
has O +
been O +
reported O -
. O +

The O +
current O +
study O +
investigated O +
the O +
visual O +
fields O +
and O +
visual O +
electrophysiology O +
of O +
eight O +
patients O +
with O +
known O +
vigabatrin O -
- O -
attributed O +
visual B-Disease +
field I-Disease +
loss I-Disease -
, O +
three O +
of O +
whom O +
were O +
reported O +
previously O -
. O +

Six O +
of O +
the O +
patients O +
were O +
no O +
longer O +
receiving O +
vigabatrin O -
. O +

METHODS O -
: O +
The O +
central O +
and O +
peripheral O +
fields O +
were O +
examined O +
with O +
the O +
Humphrey O +
Visual O +
Field O +
Analyzer O -
. O +

Full O +
visual O +
electrophysiology O -
, O +
including O +
flash O +
electroretinography O +
( O -
ERG O -
) O -
, O +
pattern O +
electroretinography O -
, O +
multifocal O +
ERG O +
using O +
the O +
VERIS O +
system O -
, O +
electro O -
- O -
oculography O -
, O +
and O +
flash O +
and O +
pattern O +
visual O +
evoked O +
potentials O -
, O +
was O +
undertaken O -
. O +

RESULTS O -
: O +
Seven O +
patients O +
showed O +
marked O +
visual B-Disease +
field I-Disease +
constriction I-Disease +
with O +
some O +
sparing O +
of O +
the O +
temporal O +
visual O +
field O -
. O +

The O +
eighth O +
exhibited O +
concentric O +
constriction O -
. O +

Most O +
electrophysiological O +
responses O +
were O +
usually O +
just O +
within O +
normal O +
limits O -
; O +
two O +
patients O +
had O +
subnormal O +
Arden O +
electro O -
- O -
oculography O +
indices O -
; O +
and O +
one O +
patient O +
showed O +
an O +
abnormally O +
delayed O +
photopic O +
b O +
wave O -
. O +

However O -
, O +
five O +
patients O +
showed O +
delayed O +
30-Hz O +
flicker O +
b O +
waves O -
, O +
and O +
seven O +
patients O +
showed O +
delayed O +
oscillatory O +
potentials O -
. O +

Multifocal O +
ERG O +
showed O +
abnormalities O +
that O +
sometimes O +
correlated O +
with O +
the O +
visual O +
field O +
appearance O +
and O +
confirmed O +
that O +
the O +
deficit O +
occurs O +
at O +
the O +
retinal O +
level O -
. O +

CONCLUSION O -
: O +
Marked O +
visual B-Disease +
field I-Disease +
constriction I-Disease +
appears O +
to O +
be O +
associated O +
with O +
vigabatrin O +
therapy O -
. O +

The O +
field O +
defects O +
and O +
some O +
electrophysiological O +
abnormalities O +
persist O +
when O +
vigabatrin O +
therapy O +
is O +
withdrawn O -
. O +

Myocardial B-Disease +
ischemia I-Disease +
due O +
to O +
coronary B-Disease +
artery I-Disease +
spasm I-Disease +
during O +
dobutamine O +
stress O +
echocardiography O -
. O +

Dobutamine O +
stress O +
echocardiography O +
( O -
DSE O -
) O +
is O +
a O +
useful O +
and O +
safe O +
provocation O +
test O +
for O +
myocardial B-Disease +
ischemia I-Disease -
. O +

Until O +
now O -
, O +
the O +
test O +
has O +
been O +
focused O +
only O +
on O +
the O +
organic O +
lesion O +
in O +
the O +
coronary O +
artery O -
, O +
and O +
positive O +
DSE O +
has O +
indicated O +
the O +
presence O +
of O +
significant O +
fixed O +
coronary B-Disease +
artery I-Disease +
stenosis I-Disease -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
is O +
to O +
examine O +
whether O +
myocardial B-Disease +
ischemia I-Disease +
due O +
to O +
coronary B-Disease +
spasm I-Disease +
is O +
induced O +
by O +
dobutamine O -
. O +

We O +
performed O +
DSE O +
on O +
51 O +
patients O +
with O +
coronary B-Disease +
spastic I-Disease +
angina I-Disease +
but O +
without O +
significant O +
fixed O +
coronary B-Disease +
artery I-Disease +
stenosis I-Disease -
. O +

All O +
patients O +
had O +
anginal B-Disease +
attacks O +
at O +
rest O +
with O +
ST O +
elevation O +
on O +
the O +
electrocardiogram O +
( O -
variant B-Disease +
angina I-Disease -
) O -
. O +

Coronary O +
spasm O +
was O +
induced O +
by O +
intracoronary O +
injection O +
of O +
acetylcholine O -
, O +
and O +
no O +
fixed O +
coronary B-Disease +
artery I-Disease +
stenosis I-Disease +
was O +
documented O +
on O +
angiograms O +
in O +
all O +
patients O -
. O +

DSE O +
was O +
performed O +
with O +
intravenous O +
dobutamine O +
infusion O +
with O +
an O +
incremental O +
doses O +
of O +
5 O -
, O +
10 O -
, O +
20 O -
, O +
30 O -
, O +
and O +
40 O +
microg O -
/ O -
kg O -
/ O -
min O +
every O +
5 O +
minutes O -
. O +

Of O +
the O +
51 O +
patients O -
, O +
7 O +
patients O +
showed O +
asynergy O +
with O +
ST O +
elevation O -
. O +

All O +
7 O +
patients O +
( O -
13.7 O -
% O -
) O +
had O +
chest B-Disease +
pain I-Disease +
during O +
asynergy O -
, O +
and O +
both O +
chest B-Disease +
pain I-Disease +
and O +
electrocardiographic O +
changes O +
were O +
preceded O +
by O +
asynergy O -
. O +

These O +
findings O +
indicate O +
that O +
dobutamine O +
can O +
provoke O +
coronary B-Disease +
spasm I-Disease +
in O +
some O +
patients O +
with O +
coronary B-Disease +
spastic I-Disease +
angina I-Disease -
. O +

When O +
DSE O +
is O +
performed O +
to O +
evaluate O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
, O +
not O +
only O +
fixed O +
coronary B-Disease +
stenosis I-Disease -
, O +
but O +
also O +
coronary B-Disease +
spasm I-Disease +
should O +
be O +
considered O +
as O +
a O +
genesis O +
of O +
asynergy O -
. O +

Effect O +
of O +
intravenous O +
metoprolol O +
or O +
intravenous O +
metoprolol O +
plus O +
glucagon O +
on O +
dobutamine O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease -
. O +

STUDY O +
OBJECTIVE O -
: O +
To O +
determine O +
the O +
effect O +
of O +
metoprolol O +
on O +
dobutamine O +
stress O +
testing O +
with O +
technetium-99 O -
m O +
sestamibi O +
single O -
- O -
photon O +
emission O +
computed O +
tomography O +
imaging O +
and O +
ST O -
- O -
segment O +
monitoring O -
, O +
and O +
to O +
assess O +
the O +
impact O +
of O +
intravenous O +
glucagon O +
on O +
metoprolol O -
's O +
effects O -
. O +

DESIGN O -
: O +
Randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
trial O -
. O +

SETTING O -
: O +
Community O +
hospital O -
. O +

PATIENTS O -
: O +
Twenty O -
- O -
two O +
patients O +
with O +
known O +
reversible O +
perfusion O +
defects O -
. O +

INTERVENTION O -
: O +
Patients O +
underwent O +
dobutamine O +
stress O +
tests O +
per O +
standard O +
protocol O -
. O +

Before O +
dobutamine O +
was O +
begun O -
, O +
no O +
therapy O +
was O +
given O +
during O +
the O +
first O +
visit O -
, O +
and O +
patients O +
were O +
randomized O +
on O +
subsequent O +
visits O +
to O +
receive O +
metoprolol O +
or O +
metoprolol O +
plus O +
glucagon O +
1 O +
mg O -
. O +

Metoprolol O +
was O +
dosed O +
to O +
achieve O +
a O +
resting O +
predobutamine O +
heart O +
rate O +
below O +
65 O +
beats O -
/ O -
minute O +
or O +
a O +
total O +
intravenous O +
dose O +
of O +
20 O +
mg O -
. O +

MEASUREMENTS O +
AND O +
MAIN O +
RESULTS O -
: O +
Metoprolol O +
reduced O +
maximum O +
heart O +
rate O +
31 O -
% O -
, O +
summed O +
stress O +
scores O +
29 O -
% O -
, O +
and O +
summed O +
difference O +
scores O +
43 O -
% O +
versus O +
control O -
. O +

Metoprolol O +
plus O +
glucagon O +
also O +
reduced O +
the O +
maximum O +
heart O +
rate O +
29 O -
% O +
versus O +
control O -
. O +

Summed O +
stress O +
and O +
summed O +
difference O +
scores O +
were O +
not O +
significantly O +
reduced O -
, O +
although O +
they O +
were O +
18 O -
% O +
and O +
30 O -
% O +
lower O -
, O +
respectively O -
, O +
than O +
control O -
. O +

No O +
significant O +
differences O +
were O +
found O +
in O +
any O +
parameter O +
between O +
metoprolol O +
and O +
metoprolol O -
- O -
glucagon O -
. O +

CONCLUSION O -
: O +
During O +
dobutamine O +
stress O +
testing O -
, O +
metoprolol O +
attenuates O +
or O +
eliminates O +
evidence O +
of O +
myocardial B-Disease +
ischemia I-Disease -
. O +

Glucagon O +
1 O +
mg O -
, O +
although O +
somewhat O +
effective O -
, O +
does O +
not O +
correct O +
this O +
effect O +
to O +
the O +
extent O +
that O +
it O +
can O +
be O +
administered O +
clinically O -
. O +

Evidence O +
of O +
functional O +
somatotopy O +
in O +
GPi O +
from O +
results O +
of O +
pallidotomy O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
explore O +
the O +
functional O +
anatomy O +
of O +
the O +
globus O +
pallidus O +
internus O +
( O -
GPi O -
) O +
by O +
studying O +
the O +
effects O +
of O +
unilateral O +
pallidotomy O +
on O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O +
and O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
( O -
LID B-Disease -
) O -
. O +

We O +
found O +
significant O +
positive O +
correlations O +
between O +
the O +
preoperative O +
levodopa O +
responsiveness O +
of O +
motor O +
signs O +
and O +
the O +
levodopa O +
responsiveness O +
of O +
scores O +
in O +
timed O +
tests O +
( O -
Core O +
Assessment O +
Program O +
for O +
Intracerebral O +
Transplantations O -
) O +
in O +
the O +
contralateral O +
limbs O +
and O +
the O +
improvement O +
in O +
these O +
scores O +
after O +
surgery O -
, O +
whereas O +
there O +
was O +
no O +
correlation O +
with O +
the O +
improvement O +
in O +
LID B-Disease -
. O +

We O +
also O +
found O +
a O +
highly O +
significant O +
correlation O +
( O -
P O -
: O +
< O +
0.0001 O -
, O +
r O +
= O +
0.8 O -
) O +
between O +
the O +
volume O +
of O +
the O +
ventral O +
lesion O +
in O +
the O +
GPi O +
and O +
the O +
improvement O +
in O +
LID B-Disease +
in O +
the O +
contralateral O +
limbs O -
, O +
whereas O +
there O +
was O +
no O +
correlation O +
between O +
the O +
ventral O +
volume O +
and O +
the O +
improvement O +
in O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O -
. O +

The O +
volumes O +
of O +
the O +
total O +
lesion O +
cylinder O +
and O +
the O +
dorsal O +
lesion O +
did O +
not O +
correlate O +
with O +
the O +
outcome O +
of O +
either O +
dyskinesias B-Disease +
or O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O -
. O +

The O +
differential O +
predictive O +
value O +
of O +
levodopa O +
responsiveness O +
for O +
the O +
outcome O +
of O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O +
and O +
LID B-Disease +
and O +
the O +
different O +
correlations O +
of O +
ventral O +
lesion O +
volume O +
with O +
dyskinesias B-Disease +
and O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O +
indicate O +
that O +
different O +
anatomical O +
or O +
pathophysiological O +
substrates O +
may O +
be O +
responsible O +
for O +
the O +
generation O +
of O +
parkinsonian B-Disease +
' O -
off O -
' O +
signs O +
and O +
dyskinesias B-Disease -
. O +

Whereas O +
cells O +
in O +
a O +
wider O +
area O +
of O +
the O +
GPi O +
may O +
be O +
implicated O +
in O +
parkinsonism B-Disease -
, O +
the O +
ventral O +
GPi O +
seems O +
to O +
be O +
crucial O +
for O +
the O +
manifestation O +
of O +
LID B-Disease -
. O +

We O +
suggest O +
that O +
our O +
observations O +
are O +
additional O +
proof O +
of O +
the O +
functional O +
somatotopy O +
of O +
the O +
systems O +
within O +
the O +
GPi O +
that O +
mediate O +
parkinsonism B-Disease +
and O +
dyskinesias B-Disease -
, O +
especially O +
along O +
the O +
dorsoventral O +
trajectory O +
used O +
in O +
pallidotomy O -
. O +

The O +
outcome O +
of O +
pallidotomy O +
in O +
which O +
the O +
lesion O +
involves O +
the O +
ventral O +
and O +
dorsal O +
GPi O +
could O +
be O +
the O +
net O +
effect O +
of O +
alteration O +
in O +
the O +
activity O +
of O +
pathways O +
which O +
mediate O +
different O +
symptoms O -
, O +
and O +
hence O +
could O +
be O +
variable O -
. O +

Paclitaxel O -
, O +
cisplatin O -
, O +
and O +
gemcitabine O +
combination O +
chemotherapy O +
within O +
a O +
multidisciplinary O +
therapeutic O +
approach O +
in O +
metastatic O +
nonsmall B-Disease +
cell I-Disease +
lung I-Disease +
carcinoma I-Disease -
. O +

BACKGROUND O -
: O +
Cisplatin O -
- O -
based O +
chemotherapy O +
combinations O +
improve O +
quality O +
of O +
life O +
and O +
survival O +
in O +
advanced O +
nonsmall B-Disease +
cell I-Disease +
lung I-Disease +
carcinoma I-Disease +
( O -
NSCLC B-Disease -
) O -
. O +

The O +
emergence O +
of O +
new O +
active O +
drugs O +
might O +
translate O +
into O +
more O +
effective O +
regimens O +
for O +
the O +
treatment O +
of O +
this O +
disease O -
. O +

METHODS O -
: O +
The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
feasibility O -
, O +
response O +
rate O -
, O +
and O +
toxicity B-Disease +
of O +
a O +
paclitaxel O -
, O +
cisplatin O -
, O +
and O +
gemcitabine O +
combination O +
to O +
treat O +
metastatic O +
NSCLC B-Disease -
. O +

Thirty O -
- O -
five O +
consecutive O +
chemotherapy O -
- O -
naive O +
patients O +
with O +
Stage O +
IV O +
NSCLC B-Disease +
and O +
an O +
Eastern O +
Cooperative O +
Oncology O +
Group O +
performance O +
status O +
of O +
0 O -
- O -
2 O +
were O +
treated O +
with O +
a O +
combination O +
of O +
paclitaxel O +
( O -
135 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
given O +
intravenously O +
in O +
3 O +
hours O -
) O +
on O +
Day O +
1 O -
, O +
cisplatin O +
( O -
120 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
given O +
intravenously O +
in O +
6 O +
hours O -
) O +
on O +
Day O +
1 O -
, O +
and O +
gemcitabine O +
( O -
800 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
given O +
intravenously O +
in O +
30 O +
minutes O -
) O +
on O +
Days O +
1 O +
and O +
8 O -
, O +
every O +
4 O +
weeks O -
. O +

Although O +
responding O +
patients O +
were O +
scheduled O +
to O +
receive O +
consolidation O +
radiotherapy O +
and O +
24 O +
patients O +
received O +
preplanned O +
second O -
- O -
line O +
chemotherapy O +
after O +
disease O +
progression O -
, O +
the O +
response O +
and O +
toxicity B-Disease +
rates O +
reported O +
refer O +
only O +
to O +
the O +
chemotherapy O +
regimen O +
given O -
. O +

RESULTS O -
: O +
All O +
the O +
patients O +
were O +
examined O +
for O +
toxicity B-Disease -
; O +
34 O +
were O +
examinable O +
for O +
response O -
. O +

An O +
objective O +
response O +
was O +
observed O +
in O +
73.5 O -
% O +
of O +
the O +
patients O +
( O -
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O -
, O +
55.6 O -
- O -
87.1 O -
% O -
) O -
, O +
including O +
4 O +
complete O +
responses O +
( O -
11.7 O -
% O -
) O -
. O +

According O +
to O +
intention O -
- O -
to O -
- O -
treat O -
, O +
the O +
overall O +
response O +
rate O +
was O +
71.4 O -
% O +
( O -
95 O -
% O +
CI O -
, O +
53 O -
. O +
7 O -
- O -
85.4 O -
% O -
) O -
. O +

After O +
154 O +
courses O +
of O +
therapy O -
, O +
the O +
median O +
dose O +
intensity O +
was O +
131 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
for O +
paclitaxel O +
( O -
97.3 O -
% O -
) O -
, O +
117 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
for O +
cisplatin O +
( O -
97.3 O -
% O -
) O -
, O +
and O +
1378 O +
mg O -
/ O -
m O -
( O -
2 O -
) O +
for O +
gemcitabine O +
( O -
86.2 O -
% O -
) O -
. O +

World O +
Health O +
Organization O +
Grade O +
3 O -
- O -
4 O +
neutropenia B-Disease +
and O +
thrombocytopenia B-Disease +
occurred O +
in O +
39.9 O -
% O +
and O +
11.4 O -
% O +
of O +
patients O -
, O +
respectively O -
. O +

There O +
was O +
one O +
treatment O -
- O -
related O +
death B-Disease -
. O +

Nonhematologic O +
toxicities B-Disease +
were O +
mild O -
. O +

After O +
a O +
median O +
follow O -
- O -
up O +
of O +
22 O +
months O -
, O +
the O +
median O +
progression O +
free O +
survival O +
rate O +
was O +
7 O +
months O -
, O +
and O +
the O +
median O +
survival O +
time O +
was O +
16 O +
months O -
. O +

CONCLUSIONS O -
: O +
The O +
combination O +
of O +
paclitaxel O -
, O +
cisplatin O -
, O +
and O +
gemcitabine O +
is O +
well O +
tolerated O +
and O +
shows O +
high O +
activity O +
in O +
metastatic O +
NSCLC B-Disease -
. O +

This O +
treatment O +
merits O +
further O +
comparison O +
with O +
other O +
cisplatin O -
- O -
based O +
regimens O -
. O +

Serotonergic O +
antidepressants O +
and O +
urinary B-Disease +
incontinence I-Disease -
. O +

Many O +
new O +
serotonergic O +
antidepressants O +
have O +
been O +
introduced O +
over O +
the O +
past O +
decade O -
. O +

Although O +
urinary B-Disease +
incontinence I-Disease +
is O +
listed O +
as O +
one O +
side O +
effect O +
of O +
these O +
drugs O +
in O +
their O +
package O +
inserts O +
there O +
is O +
only O +
one O +
report O +
in O +
the O +
literature O -
. O +

This O +
concerns O +
2 O +
male O +
patients O +
who O +
experienced O +
incontinence B-Disease +
while O +
taking O +
venlafaxine O -
. O +

In O +
the O +
present O +
paper O +
the O +
authors O +
describe O +
2 O +
female O +
patients O +
who O +
developed O +
incontinence B-Disease +
secondary O +
to O +
the O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
paroxetine O +
and O +
sertraline O -
, O +
as O +
well O +
as O +
a O +
third O +
who O +
developed O +
this O +
side O +
effect O +
on O +
venlafaxine O -
. O +

In O +
2 O +
of O +
the O +
3 O +
cases O +
the O +
patients O +
were O +
also O +
taking O +
lithium O +
carbonate O +
and O +
beta O -
- O -
blockers O -
, O +
both O +
of O +
which O +
could O +
have O +
contributed O +
to O +
the O +
incontinence B-Disease -
. O +

Animal O +
studies O +
suggest O +
that O +
incontinence B-Disease +
secondary O +
to O +
serotonergic O +
antidepressants O +
could O +
be O +
mediated O +
by O +
the O +
5HT4 O +
receptors O +
found O +
on O +
the O +
bladder O -
. O +

Further O +
research O +
is O +
needed O +
to O +
delineate O +
the O +
frequency O +
of O +
this O +
troubling O +
side O +
effect O +
and O +
how O +
best O +
to O +
treat O +
it O -
. O +

Acute O +
cocaine O -
- O -
induced O +
seizures B-Disease -
: O +
differential O +
sensitivity O +
of O +
six O +
inbred O +
mouse O +
strains O -
. O +

Mature O +
male O +
and O +
female O +
mice O +
from O +
six O +
inbred O +
stains O +
were O +
tested O +
for O +
susceptibility O +
to O +
behavioral O +
seizures B-Disease +
induced O +
by O +
a O +
single O +
injection O +
of O +
cocaine O -
. O +

Cocaine O +
was O +
injected O +
ip O +
over O +
a O +
range O +
of O +
doses O +
( O -
50 O -
- O -
100 O +
mg O -
/ O -
kg O -
) O +
and O +
behavior O +
was O +
monitored O +
for O +
20 O +
minutes O -
. O +

Seizure B-Disease +
end O +
points O +
included O +
latency O +
to O +
forelimb O +
or O +
hindlimb O +
clonus O -
, O +
latency O +
to O +
clonic O +
running O +
seizure B-Disease +
and O +
latency O +
to O +
jumping O +
bouncing O +
seizure B-Disease -
. O +

A O +
range O +
of O +
strain O +
specific O +
sensitivities O +
was O +
documented O +
with O +
A O -
/ O -
J O +
and O +
SJL O +
mice O +
being O +
most O +
sensitive O +
and O +
C57BL O -
/ O -
6J O +
most O +
resistant O -
. O +

DBA O -
/ O -
2J O -
, O +
BALB O -
/ O -
cByJ O +
and O +
NZW O -
/ O -
LacJ O +
strains O +
exhibited O +
intermediate O +
sensitivity O -
. O +

EEG O +
recordings O +
were O +
made O +
in O +
SJL O -
, O +
A O -
/ O -
J O +
and O +
C57BL O -
/ O -
6J O +
mice O +
revealing O +
a O +
close O +
correspondence O +
between O +
electrical O +
activity O +
and O +
behavior O -
. O +

Additionally O -
, O +
levels O +
of O +
cocaine O +
determined O +
in O +
hippocampus O +
and O +
cortex O +
were O +
not O +
different O +
between O +
sensitive O +
and O +
resistant O +
strains O -
. O +

Additional O +
studies O +
of O +
these O +
murine O +
strains O +
may O +
be O +
useful O +
for O +
investigating O +
genetic O +
influences O +
on O +
cocaine O -
- O -
induced O +
seizures B-Disease -
. O +

Screening O +
for O +
stimulant O +
use O +
in O +
adult O +
emergency O +
department O +
seizure B-Disease +
patients O -
. O +

OBJECTIVE O -
: O +
The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
prevalence O +
of O +
positive O +
plasma O +
drug O +
screening O +
for O +
cocaine O +
or O +
amphetamine O +
in O +
adult O +
emergency O +
department O +
seizure B-Disease +
patients O -
. O +

METHODS O -
: O +
This O +
prospective O +
study O +
evaluated O +
consecutive O +
eligible O +
seizure B-Disease +
patients O +
who O +
had O +
a O +
plasma O +
sample O +
collected O +
as O +
part O +
of O +
their O +
clinical O +
evaluation O -
. O +

Plasma O +
was O +
tested O +
for O +
amphetamine O +
and O +
the O +
cocaine O +
metabolite O +
benzoylecgonine O +
using O +
enzyme O -
- O -
mediated O +
immunoassay O +
methodology O -
. O +

Plasma O +
samples O +
with O +
benzoylecgonine O +
greater O +
than O +
150 O +
ng O -
/ O -
mL O +
or O +
an O +
amphetamine O +
greater O +
than O +
500 O +
ng O -
/ O -
mL O +
were O +
defined O +
as O +
positive O -
. O +

Patient O +
demographics O -
, O +
history O +
of O +
underlying O +
drug O +
or O +
alcohol O -
- O -
related O +
seizure B-Disease +
disorder O -
, O +
estimated O +
time O +
from O +
seizure B-Disease +
to O +
sample O +
collection O -
, O +
history O +
or O +
suspicion O +
of O +
cocaine B-Disease +
or I-Disease +
amphetamine I-Disease +
abuse I-Disease -
, O +
results O +
of O +
clinical O +
urine O +
testing O +
for O +
drugs O +
of O +
abuse O -
, O +
and O +
assay O +
results O +
were O +
recorded O +
without O +
patient O +
identifiers O -
. O +

RESULTS O -
: O +
Fourteen O +
of O +
248 O +
( O -
5.6 O -
% O -
, O +
95 O -
% O +
CI O +
2.7%-8.5 O -
% O -
) O +
plasma O +
samples O +
were O +
positive O +
by O +
immunoassay O +
testing O +
for O +
benzoylecgonine O +
and O +
no O +
samples O +
( O -
0 O -
% O -
, O +
95 O -
% O +
CI O +
0 O -
- O -
1.2 O -
% O -
) O +
were O +
positive O +
for O +
amphetamine O -
. O +

Positive O +
test O +
results O +
were O +
more O +
common O +
in O +
patient O +
visits O +
where O +
there O +
was O +
a O +
history O +
or O +
suspicion O +
of O +
cocaine B-Disease +
or I-Disease +
amphetamine I-Disease +
abuse I-Disease +
( O -
p O +
< O +
0.0005 O -
) O -
. O +

CONCLUSIONS O -
: O +
During O +
this O +
study O +
period O -
, O +
routine O +
plasma O +
screening O +
for O +
cocaine O +
and O +
amphetamines O +
in O +
adult O +
seizure B-Disease +
patients O +
had O +
a O +
low O +
yield O -
. O +

As O +
a O +
result O -
, O +
routine O +
plasma O +
screening O +
would O +
yield O +
few O +
cases O +
of O +
stimulant O +
drug O +
in O +
which O +
there O +
was O +
neither O +
a O +
history O +
nor O +
suspicion O +
of O +
drug B-Disease +
abuse I-Disease +
in O +
this O +
population O -
. O +

Contribution O +
of O +
sodium O +
valproate O +
to O +
the O +
syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
secretion I-Disease +
of I-Disease +
antidiuretic I-Disease +
hormone I-Disease -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
62-year O -
- O -
old O +
man O +
who O +
was O +
administered O +
sodium O +
valproate O +
( O -
VPA O -
) O +
and O +
who O +
subsequently O +
developed O +
the O +
syndrome B-Disease +
of I-Disease +
inappropriate I-Disease +
secretion I-Disease +
of I-Disease +
antidiuretic I-Disease +
hormone I-Disease +
( O -
SIADH B-Disease -
) O -
. O +

He O +
had O +
been O +
taking O +
VPA O +
for O +
treatment O +
of O +
idiopathic O +
generalized O +
tonic B-Disease -
- I-Disease -
clonic I-Disease +
convulsions I-Disease +
since O +
he O +
was O +
56 O +
years O +
old O -
. O +

After O +
substituting O +
VPA O +
with O +
zonisamide O -
, O +
the O +
serum O +
sodium O +
level O +
returned O +
to O +
normal O -
. O +

We O +
consider O +
this O +
episode O +
of O +
SIADH B-Disease +
to O +
be O +
the O +
result O +
of O +
a O +
combination O +
of O +
factors O +
including O +
a O +
weakness B-Disease +
of I-Disease +
the I-Disease +
central I-Disease +
nervous I-Disease +
system I-Disease +
and O +
the O +
long O -
- O -
term O +
administration O +
of O +
VPA O -
. O +

Hypotension B-Disease +
following O +
the O +
initiation O +
of O +
tizanidine O +
in O +
a O +
patient O +
treated O +
with O +
an O +
angiotensin O +
converting O +
enzyme O +
inhibitor O +
for O +
chronic O +
hypertension B-Disease -
. O +

Centrally O +
acting O +
alpha-2 O +
adrenergic O +
agonists O +
are O +
one O +
of O +
several O +
pharmacologic O +
agents O +
used O +
in O +
the O +
treatment O +
of O +
spasticity B-Disease +
related O +
to O +
disorders B-Disease +
of I-Disease +
the I-Disease +
central I-Disease +
nervous I-Disease +
system I-Disease -
. O +

In O +
addition O +
to O +
their O +
effects O +
on O +
spasticity B-Disease -
, O +
certain O +
adverse O +
cardiorespiratory O +
effects O +
have O +
been O +
reported O -
. O +

Adults O +
chronically O +
treated O +
with O +
angiotensin O +
converting O +
enzyme O +
inhibitors O +
may O +
have O +
a O +
limited O +
ability O +
to O +
respond O +
to O +
hypotension B-Disease +
when O +
the O +
sympathetic O +
response O +
is O +
simultaneously O +
blocked O -
. O +

The O +
authors O +
present O +
a O +
10-year O -
- O -
old O +
boy O +
chronically O +
treated O +
with O +
lisinopril O -
, O +
an O +
angiotensin O +
converting O +
enzyme O +
inhibitor O -
, O +
to O +
control O +
hypertension B-Disease +
who O +
developed O +
hypotension B-Disease +
following O +
the O +
addition O +
of O +
tizanidine O -
, O +
an O +
alpha-2 O +
agonist O -
, O +
for O +
the O +
treatment O +
of O +
spasticity B-Disease -
. O +

The O +
possible O +
interaction O +
of O +
tizanidine O +
and O +
other O +
antihypertensive O +
agents O +
should O +
be O +
kept O +
in O +
mind O +
when O +
prescribing O +
therapy O +
to O +
treat O +
either O +
hypertension B-Disease +
or O +
spasticity B-Disease +
in O +
such O +
patients O -
. O +

Two O +
mouse O +
lines O +
selected O +
for O +
differential O +
sensitivities O +
to O +
beta O -
- O -
carboline O -
- O -
induced O +
seizures B-Disease +
are O +
also O +
differentially O +
sensitive O +
to O +
various O +
pharmacological O +
effects O +
of O +
other O +
GABA O -
( O -
A O -
) O +
receptor O +
ligands O -
. O +

Two O +
mouse O +
lines O +
were O +
selectively O +
bred O +
according O +
to O +
their O +
sensitivity O +
( O -
BS O +
line O -
) O +
or O +
resistance O +
( O -
BR O +
line O -
) O +
to O +
seizures B-Disease +
induced O +
by O +
a O +
single O +
i.p O -
. O +

injection O +
of O +
methyl O +
beta O -
- O -
carboline-3-carboxylate O +
( O -
beta O -
- O -
CCM O -
) O -
, O +
an O +
inverse O +
agonist O +
of O +
the O +
GABA O -
( O -
A O -
) O +
receptor O +
benzodiazepine O +
site O -
. O +

Our O +
aim O +
was O +
to O +
characterize O +
both O +
lines O -
' O +
sensitivities O +
to O +
various O +
physiological O +
effects O +
of O +
other O +
ligands O +
of O +
the O +
GABA O -
( O -
A O -
) O +
receptor O -
. O +

We O +
measured O +
diazepam O -
- O -
induced O +
anxiolysis O +
with O +
the O +
elevated O +
plus O -
- O -
maze O +
test O -
, O +
diazepam O -
- O -
induced O +
sedation O +
by O +
recording O +
the O +
vigilance O +
states O -
, O +
and O +
picrotoxin- O +
and O +
pentylenetetrazol O -
- O -
induced O +
seizures B-Disease +
after O +
i.p O -
. O +

injections O -
. O +

Results O +
presented O +
here O +
show O +
that O +
the O +
differential O +
sensitivities O +
of O +
BS O +
and O +
BR O +
lines O +
to O +
beta O -
- O -
CCM O +
can O +
be O +
extended O +
to O +
diazepam O -
, O +
picrotoxin O -
, O +
and O +
pentylenetetrazol O -
, O +
suggesting O +
a O +
genetic O +
selection O +
of O +
a O +
general O +
sensitivity O +
and O +
resistance O +
to O +
several O +
ligands O +
of O +
the O +
GABA O -
( O -
A O -
) O +
receptor O -
. O +

Association O +
of O +
nitric O +
oxide O +
production O +
and O +
apoptosis O +
in O +
a O +
model O +
of O +
experimental O +
nephropathy B-Disease -
. O +

BACKGROUND O -
: O +
In O +
recent O +
studies O +
increased O +
amounts O +
of O +
nitric O +
oxide O +
( O -
NO O -
) O +
and O +
apoptosis O +
have O +
been O +
implicated O +
in O +
various O +
pathological O +
conditions O +
in O +
the O +
kidney O -
. O +

We O +
have O +
studied O +
the O +
role O +
of O +
NO O +
and O +
its O +
association O +
with O +
apoptosis O +
in O +
an O +
experimental O +
model O +
of O +
nephrotic B-Disease +
syndrome I-Disease +
induced O +
by O +
a O +
single O +
injection O +
of O +
adriamycin O +
( O -
ADR O -
) O -
. O +

METHODS O -
: O +
The O +
alteration O +
in O +
the O +
NO O +
pathway O +
was O +
assessed O +
by O +
measuring O +
nitrite O +
levels O +
in O +
serum O -
/ O -
urine O +
and O +
by O +
evaluating O +
the O +
changes O +
in O +
vascular O +
reactivity O +
of O +
the O +
isolated O +
perfused O +
rat O +
kidney O +
( O -
IPRK O -
) O +
system O -
. O +

Rats O +
were O +
stratified O +
into O +
control O +
groups O +
and O +
ADR O -
- O -
induced O +
nephropathy B-Disease +
groups O -
. O +

These O +
two O +
groups O +
were O +
then O +
divided O +
into O -
: O +
group O +
1 O -
, O +
animals O +
receiving O +
saline O -
; O +
and O +
group O +
2 O -
, O +
animals O +
receiving O +
aminoguanidine O +
( O -
AG O -
) O +
which O +
is O +
a O +
specific O +
inhibitor O +
of O +
inducible O -
- O -
NO O +
synthase O -
. O +

On O +
day O +
21 O -
, O +
rats O +
were O +
sacrificed O +
after O +
obtaining O +
material O +
for O +
biochemical O +
analysis O -
. O +

RESULTS O -
: O +
Histopathological O +
examination O +
of O +
the O +
kidneys O +
of O +
rats O +
treated O +
with O +
ADR O +
revealed O +
focal O +
areas O +
of O +
mesangial B-Disease +
proliferation I-Disease +
and O +
mild O +
tubulointerstitial B-Disease +
inflammation I-Disease -
. O +

They O +
also O +
had O +
significantly O +
higher O +
levels O +
of O +
proteinuria B-Disease +
compared O +
with O +
control O +
and O +
treatment O +
groups O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Urine O +
nitrite O +
levels O +
were O +
significantly O +
increased O +
in O +
the O +
ADR O -
- O -
nephropathy B-Disease +
group O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

In O +
the O +
IPRK O +
phenylephrine O +
and O +
acetylcholine O +
related O +
responses O +
were O +
significantly O +
impaired O +
in O +
the O +
ADR O -
- O -
nephropathy B-Disease +
group O -
. O +

Apoptosis O +
was O +
not O +
detected O +
in O +
controls O -
. O +

However O -
, O +
in O +
the O +
ADR O -
- O -
nephropathy B-Disease +
group O -
, O +
numerous O +
apoptotic O +
cells O +
were O +
identified O +
in O +
the O +
tubulointerstitial O +
areas O -
. O +

Double O +
staining O +
revealed O +
numerous O +
interstitial O +
apoptotic O +
cells O +
to O +
stain O +
for O +
ED1 O -
, O +
a O +
marker O +
for O +
monocytes O -
/ O -
macrophages O -
. O +

Treatment O +
with O +
AG O +
prevented O +
the O +
impairment O +
of O +
renal O +
vascular O +
bed O +
responses O +
and O +
reduced O +
both O +
urine O +
nitrite O +
levels O +
and O +
apoptosis O +
to O +
control O +
levels O -
. O +

CONCLUSION O -
: O +
We O +
suggest O +
that O +
interactions O +
between O +
NO O +
and O +
apoptosis O +
are O +
important O +
in O +
the O +
pathogenesis O +
of O +
the O +
ADR O -
- O -
induced O +
nephrosis B-Disease -
. O +

Dual O +
effects O +
of O +
melatonin O +
on O +
barbiturate O -
- O -
induced O +
narcosis B-Disease +
in O +
rats O -
. O +

Melatonin O +
affects O +
the O +
circadian O +
sleep O -
/ O -
wake O +
cycle O -
, O +
but O +
it O +
is O +
not O +
clear O +
whether O +
it O +
may O +
influence O +
drug O -
- O -
induced O +
narcosis B-Disease -
. O +

Sodium O +
thiopenthal O +
was O +
administered O +
intraperitoneally O +
into O +
male O +
rats O +
pre O -
- O -
treated O +
with O +
melatonin O +
( O -
0.05 O -
, O +
0.5 O -
, O +
5 O +
and O +
50 O +
mg O -
/ O -
kg O -
) O -
. O +

Melatonin O +
pre O -
- O -
treatment O +
affected O +
in O +
a O +
dual O +
manner O +
barbiturate O +
narcosis B-Disease -
, O +
however O -
, O +
no O +
dose O -
- O -
effect O +
correlation O +
was O +
found O -
. O +

In O +
particular O -
, O +
low O +
doses O +
reduced O +
the O +
latency O +
to O +
and O +
prolonged O +
the O +
duration O +
of O +
barbiturate O +
narcosis B-Disease -
. O +

In O +
contrast O -
, O +
the O +
highest O +
dose O +
of O +
melatonin O +
( O -
50 O +
mg O -
/ O -
kg O -
) O +
caused O +
a O +
paradoxical O +
increase O +
in O +
the O +
latency O +
and O +
produced O +
a O +
sustained O +
reduction O +
of O +
the O +
duration O +
of O +
narcosis B-Disease -
, O +
and O +
a O +
reduction O +
in O +
mortality O +
rate O -
. O +

Melatonin O +
0.5 O +
and O +
5 O +
mg O -
/ O -
kg O +
influenced O +
the O +
duration O +
but O +
not O +
the O +
latency O +
of O +
ketamine- O +
or O +
diazepam O -
- O -
induced O +
narcosis B-Disease -
. O +

Thus O -
, O +
the O +
dual O +
action O +
of O +
melatonin O +
on O +
pharmacological O +
narcosis B-Disease +
seems O +
to O +
be O +
specific O +
for O +
the O +
barbiturate O +
mechanism O +
of O +
action O -
. O +

The O +
role O +
of O +
nitrergic O +
system O +
in O +
lidocaine O -
- O -
induced O +
convulsion B-Disease +
in O +
the O +
mouse O -
. O +

The O +
effects O +
of O +
N O -
- O -
nitro O -
- O -
L O -
- O -
arginine O -
- O -
methyl O +
ester O +
( O -
L O -
- O -
NAME O -
) O +
a O +
nitric O +
oxide O +
( O -
NO O -
) O +
synthase O +
inhibitor O +
and O +
L O -
- O -
arginine O -
, O +
a O +
NO O +
precursor O -
, O +
were O +
investigated O +
on O +
lidocaine O -
- O -
induced O +
convulsions B-Disease -
. O +

In O +
the O +
first O +
experiment O -
, O +
four O +
groups O +
of O +
mice O +
received O +
physiological O +
saline O +
( O -
0.9 O -
% O -
) O -
, O +
L O -
- O -
arginine O +
( O -
300 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
, O +
L O -
- O -
NAME O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
diazepam O +
( O -
2 O +
mg O -
/ O -
kg O -
) O -
, O +
respectively O -
. O +

Thirty O +
minutes O +
after O +
these O +
injections O -
, O +
all O +
mice O +
received O +
lidocaine O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O +

In O +
the O +
second O +
experiment O -
, O +
four O +
groups O +
of O +
mice O +
received O +
similar O +
treatment O +
in O +
the O +
first O +
experiment O -
, O +
and O +
30 O +
min O +
after O +
these O +
injections O -
, O +
all O +
mice O +
received O +
a O +
higher O +
dose O +
of O +
lidocaine O +
( O -
80 O +
mg O -
/ O -
kg O -
) O -
. O +

L O -
- O -
NAME O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
diazepam O +
( O -
2 O +
mg O -
/ O -
kg O -
) O +
significantly O +
decreased O +
the O +
incidence O +
of O +
lidocaine O +
( O -
50 O +
mg O -
/ O -
kg O -
) O -
-induced O +
convulsions B-Disease -
. O +

In O +
contrast O -
, O +
the O +
L O -
- O -
arginine O +
treatment O +
increased O +
the O +
incidence O +
of O +
lidocaine O +
( O -
80 O +
mg O -
/ O -
kg O -
, O +
i.p. O -
) O -
-induced O +
convulsions B-Disease +
significantly O -
. O +

These O +
results O +
may O +
suggest O +
that O +
NO O +
is O +
a O +
proconvulsant O +
mediator O +
in O +
lidocaine O -
- O -
induced O +
convulsions B-Disease -
. O +

Erythropoietin O +
restores O +
the O +
anemia B-Disease -
- O -
induced O +
reduction O +
in O +
cyclophosphamide O +
cytotoxicity B-Disease +
in O +
rat O +
tumors B-Disease -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
impact O +
of O +
anemia B-Disease +
prevention O +
by O +
recombinant O +
human O +
erythropoietin O +
( O -
rHuEPO O -
) O +
treatment O +
on O +
the O +
cytotoxicity B-Disease +
of O +
cyclophosphamide O +
in O +
solid O +
experimental O +
tumors B-Disease -
. O +

Anemia B-Disease +
was O +
induced O +
using O +
a O +
single O +
dose O +
of O +
carboplatin O +
( O -
50 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
resulting O +
in O +
a O +
long O -
- O -
lasting O +
reduction O +
( O -
30 O -
% O -
) O +
of O +
the O +
hemoglobin O +
concentration O -
. O +

In O +
a O +
second O +
group O -
, O +
the O +
development O +
of O +
anemia B-Disease +
was O +
prevented O +
by O +
rHuEPO O +
( O -
1000 O +
IU O -
/ O -
kg O -
) O +
administered O +
s.c O -
. O +

three O +
times O -
/ O -
week O +
starting O +
7 O +
days O +
before O +
carboplatin O +
application O -
. O +

Four O +
days O +
after O +
carboplatin O +
treatment O -
, O +
tumors B-Disease +
( O -
DS O -
- O -
sarcoma B-Disease +
of O +
the O +
rat O -
) O +
were O +
implanted O +
s.c O -
. O +

onto O +
the O +
hind O +
food O +
dorsum O -
. O +

Neither O +
carboplatin O +
nor O +
rHuEPO O +
treatment O +
influenced O +
tumor B-Disease +
growth O +
rate O +
per O +
se O -
. O +

When O +
tumors B-Disease +
were O +
treated O +
with O +
a O +
single O +
dose O +
of O +
cyclophosphamide O +
( O -
60 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
5 O +
days O +
after O +
implantation O -
, O +
a O +
growth O +
delay O +
with O +
a O +
subsequent O +
regrowth O +
of O +
the O +
tumors B-Disease +
was O +
observed O -
. O +

In O +
the O +
anemia B-Disease +
group O -
, O +
the O +
growth O +
delay O +
was O +
significantly O +
shorter O +
compared O +
with O +
nonanemic O +
controls O +
( O -
13.3 O +
days O +
versus O +
8.6 O +
days O -
) O -
. O +

In O +
the O +
group O +
where O +
anemia B-Disease +
was O +
prevented O +
by O +
rHuEPO O +
treatment O -
, O +
growth O +
delay O +
was O +
comparable O +
with O +
that O +
of O +
nonanemic O +
controls O +
( O -
13.3 O +
days O -
) O -
. O +

These O +
results O +
suggest O +
that O +
chemotherapy O -
- O -
induced O +
anemia B-Disease +
reduces O +
cytotoxicity B-Disease +
of O +
cyclophosphamide O +
in O +
tumors B-Disease -
, O +
whereas O +
correction O +
of O +
anemia B-Disease +
by O +
rHuEPO O +
treatment O +
( O -
epoetin O +
alpha O -
) O +
increases O +
the O +
sensitivity O -
, O +
probably O +
as O +
a O +
result O +
of O +
an O +
improved O +
oxygen O +
supply O +
to O +
tumor B-Disease +
tissue O -
. O +

Propylthiouracil O -
- O -
induced O +
perinuclear O -
- O -
staining O +
antineutrophil O +
cytoplasmic O +
autoantibody O -
- O -
positive O +
vasculitis B-Disease +
in O +
conjunction O +
with O +
pericarditis B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
describe O +
a O +
case O +
of O +
propylthiouracil O -
- O -
induced O +
vasculitis B-Disease +
manifesting O +
with O +
pericarditis B-Disease -
. O +

METHODS O -
: O +
We O +
present O +
the O +
first O +
case O +
report O +
of O +
a O +
woman O +
with O +
hyperthyroidism B-Disease +
treated O +
with O +
propylthiouracil O +
in O +
whom O +
a O +
syndrome O +
of O +
pericarditis B-Disease -
, O +
fever B-Disease -
, O +
and O +
glomerulonephritis B-Disease +
developed O -
. O +

Serologic O +
testing O +
and O +
immunologic O +
studies O +
were O +
done O -
, O +
and O +
a O +
pericardial O +
biopsy O +
was O +
performed O -
. O +

RESULTS O -
: O +
A O +
25-year O -
- O -
old O +
woman O +
with O +
Graves B-Disease -
' I-Disease +
disease I-Disease +
had O +
a O +
febrile B-Disease +
illness I-Disease +
and O +
evidence O +
of O +
pericarditis B-Disease -
, O +
which O +
was O +
confirmed O +
by O +
biopsy O -
. O +

Serologic O +
evaluation O +
revealed O +
the O +
presence O +
of O +
perinuclear O -
- O -
staining O +
antineutrophil O +
cytoplasmic O +
autoantibodies O +
( O -
pANCA O -
) O +
against O +
myeloperoxidase O +
( O -
MPO O -
) O -
. O +

Propylthiouracil O +
therapy O +
was O +
withdrawn O -
, O +
and O +
she O +
was O +
treated O +
with O +
a O +
1-month O +
course O +
of O +
prednisone O -
, O +
which O +
alleviated O +
her O +
symptoms O -
. O +

A O +
literature O +
review O +
revealed O +
no O +
prior O +
reports O +
of O +
pericarditis B-Disease +
in O +
anti O -
- O -
MPO O +
pANCA O -
- O -
positive O +
vasculitis B-Disease +
associated O +
with O +
propylthio- O +
uracil O +
therapy O -
. O +

CONCLUSION O -
: O +
Pericarditis B-Disease +
may O +
be O +
the O +
initial O +
manifestation O +
of O +
drug O -
- O -
induced O +
vasculitis B-Disease +
attributable O +
to O +
propylthio- O +
uracil O +
therapy O -
. O +

Repeated O +
transient O +
anuria B-Disease +
following O +
losartan O +
administration O +
in O +
a O +
patient O +
with O +
a O +
solitary O +
kidney O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
70-year O -
- O -
old O +
hypertensive B-Disease +
man O +
with O +
a O +
solitary O +
kidney O +
and O +
chronic B-Disease +
renal I-Disease +
insufficiency I-Disease +
who O +
developed O +
two O +
episodes O +
of O +
transient O +
anuria B-Disease +
after O +
losartan O +
administration O -
. O +

He O +
was O +
hospitalized O +
for O +
a O +
myocardial B-Disease +
infarction I-Disease +
with O +
pulmonary B-Disease +
edema I-Disease -
, O +
treated O +
with O +
high O -
- O -
dose O +
diuretics O -
. O +

Due O +
to O +
severe O +
systolic B-Disease +
dysfunction I-Disease +
losartan O +
was O +
prescribed O -
. O +

Surprisingly O -
, O +
the O +
first O +
dose O +
of O +
50 O +
mg O +
of O +
losartan O +
resulted O +
in O +
a O +
sudden O +
anuria B-Disease -
, O +
which O +
lasted O +
eight O +
hours O +
despite O +
high O -
- O -
dose O +
furosemide O +
and O +
amine O +
infusion O -
. O +

One O +
week O +
later O -
, O +
by O +
mistake O -
, O +
losartan O +
was O +
prescribed O +
again O +
and O +
after O +
the O +
second O +
dose O +
of O +
50 O +
mg O -
, O +
the O +
patient O +
developed O +
a O +
second O +
episode O +
of O +
transient O +
anuria B-Disease +
lasting O +
10 O +
hours O -
. O +

During O +
these O +
two O +
episodes O -
, O +
his O +
blood O +
pressure O +
diminished O +
but O +
no O +
severe O +
hypotension B-Disease +
was O +
noted O -
. O +

Ultimately O -
, O +
an O +
arteriography O +
showed O +
a O +
70 O -
- O -
80 O -
% O +
renal B-Disease +
artery I-Disease +
stenosis I-Disease -
. O +

In O +
this O +
patient O -
, O +
renal B-Disease +
artery I-Disease +
stenosis I-Disease +
combined O +
with O +
heart B-Disease +
failure I-Disease +
and O +
diuretic O +
therapy O +
certainly O +
resulted O +
in O +
a O +
strong O +
activation O +
of O +
the O +
renin O -
- O -
angiotensin O +
system O +
( O -
RAS O -
) O -
. O +

Under O +
such O +
conditions O -
, O +
angiotensin O +
II O +
receptor O +
blockade O +
by O +
losartan O +
probably O +
induced O +
a O +
critical O +
fall O +
in O +
glomerular O +
filtration O +
pressure O -
. O +

This O +
case O +
report O +
highlights O +
the O +
fact O +
that O +
the O +
angiotensin O +
II O +
receptor O +
antagonist O +
losartan O +
can O +
cause O +
serious O +
unexpected O +
complications O +
in O +
patients O +
with O +
renovascular B-Disease +
disease I-Disease +
and O +
should O +
be O +
used O +
with O +
extreme O +
caution O +
in O +
this O +
setting O -
. O +

Calcineurin O -
- O -
inhibitor O +
induced O +
pain B-Disease +
syndrome O +
( O -
CIPS B-Disease -
) O -
: O +
a O +
severe O +
disabling O +
complication O +
after O +
organ O +
transplantation O -
. O +

Bone O +
pain B-Disease +
after O +
transplantation O +
is O +
a O +
frequent O +
complication O +
that O +
can O +
be O +
caused O +
by O +
several O +
diseases O -
. O +

Treatment O +
strategies O +
depend O +
on O +
the O +
correct O +
diagnosis O +
of O +
the O +
pain B-Disease -
. O +

Nine O +
patients O +
with O +
severe O +
pain B-Disease +
in O +
their O +
feet O -
, O +
which O +
was O +
registered O +
after O +
transplantation O -
, O +
were O +
investigated O -
. O +

Bone O +
scans O +
showed O +
an O +
increased O +
tracer O +
uptake O +
of O +
the O +
foot O +
bones O -
. O +

Magnetic O +
resonance O +
imaging O +
demonstrated O +
bone B-Disease +
marrow I-Disease +
oedema B-Disease +
in O +
the O +
painful O +
bones O -
. O +

Pain B-Disease +
was O +
not O +
explained O +
by O +
other O +
diseases O +
causing O +
foot O +
pain B-Disease -
, O +
like O +
reflex B-Disease +
sympathetic I-Disease +
dystrophy I-Disease -
, O +
polyneuropathy B-Disease -
, O +
Morton B-Disease -
's I-Disease +
neuralgia I-Disease -
, O +
gout B-Disease -
, O +
osteoporosis B-Disease -
, O +
avascular B-Disease +
necrosis I-Disease -
, O +
intermittent B-Disease +
claudication I-Disease -
, O +
orthopaedic O +
foot B-Disease +
deformities I-Disease -
, O +
stress B-Disease +
fractures I-Disease -
, O +
and O +
hyperparathyroidism B-Disease -
. O +

The O +
reduction O +
of O +
cyclosporine- O +
or O +
tacrolimus O +
trough O +
levels O +
and O +
the O +
administration O +
of O +
calcium O +
channel O +
blockers O +
led O +
to O +
relief O +
of O +
pain B-Disease -
. O +

The O +
Calcineurin O -
- O -
inhibitor O +
Induced O +
Pain B-Disease +
Syndrome O +
( O -
CIPS B-Disease -
) O +
is O +
a O +
rare O +
but O +
severe O +
side O +
effect O +
of O +
cyclosporine O +
or O +
tacrolimus O +
and O +
is O +
accurately O +
diagnosed O +
by O +
its O +
typical O +
presentation O -
, O +
magnetic O +
resonance O +
imaging O +
and O +
bone O +
scans O -
. O +

Incorrect O +
diagnosis O +
of O +
the O +
syndrome O +
will O +
lead O +
to O +
a O +
significant O +
reduction O +
of O +
life O +
quality O +
in O +
patients O +
suffering O +
from O +
CIPS B-Disease -
. O +

Fatal O +
haemorrhagic B-Disease +
myocarditis B-Disease +
secondary O +
to O +
cyclophosphamide O +
therapy O -
. O +

Haemorrhagic B-Disease +
myocarditis B-Disease +
is O +
a O +
rare O +
but O +
important O +
complication O +
of O +
cyclophosphamide O +
therapy O -
. O +

Echocardiographic O +
identification O +
of O +
the O +
disorder O +
can O +
be O +
made O -
. O +

We O +
believe O +
that O +
the O +
ultrasound O +
features O +
of O +
this O +
disorder O +
have O +
not O +
been O +
previously O +
reported O -
. O +

Brain O +
natriuretic O +
peptide O +
is O +
a O +
predictor O +
of O +
anthracycline O -
- O -
induced O +
cardiotoxicity B-Disease -
. O +

Anthracyclines O +
are O +
effective O +
antineoplastic O +
drugs O -
, O +
but O +
they O +
frequently O +
cause O +
dose O -
- O -
related O +
cardiotoxicity B-Disease -
. O +

The O +
cardiotoxicity B-Disease +
of O +
conventional O +
anthracycline O +
therapy O +
highlights O +
a O +
need O +
to O +
search O +
for O +
methods O +
that O +
are O +
highly O +
sensitive O +
and O +
capable O +
of O +
predicting O +
cardiac B-Disease +
dysfunction I-Disease -
. O +

We O +
measured O +
the O +
plasma O +
level O +
of O +
brain O +
natriuretic O +
peptide O +
( O -
BNP O -
) O +
to O +
determine O +
whether O +
BNP O +
might O +
serve O +
as O +
a O +
simple O +
diagnostic O +
indicator O +
of O +
anthracycline O -
- O -
induced O +
cardiotoxicity B-Disease +
in O +
patients O +
with O +
acute B-Disease +
leukemia I-Disease +
treated O +
with O +
a O +
daunorubicin O +
( O -
DNR O -
) O -
-containing O +
regimen O -
. O +

Thirteen O +
patients O +
with O +
acute B-Disease +
leukemia I-Disease +
were O +
treated O +
with O +
a O +
DNR O -
- O -
containing O +
regimen O -
. O +

Cardiac O +
functions O +
were O +
evaluated O +
with O +
radionuclide O +
angiography O +
before O +
chemotherapies O -
. O +

The O +
plasma O +
levels O +
of O +
atrial O +
natriuretic O +
peptide O +
( O -
ANP O -
) O +
and O +
BNP O +
were O +
measured O +
at O +
the O +
time O +
of O +
radionuclide O +
angiography O -
. O +

Three O +
patients O +
developed O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
after O +
the O +
completion O +
of O +
chemotherapy O -
. O +

Five O +
patients O +
were O +
diagnosed O +
as O +
having O +
subclinical O +
heart B-Disease +
failure I-Disease +
after O +
the O +
completion O +
of O +
chemotherapy O -
. O +

The O +
plasma O +
levels O +
of O +
BNP O +
in O +
all O +
the O +
patients O +
with O +
clinical O +
and O +
subclinical O +
heart B-Disease +
failure I-Disease +
increased O +
above O +
the O +
normal O +
limit O +
( O -
40 O +
pg O -
/ O -
ml O -
) O +
before O +
the O +
detection O +
of O +
clinical O +
or O +
subclinical O +
heart B-Disease +
failure I-Disease +
by O +
radionuclide O +
angiography O -
. O +

On O +
the O +
other O +
hand O -
, O +
BNP O +
did O +
not O +
increase O +
in O +
the O +
patients O +
without O +
heart B-Disease +
failure I-Disease +
given O +
DNR O -
, O +
even O +
at O +
more O +
than O +
700 O +
mg O -
/ O -
m O -
( O -
2 O -
) O -
. O +

The O +
plasma O +
level O +
of O +
ANP O +
did O +
not O +
always O +
increase O +
in O +
all O +
the O +
patients O +
with O +
clinical O +
and O +
subclinical O +
heart B-Disease +
failure I-Disease -
. O +

These O +
preliminary O +
results O +
suggest O +
that O +
BNP O +
may O +
be O +
useful O +
as O +
an O +
early O +
and O +
sensitive O +
indicator O +
of O +
anthracycline O -
- O -
induced O +
cardiotoxicity B-Disease -
. O +

Effects O +
of O +
verapamil O +
on O +
atrial B-Disease +
fibrillation I-Disease +
and O +
its O +
electrophysiological O +
determinants O +
in O +
dogs O -
. O +

BACKGROUND O -
: O +
Atrial B-Disease +
tachycardia I-Disease -
- O -
induced O +
remodeling O +
promotes O +
the O +
occurrence O +
and O +
maintenance O +
of O +
atrial B-Disease +
fibrillation I-Disease +
( O -
AF B-Disease -
) O +
and O +
decreases O +
L O -
- O -
type O +
Ca O -
( O -
2 O -
+ O -
) O +
current O -
. O +

There O +
is O +
also O +
a O +
clinical O +
suggestion O +
that O +
acute O +
L O -
- O -
type O +
Ca O -
( O -
2 O -
) O +
channel O +
blockade O +
can O +
promote O +
AF B-Disease -
, O +
consistent O +
with O +
an O +
AF B-Disease +
promoting O +
effect O +
of O +
Ca O -
( O -
2 O -
+ O -
) O +
channel O +
inhibition O -
. O +

METHODS O -
: O +
To O +
evaluate O +
the O +
potential O +
mechanisms O +
of O +
AF B-Disease +
promotion O +
by O +
Ca O -
( O -
2 O -
+ O -
) O +
channel O +
blockers O -
, O +
we O +
administered O +
verapamil O +
to O +
morphine O -
- O -
chloralose O +
anesthetized O +
dogs O -
. O +

Diltiazem O +
was O +
used O +
as O +
a O +
comparison O +
drug O +
and O +
autonomic O +
blockade O +
with O +
atropine O +
and O +
nadolol O +
was O +
applied O +
in O +
some O +
experiments O -
. O +

Epicardial O +
mapping O +
with O +
240 O +
epicardial O +
electrodes O +
was O +
used O +
to O +
evaluate O +
activation O +
during O +
AF B-Disease -
. O +

RESULTS O -
: O +
Verapamil O +
caused O +
AF B-Disease +
promotion O +
in O +
six O +
dogs O -
, O +
increasing O +
mean O +
duration O +
of O +
AF B-Disease +
induced O +
by O +
burst O +
pacing O -
, O +
from O +
8+ O -
/ O -
-4 O +
s O +
( O -
mean+ O -
/ O -
-S.E. O -
) O +
to O +
95+ O -
/ O -
-39 O +
s O +
( O -
P<0.01 O +
vs. O +
control O -
) O +
at O +
a O +
loading O +
dose O +
of O +
0.1 O +
mg O -
/ O -
kg O +
and O +
228+ O -
/ O -
-101 O +
s O +
( O -
P<0.0005 O +
vs. O +
control O -
) O +
at O +
a O +
dose O +
of O +
0.2 O +
mg O -
/ O -
kg O -
. O +

Underlying O +
electrophysiological O +
mechanisms O +
were O +
studied O +
in O +
detail O +
in O +
five O +
additional O +
dogs O +
under O +
control O +
conditions O +
and O +
in O +
the O +
presence O +
of O +
the O +
higher O +
dose O +
of O +
verapamil O -
. O +

In O +
these O +
experiments O -
, O +
verapamil O +
shortened O +
mean O +
effective O +
refractory O +
period O +
( O -
ERP O -
) O +
from O +
122+ O -
/ O -
-5 O +
to O +
114+ O -
/ O -
-4 O +
ms O +
( O -
P<0.02 O -
) O +
at O +
a O +
cycle O +
length O +
of O +
300 O +
ms O -
, O +
decreased O +
ERP O +
heterogeneity O +
( O -
from O +
15+ O -
/ O -
-1 O +
to O +
10+ O -
/ O -
-1 O -
% O -
, O +
P<0.05 O -
) O -
, O +
heterogeneously O +
accelerated O +
atrial O +
conduction O +
and O +
decreased O +
the O +
cycle O +
length O +
of O +
AF B-Disease +
( O -
94+ O -
/ O -
-4 O +
to O +
84+ O -
/ O -
-3 O +
ms O -
, O +
P<0.005 O -
) O -
. O +

Diltiazem O +
did O +
not O +
affect O +
ERP O -
, O +
AF B-Disease +
cycle O +
length O +
or O +
AF B-Disease +
duration O -
, O +
but O +
produced O +
conduction O +
acceleration O +
similar O +
to O +
that O +
caused O +
by O +
verapamil O +
( O -
n=5 O -
) O -
. O +

In O +
the O +
presence O +
of O +
autonomic O +
blockade O -
, O +
verapamil O +
failed O +
to O +
promote O +
AF B-Disease +
and O +
increased O -
, O +
rather O +
than O +
decreasing O -
, O +
refractoriness O -
. O +

Neither O +
verapamil O +
nor O +
diltiazem O +
affected O +
atrial O +
conduction O +
in O +
the O +
presence O +
of O +
autonomic O +
blockade O -
. O +

Epicardial O +
mapping O +
suggested O +
that O +
verapamil O +
promoted O +
AF B-Disease +
by O +
increasing O +
the O +
number O +
of O +
simultaneous O +
wavefronts O +
reflected O +
by O +
separate O +
zones O +
of O +
reactivation O +
in O +
each O +
cycle O -
. O +

CONCLUSIONS O -
: O +
Verapamil O +
promotes O +
AF B-Disease +
in O +
normal O +
dogs O +
by O +
promoting O +
multiple O +
circuit O +
reentry O -
, O +
an O +
effect O +
dependent O +
on O +
intact O +
autonomic O +
tone O +
and O +
not O +
shared O +
by O +
diltiazem O -
. O +

Calcitonin O +
gene O -
- O -
related O +
peptide O +
levels O +
during O +
nitric O +
oxide O -
- O -
induced O +
headache B-Disease +
in O +
patients O +
with O +
chronic O +
tension B-Disease -
- I-Disease -
type I-Disease +
headache I-Disease -
. O +

It O +
has O +
been O +
proposed O +
that O +
nitric O +
oxide O +
( O -
NO O -
) O +
induced O +
headache B-Disease +
in O +
primary B-Disease +
headaches I-Disease +
may O +
be O +
associated O +
with O +
release O +
of O +
calcitonin O +
gene O -
- O -
related O +
peptide O +
( O -
CGRP O -
) O -
. O +

In O +
the O +
present O +
study O +
we O +
aimed O +
to O +
investigate O +
plasma O +
levels O +
of O +
CGRP O +
during O +
headache B-Disease +
induced O +
by O +
the O +
NO O +
donor O +
glyceryl O +
trinitrate O +
( O -
GTN O -
) O +
in O +
16 O +
patients O +
with O +
chronic O +
tension B-Disease -
- I-Disease -
type I-Disease +
headache I-Disease +
and O +
16 O +
healthy O +
controls O -
. O +

The O +
subjects O +
were O +
randomly O +
allocated O +
to O +
receive O +
0.5 O +
microg O -
/ O -
kg O -
/ O -
min O +
GTN O +
or O +
placebo O +
over O +
20 O +
min O +
on O +
two O +
headache B-Disease -
- O -
free O +
days O -
. O +

Blood O +
samples O +
were O +
collected O +
at O +
baseline O -
, O +
10 O -
, O +
20 O +
and O +
60 O +
min O +
after O +
start O +
of O +
infusion O -
. O +

Both O +
patients O +
and O +
controls O +
developed O +
significantly O +
stronger O +
immediate O +
headache B-Disease +
on O +
the O +
GTN O +
day O +
than O +
on O +
the O +
placebo O +
day O +
and O +
the O +
headache B-Disease +
was O +
significantly O +
more O +
pronounced O +
in O +
patients O +
than O +
in O +
controls O -
. O +

There O +
was O +
no O +
difference O +
between O +
the O +
area O +
under O +
the O +
CGRP O +
curve O +
( O -
AUCCGRP O -
) O +
on O +
GTN O +
vs. O +
placebo O +
day O +
in O +
either O +
patients O +
( O -
P=0.65 O -
) O +
or O +
controls O +
( O -
P=0.48 O -
) O -
. O +

The O +
AUCCGRP O +
recorded O +
on O +
the O +
GTN O +
day O +
did O +
not O +
differ O +
between O +
patients O +
and O +
controls O +
( O -
P=0.36 O -
) O -
. O +

Both O +
in O +
patients O +
and O +
controls O -
, O +
CGRP O +
levels O +
changed O +
significantly O +
over O +
time O -
, O +
on O +
both O +
the O +
GTN O +
and O +
placebo O +
days O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

The O +
present O +
study O +
indicates O +
that O +
NO O -
- O -
induced O +
immediate O +
headache B-Disease +
is O +
not O +
associated O +
with O +
release O +
of O +
CGRP O -
. O +

Nephrotoxicity B-Disease +
of O +
combined O +
cephalothin O -
- O -
gentamicin O +
regimen O -
. O +

Two O +
patients O +
developed O +
acute B-Disease +
tubular I-Disease +
necrosis I-Disease -
, O +
characterized O +
clinically O +
by O +
acute O +
oliguric B-Disease +
renal B-Disease +
failure I-Disease -
, O +
while O +
they O +
were O +
receiving O +
a O +
combination O +
of O +
cephalothin O +
sodium O +
and O +
gentamicin O +
sulfate O +
therapy O -
. O +

Patients O +
who O +
are O +
given O +
this O +
drug O +
regimen O +
should O +
be O +
observed O +
very O +
carefully O +
for O +
early O +
signs O +
of O +
nephrotoxicity B-Disease -
. O +

High O +
doses O +
of O +
this O +
antibiotic O +
combination O +
should O +
be O +
avoided O +
especially O +
in O +
elderly O +
patients O -
. O +

Patients O +
with O +
renal B-Disease +
insufficiency I-Disease +
should O +
not O +
be O +
given O +
this O +
regimen O -
. O +

In O +
vivo O +
protection O +
of O +
dna O +
damage O +
associated O +
apoptotic O +
and O +
necrotic B-Disease +
cell O +
deaths O +
during O +
acetaminophen O -
- O -
induced O +
nephrotoxicity B-Disease -
, O +
amiodarone O -
- O -
induced O +
lung B-Disease +
toxicity I-Disease +
and O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease +
by O +
a O +
novel O +
IH636 O +
grape O +
seed O +
proanthocyanidin O +
extract O -
. O +

Grape O +
seed O +
extract O -
, O +
primarily O +
a O +
mixture O +
of O +
proanthocyanidins O -
, O +
has O +
been O +
shown O +
to O +
modulate O +
a O +
wide O -
- O -
range O +
of O +
biological O -
, O +
pharmacological O +
and O +
toxicological O +
effects O +
which O +
are O +
mainly O +
cytoprotective O -
. O +

This O +
study O +
assessed O +
the O +
ability O +
of O +
IH636 O +
grape O +
seed O +
proanthocyanidin O +
extract O +
( O -
GSPE O -
) O +
to O +
prevent O +
acetaminophen O +
( O -
AAP O -
) O -
-induced O +
nephrotoxicity B-Disease -
, O +
amiodarone O +
( O -
AMI O -
) O -
-induced O +
lung B-Disease +
toxicity I-Disease -
, O +
and O +
doxorubicin O +
( O -
DOX O -
) O -
-induced O +
cardiotoxicity B-Disease +
in O +
mice O -
. O +

Experimental O +
design O +
consisted O +
of O +
four O +
groups O -
: O +
control O +
( O -
vehicle O +
alone O -
) O -
, O +
GSPE O +
alone O -
, O +
drug O +
alone O +
and O +
GSPE+drug O -
. O +

For O +
the O +
cytoprotection O +
study O -
, O +
animals O +
were O +
orally O +
gavaged O +
100 O +
mg O -
/ O -
Kg O +
GSPE O +
for O +
7 O -
- O -
10 O +
days O +
followed O +
by O +
i.p O -
. O +

injections O +
of O +
organ O +
specific O +
three O +
drugs O +
( O -
AAP O -
: O +
500 O +
mg O -
/ O -
Kg O +
for O +
24 O +
h O -
; O +
AMI O -
: O +
50 O +
mg O -
/ O -
Kg O -
/ O -
day O +
for O +
four O +
days O -
; O +
DOX O -
: O +
20 O +
mg O -
/ O -
Kg O +
for O +
48 O +
h O -
) O -
. O +

Parameters O +
of O +
study O +
included O +
analysis O +
of O +
serum O +
chemistry O +
( O -
ALT O -
, O +
BUN O +
and O +
CPK O -
) O -
, O +
and O +
orderly O +
fragmentation O +
of O +
genomic O +
DNA O +
( O -
both O +
endonuclease O -
- O -
dependent O +
and O +
independent O -
) O +
in O +
addition O +
to O +
microscopic O +
evaluation O +
of O +
damage O +
and/or O +
protection O +
in O +
corresponding O +
PAS O +
stained O +
tissues O -
. O +

Results O +
indicate O +
that O +
GSPE O +
preexposure O +
prior O +
to O +
AAP O -
, O +
AMI O +
and O +
DOX O -
, O +
provided O +
near O +
complete O +
protection O +
in O +
terms O +
of O +
serum O +
chemistry O +
changes O +
( O -
ALT O -
, O +
BUN O +
and O +
CPK O -
) O -
, O +
and O +
significantly O +
reduced O +
DNA O +
fragmentation O -
. O +

Histopathological O +
examination O +
of O +
kidney O -
, O +
heart O +
and O +
lung O +
sections O +
revealed O +
moderate O +
to O +
massive O +
tissue B-Disease +
damage I-Disease +
with O +
a O +
variety O +
of O +
morphological O +
aberrations O +
by O +
all O +
the O +
three O +
drugs O +
in O +
the O +
absence O +
of O +
GSPE O +
preexposure O +
than O +
in O +
its O +
presence O -
. O +

GSPE+drug O +
exposed O +
tissues O +
exhibited O +
minor O +
residual O +
damage O +
or O +
near O +
total O +
recovery O -
. O +

Additionally O -
, O +
histopathological O +
alterations O +
mirrored O +
both O +
serum O +
chemistry O +
changes O +
and O +
the O +
pattern O +
of O +
DNA O +
fragmentation O -
. O +

Interestingly O -
, O +
all O +
the O +
drugs O -
, O +
such O +
as O -
, O +
AAP O -
, O +
AMI O +
and O +
DOX O +
induced O +
apoptotic O +
death O +
in O +
addition O +
to O +
necrosis B-Disease +
in O +
the O +
respective O +
organs O +
which O +
was O +
very O +
effectively O +
blocked O +
by O +
GSPE O -
. O +

Since O +
AAP O -
, O +
AMI O +
and O +
DOX O +
undergo O +
biotransformation O +
and O +
are O +
known O +
to O +
produce O +
damaging O +
radicals O +
in O +
vivo O -
, O +
the O +
protection O +
by O +
GSPE O +
may O +
be O +
linked O +
to O +
both O +
inhibition O +
of O +
metabolism O +
and/or O +
detoxification O +
of O +
cytotoxic O +
radicals O -
. O +

In O +
addition O -
, O +
its O -
' O +
presumed O +
contribution O +
to O +
DNA O +
repair O +
may O +
be O +
another O +
important O +
attribute O -
, O +
which O +
played O +
a O +
role O +
in O +
the O +
chemoprevention O +
process O -
. O +

Additionally O -
, O +
this O +
may O +
have O +
been O +
the O +
first O +
report O +
on O +
AMI O -
- O -
induced O +
apoptotic O +
death O +
in O +
the O +
lung O +
tissue O -
. O +

Taken O +
together O -
, O +
these O +
events O +
undoubtedly O +
establish O +
GSPE O -
's O +
abundant O +
bioavailability O -
, O +
and O +
the O +
power O +
to O +
defend O +
multiple O +
target O +
organs O +
from O +
toxic O +
assaults O +
induced O +
by O +
structurally O +
diverse O +
and O +
functionally O +
different O +
entities O +
in O +
vivo O -
. O +

Antidepressant O -
- O -
induced O +
mania B-Disease +
in O +
bipolar B-Disease +
patients O -
: O +
identification O +
of O +
risk O +
factors O -
. O +

BACKGROUND O -
: O +
Concerns O +
about O +
possible O +
risks O +
of O +
switching O +
to O +
mania B-Disease +
associated O +
with O +
antidepressants O +
continue O +
to O +
interfere O +
with O +
the O +
establishment O +
of O +
an O +
optimal O +
treatment O +
paradigm O +
for O +
bipolar B-Disease +
depression I-Disease -
. O +

METHOD O -
: O +
The O +
response O +
of O +
44 O +
patients O +
meeting O +
DSM O -
- O -
IV O +
criteria O +
for O +
bipolar B-Disease +
disorder I-Disease +
to O +
naturalistic O +
treatment O +
was O +
assessed O +
for O +
at O +
least O +
6 O +
weeks O +
using O +
the O +
Montgomery O -
- O -
Asberg O +
Depression O +
Rating O +
Scale O +
and O +
the O +
Bech O -
- O -
Rafaelson O +
Mania O +
Rating O +
Scale O -
. O +

Patients O +
who O +
experienced O +
a O +
manic B-Disease +
or O +
hypomanic B-Disease +
switch O +
were O +
compared O +
with O +
those O +
who O +
did O +
not O +
on O +
several O +
variables O +
including O +
age O -
, O +
sex O -
, O +
diagnosis O +
( O -
DSM B-Disease -
- I-Disease -
IV I-Disease +
bipolar I-Disease +
I I-Disease +
vs. O +
bipolar B-Disease +
II I-Disease -
) O -
, O +
number O +
of O +
previous O +
manic B-Disease +
episodes O -
, O +
type O +
of O +
antidepressant O +
therapy O +
used O +
( O -
electroconvulsive O +
therapy O +
vs. O +
antidepressant O +
drugs O +
and O -
, O +
more O +
particularly O -
, O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
[ O -
SSRIs O -
] O -
) O -
, O +
use O +
and O +
type O +
of O +
mood O +
stabilizers O +
( O -
lithium O +
vs. O +
anticonvulsants O -
) O -
, O +
and O +
temperament O +
of O +
the O +
patient O -
, O +
assessed O +
during O +
a O +
normothymic O +
period O +
using O +
the O +
hyperthymia O +
component O +
of O +
the O +
Semi O -
- O -
structured O +
Affective O +
Temperament O +
Interview O -
. O +

RESULTS O -
: O +
Switches O +
to O +
hypomania B-Disease +
or O +
mania B-Disease +
occurred O +
in O +
27 O -
% O +
of O +
all O +
patients O +
( O -
N O +
= O +
12 O -
) O +
( O -
and O +
in O +
24 O -
% O +
of O +
the O +
subgroup O +
of O +
patients O +
treated O +
with O +
SSRIs O +
[ O -
8 O -
/ O -
33 O -
] O -
) O -
; O +
16 O -
% O +
( O -
N O +
= O +
7 O -
) O +
experienced O +
manic B-Disease +
episodes O -
, O +
and O +
11 O -
% O +
( O -
N O +
= O +
5 O -
) O +
experienced O +
hypomanic B-Disease +
episodes O -
. O +

Sex O -
, O +
age O -
, O +
diagnosis O +
( O -
bipolar B-Disease +
I I-Disease +
vs. O +
bipolar B-Disease +
II I-Disease -
) O -
, O +
and O +
additional O +
treatment O +
did O +
not O +
affect O +
the O +
risk O +
of O +
switching O -
. O +

The O +
incidence O +
of O +
mood O +
switches O +
seemed O +
not O +
to O +
differ O +
between O +
patients O +
receiving O +
an O +
anticonvulsant O +
and O +
those O +
receiving O +
no O +
mood O +
stabilizer O -
. O +

In O +
contrast O -
, O +
mood O +
switches O +
were O +
less O +
frequent O +
in O +
patients O +
receiving O +
lithium O +
( O -
15 O -
% O -
, O +
4 O -
/ O -
26 O -
) O +
than O +
in O +
patients O +
not O +
treated O +
with O +
lithium O +
( O -
44 O -
% O -
, O +
8 O -
/ O -
18 O -
; O +
p O +
= O +
.04 O -
) O -
. O +

The O +
number O +
of O +
previous O +
manic B-Disease +
episodes O +
did O +
not O +
affect O +
the O +
probability O +
of O +
switching O -
, O +
whereas O +
a O +
high O +
score O +
on O +
the O +
hyperthymia O +
component O +
of O +
the O +
Semistructured O +
Affective O +
Temperament O +
Interview O +
was O +
associated O +
with O +
a O +
greater O +
risk O +
of O +
switching O +
( O -
p O +
= O +
.008 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
frequency O +
of O +
mood O +
switching O +
associated O +
with O +
acute O +
antidepressant O +
therapy O +
may O +
be O +
reduced O +
by O +
lithium O +
treatment O -
. O +

Particular O +
attention O +
should O +
be O +
paid O +
to O +
patients O +
with O +
a O +
hyperthymic O +
temperament O -
, O +
who O +
have O +
a O +
greater O +
risk O +
of O +
mood O +
switches O -
. O +

Peritubular O +
capillary O +
basement O +
membrane O +
reduplication O +
in O +
allografts O +
and O +
native O +
kidney B-Disease +
disease I-Disease -
: O +
a O +
clinicopathologic O +
study O +
of O +
278 O +
consecutive O +
renal O +
specimens O -
. O +

BACKGROUND O -
: O +
An O +
association O +
has O +
been O +
found O +
between O +
transplant B-Disease +
glomerulopathy I-Disease +
( O -
TG B-Disease -
) O +
and O +
reduplication O +
of O +
peritubular O +
capillary O +
basement O +
membranes O +
( O -
PTCR O -
) O -
. O +

Although O +
such O +
an O +
association O +
is O +
of O +
practical O +
and O +
theoretical O +
importance O -
, O +
only O +
one O +
prospective O +
study O +
has O +
tried O +
to O +
confirm O +
it O -
. O +

METHODS O -
: O +
We O +
examined O +
278 O +
consecutive O +
renal O +
specimens O +
( O -
from O +
135 O +
transplants O +
and O +
143 O +
native O +
kidneys O -
) O +
for O +
ultrastructural O +
evidence O +
of O +
PTCR O -
. O +

In O +
addition O +
to O +
renal O +
allografts O +
with O +
TG B-Disease -
, O +
we O +
also O +
examined O +
grafts O +
with O +
acute O +
rejection O -
, O +
recurrent O +
glomerulonephritis B-Disease -
, O +
chronic B-Disease +
allograft I-Disease +
nephropathy I-Disease +
and O +
stable O +
grafts O +
( O -
" O -
protocol O +
biopsies O -
" O -
) O -
. O +

Native O +
kidney O +
specimens O +
included O +
a O +
wide O +
range O +
of O +
glomerulopathies B-Disease +
as O +
well O +
as O +
cases O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease -
, O +
malignant B-Disease +
hypertension I-Disease -
, O +
acute O +
interstitial B-Disease +
nephritis I-Disease -
, O +
and O +
acute B-Disease +
tubular I-Disease +
necrosis I-Disease -
. O +

RESULTS O -
: O +
We O +
found O +
PTCR O +
in O +
14 O +
of O +
15 O +
cases O +
of O +
TG B-Disease -
, O +
in O +
7 O +
transplant O +
biopsy O +
specimens O +
without O +
TG B-Disease -
, O +
and O +
in O +
13 O +
of O +
143 O +
native O +
kidney O +
biopsy O +
specimens O -
. O +

These O +
13 O +
included O +
cases O +
of O +
malignant B-Disease +
hypertension I-Disease -
, O +
thrombotic B-Disease +
microangiopathy I-Disease -
, O +
lupus B-Disease +
nephritis I-Disease -
, O +
Henoch B-Disease -
- I-Disease -
Schonlein I-Disease +
nephritis I-Disease -
, O +
crescentic O +
glomerulonephritis B-Disease -
, O +
and O +
cocaine O -
- O -
related O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

Mild O +
PTCR O +
in O +
allografts O +
without O +
TG B-Disease +
did O +
not O +
predict O +
renal B-Disease +
failure I-Disease +
or O +
significant O +
proteinuria B-Disease +
after O +
follow O -
- O -
up O +
periods O +
of O +
between O +
3 O +
months O +
and O +
1 O +
year O -
. O +

CONCLUSIONS O -
: O +
We O +
conclude O +
that O +
in O +
transplants O -
, O +
there O +
is O +
a O +
strong O +
association O +
between O +
well O -
- O -
developed O +
PTCR O +
and O +
TG B-Disease -
, O +
while O +
the O +
significance O +
of O +
mild O +
PTCR O +
and O +
its O +
predictive O +
value O +
in O +
the O +
absence O +
of O +
TG B-Disease +
is O +
unclear O -
. O +

PTCR O +
also O +
occurs O +
in O +
certain O +
native O +
kidney B-Disease +
diseases I-Disease -
, O +
though O +
the O +
association O +
is O +
not O +
as O +
strong O +
as O +
that O +
for O +
TG B-Disease -
. O +

We O +
suggest O +
that O +
repeated O +
endothelial B-Disease +
injury I-Disease -
, O +
including O +
immunologic B-Disease +
injury I-Disease -
, O +
may O +
be O +
the O +
cause O +
of O +
this O +
lesion O +
both O +
in O +
allografts O +
and O +
native O +
kidneys O -
. O +

The O +
renal O +
pathology O +
in O +
a O +
case O +
of O +
lithium O -
- O -
induced O +
diabetes B-Disease +
insipidus I-Disease -
. O +

A O +
case O +
of O +
lithium O -
- O -
induced O +
diabetes B-Disease +
insipidus I-Disease +
is O +
reported O -
. O +

At O +
necropsy O +
microscopy O +
shoed O +
unique O +
and O +
extensive O +
damage O +
to O +
cells O +
lining O +
the O +
distal O +
nephron O -
. O +

It O +
is O +
suggested O +
that O +
these O +
changes O +
represent O +
a O +
specific O +
toxic O +
effect O +
of O +
lithium O -
, O +
reported O +
here O +
for O +
the O +
first O +
time O +
in O +
man O -
. O +

Caffeine O -
- O -
induced O +
cardiac B-Disease +
arrhythmia I-Disease -
: O +
an O +
unrecognised O +
danger O +
of O +
healthfood O +
products O -
. O +

We O +
describe O +
a O +
25-year O -
- O -
old O +
woman O +
with O +
pre O -
- O -
existing O +
mitral B-Disease +
valve I-Disease +
prolapse I-Disease +
who O +
developed O +
intractable O +
ventricular B-Disease +
fibrillation I-Disease +
after O +
consuming O +
a O +
" O -
natural O +
energy O -
" O +
guarana O +
health O +
drink O +
containing O +
a O +
high O +
concentration O +
of O +
caffeine O -
. O +

This O +
case O +
highlights O +
the O +
need O +
for O +
adequate O +
labelling O +
and O +
regulation O +
of O +
such O +
products O -
. O +

Conformationally O +
restricted O +
analogs O +
of O +
BD1008 O +
and O +
an O +
antisense O +
oligodeoxynucleotide O +
targeting O +
sigma1 O +
receptors O +
produce O +
anti O -
- O -
cocaine O +
effects O +
in O +
mice O -
. O +

Cocaine O -
's O +
ability O +
to O +
interact O +
with O +
sigma O +
receptors O +
suggests O +
that O +
these O +
proteins O +
mediate O +
some O +
of O +
its O +
behavioral O +
effects O -
. O +

Therefore O -
, O +
three O +
novel O +
sigma O +
receptor O +
ligands O +
with O +
antagonist O +
activity O +
were O +
evaluated O +
in O +
Swiss O +
Webster O +
mice O -
: O +
BD1018 O +
( O -
3S-1- O -
[ O -
2- O -
( O -
3,4-dichlorophenyl O -
) O -
ethyl O -
] O -
-1,4-diazabicyclo O -
[ O -
4.3.0 O -
] O -
nonane O -
) O -
, O +
BD1063 O +
( O -
1- O -
[ O -
2- O -
( O -
3,4-dichlorophenyl O -
) O -
ethyl O -
] O -
-4-methylpiperazine O -
) O -
, O +
and O +
LR132 O +
( O -
1R,2S- O -
( O -
+ O -
) O -
-cis O -
- O -
N- O -
[ O -
2- O -
( O -
3,4-dichlorophenyl O -
) O -
ethyl O -
] O -
-2- O -
( O -
1-pyrrolidinyl O -
) O -
cyclohexylamine O -
) O -
. O +

Competition O +
binding O +
assays O +
demonstrated O +
that O +
all O +
three O +
compounds O +
have O +
high O +
affinities O +
for O +
sigma1 O +
receptors O -
. O +

The O +
three O +
compounds O +
vary O +
in O +
their O +
affinities O +
for O +
sigma2 O +
receptors O +
and O +
exhibit O +
negligible O +
affinities O +
for O +
dopamine O -
, O +
opioid O -
, O +
GABA O -
( O -
A O -
) O +
and O +
NMDA O +
receptors O -
. O +

In O +
behavioral O +
studies O -
, O +
pre O -
- O -
treatment O +
of O +
mice O +
with O +
BD1018 O -
, O +
BD1063 O -
, O +
or O +
LR132 O +
significantly O +
attenuated O +
cocaine O -
- O -
induced O +
convulsions B-Disease +
and O +
lethality O -
. O +

Moreover O -
, O +
post O -
- O -
treatment O +
with O +
LR132 O +
prevented O +
cocaine O -
- O -
induced O +
lethality O +
in O +
a O +
significant O +
proportion O +
of O +
animals O -
. O +

In O +
contrast O +
to O +
the O +
protection O +
provided O +
by O +
the O +
putative O +
antagonists O -
, O +
the O +
well O -
- O -
characterized O +
sigma O +
receptor O +
agonist O +
di O -
- O -
o O -
- O -
tolylguanidine O +
( O -
DTG O -
) O +
and O +
the O +
novel O +
sigma O +
receptor O +
agonist O +
BD1031 O +
( O -
3R-1- O -
[ O -
2- O -
( O -
3,4-dichlorophenyl O -
) O -
ethyl O -
] O -
-1,4-diazabicyclo O -
[ O -
4.3.0 O -
] O -
nonane O -
) O +
each O +
worsened O +
the O +
behavioral O +
toxicity B-Disease +
of O +
cocaine O -
. O +

At O +
doses O +
where O +
alone O -
, O +
they O +
produced O +
no O +
significant O +
effects O +
on O +
locomotion O -
, O +
BD1018 O -
, O +
BD1063 O +
and O +
LR132 O +
significantly O +
attenuated O +
the O +
locomotor O +
stimulatory O +
effects O +
of O +
cocaine O -
. O +

To O +
further O +
validate O +
the O +
hypothesis O +
that O +
the O +
anti O -
- O -
cocaine O +
effects O +
of O +
the O +
novel O +
ligands O +
involved O +
antagonism O +
of O +
sigma O +
receptors O -
, O +
an O +
antisense O +
oligodeoxynucleotide O +
against O +
sigma1 O +
receptors O +
was O +
also O +
shown O +
to O +
significantly O +
attenuate O +
the O +
convulsive B-Disease +
and O +
locomotor O +
stimulatory O +
effects O +
of O +
cocaine O -
. O +

Together O -
, O +
the O +
data O +
suggests O +
that O +
functional O +
antagonism O +
of O +
sigma O +
receptors O +
is O +
capable O +
of O +
attenuating O +
a O +
number O +
of O +
cocaine O -
- O -
induced O +
behaviors O -
. O +

Ranitidine O -
- O -
induced O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
in O +
a O +
cadaveric O +
renal O +
allograft O -
. O +

Ranitidine O +
frequently O +
is O +
used O +
for O +
preventing O +
peptic O +
ulceration O +
after O +
renal O +
transplantation O -
. O +

This O +
drug O +
occasionally O +
has O +
been O +
associated O +
with O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
in O +
native O +
kidneys O -
. O +

There O +
are O +
no O +
similar O +
reports O +
with O +
renal O +
transplantation O -
. O +

We O +
report O +
a O +
case O +
of O +
ranitidine O -
- O -
induced O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
in O +
a O +
recipient O +
of O +
a O +
cadaveric O +
renal O +
allograft O +
presenting O +
with O +
acute O +
allograft O +
dysfunction O +
within O +
48 O +
hours O +
of O +
exposure O +
to O +
the O +
drug O -
. O +

The O +
biopsy O +
specimen O +
showed O +
pathognomonic O +
features O -
, O +
including O +
eosinophilic O +
infiltration O +
of O +
the O +
interstitial O +
compartment O -
. O +

Allograft O +
function O +
improved O +
rapidly O +
and O +
returned O +
to O +
baseline O +
after O +
stopping O +
the O +
drug O -
. O +

Cholestatic B-Disease +
jaundice I-Disease +
associated O +
with O +
the O +
use O +
of O +
metformin O -
. O +

We O +
report O +
a O +
patient O +
who O +
developed O +
cholestatic B-Disease +
jaundice I-Disease +
shortly O +
after O +
initiation O +
of O +
treatment O +
with O +
metformin O +
hydrochloride O -
. O +

Ultrasound O +
of O +
the O +
liver O +
and O +
abdominal O +
CT O +
were O +
normal O -
. O +

An O +
ERCP O +
showed O +
normal O +
biliary O +
anatomy O -
. O +

A O +
percutaneous O +
liver O +
biopsy O +
was O +
obtained O +
showing O +
marked O +
cholestasis B-Disease -
, O +
with O +
portal O +
edema B-Disease -
, O +
ductular O +
proliferation O -
, O +
and O +
acute O +
inflammation B-Disease -
. O +

Metformin O +
hydrochloride O +
was O +
discontinued O -
, O +
and O +
the O +
patient O -
's O +
jaundice B-Disease +
resolved O +
slowly O +
over O +
a O +
period O +
of O +
several O +
months O -
. O +

Given O +
the O +
onset O +
of O +
his O +
jaundice B-Disease +
2 O +
wk O +
after O +
the O +
initiation O +
of O +
metformin O -
, O +
we O +
believe O +
that O +
this O +
case O +
represents O +
an O +
example O +
of O +
metformin O -
- O -
associated O +
hepatotoxicity B-Disease -
, O +
the O +
first O +
such O +
case O +
reported O -
. O +

Liver B-Disease +
disease I-Disease +
caused O +
by O +
propylthiouracil O -
. O +

This O +
report O +
presents O +
the O +
clinical O -
, O +
laboratory O -
, O +
and O +
light O +
and O +
electron O +
microscopic O +
observations O +
on O +
a O +
patient O +
with O +
chronic B-Disease +
active I-Disease +
( I-Disease -
aggressive I-Disease -
) I-Disease +
hepatitis I-Disease +
caused O +
by O +
the O +
administration O +
of O +
propylthiouracil O -
. O +

This O +
is O +
an O +
addition O +
to O +
the O +
list O +
of O +
drugs O +
that O +
must O +
be O +
considered O +
in O +
the O +
evaluation O +
of O +
chronic O +
liver B-Disease +
disease I-Disease -
. O +

Systemic O +
toxicity B-Disease +
and O +
resuscitation O +
in O +
bupivacaine- O -
, O +
levobupivacaine- O -
, O +
or O +
ropivacaine O -
- O -
infused O +
rats O -
. O +

We O +
compared O +
the O +
systemic O +
toxicity B-Disease +
of O +
bupivacaine O -
, O +
levobupivacaine O -
, O +
and O +
ropivacaine O +
in O +
anesthetized O +
rats O -
. O +

We O +
also O +
compared O +
the O +
ability O +
to O +
resuscitate O +
rats O +
after O +
lethal O +
doses O +
of O +
these O +
local O +
anesthetics O -
. O +

Bupivacaine O -
, O +
levobupivacaine O -
, O +
or O +
ropivacaine O +
was O +
infused O +
at O +
a O +
rate O +
of O +
2 O +
mg O -
. O +

kg O -
( O -
-1 O -
) O -
. O +

min O -
( O -
-1 O -
) O +
while O +
electrocardiogram O -
, O +
electroencephalogram O -
, O +
and O +
arterial O +
pressure O +
were O +
continuously O +
monitored O -
. O +

When O +
asystole B-Disease +
was O +
recorded O -
, O +
drug O +
infusion O +
was O +
stopped O +
and O +
a O +
resuscitation O +
sequence O +
was O +
begun O -
. O +

Epinephrine O +
0.01 O +
mg O -
/ O -
kg O +
was O +
administered O +
at O +
1-min O +
intervals O +
while O +
external O +
cardiac O +
compressions O +
were O +
applied O -
. O +

Resuscitation O +
was O +
considered O +
successful O +
when O +
a O +
systolic O +
arterial O +
pressure O +
> O +
or O +
= O -
100 O +
mm O +
Hg O +
was O +
achieved O +
within O +
5 O +
min O -
. O +

The O +
cumulative O +
doses O +
of O +
levobupivacaine O +
and O +
ropivacaine O +
that O +
produced O +
seizures B-Disease +
were O +
similar O +
and O +
were O +
larger O +
than O +
those O +
of O +
bupivacaine O -
. O +

The O +
cumulative O +
doses O +
of O +
levobupivacaine O +
that O +
produced O +
dysrhythmias B-Disease +
and O +
asystole B-Disease +
were O +
smaller O +
than O +
the O +
corresponding O +
doses O +
of O +
ropivacaine O -
, O +
but O +
they O +
were O +
larger O +
than O +
those O +
of O +
bupivacaine O -
. O +

The O +
number O +
of O +
successful O +
resuscitations O +
did O +
not O +
differ O +
among O +
groups O -
. O +

However O -
, O +
a O +
smaller O +
dose O +
of O +
epinephrine O +
was O +
required O +
in O +
the O +
Ropivacaine O +
group O +
than O +
in O +
the O +
other O +
groups O -
. O +

We O +
conclude O +
that O +
the O +
systemic O +
toxicity B-Disease +
of O +
levobupivacaine O +
is O +
intermediate O +
between O +
that O +
of O +
ropivacaine O +
and O +
bupivacaine O +
when O +
administered O +
at O +
the O +
same O +
rate O +
and O +
that O +
ropivacaine O -
- O -
induced O +
cardiac B-Disease +
arrest I-Disease +
appears O +
to O +
be O +
more O +
susceptible O +
to O +
treatment O +
than O +
that O +
induced O +
by O +
bupivacaine O +
or O +
levobupivacaine O -
. O +

Withdrawal B-Disease -
- I-Disease -
emergent I-Disease +
rabbit I-Disease +
syndrome I-Disease +
during O +
dose O +
reduction O +
of O +
risperidone O -
. O +

Rabbit B-Disease +
syndrome I-Disease +
( O -
RS B-Disease -
) O +
is O +
a O +
rare O +
extrapyramidal O +
side O +
effect O +
caused O +
by O +
prolonged O +
neuroleptic O +
medication O -
. O +

Here O +
we O +
present O +
a O +
case O +
of O +
withdrawal B-Disease -
- I-Disease -
emergent I-Disease +
RS I-Disease -
, O +
which O +
is O +
the O +
first O +
of O +
its O +
kind O +
to O +
be O +
reported O -
. O +

The O +
patient O +
developed O +
RS B-Disease +
during O +
dose O +
reduction O +
of O +
risperidone O -
. O +

The O +
symptom O +
was O +
treated O +
successfully O +
with O +
trihexyphenidyl O +
anticholinergic O +
therapy O -
. O +

The O +
underlying O +
mechanism O +
of O +
withdrawal B-Disease -
- I-Disease -
emergent I-Disease +
RS I-Disease +
in O +
the O +
present O +
case O +
may O +
have O +
been O +
related O +
to O +
the O +
pharmacological O +
profile O +
of O +
risperidone O -
, O +
a O +
serotonin O -
- O -
dopamine O +
antagonist O -
, O +
suggesting O +
the O +
pathophysiologic O +
influence O +
of O +
the O +
serotonin O +
system O +
in O +
the O +
development O +
of O +
RS B-Disease -
. O +

Pharmacokinetic O -
/ O -
pharmacodynamic O +
assessment O +
of O +
the O +
effects O +
of O +
E4031 O -
, O +
cisapride O -
, O +
terfenadine O +
and O +
terodiline O +
on O +
monophasic O +
action O +
potential O +
duration O +
in O +
dog O -
. O +

1 O -
. O +

Torsades B-Disease +
de I-Disease +
pointes I-Disease +
( O -
TDP B-Disease -
) O +
is O +
a O +
potentially O +
fatal O +
ventricular B-Disease +
tachycardia I-Disease +
associated O +
with O +
increases O +
in O +
QT O +
interval O +
and O +
monophasic O +
action O +
potential O +
duration O +
( O -
MAPD O -
) O -
. O +

TDP B-Disease +
is O +
a O +
side O -
- O -
effect O +
that O +
has O +
led O +
to O +
withdrawal O +
of O +
several O +
drugs O +
from O +
the O +
market O +
( O -
e.g. O +
terfenadine O +
and O +
terodiline O -
) O -
. O +

2 O -
. O +

The O +
potential O +
of O +
compounds O +
to O +
cause O +
TDP B-Disease +
was O +
evaluated O +
by O +
monitoring O +
their O +
effects O +
on O +
MAPD O +
in O +
dog O -
. O +

Four O +
compounds O +
known O +
to O +
increase O +
QT O +
interval O +
and O +
cause O +
TDP B-Disease +
were O +
investigated O -
: O +
terfenadine O -
, O +
terodiline O -
, O +
cisapride O +
and O +
E4031 O -
. O +

On O +
the O +
basis O +
that O +
only O +
free O +
drug O +
in O +
the O +
systemic O +
circulation O +
will O +
elicit O +
a O +
pharmacological O +
response O +
target O -
, O +
free O +
concentrations O +
in O +
plasma O +
were O +
selected O +
to O +
mimic O +
the O +
free O +
drug O +
exposures O +
in O +
man O -
. O +

Infusion O +
regimens O +
were O +
designed O +
that O +
rapidly O +
achieved O +
and O +
maintained O +
target O -
- O -
free O +
concentrations O +
of O +
these O +
drugs O +
in O +
plasma O +
and O +
data O +
on O +
the O +
relationship O +
between O +
free O +
concentration O +
and O +
changes O +
in O +
MAPD O +
were O +
obtained O +
for O +
these O +
compounds O -
. O +

3 O -
. O +

These O +
data O +
indicate O +
that O +
the O +
free O +
ED50 O +
in O +
plasma O +
for O +
terfenadine O +
( O -
1.9 O +
nM O -
) O -
, O +
terodiline O +
( O -
76 O +
nM O -
) O -
, O +
cisapride O +
( O -
11 O +
nM O -
) O +
and O +
E4031 O +
( O -
1.9 O +
nM O -
) O +
closely O +
correlate O +
with O +
the O +
free O +
concentration O +
in O +
man O +
causing O +
QT O +
effects O -
. O +

For O +
compounds O +
that O +
have O +
shown O +
TDP B-Disease +
in O +
the O +
clinic O +
( O -
terfenadine O -
, O +
terodiline O -
, O +
cisapride O -
) O +
there O +
is O +
little O +
differentiation O +
between O +
the O +
dog O +
ED50 O +
and O +
the O +
efficacious O +
free O +
plasma O +
concentrations O +
in O +
man O +
( O -
< O +
10-fold O -
) O +
reflecting O +
their O +
limited O +
safety O +
margins O -
. O +

These O +
data O +
underline O +
the O +
need O +
to O +
maximize O +
the O +
therapeutic O +
ratio O +
with O +
respect O +
to O +
TDP B-Disease +
in O +
potential O +
development O +
candidates O +
and O +
the O +
importance O +
of O +
using O +
free O +
drug O +
concentrations O +
in O +
pharmacokinetic O -
/ O -
pharmacodynamic O +
studies O -
. O +

Amphotericin O +
B O -
- O -
induced O +
seizures B-Disease +
in O +
a O +
patient O +
with O +
AIDS B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
multiple O +
episodes O +
of O +
seizure B-Disease +
activity O +
in O +
an O +
AIDS B-Disease +
patent O +
following O +
amphotericin O +
B O +
infusion O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
46-year O -
- O -
old O +
African O -
- O -
American O +
man O +
experienced O +
recurrent O +
grand B-Disease +
mal I-Disease +
seizures I-Disease +
during O +
intravenous O +
infusion O +
of O +
amphotericin O +
B O -
, O +
then O +
petit O +
mal O +
seizures B-Disease +
as O +
the O +
infusion O +
was O +
stopped O +
and O +
the O +
drug O +
concentrations O +
decreased O +
with O +
time O -
. O +

The O +
patients O +
concurrent O +
medications O +
included O +
didanosine O -
, O +
hydroxyzine O -
, O +
promethazine O -
, O +
hydrocortisone O -
, O +
and O +
prochlorperazine O -
. O +

Despite O +
administration O +
of O +
phenytoin O +
and O +
lorazepam O -
, O +
the O +
seizures B-Disease +
persisted O +
and O +
occurred O +
only O +
during O +
amphotercin O +
B O +
administration O -
. O +

DISCUSSION O -
: O +
AIDS B-Disease +
and O +
cryptococcal B-Disease +
meningitis I-Disease -
, O +
both O +
of O +
which O +
the O +
patient O +
had O -
, O +
can O +
potentially O +
cause O +
seizures B-Disease -
. O +

The O +
patient O +
had O +
a O +
history O +
of O +
alcohol B-Disease +
abuse I-Disease -
; O +
alcohol O +
intake O +
as O +
well O +
as O +
withdrawal O +
can O +
also O +
cause O +
seizures B-Disease -
. O +

Didanosine O +
also O +
has O +
a O +
potential O +
for O +
inducing O +
seizures B-Disease -
. O +

However O -
, O +
these O +
other O +
potential O +
causes O +
of O +
seizure B-Disease +
were O +
ruled O +
out O -
. O +

The O +
time O +
course O +
of O +
events O +
suggested O +
that O +
amphotericin O +
B O +
was O +
the O +
cause O +
of O +
the O +
seizures B-Disease +
in O +
this O +
AIDS B-Disease +
patient O -
. O +

CONCLUSIONS O -
: O +
Amphotericin O +
B O +
seems O +
to O +
be O +
the O +
probable O +
cause O +
of O +
the O +
seizures B-Disease -
. O +

To O +
date O -
, O +
only O +
three O +
cases O +
of O +
seizures B-Disease +
associated O +
with O +
amphotericin O +
B O +
have O +
been O +
reported O +
in O +
the O +
literature O -
, O +
but O +
healthcare O +
providers O +
should O +
be O +
aware O +
of O +
the O +
potential O +
for O +
this O +
rare O +
adverse O +
effect O -
. O +

Bladder O +
retention B-Disease +
of I-Disease +
urine I-Disease +
as O +
a O +
result O +
of O +
continuous O +
intravenous O +
infusion O +
of O +
fentanyl O -
: O +
2 O +
case O +
reports O -
. O +

Sedation O +
has O +
been O +
commonly O +
used O +
in O +
the O +
neonate O +
to O +
decrease O +
the O +
stress O +
and O +
pain B-Disease +
from O +
the O +
noxious O +
stimuli O +
and O +
invasive O +
procedures O +
in O +
the O +
neonatal O +
intensive O +
care O +
unit O -
, O +
as O +
well O +
as O +
to O +
facilitate O +
synchrony O +
between O +
ventilator O +
and O +
spontaneous O +
breaths O -
. O +

Fentanyl O -
, O +
an O +
opioid O +
analgesic O -
, O +
is O +
frequently O +
used O +
in O +
the O +
neonatal O +
intensive O +
care O +
unit O +
setting O +
for O +
these O +
very O +
purposes O -
. O +

Various O +
reported O +
side O +
effects O +
of O +
fentanyl O +
administration O +
include O +
chest B-Disease +
wall I-Disease +
rigidity I-Disease -
, O +
hypotension B-Disease -
, O +
respiratory B-Disease +
depression I-Disease -
, O +
and O +
bradycardia B-Disease -
. O +

Here O -
, O +
2 O +
cases O +
of O +
urinary B-Disease +
bladder I-Disease +
retention I-Disease +
leading O +
to O +
renal O +
pelvocalyceal O +
dilatation O +
mimicking O +
hydronephrosis B-Disease +
as O +
a O +
result O +
of O +
continuous O +
infusion O +
of O +
fentanyl O +
are O +
reported O -
. O +

Sirolimus O +
and O +
mycophenolate O +
mofetil O +
for O +
calcineurin O -
- O -
free O +
immunosuppression O +
in O +
renal O +
transplant O +
recipients O -
. O +

Calcineurin O +
inhibitors O -
, O +
such O +
as O +
cyclosporine O +
and O +
tacrolimus O -
, O +
have O +
been O +
available O +
for O +
almost O +
20 O +
years O -
. O +

Although O +
these O +
drugs O +
are O +
highly O +
effective O +
and O +
represent O +
the O +
mainstay O +
of O +
transplant O +
immunosuppression O -
, O +
they O +
are O +
associated O +
with O +
acute O +
and O +
chronic O +
nephrotoxicity B-Disease -
. O +

Acute O +
nephrotoxicity B-Disease -
, O +
which O +
occurs O +
in O +
the O +
early O +
period O +
after O +
transplantation O -
, O +
leads O +
to O +
a O +
higher O +
rate O +
of O +
dialysis O -
, O +
and O +
chronic O +
nephrotoxicity B-Disease +
may O +
eventually O +
result O +
in O +
graft O +
loss O -
. O +

Acute O +
and O +
chronic O +
nephrotoxicity B-Disease +
is O +
becoming O +
more O +
common O +
as O +
the O +
use O +
of O +
marginal O +
kidneys O +
for O +
transplantation O +
increases O -
. O +

Two O +
recently O +
available O +
immunosuppressive O +
agents O -
, O +
mycophenolate O +
mofetil O +
and O +
sirolimus O +
( O -
rapamycin O -
) O -
, O +
have O +
no O +
nephrotoxicity B-Disease -
. O +

The O +
use O +
of O +
these O +
drugs O +
in O +
combination O +
with O +
other O +
agents O +
has O +
led O +
to O +
the O +
development O +
of O +
new O +
paradigms O +
of O +
immunosuppressive O +
therapy O -
. O +

This O +
paper O +
reviews O +
the O +
results O +
of O +
clinical O +
trials O +
that O +
have O +
investigated O +
these O +
new O +
approaches O +
to O +
immunosuppression O +
in O +
renal O +
transplant O +
recipients O -
. O +

Fatal O +
myeloencephalopathy B-Disease +
due O +
to O +
accidental O +
intrathecal O +
vincristin O +
administration O -
: O +
a O +
report O +
of O +
two O +
cases O -
. O +

We O +
report O +
on O +
two O +
fatal O +
cases O +
of O +
accidental O +
intrathecal O +
vincristine O +
instillation O +
in O +
a O +
5-year O +
old O +
girl O +
with O +
recurrent O +
acute B-Disease +
lymphoblastic I-Disease +
leucemia I-Disease +
and O +
a O +
57-year O +
old O +
man O +
with O +
lymphoblastic B-Disease +
lymphoma I-Disease -
. O +

The O +
girl O +
died O +
seven O +
days O -
, O +
the O +
man O +
four O +
weeks O +
after O +
intrathecal O +
injection O +
of O +
vincristine O -
. O +

Clinically O -
, O +
the O +
onset O +
was O +
characterized O +
by O +
the O +
signs O +
of O +
opistothonus B-Disease -
, I-Disease +
sensory I-Disease +
and I-Disease +
motor I-Disease +
dysfunction I-Disease +
and O +
ascending O +
paralysis B-Disease -
. O +

Histological O +
and O +
immunohistochemical O +
investigations O +
( O -
HE O -
- O -
LFB O -
, O +
CD-68 O -
, O +
Neurofilament O -
) O +
revealed O +
degeneration B-Disease +
of I-Disease +
myelin I-Disease +
and I-Disease +
axons I-Disease +
as O +
well O +
as O +
pseudocystic B-Disease +
transformation I-Disease +
in O +
areas O +
exposed O +
to O +
vincristine O -
, O +
accompanied O +
by O +
secondary O +
changes O +
with O +
numerous O +
prominent O +
macrophages O -
. O +

The O +
clinical O +
course O +
and O +
histopathological O +
results O +
of O +
the O +
two O +
cases O +
are O +
presented O -
. O +

A O +
review O +
of O +
all O +
reported O +
cases O +
in O +
the O +
literature O +
is O +
given O -
. O +

A O +
better O +
controlled O +
regimen O +
for O +
administering O +
vincristine O +
and O +
intrathecal O +
chemotherapy O +
is O +
recommended O -
. O +

Palpebral B-Disease +
twitching I-Disease +
in O +
a O +
depressed B-Disease +
adolescent O +
on O +
citalopram O -
. O +

Current O +
estimates O +
suggest O +
that O +
between O +
0.4 O -
% O +
and O +
8.3 O -
% O +
of O +
children O +
and O +
adolescents O +
are O +
affected O +
by O +
major B-Disease +
depression I-Disease -
. O +

We O +
report O +
a O +
favorable O +
response O +
to O +
treatment O +
with O +
citalopram O +
by O +
a O +
15-year O -
- O -
old O +
boy O +
with O +
major B-Disease +
depression I-Disease +
who O +
exhibited O +
palpebral B-Disease +
twitching I-Disease +
during O +
his O +
first O +
2 O +
weeks O +
of O +
treatment O -
. O +

This O +
may O +
have O +
been O +
a O +
side O +
effect O +
of O +
citalopram O +
as O +
it O +
remitted O +
with O +
redistribution O +
of O +
doses O -
. O +

The O +
3-week O +
sulphasalazine O +
syndrome O +
strikes O +
again O -
. O +

A O +
34-year O -
- O -
old O +
lady O +
developed O +
a O +
constellation O +
of O +
dermatitis B-Disease -
, O +
fever B-Disease -
, O +
lymphadenopathy B-Disease +
and O +
hepatitis B-Disease -
, O +
beginning O +
on O +
the O +
17th O +
day O +
of O +
a O +
course O +
of O +
oral O +
sulphasalazine O +
for O +
sero O -
- O -
negative O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

Cervical O +
and O +
inguinal O +
lymph O +
node O +
biopsies O +
showed O +
the O +
features O +
of O +
severe O +
necrotising O +
lymphadenitis B-Disease -
, O +
associated O +
with O +
erythrophagocytosis O +
and O +
prominent O +
eosinophilic O +
infiltrates O -
, O +
without O +
viral O +
inclusion O +
bodies O -
, O +
suggestive O +
of O +
an O +
adverse B-Disease +
drug I-Disease +
reaction I-Disease -
. O +

A O +
week O +
later O -
, O +
fulminant O +
drug B-Disease -
- I-Disease -
induced I-Disease +
hepatitis I-Disease -
, O +
associated O +
with O +
the O +
presence O +
of O +
anti O -
- O -
nuclear O +
autoantibodies O +
( O -
but O +
not O +
with O +
other O +
markers O +
of O +
autoimmunity B-Disease -
) O -
, O +
and O +
accompanied O +
by O +
multi B-Disease -
- I-Disease -
organ I-Disease +
failure I-Disease +
and O +
sepsis B-Disease -
, O +
supervened O -
. O +

She O +
subsequently O +
died O +
some O +
5 O +
weeks O +
after O +
the O +
commencement O +
of O +
her O +
drug O +
therapy O -
. O +

Post O -
- O -
mortem O +
examination O +
showed O +
evidence O +
of O +
massive B-Disease +
hepatocellular I-Disease +
necrosis I-Disease -
, O +
acute O +
hypersensitivity O +
myocarditis B-Disease -
, O +
focal O +
acute O +
tubulo O -
- O -
interstitial O +
nephritis B-Disease +
and O +
extensive O +
bone B-Disease +
marrow I-Disease +
necrosis I-Disease -
, O +
with O +
no O +
evidence O +
of O +
malignancy B-Disease -
. O +

It O +
is O +
thought O +
that O +
the O +
clinico O -
- O -
pathological O +
features O +
and O +
chronology O +
of O +
this O +
case O +
bore O +
the O +
hallmarks O +
of O +
the O +
so O -
- O -
called O +
" O -
3-week O +
sulphasalazine O +
syndrome O -
" O -
, O +
a O +
rare O -
, O +
but O +
often O +
fatal O -
, O +
immunoallergic O +
reaction O +
to O +
sulphasalazine O -
. O +

Intravenous O +
administration O +
of O +
prochlorperazine O +
by O +
15-minute O +
infusion O +
versus O +
2-minute O +
bolus O +
does O +
not O +
affect O +
the O +
incidence O +
of O +
akathisia B-Disease -
: O +
a O +
prospective O -
, O +
randomized O -
, O +
controlled O +
trial O -
. O +

STUDY O +
OBJECTIVE O -
: O +
We O +
sought O +
to O +
compare O +
the O +
rate O +
of O +
akathisia B-Disease +
after O +
administration O +
of O +
intravenous O +
prochlorperazine O +
as O +
a O +
2-minute O +
bolus O +
or O +
15-minute O +
infusion O -
. O +

METHODS O -
: O +
We O +
conducted O +
a O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
study O +
in O +
the O +
emergency O +
department O +
of O +
a O +
central O -
- O -
city O +
teaching O +
hospital O -
. O +

Patients O +
aged O +
18 O +
years O +
or O +
older O +
treated O +
with O +
prochlorperazine O +
for O +
headache B-Disease -
, O +
nausea B-Disease -
, O +
or O +
vomiting B-Disease +
were O +
eligible O +
for O +
inclusion O -
. O +

Study O +
participants O +
were O +
randomized O +
to O +
receive O +
10 O +
mg O +
of O +
prochlorperazine O +
administered O +
intravenously O +
by O +
means O +
of O +
2-minute O +
push O +
( O -
bolus O +
group O -
) O +
or O +
10 O +
mg O +
diluted O +
in O +
50 O +
mL O +
of O +
normal O +
saline O +
solution O +
administered O +
by O +
means O +
of O +
intravenous O +
infusion O +
during O +
a O +
15-minute O +
period O +
( O -
infusion O +
group O -
) O -
. O +

The O +
main O +
outcome O +
was O +
the O +
number O +
of O +
study O +
participants O +
experiencing O +
akathisia B-Disease +
within O +
60 O +
minutes O +
of O +
administration O -
. O +

Akathisia O +
was O +
defined O +
as O +
either O +
a O +
spontaneous O +
report O +
of O +
restlessness O +
or O +
agitation B-Disease +
or O +
a O +
change O +
of O +
2 O +
or O +
more O +
in O +
the O +
patient O -
- O -
reported O +
akathisia B-Disease +
rating O +
scale O +
and O +
a O +
change O +
of O +
at O +
least O +
1 O +
in O +
the O +
investigator O -
- O -
observed O +
akathisia B-Disease +
rating O +
scale O -
. O +

The O +
intensity O +
of O +
headache B-Disease +
and O +
nausea B-Disease +
was O +
measured O +
with O +
a O +
100-mm O +
visual O +
analog O +
scale O -
. O +

RESULTS O -
: O +
One O +
hundred O +
patients O +
were O +
enrolled O -
. O +

One O +
study O +
participant O +
was O +
excluded O +
after O +
protocol O +
violation O -
. O +

Seventy O -
- O -
three O +
percent O +
( O -
73 O -
/ O -
99 O -
) O +
of O +
the O +
study O +
participants O +
were O +
treated O +
for O +
headache B-Disease +
and O +
70 O -
% O +
( O -
70 O -
/ O -
99 O -
) O +
for O +
nausea B-Disease -
. O +

In O +
the O +
bolus O +
group O -
, O +
26.0 O -
% O +
( O -
13 O -
/ O -
50 O -
) O +
had O +
akathisia B-Disease +
compared O +
with O +
32.7 O -
% O +
( O -
16 O -
/ O -
49 O -
) O +
in O +
the O +
infusion O +
group O +
( O -
Delta=-6.7 O -
% O -
; O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O +
-24.6 O -
% O +
to O +
11.2 O -
% O -
) O -
. O +

The O +
difference O +
between O +
the O +
bolus O +
and O +
infusion O +
groups O +
in O +
the O +
percentage O +
of O +
participants O +
who O +
saw O +
a O +
50 O -
% O +
reduction O +
in O +
their O +
headache B-Disease +
intensity O +
within O +
30 O +
minutes O +
was O +
11.8 O -
% O +
( O -
95 O -
% O +
CI O +
-9.6 O -
% O +
to O +
33.3 O -
% O -
) O -
. O +

The O +
difference O +
in O +
the O +
percentage O +
of O +
patients O +
with O +
a O +
50 O -
% O +
reduction O +
in O +
their O +
nausea B-Disease +
was O +
12.6 O -
% O +
( O -
95 O -
% O +
CI O +
-4.6 O -
% O +
to O +
29.8 O -
% O -
) O -
. O +

CONCLUSION O -
: O +
A O +
50 O -
% O +
reduction O +
in O +
the O +
incidence O +
of O +
akathisia B-Disease +
when O +
prochlorperazine O +
was O +
administered O +
by O +
means O +
of O +
15-minute O +
intravenous O +
infusion O +
versus O +
a O +
2-minute O +
intravenous O +
push O +
was O +
not O +
detected O -
. O +

The O +
efficacy O +
of O +
prochlorperazine O +
in O +
the O +
treatment O +
of O +
headache B-Disease +
and O +
nausea B-Disease +
likewise O +
did O +
not O +
appear O +
to O +
be O +
affected O +
by O +
the O +
rate O +
of O +
administration O -
, O +
although O +
no O +
formal O +
statistical O +
comparisons O +
were O +
made O -
. O +

Tolerability O +
of O +
nimesulide O +
and O +
paracetamol O +
in O +
patients O +
with O +
NSAID O -
- O -
induced O +
urticaria B-Disease -
/ O -
angioedema B-Disease -
. O +

Previous O +
studies O +
evaluated O +
the O +
tolerance O +
of O +
nimesulide O +
and O +
paracetamol O +
in O +
subjects O +
with O +
cutaneous O -
, O +
respiratory O +
and O +
anaphylactoid O +
reactions O +
induced O +
by O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
. O +

In O +
this O +
study O +
we O +
investigated O +
tolerability O +
and O +
reliability O +
of O +
nimesulide O +
and O +
paracetamol O +
in O +
a O +
very O +
large O +
number O +
of O +
patients O +
with O +
an O +
exclusive O +
well O -
- O -
documented O +
history O +
of O +
NSAID O -
- O -
induced O +
urticaria B-Disease -
/ O -
angioedema B-Disease -
. O +

Furthermore O -
, O +
we O +
evaluated O +
whether O +
some O +
factors O +
have O +
the O +
potential O +
to O +
increase O +
the O +
risk O +
of O +
reaction O +
to O +
paracetamol O +
and O +
nimesulide O -
. O +

A O +
single O -
- O -
placebo O -
- O -
controlled O +
oral O +
challenge O +
procedure O +
with O +
nimesulide O +
or O +
paracetamol O +
was O +
applied O +
to O +
829 O +
patients O +
with O +
a O +
history O +
of O +
NSAID O -
- O -
induced O +
urticaria B-Disease -
/ O -
angioedema B-Disease -
. O +

A O +
total O +
of O +
75 O -
/ O -
829 O +
( O -
9.4 O -
% O -
) O +
patients O +
experienced O +
reactions O +
to O +
nimesulide O +
or O +
paracetamol O -
. O +

Of O +
the O +
715 O +
patients O +
tested O +
with O +
nimesulide O +
62 O +
( O -
8.6 O -
% O -
) O +
showed O +
a O +
positive O +
test O -
, O +
while O +
of O +
114 O +
subjects O +
submitted O +
to O +
the O +
challenge O +
with O +
paracetamol O -
, O +
13 O +
( O -
9.6 O -
% O -
) O +
did O +
not O +
tolerate O +
this O +
drug O -
. O +

Furthermore O -
, O +
18.28 O -
% O +
of O +
patients O +
with O +
a O +
history O +
of O +
chronic O +
urticaria B-Disease +
and O +
11.8 O -
% O +
of O +
subjects O +
with O +
an O +
history O +
of O +
NSAID O -
- O -
induced O +
urticaria B-Disease -
/ O -
angioedema B-Disease +
or O +
angioedema B-Disease +
alone O +
( O -
with O +
or O +
without O +
chronic O +
urticaria B-Disease -
) O +
resulted O +
to O +
be O +
intolerant O +
to O +
alternative O +
drugs O -
. O +

Taken O +
together O -
, O +
our O +
results O +
confirm O +
the O +
good O +
tolerability O +
of O +
nimesulide O +
and O +
paracetamol O +
in O +
patients O +
who O +
experienced O +
urticaria B-Disease -
/ O -
angioedema B-Disease +
caused O +
by O +
NSAIDs O -
. O +

However O -
, O +
the O +
risk O +
of O +
reaction O +
to O +
these O +
alternative O +
study O +
drugs O +
is O +
statistically O +
increased O +
by O +
a O +
history O +
of O +
chronic O +
urticaria B-Disease +
and O -
, O +
above O +
all O -
, O +
by O +
a O +
history O +
of O +
NSAID O -
- O -
induced O +
angioedema B-Disease -
. O +

Comparison O +
of O +
aqueous O +
and O +
gellan O +
ophthalmic O +
timolol O +
with O +
placebo O +
on O +
the O +
24-hour O +
heart O +
rate O +
response O +
in O +
patients O +
on O +
treatment O +
for O +
glaucoma B-Disease -
. O +

PURPOSE O -
: O +
Topical O +
beta O -
- O -
blocker O +
treatment O +
is O +
routine O +
therapy O +
in O +
the O +
management O +
of O +
patients O +
with O +
glaucoma B-Disease -
. O +

Therapy O +
results O +
in O +
systemic O +
absorption O -
, O +
however O -
, O +
the O +
degree O +
of O +
reduction O +
of O +
resting O +
and O +
peak O +
heart O +
rate O +
has O +
not O +
been O +
quantified O -
. O +

DESIGN O -
: O +
This O +
trial O +
evaluated O +
the O +
effect O +
of O +
placebo O -
, O +
0.5 O -
% O +
aqueous O +
timolol O +
( O -
timolol O +
solution O -
) O +
and O +
a O +
0.5 O -
% O +
timolol O +
suspension O +
that O +
forms O +
a O +
gel O +
on O +
application O +
to O +
the O +
conjunctiva O +
( O -
timolol O +
gellan O -
) O +
on O +
the O +
24-hour O +
heart O +
rate O +
in O +
patients O +
currently O +
being O +
treated O +
for O +
glaucoma B-Disease +
to O +
quantify O +
the O +
reduction O +
in O +
mean O +
heart O +
rate O -
. O +

METHODS O -
: O +
Forty O -
- O -
three O +
Caucasian O +
patients O +
with O +
primary O +
open B-Disease -
- I-Disease -
angle I-Disease +
glaucoma I-Disease +
or O +
ocular B-Disease +
hypertension I-Disease +
with O +
a O +
mean O +
( O -
+ O -
/-SD O -
) O +
age O +
of O +
63 O +
( O -
+ O -
/-8 O -
) O +
years O +
were O +
randomized O +
and O +
crossed O +
over O +
in O +
a O +
double O -
- O -
masked O +
manner O +
to O +
14 O +
days O +
of O +
treatment O +
with O +
placebo O +
( O -
morning O +
and O +
evening O +
in O +
both O +
eyes O -
) O -
, O +
timolol O +
solution O +
( O -
morning O +
and O +
evening O +
in O +
both O +
eyes O -
) O -
, O +
or O +
timolol O +
gellan O +
( O -
morning O +
in O +
both O +
eyes O +
with O +
placebo O +
in O +
the O +
evening O -
) O -
. O +

On O +
the O +
13th O +
day O +
of O +
each O +
period O -
, O +
heart O +
rate O +
was O +
recorded O +
continuously O +
during O +
a O +
typical O -
, O +
ambulant O +
24-hour O +
period O -
. O +

RESULTS O -
: O +
Both O +
timolol O +
solution O +
and O +
timolol O +
gellan O +
reduced O +
the O +
mean O +
24-hour O +
heart O +
rate O +
compared O +
with O +
placebo O +
( O -
P O +
< O +
or O +
= O +
.001 O -
) O -
, O +
and O +
this O +
reduction O +
was O +
most O +
pronounced O +
during O +
the O +
daytime O +
( O -
-7.5 O -
% O +
change O +
in O +
mean O +
heart O +
rate O -
, O +
-5.7 O +
beats O -
/ O -
min O -
) O -
. O +

Timolol O +
gellan O +
showed O +
a O +
numerically O +
but O +
not O +
significantly O +
smaller O +
reduction O +
in O +
24-hour O +
heart O +
rate O -
, O +
compared O +
with O +
timolol O +
solution O -
. O +

During O +
the O +
night O -
, O +
the O +
mean O +
12-hour O +
heart O +
rate O +
on O +
placebo O +
and O +
timolol O +
gellan O +
were O +
both O +
significantly O +
less O +
than O +
on O +
timolol O +
solution O -
; O +
the O +
difference O +
between O +
solution O +
and O +
gellan O +
treatments O +
was O +
statistically O +
significant O +
( O -
P O +
= O +
.01 O -
) O -
. O +

CONCLUSIONS O -
: O +
Both O +
timolol O +
solution O +
and O +
timolol O +
gellan O +
decrease O +
the O +
mean O +
24-hour O +
heart O +
rate O +
compared O +
with O +
placebo O -
. O +

This O +
response O +
was O +
most O +
pronounced O +
during O +
the O +
active O +
daytime O +
period O -
. O +

These O +
data O +
quantify O +
the O +
modest O +
bradycardia B-Disease +
associated O +
with O +
ophthalmic O +
beta O -
- O -
blocker O +
therapy O +
in O +
a O +
typical O +
patient O +
population O +
on O +
therapy O +
for O +
glaucoma B-Disease -
. O +

Although O +
exercise O +
performance O +
was O +
not O +
assessed O +
in O +
this O +
trial O -
, O +
reductions O +
of O +
this O +
magnitude O +
should O +
not O +
have O +
substantial O +
clinical O +
consequences O -
. O +

Management O +
strategies O +
for O +
ribavirin O -
- O -
induced O +
hemolytic B-Disease +
anemia I-Disease +
in O +
the O +
treatment O +
of O +
hepatitis B-Disease +
C I-Disease -
: O +
clinical O +
and O +
economic O +
implications O -
. O +

OBJECTIVES O -
: O +
Recently O +
published O +
studies O +
have O +
demonstrated O +
increased O +
efficacy O +
and O +
cost O -
- O -
effectiveness O +
of O +
combination O +
therapy O +
with O +
interferon O +
and O +
alpha-2b O -
/ O -
ribavirin O +
compared O +
with O +
interferon O -
- O -
alpha O +
monotherapy O +
in O +
the O +
treatment O +
of O +
chronic B-Disease +
hepatitis I-Disease +
C I-Disease +
( O -
CHC B-Disease -
) O -
. O +

Combination O +
therapy O +
is O +
associated O +
with O +
a O +
clinically O +
important O +
adverse O +
effect O -
: O +
ribavirin O -
- O -
induced O +
hemolytic B-Disease +
anemia I-Disease +
( O -
RIHA B-Disease -
) O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
direct O +
health O -
- O -
care O +
costs O +
and O +
management O +
of O +
RIHA B-Disease +
during O +
treatment O +
of O +
CHC B-Disease +
in O +
a O +
clinical O +
trial O +
setting O -
. O +

METHODS O -
: O +
A O +
systematic O +
literature O +
review O +
was O +
conducted O +
to O +
synthesize O +
information O +
on O +
the O +
incidence O +
and O +
management O +
of O +
RIHA B-Disease -
. O +

Decision O -
- O -
analytic O +
techniques O +
were O +
used O +
to O +
estimate O +
the O +
cost O +
of O +
treating O +
RIHA B-Disease -
. O +

Uncertainty O +
was O +
evaluated O +
using O +
sensitivity O +
analyses O -
. O +

RESULTS O -
: O +
RIHA B-Disease -
, O +
defined O +
as O +
a O +
reduction O +
in O +
hemoglobin O +
to O +
less O +
than O +
100 O +
g O -
/ O -
L O -
, O +
occurs O +
in O +
approximately O +
7 O -
% O +
to O +
9 O -
% O +
of O +
patients O +
treated O +
with O +
combination O +
therapy O -
. O +

The O +
standard O +
of O +
care O +
for O +
management O +
of O +
RIHA B-Disease +
is O +
reduction O +
or O +
discontinuation O +
of O +
the O +
ribavirin O +
dosage O -
. O +

We O +
estimated O +
the O +
direct O +
cost O +
of O +
treating O +
clinically O +
significant O +
RIHA B-Disease +
to O +
be O +
170 O +
per O +
patient O +
receiving O +
combination O +
therapy O +
per O +
48-week O +
treatment O +
course O +
( O -
range O +
68- O +
692 O -
) O -
. O +

The O +
results O +
of O +
the O +
one O -
- O -
way O +
sensitivity O +
analyses O +
ranged O +
from O +
57 O +
to O +
317 O -
. O +

In O +
comparison O -
, O +
the O +
cost O +
of O +
48 O +
weeks O +
of O +
combination O +
therapy O +
is O +
16,459 O -
. O +

CONCLUSIONS O -
: O +
The O +
direct O +
cost O +
of O +
treating O +
clinically O +
significant O +
RIHA B-Disease +
is O +
1 O -
% O +
( O +
170 O -
/ O +
16,459 O -
) O +
of O +
drug O +
treatment O +
costs O -
. O +

Questions O +
remain O +
about O +
the O +
optimal O +
dose O +
of O +
ribavirin O +
and O +
the O +
incidence O +
of O +
RIHA B-Disease +
in O +
a O +
real O -
- O -
world O +
population O -
. O +

Despite O +
these O +
uncertainties O -
, O +
this O +
initial O +
evaluation O +
of O +
the O +
direct O +
cost O +
of O +
treating O +
RIHA B-Disease +
provides O +
an O +
estimate O +
of O +
the O +
cost O +
and O +
management O +
implications O +
of O +
this O +
clinically O +
important O +
adverse O +
effect O -
. O +

Combined O +
antiretroviral O +
therapy O +
causes O +
cardiomyopathy B-Disease +
and O +
elevates O +
plasma O +
lactate O +
in O +
transgenic O +
AIDS B-Disease +
mice O -
. O +

Highly O +
active O +
antiretroviral O +
therapy O +
( O -
HAART O -
) O +
is O +
implicated O +
in O +
cardiomyopathy B-Disease +
( O -
CM B-Disease -
) O +
and O +
in O +
elevated O +
plasma O +
lactate O +
( O -
LA O -
) O +
in O +
AIDS B-Disease +
through O +
mechanisms O +
of O +
mitochondrial B-Disease +
dysfunction I-Disease -
. O +

To O +
determine O +
mitochondrial O +
events O +
from O +
HAART O +
in O +
vivo O -
, O +
8-week O -
- O -
old O +
hemizygous O +
transgenic O +
AIDS B-Disease +
mice O +
( O -
NL4 O -
- O -
3Delta O +
gag O -
/ O -
pol O -
; O +
TG O -
) O +
and O +
wild O -
- O -
type O +
FVB O -
/ O -
n O +
littermates O +
were O +
treated O +
with O +
the O +
HAART O +
combination O +
of O +
zidovudine O -
, O +
lamivudine O -
, O +
and O +
indinavir O +
or O +
vehicle O +
control O +
for O +
10 O +
days O +
or O +
35 O +
days O -
. O +

At O +
termination O +
of O +
the O +
experiments O -
, O +
mice O +
underwent O +
echocardiography O -
, O +
quantitation O +
of O +
abundance O +
of O +
molecular O +
markers O +
of O +
CM B-Disease +
( O -
ventricular O +
mRNA O +
encoding O +
atrial O +
natriuretic O +
factor O +
[ O -
ANF O -
] O +
and O +
sarcoplasmic O +
calcium O +
ATPase O +
[ O -
SERCA2 O -
] O -
) O -
, O +
and O +
determination O +
of O +
plasma O +
LA O -
. O +

Myocardial O +
histologic O +
features O +
were O +
analyzed O +
semiquantitatively O +
and O +
results O +
were O +
confirmed O +
by O +
transmission O +
electron O +
microscopy O -
. O +

After O +
35 O +
days O +
in O +
the O +
TG O +
+ O +
HAART O +
cohort O -
, O +
left O +
ventricular O +
mass O +
increased O +
160 O -
% O +
by O +
echocardiography O -
. O +

Molecularly O -
, O +
ANF O +
mRNA O +
increased O +
250 O -
% O +
and O +
SERCA2 O +
mRNA O +
decreased O +
57 O -
% O -
. O +

Biochemically O -
, O +
LA O +
was O +
elevated O +
( O -
8.5 O +
+ O -
/- O +

2.0 O +
mM O -
) O -
. O +

Pathologically O -
, O +
granular O +
cytoplasmic O +
changes O +
were O +
found O +
in O +
cardiac O +
myocytes O -
, O +
indicating O +
enlarged O -
, O +
damaged O +
mitochondria O -
. O +

Findings O +
were O +
confirmed O +
ultrastructurally O -
. O +

No O +
changes O +
were O +
found O +
in O +
other O +
cohorts O -
. O +

After O +
10 O +
days O -
, O +
only O +
ANF O +
was O +
elevated O -
, O +
and O +
only O +
in O +
the O +
TG O +
+ O +
HAART O +
cohort O -
. O +

Results O +
show O +
that O +
cumulative O +
HAART O +
caused O +
mitochondrial O +
CM B-Disease +
with O +
elevated O +
LA O +
in O +
AIDS B-Disease +
transgenic O +
mice O -
. O +

A O +
Phase O +
II O +
trial O +
of O +
cisplatin O +
plus O +
WR-2721 O +
( O -
amifostine O -
) O +
for O +
metastatic O +
breast B-Disease +
carcinoma I-Disease -
: O +
an O +
Eastern O +
Cooperative O +
Oncology O +
Group O +
Study O +
( O -
E8188 O -
) O -
. O +

BACKGROUND O -
: O +
Cisplatin O +
has O +
minimal O +
antitumor O +
activity O +
when O +
used O +
as O +
second- O +
or O +
third O -
- O -
line O +
treatment O +
of O +
metastatic O +
breast B-Disease +
carcinoma I-Disease -
. O +

Older O +
reports O +
suggest O +
an O +
objective O +
response O +
rate O +
of O +
8 O -
% O +
when O +
60 O -
- O -
120 O +
mg O -
/ O -
m2 O +
of O +
cisplatin O +
is O +
administered O +
every O +
3 O -
- O -
4 O +
weeks O -
. O +

Although O +
a O +
dose O -
- O -
response O +
effect O +
has O +
been O +
observed O +
with O +
cisplatin O -
, O +
the O +
dose O -
- O -
limiting O +
toxicities B-Disease +
associated O +
with O +
cisplatin O +
( O -
e.g. O -
, O +
nephrotoxicity B-Disease -
, O +
ototoxicity B-Disease -
, O +
and O +
neurotoxicity B-Disease -
) O +
have O +
limited O +
its O +
use O +
as O +
a O +
treatment O +
for O +
breast B-Disease +
carcinoma I-Disease -
. O +

WR-2721 O +
or O +
amifostine O +
initially O +
was O +
developed O +
to O +
protect O +
military O +
personnel O +
in O +
the O +
event O +
of O +
nuclear O +
war O -
. O +

Amifostine O +
subsequently O +
was O +
shown O +
to O +
protect O +
normal O +
tissues O +
from O +
the O +
toxic O +
effects O +
of O +
alkylating O +
agents O +
and O +
cisplatin O +
without O +
decreasing O +
the O +
antitumor O +
effect O +
of O +
the O +
chemotherapy O -
. O +

Early O +
trials O +
of O +
cisplatin O +
and O +
amifostine O +
also O +
suggested O +
that O +
the O +
incidence O +
and O +
severity O +
of O +
cisplatin O -
- O -
induced O +
nephrotoxicity B-Disease -
, O +
ototoxicity B-Disease -
, O +
and O +
neuropathy B-Disease +
were O +
reduced O -
. O +

METHODS O -
: O +
A O +
Phase O +
II O +
study O +
of O +
the O +
combination O +
of O +
cisplatin O +
plus O +
amifostine O +
was O +
conducted O +
in O +
patients O +
with O +
progressive O +
metastatic O +
breast B-Disease +
carcinoma I-Disease +
who O +
had O +
received O +
one O -
, O +
but O +
not O +
more O +
than O +
one O -
, O +
chemotherapy O +
regimen O +
for O +
metastatic O +
disease O -
. O +

Patients O +
received O +
amifostine O -
, O +
910 O +
mg O -
/ O -
m2 O +
intravenously O +
over O +
15 O +
minutes O -
. O +

After O +
completion O +
of O +
the O +
amifostine O +
infusion O -
, O +
cisplatin O +
120 O +
mg O -
/ O -
m2 O +
was O +
administered O +
over O +
30 O +
minutes O -
. O +

Intravenous O +
hydration O +
and O +
mannitol O +
was O +
administered O +
before O +
and O +
after O +
cisplatin O -
. O +

Treatment O +
was O +
administered O +
every O +
3 O +
weeks O +
until O +
disease O +
progression O -
. O +

RESULTS O -
: O +
Forty O -
- O -
four O +
patients O +
were O +
enrolled O +
in O +
the O +
study O +
of O +
which O +
7 O +
( O -
16 O -
% O -
) O +
were O +
ineligible O -
. O +

A O +
median O +
of O +
2 O +
cycles O +
of O +
therapy O +
was O +
administered O +
to O +
the O +
37 O +
eligible O +
patients O -
. O +

Six O +
partial O +
responses O +
were O +
observed O +
for O +
an O +
overall O +
response O +
rate O +
of O +
16 O -
% O -
. O +

Most O +
patients O +
( O -
57 O -
% O -
) O +
stopped O +
treatment O +
because O +
of O +
disease O +
progression O -
. O +

Neurologic B-Disease +
toxicity I-Disease +
was O +
reported O +
in O +
52 O -
% O +
of O +
patients O -
. O +

Seven O +
different O +
life O -
- O -
threatening O +
toxicities B-Disease +
were O +
observed O +
in O +
patients O +
while O +
receiving O +
treatment O -
. O +

CONCLUSIONS O -
: O +
The O +
combination O +
of O +
cisplatin O +
and O +
amifostine O +
in O +
this O +
study O +
resulted O +
in O +
an O +
overall O +
response O +
rate O +
of O +
16 O -
% O -
. O +

Neither O +
a O +
tumor B-Disease -
- O -
protective O +
effect O +
nor O +
reduced O +
toxicity B-Disease +
to O +
normal O +
tissues O +
was O +
observed O +
with O +
the O +
addition O +
of O +
amifostine O +
to O +
cisplatin O +
in O +
this O +
trial O -
. O +

Oral O +
contraceptives O +
and O +
the O +
risk O +
of O +
myocardial B-Disease +
infarction I-Disease -
. O +

BACKGROUND O -
: O +
An O +
association O +
between O +
the O +
use O +
of O +
oral O +
contraceptives O +
and O +
the O +
risk O +
of O +
myocardial B-Disease +
infarction I-Disease +
has O +
been O +
found O +
in O +
some O -
, O +
but O +
not O +
all O -
, O +
studies O -
. O +

We O +
investigated O +
this O +
association O -
, O +
according O +
to O +
the O +
type O +
of O +
progestagen O +
included O +
in O +
third O -
- O -
generation O +
( O -
i.e. O -
, O +
desogestrel O +
or O +
gestodene O -
) O +
and O +
second O -
- O -
generation O +
( O -
i.e. O -
, O +
levonorgestrel O -
) O +
oral O +
contraceptives O -
, O +
the O +
dose O +
of O +
estrogen O -
, O +
and O +
the O +
presence O +
or O +
absence O +
of O +
prothrombotic O +
mutations O +
METHODS O -
: O +
In O +
a O +
nationwide O -
, O +
population O -
- O -
based O -
, O +
case O -
- O -
control O +
study O -
, O +
we O +
identified O +
and O +
enrolled O +
248 O +
women O +
18 O +
through O +
49 O +
years O +
of O +
age O +
who O +
had O +
had O +
a O +
first O +
myocardial B-Disease +
infarction I-Disease +
between O +
1990 O +
and O +
1995 O +
and O +
925 O +
control O +
women O +
who O +
had O +
not O +
had O +
a O +
myocardial B-Disease +
infarction I-Disease +
and O +
who O +
were O +
matched O +
for O +
age O -
, O +
calendar O +
year O +
of O +
the O +
index O +
event O -
, O +
and O +
area O +
of O +
residence O -
. O +

Subjects O +
supplied O +
information O +
on O +
oral O -
- O -
contraceptive O +
use O +
and O +
major O +
cardiovascular O +
risk O +
factors O -
. O +

An O +
analysis O +
for O +
factor O +
V O +
Leiden O +
and O +
the O +
G20210A O +
mutation O +
in O +
the O +
prothrombin O +
gene O +
was O +
conducted O +
in O +
217 O +
patients O +
and O +
763 O +
controls O +
RESULTS O -
: O +
The O +
odds O +
ratio O +
for O +
myocardial B-Disease +
infarction I-Disease +
among O +
women O +
who O +
used O +
any O +
type O +
of O +
combined O +
oral O +
contraceptive O -
, O +
as O +
compared O +
with O +
nonusers O -
, O +
was O +
2.0 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
1.5 O +
to O +
2.8 O -
) O -
. O +

The O +
adjusted O +
odds O +
ratio O +
was O +
2.5 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
1.5 O +
to O +
4.1 O -
) O +
among O +
women O +
who O +
used O +
second O -
- O -
generation O +
oral O +
contraceptives O +
and O +
1.3 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
0.7 O +
to O +
2.5 O -
) O +
among O +
those O +
who O +
used O +
third O -
- O -
generation O +
oral O +
contraceptives O -
. O +

Among O +
women O +
who O +
used O +
oral O +
contraceptives O -
, O +
the O +
odds O +
ratio O +
was O +
2.1 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
1.5 O +
to O +
3.0 O -
) O +
for O +
those O +
without O +
a O +
prothrombotic O +
mutation O +
and O +
1.9 O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
0.6 O +
to O +
5.5 O -
) O +
for O +
those O +
with O +
a O +
mutation O +
CONCLUSIONS O -
: O +
The O +
risk O +
of O +
myocardial B-Disease +
infarction I-Disease +
was O +
increased O +
among O +
women O +
who O +
used O +
second O -
- O -
generation O +
oral O +
contraceptives O -
. O +

The O +
results O +
with O +
respect O +
to O +
the O +
use O +
of O +
third O -
- O -
generation O +
oral O +
contraceptives O +
were O +
inconclusive O +
but O +
suggested O +
that O +
the O +
risk O +
was O +
lower O +
than O +
the O +
risk O +
associated O +
with O +
second O -
- O -
generation O +
oral O +
contraceptives O -
. O +

The O +
risk O +
of O +
myocardial B-Disease +
infarction I-Disease +
was O +
similar O +
among O +
women O +
who O +
used O +
oral O +
contraceptives O +
whether O +
or O +
not O +
they O +
had O +
a O +
prothrombotic O +
mutation O -
. O +

End B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease I-Disease +
( O -
ESRD B-Disease -
) O +
after O +
orthotopic O +
liver O +
transplantation O +
( O -
OLTX O -
) O +
using O +
calcineurin O -
- O -
based O +
immunotherapy O -
: O +
risk O +
of O +
development O +
and O +
treatment O -
. O +

BACKGROUND O -
: O +
The O +
calcineurin O +
inhibitors O +
cyclosporine O +
and O +
tacrolimus O +
are O +
both O +
known O +
to O +
be O +
nephrotoxic B-Disease -
. O +

Their O +
use O +
in O +
orthotopic O +
liver O +
transplantation O +
( O -
OLTX O -
) O +
has O +
dramatically O +
improved O +
success O +
rates O -
. O +

Recently O -
, O +
however O -
, O +
we O +
have O +
had O +
an O +
increase O +
of O +
patients O +
who O +
are O +
presenting O +
after O +
OLTX O +
with O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease I-Disease +
( O -
ESRD B-Disease -
) O -
. O +

This O +
retrospective O +
study O +
examines O +
the O +
incidence O +
and O +
treatment O +
of O +
ESRD B-Disease +
and O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
( O -
CRF B-Disease -
) O +
in O +
OLTX O +
patients O -
. O +

METHODS O -
: O +
Patients O +
receiving O +
an O +
OLTX O +
only O +
from O +
June O +
1985 O +
through O +
December O +
of O +
1994 O +
who O +
survived O +
6 O +
months O +
postoperatively O +
were O +
studied O +
( O -
n=834 O -
) O -
. O +

Our O +
prospectively O +
collected O +
database O +
was O +
the O +
source O +
of O +
information O -
. O +

Patients O +
were O +
divided O +
into O +
three O +
groups O -
: O +
Controls O -
, O +
no O +
CRF B-Disease +
or O +
ESRD B-Disease -
, O +
n=748 O -
; O +
CRF B-Disease -
, O +
sustained O +
serum O +
creatinine O +
> O -
2.5 O +
mg O -
/ O -
dl O -
, O +
n=41 O -
; O +
and O +
ESRD B-Disease -
, O +
n=45 O -
. O +

Groups O +
were O +
compared O +
for O +
preoperative O +
laboratory O +
variables O -
, O +
diagnosis O -
, O +
postoperative O +
variables O -
, O +
survival O -
, O +
type O +
of O +
ESRD B-Disease +
therapy O -
, O +
and O +
survival O +
from O +
onset O +
of O +
ESRD B-Disease -
. O +

RESULTS O -
: O +
At O +
13 O +
years O +
after O +
OLTX O -
, O +
the O +
incidence O +
of O +
severe O +
renal B-Disease +
dysfunction I-Disease +
was O +
18.1 O -
% O +
( O -
CRF B-Disease +
8.6 O -
% O +
and O +
ESRD B-Disease +
9.5 O -
% O -
) O -
. O +

Compared O +
with O +
control O +
patients O -
, O +
CRF B-Disease +
and O +
ESRD B-Disease +
patients O +
had O +
higher O +
preoperative O +
serum O +
creatinine O +
levels O -
, O +
a O +
greater O +
percentage O +
of O +
patients O +
with O +
hepatorenal B-Disease +
syndrome I-Disease -
, O +
higher O +
percentage O +
requirement O +
for O +
dialysis O +
in O +
the O +
first O +
3 O +
months O +
postoperatively O -
, O +
and O +
a O +
higher O +
1-year O +
serum O +
creatinine O -
. O +

Multivariate O +
stepwise O +
logistic O +
regression O +
analysis O +
using O +
preoperative O +
and O +
postoperative O +
variables O +
identified O +
that O +
an O +
increase O +
of O +
serum O +
creatinine O +
compared O +
with O +
average O +
at O +
1 O +
year O -
, O +
3 O +
months O -
, O +
and O +
4 O +
weeks O +
postoperatively O +
were O +
independent O +
risk O +
factors O +
for O +
the O +
development O +
of O +
CRF B-Disease +
or O +
ESRD B-Disease +
with O +
odds O +
ratios O +
of O +
2.6 O -
, O +
2.2 O -
, O +
and O +
1.6 O -
, O +
respectively O -
. O +

Overall O +
survival O +
from O +
the O +
time O +
of O +
OLTX O +
was O +
not O +
significantly O +
different O +
among O +
groups O -
, O +
but O +
by O +
year O +
13 O -
, O +
the O +
survival O +
of O +
the O +
patients O +
who O +
had O +
ESRD B-Disease +
was O +
only O +
28.2 O -
% O +
compared O +
with O +
54.6 O -
% O +
in O +
the O +
control O +
group O -
. O +

Patients O +
developing O +
ESRD B-Disease +
had O +
a O +
6-year O +
survival O +
after O +
onset O +
of O +
ESRD B-Disease +
of O +
27 O -
% O +
for O +
the O +
patients O +
receiving O +
hemodialysis O +
versus O +
71.4 O -
% O +
for O +
the O +
patients O +
developing O +
ESRD B-Disease +
who O +
subsequently O +
received O +
kidney O +
transplants O -
. O +

CONCLUSIONS O -
: O +
Patients O +
who O +
are O +
more O +
than O +
10 O +
years O +
post O -
- O -
OLTX O +
have O +
CRF B-Disease +
and O +
ESRD B-Disease +
at O +
a O +
high O +
rate O -
. O +

The O +
development O +
of O +
ESRD B-Disease +
decreases O +
survival O -
, O +
particularly O +
in O +
those O +
patients O +
treated O +
with O +
dialysis O +
only O -
. O +

Patients O +
who O +
develop O +
ESRD B-Disease +
have O +
a O +
higher O +
preoperative O +
and O +
1-year O +
serum O +
creatinine O +
and O +
are O +
more O +
likely O +
to O +
have O +
hepatorenal B-Disease +
syndrome I-Disease -
. O +

However O -
, O +
an O +
increase O +
of O +
serum O +
creatinine O +
at O +
various O +
times O +
postoperatively O +
is O +
more O +
predictive O +
of O +
the O +
development O +
of O +
CRF B-Disease +
or O +
ESRD B-Disease -
. O +

New O +
strategies O +
for O +
long O -
- O -
term O +
immunosuppression O +
may O +
be O +
needed O +
to O +
decrease O +
this O +
complication O -
. O +

Epileptic B-Disease +
seizures I-Disease +
following O +
cortical O +
application O +
of O +
fibrin O +
sealants O +
containing O +
tranexamic O +
acid O +
in O +
rats O -
. O +

BACKGROUND O -
: O +
Fibrin O +
sealants O +
( O -
FS O -
) O +
derived O +
from O +
human O +
plasma O +
are O +
frequently O +
used O +
in O +
neurosurgery O -
. O +

In O +
order O +
to O +
increase O +
clot O +
stability O -
, O +
FS O +
typically O +
contain O +
aprotinin O -
, O +
a O +
natural O +
fibrinolysis O +
inhibitor O -
. O +

Recently O -
, O +
synthetic O +
fibrinolysis O +
inhibitors O +
such O +
as O +
tranexamic O +
acid O +
( O -
tAMCA O -
) O +
have O +
been O +
considered O +
as O +
substitutes O +
for O +
aprotinin O -
. O +

However O -
, O +
tAMCA O +
has O +
been O +
shown O +
to O +
cause O +
epileptic B-Disease +
seizures I-Disease -
. O +

We O +
wanted O +
to O +
study O +
whether O +
tAMCA O +
retains O +
its O +
convulsive B-Disease +
action O +
if O +
incorporated O +
into O +
a O +
FS O -
. O +

METHOD O -
: O +
FS O +
containing O +
aprotinin O +
or O +
different O +
concentrations O +
of O +
tAMCA O +
( O -
0.5 O -
- O -
47.5 O +
mg O -
/ O -
ml O -
) O +
were O +
applied O +
to O +
the O +
pial O +
surface O +
of O +
the O +
cortex O +
of O +
anaesthetized O +
rats O -
. O +

The O +
response O +
of O +
the O +
animals O +
was O +
evaluated O +
using O +
electroencephalography O +
and O +
by O +
monitoring O +
the O +
clinical O +
behaviour O +
during O +
and O +
after O +
recovery O +
from O +
anaesthesia O -
. O +

FINDINGS O -
: O +
FS O +
containing O +
tAMCA O +
caused O +
paroxysmal O +
brain O +
activity O +
which O +
was O +
associated O +
with O +
distinct O +
convulsive B-Disease +
behaviours O -
. O +

The O +
degree O +
of O +
these O +
seizures B-Disease +
increased O +
with O +
increasing O +
concentration O +
of O +
tAMCA O -
. O +

Thus O -
, O +
FS O +
containing O +
47.5 O +
mg O -
/ O -
ml O +
tAMCA O +
evoked O +
generalized B-Disease +
seizures I-Disease +
in O +
all O +
tested O +
rats O +
( O -
n=6 O -
) O +
while O +
the O +
lowest O +
concentration O +
of O +
tAMCA O +
( O -
0.5 O +
mg O -
/ O -
ml O -
) O +
only O +
evoked O +
brief O +
episodes O +
of O +
jerk O -
- O -
correlated O +
convulsive B-Disease +
potentials O +
in O +
1 O +
of O +
6 O +
rats O -
. O +

In O +
contrast O -
, O +
FS O +
containing O +
aprotinin O +
did O +
not O +
evoke O +
any O +
paroxysmal O +
activity O -
. O +

INTERPRETATION O -
: O +
Tranexamic O +
acid O +
retains O +
its O +
convulsive B-Disease +
action O +
within O +
FS O -
. O +

Thus O -
, O +
use O +
of O +
FS O +
containing O +
tAMCA O +
for O +
surgery O +
within O +
or O +
close O +
to O +
the O +
CNS O +
may O +
pose O +
a O +
substantial O +
risk O +
to O +
the O +
patient O -
. O +

Treatment O +
of O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
with O +
a O +
dopamine O +
agonist O +
in O +
children O -
. O +

BACKGROUND O -
: O +
Risperidone O -
, O +
a O +
potent O +
antagonist O +
of O +
both O +
serotonergic O +
( O -
5HT2A O -
) O +
and O +
dopaminergic O +
D2 O +
receptors O +
is O +
associated O +
with O +
hyperprolactinemia B-Disease +
in O +
adults O +
and O +
children O -
. O +

Chronically O +
elevated O +
prolactin O +
levels O +
in O +
children O +
with O +
prolactinomas B-Disease +
may O +
be O +
associated O +
with O +
arrested O +
growth O +
and O +
development O +
resulting O +
in O +
either O +
delayed B-Disease +
puberty I-Disease +
or O +
short O +
stature O -
. O +

These O +
possibilities O +
stress O +
the O +
importance O +
of O +
developing O +
a O +
safe O +
and O +
effective O +
approach O +
to O +
drug O -
- O -
induced O +
hyperprolactinemia B-Disease +
in O +
youth O -
. O +

We O +
report O +
the O +
successful O +
treatment O +
of O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
with O +
cabergoline O +
in O +
youth O -
. O +

METHODS O -
: O +
We O +
undertook O +
a O +
retrospective O +
case O +
review O +
of O +
four O +
children O +
with O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
treated O +
with O +
cabergoline O -
. O +

RESULTS O -
: O +
Four O +
males O +
( O -
age O +
6 O -
- O -
11 O +
years O -
) O +
with O +
Diagnostic O +
and O +
Statistical O +
Manual O +
of O +
Mental B-Disease +
Disorders I-Disease +
( O -
fourth O +
edition O -
) O +
bipolar B-Disease +
disorder I-Disease +
or O +
psychoses B-Disease -
, O +
with O +
risperidone O -
- O -
induced O +
elevations O +
in O +
serum O +
prolactin O +
levels O +
( O -
57.5 O -
- O -
129 O +
ng O -
/ O -
mL O -
, O +
normal O +
5 O -
- O -
15 O +
ng O -
/ O -
mL O -
) O -
, O +
were O +
treated O +
with O +
cabergoline O +
( O -
mean O +
dose O +
2.13 O +
+ O -
/- O +

0.09 O +
mg O -
/ O -
week O -
) O -
. O +

When O +
serum O +
prolactin O +
levels O +
normalized O +
in O +
all O +
four O +
subjects O +
( O -
mean O +
11.2 O +
+ O -
/- O +

10.9 O +
ng O -
/ O -
mL O -
) O -
, O +
the O +
cabergoline O +
dose O +
was O +
reduced O +
to O +
1 O +
mg O -
/ O -
week O +
in O +
three O +
of O +
four O +
subjects O -
. O +

The O +
mean O +
duration O +
of O +
therapy O +
with O +
cabergoline O +
was O +
523.5 O +
+ O -
/- O +

129.7 O +
days O -
, O +
and O +
the O +
mean O +
duration O +
of O +
therapy O +
with O +
risperidone O +
was O +
788.5 O +
+ O -
/- O +

162.5 O +
days O -
. O +

Cabergoline O +
was O +
well O +
tolerated O +
without O +
adverse O +
effects O -
. O +

CONCLUSIONS O -
: O +
Cabergoline O +
may O +
be O +
useful O +
for O +
the O +
treatment O +
of O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
in O +
youth O -
; O +
however O -
, O +
further O +
research O +
is O +
needed O -
. O +

Acute O +
cholestatic B-Disease +
hepatitis B-Disease +
after O +
exposure O +
to O +
isoflurane O -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
acute O +
cholestatic B-Disease +
hepatitis B-Disease +
following O +
exposure O +
to O +
the O +
inhalational O +
anesthetic O +
isoflurane O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
70-year O -
- O -
old O +
healthy O +
woman O +
from O +
Iraq O +
developed O +
acute O +
cholestatic B-Disease +
hepatitis B-Disease +
3 O +
weeks O +
following O +
repair O +
of O +
the O +
right O +
rotator O +
cuff O +
under O +
general O +
anesthesia O -
. O +

There O +
was O +
no O +
evidence O +
for O +
viral O -
, O +
autoimmune O -
, O +
or O +
metabolic O +
causes O +
of O +
hepatitis B-Disease -
. O +

No O +
other O +
medications O +
were O +
involved O +
except O +
for O +
dipyrone O +
for O +
analgesia B-Disease -
. O +

The O +
alanine O +
aminotransferase O +
was O +
elevated O +
to O +
a O +
peak O +
concentration O +
of O +
1533 O +
U O -
/ O -
L O +
and O +
the O +
serum O +
bilirubin O +
reached O +
a O +
peak O +
of O +
17.0 O +
mg O -
/ O -
dL. O +
There O +
was O +
slow O +
improvement O +
over O +
4 O +
months O -
. O +

Accidental O +
reexposure O +
by O +
the O +
patient O +
to O +
dipyrone O +
was O +
uneventful O -
. O +

DISCUSSION O -
: O +
The O +
clinical O +
and O +
histologic O +
picture O +
of O +
this O +
case O +
resembles O +
halothane B-Disease +
hepatitis I-Disease -
, O +
which O +
has O +
a O +
significant O +
mortality O +
rate O -
. O +

CONCLUSIONS O -
: O +
Isoflurane O -
, O +
a O +
common O +
anesthetic O +
agent O -
, O +
can O +
cause O +
severe O +
cholestatic B-Disease +
hepatitis B-Disease -
. O +

Dopamine O +
D2 O +
receptor O +
signaling O +
controls O +
neuronal O +
cell O +
death O +
induced O +
by O +
muscarinic O +
and O +
glutamatergic O +
drugs O -
. O +

Dopamine O +
( O -
DA O -
) O -
, O +
through O +
D1 O -
/ O -
D2 O +
receptor O -
- O -
mediated O +
signaling O -
, O +
plays O +
a O +
major O +
role O +
in O +
the O +
control O +
of O +
epileptic B-Disease +
seizures I-Disease +
arising O +
in O +
the O +
limbic O +
system O -
. O +

Excitotoxicity B-Disease +
leading O +
to O +
neuronal O +
cell O +
death O +
in O +
the O +
affected O +
areas O +
is O +
a O +
major O +
consequence O +
of O +
seizures B-Disease +
at O +
the O +
cellular O +
level O -
. O +

In O +
this O +
respect O -
, O +
little O +
is O +
known O +
about O +
the O +
role O +
of O +
DA O +
receptors O +
in O +
the O +
occurrence O +
of O +
epilepsy B-Disease -
- O -
induced O +
neuronal O +
cell O +
death O -
. O +

Here O +
we O +
analyze O +
the O +
occurrence O +
of O +
seizures B-Disease +
and O +
neurotoxicity B-Disease +
in O +
D2R O +
- O -
/ O -
- O +
mice O +
treated O +
with O +
the O +
cholinergic O +
agonist O +
pilocarpine O -
. O +

We O +
compared O +
these O +
results O +
with O +
those O +
previously O +
obtained O +
with O +
kainic O +
acid O +
( O -
KA O -
) O -
, O +
a O +
potent O +
glutamate O +
agonist O -
. O +

Importantly O -
, O +
D2R O +
- O -
/ O -
- O +
mice O +
develop O +
seizures B-Disease +
at O +
doses O +
of O +
both O +
drugs O +
that O +
are O +
not O +
epileptogenic O +
for O +
WT O +
littermates O +
and O +
show O +
greater O +
neurotoxicity B-Disease -
. O +

However O -
, O +
pilocarpine O -
- O -
induced O +
seizures B-Disease +
result O +
in O +
a O +
more O +
widespread O +
neuronal O +
death O +
in O +
both O +
WT O +
and O +
D2R O +
- O -
/ O -
- O +
brains O +
in O +
comparison O +
to O +
KA O -
. O +

Thus O -
, O +
the O +
absence O +
of O +
D2R O +
lowers O +
the O +
threshold O +
for O +
seizures B-Disease +
induced O +
by O +
both O +
glutamate O +
and O +
acetylcholine O -
. O +

Moreover O -
, O +
the O +
dopaminergic O +
control O +
of O +
epilepsy B-Disease -
- O -
induced O +
neurodegeneration B-Disease +
seems O +
to O +
be O +
mediated O +
by O +
distinct O +
interactions O +
of O +
D2R O +
signaling O +
with O +
these O +
two O +
neurotransmitters O -
. O +

Spironolactone O -
: O +
is O +
it O +
a O +
novel O +
drug O +
for O +
the O +
prevention O +
of O +
amphotericin O +
B O -
- O -
related O +
hypokalemia B-Disease +
in O +
cancer B-Disease +
patients O -
? O +

OBJECTIVE O -
: O +
Nephrotoxicity B-Disease +
is O +
the O +
major O +
adverse O +
effect O +
of O +
amphotericin O +
B O +
( O -
AmB O -
) O -
, O +
often O +
limiting O +
administration O +
of O +
full O +
dosage O -
. O +

Selective O +
distal O +
tubular O +
epithelial O +
toxicity B-Disease +
seems O +
to O +
be O +
responsible O +
for O +
the O +
profound O +
potassium O +
wasting O +
that O +
is O +
a O +
major O +
clinical O +
side O +
effect O +
of O +
treatment O +
with O +
AmB. O +
Potassium O +
depletion O +
also O +
potentiates O +
the O +
tubular O +
toxicity B-Disease +
of O +
AmB. O +
This O +
study O +
was O +
designed O +
to O +
assess O +
the O +
ability O +
of O +
spironolactone O +
to O +
reduce O +
potassium O +
requirements O +
and O +
to O +
prevent O +
hypokalemia B-Disease +
in O +
neutropenic B-Disease +
patients O +
on O +
AmB O +
treatment O -
. O +

METHODS O -
: O +
In O +
this O +
study O +
26 O +
patients O +
with O +
various O +
hematological B-Disease +
disorders I-Disease +
were O +
randomized O +
to O +
receive O +
either O +
intravenous O +
AmB O +
alone O +
or O +
AmB O +
and O +
oral O +
spironolactone O +
100 O +
mg O +
twice O +
daily O +
when O +
developing O +
a O +
proven O +
or O +
suspected O +
fungal B-Disease +
infection I-Disease -
. O +

RESULTS O -
: O +
Patients O +
receiving O +
concomitant O +
AmB O +
and O +
spironolactone O +
had O +
significantly O +
higher O +
plasma O +
potassium O +
levels O +
than O +
those O +
receiving O +
AmB O +
alone O +
( O -
P O +
= O +
0.0027 O -
) O -
. O +

Those O +
patients O +
receiving O +
AmB O +
and O +
spironolactone O +
required O +
significantly O +
less O +
potassium O +
supplementation O +
to O +
maintain O +
their O +
plasma O +
potassium O +
within O +
the O +
normal O +
range O +
( O -
P O +
= O +
0.022 O -
) O -
. O +

Moreover O -
, O +
urinary O +
potassium O +
losses O +
were O +
significantly O +
less O +
in O +
patients O +
receiving O +
AmB O +
and O +
spironolactone O +
than O +
those O +
receiving O +
AmB O +
alone O +
( O -
P O +
= O +
0.040 O -
) O -
. O +

CONCLUSION O -
: O +
This O +
study O +
showed O +
that O +
spironolactone O +
can O +
reduce O +
potassium O +
requirements O +
and O +
prevent O +
hypokalemia B-Disease +
by O +
reducing O +
urinary O +
potassium O +
loss O +
in O +
neutropenic B-Disease +
patients O +
on O +
AmB O +
treatment O -
. O +

Sequential O +
observations O +
of O +
exencephaly B-Disease +
and O +
subsequent O +
morphological O +
changes O +
by O +
mouse O +
exo O +
utero O +
development O +
system O -
: O +
analysis O +
of O +
the O +
mechanism O +
of O +
transformation O +
from O +
exencephaly B-Disease +
to O +
anencephaly B-Disease -
. O +

Anencephaly B-Disease +
has O +
been O +
suggested O +
to O +
develop O +
from O +
exencephaly B-Disease -
; O +
however O -
, O +
there O +
is O +
little O +
direct O +
experimental O +
evidence O +
to O +
support O +
this O -
, O +
and O +
the O +
mechanism O +
of O +
transformation O +
remains O +
unclear O -
. O +

We O +
examined O +
this O +
theory O +
using O +
the O +
exo O +
utero O +
development O +
system O +
that O +
allows O +
direct O +
and O +
sequential O +
observations O +
of O +
mid- O +
to O +
late O -
- O -
gestation O +
mouse O +
embryos O -
. O +

We O +
observed O +
the O +
exencephaly B-Disease +
induced O +
by O +
5-azacytidine O +
at O +
embryonic O +
day O +
13.5 O +
( O -
E13.5 O -
) O -
, O +
let O +
the O +
embryos O +
develop O +
exo O +
utero O +
until O +
E18.5 O -
, O +
and O +
re O -
- O -
observed O +
the O +
same O +
embryos O +
at O +
E18.5 O -
. O +

We O +
confirmed O +
several O +
cases O +
of O +
transformation O +
from O +
exencephaly B-Disease +
to O +
anencephaly B-Disease -
. O +

However O -
, O +
in O +
many O +
cases O -
, O +
the O +
exencephalic B-Disease +
brain O +
tissue O +
was O +
preserved O +
with O +
more O +
or O +
less O +
reduction O +
during O +
this O +
period O -
. O +

To O +
analyze O +
the O +
transformation O +
patterns O -
, O +
we O +
classified O +
the O +
exencephaly B-Disease +
by O +
size O +
and O +
shape O +
of O +
the O +
exencephalic B-Disease +
tissue O +
into O +
several O +
types O +
at O +
E13.5 O +
and O +
E18.5 O -
. O +

It O +
was O +
found O +
that O +
the O +
transformation O +
of O +
exencephalic B-Disease +
tissue O +
was O +
not O +
simply O +
size O -
- O -
dependent O -
, O +
and O +
all O +
cases O +
of O +
anencephaly B-Disease +
at O +
E18.5 O +
resulted O +
from O +
embryos O +
with O +
a O +
large O +
amount O +
of O +
exencephalic B-Disease +
tissue O +
at O +
E13.5 O -
. O +

Microscopic O +
observation O +
showed O +
the O +
configuration O +
of O +
exencephaly B-Disease +
at O +
E13.5 O -
, O +
frequent O +
hemorrhaging B-Disease +
and O +
detachment O +
of O +
the O +
neural O +
plate O +
from O +
surface O +
ectoderm O +
in O +
the O +
exencephalic B-Disease +
head O +
at O +
E15.5 O -
, O +
and O +
multiple O +
modes O +
of O +
reduction O +
in O +
the O +
exencephalic B-Disease +
tissue O +
at O +
E18.5 O -
. O +

From O +
observations O +
of O +
the O +
vasculature O -
, O +
altered O +
distribution O +
patterns O +
of O +
vessels O +
were O +
identified O +
in O +
the O +
exencephalic B-Disease +
head O -
. O +

These O +
findings O +
suggest O +
that O +
overgrowth O +
of O +
the O +
exencephalic B-Disease +
neural O +
tissue O +
causes O +
the O +
altered O +
distribution O +
patterns O +
of O +
vessels O -
, O +
subsequent O +
peripheral O +
circulatory B-Disease +
failure I-Disease +
and/or O +
hemorrhaging B-Disease +
in O +
various O +
parts O +
of O +
the O +
exencephalic B-Disease +
head O -
, O +
leading O +
to O +
the O +
multiple O +
modes O +
of O +
tissue O +
reduction O +
during O +
transformation O +
from O +
exencephaly B-Disease +
to O +
anencephaly B-Disease -
. O +

Erectile B-Disease +
dysfunction I-Disease +
occurs O +
following O +
substantia O +
nigra O +
lesions O +
in O +
the O +
rat O -
. O +

Erectile O +
function O +
was O +
assessed O +
6 O +
weeks O +
following O +
uni- O +
and O +
bilateral O +
injections O +
of O +
6-hydroxydopamine O +
in O +
the O +
substantia O +
nigra O +
nucleus O +
of O +
the O +
brain O -
. O +

Behavioral O +
apomorphine O -
- O -
induced O +
penile O +
erections O +
were O +
reduced O +
( O -
5 O -
/ O -
8 O -
) O +
and O +
increased O +
( O -
3 O -
/ O -
8 O -
) O +
in O +
uni- O +
and O +
bilateral O +
lesioned O +
animals O -
. O +

Intracavernous O +
pressures O -
, O +
following O +
electrical O +
stimulation O +
of O +
the O +
cavernous O +
nerve O -
, O +
decreased O +
in O +
lesioned O +
animals O -
. O +

Lesions O +
of O +
the O +
substantia O +
nigra O +
were O +
confirmed O +
by O +
histology O -
. O +

Concentration O +
of O +
dopamine O +
and O +
its O +
metabolites O +
were O +
decreased O +
in O +
the O +
striatum O +
of O +
substantia O +
nigra O +
lesioned O +
rats O -
. O +

Lesions O +
of O +
the O +
substantia O +
nigra O +
are O +
therefore O +
associated O +
with O +
erectile B-Disease +
dysfunction I-Disease +
in O +
rats O +
and O +
may O +
serve O +
as O +
a O +
model O +
to O +
study O +
erectile B-Disease +
dysfunction I-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

99mTc O -
- O -
glucarate O +
for O +
detection O +
of O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Infarct B-Disease -
- O -
avid O +
radiopharmaceuticals O +
are O +
necessary O +
for O +
rapid O +
and O +
timely O +
diagnosis O +
of O +
acute O +
myocardial B-Disease +
infarction I-Disease -
. O +

The O +
animal O +
model O +
used O +
to O +
produce O +
infarction B-Disease +
implies O +
artery O +
ligation O +
but O +
chemical O +
induction O +
can O +
be O +
easily O +
obtained O +
with O +
isoproterenol O -
. O +

A O +
new O +
infarct B-Disease -
- O -
avid O +
radiopharmaceutical O +
based O +
on O +
glucaric O +
acid O +
was O +
prepared O +
in O +
the O +
hospital O +
radiopharmacy O +
of O +
the O +
INCMNSZ O -
. O +

99mTc O -
- O -
glucarate O +
was O +
easy O +
to O +
prepare O -
, O +
stable O +
for O +
96 O +
h O +
and O +
was O +
used O +
to O +
study O +
its O +
biodistribution O +
in O +
rats O +
with O +
isoproterenol O -
- O -
induced O +
acute O +
myocardial B-Disease +
infarction I-Disease -
. O +

Histological O +
studies O +
demonstrated O +
that O +
the O +
rats O +
developed O +
an O +
infarct B-Disease +
18 O +
h O +
after O +
isoproterenol O +
administration O -
. O +

The O +
rat O +
biodistribution O +
studies O +
showed O +
a O +
rapid O +
blood O +
clearance O +
via O +
the O +
kidneys O -
. O +

Thirty O +
minutes O +
after O +
99mTc O -
- O -
glucarate O +
administration O +
the O +
standardised O +
heart O +
uptake O +
value O +
S O -
( O -
h O -
) O -
UV O +
was O +
4.7 O +
in O +
infarcted O +
rat O +
heart O +
which O +
is O +
six O +
times O +
more O +
than O +
in O +
normal O +
rats O -
. O +

ROIs O +
drawn O +
over O +
the O +
gamma O +
camera O +
images O +
showed O +
a O +
ratio O +
of O +
4.4 O -
. O +

The O +
high O +
image O +
quality O +
suggests O +
that O +
high O +
contrast O +
images O +
can O +
be O +
obtained O +
in O +
humans O +
and O +
the O +
96 O +
h O +
stability O +
makes O +
it O +
an O +
ideal O +
agent O +
to O +
detect O -
, O +
in O +
patients O -
, O +
early O +
cardiac B-Disease +
infarction I-Disease -
. O +

Force O +
overflow O +
and O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

We O +
assessed O +
force O +
coordination O +
of O +
the O +
hand O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
and O +
its O +
relationship O +
to O +
motor O +
complications O +
of O +
levodopa O +
therapy O -
, O +
particularly O +
to O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
( O -
LID B-Disease -
) O -
. O +

We O +
studied O +
two O +
groups O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
patients O +
with O +
( O -
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
+ O +
LID B-Disease -
, O +
n O +
= O +
23 O -
) O +
and O +
without O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
( O -
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
- O +
LID B-Disease -
, O +
n O +
= O +
10 O -
) O -
, O +
and O +
age O -
- O -
matched O +
healthy O +
controls O -
. O +

The O +
motor O +
score O +
of O +
the O +
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease I-Disease +
Rating O +
Scale O -
, O +
a O +
dyskinesia B-Disease +
score O +
and O +
force O +
in O +
a O +
grip O -
- O -
lift O +
paradigm O +
were O +
assessed O +
ON O +
and O +
OFF O +
levodopa O -
. O +

A O +
pathological O +
increase O +
of O +
forces O +
was O +
seen O +
in O +
ON O -
- O -
state O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
+ O +
LID B-Disease +
only O -
. O +

In O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
+ O +
LID B-Disease -
, O +
the O +
force O +
involved O +
in O +
pressing O +
down O +
the O +
object O +
before O +
lifting O +
was O +
significantly O +
increased O +
by O +
levodopa O +
( O -
by O +
61 O -
% O -
, O +
P O +
< O +
0.05 O -
) O -
. O +

An O +
overshooting O +
of O +
peak O +
grip O +
force O +
by O +
51 O -
% O +
( O -
P O +
< O +
0.05 O -
) O +
and O +
of O +
static O +
grip O +
force O +
by O +
45 O -
% O +
( O -
P O +
< O +
0.01 O -
) O +
was O +
observed O +
in O +
the O +
ON- O +
compared O +
with O +
the O +
OFF O -
- O -
drug O +
condition O -
. O +

In O +
contrast O -
, O +
no O +
excessive O +
force O +
was O +
found O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
- O +
LID B-Disease -
. O +

Peak O +
grip O +
force O +
in O +
ON O -
- O -
state O +
was O +
140 O -
% O +
( O -
P O +
< O +
0.05 O -
) O +
higher O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
+ O +
LID B-Disease +
than O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
- O +
LID B-Disease -
, O +
while O +
static O +
grip O +
force O +
was O +
increased O +
by O +
138 O -
% O +
( O -
P O +
< O +
0.01 O -
) O +
between O +
groups O -
. O +

Severity O +
of O +
peak O -
- O -
dose O +
dyskinesias B-Disease +
was O +
strongly O +
correlated O +
with O +
grip O +
force O +
in O +
ON O -
- O -
state O +
( O -
r O +
= O +
0.79 O +
with O +
peak O +
force O -
, O +
P O +
< O +
0.01 O -
) O -
. O +

No O +
correlation O +
was O +
observed O +
between O +
forces O +
and O +
the O +
motor O +
score O +
as O +
well O +
as O +
with O +
the O +
daily O +
dose O +
of O +
dopaminergic O +
medication O -
. O +

Force O +
excess O +
was O +
only O +
observed O +
in O +
patients O +
with O +
LID B-Disease +
and O +
motor O +
fluctuations O -
. O +

A O +
close O +
relationship O +
was O +
seen O +
between O +
the O +
overshooting O +
of O +
forces O +
and O +
dyskinesias B-Disease +
in O +
the O +
ON O -
- O -
drug O +
condition O -
. O +

We O +
postulate O +
that O +
both O +
LID B-Disease +
and O +
grip O +
force O +
excess O +
share O +
common O +
pathophysiological O +
mechanisms O +
related O +
to O +
motor O +
fluctuations O -
. O +

Bupropion O +
( O -
Zyban O -
) O +
toxicity B-Disease -
. O +

Bupropion O +
is O +
a O +
monocyclic O +
antidepressant O +
structurally O +
related O +
to O +
amphetamine O -
. O +

Zyban O -
, O +
a O +
sustained O -
- O -
release O +
formulation O +
of O +
bupropion O +
hydrochloride O -
, O +
was O +
recently O +
released O +
in O +
Ireland O -
, O +
as O +
a O +
smoking O +
cessation O +
aid O -
. O +

In O +
the O +
initial O +
6 O +
months O +
since O +
it O -
's O +
introduction O -
, O +
12 O +
overdose B-Disease +
cases O +
have O +
been O +
reported O +
to O +
The O +
National O +
Poisons O +
Information O +
Centre O -
. O +

8 O +
patients O +
developed O +
symptoms O +
of O +
toxicity B-Disease -
. O +

Common O +
features O +
included O +
tachycardia B-Disease -
, O +
drowsiness O -
, O +
hallucinations B-Disease +
and O +
convulsions B-Disease -
. O +

Two O +
patients O +
developed O +
severe O +
cardiac B-Disease +
arrhythmias I-Disease -
, O +
including O +
one O +
patient O +
who O +
was O +
resuscitated O +
following O +
a O +
cardiac B-Disease +
arrest I-Disease -
. O +

All O +
patients O +
recovered O +
without O +
sequelae O -
. O +

We O +
report O +
a O +
case O +
of O +
a O +
31 O +
year O +
old O +
female O +
who O +
required O +
admission O +
to O +
the O +
Intensive O +
Care O +
Unit O +
for O +
ventilation O +
and O +
full O +
supportive O +
therapy O -
, O +
following O +
ingestion O +
of O +
13.5 O -
g O +
bupropion O -
. O +

Recurrent O +
seizures B-Disease +
were O +
treated O +
with O +
diazepam O +
and O +
broad O +
complex O +
tachycardia B-Disease +
was O +
successfully O +
treated O +
with O +
adenosine O -
. O +

Zyban O +
caused O +
significant O +
neurological B-Disease +
and I-Disease +
cardiovascular I-Disease +
toxicity I-Disease +
in O +
overdose B-Disease -
. O +

The O +
potential O +
toxic O +
effects O +
should O +
be O +
considered O +
when O +
prescribing O +
it O +
as O +
a O +
smoking O +
cessation O +
aid O -
. O +

GLEPP1 O +
receptor O +
tyrosine O +
phosphatase O +
( O -
Ptpro O -
) O +
in O +
rat O +
PAN O +
nephrosis B-Disease -
. O +

A O +
marker O +
of O +
acute O +
podocyte O +
injury O -
. O +

Glomerular O +
epithelial O +
protein O +
1 O +
( O -
GLEPP1 O -
) O +
is O +
a O +
podocyte O +
receptor O +
membrane O +
protein O +
tyrosine O +
phosphatase O +
located O +
on O +
the O +
apical O +
cell O +
membrane O +
of O +
visceral O +
glomerular O +
epithelial O +
cell O +
and O +
foot O +
processes O -
. O +

This O +
receptor O +
plays O +
a O +
role O +
in O +
regulating O +
the O +
structure O +
and O +
function O +
of O +
podocyte O +
foot O +
process O -
. O +

To O +
better O +
understand O +
the O +
utility O +
of O +
GLEPP1 O +
as O +
a O +
marker O +
of O +
glomerular B-Disease +
injury I-Disease -
, O +
the O +
amount O +
and O +
distribution O +
of O +
GLEPP1 O +
protein O +
and O +
mRNA O +
were O +
examined O +
by O +
immunohistochemistry O -
, O +
Western O +
blot O +
and O +
RNase O +
protection O +
assay O +
in O +
a O +
model O +
of O +
podocyte O +
injury O +
in O +
the O +
rat O -
. O +

Puromycin O +
aminonucleoside O +
nephrosis B-Disease +
was O +
induced O +
by O +
single O +
intraperitoneal O +
injection O +
of O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
, O +
20 O +
mg O -
/ O -
100 O -
g O +
BW O -
) O -
. O +

Tissues O +
were O +
analyzed O +
at O +
0 O -
, O +
5 O -
, O +
7 O -
, O +
11 O -
, O +
21 O -
, O +
45 O -
, O +
80 O +
and O +
126 O +
days O +
after O +
PAN O +
injection O +
so O +
as O +
to O +
include O +
both O +
the O +
acute O +
phase O +
of O +
proteinuria B-Disease +
associated O +
with O +
foot O +
process O +
effacement O +
( O -
days O +
5 O -
- O -
11 O -
) O +
and O +
the O +
chronic O +
phase O +
of O +
proteinuria B-Disease +
associated O +
with O +
glomerulosclerosis B-Disease +
( O -
days O +
45 O -
- O -
126 O -
) O -
. O +

At O +
day O +
5 O -
, O +
GLEPP1 O +
protein O +
and O +
mRNA O +
were O +
reduced O +
from O +
the O +
normal O +
range O +
( O -
265.2 O +
+ O -
/- O +

79.6 O +
x O +
10 O -
( O -
6 O -
) O +
moles O -
/ O -
glomerulus O +
and O +
100 O -
% O -
) O +
to O +
15 O -
% O +
of O +
normal O +
( O -
41.8 O +
+ O -
/- O +

4.8 O +
x O +
10 O -
( O -
6 O -
) O +
moles O -
/ O -
glomerulus O -
, O +
p O +
< O +
0.005 O -
) O -
. O +

This O +
occurred O +
in O +
association O +
with O +
an O +
increase O +
in O +
urinary O +
protein O +
content O +
from O +
1.8 O +
+ O -
/- O +

1 O +
to O +
99.0 O +
+ O -
/- O +

61 O +
mg O -
/ O -
day O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

In O +
contrast O -
, O +
podocalyxin O +
did O +
not O +
change O +
significantly O +
at O +
this O +
time O -
. O +

By O +
day O +
11 O -
, O +
GLEPP1 O +
protein O +
and O +
mRNA O +
had O +
begun O +
to O +
return O +
towards O +
baseline O -
. O +

By O +
day O +
45 O -
- O -
126 O -
, O +
at O +
a O +
time O +
when O +
glomerular O +
scarring O +
was O +
present O -
, O +
GLEPP1 O +
was O +
absent O +
from O +
glomerulosclerotic O +
areas O +
although O +
the O +
total O +
glomerular O +
content O +
of O +
GLEPP1 O +
was O +
not O +
different O +
from O +
normal O -
. O +

We O +
conclude O +
that O +
GLEPP1 O +
expression O -
, O +
unlike O +
podocalyxin O -
, O +
reflects O +
podocyte O +
injury O +
induced O +
by O +
PAN O -
. O +

GLEPP1 O +
expression O +
may O +
be O +
a O +
useful O +
marker O +
of O +
podocyte O +
injury O -
. O +

Behavioral O +
effects O +
of O +
MK-801 O +
on O +
reserpine O -
- O -
treated O +
mice O -
. O +

The O +
effects O +
of O +
dizocilpine O +
( O -
MK-801 O -
) O -
, O +
a O +
noncompetitive O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptor O +
antagonist O -
, O +
were O +
studied O +
on O +
dopamine O -
- O -
related O +
behaviors O +
induced O +
by O +
reserpine O +
treatments O -
. O +

This O +
study O +
focuses O +
on O +
behavioral O +
syndromes O +
that O +
may O +
used O +
as O +
models O +
for O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
, O +
or O +
tardive B-Disease +
dyskinesia I-Disease -
, O +
and O +
its O +
response O +
after O +
glutamatergic O +
blockage O -
. O +

Reserpine O +
( O -
1 O +
mg O -
/ O -
kg O -
) O -
, O +
administered O +
once O +
every O +
other O +
day O +
for O +
4 O +
days O -
, O +
produced O +
increases O +
in O +
orofacial B-Disease +
dyskinesia I-Disease -
, O +
tongue O +
protrusion O +
and O +
vacuous O +
chewing O +
in O +
mice O -
, O +
which O +
are O +
signs O +
indicative O +
of O +
tardive B-Disease +
dyskinesia I-Disease -
. O +

Reserpine O +
also O +
produced O +
tremor B-Disease +
and O +
catalepsy B-Disease -
, O +
which O +
are O +
signs O +
suggestive O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

MK-801 O +
( O -
0.1 O +
mg O -
/ O -
kg O -
) O -
, O +
administered O +
30 O +
min O +
before O +
the O +
observation O +
test O -
, O +
prevented O +
the O +
vacuous O +
chewing O +
movements O -
, O +
tongue O +
protrusions O +
and O +
catalepsy B-Disease +
induced O +
by O +
reserpine O -
. O +

However O -
, O +
MK-801 O +
injection O +
produced O +
a O +
significant O +
increase O +
of O +
tremor B-Disease +
in O +
reserpine O -
- O -
treated O +
mice O -
. O +

Reserpine O +
( O -
1 O +
mg O -
/ O -
kg O -
) O -
, O +
administered O +
90 O +
min O +
before O +
the O +
test O +
and O +
followed O +
by O +
apomophine O +
injection O +
( O -
0.1 O +
mg O -
/ O -
kg O -
) O +
5 O +
min O +
before O +
the O +
test O -
, O +
did O +
not O +
produce O +
oral B-Disease +
dyskinesia I-Disease +
in O +
mice O -
. O +

On O +
the O +
other O +
hand O -
, O +
reserpine O +
induced O +
increases O +
in O +
tremor B-Disease +
and O +
catalepsy B-Disease +
compared O +
to O +
control O +
mice O -
. O +

MK-801 O +
( O -
0.1 O +
mg O -
/ O -
kg O -
) O +
administration O +
attenuated O +
the O +
catalepsy B-Disease +
and O +
tremor B-Disease +
induced O +
by O +
reserpine O -
. O +

Pretreatment O +
with O +
reserpine O +
( O -
1 O +
mg O -
/ O -
kg O -
) O +
24 O +
h O +
before O +
the O +
observation O +
test O +
produced O +
increases O +
in O +
vacuous O +
chewing O +
movements O +
and O +
tongue O +
protrusion O -
, O +
as O +
well O +
as O +
increases O +
in O +
tremor B-Disease +
and O +
catalepsy B-Disease -
, O +
whereas O +
MK-801 O +
( O -
0.1 O +
mg O -
/ O -
kg O -
) O +
injection O +
90 O +
min O +
before O +
the O +
test O +
reversed O +
the O +
effects O +
of O +
reserpine O -
. O +

These O +
results O +
show O +
that O +
reserpine O +
produces O +
different O +
and O +
abnormal B-Disease +
movements I-Disease -
, O +
which O +
are O +
related O +
to O +
dose O +
and O +
schedule O +
employed O +
and O +
can O +
be O +
considered O +
as O +
parkinsonian B-Disease -
- O -
like O +
and O +
tardive B-Disease +
dsykinesia I-Disease +
signs O -
. O +

The O +
glutamatergic O +
blockage O +
produced O +
by O +
NMDA O +
can O +
restore O +
these O +
signs O -
, O +
such O +
as O +
vacuous O +
chewing O +
movements O -
, O +
tongue O +
protrusions O -
, O +
catalepsy B-Disease +
and O +
tremor B-Disease +
according O +
to O +
the O +
employed O +
model O -
. O +

Antithymocyte O +
globulin O +
in O +
the O +
treatment O +
of O +
D O -
- O -
penicillamine O -
- O -
induced O +
aplastic B-Disease +
anemia I-Disease -
. O +

A O +
patient O +
who O +
received O +
antithymocyte O +
globulin O +
therapy O +
for O +
aplastic B-Disease +
anemia I-Disease +
due O +
to O +
D O -
- O -
penicillamine O +
therapy O +
is O +
described O -
. O +

Bone O +
marrow O +
recovery O +
and O +
peripheral O +
blood O +
recovery O +
were O +
complete O +
1 O +
month O +
and O +
3 O +
months O -
, O +
respectively O -
, O +
after O +
treatment O -
, O +
and O +
blood O +
transfusion O +
or O +
other O +
therapies O +
were O +
not O +
necessary O +
in O +
a O +
follow O -
- O -
up O +
period O +
of O +
more O +
than O +
2 O +
years O -
. O +

Use O +
of O +
antithymocyte O +
globulin O +
may O +
be O +
the O +
optimal O +
treatment O +
of O +
D O -
- O -
penicillamine O -
- O -
induced O +
aplastic B-Disease +
anemia I-Disease -
. O +

Topiramate O -
- O -
induced O +
nephrolithiasis B-Disease -
. O +

Topiramate O +
is O +
a O +
recently O +
developed O +
antiepileptic O +
medication O +
that O +
is O +
becoming O +
more O +
widely O +
prescribed O +
because O +
of O +
its O +
efficacy O +
in O +
treating O +
refractory B-Disease +
seizures I-Disease -
. O +

Urologists O +
should O +
be O +
aware O +
that O +
this O +
medication O +
can O +
cause O +
metabolic B-Disease +
acidosis I-Disease +
in O +
patients O +
secondary O +
to O +
inhibition O +
of O +
carbonic O +
anhydrase O -
. O +

In O +
addition O -
, O +
a O +
distal O +
tubular O +
acidification O +
defect O +
may O +
result O -
, O +
thus O +
impairing O +
the O +
normal O +
compensatory O +
drop O +
in O +
urine O +
pH. O +
These O +
factors O +
can O +
lead O +
to O +
the O +
development O +
of O +
calcium O +
phosphate O +
nephrolithiasis B-Disease -
. O +

We O +
report O +
the O +
first O +
two O +
cases O +
of O +
topiramate O -
- O -
induced O +
nephrolithiasis B-Disease +
in O +
the O +
urologic O +
literature O -
. O +

Metamizol O +
potentiates O +
morphine O +
antinociception O +
but O +
not O +
constipation B-Disease +
after O +
chronic O +
treatment O -
. O +

This O +
work O +
evaluates O +
the O +
antinociceptive O +
and O +
constipating B-Disease +
effects O +
of O +
the O +
combination O +
of O +
3.2 O +
mg O -
/ O -
kg O +
s.c O -
. O +

morphine O +
with O +
177.8 O +
mg O -
/ O -
kg O +
s.c O -
. O +

metamizol O +
in O +
acutely O +
and O +
chronically O +
treated O +
( O -
once O +
a O +
day O +
for O +
12 O +
days O -
) O +
rats O -
. O +

On O +
the O +
13th O +
day O -
, O +
antinociceptive O +
effects O +
were O +
assessed O +
using O +
a O +
model O +
of O +
inflammatory O +
nociception O -
, O +
pain B-Disease -
- O -
induced O +
functional O +
impairment O +
model O -
, O +
and O +
the O +
charcoal O +
meal O +
test O +
was O +
used O +
to O +
evaluate O +
the O +
intestinal O +
transit O -
. O +

Simultaneous O +
administration O +
of O +
morphine O +
with O +
metamizol O +
resulted O +
in O +
a O +
markedly O +
antinociceptive O +
potentiation O +
and O +
an O +
increasing O +
of O +
the O +
duration O +
of O +
action O +
after O +
a O +
single O +
( O -
298+ O -
/ O -
-7 O +
vs. O +
139+ O -
/ O -
-36 O +
units O +
area O +
( O -
ua O -
) O -
; O +
P<0.001 O -
) O +
and O +
repeated O +
administration O +
( O -
280+ O -
/ O -
-17 O +
vs. O +
131+ O -
/ O -
-22 O +
ua O -
; O +
P<0.001 O -
) O -
. O +

Antinociceptive O +
effect O +
of O +
morphine O +
was O +
reduced O +
in O +
chronically O +
treated O +
rats O +
( O -
39+ O -
/ O -
-10 O +
vs. O +
18+ O -
/ O -
-5 O +
au O -
) O +
while O +
the O +
combination O -
- O -
induced O +
antinociception O +
was O +
remained O +
similar O +
as O +
an O +
acute O +
treatment O +
( O -
298+ O -
/ O -
-7 O +
vs. O +
280+ O -
/ O -
-17 O +
au O -
) O -
. O +

Acute O +
antinociceptive O +
effects O +
of O +
the O +
combination O +
were O +
partially O +
prevented O +
by O +
3.2 O +
mg O -
/ O -
kg O +
naloxone O +
s.c O -
. O +

( O -
P<0.05 O -
) O -
, O +
suggesting O +
the O +
partial O +
involvement O +
of O +
the O +
opioidergic O +
system O +
in O +
the O +
synergism O +
observed O -
. O +

In O +
independent O +
groups O -
, O +
morphine O +
inhibited O +
the O +
intestinal O +
transit O +
in O +
48+ O -
/ O -
-4 O -
% O +
and O +
38+ O -
/ O -
-4 O -
% O +
after O +
acute O +
and O +
chronic O +
treatment O -
, O +
respectively O -
, O +
suggesting O +
that O +
tolerance O +
did O +
not O +
develop O +
to O +
the O +
constipating B-Disease +
effects O -
. O +

The O +
combination O +
inhibited O +
intestinal O +
transit O +
similar O +
to O +
that O +
produced O +
by O +
morphine O +
regardless O +
of O +
the O +
time O +
of O +
treatment O -
, O +
suggesting O +
that O +
metamizol O +
did O +
not O +
potentiate O +
morphine O -
- O -
induced O +
constipation B-Disease -
. O +

These O +
findings O +
show O +
a O +
significant O +
interaction O +
between O +
morphine O +
and O +
metamizol O +
in O +
chronically O +
treated O +
rats O -
, O +
suggesting O +
that O +
this O +
combination O +
could O +
be O +
useful O +
for O +
the O +
treatment O +
of O +
chronic B-Disease +
pain I-Disease -
. O +

Ifosfamide O +
encephalopathy B-Disease +
presenting O +
with O +
asterixis B-Disease -
. O +

CNS O +
toxic O +
effects O +
of O +
the O +
antineoplastic O +
agent O +
ifosfamide O +
( O -
IFX O -
) O +
are O +
frequent O +
and O +
include O +
a O +
variety O +
of O +
neurological O +
symptoms O +
that O +
can O +
limit O +
drug O +
use O -
. O +

We O +
report O +
a O +
case O +
of O +
a O +
51-year O -
- O -
old O +
man O +
who O +
developed O +
severe O -
, O +
disabling O +
negative O +
myoclonus B-Disease +
of O +
the O +
upper O +
and O +
lower O +
extremities O +
after O +
the O +
infusion O +
of O +
ifosfamide O +
for O +
plasmacytoma B-Disease -
. O +

He O +
was O +
awake O -
, O +
revealed O +
no O +
changes O +
of O +
mental O +
status O +
and O +
at O +
rest O +
there O +
were O +
no O +
further O +
motor O +
symptoms O -
. O +

Cranial O +
magnetic O +
resonance O +
imaging O +
and O +
extensive O +
laboratory O +
studies O +
failed O +
to O +
reveal O +
structural B-Disease +
lesions I-Disease +
of I-Disease +
the I-Disease +
brain I-Disease +
and O +
metabolic B-Disease +
abnormalities I-Disease -
. O +

An O +
electroencephalogram O +
showed O +
continuous O -
, O +
generalized O +
irregular O +
slowing O +
with O +
admixed O +
periodic O +
triphasic O +
waves O +
indicating O +
symptomatic O +
encephalopathy B-Disease -
. O +

The O +
administration O +
of O +
ifosfamide O +
was O +
discontinued O +
and O +
within O +
12 O +
h O +
the O +
asterixis B-Disease +
resolved O +
completely O -
. O +

In O +
the O +
patient O +
described O -
, O +
the O +
presence O +
of O +
asterixis B-Disease +
during O +
infusion O +
of O +
ifosfamide O -
, O +
normal O +
laboratory O +
findings O +
and O +
imaging O +
studies O +
and O +
the O +
resolution O +
of O +
symptoms O +
following O +
the O +
discontinuation O +
of O +
the O +
drug O +
suggest O +
that O +
negative O +
myoclonus B-Disease +
is O +
associated O +
with O +
the O +
use O +
of O +
IFX O -
. O +

Antagonism O +
between O +
interleukin O +
3 O +
and O +
erythropoietin O +
in O +
mice O +
with O +
azidothymidine O -
- O -
induced O +
anemia B-Disease +
and O +
in O +
bone O +
marrow O +
endothelial O +
cells O -
. O +

Azidothymidine O +
( O -
AZT O -
) O -
-induced O +
anemia B-Disease +
in O +
mice O +
can O +
be O +
reversed O +
by O +
the O +
administration O +
of O +
IGF O -
- O -
IL-3 O +
( O -
fusion O +
protein O +
of O +
insulin O -
- O -
like O +
growth O +
factor O +
II O +
( O -
IGF O +
II O -
) O +
and O +
interleukin O +
3 O -
) O -
. O +

Although O +
interleukin O +
3 O +
( O -
IL-3 O -
) O +
and O +
erythropoietin O +
( O -
EPO O -
) O +
are O +
known O +
to O +
act O +
synergistically O +
on O +
hematopoietic O +
cell O +
proliferation O +
in O +
vitro O -
, O +
injection O +
of O +
IGF O -
- O -
IL-3 O +
and O +
EPO O +
in O +
AZT O -
- O -
treated O +
mice O +
resulted O +
in O +
a O +
reduction O +
of O +
red O +
cells O +
and O +
an O +
increase O +
of O +
plasma O +
EPO O +
levels O +
as O +
compared O +
to O +
animals O +
treated O +
with O +
IGF O -
- O -
IL-3 O +
or O +
EPO O +
alone O -
. O +

We O +
tested O +
the O +
hypothesis O +
that O +
the O +
antagonistic O +
effect O +
of O +
IL-3 O +
and O +
EPO O +
on O +
erythroid O +
cells O +
may O +
be O +
mediated O +
by O +
endothelial O +
cells O -
. O +

Bovine O +
liver O +
erythroid O +
cells O +
were O +
cultured O +
on O +
monolayers O +
of O +
human O +
bone O +
marrow O +
endothelial O +
cells O +
previously O +
treated O +
with O +
EPO O +
and O +
IGF O -
- O -
IL-3 O -
. O +

There O +
was O +
a O +
significant O +
reduction O +
of O +
thymidine O +
incorporation O +
into O +
both O +
erythroid O +
and O +
endothelial O +
cells O +
in O +
cultures O +
pre O -
- O -
treated O +
with O +
IGF O -
- O -
IL-3 O +
and O +
EPO O -
. O +

Endothelial O +
cell O +
culture O +
supernatants O +
separated O +
by O +
ultrafiltration O +
and O +
ultracentrifugation O +
from O +
cells O +
treated O +
with O +
EPO O +
and O +
IL-3 O +
significantly O +
reduced O +
thymidine O +
incorporation O +
into O +
erythroid O +
cells O +
as O +
compared O +
to O +
identical O +
fractions O +
obtained O +
from O +
the O +
media O +
of O +
cells O +
cultured O +
with O +
EPO O +
alone O -
. O +

These O +
results O +
suggest O +
that O +
endothelial O +
cells O +
treated O +
simultaneously O +
with O +
EPO O +
and O +
IL-3 O +
have O +
a O +
negative O +
effect O +
on O +
erythroid O +
cell O +
production O -
. O +

Intravenous O +
ribavirin O +
treatment O +
for O +
severe O +
adenovirus B-Disease +
disease I-Disease +
in O +
immunocompromised O +
children O -
. O +

BACKGROUND O -
: O +
Adenovirus O +
is O +
an O +
important O +
cause O +
of O +
morbidity O +
and O +
mortality O +
in O +
the O +
immunocompromised O +
host O -
. O +

The O +
incidence O +
of O +
severe O +
adenovirus B-Disease +
disease I-Disease +
in O +
pediatrics O +
is O +
increasing O +
in O +
association O +
with O +
growing O +
numbers O +
of O +
immunocompromised O +
children O -
, O +
where O +
case O +
fatality O +
rates O +
as O +
high O +
as O +
50 O -
% O +
to O +
80 O -
% O +
have O +
been O +
reported O -
. O +

There O +
are O +
no O +
approved O +
antiviral O +
agents O +
with O +
proven O +
efficacy O +
for O +
the O +
treatment O +
of O +
severe O +
adenovirus B-Disease +
disease I-Disease -
, O +
nor O +
are O +
there O +
any O +
prospective O +
randomized O -
, O +
controlled O +
trials O +
of O +
potentially O +
useful O +
anti O -
- O -
adenovirus O +
therapies O -
. O +

Apparent O +
clinical O +
success O +
in O +
the O +
treatment O +
of O +
severe O +
adenovirus B-Disease +
disease I-Disease +
is O +
limited O +
to O +
a O +
few O +
case O +
reports O +
and O +
small O +
series O -
. O +

Experience O +
is O +
greatest O +
with O +
intravenous O +
ribavirin O +
and O +
cidofovir O -
. O +

Ribavirin O -
, O +
a O +
guanosine O +
analogue O -
, O +
has O +
broad O +
antiviral O +
activity O +
against O +
both O +
RNA O +
and O +
DNA O +
viruses O -
, O +
including O +
documented O +
activity O +
against O +
adenovirus O +
in O +
vitro O -
. O +

Ribavirin O +
is O +
licensed O +
in O +
aerosol O +
form O +
for O +
the O +
treatment O +
of O +
respiratory B-Disease +
syncytial I-Disease +
virus I-Disease +
infection I-Disease -
, O +
and O +
orally O +
in O +
combination O +
with O +
interferon O +
to O +
treat O +
hepatitis B-Disease +
C. I-Disease +
Intravenous O +
ribavirin O +
is O +
the O +
treatment O +
of O +
choice O +
for O +
infection B-Disease +
with I-Disease +
hemorrhagic I-Disease +
fever I-Disease +
viruses I-Disease -
. O +

The O +
most O +
common O +
adverse O +
effect O +
of O +
intravenous O +
ribavirin O +
is O +
reversible O +
mild O +
anemia B-Disease -
. O +

The O +
use O +
of O +
cidofovir O +
in O +
severe O +
adenovirus B-Disease +
infection I-Disease +
has O +
been O +
limited O +
by O +
adverse O +
effects O -
, O +
the O +
most O +
significant O +
of O +
which O +
is O +
nephrotoxicity B-Disease -
. O +

OBJECTIVE O -
: O +
We O +
report O +
our O +
experience O +
with O +
intravenous O +
ribavirin O +
therapy O +
for O +
severe O +
adenovirus B-Disease +
disease I-Disease +
in O +
a O +
series O +
of O +
immunocompromised O +
children O +
and O +
review O +
the O +
literature O -
. O +

DESIGN O -
/ O -
METHODS O -
: O +
We O +
retrospectively O +
reviewed O +
the O +
medical O +
records O +
of O +
5 O +
children O +
treated O +
with O +
intravenous O +
ribavirin O +
for O +
documented O +
severe O +
adenovirus B-Disease +
disease I-Disease -
. O +

Two O +
patients O +
developed O +
adenovirus O +
hemorrhagic B-Disease +
cystitis B-Disease +
after O +
cardiac O +
and O +
bone O +
marrow O +
transplants O -
, O +
respectively O -
. O +

The O +
bone O +
marrow O +
transplant O +
patient O +
also O +
received O +
intravenous O +
cidofovir O +
for O +
progressive O +
disseminated O +
disease O -
. O +

An O +
additional O +
3 O +
children O +
developed O +
adenovirus B-Disease +
pneumonia B-Disease -
; O +
2 O +
were O +
neonates O -
, O +
1 O +
of O +
whom O +
had O +
partial O +
DiGeorge B-Disease +
syndrome I-Disease -
. O +

The O +
remaining O +
infant O +
had O +
recently O +
undergone O +
a O +
cardiac O +
transplant O -
. O +

Intravenous O +
ribavirin O +
was O +
administered O +
on O +
a O +
compassionate O -
- O -
use O +
protocol O -
. O +

RESULTS O -
: O +
Complete O +
clinical O +
recovery O +
followed O +
later O +
by O +
viral O +
clearance O +
was O +
observed O +
in O +
2 O +
children O -
: O +
the O +
cardiac O +
transplant O +
recipient O +
with O +
adenovirus O +
hemorrhagic B-Disease +
cystitis B-Disease +
and O +
the O +
immunocompetent O +
neonate O +
with O +
adenovirus B-Disease +
pneumonia B-Disease -
. O +

The O +
remaining O +
3 O +
children O +
died O +
of O +
adenovirus B-Disease +
disease I-Disease -
. O +

Intravenous O +
ribavirin O +
therapy O +
was O +
well O +
tolerated O -
. O +

Use O +
of O +
cidofovir O +
in O +
1 O +
child O +
was O +
associated O +
with O +
progressive B-Disease +
renal I-Disease +
failure I-Disease +
and O +
neutropenia B-Disease -
. O +

DISCUSSION O -
: O +
Our O +
series O +
of O +
patients O +
is O +
representative O +
of O +
the O +
spectrum O +
of O +
immunocompromised O +
children O +
at O +
greatest O +
risk O +
for O +
severe O +
adenovirus B-Disease +
disease I-Disease -
, O +
namely O +
solid O -
- O -
organ O +
and O +
bone O +
marrow O +
transplant O +
recipients O -
, O +
neonates O -
, O +
and O +
children O +
with O +
immunodeficiency B-Disease -
. O +

Although O +
intravenous O +
ribavirin O +
was O +
not O +
effective O +
for O +
all O +
children O +
with O +
severe O +
adenovirus B-Disease +
disease I-Disease +
in O +
this O +
series O +
or O +
in O +
the O +
literature O -
, O +
therapy O +
is O +
unlikely O +
to O +
be O +
of O +
benefit O +
if O +
begun O +
late O +
in O +
the O +
course O +
of O +
the O +
infection B-Disease -
. O +

Early O +
identification O -
, O +
eg O +
by O +
polymerase O +
chain O +
reaction O +
of O +
those O +
patients O +
at O +
risk O +
of O +
disseminated O +
adenovirus B-Disease +
disease I-Disease +
may O +
permit O +
earlier O +
antiviral O +
treatment O +
and O +
better O +
evaluation O +
of O +
therapeutic O +
response O -
. O +

CONCLUSIONS O -
: O +
Two O +
of O +
5 O +
children O +
with O +
severe O +
adenovirus B-Disease +
disease I-Disease +
treated O +
with O +
intravenous O +
ribavirin O +
recovered O -
. O +

The O +
availability O +
of O +
newer O +
rapid O +
diagnostic O +
techniques O -
, O +
such O +
as O +
polymerase O +
chain O +
reaction O -
, O +
may O +
make O +
earlier O -
, O +
more O +
effective O +
treatment O +
of O +
adenovirus B-Disease +
infection I-Disease +
possible O -
. O +

Given O +
the O +
seriousness O +
and O +
increasing O +
prevalence O +
of O +
adenovirus B-Disease +
disease I-Disease +
in O +
certain O +
hosts O -
, O +
especially O +
children O -
, O +
a O +
large O -
, O +
multicenter O +
clinical O +
trial O +
of O +
potentially O +
useful O +
anti O -
- O -
adenoviral O +
therapies O -
, O +
such O +
as O +
intravenous O +
ribavirin O -
, O +
is O +
clearly O +
required O +
to O +
demonstrate O +
the O +
most O +
effective O +
and O +
least O +
toxic O +
therapy O -
. O +

Delayed O +
asystolic B-Disease +
cardiac B-Disease +
arrest I-Disease +
after O +
diltiazem O +
overdose B-Disease -
; O +
resuscitation O +
with O +
high O +
dose O +
intravenous O +
calcium O -
. O +

A O +
51 O +
year O +
old O +
man O +
took O +
a O +
mixed O +
overdose B-Disease +
including O +
1.8 O -
- O -
3.6 O +
g O +
of O +
diltiazem O -
, O +
paracetamol O -
, O +
aspirin O -
, O +
isosorbide O +
nitrate O -
, O +
and O +
alcohol O -
. O +

He O +
initially O +
presented O +
to O +
hospital O +
after O +
six O +
hours O +
with O +
mild O +
hypotension B-Disease +
and O +
was O +
treated O +
with O +
activated O +
charcoal O +
and O +
intravenous O +
fluids O -
. O +

Eighteen O +
hours O +
after O +
the O +
overdose B-Disease +
he O +
had O +
two O +
generalised O +
tonic B-Disease -
- I-Disease -
clonic I-Disease +
seizures I-Disease -
. O +

The O +
patient O +
remained O +
unresponsive O +
with O +
junctional O +
bradycardia B-Disease -
, O +
unrecordable O +
blood O +
pressure O -
, O +
and O +
then O +
became O +
asystolic B-Disease -
. O +

He O +
was O +
resuscitated O +
with O +
high O +
dose O +
( O -
13.5 O +
g O -
) O +
intravenous O +
calcium O +
and O +
adrenaline O +
( O -
epinephrine O -
) O -
. O +

He O +
required O +
inotropic O +
support O +
and O +
temporary O +
pacing O +
over O +
the O +
next O +
48 O +
hours O -
. O +

This O +
case O +
suggests O +
there O +
is O +
a O +
role O +
for O +
aggressive O +
high O +
dose O +
intravenous O +
calcium O +
therapy O +
in O +
severe O +
diltiazem O +
overdose B-Disease -
, O +
particularly O +
with O +
the O +
onset O +
of O +
asystole B-Disease -
. O +

It O +
should O +
be O +
considered O +
early O +
in O +
cases O +
of O +
cardiac B-Disease +
arrest I-Disease +
after O +
diltiazem O +
overdose B-Disease -
. O +

The O +
case O +
also O +
highlights O +
the O +
problems O +
with O +
delayed O +
toxicity B-Disease +
when O +
whole O +
bowel O +
irrigation O +
is O +
not O +
administered O -
. O +

Low O -
- O -
molecular O -
- O -
weight O +
heparin O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
mechanical O +
heart O +
valves O -
. O +

BACKGROUND O -
: O +
The O +
interruption O +
of O +
oral O +
anticoagulant O +
( O -
OAC O -
) O +
administration O +
is O +
sometimes O +
indicated O +
in O +
patients O +
with O +
mechanical O +
heart O +
valves O -
, O +
mainly O +
before O +
noncardiac O +
surgery O -
, O +
non O -
- O -
surgical O +
interventions O -
, O +
and O +
pregnancy O -
. O +

Unfractionated O +
heparin O +
( O -
UH O -
) O +
is O +
currently O +
the O +
substitute O +
for O +
selected O +
patients O -
. O +

Low O -
- O -
molecular O -
- O -
weight O +
heparin O +
( O -
LMWH O -
) O +
offers O +
theoretical O +
advantages O +
over O +
UH O -
, O +
but O +
is O +
not O +
currently O +
considered O +
in O +
clinical O +
guidelines O +
as O +
an O +
alternative O +
to O +
UH O +
in O +
patients O +
with O +
prosthetic O +
valves O -
. O +

HYPOTHESIS O -
: O +
The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
review O +
the O +
data O +
accumulated O +
so O +
far O +
on O +
the O +
use O +
of O +
LMWH O +
in O +
this O +
patient O +
population O +
and O +
to O +
discuss O +
its O +
applicability O +
in O +
common O +
practice O -
. O +

METHODS O -
: O +
For O +
this O +
paper O -
, O +
the O +
current O +
medical O +
literature O +
on O +
LMWH O +
in O +
patients O +
with O +
mechanical O +
heart O +
valves O +
was O +
extensively O +
reviewed O -
. O +

RESULTS O -
: O +
There O +
were O +
eight O +
series O +
and O +
six O +
case O +
reports O -
. O +

None O +
of O +
the O +
studies O +
was O +
randomized O -
, O +
and O +
only O +
one O +
was O +
prospective O -
. O +

Data O +
to O +
establish O +
the O +
thromboembolic B-Disease +
risk O +
were O +
incomplete O -
. O +

After O +
excluding O +
case O +
reports O -
, O +
the O +
following O +
groups O +
were O +
constructed O -
: O +
( O -
a O -
) O +
short O -
- O -
term O +
administration O -
, O +
after O +
valve O +
insertion O +
( O -
n O +
= O +
212 O -
) O -
; O +
( O -
b O -
) O +
short O -
- O -
term O -
, O +
perioperative O +
( O -
noncardiac O -
) O -
/ O -
periprocedural O +
( O -
n O +
= O +
114 O -
) O -
; O +
( O -
c O -
) O +
long O -
- O -
term O -
, O +
due O +
to O +
intolerance O +
to O +
OAC O +
( O -
n O +
= O +
16 O -
) O -
; O +
( O -
d O -
) O +
long O -
- O -
term O -
, O +
in O +
pregnancy O +
( O -
n O +
= O +
10 O -
) O -
. O +

The O +
incidence O +
rate O +
of O +
thromboembolism B-Disease +
was O +
0.9 O -
% O +
for O +
all O +
the O +
studies O +
and O +
0.5 O -
, O +
0 O -
, O +
20 O -
, O +
and O +
0 O -
% O +
in O +
groups O +
a O -
, O +
b O -
, O +
c O -
, O +
and O +
d O -
, O +
respectively O -
; O +
for O +
hemorrhage B-Disease -
, O +
the O +
overall O +
rate O +
was O +
3.4 O -
% O +
( O -
3.8 O -
, O +
2.6 O -
, O +
10 O -
, O +
and O +
0 O -
% O +
for O +
the O +
respective O +
groups O -
) O -
. O +

CONCLUSIONS O -
: O +
In O +
patients O +
with O +
mechanical O +
heart O +
valves O -
, O +
short O -
- O -
term O +
LMWH O +
therapy O +
compares O +
favorably O +
with O +
UH O -
. O +

Data O +
on O +
mid- O +
and O +
long O -
- O -
term O +
LMWH O +
administration O +
in O +
these O +
patients O +
are O +
sparse O -
. O +

Further O +
randomized O +
studies O +
are O +
needed O +
to O +
confirm O +
the O +
safety O +
and O +
precise O +
indications O +
for O +
the O +
use O +
of O +
LMWH O +
in O +
patients O +
with O +
mechanical O +
heart O +
valves O -
. O +

Cardiac B-Disease +
arrest I-Disease +
after O +
intravenous O +
metoclopramide O +
- O +
a O +
case O +
of O +
five O +
repeated O +
injections O +
of O +
metoclopramide O +
causing O +
five O +
episodes O +
of O +
cardiac B-Disease +
arrest I-Disease -
. O +

We O +
describe O +
a O +
patient O +
where O +
intravenous O +
injection O +
of O +
metoclopramide O +
was O +
immediately O +
followed O +
by O +
asystole B-Disease +
repeatedly O -
. O +

The O +
patient O +
received O +
metoclopramide O +
10 O +
mg O +
i.v O -
. O +

five O +
times O +
during O +
48 O +
h. O +
After O +
interviewing O +
the O +
attending O +
nurses O +
and O +
reviewing O +
the O +
written O +
documentation O -
, O +
it O +
is O +
clear O +
that O +
every O +
administration O +
of O +
metoclopramide O +
was O +
immediately O +
( O -
within O +
s O -
) O +
followed O +
by O +
asystole B-Disease -
. O +

The O +
asystole B-Disease +
lasted O +
15 O -
- O -
30 O +
s O +
on O +
four O +
occasions O -
, O +
on O +
one O +
occasion O +
it O +
lasted O +
2 O +
min O -
. O +

The O +
patient O +
received O +
atropine O +
0.5 O -
- O -
1 O +
mg O +
and O +
chest O +
compressions O -
, O +
before O +
sinus O +
rhythm O +
again O +
took O +
over O -
. O +

We O +
interpret O +
this O +
as O +
episodes O +
of O +
cardiac B-Disease +
arrest I-Disease +
caused O +
by O +
metoclopramide O -
. O +

The O +
rapid O +
injection O +
via O +
the O +
central O +
venous O +
route O +
and O +
the O +
concomitant O +
tapering O +
of O +
dopamine O +
infusion O +
might O +
have O +
contributed O +
in O +
precipitating O +
the O +
adverse O +
drug O +
reaction O -
. O +

Immunohistochemical O +
study O +
on O +
inducible O +
type O +
of O +
nitric O +
oxide O +
( O -
iNOS O -
) O -
, O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
and O +
tumor B-Disease +
growth O +
factor O -
- O -
beta1 O +
( O -
TGF O -
- O -
beta1 O -
) O +
in O +
arteritis B-Disease +
induced O +
in O +
rats O +
by O +
fenoldopam O +
and O +
theophylline O -
, O +
vasodilators O -
. O +

Arteritis B-Disease +
induced O +
in O +
rats O +
by O +
vasodilators O -
, O +
fenoldopam O +
and O +
theophylline O -
, O +
was O +
examined O +
immunohistochemically O +
for O +
expressions O +
of O +
inducible O +
type O +
of O +
nitric O +
oxide O +
synthase O +
( O -
iNOS O -
) O -
, O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
and O +
tumor B-Disease +
growth O +
factor O -
- O -
beta1 O +
( O -
TGF O -
- O -
beta1 O -
) O -
. O +

Rats O +
were O +
administered O +
fenoldopam O +
for O +
24 O +
hours O +
by O +
intravenous O +
infusion O +
with O +
or O +
without O +
following O +
repeated O +
daily O +
oral O +
administrations O +
of O +
theophylline O -
. O +

Irrespective O +
of O +
theophylline O +
administration O -
, O +
iNOS O +
antigens O +
were O +
remarkably O +
abundant O +
in O +
ED-1-positive O +
cells O +
on O +
day O +
5 O +
and O +
8 O +
post O -
- O -
fenoldopam O -
- O -
infusion O +
( O -
DPI O -
) O -
; O +
bFGF O +
antigens O +
were O +
remarkably O +
abundant O +
in O +
ED-1-positive O +
cells O +
on O +
1 O +
and O +
3 O +
DPI O -
; O +
TGF O -
- O -
beta1 O +
antigens O +
were O +
observed O +
in O +
ED-1-positive O +
cells O +
on O +
and O +
after O +
5 O +
DPI O -
. O +

These O +
results O +
suggest O +
that O +
the O +
peak O +
expression O +
of O +
iNOS O +
antigen O +
was O +
followed O +
by O +
that O +
of O +
bFGF O +
antigen O -
, O +
and O +
bFGF O +
may O +
have O +
a O +
suppressive O +
effect O +
on O +
iNOS O +
expression O +
in O +
these O +
rat O +
arteritis B-Disease +
models O -
. O +

On O +
the O +
other O +
hand O -
, O +
TGF O -
- O -
beta1 O +
was O +
not O +
considered O +
to O +
have O +
a O +
suppressive O +
effect O +
on O +
iNOS O +
expression O +
in O +
these O +
models O -
. O +

The O +
relationship O +
between O +
hippocampal O +
acetylcholine O +
release O +
and O +
cholinergic O +
convulsant O +
sensitivity O +
in O +
withdrawal O +
seizure B-Disease -
- O -
prone O +
and O +
withdrawal O +
seizure B-Disease -
- O -
resistant O +
selected O +
mouse O +
lines O -
. O +

BACKGROUND O -
: O +
The O +
septo O -
- O -
hippocampal O +
cholinergic O +
pathway O +
has O +
been O +
implicated O +
in O +
epileptogenesis O -
, O +
and O +
genetic O +
factors O +
influence O +
the O +
response O +
to O +
cholinergic O +
agents O -
, O +
but O +
limited O +
data O +
are O +
available O +
on O +
cholinergic O +
involvement O +
in O +
alcohol O +
withdrawal O +
severity O -
. O +

Thus O -
, O +
the O +
relationship O +
between O +
cholinergic O +
activity O +
and O +
responsiveness O +
and O +
alcohol O +
withdrawal O +
was O +
investigated O +
in O +
a O +
genetic O +
animal O +
model O +
of O +
ethanol O +
withdrawal O +
severity O -
. O +

METHODS O -
: O +
Cholinergic O +
convulsant O +
sensitivity O +
was O +
examined O +
in O +
alcohol O -
- O -
na O +
ve O +
Withdrawal O +
Seizure B-Disease -
- O -
Prone O +
( O -
WSP O -
) O +
and O -
- O -
Resistant O +
( O -
WSR O -
) O +
mice O -
. O +

Animals O +
were O +
administered O +
nicotine O -
, O +
carbachol O -
, O +
or O +
neostigmine O +
via O +
timed O +
tail O +
vein O +
infusion O -
, O +
and O +
the O +
latencies O +
to O +
onset O +
of O +
tremor B-Disease +
and O +
clonus O +
were O +
recorded O +
and O +
converted O +
to O +
threshold O +
dose O -
. O +

We O +
also O +
used O +
microdialysis O +
to O +
measure O +
basal O +
and O +
potassium O -
- O -
stimulated O +
acetylcholine O +
( O -
ACh O -
) O +
release O +
in O +
the O +
CA1 O +
region O +
of O +
the O +
hippocampus O -
. O +

Potassium O +
was O +
applied O +
by O +
reverse O +
dialysis O +
twice O -
, O +
separated O +
by O +
75 O +
min O -
. O +

Hippocampal O +
ACh O +
also O +
was O +
measured O +
during O +
testing O +
for O +
handling O -
- O -
induced O +
convulsions B-Disease -
. O +

RESULTS O -
: O +
Sensitivity O +
to O +
several O +
convulsion B-Disease +
endpoints O +
induced O +
by O +
nicotine O -
, O +
carbachol O -
, O +
and O +
neostigmine O +
were O +
significantly O +
greater O +
in O +
WSR O +
versus O +
WSP O +
mice O -
. O +

In O +
microdialysis O +
experiments O -
, O +
the O +
lines O +
did O +
not O +
differ O +
in O +
basal O +
release O +
of O +
ACh O -
, O +
and O +
50 O +
mM O +
KCl O +
increased O +
ACh O +
output O +
in O +
both O +
lines O +
of O +
mice O -
. O +

However O -
, O +
the O +
increase O +
in O +
release O +
of O +
ACh O +
produced O +
by O +
the O +
first O +
application O +
of O +
KCl O +
was O +
2-fold O +
higher O +
in O +
WSP O +
versus O +
WSR O +
mice O -
. O +

When O +
hippocampal O +
ACh O +
was O +
measured O +
during O +
testing O +
for O +
handling O -
- O -
induced O +
convulsions B-Disease -
, O +
extracellular O +
ACh O +
was O +
significantly O +
elevated O +
( O -
192 O -
% O -
) O +
in O +
WSP O +
mice O -
, O +
but O +
was O +
nonsignificantly O +
elevated O +
( O -
59 O -
% O -
) O +
in O +
WSR O +
mice O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
differences O +
in O +
cholinergic O +
activity O +
and O +
postsynaptic O +
sensitivity O +
to O +
cholinergic O +
convulsants B-Disease +
may O +
be O +
associated O +
with O +
ethanol O +
withdrawal O +
severity O +
and O +
implicate O +
cholinergic O +
mechanisms O +
in O +
alcohol O +
withdrawal O -
. O +

Specifically O -
, O +
WSP O +
mice O +
may O +
have O +
lower O +
sensitivity O +
to O +
cholinergic O +
convulsants B-Disease +
compared O +
with O +
WSR O +
because O +
of O +
postsynaptic O +
receptor O +
desensitization O +
brought O +
on O +
by O +
higher O +
activity O +
of O +
cholinergic O +
neurons O -
. O +

Capsaicin O -
- O -
induced O +
muscle B-Disease +
pain I-Disease +
alters O +
the O +
excitability O +
of O +
the O +
human O +
jaw O -
- O -
stretch O +
reflex O -
. O +

The O +
pathophysiology O +
of O +
painful O +
temporomandibular B-Disease +
disorders I-Disease +
is O +
not O +
fully O +
understood O -
, O +
but O +
evidence O +
suggests O +
that O +
muscle B-Disease +
pain I-Disease +
modulates O +
motor O +
function O +
in O +
characteristic O +
ways O -
. O +

This O +
study O +
tested O +
the O +
hypothesis O +
that O +
activation O +
of O +
nociceptive B-Disease +
muscle I-Disease +
afferent O +
fibers O +
would O +
be O +
linked O +
to O +
an O +
increased O +
excitability O +
of O +
the O +
human O +
jaw O -
- O -
stretch O +
reflex O +
and O +
whether O +
this O +
process O +
would O +
be O +
sensitive O +
to O +
length O +
and O +
velocity O +
of O +
the O +
stretch O -
. O +

Capsaicin O +
( O -
10 O +
micro O +
g O -
) O +
was O +
injected O +
into O +
the O +
masseter O +
muscle O +
to O +
induce O +
pain B-Disease +
in O +
11 O +
healthy O +
volunteers O -
. O +

Short O -
- O -
latency O +
reflex O +
responses O +
were O +
evoked O +
in O +
the O +
masseter O +
and O +
temporalis O +
muscles O +
by O +
a O +
stretch O +
device O +
with O +
different O +
velocities O +
and O +
displacements O +
before O -
, O +
during O -
, O +
and O +
after O +
the O +
pain B-Disease -
. O +

The O +
normalized O +
reflex O +
amplitude O +
increased O +
with O +
an O +
increase O +
in O +
velocity O +
at O +
a O +
given O +
displacement O -
, O +
but O +
remained O +
constant O +
with O +
different O +
displacements O +
at O +
a O +
given O +
velocity O -
. O +

The O +
normalized O +
reflex O +
amplitude O +
was O +
significantly O +
higher O +
during O +
pain B-Disease -
, O +
but O +
only O +
at O +
faster O +
stretches O +
in O +
the O +
painful B-Disease +
muscle I-Disease -
. O +

Increased O +
sensitivity O +
of O +
the O +
fusimotor O +
system O +
during O +
acute O +
muscle B-Disease +
pain I-Disease +
could O +
be O +
one O +
likely O +
mechanism O +
to O +
explain O +
the O +
findings O -
. O +

The O +
striatum O +
as O +
a O +
target O +
for O +
anti O -
- O -
rigor O +
effects O +
of O +
an O +
antagonist O +
of O +
mGluR1 O -
, O +
but O +
not O +
an O +
agonist O +
of O +
group O +
II O +
metabotropic O +
glutamate O +
receptors O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
find O +
out O +
whether O +
the O +
metabotropic O +
receptor O +
1 O +
( O -
mGluR1 O -
) O +
and O +
group O +
II O +
mGluRs O -
, O +
localized O +
in O +
the O +
striatum O -
, O +
are O +
involved O +
in O +
antiparkinsonian O -
- O -
like O +
effects O +
in O +
rats O -
. O +

Haloperidol O +
( O -
1 O +
mg O -
/ O -
kg O +
ip O -
) O +
induced O +
parkinsonian B-Disease -
- O -
like O +
muscle B-Disease +
rigidity I-Disease -
, O +
measured O +
as O +
an O +
increased O +
resistance O +
of O +
a O +
rat O -
's O +
hind O +
foot O +
to O +
passive O +
flexion O +
and O +
extension O +
at O +
the O +
ankle O +
joint O -
. O +

( O -
RS O -
) O -
-1-aminoindan-1,5-dicarboxylic O +
acid O +
( O -
AIDA O -
; O +
0.5 O -
- O -
15 O +
microg O -
/ O -
0.5 O +
microl O -
) O -
, O +
a O +
potent O +
and O +
selective O +
mGluR1 O +
antagonist O -
, O +
or O +
( O -
2R,4R O -
) O -
-4-aminopyrrolidine-2,4-dicarboxylate O +
( O -
2R,4R O -
- O -
APDC O -
; O +
7.5 O -
- O -
15 O +
microg O -
/ O -
0.5 O +
microl O -
) O -
, O +
a O +
selective O +
group O +
II O +
agonist O -
, O +
was O +
injected O +
bilaterally O +
into O +
the O +
striatum O +
of O +
haloperidol O -
- O -
treated O +
animals O -
. O +

AIDA O +
in O +
doses O +
of O +
7.5 O -
- O -
15 O +
microg O -
/ O -
0.5 O +
microl O +
diminished O +
the O +
haloperidol O -
- O -
induced O +
muscle B-Disease +
rigidity I-Disease -
. O +

In O +
contrast O -
, O +
2R,4R O -
- O -
APDC O +
injections O +
were O +
ineffective O -
. O +

The O +
present O +
results O +
may O +
suggest O +
that O +
the O +
blockade O +
of O +
striatal O +
mGluR1 O -
, O +
but O +
not O +
the O +
stimulation O +
of O +
group O +
II O +
mGluRs O -
, O +
may O +
ameliorate O +
parkinsonian B-Disease +
muscle B-Disease +
rigidity I-Disease -
. O +

Effects O +
of O +
5-HT1B O +
receptor O +
ligands O +
microinjected O +
into O +
the O +
accumbal O +
shell O +
or O +
core O +
on O +
the O +
cocaine O -
- O -
induced O +
locomotor B-Disease +
hyperactivity I-Disease +
in O +
rats O -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
examine O +
the O +
effect O +
of O +
5-HT1B O +
receptor O +
ligands O +
microinjected O +
into O +
the O +
subregions O +
of O +
the O +
nucleus O +
accumbens O +
( O -
the O +
shell O +
and O +
the O +
core O -
) O +
on O +
the O +
locomotor B-Disease +
hyperactivity I-Disease +
induced O +
by O +
cocaine O +
in O +
rats O -
. O +

Male O +
Wistar O +
rats O +
were O +
implanted O +
bilaterally O +
with O +
cannulae O +
into O +
the O +
accumbens O +
shell O +
or O +
core O -
, O +
and O +
then O +
were O +
locally O +
injected O +
with O +
GR O +
55562 O +
( O -
an O +
antagonist O +
of O +
5-HT1B O +
receptors O -
) O +
or O +
CP O +
93129 O +
( O -
an O +
agonist O +
of O +
5-HT1B O +
receptors O -
) O -
. O +

Given O +
alone O +
to O +
any O +
accumbal O +
subregion O -
, O +
GR O +
55562 O +
( O -
0.1 O -
- O -
10 O +
microg O -
/ O -
side O -
) O +
or O +
CP O +
93129 O +
( O -
0.1 O -
- O -
10 O +
microg O -
/ O -
side O -
) O +
did O +
not O +
change O +
basal O +
locomotor O +
activity O -
. O +

Systemic O +
cocaine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
significantly O +
increased O +
the O +
locomotor O +
activity O +
of O +
rats O -
. O +

GR O +
55562 O +
( O -
0.1 O -
- O -
10 O +
microg O -
/ O -
side O -
) O -
, O +
administered O +
intra O -
- O -
accumbens O +
shell O +
prior O +
to O +
cocaine O -
, O +
dose O -
- O -
dependently O +
attenuated O +
the O +
psychostimulant O -
- O -
induced O +
locomotor B-Disease +
hyperactivity I-Disease -
. O +

Such O +
attenuation O +
was O +
not O +
found O +
in O +
animals O +
which O +
had O +
been O +
injected O +
with O +
GR O +
55562 O +
into O +
the O +
accumbens O +
core O -
. O +

When O +
injected O +
into O +
the O +
accumbens O +
shell O +
( O -
but O +
not O +
the O +
core O -
) O +
before O +
cocaine O -
, O +
CP O +
93129 O +
( O -
0.1 O -
- O -
10 O +
microg O -
/ O -
side O -
) O +
enhanced O +
the O +
locomotor O +
response O +
to O +
cocaine O -
; O +
the O +
maximum O +
effect O +
being O +
observed O +
after O +
10 O +
microg O -
/ O -
side O +
of O +
the O +
agonist O -
. O +

The O +
later O +
enhancement O +
was O +
attenuated O +
after O +
intra O -
- O -
accumbens O +
shell O +
treatment O +
with O +
GR O +
55562 O +
( O -
1 O +
microg O -
/ O -
side O -
) O -
. O +

Our O +
findings O +
indicate O +
that O +
cocaine O +
induced O +
hyperlocomotion B-Disease +
is O +
modified O +
by O +
5-HT1B O +
receptor O +
ligands O +
microinjected O +
into O +
the O +
accumbens O +
shell O -
, O +
but O +
not O +
core O -
, O +
this O +
modification O +
consisting O +
in O +
inhibitory O +
and O +
facilitatory O +
effects O +
of O +
the O +
5-HT1B O +
receptor O +
antagonist O +
( O -
GR O +
55562 O -
) O +
and O +
agonist O +
( O -
CP O +
93129 O -
) O -
, O +
respectively O -
. O +

In O +
other O +
words O -
, O +
the O +
present O +
results O +
suggest O +
that O +
the O +
accumbal O +
shell O +
5-HT1B O +
receptors O +
play O +
a O +
permissive O +
role O +
in O +
the O +
behavioural O +
response O +
to O +
the O +
psychostimulant O -
. O +

Cocaine O +
related O +
chest B-Disease +
pain I-Disease -
: O +
are O +
we O +
seeing O +
the O +
tip O +
of O +
an O +
iceberg O -
? O +

The O +
recreational O +
use O +
of O +
cocaine O +
is O +
on O +
the O +
increase O -
. O +

The O +
emergency O +
nurse O +
ought O +
to O +
be O +
familiar O +
with O +
some O +
of O +
the O +
cardiovascular O +
consequences O +
of O +
cocaine O +
use O -
. O +

In O +
particular O -
, O +
the O +
tendency O +
of O +
cocaine O +
to O +
produce O +
chest B-Disease +
pain I-Disease +
ought O +
to O +
be O +
in O +
the O +
mind O +
of O +
the O +
emergency O +
nurse O +
when O +
faced O +
with O +
a O +
young O +
victim O +
of O +
chest B-Disease +
pain I-Disease +
who O +
is O +
otherwise O +
at O +
low O +
risk O -
. O +

The O +
mechanism O +
of O +
chest B-Disease +
pain I-Disease +
related O +
to O +
cocaine O +
use O +
is O +
discussed O +
and O +
treatment O +
dilemmas O +
are O +
discussed O -
. O +

Finally O -
, O +
moral O +
issues O +
relating O +
to O +
the O +
testing O +
of O +
potential O +
cocaine O +
users O +
will O +
be O +
addressed O -
. O +

A O +
phase O +
II O +
study O +
of O +
thalidomide O +
in O +
advanced O +
metastatic O +
renal B-Disease +
cell I-Disease +
carcinoma I-Disease -
. O +

OBJECTIVES O -
: O +
To O +
evaluate O +
the O +
toxicity B-Disease +
and O +
activity O +
of O +
thalidomide O +
in O +
patients O +
with O +
advanced O +
metastatic O +
renal B-Disease +
cell I-Disease +
cancer I-Disease +
and O +
to O +
measure O +
changes O +
of O +
one O +
angiogenic O +
factor O -
, O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
165 O -
, O +
with O +
therapy O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
29 O +
patients O +
were O +
enrolled O +
on O +
a O +
study O +
of O +
thalidomide O +
using O +
an O +
intra O -
- O -
patient O +
dose O +
escalation O +
schedule O -
. O +

Patients O +
began O +
thalidomide O +
at O +
400 O +
mg O -
/ O -
d O +
and O +
escalated O +
as O +
tolerated O +
to O +
1200 O +
mg O -
/ O -
d O +
by O +
day O +
54 O -
. O +

Fifty O -
- O -
nine O +
per O +
cent O +
of O +
patients O +
had O +
had O +
previous O +
therapy O +
with O +
IL-2 O +
and O +
52 O -
% O +
were O +
performance O +
status O +
2 O +
or O +
3 O -
. O +

Systemic O +
plasma O +
VEGF165 O +
levels O +
were O +
measured O +
by O +
dual O +
monoclonal O +
ELISA O +
in O +
8 O +
patients O -
. O +

RESULTS O -
: O +
24 O +
patients O +
were O +
evaluable O +
for O +
response O +
with O +
one O +
partial O +
response O +
of O +
11 O +
months O +
duration O +
of O +
a O +
patient O +
with O +
hepatic O +
and O +
pulmonary O +
metastases B-Disease +
( O -
4 O -
% O -
) O -
, O +
one O +
minor O +
response O -
, O +
and O +
2 O +
patients O +
stable O +
for O +
over O +
6 O +
months O -
. O +

Somnolence B-Disease +
and O +
constipation B-Disease +
were O +
prominent O +
toxicities B-Disease +
and O +
most O +
patients O +
could O +
not O +
tolerate O +
the O +
1200 O +
mg O -
/ O -
day O +
dose O +
level O -
. O +

Systemic O +
plasma O +
VEGF165 O +
levels O +
did O +
not O +
change O +
with O +
therapy O -
. O +

CONCLUSION O -
: O +
These O +
results O +
are O +
consistent O +
with O +
a O +
low O +
level O +
of O +
activity O +
of O +
thalidomide O +
in O +
renal B-Disease +
cell I-Disease +
carcinoma I-Disease -
. O +

Administration O +
of O +
doses O +
over O +
800 O +
mg O -
/ O -
day O +
was O +
difficult O +
to O +
achieve O +
in O +
this O +
patient O +
population O -
, O +
however O +
lower O +
doses O +
were O +
practical O -
. O +

The O +
dose O -
- O -
response O +
relationship O -
, O +
if O +
any O -
, O +
of O +
thalidomide O +
for O +
renal B-Disease +
cell I-Disease +
carcinoma I-Disease +
is O +
unclear O -
. O +

Can O +
lidocaine O +
reduce O +
succinylcholine O +
induced O +
postoperative B-Disease +
myalgia I-Disease -
? O +

This O +
study O +
was O +
undertaken O +
to O +
determine O +
the O +
effect O +
of O +
lidocaine O +
pretreatment O +
on O +
reduction O +
of O +
succinylcholine O -
- O -
induced O +
myalgia B-Disease +
in O +
patients O +
undergoing O +
general O +
anesthesia O +
for O +
gynecological O +
surgery O -
. O +

One O +
hundred O +
and O +
thirty O -
- O -
five O +
patients O +
were O +
assigned O +
to O +
one O +
of O +
three O +
groups O +
in O +
a O +
prospective O -
, O +
double O +
blind O -
, O +
randomized O +
manner O -
. O +

Group O +
PS O -
, O +
the O +
control O +
group O -
, O +
received O +
normal O +
saline O +
and O +
succinylcholine O +
1.5 O +
mg O +
x O +
kg O -
( O -
-1 O -
) O -
; O +
Group O +
LS O -
, O +
lidocaine O +
1.5 O +
mg O +
x O +
kg O -
( O -
-1 O -
) O +
and O +
succinylcholine O +
1.5 O +
mg O +
x O +
kg O -
( O -
-1 O -
) O -
; O +
Group O +
PR O -
, O +
normal O +
saline O +
and O +
rocuronium O +
0.6 O +
mg O +
x O +
kg O -
( O -
-1 O -
) O -
. O +

Morphine O +
0.1 O +
mg O +
x O +
kg O -
( O -
-1 O -
) O +
iv O +
was O +
given O +
for O +
premedication O +
and O +
all O +
patients O +
were O +
monitored O +
with O +
a O +
noninvasive O +
blood O +
pressure O +
monitor O -
, O +
ECG O +
and O +
pulse O +
oximetry O -
. O +

Anesthesia O +
was O +
induced O +
with O +
5 O +
mg.kg O -
( O -
-1 O -
) O +
thiopental O +
iv O -
. O +

followed O +
by O +
succinylcholine O +
( O -
Group O +
PS O -
, O +
LS O -
) O +
or O +
rocuronium O +
( O -
Group O +
PR O -
) O +
for O +
tracheal O +
intubation O -
. O +

Following O +
administration O +
of O +
these O +
agents O -
, O +
the O +
presence O -
, O +
and O +
degree O +
of O +
fasciculation B-Disease +
were O +
assessed O +
visually O +
on O +
a O +
four O +
point O +
scale O +
by O +
one O +
investigator O +
who O +
was O +
blinded O +
to O +
the O +
drug O +
administered O -
. O +

The O +
blood O +
pressure O +
and O +
heart O +
rate O +
of O +
each O +
patient O +
were O +
monitored O +
on O +
nine O +
occasions O -
. O +

Twenty O -
- O -
four O +
hours O +
later O -
, O +
any O +
myalgia B-Disease +
experienced O +
was O +
assessed O +
according O +
to O +
a O +
structured O +
questionaire O +
and O +
graded O +
by O +
a O +
four O +
point O +
scale O +
by O +
one O +
investigator O +
blinded O +
to O +
the O +
intraoperative O +
management O -
. O +

The O +
results O +
indicate O +
that O +
muscle B-Disease +
fasciculation I-Disease +
was O +
not O +
found O +
in O +
Group O +
PR O +
while O +
the O +
patients O +
in O +
Group O +
LS O +
had O +
a O +
lower O +
incidence O +
of O +
muscle B-Disease +
fasciculation I-Disease +
than O +
those O +
in O +
Group O +
PS O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

At O +
24 O +
h O -
, O +
the O +
incidence O +
of O +
myalgia B-Disease +
was O +
higher O +
in O +
Group O +
PS O +
than O +
in O +
Group O +
LS O +
and O +
PR O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

A O +
correlation O +
was O +
not O +
found O +
between O +
the O +
incidence O +
of O +
myalgia B-Disease +
and O +
the O +
occurrence O +
of O +
muscle B-Disease +
fasciculation I-Disease -
. O +

The O +
changes O +
in O +
systolic O +
and O +
diastolic O +
blood O +
pressure O +
and O +
heart O +
rate O +
were O +
not O +
significant O +
among O +
the O +
three O +
groups O -
. O +

In O +
conclusion O -
, O +
where O +
succinylcholine O +
is O +
used O -
, O +
lidocaine O +
is O +
proven O +
to O +
be O +
the O +
useful O +
pretreatment O +
agent O +
for O +
the O +
reduction O +
of O +
postoperative B-Disease +
myalgia I-Disease -
. O +

Crossover O +
comparison O +
of O +
efficacy O +
and O +
preference O +
for O +
rizatriptan O +
10 O +
mg O +
versus O +
ergotamine O -
/ O -
caffeine O +
in O +
migraine B-Disease -
. O +

Rizatriptan O +
is O +
a O +
selective O +
5-HT O -
( O -
1B O -
/ O -
1D O -
) O +
receptor O +
agonist O +
with O +
rapid O +
oral O +
absorption O +
and O +
early O +
onset O +
of O +
action O +
in O +
the O +
acute O +
treatment O +
of O +
migraine B-Disease -
. O +

This O +
randomized O +
double- O +
blind O +
crossover O +
outpatient O +
study O +
assessed O +
the O +
preference O +
for O +
1 O +
rizatriptan O +
10 O +
mg O +
tablet O +
to O +
2 O +
ergotamine O +
1 O +
mg O -
/ O -
caffeine O +
100 O +
mg O +
tablets O +
in O +
439 O +
patients O +
treating O +
a O +
single O +
migraine B-Disease +
attack O +
with O +
each O +
therapy O -
. O +

Of O +
patients O +
expressing O +
a O +
preference O +
( O -
89.1 O -
% O -
) O -
, O +
more O +
than O +
twice O +
as O +
many O +
preferred O +
rizatriptan O +
to O +
ergotamine O -
/ O -
caffeine O +
( O -
69.9 O +
vs. O +
30.1 O -
% O -
, O +
p O +
< O +
or O +
= O +
0.001 O -
) O -
. O +

Faster O +
relief O +
of O +
headache B-Disease +
was O +
the O +
most O +
important O +
reason O +
for O +
preference O -
, O +
cited O +
by O +
67.3 O -
% O +
of O +
patients O +
preferring O +
rizatriptan O +
and O +
54.2 O -
% O +
of O +
patients O +
who O +
preferred O +
ergotamine O -
/ O -
caffeine O -
. O +

The O +
co O -
- O -
primary O +
endpoint O +
of O +
being O +
pain B-Disease +
free O +
at O +
2 O +
h O +
was O +
also O +
in O +
favor O +
of O +
rizatriptan O -
. O +

Forty O -
- O -
nine O +
percent O +
of O +
patients O +
were O +
pain B-Disease +
free O +
2 O +
h O +
after O +
rizatriptan O -
, O +
compared O +
with O +
24.3 O -
% O +
treated O +
with O +
ergotamine O -
/ O -
caffeine O +
( O -
p O +
< O +
or O +
= O +
0.001 O -
) O -
, O +
rizatriptan O +
being O +
superior O +
within O +
1 O +
h O +
of O +
treatment O -
. O +

Headache B-Disease +
relief O +
at O +
2 O +
h O +
was O +
75.9 O -
% O +
for O +
rizatriptan O +
and O +
47.3 O -
% O +
for O +
ergotamine O -
/ O -
caffeine O +
( O -
p O +
< O +
or O +
= O +
0.001 O -
) O -
, O +
with O +
rizatriptan O +
being O +
superior O +
to O +
ergotamine O -
/ O -
caffeine O +
within O +
30 O +
min O +
of O +
dosing O -
. O +

Almost O +
36 O -
% O +
of O +
patients O +
taking O +
rizatriptan O +
were O +
pain B-Disease +
free O +
at O +
2 O +
h O +
and O +
had O +
no O +
recurrence O +
or O +
need O +
for O +
additional O +
medication O +
within O +
24 O +
h O -
, O +
compared O +
to O +
20 O -
% O +
of O +
patients O +
on O +
ergotamine O -
/ O -
caffeine O +
( O -
p O +
< O +
or O +
= O +
0.001 O -
) O -
. O +

Rizatriptan O +
was O +
also O +
superior O +
to O +
ergotamine O -
/ O -
caffeine O +
in O +
the O +
proportions O +
of O +
patients O +
with O +
no O +
nausea B-Disease -
, O +
vomiting B-Disease -
, O +
phonophobia B-Disease +
or O +
photophobia B-Disease +
and O +
for O +
patients O +
with O +
normal O +
function O +
2 O +
h O +
after O +
drug O +
intake O +
( O -
p O +
< O +
or O +
= O +
0.001 O -
) O -
. O +

More O +
patients O +
were O +
( O -
completely O -
, O +
very O +
or O +
somewhat O -
) O +
satisfied O +
2 O +
h O +
after O +
treatment O +
with O +
rizatriptan O +
( O -
69.8 O -
% O -
) O +
than O +
at O +
2 O +
h O +
after O +
treatment O +
with O +
ergotamine O -
/ O -
caffeine O +
( O -
38.6 O -
% O -
, O +
p O +
< O +
or O +
= O +
0.001 O -
) O -
. O +

Recurrence O +
rates O +
were O +
31.4 O -
% O +
with O +
rizatriptan O +
and O +
15.3 O -
% O +
with O +
ergotamine O -
/ O -
caffeine O -
. O +

Both O +
active O +
treatments O +
were O +
well O +
tolerated O -
. O +

The O +
most O +
common O +
adverse O +
events O +
( O -
incidence O +
> O +
or O +
= O +
5 O -
% O +
in O +
one O +
group O -
) O +
after O +
rizatriptan O +
and O +
ergotamine O -
/ O -
caffeine O -
, O +
respectively O -
, O +
were O +
dizziness B-Disease +
( O -
6.7 O +
and O +
5.3 O -
% O -
) O -
, O +
nausea B-Disease +
( O -
4.2 O +
and O +
8.5 O -
% O -
) O +
and O +
somnolence B-Disease +
( O -
5.5 O +
and O +
2.3 O -
% O -
) O -
. O +

Reduced O +
sodium O +
channel O +
density O -
, O +
altered O +
voltage O +
dependence O +
of O +
inactivation O -
, O +
and O +
increased O +
susceptibility O +
to O +
seizures B-Disease +
in O +
mice O +
lacking O +
sodium O +
channel O +
beta O +
2-subunits O -
. O +

Sodium O +
channel O +
beta O -
- O -
subunits O +
modulate O +
channel O +
gating O -
, O +
assembly O -
, O +
and O +
cell O +
surface O +
expression O +
in O +
heterologous O +
cell O +
systems O -
. O +

We O +
generated O +
beta2 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
to O +
investigate O +
the O +
role O +
of O +
beta2 O +
in O +
control O +
of O +
sodium O +
channel O +
density O -
, O +
localization O -
, O +
and O +
function O +
in O +
neurons O +
in O +
vivo O -
. O +

Measurements O +
of O +
[ O -
( O -
3 O -
) O -
H O -
] O -
saxitoxin O +
( O -
STX O -
) O +
binding O +
showed O +
a O +
significant O +
reduction O +
in O +
the O +
level O +
of O +
plasma O +
membrane O +
sodium O +
channels O +
in O +
beta2 O -
( O -
- O -
/ O -
- O -
) O +
neurons O -
. O +

The O +
loss O +
of O +
beta2 O +
resulted O +
in O +
negative O +
shifts O +
in O +
the O +
voltage O +
dependence O +
of O +
inactivation O +
as O +
well O +
as O +
significant O +
decreases O +
in O +
sodium O +
current O +
density O +
in O +
acutely O +
dissociated O +
hippocampal O +
neurons O -
. O +

The O +
integral O +
of O +
the O +
compound O +
action O +
potential O +
in O +
optic O +
nerve O +
was O +
significantly O +
reduced O -
, O +
and O +
the O +
threshold O +
for O +
action O +
potential O +
generation O +
was O +
increased O -
, O +
indicating O +
a O +
reduction O +
in O +
the O +
level O +
of O +
functional O +
plasma O +
membrane O +
sodium O +
channels O -
. O +

In O +
contrast O -
, O +
the O +
conduction O +
velocity O -
, O +
the O +
number O +
and O +
size O +
of O +
axons O +
in O +
the O +
optic O +
nerve O -
, O +
and O +
the O +
specific O +
localization O +
of O +
Na O -
( O -
v O -
) O -
1.6 O +
channels O +
in O +
the O +
nodes O +
of O +
Ranvier O +
were O +
unchanged O -
. O +

beta2 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
displayed O +
increased O +
susceptibility O +
to O +
seizures B-Disease -
, O +
as O +
indicated O +
by O +
reduced O +
latency O +
and O +
threshold O +
for O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
, O +
but O +
seemed O +
normal O +
in O +
other O +
neurological O +
tests O -
. O +

Our O +
observations O +
show O +
that O +
beta2-subunits O +
play O +
an O +
important O +
role O +
in O +
the O +
regulation O +
of O +
sodium O +
channel O +
density O +
and O +
function O +
in O +
neurons O +
in O +
vivo O +
and O +
are O +
required O +
for O +
normal O +
action O +
potential O +
generation O +
and O +
control O +
of O +
excitability O -
. O +

Severe O +
ocular B-Disease +
and I-Disease +
orbital I-Disease +
toxicity I-Disease +
after O +
intracarotid O +
injection O +
of O +
carboplatin O +
for O +
recurrent O +
glioblastomas B-Disease -
. O +

BACKGROUND O -
: O +
Glioblastoma B-Disease +
is O +
a O +
malignant B-Disease +
tumor I-Disease +
that O +
occurs O +
in O +
the O +
cerebrum O +
during O +
adulthood O -
. O +

With O +
current O +
treatment O +
regimens O +
including O +
combined O +
surgery O -
, O +
radiation O +
and O +
chemotherapy O -
, O +
the O +
average O +
life O +
expectancy O +
of O +
the O +
patients O +
is O +
limited O +
to O +
approximately O +
1 O +
year O -
. O +

Therefore O -
, O +
patients O +
with O +
glioblastoma B-Disease +
sometimes O +
have O +
intracarotid O +
injection O +
of O +
carcinostatics O +
added O +
to O +
the O +
treatment O +
regimen O -
. O +

Generally O -
, O +
carboplatin O +
is O +
said O +
to O +
have O +
milder O +
side O +
effects O +
than O +
cisplatin O -
, O +
whose O +
ocular B-Disease +
and I-Disease +
orbital I-Disease +
toxicity I-Disease +
are O +
well O +
known O -
. O +

However O -
, O +
we O +
experienced O +
a O +
case O +
of O +
severe O +
ocular B-Disease +
and I-Disease +
orbital I-Disease +
toxicity I-Disease +
after O +
intracarotid O +
injection O +
of O +
carboplatin O -
, O +
which O +
is O +
infrequently O +
reported O -
. O +

CASE O -
: O +
A O +
58-year O -
- O -
old O +
man O +
received O +
an O +
intracarotid O +
injection O +
of O +
carboplatin O +
for O +
recurrent O +
glioblastomas B-Disease +
in O +
his O +
left O +
temporal O +
lobe O -
. O +

He O +
complained O +
of O +
pain B-Disease +
and I-Disease +
visual I-Disease +
disturbance I-Disease +
in I-Disease +
the I-Disease +
ipsilateral I-Disease +
eye I-Disease +
30 O +
h O +
after O +
the O +
injection O -
. O +

Various O +
ocular O +
symptoms O +
and O +
findings O +
caused O +
by O +
carboplatin O +
toxicity B-Disease +
were O +
seen O -
. O +

RESULTS O -
: O +
He O +
was O +
treated O +
with O +
intravenous O +
administration O +
of O +
corticosteroids O +
and O +
glycerin O +
for O +
6 O +
days O +
after O +
the O +
injection O -
. O +

Although O +
the O +
intraocular O +
pressure O +
elevation O +
caused O +
by O +
secondary O +
acute O +
angle O -
- O -
closure O +
glaucoma B-Disease +
decreased O +
and O +
ocular B-Disease +
pain I-Disease +
diminished O -
, O +
inexorable O +
papilledema B-Disease +
and O +
exudative O +
retinal B-Disease +
detachment I-Disease +
continued O +
for O +
3 O +
weeks O -
. O +

Finally O -
, O +
6 O +
weeks O +
later O -
, O +
diffuse O +
chorioretinal B-Disease +
atrophy I-Disease +
with O +
optic B-Disease +
atrophy I-Disease +
occurred O +
and O +
the O +
vision O +
in O +
his O +
left O +
eye O +
was O +
lost O -
. O +

CONCLUSION O -
: O +
When O +
performing O +
intracarotid O +
injection O +
of O +
carboplatin O -
, O +
we O +
must O +
be O +
aware O +
of O +
its O +
potentially O +
blinding O +
ocular B-Disease +
toxicity I-Disease -
. O +

It O +
is O +
recommended O +
that O +
further O +
studies O +
and O +
investigations O +
are O +
undertaken O +
in O +
the O +
effort O +
to O +
minimize O +
such O +
severe O +
side O +
effects O -
. O +

Visual B-Disease +
hallucinations I-Disease +
associated O +
with O +
zonisamide O -
. O +

Zonisamide O +
is O +
a O +
broad O -
- O -
spectrum O +
antiepileptic O +
drug O +
used O +
to O +
treat O +
various O +
types O +
of O +
seizures B-Disease -
. O +

Although O +
visual B-Disease +
hallucinations I-Disease +
have O +
not O +
been O +
reported O +
as O +
an O +
adverse O +
effect O +
of O +
this O +
agent O -
, O +
we O +
describe O +
three O +
patients O +
who O +
experienced O +
complex O +
visual B-Disease +
hallucinations I-Disease +
and O +
altered O +
mental O +
status O +
after O +
zonisamide O +
treatment O +
was O +
begun O +
or O +
its O +
dosage O +
increased O -
. O +

All O +
three O +
had O +
been O +
diagnosed O +
earlier O +
with O +
epilepsy B-Disease -
, O +
and O +
their O +
electroencephalogram O +
( O -
EEG O -
) O +
findings O +
were O +
abnormal O -
. O +

During O +
monitoring O -
, O +
visual B-Disease +
hallucinations I-Disease +
did O +
not O +
correlate O +
with O +
EEG O +
readings O -
, O +
nor O +
did O +
video O +
recording O +
capture O +
any O +
of O +
the O +
described O +
events O -
. O +

None O +
of O +
the O +
patients O +
had O +
experienced O +
visual B-Disease +
hallucinations I-Disease +
before O +
this O +
event O -
. O +

The O +
only O +
recent O +
change O +
in O +
their O +
treatment O +
was O +
the O +
introduction O +
or O +
increased O +
dosage O +
of O +
zonisamide O -
. O +

With O +
either O +
discontinuation O +
or O +
decreased O +
dosage O +
of O +
the O +
drug O +
the O +
symptoms O +
disappeared O +
and O +
did O +
not O +
recur O -
. O +

Further O +
observations O +
and O +
reports O +
will O +
help O +
clarify O +
this O +
adverse O +
effect O -
. O +

Until O +
then O -
, O +
clinicians O +
need O +
to O +
be O +
aware O +
of O +
this O +
possible O +
complication O +
associated O +
with O +
zonisamide O -
. O +

Anti O -
- O -
epileptic B-Disease +
drugs O -
- O -
induced O +
de O +
novo O +
absence B-Disease +
seizures I-Disease -
. O +

The O +
authors O +
present O +
three O +
patients O +
with O +
de O +
novo O +
absence B-Disease +
epilepsy I-Disease +
after O +
administration O +
of O +
carbamazepine O +
and O +
vigabatrin O -
. O +

Despite O +
the O +
underlying O +
diseases O -
, O +
the O +
prognosis O +
for O +
drug O -
- O -
induced O +
de O +
novo O +
absence B-Disease +
seizure I-Disease +
is O +
good O +
because O +
it O +
subsides O +
rapidly O +
after O +
discontinuing O +
the O +
use O +
of O +
the O +
offending O +
drugs O -
. O +

The O +
gamma O -
- O -
aminobutyric O +
acid O -
- O -
transmitted O +
thalamocortical O +
circuitry O +
accounts O +
for O +
a O +
major O +
part O +
of O +
the O +
underlying O +
neurophysiology O +
of O +
the O +
absence B-Disease +
epilepsy I-Disease -
. O +

Because O +
drug O -
- O -
induced O +
de O +
novo O +
absence B-Disease +
seizure I-Disease +
is O +
rare O -
, O +
pro O -
- O -
absence O +
drugs O +
can O +
only O +
be O +
considered O +
a O +
promoting O +
factor O -
. O +

The O +
underlying O +
epileptogenecity O +
of O +
the O +
patients O +
or O +
the O +
synergistic O +
effects O +
of O +
the O +
accompanying O +
drugs O +
is O +
required O +
to O +
trigger O +
the O +
de O +
novo O +
absence B-Disease +
seizure I-Disease -
. O +

The O +
possibility O +
of O +
drug O -
- O -
induced O +
aggravation O +
should O +
be O +
considered O +
whenever O +
an O +
unexpected O +
increase O +
in O +
seizure B-Disease +
frequency O +
and/or O +
new O +
seizure B-Disease +
types O +
appear O +
following O +
a O +
change O +
in O +
drug O +
treatment O -
. O +

By O +
understanding O +
the O +
underlying O +
mechanism O +
of O +
absence B-Disease +
epilepsy I-Disease -
, O +
we O +
can O +
avoid O +
the O +
inappropriate O +
use O +
of O +
anticonvulsants O +
in O +
children O +
with O +
epilepsy B-Disease +
and O +
prevent O +
drug O -
- O -
induced O +
absence B-Disease +
seizures I-Disease -
. O +

Acute B-Disease +
liver I-Disease +
failure I-Disease +
with O +
concurrent O +
bupropion O +
and O +
carbimazole O +
therapy O -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
fatal O +
liver B-Disease +
failure I-Disease +
possibly O +
associated O +
with O +
concurrent O +
use O +
of O +
bupropion O +
and O +
carbimazole O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
41-year O -
- O -
old O +
Chinese O +
man O +
with O +
a O +
history O +
of O +
hyperthyroidism B-Disease +
had O +
been O +
treated O +
with O +
carbimazole O +
and O +
propranolol O +
for O +
the O +
past O +
5 O +
years O -
. O +

He O +
received O +
a O +
10-day O +
course O +
of O +
bupropion O +
as O +
an O +
aid O +
for O +
smoking O +
cessation O +
10 O +
weeks O +
prior O +
to O +
presentation O -
. O +

He O +
developed O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
with O +
rapid O +
deterioration O +
of O +
renal O +
function O -
. O +

Liver O +
biopsy O +
showed O +
evidence O +
of O +
nonspecific O +
drug B-Disease -
- I-Disease -
induced I-Disease +
acute I-Disease +
liver I-Disease +
injury I-Disease -
. O +

His O +
condition O +
was O +
further O +
complicated O +
by O +
sepsis B-Disease +
and O +
coagulopathy B-Disease -
. O +

Death O +
resulted O +
19 O +
days O +
after O +
the O +
onset O +
of O +
symptoms O -
. O +

The O +
likelihood O +
that O +
bupropion O +
induced O +
hepatotoxicity B-Disease +
in O +
our O +
patient O +
was O +
possible O -
, O +
based O +
on O +
the O +
Naranjo O +
probability O +
scale O -
. O +

DISCUSSION O -
: O +
Although O +
there O +
is O +
increasing O +
evidence O +
of O +
hepatotoxicity B-Disease +
induced O +
by O +
bupropion O -
, O +
this O +
is O +
the O +
first O +
case O +
of O +
fatality O +
that O +
could O +
have O +
resulted O +
from O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
in O +
a O +
patient O +
receiving O +
bupropion O +
while O +
on O +
concomitant O +
treatment O +
with O +
carbimazole O -
. O +

CONCLUSIONS O -
: O +
Clinicians O +
should O +
be O +
aware O +
of O +
the O +
possibility O +
of O +
acute B-Disease +
liver I-Disease +
insult I-Disease +
induced O +
by O +
bupropion O +
given O +
concurrently O +
with O +
other O +
hepatotoxic B-Disease +
drugs O -
. O +

Nephrotoxic B-Disease +
effects O +
in O +
high O -
- O -
risk O +
patients O +
undergoing O +
angiography O -
. O +

BACKGROUND O -
: O +
The O +
use O +
of O +
iodinated O +
contrast O +
medium O +
can O +
result O +
in O +
nephropathy B-Disease -
. O +

Whether O +
iso O -
- O -
osmolar O +
contrast O +
medium O +
is O +
less O +
nephrotoxic B-Disease +
than O +
low O -
- O -
osmolar O +
contrast O +
medium O +
in O +
high O -
- O -
risk O +
patients O +
is O +
uncertain O -
. O +

METHODS O -
: O +
We O +
conducted O +
a O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
prospective O -
, O +
multicenter O +
study O +
comparing O +
the O +
nephrotoxic B-Disease +
effects O +
of O +
an O +
iso O -
- O -
osmolar O -
, O +
dimeric O -
, O +
nonionic O +
contrast O +
medium O -
, O +
iodixanol O -
, O +
with O +
those O +
of O +
a O +
low O -
- O -
osmolar O -
, O +
nonionic O -
, O +
monomeric O +
contrast O +
medium O -
, O +
iohexol O -
. O +

The O +
study O +
involved O +
129 O +
patients O +
with O +
diabetes B-Disease +
with O +
serum O +
creatinine O +
concentrations O +
of O +
1.5 O +
to O +
3.5 O +
mg O +
per O +
deciliter O +
who O +
underwent O +
coronary O +
or O +
aortofemoral O +
angiography O -
. O +

The O +
primary O +
end O +
point O +
was O +
the O +
peak O +
increase O +
from O +
base O +
line O +
in O +
the O +
creatinine O +
concentration O +
during O +
the O +
three O +
days O +
after O +
angiography O -
. O +

Other O +
end O +
points O +
were O +
an O +
increase O +
in O +
the O +
creatinine O +
concentration O +
of O +
0.5 O +
mg O +
per O +
deciliter O +
or O +
more O -
, O +
an O +
increase O +
of O +
1.0 O +
mg O +
per O +
deciliter O +
or O +
more O -
, O +
and O +
a O +
change O +
in O +
the O +
creatinine O +
concentration O +
from O +
day O +
0 O +
to O +
day O +
7 O -
. O +

RESULTS O -
: O +
The O +
creatinine O +
concentration O +
increased O +
significantly O +
less O +
in O +
patients O +
who O +
received O +
iodixanol O -
. O +

From O +
day O +
0 O +
to O +
day O +
3 O -
, O +
the O +
mean O +
peak O +
increase O +
in O +
creatinine O +
was O +
0.13 O +
mg O +
per O +
deciliter O +
in O +
the O +
iodixanol O +
group O +
and O +
0.55 O +
mg O +
per O +
deciliter O +
in O +
the O +
iohexol O +
group O +
( O -
P=0.001 O -
; O +
the O +
increase O +
with O +
iodixanol O +
minus O +
the O +
increase O +
with O +
iohexol O -
, O +
-0.42 O +
mg O +
per O +
deciliter O +
[ O -
95 O +
percent O +
confidence O +
interval O -
, O +
-0.73 O +
to O +
-0.22 O -
] O -
) O -
. O +

Two O +
of O +
the O +
64 O +
patients O +
in O +
the O +
iodixanol O +
group O +
( O -
3 O +
percent O -
) O +
had O +
an O +
increase O +
in O +
the O +
creatinine O +
concentration O +
of O +
0.5 O +
mg O +
per O +
deciliter O +
or O +
more O -
, O +
as O +
compared O +
with O +
17 O +
of O +
the O +
65 O +
patients O +
in O +
the O +
iohexol O +
group O +
( O -
26 O +
percent O -
) O +
( O -
P=0.002 O -
; O +
odds O +
ratio O +
for O +
such O +
an O +
increase O +
in O +
the O +
iodixanol O +
group O -
, O +
0.09 O +
[ O -
95 O +
percent O +
confidence O +
interval O -
, O +
0.02 O +
to O +
0.41 O -
] O -
) O -
. O +

No O +
patient O +
receiving O +
iodixanol O +
had O +
an O +
increase O +
of O +
1.0 O +
mg O +
per O +
deciliter O +
or O +
more O -
, O +
but O +
10 O +
patients O +
in O +
the O +
iohexol O +
group O +
( O -
15 O +
percent O -
) O +
did O -
. O +

The O +
mean O +
change O +
in O +
the O +
creatinine O +
concentration O +
from O +
day O +
0 O +
to O +
day O +
7 O +
was O +
0.07 O +
mg O +
per O +
deciliter O +
in O +
the O +
iodixanol O +
group O +
and O +
0.24 O +
mg O +
per O +
deciliter O +
in O +
the O +
iohexol O +
group O +
( O -
P=0.003 O -
; O +
value O +
in O +
the O +
iodixanol O +
group O +
minus O +
the O +
value O +
in O +
the O +
iohexol O +
group O -
, O +
-0.17 O +
mg O +
per O +
deciliter O +
[ O -
95 O +
percent O +
confidence O +
interval O -
, O +
-0.34 O +
to O +
-0.07 O -
] O -
) O -
. O +

CONCLUSIONS O -
: O +
Nephropathy B-Disease +
induced O +
by O +
contrast O +
medium O +
may O +
be O +
less O +
likely O +
to O +
develop O +
in O +
high O -
- O -
risk O +
patients O +
when O +
iodixanol O +
is O +
used O +
rather O +
than O +
a O +
low O -
- O -
osmolar O -
, O +
nonionic O +
contrast O +
medium O -
. O +

Prenatal O +
dexamethasone O +
programs O +
hypertension B-Disease +
and O +
renal B-Disease +
injury I-Disease +
in O +
the O +
rat O -
. O +

Dexamethasone O +
is O +
frequently O +
administered O +
to O +
the O +
developing O +
fetus O +
to O +
accelerate O +
pulmonary O +
development O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
if O +
prenatal O +
dexamethasone O +
programmed O +
a O +
progressive O +
increase B-Disease +
in I-Disease +
blood I-Disease +
pressure I-Disease +
and O +
renal B-Disease +
injury I-Disease +
in O +
rats O -
. O +

Pregnant O +
rats O +
were O +
given O +
either O +
vehicle O +
or O +
2 O +
daily O +
intraperitoneal O +
injections O +
of O +
dexamethasone O +
( O -
0.2 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
on O +
gestational O +
days O +
11 O +
and O +
12 O -
, O +
13 O +
and O +
14 O -
, O +
15 O +
and O +
16 O -
, O +
17 O +
and O +
18 O -
, O +
or O +
19 O +
and O +
20 O -
. O +

Offspring O +
of O +
rats O +
administered O +
dexamethasone O +
on O +
days O +
15 O +
and O +
16 O +
gestation O +
had O +
a O +
20 O -
% O +
reduction B-Disease +
in I-Disease +
glomerular I-Disease +
number I-Disease +
compared O +
with O +
control O +
at O +
6 O +
to O +
9 O +
months O +
of O +
age O +
( O -
22 O +
527+ O -
/ O -
-509 O +
versus O +
28 O +
050+ O -
/ O -
-561 O -
, O +
P<0.05 O -
) O -
, O +
which O +
was O +
comparable O +
to O +
the O +
percent O +
reduction O +
in O +
glomeruli O +
measured O +
at O +
3 O +
weeks O +
of O +
age O -
. O +

Six- O +
to O +
9-month O +
old O +
rats O +
receiving O +
prenatal O +
dexamethasone O +
on O +
days O +
17 O +
and O +
18 O +
of O +
gestation O +
had O +
a O +
17 O -
% O +
reduction O +
in O +
glomeruli O +
( O -
23 O +
380+ O -
/ O -
-587 O -
) O +
compared O +
with O +
control O +
rats O +
( O -
P<0.05 O -
) O -
. O +

Male O +
rats O +
that O +
received O +
prenatal O +
dexamethasone O +
on O +
days O +
15 O +
and O +
16 O -
, O +
17 O +
and O +
18 O -
, O +
and O +
13 O +
and O +
14 O +
of O +
gestation O +
had O +
elevated B-Disease +
blood I-Disease +
pressures I-Disease +
at O +
6 O +
months O +
of O +
age O -
; O +
the O +
latter O +
group O +
did O +
not O +
have O +
a O +
reduction B-Disease +
in I-Disease +
glomerular I-Disease +
number I-Disease -
. O +

Adult O +
rats O +
given O +
dexamethasone O +
on O +
days O +
15 O +
and O +
16 O +
of O +
gestation O +
had O +
more O +
glomeruli O +
with O +
glomerulosclerosis B-Disease +
than O +
control O +
rats O -
. O +

This O +
study O +
shows O +
that O +
prenatal O +
dexamethasone O +
in O +
rats O +
results O +
in O +
a O +
reduction B-Disease +
in I-Disease +
glomerular I-Disease +
number I-Disease -
, O +
glomerulosclerosis B-Disease -
, O +
and O +
hypertension B-Disease +
when O +
administered O +
at O +
specific O +
points O +
during O +
gestation O -
. O +

Hypertension B-Disease +
was O +
observed O +
in O +
animals O +
that O +
had O +
a O +
reduction O +
in O +
glomeruli O +
as O +
well O +
as O +
in O +
a O +
group O +
that O +
did O +
not O +
have O +
a O +
reduction B-Disease +
in I-Disease +
glomerular I-Disease +
number I-Disease -
, O +
suggesting O +
that O +
a O +
reduction B-Disease +
in I-Disease +
glomerular I-Disease +
number I-Disease +
is O +
not O +
the O +
sole O +
cause O +
for O +
the O +
development O +
of O +
hypertension B-Disease -
. O +

Kidney O +
function O +
and O +
morphology O +
after O +
short O -
- O -
term O +
combination O +
therapy O +
with O +
cyclosporine O +
A O -
, O +
tacrolimus O +
and O +
sirolimus O +
in O +
the O +
rat O -
. O +

BACKGROUND O -
: O +
Sirolimus O +
( O -
SRL O -
) O +
may O +
supplement O +
calcineurin O +
inhibitors O +
in O +
clinical O +
organ O +
transplantation O -
. O +

These O +
are O +
nephrotoxic B-Disease -
, O +
but O +
SRL O +
seems O +
to O +
act O +
differently O +
displaying O +
only O +
minor O +
nephrotoxic B-Disease +
effects O -
, O +
although O +
this O +
question O +
is O +
still O +
open O -
. O +

In O +
a O +
number O +
of O +
treatment O +
protocols O +
where O +
SRL O +
was O +
combined O +
with O +
a O +
calcineurin O +
inhibitor O +
indications O +
of O +
a O +
synergistic O +
nephrotoxic B-Disease +
effect O +
were O +
described O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
further O +
the O +
renal O +
function O -
, O +
including O +
morphological O +
analysis O +
of O +
the O +
kidneys O +
of O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
treated O +
with O +
either O +
cyclosporine O +
A O +
( O -
CsA O -
) O -
, O +
tacrolimus O +
( O -
FK506 O -
) O +
or O +
SRL O +
as O +
monotherapies O +
or O +
in O +
different O +
combinations O -
. O +

METHODS O -
: O +
For O +
a O +
period O +
of O +
2 O +
weeks O -
, O +
CsA O +
15 O +
mg O -
/ O -
kg O -
/ O -
day O +
( O -
given O +
orally O -
) O -
, O +
FK506 O +
3.0 O +
mg O -
/ O -
kg O -
/ O -
day O +
( O -
given O +
orally O -
) O +
or O +
SRL O +
0.4 O +
mg O -
/ O -
kg O -
/ O -
day O +
( O -
given O +
intraperitoneally O -
) O +
was O +
administered O +
once O +
a O +
day O +
as O +
these O +
doses O +
have O +
earlier O +
been O +
found O +
to O +
achieve O +
a O +
significant O +
immunosuppressive O +
effect O +
in O +
Sprague O -
- O -
Dawley O +
rats O -
. O +

In O +
the O +
' O -
conscious O +
catheterized O +
rat O -
' O +
model O -
, O +
the O +
glomerular O +
filtration O +
rate O +
( O -
GFR O -
) O +
was O +
measured O +
as O +
the O +
clearance O +
of O +
Cr O -
( O -
EDTA O -
) O -
. O +

The O +
morphological O +
analysis O +
of O +
the O +
kidneys O +
included O +
a O +
semi O -
- O -
quantitative O +
scoring O +
system O +
analysing O +
the O +
degree O +
of O +
striped O +
fibrosis B-Disease -
, O +
subcapsular O +
fibrosis B-Disease +
and O +
the O +
number O +
of O +
basophilic O +
tubules O -
, O +
plus O +
an O +
additional O +
stereological O +
analysis O +
of O +
the O +
total O +
grade O +
of O +
fibrosis B-Disease +
in O +
the O +
cortex O +
stained O +
with O +
Sirius O +
Red O -
. O +

RESULTS O -
: O +
CsA O -
, O +
FK506 O +
and O +
SRL O +
all O +
significantly O +
decreased O +
the O +
GFR O -
. O +

A O +
further O +
deterioration O +
was O +
seen O +
when O +
CsA O +
was O +
combined O +
with O +
either O +
FK506 O +
or O +
SRL O -
, O +
whereas O +
the O +
GFR O +
remained O +
unchanged O +
in O +
the O +
group O +
treated O +
with O +
FK506 O +
plus O +
SRL O +
when O +
compared O +
with O +
treatment O +
with O +
any O +
of O +
the O +
single O +
substances O -
. O +

The O +
morphological O +
changes O +
presented O +
a O +
similar O +
pattern O -
. O +

The O +
semi O -
- O -
quantitative O +
scoring O +
was O +
significantly O +
worst O +
in O +
the O +
group O +
treated O +
with O +
CsA O +
plus O +
SRL O +
( O -
P<0.001 O +
compared O +
with O +
controls O -
) O +
and O +
the O +
analysis O +
of O +
the O +
total O +
grade O +
of O +
fibrosis B-Disease +
also O +
showed O +
the O +
highest O +
proportion O +
in O +
the O +
same O +
group O +
and O +
was O +
significantly O +
different O +
from O +
controls O +
( O -
P<0.02 O -
) O -
. O +

The O +
FK506 O +
plus O +
SRL O +
combination O +
showed O +
only O +
a O +
marginally O +
higher O +
degree O +
of O +
fibrosis B-Disease +
as O +
compared O +
with O +
controls O +
( O -
P=0.05 O -
) O -
. O +

CONCLUSION O -
: O +
This O +
rat O +
study O +
demonstrated O +
a O +
synergistic O +
nephrotoxic B-Disease +
effect O +
of O +
CsA O +
plus O +
SRL O -
, O +
whereas O +
FK506 O +
plus O +
SRL O +
was O +
better O +
tolerated O -
. O +

Evaluation O +
of O +
cardiac O +
troponin O +
I O +
and O +
T O +
levels O +
as O +
markers O +
of O +
myocardial B-Disease +
damage I-Disease +
in O +
doxorubicin O -
- O -
induced O +
cardiomyopathy B-Disease +
rats O -
, O +
and O +
their O +
relationship O +
with O +
echocardiographic O +
and O +
histological O +
findings O -
. O +

BACKGROUND O -
: O +
Cardiac O +
troponins O +
I O +
( O -
cTnI O -
) O +
and O +
T O +
( O -
cTnT O -
) O +
have O +
been O +
shown O +
to O +
be O +
highly O +
sensitive O +
and O +
specific O +
markers O +
of O +
myocardial B-Disease +
cell I-Disease +
injury I-Disease -
. O +

We O +
investigated O +
the O +
diagnostic O +
value O +
of O +
cTnI O +
and O +
cTnT O +
for O +
the O +
diagnosis O +
of O +
myocardial B-Disease +
damage I-Disease +
in O +
a O +
rat O +
model O +
of O +
doxorubicin O +
( O -
DOX O -
) O -
-induced O +
cardiomyopathy B-Disease -
, O +
and O +
we O +
examined O +
the O +
relationship O +
between O +
serial O +
cTnI O +
and O +
cTnT O +
with O +
the O +
development O +
of O +
cardiac B-Disease +
disorders I-Disease +
monitored O +
by O +
echocardiography O +
and O +
histological O +
examinations O +
in O +
this O +
model O -
. O +

METHODS O -
: O +
Thirty O -
- O -
five O +
Wistar O +
rats O +
were O +
given O +
1.5 O +
mg O -
/ O -
kg O +
DOX O -
, O +
i.v O -
. O -
, O +
weekly O +
for O +
up O +
to O +
8 O +
weeks O +
for O +
a O +
total O +
cumulative O +
dose O +
of O +
12 O +
mg O -
/ O -
kg O +
BW O -
. O +

Ten O +
rats O +
received O +
saline O +
as O +
a O +
control O +
group O -
. O +

cTnI O +
was O +
measured O +
with O +
Access O -
( O -
R O -
) O +
( O -
ng O -
/ O -
ml O -
) O +
and O +
a O +
research O +
immunoassay O +
( O -
pg O -
/ O -
ml O -
) O -
, O +
and O +
compared O +
with O +
cTnT O -
, O +
CK O -
- O -
MB O +
mass O +
and O +
CK O -
. O +

By O +
using O +
transthoracic O +
echocardiography O -
, O +
anterior O +
and O +
posterior O +
wall O +
thickness O -
, O +
LV O +
diameters O +
and O +
LV O +
fractional O +
shortening O +
( O -
FS O -
) O +
were O +
measured O +
in O +
all O +
rats O +
before O +
DOX O +
or O +
saline O -
, O +
and O +
at O +
weeks O +
6 O +
and O +
9 O +
after O +
treatment O +
in O +
all O +
surviving O +
rats O -
. O +

Histology O +
was O +
performed O +
in O +
DOX O -
- O -
rats O +
at O +
6 O +
and O +
9 O +
weeks O +
after O +
the O +
last O +
DOX O +
dose O +
and O +
in O +
all O +
controls O -
. O +

RESULTS O -
: O +
Eighteen O +
of O +
the O +
DOX O +
rats O +
died O +
prematurely O +
of O +
general O +
toxicity B-Disease +
during O +
the O +
9-week O +
period O -
. O +

End O -
- O -
diastolic O +
( O -
ED O -
) O +
and O +
end O -
- O -
systolic O +
( O -
ES O -
) O +
LV O +
diameters O -
/ O -
BW O +
significantly O +
increased O -
, O +
whereas O +
LV O +
FS O +
was O +
decreased O +
after O +
9 O +
weeks O +
in O +
the O +
DOX O +
group O +
( O -
p<0.001 O -
) O -
. O +

These O +
parameters O +
remained O +
unchanged O +
in O +
controls O -
. O +

Histological O +
evaluation O +
of O +
hearts O +
from O +
all O +
rats O +
given O +
DOX O +
revealed O +
significant O +
slight O +
degrees O +
of O +
perivascular O +
and O +
interstitial O +
fibrosis B-Disease -
. O +

In O +
7 O +
of O +
the O +
18 O +
rats O -
, O +
degeneration O +
and O +
myocyte O +
vacuolisation O +
were O +
found O -
. O +

Only O +
five O +
of O +
the O +
controls O +
exhibited O +
evidence O +
of O +
very O +
slight O +
perivascular O +
fibrosis B-Disease -
. O +

A O +
significant O +
rise O +
in O +
cTnT O +
was O +
found O +
in O +
DOX O +
rats O +
after O +
cumulative O +
doses O +
of O +
7.5 O +
and O +
12 O +
mg O -
/ O -
kg O +
in O +
comparison O +
with O +
baseline O +
( O -
p<0.05 O -
) O -
. O +

cTnT O +
found O +
in O +
rats O +
after O +
12 O +
mg O -
/ O -
kg O +
were O +
significantly O +
greater O +
than O +
that O +
found O +
after O +
7.5 O +
mg O -
/ O -
kg O +
DOX O -
. O +

Maximal O +
cTnI O +
( O -
pg O -
/ O -
ml O -
) O +
and O +
cTnT O +
levels O +
were O +
significantly O +
increased O +
in O +
DOX O +
rats O +
compared O +
with O +
controls O +
( O -
p=0.006 O -
, O +
0.007 O -
) O -
. O +

cTnI O +
( O -
ng O -
/ O -
ml O -
) O -
, O +
CK O -
- O -
MB O +
mass O +
and O +
CK O +
remained O +
unchanged O +
in O +
DOX O +
rats O +
compared O +
with O +
controls O -
. O +

All O +
markers O +
remained O +
stable O +
in O +
controls O -
. O +

Analysis O +
of O +
data O +
revealed O +
a O +
significant O +
correlation O +
between O +
maximal O +
cTnT O +
and O +
ED O +
and O +
ES O +
LV O +
diameters O -
/ O -
BW O +
( O -
r=0.81 O +
and O +
0.65 O -
; O +
p<0.0001 O -
) O -
. O +

A O +
significant O +
relationship O +
was O +
observed O +
between O +
maximal O +
cTnT O +
and O +
the O +
extent O +
of O +
myocardial O +
morphological O +
changes O -
, O +
and O +
between O +
LV O +
diameters O -
/ O -
BW O +
and O +
histological O +
findings O -
. O +

CONCLUSIONS O -
: O +
Among O +
markers O +
of O +
ischemic B-Disease +
injury I-Disease +
after O +
DOX O +
in O +
rats O -
, O +
cTnT O +
showed O +
the O +
greatest O +
ability O +
to O +
detect O +
myocardial B-Disease +
damage I-Disease +
assessed O +
by O +
echocardiographic O +
detection O +
and O +
histological O +
changes O -
. O +

Although O +
there O +
was O +
a O +
discrepancy O +
between O +
the O +
amount O +
of O +
cTnI O +
and O +
cTnT O +
after O +
DOX O -
, O +
probably O +
due O +
to O +
heterogeneity O +
in O +
cross O -
- O -
reactivities O +
of O +
mAbs O +
to O +
various O +
cTnI O +
and O +
cTnT O +
forms O -
, O +
it O +
is O +
likely O +
that O +
cTnT O +
in O +
rats O +
after O +
DOX O +
indicates O +
cell O +
damage O +
determined O +
by O +
the O +
magnitude O +
of O +
injury O +
induced O +
and O +
that O +
cTnT O +
should O +
be O +
a O +
useful O +
marker O +
for O +
the O +
prediction O +
of O +
experimentally O +
induced O +
cardiotoxicity B-Disease +
and O +
possibly O +
for O +
cardioprotective O +
experiments O -
. O +

Octreotide O -
- O -
induced O +
hypoxemia B-Disease +
and O +
pulmonary B-Disease +
hypertension I-Disease +
in O +
premature O +
neonates O -
. O +

The O +
authors O +
report O +
2 O +
cases O +
of O +
premature O +
neonates O +
who O +
had O +
enterocutaneous O +
fistula B-Disease +
complicating O +
necrotizing B-Disease +
enterocolitis I-Disease -
. O +

Pulmonary B-Disease +
hypertension I-Disease +
developed O +
after O +
administration O +
of O +
a O +
somatostatin O +
analogue O -
, O +
octreotide O -
, O +
to O +
enhance O +
resolution O +
of O +
the O +
fistula B-Disease -
. O +

The O +
authors O +
discuss O +
the O +
mechanism O +
of O +
the O +
occurrence O +
of O +
this O +
complication O +
and O +
recommend O +
caution O +
of O +
its O +
use O +
in O +
high O -
- O -
risk O +
premature O +
neonates O -
. O +

The O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease +
in O +
women O +
prescribed O +
cyproterone O +
acetate O +
in O +
combination O +
with O +
ethinyl O +
estradiol O -
: O +
a O +
nested O +
cohort O +
analysis O +
and O +
case O -
- O -
control O +
study O -
. O +

BACKGROUND O -
: O +
Cyproterone O +
acetate O +
combined O +
with O +
ethinyl O +
estradiol O +
( O -
CPA O -
/ O -
EE O -
) O +
is O +
licensed O +
in O +
the O +
UK O +
for O +
the O +
treatment O +
of O +
women O +
with O +
acne B-Disease +
and O +
hirsutism B-Disease +
and O +
is O +
also O +
a O +
treatment O +
option O +
for O +
polycystic B-Disease +
ovary I-Disease +
syndrome I-Disease +
( O -
PCOS B-Disease -
) O -
. O +

Previous O +
studies O +
have O +
demonstrated O +
an O +
increased O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease +
( O -
VTE B-Disease -
) O +
associated O +
with O +
CPA O -
/ O -
EE O +
compared O +
with O +
conventional O +
combined O +
oral O +
contraceptives O +
( O -
COCs O -
) O -
. O +

We O +
believe O +
the O +
results O +
of O +
those O +
studies O +
may O +
have O +
been O +
affected O +
by O +
residual O +
confounding O -
. O +

METHODS O -
: O +
Using O +
the O +
General O +
Practice O +
Research O +
Database O +
we O +
conducted O +
a O +
cohort O +
analysis O +
and O +
case O -
- O -
control O +
study O +
nested O +
within O +
a O +
population O +
of O +
women O +
aged O +
between O +
15 O +
and O +
39 O +
years O +
with O +
acne B-Disease -
, O +
hirsutism B-Disease +
or O +
PCOS B-Disease +
to O +
estimate O +
the O +
risk O +
of O +
VTE B-Disease +
associated O +
with O +
CPA O -
/ O -
EE O -
. O +

RESULTS O -
: O +
The O +
age O -
- O -
adjusted O +
incidence O +
rate O +
ratio O +
for O +
CPA O -
/ O -
EE O +
versus O +
conventional O +
COCs O +
was O +
2.20 O +
[ O -
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
1.35 O -
- O -
3.58 O -
] O -
. O +

Using O +
as O +
the O +
reference O +
group O +
women O +
who O +
were O +
not O +
using O +
oral O +
contraception O -
, O +
had O +
no O +
recent O +
pregnancy O +
or O +
menopausal O +
symptoms O -
, O +
the O +
case O -
- O -
control O +
analysis O +
gave O +
an O +
adjusted O +
odds O +
ratio O +
( O -
OR O -
( O -
adj O -
) O -
) O +
of O +
7.44 O +
( O -
95 O -
% O +
CI O +
3.67 O -
- O -
15.08 O -
) O +
for O +
CPA O -
/ O -
EE O +
use O +
compared O +
with O +
an O +
OR O -
( O -
adj O -
) O +
of O +
2.58 O +
( O -
95 O -
% O +
CI O +
1.60 O -
- O -
4.18 O -
) O +
for O +
use O +
of O +
conventional O +
COCs O -
. O +

CONCLUSIONS O -
: O +
We O +
have O +
demonstrated O +
an O +
increased O +
risk O +
of O +
VTE B-Disease +
associated O +
with O +
the O +
use O +
of O +
CPA O -
/ O -
EE O +
in O +
women O +
with O +
acne B-Disease -
, O +
hirsutism B-Disease +
or O +
PCOS B-Disease +
although O +
residual O +
confounding O +
by O +
indication O +
can O -
not O +
be O +
excluded O -
. O +

The O +
effect O +
of O +
treatment O +
with O +
gum O +
Arabic O +
on O +
gentamicin O +
nephrotoxicity B-Disease +
in O +
rats O -
: O +
a O +
preliminary O +
study O -
. O +

In O +
the O +
present O +
work O +
we O +
assessed O +
the O +
effect O +
of O +
treatment O +
of O +
rats O +
with O +
gum O +
Arabic O +
on O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
induced O +
by O +
gentamicin O +
( O -
GM O -
) O +
nephrotoxicity B-Disease -
. O +

Rats O +
were O +
treated O +
with O +
the O +
vehicle O +
( O -
2 O +
mL O -
/ O -
kg O +
of O +
distilled O +
water O +
and O +
5 O -
% O +
w O -
/ O -
v O +
cellulose O -
, O +
10 O +
days O -
) O -
, O +
gum O +
Arabic O +
( O -
2 O +
mL O -
/ O -
kg O +
of O +
a O +
10 O -
% O +
w O -
/ O -
v O +
aqueous O +
suspension O +
of O +
gum O +
Arabic O +
powder O -
, O +
orally O +
for O +
10 O +
days O -
) O -
, O +
or O +
gum O +
Arabic O +
concomitantly O +
with O +
GM O +
( O -
80mg O -
/ O -
kg O -
/ O -
day O +
intramuscularly O -
, O +
during O +
the O +
last O +
six O +
days O +
of O +
the O +
treatment O +
period O -
) O -
. O +

Nephrotoxicity B-Disease +
was O +
assessed O +
by O +
measuring O +
the O +
concentrations O +
of O +
creatinine O +
and O +
urea O +
in O +
the O +
plasma O +
and O +
reduced O +
glutathione O +
( O -
GSH O -
) O +
in O +
the O +
kidney O +
cortex O -
, O +
and O +
by O +
light O +
microscopic O +
examination O +
of O +
kidney O +
sections O -
. O +

The O +
results O +
indicated O +
that O +
concomitant O +
treatment O +
with O +
gum O +
Arabic O +
and O +
GM O +
significantly O +
increased O +
creatinine O +
and O +
urea O +
by O +
about O +
183 O +
and O +
239 O -
% O -
, O +
respectively O +
( O -
compared O +
to O +
432 O +
and O +
346 O -
% O -
, O +
respectively O -
, O +
in O +
rats O +
treated O +
with O +
cellulose O +
and O +
GM O -
) O -
, O +
and O +
decreased O +
that O +
of O +
cortical O +
GSH O +
by O +
21 O -
% O +
( O -
compared O +
to O +
27 O -
% O +
in O +
the O +
cellulose O +
plus O +
GM O +
group O -
) O +

The O +
GM O -
- O -
induced O +
proximal O +
tubular B-Disease +
necrosis I-Disease +
appeared O +
to O +
be O +
slightly O +
less O +
severe O +
in O +
rats O +
given O +
GM O +
together O +
with O +
gum O +
Arabic O +
than O +
in O +
those O +
given O +
GM O +
and O +
cellulose O -
. O +

It O +
could O +
be O +
inferred O +
that O +
gum O +
Arabic O +
treatment O +
has O +
induced O +
a O +
modest O +
amelioration O +
of O +
some O +
of O +
the O +
histological O +
and O +
biochemical O +
indices O +
of O +
GM O +
nephrotoxicity B-Disease -
. O +

Further O +
work O +
is O +
warranted O +
on O +
the O +
effect O +
of O +
the O +
treatments O +
on O +
renal O +
functional O +
aspects O +
in O +
models O +
of O +
chronic B-Disease +
renal I-Disease +
failure I-Disease -
, O +
and O +
on O +
the O +
mechanism O -
( O -
s O -
) O +
involved O -
. O +

Increased O +
frequency O +
of O +
venous B-Disease +
thromboembolism I-Disease +
with O +
the O +
combination O +
of O +
docetaxel O +
and O +
thalidomide O +
in O +
patients O +
with O +
metastatic O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer I-Disease -
. O +

STUDY O +
OBJECTIVE O -
: O +
To O +
evaluate O +
the O +
frequency O +
of O +
venous B-Disease +
thromboembolism I-Disease +
( O -
VTE B-Disease -
) O +
in O +
patients O +
with O +
advanced O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer I-Disease +
who O +
were O +
treated O +
with O +
docetaxel O +
alone O +
or O +
in O +
combination O +
with O +
thalidomide O -
. O +

DESIGN O -
: O +
Retrospective O +
analysis O +
of O +
a O +
randomized O +
phase O +
II O +
trial O -
. O +

SETTING O -
: O +
National O +
Institutes O +
of O +
Health O +
clinical O +
research O +
center O -
. O +

PATIENTS O -
: O +
Seventy O +
men O -
, O +
aged O +
50 O -
- O -
80 O +
years O -
, O +
with O +
advanced O +
androgen O -
- O -
independent O +
prostate B-Disease +
cancer I-Disease -
. O +

INTERVENTION O -
: O +
Each O +
patient O +
received O +
either O +
intravenous O +
docetaxel O +
30 O +
mg O -
/ O -
m2 O -
/ O -
week O +
for O +
3 O +
consecutive O +
weeks O -
, O +
followed O +
by O +
1 O +
week O +
off O -
, O +
or O +
the O +
combination O +
of O +
continuous O +
oral O +
thalidomide O +
200 O +
mg O +
every O +
evening O +
plus O +
the O +
same O +
docetaxel O +
regimen O -
. O +

This O +
4-week O +
cycle O +
was O +
repeated O +
until O +
there O +
was O +
evidence O +
of O +
excessive O +
toxicity B-Disease +
or O +
disease O +
progression O -
. O +

MEASUREMENTS O +
AND O +
MAIN O +
RESULTS O -
: O +
None O +
of O +
23 O +
patients O +
who O +
received O +
docetaxel O +
alone O +
developed O +
VTE B-Disease -
, O +
whereas O +
9 O +
of O +
47 O +
patients O +
( O -
19 O -
% O -
) O +
who O +
received O +
docetaxel O +
plus O +
thalidomide O +
developed O +
VTE B-Disease +
( O -
p=0.025 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
addition O +
of O +
thalidomide O +
to O +
docetaxel O +
in O +
the O +
treatment O +
of O +
prostate B-Disease +
cancer I-Disease +
significantly O +
increases O +
the O +
frequency O +
of O +
VTE B-Disease -
. O +

Clinicians O +
should O +
be O +
aware O +
of O +
this O +
potential O +
complication O +
when O +
adding O +
thalidomide O +
to O +
chemotherapeutic O +
regimens O -
. O +

Ticlopidine O -
- O -
induced O +
cholestatic B-Disease +
hepatitis B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
report O +
2 O +
cases O +
of O +
ticlopidine O -
- O -
induced O +
cholestatic B-Disease +
hepatitis B-Disease -
, O +
investigate O +
its O +
mechanism O -
, O +
and O +
compare O +
the O +
observed O +
main O +
characteristics O +
with O +
those O +
of O +
the O +
published O +
cases O -
. O +

CASE O +
SUMMARIES O -
: O +
Two O +
patients O +
developed O +
prolonged O +
cholestatic B-Disease +
hepatitis B-Disease +
after O +
receiving O +
ticlopidine O +
following O +
percutaneous O +
coronary O +
angioplasty O -
, O +
with O +
complete O +
remission O +
during O +
the O +
follow O -
- O -
up O +
period O -
. O +

T O -
- O -
cell O +
stimulation O +
by O +
therapeutic O +
concentration O +
of O +
ticlopidine O +
was O +
demonstrated O +
in O +
vitro O +
in O +
the O +
patients O -
, O +
but O +
not O +
in O +
healthy O +
controls O -
. O +

DISCUSSION O -
: O +
Cholestatic B-Disease +
hepatitis B-Disease +
is O +
a O +
rare O +
complication O +
of O +
the O +
antiplatelet O +
agent O +
ticlopidine O -
; O +
several O +
cases O +
have O +
been O +
reported O +
but O +
few O +
in O +
the O +
English O +
literature O -
. O +

Our O +
patients O +
developed O +
jaundice B-Disease +
following O +
treatment O +
with O +
ticlopidine O +
and O +
showed O +
the O +
clinical O +
and O +
laboratory O +
characteristics O +
of O +
cholestatic B-Disease +
hepatitis B-Disease -
, O +
which O +
resolved O +
after O +
discontinuation O +
of O +
the O +
drug O -
. O +

Hepatitis B-Disease +
may O +
develop O +
weeks O +
after O +
discontinuation O +
of O +
the O +
drug O +
and O +
may O +
run O +
a O +
prolonged O +
course O -
, O +
but O +
complete O +
remission O +
was O +
observed O +
in O +
all O +
reported O +
cases O -
. O +

An O +
objective O +
causality O +
assessment O +
revealed O +
that O +
the O +
adverse O +
drug O +
event O +
was O +
probably O +
related O +
to O +
the O +
use O +
of O +
ticlopidine O -
. O +

The O +
mechanisms O +
of O +
this O +
ticlopidine O -
- O -
induced O +
cholestasis B-Disease +
are O +
unclear O -
. O +

Immune O +
mechanisms O +
may O +
be O +
involved O +
in O +
the O +
drug O -
's O +
hepatotoxicity B-Disease -
, O +
as O +
suggested O +
by O +
the O +
T O -
- O -
cell O +
stimulation O +
study O +
reported O +
here O -
. O +

CONCLUSIONS O -
: O +
Cholestatic B-Disease +
hepatitis B-Disease +
is O +
a O +
rare O +
adverse O +
effect O +
of O +
ticlopidine O +
that O +
may O +
be O +
immune O +
mediated O -
. O +

Patients O +
receiving O +
the O +
drug O +
should O +
be O +
monitored O +
with O +
liver O +
function O +
tests O +
along O +
with O +
complete O +
blood O +
cell O +
counts O -
. O +

This O +
complication O +
will O +
be O +
observed O +
even O +
less O +
often O +
in O +
the O +
future O +
as O +
ticlopidine O +
is O +
being O +
replaced O +
by O +
the O +
newer O +
antiplatelet O +
agent O +
clopidogrel O -
. O +

Epithelial O +
sodium O +
channel O +
( O -
ENaC O -
) O +
subunit O +
mRNA O +
and O +
protein O +
expression O +
in O +
rats O +
with O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

In O +
experimental O +
nephrotic B-Disease +
syndrome I-Disease -
, O +
urinary O +
sodium O +
excretion O +
is O +
decreased O +
during O +
the O +
early O +
phase O +
of O +
the O +
disease O -
. O +

The O +
molecular O +
mechanism O -
( O -
s O -
) O +
leading O +
to O +
salt O +
retention O +
has O +
not O +
been O +
completely O +
elucidated O -
. O +

The O +
rate O -
- O -
limiting O +
constituent O +
of O +
collecting O +
duct O +
sodium O +
transport O +
is O +
the O +
epithelial O +
sodium O +
channel O +
( O -
ENaC O -
) O -
. O +

We O +
examined O +
the O +
abundance O +
of O +
ENaC O +
subunit O +
mRNAs O +
and O +
proteins O +
in O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O -
-induced O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

The O +
time O +
courses O +
of O +
urinary O +
sodium O +
excretion O -
, O +
plasma O +
aldosterone O +
concentration O +
and O +
proteinuria B-Disease +
were O +
studied O +
in O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
treated O +
with O +
a O +
single O +
dose O +
of O +
either O +
PAN O +
or O +
vehicle O -
. O +

The O +
relative O +
amounts O +
of O +
alphaENaC O -
, O +
betaENaC O +
and O +
gammaENaC O +
mRNAs O +
were O +
determined O +
in O +
kidneys O +
from O +
these O +
rats O +
by O +
real O -
- O -
time O +
quantitative O +
TaqMan O +
PCR O -
, O +
and O +
the O +
amounts O +
of O +
proteins O +
by O +
Western O +
blot O -
. O +

The O +
kinetics O +
of O +
urinary O +
sodium O +
excretion O +
and O +
the O +
appearance O +
of O +
proteinuria B-Disease +
were O +
comparable O +
with O +
those O +
reported O +
previously O -
. O +

Sodium O +
retention O +
occurred O +
on O +
days O +
2 O -
, O +
3 O +
and O +
6 O +
after O +
PAN O +
injection O -
. O +

A O +
significant O +
up O -
- O -
regulation O +
of O +
alphaENaC O +
and O +
betaENaC O +
mRNA O +
abundance O +
on O +
days O +
1 O +
and O +
2 O +
preceded O +
sodium O +
retention O +
on O +
days O +
2 O +
and O +
3 O -
. O +

Conversely O -
, O +
down O -
- O -
regulation O +
of O +
alphaENaC O -
, O +
betaENaC O +
and O +
gammaENaC O +
mRNA O +
expression O +
on O +
day O +
3 O +
occurred O +
in O +
the O +
presence O +
of O +
high O +
aldosterone O +
concentrations O -
, O +
and O +
was O +
followed O +
by O +
a O +
return O +
of O +
sodium O +
excretion O +
to O +
control O +
values O -
. O +

The O +
amounts O +
of O +
alphaENaC O -
, O +
betaENaC O +
and O +
gammaENaC O +
proteins O +
were O +
not O +
increased O +
during O +
PAN O -
- O -
induced O +
sodium O +
retention O -
. O +

In O +
conclusion O -
, O +
ENaC O +
mRNA O +
expression O -
, O +
especially O +
alphaENaC O -
, O +
is O +
increased O +
in O +
the O +
very O +
early O +
phase O +
of O +
the O +
experimental O +
model O +
of O +
PAN O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease +
in O +
rats O -
, O +
but O +
appears O +
to O +
escape O +
from O +
the O +
regulation O +
by O +
aldosterone O +
after O +
day O +
3 O -
. O +

Sub O -
- O -
chronic O +
low O +
dose O +
gamma O -
- O -
vinyl O +
GABA O +
( O -
vigabatrin O -
) O +
inhibits O +
cocaine O -
- O -
induced O +
increases O +
in O +
nucleus O +
accumbens O +
dopamine O -
. O +

RATIONALE O -
: O +
gamma O -
- O -
Vinyl O +
GABA O +
( O -
GVG O -
) O +
irreversibly O +
inhibits O +
GABA O -
- O -
transaminase O -
. O +

This O +
non O -
- O -
receptor O +
mediated O +
inhibition O +
requires O +
de O +
novo O +
synthesis O +
for O +
restoration O +
of O +
functional O +
GABA O +
catabolism O -
. O +

OBJECTIVES O -
: O +
Given O +
its O +
preclinical O +
success O +
for O +
treating O +
substance B-Disease +
abuse I-Disease +
and O +
the O +
increased O +
risk O +
of O +
visual B-Disease +
field I-Disease +
defects I-Disease +
( O -
VFD B-Disease -
) O +
associated O +
with O +
cumulative O +
lifetime O +
exposure O -
, O +
we O +
explored O +
the O +
effects O +
of O +
sub O -
- O -
chronic O +
low O +
dose O +
GVG O +
on O +
cocaine O -
- O -
induced O +
increases O +
in O +
nucleus O +
accumbens O +
( O -
NAcc O -
) O +
dopamine O +
( O -
DA O -
) O -
. O +

METHODS O -
: O +
Using O +
in O +
vivo O +
microdialysis O -
, O +
we O +
compared O +
acute O +
exposure O +
( O -
450 O +
mg O -
/ O -
kg O -
) O +
to O +
an O +
identical O +
sub O -
- O -
chronic O +
exposure O +
( O -
150 O +
mg O -
/ O -
kg O +
per O +
day O +
for O +
3 O +
days O -
) O -
, O +
followed O +
by O +
1- O +
or O +
3-day O +
washout O -
. O +

Finally O -
, O +
we O +
examined O +
the O +
low O +
dose O +
of O +
150 O +
mg O -
/ O -
kg O +
( O -
50 O +
mg O -
/ O -
kg O +
per O +
day O -
) O +
using O +
a O +
similar O +
washout O +
period O -
. O +

RESULTS O -
: O +
Sub O -
- O -
chronic O +
GVG O +
exposure O +
inhibited O +
the O +
effect O +
of O +
cocaine O +
for O +
3 O +
days O -
, O +
which O +
exceeded O +
in O +
magnitude O +
and O +
duration O +
the O +
identical O +
acute O +
dose O -
. O +

CONCLUSIONS O -
: O +
Sub O -
- O -
chronic O +
low O +
dose O +
GVG O +
potentiates O +
and O +
extends O +
the O +
inhibition O +
of O +
cocaine O -
- O -
induced O +
increases O +
in O +
dopamine O -
, O +
effectively O +
reducing O +
cumulative O +
exposures O +
and O +
the O +
risk O +
for O +
VFDS O -
. O +

MR O +
imaging O +
with O +
quantitative O +
diffusion O +
mapping O +
of O +
tacrolimus O -
- O -
induced O +
neurotoxicity B-Disease +
in O +
organ O +
transplant O +
patients O -
. O +

Our O +
objective O +
was O +
to O +
investigate O +
brain O +
MR O +
imaging O +
findings O +
and O +
the O +
utility O +
of O +
diffusion O -
- O -
weighted O +
( O -
DW O -
) O +
imaging O +
in O +
organ O +
transplant O +
patients O +
who O +
developed O +
neurologic O +
symptoms O +
during O +
tacrolimus O +
therapy O -
. O +

Brain O +
MR O +
studies O -
, O +
including O +
DW O +
imaging O -
, O +
were O +
prospectively O +
performed O +
in O +
14 O +
organ O +
transplant O +
patients O +
receiving O +
tacrolimus O +
who O +
developed O +
neurologic B-Disease +
complications I-Disease -
. O +

In O +
each O +
patient O +
who O +
had O +
abnormalities O +
on O +
the O +
initial O +
MR O +
study O -
, O +
a O +
follow O -
- O -
up O +
MR O +
study O +
was O +
performed O +
1 O +
month O +
later O -
. O +

Apparent O +
diffusion O +
coefficient O +
( O -
ADC O -
) O +
values O +
on O +
the O +
initial O +
MR O +
study O +
were O +
correlated O +
with O +
reversibility O +
of O +
the O +
lesions O -
. O +

Of O +
the O +
14 O +
patients O -
, O +
5 O +
( O -
35.7 O -
% O -
) O +
had O +
white B-Disease +
matter I-Disease +
abnormalities I-Disease -
, O +
1 O +
( O -
7.1 O -
% O -
) O +
had O +
putaminal B-Disease +
hemorrhage I-Disease -
, O +
and O +
8 O +
( O -
57.1 O -
% O -
) O +
had O +
normal O +
findings O +
on O +
initial O +
MR O +
images O -
. O +

Among O +
the O +
5 O +
patients O +
with O +
white B-Disease +
matter I-Disease +
abnormalities I-Disease -
, O +
4 O +
patients O +
( O -
80.0 O -
% O -
) O +
showed O +
higher O +
than O +
normal O +
ADC O +
values O +
on O +
initial O +
MR O +
images O -
, O +
and O +
all O +
showed O +
complete O +
resolution O +
on O +
follow O -
- O -
up O +
images O -
. O +

The O +
remaining O +
1 O +
patient O +
( O -
20.0 O -
% O -
) O +
showed O +
lower O +
than O +
normal O +
ADC O +
value O +
and O +
showed O +
incomplete O +
resolution O +
with O +
cortical B-Disease +
laminar I-Disease +
necrosis I-Disease -
. O +

Diffusion O -
- O -
weighted O +
imaging O +
may O +
be O +
useful O +
in O +
predicting O +
the O +
outcomes O +
of O +
the O +
lesions O +
of O +
tacrolimus O -
- O -
induced O +
neurotoxicity B-Disease -
. O +

L O -
- O -
arginine O +
transport O +
in O +
humans O +
with O +
cortisol O -
- O -
induced O +
hypertension B-Disease -
. O +

A O +
deficient O +
L O -
- O -
arginine O -
- O -
nitric O +
oxide O +
system O +
is O +
implicated O +
in O +
cortisol O -
- O -
induced O +
hypertension B-Disease -
. O +

We O +
investigate O +
whether O +
abnormalities O +
in O +
L O -
- O -
arginine O +
uptake O +
contribute O +
to O +
this O +
deficiency O -
. O +

Eight O +
healthy O +
men O +
were O +
recruited O -
. O +

Hydrocortisone O +
acetate O +
( O -
50 O +
mg O -
) O +
was O +
given O +
orally O +
every O +
6 O +
hours O +
for O +
24 O +
hours O +
after O +
a O +
5-day O +
fixed O -
- O -
salt O +
diet O +
( O -
150 O +
mmol O -
/ O -
d O -
) O -
. O +

Crossover O +
studies O +
were O +
performed O +
2 O +
weeks O +
apart O -
. O +

Thirty O +
milliliters O +
of O +
blood O +
was O +
obtained O +
for O +
isolation O +
of O +
peripheral O +
blood O +
mononuclear O +
cells O +
after O +
each O +
treatment O +
period O -
. O +

L O -
- O -
arginine O +
uptake O +
was O +
assessed O +
in O +
mononuclear O +
cells O +
incubated O +
with O +
L O -
- O -
arginine O +
( O -
1 O +
to O +
300 O +
micromol O -
/ O -
L O -
) O -
, O +
incorporating O +
100 O +
nmol O -
/ O -
L O +
[ O -
3H O -
] O -
-l O -
- O -
arginine O +
for O +
a O +
period O +
of O +
5 O +
minutes O +
at O +
37 O +
degrees O +
C. O +
Forearm O +
[ O -
3H O -
] O -
-L O -
- O -
arginine O +
extraction O +
was O +
calculated O +
after O +
infusion O +
of O +
[ O -
3H O -
] O -
-L O -
- O -
arginine O +
into O +
the O +
brachial O +
artery O +
at O +
a O +
rate O +
of O +
100 O +
nCi O -
/ O -
min O +
for O +
80 O +
minutes O -
. O +

Deep O +
forearm O +
venous O +
samples O +
were O +
collected O +
for O +
determination O +
of O +
L O -
- O -
arginine O +
extraction O -
. O +

Plasma O +
cortisol O +
concentrations O +
were O +
significantly O +
raised O +
during O +
the O +
active O +
phase O +
( O -
323+ O -
/ O -
-43 O +
to O +
1082+ O -
/ O -
-245 O +
mmol O -
/ O -
L O -
, O +
P<0.05 O -
) O -
. O +

Systolic O +
blood O +
pressure O +
was O +
elevated O +
by O +
an O +
average O +
of O +
7 O +
mm O +
Hg O -
. O +

Neither O +
L O -
- O -
arginine O +
transport O +
into O +
mononuclear O +
cells O +
( O -
placebo O +
vs O +
active O -
, O +
26.3+ O -
/ O -
-3.6 O +
vs O +
29.0+ O -
/ O -
-2.1 O +
pmol O -
/ O -
10 O +
000 O +
cells O +
per O +
5 O +
minutes O -
, O +
respectively O -
, O +
at O +
an O +
l O -
- O -
arginine O +
concentration O +
of O +
300 O +
micromol O -
/ O -
L O -
) O +
nor O +
L O -
- O -
arginine O +
extraction O +
in O +
the O +
forearm O +
( O -
at O +
80 O +
minutes O -
, O +
placebo O +
vs O +
active O -
, O +
1 O +
868 O +
904+ O -
/ O -
-434 O +
962 O +
vs O +
2 O +
013 O +
910+ O -
/ O -
-770 O +
619 O +
disintegrations O +
per O +
minute O -
) O +
was O +
affected O +
by O +
cortisol O +
treatment O -
; O +
ie O -
, O +
that O +
L O -
- O -
arginine O +
uptake O +
is O +
not O +
affected O +
by O +
short O -
- O -
term O +
cortisol O +
treatment O -
. O +

We O +
conclude O +
that O +
cortisol O -
- O -
induced O +
increases B-Disease +
in I-Disease +
blood I-Disease +
pressure I-Disease +
are O +
not O +
associated O +
with O +
abnormalities O +
in O +
the O +
l O -
- O -
arginine O +
transport O +
system O -
. O +

Amount O +
of O +
bleeding B-Disease +
and O +
hematoma B-Disease +
size O +
in O +
the O +
collagenase O -
- O -
induced O +
intracerebral B-Disease +
hemorrhage I-Disease +
rat O +
model O -
. O +

The O +
aggravated O +
risk O +
on O +
intracerebral B-Disease +
hemorrhage I-Disease +
( O -
ICH B-Disease -
) O +
with O +
drugs O +
used O +
for O +
stroke B-Disease +
patients O +
should O +
be O +
estimated O +
carefully O -
. O +

We O +
therefore O +
established O +
sensitive O +
quantification O +
methods O +
and O +
provided O +
a O +
rat O +
ICH B-Disease +
model O +
for O +
detection O +
of O +
ICH B-Disease +
deterioration O -
. O +

In O +
ICH B-Disease +
intrastriatally O +
induced O +
by O +
0.014-unit O -
, O +
0.070-unit O -
, O +
and O +
0.350-unit O +
collagenase O -
, O +
the O +
amount O +
of O +
bleeding B-Disease +
was O +
measured O +
using O +
a O +
hemoglobin O +
assay O +
developed O +
in O +
the O +
present O +
study O +
and O +
was O +
compared O +
with O +
the O +
morphologically O +
determined O +
hematoma B-Disease +
volume O -
. O +

The O +
blood O +
amounts O +
and O +
hematoma B-Disease +
volumes O +
were O +
significantly O +
correlated O -
, O +
and O +
the O +
hematoma B-Disease +
induced O +
by O +
0.014-unit O +
collagenase O +
was O +
adequate O +
to O +
detect O +
ICH B-Disease +
deterioration O -
. O +

In O +
ICH B-Disease +
induction O +
using O +
0.014-unit O +
collagenase O -
, O +
heparin O +
enhanced O +
the O +
hematoma B-Disease +
volume O +
3.4-fold O +
over O +
that O +
seen O +
in O +
control O +
ICH B-Disease +
animals O +
and O +
the O +
bleeding B-Disease +
7.6-fold O -
. O +

Data O +
suggest O +
that O +
this O +
sensitive O +
hemoglobin O +
assay O +
is O +
useful O +
for O +
ICH B-Disease +
detection O -
, O +
and O +
that O +
a O +
model O +
with O +
a O +
small O +
ICH B-Disease +
induced O +
with O +
a O +
low O -
- O -
dose O +
collagenase O +
should O +
be O +
used O +
for O +
evaluation O +
of O +
drugs O +
that O +
may O +
affect O +
ICH B-Disease -
. O +

Differential O +
diagnosis O +
of O +
high O +
serum O +
creatine O +
kinase O +
levels O +
in O +
systemic B-Disease +
lupus I-Disease +
erythematosus I-Disease -
. O +

We O +
report O +
the O +
clinical O +
and O +
bioptic O +
findings O +
for O +
a O +
57-year O -
- O -
old O +
woman O +
with O +
severe O +
chloroquine O -
- O -
induced O +
myopathy B-Disease -
. O +

Since O +
1989 O -
, O +
she O +
had O +
been O +
suffering O +
from O +
systemic B-Disease +
lupus I-Disease +
erythematosus I-Disease +
( O -
SLE B-Disease -
) O +
with O +
renal B-Disease +
involvement I-Disease +
and O +
undergone O +
periods O +
of O +
treatment O +
with O +
azathioprine O +
and O +
cyclophosphamide O -
. O +

Additional O +
therapy O +
with O +
chloroquine O +
( O -
CQ O -
) O +
was O +
started O +
because O +
of O +
arthralgia B-Disease -
. O +

At O +
the O +
same O +
time O -
, O +
slightly O +
increased O +
creatine O +
kinase O +
( O -
CK O -
) O +
levels O +
were O +
noted O -
. O +

Myositis B-Disease +
was O +
suspected O -
, O +
and O +
the O +
patient O +
was O +
treated O +
with O +
steroids O -
. O +

The O +
CK O +
increase O +
persisted O -
, O +
however O -
, O +
and O +
she O +
developed O +
progressive O +
muscular B-Disease +
weakness I-Disease +
and O +
muscular B-Disease +
atrophy I-Disease -
. O +

Routine O +
controls O +
revealed O +
markedly O +
elevated O +
CK O +
levels O +
of O +
1,700 O +
U O -
/ O -
l O -
. O +

The O +
neurological O +
and O +
electrophysiological O +
findings O +
were O +
not O +
typical O +
of O +
myositis B-Disease -
. O +

Thus O -
, O +
muscle O +
biopsy O +
of O +
the O +
deltoid O +
muscle O +
was O +
performed O +
in O +
order O +
to O +
exclude O +
polymyositis B-Disease +
or O +
toxic O +
myopathy B-Disease -
. O +

As O +
it O +
revealed O +
chloroquine O -
- O -
induced O +
myopathy B-Disease -
, O +
medication O +
was O +
stopped O -
. O +

Discriminating O +
between O +
primary O +
SLE B-Disease -
- O -
induced O +
affection B-Disease +
of I-Disease +
the I-Disease +
musculoskeletal I-Disease +
system I-Disease +
and O +
drug O -
- O -
induced O +
side O +
effects O +
is O +
important O +
for O +
appropriate O +
treatment O +
of O +
SLE B-Disease +
patients O -
. O +

Seizure B-Disease +
associated O +
with O +
sleep B-Disease +
deprivation I-Disease +
and O +
sustained O -
- O -
release O +
bupropion O -
. O +

This O +
case O +
report O +
describes O +
a O +
generalized O +
seizure B-Disease +
associated O +
with O +
sustained O -
- O -
release O +
bupropion O +
use O +
and O +
sleep B-Disease +
deprivation I-Disease -
. O +

The O +
subject O -
, O +
a O +
31-year O -
- O -
old O +
female O +
smoker O -
, O +
was O +
participating O +
in O +
a O +
clinical O +
trial O +
evaluating O +
an O +
investigational O +
medication O +
for O +
smoking O +
cessation O +
that O +
used O +
sustained O -
- O -
release O +
bupropion O +
as O +
an O +
active O +
control O -
. O +

After O +
5 O +
weeks O +
of O +
bupropion O +
use O -
, O +
the O +
subject O +
experienced O +
a O +
generalized O +
tonic O +
clonic O +
seizure B-Disease +
after O +
staying O +
up O +
nearly O +
all O +
night O +
packing O +
and O +
moving O +
to O +
a O +
new O +
residence O -
. O +

The O +
patient O +
had O +
no O +
other O +
risk O +
factors O +
for O +
seizures B-Disease -
. O +

We O +
suggest O +
that O +
sleep B-Disease +
deprivation I-Disease +
may O +
add O +
to O +
the O +
risk O +
of O +
bupropion O -
- O -
associated O +
seizures B-Disease -
. O +

Estradiol O +
reduces O +
seizure B-Disease -
- O -
induced O +
hippocampal B-Disease +
injury I-Disease +
in O +
ovariectomized O +
female O +
but O +
not O +
in O +
male O +
rats O -
. O +

Estrogens O +
protect O +
ovariectomized O +
rats O +
from O +
hippocampal B-Disease +
injury I-Disease +
induced O +
by O +
kainic O +
acid O -
- O -
induced O +
status B-Disease +
epilepticus I-Disease +
( O -
SE B-Disease -
) O -
. O +

We O +
compared O +
the O +
effects O +
of O +
17beta O -
- O -
estradiol O +
in O +
adult O +
male O +
and O +
ovariectomized O +
female O +
rats O +
subjected O +
to O +
lithium O -
- O -
pilocarpine O -
- O -
induced O +
SE B-Disease -
. O +

Rats O +
received O +
subcutaneous O +
injections O +
of O +
17beta O -
- O -
estradiol O +
( O -
2 O +
microg O -
/ O -
rat O -
) O +
or O +
oil O +
once O +
daily O +
for O +
four O +
consecutive O +
days O -
. O +

SE B-Disease +
was O +
induced O +
20 O +
h O +
following O +
the O +
second O +
injection O +
and O +
terminated O +
3 O +
h O +
later O -
. O +

The O +
extent O +
of O +
silver O -
- O -
stained O +
CA3 O +
and O +
CA1 O +
hippocampal O +
neurons O +
was O +
evaluated O +
2 O +
days O +
after O +
SE B-Disease -
. O +

17beta O -
- O -
Estradiol O +
did O +
not O +
alter O +
the O +
onset O +
of O +
first O +
clonus O +
in O +
ovariectomized O +
rats O +
but O +
accelerated O +
it O +
in O +
males O -
. O +

17beta O -
- O -
Estradiol O +
reduced O +
the O +
argyrophilic O +
neurons O +
in O +
the O +
CA1 O +
and O +
CA3-C O +
sectors O +
of O +
ovariectomized O +
rats O -
. O +

In O +
males O -
, O +
estradiol O +
increased O +
the O +
total O +
damage O +
score O -
. O +

These O +
findings O +
suggest O +
that O +
the O +
effects O +
of O +
estradiol O +
on O +
seizure B-Disease +
threshold O +
and O +
damage O +
may O +
be O +
altered O +
by O +
sex O -
- O -
related O +
differences O +
in O +
the O +
hormonal O +
environment O -
. O +

Pseudoacromegaly B-Disease +
induced O +
by O +
the O +
long O -
- O -
term O +
use O +
of O +
minoxidil O -
. O +

Acromegaly B-Disease +
is O +
an O +
endocrine B-Disease +
disorder I-Disease +
caused O +
by O +
chronic O +
excessive O +
growth O +
hormone O +
secretion O +
from O +
the O +
anterior O +
pituitary O +
gland O -
. O +

Significant O +
disfiguring O +
changes O +
occur O +
as O +
a O +
result O +
of O +
bone O -
, O +
cartilage O -
, O +
and O +
soft O +
tissue O +
hypertrophy B-Disease -
, O +
including O +
the O +
thickening O +
of O +
the O +
skin O -
, O +
coarsening O +
of O +
facial O +
features O -
, O +
and O +
cutis B-Disease +
verticis I-Disease +
gyrata I-Disease -
. O +

Pseudoacromegaly B-Disease -
, O +
on O +
the O +
other O +
hand O -
, O +
is O +
the O +
presence O +
of O +
similar O +
acromegaloid O +
features O +
in O +
the O +
absence O +
of O +
elevated O +
growth O +
hormone O +
or O +
insulin O -
- O -
like O +
growth O +
factor O +
levels O -
. O +

We O +
present O +
a O +
patient O +
with O +
pseudoacromegaly B-Disease +
that O +
resulted O +
from O +
the O +
long O -
- O -
term O +
use O +
of O +
minoxidil O +
at O +
an O +
unusually O +
high O +
dose O -
. O +

This O +
is O +
the O +
first O +
case O +
report O +
of O +
pseudoacromegaly B-Disease +
as O +
a O +
side O +
effect O +
of O +
minoxidil O +
use O -
. O +

Combined O +
androgen O +
blockade O -
- O -
induced O +
anemia B-Disease +
in O +
prostate B-Disease +
cancer I-Disease +
patients O +
without O +
bone O +
involvement O -
. O +

BACKGROUND O -
: O +
To O +
determine O +
the O +
onset O +
and O +
extent O +
of O +
combined O +
androgen O +
blockade O +
( O -
CAB O -
) O -
-induced O +
anemia B-Disease +
in O +
prostate B-Disease +
cancer I-Disease +
patients O +
without O +
bone O +
involvement O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Forty O -
- O -
two O +
patients O +
with O +
biopsy O -
- O -
proven O +
prostatic B-Disease +
adenocarcinoma I-Disease +
[ O -
26 O +
with O +
stage O +
C O +
( O -
T3N0M0 O -
) O +
and O +
16 O +
with O +
stage O +
D1 O +
( O -
T3N1M0 O -
) O -
] O +
were O +
included O +
in O +
this O +
study O -
. O +

All O +
patients O +
received O +
CAB O +
[ O -
leuprolide O +
acetate O +
( O -
LHRH O -
- O -
A O -
) O +
3.75 O +
mg O -
, O +
intramuscularly O -
, O +
every O +
28 O +
days O +
plus O +
250 O +
mg O +
flutamide O -
, O +
tid O -
, O +
per O +
Os O -
] O +
and O +
were O +
evaluated O +
for O +
anemia B-Disease +
by O +
physical O +
examination O +
and O +
laboratory O +
tests O +
at O +
baseline O +
and O +
4 O +
subsequent O +
intervals O +
( O -
1 O -
, O +
2 O -
, O +
3 O +
and O +
6 O +
months O +
post O -
- O -
CAB O -
) O -
. O +

Hb O -
, O +
PSA O +
and O +
Testosterone O +
measurements O +
were O +
recorded O -
. O +

Patients O +
with O +
stage O +
D2 O -
- O -
3 O +
disease O -
, O +
abnormal O +
hemoglobin O +
level O +
or O +
renal O +
and O +
liver O +
function O +
tests O +
that O +
were O +
higher O +
than O +
the O +
upper O +
limits O +
were O +
excluded O +
from O +
the O +
study O -
. O +

The O +
duration O +
of O +
the O +
study O +
was O +
six O +
months O -
. O +

RESULTS O -
: O +
The O +
mean O +
hemoglobin O +
( O -
Hb O -
) O +
levels O +
were O +
significantly O +
declined O +
in O +
all O +
patients O +
from O +
baseline O +
of O +
14.2 O +
g O -
/ O -
dl O +
to O +
14.0 O +
g O -
/ O -
dl O -
, O +
13.5 O +
g O -
/ O -
dl O -
, O +
13.2 O +
g O -
/ O -
dl O +
and O +
12.7 O +
g O -
/ O -
dl O +
at O +
1 O -
, O +
2 O -
, O +
3 O +
and O +
6 O +
months O +
post O -
- O -
CAB O -
, O +
respectively O -
. O +

Severe O +
and O +
clinically O +
evident O +
anemia B-Disease +
of O +
Hb O +
< O +
11 O +
g O -
/ O -
dl O +
with O +
clinical O +
symptoms O +
was O +
detected O +
in O +
6 O +
patients O +
( O -
14.3 O -
% O -
) O -
. O +

This O +
CAB O -
- O -
induced O +
anemia B-Disease +
was O +
normochromic O +
and O +
normocytic O -
. O +

At O +
six O +
months O +
post O -
- O -
CAB O -
, O +
patients O +
with O +
severe O +
anemia B-Disease +
had O +
a O +
Hb O +
mean O +
value O +
of O +
10.2 O +
+ O -
/- O +

0.1 O +
g O -
/ O -
dl O +
( O -
X O +
+ O -
/- O +

SE O -
) O -
, O +
whereas O +
the O +
other O +
patients O +
had O +
mild O +
anemia B-Disease +
with O +
Hb O +
mean O +
value O +
of O +
13.2 O +
+ O -
/- O +

0.17 O +
( O -
X O +
+ O -
/- O +

SE O -
) O -
. O +

The O +
development O +
of O +
severe O +
anemia B-Disease +
at O +
6 O +
months O +
post O -
- O -
CAB O +
was O +
predictable O +
by O +
the O +
reduction O +
of O +
Hb O +
baseline O +
value O +
of O +
more O +
than O +
2.5 O +
g O -
/ O -
dl O +
after O +
3 O +
months O +
of O +
CAB O +
( O -
p O +
= O +
0.01 O -
) O -
. O +

The O +
development O +
of O +
severe O +
CAB O -
- O -
induced O +
anemia B-Disease +
in O +
prostate B-Disease +
cancer I-Disease +
patients O +
did O +
not O +
correlate O +
with O +
T O +
baseline O +
values O +
( O -
T O +
< O +
3 O +
ng O -
/ O -
ml O +
versus O +
T O +
> O +
or O +
= O +
3 O +
ng O -
/ O -
ml O -
) O -
, O +
with O +
age O +
( O -
< O +
76 O +
yrs O +
versus O +
> O +
or O +
= O +
76 O +
yrs O -
) O -
, O +
and O +
clinical O +
stage O +
( O -
stage O +
C O +
versus O +
stage O +
D1 O -
) O -
. O +

Severe O +
and O +
clinically O +
evident O +
anemia B-Disease +
was O +
easily O +
corrected O +
by O +
subcutaneous O +
injections O +
( O -
3 O +
times O -
/ O -
week O +
for O +
1 O +
month O -
) O +
of O +
recombinant O +
erythropoietin O +
( O -
rHuEPO O -
- O -
beta O -
) O -
. O +

CONCLUSION O -
: O +
Our O +
data O +
suggest O +
that O +
rHuEPO O -
- O -
beta O +
correctable O +
CAB O -
- O -
induced O +
anemia B-Disease +
occurs O +
in O +
14.3 O -
% O +
of O +
prostate B-Disease +
cancer I-Disease +
patients O +
after O +
6 O +
months O +
of O +
therapy O -
. O +

Effect O +
of O +
lindane O +
on O +
hepatic O +
and O +
brain O +
cytochrome O +
P450s O +
and O +
influence O +
of O +
P450 O +
modulation O +
in O +
lindane O +
induced O +
neurotoxicity B-Disease -
. O +

Oral O +
administration O +
of O +
lindane O +
( O -
2.5 O -
, O +
5 O -
, O +
10 O +
and O +
15 O +
mg O -
/ O -
kg O -
, O +
body O +
weight O -
) O +
for O +
5 O +
days O +
was O +
found O +
to O +
produce O +
a O +
dose O -
- O -
dependent O +
increase O +
in O +
the O +
activity O +
of O +
P450 O +
dependent O +
7-ethoxyresorufin O -
- O -
O O -
- O -
deethylase O +
( O -
EROD O -
) O -
, O +
7-pentoxyresorufin O -
- O -
O O -
- O -
dealkylase O +
( O -
PROD O -
) O +
and O +
N O -
- O -
nitrosodimethylamine O +
demethylase O +
( O -
NDMA O -
- O -
d O -
) O +
in O +
rat O +
brain O +
and O +
liver O -
. O +

A O +
significant O +
increase O +
in O +
the O +
hepatic O +
and O +
brain O +
P450 O +
monooxygenases O +
was O +
also O +
observed O +
when O +
the O +
duration O +
of O +
exposure O +
of O +
low O +
dose O +
( O -
2.5 O +
mg O -
/ O -
kg O -
) O +
of O +
lindane O +
was O +
increased O +
from O +
5 O +
days O +
to O +
15 O +
or O +
21 O +
days O -
. O +

As O +
observed O +
with O +
different O +
doses O -
, O +
the O +
magnitude O +
of O +
induction O +
in O +
the O +
activity O +
of O +
P450 O +
monooxygenases O +
was O +
several O +
fold O +
higher O +
in O +
liver O +
microsomes O +
when O +
compared O +
with O +
the O +
brain O -
. O +

Western O +
blotting O +
studies O +
have O +
indicated O +
that O +
the O +
increase O +
in O +
the O +
P450 O +
enzymes O +
could O +
be O +
due O +
to O +
the O +
increase O +
in O +
the O +
expression O +
of O +
P450 O +
1A1 O -
/ O -
1A2 O -
, O +
2B1 O -
/ O -
2B2 O +
and O +
2E1 O +
isoenzymes O -
. O +

In O +
vitro O +
studies O +
using O +
organic O +
inhibitors O +
specific O +
for O +
individual O +
P450 O +
isoenzymes O +
and O +
antibody O +
inhibition O +
experiments O +
have O +
further O +
demonstrated O +
that O +
the O +
increase O +
in O +
the O +
activity O +
of O +
PROD O -
, O +
EROD O +
and O +
NDMA O -
- O -
d O +
are O +
due O +
to O +
the O +
increase O +
in O +
the O +
levels O +
of O +
P450 O +
2B1 O -
/ O -
2B2 O -
, O +
1A1 O -
/ O -
1A2 O +
and O +
2E1 O +
isoenzymes O -
, O +
respectively O -
. O +

Induction O +
studies O +
have O +
further O +
shown O +
that O +
while O +
pretreatment O +
of O +
3-methylcholanthrene O +
( O -
MC O -
) O -
, O +
an O +
inducer O +
of O +
P4501A1 O -
/ O -
1A2 O -
, O +
did O +
not O +
produce O +
any O +
significant O +
effect O +
in O +
the O +
incidence O +
of O +
lindane O +
induced O +
convulsions B-Disease -
, O +
pretreatment O +
with O +
phenobarbital O +
( O -
PB O -
) O -
, O +
an O +
inducer O +
of O +
P450 O +
2B1 O -
/ O -
2B2 O +
or O +
ethanol O -
, O +
an O +
inducer O +
of O +
P450 O +
2E1 O +
catalysed O +
reactions O -
, O +
significantly O +
increased O +
the O +
incidence O +
of O +
lindane O +
induced O +
convulsions B-Disease -
. O +

Similarly O -
, O +
when O +
the O +
P450-mediated O +
metabolism O +
of O +
lindane O +
was O +
blocked O +
by O +
cobalt O +
chloride O +
incidence O +
of O +
convulsions B-Disease +
was O +
increased O +
in O +
animals O +
treated O +
with O +
lindane O +
indicating O +
that O +
lindane O +
per O +
se O +
or O +
its O +
metabolites O +
formed O +
by O +
PB O +
or O +
ethanol O +
inducible O +
P450 O +
isoenzymes O +
are O +
involved O +
in O +
its O +
neurobehavioral O +
toxicity B-Disease -
. O +

Absolute O +
and O +
attributable O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease +
in O +
women O +
on O +
combined O +
cyproterone O +
acetate O +
and O +
ethinylestradiol O -
. O +

OBJECTIVE O -
: O +
To O +
achieve O +
absolute O +
risk O +
estimates O +
of O +
venous B-Disease +
thromboembolism I-Disease +
( O -
VTE B-Disease -
) O +
among O +
women O +
on O +
cyproterone O +
acetate O +
plus O +
ethinylestradiol O +
( O -
CPA O -
/ O -
EE O -
) O -
, O +
and O +
among O +
women O +
on O +
combined O +
oral O +
contraceptives O +
( O -
COCs O -
) O -
. O +

METHODS O -
: O +
From O +
the O +
Danish O +
National O +
Register O +
of O +
Patients O +
( O -
NRP O -
) O -
, O +
1996 O +
to O +
1998 O -
, O +
the O +
records O +
of O +
1.1 O +
million O +
Danish O +
women O -
, O +
ages O +
15 O +
to O +
44 O +
years O -
, O +
were O +
searched O +
for O +
evidence O +
of O +
VTE B-Disease -
. O +

COC O +
use O +
was O +
ascertained O +
through O +
mailed O +
questionnaires O -
. O +

Sales O +
statistics O +
of O +
COCs O +
and O +
CPA O -
/ O -
EE O +
were O +
provided O +
through O +
Danish O +
Drug O +
Statistics O -
. O +

RESULTS O -
: O +
During O +
the O +
time O +
frame O +
of O +
the O +
study O -
, O +
330 O +
women O +
were O +
found O +
to O +
have O +
had O +
VTE B-Disease +
while O +
on O +
COCs O -
. O +

Of O +
these O +
women O -
, O +
67 O +
were O +
on O +
levonorgestrel O -
- O -
containing O +
COCs O -
. O +

Eleven O +
were O +
on O +
CPA O -
/ O -
EE O -
. O +

The O +
corresponding O +
absolute O +
risk O +
of O +
VTE B-Disease +
was O +
3.4 O +
( O -
range O -
, O +
3.1 O -
- O -
3.8 O -
) O +
per O +
10 O +
000 O +
women O +
years O +
among O +
the O +
women O +
on O +
COCs O -
, O +
4.2 O +
( O -
range O -
, O +
3.2 O -
- O -
5.2 O -
) O +
per O +
10 O +
000 O +
women O +
years O +
among O +
women O +
on O +
levonorgestrel O -
- O -
containing O +
COCs O -
, O +
and O +
3.1 O +
( O -
range O -
, O +
1.3 O -
- O -
4.9 O -
) O +
per O +
10 O +
000 O +
women O +
years O +
among O +
the O +
women O +
on O +
CPA O -
/ O -
EE O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
suggest O +
the O +
absolute O +
risk O +
of O +
VTE B-Disease +
among O +
Danish O +
women O +
on O +
COCs O +
is O +
similar O +
to O +
that O +
among O +
women O +
taking O +
CPA O -
/ O -
EE O -
. O +

Reversal O +
of O +
central O +
benzodiazepine O +
effects O +
by O +
flumazenil O +
after O +
intravenous O +
conscious O +
sedation O +
with O +
diazepam O +
and O +
opioids O -
: O +
report O +
of O +
a O +
double O -
- O -
blind O +
multicenter O +
study O -
. O +

The O +
Flumazenil O +
in O +
Intravenous O +
Conscious O +
Sedation O +
with O +
Diazepam O +
Multicenter O +
Study O +
Group O +
II O -
. O +

The O +
efficacy O +
and O +
safety O +
of O +
a O +
new O +
benzodiazepine O +
antagonist O -
, O +
flumazenil O -
, O +
were O +
assessed O +
in O +
a O +
double O -
- O -
blind O +
multicenter O +
study O -
. O +

Flumazenil O +
( O -
mean O +
dose O -
, O +
0.76 O +
mg O -
) O +
or O +
placebo O +
( O -
mean O +
dose O -
, O +
8.9 O +
ml O -
) O +
was O +
administered O +
intravenously O +
to O +
130 O +
and O +
67 O +
patients O -
, O +
respectively O -
, O +
who O +
had O +
been O +
given O +
diazepam O +
in O +
conjunction O +
with O +
an O +
opioid O +
( O -
fentanyl O -
, O +
meperidine O -
, O +
or O +
morphine O -
) O +
for O +
the O +
induction O +
and O +
maintenance O +
of O +
intravenous O +
conscious O +
sedation O +
for O +
diagnostic O +
or O +
therapeutic O +
surgical O +
procedures O -
. O +

The O +
group O +
assessable O +
for O +
efficacy O +
comprised O +
122 O +
patients O +
treated O +
with O +
flumazenil O +
and O +
64 O +
patients O +
given O +
placebo O -
. O +

After O +
5 O +
minutes O -
, O +
80 O -
/ O -
115 O +
( O -
70 O -
% O -
) O +
flumazenil O -
- O -
treated O +
patients O -
, O +
compared O +
with O +
21 O -
/ O -
63 O +
( O -
33 O -
% O -
) O +
placebo O -
- O -
treated O +
patients O -
, O +
were O +
completely O +
awake O +
and O +
alert O -
, O +
as O +
indicated O +
by O +
a O +
score O +
of O +
5 O +
on O +
the O +
Observer O -
's O +
Assessment O +
of O +
Alertness O -
/ O -
Sedation O +
Scale O -
. O +

Ninety O -
- O -
five O +
percent O +
of O +
patients O +
in O +
each O +
group O +
who O +
attained O +
a O +
score O +
of O +
5 O +
at O +
the O +
5-minute O +
assessment O +
showed O +
no O +
loss O +
of O +
alertness O +
throughout O +
the O +
180-minute O +
assessment O +
period O -
. O +

Flumazenil O -
- O -
treated O +
patients O +
also O +
performed O +
significantly O +
better O +
on O +
the O +
Finger O -
- O -
to O -
- O -
Nose O +
Test O +
and O +
the O +
recall O +
of O +
pictures O +
shown O +
at O +
the O +
5-minute O +
assessment O -
. O +

Flumazenil O +
was O +
well O +
tolerated O -
, O +
with O +
no O +
serious O +
adverse O +
effects O +
reported O -
. O +

Thirty O -
- O -
nine O +
( O -
30 O -
% O -
) O +
of O +
flumazenil O -
- O -
treated O +
patients O -
, O +
compared O +
with O +
17 O +
( O -
25 O -
% O -
) O +
of O +
placebo O -
- O -
treated O +
patients O +
had O +
one O +
or O +
more O +
drug O -
- O -
related O +
adverse O +
experiences O -
. O +

The O +
most O +
common O +
adverse O +
effects O +
were O +
nausea B-Disease +
and O +
vomiting B-Disease +
in O +
the O +
flumazenil O +
group O +
and O +
nausea B-Disease +
and O +
injection O -
- O -
site O +
pain B-Disease +
in O +
the O +
placebo O +
group O -
. O +

Flumazenil O +
was O +
found O +
to O +
promptly O +
reverse O +
sedation O +
induced O +
by O +
diazepam O +
in O +
the O +
presence O +
of O +
opioids O -
. O +

Delirium B-Disease +
during O +
clozapine O +
treatment O -
: O +
incidence O +
and O +
associated O +
risk O +
factors O -
. O +

BACKGROUND O -
: O +
Incidence O +
and O +
risk O +
factors O +
for O +
delirium B-Disease +
during O +
clozapine O +
treatment O +
require O +
further O +
clarification O -
. O +

METHODS O -
: O +
We O +
used O +
computerized O +
pharmacy O +
records O +
to O +
identify O +
all O +
adult O +
psychiatric B-Disease +
inpatients O +
treated O +
with O +
clozapine O +
( O -
1995 O -
- O -
96 O -
) O -
, O +
reviewed O +
their O +
medical O +
records O +
to O +
score O +
incidence O +
and O +
severity O +
of O +
delirium B-Disease -
, O +
and O +
tested O +
associations O +
with O +
potential O +
risk O +
factors O -
. O +

RESULTS O -
: O +
Subjects O +
( O -
n O +
= O +
139 O -
) O +
were O +
72 O +
women O +
and O +
67 O +
men O -
, O +
aged O +
40.8 O +
+ O -
/- O +

12.1 O +
years O -
, O +
hospitalized O +
for O +
24.9 O +
+ O -
/- O +

23.3 O +
days O -
, O +
and O +
given O +
clozapine O -
, O +
gradually O +
increased O +
to O +
an O +
average O +
daily O +
dose O +
of O +
282 O +
+ O -
/- O +

203 O +
mg O +
( O -
3.45 O +
+ O -
/- O +

2.45 O +
mg O -
/ O -
kg O -
) O +
for O +
18.9 O +
+ O -
/- O +

16.4 O +
days O -
. O +

Delirium B-Disease +
was O +
diagnosed O +
in O +
14 O +
( O -
10.1 O +
% O +
incidence O -
, O +
or O +
1.48 O +
cases O -
/ O -
person O -
- O -
years O +
of O +
exposure O -
) O -
; O +
71.4 O +
% O +
of O +
cases O +
were O +
moderate O +
or O +
severe O -
. O +

Associated O +
factors O +
were O +
co O -
- O -
treatment O +
with O +
other O +
centrally O +
antimuscarinic O +
agents O -
, O +
poor O +
clinical O +
outcome O -
, O +
older O +
age O -
, O +
and O +
longer O +
hospitalization O +
( O -
by O +
17.5 O +
days O -
, O +
increasing O +
cost O -
) O -
; O +
sex O -
, O +
diagnosis O +
or O +
medical O +
co O -
- O -
morbidity O -
, O +
and O +
daily O +
clozapine O +
dose O -
, O +
which O +
fell O +
with O +
age O -
, O +
were O +
unrelated O -
. O +

CONCLUSIONS O -
: O +
Delirium B-Disease +
was O +
found O +
in O +
10 O +
% O +
of O +
clozapine O -
- O -
treated O +
inpatients O -
, O +
particularly O +
in O +
older O +
patients O +
exposed O +
to O +
other O +
central O +
anticholinergics O -
. O +

Delirium B-Disease +
was O +
inconsistently O +
recognized O +
clinically O +
in O +
milder O +
cases O +
and O +
was O +
associated O +
with O +
increased O +
length O -
- O -
of O -
- O -
stay O +
and O +
higher O +
costs O -
, O +
and O +
inferior O +
clinical O +
outcome O -
. O +

Neuroprotective O +
action O +
of O +
MPEP O -
, O +
a O +
selective O +
mGluR5 O +
antagonist O -
, O +
in O +
methamphetamine O -
- O -
induced O +
dopaminergic O +
neurotoxicity B-Disease +
is O +
associated O +
with O +
a O +
decrease O +
in O +
dopamine O +
outflow O +
and O +
inhibition O +
of O +
hyperthermia B-Disease +
in O +
rats O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
the O +
role O +
of O +
metabotropic O +
glutamate O +
receptor O +
5 O +
( O -
mGluR5 O -
) O +
in O +
the O +
toxic O +
action O +
of O +
methamphetamine O +
on O +
dopaminergic O +
neurones O +
in O +
rats O -
. O +

Methamphetamine O +
( O -
10 O +
mg O -
/ O -
kg O +
sc O -
) O -
, O +
administered O +
five O +
times O -
, O +
reduced O +
the O +
levels O +
of O +
dopamine O +
and O +
its O +
metabolites O +
in O +
striatal O +
tissue O +
when O +
measured O +
72 O +
h O +
after O +
the O +
last O +
injection O -
. O +

A O +
selective O +
antagonist O +
of O +
mGluR5 O -
, O +
2-methyl-6- O -
( O -
phenylethynyl O -
) O -
pyridine O +
( O -
MPEP O -
; O +
5 O +
mg O -
/ O -
kg O +
ip O -
) O -
, O +
when O +
administered O +
five O +
times O +
immediately O +
before O +
each O +
methamphetamine O +
injection O +
reversed O +
the O +
above O -
- O -
mentioned O +
methamphetamine O +
effects O -
. O +

A O +
single O +
MPEP O +
( O -
5 O +
mg O -
/ O -
kg O +
ip O -
) O +
injection O +
reduced O +
the O +
basal O +
extracellular O +
dopamine O +
level O +
in O +
the O +
striatum O -
, O +
as O +
well O +
as O +
dopamine O +
release O +
stimulated O +
either O +
by O +
methamphetamine O +
( O -
10 O +
mg O -
/ O -
kg O +
sc O -
) O +
or O +
by O +
intrastriatally O +
administered O +
veratridine O +
( O -
100 O +
microM O -
) O -
. O +

Moreover O -
, O +
it O +
transiently O +
diminished O +
the O +
methamphetamine O +
( O -
10 O +
mg O -
/ O -
kg O +
sc O -
) O -
-induced O +
hyperthermia B-Disease +
and O +
reduced O +
basal O +
body O +
temperature O -
. O +

MPEP O +
administered O +
into O +
the O +
striatum O +
at O +
high O +
concentrations O +
( O -
500 O +
microM O -
) O +
increased O +
extracellular O +
dopamine O +
levels O -
, O +
while O +
lower O +
concentrations O +
( O -
50 O -
- O -
100 O +
microM O -
) O +
were O +
devoid O +
of O +
any O +
effect O -
. O +

The O +
results O +
of O +
this O +
study O +
suggest O +
that O +
the O +
blockade O +
of O +
mGluR5 O +
by O +
MPEP O +
may O +
protect O +
dopaminergic O +
neurones O +
against O +
methamphetamine O -
- O -
induced O +
toxicity B-Disease -
. O +

Neuroprotection O +
rendered O +
by O +
MPEP O +
may O +
be O +
associated O +
with O +
the O +
reduction O +
of O +
the O +
methamphetamine O -
- O -
induced O +
dopamine O +
efflux O +
in O +
the O +
striatum O +
due O +
to O +
the O +
blockade O +
of O +
extrastriatal O +
mGluR5 O -
, O +
and O +
with O +
a O +
decrease O +
in O +
hyperthermia B-Disease -
. O +

Methylphenidate O -
- O -
induced O +
obsessive B-Disease -
- I-Disease -
compulsive I-Disease +
symptoms I-Disease +
in O +
an O +
elderly O +
man O -
. O +

An O +
82-year O -
- O -
old O +
man O +
with O +
treatment B-Disease -
- I-Disease -
resistant I-Disease +
depression I-Disease +
and O +
early O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
was O +
started O +
on O +
methylphenidate O -
. O +

Significant O +
obsessive B-Disease -
- I-Disease -
compulsive I-Disease +
behavior I-Disease +
ensued O +
but O +
diminished O +
over O +
several O +
weeks O +
when O +
methylphenidate O +
was O +
replaced O +
by O +
fluvoxamine O -
. O +

The O +
patient O +
had O +
no O +
prior O +
psychiatric B-Disease +
history O -
, O +
but O +
he O +
had O +
a O +
sister O +
with O +
obsessive B-Disease -
- I-Disease -
compulsive I-Disease +
disorder I-Disease -
. O +

It O +
appears O +
that O +
methylphenidate O +
precipitated O +
the O +
patient O -
's O +
pathological O +
behavior O -
. O +

Ciprofloxacin O -
- O -
induced O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
and O +
autoimmune B-Disease +
hemolytic I-Disease +
anemia I-Disease -
. O +

Ciprofloxacin O +
has O +
been O +
associated O +
with O +
several O +
side O +
effects O +
including O +
interstitial B-Disease +
nephritis I-Disease +
and O +
hemolytic B-Disease +
anemia I-Disease -
. O +

The O +
combination O +
of O +
both O +
side O +
effects O +
is O +
extremely O +
rare O -
. O +

In O +
this O +
report O -
, O +
we O +
describe O +
a O +
case O +
of O +
ciprofloxacin O -
- O -
induced O +
interstitial B-Disease +
nephritis I-Disease +
and O +
autoimmune B-Disease +
hemolytic I-Disease +
anemia I-Disease -
. O +

Hemolytic B-Disease +
anemia I-Disease +
improved O +
after O +
stopping O +
the O +
drug O +
and O +
initiation O +
of O +
steroid O +
therapy O -
. O +

Unfortunately O -
, O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
was O +
irreversible O +
and O +
the O +
patient O +
developed O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease I-Disease -
. O +

Protective O +
efficacy O +
of O +
neuroactive O +
steroids O +
against O +
cocaine O +
kindled O -
- O -
seizures B-Disease +
in O +
mice O -
. O +

Neuroactive O +
steroids O +
demonstrate O +
pharmacological O +
actions O +
that O +
have O +
relevance O +
for O +
a O +
host O +
of O +
neurological B-Disease +
and I-Disease +
psychiatric I-Disease +
disorders I-Disease -
. O +

They O +
offer O +
protection O +
against O +
seizures B-Disease +
in O +
a O +
range O +
of O +
models O +
and O +
seem O +
to O +
inhibit O +
certain O +
stages O +
of O +
drug B-Disease +
dependence I-Disease +
in O +
preclinical O +
assessments O -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
evaluate O +
two O +
endogenous O +
and O +
one O +
synthetic O +
neuroactive O +
steroid O +
that O +
positively O +
modulate O +
the O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
( O -
A O -
) O -
) O +
receptor O +
against O +
the O +
increase O +
in O +
sensitivity O +
to O +
the O +
convulsant O +
effects O +
of O +
cocaine O +
engendered O +
by O +
repeated O +
cocaine O +
administration O +
( O -
seizure B-Disease +
kindling O -
) O -
. O +

Allopregnanolone O +
( O -
3alpha O -
- O -
hydroxy-5alpha O -
- O -
pregnan-20-one O -
) O -
, O +
pregnanolone O +
( O -
3alpha O -
- O -
hydroxy-5beta O -
- O -
pregnan-20-one O -
) O +
and O +
ganaxolone O +
( O -
a O +
synthetic O +
derivative O +
of O +
allopregnanolone O +
3alpha O -
- O -
hydroxy-3beta O -
- O -
methyl-5alpha O -
- O -
pregnan-20-one O -
) O +
were O +
tested O +
for O +
their O +
ability O +
to O +
suppress O +
the O +
expression O +
( O -
anticonvulsant O +
effect O -
) O +
and O +
development O +
( O -
antiepileptogenic O +
effect O -
) O +
of O +
cocaine O -
- O -
kindled O +
seizures B-Disease +
in O +
male O -
, O +
Swiss O -
- O -
Webster O +
mice O -
. O +

Kindled O +
seizures B-Disease +
were O +
induced O +
by O +
daily O +
administration O +
of O +
60 O +
mg O -
/ O -
kg O +
cocaine O +
for O +
5 O +
days O -
. O +

All O +
of O +
these O +
positive O +
GABA O -
( O -
A O -
) O +
modulators O +
suppressed O +
the O +
expression O +
of O +
kindled O +
seizures B-Disease -
, O +
whereas O +
only O +
allopregnanolone O +
and O +
ganaxolone O +
inhibited O +
the O +
development O +
of O +
kindling O -
. O +

Allopregnanolone O +
and O +
pregnanolone O -
, O +
but O +
not O +
ganaxolone O -
, O +
also O +
reduced O +
cumulative O +
lethality O +
associated O +
with O +
kindling O -
. O +

These O +
findings O +
demonstrate O +
that O +
some O +
neuroactive O +
steroids O +
attenuate O +
convulsant O +
and O +
sensitizing O +
properties O +
of O +
cocaine O +
and O +
add O +
to O +
a O +
growing O +
literature O +
on O +
their O +
potential O +
use O +
in O +
the O +
modulation O +
of O +
effects O +
of O +
drugs O +
of O +
abuse O -
. O +

Potential O +
deleterious O +
effect O +
of O +
furosemide O +
in O +
radiocontrast O +
nephropathy B-Disease -
. O +

The O +
purpose O +
of O +
the O +
study O +
was O +
to O +
determine O +
the O +
efficacy O +
of O +
furosemide O +
in O +
addition O +
to O +
intravenous O +
fluids O +
in O +
the O +
prevention O +
of O +
radiocontrast O +
nephropathy B-Disease -
. O +

18 O +
patients O -
, O +
referred O +
to O +
a O +
radiocontrast O +
study O -
, O +
considered O +
at O +
risk O +
because O +
of O +
preexisting O +
renal B-Disease +
insufficiency I-Disease -
, O +
were O +
enrolled O +
in O +
a O +
prospective O -
, O +
randomized O -
, O +
controlled O +
trial O -
, O +
performed O +
at O +
the O +
secondary O +
care O +
center O +
of O +
a O +
1,100-bed O +
private O +
university O +
hospital O -
. O +

In O +
addition O +
to O +
fluids O -
, O +
the O +
treatment O +
group O +
received O +
furosemide O +
( O -
mean O +
dose O +
110 O +
mg O -
) O +
intravenously O +
30 O +
min O +
prior O +
to O +
the O +
injection O +
of O +
contrast O +
material O -
. O +

The O +
control O +
group O +
received O +
fluids O +
( O -
mean O +
3 O +
liters O -
) O -
. O +

Radiological O +
studies O +
were O +
mostly O +
angiographies O +
performed O +
with O +
both O +
ionic O +
and O +
non O -
- O -
ionic O +
contrast O +
material O -
, O +
at O +
an O +
average O +
dose O +
of O +
245 O +
ml O -
. O +

Renal B-Disease +
function I-Disease +
significantly I-Disease +
deteriorated I-Disease +
in O +
the O +
group O +
pretreated O +
with O +
furosemide O +
( O -
p O +
< O +
0.005 O +
by O +
ANOVA O -
) O -
, O +
with O +
a O +
rise O +
in O +
serum O +
creatinine O +
from O +
145 O +
+ O -
/- O +

13 O +
to O +
182 O +
+ O -
/- O +

16 O +
mumol O -
/ O -
l O +
at O +
24 O +
h O -
, O +
while O +
no O +
change O +
occurred O +
in O +
the O +
control O +
group O +
( O -
from O +
141 O +
+ O -
/- O +

6 O +
to O +
142 O +
+ O -
/- O +

7 O +
mumol O -
/ O -
l O -
) O -
. O +

Renal B-Disease +
failure I-Disease +
was O +
associated O +
with O +
weight B-Disease +
loss I-Disease +
in O +
the O +
furosemide O -
- O -
treated O +
group O -
. O +

Furosemide O +
may O +
be O +
deleterious O +
in O +
the O +
prevention O +
of O +
radiocontrast O +
nephropathy B-Disease -
. O +

Progestational O +
agents O +
and O +
blood B-Disease +
coagulation I-Disease -
. O +

VII O -
. O +

Thromboembolic B-Disease +
and O +
other O +
complications O +
of O +
oral O +
contraceptive O +
therapy O +
in O +
relationship O +
to O +
pretreatment O +
levels O +
of O +
blood B-Disease +
coagulation I-Disease +
factors O -
: O +
summary O +
report O +
of O +
a O +
ten O -
- O -
year O +
study O -
. O +

During O +
a O +
ten O -
- O -
year O +
period O -
, O +
348 O +
women O +
were O +
studied O +
for O +
a O +
total O +
of O +
5,877 O +
patient O +
months O +
in O +
four O +
separate O +
studies O +
relating O +
oral O +
contraceptives O +
to O +
changes O +
in O +
hematologic O +
parameters O -
. O +

Significant O +
increases O +
in O +
certain O +
factors O +
of O +
the O +
blood B-Disease +
coagulation I-Disease +
and O +
fibrinolysin O +
systems O +
( O -
factors O +
I O -
, O -
II O -
, O -
VII O -
, O -
VIII O -
, O -
IX O -
, O +
and O +
X O +
and O +
plasminogen O -
) O +
were O +
observed O +
in O +
the O +
treated O +
groups O -
. O +

Severe O +
complications O +
developed O +
in O +
four O +
patients O -
. O +

All O +
four O +
had O +
an O +
abnormal O +
blood B-Disease +
coagulation I-Disease +
profile O -
, O +
suggesting O +
" O -
hypercoagulability B-Disease -
" O +
before O +
initiation O +
of O +
therapy O -
. O +

Some O +
of O +
these O +
findings O +
represented O +
the O +
most O +
extreme O +
abnormalities O +
seen O +
in O +
the O +
entire O +
group O +
of O +
patients O -
; O +
some O +
increased O +
further O +
during O +
therapy O -
. O +

One O +
of O +
these O +
patients O +
developed O +
a O +
myocardial B-Disease +
infarction I-Disease +
before O +
receiving O +
any O +
medication O -
, O +
shortly O +
after O +
the O +
base O -
- O -
line O +
values O +
were O +
obtained O -
. O +

One O +
patient O +
developed O +
retinopathy B-Disease +
19 O +
months O +
after O +
she O +
began O +
therapy O -
, O +
and O +
another O +
developed O +
thrombophlebitis B-Disease +
after O +
27 O +
months O +
of O +
therapy O -
. O +

The O +
fourth O +
patient O +
developed O +
thrombophlebitis B-Disease +
14 O +
days O +
after O +
initiation O +
of O +
contraceptive O +
therapy O -
. O +

All O +
four O +
patients O +
were O +
of O +
the O +
A O +
or O +
AB O +
blood O +
group O -
. O +

Previous O +
studies O +
suggested O +
the O +
possiblility O +
of O +
increased O +
propensity O +
for O +
thromboembolic B-Disease +
episodes I-Disease +
in O +
patients O +
possessing O +
the O +
A O +
antigen O -
. O +

It O +
appears O +
from O +
these O +
data O +
that O +
hematologic O +
work O -
- O -
ups O +
may O +
be O +
useful O +
in O +
women O +
who O +
are O +
about O +
to O +
start O +
long O -
- O -
term O +
oral O +
contraceptive O +
therapy O -
. O +

Orthostatic B-Disease +
hypotension I-Disease +
occurs O +
following O +
alpha O +
2-adrenoceptor O +
blockade O +
in O +
chronic O +
prazosin O -
- O -
pretreated O +
conscious O +
spontaneously O +
hypertensive B-Disease +
rats O -
. O +

1 O -
. O +
Studies O +
were O +
performed O +
to O +
evaluate O +
whether O +
chronic O +
prazosin O +
treatment O +
alters O +
the O +
alpha O +
2-adrenoceptor O +
function O +
for O +
orthostatic O +
control O +
of O +
arterial O +
blood O +
pressure O +
in O +
conscious O +
spontaneously O +
hypertensive B-Disease +
rats O +
( O -
SHR O -
) O -
. O +

2 O -
. O +

Conscious O +
SHR O +
( O -
male O +
300 O -
- O -
350 O +
g O -
) O +
were O +
subjected O +
to O +
90 O +
degrees O +
head O -
- O -
up O +
tilts O +
for O +
60 O +
s O +
following O +
acute O +
administration O +
of O +
prazosin O +
( O -
0.1 O +
mg O +
kg-1 O +
i.p O -
. O -
) O +
or O +
rauwolscine O +
( O -
3 O +
mg O +
kg-1 O +
i.v O -
. O -
) O -
. O +

Orthostatic B-Disease +
hypotension I-Disease +
was O +
determined O +
by O +
the O +
average O +
decrease O +
( O -
% O -
) O +
in O +
mean O +
arterial O +
pressure O +
( O -
MAP O +
femoral O -
) O +
over O +
the O +
60-s O +
tilt O +
period O -
. O +

The O +
basal O +
MAP O +
of O +
conscious O +
SHR O +
was O +
reduced O +
to O +
a O +
similar O +
extent O +
by O +
prazosin O +
( O -
-23% O -
( O -
- O -
) O -
-26 O -
% O +
MAP O -
) O +
and O +
rauwolscine O +
( O -
-16% O -
( O -
- O -
) O -
-33 O -
% O +
MAP O -
) O -
. O +

However O -
, O +
the O +
head O -
- O -
up O +
tilt O +
induced O +
orthostatic B-Disease +
hypotension I-Disease +
in O +
the O +
SHR O +
treated O +
with O +
prazosin O +
( O -
-16 O -
% O +
MAP O -
, O +
n O +
= O +
6 O -
) O -
, O +
but O +
not O +
in O +
the O +
SHR O +
treated O +
with O +
rauwolscine O +
( O -
less O +
than O +
+ O -
2 O -
% O +
MAP O -
, O +
n O +
= O +
6 O -
) O -
. O +

3 O -
. O +

Conscious O +
SHR O +
were O +
treated O +
for O +
4 O +
days O +
with O +
prazosin O +
at O +
2 O +
mg O +
kg-1 O +
day-1 O +
i.p O -
. O +

for O +
chronic O +
alpha O +
1-adrenoceptor O +
blockade O -
. O +

MAP O +
in O +
conscious O +
SHR O +
after O +
chronic O +
prazosin O +
treatment O +
was O +
14 O -
% O +
lower O +
than O +
in O +
the O +
untreated O +
SHR O +
( O -
n O +
= O +
8) O -
. O +

Head O -
- O -
up O +
tilts O +
in O +
these O +
rats O +
did O +
not O +
produce O +
orthostatic B-Disease +
hypotension I-Disease +
when O +
performed O +
either O +
prior O +
to O +
or O +
after O +
acute O +
dosing O +
of O +
prazosin O +
( O -
0.1 O +
mg O +
kg-1 O +
i.p O -
. O -
) O -
. O +

Conversely O -
, O +
administration O +
of O +
rauwolscine O +
( O -
3 O +
mg O +
kg-1 O +
i.v O -
. O -
) O +
in O +
chronic O +
prazosin O +
treated O +
SHR O +
decreased O +
the O +
basal O +
MAP O +
by O +
12 O -
- O -
31 O -
% O +
( O -
n O +
= O +
4 O -
) O -
, O +
and O +
subsequent O +
tilts O +
induced O +
further O +
drops O +
of O +
MAP O +
by O +
19 O -
- O -
23 O -
% O +
in O +
these O +
rats O -
. O +

4 O -
. O +

The O +
pressor O +
responses O +
and O +
bradycardia B-Disease +
to O +
the O +
alpha O +
1-agonist O +
cirazoline O +
( O -
0.6 O +
and O +
2 O +
micrograms O +
kg-1 O +
i.v O -
. O -
) O -
, O +
the O +
alpha O +
2-agonist O +
Abbott-53693 O +
( O -
1 O +
and O +
3 O +
micrograms O +
kg-1 O +
i.v O -
. O -
) O -
, O +
and O +
noradrenaline O +
( O -
0.1 O +
and O +
1.0 O +
micrograms O +
kg-1 O +
i.v O -
. O -
) O +
were O +
determined O +
in O +
conscious O +
SHR O +
with O +
and O +
without O +
chronic O +
prazosin O +
pretreatment O -
. O +

Both O +
the O +
pressor O +
and O +
bradycardia B-Disease +
effects O +
of O +
cirazoline O +
were O +
abolished O +
in O +
chronic O +
prazosin O +
treated O +
SHR O +
( O -
n O +
= O +
4 O -
) O +
as O +
compared O +
to O +
the O +
untreated O +
SHR O +
( O -
n O +
= O +
4 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
pressor O +
effects O +
of O +
Abbott-53693 O +
were O +
similar O +
in O +
both O +
groups O +
of O +
SHR O -
, O +
but O +
the O +
accompanying O +
bradycardia B-Disease +
was O +
greater O +
in O +
SHR O +
with O +
chronic O +
prazosin O +
treatment O +
than O +
without O +
such O +
treatment O -
. O +

Furthermore O -
, O +
the O +
bradycardia B-Disease +
that O +
accompanied O +
the O +
noradrenaline O -
- O -
induced O +
pressor O +
effect O +
in O +
SHR O +
was O +
similar O +
with O +
and O +
without O +
chronic O +
prazosin O +
treatment O +
despite O +
a O +
47 O -
- O -
71 O -
% O +
reduction O +
of O +
the O +
pressor O +
effect O +
in O +
chronic O +
alpha O +
1-receptor O +
blocked O +
SHR. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O -
) O +

Effect O +
of O +
humoral O +
modulators O +
of O +
morphine O -
- O -
induced O +
increase B-Disease +
in I-Disease +
locomotor I-Disease +
activity I-Disease +
of O +
mice O -
. O +

The O +
effect O +
of O +
humoral O +
modulators O +
on O +
the O +
morphine O -
- O -
induced O +
increase B-Disease +
in I-Disease +
locomotor I-Disease +
activity I-Disease +
of O +
mice O +
was O +
studied O -
. O +

The O +
subcutaneous O +
administration O +
of O +
10 O +
mg O -
/ O -
kg O +
of O +
morphine O -
- O -
HC1 O +
produced O +
a O +
marked O +
increase B-Disease +
in I-Disease +
locomotor I-Disease +
activity I-Disease +
in O +
mice O -
. O +

The O +
morphine O -
- O -
induced O +
hyperactivity B-Disease +
was O +
potentiated O +
by O +
scopolamine O +
and O +
attenuated O +
by O +
physostigmine O -
. O +

In O +
contrast O -
, O +
both O +
methscopolamine O +
and O +
neostigmine O -
, O +
which O +
do O +
not O +
penetrate O +
the O +
blood O -
- O -
brain O +
barrier O -
, O +
had O +
no O +
effect O +
on O +
the O +
hyperactivity B-Disease +
produced O +
by O +
morphine O -
. O +

Pretreatment O +
of O +
mice O +
with O +
alpha O -
- O -
methyltyrosine O +
( O -
20 O +
mg O -
/ O -
kg O +
i.p O -
. O -
, O +
one O +
hour O -
) O -
, O +
an O +
inhibitor O +
of O +
tyrosine O +
hydroxylase O -
, O +
significantly O +
decreased O +
the O +
activity O -
- O -
increasing O +
effects O +
of O +
morphine O -
. O +

On O +
the O +
other O +
hand O -
, O +
pretreatment O +
with O +
p O -
- O -
chlorophenylalamine O +
( O -
3 O +
X O +
320 O +
mg O -
/ O -
kg O +
i.p O -
. O -
, O +
24 O +
hr O -
) O -
, O +
a O +
serotonin O +
depletor O -
, O +
caused O +
no O +
significant O +
change O +
in O +
the O +
hyperactivity B-Disease -
. O +

The O +
study O +
suggests O +
that O +
the O +
activity O -
- O -
increasing O +
effects O +
of O +
morphine O +
are O +
mediated O +
by O +
the O +
release O +
of O +
catecholamines O +
from O +
adrenergic O +
neurons O +
in O +
the O +
brain O -
. O +

And O +
the O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
morphine O +
acts O +
by O +
retarding O +
the O +
release O +
of O +
acetylcholine O +
at O +
some O +
central O +
cholinergic O +
synapses O -
. O +

It O +
is O +
also O +
suggested O +
from O +
collected O +
evidence O +
that O +
the O +
activity O -
- O -
increasing O +
effects O +
of O +
morphine O +
in O +
mice O +
are O +
mediated O +
by O +
mechanisms O +
different O +
from O +
those O +
which O +
mediate O +
the O +
activity O -
- O -
increasing O +
effects O +
of O +
morphine O +
in O +
rats O -
. O +

Effects O +
of O +
uninephrectomy O +
and O +
high O +
protein O +
feeding O +
on O +
lithium O -
- O -
induced O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
in O +
rats O -
. O +

Rats O +
with O +
lithium O -
- O -
induced O +
nephropathy B-Disease +
were O +
subjected O +
to O +
high O +
protein O +
( O -
HP O -
) O +
feeding O -
, O +
uninephrectomy O +
( O -
NX O -
) O +
or O +
a O +
combination O +
of O +
these O -
, O +
in O +
an O +
attempt O +
to O +
induce O +
glomerular O +
hyperfiltration O +
and O +
further O +
progression O +
of O +
renal B-Disease +
failure I-Disease -
. O +

Newborn O +
female O +
Wistar O +
rats O +
were O +
fed O +
a O +
lithium O -
- O -
containing O +
diet O +
( O -
50 O +
mmol O -
/ O -
kg O -
) O +
for O +
8 O +
weeks O +
and O +
then O +
randomized O +
to O +
normal O +
diet O -
, O +
HP O +
diet O +
( O -
40 O +
vs. O +
19 O -
% O -
) O -
, O +
NX O +
or O +
HP+NX O +
for O +
another O +
8 O +
weeks O -
. O +

Corresponding O +
non O -
- O -
lithium O +
pretreated O +
groups O +
were O +
generated O -
. O +

When O +
comparing O +
all O +
lithium O +
treated O +
versus O +
non O -
- O -
lithium O -
- O -
treated O +
groups O -
, O +
lithium O +
caused O +
a O +
reduction O +
in O +
glomerular O +
filtration O +
rate O +
( O -
GFR O -
) O +
without O +
significant O +
changes O +
in O +
effective O +
renal O +
plasma O +
flow O +
( O -
as O +
determined O +
by O +
a O +
marker O +
secreted O +
into O +
the O +
proximal O +
tubules O -
) O +
or O +
lithium O +
clearance O -
. O +

Consequently O -
, O +
lithium O +
pretreatment O +
caused O +
a O +
fall O +
in O +
filtration O +
fraction O +
and O +
an O +
increase O +
in O +
fractional O +
Li O +
excretion O -
. O +

Lithium O +
also O +
caused O +
proteinuria B-Disease +
and O +
systolic O +
hypertension B-Disease +
in O +
absence O +
of O +
glomerulosclerosis B-Disease -
. O +

HP O +
failed O +
to O +
accentuante O +
progression O +
of O +
renal B-Disease +
failure I-Disease +
and O +
in O +
fact O +
tended O +
to O +
increase O +
GFR O +
and O +
decrease O +
plasma O +
creatinine O +
levels O +
in O +
lithium O +
pretreated O +
rats O -
. O +

NX O +
caused O +
an O +
additive O +
deterioration O +
in O +
GFR O +
which O -
, O +
however O -
, O +
was O +
ameliorated O +
by O +
HP O -
. O +

NX+HP O +
caused O +
a O +
further O +
rise O +
in O +
blood O +
pressure O +
in O +
Li O -
- O -
pretreated O +
rats O -
. O +

The O +
results O +
indicate O +
that O +
Li O -
- O -
induced O +
nephropathy B-Disease -
, O +
even O +
when O +
the O +
GFR O +
is O +
only O +
modestly O +
reduced O -
, O +
is O +
associated O +
with O +
proteinuria B-Disease +
and O +
arterial O +
systolic O +
hypertension B-Disease -
. O +

In O +
this O +
model O +
of O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
the O +
decline O +
in O +
GFR O +
is O +
not O +
accompanied O +
by O +
a O +
corresponding O +
fall O +
in O +
effective O +
renal O +
plasma O +
flow O -
, O +
which O +
may O +
be O +
the O +
functional O +
expression O +
of O +
the O +
formation O +
of O +
nonfiltrating O +
atubular O +
glomeruli O -
. O +

The O +
fractional O +
reabsorption O +
of O +
tubular O +
fluid O +
by O +
the O +
proximal O +
tubules O +
is O +
reduced O -
, O +
leaving O +
the O +
distal O +
delivery O +
unchanged. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Treatment O +
of O +
Crohn B-Disease -
's I-Disease +
disease I-Disease +
with O +
fusidic O +
acid O -
: O +
an O +
antibiotic O +
with O +
immunosuppressive O +
properties O +
similar O +
to O +
cyclosporin O -
. O +

Fusidic O +
acid O +
is O +
an O +
antibiotic O +
with O +
T O -
- O -
cell O +
specific O +
immunosuppressive O +
effects O +
similar O +
to O +
those O +
of O +
cyclosporin O -
. O +

Because O +
of O +
the O +
need O +
for O +
the O +
development O +
of O +
new O +
treatments O +
for O +
Crohn B-Disease -
's I-Disease +
disease I-Disease -
, O +
a O +
pilot O +
study O +
was O +
undertaken O +
to O +
estimate O +
the O +
pharmacodynamics O +
and O +
tolerability O +
of O +
fusidic O +
acid O +
treatment O +
in O +
chronic O +
active O -
, O +
therapy O -
- O -
resistant O +
patients O -
. O +

Eight O +
Crohn B-Disease -
's I-Disease +
disease I-Disease +
patients O +
were O +
included O -
. O +

Fusidic O +
acid O +
was O +
administered O +
orally O +
in O +
a O +
dose O +
of O +
500 O +
mg O +
t.d.s O -
. O +

and O +
the O +
treatment O +
was O +
planned O +
to O +
last O +
8 O +
weeks O -
. O +

The O +
disease O +
activity O +
was O +
primarily O +
measured O +
by O +
a O +
modified O +
individual O +
grading O +
score O -
. O +

Five O +
of O +
8 O +
patients O +
( O -
63 O -
% O -
) O +
improved O +
during O +
fusidic O +
acid O +
treatment O -
: O +
3 O +
at O +
two O +
weeks O +
and O +
2 O +
after O +
four O +
weeks O -
. O +

There O +
were O +
no O +
serious O +
clinical O +
side O +
effects O -
, O +
but O +
dose O +
reduction O +
was O +
required O +
in O +
two O +
patients O +
because O +
of O +
nausea B-Disease -
. O +

Biochemically O -
, O +
an O +
increase O +
in O +
alkaline O +
phosphatases O +
was O +
noted O +
in O +
5 O +
of O +
8 O +
cases O +
( O -
63 O -
% O -
) O -
, O +
and O +
the O +
greatest O +
increases O +
were O +
seen O +
in O +
those O +
who O +
had O +
elevated O +
levels O +
prior O +
to O +
treatment O -
. O +

All O +
reversed O +
to O +
pre O -
- O -
treatment O +
levels O +
after O +
cessation O +
of O +
treatment O -
. O +

The O +
results O +
of O +
this O +
pilot O +
study O +
suggest O +
that O +
fusidic O +
acid O +
may O +
be O +
of O +
benefit O +
in O +
selected O +
chronic O +
active O +
Crohn B-Disease -
's I-Disease +
disease I-Disease +
patients O +
in O +
whom O +
conventional O +
treatment O +
is O +
ineffective O -
. O +

Because O +
there O +
seems O +
to O +
exist O +
a O +
scientific O +
rationale O +
for O +
the O +
use O +
of O +
fusidic O +
acid O +
at O +
the O +
cytokine O +
level O +
in O +
inflammatory B-Disease +
bowel I-Disease +
disease I-Disease -
, O +
we O +
suggest O +
that O +
the O +
role O +
of O +
this O +
treatment O +
should O +
be O +
further O +
investigated O -
. O +

Amnestic B-Disease +
syndrome I-Disease +
associated O +
with O +
propranolol O +
toxicity B-Disease -
: O +
a O +
case O +
report O -
. O +

An O +
elderly O +
woman O +
developed O +
an O +
Alzheimer B-Disease -
- O -
like O +
subacute O +
dementia B-Disease +
as O +
a O +
result O +
of O +
propranolol O +
toxicity B-Disease -
. O +

Analysis O +
of O +
the O +
manifestations O +
showed O +
that O +
severe O +
impairment O +
of O +
memory O +
accounted O +
for O +
virtually O +
all O +
of O +
the O +
abnormalities O -
. O +

There O +
is O +
evidence O +
that O +
cerebral O +
reactions O +
to O +
drug O +
toxicity B-Disease +
can O +
exhibit O +
patterns O +
that O +
suggest O +
highly O +
selective O +
involvement O +
of O +
functional O +
subdivisions O +
of O +
the O +
brain O -
. O +

Changes O +
in O +
depressive B-Disease +
status O +
associated O +
with O +
topical O +
beta O -
- O -
blockers O -
. O +

Depression B-Disease +
and O +
sexual B-Disease +
dysfunction I-Disease +
have O +
been O +
related O +
to O +
side O +
effects O +
of O +
topical O +
beta O -
- O -
blockers O -
. O +

We O +
performed O +
a O +
preliminary O +
study O +
in O +
order O +
to O +
determine O +
any O +
difference O +
between O +
a O +
non O +
selective O +
beta O -
- O -
blocker O +
( O -
timolol O -
) O +
and O +
a O +
selective O +
beta O -
- O -
blocker O +
( O -
betaxolol O -
) O +
regarding O +
CNS O +
side O +
effects O -
. O +

Eight O +
glaucomatous B-Disease +
patients O +
chronically O +
treated O +
with O +
timolol O +
0.5% O -
/ O -
12h O -
, O +
suffering O +
from O +
depression B-Disease +
diagnosed O +
through O +
DMS O -
- O -
III O -
- O -
R O +
criteria O -
, O +
were O +
included O +
in O +
the O +
study O -
. O +

During O +
the O +
six O -
- O -
month O +
follow O +
up O -
, O +
depression B-Disease +
was O +
quantified O +
through O +
the O +
Beck O +
and O +
Zung O -
- O -
Conde O +
scales O +
every O +
two O +
months O -
. O +

In O +
a O +
double O +
blind O +
cross O -
- O -
over O +
study O +
with O +
control O +
group O -
, O +
the O +
patients O +
under O +
timolol O +
treatment O +
presented O +
higher O +
depression B-Disease +
values O +
measured O +
through O +
the O +
Beck O +
and O +
the O +
Zung O -
- O -
Conde O +
scales O +
( O -
p O +
< O +
0.001 O +
vs O +
control O -
) O -
. O +

These O +
results O +
suggest O +
that O +
betaxolol O +
could O +
be O +
less O +
of O +
a O +
depression B-Disease -
- O -
inducer O +
than O +
timolol O +
in O +
predisposed O +
patients O -
. O +

Protection O +
against O +
amphetamine O -
- O -
induced O +
neurotoxicity B-Disease +
toward O +
striatal O +
dopamine O +
neurons O +
in O +
rodents O +
by O +
LY274614 O -
, O +
an O +
excitatory O +
amino O +
acid O +
antagonist O -
. O +

LY274614 O -
, O +
3SR,4aRS,6SR,8aRS-6- O -
[ O -
phosphonomethyl O -
] O -
decahydr O +
oisoquinoline-3- O +
carboxylic O +
acid O -
, O +
has O +
been O +
described O +
as O +
a O +
potent O +
antagonist O +
of O +
the O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
subtype O +
of O +
glutamate O +
receptor O -
. O +

Here O +
its O +
ability O +
to O +
antagonize O +
the O +
prolonged O +
depletion O +
of O +
dopamine O +
in O +
the O +
striatum O +
by O +
amphetamine O +
in O +
iprindole O -
- O -
treated O +
rats O +
is O +
reported O -
. O +

A O +
single O +
18.4 O +
mg O -
/ O -
kg O +
( O -
i.p O -
. O -
) O +
dose O +
of O +
( O -
+ O -
/- O -
) O -
-amphetamine O +
hemisulfate O -
, O +
given O +
to O +
rats O +
pretreated O +
with O +
iprindole O -
, O +
resulted O +
in O +
persistent O +
depletion O +
of O +
dopamine O +
in O +
the O +
striatum O +
1 O +
week O +
later O -
. O +

This O +
prolonged O +
depletion O +
of O +
dopamine O +
in O +
the O +
striatum O +
was O +
antagonized O +
by O +
dizocilpine O +
( O -
MK-801 O -
, O +
a O +
non O -
- O -
competitive O +
antagonist O +
of O +
NMDA O +
receptors O -
) O +
or O +
by O +
LY274614 O +
( O -
a O +
competitive O +
antagonist O +
of O +
NMDA O +
receptors O -
) O -
. O +

The O +
protective O +
effect O +
of O +
LY274614 O +
was O +
dose O -
- O -
dependent O -
, O +
being O +
maximum O +
at O +
10 O -
- O -
40 O +
mgkg O +
( O -
i.p O -
. O -
) O -
. O +

A O +
10 O +
mg O -
/ O -
kg O +
dose O +
of O +
LY274614 O +
was O +
effective O +
in O +
antagonizing O +
the O +
depletion O +
of O +
dopamine O +
in O +
the O +
striatum O -
, O +
when O +
given O +
as O +
long O +
as O +
8 O +
hr O +
prior O +
to O +
amphetamine O +
but O +
not O +
when O +
given O +
24 O +
hr O +
prior O +
to O +
amphetamine O -
. O +

Depletion O +
of O +
dopamine O +
in O +
the O +
striatum O +
was O +
also O +
antagonized O +
when O +
LY274614 O +
was O +
given O +
after O +
the O +
injection O +
of O +
amphetamine O -
; O +
LY274614 O +
protected O +
when O +
given O +
up O +
to O +
4 O +
hr O +
after O +
but O +
not O +
when O +
given O +
8 O +
or O +
24 O +
hr O +
after O +
amphetamine O -
. O +

The O +
prolonged O +
depletion O +
of O +
dopamine O +
in O +
the O +
striatum O +
in O +
mice O -
, O +
given O +
multiple O +
injections O +
of O +
methamphetamine O -
, O +
was O +
also O +
antagonized O +
dose O -
- O -
dependently O +
and O +
completely O +
by O +
LY274614 O -
. O +

The O +
data O +
strengthen O +
the O +
evidence O +
that O +
the O +
neurotoxic B-Disease +
effect O +
of O +
amphetamine O +
and O +
related O +
compounds O +
toward O +
nigrostriatal O +
dopamine O +
neurons O +
involves O +
NMDA O +
receptors O +
and O +
that O +
LY274614 O +
is O +
an O +
NMDA O +
receptor O +
antagonist O +
with O +
long O -
- O -
lasting O +
in O +
vivo O +
effects O +
in O +
rats O -
. O +

Cefotetan O -
- O -
induced O +
immune O +
hemolytic B-Disease +
anemia I-Disease -
. O +

Immune O +
hemolytic B-Disease +
anemia I-Disease +
due O +
to O +
a O +
drug O -
- O -
adsorption O +
mechanism O +
has O +
been O +
described O +
primarily O +
in O +
patients O +
receiving O +
penicillins O +
and O +
first O -
- O -
generation O +
cephalosporins O -
. O +

We O +
describe O +
a O +
patient O +
who O +
developed O +
anemia B-Disease +
while O +
receiving O +
intravenous O +
cefotetan O -
. O +

Cefotetan O -
- O -
dependent O +
antibodies O +
were O +
detected O +
in O +
the O +
patient O -
's O +
serum O +
and O +
in O +
an O +
eluate O +
prepared O +
from O +
his O +
red O +
blood O +
cells O -
. O +

The O +
eluate O +
also O +
reacted O +
weakly O +
with O +
red O +
blood O +
cells O +
in O +
the O +
absence O +
of O +
cefotetan O -
, O +
suggesting O +
the O +
concomitant O +
formation O +
of O +
warm O -
- O -
reactive O +
autoantibodies O -
. O +

These O +
observations O -
, O +
in O +
conjunction O +
with O +
clinical O +
and O +
laboratory O +
evidence O +
of O +
extravascular O +
hemolysis B-Disease -
, O +
are O +
consistent O +
with O +
drug O -
- O -
induced O +
hemolytic B-Disease +
anemia I-Disease -
, O +
possibly O +
involving O +
both O +
drug O -
- O -
adsorption O +
and O +
autoantibody O +
formation O +
mechanisms O -
. O +

This O +
case O +
emphasizes O +
the O +
need O +
for O +
increased O +
awareness O +
of O +
hemolytic O +
reactions O +
to O +
all O +
cephalosporins O -
. O +

Ketoconazole O -
- O -
induced O +
neurologic B-Disease +
sequelae I-Disease -
. O +

A O +
77-y O -
- O -
old O +
patient O +
developed O +
weakness B-Disease +
of I-Disease +
extremities I-Disease -
, O +
legs B-Disease +
paralysis I-Disease -
, O +
dysarthria B-Disease +
and O +
tremor B-Disease +
1 O +
h O +
after O +
ingestion O +
of O +
200 O +
mg O +
ketoconazole O +
for O +
the O +
first O +
time O +
in O +
his O +
life O -
. O +

All O +
complaints O +
faded O +
away O +
within O +
24 O +
h. O +
Few O +
days O +
later O -
, O +
the O +
patient O +
used O +
another O +
200 O +
mg O +
ketoconazole O +
tablet O -
, O +
and O +
within O +
an O +
hour O +
experienced O +
a O +
similar O +
clinical O +
picture O -
, O +
which O +
resolved O +
again O +
spontaneously O +
within O +
hours O -
. O +

Laboratory O +
evaluations O -
, O +
including O +
head O +
CT O +
scan O -
, O +
were O +
normal O -
. O +

This O +
case O +
illustrates O +
the O +
need O +
for O +
close O +
vigilance O +
in O +
adverse B-Disease +
drug I-Disease +
reactions I-Disease -
, O +
particularly O +
in O +
the O +
elderly O -
. O +

Development O +
of O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
parkinsonian B-Disease +
monkeys O +
may O +
depend O +
upon O +
rate O +
of O +
symptom O +
onset O +
and/or O +
duration O +
of O +
symptoms O -
. O +

Levodopa O -
- O -
induced O +
dyskinesias B-Disease +
( O -
LIDs B-Disease -
) O +
present O +
a O +
major O +
problem O +
for O +
the O +
long O -
- O -
term O +
management O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
patients O -
. O +

Due O +
to O +
the O +
interdependence O +
of O +
risk O +
factors O +
in O +
clinical O +
populations O -
, O +
it O +
is O +
difficult O +
to O +
independently O +
examine O +
factors O +
that O +
may O +
influence O +
the O +
development O +
of O +
LIDs B-Disease -
. O +

Using O +
macaque O +
monkeys O +
with O +
different O +
types O +
of O +
MPTP O -
- O -
induced O +
parkinsonism B-Disease -
, O +
the O +
current O +
study O +
evaluated O +
the O +
degree O +
to O +
which O +
rate O +
of O +
symptom O +
progression O -
, O +
symptom O +
severity O -
, O +
and O +
response O +
to O +
and O +
duration O +
of O +
levodopa O +
therapy O +
may O +
be O +
involved O +
in O +
the O +
development O +
of O +
LIDs B-Disease -
. O +

Monkeys O +
with O +
acute O +
( O -
short O -
- O -
term O -
) O +
MPTP O +
exposure O -
, O +
rapid O +
symptom O +
onset O +
and O +
short O +
symptom O +
duration O +
prior O +
to O +
initiation O +
of O +
levodopa O +
therapy O +
developed O +
dyskinesia B-Disease +
between O +
11 O +
and O +
24 O +
days O +
of O +
daily O +
levodopa O +
administration O -
. O +

In O +
contrast O -
, O +
monkeys O +
with O +
long O -
- O -
term O +
MPTP O +
exposure O -
, O +
slow O +
symptom O +
progression O +
and/or O +
long O +
symptom O +
duration O +
prior O +
to O +
initiation O +
of O +
levodopa O +
therapy O +
were O +
more O +
resistant O +
to O +
developing O +
LIDs B-Disease +
( O -
e.g. O -
, O +
dyskinesia B-Disease +
developed O +
no O +
sooner O +
than O +
146 O +
days O +
of O +
chronic O +
levodopa O +
administration O -
) O -
. O +

All O +
animals O +
were O +
similarly O +
symptomatic O +
at O +
the O +
start O +
of O +
levodopa O +
treatment O +
and O +
had O +
similar O +
therapeutic O +
responses O +
to O +
the O +
drug O -
. O +

These O +
data O +
suggest O +
distinct O +
differences O +
in O +
the O +
propensity O +
to O +
develop O +
LIDs B-Disease +
in O +
monkeys O +
with O +
different O +
rates O +
of O +
symptom O +
progression O +
or O +
symptom O +
durations O +
prior O +
to O +
levodopa O +
and O +
demonstrate O +
the O +
value O +
of O +
these O +
models O +
for O +
further O +
studying O +
the O +
pathophysiology O +
of O +
LIDs B-Disease -
. O +

A O +
diet O +
promoting O +
sugar B-Disease +
dependency I-Disease +
causes O +
behavioral B-Disease +
cross I-Disease -
- I-Disease -
sensitization I-Disease +
to O +
a O +
low O +
dose O +
of O +
amphetamine O -
. O +

Previous O +
research O +
in O +
this O +
laboratory O +
has O +
shown O +
that O +
a O +
diet O +
of O +
intermittent O +
excessive O +
sugar O +
consumption O +
produces O +
a O +
state O +
with O +
neurochemical O +
and O +
behavioral O +
similarities O +
to O +
drug B-Disease +
dependency I-Disease -
. O +

The O +
present O +
study O +
examined O +
whether O +
female O +
rats O +
on O +
various O +
regimens O +
of O +
sugar O +
access O +
would O +
show O +
behavioral B-Disease +
cross I-Disease -
- I-Disease -
sensitization I-Disease +
to O +
a O +
low O +
dose O +
of O +
amphetamine O -
. O +

After O +
a O +
30-min O +
baseline O +
measure O +
of O +
locomotor O +
activity O +
( O -
day O +
0 O -
) O -
, O +
animals O +
were O +
maintained O +
on O +
a O +
cyclic O +
diet O +
of O +
12-h O +
deprivation O +
followed O +
by O +
12-h O +
access O +
to O +
10 O -
% O +
sucrose O +
solution O +
and O +
chow O +
pellets O +
( O -
12 O +
h O +
access O +
starting O +
4 O +
h O +
after O +
onset O +
of O +
the O +
dark O +
period O -
) O +
for O +
21 O +
days O -
. O +

Locomotor O +
activity O +
was O +
measured O +
again O +
for O +
30 O +
min O +
at O +
the O +
beginning O +
of O +
days O +
1 O +
and O +
21 O +
of O +
sugar O +
access O -
. O +

Beginning O +
on O +
day O +
22 O -
, O +
all O +
rats O +
were O +
maintained O +
on O +
ad O +
libitum O +
chow O -
. O +

Nine O +
days O +
later O +
locomotor O +
activity O +
was O +
measured O +
in O +
response O +
to O +
a O +
single O +
low O +
dose O +
of O +
amphetamine O +
( O -
0.5 O +
mg O -
/ O -
kg O -
) O -
. O +

The O +
animals O +
that O +
had O +
experienced O +
cyclic O +
sucrose O +
and O +
chow O +
were O +
hyperactive B-Disease +
in O +
response O +
to O +
amphetamine O +
compared O +
with O +
four O +
control O +
groups O +
( O -
ad O +
libitum O +
10 O -
% O +
sucrose O +
and O +
chow O +
followed O +
by O +
amphetamine O +
injection O -
, O +
cyclic O +
chow O +
followed O +
by O +
amphetamine O +
injection O -
, O +
ad O +
libitum O +
chow O +
with O +
amphetamine O -
, O +
or O +
cyclic O +
10 O -
% O +
sucrose O +
and O +
chow O +
with O +
a O +
saline O +
injection O -
) O -
. O +

These O +
results O +
suggest O +
that O +
a O +
diet O +
comprised O +
of O +
alternating O +
deprivation O +
and O +
access O +
to O +
a O +
sugar O +
solution O +
and O +
chow O +
produces O +
bingeing O +
on O +
sugar O +
that O +
leads O +
to O +
a O +
long O +
lasting O +
state O +
of O +
increased O +
sensitivity O +
to O +
amphetamine O -
, O +
possibly O +
due O +
to O +
a O +
lasting O +
alteration O +
in O +
the O +
dopamine O +
system O -
. O +

Use O +
of O +
dexamethasone O +
with O +
mesna O +
for O +
the O +
prevention O +
of O +
ifosfamide O -
- O -
induced O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

AIM O -
: O +
Hemorrhagic B-Disease +
cystitis B-Disease +
( O -
HC B-Disease -
) O +
is O +
a O +
limiting O +
side O -
- O -
effect O +
of O +
chemotherapy O +
with O +
ifosfamide O +
( O -
IFS O -
) O -
. O +

In O +
the O +
study O +
presented O +
here O -
, O +
we O +
investigated O +
the O +
use O +
of O +
dexamethasone O +
in O +
combination O +
with O +
mesna O +
for O +
the O +
prevention O +
of O +
IFS O -
- O -
induced O +
HC B-Disease -
. O +

METHODS O -
: O +
Male O +
Wistar O +
rats O +
( O -
150 O -
- O -
200 O +
g O -
; O +
6 O +
rats O +
per O +
group O -
) O +
were O +
treated O +
with O +
saline O +
or O +
mesna O +
5 O +
min O +
( O -
i.p O -
. O -
) O +
before O +
and O +
2 O +
and O +
6 O +
h O +
after O +
( O -
v.o O -
. O -
) O +
administration O +
of O +
IFS O -
. O +

One O -
, O +
two O +
or O +
three O +
doses O +
of O +
mesna O +
were O +
replaced O +
with O +
dexamethasone O +
alone O +
or O +
with O +
dexamethasone O +
plus O +
mesna O -
. O +

Cystitis B-Disease +
was O +
evaluated O +
24 O +
h O +
after O +
its O +
induction O +
by O +
the O +
changes O +
in O +
bladder O +
wet O +
weight O +
and O +
by O +
macroscopic O +
and O +
microscopic O +
analysis O -
. O +

RESULTS O -
: O +
The O +
replacement O +
of O +
the O +
last O +
dose O +
or O +
the O +
last O +
two O +
doses O +
of O +
mesna O +
with O +
dexamethasone O +
reduced O +
the O +
increase O +
in O +
bladder O +
wet O +
weight O +
induced O +
by O +
IFS O +
by O +
84.79 O -
% O +
and O +
89.13 O -
% O -
, O +
respectively O -
. O +

In O +
addition O -
, O +
it O +
almost O +
abolished O +
the O +
macroscopic O +
and O +
microscopic O +
alterations O +
induced O +
by O +
IFS O -
. O +

Moreover O -
, O +
the O +
addition O +
of O +
dexamethasone O +
to O +
the O +
last O +
two O +
doses O +
of O +
mesna O +
was O +
more O +
efficient O +
than O +
three O +
doses O +
of O +
mesna O +
alone O +
when O +
evaluated O +
microscopically O -
. O +

CONCLUSION O -
: O +
Dexamethasone O +
in O +
combination O +
with O +
mesna O +
was O +
efficient O +
in O +
blocking O +
IFS O -
- O -
induced O +
HC B-Disease -
. O +

However O -
, O +
the O +
replacement O +
of O +
last O +
two O +
doses O +
of O +
mesna O +
with O +
saline O +
or O +
all O +
of O +
the O +
mesna O +
doses O +
with O +
dexamethasone O +
did O +
not O +
prevent O +
HC B-Disease -
. O +

Reversible O +
dilated B-Disease +
cardiomyopathy I-Disease +
related O +
to O +
amphotericin O +
B O +
therapy O -
. O +

We O +
describe O +
a O +
patient O +
who O +
developed O +
dilated B-Disease +
cardiomyopathy I-Disease +
and O +
clinical O +
congestive O +
heart B-Disease +
failure I-Disease +
after O +
2 O +
months O +
of O +
therapy O +
with O +
amphotericin O +
B O +
( O -
AmB O -
) O +
for O +
disseminated O +
coccidioidomycosis B-Disease -
. O +

His O +
echocardiographic O +
abnormalities O +
and O +
heart B-Disease +
failure I-Disease +
resolved O +
after O +
posaconazole O +
was O +
substituted O +
for O +
AmB. O +
It O +
is O +
important O +
to O +
recognize O +
the O +
rare O +
and O +
potentially O +
reversible O +
toxicity B-Disease +
of O +
AmB. O +

NO O -
- O -
induced O +
migraine B-Disease +
attack O -
: O +
strong O +
increase O +
in O +
plasma O +
calcitonin O +
gene O -
- O -
related O +
peptide O +
( O -
CGRP O -
) O +
concentration O +
and O +
negative O +
correlation O +
with O +
platelet O +
serotonin O +
release O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
changes O +
in O +
the O +
plasma O +
calcitonin O +
gene O -
- O -
related O +
peptide O +
( O -
CGRP O -
) O +
concentration O +
and O +
platelet O +
serotonin O +
( O -
5-hydroxytriptamine O -
, O +
5-HT O -
) O +
content O +
during O +
the O +
immediate O +
headache B-Disease +
and O +
the O +
delayed O +
genuine O +
migraine B-Disease +
attack O +
provoked O +
by O +
nitroglycerin O -
. O +

Fifteen O +
female O +
migraineurs B-Disease +
( I-Disease -
without I-Disease +
aura I-Disease -
) I-Disease +
and O +
eight O +
controls O +
participated O +
in O +
the O +
study O -
. O +

Sublingual O +
nitroglycerin O +
( O -
0.5 O +
mg O -
) O +
was O +
administered O -
. O +

Blood O +
was O +
collected O +
from O +
the O +
antecubital O +
vein O +
four O +
times O -
: O +
60 O +
min O +
before O +
and O +
after O +
the O +
nitroglycerin O +
application O -
, O +
and O +
60 O +
and O +
120 O +
min O +
after O +
the O +
beginning O +
of O +
the O +
migraine B-Disease +
attack O +
( O -
mean O +
344 O +
and O +
404 O +
min O -
; O +
12 O +
subjects O -
) O -
. O +

In O +
those O +
subjects O +
who O +
had O +
no O +
migraine B-Disease +
attack O +
( O -
11 O +
subjects O -
) O +
a O +
similar O +
time O +
schedule O +
was O +
used O -
. O +

Plasma O +
CGRP O +
concentration O +
increased O +
significantly O +
( O -
P<0.01 O -
) O +
during O +
the O +
migraine B-Disease +
attack O +
and O +
returned O +
to O +
baseline O +
after O +
the O +
cessation O +
of O +
the O +
migraine B-Disease -
. O +

In O +
addition O -
, O +
both O +
change O +
and O +
peak O -
, O +
showed O +
significant O +
positive O +
correlations O +
with O +
migraine B-Disease +
headache B-Disease +
intensity O +
( O -
P<0.001 O -
) O -
. O +

However O -
, O +
plasma O +
CGRP O +
concentrations O +
failed O +
to O +
change O +
during O +
immediate O +
headache B-Disease +
and O +
in O +
the O +
subjects O +
with O +
no O +
migraine B-Disease +
attack O -
. O +

Basal O +
CGRP O +
concentration O +
was O +
significantly O +
higher O +
and O +
platelet O +
5-HT O +
content O +
tended O +
to O +
be O +
lower O +
in O +
subjects O +
who O +
experienced O +
a O +
migraine B-Disease +
attack O -
. O +

Platelet O +
serotonin O +
content O +
decreased O +
significantly O +
( O -
P<0.01 O -
) O +
after O +
nitroglycerin O +
in O +
subjects O +
with O +
no O +
migraine B-Disease +
attack O +
but O +
no O +
consistent O +
change O +
was O +
observed O +
in O +
patients O +
with O +
migraine B-Disease +
attack O -
. O +

In O +
conclusion O -
, O +
the O +
fact O +
that O +
plasma O +
CGRP O +
concentration O +
correlates O +
with O +
the O +
timing O +
and O +
severity O +
of O +
a O +
migraine B-Disease +
headache B-Disease +
suggests O +
a O +
direct O +
relationship O +
between O +
CGRP O +
and O +
migraine B-Disease -
. O +

In O +
contrast O -
, O +
serotonin O +
release O +
from O +
platelets O +
does O +
not O +
provoke O +
migraine B-Disease -
, O +
it O +
may O +
even O +
counteract O +
the O +
headache B-Disease +
and O +
the O +
concomitant O +
CGRP O +
release O +
in O +
this O +
model O -
. O +

Hyperbaric O +
oxygen O +
therapy O +
for O +
control O +
of O +
intractable O +
cyclophosphamide O -
- O -
induced O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

We O +
report O +
a O +
case O +
of O +
intractable O +
hemorrhagic B-Disease +
cystitis B-Disease +
due O +
to O +
cyclophosphamide O +
therapy O +
for O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
. O +

Conservative O +
treatment O -
, O +
including O +
bladder O +
irrigation O +
with O +
physiological O +
saline O +
and O +
instillation O +
of O +
prostaglandin O +
F2 O +
alpha O -
, O +
failed O +
to O +
totally O +
control O +
hemorrhage B-Disease -
. O +

We O +
then O +
used O +
hyperbaric O +
oxygen O +
at O +
an O +
absolute O +
pressure O +
of O +
2 O +
atm O -
, O +
5 O +
days O +
a O +
week O +
for O +
8 O +
consecutive O +
weeks O -
. O +

The O +
bleeding B-Disease +
ceased O +
completely O +
by O +
the O +
end O +
of O +
treatment O +
and O +
the O +
patient O +
remained O +
free O +
of O +
hematuria B-Disease +
thereafter O -
. O +

No O +
side O +
effect O +
was O +
noted O +
during O +
the O +
course O +
of O +
therapy O -
. O +

In O +
future O -
, O +
this O +
form O +
of O +
therapy O +
can O +
offer O +
a O +
safe O +
alternative O +
in O +
the O +
treatment O +
of O +
cyclophosphamide O -
- O -
induced O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

Acute B-Disease +
psychosis I-Disease +
due O +
to O +
treatment O +
with O +
phenytoin O +
in O +
a O +
nonepileptic O +
patient O -
. O +

The O +
development O +
of O +
psychosis B-Disease +
related O +
to O +
antiepileptic O +
drug O +
treatment O +
is O +
usually O +
attributed O +
to O +
the O +
interaction O +
between O +
the O +
epileptic B-Disease +
brain O +
substratum O +
and O +
the O +
antiepileptic O +
drugs O -
. O +

The O +
case O +
of O +
a O +
nonepileptic O +
patient O +
who O +
developed O +
psychosis B-Disease +
following O +
phenytoin O +
treatment O +
for O +
trigeminal B-Disease +
neuralgia I-Disease +
is O +
described O -
. O +

This O +
case O +
suggests O +
that O +
the O +
psychotic B-Disease +
symptoms I-Disease +
that O +
occur O +
following O +
phenytoin O +
treatment O +
in O +
some O +
epileptic B-Disease +
patients O +
may O +
be O +
the O +
direct O +
result O +
of O +
medication O -
, O +
unrelated O +
to O +
seizures B-Disease -
. O +

Effect O +
of O +
some O +
convulsants O +
on O +
the O +
protective O +
activity O +
of O +
loreclezole O +
and O +
its O +
combinations O +
with O +
valproate O +
or O +
clonazepam O +
in O +
amygdala O -
- O -
kindled O +
rats O -
. O +

Loreclezole O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
exerted O +
a O +
significant O +
protective O +
action O +
in O +
amygdala O -
- O -
kindled O +
rats O -
, O +
reducing O +
both O +
seizure B-Disease +
and O +
afterdischarge O +
durations O -
. O +

The O +
combinations O +
of O +
loreclezole O +
( O -
2.5 O +
mg O -
/ O -
kg O -
) O +
with O +
valproate O -
, O +
clonazepam O -
, O +
or O +
carbamazepine O +
( O -
applied O +
at O +
their O +
subprotective O +
doses O -
) O +
also O +
exhibited O +
antiseizure O +
effect O +
in O +
this O +
test O -
. O +

However O -
, O +
only O +
two O +
first O +
combinations O +
occurred O +
to O +
be O +
of O +
pharmacodynamic O +
nature O -
. O +

Among O +
several O +
chemoconvulsants O -
, O +
bicuculline O -
, O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartic O +
acid O +
and O +
BAY O +
k-8644 O +
( O -
the O +
opener O +
of O +
L O -
- O -
type O +
calcium O +
channels O -
) O +
reversed O +
the O +
protective O +
activity O +
of O +
loreclezole O +
alone O +
and O +
its O +
combination O +
with O +
valproate O -
. O +

On O +
the O +
other O +
hand O -
, O +
bicuculline O -
, O +
aminophylline O +
and O +
BAY O +
k-8644 O +
inhibited O +
the O +
anticonvulsive O +
action O +
of O +
loreclezole O +
combined O +
with O +
clonazepam O -
. O +

The O +
results O +
support O +
the O +
hypothesis O +
that O +
the O +
protective O +
activity O +
of O +
loreclezole O +
and O +
its O +
combinations O +
with O +
other O +
antiepileptics O +
may O +
involve O +
potentiation O +
of O +
GABAergic O +
neurotransmission O +
and O +
blockade O +
of O +
L O -
- O -
type O +
of O +
calcium O +
channels O -
. O +

Mitochondrial O +
DNA O +
and O +
its O +
respiratory O +
chain O +
products O +
are O +
defective O +
in O +
doxorubicin O +
nephrosis B-Disease -
. O +

BACKGROUND O -
: O +
Doxorubicin O +
induces O +
a O +
self O -
- O -
perpetuating O +
nephropathy B-Disease +
characterized O +
by O +
early O +
glomerular B-Disease +
and I-Disease +
late I-Disease -
- I-Disease -
onset I-Disease +
tubular I-Disease +
lesions I-Disease +
in O +
rats O -
. O +

We O +
investigated O +
the O +
potential O +
role O +
of O +
mitochondrial B-Disease +
injury I-Disease +
in O +
the O +
onset O +
of O +
these O +
lesions O -
. O +

METHODS O -
: O +
Rats O +
were O +
treated O +
with O +
intravenous O +
doxorubicin O +
( O -
1 O +
mg O +
kg O -
( O -
-1 O -
) O +
week O -
( O -
-1 O -
) O -
) O +
for O +
7 O +
weeks O +
and O +
were O +
sacrificed O +
either O +
1 O +
week O +
( O -
' O -
short O -
- O -
term O -
' O -
) O +
or O +
30 O +
weeks O +
( O -
' O -
long O -
- O -
term O -
' O -
) O +
following O +
the O +
last O +
dose O -
. O +

Additional O +
rats O +
received O +
a O +
single O +
dose O +
either O +
6 O +
days O +
or O +
2 O +
h O +
prior O +
to O +
euthanasia O -
. O +

All O +
rats O +
were O +
killed O +
at O +
48 O +
weeks O +
of O +
age O -
. O +

Glomerular B-Disease +
and I-Disease +
tubular I-Disease +
injury I-Disease +
was O +
monitored O +
and O +
correlated O +
to O +
the O +
activity O +
or O +
expression O +
of O +
respiratory O +
chain O +
components O -
. O +

Finally O -
, O +
we O +
quantified O +
both O +
nuclear O +
and O +
mitochondrial O +
DNA O +
( O -
mtDNA O -
) O +
as O +
well O +
as O +
superoxide O +
production O +
and O +
the O +
4834 O +
base O +
pair O +
' O -
common O -
' O +
mtDNA O +
deletion O -
. O +

RESULTS O -
: O +
The O +
' O -
long O -
- O -
term O -
' O +
group O +
had O +
significant O +
glomerular B-Disease +
and I-Disease +
tubular I-Disease +
lesions I-Disease -
, O +
depressed O +
activities O +
of O +
mtDNA O -
- O -
encoded O +
NADH O +
dehydrogenase O +
and O +
cytochrome O -
- O -
c O +
oxidase O +
( O -
COX O -
) O +
and O +
increased O +
citrate O +
synthase O +
activity O -
. O +

In O +
addition O -
, O +
expression O +
of O +
the O +
mtDNA O -
- O -
encoded O +
COX O +
subunit O +
I O +
was O +
reduced O +
and O +
mtDNA O +
levels O +
were O +
decreased O -
. O +

In O +
' O -
short O -
- O -
term O -
' O +
rats O -
, O +
there O +
were O +
fewer O +
tubular B-Disease +
lesions I-Disease -
, O +
but O +
similar O +
numbers O +
of O +
glomerular B-Disease +
lesions I-Disease +
activity O -
. O +

Among O +
all O +
animals O -
, O +
glomerular B-Disease +
and I-Disease +
tubular I-Disease +
injury I-Disease +
were O +
inversely O +
correlated O +
with O +
mtDNA O +
levels O -
, O +
mtDNA O -
- O -
encoded O +
respiratory O +
chain O +
activities O +
and O +
with O +
the O +
expression O +
of O +
the O +
mtDNA O -
- O -
encoded O +
respiratory O +
chain O +
subunit O +
COX O -
- O -
I. O +
Injury O +
was O +
positively O +
correlated O +
with O +
superoxide O +
production O +
and O +
the O +
activities O +
of O +
nucleus O -
- O -
encoded O +
mitochondrial O +
or O +
cytoplasmic O +
enzymes O -
. O +

Kidneys O +
from O +
the O +
' O -
long O -
- O -
term O -
' O +
group O +
showed O +
more O +
mtDNA O +
deletions O +
than O +
in O +
' O -
short O -
- O -
term O -
' O +
animals O +
and O +
these O +
were O +
not O +
observed O +
in O +
the O +
other O +
groups O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
an O +
important O +
role O +
for O +
quantitative O +
and O +
qualitative O +
mtDNA O +
alterations O +
through O +
the O +
reduction O +
of O +
mtDNA O -
- O -
encoded O +
respiratory O +
chain O +
function O +
and O +
induction O +
of O +
superoxide O +
in O +
doxorubicin O -
- O -
induced O +
renal B-Disease +
lesions I-Disease -
. O +

A O +
randomized O -
, O +
placebo O -
- O -
controlled O -
, O +
crossover O +
study O +
of O +
ephedrine O +
for O +
SSRI O -
- O -
induced O +
female O +
sexual B-Disease +
dysfunction I-Disease -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
ephedrine O -
, O +
an O +
alpha- O +
and O +
beta O -
- O -
adrenergic O +
agonist O +
previously O +
shown O +
to O +
enhance O +
genital O +
blood O +
flow O +
in O +
women O -
, O +
has O +
beneficial O +
effects O +
in O +
reversing O +
antidepressant O -
- O -
induced O +
sexual B-Disease +
dysfunction I-Disease -
. O +

Nineteen O +
sexually B-Disease +
dysfunctional I-Disease +
women O +
receiving O +
either O +
fluoxetine O -
, O +
sertraline O -
, O +
or O +
paroxetine O +
participated O +
in O +
an O +
eight O -
- O -
week O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
cross O -
- O -
over O +
study O +
of O +
the O +
effects O +
of O +
ephedrine O +
( O -
50 O +
mg O -
) O +
on O +
self O -
- O -
report O +
measures O +
of O +
sexual O +
desire O -
, O +
arousal O -
, O +
orgasm O -
, O +
and O +
sexual O +
satisfaction O -
. O +

Although O +
there O +
were O +
significant O +
improvements O +
relative O +
to O +
baseline O +
in O +
sexual O +
desire O +
and O +
orgasm O +
intensity O -
/ O -
pleasure O +
on O +
50 O +
mg O +
ephedrine O +
1-hr O +
prior O +
to O +
sexual O +
activity O -
, O +
significant O +
improvements O +
in O +
these O +
measures O -
, O +
as O +
well O +
as O +
in O +
sexual O +
arousal O +
and O +
orgasmic O +
ability O +
also O +
were O +
noted O +
with O +
placebo O -
. O +

These O +
findings O +
highlight O +
the O +
importance O +
of O +
conducting O +
placebo O -
- O -
controlled O +
trials O +
for O +
this O +
condition O -
. O +

Does O +
hormone O +
therapy O +
for O +
the O +
treatment O +
of O +
breast B-Disease +
cancer I-Disease +
have O +
a O +
detrimental B-Disease +
effect I-Disease +
on I-Disease +
memory I-Disease +
and B-Disease +
cognition I-Disease -
? O +

A O +
pilot O +
study O -
. O +

This O +
pilot O +
study O +
examines O +
whether O +
hormone O +
therapy O +
for O +
breast B-Disease +
cancer I-Disease +
affects O +
cognition O -
. O +

Patients O +
participating O +
in O +
a O +
randomised O +
trial O +
of O +
anastrozole O -
, O +
tamoxifen O +
alone O +
or O +
combined O +
( O -
ATAC O -
) O +
( O -
n=94 O -
) O +
and O +
a O +
group O +
of O +
women O +
without O +
breast B-Disease +
cancer I-Disease +
( O -
n=35 O -
) O +
completed O +
a O +
battery O +
of O +
neuropsychological O +
measures O -
. O +

Compared O +
with O +
the O +
control O +
group O -
, O +
the O +
patients O +
were O +
impaired O +
on O +
a O +
processing O +
speed O +
task O +
( O -
p=0.032 O -
) O +
and O +
on O +
a O +
measure O +
of O +
immediate O +
verbal O +
memory O +
( O -
p=0.026 O -
) O +
after O +
controlling O +
for O +
the O +
use O +
of O +
hormone O +
replacement O +
therapy O +
in O +
both O +
groups O -
. O +

Patient O +
group O +
performance O +
was O +
not O +
significantly O +
related O +
to O +
length O +
of O +
treatment O +
or O +
measures O +
of O +
psychological O +
morbidity O -
. O +

The O +
results O +
showed O +
specific O +
impairments O +
in O +
processing O +
speed O +
and O +
verbal O +
memory O +
in O +
women O +
receiving O +
hormonal O +
therapy O +
for O +
the O +
treatment O +
of O +
breast B-Disease +
cancer I-Disease -
. O +

Verbal O +
memory O +
may O +
be O +
especially O +
sensitive O +
to O +
changes O +
in O +
oestrogen O +
levels O -
, O +
a O +
finding O +
commonly O +
reported O +
in O +
studies O +
of O +
hormone O +
replacement O +
therapy O +
in O +
healthy O +
women O -
. O +

In O +
view O +
of O +
the O +
increased O +
use O +
of O +
hormone O +
therapies O +
in O +
an O +
adjuvant O +
and O +
preventative O +
setting O +
their O +
impact O +
on O +
cognitive O +
functioning O +
should O +
be O +
investigated O +
more O +
thoroughly O -
. O +

Risks O +
of O +
the O +
consumption O +
of O +
beverages O +
containing O +
quinine O -
. O +

Although O +
the O +
United O +
States O +
Food O +
and O +
Drug O +
Administration O +
banned O +
its O +
use O +
for O +
nocturnal B-Disease +
leg I-Disease +
cramps I-Disease +
due O +
to O +
lack O +
of O +
safety O +
and O +
efficacy O -
, O +
quinine O +
is O +
widely O +
available O +
in O +
beverages O +
including O +
tonic O +
water O +
and O +
bitter O +
lemon O -
. O +

Numerous O +
anecdotal O +
reports O +
suggest O +
that O +
products O +
containing O +
quinine O +
may O +
produce O +
neurological B-Disease +
complications I-Disease -
, O +
including O +
confusion B-Disease -
, O +
altered O +
mental O +
status O -
, O +
seizures B-Disease -
, O +
and O +
coma B-Disease -
, O +
particularly O +
in O +
older O +
women O -
. O +

Psychologists O +
need O +
to O +
inquire O +
about O +
consumption O +
of O +
quinine O -
- O -
containing O +
beverages O +
as O +
part O +
of O +
an O +
evaluation O +
process O -
. O +

Expression O +
of O +
p300 O +
protects O +
cardiac O +
myocytes O +
from O +
apoptosis O +
in O +
vivo O -
. O +

Doxorubicin O +
is O +
an O +
anti O -
- O -
tumor B-Disease +
agent O +
that O +
represses O +
cardiac O -
- O -
specific O +
gene O +
expression O +
and O +
induces O +
myocardial O +
cell O +
apoptosis O -
. O +

Doxorubicin O +
depletes O +
cardiac O +
p300 O -
, O +
a O +
transcriptional O +
coactivator O +
that O +
is O +
required O +
for O +
the O +
maintenance O +
of O +
the O +
differentiated O +
phenotype O +
of O +
cardiac O +
myocytes O -
. O +

However O -
, O +
the O +
role O +
of O +
p300 O +
in O +
protection O +
against O +
doxorubicin O -
- O -
induced O +
apoptosis O +
is O +
unknown O -
. O +

Transgenic O +
mice O +
overexpressing O +
p300 O +
in O +
the O +
heart O +
and O +
wild O -
- O -
type O +
mice O +
were O +
subjected O +
to O +
doxorubicin O +
treatment O -
. O +

Compared O +
with O +
wild O -
- O -
type O +
mice O -
, O +
transgenic O +
mice O +
exhibited O +
higher O +
survival O +
rate O +
as O +
well O +
as O +
more O +
preserved O +
left O +
ventricular O +
function O +
and O +
cardiac O +
expression O +
of O +
alpha O -
- O -
sarcomeric O +
actin O -
. O +

Doxorubicin O +
induced O +
myocardial O +
cell O +
apoptosis O +
in O +
wild O -
- O -
type O +
mice O +
but O +
not O +
in O +
transgenic O +
mice O -
. O +

Expression O +
of O +
p300 O +
increased O +
the O +
cardiac O +
level O +
of O +
bcl-2 O +
and O +
mdm-2 O -
, O +
but O +
not O +
that O +
of O +
p53 O +
or O +
other O +
members O +
of O +
the O +
bcl-2 O +
family O -
. O +

These O +
findings O +
demonstrate O +
that O +
overexpression O +
of O +
p300 O +
protects O +
cardiac O +
myocytes O +
from O +
doxorubicin O -
- O -
induced O +
apoptosis O +
and O +
reduces O +
the O +
extent O +
of O +
acute O +
heart B-Disease +
failure I-Disease +
in O +
adult O +
mice O +
in O +
vivo O -
. O +

Transient O +
platypnea B-Disease -
- I-Disease -
orthodeoxia I-Disease -
- I-Disease -
like I-Disease +
syndrome I-Disease +
induced O +
by O +
propafenone O +
overdose B-Disease +
in O +
a O +
young O +
woman O +
with O +
Ebstein B-Disease -
's I-Disease +
anomaly I-Disease -
. O +

In O +
this O +
report O +
we O +
describe O +
the O +
case O +
of O +
a O +
37-year O -
- O -
old O +
white O +
woman O +
with O +
Ebstein B-Disease -
's I-Disease +
anomaly I-Disease -
, O +
who O +
developed O +
a O +
rare O +
syndrome O +
called O +
platypnea B-Disease -
- I-Disease -
orthodeoxia I-Disease -
, O +
characterized O +
by O +
massive O +
right O -
- O -
to O -
- O -
left O +
interatrial O +
shunting O +
with O +
transient O +
profound O +
hypoxia B-Disease +
and O +
cyanosis B-Disease -
. O +

This O +
shunt O +
of O +
blood O +
via O +
a O +
patent B-Disease +
foramen I-Disease +
ovale I-Disease +
occurred O +
in O +
the O +
presence O +
of O +
a O +
normal O +
pulmonary O +
artery O +
pressure O -
, O +
and O +
was O +
probably O +
precipitated O +
by O +
a O +
propafenone O +
overdose B-Disease -
. O +

This O +
drug O +
caused O +
biventricular B-Disease +
dysfunction I-Disease -
, O +
due O +
to O +
its O +
negative O +
inotropic O +
effect O -
, O +
and O +
hypotension B-Disease -
, O +
due O +
to O +
its O +
peripheral O +
vasodilatory O +
effect O -
. O +

These O +
effects O +
gave O +
rise O +
to O +
an O +
increase O +
in O +
the O +
right O +
atrial O +
pressure O +
and O +
a O +
decrease O +
in O +
the O +
left O +
one O +
with O +
a O +
consequent O +
stretching O +
of O +
the O +
foramen O +
ovale O +
and O +
the O +
creation O +
of O +
massive O +
right O -
- O -
to O -
- O -
left O +
shunting O -
. O +

In O +
our O +
case O +
this O +
interatrial O +
shunt O +
was O +
very O +
accurately O +
detected O +
at O +
bubble O +
contrast O +
echocardiography O -
. O +

Methimazole O -
- O -
induced O +
cholestatic B-Disease +
jaundice I-Disease -
. O +

Methimazole O +
is O +
a O +
widely O +
used O +
and O +
generally O +
well O -
- O -
tolerated O +
antithyroid O +
agent O -
. O +

A O +
43-year O -
- O -
old O +
woman O +
had O +
severe O +
jaundice B-Disease +
and O +
itching B-Disease +
1 O +
month O +
after O +
receiving O +
methimazole O +
( O -
10 O +
mg O +
tid O -
) O +
and O +
propranolol O +
( O -
20 O +
mg O +
tid O -
) O +
for O +
treatment O +
of O +
hyperthyroidism B-Disease -
. O +

The O +
patient O +
continued O +
treatment O +
for O +
another O +
4 O +
days O +
after O +
the O +
appearance O +
of O +
jaundice B-Disease +
until O +
she O +
finished O +
both O +
medications O -
. O +

When O +
seen O +
at O +
the O +
emergency O +
department O +
2 O +
weeks O +
later O -
, O +
she O +
still O +
had O +
severe O +
icterus B-Disease -
, O +
pruritus B-Disease -
, O +
and O +
hyperbilirubinemia B-Disease -
, O +
formed O +
mainly O +
of O +
the O +
conjugated O +
fraction O -
. O +

Methimazole O -
- O -
induced O +
cholestasis B-Disease +
was O +
diagnosed O -
, O +
and O +
propranolol O +
therapy O +
was O +
resumed O -
. O +

Over O +
the O +
following O +
9 O +
days O -
, O +
the O +
symptoms O +
improved O +
and O +
plasma O +
bilirubin O +
levels O +
were O +
normal O +
after O +
12 O +
weeks O +
without O +
methimazole O -
. O +

In O +
rare O +
cases O +
within O +
the O +
first O +
few O +
weeks O +
of O +
therapy O -
, O +
this O +
drug O +
can O +
cause O +
severe O +
and O +
reversible O +
cholestatic B-Disease +
jaundice I-Disease -
. O +

Physicians O +
and O +
patients O +
should O +
be O +
aware O +
of O +
this O +
adverse O +
effect O +
so O +
that O -
, O +
upon O +
occurrence O -
, O +
they O +
can O +
discontinue O +
methimazole O +
therapy O +
and O +
avoid O +
unnecessary O +
invasive O +
procedures O -
. O +

Noxious O +
chemical O +
stimulation O +
of O +
rat O +
facial O +
mucosa O +
increases O +
intracranial O +
blood O +
flow O +
through O +
a O +
trigemino O -
- O -
parasympathetic O +
reflex O -
-- O -
an O +
experimental O +
model O +
for O +
vascular B-Disease +
dysfunctions I-Disease +
in O +
cluster B-Disease +
headache I-Disease -
. O +

Cluster B-Disease +
headache I-Disease +
is O +
characterized O +
by O +
typical O +
autonomic O +
dysfunctions O +
including O +
facial O +
and O +
intracranial B-Disease +
vascular I-Disease +
disturbances I-Disease -
. O +

Both O +
the O +
trigeminal O +
and O +
the O +
cranial O +
parasympathetic O +
systems O +
may O +
be O +
involved O +
in O +
mediating O +
these O +
dysfunctions O -
. O +

An O +
experimental O +
model O +
was O +
developed O +
in O +
the O +
rat O +
to O +
measure O +
changes O +
in O +
lacrimation O +
and O +
intracranial O +
blood O +
flow O +
following O +
noxious O +
chemical O +
stimulation O +
of O +
facial O +
mucosa O -
. O +

Blood O +
flow O +
was O +
monitored O +
in O +
arteries O +
of O +
the O +
exposed O +
cranial O +
dura O +
mater O +
and O +
the O +
parietal O +
cortex O +
using O +
laser O +
Doppler O +
flowmetry O -
. O +

Capsaicin O +
( O -
0.01 O -
- O -
1 O +
mm O -
) O +
applied O +
to O +
oral O +
or O +
nasal O +
mucosa O +
induced O +
increases B-Disease +
in I-Disease +
dural I-Disease +
and I-Disease +
cortical I-Disease +
blood I-Disease +
flow I-Disease +
and O +
provoked O +
lacrimation O -
. O +

These O +
responses O +
were O +
blocked O +
by O +
systemic O +
pre O -
- O -
administration O +
of O +
hexamethonium O +
chloride O +
( O -
20 O +
mg O -
/ O -
kg O -
) O -
. O +

The O +
evoked O +
increases B-Disease +
in I-Disease +
dural I-Disease +
blood I-Disease +
flow I-Disease +
were O +
also O +
abolished O +
by O +
topical O +
pre O -
- O -
administration O +
of O +
atropine O +
( O -
1 O +
mm O -
) O +
and O +
[ O -
Lys1 O -
, O +
Pro2,5 O -
, O +
Arg3,4 O -
, O +
Tyr6 O -
] O -
-VIP O +
( O -
0.1 O +
mm O -
) O -
, O +
a O +
vasoactive O +
intestinal O +
polypeptide O +
( O -
VIP O -
) O +
antagonist O -
, O +
onto O +
the O +
exposed O +
dura O +
mater O -
. O +

We O +
conclude O +
that O +
noxious O +
stimulation O +
of O +
facial O +
mucosa O +
increases O +
intracranial O +
blood O +
flow O +
and O +
lacrimation O +
via O +
a O +
trigemino O -
- O -
parasympathetic O +
reflex O -
. O +

The O +
blood O +
flow O +
responses O +
seem O +
to O +
be O +
mediated O +
by O +
the O +
release O +
of O +
acetylcholine O +
and O +
VIP O +
within O +
the O +
meninges O -
. O +

Similar O +
mechanisms O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
cluster B-Disease +
headache I-Disease -
. O +

Organophosphate O -
- O -
induced O +
convulsions B-Disease +
and O +
prevention O +
of O +
neuropathological B-Disease +
damages I-Disease -
. O +

Such O +
organophosphorus O +
( O -
OP O -
) O +
compounds O +
as O +
diisopropylfluorophosphate O +
( O -
DFP O -
) O -
, O +
sarin O +
and O +
soman O +
are O +
potent O +
inhibitors O +
of O +
acetylcholinesterases O +
( O -
AChEs O -
) O +
and O +
butyrylcholinesterases O +
( O -
BChEs O -
) O -
. O +

The O +
acute O +
toxicity B-Disease +
of O +
OPs O +
is O +
the O +
result O +
of O +
their O +
irreversible O +
binding O +
with O +
AChEs O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
, O +
which O +
elevates O +
acetylcholine O +
( O -
ACh O -
) O +
levels O -
. O +

The O +
protective O +
action O +
of O +
subcutaneously O +
( O -
SC O -
) O +
administered O +
antidotes O +
or O +
their O +
combinations O +
in O +
DFP O +
( O -
2.0 O +
mg O -
/ O -
kg O +
BW O -
) O +
intoxication O +
was O +
studied O +
in O +
9 O -
- O -
10-weeks O -
- O -
old O +
Han O -
- O -
Wistar O +
male O +
rats O -
. O +

The O +
rats O +
received O +
AChE O +
reactivator O +
pralidoxime-2-chloride O +
( O -
2PAM O -
) O +
( O -
30.0 O +
mg O -
/ O -
kg O +
BW O -
) O -
, O +
anticonvulsant O +
diazepam O +
( O -
2.0 O +
mg O -
/ O -
kg O +
BW O -
) O -
, O +
A O -
( O -
1 O -
) O -
-adenosine O +
receptor O +
agonist O +
N O -
( O -
6 O -
) O -
-cyclopentyl O +
adenosine O +
( O -
CPA O -
) O +
( O -
2.0 O +
mg O -
/ O -
kg O +
BW O -
) O -
, O +
NMDA O -
- O -
receptor O +
antagonist O +
dizocilpine O +
maleate O +
( O -
+ O -
-MK801 O +
hydrogen O +
maleate O -
) O +
( O -
2.0 O +
mg O -
/ O -
kg O +
BW O -
) O +
or O +
their O +
combinations O +
with O +
cholinolytic O +
drug O +
atropine O +
sulfate O +
( O -
50.0 O +
mg O -
/ O -
kg O +
BW O -
) O +
immediately O +
or O +
30 O +
min O +
after O +
the O +
single O +
SC O +
injection O +
of O +
DFP O -
. O +

The O +
control O +
rats O +
received O +
atropine O +
sulfate O -
, O +
but O +
also O +
saline O +
and O +
olive O +
oil O +
instead O +
of O +
other O +
antidotes O +
and O +
DFP O -
, O +
respectively O -
. O +

All O +
rats O +
were O +
terminated O +
either O +
24 O +
h O +
or O +
3 O +
weeks O +
after O +
the O +
DFP O +
injection O -
. O +

The O +
rats O +
treated O +
with O +
DFP O -
- O -
atropine O +
showed O +
severe O +
typical O +
OP O -
- O -
induced O +
toxicity B-Disease +
signs O -
. O +

When O +
CPA O -
, O +
diazepam O +
or O +
2PAM O +
was O +
given O +
immediately O +
after O +
DFP O -
- O -
atropine O -
, O +
these O +
treatments O +
prevented O -
, O +
delayed O +
or O +
shortened O +
the O +
occurrence O +
of O +
serious O +
signs O +
of O +
poisoning B-Disease -
. O +

Atropine O -
- O -
MK801 O +
did O +
not O +
offer O +
any O +
additional O +
protection O +
against O +
DFP O +
toxicity B-Disease -
. O +

In O +
conclusion O -
, O +
CPA O -
, O +
diazepam O +
and O +
2PAM O +
in O +
combination O +
with O +
atropine O +
prevented O +
the O +
occurrence O +
of O +
serious O +
signs O +
of O +
poisoning B-Disease +
and O +
thus O +
reduced O +
the O +
toxicity B-Disease +
of O +
DFP O +
in O +
rat O -
. O +

Atrial B-Disease +
fibrillation I-Disease +
following O +
chemotherapy O +
for O +
stage O +
IIIE O +
diffuse O +
large O +
B O -
- O -
cell O +
gastric B-Disease +
lymphoma I-Disease +
in O +
a O +
patient O +
with O +
myotonic B-Disease +
dystrophy I-Disease +
( O -
Steinert B-Disease -
's I-Disease +
disease I-Disease -
) O -
. O +

The O +
authors O +
describe O +
the O +
unusual O +
association O +
between O +
diffuse O +
B O -
- O -
cell O +
gastric B-Disease +
lymphoma I-Disease +
and O +
myotonic B-Disease +
dystrophy I-Disease -
, O +
the O +
most O +
common O +
form O +
of O +
adult O +
muscular B-Disease +
dystrophy I-Disease -
, O +
and O +
sudden O +
atrial B-Disease +
fibrillation I-Disease +
following O +
one O +
cycle O +
of O +
doxorubicin O -
- O -
based O +
chemotherapy O +
in O +
the O +
same O +
patient O -
. O +

Atrial B-Disease +
fibrillation I-Disease +
or O +
other O +
cardiac B-Disease +
arrhythmias I-Disease +
are O +
unusual O +
complications O +
in O +
patients O +
treated O +
with O +
chemotherapy O -
. O +

The O +
cardiac B-Disease +
toxicity I-Disease +
intrinsically O +
associated O +
with O +
the O +
aggressive O +
chemotherapy O +
employed O +
could O +
function O +
as O +
a O +
triggering O +
factor O +
for O +
the O +
arrhythmia B-Disease +
in O +
the O +
predisposed O +
myocardium O +
of O +
this O +
patient O -
. O +

Hypersensitivity B-Disease +
immune O +
reaction O +
as O +
a O +
mechanism O +
for O +
dilevalol O -
- O -
associated O +
hepatitis B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
assess O +
lymphocyte O +
reactivity O +
to O +
dilevalol O +
and O +
to O +
serum O +
containing O +
putative O +
ex O +
vivo O +
dilevalol O +
antigens O +
or O +
metabolites O +
in O +
a O +
case O +
of O +
dilevalol O -
- O -
induced O +
liver B-Disease +
injury I-Disease -
. O +

PATIENT O -
: O +
A O +
58-year O -
- O -
old O +
woman O +
with O +
a O +
clinical O +
diagnosis O +
of O +
dilevalol O -
- O -
induced O +
liver B-Disease +
injury I-Disease -
. O +

METHODS O -
: O +
Peripheral O +
blood O +
mononuclear O +
cells O +
collected O +
from O +
the O +
patient O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
a O +
solution O +
of O +
dilevalol O +
and O +
also O +
with O +
sera O +
collected O +
from O +
a O +
volunteer O +
before O +
and O +
after O +
dilevalol O +
intake O -
. O +

A O +
similar O +
protocol O +
was O +
performed O +
with O +
lymphocytes O +
from O +
a O +
healthy O +
subject O -
. O +

RESULTS O -
: O +
No O +
lymphocyte O +
proliferation O +
was O +
observed O +
either O +
in O +
the O +
patient O +
or O +
in O +
the O +
healthy O +
volunteer O +
in O +
the O +
presence O +
of O +
dilevalol O +
solutions O -
. O +

A O +
significant O +
proliferative O +
response O +
to O +
serum O +
collected O +
after O +
dilevalol O +
intake O +
was O +
observed O +
in O +
the O +
case O +
of O +
the O +
patient O +
compared O +
with O +
the O +
proliferative O +
response O +
to O +
the O +
serum O +
collected O +
before O +
the O +
drug O +
intake O -
. O +

No O +
reactivity O +
was O +
found O +
when O +
lymphocytes O +
from O +
the O +
healthy O +
subject O +
were O +
tested O +
under O +
similar O +
conditions O -
. O +

CONCLUSIONS O -
: O +
The O +
methodology O +
used O +
allowed O +
the O +
detection O +
of O +
lymphocyte O +
sensitization O +
to O +
sera O +
containing O +
ex O +
vivo O -
- O -
prepared O +
dilevalol O +
antigens O -
, O +
suggesting O +
the O +
involvement O +
of O +
an O +
immunologic O +
mechanism O +
in O +
dilevalol O -
- O -
induced O +
liver B-Disease +
injury I-Disease -
. O +

Increased O +
expression O +
and O +
apical O +
targeting O +
of O +
renal O +
ENaC O +
subunits O +
in O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease +
in O +
rats O -
. O +

Nephrotic B-Disease +
syndrome I-Disease +
is O +
often O +
accompanied O +
by O +
sodium O +
retention O +
and O +
generalized O +
edema B-Disease -
. O +

However O -
, O +
the O +
molecular O +
basis O +
for O +
the O +
decreased O +
renal O +
sodium O +
excretion O +
remains O +
undefined O -
. O +

We O +
hypothesized O +
that O +
epithelial O +
Na O +
channel O +
( O -
ENaC O -
) O +
subunit O +
dysregulation O +
may O +
be O +
responsible O +
for O +
the O +
increased O +
sodium O +
retention O -
. O +

An O +
experimental O +
group O +
of O +
rats O +
was O +
treated O +
with O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
; O +
180 O +
mg O -
/ O -
kg O +
iv O -
) O -
, O +
whereas O +
the O +
control O +
group O +
received O +
only O +
vehicle O -
. O +

After O +
7 O +
days O -
, O +
PAN O +
treatment O +
induced O +
significant O +
proteinuria B-Disease -
, O +
hypoalbuminemia B-Disease -
, O +
decreased O +
urinary O +
sodium O +
excretion O -
, O +
and O +
extensive O +
ascites B-Disease -
. O +

The O +
protein O +
abundance O +
of O +
alpha O -
- O -
ENaC O +
and O +
beta O -
- O -
ENaC O +
was O +
increased O +
in O +
the O +
inner O +
stripe O +
of O +
the O +
outer O +
medulla O +
( O -
ISOM O -
) O +
and O +
in O +
the O +
inner O +
medulla O +
( O -
IM O -
) O +
but O +
was O +
not O +
altered O +
in O +
the O +
cortex O -
. O +

gamma O -
- O -
ENaC O +
abundance O +
was O +
increased O +
in O +
the O +
cortex O -
, O +
ISOM O -
, O +
and O +
IM O -
. O +

Immunoperoxidase O +
brightfield- O +
and O +
laser O -
- O -
scanning O +
confocal O +
fluorescence O +
microscopy O +
demonstrated O +
increased O +
targeting O +
of O +
alpha O -
- O -
ENaC O -
, O +
beta O -
- O -
ENaC O -
, O +
and O +
gamma O -
- O -
ENaC O +
subunits O +
to O +
the O +
apical O +
plasma O +
membrane O +
in O +
the O +
distal O +
convoluted O +
tubule O +
( O -
DCT2 O -
) O -
, O +
connecting O +
tubule O -
, O +
and O +
cortical O +
and O +
medullary O +
collecting O +
duct O +
segments O -
. O +

Immunoelectron O +
microscopy O +
further O +
revealed O +
an O +
increased O +
labeling O +
of O +
alpha O -
- O -
ENaC O +
in O +
the O +
apical O +
plasma O +
membrane O +
of O +
cortical O +
collecting O +
duct O +
principal O +
cells O +
of O +
PAN O -
- O -
treated O +
rats O -
, O +
indicating O +
enhanced O +
apical O +
targeting O +
of O +
alpha O -
- O -
ENaC O +
subunits O -
. O +

In O +
contrast O -
, O +
the O +
protein O +
abundances O +
of O +
Na O -
( O -
+ O -
) O -
/ O -
H O -
( O -
+ O -
) O +
exchanger O +
type O +
3 O +
( O -
NHE3 O -
) O -
, O +
Na O -
( O -
+ O -
) O -
-K O -
( O -
+ O -
) O -
-2Cl O -
( O -
- O -
) O +
cotransporter O +
( O -
BSC-1 O -
) O -
, O +
and O +
thiazide O -
- O -
sensitive O +
Na O -
( O -
+ O -
) O -
-Cl O -
( O -
- O -
) O +
cotransporter O +
( O -
TSC O -
) O +
were O +
decreased O -
. O +

Moreover O -
, O +
the O +
abundance O +
of O +
the O +
alpha O -
( O -
1 O -
) O -
-subunit O +
of O +
the O +
Na O -
- O -
K O -
- O -
ATPase O +
was O +
decreased O +
in O +
the O +
cortex O +
and O +
ISOM O -
, O +
but O +
it O +
remained O +
unchanged O +
in O +
the O +
IM O -
. O +

In O +
conclusion O -
, O +
the O +
increased O +
or O +
sustained O +
expression O +
of O +
ENaC O +
subunits O +
combined O +
with O +
increased O +
apical O +
targeting O +
in O +
the O +
DCT2 O -
, O +
connecting O +
tubule O -
, O +
and O +
collecting O +
duct O +
are O +
likely O +
to O +
play O +
a O +
role O +
in O +
the O +
sodium O +
retention O +
associated O +
with O +
PAN O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

The O +
decreased O +
abundance O +
of O +
NHE3 O -
, O +
BSC-1 O -
, O +
TSC O -
, O +
and O +
Na O -
- O -
K O -
- O -
ATPase O +
may O +
play O +
a O +
compensatory O +
role O +
to O +
promote O +
sodium O +
excretion O -
. O +

A O +
pyridoxine O -
- O -
dependent O +
behavioral B-Disease +
disorder I-Disease +
unmasked O +
by O +
isoniazid O -
. O +

A O +
3-year O -
- O -
old O +
girl O +
had O +
behavioral B-Disease +
deterioration I-Disease -
, O +
with O +
hyperkinesis B-Disease -
, O +
irritability B-Disease -
, O +
and O +
sleeping B-Disease +
difficulties I-Disease +
after O +
the O +
therapeutic O +
administration O +
of O +
isoniazid O -
. O +

The O +
administration O +
of O +
pharmacologic O +
doses O +
of O +
pyridoxine O +
hydrochloride O +
led O +
to O +
a O +
disappearance O +
of O +
symptoms O -
. O +

After O +
discontinuing O +
isoniazid O +
therapy O +
a O +
similar O +
pattern O +
of O +
behavior O +
was O +
noted O +
that O +
was O +
controlled O +
by O +
pyridoxine O -
. O +

A O +
placebo O +
had O +
no O +
effect O -
, O +
but O +
niacinamide O +
was O +
as O +
effective O +
as O +
pyridoxine O -
. O +

Periodic O +
withdrawal O +
of O +
pyridoxine O +
was O +
associated O +
with O +
return O +
of O +
the O +
hyperkinesis B-Disease -
. O +

The O +
level O +
of O +
pyridoxal O +
in O +
the O +
blood O +
was O +
normal O +
during O +
the O +
periods O +
of O +
relapse O -
. O +

Metabolic O +
studies O +
suggested O +
a O +
block O +
in O +
the O +
kynurenine O +
pathway O +
of O +
tryptophan O +
metabolism O -
. O +

The O +
patient O +
has O +
been O +
followed O +
for O +
six O +
years O +
and O +
has O +
required O +
pharmacologic O +
doses O +
of O +
pyridoxine O +
to O +
control O +
her O +
behavior O -
. O +

Recurrent O +
excitation O +
in O +
the O +
dentate O +
gyrus O +
of O +
a O +
murine O +
model O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
. O +

Similar O +
to O +
rats O -
, O +
systemic O +
pilocarpine O +
injection O +
causes O +
status B-Disease +
epilepticus I-Disease +
( O -
SE B-Disease -
) O +
and O +
the O +
eventual O +
development O +
of O +
spontaneous O +
seizures B-Disease +
and O +
mossy O +
fiber O +
sprouting O +
in O +
C57BL O -
/ O -
6 O +
and O +
CD1 O +
mice O -
, O +
but O +
the O +
physiological O +
correlates O +
of O +
these O +
events O +
have O +
not O +
been O +
identified O +
in O +
mice O -
. O +

Population O +
responses O +
in O +
granule O +
cells O +
of O +
the O +
dentate O +
gyrus O +
were O +
examined O +
in O +
transverse O +
slices O +
of O +
the O +
ventral O +
hippocampus O +
from O +
pilocarpine O -
- O -
treated O +
and O +
untreated O +
mice O -
. O +

In O +
Mg O -
( O -
2+ O -
) O -
-free O +
bathing O +
medium O +
containing O +
bicuculline O -
, O +
conditions O +
designed O +
to O +
increase O +
excitability O +
in O +
the O +
slices O -
, O +
electrical O +
stimulation O +
of O +
the O +
hilus O +
resulted O +
in O +
a O +
single O +
population O +
spike O +
in O +
granule O +
cells O +
from O +
control O +
mice O +
and O +
pilocarpine O -
- O -
treated O +
mice O +
that O +
did O +
not O +
experience O +
SE B-Disease -
. O +

In O +
SE B-Disease +
survivors O -
, O +
similar O +
stimulation O +
resulted O +
in O +
a O +
population O +
spike O +
followed O -
, O +
at O +
a O +
variable O +
latency O -
, O +
by O +
negative O +
DC O +
shifts O +
and O +
repetitive O +
afterdischarges O +
of O +
3 O -
- O -
60 O +
s O +
duration O -
, O +
which O +
were O +
blocked O +
by O +
ionotropic O +
glutamate O +
receptor O +
antagonists O -
. O +

Focal O +
glutamate O +
photostimulation O +
of O +
the O +
granule O +
cell O +
layer O +
at O +
sites O +
distant O +
from O +
the O +
recording O +
pipette O +
resulted O +
in O +
population O +
responses O +
of O +
1 O -
- O -
30 O +
s O +
duration O +
in O +
slices O +
from O +
SE B-Disease +
survivors O +
but O +
not O +
other O +
groups O -
. O +

These O +
data O +
support O +
the O +
hypothesis O +
that O +
SE B-Disease -
- O -
induced O +
mossy O +
fiber O +
sprouting O +
and O +
synaptic O +
reorganization O +
are O +
relevant O +
characteristics O +
of O +
seizure B-Disease +
development O +
in O +
these O +
murine O +
strains O -
, O +
resembling O +
rat O +
models O +
of O +
human O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
. O +

Urinary B-Disease +
bladder I-Disease +
cancer I-Disease +
in O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
: O +
risks O +
and O +
relation O +
to O +
cyclophosphamide O -
. O +

OBJECTIVE O -
: O +
To O +
assess O +
and O +
characterise O +
the O +
risk O +
of O +
bladder B-Disease +
cancer I-Disease -
, O +
and O +
its O +
relation O +
to O +
cyclophosphamide O -
, O +
in O +
patients O +
with O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
. O +

METHODS O -
: O +
In O +
the O +
population O +
based O -
, O +
nationwide O +
Swedish O +
Inpatient O +
Register O +
a O +
cohort O +
of O +
1065 O +
patients O +
with O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
, O +
1969 O -
- O -
95 O -
, O +
was O +
identified O -
. O +

Through O +
linkage O +
with O +
the O +
Swedish O +
Cancer B-Disease +
Register O -
, O +
all O +
subjects O +
in O +
this O +
cohort O +
diagnosed O +
with O +
bladder B-Disease +
cancer I-Disease +
were O +
identified O -
. O +

Nested O +
within O +
the O +
cohort O -
, O +
a O +
matched O +
case O -
- O -
control O +
study O +
was O +
performed O +
to O +
estimate O +
the O +
association O +
between O +
cyclophosphamide O +
and O +
bladder B-Disease +
cancer I-Disease +
using O +
odds O +
ratios O +
( O -
ORs O -
) O +
as O +
relative O +
risk O -
. O +

In O +
the O +
cohort O +
the O +
cumulative O +
risk O +
of O +
bladder B-Disease +
cancer I-Disease +
after O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
, O +
and O +
the O +
relative O +
prevalence O +
of O +
a O +
history O +
of O +
bladder B-Disease +
cancer I-Disease +
at O +
the O +
time O +
of O +
diagnosis O +
of O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
, O +
were O +
also O +
estimated O -
. O +

RESULTS O -
: O +
The O +
median O +
cumulative O +
doses O +
of O +
cyclophosphamide O +
among O +
cases O +
( O -
n O +
= O +
11 O -
) O +
and O +
controls O +
( O -
n O +
= O +
25 O -
) O +
were O +
113 O +
g O +
and O +
25 O +
g O -
, O +
respectively O -
. O +

The O +
risk O +
of O +
bladder B-Disease +
cancer I-Disease +
doubled O +
for O +
every O +
10 O +
g O +
increment O +
in O +
cyclophosphamide O +
( O -
OR O +
= O +
2.0 O -
, O +
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
0.8 O +
to O +
4.9 O -
) O -
. O +

Treatment O +
duration O +
longer O +
than O +
1 O +
year O +
was O +
associated O +
with O +
an O +
eightfold O +
increased O +
risk O +
( O -
OR O +
= O +
7.7 O -
, O +
95 O -
% O +
CI O +
0.9 O +
to O +
69 O -
) O -
. O +

The O +
absolute O +
risk O +
for O +
bladder B-Disease +
cancer I-Disease +
in O +
the O +
cohort O +
reached O +
10 O -
% O +
16 O +
years O +
after O +
diagnosis O +
of O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
, O +
and O +
a O +
history O +
of O +
bladder B-Disease +
cancer I-Disease +
was O +
( O -
non O -
- O -
significantly O -
) O +
twice O +
as O +
common O +
as O +
expected O +
at O +
the O +
time O +
of O +
diagnosis O +
of O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
. O +

CONCLUSION O -
: O +
The O +
results O +
indicate O +
a O +
dose O -
- O -
response O +
relationship O +
between O +
cyclophosphamide O +
and O +
the O +
risk O +
of O +
bladder B-Disease +
cancer I-Disease -
, O +
high O +
cumulative O +
risks O +
in O +
the O +
entire O +
cohort O -
, O +
and O +
also O +
the O +
possibility O +
of O +
risk O +
factors O +
operating O +
even O +
before O +
Wegener B-Disease -
's I-Disease +
granulomatosis I-Disease -
. O +

Differential O +
modulation O +
by O +
estrogen O +
of O +
alpha2-adrenergic O +
and O +
I1-imidazoline O +
receptor O -
- O -
mediated O +
hypotension B-Disease +
in O +
female O +
rats O -
. O +

We O +
have O +
recently O +
shown O +
that O +
estrogen O +
negatively O +
modulates O +
the O +
hypotensive B-Disease +
effect O +
of O +
clonidine O +
( O -
mixed O +
alpha2- O -
/ O -
I1-receptor O +
agonist O -
) O +
in O +
female O +
rats O +
and O +
implicates O +
the O +
cardiovascular O +
autonomic O +
control O +
in O +
this O +
interaction O -
. O +

The O +
present O +
study O +
investigated O +
whether O +
this O +
effect O +
of O +
estrogen O +
involves O +
interaction O +
with O +
alpha2- O +
and/or O +
I1-receptors O -
. O +

Changes O +
evoked O +
by O +
a O +
single O +
intraperitoneal O +
injection O +
of O +
rilmenidine O +
( O -
600 O +
microg O -
/ O -
kg O -
) O +
or O +
alpha O -
- O -
methyldopa O +
( O -
100 O +
mg O -
/ O -
kg O -
) O -
, O +
selective O +
I1- O +
and O +
alpha2-receptor O +
agonists O -
, O +
respectively O -
, O +
in O +
blood O +
pressure O -
, O +
hemodynamic O +
variability O -
, O +
and O +
locomotor O +
activity O +
were O +
assessed O +
in O +
radiotelemetered O +
sham O -
- O -
operated O +
and O +
ovariectomized O +
( O -
Ovx O -
) O +
Sprague O -
- O -
Dawley O +
female O +
rats O +
with O +
or O +
without O +
12-wk O +
estrogen O +
replacement O -
. O +

Three O +
time O +
domain O +
indexes O +
of O +
hemodynamic O +
variability O +
were O +
employed O -
: O +
the O +
standard O +
deviation O +
of O +
mean O +
arterial O +
pressure O +
as O +
a O +
measure O +
of O +
blood O +
pressure O +
variability O +
and O +
the O +
standard O +
deviation O +
of O +
beat O -
- O -
to O -
- O -
beat O +
intervals O +
( O -
SDRR O -
) O +
and O +
the O +
root O +
mean O +
square O +
of O +
successive O +
differences O +
in O +
R O -
- O -
wave O -
- O -
to O -
- O -
R O -
- O -
wave O +
intervals O +
as O +
measures O +
of O +
heart O +
rate O +
variability O -
. O +

In O +
sham O -
- O -
operated O +
rats O -
, O +
rilmenidine O +
or O +
alpha O -
- O -
methyldopa O +
elicited O +
similar O +
hypotension B-Disease +
that O +
lasted O +
at O +
least O +
5 O +
h O +
and O +
was O +
associated O +
with O +
reductions O +
in O +
standard O +
deviation O +
of O +
mean O +
arterial O +
pressure O -
. O +

SDRR O +
was O +
reduced O +
only O +
by O +
alpha O -
- O -
methyldopa O -
. O +

Ovx O +
significantly O +
enhanced O +
the O +
hypotensive B-Disease +
response O +
to O +
alpha O -
- O -
methyldopa O -
, O +
in O +
contrast O +
to O +
no O +
effect O +
on O +
rilmenidine O +
hypotension B-Disease -
. O +

The O +
enhanced O +
alpha O -
- O -
methyldopa O +
hypotension B-Disease +
in O +
Ovx O +
rats O +
was O +
paralleled O +
with O +
further O +
reduction O +
in O +
SDRR O +
and O +
a B-Disease +
reduced I-Disease +
locomotor I-Disease +
activity I-Disease -
. O +

Estrogen O +
replacement O +
( O -
17beta O -
- O -
estradiol O +
subcutaneous O +
pellet O -
, O +
14.2 O +
microg O -
/ O -
day O -
, O +
12 O +
wk O -
) O +
of O +
Ovx O +
rats O +
restored O +
the O +
hemodynamic O +
and O +
locomotor O +
effects O +
of O +
alpha O -
- O -
methyldopa O +
to O +
sham O -
- O -
operated O +
levels O -
. O +

These O +
findings O +
suggest O +
that O +
estrogen O +
downregulates O +
alpha2- O +
but O +
not O +
I1-receptor O -
- O -
mediated O +
hypotension B-Disease +
and O +
highlight O +
a O +
role O +
for O +
the O +
cardiac O +
autonomic O +
control O +
in O +
alpha O -
- O -
methyldopa O -
- O -
estrogen O +
interaction O -
. O +

Severe O +
reversible O +
left B-Disease +
ventricular I-Disease +
systolic I-Disease +
and I-Disease +
diastolic I-Disease +
dysfunction I-Disease +
due O +
to O +
accidental O +
iatrogenic O +
epinephrine O +
overdose B-Disease -
. O +

Catecholamine O -
- O -
induced O +
cardiomyopathy B-Disease +
due O +
to O +
chronic O +
excess O +
of O +
endogenous O +
catecholamines O +
has O +
been O +
recognized O +
for O +
decades O +
as O +
a O +
clinical O +
phenomenon O -
. O +

In O +
contrast O -
, O +
reports O +
of O +
myocardial B-Disease +
dysfunction I-Disease +
due O +
to O +
acute O +
iatrogenic O +
overdose B-Disease +
are O +
rare O -
. O +

A O +
35-year O -
- O -
old O +
woman O +
whose O +
cervix O +
uteri O +
was O +
inadvertently O +
injected O +
with O +
8 O +
mg O +
of O +
epinephrine O +
developed O +
myocardial B-Disease +
stunning I-Disease +
that O +
was O +
characterized O +
by O +
severe O +
hemodynamic O +
compromise O -
, O +
profound O -
, O +
albeit O +
transient O -
, O +
left B-Disease +
ventricular I-Disease +
systolic I-Disease +
and I-Disease +
diastolic I-Disease +
dysfunction I-Disease -
, O +
and O +
only O +
modestly O +
elevated O +
biochemical O +
markers O +
of O +
myocardial B-Disease +
necrosis I-Disease -
. O +

Our O +
case O +
illustrates O +
the O +
serious O +
consequences O +
of O +
medical O +
errors O +
that O +
can O +
be O +
avoided O +
through O +
improved O +
medication O +
labeling O +
and O +
staff O +
supervision O -
. O +

Cardioprotective O +
effect O +
of O +
tincture O +
of O +
Crataegus O +
on O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Tincture O +
of O +
Crataegus O +
( O -
TCR O -
) O -
, O +
an O +
alcoholic O +
extract O +
of O +
the O +
berries O +
of O +
hawthorn O +
( O -
Crataegus O +
oxycantha O -
) O -
, O +
is O +
used O +
in O +
herbal O +
and O +
homeopathic O +
medicine O -
. O +

The O +
present O +
study O +
was O +
done O +
to O +
investigate O +
the O +
protective O +
effect O +
of O +
TCR O +
on O +
experimentally O +
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Pretreatment O +
of O +
TCR O -
, O +
at O +
a O +
dose O +
of O +
0.5 O +
mL O -
/ O -
100 O +
g O +
bodyweight O +
per O +
day O -
, O +
orally O +
for O +
30 O +
days O -
, O +
prevented O +
the O +
increase O +
in O +
lipid O +
peroxidation O +
and O +
activity O +
of O +
marker O +
enzymes O +
observed O +
in O +
isoproterenol O -
- O -
induced O +
rats O +
( O -
85 O +
mg O +
kg O -
( O -
-1 O -
) O +
s. O +
c. O +
for O +
2 O +
days O +
at O +
an O +
interval O +
of O +
24 O +
h O -
) O -
. O +

TCR O +
prevented O +
the O +
isoproterenol O -
- O -
induced O +
decrease O +
in O +
antioxidant O +
enzymes O +
in O +
the O +
heart O +
and O +
increased O +
the O +
rate O +
of O +
ADP O -
- O -
stimulated O +
oxygen O +
uptake O +
and O +
respiratory O +
coupling O +
ratio O -
. O +

TCR O +
protected O +
against O +
pathological O +
changes O +
induced O +
by O +
isoproterenol O +
in O +
rat O +
heart O -
. O +

The O +
results O +
show O +
that O +
pretreatment O +
with O +
TCR O +
may O +
be O +
useful O +
in O +
preventing O +
the O +
damage O +
induced O +
by O +
isoproterenol O +
in O +
rat O +
heart O -
. O +

Effects O +
of O +
the O +
cyclooxygenase-2 O +
specific O +
inhibitor O +
valdecoxib O +
versus O +
nonsteroidal O +
antiinflammatory O +
agents O +
and O +
placebo O +
on O +
cardiovascular O +
thrombotic B-Disease +
events O +
in O +
patients O +
with O +
arthritis B-Disease -
. O +

There O +
have O +
been O +
concerns O +
that O +
the O +
risk O +
of O +
cardiovascular O +
thrombotic B-Disease +
events O +
may O +
be O +
higher O +
with O +
cyclooxygenase O +
( O -
COX O -
) O -
-2-specific O +
inhibitors O +
than O +
nonselective O +
nonsteroidal O +
antiinflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
. O +

We O +
evaluated O +
cardiovascular O +
event O +
data O +
for O +
valdecoxib O -
, O +
a O +
new O +
COX-2-specific O +
inhibitor O +
in O +
approximately O +
8000 O +
patients O +
with O +
osteoarthritis B-Disease +
and O +
rheumatoid B-Disease +
arthritis I-Disease +
treated O +
with O +
this O +
agent O +
in O +
randomized O +
clinical O +
trials O -
. O +

The O +
incidence O +
of O +
cardiovascular O +
thrombotic B-Disease +
events O +
( O -
cardiac O -
, O +
cerebrovascular O +
and O +
peripheral O +
vascular O -
, O +
or O +
arterial O +
thrombotic B-Disease -
) O +
was O +
determined O +
by O +
analyzing O +
pooled O +
valdecoxib O +
( O -
10 O -
- O -
80 O +
mg O +
daily O -
) O -
, O +
nonselective O +
NSAID O +
( O -
diclofenac O +
75 O +
mg O +
bid O -
, O +
ibuprofen O +
800 O +
mg O +
tid O -
, O +
or O +
naproxen O +
500 O +
mg O +
bid O -
) O +
and O +
placebo O +
data O +
from O +
10 O +
randomized O +
osteoarthritis B-Disease +
and O +
rheumatoid B-Disease +
arthritis I-Disease +
trials O +
that O +
were O +
6 O -
- O -
52 O +
weeks O +
in O +
duration O -
. O +

The O +
incidence O +
rates O +
of O +
events O +
were O +
determined O +
in O +
all O +
patients O +
( O -
n O +
= O +
7934 O -
) O +
and O +
in O +
users O +
of O +
low O -
- O -
dose O +
( O -
< O +
or O +
= O -
325 O +
mg O +
daily O -
) O +
aspirin O +
( O -
n O +
= O +
1051 O -
) O +
and O +
nonusers O +
of O +
aspirin O +
( O -
n O +
= O +
6883 O -
) O -
. O +

Crude O +
and O +
exposure O -
- O -
adjusted O +
incidences O +
of O +
thrombotic B-Disease +
events O +
were O +
similar O +
for O +
valdecoxib O -
, O +
NSAIDs O -
, O +
and O +
placebo O -
. O +

The O +
risk O +
of O +
serious O +
thrombotic B-Disease +
events O +
was O +
also O +
similar O +
for O +
each O +
valdecoxib O +
dose O -
. O +

Thrombotic B-Disease +
risk O +
was O +
consistently O +
higher O +
for O +
users O +
of O +
aspirin O +
users O +
than O +
nonusers O +
of O +
aspirin O +
( O -
placebo O -
, O +
1.4 O -
% O +
vs. O +
0 O -
% O -
; O +
valdecoxib O -
, O +
1.7 O -
% O +
vs. O +
0.2 O -
% O -
; O +
NSAIDs O -
, O +
1.9 O -
% O +
vs. O +
0.5 O -
% O -
) O -
. O +

The O +
rates O +
of O +
events O +
in O +
users O +
of O +
aspirin O +
were O +
similar O +
for O +
all O +
3 O +
treatment O +
groups O +
and O +
across O +
valdecoxib O +
doses O -
. O +

Short- O +
and O +
intermediate O -
- O -
term O +
treatment O +
with O +
therapeutic O +
( O -
10 O +
or O +
20 O +
mg O +
daily O -
) O +
and O +
supratherapeutic O +
( O -
40 O +
or O +
80 O +
mg O +
daily O -
) O +
valdecoxib O +
doses O +
was O +
not O +
associated O +
with O +
an O +
increased O +
incidence O +
of O +
thrombotic B-Disease +
events O +
relative O +
to O +
nonselective O +
NSAIDs O +
or O +
placebo O +
in O +
osteoarthritis B-Disease +
and O +
rheumatoid B-Disease +
arthritis I-Disease +
patients O +
in O +
controlled O +
clinical O +
trials O -
. O +

Treatment O +
of O +
tinnitus B-Disease +
by O +
intratympanic O +
instillation O +
of O +
lignocaine O +
( O -
lidocaine O -
) O +
2 O +
per O +
cent O +
through O +
ventilation O +
tubes O -
. O +

Idiopathic B-Disease +
subjective I-Disease +
tinnitus I-Disease +
( O -
IST B-Disease -
) O +
is O +
one O +
of O +
the O +
most O +
obscure O +
otological O +
pathologies O -
. O +

This O +
paper O +
presents O +
the O +
results O +
of O +
treating O +
IST B-Disease +
by O +
intratympanic O +
instillation O +
of O +
lignocaine O +
( O -
lidocaine O -
) O +
2 O +
per O +
cent O +
through O +
a O +
grommet O -
, O +
for O +
five O +
weekly O +
courses O -
. O +

Fifty O -
- O -
two O +
patients O +
suffering O +
from O +
intractable O +
tinnitus B-Disease +
entered O +
this O +
therapeutic O +
trial O -
, O +
but O +
only O +
nine O +
finished O +
all O +
five O +
courses O -
. O +

In O +
one O +
patient O -
, O +
the O +
tinnitus B-Disease +
was O +
almost O +
completely O +
abolished O -
, O +
but O +
in O +
all O +
the O +
nine O +
patients O +
the O +
decompensated O +
tinnitus B-Disease +
changed O +
to O +
a O +
compensated O +
one O -
. O +

We O +
suggest O +
this O +
mode O +
of O +
treatment O +
for O +
patients O +
that O +
were O +
previously O +
treated O +
by O +
drugs O -
, O +
acupuncture O +
and O +
biofeedback O -
, O +
with O +
disappointing O +
results O -
. O +

Patients O +
should O +
be O +
warned O +
about O +
the O +
side O +
effects O +
of O +
vertigo B-Disease +
and O +
vomiting B-Disease -
, O +
which O +
subsides O +
gradually O +
with O +
every O +
new O +
instillation O -
, O +
and O +
that O +
the O +
tinnitus B-Disease +
may O +
not O +
disappear O +
but O +
will O +
be O +
alleviated O -
, O +
enabling O +
them O +
to O +
cope O +
more O +
easily O +
with O +
the O +
disease O +
and O +
lead O +
a O +
more O +
normal O +
life O -
. O +

The O +
alpha3 O +
and O +
beta4 O +
nicotinic O +
acetylcholine O +
receptor O +
subunits O +
are O +
necessary O +
for O +
nicotine O -
- O -
induced O +
seizures B-Disease +
and O +
hypolocomotion B-Disease +
in O +
mice O -
. O +

Binding O +
of O +
nicotine O +
to O +
nicotinic O +
acetylcholine O +
receptors O +
( O -
nAChRs O -
) O +
elicits O +
a O +
series O +
of O +
dose O -
- O -
dependent O +
behaviors O +
that O +
go O +
from O +
altered O +
exploration O -
, O +
sedation O -
, O +
and O +
tremors B-Disease -
, O +
to O +
seizures B-Disease +
and O +
death B-Disease -
. O +

nAChRs O +
are O +
pentameric O +
ion O +
channels O +
usually O +
composed O +
of O +
alpha O +
and O +
beta O +
subunits O -
. O +

A O +
gene O +
cluster O +
comprises O +
the O +
alpha3 O -
, O +
alpha5 O +
and O +
beta4 O +
subunits O -
, O +
which O +
coassemble O +
to O +
form O +
functional O +
receptors O -
. O +

We O +
examined O +
the O +
role O +
of O +
the O +
beta4 O +
subunits O +
in O +
nicotine O -
- O -
induced O +
seizures B-Disease +
and O +
hypolocomotion B-Disease +
in O +
beta4 O +
homozygous O +
null O +
( O -
beta4 O +
- O -
/ O -
- O -
) O +
and O +
alpha3 O +
heterozygous O +
( O -
+ O -
/- O -
) O +
mice O -
. O +

beta4 O +
- O -
/ O -
- O +
mice O +
were O +
less O +
sensitive O +
to O +
the O +
effects O +
of O +
nicotine O +
both O +
at O +
low O +
doses O -
, O +
measured O +
as O +
decreased O +
exploration O +
in O +
an O +
open O +
field O -
, O +
and O +
at O +
high O +
doses O -
, O +
measured O +
as O +
sensitivity O +
to O +
nicotine O -
- O -
induced O +
seizures B-Disease -
. O +

Using O +
in O +
situ O +
hybridization O +
probes O +
for O +
the O +
alpha3 O +
and O +
alpha5 O +
subunits O -
, O +
we O +
showed O +
that O +
alpha5 O +
mRNA O +
levels O +
are O +
unchanged O -
, O +
whereas O +
alpha3 O +
mRNA O +
levels O +
are O +
selectively O +
decreased O +
in O +
the O +
mitral O +
cell O +
layer O +
of O +
the O +
olfactory O +
bulb O -
, O +
and O +
the O +
inferior O +
and O +
the O +
superior O +
colliculus O +
of O +
beta4 O +
- O -
/ O -
- O +
brains O -
. O +

alpha3 O +
+ O -
/- O +

mice O +
were O +
partially O +
resistant O +
to O +
nicotine O -
- O -
induced O +
seizures B-Disease +
when O +
compared O +
to O +
wild O -
- O -
type O +
littermates O -
. O +

mRNA O +
levels O +
for O +
the O +
alpha5 O +
and O +
the O +
beta4 O +
subunits O +
were O +
unchanged O +
in O +
alpha3 O +
+ O -
/- O +

brains O -
. O +

Together O -
, O +
these O +
results O +
suggest O +
that O +
the O +
beta4 O +
and O +
the O +
alpha3 O +
subunits O +
are O +
mediators O +
of O +
nicotine O -
- O -
induced O +
seizures B-Disease +
and O +
hypolocomotion B-Disease -
. O +

Time O +
trends O +
in O +
warfarin O -
- O -
associated O +
hemorrhage B-Disease -
. O +

The O +
annual O +
incidence O +
of O +
warfarin O -
- O -
related O +
bleeding B-Disease +
at O +
Brigham O +
and O +
Women O -
's O +
Hospital O +
increased O +
from O +
0.97 O -
/ O -
1,000 O +
patient O +
admissions O +
in O +
the O +
first O +
time O +
period O +
( O -
January O +
1995 O +
to O +
October O +
1998 O -
) O +
to O +
1.19 O -
/ O -
1,000 O +
patient O +
admissions O +
in O +
the O +
second O +
time O +
period O +
( O -
November O +
1998 O +
to O +
August O +
2002 O -
) O +
of O +
this O +
study O -
. O +

The O +
proportion O +
of O +
patients O +
with O +
major O +
and O +
intracranial B-Disease +
bleeding I-Disease +
increased O +
from O +
20.2 O -
% O +
and O +
1.9 O -
% O -
, O +
respectively O -
, O +
in O +
the O +
first O +
time O +
period O -
, O +
to O +
33.3 O -
% O +
and O +
7.8 O -
% O -
, O +
respectively O -
, O +
in O +
the O +
second O -
. O +

The O +
effects O +
of O +
sevoflurane O +
on O +
lidocaine O -
- O -
induced O +
convulsions B-Disease -
. O +

The O +
influence O +
of O +
sevoflurane O +
on O +
lidocaine O -
- O -
induced O +
convulsions B-Disease +
was O +
studied O +
in O +
cats O -
. O +

The O +
convulsive B-Disease +
threshold O +
( O -
mean O +
+ O -
/- O +
SD O -
) O +
was O +
41.4 O +
+ O -
/- O +

6.5 O +
mg O -
. O +

l O -
( O -
-1 O -
) O +
with O +
lidocaine O +
infusion O +
( O -
6 O +
mg.kg O -
( O -
-1 O -
) O -
.min O -
( O -
-1 O -
) O -
) O -
, O +
increasing O +
significantly O +
to O +
66.6 O +
+ O -
/- O +

10.9 O +
mg O -
. O +

l O -
( O -
-1 O -
) O +
when O +
the O +
end O -
- O -
tidal O +
concentration O +
of O +
sevoflurane O +
was O +
0.8 O -
% O -
. O +

However O -
, O +
the O +
threshold O +
( O -
61.6 O +
+ O -
/- O +

8.7 O +
mg O -
. O +

l O -
( O -
-1 O -
) O -
) O +
during O +
1.6 O -
% O +
sevoflurane O +
was O +
not O +
significant O +
from O +
that O +
during O +
0.8 O -
% O +
sevoflurane O -
, O +
indicating O +
a O +
celling O +
effect O -
. O +

There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
convulsive B-Disease +
threshold O +
between O +
sevoflurane O +
and O +
enflurane O -
. O +

The O +
rise O +
in O +
blood O +
pressure O +
became O +
less O +
marked O +
when O +
higher O +
concentrations O +
of O +
sevoflurane O +
or O +
enflurane O +
were O +
administered O +
and O +
the O +
blood O +
pressure O +
at O +
convulsions B-Disease +
decreased O +
significantly O +
in O +
1.6 O -
% O +
sevoflurane O -
, O +
and O +
in O +
0.8 O -
% O +
and O +
1.6 O -
% O +
enflurane O -
. O +

However O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
lidocaine O +
concentrations O +
measured O +
when O +
the O +
systolic O +
blood O +
pressure O +
became O +
70 O +
mmHg O -
. O +

Apamin O -
, O +
a O +
selective O +
blocker O +
of O +
calcium O -
- O -
dependent O +
potassium O +
channels O -
, O +
was O +
administered O +
intracerebroventricularly O +
in O +
rats O +
anesthetized O +
with O +
0.8 O -
% O +
sevoflurane O +
to O +
investigate O +
the O +
mechanism O +
of O +
the O +
anticonvulsive O +
effects O -
. O +

Apamin O +
( O -
10 O +
ng O -
) O +
had O +
a O +
tendency O +
to O +
decrease O +
the O +
convulsive B-Disease +
threshold O +
( O -
21.6 O +
+ O -
/- O +

2.2 O +
to O +
19.9 O +
+ O -
/- O +

2.5 O +
mg O -
. O +

l O -
( O -
-1 O -
) O -
) O +
but O +
this O +
was O +
not O +
statistically O +
significant O -
. O +

It O +
is O +
suggested O +
that O +
sevoflurane O +
reduces O +
the O +
convulsive B-Disease +
effect O +
of O +
lidocaine O +
toxicity B-Disease +
but O +
carries O +
some O +
risk O +
due O +
to O +
circulatory O +
depression B-Disease -
. O +

Cardiac B-Disease +
toxicity I-Disease +
observed O +
in O +
association O +
with O +
high O -
- O -
dose O +
cyclophosphamide O -
- O -
based O +
chemotherapy O +
for O +
metastatic O +
breast B-Disease +
cancer I-Disease -
. O +

INTRODUCTION O -
: O +
Cyclophosphamide O +
is O +
an O +
alkylating O +
agent O +
given O +
frequently O +
as O +
a O +
component O +
of O +
many O +
conditioning O +
regimens O -
. O +

In O +
high O +
doses O -
, O +
its O +
nonhematological O +
dose O -
- O -
limiting O +
toxicity B-Disease +
is O +
cardiomyopathy B-Disease -
. O +

STUDY O +
DESIGN O +

: O +
We O +
combined O +
paclitaxel O -
, O +
melphalan O +
and O +
high O -
- O -
dose O +
cyclophosphamide O -
, O +
thiotepa O -
, O +
and O +
carboplatin O +
in O +
a O +
triple O +
sequential O +
high O -
- O -
dose O +
regimen O +
for O +
patients O +
with O +
metastatic O +
breast B-Disease +
cancer I-Disease -
. O +

Analysis O +
was O +
performed O +
on O +
61 O +
women O +
with O +
chemotherapy O -
- O -
responsive O +
metastatic O +
breast B-Disease +
cancer I-Disease +
receiving O +
96-h O +
infusional O +
cyclophosphamide O +
as O +
part O +
of O +
a O +
triple O +
sequential O +
high O -
- O -
dose O +
regimen O +
to O +
assess O +
association O +
between O +
presence O +
of O +
peritransplant O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
( O -
CHF B-Disease -
) O +
and O +
the O +
following O +
pretreatment O +
characteristics O -
: O +
presence O +
of O +
electrocardiogram O +
( O -
EKG O -
) O +
abnormalities O -
, O +
age O -
, O +
hypertension B-Disease -
, O +
prior O +
cardiac O +
history O -
, O +
smoking O -
, O +
diabetes B-Disease +
mellitus I-Disease -
, O +
prior O +
use O +
of O +
anthracyclines O -
, O +
and O +
left O -
- O -
sided O +
chest O +
irradiation O -
. O +

RESULTS O -
: O +
Six O +
of O +
61 O +
women O +
( O -
10 O -
% O -
) O +
developed O +
clinically O +
reversible O +
grade O +
3 O +
CHF B-Disease +
following O +
infusional O +
cyclophosphamide O +
with O +
a O +
median O +
percent O +
decline O +
in O +
ejection O +
fraction O +
of O +
31 O -
% O -
. O +

Incidence O +
of O +
transient O +
cyclophosphamide O -
- O -
related O +
cardiac B-Disease +
toxicity I-Disease +
( O -
10 O -
% O -
) O +
is O +
comparable O +
to O +
previous O +
recorded O +
literature O -
. O +

Older O +
age O +
was O +
significantly O +
correlated O +
with O +
the O +
CHF B-Disease +
development O -
; O +
with O +
median O +
ages O +
for O +
the O +
entire O +
group O +
and O +
for O +
patients O +
developing O +
CHF B-Disease +
of O +
45 O +
and O +
59 O -
, O +
respectively O -
. O +

No O +
association O +
was O +
found O +
with O +
other O +
pretreatment O +
characteristics O -
. O +

CONCLUSIONS O -
: O +
As O +
a O +
result O +
of O +
these O +
findings O -
, O +
oncologists O +
should O +
carefully O +
monitor O +
fluid O +
balance O +
in O +
older O +
patients O -
. O +

Routine O +
EKG O +
monitoring O +
during O +
infusional O +
cyclophosphamide O +
did O +
not O +
predict O +
CHF B-Disease +
development O -
. O +

Tremor B-Disease +
side O +
effects O +
of O +
salbutamol O -
, O +
quantified O +
by O +
a O +
laser O +
pointer O +
technique O -
. O +

OBJECTIVE O -
: O +
To O +
study O +
tremor B-Disease +
side O +
effects O +
of O +
salbutamol O +
an O +
easily O +
applicable O -
, O +
quick O +
and O +
low O -
- O -
priced O +
method O +
is O +
needed O -
. O +

A O +
new O +
method O +
using O +
a O +
commercially O +
available O -
, O +
pen O -
- O -
shaped O +
laser O +
pointer O +
was O +
developed O -
. O +

Aim O +
of O +
the O +
study O +
was O +
to O +
determine O +
sensitivity O -
, O +
reproducibility O -
, O +
reference O +
values O +
and O +
the O +
agreement O +
with O +
a O +
questionnaire O -
. O +

METHODS O -
: O +
Tremor B-Disease +
was O +
measured O +
using O +
a O +
laser O +
pointer O +
technique O -
. O +

To O +
determine O +
sensitivity O +
we O +
assessed O +
tremor B-Disease +
in O +
44 O +
patients O +
with O +
obstructive B-Disease +
lung I-Disease +
disease I-Disease +
after O +
administration O +
of O +
cumulative O +
doses O +
of O +
salbutamol O -
. O +

Subjects O +
were O +
asked O +
to O +
aim O +
at O +
the O +
centre O +
of O +
a O +
target O -
, O +
subdivided O +
in O +
concentric O +
circles O -
, O +
from O +
5 O +
m O +
distance O -
. O +

The O +
circle O +
in O +
which O +
the O +
participant O +
succeeded O +
to O +
aim O +
was O +
recorded O +
in O +
millimetres O +
radius O -
. O +

In O +
another O +
series O +
of O +
measurements O -
, O +
reproducibility O +
and O +
reference O +
values O +
of O +
the O +
tremor B-Disease +
was O +
assessed O +
in O +
65 O +
healthy O +
subjects O +
in O +
three O +
sessions O -
, O +
at O +
9 O +
a.m. O -
, O +
4 O +
p.m. O +
and O +
9 O +
a.m. O -
, O +
respectively O -
, O +
1 O +
week O +
later O -
. O +

Postural O +
tremor B-Disease +
was O +
measured O +
with O +
the O +
arm O +
horizontally O +
outstretched O +
rest O +
tremor B-Disease +
with O +
the O +
arm O +
supported O +
by O +
an O +
armrest O +
and O +
finally O +
tremor B-Disease +
was O +
measured O +
after O +
holding O +
a O +
2-kg O +
weight O +
until O +
exhaustion O -
. O +

Inter O -
- O -
observer O +
variability O +
was O +
measured O +
in O +
a O +
series O +
of O +
10 O +
healthy O +
subjects O -
. O +

Tremor B-Disease +
was O +
measured O +
simultaneously O +
by O +
two O +
independent O +
observers O -
. O +

RESULTS O -
: O +
Salbutamol O +
significantly O +
increased O +
tremor B-Disease +
severity O +
in O +
patients O +
in O +
a O +
dose O -
- O -
dependent O +
way O -
. O +

Within O +
healthy O +
adults O +
no O +
age O -
- O -
dependency O +
could O +
be O +
found O +
( O -
b O +
= O +
0.262 O +
mm O -
/ O -
year O -
; O +
P O +
= O +
0.72 O -
) O -
. O +

There O +
was O +
no O +
agreement O +
between O +
the O +
questionnaire O +
and O +
tremor B-Disease +
severity O +
( O -
r O +
= O +
0.093 O -
; O +
P O +
= O +
0.53 O -
) O -
. O +

Postural O +
tremor B-Disease +
showed O +
no O +
significant O +
difference O +
between O +
the O +
first O +
and O +
third O +
session O +
( O -
P O +
= O +
0.07 O -
) O -
. O +

Support O +
of O +
the O +
arm O +
decreased O +
tremor B-Disease +
severity O -
, O +
exhaustion O +
increased O +
tremor B-Disease +
severity O +
significantly O -
. O +

A O +
good O +
agreement O +
was O +
found O +
between O +
two O +
independent O +
observers O +
( O -
interclass O +
correlation O +
coefficient O +
0.72 O -
) O -
. O +

DISCUSSION O -
: O +
Quantifying O +
tremor B-Disease +
by O +
using O +
an O +
inexpensive O +
laser O +
pointer O +
is O -
, O +
with O +
the O +
exception O +
of O +
children O +
( O -
< O -
12 O +
years O -
) O +
a O +
sensitive O +
and O +
reproducible O +
method O -
. O +

Yohimbine O +
treatment O +
of O +
sexual B-Disease +
side I-Disease +
effects I-Disease +
induced O +
by O +
serotonin O +
reuptake O +
blockers O -
. O +

BACKGROUND O -
: O +
Preclinical O +
and O +
clinical O +
studies O +
suggest O +
that O +
yohimbine O +
facilitates O +
sexual O +
behavior O +
and O +
may O +
be O +
helpful O +
in O +
the O +
treatment O +
of O +
male B-Disease +
impotence I-Disease -
. O +

A O +
single O +
case O +
report O +
suggests O +
that O +
yohimbine O +
may O +
be O +
used O +
to O +
treat O +
the O +
sexual B-Disease +
side I-Disease +
effects I-Disease +
of O +
clomipramine O -
. O +

This O +
study O +
evaluated O +
yohimbine O +
as O +
a O +
treatment O +
for O +
the O +
sexual B-Disease +
side I-Disease +
effects I-Disease +
caused O +
by O +
serotonin O +
reuptake O +
blockers O -
. O +

METHOD O -
: O +
Six O +
patients O +
with O +
either O +
obsessive B-Disease +
compulsive I-Disease +
disorder I-Disease -
, O +
trichotillomania B-Disease -
, O +
anxiety B-Disease -
, O +
or O +
affective B-Disease +
disorders I-Disease +
who O +
suffered O +
sexual B-Disease +
side I-Disease +
effects I-Disease +
after O +
treatment O +
with O +
serotonin O +
reuptake O +
blockers O +
were O +
given O +
yohimbine O +
on O +
a O +
p.r.n O -
. O +

basis O +
in O +
an O +
open O +
clinical O +
trial O -
. O +

Various O +
doses O +
of O +
yohimbine O +
were O +
used O +
to O +
determine O +
the O +
ideal O +
dose O +
for O +
each O +
patient O -
. O +

RESULTS O -
: O +
Five O +
of O +
the O +
six O +
patients O +
experienced O +
improved O +
sexual O +
functioning O +
after O +
taking O +
yohimbine O -
. O +

One O +
patient O +
who O +
failed O +
to O +
comply O +
with O +
yohimbine O +
treatment O +
had O +
no O +
therapeutic O +
effects O -
. O +

Side O +
effects O +
of O +
yohimbine O +
included O +
excessive O +
sweating O -
, O +
increased O +
anxiety B-Disease -
, O +
and O +
a O +
wound O -
- O -
up O +
feeling O +
in O +
some O +
patients O -
. O +

CONCLUSION O -
: O +
The O +
results O +
of O +
this O +
study O +
indicate O +
that O +
yohimbine O +
may O +
be O +
an O +
effective O +
treatment O +
for O +
the O +
sexual B-Disease +
side I-Disease +
effects I-Disease +
caused O +
by O +
serotonin O +
reuptake O +
blockers O -
. O +

Future O +
controlled O +
studies O +
are O +
needed O +
to O +
further O +
investigate O +
the O +
effectiveness O +
and O +
safety O +
of O +
yohimbine O +
for O +
this O +
indication O -
. O +

Hemorrhagic B-Disease +
cystitis B-Disease +
complicating O +
bone O +
marrow O +
transplantation O -
. O +

Hemorrhagic B-Disease +
cystitis B-Disease +
is O +
a O +
potentially O +
serious O +
complication O +
of O +
high O -
- O -
dose O +
cyclophosphamide O +
therapy O +
administered O +
before O +
bone O +
marrow O +
transplantation O -
. O +

As O +
standard O +
practice O +
at O +
our O +
institution O -
, O +
patients O +
who O +
are O +
scheduled O +
to O +
receive O +
a O +
bone O +
marrow O +
transplant O +
are O +
treated O +
prophylactically O +
with O +
forced O +
hydration O +
and O +
bladder O +
irrigation O -
. O +

In O +
an O +
attempt O +
to O +
obviate O +
the O +
inconvenience O +
of O +
bladder O +
irrigation O -
, O +
we O +
conducted O +
a O +
feasibility O +
trial O +
of O +
uroprophylaxis O +
with O +
mesna O -
, O +
which O +
neutralizes O +
the O +
hepatic O +
metabolite O +
of O +
cyclophosphamide O +
that O +
causes O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

Of O +
97 O +
patients O +
who O +
received O +
standard O +
prophylaxis O -
, O +
4 O +
had O +
symptomatic O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

In O +
contrast O -
, O +
two O +
of O +
four O +
consecutive O +
patients O +
who O +
received O +
mesna O +
uroprophylaxis O +
before O +
allogeneic O +
bone O +
marrow O +
transplantation O +
had O +
severe O +
hemorrhagic B-Disease +
cystitis B-Disease +
for O +
at O +
least O +
2 O +
weeks O -
. O +

Because O +
of O +
this O +
suboptimal O +
result O -
, O +
we O +
resumed O +
the O +
use O +
of O +
bladder O +
irrigation O +
and O +
forced O +
hydration O +
to O +
minimize O +
the O +
risk O +
of O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

Safety O +
and O +
adverse O +
effects O +
associated O +
with O +
raloxifene O -
: O +
multiple O +
outcomes O +
of O +
raloxifene O +
evaluation O -
. O +

OBJECTIVE O -
: O +
To O +
examine O +
the O +
effect O +
of O +
raloxifene O +
on O +
major O +
adverse O +
events O +
that O +
occur O +
with O +
postmenopausal O +
estrogen O +
therapy O +
or O +
tamoxifen O -
. O +

METHODS O -
: O +
The O +
Multiple O +
Outcomes O +
of O +
Raloxifene O +
Evaluation O -
, O +
a O +
multicenter O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
trial O -
, O +
enrolled O +
7,705 O +
postmenopausal O +
women O +
with O +
osteoporosis B-Disease -
. O +

Women O +
were O +
randomly O +
assigned O +
to O +
raloxifene O +
60 O +
mg O -
/ O -
d O +
or O +
120 O +
mg O -
/ O -
d O +
or O +
placebo O -
. O +

Outcomes O +
included O +
venous B-Disease +
thromboembolism I-Disease -
, O +
cataracts B-Disease -
, O +
gallbladder B-Disease +
disease I-Disease -
, O +
and O +
endometrial B-Disease +
hyperplasia I-Disease +
or B-Disease +
cancer I-Disease -
. O +

RESULTS O -
: O +
During O +
a O +
mean O +
follow O -
- O -
up O +
of O +
3.3 O +
years O -
, O +
raloxifene O +
was O +
associated O +
with O +
an O +
increased O +
risk O +
for O +
venous B-Disease +
thromboembolism I-Disease +
( O -
relative O +
risk O +
[ O -
RR O -
] O +
2.1 O -
; O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O +
1.2 O -
- O -
3.8 O -
) O -
. O +

The O +
excess O +
event O +
rate O +
was O +
1.8 O +
per O +
1,000 O +
woman O -
- O -
years O +
( O -
95 O -
% O +
CI O +
-0.5 O -
- O -
4.1 O -
) O -
, O +
and O +
the O +
number O +
needed O +
to O +
treat O +
to O +
cause O +
1 O +
event O +
was O +
170 O +
( O -
95 O -
% O +
CI O +
100 O -
- O -
582 O -
) O +
over O +
3.3 O +
years O -
. O +

Risk O +
in O +
the O +
raloxifene O +
group O +
was O +
higher O +
than O +
in O +
the O +
placebo O +
group O +
for O +
the O +
first O +
2 O +
years O -
, O +
but O +
decreased O +
to O +
about O +
the O +
same O +
rate O +
as O +
in O +
the O +
placebo O +
group O +
thereafter O -
. O +

Raloxifene O +
did O +
not O +
increase O +
risk O +
for O +
cataracts B-Disease +
( O -
RR O +
0.9 O -
; O +
95 O -
% O +
CI O +
0.8 O -
- O -
1.1 O -
) O -
, O +
gallbladder B-Disease +
disease I-Disease +
( O -
RR O +
1.0 O -
; O +
95 O -
% O +
CI O +
0.7 O -
- O -
1.3 O -
) O -
, O +
endometrial B-Disease +
hyperplasia I-Disease +
( O -
RR O +
1.3 O -
; O +
95 O -
% O +
CI O +
0.4 O -
- O -
5.1 O -
) O -
, O +
or O +
endometrial B-Disease +
cancer I-Disease +
( O -
RR O +
0.9 O -
; O +
95 O -
% O +
CI O +
0.3 O -
- O -
2.7 O -
) O -
. O +

CONCLUSION O -
: O +
Raloxifene O +
was O +
associated O +
with O +
an O +
increased O +
risk O +
for O +
venous B-Disease +
thromboembolism I-Disease -
, O +
but O +
there O +
was O +
no O +
increased O +
risk O +
for O +
cataracts B-Disease -
, O +
gallbladder B-Disease +
disease I-Disease -
, O +
endometrial B-Disease +
hyperplasia I-Disease -
, O +
or O +
endometrial B-Disease +
cancer I-Disease -
. O +

LEVEL O +
OF O +
EVIDENCE O -
: O +
I O +

Optimization O +
of O +
levodopa O +
therapy O -
. O +

While O +
there O +
is O +
no O +
single O +
correct O +
starting O +
dose O +
for O +
levodopa O +
therapy O -
, O +
many O +
individuals O +
can O +
be O +
started O +
on O +
either O +
the O +
25 O -
/ O -
100 O +
or O +
controlled O -
- O -
release O +
formula O -
, O +
following O +
the O +
general O +
rule O +
not O +
to O +
attempt O +
to O +
titrate O +
carbidopa O -
- O -
levodopa O +
to O +
the O +
point O +
of O +
" O -
normality O -
, O -
" O +
which O +
can O +
lead O +
to O +
toxicity B-Disease -
. O +

The O +
physician O +
should O +
also O +
determine O +
the O +
proper O +
use O +
of O +
any O +
adjunctive O +
medications O -
; O +
such O +
combined O +
therapy O +
has O +
become O +
the O +
standard O +
approach O +
to O +
treatment O -
. O +

Following O +
the O +
initial O +
period O +
of O +
therapy O -
, O +
emerging O +
difficulties O +
require O +
a O +
reassessment O +
of O +
therapeutic O +
approaches O -
, O +
such O +
as O +
dosage O +
adjustment O +
or O +
introduction O +
of O +
a O +
dopamine O +
agonist O -
. O +

Other O +
possible O +
adverse O +
effects O -
-- O -
such O +
as O +
gastrointestinal B-Disease +
disorders I-Disease -
, O +
orthostatic B-Disease +
hypotension I-Disease -
, O +
levodopa O -
- O -
induced O +
psychosis B-Disease -
, O +
sleep B-Disease +
disturbances I-Disease +
or O +
parasomnias B-Disease -
, O +
or O +
drug O +
interactions O -
-- O -
also O +
require O +
carefully O +
monitored O +
individual O +
treatment O -
. O +

Nonpharmacologic O +
concerns O +
can O +
help O +
the O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
patient O +
achieve O +
and O +
maintain O +
optimal O +
functioning O -
, O +
including O +
daily O +
exercise O -
, O +
physical O +
therapy O -
, O +
and O +
involvement O +
with O +
support O +
groups O -
. O +

Long O +
term O +
audiological O +
evaluation O +
of O +
beta B-Disease -
- I-Disease -
thalassemic I-Disease +
patients O -
. O +

OBJECTIVE O -
: O +
The O +
objective O +
of O +
this O +
study O +
was O +
to O +
identify O +
the O +
incidence O +
and O +
to O +
monitor O +
the O +
progression O +
of O +
hearing B-Disease +
loss I-Disease +
in O +
children O +
and O +
young O +
adults O +
with O +
beta B-Disease -
- I-Disease -
thalassemia I-Disease +
major O -
. O +

METHODS O -
: O +
One O +
hundred O +
and O +
four O +
( O -
104 O -
) O +
patients O +
aged O +
6 O -
- O -
35 O +
years O +
( O -
mean O +
17,2 O +
years O -
) O +
participated O +
in O +
the O +
study O -
. O +

All O +
patients O +
were O +
on O +
a O +
regular O +
transfusion O -
- O -
chelation O +
program O +
maintaining O +
a O +
mean O +
hemoglobin O +
level O +
of O +
9.5 O +
gr O -
/ O -
dl O -
. O +

Subjects O +
were O +
receiving O +
desferrioxamine O +
( O -
DFO O -
) O +
chelation O +
treatment O +
with O +
a O +
mean O +
daily O +
dose O +
of O +
50 O -
- O -
60 O +
mg O -
/ O -
kg O -
, O +
5 O -
- O -
6 O +
days O +
a O +
week O +
during O +
the O +
first O +
six O +
years O +
of O +
the O +
study O -
, O +
which O +
was O +
then O +
reduced O +
to O +
40 O -
- O -
50 O +
mg O -
/ O -
kg O +
for O +
the O +
following O +
eight O +
years O -
. O +

Patients O +
were O +
followed O +
for O +
8 O -
- O -
14 O +
years O -
. O +

RESULTS O -
: O +
Overall O -
, O +
21 O +
out O +
of O +
104 O +
patients O +
( O -
20.2 O -
% O -
) O +
presented O +
with O +
high O +
frequency O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease +
( O -
SNHL B-Disease -
) O -
, O +
either O +
unilateral O +
or O +
bilateral O -
. O +

No O +
ototoxic B-Disease +
factor O -
, O +
other O +
than O +
DFO O -
, O +
was O +
present O +
in O +
any O +
of O +
the O +
patients O -
. O +

Patients O +
with O +
SNHL B-Disease +
presented O +
with O +
relatively O +
lower O +
serum O +
ferritin O +
levels O +
than O +
those O +
with O +
normal O +
hearing O -
, O +
however O -
, O +
no O +
statistically O +
significant O +
difference O +
was O +
observed O -
. O +

Subjects O +
with O +
SNHL B-Disease +
were O +
submitted O +
to O +
DFO O +
reduction O +
or O +
temporary O +
withdrawal O -
. O +

Following O +
intervention O -
, O +
7 O +
out O +
of O +
21 O +
affected O +
patients O +
recovered O -
, O +
10 O +
remained O +
stable O +
and O +
4 O +
demonstrated O +
aggravation O -
. O +

CONCLUSION O -
: O +
The O +
findings O +
are O +
indicative O +
of O +
DFO O -
's O +
contributing O +
role O +
in O +
the O +
development O +
of O +
hearing B-Disease +
impairment I-Disease -
. O +

Regular O +
audiologic O +
evaluation O +
is O +
imperative O +
in O +
all O +
thalassemic B-Disease +
patients O +
so O +
that O +
early O +
changes O +
may O +
be O +
recognized O +
and O +
treatment O +
may O +
be O +
judiciously O +
adjusted O +
in O +
order O +
to O +
prevent O +
or O +
reverse O +
hearing B-Disease +
impairment I-Disease -
. O +

Consensus O +
statement O +
concerning O +
cardiotoxicity B-Disease +
occurring O +
during O +
haematopoietic O +
stem O +
cell O +
transplantation O +
in O +
the O +
treatment O +
of O +
autoimmune B-Disease +
diseases I-Disease -
, O +
with O +
special O +
reference O +
to O +
systemic B-Disease +
sclerosis I-Disease +
and O +
multiple B-Disease +
sclerosis I-Disease -
. O +

Autologous O +
haematopoietic O +
stem O +
cell O +
transplantation O +
is O +
now O +
a O +
feasible O +
and O +
effective O +
treatment O +
for O +
selected O +
patients O +
with O +
severe O +
autoimmune B-Disease +
diseases I-Disease -
. O +

Worldwide O -
, O +
over O +
650 O +
patients O +
have O +
been O +
transplanted O +
in O +
the O +
context O +
of O +
phase O +
I O +
and O +
II O +
clinical O +
trials O -
. O +

The O +
results O +
are O +
encouraging O +
enough O +
to O +
begin O +
randomised O +
phase O +
III O +
trials O -
. O +

However O -
, O +
as O +
predicted O -
, O +
significant O +
transplant O -
- O -
related O +
morbidity O +
and O +
mortality O +
have O +
been O +
observed O -
. O +

This O +
is O +
primarily O +
due O +
to O +
complications O +
related O +
to O +
either O +
the O +
stage O +
of O +
the O +
disease O +
at O +
transplant O +
or O +
due O +
to O +
infections B-Disease -
. O +

The O +
number O +
of O +
deaths O +
related O +
to O +
cardiac B-Disease +
toxicity I-Disease +
is O +
low O -
. O +

However O -
, O +
caution O +
is O +
required O +
when O +
cyclophosphamide O +
or O +
anthracyclines O +
such O +
as O +
mitoxantrone O +
are O +
used O +
in O +
patients O +
with O +
a O +
possible O +
underlying O +
heart B-Disease +
damage I-Disease -
, O +
for O +
example O -
, O +
systemic B-Disease +
sclerosis I-Disease +
patients O -
. O +

In O +
November O +
2002 O -
, O +
a O +
meeting O +
was O +
held O +
in O +
Florence O -
, O +
bringing O +
together O +
a O +
number O +
of O +
experts O +
in O +
various O +
fields O -
, O +
including O +
rheumatology O -
, O +
cardiology O -
, O +
neurology O -
, O +
pharmacology O +
and O +
transplantation O +
medicine O -
. O +

The O +
object O +
of O +
the O +
meeting O +
was O +
to O +
analyse O +
existing O +
data O -
, O +
both O +
published O +
or O +
available O -
, O +
in O +
the O +
European O +
Group O +
for O +
Blood O +
and O +
Marrow O +
Transplantation O +
autoimmune B-Disease +
disease I-Disease +
database O -
, O +
and O +
to O +
propose O +
a O +
safe O +
approach O +
to O +
such O +
patients O -
. O +

A O +
full O +
cardiological O +
assessment O +
before O +
and O +
during O +
the O +
transplant O +
emerged O +
as O +
the O +
major O +
recommendation O -
. O +

Does O +
supplemental O +
vitamin O +
C O +
increase O +
cardiovascular B-Disease +
disease I-Disease +
risk O +
in O +
women O +
with O +
diabetes B-Disease -
? O +

BACKGROUND O -
: O +
Vitamin O +
C O +
acts O +
as O +
a O +
potent O +
antioxidant O -
; O +
however O -
, O +
it O +
can O +
also O +
be O +
a O +
prooxidant O +
and O +
glycate O +
protein O +
under O +
certain O +
circumstances O +
in O +
vitro O -
. O +

These O +
observations O +
led O +
us O +
to O +
hypothesize O +
that O +
a O +
high O +
intake O +
of O +
vitamin O +
C O +
in O +
diabetic B-Disease +
persons O +
might O +
promote O +
atherosclerosis B-Disease -
. O +

OBJECTIVE O -
: O +
The O +
objective O +
was O +
to O +
examine O +
the O +
relation O +
between O +
vitamin O +
C O +
intake O +
and O +
mortality O +
from O +
cardiovascular B-Disease +
disease I-Disease -
. O +

DESIGN O -
: O +
We O +
studied O +
the O +
relation O +
between O +
vitamin O +
C O +
intake O +
and O +
mortality O +
from O +
total O +
cardiovascular B-Disease +
disease I-Disease +
( O -
n O +
= O +
281 O -
) O -
, O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
( O -
n O +
= O +
175 O -
) O -
, O +
and O +
stroke B-Disease +
( O -
n O +
= O +
57 O -
) O +
in O +
1923 O +
postmenopausal O +
women O +
who O +
reported O +
being O +
diabetic B-Disease +
at O +
baseline O -
. O +

Diet O +
was O +
assessed O +
with O +
a O +
food O -
- O -
frequency O +
questionnaire O +
at O +
baseline O -
, O +
and O +
subjects O +
initially O +
free O +
of O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
were O +
prospectively O +
followed O +
for O +
15 O +
y. O +
RESULTS O -
: O +
After O +
adjustment O +
for O +
cardiovascular B-Disease +
disease I-Disease +
risk O +
factors O -
, O +
type O +
of O +
diabetes B-Disease +
medication O +
used O -
, O +
duration O +
of O +
diabetes B-Disease -
, O +
and O +
intakes O +
of O +
folate O -
, O +
vitamin O +
E O -
, O +
and O +
beta O -
- O -
carotene O -
, O +
the O +
adjusted O +
relative O +
risks O +
of O +
total O +
cardiovascular B-Disease +
disease I-Disease +
mortality O +
were O +
1.0 O -
, O +
0.97 O -
, O +
1.11 O -
, O +
1.47 O -
, O +
and O +
1.84 O +
( O -
P O +
for O +
trend O +
< O +
0.01 O -
) O +
across O +
quintiles O +
of O +
total O +
vitamin O +
C O +
intake O +
from O +
food O +
and O +
supplements O -
. O +

Adjusted O +
relative O +
risks O +
of O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
were O +
1.0 O -
, O +
0.81 O -
, O +
0.99 O -
, O +
1.26 O -
, O +
and O +
1.91 O +
( O -
P O +
for O +
trend O +
= O +
0.01 O -
) O +
and O +
of O +
stroke B-Disease +
were O +
1.0 O -
, O +
0.52 O -
, O +
1.23 O -
, O +
2.22 O -
, O +
and O +
2.57 O +
( O -
P O +
for O +
trend O +
< O +
0.01 O -
) O -
. O +

When O +
dietary O +
and O +
supplemental O +
vitamin O +
C O +
were O +
analyzed O +
separately O -
, O +
only O +
supplemental O +
vitamin O +
C O +
showed O +
a O +
positive O +
association O +
with O +
mortality O +
endpoints O -
. O +

Vitamin O +
C O +
intake O +
was O +
unrelated O +
to O +
mortality O +
from O +
cardiovascular B-Disease +
disease I-Disease +
in O +
the O +
nondiabetic O +
subjects O +
at O +
baseline O -
. O +

CONCLUSION O -
: O +
A O +
high O +
vitamin O +
C O +
intake O +
from O +
supplements O +
is O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
cardiovascular B-Disease +
disease I-Disease +
mortality O +
in O +
postmenopausal O +
women O +
with O +
diabetes B-Disease -
. O +

Optical O +
coherence O +
tomography O +
can O +
measure O +
axonal O +
loss O +
in O +
patients O +
with O +
ethambutol O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease -
. O +

PURPOSE O -
: O +
To O +
map O +
and O +
identify O +
the O +
pattern O -
, O +
in O +
vivo O -
, O +
of O +
axonal B-Disease +
degeneration I-Disease +
in O +
ethambutol O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease +
using O +
optical O +
coherence O +
tomography O +
( O -
OCT O -
) O -
. O +

Ethambutol O +
is O +
an O +
antimycobacterial O +
agent O +
often O +
used O +
to O +
treat O +
tuberculosis B-Disease -
. O +

A O +
serious O +
complication O +
of O +
ethambutol O +
is O +
an O +
optic B-Disease +
neuropathy I-Disease +
that O +
impairs O +
visual O +
acuity O -
, O +
contrast O +
sensitivity O -
, O +
and O +
color O +
vision O -
. O +

However O -
, O +
early O +
on O -
, O +
when O +
the O +
toxic O +
optic B-Disease +
neuropathy I-Disease +
is O +
mild O +
and O +
partly O +
reversible O -
, O +
the O +
funduscopic O +
findings O +
are O +
often O +
subtle O +
and O +
easy O +
to O +
miss O -
. O +

METHODS O -
: O +
Three O +
subjects O +
with O +
a O +
history O +
of O +
ethambutol O +
( O -
EMB O -
) O -
-induced O +
optic B-Disease +
neuropathy I-Disease +
of O +
short- O -
, O +
intermediate- O -
, O +
and O +
long O -
- O -
term O +
visual B-Disease +
deficits I-Disease +
were O +
administered O +
a O +
full O +
neuro O -
- O -
ophthalmologic O +
examination O +
including O +
visual O +
acuity O -
, O +
color O +
vision O -
, O +
contrast O +
sensitivity O -
, O +
and O +
fundus O +
examination O -
. O +

In O +
addition O -
, O +
OCT O +
( O -
OCT O +
3000 O -
, O +
Humphrey O -
- O -
Zeiss O -
, O +
Dublin O -
, O +
CA O -
) O +
was O +
performed O +
on O +
both O +
eyes O +
of O +
each O +
subject O +
using O +
the O +
retinal O +
nerve O +
fiber O +
layer O +
( O -
RNFL O -
) O +
analysis O +
protocol O -
. O +

OCT O +
interpolates O +
data O +
from O +
100 O +
points O +
around O +
the O +
optic O +
nerve O +
to O +
effectively O +
map O +
out O +
the O +
RNFL O -
. O +

RESULTS O -
: O +
The O +
results O +
were O +
compared O +
to O +
the O +
calculated O +
average O +
RNFL O +
of O +
normal O +
eyes O +
accumulated O +
from O +
four O +
prior O +
studies O +
using O +
OCT O -
, O +
n=661 O -
. O +

In O +
all O +
subjects O +
with O +
history O +
of O +
EMB O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease -
, O +
there O +
was O +
a O +
mean O +
loss O +
of O +
72 O -
% O +
nerve O +
fiber O +
layer O +
thickness O +
in O +
the O +
temporal O +
quadrant O +
( O -
patient O +
A O -
, O +
with O +
eventual O +
recovery O +
of O +
visual O +
acuity O +
and O +
fields O -
, O +
58 O -
% O +
loss O -
; O +
patient O +
B O -
, O +
with O +
intermediate O +
visual B-Disease +
deficits I-Disease -
, O +
68 O -
% O +
loss O -
; O +
patient O +
C O -
, O +
with O +
chronic O +
visual B-Disease +
deficits I-Disease -
, O +
90 O -
% O +
loss O -
) O -
, O +
with O +
an O +
average O +
mean O +
optic O +
nerve O +
thickness O +
of O +
26+ O -
/ O -
-16 O +
microm O -
. O +

There O +
was O +
a O +
combined O +
mean O +
loss O +
of O +
46 O -
% O +
of O +
fibers O +
from O +
the O +
superior O -
, O +
inferior O -
, O +
and O +
nasal O +
quadrants O +
in O +
the O +
( O -
six O -
) O +
eyes O +
of O +
all O +
three O +
subjects O +
( O -
mean O +
average O +
thickness O +
of O +
55+ O -
/ O -
-29 O +
microm O -
) O -
. O +

In O +
both O +
sets O +
( O -
four O -
) O +
of O +
eyes O +
of O +
the O +
subjects O +
with O +
persistent O +
visual B-Disease +
deficits I-Disease +
( O -
patients O +
B O +
and O +
C O -
) O -
, O +
there O +
was O +
an O +
average O +
loss O +
of O +
79 O -
% O +
of O +
nerve O +
fiber O +
thickness O +
in O +
the O +
temporal O +
quadrant O -
. O +

CONCLUSIONS O -
: O +
The O +
OCT O +
results O +
in O +
these O +
patients O +
with O +
EMB O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease +
show O +
considerable O +
loss O +
especially O +
of O +
the O +
temporal O +
fibers O -
. O +

This O +
is O +
consistent O +
with O +
prior O +
histopathological O +
studies O +
that O +
show O +
predominant O +
loss O +
of O +
parvo O -
- O -
cellular O +
axons O +
( O -
or O +
small O -
- O -
caliber O +
axons O -
) O +
within O +
the O +
papillo O -
- O -
macular O +
bundle O +
in O +
toxic O +
or O +
hereditary O +
optic B-Disease +
neuropathies I-Disease -
. O +

OCT O +
can O +
be O +
a O +
valuable O +
tool O +
in O +
the O +
quantitative O +
analysis O +
of O +
optic B-Disease +
neuropathies I-Disease -
. O +

Additionally O -
, O +
in O +
terms O +
of O +
management O +
of O +
EMB O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease -
, O +
it O +
is O +
important O +
to O +
properly O +
manage O +
ethambutol O +
dosing O +
in O +
patients O +
with O +
renal B-Disease +
impairment I-Disease +
and O +
to O +
achieve O +
proper O +
transition O +
to O +
a O +
maintenance O +
dose O +
once O +
an O +
appropriate O +
loading O +
dose O +
has O +
been O +
reached O -
. O +

Individual O +
differences O +
in O +
renal O +
ACE O +
activity O +
in O +
healthy O +
rats O +
predict O +
susceptibility O +
to O +
adriamycin O -
- O -
induced O +
renal B-Disease +
damage I-Disease -
. O +

BACKGROUND O -
: O +
In O +
man O -
, O +
differences O +
in O +
angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
levels O -
, O +
related O +
to O +
ACE O +
( O -
I O -
/ O -
D O -
) O +
genotype O -
, O +
are O +
associated O +
with O +
renal O +
prognosis O -
. O +

This O +
raises O +
the O +
hypothesis O +
that O +
individual O +
differences O +
in O +
renal O +
ACE O +
activity O +
are O +
involved O +
in O +
renal O +
susceptibility O +
to O +
inflicted O +
damage O -
. O +

Therefore O -
, O +
we O +
studied O +
the O +
predictive O +
effect O +
of O +
renal O +
ACE O +
activity O +
for O +
the O +
severity O +
of O +
renal B-Disease +
damage I-Disease +
induced O +
by O +
a O +
single O +
injection O +
of O +
adriamycin O +
in O +
rats O -
. O +

METHODS O -
: O +
Renal O +
ACE O +
activity O +
( O -
Hip O -
- O -
His O -
- O -
Leu O +
cleavage O +
by O +
cortical O +
homogenates O -
) O +
was O +
determined O +
by O +
renal O +
biopsy O +
in O +
27 O +
adult O +
male O +
Wistar O +
rats O -
. O +

After O +
1 O +
week O +
of O +
recovery O -
, O +
proteinuria B-Disease +
was O +
induced O +
by O +
adriamycin O +
[ O -
1.5 O +
mg O -
/ O -
kg O +
intravenously O +
( O -
i.v O -
. O -
) O +

n O +
= O +
18 O -
; O +
controls O -
, O +
saline O +
i.v O -
. O +

n O +
= O +
9 O -
] O -
. O +

Proteinuria B-Disease +
was O +
measured O +
every O +
2 O +
weeks O -
. O +

After O +
12 O +
weeks O -
, O +
rats O +
were O +
sacrificed O +
and O +
their O +
kidneys O +
harvested O -
. O +

RESULTS O -
: O +
As O +
anticipated O -
, O +
adriamycin O +
elicited O +
nephrotic B-Disease +
range O +
proteinuria B-Disease -
, O +
renal B-Disease +
interstitial I-Disease +
damage I-Disease +
and O +
mild O +
focal B-Disease +
glomerulosclerosis I-Disease -
. O +

Baseline O +
renal O +
ACE O +
positively O +
correlated O +
with O +
the O +
relative O +
rise O +
in O +
proteinuria B-Disease +
after O +
adriamycin O +
( O -
r O +
= O +
0.62 O -
, O +
P<0.01 O -
) O -
, O +
renal O +
interstitial O +
alpha O -
- O -
smooth O +
muscle O +
actin O +
( O -
r O +
= O +
0.49 O -
, O +
P<0.05 O -
) O -
, O +
interstitial O +
macrophage O +
influx O +
( O -
r O +
= O +
0.56 O -
, O +
P<0.05 O -
) O -
, O +
interstitial O +
collagen O +
III O +
( O -
r O +
= O +
0.53 O -
, O +
P<0.05 O -
) O -
, O +
glomerular O +
alpha O -
- O -
smooth O +
muscle O +
actin O +
( O -
r O +
= O +
0.74 O -
, O +
P<0.01 O -
) O +
and O +
glomerular O +
desmin O +
( O -
r O +
= O +
0.48 O -
, O +
P<0.05 O -
) O -
. O +

Baseline O +
renal O +
ACE O +
did O +
not O +
correlate O +
with O +
focal B-Disease +
glomerulosclerosis I-Disease +
( O -
r O +
= O +
0.22 O -
, O +
NS O -
) O -
. O +

In O +
controls O -
, O +
no O +
predictive O +
values O +
for O +
renal O +
parameters O +
were O +
observed O -
. O +

CONCLUSION O -
: O +
Individual O +
differences O +
in O +
renal O +
ACE O +
activity O +
predict O +
the O +
severity O +
of O +
adriamycin O -
- O -
induced O +
renal B-Disease +
damage I-Disease +
in O +
this O +
outbred O +
rat O +
strain O -
. O +

This O +
supports O +
the O +
assumption O +
that O +
differences O +
in O +
renal O +
ACE O +
activity O +
predispose O +
to O +
a O +
less O +
favourable O +
course O +
of O +
renal B-Disease +
damage I-Disease -
. O +

Hypoxia B-Disease +
in O +
renal B-Disease +
disease I-Disease +
with O +
proteinuria B-Disease +
and/or O +
glomerular O +
hypertension B-Disease -
. O +

Despite O +
the O +
increasing O +
need O +
to O +
identify O +
and O +
quantify O +
tissue O +
oxygenation O +
at O +
the O +
cellular O +
level O -
, O +
relatively O +
few O +
methods O +
have O +
been O +
available O -
. O +

In O +
this O +
study O -
, O +
we O +
developed O +
a O +
new O +
hypoxia B-Disease -
- O -
responsive O +
reporter O +
vector O +
using O +
a O +
hypoxia B-Disease -
- O -
responsive O +
element O +
of O +
the O +
5 O -
' O +
vascular O +
endothelial O +
growth O +
factor O +
untranslated O +
region O +
and O +
generated O +
a O +
novel O +
hypoxia B-Disease -
- O -
sensing O +
transgenic O +
rat O -
. O +

We O +
then O +
applied O +
this O +
animal O +
model O +
to O +
the O +
detection O +
of O +
tubulointerstitial O +
hypoxia B-Disease +
in O +
the O +
diseased B-Disease +
kidney I-Disease -
. O +

With O +
this O +
model O -
, O +
we O +
were O +
able O +
to O +
identify O +
diffuse O +
cortical O +
hypoxia B-Disease +
in O +
the O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease +
and O +
focal O +
and O +
segmental O +
hypoxia B-Disease +
in O +
the O +
remnant O +
kidney O +
model O -
. O +

Expression O +
of O +
the O +
hypoxia B-Disease -
- O -
responsive O +
transgene O +
increased O +
throughout O +
the O +
observation O +
period O -
, O +
reaching O +
2.2-fold O +
at O +
2 O +
weeks O +
in O +
the O +
puromycin O +
aminonucleoside O +
model O +
and O +
2.6-fold O +
at O +
4 O +
weeks O +
in O +
the O +
remnant O +
kidney O +
model O -
, O +
whereas O +
that O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
showed O +
a O +
mild O +
decrease O -
, O +
reflecting O +
distinct O +
behaviors O +
of O +
the O +
two O +
genes O -
. O +

The O +
degree O +
of O +
hypoxia B-Disease +
showed O +
a O +
positive O +
correlation O +
with O +
microscopic O +
tubulointerstitial B-Disease +
injury I-Disease +
in O +
both O +
models O -
. O +

Finally O -
, O +
we O +
identified O +
the O +
localization O +
of O +
proliferating O +
cell O +
nuclear O +
antigen O -
- O -
positive O -
, O +
ED-1-positive O -
, O +
and O +
terminal O +
dUTP O +
nick O -
- O -
end O +
labeled O -
- O -
positive O +
cells O +
in O +
the O +
hypoxic B-Disease +
cortical O +
area O +
in O +
the O +
remnant O +
kidney O +
model O -
. O +

We O +
propose O +
here O +
a O +
possible O +
pathological O +
tie O +
between O +
chronic O +
tubulointerstitial O +
hypoxia B-Disease +
and O +
progressive O +
glomerular B-Disease +
diseases I-Disease -
. O +

Adequate O +
timing O +
of O +
ribavirin O +
reduction O +
in O +
patients O +
with O +
hemolysis B-Disease +
during O +
combination O +
therapy O +
of O +
interferon O +
and O +
ribavirin O +
for O +
chronic B-Disease +
hepatitis I-Disease +
C. I-Disease +
BACKGROUND O -
: O +
Hemolytic B-Disease +
anemia I-Disease +
is O +
one O +
of O +
the O +
major O +
adverse O +
events O +
of O +
the O +
combination O +
therapy O +
of O +
interferon O +
and O +
ribavirin O -
. O +

Because O +
of O +
ribavirin O -
- O -
related O +
hemolytic B-Disease +
anemia I-Disease -
, O +
dose O +
reduction O +
is O +
a O +
common O +
event O +
in O +
this O +
therapy O -
. O +

In O +
this O +
clinical O +
retrospective O +
cohort O +
study O +
we O +
have O +
examined O +
the O +
suitable O +
timing O +
of O +
ribavirin O +
reduction O +
in O +
patients O +
with O +
hemolysis B-Disease +
during O +
combination O +
therapy O -
. O +

METHODS O -
: O +
Thirty O -
- O -
seven O +
of O +
160 O +
patients O +
who O +
had O +
HCV O -
- O -
genotype O +
1b O -
, O +
had O +
high O +
virus O +
load O -
, O +
and O +
received O +
24-week O +
combination O +
therapy O +
developed O +
anemia B-Disease +
with O +
hemoglobin O +
level O +
< O -
10 O +
g O -
/ O -
dl O +
or O +
anemia B-Disease -
- O -
related O +
signs O +
during O +
therapy O -
. O +

After O +
that O -
, O +
these O +
37 O +
patients O +
were O +
reduced O +
one O +
tablet O +
of O +
ribavirin O +
( O -
200 O +
mg O -
) O +
per O +
day O -
. O +

After O +
reduction O +
of O +
ribavirin O -
, O +
27 O +
of O +
37 O +
patients O +
could O +
continue O +
combination O +
therapy O +
for O +
a O +
total O +
of O +
24 O +
weeks O +
( O -
group O +
A O -
) O -
. O +

However O -
, O +
10 O +
of O +
37 O +
patients O +
with O +
reduction O +
of O +
ribavirin O +
could O +
not O +
continue O +
combination O +
therapy O +
because O +
their O +
< O -
8.5 O +
g O -
/ O -
dl O +
hemoglobin O +
values O +
decreased O +
to O +
or O +
anemia B-Disease -
- O -
related O +
severe O +
side O +
effects O +
occurred O +
( O -
group O +
B O -
) O -
. O +

We O +
assessed O +
the O +
final O +
efficacy O +
and O +
safety O +
after O +
reduction O +
of O +
ribavirin O +
in O +
groups O +
A O +
and O +
B. O +
RESULTS O -
: O +
A O +
sustained O +
virological O +
response O +
( O -
SVR O -
) O +
was O +
29.6 O -
% O +
( O -
8 O -
/ O -
27 O -
) O +
in O +
group O +
A O +
and O +
10 O -
% O +
( O -
1 O -
/ O -
10 O -
) O +
in O +
group O +
B O -
, O +
respectively O -
. O +

A O +
34.4 O -
% O +
( O -
12 O -
/ O -
27 O -
) O +
of O +
SVR O +
+ O +
biological O +
response O +
in O +
group O +
A O +
was O +
higher O +
than O +
10 O -
% O +
( O -
1 O -
/ O -
10 O -
) O +
in O +
group O +
B O +
( O +
P O +
= O +
0.051 O -
) O -
, O +
with O +
slight O +
significance O -
. O +

With O +
respect O +
to O +
hemoglobin O +
level O +
at O +
the O +
time O +
of O +
ribavirin O +
reduction O -
, O +
a O +
rate O +
of O +
continuation O +
of O +
therapy O +
in O +
patients O +
with O +
> O +
or O +
= O -
10 O +
g O -
/ O -
dl O +
hemoglobin O +
was O +
higher O +
than O +
that O +
in O +
patients O +
with O +
< O -
10 O +
g O -
/ O -
dl O +
( O +
P O +
= O +
0.036 O -
) O -
. O +

CONCLUSIONS O -
: O +
Reduction O +
of O +
ribavirin O +
at O +
hemoglobin O +
level O +
> O +
or O +
= O -
10 O +
g O -
/ O -
dl O +
is O +
suitable O +
in O +
terms O +
of O +
efficacy O +
and O +
side O +
effects O -
. O +

Recurrent O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
induced O +
by O +
azithromycin O -
. O +

A O +
14-year O -
- O -
old O +
girl O +
is O +
reported O +
with O +
recurrent O -
, O +
azithromycin O -
- O -
induced O -
, O +
acute O +
interstitial B-Disease +
nephritis I-Disease -
. O +

The O +
second O +
episode O +
was O +
more O +
severe O +
than O +
the O +
first O -
; O +
and O +
although O +
both O +
were O +
treated O +
with O +
intensive O +
corticosteroid O +
therapy O -
, O +
renal O +
function O +
remained O +
impaired O -
. O +

Although O +
most O +
cases O +
of O +
antibiotic O +
induced O +
acute O +
interstitial B-Disease +
nephritis I-Disease +
are O +
benign O +
and O +
self O -
- O -
limited O -
, O +
some O +
patients O +
are O +
at O +
risk O +
for O +
permanent O +
renal B-Disease +
injury I-Disease -
. O +

Spironolactone O -
- O -
induced O +
renal B-Disease +
insufficiency I-Disease +
and O +
hyperkalemia B-Disease +
in O +
patients O +
with O +
heart B-Disease +
failure I-Disease -
. O +

BACKGROUND O -
: O +
A O +
previous O +
randomized O +
controlled O +
trial O +
evaluating O +
the O +
use O +
of O +
spironolactone O +
in O +
heart B-Disease +
failure I-Disease +
patients O +
reported O +
a O +
low O +
risk O +
of O +
hyperkalemia B-Disease +
( O -
2 O -
% O -
) O +
and O +
renal B-Disease +
insufficiency I-Disease +
( O -
0 O -
% O -
) O -
. O +

Because O +
treatments O +
for O +
heart B-Disease +
failure I-Disease +
have O +
changed O +
since O +
the O +
benefits O +
of O +
spironolactone O +
were O +
reported O -
, O +
the O +
prevalence O +
of O +
these O +
complications O +
may O +
differ O +
in O +
current O +
clinical O +
practice O -
. O +

We O +
therefore O +
sought O +
to O +
determine O +
the O +
prevalence O +
and O +
clinical O +
associations O +
of O +
hyperkalemia B-Disease +
and O +
renal B-Disease +
insufficiency I-Disease +
in O +
heart B-Disease +
failure I-Disease +
patients O +
treated O +
with O +
spironolactone O -
. O +

METHODS O -
: O +
We O +
performed O +
a O +
case O +
control O +
study O +
of O +
heart B-Disease +
failure I-Disease +
patients O +
treated O +
with O +
spironolactone O +
in O +
our O +
clinical O +
practice O -
. O +

Cases O +
were O +
patients O +
who O +
developed O +
hyperkalemia B-Disease +
( O -
K O -
( O -
+ O -
) O +
> O -
5.0 O +
mEq O -
/ O -
L O -
) O +
or O +
renal B-Disease +
insufficiency I-Disease +
( O -
Cr O +
> O -
or=2.5 O +
mg O -
/ O -
dL O -
) O -
, O +
and O +
they O +
were O +
compared O +
to O +
2 O +
randomly O +
selected O +
controls O +
per O +
case O -
. O +

Clinical O +
characteristics O -
, O +
medications O -
, O +
and O +
serum O +
chemistries O +
at O +
baseline O +
and O +
follow O -
- O -
up O +
time O +
periods O +
were O +
compared O -
. O +

RESULTS O -
: O +
Sixty O -
- O -
seven O +
of O +
926 O +
patients O +
( O -
7.2 O -
% O -
) O +
required O +
discontinuation O +
of O +
spironolactone O +
due O +
to O +
hyperkalemia B-Disease +
( O -
n O +
= O +
33 O -
) O +
or O +
renal B-Disease +
failure I-Disease +
( O -
n O +
= O +
34 O -
) O -
. O +

Patients O +
who O +
developed O +
hyperkalemia B-Disease +
were O +
older O +
and O +
more O +
likely O +
to O +
have O +
diabetes B-Disease -
, O +
had O +
higher O +
baseline O +
serum O +
potassium O +
levels O +
and O +
lower O +
baseline O +
potassium O +
supplement O +
doses O -
, O +
and O +
were O +
more O +
likely O +
to O +
be O +
treated O +
with O +
beta O -
- O -
blockers O +
than O +
controls O +
( O -
n O +
= O +
134 O -
) O -
. O +

Patients O +
who O +
developed O +
renal B-Disease +
insufficiency I-Disease +
had O +
lower O +
baseline O +
body O +
weight O +
and O +
higher O +
baseline O +
serum O +
creatinine O -
, O +
required O +
higher O +
doses O +
of O +
loop O +
diuretics O -
, O +
and O +
were O +
more O +
likely O +
to O +
be O +
treated O +
with O +
thiazide O +
diuretics O +
than O +
controls O -
. O +

CONCLUSIONS O -
: O +
Spironolactone O -
- O -
induced O +
hyperkalemia B-Disease +
and O +
renal B-Disease +
insufficiency I-Disease +
are O +
more O +
common O +
in O +
our O +
clinical O +
experience O +
than O +
reported O +
previously O -
. O +

This O +
difference O +
is O +
explained O +
by O +
patient O +
comorbidities O +
and O +
more O +
frequent O +
use O +
of O +
beta O -
- O -
blockers O -
. O +

Aging O +
process O +
of O +
epithelial O +
cells O +
of O +
the O +
rat O +
prostate O +
lateral O +
lobe O +
in O +
experimental O +
hyperprolactinemia B-Disease +
induced O +
by O +
haloperidol O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
examine O +
the O +
influence O +
of O +
hyperprolactinemia B-Disease -
, O +
induced O +
by O +
haloperidol O +
( O -
HAL O -
) O +
on O +
age O +
related O +
morphology O +
and O +
function O +
changes O +
of O +
epithelial O +
cells O +
in O +
rat O +
prostate O +
lateral O +
lobe O -
. O +

The O +
study O +
was O +
performed O +
on O +
sexually O +
mature O +
male O +
rats O -
. O +

Serum O +
concentrations O +
of O +
prolactin O +
( O -
PRL O -
) O +
and O +
testosterone O +
( O -
T O -
) O +
were O +
measured O -
. O +

Tissue O +
sections O +
were O +
evaluated O +
with O +
light O +
and O +
electron O +
microscopy O -
. O +

Immunohistochemical O +
reactions O +
for O +
Anti O -
- O -
Proliferating O +
Cell O +
Nuclear O +
Antigen O +
( O -
PCNA O -
) O +
were O +
performed O -
. O +

In O +
rats O +
of O +
the O +
experimental O +
group O -
, O +
the O +
mean O +
concentration O +
of O -
: O +
PRL O +
was O +
more O +
than O +
twice O +
higher O -
, O +
whereas O +
T O +
concentration O +
was O +
almost O +
twice O +
lower O +
than O +
that O +
in O +
the O +
control O +
group O -
. O +

Light O +
microscopy O +
visualized O +
the O +
following O -
: O +
hypertrophy B-Disease +
and O +
epithelium O +
hyperplasia B-Disease +
of O +
the O +
glandular O +
ducts O -
, O +
associated O +
with O +
increased O +
PCNA O +
expression O -
. O +

Electron O +
microscopy O +
revealed O +
changes O +
in O +
columnar O +
epithelial O +
cells O -
, O +
concerning O +
organelles O -
, O +
engaged O +
in O +
protein O +
synthesis O +
and O +
secretion O -
. O +

Relation O +
of O +
perfusion O +
defects O +
observed O +
with O +
myocardial O +
contrast O +
echocardiography O +
to O +
the O +
severity O +
of O +
coronary B-Disease +
stenosis I-Disease -
: O +
correlation O +
with O +
thallium-201 O +
single O -
- O -
photon O +
emission O +
tomography O -
. O +

It O +
has O +
been O +
previously O +
shown O +
that O +
myocardial O +
contrast O +
echocardiography O +
is O +
a O +
valuable O +
technique O +
for O +
delineating O +
regions O +
of O +
myocardial O +
underperfusion O +
secondary O +
to O +
coronary B-Disease +
occlusion I-Disease +
and O +
to O +
critical O +
coronary B-Disease +
stenoses I-Disease +
in O +
the O +
presence O +
of O +
hyperemic B-Disease +
stimulation O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
myocardial O +
contrast O +
echocardiography O +
performed O +
with O +
a O +
stable O +
solution O +
of O +
sonicated O +
albumin O +
could O +
detect O +
regions O +
of O +
myocardial O +
underperfusion O +
resulting O +
from O +
various O +
degrees O +
of O +
coronary B-Disease +
stenosis I-Disease -
. O +

The O +
perfusion O +
defect O +
produced O +
in O +
16 O +
open O +
chest O +
dogs O +
was O +
compared O +
with O +
the O +
anatomic O +
area O +
at O +
risk O +
measured O +
by O +
the O +
postmortem O +
dual O -
- O -
perfusion O +
technique O +
and O +
with O +
thallium-201 O +
single O -
- O -
photon O +
emission O +
tomography O +
( O -
SPECT O -
) O -
. O +

During O +
a O +
transient O +
( O -
20-s O -
) O +
coronary B-Disease +
occlusion I-Disease -
, O +
a O +
perfusion O +
defect O +
was O +
observed O +
with O +
contrast O +
echocardiography O +
in O +
14 O +
of O +
the O +
15 O +
dogs O +
in O +
which O +
the O +
occlusion O +
was O +
produced O -
. O +

The O +
perfusion O +
defect O +
correlated O +
significantly O +
with O +
the O +
anatomic O +
area O +
at O +
risk O +
( O -
r O +
= O +
0.74 O -
; O +
p O +
less O +
than O +
0.002 O -
) O -
. O +

During O +
dipyridamole O -
- O -
induced O +
hyperemia B-Disease -
, O +
12 O +
of O +
the O +
16 O +
dogs O +
with O +
a O +
partial O +
coronary B-Disease +
stenosis I-Disease +
had O +
a O +
visible O +
area O +
of O +
hypoperfusion O +
by O +
contrast O +
echocardiography O -
. O +

The O +
four O +
dogs O +
without O +
a O +
perfusion O +
defect O +
had O +
a O +
stenosis O +
that O +
resulted O +
in O +
a O +
mild O +
( O -
0 O -
% O +
to O +
50 O -
% O -
) O +
reduction O +
in O +
dipyridamole O -
- O -
induced O +
hyperemia B-Disease -
. O +

The O +
size O +
of O +
the O +
perfusion O +
defect O +
during O +
stenosis O +
correlated O +
significantly O +
with O +
the O +
anatomic O +
area O +
at O +
risk O +
( O -
r O +
= O +
0.61 O -
; O +
p O +
= O +
0.02 O -
) O -
. O +

Thallium-201 O +
SPECT O +
demonstrated O +
a O +
perfusion O +
defect O +
in O +
all O +
14 O +
dogs O +
analyzed O +
during O +
dipyridamole O -
- O -
induced O +
hyperemia B-Disease -
; O +
the O +
size O +
of O +
the O +
perfusion O +
defect O +
correlated O +
with O +
the O +
anatomic O +
area O +
at O +
risk O +
( O -
r O +
= O +
0.58 O -
; O +
p O +
less O +
than O +
0.03 O -
) O +
and O +
with O +
the O +
perfusion O +
defect O +
by O +
contrast O +
echocardiography O +
( O -
r O +
= O +
0.58 O -
; O +
p O +
less O +
than O +
0.03 O -
) O -
. O +

Thus O -
, O +
myocardial O +
contrast O +
echocardiography O +
can O +
be O +
used O +
to O +
visualize O +
and O +
quantitate O +
the O +
amount O +
of O +
jeopardized O +
myocardium O +
during O +
moderate O +
to O +
severe O +
degrees O +
of O +
coronary B-Disease +
stenosis I-Disease -
. O +

The O +
results O +
obtained O +
show O +
a O +
correlation O +
with O +
the O +
anatomic O +
area O +
at O +
risk O +
similar O +
to O +
that O +
obtained O +
with O +
thallium-201 O +
SPECT O -
. O +

Acute O +
reserpine O +
and O +
subchronic O +
haloperidol O +
treatments O +
change O +
synaptosomal O +
brain O +
glutamate O +
uptake O +
and O +
elicit O +
orofacial B-Disease +
dyskinesia I-Disease +
in O +
rats O -
. O +

Reserpine- O +
and O +
haloperidol O -
- O -
induced O +
orofacial B-Disease +
dyskinesia I-Disease +
are O +
putative O +
animal O +
models O +
of O +
tardive B-Disease +
dyskinesia I-Disease +
( O -
TD B-Disease -
) O +
whose O +
pathophysiology O +
has O +
been O +
related O +
to O +
free O +
radical O +
generation O +
and O +
oxidative O +
stress O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
authors O +
induced O +
orofacial B-Disease +
dyskinesia I-Disease +
by O +
acute O +
reserpine O +
and O +
subchronic O +
haloperidol O +
administration O +
to O +
rats O -
. O +

Reserpine O +
injection O +
( O -
one O +
dose O +
of O +
1 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +

every O +
other O +
day O +
for O +
3 O +
days O +
caused O +
a O +
significant O +
increase O +
in O +
vacuous O +
chewing O -
, O +
tongue O +
protrusion O +
and O +
duration O +
of O +
facial O +
twitching O -
, O +
compared O +
to O +
the O +
control O -
. O +

Haloperidol O +
administration O +
( O -
one O +
dose O +
of O +
12 O +
mg O -
/ O -
kg O +
once O +
a O +
week O +
s.c O -
. O -
) O +
for O +
4 O +
weeks O +
caused O +
an O +
increase O +
in O +
vacuous O +
chewing O -
, O +
tongue O +
protrusion O +
and O +
duration O +
of O +
facial O +
twitching O +
observed O +
in O +
four O +
weekly O +
evaluations O -
. O +

After O +
the O +
treatments O +
and O +
behavioral O +
observation O -
, O +
glutamate O +
uptake O +
by O +
segments O +
of O +
the O +
brain O +
was O +
analyzed O -
. O +

A O +
decreased O +
glutamate O +
uptake O +
was O +
observed O +
in O +
the O +
subcortical O +
parts O +
of O +
animals O +
treated O +
with O +
reserpine O +
and O +
haloperidol O -
, O +
compared O +
to O +
the O +
control O -
. O +

Importantly O -
, O +
a O +
decrease O +
in O +
glutamate O +
uptake O +
correlates O +
negatively O +
with O +
an O +
increase O +
in O +
the O +
incidence O +
of O +
orofacial B-Disease +
diskinesia I-Disease -
. O +

These O +
results O +
indicate O +
that O +
early O +
changes O +
in O +
glutamate O +
transport O +
may O +
be O +
related O +
to O +
the O +
development O +
of O +
vacuous O +
chewing O +
movements O +
in O +
rats O -
. O +

The O +
activation O +
of O +
spinal O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
receptors O +
may O +
contribute O +
to O +
degeneration O +
of O +
spinal O +
motor O +
neurons O +
induced O +
by O +
neuraxial O +
morphine O +
after O +
a O +
noninjurious O +
interval O +
of O +
spinal B-Disease +
cord I-Disease +
ischemia I-Disease -
. O +

We O +
investigated O +
the O +
relationship O +
between O +
the O +
degeneration O +
of O +
spinal O +
motor O +
neurons O +
and O +
activation O +
of O +
N O -
- O -
methyl O -
- O -
d O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptors O +
after O +
neuraxial O +
morphine O +
following O +
a O +
noninjurious O +
interval O +
of O +
aortic B-Disease +
occlusion I-Disease +
in O +
rats O -
. O +

Spinal B-Disease +
cord I-Disease +
ischemia I-Disease +
was O +
induced O +
by O +
aortic B-Disease +
occlusion I-Disease +
for O +
6 O +
min O +
with O +
a O +
balloon O +
catheter O -
. O +

In O +
a O +
microdialysis O +
study O -
, O +
10 O +
muL O +
of O +
saline O +
( O -
group O +
C O -
; O +
n O +
= O +
8) O +
or O +
30 O +
mug O +
of O +
morphine O +
( O -
group O +
M O -
; O +
n O +
= O +
8) O +
was O +
injected O +
intrathecally O +
( O -
IT O -
) O +
0.5 O +
h O +
after O +
reflow O -
, O +
and O +
30 O +
mug O +
of O +
morphine O +
( O -
group O +
SM O -
; O +
n O +
= O +
8) O +
or O +
10 O +
muL O +
of O +
saline O +
( O -
group O +
SC O -
; O +
n O +
= O +
8) O +
was O +
injected O +
IT O +
0.5 O +
h O +
after O +
sham O +
operation O -
. O +

Microdialysis O +
samples O +
were O +
collected O +
preischemia O -
, O +
before O +
IT O +
injection O -
, O +
and O +
at O +
2 O -
, O +
4 O -
, O +
8 O -
, O +
24 O -
, O +
and O +
48 O +
h O +
of O +
reperfusion O +
( O -
after O +
IT O +
injection O -
) O -
. O +

Second O -
, O +
we O +
investigated O +
the O +
effect O +
of O +
IT O +
MK-801 O +
( O -
30 O +
mug O -
) O +
on O +
the O +
histopathologic O +
changes O +
in O +
the O +
spinal O +
cord O +
after O +
morphine O -
- O -
induced O +
spastic B-Disease +
paraparesis I-Disease -
. O +

After O +
IT O +
morphine O -
, O +
the O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
glutamate O +
concentration O +
was O +
increased O +
in O +
group O +
M O +
relative O +
to O +
both O +
baseline O +
and O +
group O +
C O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

This O +
increase O +
persisted O +
for O +
8 O +
hrs O -
. O +

IT O +
MK-801 O +
significantly O +
reduced O +
the O +
number O +
of O +
dark O -
- O -
stained O +
alpha O -
- O -
motoneurons O +
after O +
morphine O -
- O -
induced O +
spastic B-Disease +
paraparesis I-Disease +
compared O +
with O +
the O +
saline O +
group O -
. O +

These O +
data O +
indicate O +
that O +
IT O +
morphine O +
induces O +
spastic B-Disease +
paraparesis I-Disease +
with O +
a O +
concomitant O +
increase O +
in O +
CSF O +
glutamate O -
, O +
which O +
is O +
involved O +
in O +
NMDA O +
receptor O +
activation O -
. O +

We O +
suggest O +
that O +
opioids O +
may O +
be O +
neurotoxic B-Disease +
in O +
the O +
setting O +
of O +
spinal B-Disease +
cord I-Disease +
ischemia I-Disease +
via O +
NMDA O +
receptor O +
activation O -
. O +

Ceftriaxone O -
- O -
associated O +
biliary B-Disease +
pseudolithiasis I-Disease +
in O +
paediatric O +
surgical O +
patients O -
. O +

It O +
is O +
well O +
known O +
that O +
ceftriaxone O +
leads O +
to O +
pseudolithiasis B-Disease +
in O +
some O +
patients O -
. O +

Clinical O +
and O +
experimental O +
studies O +
also O +
suggest O +
that O +
situations O +
causing O +
gallbladder B-Disease +
dysfunction I-Disease -
, O +
such O +
as O +
fasting O -
, O +
may O +
have O +
a O +
role O +
for O +
the O +
development O +
of O +
pseudolithiasis B-Disease -
. O +

In O +
this O +
study O -
, O +
we O +
prospectively O +
evaluated O +
the O +
incidence O +
and O +
clinical O +
importance O +
of O +
pseudolithiasis B-Disease +
in O +
paediatric O +
surgical O +
patients O +
receiving O +
ceftriaxone O +
treatment O -
, O +
who O +
often O +
had O +
to O +
fast O +
in O +
the O +
post O -
- O -
operative O +
period O -
. O +

Fifty O +
children O +
who O +
were O +
given O +
ceftriaxone O +
were O +
evaluated O +
by O +
serial O +
abdominal O +
sonograms O -
. O +

Of O +
those O -
, O +
13 O +
( O -
26 O -
% O -
) O +
developed O +
biliary O +
pathology O -
. O +

Comparison O +
of O +
the O +
patients O +
with O +
or O +
without O +
pseudolithiasis B-Disease +
revealed O +
no O +
significant O +
difference O +
with O +
respect O +
to O +
age O -
, O +
sex O -
, O +
duration O +
of O +
the O +
treatment O +
and O +
starvation O +
variables O -
. O +

After O +
cessation O +
of O +
the O +
treatment O -
, O +
pseudolithiasis B-Disease +
resolved O +
spontaneously O +
within O +
a O +
short O +
period O -
. O +

The O +
incidence O +
of O +
pseudolithiasis B-Disease +
is O +
not O +
affected O +
by O +
fasting O -
. O +

Quantitative O +
drug O +
levels O +
in O +
stimulant O +
psychosis B-Disease -
: O +
relationship O +
to O +
symptom O +
severity O -
, O +
catecholamines O +
and O +
hyperkinesia B-Disease -
. O +

To O +
examine O +
the O +
relationship O +
between O +
quantitative O +
stimulant O +
drug O +
levels O -
, O +
catecholamines O -
, O +
and O +
psychotic B-Disease +
symptoms I-Disease -
, O +
nineteen O +
patients O +
in O +
a O +
psychiatric B-Disease +
emergency O +
service O +
with O +
a O +
diagnosis O +
of O +
amphetamine- O +
or O +
cocaine O -
- O -
induced O +
psychosis B-Disease +
were O +
interviewed O -
, O +
and O +
plasma O +
and O +
urine O +
were O +
collected O +
for O +
quantitative O +
assays O +
of O +
stimulant O +
drug O +
and O +
catecholamine O +
metabolite O +
levels O -
. O +

Methamphetamine O +
or O +
amphetamine O +
levels O +
were O +
related O +
to O +
several O +
psychopathology O +
scores O +
and O +
the O +
global O +
hyperkinesia B-Disease +
rating O -
. O +

HVA O +
levels O +
were O +
related O +
to O +
global O +
hyperkinesia B-Disease +
but O +
not O +
to O +
psychopathology O +
ratings O -
. O +

Although O +
many O +
other O +
factors O +
such O +
as O +
sensitization O +
may O +
play O +
a O +
role O -
, O +
intensity O +
of O +
stimulant O -
- O -
induced O +
psychotic B-Disease +
symptoms I-Disease +
and O +
stereotypies B-Disease +
appears O +
to O +
be O +
at O +
least O +
in O +
part O +
dose O -
- O -
related O -
. O +

Coronary B-Disease +
aneurysm I-Disease +
after O +
implantation O +
of O +
a O +
paclitaxel O -
- O -
eluting O +
stent O -
. O +

Formation O +
of O +
coronary B-Disease +
aneurysm I-Disease +
is O +
a O +
rare O +
complication O +
of O +
stenting O +
with O +
bare O +
metal O +
stents O -
, O +
but O +
based O +
on O +
experimental O +
studies O +
drug O -
- O -
eluting O +
stents O +
may O +
induce O +
toxic O +
effects O +
on O +
the O +
vessel O +
wall O +
with O +
incomplete O +
stent O +
apposition O -
, O +
aneurysm B-Disease +
formation O +
and O +
with O +
the O +
potential O +
of O +
stent O +
thrombosis B-Disease +
or O +
vessel B-Disease +
rupture I-Disease -
. O +

We O +
present O +
a O +
43-year O -
- O -
old O +
man O +
who O +
developed O +
a O +
coronary B-Disease +
aneurysm I-Disease +
in O +
the O +
right O +
coronary O +
artery O +
6 O +
months O +
after O +
receiving O +
a O +
paclitaxel O -
- O -
eluting O +
stent O -
. O +

The O +
patient O +
was O +
asymptomatic O +
and O +
the O +
aneurysm B-Disease +
was O +
detected O +
in O +
a O +
routine O +
control O -
. O +

Angiography O +
and O +
intracoronary O +
ultrasound O +
demonstrated O +
lack O +
of O +
contact O +
between O +
stent O +
and O +
vessel O +
wall O +
in O +
a O +
15-mm O +
long O +
segment O +
with O +
maximal O +
aneurysm B-Disease +
diameter O +
of O +
6.0 O +
mm O -
. O +

The O +
patient O +
was O +
successfully O +
treated O +
with O +
a O +
graft O +
stent O -
. O +

Pheochromocytoma B-Disease +
unmasked O +
by O +
amisulpride O +
and O +
tiapride O -
. O +

OBJECTIVE O -
: O +
To O +
describe O +
the O +
unmasking O +
of O +
pheochromocytoma B-Disease +
in O +
a O +
patient O +
treated O +
with O +
amisulpride O +
and O +
tiapride O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
42-year O -
- O -
old O +
white O +
man O +
developed O +
acute O +
hypertension B-Disease +
with O +
severe O +
headache B-Disease +
and O +
vomiting B-Disease +
2 O +
hours O +
after O +
the O +
first O +
doses O +
of O +
amisulpride O +
100 O +
mg O +
and O +
tiapride O +
100 O +
mg O -
. O +

Both O +
drugs O +
were O +
immediately O +
discontinued O -
, O +
and O +
the O +
patient O +
recovered O +
after O +
subsequent O +
nicardipine O +
and O +
verapamil O +
treatment O -
. O +

Abdominal O +
ultrasound O +
showed O +
an O +
adrenal O +
mass O -
, O +
and O +
postoperative O +
histologic O +
examination O +
confirmed O +
the O +
diagnosis O +
of O +
pheochromocytoma B-Disease -
. O +

DISCUSSION O -
: O +
Drug O -
- O -
induced O +
symptoms O +
of O +
pheochromocytoma B-Disease +
are O +
often O +
associated O +
with O +
the O +
use O +
of O +
substituted O +
benzamide O +
drugs O -
, O +
but O +
the O +
underlying O +
mechanism O +
is O +
unknown O -
. O +

In O +
our O +
case O -
, O +
use O +
of O +
the O +
Naranjo O +
probability O +
scale O +
indicated O +
a O +
possible O +
relationship O +
between O +
the O +
hypertensive B-Disease +
crisis O +
and O +
amisulpride O +
and O +
tiapride O +
therapy O -
. O +

CONCLUSIONS O -
: O +
As O +
of O +
March O +
24 O -
, O +
2005 O -
, O +
this O +
is O +
the O +
first O +
reported O +
case O +
of O +
amisulpride- O +
and O +
tiapride O -
- O -
induced O +
hypertensive B-Disease +
crisis O +
in O +
a O +
patient O +
with O +
pheochromocytoma B-Disease -
. O +

Physicians O +
and O +
other O +
healthcare O +
professionals O +
should O +
be O +
aware O +
of O +
this O +
potential O +
adverse O +
effect O +
of O +
tiapride O +
and O +
amisulpride O -
. O +

Minor O +
neurological B-Disease +
dysfunction I-Disease -
, O +
cognitive O +
development O -
, O +
and O +
somatic O +
development O +
at O +
the O +
age O +
of O +
3 O +
to O +
7 O +
years O +
after O +
dexamethasone O +
treatment O +
in O +
very O -
- O -
low O +
birth O -
- O -
weight O +
infants O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
assess O +
minor O +
neurological B-Disease +
dysfunction I-Disease -
, O +
cognitive O +
development O -
, O +
and O +
somatic O +
development O +
after O +
dexamethasone O +
therapy O +
in O +
very O -
- O -
low O -
- O -
birthweight O +
infants O -
. O +

Thirty O -
- O -
three O +
children O +
after O +
dexamethasone O +
treatment O +
were O +
matched O +
to O +
33 O +
children O +
without O +
dexamethasone O +
treatment O -
. O +

Data O +
were O +
assessed O +
at O +
the O +
age O +
of O +
3 O -
- O -
7 O +
years O -
. O +

Dexamethasone O +
was O +
started O +
between O +
the O +
7th O +
and O +
the O +
28th O +
day O +
of O +
life O +
over O +
7 O +
days O +
with O +
a O +
total O +
dose O +
of O +
2.35 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Exclusion O +
criteria O +
were O +
asphyxia B-Disease -
, O +
malformations B-Disease -
, O +
major O +
surgical O +
interventions O -
, O +
small O +
for O +
gestational O +
age O -
, O +
intraventricular O +
haemorrhage B-Disease +
grades O +
III O +
and O +
IV O -
, O +
periventricular B-Disease +
leukomalacia I-Disease -
, O +
and O +
severe O +
psychomotor B-Disease +
retardation I-Disease -
. O +

Each O +
child O +
was O +
examined O +
by O +
a O +
neuropediatrician O +
for O +
minor O +
neurological B-Disease +
dysfunctions I-Disease +
and O +
tested O +
by O +
a O +
psychologist O +
for O +
cognitive O +
development O +
with O +
a O +
Kaufman O +
Assessment O +
Battery O +
for O +
Children O +
and O +
a O +
Draw O -
- O -
a O -
- O -
Man O +
Test O -
. O +

There O +
were O +
no O +
differences O +
in O +
demographic O +
data O -
, O +
growth O -
, O +
and O +
socio O -
- O -
economic O +
status O +
between O +
the O +
two O +
groups O -
. O +

Fine O +
motor O +
skills O +
and O +
gross O +
motor O +
function O +
were O +
significantly O +
better O +
in O +
the O +
control O +
group O +
( O -
p<0.01 O -
) O -
. O +

In O +
the O +
Draw O -
- O -
a O -
- O -
Man O +
Test O -
, O +
the O +
control O +
group O +
showed O +
better O +
results O +
( O -
p<0.001 O -
) O -
. O +

There O +
were O +
no O +
differences O +
in O +
development O +
of O +
speech O -
, O +
social O +
development O -
, O +
and O +
the O +
Kaufman O +
Assessment O +
Battery O +
for O +
Children O -
. O +

After O +
dexamethasone O +
treatment O -
, O +
children O +
showed O +
a O +
higher O +
rate O +
of O +
minor O +
neurological B-Disease +
dysfunctions I-Disease -
. O +

Neurological O +
development O +
was O +
affected O +
even O +
without O +
neurological O +
diagnosis O -
. O +

Further O +
long O -
- O -
term O +
follow O -
- O -
up O +
studies O +
will O +
be O +
necessary O +
to O +
fully O +
evaluate O +
the O +
impact O +
of O +
dexamethasone O +
on O +
neurological O +
and O +
cognitive O +
development O -
. O +

Valproic O +
acid O +
I O -
: O +
time O +
course O +
of O +
lipid O +
peroxidation O +
biomarkers O -
, O +
liver B-Disease +
toxicity I-Disease -
, O +
and O +
valproic O +
acid O +
metabolite O +
levels O +
in O +
rats O -
. O +

A O +
single O +
dose O +
of O +
valproic O +
acid O +
( O -
VPA O -
) O -
, O +
which O +
is O +
a O +
widely O +
used O +
antiepileptic O +
drug O -
, O +
is O +
associated O +
with O +
oxidative O +
stress O +
in O +
rats O -
, O +
as O +
recently O +
demonstrated O +
by O +
elevated O +
levels O +
of O +
15-F O -
( O -
2t O -
) O -
-isoprostane O +
( O -
15-F O -
( O -
2t O -
) O -
-IsoP O -
) O -
. O +

To O +
determine O +
whether O +
there O +
was O +
a O +
temporal O +
relationship O +
between O +
VPA O -
- O -
associated O +
oxidative O +
stress O +
and O +
hepatotoxicity B-Disease -
, O +
adult O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
treated O +
ip O +
with O +
VPA O +
( O -
500 O +
mg O -
/ O -
kg O -
) O +
or O +
0.9 O -
% O +
saline O +
( O -
vehicle O -
) O +
once O +
daily O +
for O +
2 O -
, O +
4 O -
, O +
7 O -
, O +
10 O -
, O +
or O +
14 O +
days O -
. O +

Oxidative O +
stress O +
was O +
assessed O +
by O +
determining O +
plasma O +
and O +
liver O +
levels O +
of O +
15-F O -
( O -
2t O -
) O -
-IsoP O -
, O +
lipid O +
hydroperoxides O +
( O -
LPO O -
) O -
, O +
and O +
thiobarbituric O +
acid O +
reactive O +
substances O +
( O -
TBARs O -
) O -
. O +

Plasma O +
and O +
liver O +
15-F O -
( O -
2t O -
) O -
-IsoP O +
were O +
elevated O +
and O +
reached O +
a O +
plateau O +
after O +
day O +
2 O +
of O +
VPA O +
treatment O +
compared O +
to O +
control O -
. O +

Liver O +
LPO O +
levels O +
were O +
not O +
elevated O +
until O +
day O +
7 O +
of O +
treatment O +
( O -
1.8-fold O +
versus O +
control O -
, O +
p O +
< O +
0.05 O -
) O -
. O +

Liver O +
and O +
plasma O +
TBARs O +
were O +
not O +
increased O +
until O +
14 O +
days O +
( O -
2-fold O +
vs. O +
control O -
, O +
p O +
< O +
0.05 O -
) O -
. O +

Liver B-Disease +
toxicity I-Disease +
was O +
evaluated O +
based O +
on O +
serum O +
levels O +
of O +
alpha O -
- O -
glutathione O +
S O -
- O -
transferase O +
( O -
alpha O -
- O -
GST O -
) O +
and O +
by O +
histology O -
. O +

Serum O +
alpha O -
- O -
GST O +
levels O +
were O +
significantly O +
elevated O +
by O +
day O +
4 O -
, O +
which O +
corresponded O +
to O +
hepatotoxicity B-Disease +
as O +
shown O +
by O +
the O +
increasing O +
incidence O +
of O +
inflammation B-Disease +
of O +
the O +
liver O +
capsule O -
, O +
necrosis B-Disease -
, O +
and O +
steatosis B-Disease +
throughout O +
the O +
study O -
. O +

The O +
liver O +
levels O +
of O +
beta O -
- O -
oxidation O +
metabolites O +
of O +
VPA O +
were O +
decreased O +
by O +
day O +
14 O -
, O +
while O +
the O +
levels O +
of O +
4-ene O -
- O -
VPA O +
and O +
( O -
E O -
) O -
-2,4-diene O -
- O -
VPA O +
were O +
not O +
elevated O +
throughout O +
the O +
study O -
. O +

Overall O -
, O +
these O +
findings O +
indicate O +
that O +
VPA O +
treatment O +
results O +
in O +
oxidative O +
stress O -
, O +
as O +
measured O +
by O +
levels O +
of O +
15-F O -
( O -
2t O -
) O -
-IsoP O -
, O +
which O +
precedes O +
the O +
onset O +
of O +
necrosis B-Disease -
, O +
steatosis B-Disease -
, O +
and O +
elevated O +
levels O +
of O +
serum O +
alpha O -
- O -
GST O -
. O +

Causes O +
of O +
acute O +
thrombotic B-Disease +
microangiopathy I-Disease +
in O +
patients O +
receiving O +
kidney O +
transplantation O -
. O +

OBJECTIVES O -
: O +
Thrombotic B-Disease +
microangiopathy I-Disease +
is O +
a O +
well O -
- O -
known O +
problem O +
in O +
patients O +
following O +
renal O +
transplantation O -
. O +

In O +
postrenal O +
transplantation O -
, O +
thrombotic B-Disease +
microangiopathy I-Disease +
is O +
often O +
a O +
reflection O +
of O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease -
. O +

We O +
aimed O +
to O +
determine O +
the O +
causes O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
in O +
a O +
population O +
of O +
renal O +
transplantation O +
recipients O +
and O +
discuss O +
the O +
literature O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
We O +
investigated O +
the O +
causes O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
during O +
a O +
1-year O +
period O -
, O +
from O +
June O +
2003 O +
to O +
June O +
2004 O -
, O +
at O +
the O +
King O +
Fahad O +
National O +
Guard O +
Hospital O +
in O +
Riyadh O -
, O +
Saudi O +
Arabia O -
, O +
by O +
reviewing O +
the O +
slides O +
of O +
all O +
transplant O +
biopsies O +
( O -
n=25 O -
) O +
performed O +
during O +
this O +
interval O -
. O +

Pre- O +
and O +
posttransplant O +
crossmatching O +
was O +
done O +
when O +
possible O -
. O +

RESULTS O -
: O +
Five O +
cases O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
were O +
found O -
. O +

Three O +
of O +
these O +
cases O +
were O +
from O +
the O +
25 O +
transplantations O +
performed O +
at O +
King O +
Fahad O +
National O +
Guard O +
Hospital O -
, O +
while O +
the O +
other O +
2 O +
transplantations O +
had O +
been O +
performed O +
abroad O +
and O +
were O +
referred O +
to O +
us O +
for O +
follow O -
- O -
up O -
. O +

Three O +
cases O +
were O +
related O +
to O +
cyclosporine O -
, O +
and O +
1 O +
case O +
was O +
secondary O +
to O +
both O +
cyclosporine O +
and O +
tacrolimus O -
. O +

The O +
fifth O +
case O +
had O +
features O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
related O +
to O +
an O +
antiphospholipid B-Disease +
syndrome I-Disease +
in O +
a O +
patient O +
with O +
systemic B-Disease +
lupus I-Disease +
erythematosus I-Disease -
. O +

CONCLUSIONS O -
: O +
In O +
the O +
literature O -
, O +
the O +
most O -
- O -
frequent O +
cause O +
of O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease +
in O +
patients O +
following O +
renal O +
transplantation O +
is O +
recurrence O +
of O +
the O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease -
. O +

Other O +
causes O +
include O +
drug O -
- O -
related O +
( O -
cyclosporine O -
, O +
tacrolimus O -
) O +
toxicity B-Disease -
, O +
procoagulant O +
status O -
, O +
and O +
antibody O -
- O -
mediated O +
rejection O -
. O +

We O +
found O +
that O +
the O +
most O -
- O -
frequent O +
cause O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
was O +
drug O +
related O -
, O +
secondary O +
mainly O +
to O +
cyclosporine O -
. O +

In O +
the O +
current O +
study O -
, O +
the O +
frequency O +
of O +
thrombotic B-Disease +
microangiopathy I-Disease +
was O +
similar O +
to O +
the O +
percentage O +
reported O +
in O +
the O +
literature O +
( O -
20 O -
% O -
) O -
. O +

Comparison O +
of O +
developmental O +
toxicity B-Disease +
of O +
selective O +
and O +
non O -
- O -
selective O +
cyclooxygenase-2 O +
inhibitors O +
in O +
CRL: O -
( O -
WI O -
) O -
WUBR O +
Wistar O +
rats O -
-- O -
DFU O +
and O +
piroxicam O +
study O -
. O +

BACKGROUND O -
: O +
Cyclooxygenase O +
( O -
COX O -
) O +
inhibitors O +
are O +
one O +
of O +
the O +
most O +
often O +
ingested O +
drugs O +
during O +
pregnancy O -
. O +

Unlike O +
general O +
toxicity B-Disease +
data O -
, O +
their O +
prenatal O +
toxic O +
effects O +
were O +
not O +
extensively O +
studied O +
before O -
. O +

The O +
aim O +
of O +
the O +
experiment O +
was O +
to O +
evaluate O +
the O +
developmental O +
toxicity B-Disease +
of O +
the O +
non O -
- O -
selective O +
( O -
piroxicam O -
) O +
and O +
selective O +
( O -
DFU O -
; O +
5,5-dimethyl-3- O -
( O -
3-fluorophenyl O -
) O -
-4- O -
( O -
4-methylsulphonyl O -
) O +
phenyl-2 O -
( O -
5H O -
) O -
-furanon O -
) O +
COX-2 O +
inhibitors O -
. O +

METHODS O -
: O +
Drugs O +
were O +
separately O -
, O +
orally O +
once O +
daily O +
dosed O +
to O +
pregnant O +
rats O +
from O +
day O +
8 O +
to O +
21 O +
( O -
GD1 O -
= O -
plug O +
day O -
) O -
. O +

Doses O +
were O +
set O +
at O +
0.3 O -
, O +
3.0 O +
and O +
30.0mg O -
/ O -
kg O +
for O +
piroxicam O +
and O +
0.2 O -
, O +
2.0 O +
and O +
20.0mg O -
/ O -
kg O +
for O +
DFU O -
. O +

Fetuses O +
were O +
delivered O +
on O +
GD O +
21 O +
and O +
routinely O +
examined O -
. O +

Comprehensive O +
clinical O +
and O +
developmental O +
measurements O +
were O +
done O -
. O +

The O +
pooled O +
statistical O +
analysis O +
for O +
ventricular B-Disease +
septal I-Disease +
( I-Disease -
VSD I-Disease -
) I-Disease +
and I-Disease +
midline I-Disease +
( I-Disease -
MD I-Disease -
) I-Disease +
defects I-Disease +
was O +
performed O +
for O +
rat O +
fetuses O +
exposed O +
to O +
piroxicam O -
, O +
selective O +
and O +
non O -
- O -
selective O +
COX-2 O +
inhibitor O +
based O +
on O +
present O +
and O +
historic O +
data O -
. O +

RESULTS O -
: O +
Maternal O +
toxicity B-Disease -
, O +
intrauterine B-Disease +
growth I-Disease +
retardation I-Disease -
, O +
and O +
increase B-Disease +
of I-Disease +
external I-Disease +
and I-Disease +
skeletal I-Disease +
variations I-Disease +
were O +
found O +
in O +
rats O +
treated O +
with O +
the O +
highest O +
dose O +
of O +
piroxicam O -
. O +

Decrease O +
of O +
fetal O +
length O +
was O +
the O +
only O +
signs O +
of O +
the O +
DFU O +
developmental O +
toxicity B-Disease +
observed O +
in O +
pups O +
exposed O +
to O +
the O +
highest O +
compound O +
dose O -
. O +

Lack O +
of O +
teratogenicity O +
was O +
found O +
in O +
piroxicam O +
and O +
DFU O -
- O -
exposed O +
groups O -
. O +

Prenatal O +
exposure O +
to O +
non O -
- O -
selective O +
COX O +
inhibitors O +
increases O +
the O +
risk O +
of O +
VSD O +
and O +
MD O +
when O +
compared O +
to O +
historic O +
control O +
but O +
not O +
with O +
selective O +
COX-2 O +
inhibitors O -
. O +

CONCLUSION O -
: O +
Both O +
selective O +
and O +
non O -
- O -
selective O +
COX-2 O +
inhibitors O +
were O +
toxic O +
for O +
rats O +
fetuses O +
when O +
administered O +
in O +
the O +
highest O +
dose O -
. O +

Unlike O +
DFU O -
, O +
piroxicam O +
was O +
also O +
highly O +
toxic O +
to O +
the O +
dams O -
. O +

Prenatal O +
exposure O +
to O +
selective O +
COX-2 O +
inhibitors O +
does O +
not O +
increase O +
the O +
risk O +
of O +
ventricular B-Disease +
septal I-Disease +
and I-Disease +
midline I-Disease +
defects I-Disease +
in O +
rat O +
when O +
compared O +
to O +
non O -
- O -
selective O +
drugs O +
and O +
historic O +
control O -
. O +

Assessment O +
of O +
perinatal O +
hepatitis B-Disease +
B I-Disease +
and O +
rubella B-Disease +
prevention O +
in O +
New O +
Hampshire O +
delivery O +
hospitals O -
. O +

OBJECTIVE O -
: O +
To O +
evaluate O +
current O +
performance O +
on O +
recommended O +
perinatal O +
hepatitis B-Disease +
B I-Disease +
and O +
rubella B-Disease +
prevention O +
practices O +
in O +
New O +
Hampshire O -
. O +

METHODS O -
: O +
Data O +
were O +
extracted O +
from O +
2021 O +
paired O +
mother O -
- O -
infant O +
records O +
for O +
the O +
year O +
2000 O +
birth O +
cohort O +
in O +
New O +
Hampshire O -
's O +
25 O +
delivery O +
hospitals O -
. O +

Assessment O +
was O +
done O +
on O +
the O +
following O -
: O +
prenatal O +
screening O +
for O +
hepatitis B-Disease +
B I-Disease +
and O +
rubella B-Disease -
, O +
administration O +
of O +
the O +
hepatitis B-Disease +
B I-Disease +
vaccine O +
birth O +
dose O +
to O +
all O +
infants O -
, O +
administration O +
of O +
hepatitis B-Disease +
B I-Disease +
immune O +
globulin O +
to O +
infants O +
who O +
were O +
born O +
to O +
hepatitis O +
B O +
surface O +
antigen O -
- O -
positive O +
mothers O -
, O +
rubella B-Disease +
immunity O -
, O +
and O +
administration O +
of O +
in O -
- O -
hospital O +
postpartum O +
rubella B-Disease +
vaccine O +
to O +
rubella B-Disease +
nonimmune O +
women O -
. O +

RESULTS O -
: O +
Prenatal O +
screening O +
rates O +
for O +
hepatitis B-Disease +
B I-Disease +
( O -
98.8 O -
% O -
) O +
and O +
rubella B-Disease +
( O -
99.4 O -
% O -
) O +
were O +
high O -
. O +

Hepatitis B-Disease +
B I-Disease +
vaccine O +
birth O +
dose O +
was O +
administered O +
to O +
76.2 O -
% O +
of O +
all O +
infants O -
. O +

All O +
infants O +
who O +
were O +
born O +
to O +
hepatitis O +
B O +
surface O +
antigen O -
- O -
positive O +
mothers O +
also O +
received O +
hepatitis B-Disease +
B I-Disease +
immune O +
globulin O -
. O +

Multivariate O +
logistic O +
regression O +
showed O +
that O +
the O +
month O +
of O +
delivery O +
and O +
infant O +
birth O +
weight O +
were O +
independent O +
predictors O +
of O +
hepatitis B-Disease +
B I-Disease +
vaccination O -
. O +

The O +
proportion O +
of O +
infants O +
who O +
were O +
vaccinated O +
in O +
January O +
and O +
February O +
2000 O +
( O -
48.5 O -
% O +
and O +
67.5 O -
% O -
, O +
respectively O -
) O +
was O +
less O +
than O +
any O +
other O +
months O -
, O +
whereas O +
the O +
proportion O +
who O +
were O +
vaccinated O +
in O +
December O +
2000 O +
( O -
88.2 O -
% O -
) O +
was O +
the O +
highest O -
. O +

Women O +
who O +
were O +
born O +
between O +
1971 O +
and O +
1975 O +
had O +
the O +
highest O +
rate O +
of O +
rubella B-Disease +
nonimmunity O +
( O -
9.5 O -
% O -
) O -
. O +

In O -
- O -
hospital O +
postpartum O +
rubella B-Disease +
vaccine O +
administration O +
was O +
documented O +
for O +
75.6 O -
% O +
of O +
nonimmune O +
women O -
. O +

CONCLUSION O -
: O +
This O +
study O +
documents O +
good O +
compliance O +
in O +
New O +
Hampshire O -
's O +
birthing O +
hospitals O +
with O +
national O +
guidelines O +
for O +
perinatal O +
hepatitis B-Disease +
B I-Disease +
and O +
rubella B-Disease +
prevention O +
and O +
highlights O +
potential O +
areas O +
for O +
improvement O -
. O +

Succinylcholine O -
- O -
induced O +
masseter B-Disease +
muscle I-Disease +
rigidity I-Disease +
during O +
bronchoscopic O +
removal O +
of O +
a O +
tracheal O +
foreign O +
body O -
. O +

Masseter B-Disease +
muscle I-Disease +
rigidity I-Disease +
during O +
general O +
anesthesia O +
is O +
considered O +
an O +
early O +
warning O +
sign O +
of O +
a O +
possible O +
episode O +
of O +
malignant B-Disease +
hyperthermia I-Disease -
. O +

The O +
decision O +
whether O +
to O +
continue O +
or O +
discontinue O +
the O +
procedure O +
depends O +
on O +
the O +
urgency O +
of O +
the O +
surgery O +
and O +
severity O +
of O +
masseter B-Disease +
muscle I-Disease +
rigidity I-Disease -
. O +

Here O -
, O +
we O +
describe O +
a O +
case O +
of O +
severe O +
masseter B-Disease +
muscle I-Disease +
rigidity I-Disease +
( O -
jaw B-Disease +
of I-Disease +
steel I-Disease -
) O +
after O +
succinylcholine O +
( O -
Sch O -
) O +
administration O +
during O +
general O +
anesthetic O +
management O +
for O +
rigid O +
bronchoscopic O +
removal O +
of O +
a O +
tracheal O +
foreign O +
body O -
. O +

Anesthesia O +
was O +
continued O +
uneventfully O +
with O +
propofol O +
infusion O +
while O +
all O +
facilities O +
were O +
available O +
to O +
detect O +
and O +
treat O +
malignant B-Disease +
hyperthermia I-Disease -
. O +

Lone O +
atrial B-Disease +
fibrillation I-Disease +
associated O +
with O +
creatine O +
monohydrate O +
supplementation O -
. O +

Atrial B-Disease +
fibrillation I-Disease +
in O +
young O +
patients O +
without O +
structural O +
heart B-Disease +
disease I-Disease +
is O +
rare O -
. O +

Therefore O -
, O +
when O +
the O +
arrhythmia B-Disease +
is O +
present O +
in O +
this O +
population O -
, O +
reversible O +
causes O +
must O +
be O +
identified O +
and O +
resolved O -
. O +

Thyroid B-Disease +
disorders I-Disease -
, O +
illicit O +
drug O +
or O +
stimulant O +
use O -
, O +
and O +
acute B-Disease +
alcohol I-Disease +
intoxication I-Disease +
are O +
among O +
these O +
causes O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
30-year O -
- O -
old O +
Caucasian O +
man O +
who O +
came O +
to O +
the O +
emergency O +
department O +
in O +
atrial B-Disease +
fibrillation I-Disease +
with O +
rapid O +
ventricular O +
response O -
. O +

His O +
medical O +
history O +
was O +
unremarkable O -
, O +
except O +
for O +
minor O +
fractures B-Disease +
of O +
the O +
fingers O +
and O +
foot O -
. O +

Thyroid O -
- O -
stimulating O +
hormone O -
, O +
magnesium O -
, O +
and O +
potassium O +
levels O +
were O +
within O +
normal O +
limits O -
, O +
urine O +
drug O +
screen O +
was O +
negative O -
, O +
and O +
alcohol O +
use O +
was O +
denied O -
. O +

However O -
, O +
when O +
the O +
patient O +
was O +
questioned O +
about O +
use O +
of O +
herbal O +
products O +
and O +
supplements O -
, O +
the O +
use O +
of O +
creatine O +
monohydrate O +
was O +
revealed O -
. O +

The O +
patient O +
was O +
admitted O +
to O +
the O +
hospital O -
, O +
anticoagulated O +
with O +
unfractionated O +
heparin O -
, O +
and O +
given O +
intravenous O +
diltiazem O +
for O +
rate O +
control O +
and O +
intravenous O +
amiodarone O +
for O +
rate O +
and O +
rhythm O +
control O -
. O +

When O +
discharged O +
less O +
than O +
24 O +
hours O +
later O -
, O +
he O +
was O +
receiving O +
metoprolol O +
and O +
aspirin O -
, O +
with O +
follow O -
- O -
up O +
plans O +
for O +
echocardiography O +
and O +
nuclear O +
imaging O +
to O +
assess O +
perfusion O -
. O +

Exogenous O +
creatine O +
is O +
used O +
by O +
athletes O +
to O +
theoretically O +
improve O +
exercise O +
performance O -
. O +

Vegetarians O +
may O +
also O +
take O +
creatine O +
to O +
replace O +
what O +
they O +
are O +
not O +
consuming O +
from O +
meat O -
, O +
fish O -
, O +
and O +
other O +
animal O +
products O -
. O +

Previous O +
anecdotal O +
reports O +
have O +
linked O +
creatine O +
to O +
the O +
development O +
of O +
arrhythmia B-Disease -
. O +

Clinicians O +
must O +
be O +
diligent O +
when O +
interviewing O +
patients O +
about O +
their O +
drug O +
therapy O +
histories O +
and O +
include O +
questions O +
about O +
their O +
use O +
of O +
herbal O +
products O +
and O +
dietary O +
supplements O -
. O +

In O +
addition O -
, O +
it O +
is O +
important O +
to O +
report O +
adverse O +
effects O +
associated O +
with O +
frequently O +
consumed O +
supplements O +
and O +
herbal O +
products O +
to O +
the O +
Food O +
and O +
Drug O +
Administration O +
and O +
in O +
the O +
literature O -
. O +

Seizures B-Disease +
induced O +
by O +
the O +
cocaine O +
metabolite O +
benzoylecgonine O +
in O +
rats O -
. O +

The O +
half O -
- O -
life O +
( O -
t1 O -
/ O -
2 O -
) O +
of O +
cocaine O +
is O +
relatively O +
short O -
, O +
but O +
some O +
of O +
the O +
consequences O +
of O +
its O +
use O -
, O +
such O +
as O +
seizures B-Disease +
and O +
strokes B-Disease -
, O +
can O +
occur O +
hours O +
after O +
exposure O -
. O +

This O +
led O +
us O +
to O +
hypothesize O +
that O +
a O +
metabolite O +
of O +
cocaine O +
may O +
be O +
responsible O +
for O +
some O +
of O +
those O +
delayed O +
sequelae O -
. O +

We O +
evaluated O +
the O +
potential O +
of O +
the O +
major O +
metabolite O +
of O +
cocaine O -
, O +
benzoylecgonine O +
( O -
BE O -
) O -
, O +
to O +
cause O +
seizures B-Disease -
. O +

Two O +
separate O +
equimolar O +
doses O +
( O -
0.2 O +
and O +
0.4 O +
mumol O -
) O +
of O +
either O +
cocaine O +
or O +
BE O +
were O +
injected O +
ventricularly O +
in O +
unanesthetized O +
juvenile O +
rats O -
. O +

Treated O +
rats O +
were O +
then O +
evaluated O +
for O +
incidence O -
, O +
latency O -
, O +
and O +
seizure B-Disease +
pattern O +
or O +
for O +
locomotor O +
activity O +
in O +
animals O +
without O +
seizures B-Disease -
. O +

BE O -
- O -
Induced O +
seizures B-Disease +
occurred O +
more O +
frequently O +
and O +
had O +
significantly O +
longer O +
latencies O +
than O +
those O +
induced O +
by O +
equimolar O +
amounts O +
of O +
cocaine O -
. O +

Whereas O +
cocaine O -
- O -
induced O +
seizures B-Disease +
were O +
best O +
characterized O +
as O +
brief O -
, O +
generalized O -
, O +
and O +
tonic O +
and O +
resulted O +
in O +
death B-Disease -
, O +
those O +
induced O +
by O +
BE O +
were O +
prolonged O -
, O +
often O +
multiple O +
and O +
mixed O +
in O +
type O -
, O +
and O +
rarely O +
resulted O +
in O +
death B-Disease -
. O +

Electrical O +
recordings O +
from O +
the O +
hippocampus O +
showed O +
a O +
rhythmic O +
progression O +
in O +
EEG O +
frequency O +
and O +
voltage O +
with O +
clinical O +
seizure B-Disease +
expression O -
. O +

BE O -
- O -
Injected O +
rats O +
that O +
did O +
not O +
have O +
seizures B-Disease +
had O +
significantly O +
more O +
locomotor O +
activity O +
than O +
cocaine O -
- O -
injected O +
animals O +
without O +
seizures B-Disease -
. O +

The O +
finding O +
that O +
cocaine- O +
and O +
BE O -
- O -
induced O +
seizures B-Disease +
differ O +
in O +
several O +
respects O +
suggests O +
more O +
than O +
one O +
mechanism O +
for O +
cocaine O -
- O -
induced O +
seizures B-Disease +
and O +
emphasizes O +
the O +
importance O +
of O +
a O +
cocaine O +
metabolite O -
, O +
BE O -
. O +

Assessment O +
of O +
the O +
onset O +
and O +
persistence O +
of O +
amnesia B-Disease +
during O +
procedural O +
sedation O +
with O +
propofol O -
. O +

OBJECTIVES O -
: O +
To O +
assess O +
patients O -
' O +
ability O +
to O +
repeat O +
and O +
recall O +
words O +
presented O +
to O +
them O +
while O +
undergoing O +
procedural O +
sedation O +
with O +
propofol O -
, O +
and O +
correlate O +
their O +
recall O +
with O +
their O +
level O +
of O +
awareness O +
as O +
measured O +
by O +
bispectral O +
index O +
( O -
BIS O -
) O +
monitoring O -
. O +

METHODS O -
: O +
This O +
was O +
a O +
prospective O -
, O +
single O -
- O -
intervention O +
study O +
of O +
consenting O +
adult O +
patients O +
undergoing O +
procedural O +
sedation O +
with O +
propofol O +
between O +
December O +
28 O -
, O +
2002 O -
, O +
and O +
October O +
31 O -
, O +
2003 O -
. O +

BIS O +
monitoring O +
was O +
initiated O +
starting O +
3 O +
minutes O +
before O +
the O +
procedure O +
and O +
continuing O +
until O +
the O +
patient O +
had O +
regained O +
baseline O +
mental O +
status O -
. O +

At O +
1-minute O +
intervals O +
during O +
the O +
procedural O +
sedation O -
, O +
until O +
the O +
patient O +
regained O +
baseline O +
mental O +
status O +
at O +
the O +
end O +
of O +
the O +
procedure O -
, O +
a O +
word O +
from O +
a O +
standardized O +
list O +
was O +
read O +
aloud O -
, O +
and O +
the O +
patient O +
was O +
asked O +
to O +
immediately O +
repeat O +
the O +
word O +
to O +
the O +
investigator O -
. O +

The O +
BIS O +
score O +
at O +
the O +
time O +
the O +
word O +
was O +
read O +
and O +
the O +
patient O -
's O +
ability O +
to O +
repeat O +
the O +
word O +
were O +
recorded O -
. O +

After O +
the O +
procedure O -
, O +
the O +
patient O +
was O +
asked O +
to O +
state O +
all O +
of O +
the O +
words O +
from O +
the O +
list O +
that O +
he O +
or O +
she O +
could O +
recall O -
, O +
and O +
to O +
identify O +
the O +
last O +
word O +
recalled O +
from O +
prior O +
to O +
the O +
start O +
of O +
the O +
procedure O +
and O +
the O +
first O +
word O +
recalled O +
from O +
after O +
the O +
procedure O +
was O +
completed O -
. O +

RESULTS O -
: O +
Seventy O -
- O -
five O +
consenting O +
patients O +
were O +
enrolled O -
; O +
one O +
patient O +
was O +
excluded O +
from O +
data O +
analysis O +
for O +
a O +
protocol O +
violation O -
. O +

No O +
serious O +
adverse O +
events O +
were O +
noted O +
during O +
the O +
procedural O +
sedations O -
. O +

The O +
mean O +
( O -
+ O -
/-standard O +
deviation O -
) O +
time O +
of O +
data O +
collection O +
was O +
16.4 O +
minutes O +
( O -
+ O -
/-7.1 O -
; O +
range O +
5 O +
to O +
34 O +
minutes O -
) O -
. O +

The O +
mean O +
initial O +
( O -
preprocedure O -
) O +
BIS O +
score O +
was O +
97.1 O +
( O -
+ O -
/-2.3 O -
; O +
range O +
92 O +
to O +
99 O -
) O -
. O +

The O +
mean O +
lowest O +
BIS O +
score O +
occurring O +
during O +
these O +
procedural O +
sedations O +
was O +
66.9 O +
( O -
+ O -
/-14.4 O -
; O +
range O +
33 O +
to O +
91 O -
) O -
. O +

The O +
mean O +
lowest O +
BIS O +
score O +
corresponding O +
to O +
the O +
ability O +
of O +
the O +
patient O +
to O +
immediately O +
repeat O +
words O +
read O +
from O +
the O +
list O +
was O +
77.1 O +
( O -
95 O -
% O +
CI O +
= O +
74.3 O +
to O +
80.0 O -
) O -
. O +

The O +
mean O +
highest O +
BIS O +
score O +
corresponding O +
to O +
the O +
inability B-Disease +
to I-Disease +
repeat I-Disease +
words I-Disease +
was O +
81.5 O +
( O -
95 O -
% O +
CI O +
= O +
78.1 O +
to O +
84.8 O -
) O -
. O +

The O +
mean O +
BIS O +
score O +
corresponding O +
to O +
the O +
last O +
word O +
recalled O +
from O +
prior O +
to O +
the O +
initiation O +
of O +
the O +
sedation O +
was O +
96.7 O +
( O -
+ O -
/-2.4 O -
; O +
range O +
84 O +
to O +
98 O -
) O -
. O +

The O +
mean O +
BIS O +
score O +
corresponding O +
to O +
the O +
first O +
word O +
recalled O +
after O +
the O +
procedure O +
was O +
completed O +
was O +
91.2 O +
( O -
95 O -
% O +
CI O +
= O +
88.1 O +
to O +
94.3 O -
) O -
. O +

All O +
patients O +
recalled O +
at O +
least O +
one O +
word O +
that O +
had O +
been O +
read O +
to O +
them O +
during O +
the O +
protocol O -
. O +

The O +
mean O +
lowest O +
BIS O +
score O +
for O +
any O +
recalled O +
word O +
was O +
91.5 O +
( O -
+ O -
/-11.1 O -
; O +
range O +
79 O +
to O +
98 O -
) O -
, O +
and O +
no O +
words O +
were O +
recalled O +
when O +
the O +
corresponding O +
BIS O +
score O +
was O +
less O +
than O +
90 O -
. O +

CONCLUSIONS O -
: O +
There O +
is O +
a O +
range O +
of O +
BIS O +
scores O +
during O +
which O +
sedated O +
patients O +
are O +
able O +
to O +
repeat O +
words O +
read O +
to O +
them O +
but O +
are O +
not O +
able O +
to O +
subsequently O +
recall O +
these O +
words O -
. O +

Furthermore O -
, O +
patients O +
had O +
no O +
recall O +
of O +
words O +
repeated O +
prior O +
to O +
procedural O +
sedation O +
in O +
BIS O +
ranges O +
associated O +
with O +
recall O +
after O +
procedural O +
sedation O -
, O +
suggestive O +
of O +
retrograde B-Disease +
amnesia I-Disease -
. O +

The O +
selective O +
5-HT6 O +
receptor O +
antagonist O +
Ro4368554 O +
restores O +
memory O +
performance O +
in O +
cholinergic O +
and O +
serotonergic O +
models O +
of O +
memory B-Disease +
deficiency I-Disease +
in O +
the O +
rat O -
. O +

Antagonists O +
at O +
serotonin O +
type O +
6 O +
( O -
5-HT O -
( O -
6 O -
) O -
) O +
receptors O +
show O +
activity O +
in O +
models O +
of O +
learning O +
and O +
memory O -
. O +

Although O +
the O +
underlying O +
mechanism O -
( O -
s O -
) O +
are O +
not O +
well O +
understood O -
, O +
these O +
effects O +
may O +
involve O +
an O +
increase O +
in O +
acetylcholine O +
( O -
ACh O -
) O +
levels O -
. O +

The O +
present O +
study O +
sought O +
to O +
characterize O +
the O +
cognitive O -
- O -
enhancing O +
effects O +
of O +
the O +
5-HT O -
( O -
6 O -
) O +
antagonist O +
Ro4368554 O +
( O -
3-benzenesulfonyl-7- O -
( O -
4-methyl O -
- O -
piperazin-1-yl O -
) O -
1H O -
- O -
indole O -
) O +
in O +
a O +
rat O +
object O +
recognition O +
task O +
employing O +
a O +
cholinergic O +
( O -
scopolamine O +
pretreatment O -
) O +
and O +
a O +
serotonergic- O +
( O -
tryptophan O +
( O -
TRP O -
) O +
depletion O -
) O +
deficient O +
model O -
, O +
and O +
compared O +
its O +
pattern O +
of O +
action O +
with O +
that O +
of O +
the O +
acetylcholinesterase O +
inhibitor O +
metrifonate O -
. O +

Initial O +
testing O +
in O +
a O +
time O -
- O -
dependent O +
forgetting O +
task O +
employing O +
a O +
24-h O +
delay O +
between O +
training O +
and O +
testing O +
showed O +
that O +
metrifonate O +
improved O +
object O +
recognition O +
( O -
at O +
10 O +
and O +
30 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O -
, O +
whereas O +
Ro4368554 O +
was O +
inactive O -
. O +

Both O -
, O +
Ro4368554 O +
( O -
3 O +
and O +
10 O +
mg O -
/ O -
kg O -
, O +
intraperitoneally O +
( O -
i.p O -
. O -
) O -
) O +
and O +
metrifonate O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
, O +
respectively O -
) O +
reversed O +
memory B-Disease +
deficits I-Disease +
induced O +
by O +
scopolamine O +
and O +
TRP O +
depletion O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
, O +
and O +
3 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
, O +
respectively O -
) O -
. O +

In O +
conclusion O -
, O +
although O +
Ro4368554 O +
did O +
not O +
improve O +
a O +
time O -
- O -
related O +
retention O +
deficit O -
, O +
it O +
reversed O +
a O +
cholinergic O +
and O +
a O +
serotonergic O +
memory B-Disease +
deficit I-Disease -
, O +
suggesting O +
that O +
both O +
mechanisms O +
may O +
be O +
involved O +
in O +
the O +
facilitation O +
of O +
object O +
memory O +
by O +
Ro4368554 O +
and O -
, O +
possibly O -
, O +
other O +
5-HT O -
( O -
6 O -
) O +
receptor O +
antagonists O -
. O +

Two O +
prodrugs O +
of O +
potent O +
and O +
selective O +
GluR5 O +
kainate O +
receptor O +
antagonists O +
actives O +
in O +
three O +
animal O +
models O +
of O +
pain B-Disease -
. O +

Amino O +
acids O +
5 O +
and O +
7 O -
, O +
two O +
potent O +
and O +
selective O +
competitive O +
GluR5 O +
KA O +
receptor O +
antagonists O -
, O +
exhibited O +
high O +
GluR5 O +
receptor O +
affinity O +
over O +
other O +
glutamate O +
receptors O -
. O +

Their O +
ester O +
prodrugs O +
6 O +
and O +
8 O +
were O +
orally O +
active O +
in O +
three O +
models O +
of O +
pain B-Disease -
: O +
reversal O +
of O +
formalin O -
- O -
induced O +
paw O +
licking O -
, O +
carrageenan O -
- O -
induced O +
thermal B-Disease +
hyperalgesia I-Disease -
, O +
and O +
capsaicin O -
- O -
induced O +
mechanical B-Disease +
hyperalgesia I-Disease -
. O +

Possible O +
azithromycin O -
- O -
associated O +
hiccups B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
persistent O +
hiccups B-Disease +
associated O +
by O +
azithromycin O +
therapy O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
76-year O -
- O -
old O +
man O +
presented O +
with O +
persistent O +
hiccups B-Disease +
after O +
beginning O +
azithromycin O +
for O +
the O +
treatment O +
of O +
pharyngitis B-Disease -
. O +

Hiccups B-Disease +
were O +
persistent O +
and O +
exhausting O -
. O +

Discontinuation O +
of O +
azithromycin O +
and O +
therapy O +
with O +
baclofen O +
finally O +
resolved O +
hiccups B-Disease -
. O +

No O +
organic O +
cause O +
of O +
hiccups B-Disease +
was O +
identified O +
despite O +
extensive O +
investigation O -
. O +

DISCUSSION O -
: O +
Pharmacotherapeutic O +
agents O +
have O +
been O +
uncommonly O +
associated O +
with O +
hiccups B-Disease -
. O +

Corticosteroids O +
( O -
dexamethasone O +
and O +
methylprednisolone O -
) O -
, O +
benzodiazepines O +
( O -
midazolam O -
) O +
and O +
general O +
anaesthesia O +
have O +
been O +
the O +
specific O +
agents O +
mentioned O +
most O +
frequently O +
in O +
the O +
literature O +
as O +
being O +
associated O +
with O +
the O +
development O +
of O +
hiccups B-Disease -
. O +

Few O +
cases O +
of O +
drug O -
- O -
induced O +
hiccups B-Disease +
have O +
been O +
reported O +
related O +
to O +
macrolide O +
antimicrobials O -
. O +

Using O +
the O +
Naranjo O +
adverse O +
effect O +
reaction O +
probability O +
scale O +
this O +
event O +
could O +
be O +
classified O +
as O +
possible O +
( O -
score O +
5 O +
points O -
) O -
, O +
mostly O +
because O +
of O +
the O +
close O +
temporal O +
sequence O -
, O +
previous O +
reports O +
on O +
this O +
reaction O +
with O +
other O +
macrolides O +
and O +
the O +
absence O +
of O +
any O +
alternative O +
explanation O +
for O +
hiccups B-Disease -
. O +

Our O +
hypothesis O +
is O +
that O +
a O +
vagal O +
mechanism O +
mediated O +
by O +
azithromycin O +
could O +
be O +
the O +
pathogenesis O +
of O +
hiccups B-Disease +
in O +
our O +
patient O -
. O +

CONCLUSIONS O -
: O +
Diagnosis O +
of O +
drug O -
- O -
induced O +
hiccups B-Disease +
is O +
difficult O +
and O +
often O +
achieved O +
only O +
by O +
a O +
process O +
of O +
elimination O -
. O +

However O -
, O +
macrolide O +
antimicrobials O +
have O +
been O +
reported O +
to O +
be O +
associated O +
with O +
hiccups B-Disease +
and O +
vagal O +
mechanism O +
could O +
explain O +
the O +
development O +
of O +
this O +
side O -
- O -
effect O -
. O +

Evaluation O +
of O +
the O +
anticocaine O +
monoclonal O +
antibody O +
GNC92H2 O +
as O +
an O +
immunotherapy O +
for O +
cocaine B-Disease +
overdose I-Disease -
. O +

The O +
illicit O +
use O +
of O +
cocaine O +
continues O +
in O +
epidemic O +
proportions O +
and O +
treatment O +
for O +
cocaine B-Disease +
overdose I-Disease +
remains O +
elusive O -
. O +

Current O +
protein O -
- O -
based O +
technology O +
offers O +
a O +
new O +
therapeutic O +
venue O +
by O +
which O +
antibodies O +
bind O +
the O +
drug O +
in O +
the O +
blood O +
stream O -
, O +
inactivating O +
its O +
toxic O +
effects O -
. O +

The O +
therapeutic O +
potential O +
of O +
the O +
anticocaine O +
antibody O +
GNC92H2 O +
was O +
examined O +
using O +
a O +
model O +
of O +
cocaine B-Disease +
overdose I-Disease -
. O +

Swiss O +
albino O +
mice O +
prepared O +
with O +
intrajugular O +
catheters O +
were O +
tested O +
in O +
photocell O +
cages O +
after O +
administration O +
of O +
93 O +
mg O -
/ O -
kg O +
( O -
LD50 O -
) O +
of O +
cocaine O +
and O +
GNC92H2 O +
infusions O +
ranging O +
from O +
30 O +
to O +
190 O +
mg O -
/ O -
kg O -
. O +

GNC92H2 O +
was O +
delivered O +
30 O +
min O +
before O -
, O +
concomitantly O +
or O +
3 O +
min O +
after O +
cocaine O +
treatment O -
. O +

Significant O +
blockade O +
of O +
cocaine O +
toxicity B-Disease +
was O +
observed O +
with O +
the O +
higher O +
dose O +
of O +
GNC92H2 O +
( O -
190 O +
mg O -
/ O -
kg O -
) O -
, O +
where O +
premorbid O +
behaviors O +
were O +
reduced O +
up O +
to O +
40 O -
% O -
, O +
seizures B-Disease +
up O +
to O +
77 O -
% O +
and O +
death B-Disease +
by O +
72 O -
% O -
. O +

Importantly O -
, O +
GNC92H2 O +
prevented O +
death B-Disease +
even O +
post O -
- O -
cocaine O +
injection O -
. O +

The O +
results O +
support O +
the O +
important O +
potential O +
of O +
GNC92H2 O +
as O +
a O +
therapeutic O +
tool O +
against O +
cocaine B-Disease +
overdose I-Disease -
. O +

Calcium O +
carbonate O +
toxicity B-Disease -
: O +
the O +
updated O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome I-Disease -
; O +
report O +
of O +
3 O +
cases O +
and O +
review O +
of O +
the O +
literature O -
. O +

OBJECTIVE O -
: O +
To O +
describe O +
3 O +
patients O +
with O +
calcium O +
carbonate O -
- O -
induced O +
hypercalcemia B-Disease +
and O +
gain O +
insights O +
into O +
the O +
cause O +
and O +
management O +
of O +
the O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome I-Disease -
. O +

METHODS O -
: O +
We O +
report O +
the O +
clinical O +
and O +
laboratory O +
data O +
in O +
3 O +
patients O +
who O +
presented O +
with O +
severe O +
hypercalcemia B-Disease +
( O -
corrected O +
serum O +
calcium O +
> O +
or O +
= O +
14 O +
mg O -
/ O -
dL O -
) O +
and O +
review O +
the O +
pertinent O +
literature O +
on O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome I-Disease -
. O +

RESULTS O -
: O +
The O +
3 O +
patients O +
had O +
acute B-Disease +
renal I-Disease +
insufficiency I-Disease -
, O +
relative O +
metabolic B-Disease +
alkalosis I-Disease -
, O +
and O +
low O +
parathyroid O +
hormone O +
( O -
PTH O -
) O -
, O +
PTH O -
- O -
related O +
peptide O -
, O +
and O +
1,25-dihydroxyvitamin O +
D O +
concentrations O -
. O +

No O +
malignant O +
lesion O +
was O +
found O -
. O +

Treatment O +
included O +
aggressive O +
hydration O +
and O +
varied O +
amounts O +
of O +
furosemide O -
. O +

The O +
2 O +
patients O +
with O +
the O +
higher O +
serum O +
calcium O +
concentrations O +
received O +
pamidronate O +
intravenously O +
( O -
60 O +
and O +
30 O +
mg O -
, O +
respectively O -
) O -
, O +
which O +
caused O +
severe O +
hypocalcemia B-Disease -
. O +

Of O +
the O +
3 O +
patients O -
, O +
2 O +
were O +
ingesting O +
acceptable O +
doses O +
of O +
elemental O +
calcium O +
( O -
1 O +
g O +
and O +
2 O +
g O +
daily O -
, O +
respectively O -
) O +
in O +
the O +
form O +
of O +
calcium O +
carbonate O -
. O +

In O +
addition O +
to O +
our O +
highlighted O +
cases O -
, O +
we O +
review O +
the O +
history O -
, O +
classification O -
, O +
pathophysiologic O +
features O -
, O +
and O +
treatment O +
of O +
milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome I-Disease +
and O +
summarize O +
the O +
cases O +
reported O +
from O +
early O +
1995 O +
to O +
November O +
2003 O -
. O +

CONCLUSION O -
: O +
Milk B-Disease -
- I-Disease -
alkali I-Disease +
syndrome I-Disease +
may O +
be O +
a O +
common O +
cause O +
of O +
unexplained O +
hypercalcemia B-Disease +
and O +
can O +
be O +
precipitated O +
by O +
small O +
amounts O +
of O +
orally O +
ingested O +
calcium O +
carbonate O +
in O +
susceptible O +
persons O -
. O +

Treatment O +
with O +
hydration O -
, O +
furosemide O -
, O +
and O +
discontinuation O +
of O +
the O +
calcium O +
and O +
vitamin O +
D O +
source O +
is O +
adequate O -
. O +

Pamidronate O +
treatment O +
is O +
associated O +
with O +
considerable O +
risk O +
for O +
hypocalcemia B-Disease -
, O +
even O +
in O +
cases O +
of O +
initially O +
severe O +
hypercalcemia B-Disease -
. O +

Electrocardiographic O +
evidence O +
of O +
myocardial B-Disease +
injury I-Disease +
in O +
psychiatrically O +
hospitalized O +
cocaine O +
abusers O -
. O +

The O +
electrocardiograms O +
( O -
ECG O -
) O +
of O +
99 O +
cocaine O -
- O -
abusing O +
patients O +
were O +
compared O +
with O +
the O +
ECGs O +
of O +
50 O +
schizophrenic B-Disease +
controls O -
. O +

Eleven O +
of O +
the O +
cocaine O +
abusers O +
and O +
none O +
of O +
the O +
controls O +
had O +
ECG O +
evidence O +
of O +
significant O +
myocardial B-Disease +
injury I-Disease +
defined O +
as O +
myocardial B-Disease +
infarction I-Disease -
, O +
ischemia B-Disease -
, O +
and O +
bundle B-Disease +
branch I-Disease +
block I-Disease -
. O +

Warfarin O -
- O -
induced O +
leukocytoclastic B-Disease +
vasculitis I-Disease -
. O +

Skin O +
reactions O +
associated O +
with O +
oral O +
coumarin O -
- O -
derived O +
anticoagulants O +
are O +
an O +
uncommon O +
occurrence O -
. O +

Leukocytoclastic B-Disease +
vasculitis I-Disease +
( O -
LV B-Disease -
) O +
is O +
primarily O +
a O +
cutaneous B-Disease +
small I-Disease +
vessel I-Disease +
vasculitis I-Disease -
, O +
though O +
systemic O +
involvement O +
may O +
be O +
encountered O -
. O +

We O +
report O +
4 O +
patients O +
with O +
late O -
- O -
onset O +
LV B-Disease +
probably O +
due O +
to O +
warfarin O -
. O +

All O +
4 O +
patients O +
presented O +
with O +
skin B-Disease +
eruptions I-Disease +
that O +
developed O +
after O +
receiving O +
warfarin O +
for O +
several O +
years O -
. O +

The O +
results O +
of O +
skin B-Disease +
lesion I-Disease +
biopsies O +
were O +
available O +
in O +
3 O +
patients O -
, O +
confirming O +
LV B-Disease +
Cutaneous I-Disease +
lesions I-Disease +
resolved O +
in O +
all O +
patients O +
after O +
warfarin O +
was O +
discontinued O -
. O +

In O +
2 O +
of O +
the O +
4 O +
patients O -
, O +
rechallenge O +
with O +
warfarin O +
led O +
to O +
recurrence O +
of O +
the O +
lesions O -
. O +

LV B-Disease +
may O +
be O +
a O +
late O -
- O -
onset O +
adverse O +
reaction O +
associated O +
with O +
warfarin O +
therapy O -
. O +

Cocaine O -
- O -
induced O +
brainstem O +
seizures B-Disease +
and O +
behavior O -
. O +

A O +
variety O +
of O +
abnormal O +
sensory O -
/ O -
motor O +
behaviors O +
associated O +
with O +
electrical O +
discharges O +
recorded O +
from O +
the O +
bilateral O +
brainstem O +
were O +
induced O +
in O +
adult O +
WKY O +
rats O +
by O +
mechanical O +
( O -
electrode O +
implants O -
) O +
and O +
DC O +
electrical O +
current O +
stimulations O +
and O +
by O +
acute O +
and O +
chronic O +
administration O +
of O +
cocaine O -
. O +

The O +
electrode O +
implant O +
implicated O +
one O +
side O +
or O +
the O +
other O +
of O +
the O +
reticular O +
system O +
of O +
the O +
brainstem O +
but O +
subjects O +
were O +
not O +
incapacitated O +
by O +
the O +
stimulations O -
. O +

Cocaine O +
( O -
40 O +
mg O -
/ O -
kg O -
) O +
was O +
injected O +
subcutaneously O +
for O +
an O +
acute O +
experiment O +
and O +
subsequent O +
20 O +
mg O -
/ O -
kg O +
doses O +
twice O +
daily O +
for O +
3 O +
days O +
in O +
a O +
chronic O +
study O -
. O +

Cocaine O +
generated O +
more O +
abnormal O +
behaviors O +
in O +
the O +
brainstem O +
perturbation O +
group O -
, O +
especially O +
the O +
electrically O +
perturbated O +
subjects O -
. O +

The O +
abnormal O +
behaviors O +
were O +
yawning O -
, O +
retrocollis O -
, O +
hyperactivity B-Disease -
, O +
hypersensitivity B-Disease -
, O +
" O -
beating O +
drum O -
" O +
behavior O -
, O +
squealing O -
, O +
head O +
bobbing O -
, O +
circling O -
, O +
sniffing O -
, O +
abnormal O +
posturing O -
, O +
and O +
facial O +
twitching O -
. O +

Shifts O +
in O +
the O +
power O +
frequency O +
spectra O +
of O +
the O +
discharge O +
patterns O +
were O +
noted O +
between O +
quiet O +
and O +
pacing O +
behavioral O +
states O -
. O +

Hypersensitivity B-Disease +
to O +
various O +
auditory O -
, O +
tactile O -
, O +
and O +
visual O +
stimulation O +
was O +
present O +
and O +
shifts O +
in O +
the O +
brainstem O +
ambient O +
power O +
spectral O +
frequency O +
occurred O +
in O +
response O +
to O +
tactile O +
stimulation O -
. O +

These O +
findings O +
suggest O +
that O +
the O +
brainstem O +
generates O +
and O +
propagates O +
pathological O +
discharges O +
that O +
can O +
be O +
elicited O +
by O +
mechanical O +
and O +
DC O +
electrical O +
perturbation O -
. O +

Cocaine O +
was O +
found O +
to O +
activate O +
the O +
discharge O +
system O +
and O +
thus O +
induce O +
abnormal O +
behaviors O +
that O +
are O +
generated O +
at O +
the O +
discharge O +
site O +
and O +
at O +
distant O +
sites O +
to O +
which O +
the O +
discharge O +
propagates O -
. O +

Cognitive O +
functions O +
may O +
also O +
be O +
involved O +
since O +
dopaminergic O +
and O +
serotonergic O +
cellular O +
elements O +
at O +
the O +
brainstem O +
level O +
are O +
also O +
implicated O -
. O +

rTMS O +
of O +
supplementary O +
motor O +
area O +
modulates O +
therapy O -
- O -
induced O +
dyskinesias B-Disease +
in O +
Parkinson B-Disease +
disease I-Disease -
. O +

The O +
neural O +
mechanisms O +
and O +
circuitry O +
involved O +
in O +
levodopa O -
- O -
induced O +
dyskinesia B-Disease +
are O +
unclear O -
. O +

Using O +
repetitive O +
transcranial O +
magnetic O +
stimulation O +
( O -
rTMS O -
) O +
over O +
the O +
supplementary O +
motor O +
area O +
( O -
SMA O -
) O +
in O +
a O +
group O +
of O +
patients O +
with O +
advanced O +
Parkinson B-Disease +
disease I-Disease -
, O +
the O +
authors O +
investigated O +
whether O +
modulation O +
of O +
SMA O +
excitability O +
may O +
result O +
in O +
a O +
modification O +
of O +
a O +
dyskinetic B-Disease +
state O +
induced O +
by O +
continuous O +
apomorphine O +
infusion O -
. O +

rTMS O +
at O +
1 O +
Hz O +
was O +
observed O +
to O +
markedly O +
reduce O +
drug B-Disease -
- I-Disease -
induced I-Disease +
dyskinesias I-Disease -
, O +
whereas O +
5-Hz O +
rTMS O +
induced O +
a O +
slight O +
but O +
not O +
significant O +
increase O -
. O +

Intracavitary O +
chemotherapy O +
( O -
paclitaxel O -
/ O -
carboplatin O +
liquid O +
crystalline O +
cubic O +
phases O -
) O +
for O +
recurrent O +
glioblastoma B-Disease +
-- O +
clinical O +
observations O -
. O +

Human O +
malignant O +
brain B-Disease +
tumors I-Disease +
have O +
a O +
poor O +
prognosis O +
in O +
spite O +
of O +
surgery O +
and O +
radiation O +
therapy O -
. O +

Cubic O +
phases O +
consist O +
of O +
curved O +
biocontinuous O +
lipid O +
bilayers O -
, O +
separating O +
two O +
congruent O +
networks O +
of O +
water O +
channels O -
. O +

Used O +
as O +
a O +
host O +
for O +
cytotoxic O +
drugs O -
, O +
the O +
gel O -
- O -
like O +
matrix O +
can O +
easily O +
be O +
applied O +
to O +
the O +
walls O +
of O +
a O +
surgical O +
resection O +
cavity O -
. O +

For O +
human O +
glioblastoma B-Disease +
recurrences O -
, O +
the O +
feasibility O -
, O +
safety O -
, O +
and O +
short O -
- O -
term O +
effects O +
of O +
a O +
surgical O +
intracavitary O +
application O +
of O +
paclitaxel O +
and O +
carboplatin O +
encapsulated O +
by O +
liquid O +
crystalline O +
cubic O +
phases O +
are O +
examined O +
in O +
a O +
pilot O +
study O -
. O +

A O +
total O +
of O +
12 O +
patients O +
with O +
a O +
recurrence O +
of O +
a O +
glioblastoma B-Disease +
multiforme O +
underwent O +
re O -
- O -
resection O +
and O +
received O +
an O +
intracavitary O +
application O +
of O +
paclitaxel O +
and O +
carboplatin O +
cubic O +
phases O +
in O +
different O +
dosages O -
. O +

Six O +
of O +
the O +
patients O +
received O +
more O +
than O +
15 O +
mg O +
paclitaxel O +
and O +
suffered O +
from O +
moderate O +
to O +
severe O +
brain B-Disease +
edema I-Disease -
, O +
while O +
the O +
remaining O +
patients O +
received O +
only O +
a O +
total O +
of O +
15 O +
mg O +
paclitaxel O -
. O +

In O +
the O +
latter O +
group O -
, O +
brain B-Disease +
edema I-Disease +
was O +
markedly O +
reduced O +
and O +
dealt O +
medically O -
. O +

Intracavitary O +
chemotherapy O +
in O +
recurrent O +
glioblastoma B-Disease +
using O +
cubic O +
phases O +
is O +
feasible O +
and O +
safe O -
, O +
yet O +
the O +
clinical O +
benefit O +
remains O +
to O +
be O +
examined O +
in O +
a O +
clinical O +
phase O +
II O +
study O -
. O +

Lamotrigine O +
associated O +
with O +
exacerbation O +
or O +
de O +
novo O +
myoclonus B-Disease +
in O +
idiopathic B-Disease +
generalized I-Disease +
epilepsies I-Disease -
. O +

Five O +
patients O +
with O +
idiopathic B-Disease +
generalized I-Disease +
epilepsies I-Disease +
( O -
IGE B-Disease -
) O +
treated O +
with O +
lamotrigine O +
( O -
LTG O -
) O +
experienced O +
exacerbation O +
or O +
de O +
novo O +
appearance O +
of O +
myoclonic B-Disease +
jerks I-Disease +
( O -
MJ B-Disease -
) O -
. O +

In O +
three O +
patients O -
, O +
LTG O +
exacerbated O +
MJ B-Disease +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
with O +
early O +
aggravation O +
during O +
titration O -
. O +

MJ B-Disease +
disappeared O +
when O +
LTG O +
dose O +
was O +
decreased O +
by O +
25 O +
to O +
50 O -
% O -
. O +

In O +
two O +
patients O -
, O +
LTG O +
exacerbated O +
MJ B-Disease +
in O +
a O +
delayed O +
but O +
more O +
severe O +
manner O -
, O +
with O +
myoclonic B-Disease +
status I-Disease +
that O +
only O +
ceased O +
after O +
LTG O +
withdrawal O -
. O +

Behavioral O +
effects O +
of O +
urotensin O -
- O -
II O +
centrally O +
administered O +
in O +
mice O -
. O +

Urotensin O -
- O -
II O +
( O -
U O -
- O -
II O -
) O +
receptors O +
are O +
widely O +
distributed O +
in O +
the O +
central O +
nervous O +
system O -
. O +

Intracerebroventricular O +
( O -
i.c.v O -
. O -
) O +
injection O +
of O +
U O -
- O -
II O +
causes O +
hypertension B-Disease +
and O +
bradycardia B-Disease +
and O +
stimulates O +
prolactin O +
and O +
thyrotropin O +
secretion O -
. O +

However O -
, O +
the O +
behavioral O +
effects O +
of O +
centrally O +
administered O +
U O -
- O -
II O +
have O +
received O +
little O +
attention O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
tested O +
the O +
effects O +
of O +
i.c.v O -
. O +

injections O +
of O +
U O -
- O -
II O +
on O +
behavioral O -
, O +
metabolic O -
, O +
and O +
endocrine O +
responses O +
in O +
mice O -
. O +

Administration O +
of O +
graded O +
doses O +
of O +
U O -
- O -
II O +
( O -
1 O -
- O -
10,000 O +
ng O -
/ O -
mouse O -
) O +
provoked O -
: O +
( O -
1 O -
) O +
a O +
dose O -
- O -
dependent O +
reduction O +
in O +
the O +
number O +
of O +
head O +
dips O +
in O +
the O +
hole O -
- O -
board O +
test O -
; O +
( O -
2 O -
) O +
a O +
dose O -
- O -
dependent O +
reduction O +
in O +
the O +
number O +
of O +
entries O +
in O +
the O +
white O +
chamber O +
in O +
the O +
black O -
- O -
and O -
- O -
white O +
compartment O +
test O -
, O +
and O +
in O +
the O +
number O +
of O +
entries O +
in O +
the O +
central O +
platform O +
and O +
open O +
arms O +
in O +
the O +
plus O -
- O -
maze O +
test O -
; O +
and O +
( O -
3 O -
) O +
a O +
dose O -
- O -
dependent O +
increase O +
in O +
the O +
duration O +
of O +
immobility O +
in O +
the O +
forced O -
- O -
swimming O +
test O +
and O +
tail O +
suspension O +
test O -
. O +

Intracerebroventricular O +
injection O +
of O +
U O -
- O -
II O +
also O +
caused O +
an O +
increase O +
in O -
: O +
food O +
intake O +
at O +
doses O +
of O +
100 O +
and O +
1,000 O +
ng O -
/ O -
mouse O -
, O +
water O +
intake O +
at O +
doses O +
of O +
100 O -
- O -
10,000 O +
ng O -
/ O -
mouse O -
, O +
and O +
horizontal O +
locomotion O +
activity O +
at O +
a O +
dose O +
of O +
10,000 O +
ng O -
/ O -
mouse O -
. O +

Whatever O +
was O +
the O +
dose O -
, O +
the O +
central O +
administration O +
of O +
U O -
- O -
II O +
had O +
no O +
effect O +
on O +
body O +
temperature O -
, O +
nociception O -
, O +
apomorphine O -
- O -
induced O +
penile B-Disease +
erection I-Disease +
and O +
climbing O +
behavior O -
, O +
and O +
stress O -
- O -
induced O +
plasma O +
corticosterone O +
level O -
. O +

Taken O +
together O -
, O +
the O +
present O +
study O +
demonstrates O +
that O +
the O +
central O +
injection O +
of O +
U O -
- O -
II O +
at O +
doses O +
of O +
1 O -
- O -
10,000 O +
ng O -
/ O -
mouse O +
induces O +
anxiogenic- O +
and O +
depressant O -
- O -
like O +
effects O +
in O +
mouse O -
. O +

These O +
data O +
suggest O +
that O +
U O -
- O -
II O +
may O +
be O +
involved O +
in O +
some O +
aspects O +
of O +
psychiatric B-Disease +
disorders I-Disease -
. O +

Learning O +
of O +
rats O +
under O +
amnesia B-Disease +
caused O +
by O +
pentobarbital O -
. O +

Dissociated O +
learning O +
of O +
rats O +
in O +
the O +
normal O +
state O +
and O +
the O +
state O +
of O +
amnesia B-Disease +
produced O +
by O +
pentobarbital O +
( O -
15 O +
mg O -
/ O -
kg O -
, O +
ip O -
) O +
was O +
carried O +
out O -
. O +

Rats O +
were O +
trained O +
to O +
approach O +
a O +
shelf O +
where O +
they O +
received O +
food O +
reinforcement O -
. O +

In O +
Group O +
1 O +
the O +
rats O +
were O +
trained O +
under O +
the O +
influence O +
of O +
pentobarbital O +
to O +
run O +
to O +
the O +
same O +
shelf O +
as O +
in O +
the O +
normal O +
state O -
. O +

In O +
Group O +
2 O +
the O +
rats O +
were O +
trained O +
to O +
approach O +
different O +
shelves O +
in O +
different O +
drug O +
states O -
. O +

It O +
was O +
shown O +
that O +
memory B-Disease +
dissociation I-Disease +
occurred O +
in O +
both O +
groups O -
. O +

Differences O +
in O +
the O +
parameters O +
of O +
training O +
under O +
the O +
influence O +
of O +
pentobarbital O +
between O +
Groups O +
1 O +
and O +
2 O +
were O +
revealed O -
. O +

These O +
findings O +
show O +
that O +
the O +
brain O -
- O -
dissociated O +
state O +
induced O +
by O +
pentobarbital O +
is O +
formed O +
with O +
the O +
participation O +
of O +
the O +
mechanisms O +
of O +
information O +
perception O -
. O +

The O +
effects O +
of O +
short O -
- O -
term O +
raloxifene O +
therapy O +
on O +
fibrinolysis O +
markers O -
: O +
TAFI O -
, O +
tPA O -
, O +
and O +
PAI-1 O -
. O +

BACKGROUND O -
: O +
Markers O +
of O +
fibrinolysis O -
, O +
thrombin O -
- O -
activatable O +
fibrinolysis O +
inhibitor O +
( O -
TAFI O -
) O -
, O +
tissue O -
- O -
type O +
plasminogen O +
activator O +
( O -
tPA O -
) O -
, O +
and O +
plasminogen O +
activator O +
inhibitor-1 O +
( O -
PAI-1 O -
) O +
levels O +
were O +
studied O +
for O +
the O +
evaluation O +
of O +
short O -
- O -
term O +
effects O +
of O +
raloxifene O +
administration O +
in O +
postmenopausal O +
women O -
. O +

METHODS O -
: O +
Thirty O -
- O -
nine O +
postmenopausal O +
women O +
with O +
osteopenia B-Disease +
or O +
osteoporosis B-Disease +
were O +
included O +
in O +
this O +
prospective O -
, O +
controlled O +
clinical O +
study O -
. O +

Twenty O -
- O -
five O +
women O +
were O +
given O +
raloxifene O +
hydrochloride O +
( O -
60 O +
mg O -
/ O -
day O -
) O +
plus O +
calcium O +
( O -
500 O +
mg O -
/ O -
day O -
) O -
. O +

Age O -
- O -
matched O +
controls O +
( O -
n O +
= O +
14 O -
) O +
were O +
given O +
only O +
calcium O -
. O +

Plasma O +
TAFI O -
, O +
tPA O -
, O +
and O +
PAI-1 O +
antigen O +
levels O +
were O +
measured O +
at O +
baseline O +
and O +
after O +
3 O +
months O +
of O +
treatment O +
by O +
commercially O +
available O +
ELISA O +
kits O -
. O +

Variations O +
of O +
individuals O +
were O +
assessed O +
by O +
Wilcoxon O -
's O +
test O -
. O +

Relationship O +
between O +
those O +
markers O +
and O +
demographic O +
characteristics O +
were O +
investigated O -
. O +

RESULTS O -
: O +
Three O +
months O +
of O +
raloxifene O +
treatment O +
was O +
associated O +
with O +
a O +
significant O +
decrease O +
in O +
the O +
plasma O +
TAFI O +
antigen O +
concentrations O +
( O -
16 O -
% O +
change O -
, O +
P O +
< O +
0.01 O -
) O -
, O +
and O +
a O +
significant O +
increase O +
in O +
tPA O +
antigen O +
concentrations O +
( O -
25 O -
% O +
change O -
, O +
P O +
< O +
0.05 O -
) O -
. O +

A O +
significant O +
correlation O +
was O +
found O +
between O +
baseline O +
TAFI O +
antigen O +
concentrations O +
and O +
the O +
duration O +
of O +
amenorrhea B-Disease +
( O -
P O +
< O +
0.05 O -
; O +
r O +
= O +
0.33 O -
) O -
. O +

CONCLUSION O -
: O +
We O +
suggest O +
that O +
the O +
increased O +
risk O +
of O +
venous B-Disease +
thromboembolism I-Disease +
due O +
to O +
raloxifene O +
treatment O +
may O +
be O +
related O +
to O +
increased O +
tPA O +
levels O -
, O +
but O +
not O +
TAFI O +
levels O -
. O +

Absence O +
of O +
acute O +
cerebral O +
vasoconstriction O +
after O +
cocaine O -
- O -
associated O +
subarachnoid B-Disease +
hemorrhage I-Disease -
. O +

INTRODUCTION O -
: O +
Cocaine O +
use O +
has O +
been O +
associated O +
with O +
neurovascular B-Disease +
complications I-Disease -
, O +
including O +
arterial O +
vasoconstriction O +
and O +
vasculitis B-Disease -
. O +

However O -
, O +
there O +
are O +
few O +
studies O +
of O +
angiographic O +
effects O +
of O +
cocaine O +
on O +
human O +
cerebral O +
arteries O -
. O +

Information O +
on O +
these O +
effects O +
could O +
be O +
obtained O +
from O +
angiograms O +
of O +
patients O +
with O +
cocaine O -
- O -
associated O +
subarachnoid B-Disease +
hemorrhage I-Disease +
( O -
SAH B-Disease -
) O +
who O +
underwent O +
angiography O +
shortly O +
after O +
cocaine O +
use O -
. O +

METHODS O -
: O +
We O +
screened O +
patients O +
with O +
SAH B-Disease +
retrospectively O +
and O +
identified O +
those O +
with O +
positive O +
urine O +
toxicology O +
for O +
cocaine O +
or O +
its O +
metabolites O -
. O +

Quantitative O +
arterial O +
diameter O +
measurements O +
from O +
angiograms O +
of O +
these O +
patients O +
were O +
compared O +
to O +
measurements O +
from O +
control O +
patients O +
with O +
SAH B-Disease +
who O +
were O +
matched O +
for O +
factors O +
known O +
to O +
influence O +
arterial O +
diameter O -
. O +

Qualitative O +
comparisons O +
of O +
small O +
artery O +
changes O +
also O +
were O +
made O -
. O +

RESULTS O -
: O +
Thirteen O +
patients O +
with O +
positive O +
cocaine O +
toxicology O +
were O +
compared O +
to O +
26 O +
controls O -
. O +

There O +
were O +
no O +
significant O +
differences O +
between O +
groups O +
in O +
the O +
mean O +
diameters O +
of O +
the O +
intradural O +
internal O +
carotid O -
, O +
sphenoidal O +
segment O +
of O +
the O +
middle O +
cerebral O -
, O +
precommunicating O +
segment O +
of O +
the O +
anterior O +
cerebral O -
, O +
or O +
basilar O +
arteries O +
( O -
p O +
greater O +
than O +
0.05 O +
for O +
all O +
comparisons O -
, O +
unpaired O +
t O -
- O -
tests O -
) O -
. O +

There O +
also O +
were O +
no O +
significant O +
differences O +
between O +
groups O +
when O +
expressing O +
diameters O +
as O +
the O +
sum O +
of O +
the O +
precommunicating O +
segment O +
of O +
the O +
anterior O +
cerebral O +
+ O +
sphenoidal O +
segment O +
of O +
the O +
middle O +
cerebral O +
+ O +
supraclinoid O +
internal O +
carotid O +
artery O +
+ O +
basilar O +
artery O +
divided O +
by O +
the O +
diameter O +
of O +
the O +
petrous O +
internal O +
carotid O +
artery O +
( O -
p O +
greater O +
than O +
0.05 O -
, O +
unpaired O +
t O -
- O -
tests O -
) O -
. O +

Qualitative O +
assessments O +
showed O +
two O +
arterial O +
irregularities O +
in O +
the O +
distal O +
vasculature O +
in O +
each O +
group O -
. O +

CONCLUSION O -
: O +
No O +
quantitative O +
evidence O +
for O +
narrowing O +
of O +
large O +
cerebral O +
arteries O +
or O +
qualitative O +
angiographic O +
evidence O +
for O +
distal O +
narrowing O +
or O +
vasculitis B-Disease +
could O +
be O +
found O +
in O +
patients O +
who O +
underwent O +
angiography O +
after O +
aneurysmal B-Disease +
SAH B-Disease +
associated O +
with O +
cocaine O +
use O -
. O +

Valproate O -
- O -
induced O +
encephalopathy B-Disease -
. O +

Valproate O -
- O -
induced O +
encephalopathy B-Disease +
is O +
a O +
rare O +
syndrome O +
that O +
may O +
manifest O +
in O +
otherwise O +
normal O +
epileptic B-Disease +
individuals O -
. O +

It O +
may O +
even O +
present O +
in O +
patients O +
who O +
have O +
tolerated O +
this O +
medicine O +
well O +
in O +
the O +
past O -
. O +

It O +
is O +
usually O +
but O +
not O +
necessarily O +
associated O +
with O +
hyperammonemia B-Disease -
. O +

The O +
EEG O +
shows O +
characteristic O +
triphasic O +
waves O +
in O +
most O +
patients O +
with O +
this O +
complication O -
. O +

A O +
case O +
of O +
valproate O -
- O -
induced O +
encephalopathy B-Disease +
is O +
presented O -
. O +

The O +
problems O +
in O +
diagnosing O +
this O +
condition O +
are O +
subsequently O +
discussed O -
. O +

Methamphetamine O +
causes O +
alterations O +
in O +
the O +
MAP O +
kinase O -
- O -
related O +
pathways O +
in O +
the O +
brains O +
of O +
mice O +
that O +
display O +
increased O +
aggressiveness B-Disease -
. O +

Aggressive B-Disease +
behaviors I-Disease +
have O +
been O +
reported O +
in O +
patients O +
who O +
suffer O +
from O +
some O +
psychiatric B-Disease +
disorders I-Disease -
, O +
and O +
are O +
common O +
in O +
methamphetamine O +
( O -
METH O -
) O +
abusers O -
. O +

Herein O -
, O +
we O +
report O +
that O +
multiple O +
( O -
but O +
not O +
single O -
) O +
injections O +
of O +
METH O +
significantly O +
increased O +
aggressiveness B-Disease +
in O +
male O +
CD-1 O +
mice O -
. O +

This O +
increase O +
in O +
aggressiveness B-Disease +
was O +
not O +
secondary O +
to O +
METH O -
- O -
induced O +
hyperactivity B-Disease -
. O +

Analysis O +
of O +
protein O +
expression O +
using O +
antibody O +
microarrays O +
and O +
Western O +
blotting O +
revealed O +
differential O +
changes O +
in O +
MAP O +
kinase O -
- O -
related O +
pathways O +
after O +
multiple O +
and O +
single O +
METH O +
injections O -
. O +

There O +
were O +
statistically O +
significant O +
( O -
p<0.05 O -
) O +
decreases O +
in O +
MEK1 O -
, O +
Erk2p O -
, O +
GSK3alpha O -
, O +
14 O -
- O -
3 O -
- O -
3e O -
, O +
and O +
MEK7 O +
in O +
the O +
striata O +
of O +
mice O +
after O +
multiple O +
injections O +
of O +
METH O -
. O +

MEK1 O +
was O +
significantly O +
decreased O +
also O +
after O +
a O +
single O +
injection O +
of O +
METH O -
, O +
but O +
to O +
a O +
much O +
lesser O +
degree O +
than O +
after O +
multiple O +
injections O +
of O +
METH O -
. O +

In O +
the O +
frontal O +
cortex O -
, O +
there O +
was O +
a O +
statistically O +
significant O +
decrease O +
in O +
GSK3alpha O +
after O +
multiple O +
( O -
but O +
not O +
single O -
) O +
injections O +
of O +
METH O -
. O +

These O +
findings O +
suggest O +
that O +
alterations O +
in O +
MAP O +
kinase O -
- O -
related O +
pathways O +
in O +
the O +
prefronto O -
- O -
striatal O +
circuitries O +
might O +
be O +
involved O +
in O +
the O +
manifestation O +
of O +
aggressive B-Disease +
behaviors I-Disease +
in O +
mice O -
. O +

Recurrent O +
dysphonia B-Disease +
and O +
acitretin O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
woman O +
complaining O +
of O +
dysphonia B-Disease +
while O +
she O +
was O +
treated O +
by O +
acitretin O -
. O +

Her O +
symptoms O +
totally O +
regressed O +
after O +
drug O +
withdrawal O +
and O +
reappeared O +
when O +
acitretin O +
was O +
reintroduced O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
case O +
of O +
acitretin O -
- O -
induced O +
dysphonia B-Disease -
. O +

This O +
effect O +
may O +
be O +
related O +
to O +
the O +
pharmacological O +
effect O +
of O +
this O +
drug O +
on O +
mucous O +
membranes O -
. O +

Chloroquine O +
related O +
complete O +
heart B-Disease +
block I-Disease +
with O +
blindness B-Disease -
: O +
case O +
report O -
. O +

A O +
27-year O +
old O +
African O +
woman O +
with O +
history O +
of O +
regular O +
chloroquine O +
ingestion O +
presented O +
with O +
progressive O +
deterioration B-Disease +
of I-Disease +
vision I-Disease -
, O +
easy O +
fatiguability B-Disease -
, O +
dyspnoea B-Disease -
, O +
dizziness B-Disease +
progressing O +
to O +
syncopal B-Disease +
attacks I-Disease -
. O +

Ophthalmological O +
assessment O +
revealed O +
features O +
of O +
chloroquine O +
retinopathy B-Disease -
, O +
cardiac O +
assessment O +
revealed O +
features O +
of O +
heart B-Disease +
failure I-Disease +
and O +
a O +
complete O +
heart B-Disease +
block I-Disease +
with O +
right B-Disease +
bundle I-Disease +
branch I-Disease +
block I-Disease +
pattern O -
. O +

The O +
heart B-Disease +
block I-Disease +
was O +
treated O +
by O +
pacemaker O +
insertion O +
and O +
the O +
heart B-Disease +
failure I-Disease +
resolved O +
spontaneously O +
following O +
chloroquine O +
discontinuation O -
. O +

She O +
however O +
remains O +
blind B-Disease -
. O +

Nitro O -
- O -
L O -
- O -
arginine O +
methyl O +
ester O -
: O +
a O +
potential O +
protector O +
against O +
gentamicin O +
ototoxicity B-Disease -
. O +

The O +
nitric O +
oxide O +
( O -
NO O -
) O +
inhibitor O +
nitro O -
- O -
L O -
- O -
arginine O +
methyl O +
ester O +
( O -
L O -
- O -
NAME O -
) O +
may O +
act O +
as O +
an O +
otoprotectant O +
against O +
high B-Disease -
- I-Disease -
frequency I-Disease +
hearing I-Disease +
loss I-Disease +
caused O +
by O +
gentamicin O -
, O +
but O +
further O +
studies O +
are O +
needed O +
to O +
confirm O +
this O -
. O +

Aminoglycoside O +
antibiotics O +
are O +
still O +
widely O +
used O +
by O +
virtue O +
of O +
their O +
efficacy O +
and O +
low O +
cost O -
. O +

Their O +
ototoxicity B-Disease +
is O +
a O +
serious O +
health O +
problem O +
and O -
, O +
as O +
their O +
ototoxic B-Disease +
mechanism O +
involves O +
the O +
production O +
of O +
NO O -
, O +
we O +
need O +
to O +
assess O +
the O +
use O +
of O +
NO O +
inhibitors O +
for O +
the O +
prevention O +
of O +
aminoglycoside O -
- O -
induced O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease -
. O +

In O +
this O +
experimental O +
study O +
we O +
used O +
30 O +
Sprague O -
- O -
Dawley O +
rats O -
, O +
27 O +
of O +
which O +
had O +
gentamicin O +
instilled O +
into O +
the O +
middle O +
ear O -
. O +

The O +
otoprotectant O +
L O -
- O -
NAME O +
was O +
administered O +
topically O +
to O +
12 O -
/ O -
27 O +
animals O -
. O +

Its O +
effect O +
was O +
determined O +
in O +
terms O +
of O +
attenuation O +
of O +
hearing B-Disease +
loss I-Disease -
, O +
measured O +
by O +
shifts O +
in O +
the O +
auditory O +
brainstem O +
response O +
threshold O -
. O +

L O -
- O -
NAME O +
reduced O +
gentamicin O -
- O -
induced O +
hearing B-Disease +
loss I-Disease +
in O +
the O +
high O -
- O -
frequency O +
range O -
, O +
but O +
gave O +
no O +
protection O +
in O +
the O +
middle O +
or O +
low O +
frequencies O -
. O +

Safety O +
profile O +
of O +
a O +
nicotine O +
lozenge O +
compared O +
with O +
that O +
of O +
nicotine O +
gum O +
in O +
adult O +
smokers O +
with O +
underlying O +
medical O +
conditions O -
: O +
a O +
12-week O -
, O +
randomized O -
, O +
open O -
- O -
label O +
study O -
. O +

BACKGROUND O -
: O +
Nicotine O +
polacrilex O +
lozenges O +
deliver O +
25 O -
% O +
to O +
27 O -
% O +
more O +
nicotine O +
compared O +
with O +
equivalent O +
doses O +
of O +
nicotine O +
polacrilex O +
gum O -
. O +

The O +
increased O +
nicotine O +
exposure O +
from O +
the O +
lozenge O +
has O +
raised O +
questions O +
about O +
the O +
relative O +
safety O +
of O +
the O +
lozenge O +
and O +
gum O -
. O +

OBJECTIVE O -
: O +
The O +
objective O +
of O +
this O +
study O +
was O +
to O +
compare O +
the O +
safety O +
profiles O +
of O +
the O +
4-mg O +
nicotine O +
lozenge O +
and O +
4-mg O +
nicotine O +
gum O +
in O +
smokers O +
with O +
selected O +
label O -
- O -
restricted O +
diseases O -
. O +

METHODS O -
: O +
This O +
was O +
a O +
multicenter O -
, O +
randomized O -
, O +
open O -
- O -
label O +
study O +
in O +
adult O +
smokers O +
with O +
heart B-Disease +
disease I-Disease -
, O +
hypertension B-Disease +
not O +
controlled O +
by O +
medication O -
, O +
and/or O +
diabetes B-Disease +
mellitus I-Disease -
. O +

Patients O +
were O +
randomized O +
in O +
a O +
1:1 O +
ratio O +
to O +
receive O +
the O +
4-mg O +
nicotine O +
lozenge O +
or O +
4-mg O +
nicotine O +
gum O -
. O +

Safety O +
assessments O +
were O +
made O +
at O +
baseline O +
and O +
at O +
2 O -
, O +
4 O -
, O +
6 O -
, O +
and O +
12 O +
weeks O +
after O +
the O +
start O +
of O +
product O +
use O -
. O +

RESULTS O -
: O +
Nine O +
hundred O +
one O +
patients O +
were O +
randomized O +
to O +
treatment O -
, O +
447 O +
who O +
received O +
the O +
lozenge O +
and O +
454 O +
who O +
received O +
the O +
gum O +
( O -
safety O +
population O -
) O -
. O +

The O +
majority O +
were O +
women O +
( O -
52.7 O -
% O -
) O -
. O +

Patients O -
' O +
mean O +
age O +
was O +
53.9 O +
years O -
, O +
their O +
mean O +
weight O +
was O +
193.9 O +
pounds O -
, O +
and O +
they O +
smoked O +
a O +
mean O +
of O +
25.2 O +
cigarettes O +
per O +
day O +
at O +
baseline O -
. O +

Five O +
hundred O +
fifty O -
- O -
three O +
patients O -
, O +
264 O +
taking O +
the O +
lozenge O +
and O +
289 O +
taking O +
the O +
gum O -
, O +
used O +
the O +
study O +
product O +
for O +
> O +
or O +
= O -
4 O +
days O +
per O +
week O +
during O +
the O +
first O +
2 O +
weeks O +
( O -
evaluable O +
population O -
) O -
. O +

The O +
nicotine O +
lozenge O +
and O +
nicotine O +
gum O +
were O +
equally O +
well O +
tolerated O -
, O +
despite O +
increased O +
nicotine O +
exposure O +
from O +
the O +
lozenge O -
. O +

The O +
incidence O +
of O +
adverse O +
events O +
in O +
the O +
2 O +
groups O +
was O +
similar O +
during O +
the O +
first O +
2 O +
weeks O +
of O +
product O +
use O +
( O -
evaluation O +
population O -
: O +
55.3 O -
% O +
lozenge O -
, O +
54.7 O -
% O +
gum O -
) O -
, O +
as O +
well O +
as O +
during O +
the O +
entire O +
study O +
( O -
safety O +
population O -
: O +
63.8 O -
% O +
and O +
58.6 O -
% O -
, O +
respectively O -
) O -
. O +

Stratification O +
of O +
patients O +
by O +
sex O -
, O +
age O -
, O +
extent O +
of O +
concurrent O +
smoking O -
, O +
extent O +
of O +
product O +
use O -
, O +
and O +
severity O +
of O +
adverse O +
events O +
revealed O +
no O +
clinically O +
significant O +
differences O +
between O +
the O +
lozenge O +
and O +
gum O -
. O +

The O +
most O +
common O +
adverse O +
events O +
were O +
nausea B-Disease +
( O -
17.2 O -
% O +
and O +
16.1 O -
% O -
; O +
95 O -
% O +
CI O -
, O +
-3.7 O +
to O +
6.0 O -
) O -
, O +
hiccups B-Disease +
( O -
10.7 O -
% O +
and O +
6.6 O -
% O -
; O +
95 O -
% O +
CI O -
, O +
0.5 O +
to O +
7.8 O -
) O -
, O +
and O +
headache B-Disease +
( O -
8.7 O -
% O +
and O +
9.9 O -
% O -
; O +
95 O -
% O +
Cl O -
, O +
-5.0 O +
to O +
2.6 O -
) O -
. O +

Serious O +
adverse O +
events O +
were O +
reported O +
in O +
11 O +
and O +
13 O +
patients O +
in O +
the O +
respective O +
groups O -
. O +

Fewer O +
than O +
6 O -
% O +
of O +
patients O +
in O +
either O +
group O +
were O +
considered O +
by O +
the O +
investigator O +
to O +
have O +
a O +
worsening O +
of O +
their O +
overall O +
disease O +
condition O +
during O +
the O +
study O -
. O +

The O +
majority O +
of O +
patients O +
( O -
> O -
60 O -
% O -
) O +
experienced O +
no O +
change O +
in O +
their O +
disease O +
status O +
from O +
baseline O -
. O +

CONCLUSION O -
: O +
The O +
4-mg O +
nicotine O +
lozenge O +
and O +
4-mg O +
nicotine O +
gum O +
had O +
comparable O +
safety O +
profiles O +
in O +
these O +
patients O +
with O +
label O -
- O -
restricted O +
medical O +
conditions O -
. O +

Pharmacological O +
modulation O +
of O +
pain B-Disease -
- O -
related O +
brain O +
activity O +
during O +
normal O +
and O +
central O +
sensitization O +
states O +
in O +
humans O -
. O +

Abnormal O +
processing O +
of O +
somatosensory O +
inputs O +
in O +
the O +
central O +
nervous O +
system O +
( O -
central O +
sensitization O -
) O +
is O +
the O +
mechanism O +
accounting O +
for O +
the O +
enhanced O +
pain B-Disease +
sensitivity O +
in O +
the O +
skin O +
surrounding O +
tissue B-Disease +
injury I-Disease +
( O -
secondary B-Disease +
hyperalgesia I-Disease -
) O -
. O +

Secondary B-Disease +
hyperalgesia I-Disease +
shares O +
clinical O +
characteristics O +
with O +
neurogenic B-Disease +
hyperalgesia I-Disease +
in O +
patients O +
with O +
neuropathic B-Disease +
pain I-Disease -
. O +

Abnormal O +
brain O +
responses O +
to O +
somatosensory O +
stimuli O +
have O +
been O +
found O +
in O +
patients O +
with O +
hyperalgesia B-Disease +
as O +
well O +
as O +
in O +
normal O +
subjects O +
during O +
experimental O +
central O +
sensitization O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
assess O +
the O +
effects O +
of O +
gabapentin O -
, O +
a O +
drug O +
effective O +
in O +
neuropathic B-Disease +
pain I-Disease +
patients O -
, O +
on O +
brain O +
processing O +
of O +
nociceptive O +
information O +
in O +
normal O +
and O +
central O +
sensitization O +
states O -
. O +

Using O +
functional O +
magnetic O +
resonance O +
imaging O +
( O -
fMRI O -
) O +
in O +
normal O +
volunteers O -
, O +
we O +
studied O +
the O +
gabapentin O -
- O -
induced O +
modulation O +
of O +
brain O +
activity O +
in O +
response O +
to O +
nociceptive O +
mechanical O +
stimulation O +
of O +
normal O +
skin O +
and O +
capsaicin O -
- O -
induced O +
secondary B-Disease +
hyperalgesia I-Disease -
. O +

The O +
dose O +
of O +
gabapentin O +
was O +
1,800 O +
mg O +
per O +
os O -
, O +
in O +
a O +
single O +
administration O -
. O +

We O +
found O +
that O +
( O -
i O -
) O +
gabapentin O +
reduced O +
the O +
activations O +
in O +
the O +
bilateral O +
operculoinsular O +
cortex O -
, O +
independently O +
of O +
the O +
presence O +
of O +
central O +
sensitization O -
; O +
( O -
ii O -
) O +
gabapentin O +
reduced O +
the O +
activation O +
in O +
the O +
brainstem O -
, O +
only O +
during O +
central O +
sensitization O -
; O +
( O -
iii O -
) O +
gabapentin O +
suppressed O +
stimulus O -
- O -
induced O +
deactivations O -
, O +
only O +
during O +
central O +
sensitization O -
; O +
this O +
effect O +
was O +
more O +
robust O +
than O +
the O +
effect O +
on O +
brain O +
activation O -
. O +

The O +
observed O +
drug O -
- O -
induced O +
effects O +
were O +
not O +
due O +
to O +
changes O +
in O +
the O +
baseline O +
fMRI O +
signal O -
. O +

These O +
findings O +
indicate O +
that O +
gabapentin O +
has O +
a O +
measurable O +
antinociceptive O +
effect O +
and O +
a O +
stronger O +
antihyperalgesic O +
effect O +
most O +
evident O +
in O +
the O +
brain O +
areas O +
undergoing O +
deactivation O -
, O +
thus O +
supporting O +
the O +
concept O +
that O +
gabapentin O +
is O +
more O +
effective O +
in O +
modulating O +
nociceptive O +
transmission O +
when O +
central O +
sensitization O +
is O +
present O -
. O +

Investigation O +
of O +
mitochondrial O +
involvement O +
in O +
the O +
experimental O +
model O +
of O +
epilepsy B-Disease +
induced O +
by O +
pilocarpine O -
. O +

Mitochondrial B-Disease +
abnormalities I-Disease +
have O +
been O +
associated O +
with O +
several O +
aspects O +
of O +
epileptogenesis O -
, O +
such O +
as O +
energy O +
generation O -
, O +
control O +
of O +
cell O +
death B-Disease -
, O +
neurotransmitter O +
synthesis O -
, O +
and O +
free O +
radical O +
( O -
FR O -
) O +
production O -
. O +

Increased O +
production O +
of O +
FRs O +
may O +
cause O +
mtDNA O +
damage O +
leading O +
to O +
decreased O +
activities O +
of O +
oxidative O +
phosphorylation O +
complexes O +
containing O +
mtDNA O -
- O -
encoded O +
subunits O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
whether O +
increased O +
generation O +
of O +
FR O +
during O +
status B-Disease +
epilepticus I-Disease +
would O +
be O +
sufficient O +
to O +
provoke O +
abnormalities O +
in O +
mtDNA O +
and O +
in O +
the O +
expression O +
and O +
activity O +
of O +
cytochrome O +
c O +
oxidase O +
( O -
CCO O -
) O -
, O +
complex O +
IV O +
of O +
the O +
respiratory O +
chain O -
, O +
in O +
the O +
chronic O +
phase O +
of O +
the O +
pilocarpine O +
model O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
. O +

DNA O +
analysis O +
revealed O +
low O +
amounts O +
of O +
a O +
4.8 O +
kb O +
mtDNA O +
deletion O +
but O +
with O +
no O +
differences O +
in O +
frequency O +
or O +
quantity O +
in O +
the O +
control O +
and O +
experimental O +
groups O -
. O +

We O +
did O +
not O +
find O +
abnormalities O +
in O +
the O +
expression O +
and O +
distribution O +
of O +
an O +
mtDNA O -
- O -
encoded O +
subunit O +
of O +
CCO O +
( O -
CCO O -
- O -
I O -
) O +
or O +
a O +
relative O +
decrease O +
in O +
CCO O -
- O -
I O +
when O +
compared O +
with O +
nuclear O -
- O -
encoded O +
subunits O +
( O -
CCO O -
- O -
IV O +
and O +
SDH O -
- O -
fp O -
) O -
. O +

No O +
abnormality O +
in O +
CCO O +
activity O +
was O +
observed O +
through O +
histochemistry O -
. O +

Although O +
evidences O +
of O +
mitochondrial B-Disease +
abnormalities I-Disease +
were O +
found O +
in O +
previously O +
published O +
studies O -
, O +
our O +
results O +
do O +
not O +
suggest O +
that O +
the O +
FRs O -
, O +
generated O +
during O +
the O +
acute O +
phase O -
, O +
determined O +
important O +
abnormalities O +
in O +
mtDNA O -
, O +
in O +
expression O +
of O +
CCO O -
- O -
I O -
, O +
and O +
in O +
CCO O +
activity O -
. O +

Effects O +
of O +
suprofen O +
on O +
the O +
isolated O +
perfused O +
rat O +
kidney O -
. O +

Although O +
suprofen O +
has O +
been O +
associated O +
with O +
the O +
development O +
of O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
in O +
greater O +
than O +
100 O +
subjects O -
, O +
the O +
mechanism O +
of O +
damage O +
remains O +
unclear O -
. O +

The O +
direct O +
nephrotoxic B-Disease +
effects O +
of O +
a O +
single O +
dose O +
of O +
15 O +
mg O +
of O +
suprofen O +
were O +
compared O +
in O +
the O +
recirculating O +
isolated O +
rat O +
kidney O +
perfused O +
with O +
cell O -
- O -
free O +
buffer O +
with O +
or O +
without O +
the O +
addition O +
of O +
5 O +
mg O -
/ O -
dL O +
of O +
uric O +
acid O -
. O +

There O +
were O +
no O +
significant O +
differences O +
in O +
renal O +
sodium O +
excretion O -
, O +
oxygen O +
consumption O -
, O +
or O +
urinary O +
flow O +
rates O +
in O +
kidneys O +
perfused O +
with O +
suprofen O +
compared O +
with O +
the O +
drug O -
- O -
free O +
control O +
groups O -
. O +

In O +
contrast O -
, O +
a O +
significant O +
decline O +
in O +
glomerular O +
filtration O +
rate O +
was O +
found O +
after O +
the O +
introduction O +
of O +
suprofen O +
to O +
the O +
kidney O +
perfused O +
with O +
uric O +
acid O -
; O +
no O +
changes O +
were O +
found O +
with O +
suprofen O +
in O +
the O +
absence O +
of O +
uric O +
acid O -
. O +

A O +
significant O +
decrease O +
in O +
the O +
baseline O +
excretion O +
rate O +
of O +
uric O +
acid O +
was O +
found O +
in O +
rats O +
given O +
suprofen O -
, O +
compared O +
with O +
drug O -
- O -
free O +
controls O -
. O +

However O -
, O +
the O +
fractional O +
excretion O +
of O +
uric O +
acid O +
was O +
unchanged O +
between O +
the O +
groups O +
over O +
the O +
experimental O +
period O -
. O +

In O +
summary O -
, O +
suprofen O +
causes O +
acute B-Disease +
declines I-Disease +
in I-Disease +
renal I-Disease +
function I-Disease -
, O +
most O +
likely O +
by O +
directly O +
altering O +
the O +
intrarenal O +
distribution O +
of O +
uric O +
acid O -
. O +

Microinjection O +
of O +
ritanserin O +
into O +
the O +
CA1 O +
region O +
of O +
hippocampus O +
improves O +
scopolamine O -
- O -
induced O +
amnesia B-Disease +
in O +
adult O +
male O +
rats O -
. O +

The O +
effect O +
of O +
ritanserin O +
( O -
5-HT2 O +
antagonist O -
) O +
on O +
scopolamine O +
( O -
muscarinic O +
cholinergic O +
antagonist O -
) O -
-induced O +
amnesia B-Disease +
in O +
Morris O +
water O +
maze O +
( O -
MWM O -
) O +
was O +
investigated O -
. O +

Rats O +
were O +
divided O +
into O +
eight O +
groups O +
and O +
bilaterally O +
cannulated O +
into O +
CA1 O +
region O +
of O +
the O +
hippocampus O -
. O +

One O +
week O +
later O -
, O +
they O +
received O +
repeatedly O +
vehicles O +
( O -
saline O -
, O +
DMSO O -
, O +
saline+DMSO O -
) O -
, O +
scopolamine O +
( O -
2 O +
microg O -
/ O -
0.5 O +
microl O +
saline O -
/ O -
side O -
; O +
30 O +
min O +
before O +
training O -
) O -
, O +
ritanserin O +
( O -
2 O -
, O +
4 O +
and O +
8 O +
microg O -
/ O -
0.5 O +
microl O +
DMSO O -
/ O -
side O -
; O +
20 O +
min O +
before O +
training O -
) O +
and O +
scopolamine O +
( O -
2 O +
microg O -
/ O -
0.5 O +
microl O -
; O +
30 O +
min O +
before O +
ritanserin O +
injection O -
) O -
+ritanserin O +
( O -
4 O +
microg O -
/ O -
0.5 O +
microl O +
DMSO O -
) O +
through O +
cannulae O +
each O +
day O -
. O +

Animals O +
were O +
tested O +
for O +
four O +
consecutive O +
days O +
( O -
4 O +
trial O -
/ O -
day O -
) O +
in O +
MWM O +
during O +
which O +
the O +
position O +
of O +
hidden O +
platform O +
was O +
unchanged O -
. O +

In O +
the O +
fifth O +
day O -
, O +
the O +
platform O +
was O +
elevated O +
above O +
the O +
water O +
surface O +
in O +
another O +
position O +
to O +
evaluate O +
the O +
function O +
of O +
motor O -
, O +
motivational O +
and O +
visual O +
systems O -
. O +

The O +
results O +
showed O +
a O +
significant O +
increase O +
in O +
escape O +
latencies O +
and O +
traveled O +
distances O +
to O +
find O +
platform O +
in O +
scopolamine O -
- O -
treated O +
group O +
as O +
compared O +
to O +
saline O +
group O -
. O +

Ritanserin O -
- O -
treated O +
rats O +
( O -
4 O +
microg O -
/ O -
0.5 O +
microl O -
/ O -
side O -
) O +
showed O +
a O +
significant O +
decrease O +
in O +
the O +
mentioned O +
parameters O +
as O +
compared O +
to O +
DMSO O -
- O -
treated O +
group O -
. O +

However O -
, O +
scopolamine O +
and O +
ritanserin O +
co O -
- O -
administration O +
resulted O +
in O +
a O +
significant O +
decrease O +
in O +
escape O +
latencies O +
and O +
traveled O +
distances O +
as O +
compared O +
to O +
the O +
scopolamine O -
- O -
treated O +
rats O -
. O +

Our O +
findings O +
show O +
that O +
microinjection O +
of O +
ritanserin O +
into O +
the O +
CA1 O +
region O +
of O +
the O +
hippocampus O +
improves O +
the O +
scopolamine O -
- O -
induced O +
amnesia B-Disease -
. O +

Adverse O +
effect O +
of O +
the O +
calcium O +
channel O +
blocker O +
nitrendipine O +
on O +
nephrosclerosis B-Disease +
in O +
rats O +
with O +
renovascular B-Disease +
hypertension I-Disease -
. O +

The O +
effect O +
of O +
a O +
6-week O +
treatment O +
with O +
the O +
calcium O +
channel O +
blocker O +
nitrendipine O +
or O +
the O +
angiotensin O +
converting O +
enzyme O +
inhibitor O +
enalapril O +
on O +
blood O +
pressure O -
, O +
albuminuria B-Disease -
, O +
renal O +
hemodynamics O -
, O +
and O +
morphology O +
of O +
the O +
nonclipped O +
kidney O +
was O +
studied O +
in O +
rats O +
with O +
two O -
- O -
kidney O -
, O +
one O +
clip O +
renovascular B-Disease +
hypertension I-Disease -
. O +

Six O +
weeks O +
after O +
clipping O +
of O +
one O +
renal O +
artery O -
, O +
hypertensive B-Disease +
rats O +
( O -
178 O +
+ O -
/- O +

4 O +
mm O +
Hg O -
) O +
were O +
randomly O +
assigned O +
to O +
three O +
groups O -
: O +
untreated O +
hypertensive B-Disease +
controls O +
( O -
n O +
= O +
8) O -
, O +
enalapril O -
- O -
treated O +
( O -
n O +
= O +
8) O -
, O +
or O +
nitrendipine O -
- O -
treated O +
( O -
n O +
= O +
10 O -
) O -
. O +

Sham O -
- O -
operated O +
rats O +
served O +
as O +
normotensive O +
controls O +
( O -
128 O +
+ O -
/- O +

3 O +
mm O +
Hg O -
, O +
n O +
= O +
8) O -
. O +

After O +
6 O +
weeks O +
of O +
treatment O -
, O +
renal O +
hemodynamics O +
( O -
glomerular O +
filtration O +
rate O +
and O +
renal O +
plasma O +
flow O -
) O +
were O +
measured O +
in O +
the O +
anesthetized O +
rats O -
. O +

Renal O +
tissue O +
was O +
obtained O +
for O +
determination O +
of O +
glomerular O +
size O +
and O +
sclerosis O -
. O +

Enalapril O +
but O +
not O +
nitrendipine O +
reduced O +
blood O +
pressure O +
significantly O -
. O +

After O +
6 O +
weeks O +
of O +
therapy O -
, O +
glomerular O +
filtration O +
rate O +
was O +
not O +
different O +
among O +
the O +
studied O +
groups O -
. O +

Renal O +
plasma O +
flow O +
increased O -
, O +
but O +
albumin O +
excretion O +
and O +
glomerulosclerosis B-Disease +
did O +
not O +
change O +
after O +
enalapril O +
treatment O -
. O +

In O +
contrast O -
, O +
in O +
the O +
nitrendipine O -
- O -
treated O +
group O +
albuminuria B-Disease +
increased O +
from O +
12.8 O +
+ O -
/- O +

2 O +
progressively O +
to O +
163 O +
+ O -
/- O +

55 O +
compared O +
with O +
19.2 O +
+ O -
/- O +

9 O +
mg O -
/ O -
24 O +
hr O +
in O +
the O +
hypertensive B-Disease +
controls O -
. O +

Furthermore O -
, O +
glomerulosclerosis B-Disease +
index O +
was O +
significantly O +
increased O +
in O +
the O +
nitrendipine O -
- O -
treated O +
group O +
compared O +
with O +
the O +
hypertensive B-Disease +
controls O +
( O -
0.38 O +
+ O -
/- O +
0.1 O +
versus O +
0.13 O +
+ O -
/- O +
0.04 O -
) O -
. O +

In O +
addition O -
, O +
glomerular O +
size O +
was O +
higher O +
in O +
the O +
nitrendipine O -
- O -
treated O +
group O +
( O -
14.9 O +
+ O -
/- O +

0.17 O +
10 O -
( O -
-3 O -
) O +
mm2 O -
) O +
but O +
lower O +
in O +
the O +
enalapril O -
- O -
treated O +
group O +
( O -
11.5 O +
+ O -
/- O +

0.15 O +
10 O -
( O -
-3 O -
) O +
mm2 O -
) O +
compared O +
with O +
the O +
hypertensive B-Disease +
controls O +
( O -
12.1 O +
+ O -
/- O +

0.17 O +
10 O -
( O -
-3 O -
) O +
mm2 O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Ketoconazole O +
induced O +
torsades B-Disease +
de I-Disease +
pointes I-Disease +
without O +
concomitant O +
use O +
of O +
QT O +
interval O -
- O -
prolonging O +
drug O -
. O +

Ketoconazole O +
is O +
not O +
known O +
to O +
be O +
proarrhythmic O +
without O +
concomitant O +
use O +
of O +
QT O +
interval O -
- O -
prolonging O +
drugs O -
. O +

We O +
report O +
a O +
woman O +
with O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
who O +
developed O +
a O +
markedly O +
prolonged B-Disease +
QT I-Disease +
interval I-Disease +
and O +
torsades B-Disease +
de I-Disease +
pointes I-Disease +
( O -
TdP B-Disease -
) O +
after O +
taking O +
ketoconazole O +
for O +
treatment O +
of O +
fungal B-Disease +
infection I-Disease -
. O +

Her O +
QT O +
interval O +
returned O +
to O +
normal O +
upon O +
withdrawal O +
of O +
ketoconazole O -
. O +

Genetic O +
study O +
did O +
not O +
find O +
any O +
mutation O +
in O +
her O +
genes O +
that O +
encode O +
cardiac O +
IKr O +
channel O +
proteins O -
. O +

We O +
postulate O +
that O +
by O +
virtue O +
of O +
its O +
direct O +
blocking O +
action O +
on O +
IKr O -
, O +
ketoconazole O +
alone O +
may O +
prolong O +
QT O +
interval O +
and O +
induce O +
TdP. B-Disease +
This O +
calls O +
for O +
attention O +
when O +
ketoconazole O +
is O +
administered O +
to O +
patients O +
with O +
risk O +
factors O +
for O +
acquired O +
long B-Disease +
QT I-Disease +
syndrome I-Disease -
. O +

PTU O -
- O -
associated O +
vasculitis B-Disease +
in O +
a O +
girl O +
with O +
Turner B-Disease +
Syndrome I-Disease +
and O +
Graves B-Disease -
' I-Disease +
disease I-Disease -
. O +

Palpable O +
purpura B-Disease +
is O +
a O +
concerning O +
clinical O +
finding O +
in O +
pediatric O +
patients O +
and O +
can O +
have O +
many O +
causes O -
, O +
including O +
infectious O +
and O +
autoimmune O +
processes O -
. O +

A O +
rare O +
cause O -
, O +
drug O -
- O -
induced O +
vasculitis B-Disease -
, O +
may O +
result O +
from O +
the O +
production O +
of O +
antineutrophil O +
cytoplasmic O +
antibodies O +
( O -
ANCAs O -
) O +
in O +
response O +
to O +
a O +
medication O -
. O +

We O +
report O +
a O +
girl O +
with O +
Turner B-Disease +
syndrome I-Disease +
and O +
Graves B-Disease -
' I-Disease +
disease I-Disease +
who O +
presented O +
with O +
palpable O +
purpuric B-Disease +
lesions I-Disease -
. O +

The O +
diagnosis O +
of O +
propylthiouracil O +
( O -
PTU O -
) O -
-associated O +
vasculitis B-Disease +
was O +
made O +
by O +
observation O +
of O +
consistent O +
clinical O +
features O -
, O +
the O +
detection O +
of O +
elevated O +
ANA O +
and O +
ANCA O +
in O +
the O +
blood O -
, O +
and O +
the O +
observed O +
clinical O +
resolution O +
of O +
symptoms O +
following O +
withdrawal O +
of O +
PTU O -
. O +

Subsequent O +
treatment O +
of O +
persistent O +
hyperthyroidism B-Disease +
with O +
radioablation O +
did O +
not O +
result O +
in O +
an O +
exacerbation O +
of O +
the O +
vasculitis B-Disease -
, O +
a O +
complication O +
described O +
in O +
prior O +
case O +
reports O -
. O +

Cerebral B-Disease +
vasculitis I-Disease +
following O +
oral O +
methylphenidate O +
intake O +
in O +
an O +
adult O -
: O +
a O +
case O +
report O -
. O +

Methylphenidate O +
is O +
structurally O +
and O +
functionally O +
similar O +
to O +
amphetamine O -
. O +

Cerebral B-Disease +
vasculitis I-Disease +
associated O +
with O +
amphetamine B-Disease +
abuse I-Disease +
is O +
well O +
documented O -
, O +
and O +
in O +
rare O +
cases O +
ischaemic B-Disease +
stroke I-Disease +
has O +
been O +
reported O +
after O +
methylphenidate O +
intake O +
in O +
children O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
63-year O -
- O -
old O +
female O +
who O +
was O +
treated O +
with O +
methylphenidate O +
due O +
to O +
hyperactivity B-Disease +
and O +
suffered O +
from O +
multiple O +
ischaemic B-Disease +
strokes I-Disease -
. O +

We O +
consider O +
drug O -
- O -
induced O +
cerebral B-Disease +
vasculitis I-Disease +
as O +
the O +
most O +
likely O +
cause O +
of O +
recurrent O +
ischaemic B-Disease +
strokes I-Disease +
in O +
the O +
absence O +
of O +
any O +
pathological O +
findings O +
during O +
the O +
diagnostic O +
work O -
- O -
up O -
. O +

We O +
conclude O +
that O +
methylphenidate O +
mediated O +
vasculitis B-Disease +
should O +
be O +
considered O +
in O +
patients O +
with O +
neurological O +
symptoms O +
and O +
a O +
history O +
of O +
methylphenidate O +
therapy O -
. O +

This O +
potential O +
side O -
- O -
effect O -
, O +
though O +
very O +
rare O -
, O +
represents O +
one O +
more O +
reason O +
to O +
be O +
very O +
restrictive O +
in O +
the O +
use O +
of O +
methylphenidate O -
. O +

Daidzein O +
activates O +
choline O +
acetyltransferase O +
from O +
MC O -
- O -
IXC O +
cells O +
and O +
improves O +
drug O -
- O -
induced O +
amnesia B-Disease -
. O +

The O +
choline O +
acetyltransferase O +
( O -
ChAT O -
) O +
activator O -
, O +
which O +
enhances O +
cholinergic O +
transmission O +
via O +
an O +
augmentation O +
of O +
the O +
enzymatic O +
production O +
of O +
acetylcholine O +
( O -
ACh O -
) O -
, O +
is O +
an O +
important O +
factor O +
in O +
the O +
treatment O +
of O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
( O -
AD B-Disease -
) O -
. O +

Methanolic O +
extracts O +
from O +
Pueraria O +
thunbergiana O +
exhibited O +
an O +
activation O +
effect O +
( O -
46 O -
% O -
) O +
on O +
ChAT O +
in O +
vitro O -
. O +

Via O +
the O +
sequential O +
isolation O +
of O +
Pueraria O +
thunbergiana O -
, O +
the O +
active O +
component O +
was O +
ultimately O +
identified O +
as O +
daidzein O +
( O -
4',7-dihydroxy O -
- O -
isoflavone O -
) O -
. O +

In O +
order O +
to O +
investigate O +
the O +
effects O +
of O +
daidzein O +
from O +
Pueraria O +
thunbergiana O +
on O +
scopolamine O -
- O -
induced O +
impairments B-Disease +
of I-Disease +
learning I-Disease +
and B-Disease +
memory I-Disease -
, O +
we O +
conducted O +
a O +
series O +
of O +
in O +
vivo O +
tests O -
. O +

Administration O +
of O +
daidzein O +
( O -
4.5 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
to O +
mice O +
was O +
shown O +
significantly O +
to O +
reverse O +
scopolamine O -
- O -
induced O +
amnesia B-Disease -
, O +
according O +
to O +
the O +
results O +
of O +
a O +
Y O -
- O -
maze O +
test O -
. O +

Injections O +
of O +
scopolamine O +
into O +
mice O +
resulted O +
in O +
impaired O +
performance O +
on O +
Y O -
- O -
maze O +
tests O +
( O -
a O +
37 O -
% O +
decreases O +
in O +
alternation O +
behavior O -
) O -
. O +

By O +
way O +
of O +
contrast O -
, O +
mice O +
treated O +
with O +
daidzein O +
prior O +
to O +
the O +
scopolamine O +
injections O +
were O +
noticeably O +
protected O +
from O +
this O +
performance O +
impairment O +
( O -
an O +
approximately O +
12%-21 O -
% O +
decrease O +
in O +
alternation O +
behavior O -
) O -
. O +

These O +
results O +
indicate O +
that O +
daidzein O +
might O +
play O +
a O +
role O +
in O +
acetylcholine O +
biosynthesis O +
as O +
a O +
ChAT O +
activator O -
, O +
and O +
that O +
it O +
also O +
ameliorates O +
scopolamine O -
- O -
induced O +
amnesia B-Disease -
. O +

Urinary O +
symptoms O +
and O +
quality O +
of O +
life O +
changes O +
in O +
Thai O +
women O +
with O +
overactive B-Disease +
bladder I-Disease +
after O +
tolterodine O +
treatment O -
. O +

OBJECTIVES O -
: O +
To O +
study O +
the O +
urinary O +
symptoms O +
and O +
quality O +
of O +
life O +
changes O +
in O +
Thai O +
women O +
with O +
overactive B-Disease +
bladder I-Disease +
( O -
OAB B-Disease -
) O +
after O +
tolterodine O +
treatment O -
. O +

MATERIAL O +
AND O +
METHOD O -
: O +
Thirty O +
women O +
( O -
aged O +
30 O -
- O -
77 O +
years O -
) O +
diagnosed O +
as O +
having O +
OAB B-Disease +
at O +
the O +
Gynecology O +
Clinic O -
, O +
King O +
Chulalongkorn O +
Memorial O +
Hospital O +
from O +
January O +
to O +
April O +
2004 O +
were O +
included O +
in O +
the O +
present O +
study O -
. O +

Tolterodine O +
2 O +
mg O -
, O +
twice O +
daily O +
was O +
given O -
. O +

After O +
8 O +
weeks O +
treatment O -
, O +
changes O +
in O +
micturition O +
diary O +
variables O +
and O +
tolerability O +
were O +
determined O -
. O +

Short O +
form O +
36 O +
( O -
SF36 O -
) O +
questionaires O +
( O -
Thai O +
version O -
) O +
were O +
given O +
before O +
and O +
after O +
8 O +
weeks O +
of O +
treatment O -
. O +

RESULTS O -
: O +
At O +
8 O +
weeks O -
, O +
all O +
micturition O +
per O +
day O +
decreased O +
from O +
16 O -
. O +
7 O +
+ O -
/- O +

5 O -
. O +
3 O +
to O +
6 O -
. O +
7 O +
+ O -
/- O +

2.4 O +
times O +
per O +
day O -
. O +

The O +
number O +
of O +
nocturia B-Disease +
episodes O +
decreased O +
from O +
5.4 O +
+ O -
/- O +

4.2 O +
to O +
1.1 O +
+ O -
/- O +

1.0 O +
times O +
per O +
night O -
. O +

The O +
most O +
common O +
side O +
effect O +
was O +
dry B-Disease +
month I-Disease +
in O +
5 O +
cases O +
( O -
16.7 O -
% O -
) O +
with O +
2 O +
cases O +
reporting O +
a O +
moderate O +
degree O +
and O +
1 O +
case O +
with O +
severe O +
degree O -
. O +

Only O +
one O +
case O +
( O -
3.3 O -
% O -
) O +
withdrew O +
from O +
the O +
present O +
study O +
due O +
to O +
a O +
severe O +
dry B-Disease +
mouth I-Disease -
. O +

The O +
SF-36 O +
scores O +
changed O +
significantly O +
in O +
the O +
domains O +
of O +
physical O +
functioning O -
, O +
role O +
function O +
emotional O -
, O +
social O +
function O +
and O +
mental O +
heath O -
. O +

CONCLUSION O -
: O +
Tolterodine O +
was O +
well O +
tolerated O +
and O +
its O +
effects O +
improved O +
the O +
quality O +
of O +
life O +
in O +
Thai O +
women O +
with O +
OAB B-Disease -
. O +

Remifentanil O +
pretreatment O +
reduces O +
myoclonus B-Disease +
after O +
etomidate O -
. O +

STUDY O +
OBJECTIVE O -
: O +
The O +
aim O +
of O +
the O +
study O +
was O +
to O +
compare O +
the O +
effect O +
of O +
pretreatment O +
with O +
remifentanil O +
1 O +
microg O -
/ O -
kg O +
and O +
the O +
effect O +
of O +
gender O +
on O +
the O +
incidence O +
of O +
myoclonus B-Disease +
after O +
anesthesia O +
induction O +
with O +
etomidate O -
. O +

DESIGN O -
: O +
This O +
was O +
a O +
randomized O -
, O +
double O -
- O -
blind O +
study O -
. O +

SETTING O -
: O +
The O +
study O +
was O +
conducted O +
at O +
a O +
university O +
hospital O -
. O +

PATIENTS O -
: O +
Sixty O +
patients O +
were O +
pretreated O +
in O +
a O +
randomized O +
double O -
- O -
blinded O +
fashion O +
with O +
remifentanil O +
1 O +
microg O -
/ O -
kg O +
or O +
placebo O -
. O +

Two O +
minutes O +
after O +
remifentanil O +
or O +
placebo O +
injection O -
, O +
etomidate O +
0.3 O +
mg O -
/ O -
kg O +
was O +
given O -
. O +

MEASUREMENTS O -
: O +
Myoclonus B-Disease +
was O +
recorded O +
with O +
a O +
scale O +
of O +
0 O +
to O +
3 O -
. O +

The O +
grade O +
of O +
sedation O +
( O -
none O -
, O +
mild O -
, O +
moderate O -
, O +
severe O -
) O -
, O +
nausea B-Disease -
, O +
pruritus B-Disease -
, O +
and O +
apnea B-Disease +
were O +
recorded O +
after O +
injection O +
of O +
both O +
drugs O -
. O +

MAIN O +
RESULTS O -
: O +
The O +
incidence O +
of O +
myoclonus B-Disease +
was O +
significantly O +
lower O +
in O +
the O +
remifentanil O +
group O +
( O -
6.7 O -
% O -
) O +
than O +
in O +
the O +
placebo O +
group O +
( O -
70 O -
% O -
) O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

None O +
of O +
the O +
patients O +
experienced O +
sedation O -
, O +
apnea B-Disease -
, O +
nausea B-Disease -
, O +
or O +
pruritus B-Disease +
after O +
injection O +
of O +
both O +
drugs O -
. O +

In O +
the O +
placebo O +
group O -
, O +
male O +
patients O +
were O +
associated O +
with O +
significantly O +
increased O +
incidence O +
of O +
myoclonus B-Disease +
after O +
etomidate O +
administration O -
. O +

CONCLUSION O -
: O +
Pretreatment O +
with O +
remifentanil O +
1 O +
microg O -
/ O -
kg O +
reduced O +
myoclonus B-Disease +
after O +
etomidate O +
induction O +
without O +
side O +
effects O +
such O +
as O +
sedation O -
, O +
apnea B-Disease -
, O +
nausea B-Disease -
, O +
or O +
pruritus B-Disease -
. O +

Men O +
experience O +
increased O +
incidence O +
of O +
myoclonus B-Disease +
than O +
women O +
after O +
etomidate O +
administration O -
. O +

MDMA O +
polydrug O +
users O +
show O +
process O -
- O -
specific O +
central O +
executive O +
impairments O +
coupled O +
with O +
impaired B-Disease +
social I-Disease +
and I-Disease +
emotional I-Disease +
judgement I-Disease +
processes I-Disease -
. O +

In O +
recent O +
years O +
working O +
memory B-Disease +
deficits I-Disease +
have O +
been O +
reported O +
in O +
users O +
of O +
MDMA O +
( O -
3,4-methylenedioxymethamphetamine O -
, O +
ecstasy O -
) O -
. O +

The O +
current O +
study O +
aimed O +
to O +
assess O +
the O +
impact O +
of O +
MDMA O +
use O +
on O +
three O +
separate O +
central O +
executive O +
processes O +
( O -
set O +
shifting O -
, O +
inhibition O +
and O +
memory O +
updating O -
) O +
and O +
also O +
on O +
" O -
prefrontal O -
" O +
mediated O +
social O +
and O +
emotional O +
judgement O +
processes O -
. O +

Fifteen O +
polydrug O +
ecstasy O +
users O +
and O +
15 O +
polydrug O +
non O -
- O -
ecstasy O +
user O +
controls O +
completed O +
a O +
general O +
drug O +
use O +
questionnaire O -
, O +
the O +
Brixton O +
Spatial O +
Anticipation O +
task O +
( O -
set O +
shifting O -
) O -
, O +
Backward O +
Digit O +
Span O +
procedure O +
( O -
memory O +
updating O -
) O -
, O +
Inhibition O +
of O +
Return O +
( O -
inhibition O -
) O -
, O +
an O +
emotional O +
intelligence O +
scale O -
, O +
the O +
Tromso O +
Social O +
Intelligence O +
Scale O +
and O +
the O +
Dysexecutive O +
Questionnaire O +
( O -
DEX O -
) O -
. O +

Compared O +
with O +
MDMA O -
- O -
free O +
polydrug O +
controls O -
, O +
MDMA O +
polydrug O +
users O +
showed O +
impairments O +
in O +
set O +
shifting O +
and O +
memory O +
updating O -
, O +
and O +
also O +
in O +
social O +
and O +
emotional O +
judgement O +
processes O -
. O +

The O +
latter O +
two O +
deficits O +
remained O +
significant O +
after O +
controlling O +
for O +
other O +
drug O +
use O -
. O +

These O +
data O +
lend O +
further O +
support O +
to O +
the O +
proposal O +
that O +
cognitive O +
processes O +
mediated O +
by O +
the O +
prefrontal O +
cortex O +
may O +
be O +
impaired O +
by O +
recreational O +
ecstasy O +
use O -
. O +

Memory O +
function O +
and O +
serotonin O +
transporter O +
promoter O +
gene O +
polymorphism O +
in O +
ecstasy O +
( O -
MDMA O -
) O +
users O -
. O +

Although O +
3,4-methylenedioxymethamphetamine O +
( O -
MDMA O +
or O +
ecstasy O -
) O +
has O +
been O +
shown O +
to O +
damage O +
brain O +
serotonin O +
( O -
5-HT O -
) O +
neurons O +
in O +
animals O +
and O +
possibly O +
humans O -
, O +
little O +
is O +
known O +
about O +
the O +
long O -
- O -
term O +
consequences O +
of O +
MDMA O -
- O -
induced O +
5-HT O +
neurotoxic B-Disease +
lesions I-Disease +
on O +
functions O +
in O +
which O +
5-HT O +
is O +
involved O -
, O +
such O +
as O +
cognitive O +
function O -
. O +

Because O +
5-HT O +
transporters O +
play O +
a O +
key O +
element O +
in O +
the O +
regulation O +
of O +
synaptic O +
5-HT O +
transmission O +
it O +
may O +
be O +
important O +
to O +
control O +
for O +
the O +
potential O +
covariance O +
effect O +
of O +
a O +
polymorphism O +
in O +
the O +
5-HT O +
transporter O +
promoter O +
gene O +
region O +
( O -
5-HTTLPR O -
) O +
when O +
studying O +
the O +
effects O +
of O +
MDMA O +
as O +
well O +
as O +
cognitive O +
functioning O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
effects O +
of O +
moderate O +
and O +
heavy O +
MDMA O +
use O +
on O +
cognitive O +
function O -
, O +
as O +
well O +
as O +
the O +
effects O +
of O +
long O -
- O -
term O +
abstention O +
from O +
MDMA O -
, O +
in O +
subjects O +
genotyped O +
for O +
5-HTTLPR O -
. O +

A O +
second O +
aim O +
of O +
the O +
study O +
was O +
to O +
determine O +
whether O +
these O +
effects O +
differ O +
for O +
females O +
and O +
males O -
. O +

Fifteen O +
moderate O +
MDMA O +
users O +
( O -
< O -
55 O +
lifetime O +
tablets O -
) O -
, O +
22 O +
heavy O +
MDMA+ O +
users O +
( O -
> O -
55 O +
lifetime O +
tablets O -
) O -
, O +
16 O +
ex O -
- O -
MDMA+ O +
users O +
( O -
last O +
tablet O +
> O +
1 O +
year O +
ago O -
) O +
and O +
13 O +
controls O +
were O +
compared O +
on O +
a O +
battery O +
of O +
neuropsychological O +
tests O -
. O +

DNA O +
from O +
peripheral O +
nuclear O +
blood O +
cells O +
was O +
genotyped O +
for O +
5-HTTLPR O +
using O +
standard O +
polymerase O +
chain O +
reaction O +
methods O -
. O +

A O +
significant O +
group O +
effect O +
was O +
observed O +
only O +
on O +
memory O +
function O +
tasks O +
( O -
p O +
= O +
0.04 O -
) O +
but O +
not O +
on O +
reaction O +
times O +
( O -
p O +
= O +
0.61 O -
) O +
or O +
attention O -
/ O -
executive O +
functioning O +
( O -
p O +
= O +
0.59 O -
) O -
. O +

Heavy O +
and O +
ex O -
- O -
MDMA+ O +
users O +
performed O +
significantly O +
poorer O +
on O +
memory O +
tasks O +
than O +
controls O -
. O +

In O +
contrast O -
, O +
no O +
evidence O +
of O +
memory B-Disease +
impairment I-Disease +
was O +
observed O +
in O +
moderate O +
MDMA O +
users O -
. O +

No O +
significant O +
effect O +
of O +
5-HTTLPR O +
or O +
gender O +
was O +
observed O -
. O +

While O +
the O +
use O +
of O +
MDMA O +
in O +
quantities O +
that O +
may O +
be O +
considered O +
" O -
moderate O -
" O +
is O +
not O +
associated O +
with O +
impaired B-Disease +
memory I-Disease +
functioning I-Disease -
, O +
heavy O +
use O +
of O +
MDMA O +
use O +
may O +
lead O +
to O +
long O +
lasting O +
memory B-Disease +
impairments I-Disease -
. O +

No O +
effect O +
of O +
5-HTTLPR O +
or O +
gender O +
on O +
memory O +
function O +
or O +
MDMA O +
use O +
was O +
observed O -
. O +

Role O +
of O +
mangiferin O +
on O +
biochemical O +
alterations O +
and O +
antioxidant O +
status O +
in O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

The O +
current O +
study O +
dealt O +
with O +
the O +
protective O +
role O +
of O +
mangiferin O -
, O +
a O +
polyphenol O +
from O +
Mangifera O +
indica O +
Linn O -
. O +

( O -
Anacardiaceae O -
) O -
, O +
on O +
isoproterenol O +
( O -
ISPH O -
) O -
-induced O +
myocardial B-Disease +
infarction I-Disease +
( O -
MI B-Disease -
) O +
in O +
rats O +
through O +
its O +
antioxidative O +
mechanism O -
. O +

Subcutaneous O +
injection O +
of O +
ISPH O +
( O -
200 O +
mg O -
/ O -
kg O +
body O +
weight O +
in O +
1 O +
ml O +
saline O -
) O +
to O +
rats O +
for O +
2 O +
consecutive O +
days O +
caused O +
myocardial B-Disease +
damage I-Disease +
in O +
rat O +
heart O -
, O +
which O +
was O +
determined O +
by O +
the O +
increased O +
activity O +
of O +
serum O +
lactate O +
dehydrogenase O +
( O -
LDH O -
) O +
and O +
creatine O +
phosphokinase O +
isoenzymes O +
( O -
CK O -
- O -
MB O -
) O -
, O +
increased O +
uric O +
acid O +
level O +
and O +
reduced O +
plasma O +
iron O +
binding O +
capacity O -
. O +

The O +
protective O +
role O +
of O +
mangiferin O +
was O +
analyzed O +
by O +
triphenyl O +
tetrazolium O +
chloride O +
( O -
TTC O -
) O +
test O +
used O +
for O +
macroscopic O +
enzyme O +
mapping O +
assay O +
of O +
the O +
ischemic B-Disease +
myocardium I-Disease -
. O +

The O +
heart O +
tissue O +
antioxidant O +
enzymes O +
such O +
as O +
superoxide O +
dismutase O -
, O +
catalase O -
, O +
glutathione O +
peroxidase O -
, O +
glutathione O +
transferase O +
and O +
glutathione O +
reductase O +
activities O -
, O +
non O -
- O -
enzymic O +
antioxidants O +
such O +
as O +
cerruloplasmin O -
, O +
Vitamin O +
C O -
, O +
Vitamin O +
E O +
and O +
glutathione O +
levels O +
were O +
altered O +
in O +
MI B-Disease +
rats O -
. O +

Upon O +
pretreatment O +
with O +
mangiferin O +
( O -
100 O +
mg O -
/ O -
kg O +
body O +
weight O +
suspended O +
in O +
2 O +
ml O +
of O +
dimethyl O +
sulphoxide O -
) O +
given O +
intraperitoneally O +
for O +
28 O +
days O +
to O +
MI B-Disease +
rats O +
protected O +
the O +
above O -
- O -
mentioned O +
parameters O +
to O +
fall O +
from O +
the O +
normal O +
levels O -
. O +

Activities O +
of O +
heart O +
tissue O +
enzymic O +
antioxidants O +
and O +
serum O +
non O -
- O -
enzymic O +
antioxidants O +
levels O +
rose O +
significantly O +
upon O +
mangiferin O +
administration O +
as O +
compared O +
to O +
ISPH O -
- O -
induced O +
MI B-Disease +
rats O -
. O +

From O +
the O +
present O +
study O +
it O +
is O +
concluded O +
that O +
mangiferin O +
exerts O +
a O +
beneficial O +
effect O +
against O +
ISPH O -
- O -
induced O +
MI B-Disease +
due O +
to O +
its O +
antioxidant O +
potential O -
, O +
which O +
regulated O +
the O +
tissues O +
defense O +
system O +
against O +
cardiac B-Disease +
damage I-Disease -
. O +

Cardiovascular O +
risk O +
with O +
cyclooxygenase O +
inhibitors O -
: O +
general O +
problem O +
with O +
substance O +
specific O +
differences O -
? O +

Randomised O +
clinical O +
trials O +
and O +
observational O +
studies O +
have O +
shown O +
an O +
increased O +
risk O +
of O +
myocardial B-Disease +
infarction I-Disease -
, O +
stroke B-Disease -
, O +
hypertension B-Disease +
and O +
heart B-Disease +
failure I-Disease +
during O +
treatment O +
with O +
cyclooxygenase O +
inhibitors O -
. O +

Adverse O +
cardiovascular O +
effects O +
occurred O +
mainly O -
, O +
but O +
not O +
exclusively O -
, O +
in O +
patients O +
with O +
concomitant O +
risk O +
factors O -
. O +

Cyclooxygenase O +
inhibitors O +
cause O +
complex O +
changes O +
in O +
renal O -
, O +
vascular O +
and O +
cardiac O +
prostanoid O +
profiles O +
thereby O +
increasing O +
vascular O +
resistance O +
and O +
fluid O +
retention O -
. O +

The O +
incidence O +
of O +
cardiovascular O +
adverse O +
events O +
tends O +
to O +
increase O +
with O +
the O +
daily O +
dose O +
and O +
total O +
exposure O +
time O -
. O +

A O +
comparison O +
of O +
individual O +
selective O +
and O +
unselective O +
cyclooxygenase O +
inhibitors O +
suggests O +
substance O -
- O -
specific O +
differences O -
, O +
which O +
may O +
depend O +
on O +
differences O +
in O +
pharmacokinetic O +
parameters O +
or O +
inhibitory O +
potency O +
and O +
may O +
be O +
contributed O +
by O +
prostaglandin O -
- O -
independent O +
effects O -
. O +

Diagnostic O +
markers O +
such O +
as O +
N O -
- O -
terminal O +
pro O +
brain O +
natriuretic O +
peptide O +
( O -
NT O -
- O -
proBNP O -
) O +
or O +
high O -
- O -
sensitive O +
C O -
- O -
reactive O +
protein O +
might O +
help O +
in O +
the O +
early O +
identification O +
of O +
patients O +
at O +
risk O -
, O +
thus O +
avoiding O +
the O +
occurrence O +
of O +
serious O +
cardiovascular B-Disease +
toxicity I-Disease -
. O +

Pilocarpine O +
seizures B-Disease +
cause O +
age O -
- O -
dependent O +
impairment B-Disease +
in I-Disease +
auditory I-Disease +
location I-Disease +
discrimination I-Disease -
. O +

Children O +
who O +
have O +
status B-Disease +
epilepticus I-Disease +
have O +
continuous O +
or O +
rapidly O +
repeating O +
seizures B-Disease +
that O +
may O +
be O +
life O -
- O -
threatening O +
and O +
may O +
cause O +
life O -
- O -
long O +
changes O +
in O +
brain O +
and O +
behavior O -
. O +

The O +
extent O +
to O +
which O +
status B-Disease +
epilepticus I-Disease +
causes O +
deficits B-Disease +
in I-Disease +
auditory I-Disease +
discrimination I-Disease +
is O +
unknown O -
. O +

A O +
naturalistic O +
auditory O +
location O +
discrimination O +
method O +
was O +
used O +
to O +
evaluate O +
this O +
question O +
using O +
an O +
animal O +
model O +
of O +
status B-Disease +
epilepticus I-Disease -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
injected O +
with O +
saline O +
on O +
postnatal O +
day O +
( O -
P O -
) O +
20 O -
, O +
or O +
a O +
convulsant O +
dose O +
of O +
pilocarpine O +
on O +
P20 O +
or O +
P45 O -
. O +

Pilocarpine O +
on O +
either O +
day O +
induced O +
status B-Disease +
epilepticus I-Disease -
; O +
status B-Disease +
epilepticus I-Disease +
at O +
P45 O +
resulted O +
in O +
CA3 O +
cell O +
loss O +
and O +
spontaneous O +
seizures B-Disease -
, O +
whereas O +
P20 O +
rats O +
had O +
no O +
cell O +
loss O +
or O +
spontaneous O +
seizures B-Disease -
. O +

Mature O +
rats O +
were O +
trained O +
with O +
sound O -
- O -
source O +
location O +
and O +
sound O -
- O -
silence O +
discriminations O -
. O +

Control O +
( O -
saline O +
P20 O -
) O +
rats O +
acquired O +
both O +
discriminations O +
immediately O -
. O +

In O +
status B-Disease +
epilepticus I-Disease +
( O -
P20 O -
) O +
rats O -
, O +
acquisition O +
of O +
the O +
sound O -
- O -
source O +
location O +
discrimination O +
was O +
moderately O +
impaired O -
. O +

Status B-Disease +
epilepticus I-Disease +
( O -
P45 O -
) O +
rats O +
failed O +
to O +
acquire O +
either O +
sound O -
- O -
source O +
location O +
or O +
sound O -
- O -
silence O +
discriminations O -
. O +

Status B-Disease +
epilepticus I-Disease +
in O +
rat O +
causes O +
an O +
age O -
- O -
dependent O -
, O +
long O -
- O -
term O +
impairment B-Disease +
in I-Disease +
auditory I-Disease +
discrimination I-Disease -
. O +

This O +
impairment O +
may O +
explain O +
one O +
cause O +
of O +
impaired B-Disease +
auditory I-Disease +
location I-Disease +
discrimination I-Disease +
in O +
humans O -
. O +

Definition O +
and O +
management O +
of O +
anemia B-Disease +
in O +
patients O +
infected B-Disease +
with I-Disease +
hepatitis I-Disease +
C I-Disease +
virus I-Disease -
. O +

Chronic B-Disease +
infection I-Disease +
with I-Disease +
hepatitis I-Disease +
C I-Disease +
virus I-Disease +
( O -
HCV O -
) O +
can O +
progress O +
to O +
cirrhosis B-Disease -
, O +
hepatocellular B-Disease +
carcinoma I-Disease -
, O +
and O +
end B-Disease -
- I-Disease -
stage I-Disease +
liver I-Disease +
disease I-Disease -
. O +

The O +
current O +
best O +
treatment O +
for O +
HCV B-Disease +
infection I-Disease +
is O +
combination O +
therapy O +
with O +
pegylated O +
interferon O +
and O +
ribavirin O -
. O +

Although O +
this O +
regimen O +
produces O +
sustained O +
virologic O +
responses O +
( O -
SVRs O -
) O +
in O +
approximately O +
50 O -
% O +
of O +
patients O -
, O +
it O +
can O +
be O +
associated O +
with O +
a O +
potentially O +
dose O -
- O -
limiting O +
hemolytic B-Disease +
anemia I-Disease -
. O +

Hemoglobin O +
concentrations O +
decrease O +
mainly O +
as O +
a O +
result O +
of O +
ribavirin O -
- O -
induced O +
hemolysis B-Disease -
, O +
and O +
this O +
anemia B-Disease +
can O +
be O +
problematic O +
in O +
patients O +
with O +
HCV B-Disease +
infection I-Disease -
, O +
especially O +
those O +
who O +
have O +
comorbid O +
renal B-Disease +
or I-Disease +
cardiovascular I-Disease +
disorders I-Disease -
. O +

In O +
general O -
, O +
anemia B-Disease +
can O +
increase O +
the O +
risk O +
of O +
morbidity O +
and O +
mortality O -
, O +
and O +
may O +
have O +
negative O +
effects O +
on O +
cerebral O +
function O +
and O +
quality O +
of O +
life O -
. O +

Although O +
ribavirin O -
- O -
associated O +
anemia B-Disease +
can O +
be O +
reversed O +
by O +
dose O +
reduction O +
or O +
discontinuation O -
, O +
this O +
approach O +
compromises O +
outcomes O +
by O +
significantly O +
decreasing O +
SVR O +
rates O -
. O +

Recombinant O +
human O +
erythropoietin O +
has O +
been O +
used O +
to O +
manage O +
ribavirin O -
- O -
associated O +
anemia B-Disease +
but O +
has O +
other O +
potential O +
disadvantages O -
. O +

Viramidine O -
, O +
a O +
liver O -
- O -
targeting O +
prodrug O +
of O +
ribavirin O -
, O +
has O +
the O +
potential O +
to O +
maintain O +
the O +
virologic O +
efficacy O +
of O +
ribavirin O +
while O +
decreasing O +
the O +
risk O +
of O +
hemolytic B-Disease +
anemia I-Disease +
in O +
patients O +
with O +
chronic B-Disease +
hepatitis I-Disease +
C. I-Disease +

Impact O +
of O +
alcohol O +
exposure O +
after O +
pregnancy O +
recognition O +
on O +
ultrasonographic O +
fetal O +
growth O +
measures O -
. O +

BACKGROUND O -
: O +
More O +
than O +
3 O +
decades O +
after O +
Jones O +
and O +
Smith O +
( O -
1973 O -
) O +
reported O +
on O +
the O +
devastation O +
caused O +
by O +
alcohol O +
exposure O +
on O +
fetal O +
development O -
, O +
the O +
rates O +
of O +
heavy O +
drinking O +
during O +
pregnancy O +
remain O +
relatively O +
unchanged O -
. O +

Early O +
identification O +
of O +
fetal O +
alcohol O +
exposure O +
and O +
maternal O +
abstinence O +
led O +
to O +
better O +
infant O +
outcomes O -
. O +

This O +
study O +
examined O +
the O +
utility O +
of O +
biometry O +
for O +
detecting O +
alcohol O -
- O -
related O +
fetal O +
growth B-Disease +
impairment I-Disease -
. O +

METHODS O -
: O +
We O +
obtained O +
fetal O +
ultrasound O +
measures O +
from O +
routine O +
ultrasound O +
examinations O +
for O +
167 O +
pregnant O +
hazardous O +
drinkers O +
who O +
were O +
enrolled O +
in O +
a O +
brief O +
alcohol O +
intervention O +
study O -
. O +

The O +
fetal O +
measures O +
for O +
women O +
who O +
quit O +
after O +
learning O +
of O +
their O +
pregnancies O +
were O +
compared O +
with O +
measures O +
for O +
women O +
who O +
continued O +
some O +
drinking O +
throughout O +
the O +
course O +
of O +
their O +
pregnancies O -
. O +

Because O +
intensity O +
of O +
alcohol O +
consumption O +
is O +
associated O +
with O +
poorer O +
fetal O +
outcomes O -
, O +
separate O +
analyses O +
were O +
conducted O +
for O +
the O +
heavy O +
( O -
average O +
of O +
> O -
or=5 O +
drinks O +
per O +
drinking O +
day O -
) O +
alcohol O +
consumers O -
. O +

Fetal O +
measures O +
from O +
the O +
heavy O -
- O -
exposed O +
fetuses O +
were O +
also O +
compared O +
with O +
measures O +
from O +
a O +
nondrinking O +
group O +
that O +
was O +
representative O +
of O +
normal O -
, O +
uncomplicated O +
pregnancies O +
from O +
our O +
clinics O -
. O +

Analyses O +
of O +
covariance O +
were O +
used O +
to O +
determine O +
whether O +
there O +
were O +
differences O +
between O +
groups O +
after O +
controlling O +
for O +
influences O +
of O +
gestational O +
age O +
and O +
drug B-Disease +
abuse I-Disease -
. O +

RESULTS O -
: O +
Nearly O +
half O +
of O +
the O +
pregnant O +
drinkers O +
abstained O +
after O +
learning O +
of O +
their O +
pregnancies O -
. O +

When O +
women O +
reportedly O +
quit O +
drinking O +
early O +
in O +
their O +
pregnancies O -
, O +
fetal O +
growth O +
measures O +
were O +
not O +
significantly O +
different O +
from O +
a O +
non O -
- O -
alcohol O -
- O -
exposed O +
group O -
, O +
regardless O +
of O +
prior O +
drinking O +
patterns O -
. O +

Any O +
alcohol O +
consumption O +
postpregnancy O +
recognition O +
among O +
the O +
heavy O +
drinkers O +
resulted O +
in O +
reduced B-Disease +
cerebellar I-Disease +
growth I-Disease +
as O +
well O +
as O +
decreased B-Disease +
cranial I-Disease +
to I-Disease +
body I-Disease +
growth I-Disease +
in O +
comparison O +
with O +
women O +
who O +
either O +
quit O +
drinking O +
or O +
who O +
were O +
nondrinkers O -
. O +

Amphetamine O +
abuse O +
was O +
predictive O +
of O +
larger O +
cranial O +
to O +
body O +
growth O +
ratios O -
. O +

CONCLUSIONS O -
: O +
Alterations O +
in O +
fetal O +
biometric O +
measurements O +
were O +
observed O +
among O +
the O +
heavy O +
drinkers O +
only O +
when O +
they O +
continued O +
drinking O +
after O +
becoming O +
aware O +
of O +
their O +
pregnancies O -
. O +

Although O +
the O +
reliance O +
on O +
self O -
- O -
reported O +
drinking O +
is O +
a O +
limitation O +
in O +
this O +
study O -
, O +
these O +
findings O +
support O +
the O +
benefits O +
of O +
early O +
abstinence O +
and O +
the O +
potential O +
for O +
ultrasound O +
examinations O +
in O +
the O +
detection O +
of O +
fetal O +
alcohol O +
effects O -
. O +

Phase O +
II O +
study O +
of O +
the O +
amsacrine O +
analogue O +
CI-921 O +
( O -
NSC O +
343499 O -
) O +
in O +
non B-Disease -
- I-Disease -
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer I-Disease -
. O +

CI-921 O +
( O -
NSC O +
343499 O -
; O +
9- O -
[ O -
[ O -
2-methoxy-4- O -
[ O -
( O -
methylsulphonyl O -
) O -
amino O -
] O -
phenyl O -
] O -
amino O -
] O +
-N,5-dimethyl- O +
4-acridinecarboxamide O -
) O +
is O +
a O +
topoisomerase O +
II O +
poison O +
with O +
high O +
experimental O +
antitumour O +
activity O -
. O +

It O +
was O +
administered O +
by O +
15 O +
min O +
infusion O +
to O +
16 O +
evaluable O +
patients O +
with O +
non B-Disease -
- I-Disease -
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer I-Disease +
( O -
NSCLC B-Disease -
) O +
( O -
7 O +
with O +
no O +
prior O +
treatment O -
, O +
9 O +
patients O +
in O +
relapse O +
following O +
surgery O -
/ O -
radiotherapy O -
) O +
at O +
a O +
dose O +
( O -
648 O +
mg O -
/ O -
m2 O +
divided O +
over O +
3 O +
days O -
, O +
repeated O +
every O +
3 O +
weeks O -
) O +
determined O +
by O +
phase O +
I O +
trial O -
. O +

Patients O +
had O +
a O +
median O +
performance O +
status O +
of O +
1 O +
( O -
WHO O -
) O -
, O +
and O +
median O +
age O +
of O +
61 O +
years O -
. O +

The O +
histology O +
comprised O +
squamous B-Disease +
carcinoma I-Disease +
( O -
11 O -
) O -
, O +
adenocarcinoma B-Disease +
( O -
1 O -
) O -
, O +
mixed O +
histology O +
( O -
2 O -
) O -
, O +
bronchio B-Disease -
- I-Disease -
alveolar I-Disease +
carcinoma I-Disease +
( O -
1 O -
) O +
and O +
large O +
cell O +
undifferentiated B-Disease +
carcinoma I-Disease +
( O -
1 O -
) O -
. O +

Neutropenia B-Disease +
grade O +
greater O +
than O +
or O +
equal O +
to O +
3 O +
was O +
seen O +
in O +
15 O +
patients O -
, O +
infections B-Disease +
with O +
recovery O +
in O +
3 O -
, O +
and O +
grand O +
mal O +
seizures B-Disease +
in O +
1 O +
patient O -
. O +

Grade O +
less O +
than O +
or O +
equal O +
to O +
2 O +
nausea B-Disease +
and O +
vomiting B-Disease +
occurred O +
in O +
66 O -
% O +
courses O +
and O +
phlebitis B-Disease +
in O +
the O +
infusion O +
arm O +
in O +
37 O -
% O -
. O +

1 O +
patient O +
with O +
squamous B-Disease +
cell I-Disease +
carcinoma I-Disease +
achieved O +
a O +
partial O +
response O +
lasting O +
5 O +
months O -
. O +

Further O +
testing O +
in O +
this O +
and O +
other O +
tumour B-Disease +
types O +
using O +
multiple O +
daily O +
schedules O +
is O +
warranted O -
. O +

Pharmacokinetics O +
of O +
desipramine O +
HCl O +
when O +
administered O +
with O +
cinacalcet O +
HCl O -
. O +

OBJECTIVE O -
: O +
In O +
vitro O +
work O +
has O +
demonstrated O +
that O +
cinacalcet O +
is O +
a O +
strong O +
inhibitor O +
of O +
cytochrome O +
P450 O +
isoenzyme O +
( O -
CYP O -
) O +
2D6 O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
effect O +
of O +
cinacalcet O +
on O +
CYP2D6 O +
activity O -
, O +
using O +
desipramine O +
as O +
a O +
probe O +
substrate O -
, O +
in O +
healthy O +
subjects O -
. O +

METHODS O -
: O +
Seventeen O +
subjects O +
who O +
were O +
genotyped O +
as O +
CYP2D6 O +
extensive O +
metabolizers O +
were O +
enrolled O +
in O +
this O +
randomized O -
, O +
open O -
- O -
label O -
, O +
crossover O +
study O +
to O +
receive O +
a O +
single O +
oral O +
dose O +
of O +
desipramine O +
( O -
50 O +
mg O -
) O +
on O +
two O +
separate O +
occasions O -
, O +
once O +
alone O +
and O +
once O +
after O +
multiple O +
doses O +
of O +
cinacalcet O +
( O -
90 O +
mg O +
for O +
7 O +
days O -
) O -
. O +

Blood O +
samples O +
were O +
obtained O +
predose O +
and O +
up O +
to O +
72 O +
h O +
postdose O -
. O +

RESULTS O -
: O +
Fourteen O +
subjects O +
completed O +
both O +
treatment O +
arms O -
. O +

Relative O +
to O +
desipramine O +
alone O -
, O +
mean O +
AUC O +
and O +
C O -
( O -
max O -
) O +
of O +
desipramine O +
increased O +
3.6- O +
and O +
1.8-fold O +
when O +
coadministered O +
with O +
cinacalcet O -
. O +

The O +
t O +
( O -
1 O -
/ O -
2,z O -
) O +
of O +
desipramine O +
was O +
longer O +
when O +
desipramine O +
was O +
coadministered O +
with O +
cinacalcet O +
( O -
21.0 O +
versus O +
43.3 O +
hs O -
) O -
. O +

The O +
t O +
( O -
max O -
) O +
was O +
similar O +
between O +
the O +
regimens O -
. O +

Fewer O +
subjects O +
reported O +
adverse O +
events O +
following O +
treatment O +
with O +
desipramine O +
alone O +
than O +
when O +
receiving O +
desipramine O +
with O +
cinacalcet O +
( O -
33 O +
versus O +
86 O -
% O -
) O -
, O +
the O +
most O +
frequent O +
of O +
which O +
( O -
nausea B-Disease +
and O +
headache B-Disease -
) O +
have O +
been O +
reported O +
for O +
patients O +
treated O +
with O +
either O +
desipramine O +
or O +
cinacalcet O -
. O +

CONCLUSION O -
: O +
This O +
study O +
demonstrates O +
that O +
cinacalcet O +
is O +
a O +
strong O +
inhibitor O +
of O +
CYP2D6 O -
. O +

These O +
data O +
suggest O +
that O +
during O +
concomitant O +
treatment O +
with O +
cinacalcet O -
, O +
dose O +
adjustment O +
may O +
be O +
necessary O +
for O +
drugs O +
that O +
demonstrate O +
a O +
narrow O +
therapeutic O +
index O +
and O +
are O +
metabolized O +
by O +
CYP2D6 O -
. O +

Ethambutol O -
- O -
associated O +
optic B-Disease +
neuropathy I-Disease -
. O +

INTRODUCTION O -
: O +
Ethambutol O +
is O +
used O +
in O +
the O +
treatment O +
of O +
tuberculosis B-Disease -
, O +
which O +
is O +
still O +
prevalent O +
in O +
Southeast O +
Asia O -
, O +
and O +
can O +
be O +
associated O +
with O +
permanent O +
visual B-Disease +
loss I-Disease -
. O +

We O +
report O +
3 O +
cases O +
which O +
presented O +
with O +
bitemporal B-Disease +
hemianopia I-Disease -
. O +

CLINICAL O +
PICTURE O -
: O +
Three O +
patients O +
with O +
ethambutol O -
- O -
associated O +
toxic O +
optic B-Disease +
neuropathy I-Disease +
are O +
described O -
. O +

All O +
3 O +
patients O +
had O +
loss B-Disease +
of I-Disease +
central I-Disease +
visual I-Disease +
acuity I-Disease -
, I-Disease +
colour I-Disease +
vision I-Disease +
( I-Disease -
Ishihara I-Disease -
) I-Disease +
and I-Disease +
visual I-Disease +
field I-Disease -
. O +

The O +
visual B-Disease +
field I-Disease +
loss I-Disease +
had O +
a O +
bitemporal O +
flavour O -
, O +
suggesting O +
involvement O +
of O +
the O +
optic O +
chiasm O -
. O +

TREATMENT O -
: O +
Despite O +
stopping O +
ethambutol O +
on O +
diagnosis O -
, O +
visual O +
function O +
continued O +
to O +
deteriorate O +
for O +
a O +
few O +
months O -
. O +

Subsequent O +
improvement O +
was O +
mild O +
in O +
2 O +
cases O -
. O +

In O +
the O +
third O +
case O -
, O +
visual O +
acuity O +
and O +
colour O +
vision O +
normalised O +
but O +
the O +
optic O +
discs O +
were O +
pale O -
. O +

OUTCOME O -
: O +
All O +
3 O +
patients O +
had O +
some O +
permanent O +
loss B-Disease +
of I-Disease +
visual I-Disease +
function I-Disease -
. O +

CONCLUSIONS O -
: O +
Ethambutol O +
usage O +
is O +
associated O +
with O +
permanent O +
visual B-Disease +
loss I-Disease +
and O +
should O +
be O +
avoided O +
if O +
possible O +
or O +
used O +
with O +
caution O +
and O +
proper O +
ophthalmological O +
follow O -
- O -
up O -
. O +

The O +
author O +
postulates O +
that O +
in O +
cases O +
of O +
ethambutol O +
associated O +
chiasmopathy O -
, O +
ethambutol O +
may O +
initially O +
affect O +
the O +
optic O +
nerves O +
and O +
subsequently O +
progress O +
to O +
involve O +
the O +
optic O +
chiasm O -
. O +

Possible O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
related O +
to O +
concomitant O +
treatment O +
with O +
paroxetine O +
and O +
alprazolam O -
. O +

A O +
74-year O -
- O -
old O +
man O +
with O +
depressive B-Disease +
symptoms I-Disease +
was O +
admitted O +
to O +
a O +
psychiatric B-Disease +
hospital O +
due O +
to O +
insomnia B-Disease -
, O +
loss B-Disease +
of I-Disease +
appetite I-Disease -
, O +
exhaustion O -
, O +
and O +
agitation B-Disease -
. O +

Medical O +
treatment O +
was O +
initiated O +
at O +
a O +
daily O +
dose O +
of O +
20 O +
mg O +
paroxetine O +
and O +
1.2 O +
mg O +
alprazolam O -
. O +

On O +
the O +
10th O +
day O +
of O +
paroxetine O +
and O +
alprazolam O +
treatment O -
, O +
the O +
patient O +
exhibited O +
marked O +
psychomotor B-Disease +
retardation I-Disease -
, O +
disorientation O -
, O +
and O +
severe O +
muscle B-Disease +
rigidity I-Disease +
with O +
tremors B-Disease -
. O +

The O +
patient O +
had O +
a O +
fever B-Disease +
( O -
38.2 O +
degrees O +
C O -
) O -
, O +
fluctuating O +
blood O +
pressure O +
( O -
between O +
165 O -
/ O -
90 O +
and O +
130 O -
/ O -
70 O +
mg O +
mm O +
Hg O -
) O -
, O +
and O +
severe O +
extrapyramidal B-Disease +
symptoms I-Disease -
. O +

Laboratory O +
tests O +
showed O +
an O +
elevation O +
of O +
creatine O +
phosphokinase O +
( O -
2218 O +
IU O -
/ O -
L O -
) O -
, O +
aspartate O +
aminotransferase O +
( O -
134 O +
IU O -
/ O -
L O -
) O -
, O +
alanine O +
aminotransferase O +
( O -
78 O +
IU O -
/ O -
L O -
) O -
, O +
and O +
BUN O +
( O -
27.9 O +
mg O -
/ O -
ml O -
) O +
levels O -
. O +

The O +
patient O +
received O +
bromocriptine O +
and O +
diazepam O +
to O +
treat O +
his O +
symptoms O -
. O +

7 O +
days O +
later O -
, O +
the O +
fever B-Disease +
disappeared O +
and O +
the O +
patient O -
's O +
serum O +
CPK O +
levels O +
were O +
normalized O +
( O -
175 O +
IU O -
/ O -
L O -
) O -
. O +

This O +
patient O +
presented O +
with O +
symptoms O +
of O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
( O -
NMS B-Disease -
) O -
, O +
thus O +
demonstrating O +
that O +
NMS B-Disease -
- O -
like O +
symptoms O +
can O +
occur O +
after O +
combined O +
paroxetine O +
and O +
alprazolam O +
treatment O -
. O +

The O +
adverse O +
drug O +
reaction O +
score O +
obtained O +
by O +
the O +
Naranjo O +
algorithm O +
was O +
6 O +
in O +
our O +
case O -
, O +
indicating O +
a O +
probable O +
relationship O +
between O +
the O +
patient O -
's O +
NMS B-Disease -
- O -
like O +
adverse O +
symptoms O +
and O +
the O +
combined O +
treatment O +
used O +
in O +
this O +
case O -
. O +

The O +
involvement O +
of O +
physiologic O +
and O +
environmental O +
aspects O +
specific O +
to O +
this O +
patient O +
was O +
suspected O -
. O +

Several O +
risk O +
factors O +
for O +
NMS B-Disease +
should O +
be O +
noted O +
in O +
elderly O +
depressive B-Disease +
patients O +
whose O +
symptoms O +
often O +
include O +
dehydration B-Disease -
, O +
agitation B-Disease -
, O +
malnutrition B-Disease -
, O +
and O +
exhaustion O -
. O +

Careful O +
therapeutic O +
intervention O +
is O +
necessary O +
in O +
cases O +
involving O +
elderly O +
patients O +
who O +
suffer O +
from O +
depression B-Disease -
. O +

Down O -
- O -
regulation O +
of O +
norepinephrine O +
transporter O +
function O +
induced O +
by O +
chronic O +
administration O +
of O +
desipramine O +
linking O +
to O +
the O +
alteration O +
of O +
sensitivity O +
of O +
local O -
- O -
anesthetics O -
- O -
induced O +
convulsions B-Disease +
and O +
the O +
counteraction O +
by O +
co O -
- O -
administration O +
with O +
local O +
anesthetics O -
. O +

Alterations O +
of O +
norepinephrine O +
transporter O +
( O -
NET O -
) O +
function O +
by O +
chronic O +
inhibition O +
of O +
NET O +
in O +
relation O +
to O +
sensitization O +
to O +
seizures B-Disease +
induce O +
by O +
cocaine O +
and O +
local O +
anesthetics O +
were O +
studied O +
in O +
mice O -
. O +

Daily O +
administration O +
of O +
desipramine O -
, O +
an O +
inhibitor O +
of O +
the O +
NET O -
, O +
for O +
5 O +
days O +
decreased O +
[ O -
( O -
3 O -
) O -
H O -
] O -
norepinephrine O +
uptake O +
in O +
the O +
P2 O +
fractions O +
of O +
hippocampus O +
but O +
not O +
cortex O -
, O +
striatum O +
or O +
amygdalae O -
. O +

Co O -
- O -
administration O +
of O +
lidocaine O -
, O +
bupivacaine O +
or O +
tricaine O +
with O +
desipramine O +
reversed O +
this O +
effect O -
. O +

Daily O +
treatment O +
of O +
cocaine O +
increased O +
[ O -
( O -
3 O -
) O -
H O -
] O -
norepinephrine O +
uptake O +
into O +
the O +
hippocampus O -
. O +

Daily O +
administration O +
of O +
desipramine O +
increased O +
the O +
incidence O +
of O +
appearance O +
of O +
lidocaine O -
- O -
induced O +
convulsions B-Disease +
and O +
decreased O +
that O +
of O +
cocaine O -
- O -
induced O +
convulsions B-Disease -
. O +

Co O -
- O -
administration O +
of O +
lidocaine O +
with O +
desipramine O +
reversed O +
the O +
changes O +
of O +
convulsive B-Disease +
activity O +
of O +
lidocaine O +
and O +
cocaine O +
induced O +
by O +
repeated O +
administration O +
of O +
desipramine O -
. O +

These O +
results O +
suggest O +
that O +
down O -
- O -
regulation O +
of O +
hippocampal O +
NET O +
induced O +
by O +
chronic O +
administration O +
of O +
desipramine O +
may O +
be O +
relevant O +
to O +
desipramine O -
- O -
induced O +
sensitization O +
of O +
lidocaine O +
convulsions B-Disease -
. O +

Inhibition O +
of O +
Na O -
( O -
+ O -
) O +
channels O +
by O +
local O +
anesthetics O +
may O +
regulate O +
desipramine O -
- O -
induced O +
down O -
- O -
regulation O +
of O +
NET O +
function O -
. O +

Repeated O +
administration O +
of O +
cocaine O +
induces O +
up O -
- O -
regulation O +
of O +
hippocampal O +
NET O +
function O -
. O +

Desipramine O -
- O -
induced O +
sensitization O +
of O +
lidocaine O +
seizures B-Disease +
may O +
have O +
a O +
mechanism O +
distinct O +
from O +
kindling O +
resulting O +
from O +
repeated O +
administration O +
of O +
cocaine O -
. O +

Case O +
report O -
: O +
acute O +
unintentional O +
carbachol O +
intoxication O -
. O +

INTRODUCTION O -
: O +
Intoxications O +
with O +
carbachol O -
, O +
a O +
muscarinic O +
cholinergic O +
receptor O +
agonist O +
are O +
rare O -
. O +

We O +
report O +
an O +
interesting O +
case O +
investigating O +
a O +
( O -
near O -
) O +
fatal O +
poisoning B-Disease -
. O +

METHODS O -
: O +
The O +
son O +
of O +
an O +
84-year O -
- O -
old O +
male O +
discovered O +
a O +
newspaper O +
report O +
stating O +
clinical O +
success O +
with O +
plant O +
extracts O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

The O +
mode O +
of O +
action O +
was O +
said O +
to O +
be O +
comparable O +
to O +
that O +
of O +
the O +
synthetic O +
compound O +
' O -
carbamylcholin O -
' O -
; O +
that O +
is O -
, O +
carbachol O -
. O +

He O +
bought O +
25 O +
g O +
of O +
carbachol O +
as O +
pure O +
substance O +
in O +
a O +
pharmacy O -
, O +
and O +
the O +
father O +
was O +
administered O +
400 O +
to O +
500 O +
mg O -
. O +

Carbachol O +
concentrations O +
in O +
serum O +
and O +
urine O +
on O +
day O +
1 O +
and O +
2 O +
of O +
hospital O +
admission O +
were O +
analysed O +
by O +
HPLC O -
- O -
mass O +
spectrometry O -
. O +

RESULTS O -
: O +
Minutes O +
after O +
oral O +
administration O -
, O +
the O +
patient O +
developed O +
nausea B-Disease -
, O +
sweating O +
and O +
hypotension B-Disease -
, O +
and O +
finally O +
collapsed O -
. O +

Bradycardia B-Disease -
, O +
cholinergic O +
symptoms O +
and O +
asystole B-Disease +
occurred O -
. O +

Initial O +
cardiopulmonary O +
resuscitation O +
and O +
immediate O +
treatment O +
with O +
adrenaline O +
( O -
epinephrine O -
) O -
, O +
atropine O +
and O +
furosemide O +
was O +
successful O -
. O +

On O +
hospital O +
admission O -
, O +
blood O +
pressure O +
of O +
the O +
intubated O -
, O +
bradyarrhythmic O +
patient O +
was O +
100 O -
/ O -
65 O +
mmHg O -
. O +

Further O +
signs O +
were O +
hyperhidrosis B-Disease -
, O +
hypersalivation B-Disease -
, O +
bronchorrhoea B-Disease -
, O +
and O +
severe O +
miosis B-Disease -
; O +
the O +
electrocardiographic O +
finding O +
was O +
atrio B-Disease -
- I-Disease -
ventricular I-Disease +
dissociation I-Disease -
. O +

High O +
doses O +
of O +
atropine O +
( O -
up O +
to O +
50 O +
mg O +
per O +
24 O +
hours O -
) O -
, O +
adrenaline O +
and O +
dopamine O +
were O +
necessary O -
. O +

The O +
patient O +
was O +
extubated O +
1 O +
week O +
later O -
. O +

However O -
, O +
increased O +
dyspnoea B-Disease +
and O +
bronchospasm B-Disease +
necessitated O +
reintubation O -
. O +

Respiratory B-Disease +
insufficiency I-Disease +
was O +
further O +
worsened O +
by O +
Proteus B-Disease +
mirabilis I-Disease +
infection I-Disease +
and O +
severe O +
bronchoconstriction O -
. O +

One O +
week O +
later O -
, O +
the O +
patient O +
was O +
again O +
extubated O +
and O +
3 O +
days O +
later O +
was O +
transferred O +
to O +
a O +
peripheral O +
ward O -
. O +

On O +
the O +
next O +
day O +
he O +
died O -
, O +
probably O +
as O +
a O +
result O +
of O +
heart B-Disease +
failure I-Disease -
. O +

Serum O +
samples O +
from O +
the O +
first O +
and O +
second O +
days O +
contained O +
3.6 O +
and O +
1.9 O +
mg O -
/ O -
l O +
carbachol O -
, O +
respectively O -
. O +

The O +
corresponding O +
urine O +
concentrations O +
amounted O +
to O +
374 O +
and O +
554 O +
mg O -
/ O -
l O -
. O +

CONCLUSION O -
: O +
This O +
case O +
started O +
with O +
a O +
media O +
report O +
in O +
a O +
popular O +
newspaper O -
, O +
initiated O +
by O +
published O -
, O +
peer O -
- O -
reviewed O +
research O +
on O +
herbals O -
, O +
and O +
involved O +
human O +
failure O +
in O +
a O +
case O +
history O -
, O +
medical O +
examination O +
and O +
clinical O +
treatment O -
. O +

For O +
the O +
first O +
time O -
, O +
an O +
analytical O +
method O +
for O +
the O +
determination O +
of O +
carbachol O +
in O +
plasma O +
and O +
urine O +
has O +
been O +
developed O -
. O +

The O +
analysed O +
carbachol O +
concentration O +
exceeded O +
the O +
supposed O +
serum O +
level O +
resulting O +
from O +
a O +
therapeutic O +
dose O +
by O +
a O +
factor O +
of O +
130 O +
to O +
260 O -
. O +

Especially O +
in O +
old O +
patients O -
, O +
intensivists O +
should O +
consider O +
intoxications O +
( O -
with O +
cholinergics O -
) O +
as O +
a O +
cause O +
of O +
acute B-Disease +
cardiovascular I-Disease +
failure I-Disease -
. O +

Pharmacological O +
evidence O +
for O +
the O +
potential O +
of O +
Daucus O +
carota O +
in O +
the O +
management O +
of O +
cognitive B-Disease +
dysfunctions I-Disease -
. O +

The O +
present O +
study O +
was O +
aimed O +
at O +
investigating O +
the O +
effects O +
of O +
Daucus O +
carota O +
seeds O +
on O +
cognitive O +
functions O -
, O +
total O +
serum O +
cholesterol O +
levels O +
and O +
brain O +
cholinesterase O +
activity O +
in O +
mice O -
. O +

The O +
ethanolic O +
extract O +
of O +
Daucus O +
carota O +
seeds O +
( O -
DCE O -
) O +
was O +
administered O +
orally O +
in O +
three O +
doses O +
( O -
100 O -
, O +
200 O -
, O +
400 O +
mg O -
/ O -
kg O -
) O +
for O +
seven O +
successive O +
days O +
to O +
different O +
groups O +
of O +
young O +
and O +
aged O +
mice O -
. O +

Elevated O +
plus O +
maze O +
and O +
passive O +
avoidance O +
apparatus O +
served O +
as O +
the O +
exteroceptive O +
behavioral O +
models O +
for O +
testing O +
memory O -
. O +

Diazepam- O -
, O +
scopolamine- O +
and O +
ageing O -
- O -
induced O +
amnesia B-Disease +
served O +
as O +
the O +
interoceptive O +
behavioral O +
models O -
. O +

DCE O +
( O -
200 O -
, O +
400 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O +
showed O +
significant O +
improvement O +
in O +
memory O +
scores O +
of O +
young O +
and O +
aged O +
mice O -
. O +

The O +
extent O +
of O +
memory O +
improvement O +
evoked O +
by O +
DCE O +
was O +
23 O -
% O +
at O +
the O +
dose O +
of O +
200 O +
mg O -
/ O -
kg O +
and O +
35 O -
% O +
at O +
the O +
dose O +
of O +
400 O +
mg O -
/ O -
kg O +
in O +
young O +
mice O +
using O +
elevated O +
plus O +
maze O -
. O +

Similarly O -
, O +
significant O +
improvements O +
in O +
memory O +
scores O +
were O +
observed O +
using O +
passive O +
avoidance O +
apparatus O +
and O +
aged O +
mice O -
. O +

Furthermore O -
, O +
DCE O +
reversed O +
the O +
amnesia B-Disease +
induced O +
by O +
scopolamine O +
( O -
0.4 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
diazepam O +
( O -
1 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O +

Daucus O +
carota O +
extract O +
( O -
200 O -
, O +
400 O +
mg O -
/ O -
kg O -
, O +
p.o O -
. O -
) O +
reduced O +
significantly O +
the O +
brain O +
acetylcholinesterase O +
activity O +
and O +
cholesterol O +
levels O +
in O +
young O +
and O +
aged O +
mice O -
. O +

The O +
extent O +
of O +
inhibition O +
of O +
brain O +
cholinesterase O +
activity O +
evoked O +
by O +
DCE O +
at O +
the O +
dose O +
of O +
400 O +
mg O -
/ O -
kg O +
was O +
22 O -
% O +
in O +
young O +
and O +
19 O -
% O +
in O +
aged O +
mice O -
. O +

There O +
was O +
a O +
remarkable O +
reduction O +
in O +
total O +
cholesterol O +
level O +
as O +
well O -
, O +
to O +
the O +
extent O +
of O +
23 O -
% O +
in O +
young O +
and O +
21 O -
% O +
in O +
aged O +
animals O +
with O +
this O +
dose O +
of O +
DCE O -
. O +

Therefore O -
, O +
DCE O +
may O +
prove O +
to O +
be O +
a O +
useful O +
remedy O +
for O +
the O +
management O +
of O +
cognitive B-Disease +
dysfunctions I-Disease +
on O +
account O +
of O +
its O +
multifarious O +
beneficial O +
effects O +
such O +
as O -
, O +
memory O +
improving O +
property O -
, O +
cholesterol O +
lowering O +
property O +
and O +
anticholinesterase O +
activity O -
. O +

Valproic O +
acid O +
induced O +
encephalopathy--19 B-Disease +
new O +
cases O +
in O +
Germany O +
from O +
1994 O +
to O +
2003 O -
- O -
-a O +
side O +
effect O +
associated O +
to O +
VPA O -
- O -
therapy O +
not O +
only O +
in O +
young O +
children O -
. O +

Valproic O +
acid O +
( O -
VPA O -
) O +
is O +
a O +
broad O -
- O -
spectrum O +
antiepileptic O +
drug O +
and O +
is O +
usually O +
well O -
- O -
tolerated O -
. O +

Rare O +
serious O +
complications O +
may O +
occur O +
in O +
some O +
patients O -
, O +
including O +
haemorrhagic O +
pancreatitis B-Disease -
, O +
bone B-Disease +
marrow I-Disease +
suppression I-Disease -
, O +
VPA O -
- O -
induced O +
hepatotoxicity B-Disease +
and O +
VPA O -
- O -
induced O +
encephalopathy B-Disease -
. O +

The O +
typical O +
signs O +
of O +
VPA O -
- O -
induced O +
encephalopathy B-Disease +
are O +
impaired B-Disease +
consciousness I-Disease -
, O +
sometimes O +
marked O +
EEG O +
background O +
slowing O -
, O +
increased O +
seizure B-Disease +
frequency O -
, O +
with O +
or O +
without O +
hyperammonemia B-Disease -
. O +

There O +
is O +
still O +
no O +
proof O +
of O +
causative O +
effect O +
of O +
VPA O +
in O +
patients O +
with O +
encephalopathy B-Disease -
, O +
but O +
only O +
of O +
an O +
association O +
with O +
an O +
assumed O +
causal O +
relation O -
. O +

We O +
report O +
19 O +
patients O +
with O +
VPA O -
- O -
associated O +
encephalopathy B-Disease +
in O +
Germany O +
from O +
the O +
years O +
1994 O +
to O +
2003 O -
, O +
none O +
of O +
whom O +
had O +
been O +
published O +
previously O -
. O +

Atorvastatin O +
prevented O +
and O +
reversed O +
dexamethasone O -
- O -
induced O +
hypertension B-Disease +
in O +
the O +
rat O -
. O +

To O +
assess O +
the O +
antioxidant O +
effects O +
of O +
atorvastatin O +
( O -
atorva O -
) O +
on O +
dexamethasone O +
( O -
dex O -
) O -
-induced O +
hypertension B-Disease -
, O +
60 O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
treated O +
with O +
atorva O +
30 O +
mg O -
/ O -
kg O -
/ O -
day O +
or O +
tap O +
water O +
for O +
15 O +
days O -
. O +

Dex O +
increased O +
systolic O +
blood O +
pressure O +
( O -
SBP O -
) O +
from O +
109 O +
+ O -
/- O +

1.8 O +
to O +
135 O +
+ O -
/- O +

0.6 O +
mmHg O +
and O +
plasma O +
superoxide O +
( O -
5711 O +
+ O -
/- O +

284.9 O +
saline O -
, O +
7931 O +
+ O -
/- O +

392.8 O +
U O -
/ O -
ml O +
dex O -
, O +
P O +
< O +
0.001 O -
) O -
. O +

In O +
this O +
prevention O +
study O -
, O +
SBP O +
in O +
the O +
atorva O +
+ O +
dex O +
group O +
was O +
increased O +
from O +
115 O +
+ O -
/- O +

0.4 O +
to O +
124 O +
+ O -
/- O +

1.5 O +
mmHg O -
, O +
but O +
this O +
was O +
significantly O +
lower O +
than O +
in O +
the O +
dex O -
- O -
only O +
group O +
( O -
P O -
' O +
< O +
0.05 O -
) O -
. O +

Atorva O +
reversed O +
dex O -
- O -
induced O +
hypertension B-Disease +
( O -
129 O +
+ O -
/- O +

0.6 O +
mmHg O -
, O +
vs. O +
135 O +
+ O -
/- O +

0.6 O +
mmHg O +
P O -
' O +
< O +
0.05 O -
) O +
and O +
decreased O +
plasma O +
superoxide O +
( O -
7931 O +
+ O -
/- O +

392.8 O +
dex O -
, O +
1187 O +
+ O -
/- O +

441.2 O +
atorva O +
+ O +
dex O -
, O +
P O +
< O +
0.0001 O -
) O -
. O +

Plasma O +
nitrate O -
/ O -
nitrite O +
( O -
NOx O -
) O +
was O +
decreased O +
in O +
dex O -
- O -
treated O +
rats O +
compared O +
to O +
saline O -
- O -
treated O +
rats O +
( O -
11.2 O +
+ O -
/- O +

1.08 O +
microm O -
, O +
15.3 O +
+ O -
/- O +

1.17 O +
microm O -
, O +
respectively O -
, O +
P O +
< O +
0.05 O -
) O -
. O +

Atorva O +
affected O +
neither O +
plasma O +
NOx O +
nor O +
thymus O +
weight O -
. O +

Thus O -
, O +
atorvastatin O +
prevented O +
and O +
reversed O +
dexamethasone O -
- O -
induced O +
hypertension B-Disease +
in O +
the O +
rat O -
. O +

Peripheral B-Disease +
neuropathy I-Disease +
caused O +
by O +
high O -
- O -
dose O +
cytosine O +
arabinoside O +
treatment O +
in O +
a O +
patient O +
with O +
acute B-Disease +
myeloid I-Disease +
leukemia I-Disease -
. O +

The O +
central O +
nervous O +
system O +
toxicity B-Disease +
of O +
high O -
- O -
dose O +
cytosine O +
arabinoside O +
is O +
well O +
recognized O -
, O +
but O +
the O +
toxicity B-Disease +
of O +
cytosine O +
arabinoside O +
in O +
the O +
peripheral O +
nervous O +
system O +
has O +
been O +
infrequently O +
reported O -
. O +

A O +
49-year O -
- O -
old O +
Japanese O +
man O +
was O +
diagnosed O +
with O +
acute B-Disease +
myeloid I-Disease +
leukemia I-Disease -
. O +

After O +
he O +
achieved O +
complete O +
remission O -
, O +
he O +
received O +
high O -
- O -
dose O +
cytosine O +
arabinoside O +
treatment O +
( O -
2 O +
g O -
/ O -
m2 O +
twice O +
a O +
day O +
for O +
5 O +
days O -
; O +
total O -
, O +
20 O +
g O -
/ O -
m2 O -
) O +
as O +
consolidation O +
therapy O -
. O +

The O +
first O +
course O +
of O +
high O -
- O -
dose O +
cytosine O +
arabinoside O +
resulted O +
in O +
no O +
unusual O +
symptoms O -
, O +
but O +
on O +
day O +
21 O +
of O +
the O +
second O +
course O +
of O +
treatment O -
, O +
the O +
patient O +
complained O +
of O +
numbness B-Disease +
in O +
his O +
right O +
foot O -
. O +

Electromyogram O +
and O +
nerve O -
- O -
conduction O +
studies O +
showed O +
peripheral B-Disease +
neuropathy I-Disease +
in O +
both O +
peroneal O +
nerves O -
. O +

This O +
neuropathy B-Disease +
was O +
gradually O +
resolving O -
; O +
however O -
, O +
after O +
the O +
patient O +
received O +
allogeneic O +
bone O +
marrow O +
transplantation O -
, O +
the O +
symptoms O +
worsened O -
, O +
with O +
the O +
development O +
of O +
graft B-Disease -
- I-Disease -
versus I-Disease -
- I-Disease -
host I-Disease +
disease I-Disease -
, O +
and O +
the O +
symptoms O +
subsequently O +
responded O +
to O +
methylprednisolone O -
. O +

Although O +
the O +
mechanisms O +
of O +
peripheral B-Disease +
neuropathy I-Disease +
are O +
still O +
unclear O -
, O +
high O -
- O -
dose O +
cytosine O +
arabinoside O +
is O +
a O +
therapy O +
that O +
is O +
potentially O +
toxic O +
to O +
the O +
peripheral O +
nervous O +
system O -
, O +
and O +
auto O -
/ O -
alloimmunity O +
may O +
play O +
an O +
important O +
role O +
in O +
these O +
mechanisms O -
. O +

Effect O +
of O +
alpha O -
- O -
tocopherol O +
and O +
deferoxamine O +
on O +
methamphetamine O -
- O -
induced O +
neurotoxicity B-Disease -
. O +

Methamphetamine O +
( O -
MA O -
) O -
-induced O +
dopaminergic O +
neurotoxicity B-Disease +
is O +
believed O +
to O +
be O +
associated O +
with O +
the O +
increased O +
formation O +
of O +
free O +
radicals O -
. O +

This O +
study O +
examined O +
the O +
effect O +
of O +
alpha O -
- O -
tocopherol O +
( O -
alpha O -
- O -
TC O -
) O -
, O +
a O +
scavenger O +
of O +
reactive O +
oxygen O +
species O -
, O +
and O +
deferoxamine O +
( O -
DFO O -
) O -
, O +
an O +
iron O +
chelator O -
, O +
on O +
the O +
MA O -
- O -
induced O +
neurotoxicity B-Disease -
. O +

Male O +
rats O +
were O +
treated O +
with O +
MA O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
every O +
2 O +
h O +
for O +
four O +
injections O -
) O -
. O +

The O +
rat O +
received O +
either O +
alpha O -
- O -
TC O +
( O -
20 O +
mg O -
/ O -
kg O -
) O +
intraperitoneally O +
for O +
3 O +
days O +
and O +
30 O +
min O +
prior O +
to O +
MA O +
administration O +
or O +
DFO O +
( O -
50 O +
mg O -
/ O -
kg O -
) O +
subcutaneously O +
30 O +
min O +
before O +
MA O +
administration O -
. O +

The O +
concentrations O +
of O +
dopamine O +
( O -
DA O -
) O -
, O +
serotonin O +
and O +
their O +
metabolites O +
decreased O +
significantly O +
after O +
MA O +
administration O -
, O +
which O +
was O +
inhibited O +
by O +
the O +
alpha O -
- O -
TC O +
and O +
DFO O +
pretreatment O -
. O +

alpha O -
- O -
TC O +
and O +
DFO O +
attenuated O +
the O +
MA O -
- O -
induced O +
hyperthermia B-Disease +
as O +
well O +
as O +
the O +
alterations O +
in O +
the O +
locomotor O +
activity O -
. O +

The O +
level O +
of O +
lipid O +
peroxidation O +
was O +
higher O +
and O +
the O +
reduced O +
glutathione O +
concentration O +
was O +
lower O +
in O +
the O +
MA O -
- O -
treated O +
rats O -
. O +

These O +
changes O +
were O +
significantly O +
attenuated O +
by O +
alpha O -
- O -
TC O +
and O +
DFO O -
. O +

This O +
suggests O +
that O +
alpha O -
- O -
TC O +
and O +
DFO O +
ameliorate O +
the O +
MA O -
- O -
induced O +
neuronal B-Disease +
damage I-Disease +
by O +
decreasing O +
the O +
level O +
of O +
oxidative O +
stress O -
. O +

Cerebral B-Disease +
haemorrhage I-Disease +
induced O +
by O +
warfarin O +
- O +
the O +
influence O +
of O +
drug O -
- O -
drug O +
interactions O -
. O +

PURPOSE O -
: O +
To O +
evaluate O +
the O +
frequency O -
, O +
severity O +
and O +
preventability O +
of O +
warfarin O -
- O -
induced O +
cerebral B-Disease +
haemorrhages I-Disease +
due O +
to O +
warfarin O +
and O +
warfarin O -
- O -
drug O +
interactions O +
in O +
patients O +
living O +
in O +
the O +
county O +
of O +
Osterg O +
tland O -
, O +
Sweden O -
. O +

METHODS O -
: O +
All O +
patients O +
with O +
a O +
diagnosed O +
cerebral B-Disease +
haemorrhage I-Disease +
at O +
three O +
hospitals O +
during O +
the O +
period O +
2000 O -
- O -
2002 O +
were O +
identified O -
. O +

Medical O +
records O +
were O +
studied O +
retrospectively O +
to O +
evaluate O +
whether O +
warfarin O +
and O +
warfarin O -
- O -
drug O +
interactions O +
could O +
have O +
caused O +
the O +
cerebral B-Disease +
haemorrhage I-Disease -
. O +

The O +
proportion O +
of O +
possibly O +
avoidable O +
cases O +
due O +
to O +
drug O +
interactions O +
was O +
estimated O -
. O +

RESULTS O -
: O +
Among O +
593 O +
patients O +
with O +
cerebral B-Disease +
haemorrhage I-Disease -
, O +
59 O +
( O -
10 O -
% O -
) O +
were O +
assessed O +
as O +
related O +
to O +
warfarin O +
treatment O -
. O +

This O +
imply O +
an O +
incidence O +
of O +
1.7 O -
/ O -
100,000 O +
treatment O +
years O -
. O +

Of O +
the O +
59 O +
cases O -
, O +
26 O +
( O -
44 O -
% O -
) O +
had O +
a O +
fatal O +
outcome O -
, O +
compared O +
to O +
136 O +
( O -
25 O -
% O -
) O +
among O +
the O +
non O -
- O -
warfarin O +
patients O +
( O -
p O +
< O +
0.01 O -
) O -
. O +

A O +
warfarin O -
- O -
drug O +
interaction O +
could O +
have O +
contributed O +
to O +
the O +
haemorrhage B-Disease +
in O +
24 O +
( O -
41 O -
% O -
) O +
of O +
the O +
warfarin O +
patients O +
and O +
in O +
7 O +
of O +
these O +
( O -
12 O -
% O -
) O +
the O +
bleeding B-Disease +
complication O +
was O +
considered O +
being O +
possible O +
to O +
avoid O -
. O +

CONCLUSIONS O -
: O +
Warfarin O -
- O -
induced O +
cerebral B-Disease +
haemorrhages I-Disease +
are O +
a O +
major O +
clinical O +
problem O +
with O +
a O +
high O +
fatality O +
rate O -
. O +

Almost O +
half O +
of O +
the O +
cases O +
was O +
related O +
to O +
a O +
warfarin O -
- O -
drug O +
interaction O -
. O +

A O +
significant O +
proportion O +
of O +
warfarin O -
- O -
related O +
cerebral B-Disease +
haemorrhages I-Disease +
might O +
have O +
been O +
prevented O +
if O +
greater O +
caution O +
had O +
been O +
taken O +
when O +
prescribing O +
drugs O +
known O +
to O +
interact O +
with O +
warfarin O -
. O +

Antipsychotic O -
- O -
like O +
profile O +
of O +
thioperamide O -
, O +
a O +
selective O +
H3-receptor O +
antagonist O +
in O +
mice O -
. O +

Experimental O +
and O +
clinical O +
evidence O +
points O +
to O +
a O +
role O +
of O +
central O +
histaminergic O +
system O +
in O +
the O +
pathogenesis O +
of O +
schizophrenia B-Disease -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
study O +
the O +
effect O +
of O +
histamine O +
H O -
( O -
3 O -
) O -
-receptor O +
ligands O +
on O +
neuroleptic O -
- O -
induced O +
catalepsy B-Disease -
, O +
apomorphine O -
- O -
induced O +
climbing O +
behavior O +
and O +
amphetamine O -
- O -
induced O +
locomotor O +
activities O +
in O +
mice O -
. O +

Catalepsy B-Disease +
was O +
induced O +
by O +
haloperidol O +
( O -
2 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O -
, O +
while O +
apomorphine O +
( O -
1.5 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
and O +
amphetamine O +
( O -
2 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
were O +
used O +
for O +
studying O +
climbing O +
behavior O +
and O +
locomotor O +
activities O -
, O +
respectively O -
. O +

( O -
R O -
) O -
-alpha O -
- O -
methylhistamine O +
( O -
RAMH O -
) O +
( O -
5 O +
microg O +
i.c.v O -
. O -
) O +
and O +
thioperamide O +
( O -
THP O -
) O +
( O -
15 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O -
, O +
per O +
se O +
did O +
not O +
cause O +
catalepsy B-Disease -
. O +

Administration O +
of O +
THP O +
( O -
3.75 O -
, O +
7.5 O +
and O +
15 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
1 O +
h O +
prior O +
to O +
haloperidol O +
resulted O +
in O +
a O +
dose O -
- O -
dependent O +
increase O +
in O +
the O +
catalepsy B-Disease +
times O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

However O -
, O +
pretreatment O +
with O +
RAMH O +
significantly O +
reversed O +
such O +
an O +
effect O +
of O +
THP O +
( O -
15 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O -
. O +

RAMH O +
per O +
se O +
showed O +
significant O +
reduction O +
in O +
locomotor O +
time O -
, O +
distance O +
traveled O +
and O +
average O +
speed O +
but O +
THP O +
( O -
15 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
per O +
se O +
had O +
no O +
effect O +
on O +
these O +
parameters O -
. O +

On O +
amphetamine O -
- O -
induced O +
hyperactivity B-Disease -
, O +
THP O +
( O -
3.75 O +
and O +
7.5 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
reduced O +
locomotor O +
time O -
, O +
distance O +
traveled O +
and O +
average O +
speed O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Pretreatment O +
with O +
RAMH O +
( O -
5 O +
microg O +
i.c.v O -
. O -
) O +
could O +
partially O +
reverse O +
such O +
effects O +
of O +
THP O +
( O -
3.75 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O -
. O +

Climbing O +
behavior O +
induced O +
by O +
apomorphine O +
was O +
reduced O +
in O +
animals O +
treated O +
with O +
THP O -
. O +

Such O +
an O +
effect O +
was O -
, O +
however O -
, O +
reversed O +
in O +
presence O +
of O +
RAMH O -
. O +

THP O +
exhibited O +
an O +
antipsychotic O -
- O -
like O +
profile O +
by O +
potentiating O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease -
, O +
reducing O +
amphetamine O -
- O -
induced O +
hyperactivity B-Disease +
and O +
reducing O +
apomorphine O -
- O -
induced O +
climbing O +
in O +
mice O -
. O +

Such O +
effects O +
of O +
THP O +
were O +
reversed O +
by O +
RAMH O +
indicating O +
the O +
involvement O +
of O +
histamine O +
H O -
( O -
3 O -
) O -
-receptors O -
. O +

Findings O +
suggest O +
a O +
potential O +
for O +
H O -
( O -
3 O -
) O -
-receptor O +
antagonists O +
in O +
improving O +
the O +
refractory O +
cases O +
of O +
schizophrenia B-Disease -
. O +

Cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
after O +
epidural O +
steroid O +
injection O -
: O +
a O +
case O +
report O -
. O +

OBJECTIVE O -
: O +
Conventional O +
treatment O +
methods O +
of O +
lumbusacral O +
radiculopathy B-Disease +
are O +
physical O +
therapy O -
, O +
epidural O +
steroid O +
injections O -
, O +
oral O +
medications O -
, O +
and O +
spinal O +
manipulative O +
therapy O -
. O +

Cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
is O +
a O +
rare O +
complication O +
of O +
epidural O +
anesthesia O -
. O +

The O +
following O +
case O +
is O +
a O +
report O +
of O +
cauda B-Disease +
equina I-Disease +
syndrome I-Disease +
possibly O +
caused O +
by O +
epidural O +
injection O +
of O +
triamcinolone O +
and O +
bupivacaine O -
. O +

CLINICAL O +
FEATURES O -
: O +
A O +
50-year O -
- O -
old O +
woman O +
with O +
low B-Disease +
back I-Disease +
and I-Disease +
right I-Disease +
leg I-Disease +
pain I-Disease +
was O +
scheduled O +
for O +
epidural O +
steroid O +
injection O -
. O +

INTERVENTION O +
AND O +
OUTCOME O -
: O +
An O +
18-gauge O +
Touhy O +
needle O +
was O +
inserted O +
until O +
loss O +
of O +
resistance O +
occurred O +
at O +
the O +
L4 O -
- O -
5 O +
level O -
. O +

Spread O +
of O +
the O +
contrast O +
medium O +
within O +
the O +
epidural O +
space O +
was O +
determined O +
by O +
radiographic O +
imaging O -
. O +

After O +
verifying O +
the O +
epidural O +
space O -
, O +
bupivacaine O +
and O +
triamcinolone O +
diacetate O +
were O +
injected O -
. O +

After O +
the O +
injection O -
, O +
there O +
was O +
a O +
reduction O +
in O +
radicular O +
symptoms O -
. O +

Three O +
hours O +
later O -
, O +
she O +
complained O +
of O +
perineal O +
numbness B-Disease +
and O +
lower B-Disease +
extremity I-Disease +
weakness I-Disease -
. O +

The O +
neurologic O +
evaluation O +
revealed O +
loss B-Disease +
of I-Disease +
sensation I-Disease +
in O +
the O +
saddle O +
area O +
and O +
medial O +
aspect O +
of O +
her O +
right O +
leg O -
. O +

There O +
was O +
a O +
decrease O +
in O +
the O +
perception O +
of O +
pinprick O +
test O -
. O +

Deep O -
- O -
tendon O +
reflexes O +
were O +
decreased O +
especially O +
in O +
the O +
right O +
leg O -
. O +

She O +
was O +
unable O +
to O +
urinate O -
. O +

The O +
patient O -
's O +
symptoms O +
improved O +
slightly O +
over O +
the O +
next O +
few O +
hours O -
. O +

She O +
had O +
a O +
gradual O +
return O +
of O +
motor O +
function O +
and O +
ability O +
of O +
feeling O +
Foley O +
catheter O -
. O +

All O +
of O +
the O +
symptoms O +
were O +
completely O +
resolved O +
over O +
the O +
next O +
8 O +
hours O -
. O +

CONCLUSION O -
: O +
Complications O +
associated O +
with O +
epidural O +
steroid O +
injections O +
are O +
rare O -
. O +

Clinical O +
examination O +
and O +
continued O +
vigilance O +
for O +
neurologic B-Disease +
deterioration I-Disease +
after O +
epidural O +
steroid O +
injections O +
is O +
important O -
. O +

High O -
- O -
dose O +
testosterone O +
is O +
associated O +
with O +
atherosclerosis B-Disease +
in O +
postmenopausal O +
women O -
. O +

OBJECTIVES O -
: O +
To O +
study O +
the O +
long O -
- O -
term O +
effects O +
of O +
androgen O +
treatment O +
on O +
atherosclerosis B-Disease +
in O +
postmenopausal O +
women O -
. O +

METHODS O -
: O +
In O +
a O +
population O -
- O -
based O +
study O +
in O +
513 O +
naturally O +
postmenopausal O +
women O +
aged O +
54 O -
- O -
67 O +
years O -
, O +
we O +
studied O +
the O +
association O +
between O +
self O -
- O -
reported O +
intramuscularly O +
administered O +
high O -
- O -
dose O +
estrogen O -
- O -
testosterone O +
therapy O +
( O -
estradiol- O +
and O +
testosterone O +
esters O -
) O +
and O +
aortic O +
atherosclerosis B-Disease -
. O +

Aortic O +
atherosclerosis B-Disease +
was O +
diagnosed O +
by O +
radiographic O +
detection O +
of O +
calcified O +
deposits O +
in O +
the O +
abdominal O +
aorta O -
, O +
which O +
have O +
been O +
shown O +
to O +
reflect O +
intima O +
atherosclerosis B-Disease -
. O +

Hormone O +
therapy O +
users O +
were O +
compared O +
with O +
never O +
users O -
. O +

RESULTS O -
: O +
Intramuscular O +
hormone O +
therapy O +
use O +
for O +
1 O +
year O +
or O +
longer O +
was O +
reported O +
by O +
25 O +
women O -
. O +

In O +
almost O +
half O +
of O +
these O +
women O +
severe O +
atherosclerosis B-Disease +
of O +
the O +
aorta O +
was O +
present O +
( O -
n=11 O -
) O -
, O +
while O +
in O +
women O +
without O +
hormone O +
use O +
severe O +
atherosclerosis B-Disease +
of O +
the O +
aorta O +
was O +
present O +
in O +
less O +
than O +
20 O -
% O +
( O -
OR O +
3.1 O -
; O +
95 O -
% O +
CI O -
, O +
1.1 O -
- O -
8.5 O -
, O +
adjusted O +
for O +
age O -
, O +
years O +
since O +
menopause O -
, O +
smoking O -
, O +
and O +
body O +
mass O +
index O -
) O -
. O +

The O +
association O +
remained O +
after O +
additional O +
adjustment O +
for O +
diabetes B-Disease -
, O +
cholesterol O +
level O -
, O +
systolic O +
blood O +
pressure O -
, O +
or O +
alcohol O +
use O -
. O +

No O +
association O +
was O +
found O +
for O +
hormone O +
use O +
less O +
than O +
1 O +
year O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
suggest O +
that O +
high O -
- O -
dose O +
testosterone O +
therapy O +
may O +
adversely O +
affect O +
atherosclerosis B-Disease +
in O +
postmenopausal O +
women O +
and O +
indicate O +
that O +
androgen O +
replacement O +
in O +
these O +
women O +
may O +
not O +
be O +
harmless O -
. O +

Sustained O +
clinical O +
improvement O +
of O +
a O +
patient O +
with O +
decompensated O +
hepatitis B-Disease +
B I-Disease +
virus O -
- O -
related O +
cirrhosis B-Disease +
after O +
treatment O +
with O +
lamivudine O +
monotherapy O -
. O +

Hepatitis B-Disease +
B I-Disease +
virus I-Disease +
( I-Disease -
HBV I-Disease -
) I-Disease +
infection I-Disease -
, O +
which O +
causes O +
liver B-Disease +
cirrhosis I-Disease +
and O +
hepatocellular B-Disease +
carcinoma I-Disease -
, O +
remains O +
a O +
major O +
health O +
problem O +
in O +
Asian O +
countries O -
. O +

Recent O +
development O +
of O +
vaccine O +
for O +
prevention O +
is O +
reported O +
to O +
be O +
successful O +
in O +
reducing O +
the O +
size O +
of O +
chronically O +
infected O +
carriers O -
, O +
although O +
the O +
standard O +
medical O +
therapies O +
have O +
not O +
been O +
established O +
up O +
to O +
now O -
. O +

In O +
this O +
report O -
, O +
we O +
encountered O +
a O +
patient O +
with O +
decompensated O +
HBV O -
- O -
related O +
cirrhosis B-Disease +
who O +
exhibited O +
the O +
dramatic O +
improvements O +
after O +
antiviral O +
therapy O -
. O +

The O +
patient O +
was O +
a O +
50-year O -
- O -
old O +
woman O -
. O +

Previous O +
conventional O +
medical O +
treatments O +
were O +
not O +
effective O +
for O +
this O +
patient O -
, O +
thus O +
this O +
patient O +
had O +
been O +
referred O +
to O +
our O +
hospital O -
. O +

However O -
, O +
the O +
administration O +
of O +
lamivudine O -
, O +
a O +
reverse O +
transcriptase O +
inhibitor O -
, O +
for O +
23 O +
months O +
dramatically O +
improved O +
her O +
liver O +
severity O -
. O +

During O +
this O +
period O -
, O +
no O +
drug O +
resistant O +
mutant O +
HBV O +
emerged O -
, O +
and O +
the O +
serum O +
HBV O -
- O -
DNA O +
level O +
was O +
continuously O +
suppressed O -
. O +

These O +
virological O +
responses O +
were O +
also O +
maintained O +
even O +
after O +
the O +
antiviral O +
therapy O +
was O +
discontinued O -
. O +

Moreover O -
, O +
both O +
hepatitis O +
B O +
surface O +
antigen O +
and O +
e O +
antigen O +
were O +
observed O +
to O +
have O +
disappeared O +
in O +
this O +
patient O -
. O +

The O +
administration O +
of O +
lamivudine O +
to O +
patients O +
with O +
HBV O -
- O -
related O +
cirrhosis B-Disease -
, O +
like O +
our O +
present O +
case O -
, O +
should O +
be O +
considered O +
as O +
an O +
initial O +
medical O +
therapeutic O +
option O -
, O +
especially O +
in O +
countries O +
where O +
liver O +
transplantation O +
is O +
not O +
reliably O +
available O -
. O +

Antiarrhythmic O +
effects O +
of O +
optical O +
isomers O +
of O +
cibenzoline O +
on O +
canine O +
ventricular B-Disease +
arrhythmias I-Disease -
. O +

Antiarrhythmic O +
effects O +
of O +
( O -
+ O -
) O -
-cibenzoline O +
and O +
( O -
- O -
) O -
-cibenzoline O +
were O +
examined O +
using O +
two O +
canine O +
ventricular B-Disease +
arrhythmia I-Disease +
models O -
. O +

Digitalis O +
arrhythmia B-Disease -
, O +
which O +
is O +
suppressed O +
by O +
Na O +
channel O +
blockers O -
, O +
was O +
induced O +
by O +
intermittent O +
intravenous O +
( O -
i.v O -
. O -
) O +
injection O +
of O +
ouabain O +
in O +
pentobarbital O -
- O -
anesthetized O +
dogs O -
. O +

Adrenaline B-Disease +
arrhythmia I-Disease -
, O +
which O +
is O +
suppressed O +
by O +
Ca O +
channel O +
blockers O -
, O +
was O +
induced O +
by O +
adrenaline O +
infusion O +
in O +
halothane O -
- O -
anesthetized O +
dogs O -
. O +

Ten O +
and O +
5 O +
mg O -
/ O -
kg O +
i.v O -
. O +

( O -
+ O -
) O -
-cibenzoline O +
suppressed O +
digitalis- O +
and O +
adrenaline O -
- O -
induced O +
arrhythmias B-Disease -
, O +
respectively O -
. O +

The O +
minimum O +
effective O +
plasma O +
concentrations O +
of O +
( O -
+ O -
) O -
-cibenzoline O +
for O +
digitalis- O +
and O +
adrenaline O -
- O -
induced O +
arrhythmias B-Disease +
were O +
1.4 O +
+ O -
/- O +

0.4 O +
and O +
2.0 O +
+ O -
/- O +

0.6 O +
micrograms O -
/ O -
ml O -
, O +
respectively O +
( O -
mean O +
+ O -
/- O +

SD O -
, O +
n O +
= O +
6 O -
) O -
. O +

A O +
lower O +
dose O +
of O +
1 O +
mg O -
/ O -
kg O +
i.v O -
. O +

of O +
( O -
- O -
) O -
-cibenzoline O +
suppressed O +
the O +
digitalis O -
- O -
induced O +
arrhythmia B-Disease -
, O +
whereas O +
5 O +
mg O -
/ O -
kg O +
i.v O -
. O +
was O +
needed O +
to O +
suppress O +
adrenaline O -
- O -
induced O +
arrhythmias B-Disease -
. O +

The O +
minimum O +
effective O +
plasma O +
concentrations O +
of O +
( O -
- O -
) O -
-cibenzoline O +
for O +
digitalis- O +
and O +
adrenaline O -
- O -
induced O +
arrhythmia B-Disease +
were O +
0.06 O +
+ O -
/- O +

0.04 O +
and O +
0.7 O +
+ O -
/- O +

0.1 O +
micrograms O -
/ O -
ml O -
, O +
respectively O +
( O -
mean O +
+ O -
/- O +

SD O -
, O +
n O +
= O +
6 O -
) O -
. O +

The O +
stronger O +
antiarrhythmic O +
effect O +
of O +
( O -
- O -
) O -
-cibenzoline O +
indicates O +
that O +
( O -
- O -
) O -
-isomer O +
may O +
have O +
an O +
effect O +
nearly O +
5 O -
- O -
20 O +
times O +
stronger O +
in O +
suppressing O +
Na O +
channels O -
, O +
but O +
effects O +
of O +
both O +
drugs O +
on O +
Ca O +
channels O +
may O +
be O +
almost O +
equipotent O -
. O +

Passage O +
of O +
mannitol O +
into O +
the O +
brain O +
around O +
gliomas B-Disease -
: O +
a O +
potential O +
cause O +
of O +
rebound O +
phenomenon O -
. O +

A O +
study O +
on O +
21 O +
patients O -
. O +

AIM O -
: O +
Widespread O +
use O +
of O +
mannitol O +
to O +
reduce O +
brain B-Disease +
edema I-Disease +
and O +
lower O +
elevated B-Disease +
ICP I-Disease +
in O +
brain B-Disease +
tumor I-Disease +
patients O +
continues O +
to O +
be O +
afflicted O +
by O +
the O +
so O -
- O -
called O +
rebound O +
phenomenon O -
. O +

Leakage O +
of O +
mannitol O +
into O +
the O +
brain O +
parenchyma O +
through O +
an O +
altered O +
BBB O +
and O +
secondary O +
reversal O +
of O +
osmotic O +
gradient O +
is O +
considered O +
the O +
major O +
cause O +
of O +
rebound O +
. O +

This O +
has O +
only O +
been O +
demonstrated O +
experimentally O +
in O +
animals O -
. O +

As O +
a O +
contribution O +
to O +
this O +
issue O +
we O +
decided O +
to O +
research O +
the O +
possible O +
passage O +
of O +
mannitol O +
into O +
the O +
brain O +
after O +
administration O +
to O +
21 O +
brain B-Disease +
tumor I-Disease +
patients O -
. O +

METHODS O -
: O +
Mannitol O +
( O -
18 O -
% O +
solution O -
; O +
1 O +
g O -
/ O -
kg O -
) O +
was O +
administered O +
as O +
a O +
bolus O +
to O +
patients O +
( O -
ten O +
had O +
malignant B-Disease +
glioma I-Disease -
, O +
seven O +
brain O +
metastases B-Disease +
and O +
four O +
meningioma B-Disease -
) O +
about O +
30 O +
minutes O +
before O +
craniotomy O -
. O +

During O +
resection O -
, O +
a O +
sample O +
of O +
the O +
surrounding O +
edematous B-Disease +
white O +
matter O +
was O +
taken O +
at O +
the O +
same O +
time O +
as O +
a O +
10 O +
ml O +
venous O +
blood O +
sample O -
. O +

Mannitol O +
concentrations O +
were O +
measured O +
in O +
plasma O +
and O +
white O +
matter O +
by O +
a O +
modified O +
version O +
of O +
the O +
enzyme O +
assay O +
of O +
Blonquist O +
et O +
al. O +
RESULTS O -
: O +
In O +
most O +
glioma B-Disease +
patients O -
, O +
mannitol O +
concentrations O +
in O +
white O +
matter O +
were O +
2 O +
to O +
6 O +
times O +
higher O +
than O +
in O +
plasma O +
( O -
mean O +
3.5 O +
times O -
) O -
. O +

In O +
meningioma B-Disease +
and O +
metastases B-Disease +
patients O +
plasma O +
concentrations O +
of O +
mannitol O +
were O +
higher O +
than O +
white O +
matter O +
concentrations O +
except O +
in O +
three O +
cases O +
with O +
infiltration O +
by O +
neoplastic O +
cells O -
. O +

CONCLUSIONS O -
: O +
The O +
results O +
of O +
our O +
study O +
show O +
that O +
even O +
after O +
a O +
single O +
bolus O -
, O +
mannitol O +
may O +
leak O +
through O +
the O +
altered O +
BBB O +
near O +
gliomas B-Disease -
, O +
reversing O +
the O +
initial O +
plasma O -
- O -
to O -
- O -
blood O +
osmotic O +
gradient O -
, O +
aggravating O +
peritumoral O +
edema B-Disease +
and O +
promoting O +
rebound O +
of O +
ICP O -
. O +

Optimising O +
stroke B-Disease +
prevention O +
in O +
non O -
- O -
valvular O +
atrial B-Disease +
fibrillation I-Disease -
. O +

Atrial B-Disease +
fibrillation I-Disease +
is O +
associated O +
with O +
substantial O +
morbidity O +
and O +
mortality O -
. O +

Pooled O +
data O +
from O +
trials O +
comparing O +
antithrombotic O +
treatment O +
with O +
placebo O +
have O +
shown O +
that O +
warfarin O +
reduces O +
the O +
risk O +
of O +
stroke B-Disease +
by O +
62 O -
% O -
, O +
and O +
that O +
aspirin O +
alone O +
reduces O +
the O +
risk O +
by O +
22 O -
% O -
. O +

Overall O -
, O +
in O +
high O -
- O -
risk O +
patients O -
, O +
warfarin O +
is O +
superior O +
to O +
aspirin O +
in O +
preventing O +
strokes B-Disease -
, O +
with O +
a O +
relative O +
risk O +
reduction O +
of O +
36 O -
% O -
. O +

Ximelagatran O -
, O +
an O +
oral O +
direct O +
thrombin O +
inhibitor O -
, O +
was O +
found O +
to O +
be O +
as O +
efficient O +
as O +
vitamin O +
K O +
antagonist O +
drugs O +
in O +
the O +
prevention O +
of O +
embolic B-Disease +
events I-Disease -
, O +
but O +
has O +
been O +
recently O +
withdrawn O +
because O +
of O +
abnormal B-Disease +
liver I-Disease +
function I-Disease +
tests O -
. O +

The O +
ACTIVE O -
- O -
W O +
( O -
Atrial B-Disease +
Fibrillation I-Disease +
Clopidogrel O +
Trial O +
with O +
Irbesartan O +
for O +
Prevention O +
of O +
Vascular O +
Events O -
) O +
study O +
has O +
demonstrated O +
that O +
warfarin O +
is O +
superior O +
to O +
platelet O +
therapy O +
( O -
clopidogrel O +
plus O +
aspirin O -
) O +
in O +
the O +
prevention O +
af O +
embolic B-Disease +
events I-Disease -
. O +

Idraparinux O -
, O +
a O +
Factor O +
Xa O +
inhibitor O -
, O +
is O +
being O +
evaluated O +
in O +
patients O +
with O +
atrial B-Disease +
fibrillation I-Disease -
. O +

Angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
and O +
angiotensin O +
II O +
receptor O -
- O -
blocking O +
drugs O +
hold O +
promise O +
in O +
atrial B-Disease +
fibrillation I-Disease +
through O +
cardiac B-Disease +
remodelling I-Disease -
. O +

Preliminary O +
studies O +
suggest O +
that O +
statins O +
could O +
interfere O +
with O +
the O +
risk O +
of O +
recurrence O +
after O +
electrical O +
cardioversion O -
. O +

Finally O -
, O +
percutaneous O +
methods O +
for O +
the O +
exclusion O +
of O +
left O +
atrial O +
appendage O +
are O +
under O +
investigation O +
in O +
high O -
- O -
risk O +
patients O -
. O +

Placebo O -
- O -
level O +
incidence O +
of O +
extrapyramidal B-Disease +
symptoms I-Disease +
( O -
EPS B-Disease -
) O +
with O +
quetiapine O +
in O +
controlled O +
studies O +
of O +
patients O +
with O +
bipolar B-Disease +
mania I-Disease -
. O +

OBJECTIVES O -
: O +
To O +
evaluate O +
extrapyramidal B-Disease +
symptoms I-Disease +
( O -
EPS B-Disease -
) O -
, O +
including O +
akathisia B-Disease -
, O +
with O +
quetiapine O +
in O +
patients O +
with O +
bipolar B-Disease +
mania I-Disease -
. O +

METHODS O -
: O +
Data O +
were O +
analyzed O +
from O +
four O +
similarly O +
designed O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
3- O +
to O +
12-week O +
studies O -
. O +

Two O +
studies O +
evaluated O +
quetiapine O +
monotherapy O +
( O -
up O +
to O +
800 O +
mg O -
/ O -
day O -
) O +
( O -
n O +
= O +
209 O -
) O +
versus O +
placebo O +
( O -
n O +
= O +
198 O -
) O -
, O +
with O +
lithium O +
or O +
haloperidol O +
monotherapy O +
as O +
respective O +
active O +
controls O -
. O +

Two O +
studies O +
evaluated O +
quetiapine O +
( O -
up O +
to O +
800 O +
mg O -
/ O -
day O -
) O +
in O +
combination O +
with O +
a O +
mood O +
stabilizer O +
( O -
lithium O +
or O +
divalproex O -
, O +
QTP O +
+ O +
Li O -
/ O -
DVP O -
) O +
( O -
n O +
= O +
196 O -
) O +
compared O +
to O +
placebo O +
and O +
mood O +
stabilizer O +
( O -
PBO O +
+ O +
Li O -
/ O -
DVP O -
) O +
( O -
n O +
= O +
203 O -
) O -
. O +

Extrapyramidal B-Disease +
symptoms I-Disease +
were O +
evaluated O +
using O +
the O +
Simpson O -
- O -
Angus O +
Scale O +
( O -
SAS O -
) O -
, O +
the O +
Barnes O +
Akathisia O +
Rating O +
Scale O +
( O -
BARS O -
) O -
, O +
adverse O +
event O +
reports O +
and O +
anticholinergic O +
drug O +
usage O -
. O +

RESULTS O -
: O +
The O +
incidence O +
of O +
EPS B-Disease -
- O -
related O +
adverse O +
events O -
, O +
including O +
akathisia B-Disease -
, O +
was O +
no O +
different O +
with O +
quetiapine O +
monotherapy O +
( O -
12.9 O -
% O -
) O +
than O +
with O +
placebo O +
( O -
13.1 O -
% O -
) O -
. O +

Similarly O -
, O +
EPS B-Disease -
- O -
related O +
adverse O +
events O +
with O +
QTP O +
+ O +
Li O -
/ O -
DVP O +
( O -
21.4 O -
% O -
) O +
were O +
no O +
different O +
than O +
with O +
PBO O +
+ O +
Li O -
/ O -
DVP O +
( O -
19.2 O -
% O -
) O -
. O +

Adverse O +
events O +
related O +
to O +
EPS B-Disease +
occurred O +
in O +
59.6 O -
% O +
of O +
patients O +
treated O +
with O +
haloperidol O +
( O -
n O +
= O +
99 O -
) O +
monotherapy O -
, O +
whereas O +
26.5 O -
% O +
of O +
patients O +
treated O +
with O +
lithium O +
( O -
n O +
= O +
98 O -
) O +
monotherapy O +
experienced O +
adverse O +
events O +
related O +
to O +
EPS B-Disease -
. O +

The O +
incidence O +
of O +
akathisia B-Disease +
was O +
low O +
and O +
similar O +
with O +
quetiapine O +
monotherapy O +
( O -
3.3 O -
% O -
) O +
and O +
placebo O +
( O -
6.1 O -
% O -
) O -
, O +
and O +
with O +
QTP O +
+ O +
Li O -
/ O -
DVP O +
( O -
3.6 O -
% O -
) O +
and O +
PBO O +
+ O +
Li O -
/ O -
DVP O +
( O -
4.9 O -
% O -
) O -
. O +

Lithium O +
was O +
associated O +
with O +
a O +
significantly O +
higher O +
incidence O +
( O -
p O +
< O +
0.05 O -
) O +
of O +
tremor B-Disease +
( O -
18.4 O -
% O -
) O +
than O +
quetiapine O +
( O -
5.6 O -
% O -
) O -
; O +
cerebellar O +
tremor B-Disease -
, O +
which O +
is O +
a O +
known O +
adverse O +
effect O +
of O +
lithium O -
, O +
may O +
have O +
contributed O +
to O +
the O +
elevated O +
rate O +
of O +
tremor B-Disease +
in O +
patients O +
receiving O +
lithium O +
therapy O -
. O +

Haloperidol O +
induced O +
a O +
significantly O +
higher O +
incidence O +
( O -
p O +
< O +
0.001 O -
) O +
of O +
akathisia B-Disease +
( O -
33.3 O -
% O +
versus O +
5.9 O -
% O -
) O -
, O +
tremor B-Disease +
( O -
30.3 O -
% O +
versus O +
7.8 O -
% O -
) O -
, O +
and O +
extrapyramidal B-Disease +
syndrome I-Disease +
( O -
35.4 O -
% O +
versus O +
5.9 O -
% O -
) O +
than O +
quetiapine O -
. O +

No O +
significant O +
differences O +
were O +
observed O +
between O +
quetiapine O +
and O +
placebo O +
on O +
SAS O +
and O +
BARS O +
scores O -
. O +

Anticholinergic O +
use O +
was O +
low O +
and O +
similar O +
with O +
quetiapine O +
or O +
placebo O -
. O +

CONCLUSIONS O -
: O +
In O +
bipolar B-Disease +
mania I-Disease -
, O +
the O +
incidence O +
of O +
EPS B-Disease -
, O +
including O +
akathisia B-Disease -
, O +
with O +
quetiapine O +
therapy O +
is O +
similar O +
to O +
that O +
with O +
placebo O -
. O +

Anti O -
- O -
oxidant O +
effects O +
of O +
atorvastatin O +
in O +
dexamethasone O -
- O -
induced O +
hypertension B-Disease +
in O +
the O +
rat O -
. O +

1 O -
. O +

Dexamethasone O +
( O -
Dex O -
) O -
-induced O +
hypertension B-Disease +
is O +
characterized O +
by O +
endothelial O +
dysfunction O +
associated O +
with O +
nitric O +
oxide O +
( O -
NO O -
) O +
deficiency O +
and O +
increased O +
superoxide O +
( O -
O2- O -
) O +
production O -
. O +

Atorvastatin O +
( O -
Ato O -
) O +
possesses O +
pleiotropic O +
properties O +
that O +
have O +
been O +
reported O +
to O +
improve O +
endothelial O +
function O +
through O +
increased O +
availability O +
of O +
NO O +
and O +
reduced O +
O2- O +
production O +
in O +
various O +
forms O +
of O +
hypertension B-Disease -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
whether O +
50 O +
mg O -
/ O -
kg O +
per O +
day O -
, O +
p.o O -
. O -
, O +
Ato O +
could O +
prevent O +
endothelial O +
NO O +
synthase O +
( O -
eNOS O -
) O +
downregulation O +
and O +
the O +
increase O +
in O +
O2- O +
in O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O -
, O +
thereby O +
reducing O +
blood O +
pressure O -
. O +

2 O -
. O +

Male O +
SD O +
rats O +
( O -
n O +
= O +
30 O -
) O +
were O +
treated O +
with O +
Ato O +
( O -
50 O +
mg O -
/ O -
kg O +
per O +
day O +
in O +
drinking O +
water O -
) O +
or O +
tap O +
water O +
for O +
15 O +
days O -
. O +

Dexamethasone O +
( O -
10 O +
microg O -
/ O -
kg O +
per O +
day O -
, O +
s.c O -
. O -
) O +
or O +
saline O +
was O +
started O +
after O +
4 O +
days O +
in O +
Ato O -
- O -
treated O +
and O +
non O -
- O -
treated O +
rats O +
and O +
continued O +
for O +
11 O -
- O -
13 O +
days O -
. O +

Systolic O +
blood O +
pressure O +
( O -
SBP O -
) O +
was O +
measured O +
on O +
alternate O +
days O +
using O +
the O +
tail O -
- O -
cuff O +
method O -
. O +

Endothelial O +
function O +
was O +
assessed O +
by O +
acetylcholine O -
- O -
induced O +
vasorelaxation O +
and O +
phenylephrine O -
- O -
induced O +
vasoconstriction O +
in O +
aortic O +
segments O -
. O +

Vascular O +
eNOS O +
mRNA O +
was O +
assessed O +
by O +
semi O -
- O -
quantitative O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O -
. O +

3 O -
. O +

In O +
rats O +
treated O +
with O +
Dex O +
alone O -
, O +
SBP O +
was O +
increased O +
from O +
109 O +
+ O -
/- O +

2 O +
to O +
133 O +
+ O -
/- O +

2 O +
mmHg O +
on O +
Days O +
4 O +
and O +
Day O +
14 O -
, O +
respectively O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

In O +
the O +
Ato O +
+ O +
Dex O +
group O -
, O +
SBP O +
was O +
increased O +
from O +
113 O +
+ O -
/- O +

2 O +
to O +
119 O +
+ O -
/- O +

2 O +
mmHg O +
on O +
Days O +
4 O +
to O +
14 O -
, O +
respectively O +
( O -
P O +
< O +
0.001 O -
) O -
, O +
but O +
was O +
significantly O +
lower O +
than O +
SBP O +
in O +
the O +
group O +
treated O +
with O +
Dex O +
alone O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

Endothelial O -
- O -
dependent O +
relaxation O +
and O +
eNOS O +
mRNA O +
expression O +
were O +
greater O +
in O +
the O +
Dex O +
+ O +
Ato O +
group O +
than O +
in O +
the O +
Dex O +
only O +
group O +
( O -
P O +
< O +
0.05 O +
and O +
P O +
< O +
0.0001 O -
, O +
respectively O -
) O -
. O +

Aortic O +
superoxide O +
production O +
was O +
lower O +
in O +
the O +
Dex O +
+ O +
Ato O +
group O +
compared O +
with O +
the O +
group O +
treated O +
with O +
Dex O +
alone O +
( O -
P O +
< O +
0.0001 O -
) O -
. O +

4 O -
. O +

Treatment O +
with O +
Ato O +
improved O +
endothelial O +
function O -
, O +
reduced O +
superoxide O +
production O +
and O +
reduced O +
SBP O +
in O +
Dex O -
- O -
treated O +
SD O +
rats O -
. O +

Valproate O -
- O -
induced O +
chorea B-Disease +
and O +
encephalopathy B-Disease +
in O +
atypical O +
nonketotic B-Disease +
hyperglycinemia I-Disease -
. O +

Nonketotic B-Disease +
hyperglycinemia I-Disease +
is O +
a O +
disorder B-Disease +
of I-Disease +
amino I-Disease +
acid I-Disease +
metabolism I-Disease +
in O +
which O +
a O +
defect O +
in O +
the O +
glycine O +
cleavage O +
system O +
leads O +
to O +
an O +
accumulation O +
of O +
glycine O +
in O +
the O +
brain O +
and O +
other O +
body O +
compartments O -
. O +

In O +
the O +
classical O +
form O +
it O +
presents O +
as O +
neonatal O +
apnea B-Disease -
, O +
intractable O +
seizures B-Disease -
, O +
and O +
hypotonia B-Disease -
, O +
followed O +
by O +
significant O +
psychomotor B-Disease +
retardation I-Disease -
. O +

An O +
important O +
subset O +
of O +
children O +
with O +
nonketotic B-Disease +
hyperglycinemia I-Disease +
are O +
atypical O +
variants O +
who O +
present O +
in O +
a O +
heterogeneous O +
manner O -
. O +

This O +
report O +
describes O +
a O +
patient O +
with O +
mild O +
language B-Disease +
delay I-Disease +
and O +
mental B-Disease +
retardation I-Disease -
, O +
who O +
was O +
found O +
to O +
have O +
nonketotic B-Disease +
hyperglycinemia I-Disease +
following O +
her O +
presentation O +
with O +
acute O +
encephalopathy B-Disease +
and O +
chorea B-Disease +
shortly O +
after O +
initiation O +
of O +
valproate O +
therapy O -
. O +

Severe O +
citrate O +
toxicity B-Disease +
complicating O +
volunteer O +
apheresis O +
platelet O +
donation O -
. O +

We O +
report O +
a O +
case O +
of O +
severe O +
citrate O +
toxicity B-Disease +
during O +
volunteer O +
donor O +
apheresis O +
platelet O +
collection O -
. O +

The O +
donor O +
was O +
a O +
40-year O -
- O -
old O +
female O -
, O +
first O -
- O -
time O +
apheresis O +
platelet O +
donor O -
. O +

Past O +
medical O +
history O +
was O +
remarkable O +
for O +
hypertension B-Disease -
, O +
hyperlipidemia B-Disease -
, O +
and O +
depression B-Disease -
. O +

Reported O +
medications O +
included O +
bumetanide O -
, O +
pravastatin O -
, O +
and O +
paroxetine O -
. O +

Thirty O +
minutes O +
from O +
the O +
start O +
of O +
the O +
procedure O -
, O +
the O +
donor O +
noted O +
tingling O +
around O +
the O +
mouth O -
, O +
hands O -
, O +
and O +
feet O -
. O +

She O +
then O +
very O +
rapidly O +
developed O +
acute O +
onset O +
of O +
severe O +
facial O +
and O +
extremity O +
tetany B-Disease -
. O +

Empirical O +
treatment O +
with O +
intravenous O +
calcium O +
gluconate O +
was O +
initiated O -
, O +
and O +
muscle B-Disease +
contractions I-Disease +
slowly O +
subsided O +
over O +
approximately O +
10 O +
to O +
15 O +
minutes O -
. O +

The O +
events O +
are O +
consistent O +
with O +
a O +
severe O +
reaction O +
to O +
calcium O +
chelation O +
by O +
sodium O +
citrate O +
anticoagulant O +
resulting O +
in O +
symptomatic O +
systemic O +
hypocalcemia B-Disease -
. O +

Upon O +
additional O +
retrospective O +
analysis O -
, O +
it O +
was O +
noted O +
that O +
bumetanide O +
is O +
a O +
loop O +
diuretic O +
that O +
may O +
cause O +
significant O +
hypocalcemia B-Disease -
. O +

We O +
conclude O +
that O +
careful O +
screening O +
for O +
medications O +
and O +
underlying O +
conditions O +
predisposing O +
to O +
hypocalcemia B-Disease +
is O +
recommended O +
to O +
help O +
prevent O +
severe O +
reactions O +
due O +
to O +
citrate O +
toxicity B-Disease -
. O +

Laboratory O +
measurement O +
of O +
pre O -
- O -
procedure O +
serum O +
calcium O +
levels O +
in O +
selected O +
donors O +
may O +
identify O +
cases O +
requiring O +
heightened O +
vigilance O -
. O +

The O +
case O +
also O +
illustrates O +
the O +
importance O +
of O +
maintaining O +
preparedness O +
for O +
managing O +
rare O +
but O +
serious O +
reactions O +
in O +
volunteer O +
apheresis O +
blood O +
donors O -
. O +

Sirolimus O -
- O -
associated O +
proteinuria B-Disease +
and O +
renal B-Disease +
dysfunction I-Disease -
. O +

Sirolimus O +
is O +
a O +
novel O +
immunosuppressant O +
with O +
potent O +
antiproliferative O +
actions O +
through O +
its O +
ability O +
to O +
inhibit O +
the O +
raptor O -
- O -
containing O +
mammalian O +
target O +
of O +
rapamycin O +
protein O +
kinase O -
. O +

Sirolimus O +
represents O +
a O +
major O +
therapeutic O +
advance O +
in O +
the O +
prevention O +
of O +
acute O +
renal O +
allograft O +
rejection O +
and O +
chronic O +
allograft O +
nephropathy B-Disease -
. O +

Its O +
role O +
in O +
the O +
therapy O +
of O +
glomerulonephritis B-Disease -
, O +
autoimmunity B-Disease -
, O +
cystic B-Disease +
renal I-Disease +
diseases I-Disease +
and O +
renal B-Disease +
cancer I-Disease +
is O +
under O +
investigation O -
. O +

Because O +
sirolimus O +
does O +
not O +
share O +
the O +
vasomotor O +
renal O +
adverse O +
effects O +
exhibited O +
by O +
calcineurin O +
inhibitors O -
, O +
it O +
has O +
been O +
designated O +
a O +
' O -
non O -
- O -
nephrotoxic B-Disease +
drug O -
' O -
. O +

However O -
, O +
clinical O +
reports O +
suggest O +
that O -
, O +
under O +
some O +
circumstances O -
, O +
sirolimus O +
is O +
associated O +
with O +
proteinuria B-Disease +
and O +
acute B-Disease +
renal I-Disease +
dysfunction I-Disease -
. O +

A O +
common O +
risk O +
factor O +
appears O +
to O +
be O +
presence O +
of O +
pre O -
- O -
existing O +
chronic B-Disease +
renal I-Disease +
damage I-Disease -
. O +

The O +
mechanisms O +
of O +
sirolimus O -
- O -
associated O +
proteinuria B-Disease +
are O +
multifactorial O +
and O +
may O +
be O +
due O +
to O +
an O +
increase O +
in O +
glomerular O +
capillary O +
pressure O +
following O +
calcineurin O +
inhibitor O +
withdrawal O -
. O +

It O +
has O +
also O +
been O +
suggested O +
that O +
sirolimus O +
directly O +
causes O +
increased O +
glomerular O +
permeability O -
/ O -
injury O -
, O +
but O +
evidence O +
for O +
this O +
mechanism O +
is O +
currently O +
inconclusive O -
. O +

The O +
acute B-Disease +
renal I-Disease +
dysfunction I-Disease +
associated O +
with O +
sirolimus O +
( O -
such O +
as O +
in O +
delayed O +
graft O +
function O -
) O +
may O +
be O +
due O +
to O +
suppression O +
of O +
compensatory O +
renal O +
cell O +
proliferation O +
and O +
survival O -
/ O -
repair O +
processes O -
. O +

Although O +
these O +
adverse O +
effects O +
occur O +
in O +
some O +
patients O -
, O +
their O +
occurrence O +
could O +
be O +
minimised O +
by O +
knowledge O +
of O +
the O +
molecular O +
effects O +
of O +
sirolimus O +
on O +
the O +
kidney O -
, O +
the O +
use O +
of O +
sirolimus O +
in O +
appropriate O +
patient O +
populations O -
, O +
close O +
monitoring O +
of O +
proteinuria B-Disease +
and O +
renal O +
function O -
, O +
use O +
of O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
or O +
angiotensin O +
II O +
receptor O +
blockers O +
if O +
proteinuria B-Disease +
occurs O +
and O +
withdrawal O +
if O +
needed O -
. O +

Further O +
long O -
- O -
term O +
analysis O +
of O +
renal O +
allograft O +
studies O +
using O +
sirolimus O +
as O +
de O +
novo O +
immunosuppression O +
along O +
with O +
clinical O +
and O +
laboratory O +
studies O +
will O +
refine O +
these O +
issues O +
in O +
the O +
future O -
. O +

Proteinuria B-Disease +
after O +
conversion O +
to O +
sirolimus O +
in O +
renal O +
transplant O +
recipients O -
. O +

Sirolimus O +
( O -
SRL O -
) O +
is O +
a O +
new O -
, O +
potent O +
immunosuppressive O +
agent O -
. O +

More O +
recently O -
, O +
proteinuria B-Disease +
has O +
been O +
reported O +
as O +
a O +
consequence O +
of O +
sirolimus O +
therapy O -
, O +
although O +
the O +
mechanism O +
has O +
remained O +
unclear O -
. O +

We O +
retrospectively O +
examined O +
the O +
records O +
of O +
25 O +
renal O +
transplant O +
patients O -
, O +
who O +
developed O +
or O +
displayed O +
increased O +
proteinuria B-Disease +
after O +
SRL O +
conversion O -
. O +

The O +
patient O +
cohort O +
( O -
14 O +
men O -
, O +
11 O +
women O -
) O +
was O +
treated O +
with O +
SRL O +
as O +
conversion O +
therapy O -
, O +
due O +
to O +
chronic B-Disease +
allograft I-Disease +
nephropathy I-Disease +
( O -
CAN B-Disease -
) O +
( O -
n O +
= O +
15 O -
) O +
neoplasia B-Disease +
( O -
n O +
= O +
8) O -
; O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease -
, O +
Four O +
skin B-Disease +
cancers I-Disease -
, O +
One O +
intestinal B-Disease +
tumors I-Disease -
, O +
One O +
renal B-Disease +
cell I-Disease +
carsinom I-Disease -
) O +
or O +
BK O +
virus O +
nephropathy B-Disease +
( O -
n O +
= O +
2 O -
) O -
. O +

SRL O +
was O +
started O +
at O +
a O +
mean O +
of O +
78 O +
+ O -
/- O +

42 O +
( O -
15 O +
to O +
163 O -
) O +
months O +
after O +
transplantation O -
. O +

Mean O +
follow O -
- O -
up O +
on O +
SRL O +
therapy O +
was O +
20 O +
+ O -
/- O +

12 O +
( O -
6 O +
to O +
43 O -
) O +
months O -
. O +

Proteinuria B-Disease +
increased O +
from O +
0.445 O +
( O -
0 O +
to O +
1.5 O -
) O +
g O -
/ O -
d O +
before O +
conversion O +
to O +
3.2 O +
g O -
/ O -
dL O +
( O -
0.2 O +
to O +
12 O -
) O +
after O +
conversion O +
( O -
P O +
= O +
0.001 O -
) O -
. O +

Before O +
conversion O +
8 O +
( O -
32 O -
% O -
) O +
patients O +
had O +
no O +
proteinuria B-Disease -
, O +
whereas O +
afterwards O +
all O +
patients O +
had O +
proteinuria B-Disease -
. O +

In O +
28 O -
% O +
of O +
patients O +
proteinuria B-Disease +
remained O +
unchanged O -
, O +
whereas O +
it O +
increased O +
in O +
68 O -
% O +
of O +
patients O -
. O +

In O +
40 O -
% O +
it O +
increased O +
by O +
more O +
than O +
100 O -
% O -
. O +

Twenty O -
- O -
eight O +
percent O +
of O +
patients O +
showed O +
increased O +
proteinuria B-Disease +
to O +
the O +
nephrotic B-Disease +
range O -
. O +

Biopsies O +
performed O +
in O +
five O +
patients O +
revealed O +
new O +
pathological O +
changes O -
: O +
One O +
membranoproliferative B-Disease +
glomerulopathy I-Disease +
and O +
interstitial B-Disease +
nephritis I-Disease -
. O +

These O +
patients O +
showed O +
persistently O +
good O +
graft O +
function O -
. O +

Serum O +
creatinine O +
values O +
did O +
not O +
change O +
significantly O -
: O +
1.98 O +
+ O -
/- O +

0.8 O +
mg O -
/ O -
dL O +
before O +
SRL O +
therapy O +
and O +
2.53 O +
+ O -
/- O +

1.9 O +
mg O -
/ O -
dL O +
at O +
last O +
follow O -
- O -
up O +
( O -
P O +
= O +
.14 O -
) O -
. O +

Five O +
grafts O +
were O +
lost O +
and O +
the O +
patients O +
returned O +
to O +
dialysis O -
. O +

Five O +
patients O +
displayed O +
CAN B-Disease +
and O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease -
. O +

Mean O +
urinary O +
protein O +
of O +
patients O +
who O +
returned O +
to O +
dialysis O +
was O +
1.26 O +
( O -
0.5 O +
to O +
3.5 O -
) O +
g O -
/ O -
d O +
before O +
and O +
4.7 O +
( O -
3 O +
to O +
12 O -
) O +
g O -
/ O -
d O +
after O +
conversion O +
( O -
P O +
= O +
.01 O -
) O -
. O +

Mean O +
serum O +
creatinine O +
level O +
before O +
conversion O +
was O +
2.21 O +
mg O -
/ O -
dL O +
and O +
thereafter O -
, O +
4.93 O +
mg O -
/ O -
dL O +
( O -
P O +
= O +
.02 O -
) O -
. O +

Heavy O +
proteinuria B-Disease +
was O +
common O +
after O +
the O +
use O +
of O +
SRL O +
as O +
rescue O +
therapy O +
for O +
renal O +
transplantation O -
. O +

Therefore O -
, O +
conversion O +
should O +
be O +
considered O +
for O +
patients O +
who O +
have O +
not O +
developed O +
advanced O +
CAN B-Disease +
and O +
proteinuria B-Disease -
. O +

The O +
possibility O +
of O +
de O +
novo O +
glomerular O +
pathology O +
under O +
SRL O +
treatment O +
requires O +
further O +
investigation O +
by O +
renal O +
biopsy O -
. O +

Behavioral O +
effects O +
of O +
pubertal O +
anabolic O +
androgenic O +
steroid O +
exposure O +
in O +
male O +
rats O +
with O +
low O +
serotonin O -
. O +

The O +
goal O +
of O +
this O +
study O +
was O +
to O +
assess O +
the O +
interactive O +
effects O +
of O +
chronic O +
anabolic O +
androgenic O +
steroid O +
( O -
AAS O -
) O +
exposure O +
and O +
brain O +
serotonin O +
( O -
5-hydroxytryptamine O -
, O +
5-HT O -
) O +
depletion O +
on O +
behavior O +
of O +
pubertal O +
male O +
rats O -
. O +

Serotonin O +
was O +
depleted O +
beginning O +
on O +
postnatal O +
day O +
26 O +
with O +
parachlorophenylalanine O +
( O -
PCPA O +
100 O +
mg O -
/ O -
kg O -
, O +
every O +
other O +
day O -
) O -
; O +
controls O +
received O +
saline O -
. O +

At O +
puberty O +
( O -
P40 O -
) O -
, O +
half O +
the O +
PCPA O -
- O -
treated O +
rats O +
and O +
half O +
the O +
saline O -
- O -
treated O +
rats O +
began O +
treatment O +
with O +
testosterone O +
( O -
T O -
, O +
5 O +
mg O -
/ O -
kg O -
, O +
5 O +
days O -
/ O -
week O -
) O -
. O +

Behavioral O +
measures O +
included O +
locomotion O -
, O +
irritability B-Disease -
, O +
copulation O -
, O +
partner O +
preference O -
, O +
and O +
aggression B-Disease -
. O +

Animals O +
were O +
tested O +
for O +
aggression B-Disease +
in O +
their O +
home O +
cage O -
, O +
both O +
with O +
and O +
without O +
physical O +
provocation O +
( O -
mild O +
tail O +
pinch O -
) O -
. O +

Brain O +
levels O +
of O +
5-HT O +
and O +
its O +
metabolite O -
, O +
5-hydroxyindoleacetic O +
acid O +
( O -
5-HIAA O -
) O -
, O +
were O +
determined O +
using O +
HPLC O -
. O +

PCPA O +
significantly O +
and O +
substantially O +
depleted O +
5-HT O +
and O +
5-HIAA O +
in O +
all O +
brain O +
regions O +
examined O -
. O +

Chronic O +
T O +
treatment O +
significantly O +
decreased O +
5-HT O +
and O +
5-HIAA O +
in O +
certain O +
brain O +
areas O -
, O +
but O +
to O +
a O +
much O +
lesser O +
extent O +
than O +
PCPA O -
. O +

Chronic O +
exposure O +
to O +
PCPA O +
alone O +
significantly O +
decreased O +
locomotor O +
activity O +
and O +
increased O +
irritability B-Disease +
but O +
had O +
no O +
effect O +
on O +
sexual O +
behavior O -
, O +
partner O +
preference O -
, O +
or O +
aggression B-Disease -
. O +

T O +
alone O +
had O +
no O +
effect O +
on O +
locomotion O -
, O +
irritability B-Disease -
, O +
or O +
sexual O +
behavior O +
but O +
increased O +
partner O +
preference O +
and O +
aggression B-Disease -
. O +

The O +
most O +
striking O +
effect O +
of O +
combining O +
T+PCPA O +
was O +
a O +
significant O +
increase O +
in O +
attack O +
frequency O +
as O +
well O +
as O +
a O +
significant O +
decrease O +
in O +
the O +
latency O +
to O +
attack O -
, O +
particularly O +
following O +
physical O +
provocation O -
. O +

Based O +
on O +
these O +
data O -
, O +
it O +
can O +
be O +
speculated O +
that O +
pubertal O +
AAS O +
users O +
with O +
low O +
central O +
5-HT O +
may O +
be O +
especially O +
prone O +
to O +
exhibit O +
aggressive B-Disease +
behavior I-Disease -
. O +

Long O -
- O -
term O +
follow O -
- O -
up O +
of O +
ifosfamide O +
renal B-Disease +
toxicity I-Disease +
in O +
children O +
treated O +
for O +
malignant B-Disease +
mesenchymal I-Disease +
tumors I-Disease -
: O +
an O +
International O +
Society O +
of O +
Pediatric O +
Oncology O +
report O -
. O +

The O +
renal O +
function O +
of O +
74 O +
children O +
with O +
malignant B-Disease +
mesenchymal I-Disease +
tumors I-Disease +
in O +
complete O +
remission O +
and O +
who O +
have O +
received O +
the O +
same O +
ifosfamide O +
chemotherapy O +
protocol O +
( O -
International O +
Society O +
of O +
Pediatric O +
Oncology O +
Malignant B-Disease +
Mesenchymal I-Disease +
Tumor I-Disease +
Study O +
84 O +
[ O -
SIOP O +
MMT O +
84 O -
] O -
) O +
were O +
studied O +
1 O +
year O +
after O +
the O +
completion O +
of O +
treatment O -
. O +

Total O +
cumulative O +
doses O +
were O +
36 O +
or O +
60 O +
g O -
/ O -
m2 O +
of O +
ifosfamide O +
( O -
six O +
or O +
10 O +
cycles O +
of O +
ifosfamide O -
, O +
vincristine O -
, O +
and O +
dactinomycin O +
[ O -
IVA O -
] O -
) O -
. O +

None O +
of O +
them O +
had O +
received O +
cisplatin O +
chemotherapy O -
. O +

Ages O +
ranged O +
from O +
4 O +
months O +
to O +
17 O +
years O -
; O +
58 O +
patients O +
were O +
males O +
and O +
42 O +
females O -
. O +

The O +
most O +
common O +
primary O +
tumor B-Disease +
site O +
was O +
the O +
head O +
and O +
neck O -
. O +

Renal O +
function O +
was O +
investigated O +
by O +
measuring O +
plasma O +
and O +
urinary O +
electrolytes O -
, O +
glucosuria B-Disease -
, O +
proteinuria B-Disease -
, O +
aminoaciduria B-Disease -
, O +
urinary O +
pH O -
, O +
osmolarity O -
, O +
creatinine O +
clearance O -
, O +
phosphate O +
tubular O +
reabsorption O -
, O +
beta O +
2 O +
microglobulinuria O -
, O +
and O +
lysozymuria O -
. O +

Fifty O -
- O -
eight O +
patients O +
( O -
78 O -
% O -
) O +
had O +
normal O +
renal O +
tests O -
, O +
whereas O +
16 O +
patients O +
( O -
22 O -
% O -
) O +
had O +
renal B-Disease +
abnormalities I-Disease -
. O +

Two O +
subsets O +
of O +
patients O +
were O +
identified O +
from O +
this O +
latter O +
group O -
: O +
the O +
first O +
included O +
four O +
patients O +
( O -
5 O -
% O +
of O +
the O +
total O +
population O -
) O +
who O +
developed O +
major O +
toxicity B-Disease +
resulting O +
in O +
Fanconi B-Disease -
's I-Disease +
syndrome I-Disease +
( O -
TDFS B-Disease -
) O -
; O +
and O +
the O +
second O +
group O +
included O +
five O +
patients O +
with O +
elevated O +
beta O +
2 O +
microglobulinuria O +
and O +
low O +
phosphate O +
reabsorption O -
. O +

The O +
remaining O +
seven O +
patients O +
had O +
isolated O +
beta O +
2 O +
microglobulinuria O -
. O +

Severe O +
toxicity B-Disease +
was O +
correlated O +
with O +
the O +
higher O +
cumulative O +
dose O +
of O +
60 O +
g O -
/ O -
m2 O +
of O +
ifosfamide O -
, O +
a O +
younger O +
age O +
( O -
less O +
than O +
2 O +
1 O -
/ O -
2 O +
years O +
old O -
) O -
, O +
and O +
a O +
predominance O +
of O +
vesicoprostatic O +
tumor B-Disease +
involvement O -
. O +

This O +
low O +
percentage O +
( O -
5 O -
% O -
) O +
of O +
TDFS O +
must O +
be O +
evaluated O +
with O +
respect O +
to O +
the O +
efficacy O +
of O +
ifosfamide O +
in O +
the O +
treatment O +
of O +
mesenchymal B-Disease +
tumors I-Disease +
in O +
children O -
. O +

Effects O +
of O +
UMB24 O +
and O +
( O -
+ O -
/- O -
) O -
-SM O +
21 O -
, O +
putative O +
sigma2-preferring O +
antagonists O -
, O +
on O +
behavioral O +
toxic O +
and O +
stimulant O +
effects O +
of O +
cocaine O +
in O +
mice O -
. O +

Earlier O +
studies O +
have O +
demonstrated O +
that O +
antagonism O +
of O +
sigma1 O +
receptors O +
attenuates O +
the O +
convulsive B-Disease -
, O +
lethal O -
, O +
locomotor O +
stimulatory O +
and O +
rewarding O +
actions O +
of O +
cocaine O +
in O +
mice O -
. O +

In O +
contrast O -
, O +
the O +
contribution O +
of O +
sigma2 O +
receptors O +
is O +
unclear O +
because O +
experimental O +
tools O +
to O +
selectively O +
target O +
this O +
subtype O +
are O +
unavailable O -
. O +

To O +
begin O +
addressing O +
this O +
need O -
, O +
we O +
characterized O +
UMB24 O +
( O -
1- O -
( O -
2-phenethyl O -
) O -
-4- O -
( O -
2-pyridyl O -
) O -
-piperazine O -
) O +
and O +
( O -
+ O -
/- O -
) O -
-SM O +
21 O +
( O -
3alpha O -
- O -
tropanyl-2- O -
( O -
4-chorophenoxy O -
) O -
butyrate O -
) O +
in O +
receptor O +
binding O +
and O +
behavioral O +
studies O -
. O +

Receptor O +
binding O +
studies O +
confirmed O +
that O +
UMB24 O +
and O +
( O -
+ O -
/- O -
) O -
-SM O +
21 O +
display O +
preferential O +
affinity O +
for O +
sigma2 O +
over O +
sigma1 O +
receptors O -
. O +

In O +
behavioral O +
studies O -
, O +
pretreatment O +
of O +
Swiss O +
Webster O +
mice O +
with O +
UMB24 O +
or O +
( O -
+ O -
/- O -
) O -
-SM O +
21 O +
significantly O +
attenuated O +
cocaine O -
- O -
induced O +
convulsions B-Disease +
and O +
locomotor O +
activity O -
, O +
but O +
not O +
lethality O -
. O +

When O +
administered O +
alone O -
, O +
( O -
+ O -
/- O -
) O -
-SM O +
21 O +
produced O +
no O +
significant O +
effects O +
compared O +
to O +
control O +
injections O +
of O +
saline O -
, O +
but O +
UMB24 O +
had O +
locomotor O +
depressant O +
actions O -
. O +

Together O -
, O +
the O +
data O +
suggest O +
that O +
sigma2 O +
receptor O +
antagonists O +
have O +
the O +
potential O +
to O +
attenuate O +
some O +
of O +
the O +
behavioral O +
effects O +
of O +
cocaine O -
, O +
and O +
further O +
development O +
of O +
more O +
selective O -
, O +
high O +
affinity O +
ligands O +
are O +
warranted O -
. O +

Progressive O +
myopathy B-Disease +
with O +
up O -
- O -
regulation O +
of O +
MHC O -
- O -
I O +
associated O +
with O +
statin O +
therapy O -
. O +

Statins O +
can O +
cause O +
a O +
necrotizing O +
myopathy B-Disease +
and O +
hyperCKaemia B-Disease +
which O +
is O +
reversible O +
on O +
cessation O +
of O +
the O +
drug O -
. O +

What O +
is O +
less O +
well O +
known O +
is O +
a O +
phenomenon O +
whereby O +
statins O +
may O +
induce O +
a O +
myopathy B-Disease -
, O +
which O +
persists O +
or O +
may O +
progress O +
after O +
stopping O +
the O +
drug O -
. O +

We O +
investigated O +
the O +
muscle O +
pathology O +
in O +
8 O +
such O +
cases O -
. O +

All O +
had O +
myofibre O +
necrosis B-Disease +
but O +
only O +
3 O +
had O +
an O +
inflammatory O +
infiltrate O -
. O +

In O +
all O +
cases O +
there O +
was O +
diffuse O +
or O +
multifocal O +
up O -
- O -
regulation O +
of O +
MHC O -
- O -
I O +
expression O +
even O +
in O +
non O -
- O -
necrotic B-Disease +
fibres O -
. O +

Progressive O +
improvement O +
occurred O +
in O +
7 O +
cases O +
after O +
commencement O +
of O +
prednisolone O +
and O +
methotrexate O -
, O +
and O +
in O +
one O +
case O +
spontaneously O -
. O +

These O +
observations O +
suggest O +
that O +
statins O +
may O +
initiate O +
an O +
immune O -
- O -
mediated O +
myopathy B-Disease +
that O +
persists O +
after O +
withdrawal O +
of O +
the O +
drug O +
and O +
responds O +
to O +
immunosuppressive O +
therapy O -
. O +

The O +
mechanism O +
of O +
this O +
myopathy B-Disease +
is O +
uncertain O +
but O +
may O +
involve O +
the O +
induction O +
by O +
statins O +
of O +
an O +
endoplasmic O +
reticulum O +
stress O +
response O +
with O +
associated O +
up O -
- O -
regulation O +
of O +
MHC O -
- O -
I O +
expression O +
and O +
antigen O +
presentation O +
by O +
muscle O +
fibres O -
. O +

Use O +
of O +
chromosome O +
substitution O +
strains O +
to O +
identify O +
seizure B-Disease +
susceptibility O +
loci O +
in O +
mice O -
. O +

Seizure B-Disease +
susceptibility O +
varies O +
among O +
inbred O +
mouse O +
strains O -
. O +

Chromosome O +
substitution O +
strains O +
( O -
CSS O -
) O -
, O +
in O +
which O +
a O +
single O +
chromosome O +
from O +
one O +
inbred O +
strain O +
( O -
donor O -
) O +
has O +
been O +
transferred O +
onto O +
a O +
second O +
strain O +
( O -
host O -
) O +
by O +
repeated O +
backcrossing O -
, O +
may O +
be O +
used O +
to O +
identify O +
quantitative O +
trait O +
loci O +
( O -
QTLs O -
) O +
that O +
contribute O +
to O +
seizure B-Disease +
susceptibility O -
. O +

QTLs O +
for O +
susceptibility O +
to O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
, O +
a O +
model O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
, O +
have O +
not O +
been O +
reported O -
, O +
and O +
CSS O +
have O +
not O +
previously O +
been O +
used O +
to O +
localize O +
seizure B-Disease +
susceptibility O +
genes O -
. O +

We O +
report O +
QTLs O +
identified O +
using O +
a O +
B6 O +
( O -
host O -
) O +
x O +
A O -
/ O -
J O +
( O -
donor O -
) O +
CSS O +
panel O +
to O +
localize O +
genes O +
involved O +
in O +
susceptibility O +
to O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
. O +

Three O +
hundred O +
fifty O -
- O -
five O +
adult O +
male O +
CSS O +
mice O -
, O +
58 O +
B6 O -
, O +
and O +
39 O +
A O -
/ O -
J O +
were O +
tested O +
for O +
susceptibility O +
to O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
. O +

Highest O +
stage O +
reached O +
and O +
latency O +
to O +
each O +
stage O +
were O +
recorded O +
for O +
all O +
mice O -
. O +

B6 O +
mice O +
were O +
resistant O +
to O +
seizures B-Disease +
and O +
slower O +
to O +
reach O +
stages O +
compared O +
to O +
A O -
/ O -
J O +
mice O -
. O +

The O +
CSS O +
for O +
Chromosomes O +
10 O +
and O +
18 O +
progressed O +
to O +
the O +
most O +
severe O +
stages O -
, O +
diverging O +
dramatically O +
from O +
the O +
B6 O +
phenotype O -
. O +

Latencies O +
to O +
stages O +
were O +
also O +
significantly O +
shorter O +
for O +
CSS10 O +
and O +
CSS18 O +
mice O -
. O +

CSS O +
mapping O +
suggests O +
seizure B-Disease +
susceptibility O +
loci O +
on O +
mouse O +
Chromosomes O +
10 O +
and O +
18 O -
. O +

This O +
approach O +
provides O +
a O +
framework O +
for O +
identifying O +
potentially O +
novel O +
homologous O +
candidate O +
genes O +
for O +
human O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
. O +

In O +
vitro O +
characterization O +
of O +
parasympathetic O +
and O +
sympathetic O +
responses O +
in O +
cyclophosphamide O -
- O -
induced O +
cystitis B-Disease +
in O +
the O +
rat O -
. O +

In O +
cyclophosphamide O -
- O -
induced O +
cystitis B-Disease +
in O +
the O +
rat O -
, O +
detrusor O +
function O +
is O +
impaired O +
and O +
the O +
expression O +
and O +
effects O +
of O +
muscarinic O +
receptors O +
altered O -
. O +

Whether O +
or O +
not O +
the O +
neuronal O +
transmission O +
may O +
be O +
affected O +
by O +
cystitis B-Disease +
was O +
presently O +
investigated O -
. O +

Responses O +
of O +
urinary O +
strip O +
preparations O +
from O +
control O +
and O +
cyclophosphamide O -
- O -
pretreated O +
rats O +
to O +
electrical O +
field O +
stimulation O +
and O +
to O +
agonists O +
were O +
assessed O +
in O +
the O +
absence O +
and O +
presence O +
of O +
muscarinic O -
, O +
adrenergic O +
and O +
purinergic O +
receptor O +
antagonists O -
. O +

Generally O -
, O +
atropine O +
reduced O +
contractions O -
, O +
but O +
in O +
contrast O +
to O +
controls O -
, O +
it O +
also O +
reduced O +
responses O +
to O +
low O +
electrical O +
field O +
stimulation O +
intensity O +
( O -
1 O -
- O -
5 O +
Hz O -
) O +
in O +
inflamed O +
preparations O -
. O +

In O +
both O +
types O -
, O +
purinoceptor O +
desensitization O +
with O +
alpha O -
, O -
beta O -
- O -
methylene O +
adenosine-5'-triphosphate O +
( O -
alpha O -
, O -
beta O -
- O -
meATP O -
) O +
caused O +
further O +
reductions O +
at O +
low O +
frequencies O +
( O -
< O -
10 O +
Hz O -
) O -
. O +

The O +
muscarinic O +
receptor O +
antagonists O +
atropine O -
, O +
4-diphenylacetoxy O -
- O -
N O -
- O -
methylpiperidine O +
( O -
4-DAMP O -
) O +
( O -
' O -
M O -
( O -
1 O -
) O -
/ O -
M O -
( O -
3 O -
) O -
/ O -
M O -
( O -
5 O -
) O -
-selective O -
' O -
) O -
, O +
methoctramine O +
( O -
' O -
M O -
( O -
2 O -
) O -
-selective O -
' O -
) O +
and O +
pirenzepine O +
( O -
' O -
M O -
( O -
1 O -
) O -
-selective O -
' O -
) O +
antagonized O +
the O +
tonic O +
component O +
of O +
the O +
electrical O +
field O +
stimulation O -
- O -
evoked O +
contractile O +
response O +
more O +
potently O +
than O +
the O +
phasic O +
component O -
. O +

4-DAMP O +
inhibited O +
the O +
tonic O +
contractions O +
in O +
controls O +
more O +
potently O +
than O +
methoctramine O +
and O +
pirenzepine O -
. O +

In O +
inflamed O +
preparations O -
, O +
the O +
muscarinic O +
receptor O +
antagonism O +
on O +
the O +
phasic O +
component O +
of O +
the O +
electrical O +
field O +
stimulation O -
- O -
evoked O +
contraction O +
was O +
decreased O +
and O +
the O +
pirenzepine O +
and O +
4-DAMP O +
antagonism O +
on O +
the O +
tonic O +
component O +
was O +
much O +
less O +
efficient O +
than O +
in O +
controls O -
. O +

In O +
contrast O +
to O +
controls O -
, O +
methoctramine O +
increased O +
-- O +
instead O +
of O +
decreased O +
-- O +
the O +
tonic O +
responses O +
at O +
high O +
frequencies O -
. O +

While O +
contractions O +
to O +
carbachol O +
and O +
ATP O +
were O +
the O +
same O +
in O +
inflamed O +
and O +
in O +
control O +
strips O +
when O +
related O +
to O +
a O +
reference O +
potassium O +
response O -
, O +
isoprenaline O -
- O -
induced O +
relaxations O +
were O +
smaller O +
in O +
inflamed O +
strips O -
. O +

Thus O -
, O +
in O +
cystitis B-Disease +
substantial O +
changes O +
of O +
the O +
efferent O +
functional O +
responses O +
occur O -
. O +

While O +
postjunctional O +
beta O -
- O -
adrenoceptor O -
- O -
mediated O +
relaxations O +
are O +
reduced O -
, O +
effects O +
by O +
prejunctional O +
inhibitory O +
muscarinic O +
receptors O +
may O +
be O +
increased O -
. O +

Direct O +
inhibition O +
of O +
cardiac O +
hyperpolarization O -
- O -
activated O +
cyclic O +
nucleotide O -
- O -
gated O +
pacemaker O +
channels O +
by O +
clonidine O -
. O +

BACKGROUND O -
: O +
Inhibition O +
of O +
cardiac O +
sympathetic O +
tone O +
represents O +
an O +
important O +
strategy O +
for O +
treatment O +
of O +
cardiovascular B-Disease +
disease I-Disease -
, O +
including O +
arrhythmia B-Disease -
, O +
coronary B-Disease +
heart I-Disease +
disease I-Disease -
, O +
and O +
chronic O +
heart B-Disease +
failure I-Disease -
. O +

Activation O +
of O +
presynaptic O +
alpha2-adrenoceptors O +
is O +
the O +
most O +
widely O +
accepted O +
mechanism O +
of O +
action O +
of O +
the O +
antisympathetic O +
drug O +
clonidine O -
; O +
however O -
, O +
other O +
target O +
proteins O +
have O +
been O +
postulated O +
to O +
contribute O +
to O +
the O +
in O +
vivo O +
actions O +
of O +
clonidine O -
. O +

METHODS O +
AND O +
RESULTS O -
: O +
To O +
test O +
whether O +
clonidine O +
elicits O +
pharmacological O +
effects O +
independent O +
of O +
alpha2-adrenoceptors O -
, O +
we O +
have O +
generated O +
mice O +
with O +
a O +
targeted O +
deletion O +
of O +
all O +
3 O +
alpha2-adrenoceptor O +
subtypes O +
( O -
alpha2ABC- O -
/ O -
- O -
) O -
. O +

Alpha2ABC- O -
/ O -
- O +
mice O +
were O +
completely O +
unresponsive O +
to O +
the O +
analgesic O +
and O +
hypnotic O +
effects O +
of O +
clonidine O -
; O +
however O -
, O +
clonidine O +
significantly O +
lowered O +
heart O +
rate O +
in O +
alpha2ABC- O -
/ O -
- O +
mice O +
by O +
up O +
to O +
150 O +
bpm O -
. O +

Clonidine O -
- O -
induced O +
bradycardia B-Disease +
in O +
conscious O +
alpha2ABC- O -
/ O -
- O +
mice O +
was O +
32.3 O -
% O +
( O -
10 O +
microg O -
/ O -
kg O -
) O +
and O +
26.6 O -
% O +
( O -
100 O +
microg O -
/ O -
kg O -
) O +
of O +
the O +
effect O +
in O +
wild O -
- O -
type O +
mice O -
. O +

A O +
similar O +
bradycardic O +
effect O +
of O +
clonidine O +
was O +
observed O +
in O +
isolated O +
spontaneously O +
beating O +
right O +
atria O +
from O +
alpha2ABC O -
- O -
knockout O +
and O +
wild O -
- O -
type O +
mice O -
. O +

Clonidine O +
inhibited O +
the O +
native O +
pacemaker O +
current O +
( O -
I O -
( O -
f O -
) O -
) O +
in O +
isolated O +
sinoatrial O +
node O +
pacemaker O +
cells O +
and O +
the O +
I O -
( O -
f O -
) O -
-generating O +
hyperpolarization O -
- O -
activated O +
cyclic O +
nucleotide O -
- O -
gated O +
( O -
HCN O -
) O +
2 O +
and O +
HCN4 O +
channels O +
in O +
transfected O +
HEK293 O +
cells O -
. O +

As O +
a O +
consequence O +
of O +
blocking O +
I O -
( O -
f O -
) O -
, O +
clonidine O +
reduced O +
the O +
slope O +
of O +
the O +
diastolic O +
depolarization O +
and O +
the O +
frequency O +
of O +
pacemaker O +
potentials O +
in O +
sinoatrial O +
node O +
cells O +
from O +
wild O -
- O -
type O +
and O +
alpha2ABC O -
- O -
knockout O +
mice O -
. O +

CONCLUSIONS O -
: O +
Direct O +
inhibition O +
of O +
cardiac O +
HCN O +
pacemaker O +
channels O +
contributes O +
to O +
the O +
bradycardic O +
effects O +
of O +
clonidine O +
gene O -
- O -
targeted O +
mice O +
in O +
vivo O -
, O +
and O +
thus O -
, O +
clonidine O -
- O -
like O +
drugs O +
represent O +
novel O +
structures O +
for O +
future O +
HCN O +
channel O +
inhibitors O -
. O +

Cardiac B-Disease +
arrest I-Disease +
in O +
a O +
child O +
with O +
cerebral B-Disease +
palsy I-Disease +
undergoing O +
sevoflurane O +
induction O +
of O +
anesthesia O +
after O +
preoperative O +
clonidine O -
. O +

Clonidine O +
is O +
a O +
frequently O +
administered O +
alpha2-adrenergic O +
agonist O +
which O +
can O +
decrease O +
heart O +
rate O +
and O +
blood O +
pressure O -
. O +

We O +
present O +
a O +
case O +
of O +
a O +
5-year O -
- O -
old O +
child O +
with O +
cerebral B-Disease +
palsy I-Disease +
and O +
seizure B-Disease +
disorder I-Disease -
, O +
receiving O +
clonidine O +
for O +
restlessness B-Disease -
, O +
who O +
presented O +
for O +
placement O +
of O +
a O +
baclofen O +
pump O -
. O +

Without O +
the O +
knowledge O +
of O +
the O +
medical O +
personnel O -
, O +
the O +
patient O -
's O +
mother O +
administered O +
three O +
doses O +
of O +
clonidine O +
during O +
the O +
evening O +
before O +
and O +
morning O +
of O +
surgery O +
to O +
reduce O +
anxiety B-Disease -
. O +

During O +
induction O +
of O +
anesthesia O -
, O +
the O +
patient O +
developed O +
bradycardia B-Disease +
and O +
hypotension B-Disease +
requiring O +
cardiac O +
resuscitation O -
. O +

There O +
are O +
no O +
previous O +
reports O +
of O +
clonidine O -
- O -
associated O +
cardiac B-Disease +
arrest I-Disease +
in O +
a O +
child O +
undergoing O +
induction O +
of O +
anesthesia O -
. O +

Angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitor O -
- O -
associated O +
angioedema B-Disease +
of O +
the O +
stomach O +
and O +
small O +
intestine O -
: O +
a O +
case O +
report O -
. O +

This O +
is O +
a O +
case O +
report O +
on O +
a O +
45-year O +
old O +
African O -
- O -
American O +
female O +
with O +
newly O +
diagnosed O +
hypertension B-Disease -
, O +
who O +
was O +
started O +
on O +
a O +
combination O +
pill O +
of O +
amlodipine O -
/ O -
benazapril O +
10 O -
/ O -
5 O +
mg O -
. O +

The O +
very O +
next O +
day O -
, O +
she O +
presented O +
at O +
the O +
emergency O +
room O +
( O -
ER O -
) O +
with O +
abdominal B-Disease +
pain I-Disease -
, O +
nausea B-Disease +
and O +
vomiting B-Disease -
. O +

Physical O +
exam O -
, O +
complete O +
metabolic O +
panel O -
, O +
and O +
hemogram O +
were O +
in O +
the O +
normal O +
range O -
. O +

She O +
was O +
discharged O +
from O +
the O +
ER O +
after O +
a O +
few O +
hours O +
of O +
treatment O +
with O +
fluid O +
and O +
analgesics O -
. O +

However O -
, O +
she O +
returned O +
to O +
the O +
ER O +
the O +
next O +
day O +
with O +
the O +
same O +
complaints O -
. O +

This O +
time O +
the O +
physical O +
exam O +
was O +
significant O +
for O +
a O +
distended O +
abdomen O +
with O +
dullness O +
to O +
percussion O -
. O +

CT O +
scan O +
of O +
the O +
abdomen O +
revealed O +
markedly O +
thickened O +
antrum O +
of O +
the O +
stomach O -
, O +
duodenum O +
and O +
jejunum O -
, O +
along O +
with O +
fluid O +
in O +
the O +
abdominal O +
and O +
pelvic O +
cavity O -
. O +

Angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
( O -
ACEI O -
) O -
-induced O +
angioedema B-Disease +
was O +
suspected O -
, O +
and O +
anti O -
- O -
hypertensive B-Disease +
medications O +
were O +
discontinued O -
. O +

Her O +
symptoms O +
improved O +
within O +
the O +
next O +
24 O +
hours O -
, O +
and O +
repeat O +
CT O +
after O +
72 O +
hours O +
revealed O +
marked O +
improvement O +
in O +
stomach O +
and O +
small O +
bowel O +
thickening O +
and O +
resolution O +
of O +
ascites B-Disease -
. O +

The O +
recognition O +
of O +
angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
and O +
angiotensin O +
receptor O +
blocker O +
( O -
ARB O -
) O +
intestinal B-Disease +
angioedema B-Disease +
constitutes O +
a O +
challenge O +
to O +
primary O +
care O +
physicians O -
, O +
internists O -
, O +
emergency O +
room O +
personal O +
and O +
surgeons O -
. O +

Granulomatous B-Disease +
hepatitis B-Disease +
due O +
to O +
combination O +
of O +
amoxicillin O +
and O +
clavulanic O +
acid O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
patient O +
with O +
amoxicillin O -
- O -
clavulanic O +
acid O -
- O -
induced O +
hepatitis B-Disease +
with O +
histologic O +
multiple O +
granulomas B-Disease -
. O +

This O +
type O +
of O +
lesion O +
broadens O +
the O +
spectrum O +
of O +
liver B-Disease +
injury I-Disease +
due O +
to O +
this O +
drug O +
combination O -
, O +
mainly O +
represented O +
by O +
a O +
benign O +
cholestatic B-Disease +
syndrome I-Disease -
. O +

The O +
association O +
of O +
granulomas B-Disease +
and O +
eosinophilia B-Disease +
favor O +
an O +
immunoallergic O +
mechanism O -
. O +

As O +
penicillin O +
derivatives O +
and O +
amoxicillin O +
alone O +
are O +
known O +
to O +
induce O +
such O +
types O +
of O +
lesions O -
, O +
the O +
amoxicillin O +
component O -
, O +
with O +
or O +
without O +
a O +
potentiating O +
effect O +
of O +
clavulanic O +
acid O -
, O +
might O +
have O +
a O +
major O +
role O -
. O +

Carbamazepine O -
- O -
induced O +
cardiac B-Disease +
dysfunction I-Disease -
. O +

Characterization O +
of O +
two O +
distinct O +
clinical O +
syndromes O -
. O +

A O +
patient O +
with O +
sinus O +
bradycardia B-Disease +
and O +
atrioventricular B-Disease +
block I-Disease -
, O +
induced O +
by O +
carbamazepine O -
, O +
prompted O +
an O +
extensive O +
literature O +
review O +
of O +
all O +
previously O +
reported O +
cases O -
. O +

From O +
the O +
analysis O +
of O +
these O +
cases O -
, O +
two O +
distinct O +
forms O +
of O +
carbamazepine O -
- O -
associated O +
cardiac B-Disease +
dysfunction I-Disease +
emerged O -
. O +

One O +
patient O +
group O +
developed O +
sinus B-Disease +
tachycardias I-Disease +
in O +
the O +
setting O +
of O +
a O +
massive O +
carbamazepine O +
overdose B-Disease -
. O +

The O +
second O +
group O +
consisted O +
almost O +
exclusively O +
of O +
elderly O +
women O +
who O +
developed O +
potentially O +
life O -
- O -
threatening O +
bradyarrhythmias B-Disease +
or O +
atrioventricular B-Disease +
conduction I-Disease +
delay I-Disease -
, O +
associated O +
with O +
either O +
therapeutic O +
or O +
modestly O +
elevated O +
carbamazepine O +
serum O +
levels O -
. O +

Because O +
carbamazepine O +
is O +
widely O +
used O +
in O +
the O +
treatment O +
of O +
many O +
neurologic O +
and O +
psychiatric B-Disease +
conditions O -
, O +
the O +
recognition O +
of O +
the O +
latter O +
syndrome O +
has O +
important O +
implications O +
for O +
the O +
use O +
of O +
this O +
drug O +
in O +
elderly O +
patients O -
. O +

Dobutamine O +
stress O +
echocardiography O -
: O +
a O +
sensitive O +
indicator O +
of O +
diminished O +
myocardial O +
function O +
in O +
asymptomatic O +
doxorubicin O -
- O -
treated O +
long O -
- O -
term O +
survivors O +
of O +
childhood O +
cancer B-Disease -
. O +

Doxorubicin O +
is O +
an O +
effective O +
anticancer O +
chemotherapeutic O +
agent O +
known O +
to O +
cause O +
acute O +
and O +
chronic O +
cardiomyopathy B-Disease -
. O +

To O +
develop O +
a O +
more O +
sensitive O +
echocardiographic O +
screening O +
test O +
for O +
cardiac B-Disease +
damage I-Disease +
due O +
to O +
doxorubicin O -
, O +
a O +
cohort O +
study O +
was O +
performed O +
using O +
dobutamine O +
infusion O +
to O +
differentiate O +
asymptomatic O +
long O -
- O -
term O +
survivors O +
of O +
childhood O +
cancer B-Disease +
treated O +
with O +
doxorubicin O +
from O +
healthy O +
control O +
subjects O -
. O +

Echocardiographic O +
data O +
from O +
the O +
experimental O +
group O +
of O +
21 O +
patients O +
( O -
mean O +
age O +
16 O +
+ O -
/- O +

5 O +
years O -
) O +
treated O +
from O +
1.6 O +
to O +
14.3 O +
years O +
( O -
median O +
5.3 O -
) O +
before O +
this O +
study O +
with O +
27 O +
to O +
532 O +
mg O -
/ O -
m2 O +
of O +
doxorubicin O +
( O -
mean O +
196 O -
) O +
were O +
compared O +
with O +
echocardiographic O +
data O +
from O +
12 O +
normal O +
age O -
- O -
matched O +
control O +
subjects O -
. O +

Graded O +
dobutamine O +
infusions O +
of O +
0.5 O -
, O +
2.5 O -
, O +
5 O +
and O +
10 O +
micrograms O -
/ O -
kg O +
per O +
min O +
were O +
administered O -
. O +

Echocardiographic O +
Doppler O +
studies O +
were O +
performed O +
before O +
infusion O +
and O +
after O +
15 O +
min O +
of O +
infusion O +
at O +
each O +
rate O -
. O +

Dobutamine O +
infusion O +
at O +
10 O +
micrograms O -
/ O -
kg O +
per O +
min O +
was O +
discontinued O +
after O +
six O +
studies O +
secondary O +
to O +
a O +
50 O -
% O +
incidence O +
rate O +
of O +
adverse O +
symptoms O -
. O +

The O +
most O +
important O +
findings O +
were O +
that O +
compared O +
with O +
values O +
in O +
control O +
subjects O -
, O +
end O -
- O -
systolic O +
left O +
ventricular O +
posterior O +
wall O +
dimension O +
and O +
percent O +
of O +
left O +
ventricular O +
posterior O +
wall O +
thickening O +
in O +
doxorubicin O -
- O -
treated O +
patients O +
were O +
decreased O +
at O +
baseline O +
study O +
and O +
these O +
findings O +
were O +
more O +
clearly O +
delineated O +
with O +
dobutamine O +
stimulation O -
. O +

End O -
- O -
systolic O +
left O +
ventricular O +
posterior O +
wall O +
dimension O +
at O +
baseline O +
for O +
the O +
doxorubicin O -
- O -
treated O +
group O +
was O +
11 O +
+ O -
/- O +

1.9 O +
mm O +
versus O +
13.1 O +
+ O -
/- O +

1.5 O +
mm O +
for O +
control O +
subjects O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
. O +

End O -
- O -
systolic O +
left O +
ventricular O +
posterior O +
wall O +
dimension O +
at O +
the O +
5-micrograms O -
/ O -
kg O +
per O +
min O +
dobutamine O +
infusion O +
for O +
the O +
doxorubicin O -
- O -
treated O +
group O +
was O +
14.1 O +
+ O -
/- O +

2.4 O +
mm O +
versus O +
19.3 O +
+ O -
/- O +

2.6 O +
mm O +
for O +
control O +
subjects O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Detection O +
of O +
abnormal O +
cardiac O +
adrenergic O +
neuron O +
activity O +
in O +
adriamycin O -
- O -
induced O +
cardiomyopathy B-Disease +
with O +
iodine-125-metaiodobenzylguanidine O -
. O +

Radiolabeled O +
metaiodobenzylguanidine O +
( O -
MIBG O -
) O -
, O +
an O +
analog O +
of O +
norepinephrine O +
( O -
NE O -
) O -
, O +
serves O +
as O +
an O +
index O +
of O +
adrenergic O +
neuron O +
integrity O +
and O +
function O -
. O +

Using O +
a O +
rat O +
model O +
of O +
adriamycin O -
- O -
induced O +
cardiomyopathy B-Disease -
, O +
we O +
tested O +
the O +
hypothesis O +
that O +
abnormal O +
cardiac O +
adrenergic O +
neuron O +
activity O +
may O +
appear O +
and O +
be O +
exacerbated O +
dose O -
- O -
dependently O +
in O +
adriamycin O +
cardiomyopathy B-Disease -
. O +

The O +
degree O +
of O +
vacuolar B-Disease +
degeneration I-Disease +
of I-Disease +
myocardial I-Disease +
cells I-Disease +
was O +
analyzed O +
in O +
relation O +
to O +
the O +
duration O +
of O +
adriamycin O +
treatment O +
( O -
2 O +
mg O -
/ O -
kg O -
, O +
once O +
a O +
week O -
) O -
. O +

There O +
were O +
no O +
abnormalities O +
or O +
only O +
isolated O +
degeneration O +
in O +
the O +
1- O +
or O +
2-wk O +
treatment O +
groups O -
, O +
isolated O +
or O +
scattered O +
degeneration O +
in O +
half O +
of O +
the O +
3-wk O +
group O -
, O +
frequent O +
scattered O +
degeneration O +
in O +
the O +
4-wk O +
group O -
, O +
scattered O +
or O +
focal O +
degeneration O +
in O +
the O +
5-wk O +
group O -
, O +
and O +
extensive O +
degeneration O +
in O +
the O +
8-wk O +
group O -
. O +

Myocardial O +
accumulation O +
of O +
[ O -
125I O -
] O -
MIBG O +
4 O +
hr O +
after O +
intravenous O +
injection O +
did O +
not O +
differ O +
between O +
the O +
controls O +
and O +
the O +
groups O +
treated O +
3 O +
wk O +
or O +
less O -
. O +

However O -
, O +
the O +
4-wk O +
group O +
had O +
a O +
slightly O +
lower O +
accumulation O +
in O +
the O +
right O +
ventricular O +
wall O +
( O -
82 O -
% O +
of O +
the O +
control O -
) O +
and O +
significantly O +
lower O +
accumulation O +
in O +
the O +
left O +
ventricular O +
wall O +
( O -
about O +
66 O -
% O +
of O +
the O +
control O -
: O +
p O +
less O +
than O +
0.05 O -
) O -
. O +

In O +
the O +
5-wk O +
group O -
, O +
MIBG O +
accumulation O +
in O +
the O +
right O +
and O +
left O +
ventricular O +
wall O +
was O +
35 O -
% O +
and O +
27 O -
% O +
of O +
that O +
in O +
controls O -
, O +
respectively O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O +

In O +
the O +
8-wk O +
group O -
, O +
MIBG O +
accumulation O +
in O +
the O +
right O +
and O +
left O +
ventricular O +
wall O +
was O +
18 O -
% O +
and O +
14 O -
% O +
of O +
that O +
in O +
controls O -
, O +
respectively O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O +

Thus O -
, O +
MIBG O +
accumulation O +
in O +
the O +
myocardium O +
decreased O +
in O +
an O +
adriamycin O +
dose O -
- O -
dependent O +
manner O -
. O +

The O +
appearance O +
of O +
impaired O +
cardiac O +
adrenergic O +
neuron O +
activity O +
in O +
the O +
presence O +
of O +
slight O +
myocardial B-Disease +
impairment I-Disease +
( O -
scattered O +
or O +
focal O +
vacuolar B-Disease +
degeneration I-Disease -
) O +
indicates O +
that O +
MIBG O +
scintigraphy O +
may O +
be O +
a O +
useful O +
method O +
for O +
detection O +
of O +
adriamycin O -
- O -
induced O +
cardiomyopathy B-Disease -
. O +

Influence O +
of O +
smoking O +
on O +
developing O +
cochlea O -
. O +

Does O +
smoking O +
during O +
pregnancy O +
affect O +
the O +
amplitudes O +
of O +
transient O +
evoked O +
otoacoustic O +
emissions O +
in O +
newborns O -
? O +

OBJECTIVE O -
: O +
Maternal O +
tobacco O +
smoking O +
has O +
negative O +
effects O +
on O +
fetal O +
growth O -
. O +

The O +
influence O +
of O +
smoking O +
during O +
pregnancy O +
on O +
the O +
developing O +
cochlea O +
has O +
not O +
been O +
estimated O -
, O +
although O +
smoking O +
has O +
been O +
positively O +
associated O +
with O +
hearing B-Disease +
loss I-Disease +
in O +
adults O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
effects O +
of O +
maternal O +
smoking O +
on O +
transient O +
evoked O +
otoacoustic O +
emissions O +
( O -
TEOAEs O -
) O +
of O +
healthy O +
neonates O -
. O +

METHODS O -
: O +
This O +
study O +
was O +
undertaken O +
as O +
part O +
of O +
neonatal O +
screening O +
for O +
hearing B-Disease +
impairment I-Disease +
and O +
involved O +
both O +
ears O +
of O +
200 O +
newborns O -
. O +

Newborns O +
whose O +
mothers O +
reported O +
smoking O +
during O +
pregnancy O +
( O -
n=200 O +
ears O -
) O +
were O +
compared O +
to O +
a O +
control O +
group O +
of O +
newborns O +
( O -
n=200 O +
ears O -
) O -
, O +
whose O +
mothers O +
were O +
non O -
- O -
smokers O -
. O +

Exposure O +
to O +
tobacco O +
was O +
characterized O +
as O +
low O +
( O -
< O -
5 O +
cigarettes O +
per O +
day O -
, O +
n=88 O +
ears O -
) O -
, O +
moderate O +
( O -
5 O -
< O +
or O +
= O -
cigarettes O +
per O +
day<10 O -
, O +
n=76 O -
) O +
or O +
high O +
( O -
> O +
or O +
= O -
10 O +
cigarettes O +
per O +
day O -
, O +
n=36 O -
) O -
. O +

RESULTS O -
: O +
In O +
exposed O +
neonates O -
, O +
TEOAEs O +
mean O +
response O +
( O -
across O +
frequency O -
) O +
and O +
mean O +
amplitude O +
at O +
4000Hz O +
was O +
significantly O +
lower O +
than O +
in O +
non O -
- O -
exposed O +
neonates O -
. O +

Comparisons O +
between O +
exposed O +
newborns O -
' O +
subgroups O +
revealed O +
no O +
significant O +
differences O -
. O +

However O -
, O +
by O +
comparing O +
each O +
subgroup O +
to O +
control O +
group O -
, O +
we O +
found O +
statistically O +
significant O +
decreases B-Disease +
of I-Disease +
TEOAEs I-Disease +
amplitudes I-Disease +
at O +
4000Hz O +
for O +
all O +
three O +
groups O -
. O +

Mean O +
TEOAEs O +
responses O +
of O +
highly O +
exposed O +
newborns O +
were O +
also O +
significantly O +
lower O +
in O +
comparison O +
to O +
our O +
control O +
group O -
. O +

CONCLUSION O -
: O +
In O +
utero O -
, O +
exposure O +
to O +
tobacco O +
smoking O +
seems O +
to O +
have O +
a O +
small O +
impact O +
on O +
outer O +
hair O +
cells O -
. O +

These O +
effects O +
seem O +
to O +
be O +
equally O +
true O +
for O +
all O +
exposed O +
newborns O -
, O +
regardless O +
of O +
the O +
degree O +
of O +
exposure O -
. O +

Further O +
studies O +
are O +
needed O +
in O +
order O +
to O +
establish O +
a O +
potential O +
negative O +
effect O +
of O +
maternal O +
smoking O +
on O +
the O +
neonate O -
's O +
hearing O +
acuity O -
. O +

Syncope B-Disease +
and O +
QT B-Disease +
prolongation I-Disease +
among O +
patients O +
treated O +
with O +
methadone O +
for O +
heroin O +
dependence O +
in O +
the O +
city O +
of O +
Copenhagen O -
. O +

BACKGROUND O -
: O +
Methadone O +
is O +
prescribed O +
to O +
heroin O +
addicts O +
to O +
decrease O +
illicit O +
opioid O +
use O -
. O +

Prolongation O +
of O +
the O +
QT O +
interval O +
in O +
the O +
ECG O +
of O +
patients O +
with O +
torsade B-Disease +
de I-Disease +
pointes I-Disease +
( O -
TdP B-Disease -
) O +
has O +
been O +
reported O +
in O +
methadone O +
users O -
. O +

As O +
heroin O +
addicts O +
sometimes O +
faint O +
while O +
using O +
illicit O +
drugs O -
, O +
doctors O +
might O +
attribute O +
too O +
many O +
episodes O +
of O +
syncope B-Disease +
to O +
illicit O +
drug O +
use O +
and O +
thereby O +
underestimate O +
the O +
incidence O +
of O +
TdP B-Disease +
in O +
this O +
special O +
population O -
, O +
and O +
the O +
high O +
mortality O +
in O +
this O +
population O +
may O -
, O +
in O +
part O -
, O +
be O +
caused O +
by O +
the O +
proarrhythmic O +
effect O +
of O +
methadone O -
. O +

METHODS O -
: O +
In O +
this O +
cross O -
- O -
sectional O +
study O +
interview O -
, O +
ECGs O +
and O +
blood O +
samples O +
were O +
collected O +
in O +
a O +
population O +
of O +
adult O +
heroin O +
addicts O +
treated O +
with O +
methadone O +
or O +
buprenorphine O +
on O +
a O +
daily O +
basis O -
. O +

Of O +
the O +
patients O +
at O +
the O +
Drug O +
Addiction O +
Service O +
in O +
the O +
municipal O +
of O +
Copenhagen O -
, O +
450 O +
( O -
approximately O +
52 O -
% O -
) O +
were O +
included O -
. O +

The O +
QT O +
interval O +
was O +
estimated O +
from O +
12 O +
lead O +
ECGs O -
. O +

All O +
participants O +
were O +
interviewed O +
about O +
any O +
experience O +
of O +
syncope B-Disease -
. O +

The O +
association O +
between O +
opioid O +
dose O +
and O +
QT O -
, O +
and O +
methadone O +
dose O +
and O +
reporting O +
of O +
syncope B-Disease +
was O +
assessed O +
using O +
multivariate O +
linear O +
regression O +
and O +
logistic O +
regression O -
, O +
respectively O -
. O +

RESULTS O -
: O +
Methadone O +
dose O +
was O +
associated O +
with O +
longer O +
QT O +
interval O +
of O +
0.140 O +
ms O -
/ O -
mg O +
( O -
p O +
= O +
0.002 O -
) O -
. O +

No O +
association O +
between O +
buprenorphine O +
and O +
QTc O +
was O +
found O -
. O +

Among O +
the O +
subjects O +
treated O +
with O +
methadone O -
, O +
28 O -
% O +
men O +
and O +
32 O -
% O +
women O +
had O +
prolonged B-Disease +
QTc I-Disease +
interval I-Disease -
. O +

None O +
of O +
the O +
subjects O +
treated O +
with O +
buprenorphine O +
had O +
QTc O +
interval O +
> O -
0.440 O +
s O -
( O -
( O -
1 O -
/ O -
2 O -
) O -
) O -
. O +

A O +
50 O +
mg O +
higher O +
methadone O +
dose O +
was O +
associated O +
with O +
a O +
1.2 O +
( O -
95 O -
% O +
CI O +
1.1 O +
to O +
1.4 O -
) O +
times O +
higher O +
odds O +
for O +
syncope B-Disease -
. O +

CONCLUSIONS O -
: O +
Methadone O +
is O +
associated O +
with O +
QT B-Disease +
prolongation I-Disease +
and O +
higher O +
reporting O +
of O +
syncope B-Disease +
in O +
a O +
population O +
of O +
heroin O +
addicts O -
. O +

Simvastatin O -
- O -
induced O +
bilateral O +
leg O +
compartment B-Disease +
syndrome I-Disease +
and O +
myonecrosis B-Disease +
associated O +
with O +
hypothyroidism B-Disease -
. O +

A O +
54-year O -
- O -
old O +
hypothyroid B-Disease +
male O +
taking O +
thyroxine O +
and O +
simvastatin O +
presented O +
with O +
bilateral O +
leg O +
compartment B-Disease +
syndrome I-Disease +
and O +
myonecrosis B-Disease -
. O +

Urgent O +
fasciotomies O +
were O +
performed O +
and O +
the O +
patient O +
made O +
an O +
uneventful O +
recovery O +
with O +
the O +
withdrawal O +
of O +
simvastatin O -
. O +

It O +
is O +
likely O +
that O +
this O +
complication O +
will O +
be O +
seen O +
more O +
often O +
with O +
the O +
increased O +
worldwide O +
use O +
of O +
this O +
drug O +
and O +
its O +
approval O +
for O +
all O +
arteriopathic B-Disease +
patients O -
. O +

Neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
induced O +
by O +
ziprasidone O +
on O +
the O +
second O +
day O +
of O +
treatment O -
. O +

Neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
( O -
NMS B-Disease -
) O +
is O +
the O +
rarest O +
and O +
most O +
serious O +
of O +
the O +
neuroleptic O -
- O -
induced O +
movement B-Disease +
disorders I-Disease -
. O +

We O +
describe O +
a O +
case O +
of O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
( O -
NMS B-Disease -
) O +
associated O +
with O +
the O +
use O +
of O +
ziprasidone O -
. O +

Although O +
conventional O +
neuroleptics O +
are O +
more O +
frequently O +
associated O +
with O +
NMS B-Disease -
, O +
atypical O +
antipsychotic O +
drugs O +
like O +
ziprasidone O +
may O +
also O +
be O +
a O +
cause O -
. O +

The O +
patient O +
is O +
a O +
24-year O -
- O -
old O +
male O +
with O +
a O +
history O +
of O +
schizophrenia B-Disease +
who O +
developed O +
signs O +
and O +
symptoms O +
of O +
NMS B-Disease +
after O +
2 O +
days O +
of O +
treatment O +
with O +
an O +
80-mg O -
/ O -
day O +
dose O +
of O +
orally O +
administrated O +
ziprasidone O -
. O +

This O +
case O +
is O +
the O +
earliest O +
( O -
second O +
day O +
of O +
treatment O -
) O +
NMS B-Disease +
due O +
to O +
ziprasidone O +
reported O +
in O +
the O +
literature O -
. O +

Neuroinflammation B-Disease +
and O +
behavioral B-Disease +
abnormalities I-Disease +
after O +
neonatal O +
terbutaline O +
treatment O +
in O +
rats O -
: O +
implications O +
for O +
autism B-Disease -
. O +

Autism B-Disease +
is O +
a O +
neurodevelopmental B-Disease +
disorder I-Disease +
presenting O +
before O +
3 O +
years O +
of O +
age O +
with O +
deficits B-Disease +
in I-Disease +
communication I-Disease +
and I-Disease +
social I-Disease +
skills I-Disease +
and O +
repetitive B-Disease +
behaviors I-Disease -
. O +

In O +
addition O +
to O +
genetic O +
influences O -
, O +
recent O +
studies O +
suggest O +
that O +
prenatal O +
drug O +
or O +
chemical O +
exposures O +
are O +
risk O +
factors O +
for O +
autism B-Disease -
. O +

Terbutaline O -
, O +
a O +
beta2-adrenoceptor O +
agonist O +
used O +
to O +
arrest O +
preterm B-Disease +
labor I-Disease -
, O +
has O +
been O +
associated O +
with O +
increased O +
concordance O +
for O +
autism B-Disease +
in O +
dizygotic O +
twins O -
. O +

We O +
studied O +
the O +
effects O +
of O +
terbutaline O +
on O +
microglial O +
activation O +
in O +
different O +
brain O +
regions O +
and O +
behavioral O +
outcomes O +
in O +
developing O +
rats O -
. O +

Newborn O +
rats O +
were O +
given O +
terbutaline O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
daily O +
on O +
postnatal O +
days O +
( O -
PN O -
) O +
2 O +
to O +
5 O +
or O +
PN O +
11 O +
to O +
14 O +
and O +
examined O +
24 O +
h O +
after O +
the O +
last O +
dose O +
and O +
at O +
PN O +
30 O -
. O +

Immunohistochemical O +
studies O +
showed O +
that O +
administration O +
of O +
terbutaline O +
on O +
PN O +
2 O +
to O +
5 O +
produced O +
a O +
robust O +
increase O +
in O +
microglial O +
activation O +
on O +
PN O +
30 O +
in O +
the O +
cerebral O +
cortex O -
, O +
as O +
well O +
as O +
in O +
cerebellar O +
and O +
cerebrocortical O +
white O +
matter O -
. O +

None O +
of O +
these O +
effects O +
occurred O +
in O +
animals O +
given O +
terbutaline O +
on O +
PN O +
11 O +
to O +
14 O -
. O +

In O +
behavioral O +
tests O -
, O +
animals O +
treated O +
with O +
terbutaline O +
on O +
PN O +
2 O +
to O +
5 O +
showed O +
consistent O +
patterns O +
of O +
hyper O -
- O -
reactivity O +
to O +
novelty O +
and O +
aversive O +
stimuli O +
when O +
assessed O +
in O +
a O +
novel O +
open O +
field O -
, O +
as O +
well O +
as O +
in O +
the O +
acoustic O +
startle O +
response O +
test O -
. O +

Our O +
findings O +
indicate O +
that O +
beta2-adrenoceptor O +
overstimulation O +
during O +
an O +
early O +
critical O +
period O +
results O +
in O +
microglial O +
activation O +
associated O +
with O +
innate O +
neuroinflammatory O +
pathways O +
and O +
behavioral B-Disease +
abnormalities I-Disease -
, O +
similar O +
to O +
those O +
described O +
in O +
autism B-Disease -
. O +

This O +
study O +
provides O +
a O +
useful O +
animal O +
model O +
for O +
understanding O +
the O +
neuropathological O +
processes O +
underlying O +
autism B-Disease +
spectrum I-Disease +
disorders I-Disease -
. O +

Upregulation O +
of O +
brain O +
expression O +
of O +
P O -
- O -
glycoprotein O +
in O +
MRP2-deficient O +
TR O -
( O -
- O -
) O +
rats O +
resembles O +
seizure B-Disease -
- O -
induced O +
up O -
- O -
regulation O +
of O +
this O +
drug O +
efflux O +
transporter O +
in O +
normal O +
rats O -
. O +

PURPOSE O -
: O +
The O +
multidrug O +
resistance O +
protein O +
2 O +
( O -
MRP2 O -
) O +
is O +
a O +
drug O +
efflux O +
transporter O +
that O +
is O +
expressed O +
predominantly O +
at O +
the O +
apical O +
domain O +
of O +
hepatocytes O +
but O +
seems O +
also O +
to O +
be O +
expressed O +
at O +
the O +
apical O +
membrane O +
of O +
brain O +
capillary O +
endothelial O +
cells O +
that O +
form O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O -
. O +

MRP2 O +
is O +
absent O +
in O +
the O +
transport O -
- O -
deficient O +
( O -
TR O -
( O -
- O -
) O -
) O +

Wistar O +
rat O +
mutant O -
, O +
so O +
that O +
this O +
rat O +
strain O +
was O +
very O +
helpful O +
in O +
defining O +
substrates O +
of O +
MRP2 O +
by O +
comparing O +
tissue O +
concentrations O +
or O +
functional O +
activities O +
of O +
compounds O +
in O +
MRP2-deficient O +
rats O +
with O +
those O +
in O +
transport O -
- O -
competent O +
Wistar O +
rats O -
. O +

By O +
using O +
this O +
strategy O +
to O +
study O +
the O +
involvement O +
of O +
MRP2 O +
in O +
brain O +
access O +
of O +
antiepileptic O +
drugs O +
( O -
AEDs O -
) O -
, O +
we O +
recently O +
reported O +
that O +
phenytoin O +
is O +
a O +
substrate O +
for O +
MRP2 O +
in O +
the O +
BBB O -
. O +

However O -
, O +
one O +
drawback O +
of O +
such O +
studies O +
in O +
genetically O +
deficient O +
rats O +
is O +
the O +
fact O +
that O +
compensatory O +
changes O +
with O +
upregulation O +
of O +
other O +
transporters O +
can O +
occur O -
. O +

This O +
prompted O +
us O +
to O +
study O +
the O +
brain O +
expression O +
of O +
P O -
- O -
glycoprotein O +
( O -
Pgp O -
) O -
, O +
a O +
major O +
drug O +
efflux O +
transporter O +
in O +
many O +
tissues O -
, O +
including O +
the O +
BBB O -
, O +
in O +
TR O -
( O -
- O -
) O +
rats O +
compared O +
with O +
nonmutant O +
( O -
wild O -
- O -
type O -
) O +
Wistar O +
rats O -
. O +

METHODS O -
: O +
The O +
expression O +
of O +
MRP2 O +
and O +
Pgp O +
in O +
brain O +
and O +
liver O +
sections O +
of O +
TR O -
( O -
- O -
) O +
rats O +
and O +
normal O +
Wistar O +
rats O +
was O +
determined O +
with O +
immunohistochemistry O -
, O +
by O +
using O +
a O +
novel O -
, O +
highly O +
selective O +
monoclonal O +
MRP2 O +
antibody O +
and O +
the O +
monoclonal O +
Pgp O +
antibody O +
C219 O -
, O +
respectively O -
. O +

RESULTS O -
: O +
Immunofluorescence O +
staining O +
with O +
the O +
MRP2 O +
antibody O +
was O +
found O +
to O +
label O +
a O +
high O +
number O +
of O +
microvessels O +
throughout O +
the O +
brain O +
in O +
normal O +
Wistar O +
rats O -
, O +
whereas O +
such O +
labeling O +
was O +
absent O +
in O +
TR O -
( O -
- O -
) O +
rats O -
. O +

TR O -
( O -
- O -
) O +
rats O +
exhibited O +
a O +
significant O +
up O -
- O -
regulation O +
of O +
Pgp O +
in O +
brain O +
capillary O +
endothelial O +
cells O +
compared O +
with O +
wild O -
- O -
type O +
controls O -
. O +

No O +
such O +
obvious O +
upregulation O +
of O +
Pgp O +
was O +
observed O +
in O +
liver O +
sections O -
. O +

A O +
comparable O +
overexpression O +
of O +
Pgp O +
in O +
the O +
BBB O +
was O +
obtained O +
after O +
pilocarpine O -
- O -
induced O +
seizures B-Disease +
in O +
wild O -
- O -
type O +
Wistar O +
rats O -
. O +

Experiments O +
with O +
systemic O +
administration O +
of O +
the O +
Pgp O +
substrate O +
phenobarbital O +
and O +
the O +
selective O +
Pgp O +
inhibitor O +
tariquidar O +
in O +
TR O -
( O -
- O -
) O +
rats O +
substantiated O +
that O +
Pgp O +
is O +
functional O +
and O +
compensates O +
for O +
the O +
lack O +
of O +
MRP2 O +
in O +
the O +
BBB O -
. O +

CONCLUSIONS O -
: O +
The O +
data O +
on O +
TR O -
( O -
- O -
) O +
rats O +
indicate O +
that O +
Pgp O +
plays O +
an O +
important O +
role O +
in O +
the O +
compensation O +
of O +
MRP2 O +
deficiency O +
in O +
the O +
BBB O -
. O +

Because O +
such O +
a O +
compensatory O +
mechanism O +
most O +
likely O +
occurs O +
to O +
reduce O +
injury B-Disease +
to I-Disease +
the I-Disease +
brain I-Disease +
from O +
cytotoxic O +
compounds O -
, O +
the O +
present O +
data O +
substantiate O +
the O +
concept O +
that O +
MRP2 O +
performs O +
a O +
protective O +
role O +
in O +
the O +
BBB O -
. O +

Furthermore O -
, O +
our O +
data O +
suggest O +
that O +
TR O -
( O -
- O -
) O +
rats O +
are O +
an O +
interesting O +
tool O +
to O +
study O +
consequences O +
of O +
overexpression O +
of O +
Pgp O +
in O +
the O +
BBB O +
on O +
access O +
of O +
drugs O +
in O +
the O +
brain O -
, O +
without O +
the O +
need O +
of O +
inducing O +
seizures B-Disease +
or O +
other O +
Pgp O -
- O -
enhancing O +
events O +
for O +
this O +
purpose O -
. O +

Role O +
of O +
xanthine O +
oxidase O +
in O +
dexamethasone O -
- O -
induced O +
hypertension B-Disease +
in O +
rats O -
. O +

1 O -
. O +
Glucocorticoid O -
- O -
induced O +
hypertension B-Disease +
( O -
GC O -
- O -
HT B-Disease -
) O +
in O +
the O +
rat O +
is O +
associated O +
with O +
nitric O +
oxide O -
- O -
redox O +
imbalance O -
. O +

2 O -
. O +

We O +
studied O +
the O +
role O +
of O +
xanthine O +
oxidase O +
( O -
XO O -
) O -
, O +
which O +
is O +
implicated O +
in O +
the O +
production O +
of O +
reactive O +
oxygen O +
species O -
, O +
in O +
dexamethasone O -
- O -
induced O +
hypertension B-Disease +
( O -
dex O -
- O -
HT B-Disease -
) O -
. O +

3 O -
. O +

Thirty O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
divided O +
randomly O +
into O +
four O +
treatment O +
groups O -
: O +
saline O -
, O +
dexamethasone O +
( O -
dex O -
) O -
, O +
allopurinol O +
plus O +
saline O -
, O +
and O +
allopurinol O +
plus O +
dex O -
. O +

4 O -
. O +

Systolic O +
blood O +
pressures O +
( O -
SBP O -
) O +
and O +
bodyweights O +
were O +
recorded O +
each O +
alternate O +
day O -
. O +

Thymus O +
weight O +
was O +
used O +
as O +
a O +
marker O +
of O +
glucocorticoid O +
activity O -
, O +
and O +
serum O +
urate O +
to O +
assess O +
XO O +
inhibition O -
. O +

5 O -
. O +

Dex O +
increased B-Disease +
SBP I-Disease +
( O -
110 O +
+ O -
/- O +

2 O -
- O -
126 O +
+ O -
/- O +

3 O +
mmHg O -
; O +
P O +
< O +
0.001 O -
) O +
and O +
decreased B-Disease +
thymus I-Disease +
( I-Disease -
P I-Disease +
< I-Disease +
0.001 I-Disease -
) I-Disease +
and I-Disease +
bodyweights I-Disease +
( O -
P O -
" O +
< O +
0.01 O -
) O -
. O +

Allopurinol O +
decreased O +
serum O +
urate O +
from O +
76 O +
+ O -
/- O +

5 O +
to O +
30 O +
+ O -
/- O +

3 O +
micromol O -
/ O -
L O +
( O -
P O +
< O +
0.001 O -
) O +
in O +
saline O +
and O +
from O +
84 O +
+ O -
/- O +

13 O +
to O +
28 O +
+ O -
/- O +

2 O +
micromol O -
/ O -
L O +
in O +
dex O -
- O -
treated O +
( O -
P O +
< O +
0.01 O -
) O +
groups O -
. O +

6 O -
. O +

Allopurinol O +
did O +
not O +
prevent O +
dex O -
- O -
HT B-Disease -
. O +

This O -
, O +
together O +
with O +
our O +
previous O +
findings O +
that O +
allopurinol O +
failed O +
to O +
prevent O +
adrenocorticotrophic O +
hormone O +
induced O +
hypertension B-Disease -
, O +
suggests O +
that O +
XO O +
activity O +
is O +
not O +
a O +
major O +
determinant O +
of O +
GC O -
- O -
HT B-Disease +
in O +
the O +
rat O -
. O +

Side O +
effects O +
of O +
postoperative O +
administration O +
of O +
methylprednisolone O +
and O +
gentamicin O +
into O +
the O +
posterior O +
sub O -
- O -
Tenon O -
's O +
space O -
. O +

PURPOSE O -
: O +
To O +
assess O +
the O +
incidence O +
of O +
postoperative O +
emetic O +
side O +
effects O +
after O +
the O +
administration O +
of O +
methylprednisolone O +
and O +
gentamicin O +
into O +
the O +
posterior O +
sub O -
- O -
Tenon O -
's O +
space O +
at O +
the O +
end O +
of O +
routine O +
cataract B-Disease +
surgery O -
. O +

SETTING O -
: O +
St. O +
Luke O -
's O +
Hospital O -
, O +
Gwardamangia O -
, O +
Malta O -
. O +

METHODS O -
: O +
A O +
double O -
- O -
blind O +
double O -
- O -
armed O +
prospective O +
study O +
comprised O +
40 O +
patients O +
who O +
had O +
uneventful O +
sutureless O +
phacoemulsification O +
under O +
sub O -
- O -
Tenon O -
's O +
local O +
infiltration O +
of O +
3 O +
mL O +
of O +
plain O +
lignocaine O -
. O +

At O +
the O +
end O +
of O +
the O +
procedure O -
, O +
Group O +
A O +
( O -
n O +
= O +
20 O -
) O +
had O +
20 O +
mg O -
/ O -
0.5 O +
mL O +
of O +
methylprednisolone O +
and O +
10 O +
mg O -
/ O -
0.5 O +
mL O +
of O +
gentamicin O +
injected O +
into O +
the O +
posterior O +
sub O -
- O -
Tenon O -
's O +
space O +
and O +
Group O +
B O +
( O -
n O +
= O +
20 O -
) O +
had O +
the O +
same O +
combination O +
injected O +
into O +
the O +
anterior O +
sub O -
- O -
Tenon O -
's O +
space O -
. O +

Postoperatively O -
, O +
all O +
patients O +
were O +
assessed O +
for O +
symptoms O +
of O +
nausea B-Disease -
, I-Disease +
vomiting I-Disease -
, O +
and O +
headache B-Disease -
. O +

A O +
chi O -
- O -
square O +
test O +
was O +
used O +
to O +
assess O +
the O +
statistical O +
significance O +
of O +
results O -
. O +

RESULTS O -
: O +
Sixty O +
percent O +
in O +
Group O +
A O +
developed O +
postoperative B-Disease +
emetic I-Disease +
symptoms I-Disease -
, O +
headache B-Disease -
, O +
or O +
both O -
; O +
1 O +
patient O +
in O +
Group O +
B O +
developed O +
symptoms O -
. O +

CONCLUSIONS O -
: O +
The O +
administration O +
of O +
methylprednisolone O +
and O +
gentamicin O +
in O +
the O +
posterior O +
sub O -
- O -
Tenon O -
's O +
space O +
was O +
related O +
to O +
a O +
high O +
incidence O +
of O +
side O +
effects O +
including O +
nausea B-Disease -
, I-Disease +
vomiting I-Disease -
, O +
and O +
headache B-Disease -
. O +

All O +
adverse O +
effects O +
were O +
self O -
- O -
limiting O -
. O +

Peripheral O +
iron O +
dextran O +
induced O +
degeneration B-Disease +
of I-Disease +
dopaminergic I-Disease +
neurons I-Disease +
in O +
rat O +
substantia O +
nigra O -
. O +

Iron O +
accumulation O +
is O +
considered O +
to O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

To O +
demonstrate O +
the O +
relationship O +
between O +
peripheral O +
iron O +
overload O +
and O +
dopaminergic O +
neuron O +
loss O +
in O +
rat O +
substantia O +
nigra O +
( O -
SN O -
) O -
, O +
in O +
the O +
present O +
study O +
we O +
used O +
fast O +
cyclic O +
voltammetry O -
, O +
tyrosine O +
hydroxylase O +
( O -
TH O -
) O +
immunohistochemistry O -
, O +
Perls O -
' O +
iron O +
staining O -
, O +
and O +
high O +
performance O +
liquid O +
chromatography O -
- O -
electrochemical O +
detection O +
to O +
study O +
the O +
degeneration B-Disease +
of I-Disease +
dopaminergic I-Disease +
neurons I-Disease +
and O +
increased O +
iron O +
content O +
in O +
the O +
SN O +
of O +
iron O +
dextran O +
overloaded O +
animals O -
. O +

The O +
findings O +
showed O +
that O +
peripheral O +
iron O +
dextran O +
overload O +
increased O +
the O +
iron O +
staining O +
positive O +
cells O +
and O +
reduced O +
the O +
number O +
of O +
TH O -
- O -
immunoreactive O +
neurons O +
in O +
the O +
SN O -
. O +

As O +
a O +
result O -
, O +
dopamine O +
release O +
and O +
content O -
, O +
as O +
well O +
as O +
its O +
metabolites O +
contents O +
were O +
decreased O +
in O +
caudate O +
putamen O -
. O +

Even O +
more O +
dramatic O +
changes O +
were O +
found O +
in O +
chronic O +
overload O +
group O -
. O +

These O +
results O +
suggest O +
that O +
peripheral O +
iron O +
dextran O +
can O +
increase O +
the O +
iron O +
level O +
in O +
the O +
SN O -
, O +
where O +
excessive O +
iron O +
causes O +
the O +
degeneration B-Disease +
of I-Disease +
dopaminergic I-Disease +
neurons I-Disease -
. O +

The O +
chronic O +
iron O +
overload O +
may O +
be O +
more O +
destructive O +
to O +
dopaminergic O +
neurons O +
than O +
the O +
acute O +
iron O +
overload O -
. O +

Attenuated O +
disruption O +
of O +
prepulse O +
inhibition O +
by O +
dopaminergic O +
stimulation O +
after O +
maternal O +
deprivation O +
and O +
adolescent O +
corticosterone O +
treatment O +
in O +
rats O -
. O +

The O +
development O +
of O +
schizophrenia B-Disease +
may O +
include O +
an O +
early O +
neurodevelopmental O +
stress O +
component O +
which O +
increases O +
vulnerability O +
to O +
later O +
stressful O +
life O +
events O -
, O +
in O +
combination O +
leading O +
to O +
overt O +
disease O -
. O +

We O +
investigated O +
the O +
effect O +
of O +
an O +
early O +
stress O -
, O +
in O +
the O +
form O +
of O +
maternal O +
deprivation O -
, O +
combined O +
with O +
a O +
later O +
stress O -
, O +
simulated O +
by O +
chronic O +
periadolescent O +
corticosterone O +
treatment O -
, O +
on O +
behaviour O +
in O +
rats O -
. O +

Acute O +
treatment O +
with O +
apomorphine O +
caused O +
disruption O +
of O +
prepulse O +
inhibition O +
( O -
PPI O -
) O +
in O +
controls O +
and O +
in O +
rats O +
that O +
had O +
undergone O +
either O +
maternal O +
deprivation O +
or O +
corticosterone O +
treatment O -
, O +
but O +
was O +
surprisingly O +
absent O +
in O +
rats O +
that O +
had O +
undergone O +
the O +
combined O +
early O +
and O +
late O +
stress O -
. O +

Amphetamine O +
treatment O +
significantly O +
disrupted O +
PPI O +
in O +
both O +
non O -
- O -
deprived O +
groups O -
, O +
but O +
was O +
absent O +
in O +
both O +
maternally O +
deprived O +
groups O -
. O +

The O +
serotonin-1A O +
receptor O +
agonist O -
, O +
8-OH O -
- O -
DPAT O -
, O +
induced O +
a O +
significant O +
disruption O +
of O +
PPI O +
in O +
all O +
groups O -
. O +

Amphetamine O -
- O -
induced O +
locomotor B-Disease +
hyperactivity I-Disease +
was O +
similar O +
in O +
all O +
groups O -
. O +

These O +
results O +
show O +
an O +
inhibitory O +
interaction O +
of O +
early O +
stress O -
, O +
caused O +
by O +
maternal O +
deprivation O -
, O +
combined O +
with O +
' O -
adolescent O -
' O +
stress O -
, O +
simulated O +
by O +
corticosterone O +
treatment O -
, O +
on O +
dopaminergic O +
regulation O +
of O +
PPI O -
. O +

The O +
altered O +
effects O +
of O +
apomorphine O +
and O +
amphetamine O +
could O +
indicate O +
differential O +
changes O +
in O +
dopamine O +
receptor O +
signalling O +
leading O +
to O +
functional O +
desensitisation O -
, O +
or O +
altered O +
modulation O +
of O +
sensory O +
gating O +
in O +
the O +
nucleus O +
accumbens O +
by O +
limbic O +
structures O +
such O +
as O +
the O +
hippocampus O -
. O +

Assessment O +
of O +
a O +
new O +
non O -
- O -
invasive O +
index O +
of O +
cardiac O +
performance O +
for O +
detection O +
of O +
dobutamine O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease -
. O +

BACKGROUND O -
: O +
Electrocardiography O +
has O +
a O +
very O +
low O +
sensitivity O +
in O +
detecting O +
dobutamine O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease -
. O +

OBJECTIVES O -
: O +
To O +
assess O +
the O +
added O +
diagnostic O +
value O +
of O +
a O +
new O +
cardiac O +
performance O +
index O +
( O -
dP O -
/ O -
dtejc O -
) O +
measurement O -
, O +
based O +
on O +
brachial O +
artery O +
flow O +
changes O -
, O +
as O +
compared O +
to O +
standard O +
12-lead O +
ECG O -
, O +
for O +
detecting O +
dobutamine O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease -
, O +
using O +
Tc99m O -
- O -
Sestamibi O +
single O -
- O -
photon O +
emission O +
computed O +
tomography O +
as O +
the O +
gold O +
standard O +
of O +
comparison O +
to O +
assess O +
the O +
presence O +
or O +
absence O +
of O +
ischemia B-Disease -
. O +

METHODS O -
: O +
The O +
study O +
group O +
comprised O +
40 O +
patients O +
undergoing O +
Sestamibi O -
- O -
SPECT O -
/ O -
dobutamine O +
stress O +
test O -
. O +

Simultaneous O +
measurements O +
of O +
ECG O +
and O +
brachial O +
artery O +
dP O -
/ O -
dtejc O +
were O +
performed O +
at O +
each O +
dobutamine O +
level O -
. O +

In O +
19 O +
of O +
the O +
40 O +
patients O +
perfusion O +
defects O +
compatible O +
with O +
ischemia B-Disease +
were O +
detected O +
on O +
SPECT O -
. O +

The O +
increase O +
in O +
dP O -
/ O -
dtejc O +
during O +
infusion O +
of O +
dobutamine O +
in O +
this O +
group O +
was O +
severely O +
impaired O +
as O +
compared O +
to O +
the O +
non O -
- O -
ischemic O +
group O -
. O +

dP O -
/ O -
dtejc O +
outcome O +
was O +
combined O +
with O +
the O +
ECG O +
results O -
, O +
giving O +
an O +
ECG O -
- O -
enhanced O +
value O -
, O +
and O +
compared O +
to O +
ECG O +
alone O -
. O +

RESULTS O -
: O +
The O +
sensitivity O +
improved O +
dramatically O +
from O +
16 O -
% O +
to O +
79 O -
% O -
, O +
positive O +
predictive O +
value O +
increased O +
from O +
60 O -
% O +
to O +
68 O -
% O +
and O +
negative O +
predictive O +
value O +
from O +
54 O -
% O +
to O +
78 O -
% O -
, O +
and O +
specificity O +
decreased O +
from O +
90 O -
% O +
to O +
67 O -
% O -
. O +

CONCLUSIONS O -
: O +
If O +
ECG O +
alone O +
is O +
used O +
for O +
specificity O -
, O +
the O +
combination O +
with O +
dP O -
/ O -
dtejc O +
improved O +
the O +
sensitivity O +
of O +
the O +
test O +
and O +
could O +
be O +
a O +
cost O -
- O -
savings O +
alternative O +
to O +
cardiac O +
imaging O +
or O +
perfusion O +
studies O +
to O +
detect O +
myocardial B-Disease +
ischemia I-Disease -
, O +
especially O +
in O +
patients O +
unable O +
to O +
exercise O -
. O +

Cocaine O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease -
: O +
clinical O +
observations O +
and O +
pathogenetic O +
considerations O -
. O +

Clinical O +
and O +
experimental O +
data O +
published O +
to O +
date O +
suggest O +
several O +
possible O +
mechanisms O +
by O +
which O +
cocaine O +
may O +
result O +
in O +
acute B-Disease +
myocardial I-Disease +
infarction I-Disease -
. O +

In O +
individuals O +
with O +
preexisting O -
, O +
high O -
- O -
grade O +
coronary O +
arterial O +
narrowing O -
, O +
acute B-Disease +
myocardial I-Disease +
infarction I-Disease +
may O +
result O +
from O +
an O +
increase O +
in O +
myocardial O +
oxygen O +
demand O +
associated O +
with O +
cocaine O -
- O -
induced O +
increase O +
in O +
rate O -
- O -
pressure O +
product O -
. O +

In O +
other O +
individuals O +
with O +
no O +
underlying O +
atherosclerotic B-Disease +
obstruction I-Disease -
, O +
coronary B-Disease +
occlusion I-Disease +
may O +
be O +
due O +
to O +
spasm B-Disease -
, O +
thrombus B-Disease -
, O +
or O +
both O -
. O +

With O +
regard O +
to O +
spasm B-Disease -
, O +
the O +
clinical O +
findings O +
are O +
largely O +
circumstantial O -
, O +
and O +
the O +
locus O +
of O +
cocaine O -
- O -
induced O +
vasoconstriction O +
remains O +
speculative O -
. O +

Although O +
certain O +
clinical O +
and O +
experimental O +
findings O +
support O +
the O +
hypothesis O +
that O +
spasm B-Disease +
involves O +
the O +
epicardial O -
, O +
medium O -
- O -
size O +
vessels O -
, O +
other O +
data O +
suggest O +
intramural O +
vasoconstriction O -
. O +

Diffuse O +
intramural O +
vasoconstriction O +
is O +
not O +
consistent O +
with O +
reports O +
of O +
segmental O -
, O +
discrete O +
infarction B-Disease -
. O +

Whereas O +
certain O +
in O +
vivo O +
data O +
suggest O +
that O +
these O +
effects O +
are O +
alpha O -
- O -
mediated O -
, O +
other O +
in O +
vitro O +
data O +
suggest O +
the O +
opposite O -
. O +

The O +
finding O +
of O +
cocaine O -
- O -
induced O +
vasoconstriction O +
in O +
segments O +
of O +
( O -
noninnervated O -
) O +
human O +
umbilical O +
artery O +
suggests O +
that O +
the O +
presence O +
or O +
absence O +
of O +
intact O +
innervation O +
is O +
not O +
sufficient O +
to O +
explain O +
the O +
discrepant O +
data O +
involving O +
the O +
possibility O +
of O +
alpha O -
- O -
mediated O +
effects O -
. O +

Finally O -
, O +
the O +
contribution O +
of O +
a O +
primary O -
, O +
thrombotic B-Disease +
effect O +
of O +
cocaine O +
has O +
not O +
been O +
excluded O -
. O +

An O +
extremely O +
rare O +
case O +
of O +
delusional B-Disease +
parasitosis I-Disease +
in O +
a O +
chronic B-Disease +
hepatitis I-Disease +
C I-Disease +
patient O +
during O +
pegylated O +
interferon O +
alpha-2b O +
and O +
ribavirin O +
treatment O -
. O +

During O +
treatment O +
of O +
chronic B-Disease +
hepatitis I-Disease +
C I-Disease +
patients O +
with O +
interferon O +
and O +
ribavirin O -
, O +
a O +
lot O +
of O +
side O +
effects O +
are O +
described O -
. O +

Twenty O -
- O -
three O +
percent O +
to O +
44 O -
% O +
of O +
patients O +
develop O +
depression B-Disease -
. O +

A O +
minority O +
of O +
patients O +
evolve O +
to O +
psychosis B-Disease -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
no O +
cases O +
of O +
psychogenic B-Disease +
parasitosis I-Disease +
occurring O +
during O +
interferon O +
therapy O +
have O +
been O +
described O +
in O +
the O +
literature O -
. O +

We O +
present O +
a O +
49-year O -
- O -
old O +
woman O +
who O +
developed O +
a O +
delusional B-Disease +
parasitosis I-Disease +
during O +
treatment O +
with O +
pegylated O +
interferon O +
alpha-2b O +
weekly O +
and O +
ribavirin O -
. O +

She O +
complained O +
of O +
seeing O +
parasites O +
and O +
the O +
larvae O +
of O +
fleas O +
in O +
her O +
stools O -
. O +

This O +
could O +
not O +
be O +
confirmed O +
by O +
any O +
technical O +
examination O -
. O +

All O +
the O +
complaints O +
disappeared O +
after O +
stopping O +
pegylated O +
interferon O +
alpha-2b O +
and O +
reappeared O +
after O +
restarting O +
it O -
. O +

She O +
had O +
a O +
complete O +
sustained O +
viral O +
response O -
. O +

Proteomic O +
analysis O +
of O +
striatal O +
proteins O +
in O +
the O +
rat O +
model O +
of O +
L O -
- O -
DOPA O -
- O -
induced O +
dyskinesia B-Disease -
. O +

L O -
- O -
DOPA O -
- O -
induced O +
dyskinesia B-Disease +
( O -
LID B-Disease -
) O +
is O +
among O +
the O +
motor O +
complications O +
that O +
arise O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
patients O +
after O +
a O +
prolonged O +
treatment O +
with O +
L O -
- O -
DOPA O -
. O +

To O +
this O +
day O -
, O +
transcriptome O +
analysis O +
has O +
been O +
performed O +
in O +
a O +
rat O +
model O +
of O +
LID B-Disease +
[ O -
Neurobiol O -
. O +

Dis O -
. O -
, O +
17 O +
( O -
2004 O -
) O -
, O +
219 O -
] O +
but O +
information O +
regarding O +
the O +
proteome O +
is O +
still O +
lacking O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
the O +
changes O +
occurring O +
at O +
the O +
protein O +
level O +
in O +
striatal O +
samples O +
obtained O +
from O +
the O +
unilaterally O +
6-hydroxydopamine O -
- O -
lesion O +
rat O +
model O +
of O +
PD B-Disease +
treated O +
with O +
saline O -
, O +
L O -
- O -
DOPA O +
or O +
bromocriptine O +
using O +
two O -
- O -
dimensional O +
difference O +
gel O +
electrophoresis O +
and O +
mass O +
spectrometry O +
( O -
MS O -
) O -
. O +

Rats O +
treated O +
with O +
L O -
- O -
DOPA O +
were O +
allocated O +
to O +
two O +
groups O +
based O +
on O +
the O +
presence O +
or O +
absence O +
of O +
LID B-Disease -
. O +

Among O +
the O +
2000 O +
spots O +
compared O +
for O +
statistical O +
difference O -
, O +
67 O +
spots O +
were O +
significantly O +
changed O +
in O +
abundance O +
and O +
identified O +
using O +
matrix O -
- O -
assisted O +
laser O +
desorption O -
/ O -
ionization O +
time O -
- O -
of O -
- O -
flight O +
MS O -
, O +
atmospheric O +
pressure O +
matrix O -
- O -
assisted O +
laser O +
desorption O -
/ O -
ionization O +
and O +
HPLC O +
coupled O +
tandem O +
MS O +
( O -
LC O -
/ O -
MS O -
/ O -
MS O -
) O -
. O +

Out O +
of O +
these O +
67 O +
proteins O -
, O +
LID B-Disease +
significantly O +
changed O +
the O +
expression O +
level O +
of O +
five O +
proteins O -
: O +
alphabeta O -
- O -
crystalin O -
, O +
gamma O -
- O -
enolase O -
, O +
guanidoacetate O +
methyltransferase O -
, O +
vinculin O -
, O +
and O +
proteasome O +
alpha-2 O +
subunit O -
. O +

Complementary O +
techniques O +
such O +
as O +
western O +
immunoblotting O +
and O +
immunohistochemistry O +
were O +
performed O +
to O +
investigate O +
the O +
validity O +
of O +
the O +
data O +
obtained O +
using O +
the O +
proteomic O +
approach O -
. O +

In O +
conclusion O -
, O +
this O +
study O +
provides O +
new O +
insights O +
into O +
the O +
protein O +
changes O +
occurring O +
in O +
LID B-Disease -
. O +

Cardiac O +
Angiography O +
in O +
Renally O +
Impaired O +
Patients O +
( O -
CARE O -
) O +
study O -
: O +
a O +
randomized O +
double O -
- O -
blind O +
trial O +
of O +
contrast O -
- O -
induced O +
nephropathy B-Disease +
in O +
patients O +
with O +
chronic B-Disease +
kidney I-Disease +
disease I-Disease -
. O +

BACKGROUND O -
: O +
No O +
direct O +
comparisons O +
exist O +
of O +
the O +
renal O +
tolerability O +
of O +
the O +
low O -
- O -
osmolality O +
contrast O +
medium O +
iopamidol O +
with O +
that O +
of O +
the O +
iso O -
- O -
osmolality O +
contrast O +
medium O +
iodixanol O +
in O +
high O -
- O -
risk O +
patients O -
. O +

METHODS O +
AND O +
RESULTS O -
: O +
The O +
present O +
study O +
is O +
a O +
multicenter O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
comparison O +
of O +
iopamidol O +
and O +
iodixanol O +
in O +
patients O +
with O +
chronic B-Disease +
kidney I-Disease +
disease I-Disease +
( O -
estimated O +
glomerular O +
filtration O +
rate O -
, O +
20 O +
to O +
59 O +
mL O -
/ O -
min O -
) O +
who O +
underwent O +
cardiac O +
angiography O +
or O +
percutaneous O +
coronary O +
interventions O -
. O +

Serum O +
creatinine O +
( O -
SCr O -
) O +
levels O +
and O +
estimated O +
glomerular O +
filtration O +
rate O +
were O +
assessed O +
at O +
baseline O +
and O +
2 O +
to O +
5 O +
days O +
after O +
receiving O +
medications O -
. O +

The O +
primary O +
outcome O +
was O +
a O +
postdose O +
SCr O +
increase O +
> O +
or O +
= O +
0.5 O +
mg O -
/ O -
dL O +
( O -
44.2 O +
micromol O -
/ O -
L O -
) O +
over O +
baseline O -
. O +

Secondary O +
outcomes O +
were O +
a O +
postdose O +
SCr O +
increase O +
> O +
or O +
= O +
25 O -
% O -
, O +
a O +
postdose O +
estimated O +
glomerular O +
filtration O +
rate O +
decrease O +
of O +
> O +
or O +
= O +
25 O -
% O -
, O +
and O +
the O +
mean O +
peak O +
change O +
in O +
SCr O -
. O +

In O +
414 O +
patients O -
, O +
contrast O +
volume O -
, O +
presence O +
of O +
diabetes B-Disease +
mellitus I-Disease -
, O +
use O +
of O +
N O -
- O -
acetylcysteine O -
, O +
mean O +
baseline O +
SCr O -
, O +
and O +
estimated O +
glomerular O +
filtration O +
rate O +
were O +
comparable O +
in O +
the O +
2 O +
groups O -
. O +

SCr O +
increases O +
> O +
or O +
= O +
0.5 O +
mg O -
/ O -
dL O +
occurred O +
in O +
4.4 O -
% O +
( O -
9 O +
of O +
204 O +
patients O -
) O +
after O +
iopamidol O +
and O +
6.7 O -
% O +
( O -
14 O +
of O +
210 O +
patients O -
) O +
after O +
iodixanol O +
( O -
P=0.39 O -
) O -
, O +
whereas O +
rates O +
of O +
SCr O +
increases O +
> O +
or O +
= O +
25 O -
% O +
were O +
9.8 O -
% O +
and O +
12.4 O -
% O -
, O +
respectively O +
( O -
P=0.44 O -
) O -
. O +

In O +
patients O +
with O +
diabetes B-Disease -
, O +
SCr O +
increases O +
> O +
or O +
= O +
0.5 O +
mg O -
/ O -
dL O +
were O +
5.1 O -
% O +
( O -
4 O +
of O +
78 O +
patients O -
) O +
with O +
iopamidol O +
and O +
13.0 O -
% O +
( O -
12 O +
of O +
92 O +
patients O -
) O +
with O +
iodixanol O +
( O -
P=0.11 O -
) O -
, O +
whereas O +
SCr O +
increases O +
> O +
or O +
= O +
25 O -
% O +
were O +
10.3 O -
% O +
and O +
15.2 O -
% O -
, O +
respectively O +
( O -
P=0.37 O -
) O -
. O +

Mean O +
post O -
- O -
SCr O +
increases O +
were O +
significantly O +
less O +
with O +
iopamidol O +
( O -
all O +
patients O -
: O +
0.07 O +
versus O +
0.12 O +
mg O -
/ O -
dL O -
, O +
6.2 O +
versus O +
10.6 O +
micromol O -
/ O -
L O -
, O +
P=0.03 O -
; O +
patients O +
with O +
diabetes B-Disease -
: O +
0.07 O +
versus O +
0.16 O +
mg O -
/ O -
dL O -
, O +
6.2 O +
versus O +
14.1 O +
micromol O -
/ O -
L O -
, O +
P=0.01 O -
) O -
. O +

CONCLUSIONS O -
: O +
The O +
rate O +
of O +
contrast O -
- O -
induced O +
nephropathy B-Disease -
, O +
defined O +
by O +
multiple O +
end O +
points O -
, O +
is O +
not O +
statistically O +
different O +
after O +
the O +
intraarterial O +
administration O +
of O +
iopamidol O +
or O +
iodixanol O +
to O +
high O -
- O -
risk O +
patients O -
, O +
with O +
or O +
without O +
diabetes B-Disease +
mellitus I-Disease -
. O +

Any O +
true O +
difference O +
between O +
the O +
agents O +
is O +
small O +
and O +
not O +
likely O +
to O +
be O +
clinically O +
significant O -
. O +

Hepatonecrosis B-Disease +
and O +
cholangitis B-Disease +
related O +
to O +
long O -
- O -
term O +
phenobarbital O +
therapy O -
: O +
an O +
autopsy O +
report O +
of O +
two O +
patients O -
. O +

Phenobarbital O +
( O -
PB O -
) O +
has O +
a O +
reputation O +
for O +
safety O -
, O +
and O +
it O +
is O +
commonly O +
believed O +
that O +
PB O -
- O -
related O +
increases O +
in O +
serum O +
aminotransferase O +
levels O +
do O +
not O +
indicate O +
or O +
predict O +
the O +
development O +
of O +
significant O +
chronic O +
liver B-Disease +
disease I-Disease -
. O +

Here O +
we O +
report O +
of O +
two O +
adult O +
patients O +
with O +
a O +
long O +
history O +
of O +
epilepsy B-Disease +
treated O +
with O +
PB O +
who O +
died O +
suddenly O -
: O +
one O +
as O +
consequence O +
of O +
cardiac B-Disease +
arrest I-Disease -
, O +
the O +
other O +
of O +
acute O +
bronchopneumonia B-Disease -
. O +

At O +
autopsy O -
, O +
analysis O +
of O +
liver O +
parenchyma O +
revealed O +
rich O +
portal O +
inflammatory O +
infiltrate O -
, O +
which O +
consisted O +
of O +
mixed O +
eosinophil O +
and O +
monocyte O +
cells O -
, O +
associated O +
with O +
several O +
foci O +
of O +
necrosis B-Disease +
surrounded O +
by O +
a O +
hard O +
ring O +
of O +
non O -
- O -
specific O +
granulomatous O +
tissue O -
. O +

Inflammatory O +
reactions O +
of O +
internal O +
and O +
external O +
hepatic O +
biliary O +
ducts O +
were O +
also O +
seen O -
. O +

Our O +
findings O +
illustrate O +
that O +
PB O +
may O +
be O +
associated O +
with O +
chronic O +
liver B-Disease +
damage I-Disease -
, O +
which O +
may O +
lead O +
to O +
more O +
serious O +
and O +
deleterious O +
consequences O -
. O +

For O +
this O +
reason O -
, O +
each O +
clinician O +
should O +
recognize O +
this O +
entity O +
in O +
the O +
differential O +
diagnosis O +
of O +
PB O -
- O -
related O +
asymptomatic O +
chronic B-Disease +
hepatic I-Disease +
enzyme I-Disease +
dysfunction I-Disease -
. O +

A O +
novel O +
compound O -
, O +
maltolyl O +
p O -
- O -
coumarate O -
, O +
attenuates O +
cognitive B-Disease +
deficits I-Disease +
and O +
shows O +
neuroprotective O +
effects O +
in O +
vitro O +
and O +
in O +
vivo O +
dementia B-Disease +
models O -
. O +

To O +
develop O +
a O +
novel O +
and O +
effective O +
drug O +
that O +
could O +
enhance O +
cognitive O +
function O +
and O +
neuroprotection O -
, O +
we O +
newly O +
synthesized O +
maltolyl O +
p O -
- O -
coumarate O +
by O +
the O +
esterification O +
of O +
maltol O +
and O +
p O -
- O -
coumaric O +
acid O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
investigated O +
whether O +
maltolyl O +
p O -
- O -
coumarate O +
could O +
improve O +
cognitive B-Disease +
decline I-Disease +
in O +
scopolamine O -
- O -
injected O +
rats O +
and O +
in O +
amyloid O +
beta O +
peptide O -
( O -
1 O -
- O -
42 O -
) O -
-infused O +
rats O -
. O +

Maltolyl O +
p O -
- O -
coumarate O +
was O +
found O +
to O +
attenuate O +
cognitive B-Disease +
deficits I-Disease +
in O +
both O +
rat O +
models O +
using O +
passive O +
avoidance O +
test O +
and O +
to O +
reduce O +
apoptotic O +
cell O +
death O +
observed O +
in O +
the O +
hippocampus O +
of O +
the O +
amyloid O +
beta O +
peptide O -
( O -
1 O -
- O -
42 O -
) O -
-infused O +
rats O -
. O +

We O +
also O +
examined O +
the O +
neuroprotective O +
effects O +
of O +
maltolyl O +
p O -
- O -
coumarate O +
in O +
vitro O +
using O +
SH O -
- O -
SY5Y O +
cells O -
. O +

Cells O +
were O +
pretreated O +
with O +
maltolyl O +
p O -
- O -
coumarate O -
, O +
before O +
exposed O +
to O +
amyloid O +
beta O +
peptide O -
( O -
1 O -
- O -
42 O -
) O -
, O +
glutamate O +
or O +
H2O2 O -
. O +

We O +
found O +
that O +
maltolyl O +
p O -
- O -
coumarate O +
significantly O +
decreased O +
apoptotic O +
cell O +
death O +
and O +
reduced O +
reactive O +
oxygen O +
species O -
, O +
cytochrome O +
c O +
release O -
, O +
and O +
caspase O +
3 O +
activation O -
. O +

Taking O +
these O +
in O +
vitro O +
and O +
in O +
vivo O +
results O +
together O -
, O +
our O +
study O +
suggests O +
that O +
maltolyl O +
p O -
- O -
coumarate O +
is O +
a O +
potentially O +
effective O +
candidate O +
against O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
that O +
is O +
characterized O +
by O +
wide O +
spread O +
neuronal B-Disease +
death I-Disease +
and O +
progressive O +
decline B-Disease +
of I-Disease +
cognitive I-Disease +
function I-Disease -
. O +

Attenuation O +
of O +
methamphetamine O -
- O -
induced O +
nigrostriatal O +
dopaminergic O +
neurotoxicity B-Disease +
in O +
mice O +
by O +
lipopolysaccharide O +
pretreatment O -
. O +

Immunological O +
activation O +
has O +
been O +
proposed O +
to O +
play O +
a O +
role O +
in O +
methamphetamine O -
- O -
induced O +
dopaminergic B-Disease +
terminal I-Disease +
damage I-Disease -
. O +

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
roles O +
of O +
lipopolysaccharide O -
, O +
a O +
pro O -
- O -
inflammatory O +
and O +
inflammatory O +
factor O -
, O +
treatment O +
in O +
modulating O +
the O +
methamphetamine O -
- O -
induced O +
nigrostriatal O +
dopamine O +
neurotoxicity B-Disease -
. O +

Lipopolysaccharide O +
pretreatment O +
did O +
not O +
affect O +
the O +
basal O +
body O +
temperature O +
or O +
methamphetamine O -
- O -
elicited O +
hyperthermia B-Disease +
three O +
days O +
later O -
. O +

Such O +
systemic O +
lipopolysaccharide O +
treatment O +
mitigated O +
methamphetamine O -
- O -
induced O +
striatal O +
dopamine O +
and O +
3,4-dihydroxyphenylacetic O +
acid O +
depletions O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

As O +
the O +
most O +
potent O +
dose O +
( O -
1 O +
mg O -
/ O -
kg O -
) O +
of O +
lipopolysaccharide O +
was O +
administered O +
two O +
weeks O -
, O +
one O +
day O +
before O +
or O +
after O +
the O +
methamphetamine O +
dosing O +
regimen O -
, O +
methamphetamine O -
- O -
induced O +
striatal O +
dopamine O +
and O +
3,4-dihydroxyphenylacetic O +
acid O +
depletions O +
remained O +
unaltered O -
. O +

Moreover O -
, O +
systemic O +
lipopolysaccharide O +
pretreatment O +
( O -
1 O +
mg O -
/ O -
kg O -
) O +
attenuated O +
local O +
methamphetamine O +
infusion O -
- O -
produced O +
dopamine O +
and O +
3,4-dihydroxyphenylacetic O +
acid O +
depletions O +
in O +
the O +
striatum O -
, O +
indicating O +
that O +
the O +
protective O +
effect O +
of O +
lipopolysaccharide O +
is O +
less O +
likely O +
due O +
to O +
interrupted O +
peripheral O +
distribution O +
or O +
metabolism O +
of O +
methamphetamine O -
. O +

We O +
concluded O +
a O +
critical O +
time O +
window O +
for O +
systemic O +
lipopolysaccharide O +
pretreatment O +
in O +
exerting O +
effective O +
protection O +
against O +
methamphetamine O -
- O -
induced O +
nigrostriatal O +
dopamine O +
neurotoxicity B-Disease -
. O +

Acute O +
myocarditis B-Disease +
associated O +
with O +
clozapine O -
. O +

OBJECTIVE O -
: O +
A O +
case O +
of O +
acute O +
myocarditis B-Disease +
associated O +
with O +
the O +
commencement O +
of O +
clozapine O +
is O +
described O -
, O +
highlighting O +
the O +
onset O -
, O +
course O +
and O +
possible O +
contributing O +
factors O -
. O +

There O +
is O +
an O +
urgent O +
need O +
to O +
raise O +
awareness O +
about O +
this O +
potentially O +
fatal O +
complication O +
of O +
clozapine O +
use O -
. O +

RESULTS O -
: O +
A O +
20-year O -
- O -
old O +
male O +
with O +
schizophrenia B-Disease +
developed O +
a O +
sudden O +
onset O +
of O +
myocarditis B-Disease +
after O +
commencement O +
of O +
clozapine O -
. O +

The O +
patient O +
recovered O +
with O +
intensive O +
medical O +
support O -
. O +

The O +
symptoms O +
occurred O +
around O +
2 O +
weeks O +
after O +
starting O +
clozapine O +
in O +
an O +
inpatient O +
setting O -
. O +

Possible O +
contributing O +
factors O +
may O +
have O +
been O +
concomitant O +
antidepressant O +
use O +
and O +
unaccustomed O +
physical O +
activity O -
. O +

CONCLUSIONS O -
: O +
Myocarditis B-Disease +
is O +
an O +
increasingly O +
recognized O +
complication O +
associated O +
with O +
the O +
use O +
of O +
clozapine O -
. O +

It O +
can O +
be O +
fatal O +
if O +
not O +
recognized O +
and O +
treated O +
early O -
. O +

Considering O +
that O +
clozapine O +
remains O +
the O +
gold O +
standard O +
in O +
treatment O +
of O +
resistant O +
psychosis B-Disease -
, O +
there O +
is O +
an O +
urgent O +
need O +
to O +
raise O +
awareness O +
among O +
medical O +
and O +
paramedical O +
staff O +
involved O +
in O +
the O +
care O +
of O +
these O +
patients O -
. O +

There O +
are O +
also O +
implications O +
for O +
recommendations O +
and O +
regulations O +
regarding O +
the O +
use O +
of O +
clozapine O -
. O +

Severe O +
rhabdomyolysis B-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
secondary O +
to O +
concomitant O +
use O +
of O +
simvastatin O -
, O +
amiodarone O -
, O +
and O +
atazanavir O -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
a O +
severe O +
interaction O +
between O +
simvastatin O -
, O +
amiodarone O -
, O +
and O +
atazanavir O +
resulting O +
in O +
rhabdomyolysis B-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

BACKGROUND O -
: O +
A O +
72-year O -
- O -
old O +
white O +
man O +
with O +
underlying O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease -
, O +
atrial B-Disease +
fibrillation I-Disease -
, O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
, O +
and O +
hyperlipidemia B-Disease +
presented O +
with O +
generalized O +
pain B-Disease -
, O +
fatigue B-Disease -
, O +
and O +
dark O +
orange O +
urine O +
for O +
3 O +
days O -
. O +

The O +
patient O +
was O +
taking O +
80 O +
mg O +
simvastatin O +
at O +
bedtime O +
( O -
initiated O +
27 O +
days O +
earlier O -
) O -
; O +
amiodarone O +
at O +
a O +
dose O +
of O +
400 O +
mg O +
daily O +
for O +
7 O +
days O -
, O +
then O +
200 O +
mg O +
daily O +
( O -
initiated O +
19 O +
days O +
earlier O -
) O -
; O +
and O +
400 O +
mg O +
atazanavir O +
daily O +
( O -
initiated O +
at O +
least O +
2 O +
years O +
previously O -
) O -
. O +

Laboratory O +
evaluation O +
revealed O +
66,680 O +
U O -
/ O -
L O +
creatine O +
kinase O -
, O +
93 O +
mg O -
/ O -
dL O +
blood O +
urea O +
nitrogen O -
, O +
4.6 O +
mg O -
/ O -
dL O +
creatinine O -
, O +
1579 O +
U O -
/ O -
L O +
aspartate O +
aminotransferase O -
, O +
and O +
738 O +
U O -
/ O -
L O +
alanine O +
aminotransferase O -
. O +

Simvastatin O -
, O +
amiodarone O -
, O +
and O +
the O +
patient O -
's O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
medications O +
were O +
all O +
temporarily O +
discontinued O +
and O +
the O +
patient O +
was O +
given O +
forced O +
alkaline O +
diuresis O +
and O +
started O +
on O +
dialysis O -
. O +

Nine O +
days O +
later O +
the O +
patient O -
's O +
creatine O +
kinase O +
had O +
dropped O +
to O +
1695 O +
U O -
/ O -
L O +
and O +
creatinine O +
was O +
3.3 O +
mg O -
/ O -
dL. O +
The O +
patient O +
was O +
discharged O +
and O +
continued O +
outpatient O +
dialysis O +
for O +
1 O +
month O +
until O +
his O +
renal O +
function O +
recovered O -
. O +

DISCUSSION O -
: O +
The O +
risk O +
of O +
rhabdomyolysis B-Disease +
is O +
increased O +
in O +
the O +
presence O +
of O +
concomitant O +
drugs O +
that O +
inhibit O +
simvastatin O +
metabolism O -
. O +

Simvastatin O +
is O +
metabolized O +
by O +
CYP3A4 O -
. O +

Amiodarone O +
and O +
atazanavir O +
are O +
recognized O +
CYP3A4 O +
inhibitors O -
. O +

CONCLUSIONS O -
: O +
Pharmacokinetic O +
differences O +
in O +
statins O +
are O +
an O +
important O +
consideration O +
for O +
assessing O +
the O +
risk O +
of O +
potential O +
drug O +
interactions O -
. O +

In O +
patients O +
requiring O +
the O +
concurrent O +
use O +
of O +
statins O +
and O +
CYP3A4 O +
inhibitors O -
, O +
pravastatin O -
, O +
fluvastatin O -
, O +
and O +
rosuvastatin O +
carry O +
the O +
lowest O +
risk O +
of O +
drug O +
interactions O -
; O +
atorvastatin O +
carries O +
moderate O +
risk O -
, O +
whereas O +
simvastatin O +
and O +
lovastatin O +
have O +
the O +
highest O +
risk O +
and O +
should O +
be O +
avoided O +
in O +
patients O +
taking O +
concomitant O +
CYP3A4 O +
inhibitors O -
. O +

Interaction O +
between O +
warfarin O +
and O +
levofloxacin O -
: O +
case O +
series O -
. O +

Warfarin O +
is O +
the O +
most O +
widely O +
used O +
oral O +
anticoagulant O +
and O +
is O +
indicated O +
for O +
many O +
clinical O +
conditions O -
. O +

Levofloxacin O -
, O +
a O +
fluoroquinolone O -
, O +
is O +
one O +
of O +
the O +
most O +
commonly O +
prescribed O +
antibiotics O +
in O +
clinical O +
practice O +
and O +
is O +
effective O +
against O +
Gram O -
- O -
positive O -
, O +
Gram O -
- O -
negative O -
, O +
and O +
atypical O +
bacteria O -
. O +

While O +
small O +
prospective O +
studies O +
have O +
not O +
revealed O +
any O +
significant O +
drug O -
- O -
drug O +
interaction O +
between O +
warfarin O +
and O +
levofloxacin O -
, O +
several O +
case O +
reports O +
have O +
indicated O +
that O +
levofloxacin O +
may O +
significantly O +
potentiate O +
the O +
anticoagulation O +
effect O +
of O +
warfarin O -
. O +

We O +
report O +
3 O +
cases O +
of O +
serious O +
bleeding B-Disease +
complications O +
that O +
appear O +
to O +
be O +
the O +
result O +
of O +
the O +
interaction O +
between O +
warfarin O +
and O +
levofloxacin O -
. O +

Physicians O +
should O +
be O +
aware O +
of O +
this O +
potential O +
interaction O +
and O +
use O +
caution O +
when O +
prescribing O +
levofloxacin O +
to O +
patients O +
taking O +
warfarin O -
. O +

Delayed O +
leukoencephalopathy B-Disease +
with O +
stroke B-Disease -
- O -
like O +
presentation O +
in O +
chemotherapy O +
recipients O -
. O +

BACKGROUND O -
: O +
A O +
transient O +
leukoencephalopathy B-Disease +
mimicking O +
cerebrovascular B-Disease +
accident I-Disease +
has O +
been O +
described O +
as O +
a O +
complication O +
of O +
chemotherapy O -
, O +
most O +
commonly O +
in O +
recipients O +
of O +
intrathecal O +
methotrexate O +
for O +
childhood O +
leukaemia B-Disease -
. O +

Recently O +
published O +
neuroimaging O +
data O +
suggest O +
a O +
common O +
pathophysiology O +
associated O +
with O +
a O +
variety O +
of O +
chemotherapy O +
agents O +
and O +
modes O +
of O +
administration O -
. O +

METHODS O -
: O +
We O +
reviewed O +
the O +
medical O +
literature O +
for O +
single O +
reports O +
and O +
case O +
series O +
of O +
patients O +
presenting O +
with O +
stroke B-Disease -
- O -
like O +
episodes O +
while O +
receiving O +
systemic O +
or O +
intrathecal O +
chemotherapy O -
. O +

We O +
only O +
included O +
studies O +
providing O +
detailed O +
neuroimaging O +
data O -
. O +

Patients O +
with O +
cerebrovascular B-Disease +
accidents I-Disease +
were O +
excluded O -
. O +

RESULTS O -
: O +
We O +
identified O +
27 O +
reports O +
of O +
toxic O +
leukoencephalopathy B-Disease +
in O +
patients O +
treated O +
with O +
methotrexate O +
( O -
intrathecal O -
, O +
systemic O -
) O -
, O +
5-fluorouracil O +
and O +
its O +
derivative O +
carmofur O -
, O +
and O +
capecitabine O -
. O +

Diffusion O +
weighted O +
imaging O +
( O -
DWI O -
) O +
of O +
all O +
patients O +
revealed O +
well O +
demarcated O +
hyperintense O +
lesions B-Disease +
within I-Disease +
the I-Disease +
subcortical I-Disease +
white I-Disease +
matter I-Disease +
of O +
the O +
cerebral O +
hemispheres O +
and O +
the O +
corpus O +
callosum O -
, O +
corresponding O +
to O +
areas O +
of O +
decreased O +
proton O +
diffusion O +
on O +
apparent O +
diffusion O +
coefficient O +
( O -
ADC O -
) O +
maps O +
( O -
available O +
in O +
21 O -
/ O -
27 O +
patients O -
) O -
. O +

Lesions O +
exceeded O +
the O +
confines O +
of O +
adjacent O +
vascular O +
territories O -
. O +

Complete O +
resolution O +
of O +
symptoms O +
within O +
1 O -
- O -
4 O +
days O +
was O +
accompanied O +
by O +
normalisation O +
of O +
ADC O +
abnormalities O -
. O +

However O -
, O +
fluid O +
attenuated O +
inversion O +
recovery O +
( O -
FLAIR O -
) O +
sequences O +
frequently O +
revealed O +
persistent O +
white B-Disease +
matter I-Disease +
abnormalities I-Disease -
. O +

CONCLUSIONS O -
: O +
Several O +
pathophysiological O +
models O +
of O +
delayed O +
leukoencephalopathy B-Disease +
after O +
exposure O +
to O +
intrathecal O +
or O +
systemic O +
chemotherapy O +
have O +
been O +
proposed O -
. O +

DWI O +
findings O +
in O +
this O +
cohort O +
are O +
indicative O +
of O +
cytotoxic B-Disease +
oedema I-Disease +
within I-Disease +
cerebral I-Disease +
white I-Disease +
matter I-Disease +
and O +
lend O +
support O +
to O +
an O +
at O +
least O +
partially O +
reversible O +
metabolic O +
derangement O +
as O +
the O +
basis O +
for O +
this O +
syndrome O -
. O +

Prenatal O +
exposure O +
to O +
fluoxetine O +
induces O +
fetal B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
in O +
the O +
rat O -
. O +

RATIONALE O -
: O +
Fluoxetine O +
is O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O +
antidepressant O +
widely O +
used O +
by O +
pregnant O +
women O -
. O +

Epidemiological O +
data O +
suggest O +
that O +
fluoxetine O +
exposure O +
prenatally O +
increases O +
the O +
prevalence O +
of O +
persistent O +
pulmonary B-Disease +
hypertension I-Disease +
syndrome I-Disease +
of O +
the O +
newborn O -
. O +

The O +
mechanism O +
responsible O +
for O +
this O +
effect O +
is O +
unclear O +
and O +
paradoxical O -
, O +
considering O +
the O +
current O +
evidence O +
of O +
a O +
pulmonary B-Disease +
hypertension I-Disease +
protective O +
fluoxetine O +
effect O +
in O +
adult O +
rodents O -
. O +

OBJECTIVES O -
: O +
To O +
evaluate O +
the O +
fluoxetine O +
effect O +
on O +
fetal O +
rat O +
pulmonary O +
vascular O +
smooth O +
muscle O +
mechanical O +
properties O +
and O +
cell O +
proliferation O +
rate O -
. O +

METHODS O -
: O +
Pregnant O +
rats O +
were O +
treated O +
with O +
fluoxetine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
from O +
Day O +
11 O +
through O +
Day O +
21 O +
of O +
gestation O -
. O +

MEASUREMENTS O +
AND O +
MAIN O +
RESULTS O -
: O +
Fetuses O +
were O +
delivered O +
by O +
cesarean O +
section O -
. O +

As O +
compared O +
with O +
controls O -
, O +
fluoxetine O +
exposure O +
resulted O +
in O +
fetal B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
as O +
evidenced O +
by O +
an O +
increase O +
in O +
the O +
weight O +
ratio O +
of O +
the O +
right O +
ventricle O +
to O +
the O +
left O +
ventricle O +
plus O +
septum O +
( O -
P O +
= O +
0.02 O -
) O +
and O +
by O +
an O +
increase O +
in O +
pulmonary O +
arterial O +
medial O +
thickness O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

Postnatal O +
mortality O +
was O +
increased O +
among O +
experimental O +
animals O -
, O +
and O +
arterial O +
oxygen O +
saturation O +
was O +
96 O +
+ O -
/- O +

1 O -
% O +
in O +
1-day O -
- O -
old O +
control O +
animals O +
and O +
significantly O +
lower O +
( O -
P O +
< O +
0.01 O -
) O +
in O +
fluoxetine O -
- O -
exposed O +
pups O +
( O -
79 O +
+ O -
/- O +

2 O -
% O -
) O -
. O +

In O +
vitro O -
, O +
fluoxetine O +
induced O +
pulmonary O +
arterial O +
muscle O +
contraction O +
in O +
fetal O -
, O +
but O +
not O +
adult O -
, O +
animals O +
( O -
P O +
< O +
0.01 O -
) O +
and O +
reduced O +
serotonin O -
- O -
induced O +
contraction O +
at O +
both O +
ages O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

After O +
in O +
utero O +
exposure O +
to O +
a O +
low O +
fluoxetine O +
concentration O +
the O +
pulmonary O +
arterial O +
smooth O +
muscle O +
cell O +
proliferation O +
rate O +
was O +
significantly O +
increased O +
in O +
fetal O -
, O +
but O +
not O +
adult O -
, O +
cells O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

CONCLUSIONS O -
: O +
In O +
contrast O +
to O +
the O +
adult O -
, O +
fluoxetine O +
exposure O +
in O +
utero O +
induces O +
pulmonary B-Disease +
hypertension I-Disease +
in O +
the O +
fetal O +
rat O +
as O +
a O +
result O +
of O +
a O +
developmentally O +
regulated O +
increase O +
in O +
pulmonary O +
vascular O +
smooth O +
muscle O +
proliferation O -
. O +

Disulfiram O -
- O -
induced O +
transient O +
optic B-Disease +
and I-Disease +
peripheral I-Disease +
neuropathy I-Disease -
: O +
a O +
case O +
report O -
. O +

AIM O -
: O +
To O +
report O +
a O +
case O +
of O +
optic B-Disease +
and I-Disease +
peripheral I-Disease +
neuropathy I-Disease +
after O +
chronic O +
use O +
of O +
disulfiram O +
for O +
alcohol B-Disease +
dependence I-Disease +
management O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
A O +
case O +
report O -
. O +

RESULTS O -
: O +
A O +
57-year O -
- O -
old O +
male O +
presented O +
with O +
gradual O +
loss B-Disease +
of I-Disease +
vision I-Disease +
in O +
both O +
eyes O +
with O +
intermittent O +
headaches B-Disease +
for O +
2 O +
months O -
. O +

He O +
also O +
complained O +
of O +
paraesthesia B-Disease +
with O +
numbness B-Disease +
in O +
both O +
feet O -
. O +

His O +
vision O +
was O +
6 O -
/ O -
15 O +
and O +
2 O -
/ O -
60 O +
in O +
the O +
right O +
and O +
left O +
eyes O -
, O +
respectively O -
. O +

Fundoscopy O +
revealed O +
bilaterally O +
swollen O +
optic O +
nerve O +
heads O -
. O +

Visual O +
field O +
testing O +
confirmed O +
bilateral O +
central O -
- O -
caecal O +
scotomata B-Disease -
. O +

He O +
had O +
been O +
taking O +
disulfiram O +
for O +
alcohol B-Disease +
dependence I-Disease +
for O +
the O +
preceding O +
3 O +
years O -
. O +

Disulfiram O +
discontinuation O +
lead O +
to O +
an O +
immediate O +
symptomatic O +
improvement O -
. O +

CONCLUSION O -
: O +
Physicians O +
initiating O +
long O -
- O -
term O +
disulfiram O +
therapy O +
should O +
be O +
aware O +
of O +
these O +
adverse O +
effects O -
. O +

They O +
should O +
recommend O +
annual O +
ophthalmic O +
reviews O +
with O +
visual O +
field O +
testing O -
. O +

Patients O +
should O +
be O +
reassured O +
with O +
respect O +
to O +
the O +
reversibility O +
of O +
these O +
adverse O +
effects O -
. O +

Mutations O +
associated O +
with O +
lamivudine O -
- O -
resistance O +
in O +
therapy O -
- O -
na O +
ve O +
hepatitis B-Disease +
B I-Disease +
virus I-Disease +
( I-Disease -
HBV I-Disease -
) I-Disease +
infected I-Disease +
patients O +
with O +
and O +
without O +
HIV B-Disease +
co I-Disease -
- I-Disease -
infection I-Disease -
: O +
implications O +
for O +
antiretroviral O +
therapy O +
in O +
HBV B-Disease +
and I-Disease +
HIV I-Disease +
co I-Disease -
- I-Disease -
infected I-Disease +
South O +
African O +
patients O -
. O +

This O +
was O +
an O +
exploratory O +
study O +
to O +
investigate O +
lamivudine O -
- O -
resistant O +
hepatitis B-Disease +
B I-Disease +
virus O +
( O -
HBV O -
) O +
strains O +
in O +
selected O +
lamivudine O -
- O -
na O +
ve O +
HBV O +
carriers O +
with O +
and O +
without O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
( I-Disease -
HIV I-Disease -
) I-Disease +
co I-Disease -
- I-Disease -
infection I-Disease +
in O +
South O +
African O +
patients O -
. O +

Thirty O -
- O -
five O +
lamivudine O -
- O -
na O +
ve O +
HBV B-Disease +
infected I-Disease +
patients O +
with O +
or O +
without O +
HIV B-Disease +
co I-Disease -
- I-Disease -
infection I-Disease +
were O +
studied O -
: O +
15 O +
chronic O +
HBV B-Disease +
mono I-Disease -
- I-Disease -
infected I-Disease +
patients O +
and O +
20 O +
HBV B-Disease -
- I-Disease -
HIV I-Disease +
co I-Disease -
- I-Disease -
infected I-Disease +
patients O -
. O +

The O +
latter O +
group O +
was O +
further O +
sub O -
- O -
divided O +
into O +
13 O +
occult O +
HBV O +
( O -
HBsAg O -
- O -
negative O -
) O +
and O +
7 O +
overt O +
HBV O +
( O -
HBsAg- O +
positive O -
) O +
patients O -
. O +

HBsAg O -
, O +
anti O -
- O -
HBs O -
, O +
anti O -
- O -
HBc O -
, O +
and O +
anti O -
- O -
HIV O +
1 O -
/ O -
2 O +
were O +
determined O +
as O +
part O +
of O +
routine O +
diagnosis O +
using O +
Axsym O +
assays O +
( O -
Abbott O +
Laboratories O -
, O +
North O +
Chicago O -
, O +
IL O -
) O -
. O +

Serum O +
samples O +
were O +
PCR O +
amplified O +
with O +
HBV O +
reverse O +
transcriptase O +
( O -
RT O -
) O +
primers O -
, O +
followed O +
by O +
direct O +
sequencing O +
across O +
the O +
tyrosine O -
- O -
methionine O -
- O -
aspartate O -
- O -
aspartate O +
( O -
YMDD O -
) O +
motif O +
of O +
the O +
major O +
catalytic O +
region O +
in O +
the O +
C O +
domain O +
of O +
the O +
HBV O +
RT O +
enzyme O -
. O +

HBV O +
viral O +
load O +
was O +
performed O +
with O +
Amplicor O +
HBV O +
Monitor O +
test O +
v2.0 O +
( O -
Roche O +
Diagnostics O -
, O +
Penzberg O -
, O +
Germany O -
) O -
. O +

HBV O +
lamivudine O -
- O -
resistant O +
strains O +
were O +
detected O +
in O +
3 O +
of O +
15 O +
mono O -
- O -
infected O +
chronic O +
hepatitis B-Disease +
B I-Disease +
patients O +
and O +
10 O +
of O +
20 O +
HBV B-Disease -
- I-Disease -
HIV I-Disease +
co I-Disease -
- I-Disease -
infected I-Disease +
patients O -
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
this O +
constitutes O +
the O +
first O +
report O +
of O +
HBV O +
lamivudine O -
- O -
resistant O +
strains O +
in O +
therapy O -
- O -
na O +
ve O +
HBV B-Disease -
- I-Disease -
HIV I-Disease +
co I-Disease -
- I-Disease -
infected I-Disease +
patients O -
. O +

The O +
HBV O +
viral O +
loads O +
for O +
mono O -
- O -
infected O +
and O +
co O -
- O -
infected O +
patients O +
ranged O +
from O +
3.32 O +
x O +
10 O -
( O -
2 O -
) O +
to O +
3.82 O +
x O +
10 O -
( O -
7 O -
) O +
and O +
< O -
200 O +
to O +
4.40 O +
x O +
10 O -
( O -
3 O -
) O +
copies O -
/ O -
ml O -
, O +
respectively O -
. O +

It O +
remains O +
to O +
be O +
seen O +
whether O +
such O +
pre O -
- O -
existing O +
antiviral O +
mutations O +
could O +
result O +
in O +
widespread O +
emergence O +
of O +
HBV O +
resistant O +
strains O +
when O +
lamivudine O -
- O -
containing O +
highly O +
active O +
antiretroviral O +
( O -
ARV O -
) O +
treatment O +
( O -
HAART O -
) O +
regimens O +
become O +
widely O +
applied O +
in O +
South O +
Africa O -
, O +
as O +
this O +
is O +
likely O +
to O +
have O +
potential O +
implications O +
in O +
the O +
management O +
of O +
HBV B-Disease -
- I-Disease -
HIV I-Disease +
co I-Disease -
- I-Disease -
infected I-Disease +
patients O -
. O +

Rabbit B-Disease +
syndrome I-Disease -
, O +
antidepressant O +
use O -
, O +
and O +
cerebral O +
perfusion O +
SPECT O +
scan O +
findings O -
. O +

The O +
rabbit B-Disease +
syndrome I-Disease +
is O +
an O +
extrapyramidal O +
side O +
effect O +
associated O +
with O +
chronic O +
neuroleptic O +
therapy O -
. O +

Its O +
occurrence O +
in O +
a O +
patient O +
being O +
treated O +
with O +
imipramine O +
is O +
described O -
, O +
representing O +
the O +
first O +
reported O +
case O +
of O +
this O +
syndrome O +
in O +
conjunction O +
with O +
antidepressants O -
. O +

Repeated O +
cerebral O +
perfusion O +
SPECT O +
scans O +
revealed O +
decreased B-Disease +
basal I-Disease +
ganglia I-Disease +
perfusion I-Disease +
while O +
the O +
movement B-Disease +
disorder I-Disease +
was O +
present O -
, O +
and O +
a O +
return O +
to O +
normal O +
perfusion O +
when O +
the O +
rabbit B-Disease +
syndrome I-Disease +
resolved O -
. O +

Estrogen O +
prevents O +
cholesteryl O +
ester O +
accumulation O +
in O +
macrophages O +
induced O +
by O +
the O +
HIV O +
protease O +
inhibitor O +
ritonavir O -
. O +

Individuals O +
with O +
HIV O +
can O +
now O +
live O +
long O +
lives O +
with O +
drug O +
therapy O +
that O +
often O +
includes O +
protease O +
inhibitors O +
such O +
as O +
ritonavir O -
. O +

Many O +
patients O -
, O +
however O -
, O +
develop O +
negative O +
long O -
- O -
term O +
side O +
effects O +
such O +
as O +
premature B-Disease +
atherosclerosis I-Disease -
. O +

We O +
have O +
previously O +
demonstrated O +
that O +
ritonavir O +
treatment O +
increases O +
atherosclerotic B-Disease +
lesion I-Disease +
formation O +
in O +
male O +
mice O +
to O +
a O +
greater O +
extent O +
than O +
in O +
female O +
mice O -
. O +

Furthermore O -
, O +
peripheral O +
blood O +
monocytes O +
isolated O +
from O +
ritonavir O -
- O -
treated O +
females O +
had O +
less O +
cholesteryl O +
ester O +
accumulation O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
have O +
investigated O +
the O +
molecular O +
mechanisms O +
by O +
which O +
female O +
hormones O +
influence O +
cholesterol O +
metabolism O +
in O +
macrophages O +
in O +
response O +
to O +
the O +
HIV O +
protease O +
inhibitor O +
ritonavir O -
. O +

We O +
have O +
utilized O +
the O +
human O +
monocyte O +
cell O +
line O -
, O +
THP-1 O +
as O +
a O +
model O +
to O +
address O +
this O +
question O -
. O +

Briefly O -
, O +
cells O +
were O +
differentiated O +
for O +
72 O +
h O +
with O +
100 O +
nM O +
PMA O +
to O +
obtain O +
a O +
macrophage O -
- O -
like O +
phenotype O +
in O +
the O +
presence O +
or O +
absence O +
of O +
1 O +
nM O +
17beta O -
- O -
estradiol O +
( O -
E2 O -
) O -
, O +
100 O +
nM O +
progesterone O +
or O +
vehicle O +
( O -
0.01 O -
% O +
ethanol O -
) O -
. O +

Cells O +
were O +
then O +
treated O +
with O +
30 O +
ng O -
/ O -
ml O +
ritonavir O +
or O +
vehicle O +
in O +
the O +
presence O +
of O +
aggregated O +
LDL O +
for O +
24 O +
h. O +
Cell O +
extracts O +
were O +
harvested O -
, O +
and O +
lipid O +
or O +
total O +
RNA O +
was O +
isolated O -
. O +

E2 O +
decreased O +
the O +
accumulation O +
of O +
cholesteryl O +
esters O +
in O +
macrophages O +
following O +
ritonavir O +
treatment O -
. O +

Ritonavir O +
increased O +
the O +
expression O +
of O +
the O +
scavenger O +
receptor O -
, O +
CD36 O +
mRNA O -
, O +
responsible O +
for O +
the O +
uptake O +
of O +
LDL O -
. O +

Additionally O -
, O +
ritonavir O +
treatment O +
selectively O +
increased O +
the O +
relative O +
levels O +
of O +
PPARgamma O +
mRNA O -
, O +
a O +
transcription O +
factor O +
responsible O +
for O +
the O +
regulation O +
of O +
CD36 O +
mRNA O +
expression O -
. O +

Treatment O +
with O +
E2 O -
, O +
however O -
, O +
failed O +
to O +
prevent O +
these O +
increases O +
at O +
the O +
mRNA O +
level O -
. O +

E2 O +
did O -
, O +
however O -
, O +
significantly O +
suppress O +
CD36 O +
protein O +
levels O +
as O +
measured O +
by O +
fluorescent O +
immunocytochemistry O -
. O +

This O +
data O +
suggests O +
that O +
E2 O +
modifies O +
the O +
expression O +
of O +
CD36 O +
at O +
the O +
level O +
of O +
protein O +
expression O +
in O +
monocyte O -
- O -
derived O +
macrophages O +
resulting O +
in O +
reduced O +
cholesteryl O +
ester O +
accumulation O +
following O +
ritonavir O +
treatment O -
. O +

Acute O +
hepatitis B-Disease +
attack O +
after O +
exposure O +
to O +
telithromycin O -
. O +

INTRODUCTION O -
: O +
Antibiotic O -
- O -
associated O +
hepatotoxicity B-Disease +
is O +
rare O -
. O +

With O +
widespread O +
use O +
of O +
antimicrobial O +
agents O -
, O +
however O -
, O +
hepatic B-Disease +
injury I-Disease +
occurs O +
frequently O -
, O +
and O +
among O +
adverse B-Disease +
drug I-Disease +
reactions I-Disease -
, O +
idiosyncratic O +
reactions O +
are O +
the O +
most O +
serious O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
25-year O -
- O -
old O +
male O +
patient O -
, O +
with O +
a O +
height O +
of O +
175 O +
cm O +
and O +
weight O +
of O +
72 O +
kg O +
presented O +
to O +
Marmara O +
University O +
Hospital O +
Emergency O +
Department O -
, O +
Istanbul O -
, O +
Turkey O -
, O +
with O +
5 O +
days O -
' O +
history O +
of O +
jaundice B-Disease -
, O +
malaise O -
, O +
nausea B-Disease -
, O +
and O +
vomiting B-Disease -
. O +

He O +
had O +
been O +
prescribed O +
telithromycin O +
400 O +
mg O -
/ O -
d O +
PO O +
to O +
treat O +
an O +
upper B-Disease +
respiratory I-Disease +
tract I-Disease +
infection I-Disease +
7 O +
days O +
prior O -
. O +

Admission O +
laboratory O +
tests O +
were O +
as O +
follows O -
: O +
alanine O +
aminotransferase O -
, O +
67 O +
U O -
/ O -
L O +
( O -
reference O +
range O -
, O +
10 O -
- O -
37 O +
U O -
/ O -
L O -
) O -
; O +
aspartate O +
aminotransferase O -
, O +
98 O +
U O -
/ O -
L O +
( O -
10 O -
- O -
40 O +
U O -
/ O -
L O -
) O -
; O +
alkaline O +
phosphatase O -
, O +
513 O +
U O -
/ O -
L O +
( O -
0 O -
- O -
270 O +
U O -
/ O -
L O -
) O -
; O +
gamma O -
- O -
glutamyltransferase O -
, O +
32 O +
U O -
/ O -
L O +
( O -
7 O -
- O -
49 O +
U O -
/ O -
L O -
) O -
; O +
amylase O -
, O +
46 O +
U O -
/ O -
L O +
( O -
0 O -
- O -
220 O +
U O -
/ O -
L O -
) O -
; O +
total O +
bilirubin O -
, O +
20.1 O +
mg O -
/ O -
dL O +
( O -
0.2 O -
- O -
1.0 O +
mg O -
/ O -
dL O -
) O -
; O +
direct O +
bilirubin O -
, O +
14.8 O +
mg O -
/ O -
dL O +
( O -
0 O -
- O -
0.3 O +
mg O -
/ O -
dL O -
) O -
; O +
and O +
albumin O -
, O +
4.7 O +
mg O -
/ O -
dL O +
( O -
3.5 O -
- O -
5.4 O +
mg O -
/ O -
dL O -
) O -
. O +

No O +
toxin O -
, O +
alcohol O -
, O +
or O +
other O +
drugs O +
were O +
reported O -
. O +

The O +
patient O +
had O +
suffered O +
a O +
previous O +
episode O +
of O +
" O -
acute O +
hepatitis B-Disease +
of O +
unknown O +
origin O -
, O -
" O +
that O +
occurred O +
after O +
telithromycin O +
usage O -
. O +

Both O +
incidents O +
occurred O +
within O +
a O +
year O -
. O +

DISCUSSION O +

: O +
Telithromycin O +
is O +
the O +
first O +
of O +
the O +
ketolide O +
antibacterials O +
to O +
receive O +
US O +
Food O +
and O +
Drug O +
Administration O +
approval O +
for O +
clinical O +
use O -
. O +

It O +
has O +
been O +
associated O +
with O +
infrequent O +
and O +
usually O +
reversible O +
severe O +
hepatic B-Disease +
dysfunction I-Disease -
. O +

Based O +
on O +
a O +
score O +
of O +
8 O +
on O +
the O +
Naranjo O +
adverse B-Disease +
drug I-Disease +
reaction I-Disease +
probability O +
scale O -
, O +
telithromycin O +
was O +
the O +
probable O +
cause O +
of O +
acute O +
hepatitis B-Disease +
in O +
this O +
patient O -
, O +
and O +
pathological O +
findings O +
suggested O +
drug O -
- O -
induced O +
toxic B-Disease +
hepatitis I-Disease -
. O +

Recurrence O +
of O +
hepatitis B-Disease +
attack O +
might O +
have O +
been O +
avoided O +
if O +
the O +
initial O +
incident O +
had O +
been O +
communicated O +
to O +
the O +
attending O +
physician O +
who O +
prescribed O +
telithromycin O +
the O +
second O +
time O -
. O +

CONCLUSION O -
: O +
Here O +
we O +
report O +
a O +
case O +
of O +
acute O +
hepatitis B-Disease +
probably O +
associated O +
with O +
the O +
administration O +
of O +
telithromycin O -
. O +

A O +
study O +
on O +
the O +
effect O +
of O +
the O +
duration O +
of O +
subcutaneous O +
heparin O +
injection O +
on O +
bruising B-Disease +
and O +
pain B-Disease -
. O +

AIM O -
: O +
This O +
study O +
was O +
carried O +
out O +
to O +
determine O +
the O +
effect O +
of O +
injection O +
duration O +
on O +
bruising B-Disease +
and O +
pain B-Disease +
following O +
the O +
administration O +
of O +
the O +
subcutaneous O +
injection O +
of O +
heparin O -
. O +

BACKGROUND O -
: O +
Although O +
different O +
methods O +
to O +
prevent O +
bruising B-Disease +
and O +
pain B-Disease +
following O +
the O +
subcutaneous O +
injection O +
of O +
heparin O +
have O +
been O +
widely O +
studied O +
and O +
described O -
, O +
the O +
effect O +
of O +
injection O +
duration O +
on O +
the O +
occurrence O +
of O +
bruising B-Disease +
and O +
pain B-Disease +
is O +
little O +
documented O -
. O +

DESIGN O -
: O +
This O +
study O +
was O +
designed O +
as O +
within O -
- O -
subject O -
, O +
quasi O -
- O -
experimental O +
research O -
. O +

METHOD O -
: O +
The O +
sample O +
for O +
the O +
study O +
consisted O +
of O +
50 O +
patients O +
to O +
whom O +
subcutaneous O +
heparin O +
was O +
administered O -
. O +

Heparin O +
was O +
injected O +
over O +
10 O +
seconds O +
on O +
the O +
right O +
abdominal O +
site O +
and O +
30 O +
seconds O +
on O +
the O +
left O +
abdominal O +
site O -
. O +

Injections O +
areas O +
were O +
assessed O +
for O +
the O +
presence O +
of O +
bruising B-Disease +
at O +
48 O +
and O +
72 O +
hours O +
after O +
each O +
injection O -
. O +

Dimensions O +
of O +
the O +
bruising B-Disease +
on O +
the O +
heparin O +
applied O +
areas O +
were O +
measured O +
using O +
transparent O +
millimetric O +
measuring O +
paper O -
. O +

The O +
visual O +
analog O +
scale O +
( O -
VAS O -
) O +
was O +
used O +
to O +
measure O +
pain B-Disease +
intensity O +
and O +
a O +
stop O -
- O -
watch O +
was O +
used O +
to O +
time O +
the O +
pain B-Disease +
period O -
. O +

Data O +
were O +
analysed O +
using O +
chi O -
- O -
square O +
test O -
, O +
Mann O -
- O -
Whitney O +
U O -
, O +
Wilcoxon O +
signed O +
ranks O +
tests O +
and O +
correlation O -
. O +

RESULTS O -
: O +
The O +
percentage O +
of O +
bruising B-Disease +
occurrence O +
was O +
64 O -
% O +
with O +
the O +
injection O +
of O +
10 O +
seconds O +
duration O +
and O +
42 O -
% O +
in O +
the O +
30-second O +
injection O -
. O +

It O +
was O +
determined O +
that O +
the O +
size O +
of O +
the O +
bruising B-Disease +
was O +
smaller O +
in O +
the O +
30-second O +
injection O -
. O +

Pain B-Disease +
intensity O +
and O +
pain B-Disease +
period O +
were O +
statistically O +
significantly O +
lower O +
for O +
the O +
30-second O +
injection O +
than O +
for O +
the O +
10-second O +
injection O -
. O +

CONCLUSIONS O -
: O +
It O +
was O +
determined O +
that O +
injection O +
duration O +
had O +
an O +
effect O +
on O +
bruising B-Disease +
and O +
pain B-Disease +
following O +
the O +
subcutaneous O +
administration O +
of O +
heparin O -
. O +

This O +
study O +
should O +
be O +
repeated O +
on O +
a O +
larger O +
sample O -
. O +

RELEVANCE O +
TO O +
CLINICAL O +
PRACTICE O -
: O +
When O +
administering O +
subcutaneous O +
heparin O +
injections O -
, O +
it O +
is O +
important O +
to O +
extend O +
the O +
duration O +
of O +
the O +
injection O -
. O +

Myocardial O +
Fas O +
ligand O +
expression O +
increases O +
susceptibility O +
to O +
AZT O -
- O -
induced O +
cardiomyopathy B-Disease -
. O +

BACKGROUND O -
: O +
Dilated B-Disease +
cardiomyopathy I-Disease +
( O -
DCM B-Disease -
) O +
and O +
myocarditis B-Disease +
occur O +
in O +
many O +
HIV B-Disease -
- I-Disease -
infected I-Disease +
individuals O -
, O +
resulting O +
in O +
symptomatic O +
heart B-Disease +
failure I-Disease +
in O +
up O +
to O +
5 O -
% O +
of O +
patients O -
. O +

Highly O +
active O +
antiretroviral O +
therapy O +
( O -
HAART O -
) O +
has O +
significantly O +
reduced O +
morbidity O +
and O +
mortality O +
of O +
acquired B-Disease +
immunodeficiency I-Disease +
syndrome I-Disease +
( O -
AIDS B-Disease -
) O -
, O +
but O +
has O +
resulted O +
in O +
an O +
increase O +
in O +
cardiac B-Disease +
and I-Disease +
skeletal I-Disease +
myopathies I-Disease -
. O +

METHODS O +
AND O +
RESULTS O -
: O +
In O +
order O +
to O +
investigate O +
whether O +
the O +
HAART O +
component O +
zidovudine O +
( O -
3'-azido-2',3'-deoxythymidine O -
; O +
AZT O -
) O +
triggers O +
the O +
Fas O -
- O -
dependent O +
cell O -
- O -
death O +
pathway O +
and O +
cause O +
cytoskeletal O +
disruption O +
in O +
a O +
murine O +
model O +
of O +
DCM B-Disease -
, O +
8-week O -
- O -
old O +
transgenic O +
( O -
expressing O +
Fas O +
ligand O +
in O +
the O +
myocardium O -
: O +
FasL O +
Tg O -
) O +
and O +
non O -
- O -
transgenic O +
( O -
NTg O -
) O +
mice O +
received O +
water O +
ad O +
libitum O +
containing O +
different O +
concentrations O +
of O +
AZT O +
( O -
0 O -
, O +
0.07 O -
, O +
0.2 O -
, O +
and O +
0.7 O +
mg O -
/ O -
ml O -
) O -
. O +

After O +
6 O +
weeks O -
, O +
cardiac O +
function O +
was O +
assessed O +
by O +
echocardiography O +
and O +
morphology O +
was O +
assessed O +
by O +
histopathologic O +
and O +
immunohistochemical O +
methods O -
. O +

NTg O +
and O +
untreated O +
FasL O +
Tg O +
mice O +
showed O +
little O +
or O +
no O +
change O +
in O +
cardiac O +
structure O +
or O +
function O -
. O +

In O +
contrast O -
, O +
AZT O -
- O -
treated O +
FasL O +
Tg O +
mice O +
developed O +
cardiac B-Disease +
dilation I-Disease +
and O +
depressed O +
cardiac O +
function O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
with O +
concomitant O +
inflammatory O +
infiltration O +
of O +
both O +
ventricles O -
. O +

These O +
changes O +
were O +
associated O +
with O +
an O +
increased O +
sarcolemmal O +
expression O +
of O +
Fas O +
and O +
FasL O -
, O +
as O +
well O +
as O +
increased O +
activation O +
of O +
caspase O +
3 O -
, O +
translocation O +
of O +
calpain O +
1 O +
to O +
the O +
sarcolemma O +
and O +
sarcomere O -
, O +
and O +
increased O +
numbers O +
of O +
cells O +
undergoing O +
apoptosis O -
. O +

These O +
were O +
associated O +
with O +
changes O +
in O +
dystrophin O +
and O +
cardiac O +
troponin O +
I O +
localization O -
, O +
as O +
well O +
as O +
loss O +
of O +
sarcolemmal O +
integrity O -
. O +

CONCLUSIONS O -
: O +
The O +
expression O +
of O +
Fas O +
ligand O +
in O +
the O +
myocardium O -
, O +
as O +
identified O +
in O +
HIV O -
- O -
positive O +
patients O -
, O +
might O +
increase O +
the O +
susceptibility O +
to O +
HAART O -
- O -
induced O +
cardiomyopathy B-Disease +
due O +
to O +
activation O +
of O +
apoptotic O +
pathways O -
, O +
resulting O +
in O +
cardiac B-Disease +
dilation I-Disease +
and I-Disease +
dysfunction I-Disease -
. O +

Gastrointestinal O +
tolerability O +
of O +
etoricoxib O +
in O +
rheumatoid B-Disease +
arthritis I-Disease +
patients O -
: O +
results O +
of O +
the O +
etoricoxib O +
vs O +
diclofenac O +
sodium O +
gastrointestinal O +
tolerability O +
and O +
effectiveness O +
trial O +
( O -
EDGE O -
- O -
II O -
) O -
. O +

OBJECTIVE O -
: O +
A O +
randomised O -
, O +
double O -
- O -
blind O +
study O +
to O +
compare O +
the O +
gastrointestinal O +
( O -
GI O -
) O +
tolerability O -
, O +
safety O +
and O +
efficacy O +
of O +
etoricoxib O +
and O +
diclofenac O +
in O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
( O -
RA B-Disease -
) O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
A O +
total O +
of O +
4086 O +
patients O +
( O -
mean O +
age O +
60.8 O +
years O -
) O +
diagnosed O +
with O +
RA B-Disease +
were O +
enrolled O +
and O +
received O +
etoricoxib O +
90 O +
mg O +
daily O +
( O -
n O +
= O +
2032 O -
) O +
or O +
diclofenac O +
75 O +
mg O +
twice O +
daily O +
( O -
n O +
= O +
2054 O -
) O -
. O +

Use O +
of O +
gastroprotective O +
agents O +
and O +
low O -
- O -
dose O +
aspirin O +
was O +
allowed O -
. O +

The O +
prespecified O +
primary O +
end O +
point O +
consisted O +
of O +
the O +
cumulative O +
rate O +
of O +
patient O +
discontinuations O +
due O +
to O +
clinical O +
and O +
laboratory O +
GI O +
adverse O +
experiences O +
( O -
AEs O -
) O -
. O +

General O +
safety O +
was O +
also O +
assessed O -
, O +
including O +
adjudicated O +
thrombotic B-Disease +
cardiovascular I-Disease +
event O +
data O -
. O +

Efficacy O +
was O +
evaluated O +
using O +
the O +
Patient O +
Global O +
Assessment O +
of O +
Disease O +
Status O +
( O -
PGADS O -
; O +
0 O -
- O -
4 O +
point O +
scale O -
) O -
. O +

RESULTS O -
: O +
Mean O +
( O -
SD O -
; O +
maximum O -
) O +
duration O +
of O +
treatment O +
was O +
19.3 O +
( O -
10.3 O -
; O +
32.9 O -
) O +
and O +
19.1 O +
( O -
10.4 O -
; O +
33.1 O -
) O +
months O +
in O +
the O +
etoricoxib O +
and O +
diclofenac O +
groups O -
, O +
respectively O -
. O +

The O +
cumulative O +
discontinuation O +
rate O +
due O +
to O +
GI B-Disease +
AEs I-Disease +
was O +
significantly O +
lower O +
with O +
etoricoxib O +
than O +
diclofenac O +
( O -
5.2 O +
vs O +
8.5 O +
events O +
per O +
100 O +
patient O -
- O -
years O -
, O +
respectively O -
; O +
hazard O +
ratio O +
0.62 O +
( O -
95 O -
% O +
CI O -
: O +
0.47 O -
, O +
0.81 O -
; O +
p O -
< O -
or=0.001 O -
) O -
) O -
. O +

The O +
incidence O +
of O +
discontinuations O +
for O +
hypertension B-Disease -
- O -
related O +
and O +
oedema B-Disease -
- O -
related O +
AEs O +
were O +
significantly O +
higher O +
with O +
etoricoxib O +
( O -
2.5 O -
% O +
and O +
1.1 O -
% O +
respectively O -
) O +
compared O +
with O +
diclofenac O +
( O -
1.5 O -
% O +
and O +
0.4 O -
% O +
respectively O -
; O +
p<0.001 O +
for O +
hypertension B-Disease +
and O +
p<0.01 O +
for O +
oedema B-Disease -
) O -
. O +

Etoricoxib O +
and O +
diclofenac O +
treatment O +
resulted O +
in O +
similar O +
efficacy O +
( O -
PGADS O +
mean O +
changes O +
from O +
baseline O +
-0.62 O +
vs O +
-0.58 O -
, O +
respectively O -
) O -
. O +

CONCLUSIONS O -
: O +
Etoricoxib O +
90 O +
mg O +
demonstrated O +
a O +
significantly O +
lower O +
risk O +
for O +
discontinuing O +
treatment O +
due O +
to O +
GI B-Disease +
AEs I-Disease +
compared O +
with O +
diclofenac O +
150 O +
mg O -
. O +

Discontinuations O +
from O +
renovascular O +
AEs O -
, O +
although O +
less O +
common O +
than O +
discontinuations O +
from O +
GI B-Disease +
AEs I-Disease -
, O +
were O +
significantly O +
higher O +
with O +
etoricoxib O -
. O +

Anxiogenic O +
potential O +
of O +
ciprofloxacin O +
and O +
norfloxacin O +
in O +
rats O -
. O +

INTRODUCTION O -
: O +
The O +
possible O +
anxiogenic O +
effects O +
of O +
fluoroquinolones O -
, O +
namely O +
ciprofloxacin O +
and O +
norfloxacin O -
, O +
were O +
investigated O +
in O +
adult O +
Charles O +
Foster O +
albino O +
rats O +
of O +
either O +
sex O -
, O +
weighing O +
150 O -
- O -
200 O +
g. O +
METHODS O -
: O +
The O +
drugs O +
were O +
given O +
orally O -
, O +
in O +
doses O +
of O +
50 O +
mg O -
/ O -
kg O +
for O +
five O +
consecutive O +
days O +
and O +
the O +
experiments O +
were O +
performed O +
on O +
the O +
fifth O +
day O -
. O +

The O +
tests O +
included O +
open O -
- O -
field O +
exploratory O +
behaviour O -
, O +
elevated O +
plus O +
maze O +
and O +
elevated O +
zero O +
maze O -
, O +
social O +
interaction O +
and O +
novelty O -
- O -
suppressed O +
feeding O +
latency O +
behaviour O -
. O +

RESULTS O -
: O +
The O +
results O +
indicate O +
that O +
ciprofloxacin- O +
and O +
norfloxacin O -
- O -
treated O +
rats O +
showed O +
anxious B-Disease +
behaviour I-Disease +
in O +
comparison O +
to O +
control O +
rats O +
in O +
all O +
the O +
parameters O +
studied O -
. O +

However O -
, O +
ciprofloxacin- O +
and O +
norfloxacin O -
- O -
treated O +
rats O +
did O +
not O +
differ O +
significantly O +
from O +
each O +
other O +
in O +
various O +
behavioural O +
parameters O -
. O +

CONCLUSION O -
: O +
The O +
present O +
experimental O +
findings O +
substantiate O +
the O +
clinically O +
observed O +
anxiogenic O +
potential O +
of O +
ciprofloxacin O +
and O +
norfloxacin O -
. O +

Acute B-Disease +
liver I-Disease +
failure I-Disease +
in O +
two O +
patients O +
with O +
regular O +
alcohol O +
consumption O +
ingesting O +
paracetamol O +
at O +
therapeutic O +
dosage O -
. O +

BACKGROUND O -
: O +
The O +
possible O +
role O +
of O +
alcohol O +
in O +
the O +
development O +
of O +
hepatotoxicity B-Disease +
associated O +
with O +
therapeutic O +
doses O +
of O +
paracetamol O +
( O -
acetaminophen O -
) O +
is O +
currently O +
debated O -
. O +

CASE O +
REPORT O -
: O +
We O +
describe O +
2 O +
patients O +
who O +
were O +
regular O +
consumers O +
of O +
alcohol O +
and O +
who O +
developed O +
liver B-Disease +
failure I-Disease +
within O +
3 O -
- O -
5 O +
days O +
after O +
hospitalization O +
and O +
stopping O +
alcohol O +
consumption O +
while O +
being O +
treated O +
with O +
4 O +
g O +
paracetamol O -
/ O -
day O -
. O +

A O +
paracetamol O +
serum O +
level O +
obtained O +
in O +
one O +
of O +
these O +
patients O +
was O +
not O +
in O +
the O +
toxic O +
range O -
. O +

Possible O +
risk O +
factors O +
for O +
the O +
development O +
of O +
hepatotoxicity B-Disease +
in O +
patients O +
treated O +
with O +
therapeutic O +
doses O +
of O +
paracetamol O +
are O +
discussed O -
. O +

CONCLUSION O -
: O +
In O +
patients O +
with O +
risk O +
factors O -
, O +
e.g. O +
regular O +
consumption O +
of O +
alcohol O -
, O +
liver B-Disease +
failure I-Disease +
is O +
possible O +
when O +
therapeutic O +
doses O +
are O +
ingested O -
. O +

We O +
propose O +
that O +
the O +
paracetamol O +
dose O +
should O +
not O +
exceed O +
2 O +
g O -
/ O -
day O +
in O +
such O +
patients O +
and O +
that O +
their O +
liver O +
function O +
should O +
be O +
monitored O +
closely O +
while O +
being O +
treated O +
with O +
paracetamol O -
. O +

Reduction O +
of O +
pain B-Disease +
during O +
induction O +
with O +
target O -
- O -
controlled O +
propofol O +
and O +
remifentanil O -
. O +

BACKGROUND O -
: O +
Pain B-Disease +
on O +
injection O +
of O +
propofol O +
is O +
unpleasant O -
. O +

We O +
hypothesized O +
that O +
propofol O +
infusion O +
pain B-Disease +
might O +
be O +
prevented O +
by O +
infusing O +
remifentanil O +
before O +
starting O +
the O +
propofol O +
infusion O +
in O +
a O +
clinical O +
setting O +
where O +
target O -
- O -
controlled O +
infusions O +
( O -
TCI O -
) O +
of O +
both O +
drugs O +
were O +
used O -
. O +

A O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
trial O +
was O +
performed O +
to O +
determine O +
the O +
effect O -
- O -
site O +
concentration O +
( O -
Ce O -
) O +
of O +
remifentanil O +
to O +
prevent O +
the O +
pain B-Disease +
without O +
producing O +
complications O -
. O +

METHODS O -
: O +
A O +
total O +
of O +
128 O +
patients O +
undergoing O +
general O +
surgery O +
were O +
randomly O +
allocated O +
to O +
receive O +
normal O +
saline O +
( O -
control O -
) O +
or O +
remifentanil O +
to O +
a O +
target O +
Ce O +
of O +
2 O +
ng O +
ml O -
( O -
-1 O -
) O +
( O -
R2 O -
) O -
, O +
4 O +
ng O +
ml O -
( O -
-1 O -
) O +
( O -
R4 O -
) O -
, O +
or O +
6 O +
ng O +
ml O -
( O -
-1 O -
) O +
( O -
R6 O -
) O +
administered O +
via O +
TCI O -
. O +

After O +
the O +
target O +
Ce O +
was O +
achieved O -
, O +
the O +
infusion O +
of O +
propofol O +
was O +
started O -
. O +

Remifentanil O -
- O -
related O +
complications O +
were O +
assessed O +
during O +
the O +
remifentanil O +
infusion O -
, O +
and O +
pain B-Disease +
caused O +
by O +
propofol O +
was O +
evaluated O +
using O +
a O +
four O -
- O -
point O +
scale O +
during O +
the O +
propofol O +
infusion O -
. O +

RESULTS O -
: O +
The O +
incidence O +
of O +
pain B-Disease +
was O +
significantly O +
lower O +
in O +
Groups O +
R4 O +
and O +
R6 O +
than O +
in O +
the O +
control O +
and O +
R2 O +
groups O +
( O -
12 O -
/ O -
32 O +
and O +
6 O -
/ O -
31 O +
vs O +
26 O -
/ O -
31 O +
and O +
25 O -
/ O -
32 O -
, O +
respectively O -
, O +
P<0.001 O -
) O -
. O +

Pain B-Disease +
was O +
less O +
severe O +
in O +
Groups O +
R4 O +
and O +
R6 O +
than O +
in O +
the O +
control O +
and O +
R2 O +
groups O +
( O -
P<0.001 O -
) O -
. O +

However O -
, O +
both O +
incidence O +
and O +
severity O +
of O +
pain B-Disease +
were O +
not O +
different O +
between O +
Groups O +
R4 O +
and O +
R6 O -
. O +

No O +
significant O +
complications O +
were O +
observed O +
during O +
the O +
study O -
. O +

CONCLUSIONS O -
: O +
During O +
induction O +
of O +
anaesthesia O +
with O +
TCI O +
of O +
propofol O +
and O +
remifentanil O -
, O +
a O +
significant O +
reduction O +
in O +
propofol O +
infusion O +
pain B-Disease +
was O +
achieved O +
without O +
significant O +
complications O +
by O +
prior O +
administration O +
of O +
remifentanil O +
at O +
a O +
target O +
Ce O +
of O +
4 O +
ng O +
ml O -
( O -
-1 O -
) O -
. O +

Associations O +
between O +
use O +
of O +
benzodiazepines O +
or O +
related O +
drugs O +
and O +
health O -
, O +
physical O +
abilities O +
and O +
cognitive O +
function O -
: O +
a O +
non O -
- O -
randomised O +
clinical O +
study O +
in O +
the O +
elderly O -
. O +

OBJECTIVE O -
: O +
To O +
describe O +
associations O +
between O +
the O +
use O +
of O +
benzodiazepines O +
or O +
related O +
drugs O +
( O -
BZDs O -
/ O -
RDs O -
) O +
and O +
health O -
, O +
functional O +
abilities O +
and O +
cognitive O +
function O +
in O +
the O +
elderly O -
. O +

METHODS O -
: O +
A O +
non O -
- O -
randomised O +
clinical O +
study O +
of O +
patients O +
aged O +
> O +
or O +
= O -
65 O +
years O +
admitted O +
to O +
acute O +
hospital O +
wards O +
during O +
1 O +
month O -
. O +

164 O +
patients O +
( O -
mean O +
age O +
+ O -
/- O +

standard O +
deviation O +
[ O -
SD O -
] O +
81.6 O +
+ O -
/- O +

6.8 O +
years O -
) O +
were O +
admitted O -
. O +

Of O +
these O -
, O +
nearly O +
half O +
( O -
n O +
= O +
78 O -
) O +
had O +
used O +
BZDs O -
/ O -
RDs O +
before O +
admission O -
, O +
and O +
the O +
remainder O +
( O -
n O +
= O +
86 O -
) O +
were O +
non O -
- O -
users O -
. O +

Cognitive O +
ability O +
was O +
assessed O +
by O +
the O +
Mini O -
- O -
Mental O +
State O +
Examination O +
( O -
MMSE O -
) O -
. O +

Patients O +
scoring O +
> O +
or O +
= O -
20 O +
MMSE O +
sum O +
points O +
were O +
interviewed O +
( O -
n O +
= O +
79 O -
) O +
and O +
questioned O +
regarding O +
symptoms O +
and O +
functional O +
abilities O +
during O +
the O +
week O +
prior O +
to O +
admission O -
. O +

Data O +
on O +
use O +
of O +
BZDs O -
/ O -
RDs O +
before O +
admission O -
, O +
current O +
medications O +
and O +
discharge O +
diagnoses O +
were O +
collected O +
from O +
medical O +
records O -
. O +

Health O -
, O +
physical O +
abilities O +
and O +
cognitive O +
function O +
were O +
compared O +
between O +
BZD O -
/ O -
RD O +
users O +
and O +
non O -
- O -
users O -
, O +
and O +
adjustments O +
were O +
made O +
for O +
confounding O +
variables O -
. O +

The O +
residual O +
serum O +
concentrations O +
of O +
oxazepam O -
, O +
temazepam O +
and O +
zopiclone O +
were O +
analysed O -
. O +

RESULTS O -
: O +
The O +
mean O +
+ O -
/- O +

SD O +
duration O +
of O +
BZD O -
/ O -
RD O +
use O +
was O +
7 O +
+ O -
/- O +

7 O +
years O +
( O -
range O +
1 O -
- O -
31 O -
) O -
. O +

Two O +
or O +
three O +
BZDs O -
/ O -
RDs O +
were O +
concomitantly O +
taken O +
by O +
26 O -
% O +
of O +
users O +
( O -
n O +
= O +
20 O -
) O -
. O +

Long O -
- O -
term O +
use O +
of O +
these O +
drugs O +
was O +
associated O +
with O +
female O +
sex O +
and O +
use O +
of O +
a O +
higher O +
number O +
of O +
drugs O +
with O +
effects O +
on O +
the O +
CNS O -
, O +
which O +
tended O +
to O +
be O +
related O +
to O +
diagnosed O +
dementia B-Disease -
. O +

After O +
adjustment O +
for O +
these O +
variables O +
as O +
confounders O -
, O +
use O +
of O +
BZDs O -
/ O -
RDs O +
was O +
not O +
associated O +
with O +
cognitive O +
function O +
as O +
measured O +
by O +
the O +
MMSE O -
. O +

However O -
, O +
use O +
of O +
BZDs O -
/ O -
RDs O +
was O +
associated O +
with O +
dizziness B-Disease -
, O +
inability B-Disease +
to I-Disease +
sleep I-Disease +
after O +
awaking O +
at O +
night O +
and O +
tiredness B-Disease +
in O +
the O +
mornings O +
during O +
the O +
week O +
prior O +
to O +
admission O +
and O +
with O +
stronger O +
depressive B-Disease +
symptoms I-Disease +
measured O +
at O +
the O +
beginning O +
of O +
the O +
hospital O +
stay O -
. O +

Use O +
of O +
BZDs O -
/ O -
RDs O +
tended O +
to O +
be O +
associated O +
with O +
a O +
reduced O +
ability O +
to O +
walk O +
and O +
shorter O +
night O -
- O -
time O +
sleep O +
during O +
the O +
week O +
prior O +
to O +
admission O -
. O +

A O +
higher O +
residual O +
serum O +
concentration O +
of O +
temazepam O +
correlated O +
with O +
a O +
lower O +
MMSE O +
sum O +
score O +
after O +
adjustment O +
for O +
confounding O +
variables O -
. O +

CONCLUSIONS O -
: O +
Long O -
- O -
term O +
use O +
and O +
concomitant O +
use O +
of O +
more O +
than O +
one O +
BZD O -
/ O -
RD O +
were O +
common O +
in O +
elderly O +
patients O +
hospitalised O +
because O +
of O +
acute O +
illnesses O -
. O +

Long O -
- O -
term O +
use O +
was O +
associated O +
with O +
daytime O +
and O +
night O -
- O -
time O +
symptoms O +
indicative O +
of O +
poorer O +
health O +
and O +
potentially O +
caused O +
by O +
the O +
adverse O +
effects O +
of O +
these O +
drugs O -
. O +

Acute O +
vocal B-Disease +
fold I-Disease +
palsy I-Disease +
after O +
acute O +
disulfiram O +
intoxication O -
. O +

Acute O +
peripheral B-Disease +
neuropathy I-Disease +
caused O +
by O +
a O +
disulfiram O +
overdose B-Disease +
is O +
very O +
rare O +
and O +
there O +
is O +
no O +
report O +
of O +
it O +
leading O +
to O +
vocal B-Disease +
fold I-Disease +
palsy I-Disease -
. O +

A O +
49-year O -
- O -
old O +
woman O +
was O +
transferred O +
to O +
our O +
department O +
because O +
of O +
quadriparesis B-Disease -
, O +
lancinating O +
pain B-Disease -
, O +
sensory B-Disease +
loss I-Disease -
, O +
and O +
paresthesia B-Disease +
of O +
the O +
distal O +
limbs O -
. O +

One O +
month O +
previously O -
, O +
she O +
had O +
taken O +
a O +
single O +
high O +
dose O +
of O +
disulfiram O +
( O -
130 O +
tablets O +
of O +
ALCOHOL O +
STOP O +
TAB O -
, O +
Shin O -
- O -
Poong O +
Pharm O -
. O +

Co. O -
, O +
Ansan O -
, O +
Korea O -
) O +
in O +
a O +
suicide O +
attempt O -
. O +

She O +
was O +
not O +
an O +
alcoholic O -
. O +

For O +
the O +
first O +
few O +
days O +
after O +
ingestion O -
, O +
she O +
was O +
in O +
a O +
confused O +
state O +
and O +
had O +
mild O +
to O +
moderate O +
ataxia B-Disease +
and O +
giddiness B-Disease -
. O +

She O +
noticed O +
hoarseness B-Disease +
and O +
distally O +
accentuated O +
motor O +
and O +
sensory O +
dysfunction O +
after O +
she O +
had O +
recovered O +
from O +
this O +
state O -
. O +

A O +
nerve O +
conduction O +
study O +
was O +
consistent O +
with O +
severe O +
sensorimotor O +
axonal O +
polyneuropathy B-Disease -
. O +

Laryngeal O +
electromyography O +
( O -
thyroarytenoid O +
muscle O -
) O +
showed O +
ample O +
denervation O +
potentials O -
. O +

Laryngoscopy O +
revealed O +
asymmetric O +
vocal O +
fold O +
movements O +
during O +
phonation O -
. O +

Her O +
vocal O +
change O +
and O +
weakness O +
began O +
to O +
improve O +
spontaneously O +
about O +
3 O +
weeks O +
after O +
transfer O -
. O +

This O +
was O +
a O +
case O +
of O +
acute O +
palsy B-Disease +
of O +
the O +
recurrent O +
laryngeal O +
nerve O +
and O +
superimposed O +
severe O +
acute O +
sensorimotor O +
axonal O +
polyneuropathy B-Disease +
caused O +
by O +
high O -
- O -
dose O +
disulfiram O +
intoxication O -
. O +

Encephalopathy B-Disease +
induced O +
by O +
levetiracetam O +
added O +
to O +
valproate O -
. O +

BACKGROUND O -
: O +
We O +
report O +
on O +
the O +
manifestation O +
of O +
a O +
levetiracetam O +
( O -
LEV O -
) O -
-induced O +
encephalopathy B-Disease -
. O +

FINDINGS O -
: O +
A O +
28-year O -
- O -
old O +
man O +
suffering O +
from O +
idiopathic B-Disease +
epilepsy I-Disease +
with O +
generalized O +
seizures B-Disease +
was O +
treated O +
with O +
LEV O +
( O -
3000 O +
mg O -
) O +
added O +
to O +
valproate O +
( O -
VPA O -
) O +
( O -
2000 O +
mg O -
) O -
. O +

Frequency O +
of O +
generalized O +
tonic B-Disease -
- I-Disease -
clonic I-Disease +
seizures I-Disease +
increased O +
from O +
one O +
per O +
6 O +
months O +
to O +
two O +
per O +
month O -
. O +

Neuropsychological O +
testing O +
showed O +
impaired B-Disease +
word I-Disease +
fluency I-Disease -
, I-Disease +
psychomotor I-Disease +
speed I-Disease +
and I-Disease +
working I-Disease +
memory I-Disease -
. O +

The O +
interictal O +
electroencephalogram O +
( O -
EEG O -
) O +
showed O +
a O +
generalized O +
slowing O +
to O +
5 O +
per O +
second O +
theta O +
rhythms O +
with O +
bilateral O +
generalized O +
high O -
- O -
amplitude O +
discharges O -
. O +

OUTCOME O -
: O +
Following O +
discontinuation O +
of O +
LEV O -
, O +
EEG O +
and O +
neuropsychological O +
findings O +
improved O +
and O +
seizure B-Disease +
frequency O +
decreased O -
. O +

Norepinephrine O +
signaling O +
through O +
beta O -
- O -
adrenergic O +
receptors O +
is O +
critical O +
for O +
expression O +
of O +
cocaine O -
- O -
induced O +
anxiety B-Disease -
. O +

BACKGROUND O -
: O +
Cocaine O +
is O +
a O +
widely O +
abused O +
psychostimulant O +
that O +
has O +
both O +
rewarding O +
and O +
aversive O +
properties O -
. O +

While O +
the O +
mechanisms O +
underlying O +
cocaine O -
's O +
rewarding O +
effects O +
have O +
been O +
studied O +
extensively O -
, O +
less O +
attention O +
has O +
been O +
paid O +
to O +
the O +
unpleasant O +
behavioral O +
states O +
induced O +
by O +
cocaine O -
, O +
such O +
as O +
anxiety B-Disease -
. O +

METHODS O -
: O +
In O +
this O +
study O -
, O +
we O +
evaluated O +
the O +
performance O +
of O +
dopamine O +
beta O -
- O -
hydroxylase O +
knockout O +
( O -
Dbh O +
- O -
/ O -
- O -
) O +
mice O -
, O +
which O +
lack O +
norepinephrine O +
( O -
NE O -
) O -
, O +
in O +
the O +
elevated O +
plus O +
maze O +
( O -
EPM O -
) O +
to O +
examine O +
the O +
contribution O +
of O +
noradrenergic O +
signaling O +
to O +
cocaine O -
- O -
induced O +
anxiety B-Disease -
. O +

RESULTS O -
: O +
We O +
found O +
that O +
cocaine O +
dose O -
- O -
dependently O +
increased O +
anxiety B-Disease -
- O -
like O +
behavior O +
in O +
control O +
( O -
Dbh O +
+ O -
/- O -
) O +
mice O -
, O +
as O +
measured O +
by O +
a O +
decrease O +
in O +
open O +
arm O +
exploration O -
. O +

The O +
Dbh O +
- O -
/ O -
- O +
mice O +
had O +
normal O +
baseline O +
performance O +
in O +
the O +
EPM O +
but O +
were O +
completely O +
resistant O +
to O +
the O +
anxiogenic O +
effects O +
of O +
cocaine O -
. O +

Cocaine O -
- O -
induced O +
anxiety B-Disease +
was O +
also O +
attenuated O +
in O +
Dbh O +
+ O -
/- O +

mice O +
following O +
administration O +
of O +
disulfiram O -
, O +
a O +
dopamine O +
beta O -
- O -
hydroxylase O +
( O -
DBH O -
) O +
inhibitor O -
. O +

In O +
experiments O +
using O +
specific O +
adrenergic O +
antagonists O -
, O +
we O +
found O +
that O +
pretreatment O +
with O +
the O +
beta O -
- O -
adrenergic O +
receptor O +
antagonist O +
propranolol O +
blocked O +
cocaine O -
- O -
induced O +
anxiety B-Disease -
- O -
like O +
behavior O +
in O +
Dbh O +
+ O -
/- O +
and O +
wild O -
- O -
type O +
C57BL6 O -
/ O -
J O +
mice O -
, O +
while O +
the O +
alpha O -
( O -
1 O -
) O +
antagonist O +
prazosin O +
and O +
the O +
alpha O -
( O -
2 O -
) O +
antagonist O +
yohimbine O +
had O +
no O +
effect O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
indicate O +
that O +
noradrenergic O +
signaling O +
via O +
beta O -
- O -
adrenergic O +
receptors O +
is O +
required O +
for O +
cocaine O -
- O -
induced O +
anxiety B-Disease +
in O +
mice O -
. O +

Dexmedetomidine O +
and O +
cardiac O +
protection O +
for O +
non O -
- O -
cardiac O +
surgery O -
: O +
a O +
meta O -
- O -
analysis O +
of O +
randomised O +
controlled O +
trials O -
. O +

We O +
conducted O +
a O +
systematic O +
review O +
of O +
the O +
effects O +
of O +
dexmedetomidine O +
on O +
cardiac O +
outcomes O +
following O +
non O -
- O -
cardiac O +
surgery O -
. O +

We O +
included O +
prospective O -
, O +
randomised O +
peri O -
- O -
operative O +
studies O +
of O +
dexmedetomidine O +
that O +
reported O +
mortality O -
, O +
cardiac O +
morbidity O +
or O +
adverse O +
drug O +
events O -
. O +

A O +
PubMed O +
Central O +
and O +
EMBASE O +
search O +
was O +
conducted O +
up O +
to O +
July O +
2007 O -
. O +

The O +
reference O +
lists O +
of O +
identified O +
papers O +
were O +
examined O +
for O +
further O +
trials O -
. O +

Of O +
425 O +
studies O +
identified O -
, O +
20 O +
were O +
included O +
in O +
the O +
meta O -
- O -
analysis O +
( O -
840 O +
patients O -
) O -
. O +

Dexmedetomidine O +
was O +
associated O +
with O +
a O +
trend O +
towards O +
improved O +
cardiac O +
outcomes O -
; O +
all O -
- O -
cause O +
mortality O +
( O -
OR O +
0.27 O -
, O +
95 O -
% O +
CI O +
0.01 O -
- O -
7.13 O -
, O +
p O +
= O +
0.44 O -
) O -
, O +
non O -
- O -
fatal O +
myocardial B-Disease +
infarction I-Disease +
( O -
OR O +
0.26 O -
, O +
95 O -
% O +
CI O +
0.04 O -
- O -
1.60 O -
, O +
p O +
= O +
0.14 O -
) O -
, O +
and O +
myocardial B-Disease +
ischaemia I-Disease +
( O -
OR O +
0.65 O -
, O +
95 O -
% O +
CI O +
0.26 O -
- O -
1.63 O -
, O +
p O +
= O +
0.36 O -
) O -
. O +

Peri O -
- O -
operative O +
hypotension B-Disease +
( O -
26 O -
% O -
, O +
OR O +
3.80 O -
, O +
95 O -
% O +
CI O +
1.91 O -
- O -
7.54 O -
, O +
p O +
= O +
0.0001 O -
) O +
and O +
bradycardia B-Disease +
( O -
17 O -
% O -
, O +
OR O +
5.45 O -
, O +
95 O -
% O +
CI O +
2.98 O -
- O -
9.95 O -
, O +
p O +
< O +
0.00001 O -
) O +
were O +
significantly O +
increased O -
. O +

An O +
anticholinergic O +
did O +
not O +
reduce O +
the O +
incidence O +
of O +
bradycardia B-Disease +
( O -
p O +
= O +
0.43 O -
) O -
. O +

A O +
randomised O +
placebo O -
- O -
controlled O +
trial O +
of O +
dexmedetomidine O +
is O +
warranted O -
. O +

Myocardial B-Disease +
infarction I-Disease +
in O +
pregnancy O +
associated O +
with O +
clomiphene O +
citrate O +
for O +
ovulation O +
induction O -
: O +
a O +
case O +
report O -
. O +

BACKGROUND O -
: O +
Clomiphene O +
citrate O +
( O -
CC O -
) O +
is O +
commonly O +
prescribed O +
for O +
ovulation O +
induction O -
. O +

It O +
is O +
considered O +
safe O -
, O +
with O +
minimal O +
side O +
effects O -
. O +

Thromboembolism B-Disease +
is O +
a O +
rare O +
but O +
life O -
- O -
threatening O +
complication O +
that O +
has O +
been O +
reported O +
after O +
ovulation O +
induction O +
with O +
CC O -
. O +

Spontaneous O +
coronary B-Disease +
thrombosis I-Disease +
or O +
thromboembolism B-Disease +
with O +
subsequent O +
clot O +
lysis O +
has O +
been O +
suggested O +
as O +
one O +
of O +
the O +
most O +
common O +
causes O +
of O +
myocardial B-Disease +
infarction I-Disease +
( O -
MI B-Disease -
) O +
during O +
pregnancy O -
, O +
with O +
a O +
subsequently O +
normal O +
coronary O +
angiogram O -
. O +

CASE O -
: O +
A O +
33-year O -
- O -
old O +
woman O +
with O +
a O +
5-week O +
gestation O +
had O +
recently O +
received O +
CC O +
for O +
ovulation O +
induction O +
and O +
presented O +
with O +
chest B-Disease +
pain I-Disease -
. O +

An O +
electrocardiogram O +
showed O +
a O +
lateral O +
and O +
anterior O +
wall O +
myocardial B-Disease +
infarction I-Disease -
. O +

Cardiac O +
enzymes O +
showed O +
a O +
peak O +
rise O +
in O +
troponin O +
I O +
to O +
9.10 O +
ng O -
/ O -
mL. O +
An O +
initial O +
exercise O +
stress O +
test O +
was O +
normal O -
. O +

At O +
the O +
time O +
of O +
admission O -
, O +
the O +
patient O +
was O +
at O +
high O +
risk O +
of O +
radiation B-Disease +
injury I-Disease +
to O +
the O +
fetus O -
, O +
so O +
a O +
coronary O +
angiogram O +
was O +
postponed O +
until O +
the O +
second O +
trimester O -
. O +

It O +
showed O +
normal O +
coronary O +
vessels O -
. O +

CONCLUSION O -
: O +
This O +
appears O +
to O +
be O +
the O +
first O +
reported O +
case O +
documenting O +
a O +
possible O +
association O +
between O +
CC O +
and O +
myocardial B-Disease +
infarction I-Disease -
. O +

Thrombosis B-Disease +
might O +
be O +
a O +
rare O +
but O +
hazardous O +
complication O +
of O +
CC O -
. O +

Given O +
this O +
life O -
- O -
threatening O +
complication O -
, O +
appropriate O +
prophylactic O +
measures O +
should O +
be O +
used O +
in O +
high O -
- O -
risk O +
woman O +
undergoing O +
ovarian O +
stimulation O -
. O +

Hypothalamic O +
prolactin O +
receptor O +
messenger O +
ribonucleic O +
acid O +
levels O -
, O +
prolactin O +
signaling O -
, O +
and O +
hyperprolactinemic B-Disease +
inhibition O +
of O +
pulsatile O +
luteinizing O +
hormone O +
secretion O +
are O +
dependent O +
on O +
estradiol O -
. O +

Hyperprolactinemia B-Disease +
can O +
reduce O +
fertility O +
and O +
libido O -
. O +

Although O +
central O +
prolactin O +
actions O +
are O +
thought O +
to O +
contribute O +
to O +
this O -
, O +
the O +
mechanisms O +
are O +
poorly O +
understood O -
. O +

We O +
first O +
tested O +
whether O +
chronic O +
hyperprolactinemia B-Disease +
inhibited O +
two O +
neuroendocrine O +
parameters O +
necessary O +
for O +
female O +
fertility O -
: O +
pulsatile O +
LH O +
secretion O +
and O +
the O +
estrogen O -
- O -
induced O +
LH O +
surge O -
. O +

Chronic O +
hyperprolactinemia B-Disease +
induced O +
by O +
the O +
dopamine O +
antagonist O +
sulpiride O +
caused O +
a O +
40 O -
% O +
reduction O +
LH O +
pulse O +
frequency O +
in O +
ovariectomized O +
rats O -
, O +
but O +
only O +
in O +
the O +
presence O +
of O +
chronic O +
low O +
levels O +
of O +
estradiol O -
. O +

Sulpiride O +
did O +
not O +
affect O +
the O +
magnitude O +
of O +
a O +
steroid O -
- O -
induced O +
LH O +
surge O +
or O +
the O +
percentage O +
of O +
GnRH O +
neurons O +
activated O +
during O +
the O +
surge O -
. O +

Estradiol O +
is O +
known O +
to O +
influence O +
expression O +
of O +
the O +
long O +
form O +
of O +
prolactin O +
receptors O +
( O -
PRL O -
- O -
R O -
) O +
and O +
components O +
of O +
prolactin O -
's O +
signaling O +
pathway O -
. O +

To O +
test O +
the O +
hypothesis O +
that O +
estrogen O +
increases O +
PRL O -
- O -
R O +
expression O +
and O +
sensitivity O +
to O +
prolactin O -
, O +
we O +
next O +
demonstrated O +
that O +
estradiol O +
greatly O +
augments O +
prolactin O -
- O -
induced O +
STAT5 O +
activation O -
. O +

Lastly O -
, O +
we O +
measured O +
PRL O -
- O -
R O +
and O +
suppressor O +
of O +
cytokine O +
signaling O +
( O -
SOCS-1 O +
and O +
-3 O +
and O +
CIS O -
, O +
which O +
reflect O +
the O +
level O +
of O +
prolactin O +
signaling O -
) O +
mRNAs O +
in O +
response O +
to O +
sulpiride O +
and O +
estradiol O -
. O +

Sulpiride O +
induced O +
only O +
SOCS-1 O +
in O +
the O +
medial O +
preoptic O +
area O -
, O +
where O +
GnRH O +
neurons O +
are O +
regulated O -
, O +
but O +
in O +
the O +
arcuate O +
nucleus O +
and O +
choroid O +
plexus O -
, O +
PRL O -
- O -
R O -
, O +
SOCS-3 O -
, O +
and O +
CIS O +
mRNA O +
levels O +
were O +
also O +
induced O -
. O +

Estradiol O +
enhanced O +
these O +
effects O +
on O +
SOCS-3 O +
and O +
CIS O -
. O +

Interestingly O -
, O +
estradiol O +
also O +
induced O +
PRL O -
- O -
R O -
, O +
SOCS-3 O -
, O +
and O +
CIS O +
mRNA O +
levels O +
independently O -
. O +

These O +
data O +
show O +
that O +
GnRH O +
pulse O +
frequency O +
is O +
inhibited O +
by O +
chronic O +
hyperprolactinemia B-Disease +
in O +
a O +
steroid O -
- O -
dependent O +
manner O -
. O +

They O +
also O +
provide O +
evidence O +
for O +
estradiol O -
- O -
dependent O +
and O +
brain O +
region O -
- O -
specific O +
regulation O +
of O +
PRL O -
- O -
R O +
expression O +
and O +
signaling O +
responses O +
by O +
prolactin O -
. O +

Reverse O +
or O +
inverted O +
left B-Disease +
ventricular I-Disease +
apical I-Disease +
ballooning I-Disease +
syndrome I-Disease +
( O -
reverse O +
Takotsubo B-Disease +
cardiomyopathy I-Disease -
) O +
in O +
a O +
young O +
woman O +
in O +
the O +
setting O +
of O +
amphetamine O +
use O -
. O +

Transient O +
left B-Disease +
ventricular I-Disease +
apical I-Disease +
ballooning I-Disease +
syndrome I-Disease +
was O +
first O +
described O +
in O +
Japan O +
as O +
" O -
Takotsubo B-Disease +
cardiomyopathy I-Disease -
. O -
" O +

This O +
syndrome O +
has O +
been O +
identified O +
in O +
many O +
other O +
countries O -
. O +

Many O +
variations O +
of O +
this O +
syndrome O +
have O +
been O +
recently O +
described O +
in O +
the O +
literature O -
. O +

One O +
of O +
the O +
rarest O +
is O +
the O +
reverse O +
type O +
of O +
this O +
syndrome O -
, O +
with O +
hyperdynamic O +
apex O +
and O +
complete O +
akinesia B-Disease +
of O +
the O +
base O +
( O -
as O +
opposed O +
to O +
the O +
classic O +
apical B-Disease +
ballooning I-Disease -
) O -
. O +

In O +
this O +
article O -
, O +
we O +
report O +
an O +
interesting O +
case O +
of O +
a O +
young O +
woman O +
who O +
presented O +
with O +
this O +
rare O +
type O +
of O +
reverse O +
apical B-Disease +
ballooning I-Disease +
syndrome I-Disease +
occurring O +
after O +
amphetamine O +
use O -
. O +

This O +
report O +
is O +
followed O +
by O +
review O +
of O +
the O +
literature O -
. O +

Clonidine O +
for O +
attention B-Disease -
- I-Disease -
deficit I-Disease -
/ I-Disease -
hyperactivity I-Disease +
disorder I-Disease -
: O +
II O -
. O +

ECG O +
changes O +
and O +
adverse O +
events O +
analysis O -
. O +

OBJECTIVE O -
: O +
To O +
examine O +
the O +
safety O +
and O +
tolerability O +
of O +
clonidine O +
used O +
alone O +
or O +
with O +
methylphenidate O +
in O +
children O +
with O +
attention B-Disease -
- I-Disease -
deficit I-Disease -
/ I-Disease -
hyperactivity I-Disease +
disorder I-Disease +
( O -
ADHD B-Disease -
) O -
. O +

METHOD O -
: O +
In O +
a O +
16-week O +
multicenter O -
, O +
double O -
- O -
blind O +
trial O -
, O +
122 O +
children O +
with O +
ADHD B-Disease +
were O +
randomly O +
assigned O +
to O +
clonidine O +
( O -
n O +
= O +
31 O -
) O -
, O +
methylphenidate O +
( O -
n O +
= O +
29 O -
) O -
, O +
clonidine O +
and O +
methylphenidate O +
( O -
n O +
= O +
32 O -
) O -
, O +
or O +
placebo O +
( O -
n O +
= O +
30 O -
) O -
. O +

Doses O +
were O +
flexibly O +
titrated O +
up O +
to O +
0.6 O +
mg O -
/ O -
day O +
for O +
clonidine O +
and O +
60 O +
mg O -
/ O -
day O +
for O +
methylphenidate O +
( O -
both O +
with O +
divided O +
dosing O -
) O -
. O +

Groups O +
were O +
compared O +
regarding O +
adverse O +
events O +
and O +
changes O +
from O +
baseline O +
to O +
week O +
16 O +
in O +
electrocardiograms O +
and O +
vital O +
signs O -
. O +

RESULTS O -
: O +
There O +
were O +
more O +
incidents O +
of O +
bradycardia B-Disease +
in O +
subjects O +
treated O +
with O +
clonidine O +
compared O +
with O +
those O +
not O +
treated O +
with O +
clonidine O +
( O -
17.5 O -
% O +
versus O +
3.4 O -
% O -
; O +
p O +
= O -
.02 O -
) O -
, O +
but O +
no O +
other O +
significant O +
group O +
differences O +
regarding O +
electrocardiogram O +
and O +
other O +
cardiovascular O +
outcomes O -
. O +

There O +
were O +
no O +
suggestions O +
of O +
interactions O +
between O +
clonidine O +
and O +
methylphenidate O +
regarding O +
cardiovascular O +
outcomes O -
. O +

Moderate O +
or O +
severe O +
adverse O +
events O +
were O +
more O +
common O +
in O +
subjects O +
on O +
clonidine O +
( O -
79.4 O -
% O +
versus O +
49.2 O -
% O -
; O +
p O +
= O -
.0006 O -
) O +
but O +
not O +
associated O +
with O +
higher O +
rates O +
of O +
early O +
study O +
withdrawal O -
. O +

Drowsiness B-Disease +
was O +
common O +
on O +
clonidine O -
, O +
but O +
generally O +
resolved O +
by O +
6 O +
to O +
8 O +
weeks O -
. O +

CONCLUSIONS O -
: O +
Clonidine O -
, O +
used O +
alone O +
or O +
with O +
methylphenidate O -
, O +
appears O +
safe O +
and O +
well O +
tolerated O +
in O +
childhood O +
ADHD B-Disease -
. O +

Physicians O +
prescribing O +
clonidine O +
should O +
monitor O +
for O +
bradycardia B-Disease +
and O +
advise O +
patients O +
about O +
the O +
high O +
likelihood O +
of O +
initial O +
drowsiness B-Disease -
. O +

Renal B-Disease +
Fanconi I-Disease +
syndrome I-Disease +
and O +
myopathy B-Disease +
after O +
liver O +
transplantation O -
: O +
drug O -
- O -
related O +
mitochondrial B-Disease +
cytopathy I-Disease -
? O +

Advances O +
in O +
the O +
field O +
of O +
transplantation O +
provide O +
a O +
better O +
quality O +
of O +
life O +
and O +
allow O +
more O +
favorable O +
conditions O +
for O +
growth O +
and O +
development O +
in O +
children O -
. O +

However O -
, O +
combinations O +
of O +
different O +
therapeutic O +
regimens O +
require O +
consideration O +
of O +
potential O +
adverse O +
reactions O -
. O +

We O +
describe O +
a O +
15-yr O -
- O -
old O +
girl O +
who O +
had O +
orthotopic O +
liver O +
transplantation O +
because O +
of O +
Wilson B-Disease -
's I-Disease +
disease I-Disease -
. O +

Tacrolimus O -
, O +
MMF O -
, O +
and O +
steroids O +
were O +
given O +
as O +
immunosuppressant O -
. O +

Lamivudine O +
was O +
added O +
because O +
of O +
de O +
nova O +
hepatitis B-Disease +
B I-Disease +
infection I-Disease +
during O +
her O +
follow O -
- O -
up O -
. O +

Three O +
yr O +
after O +
transplantation O +
she O +
developed O +
renal B-Disease +
Fanconi I-Disease +
syndrome I-Disease +
with O +
severe O +
metabolic B-Disease +
acidosis I-Disease -
, O +
hypophosphatemia B-Disease -
, O +
glycosuria B-Disease -
, O +
and O +
aminoaciduria B-Disease -
. O +

Although O +
tacrolimus O +
was O +
suspected O +
to O +
be O +
the O +
cause O +
of O +
late O +
post O -
- O -
transplant O +
renal O +
acidosis B-Disease +
and O +
was O +
replaced O +
by O +
sirolimus O -
, O +
acidosis B-Disease -
, O +
and O +
electrolyte O +
imbalance O +
got O +
worse O -
. O +

Proximal O +
muscle B-Disease +
weakness I-Disease +
has O +
developed O +
during O +
her O +
follow O -
- O -
up O -
. O +

Fanconi B-Disease +
syndrome I-Disease -
, O +
as O +
well O +
as O +
myopathy B-Disease -
, O +
is O +
well O +
recognized O +
in O +
patients O +
with O +
mitochondrial B-Disease +
disorders I-Disease +
and O +
caused O +
by O +
depletion O +
of O +
mtDNA O -
. O +

We O +
suggest O +
that O +
our O +
patient O -
's O +
tubular B-Disease +
dysfunction I-Disease +
and O +
myopathy B-Disease +
may O +
have O +
resulted O +
from O +
mitochondrial B-Disease +
dysfunction I-Disease +
which O +
is O +
triggered O +
by O +
tacrolimus O +
and O +
augmented O +
by O +
lamivudine O -
. O +

Higher O +
optical O +
density O +
of O +
an O +
antigen O +
assay O +
predicts O +
thrombosis B-Disease +
in O +
patients O +
with O +
heparin O -
- O -
induced O +
thrombocytopenia B-Disease -
. O +

OBJECTIVES O -
: O +
To O +
correlate O +
optical O +
density O +
and O +
percent O +
inhibition O +
of O +
a O +
two O -
- O -
step O +
heparin O -
- O -
induced O +
thrombocytopenia B-Disease +
( O -
HIT B-Disease -
) O +
antigen O +
assay O +
with O +
thrombosis B-Disease -
; O +
the O +
assay O +
utilizes O +
reaction O +
inhibition O +
characteristics O +
of O +
a O +
high O +
heparin O +
concentration O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Patients O +
with O +
more O +
than O +
50 O -
% O +
decrease O +
in O +
platelet O +
count O +
or O +
thrombocytopenia B-Disease +
( O -
< O -
150 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O -
) O +
after O +
exposure O +
to O +
heparin O -
, O +
who O +
had O +
a O +
positive O +
two O -
- O -
step O +
antigen O +
assay O +
[ O -
optical O +
density O +
( O -
OD O -
) O +
> O -
0.4 O +
and O +
> O -
50 O +
inhibition O +
with O +
high O +
concentration O +
of O +
heparin O -
] O +
were O +
included O +
in O +
the O +
study O -
. O +

RESULTS O -
: O +
Forty O +
of O +
94 O +
HIT B-Disease +
patients O +
had O +
thrombosis B-Disease +
at O +
diagnosis O -
; O +
54 O -
/ O -
94 O +
had O +
isolated O -
- O -
HIT B-Disease +
without O +
thrombosis B-Disease -
. O +

Eight O +
of O +
the O +
isolated O -
- O -
HIT B-Disease +
patients O +
developed O +
thrombosis B-Disease +
within O +
the O +
next O +
30 O +
d O -
; O +
thus O -
, O +
a O +
total O +
of O +
48 O +
patients O +
had O +
thrombosis B-Disease +
at O +
day O +
30 O -
. O +

At O +
diagnosis O +
there O +
was O +
no O +
significant O +
difference O +
in O +
OD O +
between O +
HIT B-Disease +
patients O +
with O +
thrombosis B-Disease +
and O +
those O +
with O +
isolated O -
- O -
HIT B-Disease -
. O +

However O -
, O +
OD O +
was O +
significantly O +
higher O +
in O +
all O +
patients O +
with O +
thrombosis B-Disease +
( O -
n O +
= O +
48 O -
, O +
1.34 O +
+ O -
/- O +

0.89 O -
) O -
, O +
including O +
isolated O -
- O -
HIT B-Disease +
patients O +
who O +
later O +
developed O +
thrombosis B-Disease +
within O +
30 O +
d O +
( O -
n O +
= O +
8 O -
, O +
1.84 O +
+ O -
/- O +
0.64 O -
) O +
as O +
compared O +
to O +
isolated O -
- O -
HIT B-Disease +
patients O +
who O +
did O +
not O +
develop O +
thrombosis B-Disease +
( O -
0.96 O +
+ O -
/- O +

0.75 O -
; O +
P O +
= O +
0.011 O +
and O +
P O +
= O +
0.008 O -
) O -
. O +

The O +
Receiver O +
Operative O +
Characteristic O +
Curve O +
showed O +
that O +
OD O +
> O -
1.27 O +
in O +
the O +
isolated O -
- O -
HIT B-Disease +
group O +
had O +
a O +
significantly O +
higher O +
chance O +
of O +
developing O +
thrombosis B-Disease +
by O +
day O +
30 O -
. O +

None O +
of O +
these O +
groups O +
showed O +
significant O +
difference O +
in O +
percent O +
inhibition O -
. O +

Multivariate O +
analysis O +
showed O +
a O +
2.8-fold O +
increased O +
risk O +
of O +
thrombosis B-Disease +
in O +
females O -
. O +

Similarly O -
, O +
thrombotic B-Disease +
risk O +
increased O +
with O +
age O +
and O +
OD O +
values O -
. O +

CONCLUSION O -
: O +
Higher O +
OD O +
is O +
associated O +
with O +
significant O +
risk O +
of O +
subsequent O +
thrombosis B-Disease +
in O +
patients O +
with O +
isolated O -
- O -
HIT B-Disease -
; O +
percent O +
inhibition O -
, O +
however O -
, O +
was O +
not O +
predictive O -
. O +

Thalidomide O +
has O +
limited O +
single O -
- O -
agent O +
activity O +
in O +
relapsed O +
or O +
refractory O +
indolent O +
non B-Disease -
- I-Disease -
Hodgkin I-Disease +
lymphomas I-Disease -
: O +
a O +
phase O +
II O +
trial O +
of O +
the O +
Cancer B-Disease +
and O +
Leukemia B-Disease +
Group O +
B. O +
Thalidomide O +
is O +
an O +
immunomodulatory O +
agent O +
with O +
demonstrated O +
activity O +
in O +
multiple B-Disease +
myeloma I-Disease -
, O +
mantle B-Disease +
cell I-Disease +
lymphoma I-Disease +
and O +
lymphoplasmacytic B-Disease +
lymphoma I-Disease -
. O +

Its O +
activity O +
is O +
believed O +
to O +
be O +
due O +
modulation O +
of O +
the O +
tumour B-Disease +
milieu O -
, O +
including O +
downregulation O +
of O +
angiogenesis O +
and O +
inflammatory O +
cytokines O -
. O +

Between O +
July O +
2001 O +
and O +
April O +
2004 O -
, O +
24 O +
patients O +
with O +
relapsed O -
/ O -
refractory O +
indolent O +
lymphomas B-Disease +
received O +
thalidomide O +
200 O +
mg O +
daily O +
with O +
escalation O +
by O +
100 O +
mg O +
daily O +
every O +
1 O -
- O -
2 O +
weeks O +
as O +
tolerated O -
, O +
up O +
to O +
a O +
maximum O +
of O +
800 O +
mg O +
daily O -
. O +

Patients O +
had O +
received O +
a O +
median O +
of O +
2 O +
( O -
range O -
, O +
1 O -
- O -
4 O -
) O +
prior O +
regimens O -
. O +

Of O +
24 O +
evaluable O +
patients O -
, O +
two O +
achieved O +
a O +
complete O +
remission O +
and O +
one O +
achieved O +
a O +
partial O +
remission O +
for O +
an O +
overall O +
response O +
rate O +
of O +
12.5 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
: O +
2.6 O -
- O -
32.4 O -
% O -
) O -
. O +

Eleven O +
patients O +
progressed O +
during O +
therapy O -
. O +

Grade O +
3 O -
- O -
4 O +
adverse O +
effects O +
included O +
myelosuppression B-Disease -
, O +
fatigue B-Disease -
, O +
somnolence B-Disease -
/ O -
depressed B-Disease +
mood I-Disease -
, O +
neuropathy B-Disease +
and O +
dyspnea B-Disease -
. O +

Of O +
concern O +
was O +
the O +
occurrence O +
of O +
four O +
thromboembolic B-Disease +
events O -
. O +

Our O +
results O +
failed O +
to O +
demonstrate O +
an O +
important O +
response O +
rate O +
to O +
single O +
agent O +
thalidomide O +
in O +
indolent O +
lymphomas B-Disease +
and O +
contrast O +
with O +
the O +
higher O +
activity O +
level O +
reported O +
with O +
the O +
second O +
generation O +
immunomodulatory O +
agent O -
, O +
lenalidomide O -
. O +

Sex O +
differences O +
in O +
NMDA O +
antagonist O +
enhancement O +
of O +
morphine O +
antihyperalgesia O +
in O +
a O +
capsaicin O +
model O +
of O +
persistent O +
pain B-Disease -
: O +
comparisons O +
to O +
two O +
models O +
of O +
acute B-Disease +
pain I-Disease -
. O +

In O +
acute B-Disease +
pain I-Disease +
models O -
, O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
antagonists O +
enhance O +
the O +
antinociceptive O +
effects O +
of O +
morphine O +
to O +
a O +
greater O +
extent O +
in O +
males O +
than O +
females O -
. O +

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
extend O +
these O +
findings O +
to O +
a O +
persistent O +
pain B-Disease +
model O +
which O +
could O +
be O +
distinguished O +
from O +
acute B-Disease +
pain I-Disease +
models O +
on O +
the O +
basis O +
of O +
the O +
nociceptive O +
fibers O +
activated O -
, O +
neurochemical O +
substrates O -
, O +
and O +
duration O +
of O +
the O +
nociceptive O +
stimulus O -
. O +

To O +
this O +
end O -
, O +
persistent O +
hyperalgesia B-Disease +
was O +
induced O +
by O +
administration O +
of O +
capsaicin O +
in O +
the O +
tail O +
of O +
gonadally O +
intact O +
F344 O +
rats O -
, O +
following O +
which O +
the O +
tail O +
was O +
immersed O +
in O +
a O +
mildly O +
noxious O +
thermal O +
stimulus O -
, O +
and O +
tail O -
- O -
withdrawal O +
latencies O +
measured O -
. O +

For O +
comparison O -
, O +
tests O +
were O +
conducted O +
in O +
two O +
acute B-Disease +
pain I-Disease +
models O -
, O +
the O +
hotplate O +
and O +
warm O +
water O +
tail O -
- O -
withdrawal O +
procedures O -
. O +

In O +
males O -
, O +
the O +
non O -
- O -
competitive O +
NMDA O +
antagonist O +
dextromethorphan O +
enhanced O +
the O +
antihyperalgesic O +
effect O +
of O +
low O +
to O +
moderate O +
doses O +
of O +
morphine O +
in O +
a O +
dose O -
- O -
and O +
time O -
- O -
dependent O +
manner O -
. O +

Across O +
the O +
doses O +
and O +
pretreatment O +
times O +
examined O -
, O +
enhancement O +
was O +
not O +
observed O +
in O +
females O -
. O +

Enhancement O +
of O +
morphine O +
antinociception O +
by O +
dextromethorphan O +
was O +
seen O +
in O +
both O +
males O +
and O +
females O +
in O +
the O +
acute B-Disease +
pain I-Disease +
models O -
, O +
with O +
the O +
magnitude O +
of O +
this O +
effect O +
being O +
greater O +
in O +
males O -
. O +

These O +
findings O +
demonstrate O +
a O +
sexually O -
- O -
dimorphic O +
interaction O +
between O +
NMDA O +
antagonists O +
and O +
morphine O +
in O +
a O +
persistent O +
pain B-Disease +
model O +
that O +
can O +
be O +
distinguished O +
from O +
those O +
observed O +
in O +
acute B-Disease +
pain I-Disease +
models O -
. O +

Increased O +
mental B-Disease +
slowing I-Disease +
associated O +
with O +
the O +
APOE O +
epsilon4 O +
allele O +
after O +
trihexyphenidyl O +
oral O +
anticholinergic O +
challenge O +
in O +
healthy O +
elderly O -
. O +

OBJECTIVES O -
: O +
The O +
objectives O +
of O +
this O +
study O +
were O +
to O +
examine O +
the O +
relationship O +
between O +
APOE O +
epsilon4 O +
and O +
subjective O +
effects O +
of O +
trihexyphenidyl O +
on O +
measures O +
reflecting O +
sedation O +
and O +
confusion B-Disease +
and O +
to O +
investigate O +
the O +
relationship O +
between O +
trihexyphenidyl O -
- O -
induced O +
subjective O +
effects O +
and O +
objective O +
memory O +
performance O -
. O +

METHODS O -
: O +
This O +
study O +
comprised O +
24 O +
cognitively O +
intact O -
, O +
health O +
elderly O +
adults O +
( O -
12 O +
APOE O +
epsilon4 O +
carriers O -
) O +
at O +
an O +
outpatient O +
geriatric O +
psychiatry O +
research O +
clinic O -
. O +

This O +
was O +
a O +
randomized O -
, O +
double O +
blind O -
, O +
placebo O -
- O -
controlled O -
, O +
three O -
- O -
way O -
, O +
crossover O +
experimental O +
design O -
. O +

All O +
participants O +
received O +
1.0 O +
mg O +
or O +
2.0 O +
mg O +
trihexyphenidyl O +
or O +
placebo O +
administered O +
in O +
counterbalanced O +
sequences O +
over O +
a O +
period O +
of O +
three O +
consecutive O +
weeks O -
. O +

Bond O +
and O +
Lader O -
's O +
visual O +
analog O +
scales O +
and O +
alternate O +
versions O +
of O +
the O +
Buschke O +
Selective O +
Reminding O +
Test O +
were O +
administered O +
in O +
a O +
repeated O +
measures O +
design O +
at O +
baseline O -
, O +
1 O -
, O +
2.5 O -
, O +
and O +
5 O +
hours O +
postdrug O +
administration O -
. O +

RESULTS O -
: O +
A O +
2.0-mg O +
oral O +
dose O +
of O +
trihexyphenidyl O +
resulted O +
in O +
increased O +
subjective O +
ratings O +
of O +
mental B-Disease +
slowness I-Disease +
in O +
carriers O +
of O +
the O +
APOE O +
epsilon4 O +
allele O +
only O -
. O +

Drug O +
effects O +
as O +
determined O +
by O +
difference O +
scores O +
between O +
2.0 O +
mg O +
trihexyphenidyl O +
and O +
placebo O +
on O +
ratings O +
of O +
mental B-Disease +
slowness I-Disease +
significantly O +
correlated O +
with O +
total O +
and O +
delayed O +
recall O +
on O +
the O +
Buschke O +
Selective O +
Reminding O +
Test O +
in O +
carriers O +
of O +
the O +
APOE O +
epsilon4 O +
allele O +
only O -
. O +

However O -
, O +
no O +
significant O +
effects O +
were O +
found O +
with O +
other O +
visual O +
analog O +
scales O +
reflecting O +
subjective O +
sedation O +
and O +
clear O -
- O -
headedness O -
. O +

CONCLUSION O -
: O +
The O +
epsilon4 O +
allele O +
in O +
healthy O +
elderly O +
was O +
associated O +
with O +
increased O +
subjective O +
mental B-Disease +
slowing I-Disease +
after O +
trihexyphenidyl O +
anticholinergic O +
challenge O -
. O +

Development O +
of O +
proteinuria B-Disease +
after O +
switch O +
to O +
sirolimus O -
- O -
based O +
immunosuppression O +
in O +
long O -
- O -
term O +
cardiac O +
transplant O +
patients O -
. O +

Calcineurin O -
- O -
inhibitor O +
therapy O +
can O +
lead O +
to O +
renal B-Disease +
dysfunction I-Disease +
in O +
heart O +
transplantation O +
patients O -
. O +

The O +
novel O +
immunosuppressive O +
( O -
IS O -
) O +
drug O +
sirolmus O +
( O -
Srl O -
) O +
lacks O +
nephrotoxic B-Disease +
effects O -
; O +
however O -
, O +
proteinuria B-Disease +
associated O +
with O +
Srl O +
has O +
been O +
reported O +
following O +
renal O +
transplantation O -
. O +

In O +
cardiac O +
transplantation O -
, O +
the O +
incidence O +
of O +
proteinuria B-Disease +
associated O +
with O +
Srl O +
is O +
unknown O -
. O +

In O +
this O +
study O -
, O +
long O -
- O -
term O +
cardiac O +
transplant O +
patients O +
were O +
switched O +
from O +
cyclosporine O +
to O +
Srl O -
- O -
based O +
IS O -
. O +

Concomitant O +
IS O +
consisted O +
of O +
mycophenolate O +
mofetil O +
+ O -
/- O +

steroids O -
. O +

Proteinuria O +
increased O +
significantly O +
from O +
a O +
median O +
of O +
0.13 O +
g O -
/ O -
day O +
( O -
range O +
0 O -
- O -
5.7 O -
) O +
preswitch O +
to O +
0.23 O +
g O -
/ O -
day O +
( O -
0 O -
- O -
9.88 O -
) O +
at O +
24 O +
months O +
postswitch O +
( O -
p O +
= O +
0.0024 O -
) O -
. O +

Before O +
the O +
switch O -
, O +
11.5 O -
% O +
of O +
patients O +
had O +
high O -
- O -
grade O +
proteinuria B-Disease +
( O -
> O -
1.0 O +
g O -
/ O -
day O -
) O -
; O +
this O +
increased O +
to O +
22.9 O -
% O +
postswitch O +
( O -
p O +
= O +
0.006 O -
) O -
. O +

ACE O +
inhibitor O +
and O +
angiotensin O -
- O -
releasing O +
blocker O +
( O -
ARB O -
) O +
therapy O +
reduced O +
proteinuria B-Disease +
development O -
. O +

Patients O +
without O +
proteinuria B-Disease +
had O +
increased O +
renal O +
function O +
( O -
median O +
42.5 O +
vs. O +
64.1 O -
, O +
p O +
= O +
0.25 O -
) O -
, O +
whereas O +
patients O +
who O +
developed O +
high O -
- O -
grade O +
proteinuria B-Disease +
showed O +
decreased O +
renal O +
function O +
at O +
the O +
end O +
of O +
follow O -
- O -
up O +
( O -
median O +
39.6 O +
vs. O +
29.2 O -
, O +
p O +
= O +
0.125 O -
) O -
. O +

Thus O -
, O +
proteinuria B-Disease +
may O +
develop O +
in O +
cardiac O +
transplant O +
patients O +
after O +
switch O +
to O +
Srl O -
, O +
which O +
may O +
have O +
an O +
adverse O +
effect O +
on O +
renal O +
function O +
in O +
these O +
patients O -
. O +

Srl O +
should O +
be O +
used O +
with O +
ACEi O -
/ O -
ARB O +
therapy O +
and O +
patients O +
monitored O +
for O +
proteinuria B-Disease +
and O +
increased O +
renal B-Disease +
dysfunction I-Disease -
. O +

Ginsenoside O +
Rg1 O +
restores O +
the O +
impairment B-Disease +
of I-Disease +
learning I-Disease +
induced O +
by O +
chronic O +
morphine O +
administration O +
in O +
rats O -
. O +

Rg1 O -
, O +
as O +
a O +
ginsenoside O +
extracted O +
from O +
Panax O +
ginseng O -
, O +
could O +
ameliorate O +
spatial O +
learning B-Disease +
impairment I-Disease -
. O +

Previous O +
studies O +
have O +
demonstrated O +
that O +
Rg1 O +
might O +
be O +
a O +
useful O +
agent O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
the O +
adverse O +
effects O +
of O +
morphine O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
Rg1 O +
on O +
learning B-Disease +
impairment I-Disease +
by O +
chronic O +
morphine O +
administration O +
and O +
the O +
mechanism O +
responsible O +
for O +
this O +
effect O -
. O +

Male O +
rats O +
were O +
subcutaneously O +
injected O +
with O +
morphine O +
( O -
10 O +
mg O -
/ O -
kg O -
) O +
twice O +
a O +
day O +
at O +
12 O +
hour O +
intervals O +
for O +
10 O +
days O -
, O +
and O +
Rg1 O +
( O -
30 O +
mg O -
/ O -
kg O -
) O +
was O +
intraperitoneally O +
injected O +
2 O +
hours O +
after O +
the O +
second O +
injection O +
of O +
morphine O +
once O +
a O +
day O +
for O +
10 O +
days O -
. O +

Spatial O +
learning O +
capacity O +
was O +
assessed O +
in O +
the O +
Morris O +
water O +
maze O -
. O +

The O +
results O +
showed O +
that O +
rats O +
treated O +
with O +
Morphine O -
/ O -
Rg1 O +
decreased O +
escape O +
latency O +
and O +
increased O +
the O +
time O +
spent O +
in O +
platform O +
quadrant O +
and O +
entering O +
frequency O -
. O +

By O +
implantation O +
of O +
electrodes O +
and O +
electrophysiological O +
recording O +
in O +
vivo O -
, O +
the O +
results O +
showed O +
that O +
Rg1 O +
restored O +
the O +
long O -
- O -
term O +
potentiation O +
( O -
LTP O -
) O +
impaired O +
by O +
morphine O +
in O +
both O +
freely O +
moving O +
and O +
anaesthetised O +
rats O -
. O +

The O +
electrophysiological O +
recording O +
in O +
vitro O +
showed O +
that O +
Rg1 O +
restored O +
the O +
LTP O +
in O +
slices O +
from O +
the O +
rats O +
treated O +
with O +
morphine O -
, O +
but O +
not O +
changed O +
LTP O +
in O +
the O +
slices O +
from O +
normal O +
saline- O +
or O +
morphine O -
/ O -
Rg1-treated O +
rats O -
; O +
this O +
restoration O +
could O +
be O +
inhibited O +
by O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptor O +
antagonist O +
MK801 O -
. O +

We O +
conclude O +
that O +
Rg1 O +
may O +
significantly O +
improve O +
the O +
spatial O +
learning O +
capacity O +
impaired O +
by O +
chonic O +
morphine O +
administration O +
and O +
restore O +
the O +
morphine O -
- O -
inhibited O +
LTP O -
. O +

This O +
effect O +
is O +
NMDA O +
receptor O +
dependent O -
. O +

Synthesis O +
of O +
N O -
- O -
pyrimidinyl-2-phenoxyacetamides O +
as O +
adenosine O +
A2A O +
receptor O +
antagonists O -
. O +

A O +
series O +
of O +
N O -
- O -
pyrimidinyl-2-phenoxyacetamide O +
adenosine O +
A O -
( O -
2A O -
) O +
antagonists O +
is O +
described O -
. O +

SAR O +
studies O +
led O +
to O +
compound O +
14 O +
with O +
excellent O +
potency O +
( O -
K O -
( O -
i O -
) O +
= O +
0.4 O +
nM O -
) O -
, O +
selectivity O +
( O -
A O -
( O -
1 O -
) O -
/ O -
A O -
( O -
2A O -
) O +
> O +
100 O -
) O -
, O +
and O +
efficacy O +
( O -
MED O +
10 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O +
in O +
the O +
rat O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
model O +
for O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

Evidence O +
for O +
an O +
involvement O +
of O +
D1 O +
and O +
D2 O +
dopamine O +
receptors O +
in O +
mediating O +
nicotine O -
- O -
induced O +
hyperactivity B-Disease +
in O +
rats O -
. O +

Previous O +
studies O +
have O +
suggested O +
that O +
repeated O +
exposure O +
of O +
rats O +
to O +
the O +
drug O +
or O +
to O +
the O +
experimental O +
environment O +
is O +
necessary O +
to O +
observe O +
nicotine O -
- O -
induced O +
locomotor O +
stimulation O -
. O +

In O +
the O +
present O +
study O +
the O +
role O +
of O +
habituation O +
to O +
the O +
experimental O +
environment O +
on O +
the O +
stimulant O +
effect O +
of O +
nicotine O +
in O +
rats O +
was O +
examined O -
. O +

In O +
addition O -
, O +
the O +
role O +
of O +
dopamine O +
receptors O +
in O +
mediating O +
nicotine O -
- O -
induced O +
locomotor O +
stimulation O +
was O +
investigated O +
by O +
examining O +
the O +
effects O +
of O +
selective O +
D1 O +
and O +
D2 O +
dopamine O +
receptor O +
antagonists O +
on O +
activity O +
induced O +
by O +
nicotine O -
. O +

Locomotor O +
activity O +
was O +
assessed O +
in O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
tested O +
in O +
photocell O +
cages O -
. O +

Nicotine O +
( O -
1.0 O +
mg O -
/ O -
kg O -
) O +
caused O +
a O +
significant O +
increase B-Disease +
in I-Disease +
locomotor I-Disease +
activity I-Disease +
in O +
rats O +
that O +
were O +
habituated O +
to O +
the O +
test O +
environment O -
, O +
but O +
had O +
only O +
a O +
weak O +
and O +
delayed O +
stimulant O +
action O +
in O +
rats O +
that O +
were O +
unfamiliar O +
with O +
the O +
test O +
environment O -
. O +

The O +
stimulant O +
action O +
of O +
nicotine O +
was O +
blocked O +
by O +
the O +
central O +
nicotinic O +
antagonist O +
mecamylamine O +
but O +
not O +
by O +
the O +
peripheral O +
nicotinic O +
blocker O +
hexamethonium O -
, O +
indicating O +
that O +
the O +
response O +
is O +
probably O +
mediated O +
by O +
central O +
nicotinic O +
receptors O -
. O +

Nicotine O -
- O -
induced O +
hyperactivity B-Disease +
was O +
blocked O +
by O +
the O +
selective O +
D1 O +
antagonist O +
SCH O +
23390 O -
, O +
the O +
selective O +
D2 O +
antagonist O +
raclopride O +
and O +
the O +
D1 O -
/ O -
D2 O +
antagonist O +
fluphenazine O -
. O +

Pretreatment O +
with O +
the O +
D2 O +
agonist O +
PHNO O +
enhanced O +
nicotine O -
- O -
induced O +
hyperactivity B-Disease -
, O +
whereas O +
the O +
D1 O +
agonist O +
SKF O +
38393 O +
had O +
no O +
effect O -
. O +

The O +
results O +
indicate O +
that O +
acute O +
nicotine O +
injection O +
induces O +
a O +
pronounced O +
hyperactivity B-Disease +
in O +
rats O +
habituated O +
to O +
the O +
test O +
environment O -
. O +

The O +
effect O +
appears O +
to O +
be O +
mediated O +
by O +
central O +
nicotine O +
receptors O -
, O +
possibly O +
located O +
on O +
dopaminergic O +
neurons O -
, O +
and O +
also O +
requires O +
the O +
activation O +
of O +
both O +
D1 O +
and O +
D2 O +
dopamine O +
receptors O -
. O +

Central O +
retinal B-Disease +
vein I-Disease +
occlusion I-Disease +
associated O +
with O +
clomiphene O -
- O -
induced O +
ovulation O -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
central O +
retinal B-Disease +
vein I-Disease +
occlusion I-Disease +
associated O +
with O +
clomiphene O +
citrate O +
( O -
CC O -
) O -
. O +

DESIGN O -
: O +
Case O +
study O -
. O +

SETTING O -
: O +
Ophthalmology O +
clinic O +
of O +
an O +
academic O +
hospital O -
. O +

PATIENT O -
( O -
S O -
) O -
: O +
A O +
36-year O -
- O -
old O +
woman O +
referred O +
from O +
the O +
infertility B-Disease +
clinic O +
for O +
blurred B-Disease +
vision I-Disease -
. O +

INTERVENTION O -
( O -
S O -
) O -
: O +
Ophthalmic O +
examination O +
after O +
CC O +
therapy O -
. O +

MAIN O +
OUTCOME O +
MEASURE O -
( O -
S O -
) O -
: O +
Central O +
retinal B-Disease +
vein I-Disease +
occlusion I-Disease +
after O +
ovulation O +
induction O +
with O +
CC O -
. O +

RESULT O -
( O -
S O -
) O -
: O +
A O +
36-year O -
- O -
old O +
Chinese O +
woman O +
developed O +
central O +
retinal B-Disease +
vein I-Disease +
occlusion I-Disease +
after O +
eight O +
courses O +
of O +
CC O -
. O +

A O +
search O +
of O +
the O +
literature O +
on O +
the O +
thromboembolic B-Disease +
complications O +
of O +
CC O +
does O +
not O +
include O +
this O +
severe O +
ophthalmic O +
complication O -
, O +
although O +
mild O +
visual B-Disease +
disturbance I-Disease +
after O +
CC O +
intake O +
is O +
not O +
uncommon O -
. O +

CONCLUSION O -
( O -
S O -
) O -
: O +
This O +
is O +
the O +
first O +
reported O +
case O +
of O +
central O +
retinal B-Disease +
vein I-Disease +
occlusion I-Disease +
after O +
treatment O +
with O +
CC O -
. O +

Extra O +
caution O +
is O +
warranted O +
in O +
treating O +
infertility B-Disease +
patients O +
with O +
CC O -
, O +
and O +
patients O +
should O +
be O +
well O +
informed O +
of O +
this O +
side O +
effect O +
before O +
commencement O +
of O +
therapy O -
. O +

Acute O +
bronchodilating O +
effects O +
of O +
ipratropium O +
bromide O +
and O +
theophylline O +
in O +
chronic B-Disease +
obstructive I-Disease +
pulmonary I-Disease +
disease I-Disease -
. O +

The O +
bronchodilator O +
effects O +
of O +
a O +
single O +
dose O +
of O +
ipratropium O +
bromide O +
aerosol O +
( O -
36 O +
micrograms O -
) O +
and O +
short O -
- O -
acting O +
theophylline O +
tablets O +
( O -
dose O +
titrated O +
to O +
produce O +
serum O +
levels O +
of O +
10 O -
- O -
20 O +
micrograms O -
/ O -
mL O -
) O +
were O +
compared O +
in O +
a O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
crossover O +
study O +
in O +
21 O +
patients O +
with O +
stable O -
, O +
chronic B-Disease +
obstructive I-Disease +
pulmonary I-Disease +
disease I-Disease -
. O +

Mean O +
peak O +
forced O +
expiratory O +
volume O +
in O +
1 O +
second O +
( O -
FEV1 O -
) O +
increases O +
over O +
baseline O +
and O +
the O +
proportion O +
of O +
patients O +
attaining O +
at O +
least O +
a O +
15 O -
% O +
increase O +
in O +
the O +
FEV1 O +
( O -
responders O -
) O +
were O +
31 O -
% O +
and O +
90 O -
% O -
, O +
respectively O -
, O +
for O +
ipratropium O +
and O +
17 O -
% O +
and O +
50 O -
% O -
, O +
respectively O -
, O +
for O +
theophylline O -
. O +

The O +
average O +
FEV1 O +
increases O +
during O +
the O +
6-hour O +
observation O +
period O +
were O +
18 O -
% O +
for O +
ipratropium O +
and O +
8 O -
% O +
for O +
theophylline O -
. O +

The O +
mean O +
duration O +
of O +
action O +
was O +
3.8 O +
hours O +
with O +
ipratropium O +
and O +
2.4 O +
hours O +
with O +
theophylline O -
. O +

While O +
side O +
effects O +
were O +
rare O -
, O +
those O +
experienced O +
after O +
theophylline O +
use O +
did O +
involve O +
the O +
cardiovascular B-Disease +
and I-Disease +
gastrointestinal I-Disease +
systems I-Disease -
. O +

These O +
results O +
show O +
that O +
ipratropium O +
is O +
a O +
more O +
potent O +
bronchodilator O +
than O +
oral O +
theophylline O +
in O +
patients O +
with O +
chronic B-Disease +
airflow I-Disease +
obstruction I-Disease -
. O +

An O +
evaluation O +
of O +
amikacin O +
nephrotoxicity B-Disease +
in O +
the O +
hematology O -
/ O -
oncology O +
population O -
. O +

Amikacin O +
is O +
an O +
aminoglycoside O +
commonly O +
used O +
to O +
provide O +
empirical O +
double O +
gram O -
- O -
negative O +
treatment O +
for O +
febrile B-Disease +
neutropenia I-Disease +
and O +
other O +
suspected O +
infections B-Disease -
. O +

Strategies O +
of O +
extended O -
- O -
interval O +
and O +
conventional O +
dosing O +
have O +
been O +
utilized O +
extensively O +
in O +
the O +
general O +
medical O +
population O -
; O +
however O -
, O +
data O +
are O +
lacking O +
to O +
support O +
a O +
dosing O +
strategy O +
in O +
the O +
hematology O -
/ O -
oncology O +
population O -
. O +

To O +
evaluate O +
amikacin O -
- O -
associated O +
nephrotoxicity B-Disease +
in O +
an O +
adult O +
hematology O -
/ O -
oncology O +
population O -
, O +
a O +
prospective O -
, O +
randomized O -
, O +
open O -
- O -
label O +
trial O +
was O +
conducted O +
at O +
a O +
university O -
- O -
affiliated O +
medical O +
center O -
. O +

Forty O +
patients O +
with O +
a O +
diagnosis O +
consistent O +
with O +
a O +
hematologic B-Disease -
/ I-Disease -
oncologic I-Disease +
disorder I-Disease +
that O +
required O +
treatment O +
with O +
an O +
aminoglycoside O +
were O +
randomized O +
to O +
either O +
conventional O +
or O +
extended O -
- O -
interval O +
amikacin O -
. O +

The O +
occurrence O +
of O +
nephrotoxicity B-Disease +
by O +
means O +
of O +
an O +
increase O +
in O +
serum O +
creatinine O +
and O +
evaluation O +
of O +
efficacy O +
via O +
amikacin O +
serum O +
concentrations O +
with O +
respective O +
pathogens O +
were O +
assessed O -
. O +

The O +
occurrence O +
of O +
nephrotoxicity B-Disease +
was O +
similar O +
between O +
the O +
conventional O +
and O +
extended O -
- O -
interval O +
groups O -
, O +
at O +
10 O -
% O +
and O +
5 O -
% O -
, O +
respectively O +
( O -
P O +
= O +
1.00 O -
) O -
. O +

Six O +
patients O +
in O +
the O +
conventional O +
group O +
had O +
a O +
positive O +
culture O -
, O +
compared O +
with O +
none O +
in O +
the O +
extended O -
- O -
interval O +
group O +
( O -
P O +
= O +
0.002 O -
) O -
. O +

The O +
occurrence O +
of O +
nephrotoxicity B-Disease +
was O +
similar O +
between O +
the O +
two O +
dosing O +
regimens O -
, O +
but O +
the O +
distribution O +
of O +
risk O +
factors O +
was O +
variable O +
between O +
the O +
two O +
groups O -
. O +

Efficacy O +
could O +
not O +
be O +
assessed O -
. O +

High O +
dose O +
dexmedetomidine O +
as O +
the O +
sole O +
sedative O +
for O +
pediatric O +
MRI O -
. O +

OBJECTIVE O -
: O +
This O +
large O -
- O -
scale O +
retrospective O +
review O +
evaluates O +
the O +
sedation O +
profile O +
of O +
dexmedetomidine O -
. O +

AIM O -
: O +
To O +
determine O +
the O +
hemodynamic O +
responses O -
, O +
efficacy O +
and O +
adverse O +
events O +
associated O +
with O +
the O +
use O +
of O +
high O +
dose O +
dexmedetomidine O +
as O +
the O +
sole O +
sedative O +
for O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
studies O -
. O +

BACKGROUND O -
: O +
Dexmedetomidine O +
has O +
been O +
used O +
at O +
our O +
institution O +
since O +
2005 O +
to O +
provide O +
sedation O +
for O +
pediatric O +
radiological O +
imaging O +
studies O -
. O +

Over O +
time O -
, O +
an O +
effective O +
protocol O +
utilizing O +
high O +
dose O +
dexmedetomidine O +
as O +
the O +
sole O +
sedative O +
agent O +
has O +
evolved O -
. O +

METHODS O -
/ O -
MATERIALS O -
: O +
As O +
part O +
of O +
the O +
ongoing O +
Quality O +
Assurance O +
process O -
, O +
data O +
on O +
all O +
sedations O +
are O +
reviewed O +
monthly O +
and O +
protocols O +
modified O +
as O +
needed O -
. O +

Data O +
were O +
analyzed O +
from O +
all O +
747 O +
consecutive O +
patients O +
who O +
received O +
dexmedetomidine O +
for O +
MRI O +
sedation O +
from O +
April O +
2005 O +
to O +
April O +
2007 O -
. O +

RESULTS O -
: O +
Since O +
2005 O -
, O +
the O +
10-min O +
loading O +
dose O +
of O +
our O +
dexmedetomidine O +
protocol O +
increased O +
from O +
2 O +
to O +
3 O +
microg.kg O -
( O -
-1 O -
) O -
, O +
and O +
the O +
infusion O +
rate O +
increased O +
from O +
1 O +
to O +
1.5 O +
to O +
2 O +
microg.kg O -
( O -
-1 O -
) O -
.h O -
( O -
-1 O -
) O -
. O +

The O +
current O +
sedation O +
protocol O +
progressively O +
increased O +
the O +
rate O +
of O +
successful O +
sedation O +
( O -
able O +
to O +
complete O +
the O +
imaging O +
study O -
) O +
when O +
using O +
dexmedetomidine O +
alone O +
from O +
91.8 O -
% O +
to O +
97.6 O -
% O +
( O -
P O +
= O +
0.009 O -
) O -
, O +
reducing O +
the O +
requirement O +
for O +
adjuvant O +
pentobarbital O +
in O +
the O +
event O +
of O +
sedation O +
failure O +
with O +
dexmedetomidine O +
alone O +
and O +
decreased O +
the O +
mean O +
recovery O +
time O +
by O +
10 O +
min O +
( O -
P O +
< O +
0.001 O -
) O -
. O +

Although O +
dexmedetomidine O +
sedation O +
was O +
associated O +
with O +
a O +
16 O -
% O +
incidence O +
of O +
bradycardia B-Disease -
, O +
all O +
concomitant O +
mean O +
arterial O +
blood O +
pressures O +
were O +
within O +
20 O -
% O +
of O +
age O -
- O -
adjusted O +
normal O +
range O +
and O +
oxygen O +
saturations O +
were O +
95 O -
% O +
or O +
higher O -
. O +

CONCLUSION O -
: O +
Dexmedetomidine O +
in O +
high O +
doses O +
provides O +
adequate O +
sedation O +
for O +
pediatric O +
MRI O +
studies O -
. O +

While O +
use O +
of O +
high O +
dose O +
dexmedetomidine O +
is O +
associated O +
with O +
decreases O +
in O +
heart O +
rate O +
and O +
blood O +
pressure O +
outside O +
the O +
established O +
' O -
awake O -
' O +
norms O -
, O +
this O +
deviation O +
is O +
generally O +
within O +
20 O -
% O +
of O +
norms O -
, O +
and O +
is O +
not O +
associated O +
with O +
adverse O +
sequelae O -
. O +

Dexmedetomidine O +
is O +
useful O +
as O +
the O +
sole O +
sedative O +
for O +
pediatric O +
MRI O -
. O +

Hepatotoxicity B-Disease +
associated O +
with O +
sulfasalazine O +
in O +
inflammatory O +
arthritis B-Disease -
: O +
A O +
case O +
series O +
from O +
a O +
local O +
surveillance O +
of O +
serious O +
adverse O +
events O -
. O +

BACKGROUND O -
: O +
Spontaneous O +
reporting O +
systems O +
for O +
adverse O +
drug O +
reactions O +
( O -
ADRs O -
) O +
are O +
handicapped O +
by O +
under O -
- O -
reporting O +
and O +
limited O +
detail O +
on O +
individual O +
cases O -
. O +

We O +
report O +
an O +
investigation O +
from O +
a O +
local O +
surveillance O +
for O +
serious O +
adverse O +
drug O +
reactions O +
associated O +
with O +
disease O +
modifying O +
anti O -
- O -
rheumatic O +
drugs O +
that O +
was O +
triggered O +
by O +
the O +
occurrence O +
of O +
liver B-Disease +
failure I-Disease +
in O +
two O +
of O +
our O +
patients O -
. O +

METHODS O -
: O +
Serious O +
ADR O +
reports O +
have O +
been O +
solicited O +
from O +
local O +
clinicians O +
by O +
regular O +
postcards O +
over O +
the O +
past O +
seven O +
years O -
. O +

Patients O -
' O -
, O +
who O +
had O +
hepatotoxicity B-Disease +
on O +
sulfasalazine O +
and O +
met O +
a O +
definition O +
of O +
a O +
serious O +
ADR O -
, O +
were O +
identified O -
. O +

Two O +
clinicians O +
reviewed O +
structured O +
case O +
reports O +
and O +
assessed O +
causality O +
by O +
consensus O +
and O +
by O +
using O +
a O +
causality O +
assessment O +
instrument O -
. O +

The O +
likely O +
frequency O +
of O +
hepatotoxicity B-Disease +
with O +
sulfasalazine O +
was O +
estimated O +
by O +
making O +
a O +
series O +
of O +
conservative O +
assumptions O -
. O +

RESULTS O -
: O +
Ten O +
cases O +
were O +
identified O -
: O +
eight O +
occurred O +
during O +
surveillance O -
. O +

Eight O +
patients O +
were O +
hospitalised O -
, O +
two O +
in O +
hepatic B-Disease +
failure I-Disease +
- O +
one O +
died O +
after O +
a O +
liver O +
transplant O -
. O +

All O +
but O +
one O +
event O +
occurred O +
within O +
6 O +
weeks O +
of O +
treatment O -
. O +

Seven O +
patients O +
had O +
a O +
skin B-Disease +
rash I-Disease -
, O +
three O +
eosinophilia B-Disease +
and O +
one O +
interstitial B-Disease +
nephritis I-Disease -
. O +

Five O +
patients O +
were O +
of O +
Black O +
British O +
of O +
African O +
or O +
Caribbean O +
descent O -
. O +

Liver O +
enzymes O +
showed O +
a O +
hepatocellular O +
pattern O +
in O +
four O +
cases O +
and O +
a O +
mixed O +
pattern O +
in O +
six O -
. O +

Drug O -
- O -
related O +
hepatotoxicity B-Disease +
was O +
judged O +
probable O +
or O +
highly O +
probable O +
in O +
8 O +
patients O -
. O +

The O +
likely O +
frequency O +
of O +
serious O +
hepatotoxicity B-Disease +
with O +
sulfasalazine O +
was O +
estimated O +
at O +
0.4 O -
% O +
of O +
treated O +
patients O -
. O +

CONCLUSION O -
: O +
Serious O +
hepatotoxicity B-Disease +
associated O +
with O +
sulfasalazine O +
appears O +
to O +
be O +
under O -
- O -
appreciated O +
and O +
intensive O +
monitoring O +
and O +
vigilance O +
in O +
the O +
first O +
6 O +
weeks O +
of O +
treatment O +
is O +
especially O +
important O -
. O +

Methamphetamine O -
- O -
induced O +
neurotoxicity B-Disease +
and O +
microglial O +
activation O +
are O +
not O +
mediated O +
by O +
fractalkine O +
receptor O +
signaling O -
. O +

Methamphetamine O +
( O -
METH O -
) O +
damages O +
dopamine O +
( O -
DA O -
) O +
nerve O +
endings O +
by O +
a O +
process O +
that O +
has O +
been O +
linked O +
to O +
microglial O +
activation O +
but O +
the O +
signaling O +
pathways O +
that O +
mediate O +
this O +
response O +
have O +
not O +
yet O +
been O +
delineated O -
. O +

Cardona O +
et O +
al. O +
[ O -
Nat O -
. O +

Neurosci O -
. O +

9 O +
( O -
2006 O -
) O -
, O +
917 O -
] O +
recently O +
identified O +
the O +
microglial O -
- O -
specific O +
fractalkine O +
receptor O +
( O -
CX3CR1 O -
) O +
as O +
an O +
important O +
mediator O +
of O +
MPTP O -
- O -
induced O +
neurodegeneration B-Disease +
of O +
DA O +
neurons O -
. O +

Because O +
the O +
CNS B-Disease +
damage I-Disease +
caused O +
by O +
METH O +
and O +
MPTP O +
is O +
highly O +
selective O +
for O +
the O +
DA O +
neuronal O +
system O +
in O +
mouse O +
models O +
of O +
neurotoxicity B-Disease -
, O +
we O +
hypothesized O +
that O +
the O +
CX3CR1 O +
plays O +
a O +
role O +
in O +
METH O -
- O -
induced O +
neurotoxicity B-Disease +
and O +
microglial O +
activation O -
. O +

Mice O +
in O +
which O +
the O +
CX3CR1 O +
gene O +
has O +
been O +
deleted O +
and O +
replaced O +
with O +
a O +
cDNA O +
encoding O +
enhanced O +
green O +
fluorescent O +
protein O +
( O -
eGFP O -
) O +
were O +
treated O +
with O +
METH O +
and O +
examined O +
for O +
striatal O +
neurotoxicity B-Disease -
. O +

METH O +
depleted O +
DA O -
, O +
caused O +
microglial O +
activation O -
, O +
and O +
increased O +
body O +
temperature O +
in O +
CX3CR1 O +
knockout O +
mice O +
to O +
the O +
same O +
extent O +
and O +
over O +
the O +
same O +
time O +
course O +
seen O +
in O +
wild O -
- O -
type O +
controls O -
. O +

The O +
effects O +
of O +
METH O +
in O +
CX3CR1 O +
knockout O +
mice O +
were O +
not O +
gender O -
- O -
dependent O +
and O +
did O +
not O +
extend O +
beyond O +
the O +
striatum O -
. O +

Striatal O +
microglia O +
expressing O +
eGFP O +
constitutively O +
show O +
morphological O +
changes O +
after O +
METH O +
that O +
are O +
characteristic O +
of O +
activation O -
. O +

This O +
response O +
was O +
restricted O +
to O +
the O +
striatum O +
and O +
contrasted O +
sharply O +
with O +
unresponsive O +
eGFP O -
- O -
microglia O +
in O +
surrounding O +
brain O +
areas O +
that O +
are O +
not O +
damaged O +
by O +
METH O -
. O +

We O +
conclude O +
from O +
these O +
studies O +
that O +
CX3CR1 O +
signaling O +
does O +
not O +
modulate O +
METH O +
neurotoxicity B-Disease +
or O +
microglial O +
activation O -
. O +

Furthermore O -
, O +
it O +
appears O +
that O +
striatal O -
- O -
resident O +
microglia O +
respond O +
to O +
METH O +
with O +
an O +
activation O +
cascade O +
and O +
then O +
return O +
to O +
a O +
surveying O +
state O +
without O +
undergoing O +
apoptosis O +
or O +
migration O -
. O +

Nicotine O -
- O -
induced O +
nystagmus B-Disease +
correlates O +
with O +
midpontine O +
activation O -
. O +

The O +
pathomechanism O +
of O +
nicotine O -
- O -
induced O +
nystagmus B-Disease +
( O -
NIN B-Disease -
) O +
is O +
unknown O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
delineate O +
brain O +
structures O +
that O +
are O +
involved O +
in O +
NIN B-Disease +
generation O -
. O +

Eight O +
healthy O +
volunteers O +
inhaled O +
nicotine O +
in O +
darkness O +
during O +
a O +
functional O +
magnetic O +
resonance O +
imaging O +
( O -
fMRI O -
) O +
experiment O -
; O +
eye O +
movements O +
were O +
registered O +
using O +
video O -
- O -
oculography O -
. O +

NIN B-Disease +
correlated O +
with O +
blood O +
oxygen O +
level O -
- O -
dependent O +
( O -
BOLD O -
) O +
activity O +
levels O +
in O +
a O +
midpontine O +
site O +
in O +
the O +
posterior O +
basis O +
pontis O -
. O +

NIN B-Disease -
- O -
induced O +
midpontine O +
activation O +
may O +
correspond O +
to O +
activation O +
of O +
the O +
dorsomedial O +
pontine O +
nuclei O +
and O +
the O +
nucleus O +
reticularis O +
tegmenti O +
pontis O -
, O +
structures O +
known O +
to O +
participate O +
in O +
the O +
generation O +
of O +
multidirectional O +
saccades O +
and O +
smooth O +
pursuit O +
eye O +
movements O -
. O +

Acute O +
effects O +
of O +
N- O -
( O -
2-propylpentanoyl O -
) O -
urea O +
on O +
hippocampal O +
amino O +
acid O +
neurotransmitters O +
in O +
pilocarpine O -
- O -
induced O +
seizure B-Disease +
in O +
rats O -
. O +

The O +
present O +
study O +
aimed O +
to O +
investigate O +
the O +
anticonvulsant O +
activity O +
as O +
well O +
as O +
the O +
effects O +
on O +
the O +
level O +
of O +
hippocampal O +
amino O +
acid O +
neurotransmitters O +
( O -
glutamate O -
, O +
aspartate O -
, O +
glycine O +
and O +
GABA O -
) O +
of O +
N- O -
( O -
2-propylpentanoyl O -
) O -
urea O +
( O -
VPU O -
) O +
in O +
comparison O +
to O +
its O +
parent O +
compound O -
, O +
valproic O +
acid O +
( O -
VPA O -
) O -
. O +

VPU O +
was O +
more O +
potent O +
than O +
VPA O -
, O +
exhibiting O +
the O +
median O +
effective O +
dose O +
( O -
ED O -
( O -
50 O -
) O -
) O +
of O +
49 O +
mg O -
/ O -
kg O +
in O +
protecting O +
rats O +
against O +
pilocarpine O -
- O -
induced O +
seizure B-Disease +
whereas O +
the O +
corresponding O +
value O +
for O +
VPA O +
was O +
322 O +
mg O -
/ O -
kg O -
. O +

In O +
vivo O +
microdialysis O +
demonstrated O +
that O +
an O +
intraperitoneal O +
administration O +
of O +
pilocarpine O +
induced O +
a O +
pronounced O +
increment O +
of O +
hippocampal O +
glutamate O +
and O +
aspartate O +
whereas O +
no O +
significant O +
change O +
was O +
observed O +
on O +
the O +
level O +
of O +
glycine O +
and O +
GABA O -
. O +

Pretreatment O +
with O +
either O +
VPU O +
( O -
50 O +
and O +
100 O +
mg O -
/ O -
kg O -
) O +
or O +
VPA O +
( O -
300 O +
and O +
600 O +
mg O -
/ O -
kg O -
) O +
completely O +
abolished O +
pilocarpine O -
- O -
evoked O +
increases O +
in O +
extracellular O +
glutamate O +
and O +
aspartate O -
. O +

In O +
addition O -
, O +
a O +
statistically O +
significant O +
reduction O +
was O +
also O +
observed O +
on O +
the O +
level O +
of O +
GABA O +
and O +
glycine O +
but O +
less O +
than O +
a O +
drastic O +
reduction O +
of O +
glutamate O +
and O +
aspartate O +
level O -
. O +

Based O +
on O +
the O +
finding O +
that O +
VPU O +
and O +
VPA O +
could O +
protect O +
the O +
animals O +
against O +
pilocarpine O -
- O -
induced O +
seizure B-Disease +
it O +
is O +
suggested O +
that O +
the O +
reduction O +
of O +
inhibitory O +
amino O +
acid O +
neurotransmitters O +
was O +
comparatively O +
minor O +
and O +
offset O +
by O +
a O +
pronounced O +
reduction O +
of O +
glutamate O +
and O +
aspartate O -
. O +

Therefore O -
, O +
like O +
VPA O -
, O +
the O +
finding O +
that O +
VPU O +
could O +
drastically O +
reduce O +
pilocarpine O -
- O -
induced O +
increases O +
in O +
glutamate O +
and O +
aspartate O +
should O +
account O -
, O +
at O +
least O +
partly O -
, O +
for O +
its O +
anticonvulsant O +
activity O +
observed O +
in O +
pilocarpine O -
- O -
induced O +
seizure B-Disease +
in O +
experimental O +
animals O -
. O +

Some O +
other O +
mechanism O +
than O +
those O +
being O +
reported O +
herein O +
should O +
be O +
further O +
investigated O -
. O +

Complete O +
atrioventricular B-Disease +
block I-Disease +
secondary O +
to O +
lithium O +
therapy O -
. O +

Sinus B-Disease +
node I-Disease +
dysfunction I-Disease +
has O +
been O +
reported O +
most O +
frequently O +
among O +
the O +
adverse O +
cardiovascular O +
effects O +
of O +
lithium O -
. O +

In O +
the O +
present O +
case O -
, O +
complete O +
atrioventricular B-Disease +
( I-Disease -
AV I-Disease -
) I-Disease +
block I-Disease +
with O +
syncopal B-Disease +
attacks I-Disease +
developed O +
secondary O +
to O +
lithium O +
therapy O -
, O +
necessitating O +
permanent O +
pacemaker O +
implantation O -
. O +

Serum O +
lithium O +
levels O +
remained O +
under O +
or O +
within O +
the O +
therapeutic O +
range O +
during O +
the O +
syncopal B-Disease +
attacks I-Disease -
. O +

Lithium O +
should O +
be O +
used O +
with O +
extreme O +
caution O -
, O +
especially O +
in O +
patients O +
with O +
mild O +
disturbance O +
of O +
AV O +
conduction O -
. O +

Protective O +
effect O +
of O +
verapamil O +
on O +
gastric B-Disease +
hemorrhagic I-Disease +
ulcers B-Disease +
in O +
severe O +
atherosclerotic B-Disease +
rats O -
. O +

Studies O +
concerning O +
with O +
pathogenesis O +
of O +
gastric B-Disease +
hemorrhage I-Disease +
and O +
mucosal O +
ulceration O +
produced O +
in O +
atherosclerotic B-Disease +
rats O +
are O +
lacking O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
examine O +
the O +
role O +
of O +
gastric O +
acid O +
back O -
- O -
diffusion O -
, O +
mast O +
cell O +
histamine O +
release O -
, O +
lipid O +
peroxide O +
( O -
LPO O -
) O +
generation O +
and O +
mucosal O +
microvascular O +
permeability O +
in O +
modulating O +
gastric B-Disease +
hemorrhage I-Disease +
and O +
ulcer B-Disease +
in O +
rats O +
with O +
atherosclerosis B-Disease +
induced O +
by O +
coadministration O +
of O +
vitamin O +
D2 O +
and O +
cholesterol O -
. O +

Additionally O -
, O +
the O +
protective O +
effect O +
of O +
verapamil O +
on O +
this O +
ulcer B-Disease +
model O +
was O +
evaluated O -
. O +

Male O +
Wistar O +
rats O +
were O +
challenged O +
intragastrically O +
once O +
daily O +
for O +
9 O +
days O +
with O +
1.0 O +
ml O -
/ O -
kg O +
of O +
corn O +
oil O +
containing O +
vitamin O +
D2 O +
and O +
cholesterol O +
to O +
induce O +
atherosclerosis B-Disease -
. O +

Control O +
rats O +
received O +
corn O +
oil O +
only O -
. O +

After O +
gastric O +
surgery O -
, O +
rat O +
stomachs O +
were O +
irrigated O +
for O +
3 O +
h O +
with O +
either O +
simulated O +
gastric O +
juice O +
or O +
normal O +
saline O -
. O +

Gastric O +
acid O +
back O -
- O -
diffusion O -
, O +
mucosal O +
LPO O +
generation O -
, O +
histamine O +
concentration O -
, O +
microvascular O +
permeability O -
, O +
luminal O +
hemoglobin O +
content O +
and O +
ulcer B-Disease +
areas O +
were O +
determined O -
. O +

Elevated O +
atherosclerotic B-Disease +
parameters O -
, O +
such O +
as O +
serum O +
calcium O -
, O +
total O +
cholesterol O +
and O +
low O -
- O -
density O +
lipoprotein O +
concentration O +
were O +
obtained O +
in O +
atherosclerotic B-Disease +
rats O -
. O +

Severe O +
gastric O +
ulcers B-Disease +
accompanied O +
with O +
increased O +
ulcerogenic O +
factors O -
, O +
including O +
gastric O +
acid O +
back O -
- O -
diffusion O -
, O +
histamine O +
release O -
, O +
LPO O +
generation O +
and O +
luminal O +
hemoglobin O +
content O +
were O +
also O +
observed O +
in O +
these O +
rats O -
. O +

Moreover O -
, O +
a O +
positive O +
correlation O +
of O +
histamine O +
to O +
gastric B-Disease +
hemorrhage I-Disease +
and O +
to O +
ulcer B-Disease +
was O +
found O +
in O +
those O +
atherosclerotic B-Disease +
rats O -
. O +

This O +
hemorrhagic B-Disease +
ulcer B-Disease +
and O +
various O +
ulcerogenic O +
parameters O +
were O +
dose O -
- O -
dependently O +
ameliorated O +
by O +
daily O +
intragastric O +
verapamil O -
. O +

Atherosclerosis B-Disease +
could O +
produce O +
gastric B-Disease +
hemorrhagic I-Disease +
ulcer B-Disease +
via O +
aggravation O +
of O +
gastric O +
acid O +
back O -
- O -
diffusion O -
, O +
LPO O +
generation O -
, O +
histamine O +
release O +
and O +
microvascular O +
permeability O +
that O +
could O +
be O +
ameliorated O +
by O +
verapamil O +
in O +
rats O -
. O +

Lamivudine O +
for O +
the O +
prevention O +
of O +
hepatitis B-Disease +
B I-Disease +
virus O +
reactivation O +
in O +
hepatitis O -
- O -
B O +
surface O +
antigen O +
( O -
HBSAG O -
) O +
seropositive O +
cancer B-Disease +
patients O +
undergoing O +
cytotoxic O +
chemotherapy O -
. O +

Hepatitis B-Disease +
B I-Disease +
virus O +
( O -
HBV O -
) O +
is O +
one O +
of O +
the O +
major O +
causes O +
of O +
chronic O +
liver B-Disease +
disease I-Disease +
worldwide O -
. O +

Cancer B-Disease +
patients O +
who O +
are O +
chronic O +
carriers O +
of O +
HBV O +
have O +
a O +
higher O +
hepatic B-Disease +
complication I-Disease +
rate O +
while O +
receiving O +
cytotoxic O +
chemotherapy O +
( O -
CT O -
) O +
and O +
this O +
has O +
mainly O +
been O +
attributed O +
to O +
HBV O +
reactivation O -
. O +

In O +
this O +
study O -
, O +
cancer B-Disease +
patients O +
who O +
have O +
solid O +
and O +
hematological B-Disease +
malignancies I-Disease +
with O +
chronic O +
HBV B-Disease +
infection I-Disease +
received O +
the O +
antiviral O +
agent O +
lamivudine O +
prior O +
and O +
during O +
CT O +
compared O +
with O +
historical O +
control O +
group O +
who O +
did O +
not O +
receive O +
lamivudine O -
. O +

The O +
objectives O +
were O +
to O +
assess O +
the O +
efficacy O +
of O +
lamivudine O +
in O +
reducing O +
the O +
incidence O +
of O +
HBV O +
reactivation O -
, O +
and O +
diminishing O +
morbidity O +
and O +
mortality O +
during O +
CT O -
. O +

Two O +
groups O +
were O +
compared O +
in O +
this O +
study O -
. O +

The O +
prophylactic O +
lamivudin O +
group O +
consisted O +
of O +
37 O +
patients O +
who O +
received O +
prophylactic O +
lamivudine O +
treatment O -
. O +

The O +
historical O +
controls O +
consisted O +
of O +
50 O +
consecutive O +
patients O +
who O +
underwent O +
CT O +
without O +
prophylactic O +
lamivudine O -
. O +

They O +
were O +
followed O +
up O +
during O +
and O +
for O +
8 O +
weeks O +
after O +
CT O -
. O +

The O +
outcomes O +
were O +
compared O +
for O +
both O +
groups O -
. O +

Of O +
our O +
control O +
group O +
( O -
n= O +
50 O -
) O -
, O +
21 O +
patients O +
( O -
42 O -
% O -
) O +
were O +
established O +
hepatitis B-Disease -
. O +

Twelve O +
( O -
24 O -
% O -
) O +
of O +
them O +
were O +
evaluated O +
as O +
severe O +
hepatitis B-Disease -
. O +

In O +
the O +
prophylactic O +
lamivudine O +
group O +
severe O +
hepatitis B-Disease +
were O +
observed O +
only O +
in O +
1 O +
patient O +
( O -
2.7 O -
% O -
) O +
of O +
37 O +
patients O +
( O -
p O +
< O +
0.006 O -
) O -
. O +

Comparison O +
of O +
the O +
mean O +
ALT O +
values O +
revealed O +
significantly O +
higher O +
mean O +
alanine O +
aminotransferase O +
( O -
ALT O -
) O +
values O +
in O +
the O +
control O +
group O +
than O +
the O +
prophylactic O +
lamivudine O +
group O -
; O +
154:64 O +
( O -
p O +
< O +
0.32 O -
) O -
. O +

Our O +
study O +
suggests O +
that O +
prophylactic O +
lamivudine O +
significantly O +
decreases O +
the O +
incidence O +
of O +
HBV O +
reactivation O +
and O +
overall O +
morbidity O +
in O +
cancer B-Disease +
patients O +
during O +
and O +
after O +
immunosuppressive O +
therapy O -
. O +

Further O +
studies O +
are O +
needed O +
to O +
determine O +
the O +
most O +
appropriate O +
nucleoside O +
or O +
nucleotide O +
analogue O +
for O +
antiviral O +
prophylaxis O +
during O +
CT O +
and O +
the O +
optimal O +
duration O +
of O +
administration O +
after O +
completion O +
of O +
CT O -
. O +

Debrisoquine O +
phenotype O +
and O +
the O +
pharmacokinetics O +
and O +
beta-2 O +
receptor O +
pharmacodynamics O +
of O +
metoprolol O +
and O +
its O +
enantiomers O -
. O +

The O +
metabolism O +
of O +
the O +
cardioselective O +
beta O -
- O -
blocker O +
metoprolol O +
is O +
under O +
genetic O +
control O +
of O +
the O +
debrisoquine O -
/ O -
sparteine O +
type O -
. O +

The O +
two O +
metabolic O +
phenotypes O -
, O +
extensive O +
( O -
EM O -
) O +
and O +
poor O +
metabolizers O +
( O -
PM O -
) O -
, O +
show O +
different O +
stereoselective O +
metabolism O -
, O +
resulting O +
in O +
apparently O +
higher O +
beta-1 O +
adrenoceptor O +
antagonistic O +
potency O +
of O +
racemic O +
metoprolol O +
in O +
EMs O -
. O +

We O +
investigated O +
if O +
the O +
latter O +
also O +
applies O +
to O +
the O +
beta-2 O +
adrenoceptor O +
antagonism O +
by O +
metoprolol O -
. O +

The O +
drug O +
effect O +
studied O +
was O +
the O +
antagonism O +
by O +
metoprolol O +
of O +
terbutaline O -
- O -
induced O +
hypokalemia B-Disease -
. O +

By O +
using O +
pharmacokinetic O +
pharmacodynamic O +
modeling O +
the O +
pharmacodynamics O +
of O +
racemic O +
metoprolol O +
and O +
the O +
active O +
S O -
- O -
isomer O -
, O +
were O +
quantitated O +
in O +
EMs O +
and O +
PMs O +
in O +
terms O +
of O +
IC50 O +
values O -
, O +
representing O +
metoprolol O +
plasma O +
concentrations O +
resulting O +
in O +
half O -
- O -
maximum O +
receptor O +
occupancy O -
. O +

Six O +
EMs O +
received O +
0.5 O +
mg O +
of O +
terbutaline O +
s.c O -
. O +

on O +
two O +
different O +
occasions O -
: O +
1 O -
) O +
1 O +
hr O +
after O +
administration O +
of O +
a O +
placebo O +
and O +
2 O -
) O +
1 O +
hr O +
after O +
150 O +
mg O +
of O +
metoprolol O +
p.o O -
. O +

Five O +
PMs O +
were O +
studied O +
according O +
to O +
the O +
same O +
protocol O -
, O +
except O +
for O +
a O +
higher O +
terbutaline O +
dose O +
( O -
0.75 O +
mg O -
) O +
on O +
day O +
2 O -
. O +

Blood O +
samples O +
for O +
the O +
analysis O +
of O +
plasma O +
potassium O -
, O +
terbutaline O -
, O +
metoprolol O +
( O -
racemic O -
, O +
R- O +
and O +
S O -
- O -
isomer O -
) O -
, O +
and O +
alpha O -
- O -
hydroxymetoprolol O +
concentrations O +
were O +
taken O +
at O +
regular O +
time O +
intervals O -
, O +
during O +
8 O +
hr O +
after O +
metoprolol O -
. O +

In O +
PMs O -
, O +
metoprolol O +
increased O +
the O +
terbutaline O +
area O +
under O +
the O +
plasma O +
concentration O +
vs. O +
time O +
curve O +
( O -
+ O -
67 O -
% O -
) O -
. O +

Higher O +
metoprolol O -
/ O -
alpha O -
- O -
hydroxymetoprolol O +
ratios O +
in O +
PMs O +
were O +
predictive O +
for O +
higher O +
R- O -
/ O -
S O -
- O -
isomer O +
ratios O +
of O +
unchanged O +
drug O -
. O +

There O +
was O +
a O +
difference O +
in O +
metoprolol O +
potency O +
with O +
higher O +
racemic O +
metoprolol O +
IC50 O +
values O +
in O +
PMs O +
( O -
72 O +
+ O -
/- O +

7 O +
ng.ml-1 O -
) O +
than O +
EMs O +
( O -
42 O +
+ O -
/- O +

8 O +
ng.ml-1 O -
, O +
P O +
less O +
than O +
.001 O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Recovery O +
of O +
tacrolimus O -
- O -
associated O +
brachial B-Disease +
neuritis I-Disease +
after O +
conversion O +
to O +
everolimus O +
in O +
a O +
pediatric O +
renal O +
transplant O +
recipient O -
-- O -
case O +
report O +
and O +
review O +
of O +
the O +
literature O -
. O +

TAC O +
has O +
been O +
shown O +
to O +
be O +
a O +
potent O +
immunosuppressive O +
agent O +
for O +
solid O +
organ O +
transplantation O +
in O +
pediatrics O -
. O +

Neurotoxicity B-Disease +
is O +
a O +
potentially O +
serious O +
toxic O +
effect O -
. O +

It O +
is O +
characterized O +
by O +
encephalopathy B-Disease -
, O +
headaches B-Disease -
, O +
seizures B-Disease -
, O +
or O +
neurological B-Disease +
deficits I-Disease -
. O +

Here O -
, O +
we O +
describe O +
an O +
eight O -
- O -
and O -
- O -
a O -
- O -
half O -
- O -
yr O -
- O -
old O +
male O +
renal O +
transplant O +
recipient O +
with O +
right O +
BN O -
. O +

MRI O +
demonstrated O +
hyperintense O +
T2 O +
signals O +
in O +
the O +
cervical O +
cord O +
and O +
right O +
brachial O +
plexus O +
roots O +
indicative O +
of O +
both O +
myelitis B-Disease +
and O +
right O +
brachial B-Disease +
plexitis I-Disease -
. O +

Symptoms O +
persisted O +
for O +
three O +
months O +
despite O +
TAC O +
dose O +
reduction O -
, O +
administration O +
of O +
IVIG O +
and O +
four O +
doses O +
of O +
methylprednisolone O +
pulse O +
therapy O -
. O +

Improvement O +
and O +
eventually O +
full O +
recovery O +
only O +
occurred O +
after O +
TAC O +
was O +
completely O +
discontinued O +
and O +
successfully O +
replaced O +
by O +
everolimus O -
. O +

Protective O +
effects O +
of O +
antithrombin O +
on O +
puromycin O +
aminonucleoside O +
nephrosis B-Disease +
in O +
rats O -
. O +

We O +
investigated O +
the O +
effects O +
of O +
antithrombin O -
, O +
a O +
plasma O +
inhibitor O +
of O +
coagulation O +
factors O -
, O +
in O +
rats O +
with O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrosis B-Disease -
, O +
which O +
is O +
an O +
experimental O +
model O +
of O +
human O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Antithrombin O +
( O -
50 O +
or O +
500 O +
IU O -
/ O -
kg O -
/ O -
i.v O -
. O -
) O +
was O +
administered O +
to O +
rats O +
once O +
a O +
day O +
for O +
10 O +
days O +
immediately O +
after O +
the O +
injection O +
of O +
puromycin O +
aminonucleoside O +
( O -
50 O +
mg O -
/ O -
kg O -
/ O -
i.v O -
. O -
) O -
. O +

Treatment O +
with O +
antithrombin O +
attenuated O +
the O +
puromycin O +
aminonucleoside O -
- O -
induced O +
hematological B-Disease +
abnormalities I-Disease -
. O +

Puromycin O +
aminonucleoside O -
- O -
induced O +
renal B-Disease +
dysfunction I-Disease +
and O +
hyperlipidemia B-Disease +
were O +
also O +
suppressed O -
. O +

Histopathological O +
examination O +
revealed O +
severe O +
renal B-Disease +
damage I-Disease +
such O +
as O +
proteinaceous O +
casts O +
in O +
tubuli O +
and O +
tubular O +
expansion O +
in O +
the O +
kidney O +
of O +
control O +
rats O -
, O +
while O +
an O +
improvement O +
of O +
the O +
damage O +
was O +
seen O +
in O +
antithrombin O -
- O -
treated O +
rats O -
. O +

In O +
addition O -
, O +
antithrombin O +
treatment O +
markedly O +
suppressed O +
puromycin O +
aminonucleoside O -
- O -
induced O +
apoptosis O +
of O +
renal O +
tubular O +
epithelial O +
cells O -
. O +

Furthermore O -
, O +
puromycin O +
aminonucleoside O -
- O -
induced O +
increases O +
in O +
renal O +
cytokine O +
content O +
were O +
also O +
decreased O -
. O +

These O +
findings O +
suggest O +
that O +
thrombin O +
plays O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Treatment O +
with O +
antithrombin O +
may O +
be O +
clinically O +
effective O +
in O +
patients O +
with O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Omitting O +
fentanyl O +
reduces O +
nausea B-Disease +
and O +
vomiting B-Disease -
, O +
without O +
increasing O +
pain B-Disease -
, O +
after O +
sevoflurane O +
for O +
day O +
surgery O -
. O +

BACKGROUND O +
AND O +
OBJECTIVE O -
: O +
Despite O +
advantages O +
of O +
induction O +
and O +
maintenance O +
of O +
anaesthesia O +
with O +
sevoflurane O -
, O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease +
occurs O +
frequently O -
. O +

Fentanyl O +
is O +
a O +
commonly O +
used O +
supplement O +
that O +
may O +
contribute O +
to O +
this O -
, O +
although O +
it O +
may O +
also O +
improve O +
analgesia O -
. O +

METHODS O -
: O +
This O +
double O -
- O -
blind O +
study O +
examined O +
the O +
incidence O +
and O +
severity O +
of O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease +
and O +
pain B-Disease +
in O +
the O +
first O +
24 O +
h O +
after O +
sevoflurane O +
anaesthesia O +
in O +
216 O +
adult O +
day O +
surgery O +
patients O -
. O +

Patients O +
were O +
randomly O +
allocated O +
to O +
either O +
receive O +
or O +
not O +
receive O +
1 O +
1 O +
fentanyl O -
, O +
while O +
a O +
third O +
group O +
received O +
dexamethasone O +
in O +
addition O +
to O +
fentanyl O -
. O +

RESULTS O -
: O +
Omission O +
of O +
fentanyl O +
did O +
not O +
reduce O +
the O +
overall O +
incidence O +
of O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease -
, O +
but O +
did O +
reduce O +
the O +
incidence O +
of O +
vomiting B-Disease +
and/or O +
moderate O +
to O +
severe O +
nausea B-Disease +
prior O +
to O +
discharge O +
from O +
20 O -
% O +
and O +
17 O -
% O +
with O +
fentanyl O +
and O +
fentanyl O -
- O -
dexamethasone O -
, O +
respectively O -
, O +
to O +
5 O -
% O +
( O -
P O +
= O +
0.013 O -
) O -
. O +

Antiemetic O +
requirements O +
were O +
reduced O +
from O +
24 O -
% O +
and O +
31 O -
% O +
to O +
7 O -
% O +
( O -
P O +
= O +
0.0012 O -
) O -
. O +

Dexamethasone O +
had O +
no O +
significant O +
effect O +
on O +
the O +
incidence O +
or O +
severity O +
of O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease -
. O +

Combining O +
the O +
two O +
fentanyl O +
groups O +
revealed O +
further O +
significant O +
benefits O +
from O +
the O +
avoidance O +
of O +
opioids O -
, O +
reducing O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease +
and O +
nausea B-Disease +
prior O +
to O +
discharge O +
from O +
35 O -
% O +
and O +
33 O -
% O +
to O +
22 O -
% O +
and O +
19 O -
% O +
( O -
P O +
= O +
0.049 O +
and O +
P O +
= O +
0.035 O -
) O -
, O +
respectively O -
, O +
while O +
nausea B-Disease +
in O +
the O +
first O +
24 O +
h O +
was O +
decreased O +
from O +
42 O -
% O +
to O +
27 O -
% O +
( O -
P O +
= O +
0.034 O -
) O -
. O +

Pain B-Disease +
severity O +
and O +
analgesic O +
requirements O +
were O +
unaffected O +
by O +
the O +
omission O +
of O +
fentanyl O -
. O +

Fentanyl O +
did O +
reduce O +
minor O +
intraoperative O +
movement O +
but O +
had O +
no O +
sevoflurane O -
- O -
sparing O +
effect O +
and O +
increased O +
respiratory B-Disease +
depression I-Disease -
, O +
hypotension B-Disease +
and O +
bradycardia B-Disease -
. O +

CONCLUSION O -
: O +
As O +
fentanyl O +
exacerbated O +
postoperative B-Disease +
nausea I-Disease +
and I-Disease +
vomiting I-Disease +
without O +
an O +
improvement O +
in O +
postoperative B-Disease +
pain I-Disease +
and O +
also O +
had O +
adverse O +
cardiorespiratory O +
effects O -
, O +
it O +
appears O +
to O +
be O +
an O +
unnecessary O +
and O +
possibly O +
detrimental O +
supplement O +
to O +
sevoflurane O +
in O +
day O +
surgery O -
. O +

Valvular B-Disease +
heart I-Disease +
disease I-Disease +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
treated O +
with O +
pergolide O -
. O +

Course O +
following O +
treatment O +
modifications O -
. O +

Valvular B-Disease +
heart I-Disease +
abnormalities I-Disease +
have O +
been O +
reported O +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
treated O +
with O +
pergolide O -
. O +

However O -
, O +
the O +
incidence O +
and O +
severity O +
of O +
these O +
abnormalities O +
vary O +
from O +
study O +
to O +
study O +
and O +
their O +
course O +
after O +
drug O +
withdrawal O +
has O +
not O +
been O +
systematically O +
assessed O -
. O +

OBJECTIVES O -
: O +
To O +
estimate O +
the O +
frequency O +
and O +
severity O +
of O +
valvular B-Disease +
heart I-Disease +
abnormality I-Disease +
and O +
its O +
possible O +
reversibility O +
after O +
drug O +
withdrawal O +
in O +
a O +
case O -
- O -
control O +
study O -
. O +

METHODS O -
: O +
All O +
PD B-Disease +
patients O +
in O +
the O +
Amiens O +
area O +
treated O +
with O +
pergolide O +
were O +
invited O +
to O +
attend O +
a O +
cardiologic O +
assessment O +
including O +
transthoracic O +
echocardiography O -
. O +

Thirty O +
PD B-Disease +
patients O +
participated O +
in O +
the O +
study O -
. O +

A O +
second O +
echocardiography O +
was O +
performed O +
( O -
median O +
interval O -
: O +
13 O +
months O -
) O +
after O +
pergolide O +
withdrawal O +
( O -
n=10 O +
patients O -
) O -
. O +

Controls O +
were O +
age- O +
and O +
sex O -
- O -
matched O +
non O -
- O -
PD B-Disease +
patients O +
referred O +
to O +
the O +
cardiology O +
department O -
. O +

RESULTS O -
: O +
Compared O +
to O +
controls O -
, O +
aortic B-Disease +
regurgitation I-Disease +
( O -
OR O -
: O +
3.1 O -
; O +
95 O -
% O +
IC O -
: O +
1.1 O -
- O -
8.8 O -
) O +
and O +
mitral B-Disease +
regurgitation I-Disease +
( O -
OR O -
: O +
10.7 O -
; O +
95 O -
% O +
IC O -
: O +
2.1 O -
- O -
53 O -
) O +
were O +
more O +
frequent O +
in O +
PD B-Disease +
patients O +
( O -
tricuspid O -
: O +
NS O -
) O -
. O +

The O +
number O +
of O +
affected O +
valves O +
( O -
n=2.4+ O -
/ O -
-0.7 O -
) O +
and O +
the O +
sum O +
of O +
regurgitation O +
grades O +
( O -
n=2.8+ O -
/ O -
-1.09 O -
) O +
were O +
higher O +
( O -
p=0.008 O +
and O +
p=0.006 O -
, O +
respectively O -
) O +
in O +
the O +
pergolide O +
group O -
. O +

Severity O +
of O +
regurgitation O +
was O +
not O +
correlated O +
with O +
pergolide O +
cumulative O +
dose O -
. O +

A O +
restrictive O +
pattern O +
of O +
valvular B-Disease +
regurgitation I-Disease -
, O +
suggestive O +
of O +
the O +
role O +
of O +
pergolide O -
, O +
was O +
observed O +
in O +
12 O -
/ O -
30 O +
( O -
40 O -
% O -
) O +
patients O +
including O +
two O +
with O +
heart B-Disease +
failure I-Disease -
. O +

Pergolide O +
was O +
discontinued O +
in O +
10 O +
patients O +
with O +
valvular B-Disease +
heart I-Disease +
disease I-Disease -
, O +
resulting O +
in O +
a O +
lower O +
regurgitation O +
grade O +
( O -
p=0.01 O -
) O +
at O +
the O +
second O +
transthoracic O +
echocardiography O +
and O +
the O +
two O +
patients O +
with O +
heart B-Disease +
failure I-Disease +
returned O +
to O +
nearly O +
normal O +
clinical O +
examination O -
. O +

This O +
study O +
supports O +
the O +
high O +
frequency O +
of O +
restrictive O +
valve B-Disease +
regurgitation I-Disease +
in O +
PD B-Disease +
patients O +
treated O +
with O +
pergolide O +
and O +
reveals O +
that O +
a O +
significant O +
improvement O +
is O +
usual O +
when O +
the O +
treatment O +
is O +
converted O +
to O +
non O -
- O -
ergot O +
dopamine O +
agonists O -
. O +

Heparin O -
- O -
induced O +
thrombocytopenia B-Disease +
after O +
liver O +
transplantation O -
. O +

BACKGROUND O -
: O +
Unfractionated O +
heparin O +
sodium O +
( O -
UFH O -
) O +
or O +
low O -
- O -
molecular O +
weight O +
heparin O +
( O -
LMWH O -
) O +
is O +
used O +
in O +
anticoagulant O +
protocols O +
at O +
several O +
institutions O +
to O +
prevent O +
thrombosis B-Disease +
after O +
liver O +
transplantation O -
. O +

Heparin O -
- O -
induced O +
thrombocytopenia B-Disease +
( O -
HIT B-Disease -
) O +
is O +
an O +
adverse O +
immune O -
- O -
mediated O +
reaction O +
to O +
heparin O -
, O +
resulting O +
in O +
platelet O +
count O +
decreases O +
of O +
more O +
than O +
50 O -
% O -
. O +

The O +
frequencies O +
of O +
HIT B-Disease +
after O +
liver O +
transplantation O +
and O +
platelet O +
factor O +
4 O -
/ O -
heparin O -
- O -
reactive O +
antibody O +
( O -
HIT B-Disease +
antibody O -
) O +
positivity O +
in O +
liver O +
transplantation O +
patients O -
, O +
however O -
, O +
are O +
unknown O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
The O +
32 O +
men O +
and O +
20 O +
women O +
underwent O +
living O +
donor O +
liver O +
transplantation O -
. O +

We O +
started O +
LMWH O +
( O -
25 O +
IU O -
/ O -
kg O -
/ O -
h O -
) O +
on O +
postoperative O +
day O +
( O -
POD O -
) O +
1 O -
, O +
switching O +
to O +
UFH O +
( O -
5000 O +
U O -
/ O -
d O -
) O +
on O +
POD O +
2 O +
or O +
3 O -
. O +

The O +
dose O +
of O +
UFH O +
was O +
changed O +
according O +
to O +
the O +
activated O +
clotting O +
time O +
level O -
. O +

HIT B-Disease +
antibody O +
levels O +
were O +
measured O +
the O +
day O +
before O +
surgery O +
and O +
on O +
POD O +
7 O +
and O +
14 O -
. O +

Platelet O +
count O +
was O +
measured O +
daily O +
for O +
3 O +
weeks O -
. O +

RESULTS O -
: O +
The O +
average O +
platelet O +
counts O +
preoperatively O -
, O +
and O +
on O +
POD O +
7 O -
, O +
14 O -
, O +
and O +
21 O +
were O +
65 O -
, O +
88 O -
, O +
149 O -
, O +
and O +
169 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O -
, O +
respectively O -
. O +

Two O +
patients O +
developed O +
hepatic O +
artery O +
thrombosis B-Disease +
on O +
POD O +
11 O +
and O +
19 O -
, O +
respectively O -
, O +
although O +
they O +
were O +
HIT B-Disease +
antibody O -
- O -
negative O +
and O +
their O +
platelet O +
counts O +
were O +
stable O -
. O +

In O +
2 O +
other O +
patients O -
, O +
the O +
platelet O +
count O +
decreased O +
suddenly O +
from O +
107 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O +
on O +
POD O +
4 O +
to O +
65 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O +
on O +
POD O +
6 O +
and O +
from O +
76 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O +
on O +
POD O +
7 O +
to O +
33 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
L O +
on O +
POD O +
9 O -
, O +
respectively O -
. O +

The O +
heparin O -
- O -
induced O +
platelet B-Disease +
aggregation I-Disease +
test O +
was O +
negative O +
in O +
these O +
patients O -
. O +

The O +
percentage O +
of O +
HIT B-Disease +
antibody O -
- O -
positive O +
patients O +
was O +
0.5 O -
% O +
preoperatively O -
, O +
5.6 O -
% O +
on O +
POD O +
7 O -
, O +
and O +
5.6 O -
% O +
on O +
POD O +
14 O -
. O +

None O +
of O +
the O +
subjects O -
/ O -
patients O +
developed O +
UFH O -
- O -
related O +
HIT B-Disease -
. O +

CONCLUSIONS O -
: O +
In O +
our O +
series O -
, O +
the O +
occurrence O +
of O +
HIT B-Disease +
after O +
liver O +
transplantation O +
was O +
uncommon O -
. O +

Adriamycin O -
- O -
induced O +
autophagic O +
cardiomyocyte O +
death B-Disease +
plays O +
a O +
pathogenic O +
role O +
in O +
a O +
rat O +
model O +
of O +
heart B-Disease +
failure I-Disease -
. O +

BACKGROUND O -
: O +
The O +
mechanisms O +
underlying O +
heart B-Disease +
failure I-Disease +
induced O +
by O +
adriamycin O +
are O +
very O +
complicated O +
and O +
still O +
unclear O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
whether O +
autophagy O +
was O +
involved O +
in O +
the O +
progression O +
of O +
heart B-Disease +
failure I-Disease +
induced O +
by O +
adriamycin O -
, O +
so O +
that O +
we O +
can O +
develop O +
a O +
novel O +
treatment O +
strategy O +
for O +
heart B-Disease +
failure I-Disease -
. O +

METHODS O -
: O +
3-methyladenine O +
( O -
3MA O -
) O -
, O +
a O +
specific O +
inhibitor O +
on O +
autophagy O +
was O +
used O +
in O +
a O +
heart B-Disease +
failure I-Disease +
model O +
of O +
rats O +
induced O +
by O +
adriamycin O -
. O +

Neonatal O +
cardiomyocytes O +
were O +
isolated O +
from O +
Sprague O -
- O -
Dawley O +
rat O +
hearts O +
and O +
randomly O +
divided O +
into O +
controls O -
, O +
an O +
adriamycin O -
- O -
treated O +
group O -
, O +
and O +
a O +
3MA O +
plus O +
adriamycin O -
- O -
treated O +
group O -
. O +

We O +
then O +
examined O +
the O +
morphology O -
, O +
expression O +
of O +
beclin O +
1 O +
gene O -
, O +
mitochondrial O +
permeability O +
transition O +
( O -
MPT O -
) O -
, O +
and O +
Na+-K+ O +
ATPase O +
activity O +
in O +
vivo O -
. O +

We O +
also O +
assessed O +
cell O +
viability O -
, O +
mitochondrial O +
membrane O +
potential O +
changes O +
and O +
counted O +
autophagic O +
vacuoles O +
in O +
cultured O +
cardiomyocytes O -
. O +

In O +
addition O -
, O +
we O +
analyzed O +
the O +
expression O +
of O +
autophagy O +
associated O +
gene O -
, O +
beclin O +
1 O +
using O +
RT O -
- O -
PCR O +
and O +
Western O +
blotting O +
in O +
an O +
animal O +
model O -
. O +

RESULTS O -
: O +
3MA O +
significantly O +
improved O +
cardiac O +
function O +
and O +
reduced O +
mitochondrial O +
injury O -
. O +

Furthermore O -
, O +
adriamycin O +
induced O +
the O +
formation O +
of O +
autophagic O +
vacuoles O -
, O +
and O +
3MA O +
strongly O +
downregulated O +
the O +
expression O +
of O +
beclin O +
1 O +
in O +
adriamycin O -
- O -
induced O +
failing O +
heart O +
and O +
inhibited O +
the O +
formation O +
of O +
autophagic O +
vacuoles O -
. O +

CONCLUSION O -
: O +
Autophagic O +
cardiomyocyte O +
death B-Disease +
plays O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
heart B-Disease +
failure I-Disease +
in O +
rats O +
induced O +
by O +
adriamycin O -
. O +

Mitochondrial O +
injury O +
may O +
be O +
involved O +
in O +
the O +
progression O +
of O +
heart B-Disease +
failure I-Disease +
caused O +
by O +
adriamycin O +
via O +
the O +
autophagy O +
pathway O -
. O +

Doxorubicin O +
cardiomyopathy B-Disease -
- O -
induced O +
inflammation B-Disease +
and O +
apoptosis O +
are O +
attenuated O +
by O +
gene O +
deletion O +
of O +
the O +
kinin O +
B1 O +
receptor O -
. O +

Clinical O +
use O +
of O +
the O +
anthracycline O +
doxorubicin O +
( O -
DOX O -
) O +
is O +
limited O +
by O +
its O +
cardiotoxic B-Disease +
effects O -
, O +
which O +
are O +
attributed O +
to O +
the O +
induction O +
of O +
apoptosis O -
. O +

To O +
elucidate O +
the O +
possible O +
role O +
of O +
the O +
kinin O +
B1 O +
receptor O +
( O -
B1R O -
) O +
during O +
the O +
development O +
of O +
DOX O +
cardiomyopathy B-Disease -
, O +
we O +
studied O +
B1R O +
knockout O +
mice O +
( O -
B1R O -
( O -
- O -
/ O -
- O -
) O -
) O +
by O +
investigating O +
cardiac O +
inflammation B-Disease +
and O +
apoptosis O +
after O +
induction O +
of O +
DOX O -
- O -
induced O +
cardiomyopathy B-Disease -
. O +

DOX O +
control O +
mice O +
showed O +
cardiac B-Disease +
dysfunction I-Disease +
measured O +
by O +
pressure O -
- O -
volume O +
loops O +
in O +
vivo O -
. O +

This O +
was O +
associated O +
with O +
a O +
reduced O +
activation O +
state O +
of O +
AKT O -
, O +
as O +
well O +
as O +
an O +
increased O +
bax O -
/ O -
bcl2 O +
ratio O +
in O +
Western O +
blots O -
, O +
indicating O +
cardiac B-Disease +
apoptosis I-Disease -
. O +

Furthermore O -
, O +
mRNA O +
levels O +
of O +
the O +
proinflammatory O +
cytokine O +
interleukin O +
6 O +
were O +
increased O +
in O +
the O +
cardiac O +
tissue O -
. O +

In O +
DOX O +
B1R O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
cardiac B-Disease +
dysfunction I-Disease +
was O +
improved O +
compared O +
to O +
DOX O +
control O +
mice O -
, O +
which O +
was O +
associated O +
with O +
normalization O +
of O +
the O +
bax O -
/ O -
bcl-2 O +
ratio O +
and O +
interleukin O +
6 O -
, O +
as O +
well O +
as O +
AKT O +
activation O +
state O -
. O +

These O +
findings O +
suggest O +
that O +
B1R O +
is O +
detrimental O +
in O +
DOX O +
cardiomyopathy B-Disease +
in O +
that O +
it O +
mediates O +
the O +
inflammatory O +
response O +
and O +
apoptosis O -
. O +

These O +
insights O +
might O +
have O +
useful O +
implications O +
for O +
future O +
studies O +
utilizing O +
B1R O +
antagonists O +
for O +
treatment O +
of O +
human O +
DOX O +
cardiomyopathy B-Disease -
. O +

mToR O +
inhibitors O -
- O -
induced O +
proteinuria B-Disease -
: O +
mechanisms O -
, O +
significance O -
, O +
and O +
management O -
. O +

Massive O +
urinary O +
protein O +
excretion O +
has O +
been O +
observed O +
after O +
conversion O +
from O +
calcineurin O +
inhibitors O +
to O +
mammalian O +
target O +
of O +
rapamycin O +
( O -
mToR O -
) O +
inhibitors O -
, O +
especially O +
sirolimus O -
, O +
in O +
renal O +
transplant O +
recipients O +
with O +
chronic B-Disease +
allograft I-Disease +
nephropathy I-Disease -
. O +

Because O +
proteinuria B-Disease +
is O +
a O +
major O +
predictive O +
factor O +
of O +
poor O +
transplantation O +
outcome O -
, O +
many O +
studies O +
focused O +
on O +
this O +
adverse O +
event O +
during O +
the O +
past O +
years O -
. O +

Whether O +
proteinuria B-Disease +
was O +
due O +
to O +
sirolimus O +
or O +
only O +
a O +
consequence O +
of O +
calcineurin O +
inhibitors O +
withdrawal O +
remained O +
unsolved O +
until O +
high O +
range O +
proteinuria B-Disease +
has O +
been O +
observed O +
during O +
sirolimus O +
therapy O +
in O +
islet O +
transplantation O +
and O +
in O +
patients O +
who O +
received O +
sirolimus O +
de O +
novo O -
. O +

Podocyte O +
injury O +
and O +
focal O +
segmental O +
glomerulosclerosis B-Disease +
have O +
been O +
related O +
to O +
mToR O +
inhibition O +
in O +
some O +
patients O -
, O +
but O +
the O +
pathways O +
underlying O +
these O +
lesions O +
remain O +
hypothetic O -
. O +

We O +
discuss O +
herein O +
the O +
possible O +
mechanisms O +
and O +
the O +
significance O +
of O +
mToR O +
blockade O -
- O -
induced O +
proteinuria B-Disease -
. O +

Detailed O +
spectral O +
profile O +
analysis O +
of O +
penicillin O -
- O -
induced O +
epileptiform B-Disease +
activity I-Disease +
in O +
anesthetized O +
rats O -
. O +

Penicillin O +
model O +
is O +
a O +
widely O +
used O +
experimental O +
model O +
for O +
epilepsy B-Disease +
research O -
. O +

In O +
the O +
present O +
study O +
we O +
aimed O +
to O +
portray O +
a O +
detailed O +
spectral O +
analysis O +
of O +
penicillin O -
- O -
induced O +
epileptiform B-Disease +
activity I-Disease +
in O +
comparison O +
with O +
basal O +
brain O +
activity O +
in O +
anesthetized O +
Wistar O +
rats O -
. O +

Male O +
Wistar O +
rats O +
were O +
anesthetized O +
with O +
i.p O -
. O +

urethane O +
and O +
connected O +
to O +
an O +
electrocorticogram O +
setup O -
. O +

After O +
a O +
short O +
period O +
of O +
basal O +
activity O +
recording O -
, O +
epileptic B-Disease +
focus O +
was O +
induced O +
by O +
injecting O +
400IU O -
/ O -
2 O +
microl O +
penicillin O -
- O -
G O +
potassium O +
into O +
the O +
left O +
lateral O +
ventricle O +
while O +
the O +
cortical O +
activity O +
was O +
continuously O +
recorded O -
. O +

Basal O +
activity O -
, O +
latent O +
period O +
and O +
the O +
penicillin O -
- O -
induced O +
epileptiform B-Disease +
activity I-Disease +
periods O +
were O +
then O +
analyzed O +
using O +
both O +
conventional O +
methods O +
and O +
spectral O +
analysis O -
. O +

Spectral O +
analyses O +
were O +
conducted O +
by O +
dividing O +
the O +
whole O +
spectrum O +
into O +
different O +
frequency O +
bands O +
including O +
delta O -
, O +
theta O +
( O -
slow O +
and O +
fast O -
) O -
, O +
alpha O -
- O -
sigma O -
, O +
beta O +
( O -
1 O +
and O +
2 O -
) O +
and O +
gamma O +
( O -
1 O +
and O +
2 O -
) O +
bands O -
. O +

Our O +
results O +
show O +
that O +
the O +
most O +
affected O +
frequency O +
bands O +
were O +
delta O -
, O +
theta O -
, O +
beta-2 O +
and O +
gamma-2 O +
bands O +
during O +
the O +
epileptiform B-Disease +
activity I-Disease +
and O +
there O +
were O +
marked O +
differences O +
in O +
terms O +
of O +
spectral O +
densities O +
between O +
three O +
investigated O +
episodes O +
( O -
basal O +
activity O -
, O +
latent O +
period O +
and O +
epileptiform B-Disease +
activity I-Disease -
) O -
. O +

Our O +
results O +
may O +
help O +
to O +
analyze O +
novel O +
data O +
obtained O +
using O +
similar O +
experimental O +
models O +
and O +
the O +
simple O +
analysis O +
method O +
described O +
here O +
can O +
be O +
used O +
in O +
similar O +
studies O +
to O +
investigate O +
the O +
basic O +
neuronal O +
mechanism O +
of O +
this O +
or O +
other O +
types O +
of O +
experimental O +
epilepsies B-Disease -
. O +

Neuropsychiatric O +
side O +
effects O +
after O +
the O +
use O +
of O +
mefloquine O -
. O +

This O +
study O +
describes O +
neuropsychiatric O +
side O +
effects O +
in O +
patients O +
after O +
treatment O +
with O +
mefloquine O -
. O +

Reactions O +
consisted O +
mainly O +
of O +
seizures B-Disease -
, O +
acute O +
psychoses B-Disease -
, O +
anxiety B-Disease +
neurosis I-Disease -
, O +
and O +
major O +
disturbances B-Disease +
of I-Disease +
sleep I-Disease -
- I-Disease -
wake I-Disease +
rhythm I-Disease -
. O +

Side O +
effects O +
occurred O +
after O +
both O +
therapeutic O +
and O +
prophylactic O +
intake O +
and O +
were O +
graded O +
from O +
moderate O +
to O +
severe O -
. O +

In O +
a O +
risk O +
analysis O +
of O +
neuropsychiatric O +
side O +
effects O +
in O +
Germany O -
, O +
it O +
is O +
estimated O +
that O +
one O +
of O +
8,000 O +
mefloquine O +
users O +
suffers O +
from O +
such O +
reactions O -
. O +

The O +
incidence O +
calculation O +
revealed O +
that O +
one O +
of O +
215 O +
therapeutic O +
users O +
had O +
reactions O -
, O +
compared O +
with O +
one O +
of O +
13,000 O +
in O +
the O +
prophylaxis O +
group O -
, O +
making O +
the O +
risk O +
of O +
neuropsychiatric O +
reactions O +
after O +
mefloquine O +
treatment O +
60 O +
times O +
higher O +
than O +
after O +
prophylaxis O -
. O +

Therefore O -
, O +
certain O +
limitations O +
for O +
malaria B-Disease +
prophylaxis O +
and O +
treatment O +
with O +
mefloquine O +
are O +
recommended O -
. O +

High O +
fat O +
diet O -
- O -
fed O +
obese B-Disease +
rats O +
are O +
highly O +
sensitive O +
to O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease -
. O +

Often O -
, O +
chemotherapy O +
by O +
doxorubicin O +
( O -
Adriamycin O -
) O +
is O +
limited O +
due O +
to O +
life O +
threatening O +
cardiotoxicity B-Disease +
in O +
patients O +
during O +
and O +
posttherapy O -
. O +

Recently O -
, O +
we O +
have O +
shown O +
that O +
moderate O +
diet O +
restriction O +
remarkably O +
protects O +
against O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease -
. O +

This O +
cardioprotection O +
is O +
accompanied O +
by O +
decreased O +
cardiac O +
oxidative O +
stress O +
and O +
triglycerides O +
and O +
increased O +
cardiac O +
fatty O -
- O -
acid O +
oxidation O -
, O +
ATP O +
synthesis O -
, O +
and O +
upregulated O +
JAK O -
/ O -
STAT3 O +
pathway O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
investigated O +
whether O +
a O +
physiological O +
intervention O +
by O +
feeding O +
40 O -
% O +
high O +
fat O +
diet O +
( O -
HFD O -
) O -
, O +
which O +
induces O +
obesity B-Disease +
in O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
( O -
250 O -
- O -
275 O +
g O -
) O -
, O +
sensitizes O +
to O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease -
. O +

A O +
LD O -
( O -
10 O -
) O +
dose O +
( O -
8 O +
mg O +
doxorubicin O -
/ O -
kg O -
, O +
ip O -
) O +
administered O +
on O +
day O +
43 O +
of O +
the O +
HFD O +
feeding O +
regimen O +
led O +
to O +
higher O +
cardiotoxicity B-Disease -
, O +
cardiac B-Disease +
dysfunction I-Disease -
, O +
lipid O +
peroxidation O -
, O +
and O +
80 O -
% O +
mortality O +
in O +
the O +
obese B-Disease +
( O -
OB B-Disease -
) O +
rats O +
in O +
the O +
absence O +
of O +
any O +
significant O +
renal B-Disease +
or I-Disease +
hepatic I-Disease +
toxicity I-Disease -
. O +

Doxorubicin O +
toxicokinetics O +
studies O +
revealed O +
no O +
change O +
in O +
accumulation O +
of O +
doxorubicin O +
and O +
doxorubicinol O +
( O -
toxic O +
metabolite O -
) O +
in O +
the O +
normal O +
diet O -
- O -
fed O +
( O -
ND O -
) O +
and O +
OB B-Disease +
hearts O -
. O +

Mechanistic O +
studies O +
revealed O +
that O +
OB B-Disease +
rats O +
are O +
sensitized O +
due O +
to O -
: O +
( O -
1 O -
) O +
higher O +
oxyradical O +
stress O +
leading O +
to O +
upregulation O +
of O +
uncoupling O +
proteins O +
2 O +
and O +
3 O -
, O +
( O -
2 O -
) O +
downregulation O +
of O +
cardiac O +
peroxisome O +
proliferators O +
activated O +
receptor O -
- O -
alpha O -
, O +
( O -
3 O -
) O +
decreased O +
plasma O +
adiponectin O +
levels O -
, O +
( O -
4 O -
) O +
decreased O +
cardiac O +
fatty O -
- O -
acid O +
oxidation O +
( O -
666.9+ O -
/ O -
-14.0 O +
nmol O -
/ O -
min O -
/ O -
g O +
heart O +
in O +
ND O +
versus O +
400.2+ O -
/ O -
-11.8 O +
nmol O -
/ O -
min O -
/ O -
g O +
heart O +
in O +
OB B-Disease -
) O -
, O +
( O -
5 O -
) O +
decreased O +
mitochondrial O +
AMP O -
- O -
alpha2 O +
protein O +
kinase O -
, O +
and O +
( O -
6 O -
) O +
86 O -
% O +
drop O +
in O +
cardiac O +
ATP O +
levels O +
accompanied O +
by O +
decreased O +
ATP O -
/ O -
ADP O +
ratio O +
after O +
doxorubicin O +
administration O -
. O +

Decreased O +
cardiac O +
erythropoietin O +
and O +
increased O +
SOCS3 O +
further O +
downregulated O +
the O +
cardioprotective O +
JAK O -
/ O -
STAT3 O +
pathway O -
. O +

In O +
conclusion O -
, O +
HFD O -
- O -
induced O +
obese B-Disease +
rats O +
are O +
highly O +
sensitized O +
to O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease +
by O +
substantially O +
downregulating O +
cardiac O +
mitochondrial O +
ATP O +
generation O -
, O +
increasing O +
oxidative O +
stress O +
and O +
downregulating O +
the O +
JAK O -
/ O -
STAT3 O +
pathway O -
. O +

Prenatal O +
protein O +
deprivation O +
alters O +
dopamine O -
- O -
mediated O +
behaviors O +
and O +
dopaminergic O +
and O +
glutamatergic O +
receptor O +
binding O -
. O +

Epidemiological O +
evidence O +
indicates O +
that O +
prenatal O +
nutritional O +
deprivation O +
may O +
increase O +
the O +
risk O +
of O +
schizophrenia B-Disease -
. O +

The O +
goal O +
of O +
these O +
studies O +
was O +
to O +
use O +
an O +
animal O +
model O +
to O +
examine O +
the O +
effects O +
of O +
prenatal O +
protein O +
deprivation O +
on O +
behaviors O +
and O +
receptor O +
binding O +
with O +
relevance O +
to O +
schizophrenia B-Disease -
. O +

We O +
report O +
that O +
prenatally O +
protein O +
deprived O +
( O -
PD O -
) O +
female O +
rats O +
showed O +
an O +
increased O +
stereotypic O +
response O +
to O +
apomorphine O +
and O +
an O +
increased O +
locomotor O +
response O +
to O +
amphetamine O +
in O +
adulthood O -
. O +

These O +
differences O +
were O +
not O +
observed O +
during O +
puberty O -
. O +

No O +
changes O +
in O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
or O +
MK-801-induced O +
locomotion O +
were O +
seen O +
following O +
PD O -
. O +

In O +
addition O -
, O +
PD O +
female O +
rats O +
showed O +
increased O +
( O -
3 O -
) O -
H O -
- O -
MK-801 O +
binding O +
in O +
the O +
striatum O +
and O +
hippocampus O -
, O +
but O +
not O +
in O +
the O +
cortex O -
. O +

PD O +
female O +
rats O +
also O +
showed O +
increased O +
( O -
3 O -
) O -
H O -
- O -
haloperidol O +
binding O +
and O +
decreased O +
dopamine O +
transporter O +
binding O +
in O +
striatum O -
. O +

No O +
statistically O +
significant O +
changes O +
in O +
behavior O +
or O +
receptor O +
binding O +
were O +
found O +
in O +
PD O +
males O +
with O +
the O +
exception O +
of O +
increased O +
( O -
3 O -
) O -
H O -
- O -
MK-801 O +
binding O +
in O +
cortex O -
. O +

This O +
animal O +
model O +
may O +
be O +
useful O +
to O +
explore O +
the O +
mechanisms O +
by O +
which O +
prenatal O +
nutritional B-Disease +
deficiency I-Disease +
enhances O +
risk O +
for O +
schizophrenia B-Disease +
in O +
humans O +
and O +
may O +
also O +
have O +
implications O +
for O +
developmental O +
processes O +
leading O +
to O +
differential O +
sensitivity O +
to O +
drugs O +
of O +
abuse O -
. O +

Adverse O +
effects O +
of O +
topical O +
papaverine O +
on O +
auditory O +
nerve O +
function O -
. O +

BACKGROUND O -
: O +
Papaverine O +
hydrochloride O +
is O +
a O +
direct O -
- O -
acting O +
vasodilator O +
used O +
to O +
manage O +
vasospasm B-Disease +
during O +
various O +
neurosurgical O +
operations O -
. O +

Transient O +
cranial B-Disease +
nerve I-Disease +
dysfunction I-Disease +
has O +
been O +
described O +
in O +
a O +
few O +
cases O +
with O +
topical O +
papaverine O -
. O +

This O +
study O +
supports O +
previous O +
reports O +
and O +
provides O +
neurophysiological O +
evidence O +
of O +
an O +
adverse O +
effect O +
on O +
the O +
auditory O +
nerve O -
. O +

METHODS O -
: O +
We O +
conducted O +
a O +
retrospective O +
review O +
of O +
70 O +
consecutive O +
microvascular O +
decompression O +
operations O +
and O +
studied O +
those O +
patients O +
who O +
received O +
topical O +
papaverine O +
for O +
vasospasm B-Disease -
. O +

Topical O +
papaverine O +
was O +
used O +
as O +
a O +
direct O +
therapeutic O +
action O +
to O +
manage O +
vasospasm B-Disease +
in O +
a O +
total O +
of O +
11 O +
patients O -
. O +

The O +
timing O +
of O +
papaverine O +
application O +
and O +
ongoing O +
operative O +
events O +
was O +
reviewed O +
relative O +
to O +
changes O +
in O +
neurophysiological O +
recordings O -
. O +

Brainstem O +
auditory O +
evoked O +
potentials O +
( O -
BAEPs O -
) O +
were O +
routinely O +
used O +
to O +
monitor O +
cochlear O +
nerve O +
function O +
during O +
these O +
operations O -
. O +

FINDINGS O -
: O +
A O +
temporal O +
relationship O +
was O +
found O +
between O +
topical O +
papaverine O +
and O +
BAEP O +
changes O +
leading O +
to O +
complete O +
waveform O +
loss O -
. O +

The O +
average O +
temporal O +
delay O +
between O +
papaverine O +
and O +
the O +
onset O +
of O +
an O +
adverse O +
BAEP O +
change O +
was O +
5 O +
min O -
. O +

In O +
10 O +
of O +
11 O +
patients O -
, O +
BAEP O +
waves O +
II O -
/ O -
III O -
- O -
V O +
completely O +
disappeared O +
within O +
2 O +
to O +
25 O +
min O +
after O +
papaverine O -
. O +

Eight O +
of O +
these O +
10 O +
patients O +
had O +
complete O +
loss O +
of O +
BAEP O +
waveforms O +
within O +
10 O +
min O -
. O +

One O +
patient O +
showed O +
no O +
recovery O +
of O +
later O +
waves O +
and O +
a O +
delayed O +
profound O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease -
. O +

The O +
average O +
recovery O +
time O +
of O +
BAEP O +
waveforms O +
to O +
pre O -
- O -
papaverine O +
baseline O +
values O +
was O +
39 O +
min O -
. O +

CONCLUSIONS O -
: O +
Topical O +
papaverine O +
for O +
the O +
treatment O +
of O +
vasospasm B-Disease +
was O +
associated O +
with O +
the O +
onset O +
of O +
a O +
transient O +
disturbance O +
in O +
neurophysiological O +
function O +
of O +
the O +
ascending O +
auditory O +
brainstem O +
pathway O -
. O +

The O +
complete O +
disappearance O +
of O +
BAEP O +
waveforms O +
with O +
a O +
consistent O +
temporal O +
delay O +
suggests O +
a O +
possible O +
adverse B-Disease +
effect I-Disease +
on I-Disease +
the I-Disease +
proximal I-Disease +
eighth I-Disease +
nerve I-Disease -
. O +

Recommendations O +
to O +
avoid O +
potential O +
cranial B-Disease +
nerve I-Disease +
deficits I-Disease +
from O +
papaverine O +
are O +
provided O -
. O +

Simvastatin O -
- O -
ezetimibe O -
- O -
induced O +
hepatic B-Disease +
failure I-Disease +
necessitating O +
liver O +
transplantation O -
. O +

Abstract O +
Serum O +
aminotransferase O +
elevations O +
are O +
a O +
commonly O +
known O +
adverse O +
effect O +
of O +
3-hydroxy-3-methylglutaryl O +
coenzyme O +
A O +
reductase O +
inhibitor O +
( O -
statin O -
) O +
therapy O -
. O +

However O -
, O +
hepatotoxic B-Disease +
events O +
have O +
not O +
been O +
widely O +
published O +
with O +
ezetimibe O +
or O +
the O +
combination O +
agent O +
simvastatin O -
- O -
ezetimibe O -
. O +

We O +
describe O +
a O +
70-year O -
- O -
old O +
Hispanic O +
woman O +
who O +
developed O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease +
necessitating O +
liver O +
transplantation O +
10 O +
weeks O +
after O +
conversion O +
from O +
simvastatin O +
40 O +
mg O -
/ O -
day O +
to O +
simvastatin O +
10 O +
mg O -
- O -
ezetimibe O +
40 O +
mg O -
/ O -
day O -
. O +

The O +
patient O -
's O +
lipid O +
panel O +
had O +
been O +
maintained O +
with O +
simvastatin O +
for O +
18 O +
months O +
before O +
the O +
conversion O +
without O +
evidence O +
of O +
hepatotoxicity B-Disease -
. O +

A O +
routine O +
laboratory O +
work O -
- O -
up O +
10 O +
weeks O +
after O +
conversion O +
revealed O +
elevated O +
serum O +
aminotransferase O +
levels O -
. O +

Simvastatinezetimibe O +
and O +
escitalopram O +
( O -
which O +
she O +
was O +
taking O +
for O +
depression B-Disease -
) O +
were O +
discontinued O -
, O +
and O +
other O +
potential O +
causes O +
of O +
hepatotoxicity B-Disease +
were O +
excluded O -
. O +

A O +
repeat O +
work O -
- O -
up O +
revealed O +
further O +
elevations O +
in O +
aminotransferase O +
levels O -
, O +
and O +
liver O +
biopsy O +
revealed O +
evidence O +
of O +
moderate O -
- O -
to O -
- O -
severe O +
drug B-Disease +
toxicity I-Disease -
. O +

She O +
underwent O +
liver O +
transplantation O +
with O +
an O +
uneventful O +
postoperative O +
course O -
. O +

Her O +
aminotransferase O +
levels O +
returned O +
to O +
normal O +
by O +
postoperative O +
day O +
23 O -
, O +
and O +
her O +
2-year O +
follow O -
- O -
up O +
showed O +
no O +
adverse O +
events O -
. O +

Ezetimibe O +
undergoes O +
extensive O +
glucuronidation O +
by O +
uridine O +
diphosphate O +
glucoronosyltransferases O +
( O -
UGT O -
) O +
in O +
the O +
intestine O +
and O +
liver O +
and O +
may O +
have O +
inhibited O +
the O +
glucuronidation O +
of O +
simvastatin O +
hydroxy O +
acid O -
, O +
resulting O +
in O +
increased O +
simvastatin O +
exposure O +
and O +
subsequent O +
hepatotoxicity B-Disease -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
case O +
report O +
of O +
simvastatin O -
- O -
ezetimibe O -
- O -
induced O +
liver B-Disease +
failure I-Disease +
that O +
resulted O +
in O +
liver O +
transplantation O -
. O +

We O +
postulate O +
that O +
the O +
mechanism O +
of O +
the O +
simvastatinezetimibe O -
- O -
induced O +
hepatotoxicity B-Disease +
is O +
the O +
increased O +
simvastatin O +
exposure O +
by O +
ezetimibe O +
inhibition O +
of O +
UGT O +
enzymes O -
. O +

Clinicians O +
should O +
be O +
aware O +
of O +
potential O +
hepatotoxicity B-Disease +
with O +
simvastatin O -
- O -
ezetimibe O +
especially O +
in O +
elderly O +
patients O +
and O +
should O +
carefully O +
monitor O +
serum O +
aminotransferase O +
levels O +
when O +
starting O +
therapy O +
and O +
titrating O +
the O +
dosage O -
. O +

Massive O +
proteinuria B-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
after O +
oral O +
bisphosphonate O +
( O -
alendronate O -
) O +
administration O +
in O +
a O +
patient O +
with O +
focal B-Disease +
segmental I-Disease +
glomerulosclerosis I-Disease -
. O +

A O +
61-year O -
- O -
old O +
Japanese O +
man O +
with O +
nephrotic B-Disease +
syndrome I-Disease +
due O +
to O +
focal B-Disease +
segmental I-Disease +
glomerulosclerosis I-Disease +
was O +
initially O +
responding O +
well O +
to O +
steroid O +
therapy O -
. O +

The O +
amount O +
of O +
daily O +
urinary O +
protein O +
decreased O +
from O +
15.6 O +
to O +
2.8 O +
g. O +
Within O +
14 O +
days O +
of O +
the O +
oral O +
bisphosphonate O +
( O -
alendronate O +
sodium O -
) O +
administration O -
, O +
the O +
amount O +
of O +
daily O +
urinary O +
protein O +
increased O +
rapidly O +
up O +
to O +
12.8 O +
g O +
with O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

After O +
discontinuing O +
the O +
oral O +
alendronate O -
, O +
the O +
patient O +
underwent O +
six O +
cycles O +
of O +
hemodialysis O +
and O +
four O +
cycles O +
of O +
LDL O +
apheresis O -
. O +

Urinary O +
volume O +
and O +
serum O +
creatinine O +
levels O +
recovered O +
to O +
the O +
normal O +
range O -
, O +
with O +
urinary O +
protein O +
disappearing O +
completely O +
within O +
40 O +
days O -
. O +

This O +
report O +
demonstrates O +
that O +
not O +
only O +
intravenous O -
, O +
but O +
also O +
oral O +
bisphosphonates O +
can O +
aggravate O +
proteinuria B-Disease +
and O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

Serum- O +
and O +
glucocorticoid O -
- O -
inducible O +
kinase O +
1 O +
in O +
doxorubicin O -
- O -
induced O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Doxorubicin O -
- O -
induced O +
nephropathy B-Disease +
leads O +
to O +
epithelial O +
sodium O +
channel O +
( O -
ENaC O -
) O -
-dependent O +
volume B-Disease +
retention I-Disease +
and O +
renal O +
fibrosis B-Disease -
. O +

The O +
aldosterone O -
- O -
sensitive O +
serum- O +
and O +
glucocorticoid O -
- O -
inducible O +
kinase O +
SGK1 O +
has O +
been O +
shown O +
to O +
participate O +
in O +
the O +
stimulation O +
of O +
ENaC O +
and O +
to O +
mediate O +
renal O +
fibrosis B-Disease +
following O +
mineralocorticoid O +
and O +
salt O +
excess O -
. O +

The O +
present O +
study O +
was O +
performed O +
to O +
elucidate O +
the O +
role O +
of O +
SGK1 O +
in O +
the O +
volume B-Disease +
retention I-Disease +
and O +
fibrosis B-Disease +
during O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

To O +
this O +
end O -
, O +
doxorubicin O +
( O -
15 O +
mug O -
/ O -
g O +
body O +
wt O -
) O +
was O +
injected O +
intravenously O +
into O +
gene O -
- O -
targeted O +
mice O +
lacking O +
SGK1 O +
( O -
sgk1 O -
( O -
- O -
/ O -
- O -
) O -
) O +
and O +
their O +
wild O -
- O -
type O +
littermates O +
( O -
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O -
) O -
. O +

Doxorubicin O +
treatment O +
resulted O +
in O +
heavy O +
proteinuria B-Disease +
( O -
> O -
100 O +
mg O +
protein O -
/ O -
mg O +
crea O -
) O +
in O +
15 O -
/ O -
44 O +
of O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
and O +
15 O -
/ O -
44 O +
of O +
sgk1 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
leading O +
to O +
severe O +
nephrotic B-Disease +
syndrome I-Disease +
with O +
ascites B-Disease -
, O +
lipidemia B-Disease -
, O +
and O +
hypoalbuminemia B-Disease +
in O +
both O +
genotypes O -
. O +

Plasma O +
aldosterone O +
levels O +
increased O +
in O +
nephrotic B-Disease +
mice O +
of O +
both O +
genotypes O +
and O +
was O +
followed O +
by O +
increased O +
SGK1 O +
protein O +
expression O +
in O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
mice O -
. O +

Urinary O +
sodium O +
excretion O +
reached O +
signficantly O +
lower O +
values O +
in O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
mice O +
( O -
15 O +
+ O -
/- O +

5 O +
mumol O -
/ O -
mg O +
crea O -
) O +
than O +
in O +
sgk1 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
( O -
35 O +
+ O -
/- O +

5 O +
mumol O -
/ O -
mg O +
crea O -
) O +
and O +
was O +
associated O +
with O +
a O +
significantly O +
higher O +
body O +
weight B-Disease +
gain I-Disease +
in O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
compared O +
with O +
sgk1 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
( O -
+ O -
6.6 O +
+ O -
/- O +

0.7 O +
vs. O +
+ O -
4.1 O +
+ O -
/- O +

0.8 O +
g O -
) O -
. O +

During O +
the O +
course O +
of O +
nephrotic B-Disease +
syndrome I-Disease -
, O +
serum O +
urea O +
concentrations O +
increased O +
significantly O +
faster O +
in O +
sgk1 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
than O +
in O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
mice O +
leading O +
to O +
uremia B-Disease +
and O +
a O +
reduced O +
median O +
survival O +
in O +
sgk1 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
( O -
29 O +
vs. O +
40 O +
days O +
in O +
sgk1 O -
( O -
+ O -
/ O -
+ O -
) O +
mice O -
) O -
. O +

In O +
conclusion O -
, O +
gene O -
- O -
targeted O +
mice O +
lacking O +
SGK1 O +
showed O +
blunted O +
volume B-Disease +
retention I-Disease -
, O +
yet O +
were O +
not O +
protected O +
against O +
renal O +
fibrosis B-Disease +
during O +
experimental O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Severe O +
thrombocytopenia B-Disease +
and O +
haemolytic B-Disease +
anaemia I-Disease +
associated O +
with O +
ciprofloxacin O -
: O +
a O +
case O +
report O +
with O +
fatal O +
outcome O -
. O +

Haematological O +
adverse O +
reactions O +
associated O +
with O +
fatal O +
outcome O +
are O +
rare O +
during O +
treatment O +
with O +
ciprofloxacin O -
. O +

A O +
30-year O +
old O +
Caucasian O +
man O +
reported O +
with O +
abdominal B-Disease +
pain I-Disease +
and O +
jaundice B-Disease +
after O +
3-day O +
administration O +
of O +
oral O +
ciprofloxacin O +
for O +
a O +
suspect O +
of O +
urinary B-Disease +
tract I-Disease +
infection I-Disease -
. O +

Clinical O +
evaluations O +
suggested O +
an O +
initial O +
diagnosis O +
of O +
severe O +
thrombocytopenia B-Disease +
and O +
haemolysis B-Disease -
. O +

The O +
patient O +
progressively O +
developed O +
petechiae B-Disease +
and O +
purpura B-Disease +
on O +
thorax O +
and O +
lower O +
limbs O -
. O +

Despite O +
pharmacological O +
and O +
supportive O +
interventions O -
, O +
laboratory O +
parameters O +
worsened O +
and O +
the O +
patient O +
died O +
17 O +
hours O +
after O +
admission O -
. O +

An O +
accurate O +
autopsy O +
revealed O +
most O +
organs O +
with O +
diffuse O +
petechial O +
haemorrhages B-Disease -
. O +

No O +
signs O +
of O +
bone B-Disease +
marrow I-Disease +
depression I-Disease +
were O +
found O -
. O +

No O +
thrombi B-Disease +
or O +
signs O +
of O +
microangiopathies B-Disease +
were O +
observed O +
in O +
arterial O +
vessels O -
. O +

Blood O +
and O +
urine O +
cultures O +
did O +
not O +
show O +
any O +
bacterial O +
growth O -
. O +

This O +
case O +
report O +
shows O +
that O +
ciprofloxacin O +
may O +
precipitate O +
life O -
- O -
threatening O +
thrombocytopenia B-Disease +
and O +
haemolytic B-Disease +
anaemia I-Disease -
, O +
even O +
in O +
the O +
early O +
phases O +
of O +
treatment O +
and O +
without O +
apparent O +
previous O +
exposures O -
. O +

Isoproterenol O +
induces O +
primary O +
loss O +
of O +
dystrophin O +
in O +
rat O +
hearts O -
: O +
correlation O +
with O +
myocardial B-Disease +
injury I-Disease -
. O +

The O +
mechanism O +
of O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
damage I-Disease +
is O +
unknown O -
, O +
but O +
a O +
mismatch O +
of O +
oxygen O +
supply O +
vs. O +
demand O +
following O +
coronary O +
hypotension B-Disease +
and O +
myocardial B-Disease +
hyperactivity I-Disease +
is O +
the O +
best O +
explanation O +
for O +
the O +
complex O +
morphological O +
alterations O +
observed O -
. O +

Severe O +
alterations O +
in O +
the O +
structural O +
integrity O +
of O +
the O +
sarcolemma O +
of O +
cardiomyocytes O +
have O +
been O +
demonstrated O +
to O +
be O +
caused O +
by O +
isoproterenol O -
. O +

Taking O +
into O +
account O +
that O +
the O +
sarcolemmal O +
integrity O +
is O +
stabilized O +
by O +
the O +
dystrophin O -
- O -
glycoprotein O +
complex O +
( O -
DGC O -
) O +
that O +
connects O +
actin O +
and O +
laminin O +
in O +
contractile O +
machinery O +
and O +
extracellular O +
matrix O +
and O +
by O +
integrins O -
, O +
this O +
study O +
tests O +
the O +
hypothesis O +
that O +
isoproterenol O +
affects O +
sarcolemmal O +
stability O +
through O +
changes O +
in O +
the O +
DGC O +
and O +
integrins O -
. O +

We O +
found O +
different O +
sensitivity O +
of O +
the O +
DGC O +
and O +
integrin O +
to O +
isoproterenol O +
subcutaneous O +
administration O -
. O +

Immunofluorescent O +
staining O +
revealed O +
that O +
dystrophin O +
is O +
the O +
most O +
sensitive O +
among O +
the O +
structures O +
connecting O +
the O +
actin O +
in O +
the O +
cardiomyocyte O +
cytoskeleton O +
and O +
the O +
extracellular O +
matrix O -
. O +

The O +
sarcomeric O +
actin O +
dissolution O +
occurred O +
after O +
the O +
reduction O +
or O +
loss O +
of O +
dystrophin O -
. O +

Subsequently O -
, O +
after O +
lysis O +
of O +
myofilaments O -
, O +
gamma O -
- O -
sarcoglycan O -
, O +
beta O -
- O -
dystroglycan O -
, O +
beta1-integrin O -
, O +
and O +
laminin O +
alpha-2 O +
expressions O +
were O +
reduced O +
followed O +
by O +
their O +
breakdown O -
, O +
as O +
epiphenomena O +
of O +
the O +
myocytolytic O +
process O -
. O +

In O +
conclusion O -
, O +
administration O +
of O +
isoproterenol O +
to O +
rats O +
results O +
in O +
primary O +
loss O +
of O +
dystrophin O -
, O +
the O +
most O +
sensitive O +
among O +
the O +
structural O +
proteins O +
that O +
form O +
the O +
DGC O +
that O +
connects O +
the O +
extracellular O +
matrix O +
and O +
the O +
cytoskeleton O +
in O +
cardiomyocyte O -
. O +

These O +
changes O -
, O +
related O +
to O +
ischaemic B-Disease +
injury I-Disease -
, O +
explain O +
the O +
severe O +
alterations O +
in O +
the O +
structural O +
integrity O +
of O +
the O +
sarcolemma O +
of O +
cardiomyocytes O +
and O +
hence O +
severe O +
and O +
irreversible O +
injury O +
induced O +
by O +
isoproterenol O -
. O +

Alpha O -
- O -
lipoic O +
acid O +
prevents O +
mitochondrial B-Disease +
damage I-Disease +
and O +
neurotoxicity B-Disease +
in O +
experimental O +
chemotherapy O +
neuropathy B-Disease -
. O +

The O +
study O +
investigates O +
if O +
alpha O -
- O -
lipoic O +
acid O +
is O +
neuroprotective O +
against O +
chemotherapy O +
induced O +
neurotoxicity B-Disease -
, O +
if O +
mitochondrial B-Disease +
damage I-Disease +
plays O +
a O +
critical O +
role O +
in O +
toxic B-Disease +
neurodegenerative I-Disease +
cascade I-Disease -
, O +
and O +
if O +
neuroprotective O +
effects O +
of O +
alpha O -
- O -
lipoic O +
acid O +
depend O +
on O +
mitochondria O +
protection O -
. O +

We O +
used O +
an O +
in O +
vitro O +
model O +
of O +
chemotherapy O +
induced O +
peripheral B-Disease +
neuropathy I-Disease +
that O +
closely O +
mimic O +
the O +
in O +
vivo O +
condition O +
by O +
exposing O +
primary O +
cultures O +
of O +
dorsal O +
root O +
ganglion O +
( O -
DRG O -
) O +
sensory O +
neurons O +
to O +
paclitaxel O +
and O +
cisplatin O -
, O +
two O +
widely O +
used O +
and O +
highly O +
effective O +
chemotherapeutic O +
drugs O -
. O +

This O +
approach O +
allowed O +
investigating O +
the O +
efficacy O +
of O +
alpha O -
- O -
lipoic O +
acid O +
in O +
preventing O +
axonal B-Disease +
damage I-Disease +
and O +
apoptosis O +
and O +
the O +
function O +
and O +
ultrastructural O +
morphology O +
of O +
mitochondria O +
after O +
exposure O +
to O +
toxic O +
agents O +
and O +
alpha O -
- O -
lipoic O +
acid O -
. O +

Our O +
results O +
demonstrate O +
that O +
both O +
cisplatin O +
and O +
paclitaxel O +
cause O +
early O +
mitochondrial B-Disease +
impairment I-Disease +
with O +
loss O +
of O +
membrane O +
potential O +
and O +
induction O +
of O +
autophagic O +
vacuoles O +
in O +
neurons O -
. O +

Alpha O -
- O -
lipoic O +
acid O +
exerts O +
neuroprotective O +
effects O +
against O +
chemotherapy O +
induced O +
neurotoxicity B-Disease +
in O +
sensory O +
neurons O -
: O +
it O +
rescues O +
the O +
mitochondrial B-Disease +
toxicity I-Disease +
and O +
induces O +
the O +
expression O +
of O +
frataxin O -
, O +
an O +
essential O +
mitochondrial O +
protein O +
with O +
anti O -
- O -
oxidant O +
and O +
chaperone O +
properties O -
. O +

In O +
conclusion O +
mitochondrial B-Disease +
toxicity I-Disease +
is O +
an O +
early O +
common O +
event O +
both O +
in O +
paclitaxel O +
and O +
cisplatin O +
induced O +
neurotoxicity B-Disease -
. O +

Alpha O -
- O -
lipoic O +
acid O +
protects O +
sensory O +
neurons O +
through O +
its O +
anti O -
- O -
oxidant O +
and O +
mitochondrial O +
regulatory O +
functions O -
, O +
possibly O +
inducing O +
the O +
expression O +
of O +
frataxin O -
. O +

These O +
findings O +
suggest O +
that O +
alpha O -
- O -
lipoic O +
acid O +
might O +
reduce O +
the O +
risk O +
of O +
developing O +
peripheral B-Disease +
nerve I-Disease +
toxicity I-Disease +
in O +
patients O +
undergoing O +
chemotherapy O +
and O +
encourage O +
further O +
confirmatory O +
clinical O +
trials O -
. O +

Toxicity B-Disease +
in O +
rhesus O +
monkeys O +
following O +
administration O +
of O +
the O +
8-aminoquinoline O +
8- O -
[ O -
( O -
4-amino O -
- O -
l O -
- O -
methylbutyl O -
) O -
amino O -
] O -
- O +
5- O -
( O -
l O -
- O -
hexyloxy O -
) O -
-6-methoxy-4-methylquinoline O +
( O -
WR242511 O -
) O -
. O +

INTRODUCTION O -
: O +
Many O +
substances O +
that O +
form O +
methemoglobin O +
( O -
MHb O -
) O +
effectively O +
counter O +
cyanide O +
( O -
CN O -
) O +
toxicity B-Disease -
. O +

Although O +
MHb O +
formers O +
are O +
generally O +
applied O +
as O +
treatments O +
for O +
CN O +
poisoning B-Disease -
, O +
it O +
has O +
been O +
proposed O +
that O +
a O +
stable O -
, O +
long O -
- O -
acting O +
MHb O +
former O +
could O +
serve O +
as O +
a O +
CN O +
pretreatment O -
. O +

Using O +
this O +
rationale O -
, O +
the O +
8-aminoquinoline O +
WR242511 O -
, O +
a O +
potent O +
long O -
- O -
lasting O +
MHb O +
former O +
in O +
rodents O +
and O +
beagle O +
dogs O -
, O +
was O +
studied O +
in O +
the O +
rhesus O +
monkey O +
for O +
advanced O +
development O +
as O +
a O +
potential O +
CN O +
pretreatment O -
. O +

METHODS O -
: O +
In O +
this O +
study O -
, O +
WR242511 O +
was O +
administered O +
intravenously O +
( O -
IV O -
) O +
in O +
2 O +
female O +
and O +
4 O +
male O +
rhesus O +
monkeys O +
in O +
doses O +
of O +
3.5 O +
and/or O +
7.0 O +
mg O -
/ O -
kg O -
; O +
a O +
single O +
male O +
also O +
received O +
WR242511 O +
orally O +
( O -
PO O -
) O +
at O +
7.0 O +
mg O -
/ O -
kg O -
. O +

Health O +
status O +
and O +
MHb O +
levels O +
were O +
monitored O +
following O +
exposure O -
. O +

RESULTS O -
: O +
The O +
selected O +
doses O +
of O +
WR242511 O -
, O +
which O +
produced O +
significant O +
methemoglobinemia B-Disease +
in O +
beagle O +
dogs O +
in O +
earlier O +
studies O +
conducted O +
elsewhere O -
, O +
produced O +
very O +
little O +
MHb O +
( O -
mean O +
< O +
2.0 O -
% O -
) O +
in O +
the O +
rhesus O +
monkey O -
. O +

Furthermore O -
, O +
transient O +
hemoglobinuria B-Disease +
was O +
noted O +
approximately O +
60 O +
minutes O +
postinjection O +
of O +
WR242511 O +
( O -
3.5 O +
or O +
7.0 O +
mg O -
/ O -
kg O -
) O -
, O +
and O +
2 O +
lethalities O +
occurred O +
( O -
one O +
IV O +
and O +
one O +
PO O -
) O +
following O +
the O +
7.0 O +
mg O -
/ O -
kg O +
dose O -
. O +

Myoglobinuria B-Disease +
was O +
also O +
observed O +
following O +
the O +
7.0 O +
mg O -
/ O -
kg O +
dose O -
. O +

Histopathology O +
analyses O +
in O +
the O +
2 O +
animals O +
that O +
died O +
revealed O +
liver B-Disease +
and I-Disease +
kidney I-Disease +
toxicity I-Disease -
, O +
with O +
greater O +
severity O +
in O +
the O +
orally O -
- O -
treated O +
animal O -
. O +

CONCLUSIONS O -
: O +
These O +
data O +
demonstrate O +
direct O +
and/or O +
indirect O +
drug O -
- O -
induced O +
toxicity B-Disease -
. O +

It O +
is O +
concluded O +
that O +
WR242511 O +
should O +
not O +
be O +
pursued O +
as O +
a O +
pretreatment O +
for O +
CN O +
poisoning B-Disease +
unless O +
the O +
anti O -
- O -
CN O +
characteristics O +
of O +
this O +
compound O +
can O +
be O +
successfully O +
dissociated O +
from O +
those O +
producing O +
undesirable O +
toxicity B-Disease -
. O +

Etiologic O +
factors O +
in O +
the O +
pathogenesis O +
of O +
liver B-Disease +
tumors I-Disease +
associated O +
with O +
oral O +
contraceptives O -
. O +

Within O +
the O +
last O +
several O +
years O -
, O +
previously O +
rare O +
liver B-Disease +
tumors I-Disease +
have O +
been O +
seen O +
in O +
young O +
women O +
using O +
oral O +
contraceptive O +
steroids O -
. O +

The O +
Registry O +
for O +
Liver B-Disease +
Tumors I-Disease +
Associated O +
with O +
Oral O +
Contraceptives O +
at O +
the O +
University O +
of O +
California O -
, O +
Irvine O -
, O +
has O +
clearly O +
identified O +
27 O +
cases O -
. O +

The O +
recent O +
literature O +
contains O +
44 O +
case O +
reports O -
. O +

Common O +
to O +
these O +
71 O +
cases O +
has O +
been O +
a O +
histopathologic O +
diagnosis O +
of O +
focal B-Disease +
nodular I-Disease +
hyperplasia I-Disease -
, O +
adenoma B-Disease -
, O +
hamartoma B-Disease -
, O +
and O +
hepatoma B-Disease -
. O +

Significant O +
statistical O +
etiologic O +
factors O +
include O +
prolonged O +
uninterrupted O +
usage O +
of O +
oral O +
contraceptive O +
steroids O -
. O +

Eight O +
deaths O +
and O +
liver O +
rupture B-Disease +
in O +
18 O +
patients O +
attest O +
to O +
the O +
seriousness O +
of O +
this O +
new O +
potentially O +
lethal O +
adverse O +
phenomenon O -
. O +

Repetitive O +
transcranial O +
magnetic O +
stimulation O +
for O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

In O +
a O +
placebo O -
- O -
controlled O -
, O +
single O -
- O -
blinded O -
, O +
crossover O +
study O -
, O +
we O +
assessed O +
the O +
effect O +
of O +
" O -
real O -
" O +
repetitive O +
transcranial O +
magnetic O +
stimulation O +
( O -
rTMS O -
) O +
versus O +
" O -
sham O -
" O +
rTMS O +
( O -
placebo O -
) O +
on O +
peak O +
dose O +
dyskinesias B-Disease +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O -
. O +

Ten O +
patients O +
with O +
PD B-Disease +
and O +
prominent O +
dyskinesias B-Disease +
had O +
rTMS O +
( O -
1,800 O +
pulses O -
; O +
1 O +
Hz O +
rate O -
) O +
delivered O +
over O +
the O +
motor O +
cortex O +
for O +
4 O +
consecutive O +
days O +
twice O -
, O +
once O +
real O +
stimuli O +
and O +
once O +
sham O +
stimulation O +
were O +
used O -
; O +
evaluations O +
were O +
done O +
at O +
the O +
baseline O +
and O +
1 O +
day O +
after O +
the O +
end O +
of O +
each O +
of O +
the O +
treatment O +
series O -
. O +

Direct O +
comparison O +
between O +
sham O +
and O +
real O +
rTMS O +
effects O +
showed O +
no O +
significant O +
difference O +
in O +
clinician O -
- O -
assessed O +
dyskinesia B-Disease +
severity O -
. O +

However O -
, O +
comparison O +
with O +
the O +
baseline O +
showed O +
small O +
but O +
significant O +
reduction O +
in O +
dyskinesia B-Disease +
severity O +
following O +
real O +
rTMS O +
but O +
not O +
placebo O -
. O +

The O +
major O +
effect O +
was O +
on O +
dystonia B-Disease +
subscore O -
. O +

Similarly O -
, O +
in O +
patient O +
diaries O -
, O +
although O +
both O +
treatments O +
caused O +
reduction O +
in O +
subjective O +
dyskinesia B-Disease +
scores O +
during O +
the O +
days O +
of O +
intervention O -
, O +
the O +
effect O +
was O +
sustained O +
for O +
3 O +
days O +
after O +
the O +
intervention O +
for O +
the O +
real O +
rTMS O +
only O -
. O +

Following O +
rTMS O -
, O +
no O +
side O +
effects O +
and O +
no O +
adverse O +
effects O +
on O +
motor O +
function O +
and O +
PD B-Disease +
symptoms O +
were O +
noted O -
. O +

The O +
results O +
suggest O +
the O +
existence O +
of O +
residual O +
beneficial O +
clinical O +
aftereffects O +
of O +
consecutive O +
daily O +
applications O +
of O +
low O -
- O -
frequency O +
rTMS O +
on O +
dyskinesias B-Disease +
in O +
PD B-Disease -
. O +

The O +
effects O +
may O +
be O +
further O +
exploited O +
for O +
potential O +
therapeutic O +
uses O -
. O +

Ifosfamide O +
continuous O +
infusion O +
without O +
mesna O -
. O +

A O +
phase O +
I O +
trial O +
of O +
a O +
14-day O +
cycle O -
. O +

Twenty O +
patients O +
received O +
27 O +
courses O +
of O +
ifosfamide O +
administered O +
as O +
a O +
24-hour O +
continuous O +
infusion O +
for O +
14 O +
days O +
without O +
Mesna O -
. O +

The O +
goal O +
of O +
the O +
study O +
was O +
to O +
deliver O +
a O +
dose O +
rate O +
and O +
total O +
cumulative O +
dose O +
of O +
ifosfamide O +
that O +
would O +
be O +
comparable O +
to O +
standard O +
bolus O +
or O +
short O -
- O -
term O +
infusions O +
administered O +
with O +
Mesna O -
. O +

Dose O +
escalations O +
proceeded O +
from O +
200 O +
to O +
300 O -
, O +
400 O -
, O +
450 O -
, O +
500 O -
, O +
and O +
550 O +
mg O -
/ O -
m2 O -
/ O -
d O -
. O +

Four O +
patients O +
developed O +
transient O +
microscopic O +
hematuria B-Disease +
at O +
400 O -
, O +
450 O -
, O +
and O +
500 O +
mg O -
/ O -
m2 O -
/ O -
d O -
. O +

There O +
were O +
no O +
instances O +
of O +
macroscopic O +
hematuria B-Disease -
. O +

At O +
550 O +
mg O -
/ O -
m2 O -
/ O -
d O -
, O +
three O +
patients O +
experienced O +
nonurologic O +
toxicity B-Disease -
; O +
confusion B-Disease +
( O -
1 O -
) O -
, O +
nausea B-Disease +
( O -
1 O -
) O -
, O +
and O +
Grade O +
2 O +
leukopenia B-Disease +
( O -
1 O -
) O -
. O +

The O +
recommended O +
dose O +
of O +
500 O +
mg O -
/ O -
m2 O -
/ O -
d O +
delivers O +
a O +
total O +
dose O +
of O +
7 O +
g O -
/ O -
m2 O +
per O +
cycle O -
, O +
which O +
is O +
comparable O +
to O +
that O +
delivered O +
in O +
clinical O +
practice O +
for O +
bolus O +
or O +
short O -
- O -
term O +
infusion O -
. O +

Because O +
few O +
patients O +
received O +
multiple O +
courses O +
over O +
time O -
, O +
the O +
cumulative O +
effects O +
are O +
indeterminate O +
in O +
the O +
present O +
trial O -
. O +

The O +
frequency O +
and O +
predictability O +
of O +
hematuria B-Disease +
are O +
not O +
precise O -
, O +
and O +
at O +
least O +
daily O +
monitoring O +
by O +
urine O +
Hematest O +
is O +
essential O -
, O +
adding O +
Mesna O +
to O +
the O +
infusate O +
in O +
patients O +
with O +
persistent O +
hematuria B-Disease -
. O +

The O +
protracted O +
infusion O +
schedule O +
for O +
ifosfamide O +
permits O +
convenient O +
outpatient O +
administration O +
without O +
Mesna O +
and O +
reduces O +
the O +
drug O +
cost O +
of O +
clinical O +
usage O +
of O +
this O +
agent O +
by O +
up O +
to O +
890 O +
per O +
cycle O -
. O +

Clinical O +
activity O +
was O +
demonstrated O +
in O +
a O +
single O +
patient O -
, O +
but O +
a O +
comparative O +
trial O +
of O +
standard O +
bolus O +
schedules O +
with O +
the O +
protracted O +
infusion O +
schedule O +
will O +
be O +
necessary O +
to O +
determine O +
if O +
the O +
clinical O +
effectiveness O +
of O +
the O +
drug O +
is O +
maintained O -
. O +

Intracavernous O +
epinephrine O -
: O +
a O +
minimally O +
invasive O +
treatment O +
for O +
priapism B-Disease +
in O +
the O +
emergency O +
department O -
. O +

Priapism B-Disease +
is O +
the O +
prolonged O +
erection O +
of O +
the O +
penis O +
in O +
the O +
absence O +
of O +
sexual O +
arousal O -
. O +

A O +
45-year O -
- O -
old O +
man O -
, O +
an O +
admitted O +
frequent O +
cocaine O +
user O -
, O +
presented O +
to O +
the O +
Emergency O +
Department O +
( O -
ED O -
) O +
on O +
two O +
separate O +
occasions O +
with O +
a O +
history O +
of O +
priapism B-Disease +
after O +
cocaine O +
use O -
. O +

The O +
management O +
options O +
in O +
the O +
ED O -
, O +
as O +
exemplified O +
by O +
four O +
individual O +
case O +
reports O -
, O +
in O +
particular O +
the O +
use O +
of O +
a O +
minimally O +
invasive O +
method O +
of O +
intracorporal O +
epinephrine O +
instillation O -
, O +
are O +
discussed O -
. O +

A O +
case O +
of O +
ventricular B-Disease +
tachycardia I-Disease +
related O +
to O +
caffeine O +
pretreatment O -
. O +

Suboptimal O +
seizure B-Disease +
duration O +
is O +
commonly O +
encountered O +
in O +
electroconvulsive O +
therapy O +
practice O -
, O +
especially O +
in O +
older O +
patients O +
with O +
higher O +
seizure B-Disease +
thresholds O -
. O +

Intravenous O +
caffeine O +
is O +
commonly O +
used O +
to O +
improve O +
seizure B-Disease +
duration O +
and O +
quality O +
in O +
such O +
patients O +
and O +
is O +
generally O +
well O +
tolerated O +
aside O +
from O +
occasional O +
reports O +
of O +
relatively O +
benign O +
ventricular B-Disease +
ectopy I-Disease -
. O +

We O +
describe O +
a O +
patient O +
with O +
no O +
previous O +
history O +
of O +
cardiac B-Disease +
disease I-Disease +
or O +
arrhythmia B-Disease +
who O +
developed O +
sustained O +
bigeminy O +
and O +
2 O +
brief O +
runs O +
of O +
ventricular B-Disease +
tachycardia I-Disease +
after O +
caffeine O +
administration O -
. O +

Although O +
intravenous O +
caffeine O +
is O +
generally O +
well O +
tolerated O -
, O +
the O +
clinician O +
should O +
be O +
aware O +
of O +
the O +
potential O +
for O +
unpredictable O +
and O +
serious O +
ventricular B-Disease +
arrhythmias I-Disease -
. O +

Prophylactic O +
use O +
of O +
lamivudine O +
with O +
chronic O +
immunosuppressive O +
therapy O +
for O +
rheumatologic B-Disease +
disorders I-Disease -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
report O +
our O +
experience O +
concerning O +
the O +
effectiveness O +
of O +
the O +
prophylactic O +
administration O +
of O +
lamivudine O +
in O +
hepatitis O +
B O +
virus O +
surface O +
antigen O +
( O -
HBs O +
Ag O -
) O +
positive O +
patients O +
with O +
rheumatologic B-Disease +
disease I-Disease -
. O +

From O +
June O +
2004 O +
to O +
October O +
2006 O -
, O +
11 O +
HBs O +
Ag O +
positive O +
patients O +
with O +
rheumatologic B-Disease +
diseases I-Disease -
, O +
who O +
were O +
on O +
both O +
immunosuppressive O +
and O +
prophylactic O +
lamivudine O +
therapies O -
, O +
were O +
retrospectively O +
assessed O -
. O +

Liver O +
function O +
tests O -
, O +
hepatitis B-Disease +
B I-Disease +
virus O +
( O -
HBV O -
) O +
serologic O +
markers O -
, O +
and O +
HBV O +
DNA O +
levels O +
of O +
the O +
patients O +
during O +
follow O -
- O -
up O +
were O +
obtained O +
from O +
hospital O +
file O +
records O -
. O +

Eleven O +
patients O +
( O -
six O +
male O -
) O +
with O +
median O +
age O +
47 O +
years O +
( O -
range O +
27 O -
- O -
73 O -
) O -
, O +
median O +
disease O +
duration O +
50 O +
months O +
( O -
range O +
9 O -
- O -
178 O -
) O +
and O +
median O +
follow O -
- O -
up O +
period O +
of O +
patients O +
13.8 O +
months O +
( O -
range O +
5 O -
- O -
27 O -
) O +
were O +
enrolled O +
in O +
this O +
study O -
. O +

Lamivudine O +
therapy O +
was O +
started O +
3 O -
- O -
7 O +
days O +
prior O +
to O +
immunosuppressive O +
therapy O +
in O +
all O +
patients O -
. O +

Baseline O -
, O +
liver O +
function O +
tests O +
were O +
elevated O +
in O +
two O +
patients O +
( O -
fourth O +
patient O -
: O +
ALT:122 O +
IU O -
/ O -
l O -
, O +
AST:111 O +
IU O -
/ O -
l O -
, O +
tenth O +
patient O -
: O -
ALT:294 O +
IU O -
/ O -
l O -
, O +
AST:274 O +
IU O -
/ O -
l O -
, O +
with O +
minimal O +
changes O +
in O +
the O +
liver O +
biopsy O +
in O +
both O -
) O -
. O +

Shortly O +
after O +
treatment O +
their O +
tests O +
normalized O +
and O +
during O +
follow O -
- O -
up O +
period O +
none O +
of O +
the O +
patients O +
had O +
abnormal B-Disease +
liver I-Disease +
function I-Disease +
tests O -
. O +

In O +
four O +
patients O +
HBV O +
DNA O +
levels O +
were O +
higher O +
than O +
normal O +
at O +
baseline O -
. O +

Two O +
of O +
these O +
normalized O +
and O +
the O +
others O +
increased O +
later O -
. O +

In O +
three O +
additional O +
patients O -
, O +
HBV O +
DNA O +
levels O +
were O +
increased O +
during O +
follow O -
- O -
up O -
. O +

None O +
of O +
the O +
patients O +
had O +
significant O +
clinical O +
sings O +
of O +
HBV O +
activation O -
. O +

Lamivudine O +
was O +
well O +
tolerated O +
and O +
was O +
continued O +
in O +
all O +
patients O -
. O +

Prophylactic O +
administration O +
of O +
lamivudine O +
in O +
patients O +
who O +
required O +
immunosuppressive O +
therapy O +
seems O +
to O +
be O +
safe O -
, O +
well O +
tolerated O +
and O +
effective O +
in O +
preventing O +
HBV O +
reactivation O -
. O +

Effect O +
of O +
green O +
tea O +
and O +
vitamin O +
E O +
combination O +
in O +
isoproterenol O +
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

The O +
present O +
study O +
was O +
aimed O +
to O +
investigate O +
the O +
combined O +
effects O +
of O +
green O +
tea O +
and O +
vitamin O +
E O +
on O +
heart O +
weight O -
, O +
body O +
weight O -
, O +
serum O +
marker O +
enzymes O -
, O +
lipid O +
peroxidation O -
, O +
endogenous O +
antioxidants O +
and O +
membrane O +
bound O +
ATPases O +
in O +
isoproterenol O +
( O -
ISO O -
) O -
-induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Adult O +
male O +
albino O +
rats O -
, O +
treated O +
with O +
ISO O +
( O -
200 O +
mg O -
/ O -
kg O -
, O +
s.c O -
. O -
) O +
for O +
2 O +
days O +
at O +
an O +
interval O +
of O +
24 O +
h O +
caused O +
a O +
significant O +
( O -
P<0.05 O -
) O +
elevation O +
of O +
heart O +
weight O -
, O +
serum O +
marker O +
enzymes O -
, O +
lipid O +
peroxidation O +
and O +
Ca+2 O +
ATPase O +
level O +
whereas O +
there O +
was O +
a O +
significant O +
( O -
P<0.05 O -
) O +
decrease O +
in O +
body O +
weight O -
, O +
endogenous O +
antioxidants O -
, O +
Na+ O -
/ O +
K+ O +
ATPase O +
and O +
Mg+2 O +
ATPase O +
levels O -
. O +

Administration O +
of O +
green O +
tea O +
( O -
100 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
p.o O -
. O -
) O +
and O +
vitamin O +
E O +
( O -
100 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
p.o O -
. O -
) O +
together O +
for O +
30 O +
consecutive O +
days O +
and O +
challenged O +
with O +
ISO O +
on O +
the O +
day O +
29th O +
and O +
30th O -
, O +
showed O +
a O +
significant O +
( O -
P<0.05 O -
) O +
decrease O +
in O +
heart O +
weight O -
, O +
serum O +
marker O +
enzymes O -
, O +
lipid O +
peroxidation O -
, O +
Ca+2 O +
ATPase O +
and O +
a O +
significant O +
increase O +
in O +
the O +
body O +
weight O -
, O +
endogenous O +
antioxidants O -
, O +
Na+ O -
/ O -
K+ O +
ATPase O +
and O +
Mg+2 O +
ATPase O +
when O +
compared O +
with O +
ISO O +
treated O +
group O +
and O +
green O +
tea O +
or O +
vitamin O +
E O +
alone O +
treated O +
groups O -
. O +

These O +
findings O +
indicate O +
the O +
synergistic O +
protective O +
effect O +
of O +
green O +
tea O +
and O +
vitamin O +
E O +
during O +
ISO O +
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Fatal O +
haemopericardium B-Disease +
and O +
gastrointestinal B-Disease +
haemorrhage I-Disease +
due O +
to O +
possible O +
interaction O +
of O +
cranberry O +
juice O +
with O +
warfarin O -
. O +

We O +
report O +
a O +
case O +
of O +
fatal O +
internal O +
haemorrhage B-Disease +
in O +
an O +
elderly O +
man O +
who O +
consumed O +
only O +
cranberry O +
juice O +
for O +
two O +
weeks O +
while O +
maintaining O +
his O +
usual O +
dosage O +
of O +
warfarin O -
. O +

We O +
propose O +
that O +
naturally O +
occurring O +
compounds O +
such O +
as O +
flavonoids O -
, O +
which O +
are O +
present O +
in O +
fruit O +
juices O -
, O +
may O +
increase O +
the O +
potency O +
of O +
warfarin O +
by O +
competing O +
for O +
the O +
enzymes O +
that O +
normally O +
inactivate O +
warfarin O -
. O +

While O +
traditionally O +
regarded O +
as O +
foodstuffs O -
, O +
consumption O +
of O +
fruit O +
juices O +
should O +
be O +
considered O +
when O +
patients O +
develop O +
adverse O +
drug O +
reactions O -
. O +

Effect O +
of O +
increasing O +
intraperitoneal O +
infusion O +
rates O +
on O +
bupropion O +
hydrochloride O -
- O -
induced O +
seizures B-Disease +
in O +
mice O -
. O +

BACKGROUND O -
: O +
It O +
is O +
not O +
known O +
if O +
there O +
is O +
a O +
relationship O +
between O +
input O +
rate O +
and O +
incidence O +
of O +
bupropion O -
- O -
induced O +
seizures B-Disease -
. O +

This O +
is O +
important O -
, O +
since O +
different O +
controlled O +
release O +
formulations O +
of O +
bupropion O +
release O +
the O +
active O +
drug O +
at O +
different O +
rates O -
. O +

METHODS O -
: O +
We O +
investigated O +
the O +
effect O +
of O +
varying O +
the O +
intraperitoneal O +
infusion O +
rates O +
of O +
bupropion O +
HCl O +
120 O +
mg O -
/ O -
kg O -
, O +
a O +
known O +
convulsive B-Disease +
dose O +
50 O +
( O -
CD50 O -
) O -
, O +
on O +
the O +
incidence O +
and O +
severity O +
of O +
bupropion O -
- O -
induced O +
convulsions B-Disease +
in O +
the O +
Swiss O +
albino O +
mice O -
. O +

A O +
total O +
of O +
69 O +
mice O -
, O +
approximately O +
7 O +
weeks O +
of O +
age O -
, O +
and O +
weighing O +
21.0 O +
to O +
29.1 O +
g O +
were O +
randomly O +
assigned O +
to O +
bupropion O +
HCl O +
120 O +
mg O -
/ O -
kg O +
treatment O +
by O +
intraperitoneal O +
( O -
IP O -
) O +
administration O +
in O +
7 O +
groups O +
( O -
9 O +
to O +
10 O +
animals O +
per O +
group O -
) O -
. O +

Bupropion O +
HCl O +
was O +
infused O +
through O +
a O +
surgically O +
implanted O +
IP O +
dosing O +
catheter O +
with O +
infusions O +
in O +
each O +
group O +
of O +
0 O +
min O -
, O +
15 O +
min O -
, O +
30 O +
min O -
, O +
60 O +
min O -
, O +
90 O +
min O -
, O +
120 O +
min O -
, O +
and O +
240 O +
min O -
. O +

The O +
number O -
, O +
time O +
of O +
onset O -
, O +
duration O +
and O +
the O +
intensity O +
of O +
the O +
convulsions B-Disease +
or O +
absence O +
of O +
convulsions B-Disease +
were O +
recorded O -
. O +

RESULTS O -
: O +
The O +
results O +
showed O +
that O +
IP O +
administration O +
of O +
bupropion O +
HCl O +
120 O +
mg O -
/ O -
kg O +
by O +
bolus O +
injection O +
induced O +
convulsions B-Disease +
in O +
6 O +
out O +
of O +
10 O +
mice O +
( O -
60 O -
% O +
of O +
convulsing O +
mice O -
) O +
in O +
group O +
1 O -
. O +

Logistic O +
regression O +
analysis O +
revealed O +
that O +
infusion O +
time O +
was O +
significant O +
( O -
p O +
= O +
0.0004 O -
; O +
odds O +
ratio O +
= O +
0.974 O -
) O +
and O +
increasing O +
the O +
IP O +
infusion O +
time O +
of O +
bupropion O +
HCl O +
120 O +
mg O -
/ O -
kg O +
was O +
associated O +
with O +
a O +
91 O -
% O +
reduced O +
odds O +
of O +
convulsions B-Disease +
at O +
infusion O +
times O +
of O +
15 O +
to O +
90 O +
min O +
compared O +
to O +
bolus O +
injection O -
. O +

Further O +
increase O +
in O +
infusion O +
time O +
resulted O +
in O +
further O +
reduction O +
in O +
the O +
odds O +
of O +
convulsions B-Disease +
to O +
99.8 O -
% O +
reduction O +
at O +
240 O +
min O -
. O +

CONCLUSION O -
: O +
In O +
conclusion O -
, O +
the O +
demonstration O +
of O +
an O +
inverse O +
relationship O +
between O +
infusion O +
time O +
of O +
a O +
fixed O +
and O +
convulsive B-Disease +
dose O +
of O +
bupropion O +
and O +
the O +
risk O +
of O +
convulsions B-Disease +
in O +
a O +
prospective O +
study O +
is O +
novel O -
. O +

Graft B-Disease -
- I-Disease -
versus I-Disease -
- I-Disease -
host I-Disease +
disease I-Disease +
prophylaxis O +
with O +
everolimus O +
and O +
tacrolimus O +
is O +
associated O +
with O +
a O +
high O +
incidence O +
of O +
sinusoidal B-Disease +
obstruction I-Disease +
syndrome I-Disease +
and O +
microangiopathy B-Disease -
: O +
results O +
of O +
the O +
EVTAC O +
trial O -
. O +

A O +
calcineurin O +
inhibitor O +
combined O +
with O +
methotrexate O +
is O +
the O +
standard O +
prophylaxis O +
for O +
graft B-Disease -
- I-Disease -
versus I-Disease -
- I-Disease -
host I-Disease +
disease I-Disease +
( O -
GVHD B-Disease -
) O +
after O +
allogeneic O +
hematopoietic O +
stem O +
cell O +
transplantation O +
( O -
HSCT O -
) O -
. O +

Everolimus O -
, O +
a O +
derivative O +
of O +
sirolimus O -
, O +
seems O +
to O +
mediate O +
antileukemia O +
effects O -
. O +

We O +
report O +
on O +
a O +
combination O +
of O +
everolimus O +
and O +
tacrolimus O +
in O +
24 O +
patients O +
( O -
median O +
age O -
, O +
62 O +
years O -
) O +
with O +
either O +
myelodysplastic B-Disease +
syndrome I-Disease +
( O -
MDS B-Disease -
; O +
n O +
= O +
17 O -
) O +
or O +
acute B-Disease +
myeloid I-Disease +
leukemia I-Disease +
( O -
AML B-Disease -
; O +
n O +
= O +
7 O -
) O +
undergoing O +
intensive O +
conditioning O +
followed O +
by O +
HSCT O +
from O +
related O +
( O -
n O +
= O +
4 O -
) O +
or O +
unrelated O +
( O -
n O +
= O +
20 O -
) O +
donors O -
. O +

All O +
patients O +
engrafted O -
, O +
and O +
only O +
1 O +
patient O +
experienced O +
grade O +
IV O +
mucositis B-Disease -
. O +

Nine O +
patients O +
( O -
37 O -
% O -
) O +
developed O +
acute O +
grade O +
II O -
- O -
IV O +
GVHD B-Disease -
, O +
and O +
11 O +
of O +
17 O +
evaluable O +
patients O +
( O -
64 O -
% O -
) O +
developed O +
chronic O +
extensive O +
GVHD B-Disease -
. O +

Transplantation B-Disease -
- I-Disease -
associated I-Disease +
microangiopathy I-Disease +
( O -
TMA B-Disease -
) O +
occurred O +
in O +
7 O +
patients O +
( O -
29 O -
% O -
) O -
, O +
with O +
2 O +
cases O +
of O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

The O +
study O +
was O +
terminated O +
prematurely O +
because O +
an O +
additional O +
6 O +
patients O +
( O -
25 O -
% O -
) O +
developed O +
sinusoidal B-Disease +
obstruction I-Disease +
syndrome I-Disease +
( O -
SOS B-Disease -
) O -
, O +
which O +
was O +
fatal O +
in O +
2 O +
cases O -
. O +

With O +
a O +
median O +
follow O -
- O -
up O +
of O +
26 O +
months O -
, O +
the O +
2-year O +
overall O +
survival O +
rate O +
was O +
47 O -
% O -
. O +

Although O +
this O +
new O +
combination O +
appears O +
to O +
be O +
effective O +
as O +
a O +
prophylactic O +
regimen O +
for O +
acute O +
GVHD B-Disease -
, O +
the O +
incidence O +
of O +
TMA B-Disease +
and O +
SOS B-Disease +
is O +
considerably O +
higher O +
than O +
seen O +
with O +
other O +
regimens O -
. O +

Longitudinal O +
assessment O +
of O +
air O +
conduction O +
audiograms O +
in O +
a O +
phase O +
III O +
clinical O +
trial O +
of O +
difluoromethylornithine O +
and O +
sulindac O +
for O +
prevention O +
of O +
sporadic O +
colorectal B-Disease +
adenomas I-Disease -
. O +

A O +
phase O +
III O +
clinical O +
trial O +
assessed O +
the O +
recurrence O +
of O +
adenomatous B-Disease +
polyps I-Disease +
after O +
treatment O +
for O +
36 O +
months O +
with O +
difluoromethylornithine O +
( O -
DFMO O -
) O +
plus O +
sulindac O +
or O +
matched O +
placebos O -
. O +

Temporary O +
hearing B-Disease +
loss I-Disease +
is O +
a O +
known O +
toxicity B-Disease +
of O +
treatment O +
with O +
DFMO O -
, O +
thus O +
a O +
comprehensive O +
approach O +
was O +
developed O +
to O +
analyze O +
serial O +
air O +
conduction O +
audiograms O -
. O +

The O +
generalized O +
estimating O +
equation O +
method O +
estimated O +
the O +
mean O +
difference O +
between O +
treatment O +
arms O +
with O +
regard O +
to O +
change O +
in O +
air O +
conduction O +
pure O +
tone O +
thresholds O +
while O +
accounting O +
for O +
within O -
- O -
subject O +
correlation O +
due O +
to O +
repeated O +
measurements O +
at O +
frequencies O -
. O +

Based O +
on O +
290 O +
subjects O -
, O +
there O +
was O +
an O +
average O +
difference O +
of O +
0.50 O +
dB O +
between O +
subjects O +
treated O +
with O +
DFMO O +
plus O +
sulindac O +
compared O +
with O +
those O +
treated O +
with O +
placebo O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
-0.64 O +
to O +
1.63 O +
dB O -
; O +
P O +
= O +
0.39 O -
) O -
, O +
adjusted O +
for O +
baseline O +
values O -
, O +
age O -
, O +
and O +
frequencies O -
. O +

In O +
the O +
normal O +
speech O +
range O +
of O +
500 O +
to O +
3,000 O +
Hz O -
, O +
an O +
estimated O +
difference O +
of O +
0.99 O +
dB O +
( O -
-0.17 O +
to O +
2.14 O +
dB O -
; O +
P O +
= O +
0.09 O -
) O +
was O +
detected O -
. O +

Dose O +
intensity O +
did O +
not O +
add O +
information O +
to O +
models O -
. O +

There O +
were O +
14 O +
of O +
151 O +
( O -
9.3 O -
% O -
) O +
in O +
the O +
DFMO O +
plus O +
sulindac O +
group O +
and O +
4 O +
of O +
139 O +
( O -
2.9 O -
% O -
) O +
in O +
the O +
placebo O +
group O +
who O +
experienced O +
at O +
least O +
15 O +
dB O +
hearing O +
reduction O +
from O +
baseline O +
in O +
2 O +
or O +
more O +
consecutive O +
frequencies O +
across O +
the O +
entire O +
range O +
tested O +
( O -
P O +
= O +
0.02 O -
) O -
. O +

Follow O -
- O -
up O +
air O +
conduction O +
done O +
at O +
least O +
6 O +
months O +
after O +
end O +
of O +
treatment O +
showed O +
an O +
adjusted O +
mean O +
difference O +
in O +
hearing O +
thresholds O +
of O +
1.08 O +
dB O +
( O -
-0.81 O +
to O +
2.96 O +
dB O -
; O +
P O +
= O +
0.26 O -
) O +
between O +
treatment O +
arms O -
. O +

There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
proportion O +
of O +
subjects O +
in O +
the O +
DFMO O +
plus O +
sulindac O +
group O +
who O +
experienced O +
clinically O +
significant O +
hearing B-Disease +
loss I-Disease +
compared O +
with O +
the O +
placebo O +
group O -
. O +

The O +
estimated O +
attributable O +
risk O +
of O +
ototoxicity B-Disease +
from O +
exposure O +
to O +
the O +
drug O +
is O +
8.4 O -
% O +
( O -
95 O -
% O +
confidence O +
interval O -
, O +
-2.0 O -
% O +
to O +
18.8 O -
% O -
; O +
P O +
= O +
0.12 O -
) O -
. O +

There O +
is O +
a O +
< O -
2 O +
dB O +
difference O +
in O +
mean O +
threshold O +
for O +
patients O +
treated O +
with O +
DFMO O +
plus O +
sulindac O +
compared O +
with O +
those O +
treated O +
with O +
placebo O -
. O +

Irreversible O +
damage O +
to O +
the O +
medullary O +
interstitium O +
in O +
experimental O +
analgesic O +
nephropathy B-Disease +
in O +
F344 O +
rats O -
. O +

Renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
( O -
RPN B-Disease -
) O +
and O +
a O +
decreased O +
urinary O +
concentrating O +
ability O +
developed O +
during O +
continuous O +
long O -
- O -
term O +
treatment O +
with O +
aspirin O +
and O +
paracetamol O +
in O +
female O +
Fischer O +
344 O +
rats O -
. O +

Renal O +
structure O +
and O +
concentrating O +
ability O +
were O +
examined O +
after O +
a O +
recovery O +
period O +
of O +
up O +
to O +
18 O +
weeks O -
, O +
when O +
no O +
analgesics O +
were O +
given O -
, O +
to O +
investigate O +
whether O +
the O +
analgesic O -
- O -
induced O +
changes O +
were O +
reversible O -
. O +

There O +
was O +
no O +
evidence O +
of O +
repair O +
to O +
the O +
damaged O +
medullary O +
interstitial O +
matrix O -
, O +
or O +
proliferation O +
of O +
remaining O +
undamaged O +
type O +
1 O +
medullary O +
interstitial O +
cells O +
after O +
the O +
recovery O +
period O +
following O +
analgesic O +
treatment O -
. O +

The O +
recovery O +
of O +
urinary O +
concentrating O +
ability O +
was O +
related O +
to O +
the O +
length O +
of O +
analgesic O +
treatment O +
and O +
the O +
extent O +
of O +
the O +
resulting O +
inner O +
medullary O +
structural O +
damage O -
. O +

During O +
the O +
early O +
stages O +
of O +
analgesic O +
treatment O -
, O +
the O +
changes O +
in O +
urinary O +
concentrating O +
ability O +
were O +
reversible O -
, O +
but O +
after O +
prolonged O +
analgesic O +
treatment O -
, O +
maximum O +
urinary O +
concentrating O +
ability O +
failed O +
to O +
recover O -
. O +

This O +
study O +
shows O +
that O +
prolonged O +
analgesic O +
treatment O +
in O +
Fischer O +
344 O +
rats O +
causes O +
progressive O +
and O +
irreversible O +
damage O +
to O +
the O +
interstitial O +
matrix O +
and O +
type O +
1 O +
interstitial O +
cells O +
leading O +
to O +
RPN B-Disease -
. O +

The O +
associated O +
urinary O +
concentrating O +
defect O +
is O +
reversible O +
only O +
during O +
the O +
early O +
stages O +
of O +
structural O +
damage O +
to O +
the O +
inner O +
medulla O -
. O +

Testosterone O -
- O -
dependent O +
hypertension B-Disease +
and O +
upregulation O +
of O +
intrarenal O +
angiotensinogen O +
in O +
Dahl O +
salt O -
- O -
sensitive O +
rats O -
. O +

Blood O +
pressure O +
( O -
BP O -
) O +
is O +
more O +
salt O +
sensitive O +
in O +
men O +
than O +
in O +
premenopausal O +
women O -
. O +

In O +
Dahl O +
salt O -
- O -
sensitive O +
rats O +
( O -
DS O -
) O -
, O +
high O -
- O -
salt O +
( O -
HS O -
) O +
diet O +
increases O +
BP O +
more O +
in O +
males O +
than O +
females O -
. O +

In O +
contrast O +
to O +
the O +
systemic O +
renin O -
- O -
angiotensin O +
system O -
, O +
which O +
is O +
suppressed O +
in O +
response O +
to O +
HS O +
in O +
male O +
DS O -
, O +
intrarenal O +
angiotensinogen O +
expression O +
is O +
increased O -
, O +
and O +
intrarenal O +
levels O +
of O +
ANG O +
II O +
are O +
not O +
suppressed O -
. O +

In O +
this O +
study O -
, O +
the O +
hypothesis O +
was O +
tested O +
that O +
there O +
is O +
a O +
sexual O +
dimorphism O +
in O +
HS O -
- O -
induced O +
upregulation O +
of O +
intrarenal O +
angiotensinogen O +
mediated O +
by O +
testosterone O +
that O +
also O +
causes O +
increases O +
in O +
BP O +
and O +
renal B-Disease +
injury I-Disease -
. O +

On O +
a O +
low O -
- O -
salt O +
( O -
LS O -
) O +
diet O -
, O +
male O +
DS O +
had O +
higher O +
levels O +
of O +
intrarenal O +
angiotensinogen O +
mRNA O +
than O +
females O -
. O +

HS O +
diet O +
for O +
4 O +
wk O +
increased O +
renal O +
cortical O +
angiotensinogen O +
mRNA O +
and O +
protein O +
only O +
in O +
male O +
DS O -
, O +
which O +
was O +
prevented O +
by O +
castration O -
. O +

Ovariectomy O +
of O +
female O +
DS O +
had O +
no O +
effect O +
on O +
intrarenal O +
angiotensinogen O +
expression O +
on O +
either O +
diet O -
. O +

Radiotelemetric O +
BP O +
was O +
similar O +
between O +
males O +
and O +
castrated O +
rats O +
on O +
LS O +
diet O -
. O +

HS O +
diet O +
for O +
4 O +
wk O +
caused O +
a O +
progressive O +
increase O +
in O +
BP O -
, O +
protein O +
and O +
albumin O +
excretion O -
, O +
and O +
glomerular B-Disease +
sclerosis I-Disease +
in O +
male O +
DS O +
rats O -
, O +
which O +
were O +
attenuated O +
by O +
castration O -
. O +

Testosterone O +
replacement O +
in O +
castrated O +
DS O +
rats O +
increased O +
BP O -
, O +
renal B-Disease +
injury I-Disease -
, O +
and O +
upregulation O +
of O +
renal O +
angiotensinogen O +
associated O +
with O +
HS O +
diet O -
. O +

Testosterone O +
contributes O +
to O +
the O +
development O +
of O +
hypertension B-Disease +
and O +
renal B-Disease +
injury I-Disease +
in O +
male O +
DS O +
rats O +
on O +
HS O +
diet O +
possibly O +
through O +
upregulation O +
of O +
the O +
intrarenal O +
renin O -
- O -
angiotensin O +
system O -
. O +

Comparison O +
of O +
unilateral O +
pallidotomy O +
and O +
subthalamotomy O +
findings O +
in O +
advanced O +
idiopathic B-Disease +
Parkinson I-Disease -
's I-Disease +
disease I-Disease -
. O +

A O +
prospective O -
, O +
randomized O -
, O +
double O -
- O -
blind O +
pilot O +
study O +
to O +
compare O +
the O +
results O +
of O +
stereotactic O +
unilateral O +
pallidotomy O +
and O +
subthalamotomy O +
in O +
advanced O +
idiopathic B-Disease +
Parkinson I-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
refractory O +
to O +
medical O +
treatment O +
was O +
designed O -
. O +

Ten O +
consecutive O +
patients O +
( O -
mean O +
age O -
, O +
58.4 O +
+ O -
/- O +

6.8 O +
years O -
; O +
7 O +
men O -
, O +
3 O +
women O -
) O +
with O +
similar O +
characteristics O +
at O +
the O +
duration O +
of O +
disease O +
( O -
mean O +
disease O +
time O -
, O +
8.4 O +
+ O -
/- O +

3.5 O +
years O -
) O -
, O +
disabling O +
motor O +
fluctuations O +
( O -
Hoehn O +
_ O +
Yahr O +
stage O +
3 O -
- O -
5 O +
in O +
off O -
- O -
drug O +
phases O -
) O +
and O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
were O +
selected O -
. O +

All O +
patients O +
had O +
bilateral O +
symptoms O +
and O +
their O +
levodopa O +
equivalent O +
dosing O +
were O +
analysed O -
. O +

Six O +
patients O +
were O +
operated O +
on O +
in O +
the O +
globus O +
pallidus O +
interna O +
( O -
GPi O -
) O +
and O +
four O +
in O +
the O +
subthalamic O +
nucleus O +
( O -
STN O -
) O -
. O +

Clinical O +
evaluation O +
included O +
the O +
use O +
of O +
the O +
Unified O +
Parkinson B-Disease -
's I-Disease +
Disease I-Disease +
Rating O +
Scale O +
( O -
UPDRS O -
) O -
, O +
Hoehn_Yahr O +
score O +
and O +
Schwab O +
England O +
activities O +
of O +
daily O +
living O +
( O -
ADL O -
) O +
score O +
in O +
' O -
on'- O +
and O +
' O -
off'-drug O +
conditions O +
before O +
surgery O +
and O +
6 O +
months O +
after O +
surgery O -
. O +

There O +
was O +
statistically O +
significant O +
improvement O +
in O +
all O +
contralateral O +
major O +
parkinsonian B-Disease +
motor O +
signs O +
in O +
all O +
patients O +
followed O +
for O +
6 O +
months O -
. O +

Levodopa O +
equivalent O +
daily O +
intake O +
was O +
significantly O +
reduced O +
in O +
the O +
STN O +
group O -
. O +

Changes O +
in O +
UPDRS O -
, O +
Hoehn O +
_ O +
Yahr O +
and O +
Schwab O +
England O +
ADL O +
scores O +
were O +
similar O +
in O +
both O +
groups O -
. O +

Cognitive O +
functions O +
were O +
unchanged O +
in O +
both O +
groups O -
. O +

Complications O +
were O +
observed O +
in O +
two O +
patients O -
: O +
one O +
had O +
a O +
left O +
homonymous B-Disease +
hemianopsia I-Disease +
after O +
pallidotomy O +
and O +
another O +
one O +
developed O +
left O +
hemiballistic O +
movements O +
3 O +
days O +
after O +
subthalamotomy O +
which O +
partly O +
improved O +
within O +
1 O +
month O +
with O +
Valproate O +
1000 O +
mg O -
/ O -
day O -
. O +

The O +
findings O +
of O +
this O +
study O +
suggest O +
that O +
lesions O +
of O +
the O +
unilateral O +
STN O +
and O +
GPi O +
are O +
equally O +
effective O +
treatment O +
for O +
patients O +
with O +
advanced O +
PD B-Disease +
refractory O +
to O +
medical O +
treatment O -
. O +

Explicit O +
episodic O +
memory O +
for O +
sensory O -
- O -
discriminative O +
components O +
of O +
capsaicin O -
- O -
induced O +
pain B-Disease -
: O +
immediate O +
and O +
delayed O +
ratings O -
. O +

Pain B-Disease +
memory O +
is O +
thought O +
to O +
affect O +
future O +
pain B-Disease +
sensitivity O +
and O +
thus O +
contribute O +
to O +
clinical O +
pain B-Disease +
conditions O -
. O +

Systematic O +
investigations O +
of O +
the O +
human O +
capacity O +
to O +
remember O +
sensory O +
features O +
of O +
experimental O +
pain B-Disease +
are O +
sparse O -
. O +

In O +
order O +
to O +
address O +
long O -
- O -
term O +
pain B-Disease +
memory O -
, O +
nine O +
healthy O +
male O +
volunteers O +
received O +
intradermal O +
injections O +
of O +
three O +
doses O +
of O +
capsaicin O +
( O -
0.05 O -
, O +
1 O +
and O +
20 O +
microg O -
, O +
separated O +
by O +
15 O +
min O +
breaks O -
) O -
, O +
each O +
given O +
three O +
times O +
in O +
a O +
balanced O +
design O +
across O +
three O +
sessions O +
at O +
one O +
week O +
intervals O -
. O +

Pain B-Disease +
rating O +
was O +
performed O +
using O +
a O +
computerized O +
visual O +
analogue O +
scale O +
( O -
0 O -
- O -
100 O -
) O +
digitized O +
at O +
1 O -
/ O -
s O -
, O +
either O +
immediately O +
online O +
or O +
one O +
hour O +
or O +
one O +
day O +
after O +
injection O -
. O +

Subjects O +
also O +
recalled O +
their O +
pains B-Disease +
one O +
week O +
later O -
. O +

Capsaicin O +
injection O +
reliably O +
induced O +
a O +
dose O -
- O -
dependent O +
flare O +
( O -
p<0.001 O -
) O +
without O +
any O +
difference O +
within O +
or O +
across O +
sessions O -
. O +

The O +
strong O +
burning O +
pain B-Disease +
decayed O +
exponentially O +
within O +
a O +
few O +
minutes O -
. O +

Subjects O +
were O +
able O +
to O +
reliably O +
discriminate O +
pain B-Disease +
magnitude O +
and O +
duration O +
across O +
capsaicin O +
doses O +
( O -
both O +
p<0.001 O -
) O -
, O +
regardless O +
of O +
whether O +
first O -
- O -
time O +
ratings O +
were O +
requested O +
immediately O -
, O +
after O +
one O +
hour O +
or O +
after O +
one O +
day O -
. O +

Pain B-Disease +
recall O +
after O +
one O +
week O +
was O +
similarly O +
precise O +
( O -
magnitude O -
: O +
p<0.01 O -
, O +
duration O -
: O +
p<0.05 O -
) O -
. O +

Correlation O +
with O +
rating O +
recall O +
after O +
one O +
week O +
was O +
best O +
when O +
first O -
- O -
time O +
ratings O +
were O +
requested O +
as O +
late O +
as O +
one O +
day O +
after O +
injection O +
( O -
R O -
( O -
2 O -
) O -
=0.79 O -
) O +
indicating O +
that O +
both O +
rating O +
retrievals O +
utilized O +
similar O +
memory O +
traces O -
. O +

These O +
results O +
indicate O +
a O +
reliable O +
memory O +
for O +
magnitude O +
and O +
duration O +
of O +
experimentally O +
induced O +
pain B-Disease -
. O +

The O +
data O +
further O +
suggest O +
that O +
the O +
consolidation O +
of O +
this O +
memory O +
is O +
an O +
important O +
interim O +
stage O -
, O +
and O +
may O +
take O +
up O +
to O +
one O +
day O -
. O +

Naloxone O +
reversal O +
of O +
hypotension B-Disease +
due O +
to O +
captopril O +
overdose B-Disease -
. O +

The O +
hemodynamic O +
effects O +
of O +
captopril O +
and O +
other O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
may O +
be O +
mediated O +
by O +
the O +
endogenous O +
opioid O +
system O -
. O +

The O +
opioid O +
antagonist O +
naloxone O +
has O +
been O +
shown O +
to O +
block O +
or O +
reverse O +
the O +
hypotensive B-Disease +
actions O +
of O +
captopril O -
. O +

We O +
report O +
a O +
case O +
of O +
an O +
intentional O +
captopril O +
overdose B-Disease -
, O +
manifested O +
by O +
marked O +
hypotension B-Disease -
, O +
that O +
resolved O +
promptly O +
with O +
the O +
administration O +
of O +
naloxone O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
reported O +
case O +
of O +
captopril O -
- O -
induced O +
hypotension B-Disease +
treated O +
with O +
naloxone O -
. O +

Our O +
experience O +
demonstrates O +
a O +
possible O +
role O +
of O +
naloxone O +
in O +
the O +
reversal O +
of O +
hypotension B-Disease +
resulting O +
from O +
captopril O -
. O +

Identification O +
of O +
a O +
simple O +
and O +
sensitive O +
microplate O +
method O +
for O +
the O +
detection O +
of O +
oversulfated O +
chondroitin O +
sulfate O +
in O +
heparin O +
products O -
. O +

Heparin O +
is O +
a O +
commonly O +
implemented O +
anticoagulant O +
used O +
to O +
treat O +
critically O +
ill O +
patients O -
. O +

Recently O -
, O +
a O +
number O +
of O +
commercial O +
lots O +
of O +
heparin O +
products O +
were O +
found O +
to O +
be O +
contaminated O +
with O +
an O +
oversulfated O +
chondroitin O +
sulfate O +
( O -
OSCS O -
) O +
derivative O +
that O +
could O +
elicit O +
a O +
hypotensive B-Disease +
response O +
in O +
pigs O +
following O +
a O +
single O +
high O -
- O -
dose O +
infusion O -
. O +

Using O +
both O +
contaminated O +
heparin O +
products O +
and O +
the O +
synthetically O +
produced O +
derivative O -
, O +
we O +
showed O +
that O +
the O +
OSCS O +
produces O +
dose O -
- O -
dependent O +
hypotension B-Disease +
in O +
pigs O -
. O +

The O +
no O +
observed O +
effect O +
level O +
( O -
NOEL O -
) O +
for O +
this O +
contaminant O +
appears O +
to O +
be O +
approximately O +
1mg O -
/ O -
kg O -
, O +
corresponding O +
to O +
a O +
contamination O +
level O +
of O +
approximately O +
3 O -
% O -
. O +

We O +
also O +
demonstrated O +
that O +
OSCS O +
can O +
be O +
identified O +
in O +
heparin O +
products O +
using O +
a O +
simple O -
, O +
inexpensive O -
, O +
commercially O +
available O +
heparin O +
enzyme O +
immunoassay O +
( O -
EIA O -
) O +
kit O +
that O +
has O +
a O +
limit O +
of O +
detection O +
of O +
approximately O +
0.1 O -
% O -
, O +
well O +
below O +
the O +
NOEL O -
. O +

This O +
kit O +
may O +
provide O +
a O +
useful O +
method O +
to O +
test O +
heparin O +
products O +
for O +
contamination O +
with O +
oversulfated O +
GAG O +
derivatives O -
. O +

Severe O +
and O +
long O +
lasting O +
cholestasis B-Disease +
after O +
high O -
- O -
dose O +
co O -
- O -
trimoxazole O +
treatment O +
for O +
Pneumocystis B-Disease +
pneumonia I-Disease +
in O +
HIV B-Disease -
- I-Disease -
infected I-Disease +
patients O -
-- O -
a O +
report O +
of O +
two O +
cases O -
. O +

Pneumocystis B-Disease +
pneumonia I-Disease +
( O -
PCP B-Disease -
) O -
, O +
a O +
common O +
opportunistic B-Disease +
infection I-Disease +
in O +
HIV B-Disease -
- I-Disease -
infected I-Disease +
individuals O -
, O +
is O +
generally O +
treated O +
with O +
high O +
doses O +
of O +
co O -
- O -
trimoxazole O -
. O +

However O -
, O +
treatment O +
is O +
often O +
limited O +
by O +
adverse O +
effects O -
. O +

Here O -
, O +
we O +
report O +
two O +
cases O +
of O +
severely O +
immunocompromised O +
HIV B-Disease -
- I-Disease -
infected I-Disease +
patients O +
who O +
developed O +
severe O +
intrahepatic B-Disease +
cholestasis I-Disease -
, O +
and O +
in O +
one O +
patient O +
lesions O +
mimicking O +
liver B-Disease +
abscess I-Disease +
formation O +
on O +
radiologic O +
exams O -
, O +
during O +
co O -
- O -
trimoxazole O +
treatment O +
for O +
PCP B-Disease -
. O +

Whereas O +
patient O +
1 O +
showed O +
lesions O +
of O +
up O +
to O +
1 O +
cm O +
readily O +
detectable O +
on O +
magnetic O +
resonance O +
imaging O +
under O +
prolonged O +
co O -
- O -
trimoxazole O +
treatment O -
, O +
therapy O +
of O +
patient O +
2 O +
was O +
switched O +
early O -
. O +

5 O +
flourouracil O -
- O -
induced O +
apical B-Disease +
ballooning I-Disease +
syndrome I-Disease -
: O +
a O +
case O +
report O -
. O +

The O +
apical B-Disease +
ballooning I-Disease +
syndrome I-Disease +
( O -
ABS B-Disease -
) O +
is O +
a O +
recently O +
described O +
stress O -
- O -
mediated O +
acute B-Disease +
cardiac I-Disease +
syndrome I-Disease +
characterized O +
by O +
transient O +
wall O -
- O -
motion O +
abnormalities O +
involving O +
the O +
apex O +
and O +
midventricle O +
with O +
hyperkinesis B-Disease +
of O +
the O +
basal O +
left O +
ventricular O +
( O -
LV O -
) O +
segments O +
without O +
obstructive O +
epicardial B-Disease +
coronary I-Disease +
disease I-Disease -
. O +

Cardiotoxicity B-Disease +
is O +
not O +
an O +
uncommon O +
adverse O +
effect O +
of O +
chemotherapeutic O +
agents O -
. O +

However O -
, O +
there O +
are O +
no O +
reports O +
of O +
ABS B-Disease +
secondary O +
to O +
chemotherapeutic O +
agents O -
. O +

We O +
describe O +
the O +
case O +
of O +
a O +
woman O +
who O +
developed O +
the O +
syndrome O +
after O +
chemotherapy O +
for O +
metastatic O +
cancer B-Disease -
. O +

A O +
79-year O -
- O -
old O +
woman O +
presented O +
with O +
typical O +
ischemic B-Disease +
chest B-Disease +
pain I-Disease -
, O +
elevated O +
cardiac O +
enzymes O +
with O +
significant O +
ST O -
- O -
segment O +
abnormalities O +
on O +
her O +
electrocardiogram O -
. O +

She O +
underwent O +
recent O +
chemotherapy O +
with O +
fluorouracil O +
for O +
metastatic O +
colorectal B-Disease +
cancer I-Disease -
. O +

Echocardiography O +
revealed O +
a O +
wall O -
- O -
motion O +
abnormality O +
involving O +
the O +
apical O +
and O +
periapical O +
segments O +
which O +
appeared O +
akinetic B-Disease -
. O +

Coronary O +
angiography O +
revealed O +
no O +
obstructive O +
coronary O +
lesions O -
. O +

The O +
patient O +
was O +
stabilized O +
with O +
medical O +
therapy O -
. O +

Four O +
weeks O +
later O +
she O +
remained O +
completely O +
asymptomatic O -
. O +

Echocardiogram O +
revealed O +
a O +
normal O +
ejection O +
fraction O +
and O +
a O +
resolution O +
of O +
the O +
apical O +
akinesis B-Disease -
. O +

Pathogenetic O +
mechanisms O +
of O +
cardiac B-Disease +
complications I-Disease +
in O +
cancer B-Disease +
patients O +
undergoing O +
chemotherapy O +
include O +
coronary B-Disease +
vasospasm I-Disease -
, O +
endothelial O +
damage O +
and O +
consequent O +
thrombus B-Disease +
formation O -
. O +

In O +
our O +
patient O -
, O +
both O +
supraphysiologic O +
levels O +
of O +
plasma O +
catecholamines O +
and O +
stress O +
related O +
neuropeptides O +
caused O +
by O +
cancer B-Disease +
diagnosis O +
as O +
well O +
as O +
chemotherapy O +
may O +
have O +
contributed O +
the O +
development O +
of O +
ABS B-Disease -
. O +

Bradykinin O +
receptors O +
antagonists O +
and O +
nitric O +
oxide O +
synthase O +
inhibitors O +
in O +
vincristine O +
and O +
streptozotocin O +
induced O +
hyperalgesia B-Disease +
in O +
chemotherapy O +
and O +
diabetic B-Disease +
neuropathy I-Disease +
rat O +
model O -
. O +

PURPOSE O -
: O +
The O +
influence O +
of O +
an O +
irreversible O +
inhibitor O +
of O +
constitutive O +
NO O +
synthase O +
( O -
L O -
- O -
NOArg O -
; O +
1.0 O +
mg O -
/ O -
kg O +
ip O -
) O -
, O +
a O +
relatively O +
selective O +
inhibitor O +
of O +
inducible O +
NO O +
synthase O +
( O -
L O -
- O -
NIL O -
; O +
1.0 O +
mg O -
/ O -
kg O +
ip O -
) O +
and O +
a O +
relatively O +
specific O +
inhibitor O +
of O +
neuronal O +
NO O +
synthase O +
( O -
7-NI O -
; O +
0.1 O +
mg O -
/ O -
kg O +
ip O -
) O -
, O +
on O +
antihyperalgesic O +
action O +
of O +
selective O +
antagonists O +
of O +
B2 O +
and O +
B1 O +
receptors O -
: O +
D O -
- O -
Arg- O -
[ O -
Hyp3,Thi5,D O -
- O -
Tic7,Oic8 O -
] O +
bradykinin O +
( O -
HOE O +
140 O -
; O +
70 O +
nmol O -
/ O -
kg O +
ip O -
) O +
or O +
des O +
Arg10 O +
HOE O +
140 O +
( O -
70 O +
nmol O -
/ O -
kg O +
ip O -
) O +
respectively O -
, O +
in O +
model O +
of O +
diabetic B-Disease +
( I-Disease -
streptozotocin I-Disease -
- I-Disease -
induced I-Disease -
) I-Disease +
and I-Disease +
toxic I-Disease +
( I-Disease -
vincristine I-Disease -
- I-Disease -
induced I-Disease -
) I-Disease +
neuropathy I-Disease +
was O +
investigated O -
. O +

METHODS O -
: O +
The O +
changes O +
in O +
pain B-Disease +
thresholds O +
were O +
determined O +
using O +
mechanical O +
stimuli O -
-- O -
the O +
modification O +
of O +
the O +
classic O +
paw O +
withdrawal O +
test O +
described O +
by O +
Randall O -
- O -
Selitto O -
. O +

RESULTS O -
: O +
The O +
results O +
of O +
this O +
paper O +
confirm O +
that O +
inhibition O +
of O +
bradykinin O +
receptors O +
and O +
inducible O +
NO O +
synthase O +
but O +
not O +
neuronal O +
NO O +
synthase O +
activity O +
reduces O +
diabetic B-Disease +
hyperalgesia I-Disease -
. O +

Pretreatment O +
with O +
L O -
- O -
NOArg O +
and O +
L O -
- O -
NIL O +
but O +
not O +
7-NI O -
, O +
significantly O +
increases O +
antihyperalgesic O +
activity O +
both O +
HOE O +
140 O +
and O +
des O +
Arg10 O +
HOE O +
140 O -
. O +

It O +
was O +
also O +
shown O +
that O +
both O +
products O +
of O +
inducible O +
NO O +
synthase O +
and O +
neuronal O +
NO O +
synthase O +
activation O +
as O +
well O +
as O +
bradykinin O +
are O +
involved O +
in O +
hyperalgesia B-Disease +
produced O +
by O +
vincristine O -
. O +

Moreover O -
, O +
L O -
- O -
NOArg O +
and O +
7-NI O +
but O +
not O +
L O -
- O -
NIL O +
intensify O +
antihyperalgesic O +
activity O +
of O +
HOE O +
140 O +
or O +
des O -
- O -
Arg10HOE O +
140 O +
in O +
toxic B-Disease +
neuropathy I-Disease -
. O +

CONCLUSIONS O -
: O +
Results O +
of O +
these O +
studies O +
suggest O +
that O +
B1 O +
and O +
B2 O +
receptors O +
are O +
engaged O +
in O +
transmission O +
of O +
nociceptive O +
stimuli O +
in O +
both O +
diabetic B-Disease +
and I-Disease +
toxic I-Disease +
neuropathy I-Disease -
. O +

In O +
streptozotocin O -
- O -
induced O +
hyperalgesia B-Disease -
, O +
inducible O +
NO O +
synthase O +
participates O +
in O +
pronociceptive O +
activity O +
of O +
bradykinin O -
, O +
whereas O +
in O +
vincristine O -
- O -
induced O +
hyperalgesia B-Disease +
bradykinin O +
seemed O +
to O +
activate O +
neuronal O +
NO O +
synthase O +
pathway O -
. O +

Therefore O -
, O +
concomitant O +
administration O +
of O +
small O +
doses O +
of O +
bradykinin O +
receptor O +
antagonists O +
and O +
NO O +
synthase O +
inhibitors O +
can O +
be O +
effective O +
in O +
alleviation O +
of O +
neuropathic B-Disease +
pain I-Disease -
, O +
even O +
in O +
hospital O +
care O -
. O +

Confusion B-Disease -
, O +
a O +
rather O +
serious O +
adverse O +
drug O +
reaction O +
with O +
valproic O +
acid O -
: O +
a O +
review O +
of O +
the O +
French O +
Pharmacovigilance O +
database O -
. O +

INTRODUCTION O -
: O +
Confusion B-Disease +
is O +
an O +
adverse O +
drug O +
reaction O +
frequently O +
observed O +
with O +
valproic O +
acid O -
. O +

Some O +
case O +
reports O +
are O +
published O +
in O +
the O +
literature O +
but O +
no O +
systematic O +
study O +
from O +
a O +
sample O +
of O +
patients O +
has O +
been O +
published O -
. O +

We O +
performed O +
this O +
study O +
in O +
order O +
to O +
describe O +
the O +
main O +
characteristics O +
of O +
this O +
adverse O +
drug O +
reaction O -
. O +

METHODS O -
: O +
Using O +
the O +
French O +
Pharmacovigilance O +
database O -
, O +
we O +
selected O +
the O +
cases O +
of O +
confusion B-Disease +
reported O +
since O +
1985 O +
with O +
valproic O +
acid O -
. O +

RESULTS O -
: O +
272 O +
cases O +
of O +
confusion B-Disease +
were O +
reported O +
with O +
valproic O +
acid O -
: O +
153 O +
women O +
and O +
119 O +
men O -
. O +

Confusion B-Disease +
mostly O +
occurred O +
during O +
the O +
two O +
first O +
weeks O +
following O +
valproic O +
acid O +
exposure O +
( O -
39.7 O -
% O -
) O -
. O +

It O +
was O +
" O -
serious O -
" O +
for O +
almost O +
2 O -
/ O -
3 O +
of O +
the O +
patients O +
( O -
62.5 O -
% O -
) O +
and O +
its O +
outcome O +
favourable O +
in O +
most O +
of O +
the O +
cases O +
( O -
82 O -
% O -
) O -
. O +

The O +
occurrence O +
of O +
this O +
ADR O +
was O +
more O +
frequent O +
in O +
patients O +
aged O +
between O +
61 O +
and O +
80 O +
years O -
. O +

CONCLUSION O -
: O +
This O +
work O +
shows O +
that O +
confusion B-Disease +
with O +
valproic O +
acid O +
is O +
a O +
serious O -
, O +
rather O +
frequent O +
but O +
reversible O +
adverse O +
drug O +
reaction O -
. O +

It O +
occurs O +
especially O +
in O +
older O +
patients O +
and O +
during O +
the O +
first O +
two O +
weeks O +
of O +
treatment O -
. O +

Rapid O +
reversal O +
of O +
anticoagulation O +
reduces O +
hemorrhage B-Disease +
volume O +
in O +
a O +
mouse O +
model O +
of O +
warfarin O -
- O -
associated O +
intracerebral B-Disease +
hemorrhage I-Disease -
. O +

Warfarin O -
- O -
associated O +
intracerebral B-Disease +
hemorrhage I-Disease +
( O -
W O -
- O -
ICH B-Disease -
) O +
is O +
a O +
severe O +
type O +
of O +
stroke B-Disease -
. O +

There O +
is O +
no O +
consensus O +
on O +
the O +
optimal O +
treatment O +
for O +
W O -
- O -
ICH B-Disease -
. O +

Using O +
a O +
mouse O +
model O -
, O +
we O +
tested O +
whether O +
the O +
rapid O +
reversal O +
of O +
anticoagulation O +
using O +
human O +
prothrombin O +
complex O +
concentrate O +
( O -
PCC O -
) O +
can O +
reduce O +
hemorrhagic O +
blood O +
volume O -
. O +

Male O +
CD-1 O +
mice O +
were O +
treated O +
with O +
warfarin O +
( O -
2 O +
mg O -
/ O -
kg O +
over O +
24 O +
h O -
) O -
, O +
resulting O +
in O +
a O +
mean O +
( O -
+ O -
/-s.d O -
. O -
) O +

International O +
Normalized O +
Ratio O +
of O +
3.5+ O -
/ O -
-0.9 O -
. O +

First O -
, O +
we O +
showed O +
that O +
an O +
intravenous O +
administration O +
of O +
human O +
PCC O +
rapidly O +
reversed O +
anticoagulation O +
in O +
mice O -
. O +

Second O -
, O +
a O +
stereotactic O +
injection O +
of O +
collagenase O +
was O +
administered O +
to O +
induce O +
hemorrhage B-Disease +
in O +
the O +
right O +
striatum O -
. O +

Forty O -
- O -
five O +
minutes O +
later O -
, O +
the O +
animals O +
were O +
randomly O +
treated O +
with O +
PCC O +
( O -
100 O +
U O -
/ O -
kg O -
) O +
or O +
saline O +
i.v O -
. O +

( O -
n=12 O +
per O +
group O -
) O -
. O +

Twenty O -
- O -
four O +
hours O +
after O +
hemorrhage B-Disease +
induction O -
, O +
hemorrhagic O +
blood O +
volume O +
was O +
quantified O +
using O +
a O +
photometric O +
hemoglobin O +
assay O -
. O +

The O +
mean O +
hemorrhagic O +
blood O +
volume O +
was O +
reduced O +
in O +
PCC O -
- O -
treated O +
animals O +
( O -
6.5+ O -
/ O -
-3.1 O +
microL O -
) O +
compared O +
with O +
saline O +
controls O +
( O -
15.3+ O -
/ O -
-11.2 O +
microL O -
, O +
P=0.015 O -
) O -
. O +

In O +
the O +
saline O +
group O -
, O +
45 O -
% O +
of O +
the O +
mice O +
developed O +
large O +
hematomas B-Disease +
( O -
i.e. O -
, O +
> O -
15 O +
microL O -
) O -
. O +

In O +
contrast O -
, O +
such O +
extensive O +
lesions O +
were O +
never O +
found O +
in O +
the O +
PCC O +
group O -
. O +

We O +
provide O +
experimental O +
data O +
suggesting O +
PCC O +
to O +
be O +
an O +
effective O +
acute O +
treatment O +
for O +
W O -
- O -
ICH B-Disease +
in O +
terms O +
of O +
reducing O +
hemorrhagic O +
blood O +
volume O -
. O +

Future O +
studies O +
are O +
needed O +
to O +
assess O +
the O +
therapeutic O +
potential O +
emerging O +
from O +
our O +
finding O +
for O +
human O +
W O -
- O -
ICH B-Disease -
. O +

Reversible O +
inferior B-Disease +
colliculus I-Disease +
lesion I-Disease +
in O +
metronidazole O -
- O -
induced O +
encephalopathy B-Disease -
: O +
magnetic O +
resonance O +
findings O +
on O +
diffusion O -
- O -
weighted O +
and O +
fluid O +
attenuated O +
inversion O +
recovery O +
imaging O -
. O +

OBJECTIVE O -
: O +
This O +
is O +
to O +
present O +
reversible O +
inferior B-Disease +
colliculus I-Disease +
lesions I-Disease +
in O +
metronidazole O -
- O -
induced O +
encephalopathy B-Disease -
, O +
to O +
focus O +
on O +
the O +
diffusion O -
- O -
weighted O +
imaging O +
( O -
DWI O -
) O +
and O +
fluid O +
attenuated O +
inversion O +
recovery O +
( O -
FLAIR O -
) O +
imaging O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
From O +
November O +
2005 O +
to O +
September O +
2007 O -
, O +
8 O +
patients O +
( O -
5 O +
men O +
and O +
3 O +
women O -
) O +
were O +
diagnosed O +
as O +
having O +
metronidazole O -
- O -
induced O +
encephalopathy B-Disease +
( O -
age O +
range O -
; O +
43 O -
- O -
78 O +
years O -
) O -
. O +

They O +
had O +
been O +
taking O +
metronidazole O +
( O -
total O +
dosage O -
, O +
45 O -
- O -
120 O +
g O -
; O +
duration O -
, O +
30 O +
days O +
to O +
2 O +
months O -
) O +
to O +
treat O +
the O +
infection B-Disease +
in O +
various O +
organs O -
. O +

Initial O +
brain O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O +
were O +
obtained O +
after O +
the O +
hospitalization O -
, O +
including O +
DWI O +
( O -
8 O -
/ O -
8 O -
) O -
, O +
apparent O +
diffusion O +
coefficient O +
( O -
ADC O -
) O +
map O +
( O -
4 O -
/ O -
8 O -
) O -
, O +
FLAIR O +
( O -
7 O -
/ O -
8 O -
) O -
, O +
and O +
T2-weighted O +
image O +
( O -
8 O -
/ O -
8 O -
) O -
. O +

Follow O -
- O -
up O +
MRIs O +
were O +
performed O +
on O +
5 O +
patients O +
from O +
third O +
to O +
14th O +
days O +
after O +
discontinuation O +
of O +
metronidazole O +
administration O -
. O +

Findings O +
of O +
initial O +
and O +
follow O -
- O -
up O +
MRIs O +
were O +
retrospectively O +
evaluated O +
by O +
2 O +
neuroradiologists O +
by O +
consensus O -
, O +
to O +
analyze O +
the O +
presence O +
of O +
abnormal O +
signal O +
intensities O -
, O +
their O +
locations O -
, O +
and O +
signal O +
changes O +
on O +
follow O -
- O -
up O +
images O -
. O +

RESULTS O -
: O +
Initial O +
MRIs O +
showed O +
abnormal O +
high O +
signal O +
intensities O +
on O +
DWI O +
and O +
FLAIR O +
( O -
or O +
T2-weighted O +
image O -
) O +
at O +
the O +
dentate O +
nucleus O +
( O -
8 O -
/ O -
8 O -
) O -
, O +
inferior O +
colliculus O +
( O -
6 O -
/ O -
8 O -
) O -
, O +
corpus O +
callosum O +
( O -
2 O -
/ O -
8 O -
) O -
, O +
pons O +
( O -
2 O -
/ O -
8 O -
) O -
, O +
medulla O +
( O -
1 O -
/ O -
8 O -
) O -
, O +
and O +
bilateral O +
cerebral O +
white O +
matter O +
( O -
1 O -
/ O -
8 O -
) O -
. O +

High O -
- O -
signal O +
intensity O +
lesions O +
on O +
DWI O +
tended O +
to O +
show O +
low O +
signal O +
intensity O +
on O +
ADC O +
map O +
( O -
3 O -
/ O -
4 O -
) O -
, O +
but O +
in O +
one O +
patient O -
, O +
high O +
signal O +
intensity O +
was O +
shown O +
at O +
bilateral O +
dentate O +
nuclei O +
on O +
not O +
only O +
DWI O +
but O +
also O +
ADC O +
map O -
. O +

All O +
the O +
lesions O +
in O +
dentate O -
, O +
inferior O +
colliculus O -
, O +
pons O -
, O +
and O +
medullas O +
had O +
been O +
resolved O +
completely O +
on O +
follow O -
- O -
up O +
MRIs O +
in O +
5 O +
patients O -
, O +
but O +
in O +
1 O +
patient O +
of O +
them O -
, O +
corpus O +
callosal B-Disease +
lesion I-Disease +
persisted O -
. O +

CONCLUSIONS O -
: O +
Reversible O +
inferior B-Disease +
colliculus I-Disease +
lesions I-Disease +
could O +
be O +
considered O +
as O +
the O +
characteristic O +
for O +
metronidazole O -
- O -
induced O +
encephalopathy B-Disease -
, O +
next O +
to O +
the O +
dentate O +
nucleus O +
involvement O -
. O +

Clinically O +
significant O +
proteinuria B-Disease +
following O +
the O +
administration O +
of O +
sirolimus O +
to O +
renal O +
transplant O +
recipients O -
. O +

BACKGROUND O -
: O +
Sirolimus O +
is O +
the O +
latest O +
immunosuppressive O +
agent O +
used O +
to O +
prevent O +
rejection O -
, O +
and O +
may O +
have O +
less O +
nephrotoxicity B-Disease +
than O +
calcineurin O +
inhibitor O +
( O -
CNI O -
) O -
-based O +
regimens O -
. O +

To O +
date O +
there O +
has O +
been O +
little O +
documentation O +
of O +
clinically O +
significant O +
proteinuria B-Disease +
linked O +
with O +
the O +
use O +
of O +
sirolimus O -
. O +

We O +
have O +
encountered O +
several O +
patients O +
who O +
developed O +
substantial O +
proteinuria B-Disease +
associated O +
with O +
sirolimus O +
use O -
. O +

In O +
each O +
patient O -
, O +
the O +
close O +
temporal O +
association O +
between O +
the O +
commencement O +
of O +
sirolimus O +
therapy O +
and O +
proteinuria B-Disease +
implicated O +
sirolimus O +
as O +
the O +
most O +
likely O +
etiology O +
of O +
the O +
proteinuria B-Disease -
. O +

METHODS O -
: O +
We O +
analyzed O +
the O +
clinical O +
and O +
laboratory O +
information O +
available O +
for O +
all O +
119 O +
patients O +
transplanted O +
at O +
the O +
Washington O +
Hospital O +
Center O +
between O +
1999 O -
- O -
2003 O +
for O +
whom O +
sirolimus O +
was O +
a O +
component O +
of O +
their O +
immunosuppressant O +
regimen O -
. O +

In O +
these O +
patients O -
, O +
the O +
magnitude O +
of O +
proteinuria B-Disease +
was O +
assessed O +
on O +
morning O +
urine O +
samples O +
by O +
turbidometric O +
measurement O +
or O +
random O +
urine O +
protein O -
: O -
creatinine O +
ratios O -
, O +
an O +
estimate O +
of O +
grams O +
of O +
proteinuria B-Disease -
/ O -
day O -
. O +

Laboratory O +
results O +
were O +
compared O +
between O +
prior O -
, O +
during O +
and O +
following O +
sirolimus O +
use O -
. O +

RESULTS O -
: O +
Twenty O -
- O -
eight O +
patients O +
( O -
24 O -
% O -
) O +
developed O +
increased O +
proteinuria B-Disease +
from O +
baseline O +
during O +
their O +
post O -
- O -
transplantation O +
course O -
. O +

In O +
21 O +
patients O +
an O +
alternative O +
cause O +
of O +
proteinuria B-Disease +
was O +
either O +
obvious O +
or O +
insufficient O +
data O +
was O +
available O +
to O +
be O +
conclusive O -
. O +

In O +
7 O +
of O +
the O +
28 O +
patients O +
there O +
was O +
a O +
striking O +
temporal O +
association O +
between O +
the O +
initiation O +
of O +
sirolimus O +
and O +
the O +
development O +
of O +
nephrotic B-Disease -
- O -
range O +
proteinuria B-Disease -
. O +

Proteinuria B-Disease +
correlated O +
most O +
strongly O +
with O +
sirolimus O +
therapy O +
when O +
compared O +
to O +
other O +
demographic O +
and O +
clinical O +
variables O -
. O +

In O +
most O +
patients O -
, O +
discontinuation O +
of O +
sirolimus O +
resulted O +
in O +
a O +
decrease O -
, O +
but O +
not O +
resolution O -
, O +
of O +
proteinuria B-Disease -
. O +

CONCLUSIONS O -
: O +
Sirolimus O +
induces O +
or O +
aggravates O +
pre O -
- O -
existing O +
proteinuria B-Disease +
in O +
an O +
unpredictable O +
subset O +
of O +
renal O +
allograft O +
recipients O -
. O +

Proteinuria B-Disease +
may O +
improve O -
, O +
but O +
does O +
not O +
resolve O -
, O +
when O +
sirolimus O +
is O +
withdrawn O -
. O +

Components O +
of O +
lemon O +
essential O +
oil O +
attenuate O +
dementia B-Disease +
induced O +
by O +
scopolamine O -
. O +

The O +
anti O -
- O -
dementia B-Disease +
effects O +
of O +
s O -
- O -
limonene O +
and O +
s O -
- O -
perillyl O +
alcohol O +
were O +
observed O +
using O +
the O +
passive O +
avoidance O +
test O +
( O -
PA O -
) O +
and O +
the O +
open O +
field O +
habituation O +
test O +
( O -
OFH O -
) O -
. O +

These O +
lemon O +
essential O +
oils O +
showed O +
strong O +
ability O +
to O +
improve O +
memory B-Disease +
impaired I-Disease +
by O +
scopolamine O -
; O +
however O -
, O +
s O -
- O -
perillyl O +
alcohol O +
relieved O +
the O +
deficit B-Disease +
of I-Disease +
associative I-Disease +
memory I-Disease +
in O +
PA O +
only O -
, O +
and O +
did O +
not O +
improve O +
non O -
- O -
associative O +
memory O +
significantly O +
in O +
OFH O -
. O +

Analysis O +
of O +
neurotransmitter O +
concentration O +
in O +
some O +
brain O +
regions O +
on O +
the O +
test O +
day O +
showed O +
that O +
dopamine O +
concentration O +
of O +
the O +
vehicle O -
/ O -
scopolamine O +
group O +
was O +
significantly O +
lower O +
than O +
that O +
of O +
the O +
vehicle O -
/ O -
vehicle O +
group O -
, O +
but O +
this O +
phenomenon O +
was O +
reversed O +
when O +
s O -
- O -
limonene O +
or O +
s O -
- O -
perillyl O +
alcohol O +
were O +
administered O +
before O +
the O +
injection O +
of O +
scopolamine O -
. O +

Simultaneously O -
, O +
we O +
found O +
that O +
these O +
two O +
lemon O +
essential O +
oil O +
components O +
could O +
inhibit O +
acetylcholinesterase O +
activity O +
in O +
vitro O +
using O +
the O +
Ellman O +
method O -
. O +

Long O +
term O +
hormone O +
therapy O +
for O +
perimenopausal O +
and O +
postmenopausal O +
women O -
. O +

BACKGROUND O -
: O +
Hormone O +
therapy O +
( O -
HT O -
) O +
is O +
widely O +
used O +
for O +
controlling O +
menopausal O +
symptoms O +
and O +
has O +
also O +
been O +
used O +
for O +
the O +
management O +
and O +
prevention O +
of O +
cardiovascular B-Disease +
disease I-Disease -
, O +
osteoporosis B-Disease +
and O +
dementia B-Disease +
in O +
older O +
women O -
. O +

This O +
is O +
an O +
updated O +
version O +
of O +
the O +
original O +
Cochrane O +
review O +
first O +
published O +
in O +
2005 O -
. O +

OBJECTIVES O -
: O +
To O +
assess O +
the O +
effect O +
of O +
long O -
- O -
term O +
HT O +
on O +
mortality O -
, O +
cardiovascular O +
outcomes O -
, O +
cancer B-Disease -
, O +
gallbladder B-Disease +
disease I-Disease -
, O +
cognition O -
, O +
fractures B-Disease +
and O +
quality O +
of O +
life O -
. O +

SEARCH O +
STRATEGY O -
: O +
We O +
searched O +
the O +
following O +
databases O +
to O +
November O +
2007 O -
: O +
Trials O +
Register O +
of O +
the O +
Cochrane O +
Menstrual B-Disease +
Disorders I-Disease +
and O +
Subfertility O +
Group O -
, O +
Cochrane O +
Central O +
Register O +
of O +
Controlled O +
Trials O -
, O +
MEDLINE O -
, O +
EMBASE O -
, O +
Biological O +
Abstracts O -
. O +

Also O +
relevant O +
non O -
- O -
indexed O +
journals O +
and O +
conference O +
abstracts O -
. O +

SELECTION O +
CRITERIA O -
: O +
Randomised O +
double O -
- O -
blind O +
trials O +
of O +
HT O +
versus O +
placebo O -
, O +
taken O +
for O +
at O +
least O +
one O +
year O +
by O +
perimenopausal O +
or O +
postmenopausal O +
women O -
. O +

HT O +
included O +
oestrogens O -
, O +
with O +
or O +
without O +
progestogens O -
, O +
via O +
oral O -
, O +
transdermal O -
, O +
subcutaneous O +
or O +
transnasal O +
routes O -
. O +

DATA O +
COLLECTION O +
AND O +
ANALYSIS O -
: O +
Two O +
authors O +
independently O +
assessed O +
trial O +
quality O +
and O +
extracted O +
data O -
. O +

MAIN O +
RESULTS O -
: O +
Nineteen O +
trials O +
involving O +
41,904 O +
women O +
were O +
included O -
. O +

In O +
relatively O +
healthy O +
women O -
, O +
combined O +
continuous O +
HT O +
significantly O +
increased O +
the O +
risk O +
of O +
venous B-Disease +
thrombo I-Disease -
- I-Disease -
embolism I-Disease +
or O +
coronary O +
event O +
( O -
after O +
one O +
year O -
's O +
use O -
) O -
, O +
stroke B-Disease +
( O -
after O +
three O +
years O -
) O -
, O +
breast B-Disease +
cancer I-Disease +
and O +
gallbladder B-Disease +
disease I-Disease -
. O +

Long O -
- O -
term O +
oestrogen O -
- O -
only O +
HT O +
significantly O +
increased O +
the O +
risk O +
of O +
venous B-Disease +
thrombo I-Disease -
- I-Disease -
embolism I-Disease -
, O +
stroke B-Disease +
and O +
gallbladder B-Disease +
disease I-Disease +
( O -
after O +
one O +
to O +
two O +
years O -
, O +
three O +
years O +
and O +
seven O +
years O -
' O +
use O +
respectively O -
) O -
, O +
but O +
did O +
not O +
significantly O +
increase O +
the O +
risk O +
of O +
breast B-Disease +
cancer I-Disease -
. O +

The O +
only O +
statistically O +
significant O +
benefits O +
of O +
HT O +
were O +
a O +
decreased O +
incidence O +
of O +
fractures B-Disease +
and O +
( O -
for O +
combined O +
HT O -
) O +
colon B-Disease +
cancer I-Disease -
, O +
with O +
long O -
- O -
term O +
use O -
. O +

Among O +
women O +
aged O +
over O +
65 O +
who O +
were O +
relatively O +
healthy O +
( O -
i.e. O +
generally O +
fit O -
, O +
without O +
overt O +
disease O -
) O +
and O +
taking O +
continuous O +
combined O +
HT O -
, O +
there O +
was O +
a O +
statistically O +
significant O +
increase O +
in O +
the O +
incidence O +
of O +
dementia B-Disease -
. O +

Among O +
women O +
with O +
cardiovascular B-Disease +
disease I-Disease -
, O +
long O -
- O -
term O +
use O +
of O +
combined O +
continuous O +
HT O +
significantly O +
increased O +
the O +
risk O +
of O +
venous B-Disease +
thrombo I-Disease -
- I-Disease -
embolism I-Disease -
. O +

One O +
trial O +
analysed O +
subgroups O +
of O +
2839 O +
relatively O +
healthy O +
50 O +
to O +
59 O +
year O +
old O +
women O +
taking O +
combined O +
continuous O +
HT O +
and O +
1637 O +
taking O +
oestrogen O -
- O -
only O +
HT O -
, O +
versus O +
similar O -
- O -
sized O +
placebo O +
groups O -
. O +

The O +
only O +
significantly O +
increased O +
risk O +
reported O +
was O +
for O +
venous B-Disease +
thrombo I-Disease -
- I-Disease -
embolism I-Disease +
in O +
women O +
taking O +
combined O +
continuous O +
HT O -
: O +
their O +
absolute O +
risk O +
remained O +
low O -
, O +
at O +
less O +
than O +
1 O -
/ O -
500 O -
. O +

However O -
, O +
this O +
study O +
was O +
not O +
powered O +
to O +
detect O +
differences O +
between O +
groups O +
of O +
younger O +
women O -
. O +

AUTHORS O -
' O +
CONCLUSIONS O -
: O +
HT O +
is O +
not O +
indicated O +
for O +
the O +
routine O +
management O +
of O +
chronic O +
disease O -
. O +

We O +
need O +
more O +
evidence O +
on O +
the O +
safety O +
of O +
HT O +
for O +
menopausal O +
symptom O +
control O -
, O +
though O +
short O -
- O -
term O +
use O +
appears O +
to O +
be O +
relatively O +
safe O +
for O +
healthy O +
younger O +
women O -
. O +

Attentional O +
modulation O +
of O +
perceived O +
pain B-Disease +
intensity O +
in O +
capsaicin O -
- O -
induced O +
secondary O +
hyperalgesia B-Disease -
. O +

Perceived O +
pain B-Disease +
intensity O +
is O +
modulated O +
by O +
attention O -
. O +

However O -
, O +
it O +
is O +
not O +
known O +
that O +
how O +
pain B-Disease +
intensity O +
ratings O +
are O +
affected O +
by O +
attention O +
in O +
capsaicin O -
- O -
induced O +
secondary O +
hyperalgesia B-Disease -
. O +

Here O +
we O +
show O +
that O +
perceived O +
pain B-Disease +
intensity O +
in O +
secondary O +
hyperalgesia B-Disease +
is O +
decreased O +
when O +
attention O +
is O +
distracted O +
away O +
from O +
the O +
painful O +
pinprick O +
stimulus O +
with O +
a O +
visual O +
task O -
. O +

Furthermore O -
, O +
it O +
was O +
found O +
that O +
the O +
magnitude O +
of O +
attentional O +
modulation O +
in O +
secondary O +
hyperalgesia B-Disease +
is O +
very O +
similar O +
to O +
that O +
of O +
capsaicin O -
- O -
untreated O -
, O +
control O +
condition O -
. O +

Our O +
findings O -
, O +
showing O +
no O +
interaction O +
between O +
capsaicin O +
treatment O +
and O +
attentional O +
modulation O +
suggest O +
that O +
capsaicin O -
- O -
induced O +
secondary O +
hyperalgesia B-Disease +
and O +
attention O +
might O +
affect O +
mechanical O +
pain B-Disease +
through O +
independent O +
mechanisms O -
. O +

Cardioprotective O +
effect O +
of O +
salvianolic O +
acid O +
A O +
on O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
cardioprotective O +
potential O +
of O +
salvianolic O +
acid O +
A O +
on O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
in O +
rats O -
. O +

Hemodynamic O +
parameters O +
and O +
lead O +
II O +
electrocardiograph O +
were O +
monitored O +
and O +
recorded O +
continuously O -
. O +

Cardiac O +
marker O +
enzymes O +
and O +
antioxidative O +
parameters O +
in O +
serum O +
and O +
heart O +
tissues O +
were O +
measured O -
. O +

Assay O +
for O +
mitochondrial O +
respiratory O +
function O +
and O +
histopathological O +
examination O +
of O +
heart O +
tissues O +
were O +
performed O -
. O +

Isoproterenol O -
- O -
treated O +
rats O +
showed O +
significant O +
increases O +
in O +
the O +
levels O +
of O +
lactate O +
dehydrogenase O -
, O +
aspartate O +
transaminase O -
, O +
creatine O +
kinase O +
and O +
malondialdehyde O +
and O +
significant O +
decreases O +
in O +
the O +
activities O +
of O +
superoxide O +
dismutase O -
, O +
catalase O +
and O +
glutathione O +
peroxidase O +
in O +
serum O +
and O +
heart O -
. O +

These O +
rats O +
also O +
showed O +
declines O +
in O +
left O +
ventricular O +
systolic O +
pressure O -
, O +
maximum O +
and O +
minimum O +
rate O +
of O +
developed O +
left O +
ventricular O +
pressure O -
, O +
and O +
elevation O +
of O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
ST O -
- O -
segment O -
. O +

In O +
addition O -
, O +
mitochondrial O +
respiratory B-Disease +
dysfunction I-Disease +
characterized O +
by O +
decreased O +
respiratory O +
control O +
ratio O +
and O +
ADP O -
/ O -
O O +
was O +
observed O +
in O +
isoproterenol O -
- O -
treated O +
rats O -
. O +

Administration O +
of O +
salvianolic O +
acid O +
A O +
for O +
a O +
period O +
of O +
8 O +
days O +
significantly O +
attenuated O +
isoproterenol O -
- O -
induced O +
cardiac B-Disease +
dysfunction I-Disease +
and O +
myocardial B-Disease +
injury I-Disease +
and O +
improved O +
mitochondrial O +
respiratory O +
function O -
. O +

The O +
protective O +
role O +
of O +
salvianolic O +
acid O +
A O +
against O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
damage I-Disease +
was O +
further O +
confirmed O +
by O +
histopathological O +
examination O -
. O +

The O +
results O +
of O +
our O +
study O +
suggest O +
that O +
salvianolic O +
acid O +
A O +
possessing O +
antioxidant O +
activity O +
has O +
a O +
significant O +
protective O +
effect O +
against O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease -
. O +

Long O -
- O -
term O +
glutamate O +
supplementation O +
failed O +
to O +
protect O +
against O +
peripheral B-Disease +
neurotoxicity I-Disease +
of O +
paclitaxel O -
. O +

Toxic O +
peripheral B-Disease +
neuropathy I-Disease +
is O +
still O +
a O +
significant O +
limiting O +
factor O +
for O +
chemotherapy O +
with O +
paclitaxel O +
( O -
PAC O -
) O -
, O +
although O +
glutamate O +
and O +
its O +
closely O +
related O +
amino O +
acid O +
glutamine O +
were O +
claimed O +
to O +
ameliorate O +
PAC O +
neurotoxicity B-Disease -
. O +

This O +
pilot O +
trial O +
aimed O +
to O +
evaluate O +
the O +
role O +
of O +
glutamate O +
supplementation O +
for O +
preventing O +
PAC O -
- O -
induced O +
peripheral B-Disease +
neuropathy I-Disease +
in O +
a O +
randomized O -
, O +
placebo O -
- O -
controlled O -
, O +
double O -
- O -
blinded O +
clinical O +
and O +
electro O -
- O -
diagnostic O +
study O -
. O +

Forty O -
- O -
three O +
ovarian B-Disease +
cancer I-Disease +
patients O +
were O +
available O +
for O +
analysis O +
following O +
six O +
cycles O +
of O +
the O +
same O +
PAC O -
- O -
containing O +
regimen O -
: O +
23 O +
had O +
been O +
supplemented O +
by O +
glutamate O +
all O +
along O +
the O +
treatment O +
period O -
, O +
at O +
a O +
daily O +
dose O +
of O +
three O +
times O +
500 O +
mg O +
( O -
group O +
G O -
) O -
, O +
and O +
20 O +
had O +
received O +
a O +
placebo O +
( O -
group O +
P O -
) O -
. O +

Patients O +
were O +
evaluated O +
by O +
neurological O +
examinations O -
, O +
questionnaires O +
and O +
sensory O -
- O -
motor O +
nerve O +
conduction O +
studies O -
. O +

There O +
was O +
no O +
significant O +
difference O +
in O +
the O +
frequency O +
of O +
signs O +
or O +
symptoms O +
between O +
the O +
two O +
groups O +
although O +
neurotoxicity B-Disease +
symptoms O +
presented O +
mostly O +
with O +
lower O +
scores O +
of O +
severity O +
in O +
group O +
G. O +
However O -
, O +
this O +
difference O +
reached O +
statistical O +
significance O +
only O +
with O +
regard O +
to O +
reported O +
pain B-Disease +
sensation O +
( O -
P O +
= O +
0.011 O -
) O -
. O +

Also O +
the O +
frequency O +
of O +
abnormal O +
electro O -
- O -
diagnostic O +
findings O +
showed O +
similarity O +
between O +
the O +
two O +
groups O +
( O -
G O -
: O +
7 O -
/ O -
23 O +
= O +
30.4 O -
% O -
; O +
P O -
: O +
6 O -
/ O -
20 O +
= O +
30 O -
% O -
) O -
. O +

This O +
pilot O +
study O +
leads O +
to O +
the O +
conclusion O +
that O +
glutamate O +
supplementation O +
at O +
the O +
chosen O +
regimen O +
fails O +
to O +
protect O +
against O +
peripheral B-Disease +
neurotoxicity I-Disease +
of O +
PAC O -
. O +

Development O +
of O +
ocular B-Disease +
myasthenia I-Disease +
during O +
pegylated O +
interferon O +
and O +
ribavirin O +
treatment O +
for O +
chronic B-Disease +
hepatitis I-Disease +
C. I-Disease +
A O +
63-year O -
- O -
old O +
male O +
experienced O +
sudden O +
diplopia B-Disease +
after O +
9 O +
weeks O +
of O +
administration O +
of O +
pegylated O +
interferon O +
( O -
IFN O -
) O +
alpha-2b O +
and O +
ribavirin O +
for O +
chronic B-Disease +
hepatitis I-Disease +
C I-Disease +
( O -
CHC B-Disease -
) O -
. O +

Ophthalmologic O +
examinations O +
showed O +
ptosis B-Disease +
on I-Disease +
the I-Disease +
right I-Disease +
upper I-Disease +
lid I-Disease +
and O +
restricted B-Disease +
right I-Disease +
eye I-Disease +
movement I-Disease +
without O +
any O +
other O +
neurological O +
signs O -
. O +

A O +
brain O +
imaging O +
study O +
and O +
repetitive O +
nerve O +
stimulation O +
test O +
indicated O +
no O +
abnormality O -
. O +

The O +
acetylcholine O +
receptor O +
antibody O +
titer O +
and O +
response O +
to O +
acetylcholinesterase O +
inhibitors O +
were O +
negative O -
, O +
and O +
the O +
results O +
of O +
thyroid O +
function O +
tests O +
were O +
normal O -
. O +

The O +
patient O -
's O +
ophthalmological O +
symptoms O +
improved O +
rapidly O +
3 O +
weeks O +
after O +
discontinuation O +
of O +
pegylated O +
IFN O +
alpha-2b O +
and O +
ribavirin O -
. O +

The O +
ocular B-Disease +
myasthenia I-Disease +
associated O +
with O +
combination O +
therapy O +
of O +
pegylated O +
IFN O +
alpha-2b O +
and O +
ribavirin O +
for O +
CHC B-Disease +
is O +
very O +
rarely O +
reported O -
; O +
therefore O -
, O +
we O +
present O +
this O +
case O +
with O +
a O +
review O +
of O +
the O +
various O +
eye O +
complications O +
of O +
IFN O +
therapy O -
. O +

Learning B-Disease +
and I-Disease +
memory I-Disease +
deficits I-Disease +
in O +
ecstasy O +
users O +
and O +
their O +
neural O +
correlates O +
during O +
a O +
face O -
- O -
learning O +
task O -
. O +

It O +
has O +
been O +
consistently O +
shown O +
that O +
ecstasy O +
users O +
display O +
impairments B-Disease +
in I-Disease +
learning I-Disease +
and B-Disease +
memory I-Disease +
performance O -
. O +

In O +
addition O -
, O +
working O +
memory O +
processing O +
in O +
ecstasy O +
users O +
has O +
been O +
shown O +
to O +
be O +
associated O +
with O +
neural O +
alterations O +
in O +
hippocampal O +
and/or O +
cortical O +
regions O +
as O +
measured O +
by O +
functional O +
magnetic O +
resonance O +
imaging O +
( O -
fMRI O -
) O -
. O +

Using O +
functional O +
imaging O +
and O +
a O +
face O -
- O -
learning O +
task O -
, O +
we O +
investigated O +
neural O +
correlates O +
of O +
encoding O +
and O +
recalling O +
face O -
- O -
name O +
associations O +
in O +
20 O +
recreational O +
drug O +
users O +
whose O +
predominant O +
drug O +
use O +
was O +
ecstasy O +
and O +
20 O +
controls O -
. O +

To O +
address O +
the O +
potential O +
confounding O +
effects O +
of O +
the O +
cannabis O +
use O +
of O +
the O +
ecstasy O +
using O +
group O -
, O +
a O +
second O +
analysis O +
included O +
14 O +
previously O +
tested O +
cannabis O +
users O +
( O -
Nestor O -
, O +
L. O -
, O +
Roberts O -
, O +
G. O -
, O +
Garavan O -
, O +
H. O -
, O +
Hester O -
, O +
R. O -
, O +
2008 O -
. O +

Deficits B-Disease +
in I-Disease +
learning I-Disease +
and B-Disease +
memory I-Disease -
: O +
parahippocampal O +
hyperactivity B-Disease +
and O +
frontocortical O +
hypoactivity O +
in O +
cannabis O +
users O -
. O +

Neuroimage O +
40 O -
, O +
1328 O -
- O -
1339 O -
) O -
. O +

Ecstasy O +
users O +
performed O +
significantly O +
worse O +
in O +
learning O +
and O +
memory O +
compared O +
to O +
controls O +
and O +
cannabis O +
users O -
. O +

A O +
conjunction O +
analysis O +
of O +
the O +
encode O +
and O +
recall O +
phases O +
of O +
the O +
task O +
revealed O +
ecstasy O -
- O -
specific O +
hyperactivity B-Disease +
in O +
bilateral O +
frontal O +
regions O -
, O +
left O +
temporal O -
, O +
right O +
parietal O -
, O +
bilateral O +
temporal O -
, O +
and O +
bilateral O +
occipital O +
brain O +
regions O -
. O +

Ecstasy O -
- O -
specific O +
hypoactivity O +
was O +
evident O +
in O +
the O +
right O +
dorsal O +
anterior O +
cingulated O +
cortex O +
( O -
ACC O -
) O +
and O +
left O +
posterior O +
cingulated O +
cortex O -
. O +

In O +
both O +
ecstasy O +
and O +
cannabis O +
groups O +
brain O +
activation O +
was O +
decreased O +
in O +
the O +
right O +
medial O +
frontal O +
gyrus O -
, O +
left O +
parahippocampal O +
gyrus O -
, O +
left O +
dorsal O +
cingulate O +
gyrus O -
, O +
and O +
left O +
caudate O -
. O +

These O +
results O +
elucidated O +
ecstasy O -
- O -
related O +
deficits O -
, O +
only O +
some O +
of O +
which O +
might O +
be O +
attributed O +
to O +
cannabis O +
use O -
. O +

These O +
ecstasy O -
- O -
specific O +
effects O +
may O +
be O +
related O +
to O +
the O +
vulnerability O +
of O +
isocortical O +
and O +
allocortical O +
regions O +
to O +
the O +
neurotoxic B-Disease +
effects O +
of O +
ecstasy O -
. O +

Acute B-Disease +
renal I-Disease +
failure I-Disease +
in O +
patients O +
with O +
AIDS B-Disease +
on O +
tenofovir O +
while O +
receiving O +
prolonged O +
vancomycin O +
course O +
for O +
osteomyelitis B-Disease -
. O +

Renal B-Disease +
failure I-Disease +
developed O +
after O +
a O +
prolonged O +
course O +
of O +
vancomycin O +
therapy O +
in O +
2 O +
patients O +
who O +
were O +
receiving O +
tenofovir O +
disoproxil O +
fumarate O +
as O +
part O +
of O +
an O +
antiretroviral O +
regimen O -
. O +

Tenofovir O +
has O +
been O +
implicated O +
in O +
the O +
development O +
of O +
Fanconi B-Disease +
syndrome I-Disease +
and O +
renal B-Disease +
insufficiency I-Disease +
because O +
of O +
its O +
effects O +
on O +
the O +
proximal O +
renal O +
tubule O -
. O +

Vancomycin O +
nephrotoxicity B-Disease +
is O +
infrequent O +
but O +
may O +
result O +
from O +
coadministration O +
with O +
a O +
nephrotoxic B-Disease +
agent O -
. O +

Clinicians O +
should O +
be O +
aware O +
that O +
tenofovir O +
may O +
raise O +
the O +
risk O +
of O +
renal B-Disease +
failure I-Disease +
during O +
prolonged O +
administration O +
of O +
vancomycin O -
. O +

Disulfiram O -
- O -
like O +
syndrome O +
after O +
hydrogen O +
cyanamide O +
professional O +
skin O +
exposure O -
: O +
two O +
case O +
reports O +
in O +
France O -
. O +

Hydrogen O +
cyanamide O +
is O +
a O +
plant O +
growth O +
regulator O +
used O +
in O +
agriculture O +
to O +
induce O +
bud O +
break O +
in O +
fruit O +
trees O -
. O +

Contact O +
with O +
the O +
skin O +
can O +
result O +
in O +
percutaneous O +
absorption O +
of O +
the O +
substance O +
that O +
inhibits O +
aldehyde O +
dehydrogenase O +
and O +
can O +
induce O +
acetaldehyde O +
syndrome O +
in O +
case O +
of O +
alcohol O +
use O -
. O +

The O +
purpose O +
of O +
this O +
report O +
is O +
to O +
describe O +
two O +
cases O +
of O +
a O +
disulfiram O -
- O -
like O +
syndrome O +
following O +
occupational O +
exposure O +
to O +
hydrogen O +
cyanamide O -
. O +

The O +
first O +
case O +
involved O +
a O +
59-year O -
- O -
old O +
man O +
who O +
used O +
Dormex O -
, O +
which O +
contains O +
hydrogen O +
cyanamide O -
, O +
without O +
protection O +
after O +
consuming O +
a O +
large O +
amount O +
of O +
alcohol O +
during O +
a O +
meal O -
. O +

In O +
less O +
than O +
1 O +
hour O +
after O +
the O +
ingestion O +
of O +
alcohol O -
, O +
he O +
developed O +
malaise O +
with O +
flushing B-Disease +
of I-Disease +
the I-Disease +
face I-Disease -
, O +
tachycardia B-Disease -
, O +
and O +
dyspnea B-Disease -
. O +

Manifestations O +
regressed O +
spontaneously O +
under O +
surveillance O +
in O +
the O +
hospital O -
. O +

The O +
second O +
case O +
occurred O +
in O +
a O +
55-year O -
- O -
old O +
farmer O +
following O +
cutaneous O +
contact O +
with O +
Dormex O -
. O +

Five O +
hours O +
after O +
exposure O -
, O +
he O +
developed O +
disulfiram O -
- O -
like O +
syndrome O +
with O +
flushing B-Disease -
, O +
tachycardia B-Disease -
, O +
and O +
arterial B-Disease +
hypotension I-Disease +
after O +
consuming O +
three O +
glasses O +
of O +
wine O -
. O +

The O +
patient O +
recovered O +
spontaneously O +
in O +
3 O +
hours O +
under O +
surveillance O +
in O +
the O +
hospital O -
. O +

These O +
cases O +
confirm O +
the O +
necessity O +
of O +
avoiding O +
alcohol O +
consumption O +
as O +
recommended O +
in O +
the O +
instructions O +
for O +
use O +
of O +
Dormex O +
and O +
of O +
preventing O +
cutaneous O +
contact O +
during O +
use O -
. O +

Recurrent O +
dysosmia B-Disease +
induced O +
by O +
pyrazinamide O -
. O +

Pyrazinamide O +
can O +
have O +
adverse O +
effects O +
such O +
as O +
hepatic B-Disease +
toxicity I-Disease -
, O +
hyperuricemia B-Disease +
or O +
digestive O +
disorders O -
. O +

In O +
rare O +
cases O -
, O +
alterations O +
in O +
taste O +
and O +
smell O +
function O +
have O +
been O +
reported O +
for O +
pyrazinamide O +
when O +
combined O +
with O +
other O +
drugs O -
. O +

We O +
report O +
a O +
case O +
of O +
reversible O +
olfactory B-Disease +
disorder I-Disease +
related O +
to O +
pyrazinamide O +
in O +
a O +
woman O -
, O +
with O +
a O +
positive O +
rechallenge O -
. O +

The O +
patient O +
presented O +
every O +
day O +
a O +
sensation O +
of O +
smelling O +
something O +
burning O +
15 O +
min O +
after O +
drug O +
intake O -
. O +

Dysosmia B-Disease +
disappeared O +
completely O +
after O +
pyrazinamide O +
withdrawal O +
and O +
recurred O +
after O +
its O +
rechallenge O -
. O +

The O +
case O +
was O +
reported O +
to O +
the O +
Tunisian O +
Centre O +
of O +
Pharmacovigilance O -
. O +

Sulpiride O -
- O -
induced O +
tardive B-Disease +
dystonia I-Disease -
. O +

Sulpiride O +
is O +
a O +
selective O +
D2-receptor O +
antagonist O +
with O +
antipsychotic O +
and O +
antidepressant O +
properties O -
. O +

Although O +
initially O +
thought O +
to O +
be O +
free O +
of O +
extrapyramidal O +
side O +
effects O -
, O +
sulpiride O -
- O -
induced O +
tardive B-Disease +
dyskinesia I-Disease +
and O +
parkinsonism B-Disease +
have O +
been O +
reported O +
occasionally O -
. O +

We O +
studied O +
a O +
37-year O -
- O -
old O +
man O +
who O +
developed O +
persistent O +
segmental O +
dystonia B-Disease +
within O +
2 O +
months O +
after O +
starting O +
sulpiride O +
therapy O -
. O +

We O +
could O +
not O +
find O +
any O +
previous O +
reports O +
of O +
sulpiride O -
- O -
induced O +
tardive B-Disease +
dystonia I-Disease -
. O +

Mice O +
lacking O +
mPGES-1 O +
are O +
resistant O +
to O +
lithium O -
- O -
induced O +
polyuria B-Disease -
. O +

Cyclooxygenase-2 O +
activity O +
is O +
required O +
for O +
the O +
development O +
of O +
lithium O -
- O -
induced O +
polyuria B-Disease -
. O +

However O -
, O +
the O +
involvement O +
of O +
a O +
specific O -
, O +
terminal O +
prostaglandin O +
( O -
PG O -
) O +
isomerase O +
has O +
not O +
been O +
evaluated O -
. O +

The O +
present O +
study O +
was O +
undertaken O +
to O +
assess O +
lithium O -
- O -
induced O +
polyuria B-Disease +
in O +
mice O +
deficient O +
in O +
microsomal O +
prostaglandin O +
E O +
synthase-1 O +
( O -
mPGES-1 O -
) O -
. O +

A O +
2-wk O +
administration O +
of O +
LiCl O +
( O -
4 O +
mmol.kg O -
( O -
-1 O -
) O -
.day O -
( O -
-1 O -
) O +
ip O -
) O +
in O +
mPGES-1 O +
+ O -
/+ O +
mice O +
led O +
to O +
a O +
marked O +
polyuria B-Disease +
with O +
hyposmotic O +
urine O -
. O +

This O +
was O +
associated O +
with O +
elevated O +
renal O +
mPGES-1 O +
protein O +
expression O +
and O +
increased O +
urine O +
PGE O -
( O -
2 O -
) O +
excretion O -
. O +

In O +
contrast O -
, O +
mPGES-1 O +
- O -
/ O -
- O +
mice O +
were O +
largely O +
resistant O +
to O +
lithium O -
- O -
induced O +
polyuria B-Disease +
and O +
a O +
urine O +
concentrating O +
defect O -
, O +
accompanied O +
by O +
nearly O +
complete O +
blockade O +
of O +
high O +
urine O +
PGE O -
( O -
2 O -
) O +
and O +
cAMP O +
output O -
. O +

Immunoblotting O -
, O +
immunohistochemistry O -
, O +
and O +
quantitative O +
( O -
q O -
) O +
RT O -
- O -
PCR O +
consistently O +
detected O +
a O +
significant O +
decrease O +
in O +
aquaporin-2 O +
( O -
AQP2 O -
) O +
protein O +
expression O +
in O +
both O +
the O +
renal O +
cortex O +
and O +
medulla O +
of O +
lithium O -
- O -
treated O +
+ O -
/+ O +
mice O -
. O +

This O +
decrease O +
was O +
significantly O +
attenuated O +
in O +
the O +
- O -
/ O -
- O +
mice O -
. O +

qRT O -
- O -
PCR O +
detected O +
similar O +
patterns O +
of O +
changes O +
in O +
AQP2 O +
mRNA O +
in O +
the O +
medulla O +
but O +
not O +
in O +
the O +
cortex O -
. O +

Similarly O -
, O +
the O +
total O +
protein O +
abundance O +
of O +
the O +
Na O -
- O -
K-2Cl O +
cotransporter O +
( O -
NKCC2 O -
) O +
in O +
the O +
medulla O +
but O +
not O +
in O +
the O +
cortex O +
of O +
the O +
+ O -
/+ O +
mice O +
was O +
significantly O +
reduced O +
by O +
lithium O +
treatment O -
. O +

In O +
contrast O -
, O +
the O +
dowregulation O +
of O +
renal O +
medullary O +
NKCC2 O +
expression O +
was O +
significantly O +
attenuated O +
in O +
the O +
- O -
/ O -
- O +
mice O -
. O +

We O +
conclude O +
that O +
mPGES-1-derived O +
PGE O -
( O -
2 O -
) O +
mediates O +
lithium O -
- O -
induced O +
polyuria B-Disease +
likely O +
via O +
inhibition O +
of O +
AQP2 O +
and O +
NKCC2 O +
expression O -
. O +

Preservation O +
of O +
renal O +
blood O +
flow O +
during O +
hypotension B-Disease +
induced O +
with O +
fenoldopam O +
in O +
dogs O -
. O +

The O +
introduction O +
of O +
drugs O +
that O +
could O +
induce O +
hypotension B-Disease +
with O +
different O +
pharmacological O +
actions O +
would O +
be O +
advantageous O +
because O +
side O +
effects O +
unique O +
to O +
a O +
specific O +
drug O +
could O +
be O +
minimized O +
by O +
selecting O +
appropriate O +
therapy O -
. O +

Specific O +
dopamine-1 O -
, O +
( O -
DA1 O -
) O +
and O +
dopamine-2 O +
( O -
DA2 O -
) O +
receptor O +
agonists O +
are O +
now O +
under O +
clinical O +
investigation O -
. O +

Fenoldopam O +
mesylate O +
is O +
a O +
specific O +
DA1 O +
receptor O +
agonist O +
that O +
lowers O +
blood O +
pressure O +
by O +
vasodilatation O -
. O +

The O +
hypothesis O +
that O +
fenoldopam O +
could O +
be O +
used O +
to O +
induce O +
hypotension B-Disease +
and O +
preserve O +
blood O +
flow O +
to O +
the O +
kidney O +
was O +
tested O -
. O +

Systemic O +
aortic O +
blood O +
pressure O +
and O +
renal O +
blood O +
flow O +
were O +
measured O +
continuously O +
with O +
a O +
carotid O +
arterial O +
catheter O +
and O +
an O +
electromagnetic O +
flow O +
probe O +
respectively O -
, O +
in O +
order O +
to O +
compare O +
the O +
cardiovascular O +
and O +
renal O +
vascular O +
effects O +
of O +
fenoldopam O +
and O +
sodium O +
nitroprusside O +
in O +
ten O +
dogs O +
under O +
halothane O +
general O +
anaesthesia O -
. O +

Mean O +
arterial O +
pressure O +
was O +
decreased O +
30 O +
+ O -
/- O +

8 O +
per O +
cent O +
from O +
control O +
with O +
infusion O +
of O +
fenoldopam O +
( O -
3.4 O +
+ O -
/- O +

2.0 O +
micrograms.kg-1.min-1 O -
) O +
and O +
34 O +
+ O -
/- O +

4 O +
per O +
cent O +
with O +
infusion O +
of O +
sodium O +
nitroprusside O +
( O -
5.9 O +
micrograms.kg-1.min-1 O -
) O +
( O -
NS O -
) O -
. O +

Renal O +
blood O +
flow O +
( O -
RBF O -
) O +
increased O +
during O +
fenoldopam O -
- O -
induced O +
hypotension B-Disease +
11 O +
+ O -
/- O +

7 O +
per O +
cent O +
and O +
decreased O +
21 O +
+ O -
/- O +

8 O +
per O +
cent O +
during O +
sodium O +
nitroprusside O -
- O -
induced O +
hypotension B-Disease +
( O -
P O +
less O +
than O +
0.01 O -
) O -
. O +

Sodium O +
nitroprusside O +
is O +
a O +
non O -
- O -
selective O +
arteriolar O +
and O +
venous O +
vasodilator O +
that O +
can O +
produce O +
redistribution O +
of O +
blood O +
flow O +
away O +
from O +
the O +
kidney O +
during O +
induced O +
hypotension B-Disease -
. O +

Fenoldopam O +
is O +
a O +
selective O +
dopamine-1 O +
( O -
DA1 O -
) O +
receptor O +
agonist O +
that O +
causes O +
vasodilatation O +
to O +
the O +
kidney O +
and O +
other O +
organs O +
with O +
DA1 O +
receptors O +
and O +
preserves O +
blood O +
flow O +
to O +
the O +
kidney O +
during O +
induced O +
hypotension B-Disease -
. O +

Seizures B-Disease +
associated O +
with O +
levofloxacin O -
: O +
case O +
presentation O +
and O +
literature O +
review O -
. O +

PURPOSE O -
: O +
We O +
present O +
a O +
case O +
of O +
a O +
patient O +
who O +
developed O +
seizures B-Disease +
shortly O +
after O +
initiating O +
treatment O +
with O +
levofloxacin O +
and O +
to O +
discuss O +
the O +
potential O +
drug O -
- O -
drug O +
interactions O +
related O +
to O +
the O +
inhibition O +
of O +
cytochrome O +
P450 O +
( O -
CYP O -
) O +
1A2 O +
in O +
this O +
case O -
, O +
as O +
well O +
as O +
in O +
other O +
cases O -
, O +
of O +
levofloxacin O -
- O -
induced O +
seizures B-Disease -
. O +

METHODS O -
: O +
Several O +
biomedical O +
databases O +
were O +
searched O +
including O +
MEDLINE O -
, O +
Cochrane O +
and O +
Ovid O -
. O +

The O +
main O +
search O +
terms O +
utilized O +
were O +
case O +
report O +
and O +
levofloxacin O -
. O +

The O +
search O +
was O +
limited O +
to O +
studies O +
published O +
in O +
English O -
. O +

RESULTS O -
: O +
Six O +
cases O +
of O +
levofloxacin O -
- O -
induced O +
seizures B-Disease +
have O +
been O +
reported O +
in O +
the O +
literature O -
. O +

Drug O -
- O -
drug O +
interactions O +
related O +
to O +
the O +
inhibition O +
of O +
CYP1A2 O +
by O +
levofloxacin O +
are O +
likely O +
involved O +
in O +
the O +
clinical O +
outcome O +
of O +
these O +
cases O -
. O +

CONCLUSIONS O -
: O +
Clinicians O +
are O +
exhorted O +
to O +
pay O +
close O +
attention O +
when O +
initiating O +
levofloxacin O +
therapy O +
in O +
patients O +
taking O +
medications O +
with O +
epileptogenic O +
properties O +
that O +
are O +
CYP1A2 O +
substrates O -
. O +

The O +
antiarrhythmic O +
effect O +
and O +
possible O +
ionic O +
mechanisms O +
of O +
pilocarpine O +
on O +
animal O +
models O -
. O +

This O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
effects O +
of O +
pilocarpine O +
and O +
explore O +
the O +
underlying O +
ionic O +
mechanism O -
, O +
using O +
both O +
aconitine O -
- O -
induced O +
rat O +
and O +
ouabain O -
- O -
induced O +
guinea O +
pig O +
arrhythmia B-Disease +
models O -
. O +

Confocal O +
microscopy O +
was O +
used O +
to O +
measure O +
intracellular O +
free O -
- O -
calcium O +
concentrations O +
( O -
[ O -
Ca O -
( O -
2+ O -
) O -
] O -
( O -
i O -
) O -
) O +
in O +
isolated O +
myocytes O -
. O +

The O +
current O +
data O +
showed O +
that O +
pilocarpine O +
significantly O +
delayed O +
onset O +
of O +
arrhythmias B-Disease -
, O +
decreased O +
the O +
time O +
course O +
of O +
ventricular B-Disease +
tachycardia I-Disease +
and B-Disease +
fibrillation I-Disease -
, O +
reduced O +
arrhythmia B-Disease +
score O -
, O +
and O +
increased O +
the O +
survival O +
time O +
of O +
arrhythmic B-Disease +
rats O +
and O +
guinea O +
pigs O -
. O +

[ O -
Ca O -
( O -
2+ O -
) O -
] O -
( O -
i O -
) O +
overload O +
induced O +
by O +
aconitine O +
or O +
ouabain O +
was O +
reduced O +
in O +
isolated O +
myocytes O +
pretreated O +
with O +
pilocarpine O -
. O +

Moreover O -
, O +
M O -
( O -
3 O -
) O -
-muscarinic O +
acetylcholine O +
receptor O +
( O -
mAChR O -
) O +
antagonist O +
4-DAMP O +
( O -
4-diphenylacetoxy O -
- O -
N O -
- O -
methylpiperidine O -
- O -
methiodide O -
) O +
partially O +
abolished O +
the O +
beneficial O +
effects O +
of O +
pilocarpine O -
. O +

These O +
data O +
suggest O +
that O +
pilocarpine O +
produced O +
antiarrhythmic O +
actions O +
on O +
arrhythmic B-Disease +
rat O +
and O +
guinea O +
pig O +
models O +
induced O +
by O +
aconitine O +
or O +
ouabain O +
via O +
stimulating O +
the O +
cardiac O +
M O -
( O -
3 O -
) O -
-mAChR. O +
The O +
mechanism O +
may O +
be O +
related O +
to O +
the O +
improvement O +
of O +
Ca O -
( O -
2 O -
+ O -
) O +
handling O -
. O +

Comparative O +
cognitive O +
and O +
subjective O +
side O +
effects O +
of O +
immediate O -
- O -
release O +
oxycodone O +
in O +
healthy O +
middle O -
- O -
aged O +
and O +
older O +
adults O -
. O +

This O +
study O +
measured O +
the O +
objective O +
and O +
subjective O +
neurocognitive O +
effects O +
of O +
a O +
single O +
10-mg O +
dose O +
of O +
immediate O -
- O -
release O +
oxycodone O +
in O +
healthy O -
, O +
older O +
( O -
> O +
65 O +
years O -
) O -
, O +
and O +
middle O -
- O -
aged O +
( O -
35 O +
to O +
55 O +
years O -
) O +
adults O +
who O +
were O +
not O +
suffering O +
from O +
chronic O +
or O +
significant O +
daily O +
pain B-Disease -
. O +

Seventy O -
- O -
one O +
participants O +
completed O +
2 O +
separate O +
study O +
days O +
and O +
were O +
blind O +
to O +
medication O +
condition O +
( O -
placebo O -
, O +
10-mg O +
oxycodone O -
) O -
. O +

Plasma O +
oxycodone O +
concentration O +
peaked O +
between O +
60 O +
and O +
90 O +
minutes O +
postdose O +
( O -
P O +
< O +
.01 O -
) O +
and O +
pupil O +
size O -
, O +
an O +
indication O +
of O +
physiological O +
effects O +
of O +
the O +
medication O -
, O +
peaked O +
at O +
approximately O +
90 O +
to O +
120 O +
minutes O +
postdose O +
( O -
P O +
< O +
.01 O -
) O -
. O +

Significant O +
declines B-Disease +
in I-Disease +
simple I-Disease +
and I-Disease +
sustained I-Disease +
attention I-Disease -
, B-Disease +
working I-Disease +
memory I-Disease -
, I-Disease +
and I-Disease +
verbal I-Disease +
memory I-Disease +
were O +
observed O +
at O +
1 O +
hour O +
postdose O +
compared O +
to O +
baseline O +
for O +
both O +
age O +
groups O +
with O +
a O +
trend O +
toward O +
return O +
to O +
baseline O +
by O +
5 O +
hours O +
postdose O -
. O +

For O +
almost O +
all O +
cognitive O +
measures O -
, O +
there O +
were O +
no O +
medication O +
by O +
age O -
- O -
interaction O +
effects O -
, O +
which O +
indicates O +
that O +
the O +
2 O +
age O +
groups O +
exhibited O +
similar O +
responses O +
to O +
the O +
medication O +
challenge O -
. O +

This O +
study O +
suggests O +
that O +
for O +
healthy O +
older O +
adults O +
who O +
are O +
not O +
suffering O +
from O +
chronic B-Disease +
pain I-Disease -
, O +
neurocognitive O +
and O +
pharmacodynamic O +
changes O +
in O +
response O +
to O +
a O +
10-mg O +
dose O +
of O +
immediate O -
- O -
release O +
oxycodone O +
are O +
similar O +
to O +
those O +
observed O +
for O +
middle O -
- O -
aged O +
adults O -
. O +

PERSPECTIVE O -
: O +
Study O +
findings O +
indicate O +
that O +
the O +
metabolism O -
, O +
neurocognitive O +
effects O -
, O +
and O +
physical O +
side O +
effects O +
of O +
oral O +
oxycodone O +
are O +
similar O +
for O +
healthy O +
middle O -
- O -
aged O +
and O +
older O +
adults O -
. O +

Therefore O -
, O +
clinicians O +
should O +
not O +
avoid O +
prescribing O +
oral O +
opioids O +
to O +
older O +
adults O +
based O +
on O +
the O +
belief O +
that O +
older O +
adults O +
are O +
at O +
higher O +
risk O +
for O +
side O +
effects O +
than O +
younger O +
adults O -
. O +

The O +
glycine O +
transporter-1 O +
inhibitor O +
SSR103800 O +
displays O +
a O +
selective O +
and O +
specific O +
antipsychotic O -
- O -
like O +
profile O +
in O +
normal O +
and O +
transgenic O +
mice O -
. O +

Schizophrenia B-Disease +
has O +
been O +
initially O +
associated O +
with O +
dysfunction O +
in O +
dopamine O +
neurotransmission O -
. O +

However O -
, O +
the O +
observation O +
that O +
antagonists O +
of O +
the O +
glutamate O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptor O +
produce O +
schizophrenic B-Disease -
- O -
like O +
symptoms O +
in O +
humans O +
has O +
led O +
to O +
the O +
idea O +
of O +
a O +
dysfunctioning O +
of O +
the O +
glutamatergic O +
system O +
via O +
its O +
NMDA O +
receptor O -
. O +

As O +
a O +
result O -
, O +
there O +
is O +
a O +
growing O +
interest O +
in O +
the O +
development O +
of O +
pharmacological O +
agents O +
with O +
potential O +
antipsychotic O +
properties O +
that O +
enhance O +
the O +
activity O +
of O +
the O +
glutamatergic O +
system O +
via O +
a O +
modulation O +
of O +
the O +
NMDA O +
receptor O -
. O +

Among O +
them O +
are O +
glycine O +
transporter-1 O +
( O -
GlyT1 O -
) O +
inhibitors O +
such O +
as O +
SSR103800 O -
, O +
which O +
indirectly O +
enhance O +
NMDA O +
receptor O +
function O +
by O +
increasing O +
the O +
glycine O +
( O -
a O +
co O -
- O -
agonist O +
for O +
the O +
NMDA O +
receptor O -
) O +
levels O +
in O +
the O +
synapse O -
. O +

This O +
study O +
aimed O +
at O +
investigating O +
the O +
potential O +
antipsychotic O -
- O -
like O +
properties O +
of O +
SSR103800 O -
, O +
with O +
a O +
particular O +
focus O +
on O +
models O +
of O +
hyperactivity B-Disease -
, O +
involving O +
either O +
drug O +
challenge O +
( O -
ie O -
, O +
amphetamine O +
and O +
MK-801 O -
) O +
or O +
transgenic O +
mice O +
( O -
ie O -
, O +
NMDA O +
Nr1 O -
( O -
neo- O -
/ O -
- O -
) O +
and O +
DAT O -
( O -
- O -
/ O -
- O -
) O -
) O -
. O +

Results O +
showed O +
that O +
SSR103800 O +
( O -
10 O -
- O -
30 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O +
blocked O +
hyperactivity B-Disease +
induced O +
by O +
the O +
non O -
- O -
competitive O +
NMDA O +
receptor O +
antagonist O -
, O +
MK-801 O +
and O +
partially O +
reversed O +
spontaneous O +
hyperactivity B-Disease +
of O +
NMDA O +
Nr1 O -
( O -
neo- O -
/ O -
- O -
) O +
mice O -
. O +

In O +
contrast O -
, O +
SSR103800 O +
failed O +
to O +
affect O +
hyperactivity B-Disease +
induced O +
by O +
amphetamine O +
or O +
naturally O +
observed O +
in O +
dopamine O +
transporter O +
( O -
DAT O -
( O -
- O -
/ O -
- O -
) O -
) O +
knockout O +
mice O +
( O -
10 O -
- O -
30 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O -
. O +

Importantly O -
, O +
both O +
classical O +
( O -
haloperidol O -
) O +
and O +
atypical O +
( O -
olanzapine O -
, O +
clozapine O +
and O +
aripiprazole O -
) O +
antipsychotics O +
were O +
effective O +
in O +
all O +
these O +
models O +
of O +
hyperactivity B-Disease -
. O +

However O -
, O +
unlike O +
these O +
latter O -
, O +
SSR103800 O +
did O +
not O +
produce O +
catalepsy B-Disease +
( O -
retention O +
on O +
the O +
bar O +
test O -
) O +
up O +
to O +
30 O +
mg O -
/ O -
kg O +
p.o O -
. O +

Together O +
these O +
findings O +
show O +
that O +
the O +
GlyT1 O +
inhibitor O -
, O +
SSR103800 O -
, O +
produces O +
antipsychotic O -
- O -
like O +
effects O -
, O +
which O +
differ O +
from O +
those O +
observed O +
with O +
compounds O +
primarily O +
targeting O +
the O +
dopaminergic O +
system O -
, O +
and O +
has O +
a O +
reduced O +
side O -
- O -
effect O +
potential O +
as O +
compared O +
with O +
these O +
latter O +
drugs O -
. O +

Effect O +
of O +
Hibiscus O +
rosa O +
sinensis O +
on O +
reserpine O -
- O -
induced O +
neurobehavioral O +
and O +
biochemical O +
alterations O +
in O +
rats O -
. O +

Effect O +
of O +
methanolic O +
extract O +
of O +
Hibiscus O +
rosa O +
sinensis O +
( O -
100 O -
- O -
300 O +
mg O -
/ O -
kg O -
) O +
was O +
studied O +
on O +
reserpine O -
- O -
induced O +
orofacial O +
dyskinesia B-Disease +
and O +
neurochemical O +
alterations O -
. O +

The O +
rats O +
were O +
treated O +
with O +
intraperitoneal O +
reserpine O +
( O -
1 O +
mg O -
/ O -
kg O -
, O +
ip O -
) O +
for O +
3 O +
days O +
every O +
other O +
day O -
. O +

On O +
day O +
5 O -
, O +
vacuous O +
chewing O +
movements O +
and O +
tongue O +
protrusions O +
were O +
counted O +
for O +
5 O +
min O -
. O +

Reserpine O +
treated O +
rats O +
significantly O +
developed O +
vacuous O +
chewing O +
movements O +
and O +
tongue O +
protrusions O +
however O -
, O +
coadministration O +
of O +
Hibiscus O +
rosa O +
sinensis O +
roots O +
extract O +
( O -
100 O -
, O +
200 O +
and O +
300 O +
mg O -
/ O -
kg O -
, O +
per O +
orally O -
) O +
attenuated O +
the O +
effects O -
. O +

Biochemical O +
analysis O +
of O +
brain O +
revealed O +
that O +
the O +
reserpine O +
treatment O +
significantly O +
increased O +
lipid O +
peroxidation O +
and O +
decreased O +
levels O +
of O +
superoxide O +
dismutase O +
( O -
SOD O -
) O -
, O +
catalase O +
( O -
CAT O -
) O +
and O +
glutathione O +
reductase O +
( O -
GSH O -
) O -
, O +
an O +
index O +
of O +
oxidative O +
stress O +
process O -
. O +

Coadministration O +
of O +
extract O +
significantly O +
reduced O +
the O +
lipid O +
peroxidation O +
and O +
reversed O +
the O +
decrease O +
in O +
brain O +
SOD O -
, O +
CAT O +
and O +
GSH O +
levels O -
. O +

The O +
results O +
of O +
the O +
present O +
study O +
suggested O +
that O +
Hibiscus O +
rosa O +
sinensis O +
had O +
a O +
protective O +
role O +
against O +
reserpine O -
- O -
induced O +
orofacial O +
dyskinesia B-Disease +
and O +
oxidative O +
stress O -
. O +

Pyrrolidine O +
dithiocarbamate O +
protects O +
the O +
piriform O +
cortex O +
in O +
the O +
pilocarpine O +
status B-Disease +
epilepticus I-Disease +
model O -
. O +

Pyrrolidine O +
dithiocarbamate O +
( O -
PDTC O -
) O +
has O +
a O +
dual O +
mechanism O +
of O +
action O +
as O +
an O +
antioxidant O +
and O +
an O +
inhibitor O +
of O +
the O +
transcription O +
factor O +
kappa O -
- O -
beta O -
. O +

Both O -
, O +
production O +
of O +
reactive O +
oxygen O +
species O +
as O +
well O +
as O +
activation O +
of O +
NF O -
- O -
kappaB O +
have O +
been O +
implicated O +
in O +
severe O +
neuronal B-Disease +
damage I-Disease +
in O +
different O +
sub O -
- O -
regions O +
of O +
the O +
hippocampus O +
as O +
well O +
as O +
in O +
the O +
surrounding O +
cortices O -
. O +

The O +
effect O +
of O +
PDTC O +
on O +
status B-Disease +
epilepticus I-Disease -
- O -
associated O +
cell O +
loss O +
in O +
the O +
hippocampus O +
and O +
piriform O +
cortex O +
was O +
evaluated O +
in O +
the O +
rat O +
fractionated O +
pilocarpine O +
model O -
. O +

Treatment O +
with O +
150 O +
mg O -
/ O -
kg O +
PDTC O +
before O +
and O +
following O +
status B-Disease +
epilepticus I-Disease +
significantly O +
increased O +
the O +
mortality O +
rate O +
to O +
100 O -
% O -
. O +

Administration O +
of O +
50 O +
mg O -
/ O -
kg O +
PDTC O +
( O -
low O -
- O -
dose O -
) O +
did O +
not O +
exert O +
major O +
effects O +
on O +
the O +
development O +
of O +
a O +
status B-Disease +
epilepticus I-Disease +
or O +
the O +
mortality O +
rate O -
. O +

In O +
vehicle O -
- O -
treated O +
rats O -
, O +
status B-Disease +
epilepticus I-Disease +
caused O +
pronounced O +
neuronal B-Disease +
damage I-Disease +
in O +
the O +
piriform O +
cortex O +
comprising O +
both O +
pyramidal O +
cells O +
and O +
interneurons O -
. O +

Low O -
- O -
dose O +
PDTC O +
treatment O +
almost O +
completely O +
protected O +
from O +
lesions O +
in O +
the O +
piriform O +
cortex O -
. O +

A O +
significant O +
decrease O +
in O +
neuronal O +
density O +
of O +
the O +
hippocampal O +
hilar O +
formation O +
was O +
identified O +
in O +
vehicle- O +
and O +
PDTC O -
- O -
treated O +
rats O +
following O +
status B-Disease +
epilepticus I-Disease -
. O +

In O +
conclusion O -
, O +
the O +
NF O -
- O -
kappaB O +
inhibitor O +
and O +
antioxidant O +
PDTC O +
protected O +
the O +
piriform O +
cortex O -
, O +
whereas O +
it O +
did O +
not O +
affect O +
hilar O +
neuronal B-Disease +
loss I-Disease -
. O +

These O +
data O +
might O +
indicate O +
that O +
the O +
generation O +
of O +
reactive O +
oxygen O +
species O +
and O +
activation O +
of O +
NF O -
- O -
kappaB O +
plays O +
a O +
more O +
central O +
role O +
in O +
seizure B-Disease -
- O -
associated O +
neuronal B-Disease +
damage I-Disease +
in O +
the O +
temporal O +
cortex O +
as O +
compared O +
to O +
the O +
hippocampal O +
hilus O -
. O +

However O -
, O +
future O +
investigations O +
are O +
necessary O +
to O +
exactly O +
analyze O +
the O +
biochemical O +
mechanisms O +
by O +
which O +
PDTC O +
exerted O +
its O +
beneficial O +
effects O +
in O +
the O +
piriform O +
cortex O -
. O +

Anaesthetists O -
' O +
nightmare O -
: O +
masseter B-Disease +
spasm I-Disease +
after O +
induction O +
in O +
an O +
undiagnosed O +
case O +
of O +
myotonia B-Disease +
congenita I-Disease -
. O +

We O +
report O +
an O +
undiagnosed O +
case O +
of O +
myotonia B-Disease +
congenita I-Disease +
in O +
a O +
24-year O -
- O -
old O +
previously O +
healthy O +
primigravida O -
, O +
who O +
developed O +
life O +
threatening O +
masseter B-Disease +
spasm I-Disease +
following O +
a O +
standard O +
dose O +
of O +
intravenous O +
suxamethonium O +
for O +
induction O +
of O +
anaesthesia O -
. O +

Neither O +
the O +
patient O +
nor O +
the O +
anaesthetist O +
was O +
aware O +
of O +
the O +
diagnosis O +
before O +
this O +
potentially O +
lethal O +
complication O +
occurred O -
. O +

Twin O +
preterm O +
neonates O +
with O +
cardiac B-Disease +
toxicity I-Disease +
related O +
to O +
lopinavir O -
/ O -
ritonavir O +
therapy O -
. O +

We O +
report O +
twin O +
neonates O +
who O +
were O +
born O +
prematurely O +
at O +
32 O +
weeks O +
of O +
gestation O +
to O +
a O +
mother O +
with O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
infection I-Disease -
. O +

One O +
of O +
the O +
twins O +
developed O +
complete O +
heart B-Disease +
block I-Disease +
and O +
dilated B-Disease +
cardiomyopathy I-Disease +
related O +
to O +
lopinavir O -
/ O -
ritonavir O +
therapy O -
, O +
a O +
boosted O +
protease O -
- O -
inhibitor O +
agent O -
, O +
while O +
the O +
other O +
twin O +
developed O +
mild O +
bradycardia B-Disease -
. O +

We O +
recommend O +
caution O +
in O +
the O +
use O +
of O +
lopinavir O -
/ O -
ritonavir O +
in O +
the O +
immediate O +
neonatal O +
period O -
. O +

When O +
drugs O +
disappear O +
from O +
the O +
patient O -
: O +
elimination O +
of O +
intravenous O +
medication O +
by O +
hemodiafiltration O -
. O +

Twenty O -
- O -
three O +
hours O +
after O +
heart O +
transplantation O -
, O +
life O -
- O -
threatening O +
acute O +
right B-Disease +
heart I-Disease +
failure I-Disease +
was O +
diagnosed O +
in O +
a O +
patient O +
requiring O +
continuous O +
venovenous O +
hemodiafiltration O +
( O -
CVVHDF O -
) O -
. O +

Increasing O +
doses O +
of O +
catecholamines O -
, O +
sedatives O -
, O +
and O +
muscle O +
relaxants O +
administered O +
through O +
a O +
central O +
venous O +
catheter O +
were O +
ineffective O -
. O +

However O -
, O +
a O +
bolus O +
of O +
epinephrine O +
injected O +
through O +
an O +
alternative O +
catheter O +
provoked O +
a O +
hypertensive B-Disease +
crisis O -
. O +

Thus O -
, O +
interference O +
with O +
the O +
central O +
venous O +
infusion O +
by O +
the O +
dialysis O +
catheter O +
was O +
suspected O -
. O +

The O +
catheters O +
were O +
changed O -
, O +
and O +
hemodynamics O +
stabilized O +
at O +
lower O +
catecholamine O +
doses O -
. O +

When O +
the O +
effects O +
of O +
IV O +
drugs O +
are O +
inadequate O +
in O +
patients O +
receiving O +
CVVHDF O -
, O +
interference O +
with O +
adjacent O +
catheters O +
resulting O +
in O +
elimination O +
of O +
the O +
drug O +
by O +
CVVHDF O +
should O +
be O +
suspected O -
. O +

Less O +
frequent O +
lithium O +
administration O +
and O +
lower O +
urine O +
volume O -
. O +

OBJECTIVE O -
: O +
This O +
study O +
was O +
designed O +
to O +
determine O +
whether O +
patients O +
maintained O +
on O +
a O +
regimen O +
of O +
lithium O +
on O +
a O +
once O -
- O -
per O -
- O -
day O +
schedule O +
have O +
lower O +
urine O +
volumes O +
than O +
do O +
patients O +
receiving O +
multiple O +
doses O +
per O +
day O -
. O +

METHOD O -
: O +
This O +
was O +
a O +
cross O -
- O -
sectional O +
study O +
of O +
85 O +
patients O +
from O +
a O +
lithium O +
clinic O +
who O +
received O +
different O +
dose O +
schedules O -
. O +

Patients O +
were O +
admitted O +
to O +
the O +
hospital O +
for O +
measurement O +
of O +
lithium O +
level O -
, O +
creatinine O +
clearance O -
, O +
urine O +
volume O -
, O +
and O +
maximum O +
osmolality O -
. O +

RESULTS O -
: O +
Multiple O +
daily O +
doses O +
of O +
lithium O +
were O +
associated O +
with O +
higher O +
urine O +
volumes O -
. O +

The O +
dosing O +
schedule O -
, O +
duration O +
of O +
lithium O +
treatment O -
, O +
and O +
daily O +
dose O +
of O +
lithium O +
did O +
not O +
affect O +
maximum O +
osmolality O +
or O +
creatinine O +
clearance O -
. O +

CONCLUSIONS O -
: O +
Urine O +
volume O +
can O +
be O +
reduced O +
by O +
giving O +
lithium O +
once O +
daily O +
and/or O +
by O +
lowering O +
the O +
total O +
daily O +
dose O -
. O +

Lithium O -
- O -
induced O +
polyuria B-Disease +
seems O +
to O +
be O +
related O +
to O +
extrarenal O +
as O +
well O +
as O +
to O +
renal O +
effects O -
. O +

Antibacterial O +
medication O +
use O +
during O +
pregnancy O +
and O +
risk O +
of O +
birth B-Disease +
defects I-Disease -
: O +
National O +
Birth B-Disease +
Defects I-Disease +
Prevention O +
Study O -
. O +

OBJECTIVE O -
: O +
To O +
estimate O +
the O +
association O +
between O +
antibacterial O +
medications O +
and O +
selected O +
birth B-Disease +
defects I-Disease -
. O +

DESIGN O -
, O +
SETTING O -
, O +
AND O +
PARTICIPANTS O -
: O +
Population O -
- O -
based O -
, O +
multisite O -
, O +
case O -
- O -
control O +
study O +
of O +
women O +
who O +
had O +
pregnancies O +
affected O +
by O +
1 O +
of O +
more O +
than O +
30 O +
eligible O +
major O +
birth B-Disease +
defects I-Disease +
identified O +
via O +
birth B-Disease +
defect I-Disease +
surveillance O +
programs O +
in O +
10 O +
states O +
( O -
n O +
= O +
13 O +
155 O -
) O +
and O +
control O +
women O +
randomly O +
selected O +
from O +
the O +
same O +
geographical O +
regions O +
( O -
n O +
= O +
4941 O -
) O -
. O +

MAIN O +
EXPOSURE O -
: O +
Reported O +
maternal O +
use O +
of O +
antibacterials O +
( O -
1 O +
month O +
before O +
pregnancy O +
through O +
the O +
end O +
of O +
the O +
first O +
trimester O -
) O -
. O +

MAIN O +
OUTCOME O +
MEASURE O -
: O +
Odds O +
ratios O +
( O -
ORs O -
) O +
measuring O +
the O +
association O +
between O +
antibacterial O +
use O +
and O +
selected O +
birth B-Disease +
defects I-Disease +
adjusted O +
for O +
potential O +
confounders O -
. O +

RESULTS O -
: O +
The O +
reported O +
use O +
of O +
antibacterials O +
increased O +
during O +
pregnancy O -
, O +
peaking O +
during O +
the O +
third O +
month O -
. O +

Sulfonamides O +
were O +
associated O +
with O +
anencephaly B-Disease +
( O -
adjusted O +
OR O +
[ O -
AOR O -
] O +
= O +
3.4 O -
; O +
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O -
, O +
1.3 O -
- O -
8.8 O -
) O -
, O +
hypoplastic B-Disease +
left I-Disease +
heart I-Disease +
syndrome I-Disease +
( O -
AOR O +
= O +
3.2 O -
; O +
95 O -
% O +
CI O -
, O +
1.3 O -
- O -
7.6 O -
) O -
, O +
coarctation B-Disease +
of I-Disease +
the I-Disease +
aorta I-Disease +
( O -
AOR O +
= O +
2.7 O -
; O +
95 O -
% O +
CI O -
, O +
1.3 O -
- O -
5.6 O -
) O -
, O +
choanal B-Disease +
atresia I-Disease +
( O -
AOR O +
= O +
8.0 O -
; O +
95 O -
% O +
CI O -
, O +
2.7 O -
- O -
23.5 O -
) O -
, O +
transverse B-Disease +
limb I-Disease +
deficiency I-Disease +
( O -
AOR O +
= O +
2.5 O -
; O +
95 O -
% O +
CI O -
, O +
1.0 O -
- O -
5.9 O -
) O -
, O +
and O +
diaphragmatic B-Disease +
hernia I-Disease +
( O -
AOR O +
= O +
2.4 O -
; O +
95 O -
% O +
CI O -
, O +
1.1 O -
- O -
5.4 O -
) O -
. O +

Nitrofurantoins O +
were O +
associated O +
with O +
anophthalmia B-Disease +
or O +
microphthalmos B-Disease +
( O -
AOR O +
= O +
3.7 O -
; O +
95 O -
% O +
CI O -
, O +
1.1 O -
- O -
12.2 O -
) O -
, O +
hypoplastic B-Disease +
left I-Disease +
heart I-Disease +
syndrome I-Disease +
( O -
AOR O +
= O +
4.2 O -
; O +
95 O -
% O +
CI O -
, O +
1.9 O -
- O -
9.1 O -
) O -
, O +
atrial B-Disease +
septal I-Disease +
defects I-Disease +
( O -
AOR O +
= O +
1.9 O -
; O +
95 O -
% O +
CI O -
, O +
1.1 O -
- O -
3.4 O -
) O -
, O +
and O +
cleft B-Disease +
lip I-Disease +
with O +
cleft B-Disease +
palate I-Disease +
( O -
AOR O +
= O +
2.1 O -
; O +
95 O -
% O +
CI O -
, O +
1.2 O -
- O -
3.9 O -
) O -
. O +

Other O +
antibacterial O +
agents O +
that O +
showed O +
associations O +
included O +
erythromycins O +
( O -
2 O +
defects O -
) O -
, O +
penicillins O +
( O -
1 O +
defect O -
) O -
, O +
cephalosporins O +
( O -
1 O +
defect O -
) O -
, O +
and O +
quinolones O +
( O -
1 O +
defect O -
) O -
. O +

CONCLUSIONS O -
: O +
Reassuringly O -
, O +
penicillins O -
, O +
erythromycins O -
, O +
and O +
cephalosporins O -
, O +
although O +
used O +
commonly O +
by O +
pregnant O +
women O -
, O +
were O +
not O +
associated O +
with O +
many O +
birth B-Disease +
defects I-Disease -
. O +

Sulfonamides O +
and O +
nitrofurantoins O +
were O +
associated O +
with O +
several O +
birth B-Disease +
defects I-Disease -
, O +
indicating O +
a O +
need O +
for O +
additional O +
scrutiny O -
. O +

Differential O +
impact O +
of O +
immune O +
escape O +
mutations O +
G145R O +
and O +
P120 O -
T O +
on O +
the O +
replication O +
of O +
lamivudine O -
- O -
resistant O +
hepatitis O +
B O +
virus O +
e O +
antigen O -
- O -
positive O +
and O +
-negative O +
strains O -
. O +

Immune O +
escape O +
variants O +
of O +
the O +
hepatitis B-Disease +
B I-Disease +
virus O +
( O -
HBV O -
) O +
represent O +
an O +
emerging O +
clinical O +
challenge O -
, O +
because O +
they O +
can O +
be O +
associated O +
with O +
vaccine O +
escape O -
, O +
HBV O +
reactivation O -
, O +
and O +
failure O +
of O +
diagnostic O +
tests O -
. O +

Recent O +
data O +
suggest O +
a O +
preferential O +
selection O +
of O +
immune O +
escape O +
mutants O +
in O +
distinct O +
peripheral O +
blood O +
leukocyte O +
compartments O +
of O +
infected O +
individuals O -
. O +

We O +
therefore O +
systematically O +
analyzed O +
the O +
functional O +
impact O +
of O +
the O +
most O +
prevalent O +
immune O +
escape O +
variants O -
, O +
the O +
sG145R O +
and O +
sP120 O -
T O +
mutants O -
, O +
on O +
the O +
viral O +
replication O +
efficacy O +
and O +
antiviral O +
drug O +
susceptibility O +
of O +
common O +
treatment O -
- O -
associated O +
mutants O +
with O +
resistance O +
to O +
lamivudine O +
( O -
LAM O -
) O +
and/or O +
HBeAg O +
negativity O -
. O +

Replication O -
- O -
competent O +
HBV O +
strains O +
with O +
sG145R O +
or O +
sP120 O -
T O +
and O +
LAM O +
resistance O +
( O -
rtM204I O +
or O +
rtL180M O -
/ O -
rtM204V O -
) O +
were O +
generated O +
on O +
an O +
HBeAg O -
- O -
positive O +
and O +
an O +
HBeAg O -
- O -
negative O +
background O +
with O +
precore O +
( O -
PC O -
) O +
and O +
basal O +
core O +
promoter O +
( O -
BCP O -
) O +
mutants O -
. O +

The O +
sG145R O +
mutation O +
strongly O +
reduced O +
HBsAg O +
levels O +
and O +
was O +
able O +
to O +
fully O +
restore O +
the O +
impaired O +
replication O +
of O +
LAM O -
- O -
resistant O +
HBV O +
mutants O +
to O +
the O +
levels O +
of O +
wild O -
- O -
type O +
HBV O -
, O +
and O +
PC O +
or O +
BCP O +
mutations O +
further O +
enhanced O +
viral O +
replication O -
. O +

Although O +
the O +
sP120 O -
T O +
substitution O +
also O +
impaired O +
HBsAg O +
secretion O -
, O +
it O +
did O +
not O +
enhance O +
the O +
replication O +
of O +
LAM O -
- O -
resistant O +
clones O -
. O +

However O -
, O +
the O +
concomitant O +
occurrence O +
of O +
HBeAg O +
negativity O +
( O -
PC O -
/ O -
BCP O -
) O -
, O +
sP120 O -
T O -
, O +
and O +
LAM O +
resistance O +
resulted O +
in O +
the O +
restoration O +
of O +
replication O +
to O +
levels O +
of O +
wild O -
- O -
type O +
HBV O -
. O +

In O +
all O +
clones O +
with O +
combined O +
immune O +
escape O +
and O +
LAM O +
resistance O +
mutations O -
, O +
the O +
nucleotide O +
analogues O +
adefovir O +
and O +
tenofovir O +
remained O +
effective O +
in O +
suppressing O +
viral O +
replication O +
in O +
vitro O -
. O +

These O +
findings O +
reveal O +
the O +
differential O +
impact O +
of O +
immune O +
escape O +
variants O +
on O +
the O +
replication O +
and O +
drug O +
susceptibility O +
of O +
complex O +
HBV O +
mutants O -
, O +
supporting O +
the O +
need O +
of O +
close O +
surveillance O +
and O +
treatment O +
adjustment O +
in O +
response O +
to O +
the O +
selection O +
of O +
distinct O +
mutational O +
patterns O -
. O +

Reversible O +
myocardial B-Disease +
hypertrophy I-Disease +
induced O +
by O +
tacrolimus O +
in O +
a O +
pediatric O +
heart O +
transplant O +
recipient O -
: O +
case O +
report O -
. O +

Tacrolimus O +
is O +
a O +
potent O +
immunosuppressant O +
that O +
is O +
frequently O +
used O +
in O +
organ O +
transplantation O -
. O +

However O -
, O +
adverse O +
effects O +
include O +
cardiac B-Disease +
toxicity I-Disease -
. O +

Herein O +
we O +
describe O +
transient O +
myocardial B-Disease +
hypertrophy I-Disease +
induced O +
by O +
tacrolimus O +
after O +
heart O +
transplantation O -
. O +

The O +
hypertrophy B-Disease +
caused O +
no O +
clinical O +
symptoms O +
but O +
was O +
noted O +
because O +
of O +
elevation O +
of O +
plasma O +
brain O +
natriuretic O +
peptide O +
concentration O +
and O +
confirmed O +
at O +
echocardiography O -
. O +

Initially O -
, O +
allograft O +
rejection O +
was O +
feared O -
; O +
however O -
, O +
myocardial O +
biopsy O +
samples O +
revealed O +
only O +
interstitial O +
edema B-Disease +
and O +
mild O +
myocardial B-Disease +
hypertrophy I-Disease -
; O +
neither O +
cellular O +
nor O +
humoral O +
rejection O +
was O +
detected O -
. O +

The O +
blood O +
tacrolimus O +
concentration O +
was O +
higher O +
than O +
usual O +
at O +
that O +
time O -
; O +
thus O -
, O +
tacrolimus O +
dosage O +
was O +
reduced O -
. O +

Myocardial B-Disease +
hypertrophy I-Disease +
completely O +
resolved O +
upon O +
reducing O +
the O +
target O +
concentration O +
of O +
tacrolimus O +
and O +
did O +
not O +
recur O -
, O +
as O +
confirmed O +
at O +
echocardiography O +
and O +
myocardial O +
biopsy O -
. O +

Thus O -
, O +
we O +
conclude O +
that O +
tacrolimus O +
induces O +
reversible O +
myocardial B-Disease +
hypertrophy I-Disease -
. O +

In O +
patients O +
receiving O +
tacrolimus O +
therapy O -
, O +
blood O +
concentration O +
should O +
be O +
carefully O +
controlled O +
and O +
extreme O +
attention O +
paid O +
to O +
cardiac O +
involvement O -
. O +

Nimodipine O +
prevents O +
memory B-Disease +
impairment I-Disease +
caused O +
by O +
nitroglycerin O -
- O -
induced O +
hypotension B-Disease +
in O +
adult O +
mice O -
. O +

BACKGROUND O -
: O +
Hypotension B-Disease +
and O +
a O +
resultant O +
decrease O +
in O +
cerebral O +
blood O +
flow O +
have O +
been O +
implicated O +
in O +
the O +
development O +
of O +
cognitive B-Disease +
dysfunction I-Disease -
. O +

We O +
tested O +
the O +
hypothesis O +
that O +
nimodipine O +
( O -
NIMO O -
) O +
administered O +
at O +
the O +
onset O +
of O +
nitroglycerin O +
( O -
NTG O -
) O -
-induced O +
hypotension B-Disease +
would O +
preserve O +
long O -
- O -
term O +
associative O +
memory O -
. O +

METHODS O -
: O +
The O +
passive O +
avoidance O +
( O -
PA O -
) O +
paradigm O +
was O +
used O +
to O +
assess O +
memory O +
retention O -
. O +

For O +
PA O +
training O -
, O +
latencies O +
( O -
seconds O -
) O +
were O +
recorded O +
for O +
entry O +
from O +
a O +
suspended O +
platform O +
into O +
a O +
Plexiglas O +
tube O +
where O +
a O +
shock O +
was O +
automatically O +
delivered O -
. O +

Latencies O +
were O +
recorded O +
48 O +
h O +
later O +
for O +
a O +
testing O +
trial O -
. O +

Ninety O -
- O -
six O +
Swiss O -
- O -
Webster O +
mice O +
( O -
30 O -
- O -
35 O +
g O -
, O +
6 O -
- O -
8 O +
wk O -
) O -
, O +
were O +
randomized O +
into O +
6 O +
groups O +
1 O -
) O +
saline O +
( O -
control O -
) O -
, O +
2 O -
) O +
NTG O +
immediately O +
after O +
learning O -
, O +
3 O -
) O +
NTG O +
3 O +
h O +
after O +
learning O -
, O +
4 O -
) O +
NTG O +
and O +
NIMO O -
, O +
5 O -
) O +
vehicle O -
, O +
and O +
6 O -
) O +
NIMO O +
alone O -
. O +

The O +
extent O +
of O +
hypotension B-Disease +
and O +
changes O +
in O +
brain O +
tissue O +
oxygenation O +
( O -
PbtO O -
( O -
2 O -
) O -
) O +
and O +
in O +
cerebral O +
blood O +
flow O +
were O +
studied O +
in O +
a O +
separate O +
group O +
of O +
animals O -
. O +

RESULTS O -
: O +
All O +
groups O +
exhibited O +
similar O +
training O +
latencies O +
( O -
17.0 O +
+ O -
/- O +

4.6 O +
s O -
) O -
. O +

Mice O +
subjected O +
to O +
hypotensive B-Disease +
episodes O +
showed O +
a O +
significant O +
decrease O +
in O +
latency O +
time O +
( O -
178 O +
+ O -
/- O +

156 O +
s O -
) O +
compared O +
with O +
those O +
injected O +
with O +
saline O -
, O +
NTG O +
+ O +
NIMO O -
, O +
or O +
delayed O +
NTG O +
( O -
580 O +
+ O -
/- O +

81 O +
s O -
, O +
557 O +
+ O -
/- O +

67 O +
s O -
, O +
and O +
493 O +
+ O -
/- O +

146 O +
s O -
, O +
respectively O -
) O -
. O +

A O +
Kruskal O -
- O -
Wallis O +
1-way O +
analysis O +
of O +
variance O +
indicated O +
a O +
significant O +
difference O +
among O +
the O +
4 O +
treatment O +
groups O +
( O -
H O +
= O +
15.34 O -
; O +
P O +
< O +
0.001 O -
) O -
. O +

In O +
a O +
separate O +
group O +
of O +
mice O +
not O +
subjected O +
to O +
behavioral O +
studies O -
, O +
the O +
same O +
dose O +
of O +
NTG O +
( O -
n O +
= O +
3 O -
) O +
and O +
NTG O +
+ O +
NIMO O +
( O -
n O +
= O +
3 O -
) O +
caused O +
mean O +
arterial O +
blood O +
pressure O +
to O +
decrease O +
from O +
85.9 O +
+ O -
/- O +

3.8 O +
mm O +

Hg O +
sem O +
to O +
31.6 O +
+ O -
/- O +

0.8 O +
mm O +

Hg O +
sem O +
and O +
from O +
86.2 O +
+ O -
/- O +

3.7 O +
mm O +

Hg O +
sem O +
to O +
32.6 O +
+ O -
/- O +

0.2 O +
mm O +
Hg O +
sem O -
, O +
respectively O -
. O +

Mean O +
arterial O +
blood O +
pressure O +
in O +
mice O +
treated O +
with O +
NIMO O +
alone O +
decreased O +
from O +
88.1 O +
+ O -
/- O +

3.8 O +
mm O +
Hg O +
to O +
80.0 O +
+ O -
/- O +

2.9 O +
mm O +
Hg O -
. O +

The O +
intergroup O +
difference O +
was O +
statistically O +
significant O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

PbtO O -
( O -
2 O -
) O +
decreased O +
from O +
51.7 O +
+ O -
/- O +

4.5 O +
mm O +

Hg O +
sem O +
to O +
33.8 O +
+ O -
/- O +

5.2 O +
mm O +

Hg O +
sem O +
in O +
the O +
NTG O +
group O +
and O +
from O +
38.6 O +
+ O -
/- O +

6.1 O +
mm O +

Hg O +
sem O +
to O +
25.4 O +
+ O -
/- O +

2.0 O +
mm O +

Hg O +
sem O +
in O +
the O +
NTG O +
+ O +
NIMO O +
groups O -
, O +
respectively O -
. O +

There O +
were O +
no O +
significant O +
differences O +
among O +
groups O -
. O +

CONCLUSION O -
: O +
In O +
a O +
PA O +
retention O +
paradigm O -
, O +
the O +
injection O +
of O +
NTG O +
immediately O +
after O +
learning O +
produced O +
a O +
significant O +
impairment O +
of O +
long O -
- O -
term O +
associative O +
memory O +
in O +
mice O -
, O +
whereas O +
delayed O +
induced O +
hypotension B-Disease +
had O +
no O +
effect O -
. O +

NIMO O +
attenuated O +
the O +
disruption O +
in O +
consolidation O +
of O +
long O -
- O -
term O +
memory O +
caused O +
by O +
NTG O +
but O +
did O +
not O +
improve O +
latency O +
in O +
the O +
absence O +
of O +
hypotension B-Disease -
. O +

The O +
observed O +
effect O +
of O +
NIMO O +
may O +
have O +
been O +
attributable O +
to O +
the O +
preservation O +
of O +
calcium O +
homeostasis O +
during O +
hypotension B-Disease -
, O +
because O +
there O +
were O +
no O +
differences O +
in O +
the O +
PbtO O -
( O -
2 O -
) O +
indices O +
among O +
groups O -
. O +

Hemolytic B-Disease +
anemia I-Disease +
associated O +
with O +
the O +
use O +
of O +
omeprazole O -
. O +

Omeprazole O +
is O +
the O +
first O +
drug O +
designed O +
to O +
block O +
the O +
final O +
step O +
in O +
the O +
acid O +
secretory O +
process O +
within O +
the O +
parietal O +
cell O -
. O +

It O +
has O +
been O +
shown O +
to O +
be O +
extremely O +
effective O +
in O +
the O +
treatment O +
of O +
peptic B-Disease +
ulcer I-Disease +
disease I-Disease -
, O +
reflux B-Disease +
esophagitis I-Disease -
, O +
and O +
the O +
Zollinger B-Disease -
- I-Disease -
Ellison I-Disease +
syndrome I-Disease -
. O +

Although O +
clinical O +
experience O +
with O +
omeprazole O +
is O +
still O +
limited O -
, O +
many O +
controlled O +
studies O +
have O +
established O +
the O +
short O -
- O -
term O +
safety O +
of O +
this O +
drug O -
. O +

We O +
report O +
the O +
first O +
case O +
of O +
a O +
serious O +
short O -
- O -
term O +
adverse O +
reaction O +
with O +
the O +
use O +
of O +
omeprazole O -
: O +
hemolytic B-Disease +
anemia I-Disease -
. O +

The O +
patient O +
developed O +
weakness O -
, O +
lethargy B-Disease -
, O +
and O +
shortness B-Disease +
of I-Disease +
breath I-Disease +
2 O +
days O +
after O +
starting O +
therapy O +
with O +
omeprazole O -
. O +

Two O +
weeks O +
after O +
the O +
initiation O +
of O +
therapy O -
, O +
her O +
hematocrit O +
had O +
decreased O +
from O +
44.1 O -
% O +
to O +
20.4 O -
% O -
, O +
and O +
she O +
had O +
a O +
positive O +
direct O +
Coombs O +
antiglobulin O +
test O +
and O +
an O +
elevated O +
indirect O +
bilirubin O -
. O +

After O +
she O +
discontinued O +
the O +
omeprazole O -
, O +
her O +
hemoglobin O +
and O +
hematocrit O +
gradually O +
returned O +
to O +
normal O -
. O +

The O +
mechanism O +
by O +
which O +
omeprazole O +
caused O +
the O +
patient O -
's O +
hemolytic B-Disease +
anemia I-Disease +
is O +
uncertain O -
, O +
but O +
physicians O +
should O +
be O +
alerted O +
to O +
this O +
possible O +
adverse O +
effect O -
. O +

Metabotropic O +
glutamate O +
7 O +
receptor O +
subtype O +
modulates O +
motor O +
symptoms O +
in O +
rodent O +
models O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

Metabotropic O +
glutamate O +
( O -
mGlu O -
) O +
receptors O +
modulate O +
synaptic O +
transmission O +
in O +
the O +
central O +
nervous O +
system O +
and O +
represent O +
promising O +
therapeutic O +
targets O +
for O +
symptomatic O +
treatment O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O -
. O +

Among O +
the O +
eight O +
mGlu O +
receptor O +
subtypes O -
, O +
mGlu7 O +
receptor O +
is O +
prominently O +
expressed O +
in O +
the O +
basal O +
ganglia O -
, O +
but O +
its O +
role O +
in O +
restoring O +
motor O +
function O +
in O +
animal O +
models O +
of O +
PD B-Disease +
is O +
not O +
known O -
. O +

The O +
effects O +
of O +
N O -
, O -
N'-dibenzhydrylethane-1,2-diamine O +
dihydrochloride O +
( O -
AMN082 O -
) O -
, O +
the O +
first O +
selective O +
allosteric O +
activator O +
of O +
mGlu7 O +
receptors O -
, O +
were O +
thus O +
tested O +
in O +
different O +
rodent O +
models O +
of O +
PD B-Disease -
. O +

Here O -
, O +
we O +
show O +
that O +
oral O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
or O +
intrastriatal O +
administration O +
( O -
0.1 O +
and O +
0.5 O +
nmol O -
) O +
of O +
AMN082 O +
reverses O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
in O +
rats O -
. O +

AMN082 O +
( O -
2.5 O +
and O +
5 O +
mg O -
/ O -
kg O -
) O +
reduces O +
apomorphine O -
- O -
induced O +
rotations O +
in O +
unilateral O +
6-hydroxydopamine O +
( O -
6-OHDA O -
) O -
-lesioned O +
rats O -
. O +

In O +
a O +
more O +
complex O +
task O +
commonly O +
used O +
to O +
evaluate O +
major O +
akinetic B-Disease +
symptoms O +
of O +
PD B-Disease +
patients O -
, O +
5 O +
mg O -
/ O -
kg O +
AMN082 O +
reverses O +
the O +
increased O +
reaction O +
time O +
to O +
respond O +
to O +
a O +
cue O +
of O +
bilateral O +
6-OHDA O -
- O -
lesioned O +
rats O -
. O +

In O +
addition O -
, O +
AMN082 O +
reduces O +
the O +
duration O +
of O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
in O +
a O +
mGlu7 O +
receptor O -
- O -
dependent O +
manner O +
in O +
wild O -
- O -
type O +
but O +
not O +
mGlu7 O +
receptor O +
knockout O +
mice O -
. O +

Higher O +
doses O +
of O +
AMN082 O +
( O -
10 O +
and O +
20 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O +
have O +
no O +
effect O +
on O +
the O +
same O +
models O +
of O +
PD B-Disease -
. O +

Overall O +
these O +
findings O +
suggest O +
that O +
mGlu7 O +
receptor O +
activation O +
can O +
reverse O +
motor O +
dysfunction O +
associated O +
with O +
reduced O +
dopamine O +
activity O -
. O +

Selective O +
ligands O +
of O +
mGlu7 O +
receptor O +
subtypes O +
may O +
thus O +
be O +
considered O +
as O +
promising O +
compounds O +
for O +
the O +
development O +
of O +
antiparkinsonian O +
therapeutic O +
strategies O -
. O +

Sorafenib O -
- O -
induced O +
acute O +
myocardial B-Disease +
infarction I-Disease +
due O +
to O +
coronary B-Disease +
artery I-Disease +
spasm I-Disease -
. O +

A O +
65-year O -
- O -
old O +
man O +
with O +
advanced O +
renal B-Disease +
cell I-Disease +
carcinoma I-Disease +
was O +
admitted O +
due O +
to O +
continuing O +
chest B-Disease +
pain I-Disease +
at O +
rest O -
. O +

Two O +
weeks O +
before O +
his O +
admission O -
, O +
sorafenib O +
had O +
been O +
started O -
. O +

He O +
was O +
diagnosed O +
with O +
non O -
- O -
ST O -
- O -
elevation O +
myocardial B-Disease +
infarction I-Disease +
by O +
laboratory O +
data O +
and O +
electrocardiogram O -
. O +

Enhanced O +
heart O +
magnetic O +
resonance O +
imaging O +
also O +
showed O +
subendocardial B-Disease +
infarction I-Disease -
. O +

However O -
, O +
there O +
was O +
no O +
stenosis O +
in O +
coronary O +
arteries O +
on O +
angiography O -
. O +

Coronary B-Disease +
artery I-Disease +
spasm I-Disease +
was O +
induced O +
by O +
a O +
provocative O +
test O -
. O +

Cessation O +
of O +
sorafenib O +
and O +
administration O +
of O +
Ca O -
- O -
channel O +
blocker O +
and O +
nitrates O +
ameliorated O +
his O +
symptoms O -
, O +
but O +
relapse O +
occurred O +
after O +
resumption O +
of O +
sorafenib O -
. O +

Addition O +
of O +
oral O +
nicorandil O +
reduced O +
his O +
symptoms O +
and O +
maintained O +
stable B-Disease +
angina I-Disease +
status O -
. O +

We O +
report O +
the O +
first O +
case O +
of O +
sorafenib O -
- O -
induced O +
coronary B-Disease +
artery I-Disease +
spasm I-Disease -
. O +

Sorafenib O +
is O +
a O +
multikinase O +
inhibitor O +
that O +
targets O +
signaling O +
pathways O +
necessary O +
for O +
cellular O +
proliferation O +
and O +
survival O -
. O +

On O +
the O +
other O +
hand O -
, O +
the O +
Rho O -
/ O -
ROCK O +
pathway O +
has O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
coronary B-Disease +
artery I-Disease +
spasm I-Disease -
. O +

Our O +
report O +
may O +
show O +
an O +
adverse O +
effect O +
on O +
the O +
Rho O -
/ O -
ROCK O +
pathway O +
by O +
sorafenib O +
use O -
. O +

A O +
novel O +
animal O +
model O +
to O +
evaluate O +
the O +
ability O +
of O +
a O +
drug O +
delivery O +
system O +
to O +
promote O +
the O +
passage O +
through O +
the O +
BBB O -
. O +

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
explore O +
the O +
potentiality O +
of O +
a O +
novel O +
animal O +
model O +
to O +
be O +
used O +
for O +
the O +
in O +
vivo O +
evaluation O +
of O +
the O +
ability O +
of O +
a O +
drug O +
delivery O +
system O +
to O +
promote O +
the O +
passage O +
through O +
the O +
blood O -
- O -
brain O +
barrier O +
( O -
BBB O -
) O +
and/or O +
to O +
improve O +
the O +
brain O +
localization O +
of O +
a O +
bioactive O +
compound O -
. O +

A O +
Tween O +
80-coated O +
poly O -
- O -
L O -
- O -
lactid O +
acid O +
nanoparticles O +
was O +
used O +
as O +
a O +
model O +
of O +
colloidal O +
drug O +
delivery O +
system O -
, O +
able O +
to O +
trespass O +
the O +
BBB O -
. O +

Tacrine O -
, O +
administered O +
in O +
LiCl O +
pre O -
- O -
treated O +
rats O -
, O +
induces O +
electrocorticographic O +
seizures B-Disease +
and O +
delayed O +
hippocampal B-Disease +
damage I-Disease -
. O +

The O +
toxic O +
effects O +
of O +
tacrine O -
- O -
loaded O +
poly O -
- O -
L O -
- O -
lactid O +
acid O +
nanoparticles O +
( O -
5mg O -
/ O -
kg O -
) O -
, O +
a O +
saline O +
solution O +
of O +
tacrine O +
( O -
5mg O -
/ O -
kg O -
) O +
and O +
an O +
empty O +
colloidal O +
nanoparticle O +
suspension O +
were O +
compared O +
following O +
i.p O -
. O +

administration O +
in O +
LiCl O -
- O -
pre O -
- O -
treated O +
Wistar O +
rats O -
. O +

All O +
the O +
animals O +
treated O +
with O +
tacrine O -
- O -
loaded O +
nanoparticles O +
showed O +
an O +
earlier O +
outcome O +
of O +
CNS O +
adverse O +
symptoms O -
, O +
i.e. O +
epileptic B-Disease +
onset O -
, O +
with O +
respect O +
to O +
those O +
animals O +
treated O +
with O +
the O +
free O +
compound O +
( O -
10 O +
min O +
vs. O +
22 O +
min O +
respectively O -
) O -
. O +

In O +
addition O -
, O +
tacrine O -
- O -
loaded O +
nanoparticles O +
administration O +
induced O +
damage B-Disease +
of I-Disease +
neuronal I-Disease +
cells I-Disease +
in O +
CA1 O +
field O +
of O +
the O +
hippocampus O +
in O +
all O +
treated O +
animals O -
, O +
while O +
the O +
saline O +
solution O +
of O +
tacrine O +
only O +
in O +
60 O -
% O +
of O +
animals O -
. O +

Empty O +
nanoparticles O +
provided O +
similar O +
results O +
to O +
control O +
( O -
saline O -
- O -
treated O -
) O +
group O +
of O +
animals O -
. O +

In O +
conclusion O -
, O +
the O +
evaluation O +
of O +
time O -
- O -
to O -
- O -
onset O +
of O +
symptoms O +
and O +
the O +
severity O +
of O +
neurodegenerative O +
processes O +
induced O +
by O +
the O +
tacrine O -
- O -
lithium O +
model O +
of O +
epilepsy B-Disease +
in O +
the O +
rat O -
, O +
could O +
be O +
used O +
to O +
evaluate O +
preliminarily O +
the O +
capability O +
of O +
a O +
drug O +
delivery O +
system O +
to O +
trespass O +
( O -
or O +
not O -
) O +
the O +
BBB O +
in O +
vivo O -
. O +

Phenylephrine O +
but O +
not O +
ephedrine O +
reduces B-Disease +
frontal I-Disease +
lobe I-Disease +
oxygenation I-Disease +
following O +
anesthesia O -
- O -
induced O +
hypotension B-Disease -
. O +

BACKGROUND O -
: O +
Vasopressor O +
agents O +
are O +
used O +
to O +
correct O +
anesthesia O -
- O -
induced O +
hypotension B-Disease -
. O +

We O +
describe O +
the O +
effect O +
of O +
phenylephrine O +
and O +
ephedrine O +
on O +
frontal O +
lobe O +
oxygenation O +
( O -
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O -
) O +
following O +
anesthesia O -
- O -
induced O +
hypotension B-Disease -
. O +

METHODS O -
: O +
Following O +
induction O +
of O +
anesthesia O +
by O +
fentanyl O +
( O -
0.15 O +
mg O +
kg O -
( O -
-1 O -
) O -
) O +
and O +
propofol O +
( O -
2.0 O +
mg O +
kg O -
( O -
-1 O -
) O -
) O -
, O +
13 O +
patients O +
received O +
phenylephrine O +
( O -
0.1 O +
mg O +
iv O -
) O +
and O +
12 O +
patients O +
received O +
ephedrine O +
( O -
10 O +
mg O +
iv O -
) O +
to O +
restore O +
mean O +
arterial O +
pressure O +
( O -
MAP O -
) O -
. O +

Heart O +
rate O +
( O -
HR O -
) O -
, O +
MAP O -
, O +
stroke B-Disease +
volume O +
( O -
SV O -
) O -
, O +
cardiac O +
output O +
( O -
CO O -
) O -
, O +
and O +
frontal O +
lobe O +
oxygenation O +
( O -
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O -
) O +
were O +
registered O -
. O +

RESULTS O -
: O +
Induction O +
of O +
anesthesia O +
was O +
followed O +
by O +
a B-Disease +
decrease I-Disease +
in I-Disease +
MAP I-Disease -
, B-Disease +
HR I-Disease -
, I-Disease +
SV I-Disease -
, I-Disease +
and I-Disease +
CO I-Disease +
concomitant O +
with O +
an O +
elevation O +
in O +
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O -
. O +

After O +
administration O +
of O +
phenylephrine O -
, O +
MAP O +
increased O +
( O -
51 O +
+ O -
/- O +

12 O +
to O +
81 O +
+ O -
/- O +

13 O +
mmHg O -
; O +
P O +
< O +
0.001 O -
; O +
mean O +
+ O -
/- O +

SD O -
) O -
. O +

However O -
, O +
a O +
14 O -
% O +
( O -
from O +
70 O +
+ O -
/- O +

8 O -
% O +
to O +
60 O +
+ O -
/- O +

7 O -
% O -
) O +
reduction O +
in O +
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O +
( O -
P O +
< O +
0.05 O -
) O +
followed O +
with O +
no O +
change O +
in O +
CO O +
( O -
3.7 O +
+ O -
/- O +

1.1 O +
to O +
3.4 O +
+ O -
/- O +

0.9 O +
l O +
min O -
( O -
-1 O -
) O -
) O -
. O +

The O +
administration O +
of O +
ephedrine O +
led O +
to O +
a O +
similar O +
increase O +
in O +
MAP O +
( O -
53 O +
+ O -
/- O +

9 O +
to O +
79 O +
+ O -
/- O +

8 O +
mmHg O -
; O +
P O +
< O +
0.001 O -
) O -
, O +
restored O +
CO O +
( O -
3.2 O +
+ O -
/- O +

1.2 O +
to O +
5.0 O +
+ O -
/- O +

1.3 O +
l O +
min O -
( O -
-1 O -
) O -
) O -
, O +
and O +
preserved O +
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O -
. O +

CONCLUSIONS O -
: O +
The O +
utilization O +
of O +
phenylephrine O +
to O +
correct O +
hypotension B-Disease +
induced O +
by O +
anesthesia O +
has O +
a O +
negative O +
impact O +
on O +
S O -
( O -
c O -
) O -
O O -
( O -
2 O -
) O +
while O +
ephedrine O +
maintains O +
frontal O +
lobe O +
oxygenation O +
potentially O +
related O +
to O +
an O +
increase O +
in O +
CO O -
. O +

High O -
- O -
dose O +
tranexamic O +
Acid O +
is O +
associated O +
with O +
nonischemic O +
clinical O +
seizures B-Disease +
in O +
cardiac O +
surgical O +
patients O -
. O +

BACKGROUND O -
: O +
In O +
2 O +
separate O +
centers O -
, O +
we O +
observed O +
a O +
notable O +
increase O +
in O +
the O +
incidence O +
of O +
postoperative O +
convulsive B-Disease +
seizures B-Disease +
from O +
1.3 O -
% O +
to O +
3.8 O -
% O +
in O +
patients O +
having O +
undergone O +
major O +
cardiac O +
surgical O +
procedures O -
. O +

These O +
events O +
were O +
temporally O +
coincident O +
with O +
the O +
initial O +
use O +
of O +
high O -
- O -
dose O +
tranexamic O +
acid O +
( O -
TXA O -
) O +
therapy O +
after O +
withdrawal O +
of O +
aprotinin O +
from O +
general O +
clinical O +
usage O -
. O +

The O +
purpose O +
of O +
this O +
review O +
was O +
to O +
perform O +
a O +
retrospective O +
analysis O +
to O +
examine O +
whether O +
there O +
was O +
a O +
relation O +
between O +
TXA O +
usage O +
and O +
seizures B-Disease +
after O +
cardiac O +
surgery O -
. O +

METHODS O -
: O +
An O +
in O -
- O -
depth O +
chart O +
review O +
was O +
undertaken O +
in O +
all O +
24 O +
patients O +
who O +
developed O +
perioperative O +
seizures B-Disease -
. O +

Electroencephalographic O +
activity O +
was O +
recorded O +
in O +
11 O +
of O +
these O +
patients O -
, O +
and O +
all O +
patients O +
had O +
a O +
formal O +
neurological O +
evaluation O +
and O +
brain O +
imaging O +
studies O -
. O +

RESULTS O -
: O +
Twenty O -
- O -
one O +
of O +
the O +
24 O +
patients O +
did O +
not O +
have O +
evidence O +
of O +
new O +
cerebral B-Disease +
ischemic I-Disease +
injury I-Disease -
, O +
but O +
seizures B-Disease +
were O +
likely O +
due O +
to O +
ischemic B-Disease +
brain I-Disease +
injury I-Disease +
in O +
3 O +
patients O -
. O +

All O +
patients O +
with O +
seizures B-Disease +
did O +
not O +
have O +
permanent O +
neurological B-Disease +
abnormalities I-Disease -
. O +

All O +
24 O +
patients O +
with O +
seizures B-Disease +
received O +
high O +
doses O +
of O +
TXA O +
intraoperatively O +
ranging O +
from O +
61 O +
to O +
259 O +
mg O -
/ O -
kg O -
, O +
had O +
a O +
mean O +
age O +
of O +
69.9 O +
years O -
, O +
and O +
21 O +
of O +
24 O +
had O +
undergone O +
open O +
chamber O +
rather O +
than O +
coronary O +
bypass O +
procedures O -
. O +

All O +
but O +
one O +
patient O +
were O +
managed O +
using O +
cardiopulmonary O +
bypass O -
. O +

No O +
evidence O +
of O +
brain B-Disease +
ischemic I-Disease -
, O +
metabolic O -
, O +
or O +
hyperthermia B-Disease -
- O -
induced O +
causes O +
for O +
their O +
seizures B-Disease +
was O +
apparent O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
suggest O +
that O +
use O +
of O +
high O -
- O -
dose O +
TXA O +
in O +
older O +
patients O +
in O +
conjunction O +
with O +
cardiopulmonary O +
bypass O +
and O +
open O -
- O -
chamber O +
cardiac O +
surgery O +
is O +
associated O +
with O +
clinical O +
seizures B-Disease +
in O +
susceptible O +
patients O -
. O +

Prolonged O +
elevation O +
of O +
plasma O +
argatroban O +
in O +
a O +
cardiac O +
transplant O +
patient O +
with O +
a O +
suspected O +
history O +
of O +
heparin O -
- O -
induced O +
thrombocytopenia B-Disease +
with O +
thrombosis B-Disease -
. O +

BACKGROUND O -
: O +
Direct O +
thrombin O +
inhibitors O +
( O -
DTIs O -
) O +
provide O +
an O +
alternative O +
method O +
of O +
anticoagulation O +
for O +
patients O +
with O +
a O +
history O +
of O +
heparin O -
- O -
induced O +
thrombocytopenia B-Disease +
( O -
HIT B-Disease -
) O +
or O +
HIT B-Disease +
with O +
thrombosis B-Disease +
( O -
HITT B-Disease -
) O +
undergoing O +
cardiopulmonary O +
bypass O +
( O -
CPB O -
) O -
. O +

In O +
the O +
following O +
report O -
, O +
a O +
65-year O -
- O -
old O +
critically B-Disease +
ill I-Disease +
patient O +
with O +
a O +
suspected O +
history O +
of O +
HITT B-Disease +
was O +
administered O +
argatroban O +
for O +
anticoagulation O +
on O +
bypass O +
during O +
heart O +
transplantation O -
. O +

The O +
patient O +
required O +
massive O +
transfusion O +
support O +
( O -
55 O +
units O +
of O +
red O +
blood O +
cells O -
, O +
42 O +
units O +
of O +
fresh O -
- O -
frozen O +
plasma O -
, O +
40 O +
units O +
of O +
cryoprecipitate O -
, O +
40 O +
units O +
of O +
platelets O -
, O +
and O +
three O +
doses O +
of O +
recombinant O +
Factor O +
VIIa O -
) O +
for O +
severe O +
intraoperative B-Disease +
and I-Disease +
postoperative I-Disease +
bleeding I-Disease -
. O +

STUDY O +
DESIGN O +
AND O +
METHODS O -
: O +
Plasma O +
samples O +
from O +
before O +
and O +
after O +
CPB O +
were O +
analyzed O +
postoperatively O +
for O +
argatroban O +
concentration O +
using O +
a O +
modified O +
ecarin O +
clotting O +
time O +
( O -
ECT O -
) O +
assay O -
. O +

RESULTS O -
: O +
Unexpectedly O +
high O +
concentrations O +
of O +
argatroban O +
were O +
measured O +
in O +
these O +
samples O +
( O -
range O -
, O +
0 O -
- O -
32 O +
microg O -
/ O -
mL O -
) O -
, O +
and O +
a O +
prolonged O +
plasma O +
argatroban O +
half O +
life O +
( O -
t O -
( O -
1 O -
/ O -
2 O -
) O -
) O +
of O +
514 O +
minutes O +
was O +
observed O +
( O -
published O +
elimination O +
t O -
( O -
1 O -
/ O -
2 O -
) O +
is O +
39 O -
- O -
51 O +
minutes O +
[ O -
< O +
or O +
= O +
181 O +
minutes O +
with O +
hepatic B-Disease +
impairment I-Disease -
] O -
) O -
. O +

CONCLUSIONS O -
: O +
Correlation O +
of O +
plasma O +
argatroban O +
concentration O +
versus O +
the O +
patient O -
's O +
coagulation O +
variables O +
and O +
clinical O +
course O +
suggest O +
that O +
prolonged O +
elevated O +
levels O +
of O +
plasma O +
argatroban O +
may O +
have O +
contributed O +
to O +
the O +
patient O -
's O +
extended O +
coagulopathy B-Disease -
. O +

Because O +
DTIs O +
do O +
not O +
have O +
reversal O +
agents O -
, O +
surgical O +
teams O +
and O +
transfusion O +
services O +
should O +
remain O +
aware O +
of O +
the O +
possibility O +
of O +
massive O +
transfusion O +
events O +
during O +
anticoagulation O +
with O +
these O +
agents O -
. O +

This O +
is O +
the O +
first O +
report O +
to O +
measure O +
plasma O +
argatroban O +
concentration O +
in O +
the O +
context O +
of O +
CPB O +
and O +
extended O +
coagulopathy B-Disease -
. O +

Electrocardiographic O +
changes O +
and O +
cardiac B-Disease +
arrhythmias I-Disease +
in O +
patients O +
receiving O +
psychotropic O +
drugs O -
. O +

Eight O +
patients O +
had O +
cardiac O +
manifestations O +
that O +
were O +
life O -
- O -
threatening O +
in O +
five O +
while O +
taking O +
psychotropic O +
drugs O -
, O +
either O +
phenothiazines O +
or O +
tricyclic O +
antidepressants O -
. O +

Although O +
most O +
patients O +
were O +
receiving O +
several O +
drugs O -
, O +
Mellaril O +
( O -
thioridazine O -
) O +
appeared O +
to O +
be O +
responsible O +
for O +
five O +
cases O +
of O +
ventricular B-Disease +
tachycardia I-Disease -
, O +
one O +
of O +
which O +
was O +
fatal O +
in O +
a O +
35 O +
year O +
old O +
woman O -
. O +

Supraventricular B-Disease +
tachycardia I-Disease +
developed O +
in O +
one O +
patient O +
receiving O +
Thorazine O +
( O -
chlorpromazine O -
) O -
. O +

Aventyl O +
( O -
nortriptyline O -
) O +
and O +
Elavil O +
( O -
amitriptyline O -
) O +
each O +
produced O +
left B-Disease +
bundle I-Disease +
branch I-Disease +
block I-Disease +
in O +
a O +
73 O +
year O +
old O +
woman O -
. O +

Electrocardiographic O +
T O +
and O +
U O +
wave O +
abnormalities O +
were O +
present O +
in O +
most O +
patients O -
. O +

The O +
ventricular B-Disease +
arrhythmias I-Disease +
responded O +
to O +
intravenous O +
administration O +
of O +
lidocaine O +
and O +
to O +
direct O +
current O +
electric O +
shock O -
; O +
ventricular O +
pacing O +
was O +
required O +
in O +
some O +
instances O +
and O +
intravenous O +
administration O +
of O +
propranolol O +
combined O +
with O +
ventricular O +
pacing O +
in O +
one O -
. O +

The O +
tachyarrhythmias B-Disease +
generally O +
subsided O +
within O +
48 O +
hours O +
after O +
administration O +
of O +
the O +
drugs O +
was O +
stopped O -
. O +

Five O +
of O +
the O +
eight O +
patients O +
were O +
50 O +
years O +
of O +
age O +
or O +
younger O -
; O +
only O +
one O +
clearly O +
had O +
antecedent O +
heart B-Disease +
disease I-Disease -
. O +

Major O +
cardiac B-Disease +
arrhythmias I-Disease +
are O +
a O +
potential O +
hazard O +
in O +
patients O +
without O +
heart B-Disease +
disease I-Disease +
who O +
are O +
receiving O +
customary O +
therapeutic O +
doses O +
of O +
psychotropic O +
drugs O -
. O +

A O +
prospective O +
clinical O +
trial O +
is O +
suggested O +
to O +
quantify O +
the O +
risk O +
of O +
cardiac B-Disease +
complications I-Disease +
to O +
patients O +
receiving O +
phenothiazines O +
or O +
tricyclic O +
antidepressant O +
drugs O -
. O +

Sensitivity O +
of O +
erythroid O +
progenitor O +
colonies O +
to O +
erythropoietin O +
in O +
azidothymidine O +
treated O +
immunodeficient B-Disease +
mice O -
. O +

The O +
anaemia B-Disease +
induced O +
by O +
3'-azido-3'dideoxythymidine O +
( O -
AZT O -
) O +
is O +
poorly O +
understood O -
. O +

We O +
have O +
used O +
a O +
murine O +
model O +
of O +
AIDS B-Disease -
, O +
infection B-Disease +
of O +
female O +
C57BL O -
/ O -
6 O +
mice O +
with O +
LP O -
- O -
BM5 O +
murine O +
leukaemia B-Disease +
( O -
MuLV O -
) O +
virus O -
, O +
to O +
determine O +
if O +
AZT O -
- O -
induced O +
anaemia B-Disease +
is O +
due O -
, O +
in O +
part O -
, O +
to O +
decreased O +
responsiveness O +
of O +
erythropoietic O +
precursors O +
( O -
BFU O -
- O -
e O -
) O +
to O +
erythropoietin O +
( O -
EPO O -
) O -
. O +

Mice O +
in O +
the O +
early O +
stage O +
of O +
LP O -
- O -
BM5 O +
MuLV O +
disease O +
were O +
given O +
AZT O +
in O +
their O +
drinking O +
water O +
at O +
1.0 O +
and O +
2.5 O +
mg O -
/ O -
ml O -
. O +

AZT O +
produced O +
anaemia B-Disease +
in O +
both O +
groups O -
, O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O -
. O +

Despite O +
the O +
anaemia B-Disease -
, O +
the O +
number O +
of O +
splenic O +
and O +
bone O +
marrow O +
BFU O -
- O -
e O +
in O +
AZT O +
treated O +
mice O +
increased O +
up O +
to O +
five O -
- O -
fold O +
over O +
levels O +
observed O +
in O +
infected O +
untreated O +
animals O +
after O +
15 O +
d O +
of O +
treatment O -
. O +

Colony O +
formation O +
by O +
splenic O +
and O +
bone O +
marrow O +
BFUe O +
was O +
stimulated O +
at O +
lower O +
concentrations O +
of O +
EPO O +
in O +
mice O +
receiving O +
AZT O +
for O +
15 O +
d O +
than O +
for O +
infected O -
, O +
untreated O +
mice O -
. O +

By O +
day O +
30 O -
, O +
sensitivity O +
of O +
both O +
splenic O +
and O +
bone O +
marrow O +
BFU O -
- O -
e O +
of O +
treated O +
animals O +
returned O +
to O +
that O +
observed O +
from O +
cells O +
of O +
infected O +
untreated O +
animals O -
. O +

The O +
mean O +
plasma O +
levels O +
of O +
EPO O +
observed O +
in O +
AZT O +
treated O +
mice O +
were O +
appropriate O +
for O +
the O +
degree O +
of O +
anaemia B-Disease +
observed O +
when O +
compared O +
with O +
phenylhydrazine O +
( O -
PHZ O -
) O +
treated O +
mice O -
. O +

The O +
numbers O +
of O +
BFU O -
- O -
e O +
and O +
the O +
percentage O +
of O +
bone O +
marrow O +
erythroblasts O +
observed O +
were O +
comparable O +
in O +
AZT O +
and O +
PHZ O +
treated O +
mice O +
with O +
similar O +
degrees O +
of O +
anaemia B-Disease -
. O +

However O -
, O +
reticulocytosis B-Disease +
was O +
inappropriate O +
for O +
the O +
degree O +
of O +
anaemia B-Disease +
observed O +
in O +
AZT O +
treated O +
infected O +
mice O -
. O +

AZT O -
- O -
induced O +
peripheral O +
anaemia B-Disease +
in O +
the O +
face O +
of O +
increased O +
numbers O +
of O +
BFU O -
- O -
e O +
and O +
increased O +
levels O +
of O +
plasma O +
EPO O +
suggest O +
a O +
lesion O +
in O +
terminal O +
differentiation O -
. O +

Sedation O +
depth O +
during O +
spinal O +
anesthesia O +
and O +
the O +
development O +
of O +
postoperative B-Disease +
delirium I-Disease +
in O +
elderly O +
patients O +
undergoing O +
hip B-Disease +
fracture I-Disease +
repair O -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
whether O +
limiting O +
intraoperative O +
sedation O +
depth O +
during O +
spinal O +
anesthesia O +
for O +
hip B-Disease +
fracture I-Disease +
repair O +
in O +
elderly O +
patients O +
can O +
decrease O +
the O +
prevalence O +
of O +
postoperative B-Disease +
delirium I-Disease -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
We O +
performed O +
a O +
double O -
- O -
blind O -
, O +
randomized O +
controlled O +
trial O +
at O +
an O +
academic O +
medical O +
center O +
of O +
elderly O +
patients O +
( O -
> O -
or=65 O +
years O -
) O +
without O +
preoperative O +
delirium B-Disease +
or O +
severe O +
dementia B-Disease +
who O +
underwent O +
hip B-Disease +
fracture I-Disease +
repair O +
under O +
spinal O +
anesthesia O +
with O +
propofol O +
sedation O -
. O +

Sedation O +
depth O +
was O +
titrated O +
using O +
processed O +
electroencephalography O +
with O +
the O +
bispectral O +
index O +
( O -
BIS O -
) O -
, O +
and O +
patients O +
were O +
randomized O +
to O +
receive O +
either O +
deep O +
( O -
BIS O -
, O +
approximately O +
50 O -
) O +
or O +
light O +
( O -
BIS O -
, O +
> O -
or=80 O -
) O +
sedation O -
. O +

Postoperative B-Disease +
delirium I-Disease +
was O +
assessed O +
as O +
defined O +
by O +
Diagnostic O +
and O +
Statistical O +
Manual O +
of O +
Mental B-Disease +
Disorders I-Disease +
( O -
Third O +
Edition O +
Revised O -
) O +
criteria O +
using O +
the O +
Confusion O +
Assessment O +
Method O +
beginning O +
at O +
any O +
time O +
from O +
the O +
second O +
day O +
after O +
surgery O -
. O +

RESULTS O -
: O +
From O +
April O +
2 O -
, O +
2005 O -
, O +
through O +
October O +
30 O -
, O +
2008 O -
, O +
a O +
total O +
of O +
114 O +
patients O +
were O +
randomized O -
. O +

The O +
prevalence O +
of O +
postoperative B-Disease +
delirium I-Disease +
was O +
significantly O +
lower O +
in O +
the O +
light O +
sedation O +
group O +
( O -
11 O -
/ O -
57 O +
[ O -
19 O -
% O -
] O +
vs O +
23 O -
/ O -
57 O +
[ O -
40 O -
% O -
] O +
in O +
the O +
deep O +
sedation O +
group O -
; O +
P=.02 O -
) O -
, O +
indicating O +
that O +
1 O +
incident O +
of O +
delirium B-Disease +
will O +
be O +
prevented O +
for O +
every O +
4.7 O +
patients O +
treated O +
with O +
light O +
sedation O -
. O +

The O +
mean O +
+ O -
/- O +

SD O +
number O +
of O +
days O +
of O +
delirium B-Disease +
during O +
hospitalization O +
was O +
lower O +
in O +
the O +
light O +
sedation O +
group O +
than O +
in O +
the O +
deep O +
sedation O +
group O +
( O -
0.5+ O -
/ O -
-1.5 O +
days O +
vs O +
1.4+ O -
/ O -
-4.0 O +
days O -
; O +
P=.01 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
use O +
of O +
light O +
propofol O +
sedation O +
decreased O +
the O +
prevalence O +
of O +
postoperative B-Disease +
delirium I-Disease +
by O +
50 O -
% O +
compared O +
with O +
deep O +
sedation O -
. O +

Limiting O +
depth O +
of O +
sedation O +
during O +
spinal O +
anesthesia O +
is O +
a O +
simple O -
, O +
safe O -
, O +
and O +
cost O -
- O -
effective O +
intervention O +
for O +
preventing O +
postoperative B-Disease +
delirium I-Disease +
in O +
elderly O +
patients O +
that O +
could O +
be O +
widely O +
and O +
readily O +
adopted O -
. O +

The O +
effects O +
of O +
the O +
adjunctive O +
bupropion O +
on O +
male O +
sexual B-Disease +
dysfunction I-Disease +
induced O +
by O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O -
: O +
a O +
double O -
- O -
blind O +
placebo O -
- O -
controlled O +
and O +
randomized O +
study O -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
the O +
safety O +
and O +
efficacy O +
of O +
adjunctive O +
bupropion O +
sustained O -
- O -
release O +
( O -
SR O -
) O +
on O +
male O +
sexual B-Disease +
dysfunction I-Disease +
( O -
SD B-Disease -
) O +
induced O +
by O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O +
( O -
SSRI O -
) O -
, O +
as O +
SD B-Disease +
is O +
a O +
common O +
side O -
- O -
effect O +
of O +
SSRIs O +
and O +
the O +
most O +
effective O +
treatments O +
have O +
yet O +
to O +
be O +
determined O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
The O +
randomized O +
sample O +
consisted O +
of O +
234 O +
euthymic O +
men O +
who O +
were O +
receiving O +
some O +
type O +
of O +
SSRI O -
. O +

The O +
men O +
were O +
randomly O +
assigned O +
to O +
bupropion O +
SR O +
( O -
150 O +
mg O +
twice O +
daily O -
, O +
117 O -
) O +
or O +
placebo O +
( O -
twice O +
daily O -
, O +
117 O -
) O +
for O +
12 O +
weeks O -
. O +

Efficacy O +
was O +
evaluated O +
using O +
the O +
Clinical O +
Global O +
Impression O -
- O -
Sexual O +
Function O +
( O -
CGI O -
- O -
SF O -
; O +
the O +
primary O +
outcome O +
measure O -
) O -
, O +
the O +
International O +
Index O +
of O +
Erectile O +
Function O +
( O -
IIEF O -
) O -
, O +
Arizona O +
Sexual O +
Experience O +
Scale O +
( O -
ASEX O -
) O -
, O +
and O +
Erectile B-Disease +
Dysfunction I-Disease +
Inventory O +
of O +
Treatment O +
Satisfaction O +
( O -
EDITS O -
) O +
( O -
secondary O +
outcome O +
measures O -
) O -
. O +

Participants O +
were O +
followed O +
biweekly O +
during O +
study O +
period O -
. O +

RESULTS O -
: O +
After O +
12 O +
weeks O +
of O +
treatment O -
, O +
the O +
mean O +
( O -
sd O -
) O +
scores O +
for O +
CGI O -
- O -
SF O +
were O +
significantly O +
lower O -
, O +
i.e. O +
better O -
, O +
in O +
patients O +
on O +
bupropion O +
SR O -
, O +
at O +
2.4 O +
( O -
1.2 O -
) O -
, O +
than O +
in O +
the O +
placebo O +
group O -
, O +
at O +
3.9 O +
( O -
1.1 O -
) O +
( O -
P= O +
0.01 O -
) O -
. O +

Men O +
who O +
received O +
bupropion O +
had O +
a O +
significant O +
increase O +
in O +
the O +
total O +
IIEF O +
score O +
( O -
54.4 O -
% O +
vs O +
1.2 O -
% O -
; O +
P= O +
0.003 O -
) O -
, O +
and O +
in O +
the O +
five O +
different O +
domains O +
of O +
the O +
IIEF O -
. O +

Total O +
ASEX O +
scores O +
were O +
significantly O +
lower O -
, O +
i.e. O +
better O -
, O +
among O +
men O +
who O +
received O +
bupropion O +
than O +
placebo O -
, O +
at O +
15.5 O +
( O -
4.3 O -
) O +
vs O +
21.5 O +
( O -
4.7 O -
) O +
( O -
P= O +
0.002 O -
) O -
. O +

The O +
EDITS O +
scores O +
were O +
67.4 O +
( O -
10.2 O -
) O +
for O +
the O +
bupropion O +
and O +
36.3 O +
( O -
11.7 O -
) O +
for O +
the O +
placebo O +
group O +
( O -
P= O +
0.001 O -
) O -
. O +

The O +
ASEX O +
score O +
and O +
CGI O -
- O -
SF O +
score O +
were O +
correlated O +
( O -
P= O +
0.003 O -
) O -
. O +

In O +
linear O +
regression O +
analyses O +
the O +
CGI O -
- O -
SF O +
score O +
was O +
not O +
affected O +
significantly O +
by O +
the O +
duration O +
of O +
SD B-Disease -
, O +
type O +
of O +
SSRI O +
used O +
and O +
age O -
. O +

CONCLUSIONS O -
: O +
Bupropion O +
is O +
an O +
effective O +
treatment O +
for O +
male O +
SD B-Disease +
induced O +
by O +
SSRIs O -
. O +

These O +
results O +
provide O +
empirical O +
support O +
for O +
conducting O +
a O +
further O +
study O +
of O +
bupropion O -
. O +

Prevention O +
of O +
seizures B-Disease +
and O +
reorganization O +
of O +
hippocampal O +
functions O +
by O +
transplantation O +
of O +
bone O +
marrow O +
cells O +
in O +
the O +
acute O +
phase O +
of O +
experimental O +
epilepsy B-Disease -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
therapeutic O +
potential O +
of O +
bone O +
marrow O +
mononuclear O +
cells O +
( O -
BMCs O -
) O +
in O +
a O +
model O +
of O +
epilepsy B-Disease +
induced O +
by O +
pilocarpine O +
in O +
rats O -
. O +

BMCs O +
obtained O +
from O +
green O +
fluorescent O +
protein O +
( O -
GFP O -
) O +
transgenic O +
mice O +
or O +
rats O +
were O +
transplanted O +
intravenously O +
after O +
induction O +
of O +
status B-Disease +
epilepticus I-Disease +
( O -
SE B-Disease -
) O -
. O +

Spontaneous B-Disease +
recurrent I-Disease +
seizures I-Disease +
( O -
SRS B-Disease -
) O +
were O +
monitored O +
using O +
Racine O -
's O +
seizure B-Disease +
severity O +
scale O -
. O +

All O +
of O +
the O +
rats O +
in O +
the O +
saline O -
- O -
treated O +
epileptic B-Disease +
control O +
group O +
developed O +
SRS B-Disease -
, O +
whereas O +
none O +
of O +
the O +
BMC O -
- O -
treated O +
epileptic B-Disease +
animals O +
had O +
seizures B-Disease +
in O +
the O +
short O +
term O +
( O -
15 O +
days O +
after O +
transplantation O -
) O -
, O +
regardless O +
of O +
the O +
BMC O +
source O -
. O +

Over O +
the O +
long O -
- O -
term O +
chronic O +
phase O +
( O -
120 O +
days O +
after O +
transplantation O -
) O -
, O +
only O +
25 O -
% O +
of O +
BMC O -
- O -
treated O +
epileptic B-Disease +
animals O +
had O +
seizures B-Disease -
, O +
but O +
with O +
a O +
lower O +
frequency O +
and O +
duration O +
compared O +
to O +
the O +
epileptic B-Disease +
control O +
group O -
. O +

The O +
density O +
of O +
hippocampal O +
neurons O +
in O +
the O +
brains O +
of O +
animals O +
treated O +
with O +
BMCs O +
was O +
markedly O +
preserved O -
. O +

At O +
hippocampal O +
Schaeffer O +
collateral O -
- O -
CA1 O +
synapses O -
, O +
long O -
- O -
term O +
potentiation O +
was O +
preserved O +
in O +
BMC O -
- O -
transplanted O +
rats O +
compared O +
to O +
epileptic B-Disease +
controls O -
. O +

The O +
donor O -
- O -
derived O +
GFP O -
( O -
+ O -
) O +
cells O +
were O +
rarely O +
found O +
in O +
the O +
brains O +
of O +
transplanted O +
epileptic B-Disease +
rats O -
. O +

In O +
conclusion O -
, O +
treatment O +
with O +
BMCs O +
can O +
prevent O +
the O +
development O +
of O +
chronic O +
seizures B-Disease -
, O +
reduce O +
neuronal B-Disease +
loss I-Disease -
, O +
and O +
influence O +
the O +
reorganization O +
of O +
the O +
hippocampal O +
neuronal O +
network O -
. O +

Normalizing O +
effects O +
of O +
modafinil O +
on O +
sleep O +
in O +
chronic O +
cocaine O +
users O -
. O +

OBJECTIVE O -
: O +
The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
determine O +
the O +
effect O +
of O +
morning O -
- O -
dosed O +
modafinil O +
on O +
sleep O +
and O +
daytime B-Disease +
sleepiness I-Disease +
in O +
chronic O +
cocaine O +
users O -
. O +

METHOD O -
: O +
Twenty O +
cocaine O -
- O -
dependent O +
participants O +
were O +
randomly O +
assigned O +
to O +
receive O +
modafinil O -
, O +
400 O +
mg O +
( O -
N=10 O -
) O -
, O +
or O +
placebo O +
( O -
N=10 O -
) O +
every O +
morning O +
at O +
7:30 O +
a.m. O +
for O +
16 O +
days O +
in O +
an O +
inpatient O -
, O +
double O -
- O -
blind O +
randomized O +
trial O -
. O +

Participants O +
underwent O +
polysomnographic O +
sleep O +
recordings O +
on O +
days O +
1 O +
to O +
3 O -
, O +
7 O +
to O +
9 O -
, O +
and O +
14 O +
to O +
16 O +
( O -
first O -
, O +
second O -
, O +
and O +
third O +
weeks O +
of O +
abstinence O -
) O -
. O +

The O +
Multiple O +
Sleep O +
Latency O +
Test O +
was O +
performed O +
at O +
11:30 O +
a.m. O -
, O +
2:00 O +
p.m. O -
, O +
and O +
4:30 O +
p.m. O +
on O +
days O +
2 O -
, O +
8 O -
, O +
and O +
15 O -
. O +

For O +
comparison O +
of O +
sleep O +
architecture O +
variables O -
, O +
12 O +
healthy O +
comparison O +
participants O +
underwent O +
a O +
single O +
night O +
of O +
experimental O +
polysomnography O +
that O +
followed O +
1 O +
night O +
of O +
accommodation O +
polysomnography O -
. O +

RESULTS O -
: O +
Progressive O +
abstinence O +
from O +
cocaine O +
was O +
associated O +
with O +
worsening O +
of O +
all O +
measured O +
polysomnographic O +
sleep O +
outcomes O -
. O +

Compared O +
with O +
placebo O -
, O +
modafinil O +
decreased O +
nighttime O +
sleep O +
latency O +
and O +
increased O +
slow O -
- O -
wave O +
sleep O +
time O +
in O +
cocaine O -
- O -
dependent O +
participants O -
. O +

The O +
effect O +
of O +
modafinil O +
interacted O +
with O +
the O +
abstinence O +
week O +
and O +
was O +
associated O +
with O +
longer O +
total O +
sleep O +
time O +
and O +
shorter O +
REM O +
sleep O +
latency O +
in O +
the O +
third O +
week O +
of O +
abstinence O -
. O +

Comparison O +
of O +
slow O -
- O -
wave O +
sleep O +
time O -
, O +
total O +
sleep O +
time O -
, O +
and O +
sleep O +
latency O +
in O +
cocaine O -
- O -
dependent O +
and O +
healthy O +
participants O +
revealed O +
a O +
normalizing O +
effect O +
of O +
modafinil O +
in O +
cocaine O -
- O -
dependent O +
participants O -
. O +

Modafinil O +
was O +
associated O +
with O +
increased O +
daytime O +
sleep O +
latency O -
, O +
as O +
measured O +
by O +
the O +
Multiple O +
Sleep O +
Latency O +
Test O -
, O +
and O +
a O +
nearly O +
significant O +
decrease O +
in O +
subjective O +
daytime B-Disease +
sleepiness I-Disease -
. O +

CONCLUSIONS O -
: O +
Morning O -
- O -
dosed O +
modafinil O +
promotes O +
nocturnal O +
sleep O -
, O +
normalizes O +
sleep O +
architecture O -
, O +
and O +
decreases O +
daytime B-Disease +
sleepiness I-Disease +
in O +
abstinent O +
cocaine O +
users O -
. O +

These O +
effects O +
may O +
be O +
relevant O +
in O +
the O +
treatment O +
of O +
cocaine O +
dependence O -
. O +

Safety O +
of O +
transesophageal O +
echocardiography O +
in O +
adults O -
: O +
study O +
in O +
a O +
multidisciplinary O +
hospital O -
. O +

BACKGROUND O -
: O +
TEE O +
is O +
a O +
semi O -
- O -
invasive O +
tool O +
broadly O +
used O +
and O +
its O +
utilization O +
associated O +
to O +
sedatives O +
drugs O +
might O +
to O +
affect O +
the O +
procedure O +
safety O -
. O +

OBJECTIVE O -
: O +
to O +
analyze O +
aspects O +
of O +
TEE O +
safety O +
associated O +
to O +
the O +
use O +
of O +
Midazolan O +
( O -
MZ O -
) O +
and O +
Flumazenil O +
( O -
FL O -
) O +
and O +
the O +
influence O +
of O +
the O +
clinical O +
variables O +
on O +
the O +
event O +
rate O -
. O +

METHOD O -
: O +
prospective O +
study O +
with O +
137 O +
patients O +
that O +
underwent O +
TEE O +
with O +
MZ O +
associated O +
to O +
moderate O +
sedation O -
. O +

We O +
analyzed O +
the O +
following O +
events O -
: O +
complications O +
related O +
with O +
the O +
topical O +
anesthesia O -
, O +
with O +
MZ O +
use O +
and O +
with O +
the O +
procedure O -
. O +

Uni- O +
and O +
multivariate O +
analyses O +
were O +
used O +
to O +
test O +
the O +
influence O +
of O +
the O +
clinical O +
variables O -
: O +
age O -
, O +
sex O -
, O +
stroke B-Disease -
, O +
myocardiopathy B-Disease +
( O -
MP B-Disease -
) O -
, O +
duration O +
of O +
the O +
test O -
, O +
mitral B-Disease +
regurgitation I-Disease +
( O -
MR B-Disease -
) O +
and O +
the O +
MZ O +
dose O -
. O +

RESULTS O -
: O +
All O +
patients O +
( O -
65+ O -
/ O -
-16 O +
yrs O -
; O +
58 O -
% O +
males O -
) O +
finished O +
the O +
examination O -
. O +

The O +
mean O +
doses O +
of O +
MZ O +
and O +
FL O +
were O +
4.3+ O -
/ O -
-1.9 O +
mg O +
and O +
0.28+ O -
/ O -
-0.2 O +
mg O -
, O +
respectively O -
. O +

The O +
duration O +
of O +
the O +
examination O +
and O +
the O +
mean O +
ejection O +
fraction O +
( O -
EF O -
) O +
were O +
16.4+ O -
/ O -
-6.1 O +
minutes O +
and O +
60+ O -
/ O -
-9 O -
% O -
, O +
respectively O -
. O +

Mild O +
hypoxia B-Disease +
( O -
SO2<90 O -
% O -
) O +
was O +
the O +
most O +
common O +
event O +
( O -
11 O +
patients O -
) O -
; O +
3 O +
patients O +
( O -
2 O -
% O -
) O +
presented O +
transient O +
hypoxia B-Disease +
due O +
to O +
upper O +
airway B-Disease +
obstruction I-Disease +
by O +
probe O +
introduction O +
and O +
8 O +
( O -
5.8 O -
% O -
) O +
due O +
to O +
hypoxia B-Disease +
caused O +
by O +
MZ O +
use O -
. O +

Transient O +
hypotension B-Disease +
( O -
SAP<90mmHg O -
) O +
occurred O +
in O +
1 O +
patient O +
( O -
0.7 O -
% O -
) O -
. O +

The O +
multivariate O +
analysis O +
showed O +
that O +
severe O +
MR B-Disease -
, O +
MP B-Disease +
( O -
EF<45 O -
% O -
) O +
and O +
high O +
doses O +
of O +
MZ O +
( O -
> O -
5 O -
mg O -
) O +
were O +
associated O +
with O +
events O +
( O -
p<0.001 O -
) O -
. O +

The O +
EF O +
was O +
40 O -
% O -
, O +
in O +
the O +
group O +
with O +
MP B-Disease +
and O +
44 O -
% O +
in O +
the O +
group O +
with O +
severe O +
MR B-Disease +
and O +
it O +
can O +
be O +
a O +
factor O +
associated O +
with O +
clinical O +
events O +
in O +
the O +
last O +
group O -
. O +

CONCLUSION O -
: O +
TEE O +
with O +
sedation O +
presents O +
a O +
low O +
rate O +
of O +
events O -
. O +

There O +
were O +
no O +
severe O +
events O +
and O +
there O +
was O +
no O +
need O +
to O +
interrupt O +
the O +
examinations O -
. O +

Effect O +
of O +
direct O +
intracoronary O +
administration O +
of O +
methylergonovine O +
in O +
patients O +
with O +
and O +
without O +
variant B-Disease +
angina I-Disease -
. O +

The O +
effects O +
of O +
intracoronary O +
administration O +
of O +
methylergonovine O +
were O +
studied O +
in O +
21 O +
patients O +
with O +
variant B-Disease +
angina I-Disease +
and O +
22 O +
patients O +
with O +
atypical O +
chest B-Disease +
pain I-Disease +
and O +
in O +
others O +
without O +
angina B-Disease +
pectoris I-Disease +
( O -
control O +
group O -
) O -
. O +

Methylergonovine O +
was O +
administered O +
continuously O +
at O +
a O +
rate O +
of O +
10 O +
micrograms O -
/ O -
min O +
up O +
to O +
50 O +
micrograms O -
. O +

In O +
all O +
patients O +
with O +
variant B-Disease +
angina I-Disease -
, O +
coronary B-Disease +
spasm I-Disease +
was O +
provoked O +
at O +
a O +
mean O +
dose O +
of O +
28 O +
+ O -
/- O +

13 O +
micrograms O +
( O -
mean O +
+ O -
/- O +
SD O -
) O -
. O +

In O +
the O +
control O +
group O +
neither O +
ischemic O +
ST O +
change O +
nor O +
localized O +
spasm B-Disease +
occurred O -
. O +

The O +
basal O +
tone O +
of O +
the O +
right O +
coronary O +
artery O +
was O +
significantly O +
lower O +
than O +
that O +
of O +
the O +
left O +
coronary O +
artery O -
. O +

The O +
percentage O +
of O +
vasoconstriction O +
of O +
the O +
right O +
coronary O +
artery O +
was O +
significantly O +
higher O +
than O +
that O +
of O +
the O +
left O +
coronary O +
artery O -
. O +

These O +
results O +
suggest O +
that O +
spasm B-Disease +
provocation O +
tests O -
, O +
which O +
use O +
an O +
intracoronary O +
injection O +
of O +
a O +
relatively O +
low O +
dose O +
of O +
methylergonovine O -
, O +
have O +
a O +
high O +
sensitivity O +
in O +
variant B-Disease +
angina I-Disease +
and O +
the O +
vasoreactivity O +
of O +
the O +
right O +
coronary O +
artery O +
may O +
be O +
greater O +
than O +
that O +
of O +
the O +
other O +
coronary O +
arteries O -
. O +

Oral O +
manifestations O +
of O +
" O -
meth B-Disease +
mouth I-Disease -
" O -
: O +
a O +
case O +
report O -
. O +

AIM O -
: O +
The O +
aim O +
of O +
the O +
documentation O +
of O +
this O +
clinical O +
case O +
is O +
to O +
make O +
clinicians O +
aware O +
of O +
" O -
meth B-Disease +
mouth I-Disease -
" O +
and O +
the O +
medical O +
risks O +
associated O +
with O +
this O +
serious O +
condition O -
. O +

BACKGROUND O -
: O +
Methamphetamine O +
is O +
a O +
very O +
addictive O -
, O +
powerful O +
stimulant O +
that O +
increases O +
wakefulness O +
and O +
physical O +
activity O +
and O +
can O +
produce O +
other O +
effects O +
such O +
as O +
cardiac B-Disease +
dysrhythmias I-Disease -
, O +
hypertension B-Disease -
, O +
hallucinations B-Disease -
, O +
and O +
violent B-Disease +
behavior I-Disease -
. O +

Dental O +
patients O +
abusing O +
methamphetamine O +
can O +
present O +
with O +
poor O +
oral O +
hygiene O -
, O +
xerostomia B-Disease -
, O +
rampant O +
caries B-Disease +
( O -
" O -
meth B-Disease +
mouth I-Disease -
" O -
) O -
, O +
and O +
excessive O +
tooth B-Disease +
wear I-Disease -
. O +

Oral O +
rehabilitation O +
of O +
patients O +
using O +
methamphetamine O +
can O +
be O +
challenging O -
. O +

CASE O +
DESCRIPTION O -
: O +
A O +
30-year O -
- O -
old O +
Caucasian O +
woman O +
presented O +
with O +
dental O +
pain B-Disease -
, O +
bad B-Disease +
breath I-Disease -
, O +
and O +
self O -
- O -
reported O +
poor O +
esthetics O -
. O +

A O +
comprehensive O +
examination O +
including O +
her O +
medical O +
history O -
, O +
panoramic O +
radiograph O -
, O +
and O +
intraoral O +
examination O +
revealed O +
19 O +
carious B-Disease +
lesions I-Disease -
, O +
which O +
is O +
not O +
very O +
common O +
for O +
a O +
healthy O +
adult O -
. O +

She O +
reported O +
her O +
use O +
of O +
methamphetamine O +
for O +
five O +
years O +
and O +
had O +
not O +
experienced O +
any O +
major O +
carious B-Disease +
episodes I-Disease +
before O +
she O +
started O +
using O +
the O +
drug O -
. O +

SUMMARY O -
: O +
The O +
patient O -
's O +
medical O +
and O +
dental O +
histories O +
along O +
with O +
radiographic O +
and O +
clinical O +
findings O +
lead O +
to O +
a O +
diagnosis O +
of O +
" O -
meth B-Disease +
mouth I-Disease -
. O -
" O +
Although O +
three O +
different O +
dental O +
treatment O +
modalities O +
( O -
either O +
conventional O +
or O +
implant O -
- O -
supported O -
) O +
have O +
been O +
offered O +
to O +
the O +
patient O +
since O +
August O +
2007 O -
, O +
the O +
patient O +
has O +
yet O +
to O +
initiate O +
any O +
treatment O -
. O +

CLINICAL O +
SIGNIFICANCE O -
: O +
This O +
clinical O +
case O +
showing O +
oral O +
manifestations O +
of O +
meth B-Disease +
mouth I-Disease +
was O +
presented O +
to O +
help O +
dental O +
practitioners O +
recognize O +
and O +
manage O +
patients O +
who O +
may O +
be O +
abusing O +
methamphetamines O -
. O +

Dental O +
practitioners O +
also O +
may O +
be O +
skeptical O +
about O +
the O +
reliability O +
of O +
appointment O +
keeping O +
by O +
these O +
patients O -
, O +
as O +
they O +
frequently O +
miss O +
their O +
appointments O +
without O +
reasonable O +
justification O -
. O +

The O +
protective O +
role O +
of O +
Nrf2 O +
in O +
streptozotocin O -
- O -
induced O +
diabetic B-Disease +
nephropathy I-Disease -
. O +

OBJECTIVE O -
: O +
Diabetic B-Disease +
nephropathy I-Disease +
is O +
one O +
of O +
the O +
major O +
causes O +
of O +
renal B-Disease +
failure I-Disease -
, O +
which O +
is O +
accompanied O +
by O +
the O +
production O +
of O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O -
. O +

Nrf2 O +
is O +
the O +
primary O +
transcription O +
factor O +
that O +
controls O +
the O +
antioxidant O +
response O +
essential O +
for O +
maintaining O +
cellular O +
redox O +
homeostasis O -
. O +

Here O -
, O +
we O +
report O +
our O +
findings O +
demonstrating O +
a O +
protective O +
role O +
of O +
Nrf2 O +
against O +
diabetic B-Disease +
nephropathy I-Disease -
. O +

RESEARCH O +
DESIGN O +
AND O +
METHODS O -
: O +
We O +
explore O +
the O +
protective O +
role O +
of O +
Nrf2 O +
against O +
diabetic B-Disease +
nephropathy I-Disease +
using O +
human O +
kidney O +
biopsy O +
tissues O +
from O +
diabetic B-Disease +
nephropathy I-Disease +
patients O -
, O +
a O +
streptozotocin O -
- O -
induced O +
diabetic B-Disease +
nephropathy I-Disease +
model O +
in O +
Nrf2 O -
( O -
- O -
/ O -
- O -
) O +
mice O -
, O +
and O +
cultured O +
human O +
mesangial O +
cells O -
. O +

RESULTS O -
: O +
The O +
glomeruli O +
of O +
human O +
diabetic B-Disease +
nephropathy I-Disease +
patients O +
were O +
under O +
oxidative O +
stress O +
and O +
had O +
elevated O +
Nrf2 O +
levels O -
. O +

In O +
the O +
animal O +
study O -
, O +
Nrf2 O +
was O +
demonstrated O +
to O +
be O +
crucial O +
in O +
ameliorating O +
streptozotocin O -
- O -
induced O +
renal B-Disease +
damage I-Disease -
. O +

This O +
is O +
evident O +
by O +
Nrf2 O -
( O -
- O -
/ O -
- O -
) O +
mice O +
having O +
higher O +
ROS O +
production O +
and O +
suffering O +
from O +
greater O +
oxidative O +
DNA O +
damage O +
and O +
renal B-Disease +
injury I-Disease +
compared O +
with O +
Nrf2 O -
( O -
+ O -
/ O -
+ O -
) O +
mice O -
. O +

Mechanistic O +
studies O +
in O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
systems O +
showed O +
that O +
the O +
Nrf2-mediated O +
protection O +
against O +
diabetic B-Disease +
nephropathy I-Disease +
is O -
, O +
at O +
least O -
, O +
partially O +
through O +
inhibition O +
of O +
transforming O +
growth O +
factor O -
- O -
beta1 O +
( O -
TGF O -
- O -
beta1 O -
) O +
and O +
reduction O +
of O +
extracellular O +
matrix O +
production O -
. O +

In O +
human O +
renal O +
mesangial O +
cells O -
, O +
high O +
glucose O +
induced O +
ROS O +
production O +
and O +
activated O +
expression O +
of O +
Nrf2 O +
and O +
its O +
downstream O +
genes O -
. O +

Furthermore O -
, O +
activation O +
or O +
overexpression O +
of O +
Nrf2 O +
inhibited O +
the O +
promoter O +
activity O +
of O +
TGF O -
- O -
beta1 O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
, O +
whereas O +
knockdown O +
of O +
Nrf2 O +
by O +
siRNA O +
enhanced O +
TGF O -
- O -
beta1 O +
transcription O +
and O +
fibronectin O +
production O -
. O +

CONCLUSIONS O -
: O +
This O +
work O +
clearly O +
indicates O +
a O +
protective O +
role O +
of O +
Nrf2 O +
in O +
diabetic B-Disease +
nephropathy I-Disease -
, O +
suggesting O +
that O +
dietary O +
or O +
therapeutic O +
activation O +
of O +
Nrf2 O +
could O +
be O +
used O +
as O +
a O +
strategy O +
to O +
prevent O +
or O +
slow O +
down O +
the O +
progression O +
of O +
diabetic B-Disease +
nephropathy I-Disease -
. O +

Metformin O +
prevents O +
experimental O +
gentamicin O -
- O -
induced O +
nephropathy B-Disease +
by O +
a O +
mitochondria O -
- O -
dependent O +
pathway O -
. O +

The O +
antidiabetic O +
drug O +
metformin O +
can O +
diminish O +
apoptosis O +
induced O +
by O +
oxidative O +
stress O +
in O +
endothelial O +
cells O +
and O +
prevent O +
vascular B-Disease +
dysfunction I-Disease +
even O +
in O +
nondiabetic O +
patients O -
. O +

Here O +
we O +
tested O +
whether O +
it O +
has O +
a O +
beneficial O +
effect O +
in O +
a O +
rat O +
model O +
of O +
gentamicin O +
toxicity B-Disease -
. O +

Mitochondrial O +
analysis O -
, O +
respiration O +
intensity O -
, O +
levels O +
of O +
reactive O +
oxygen O +
species O -
, O +
permeability O +
transition O -
, O +
and O +
cytochrome O +
c O +
release O +
were O +
assessed O +
3 O +
and O +
6 O +
days O +
after O +
gentamicin O +
administration O -
. O +

Metformin O +
treatment O +
fully O +
blocked O +
gentamicin O -
- O -
mediated O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

This O +
was O +
accompanied O +
by O +
a O +
lower O +
activity O +
of O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
D O -
- O -
glucosaminidase O -
, O +
together O +
with O +
a O +
decrease O +
of O +
lipid O +
peroxidation O +
and O +
increase O +
of O +
antioxidant O +
systems O -
. O +

Metformin O +
also O +
protected O +
the O +
kidney O +
from O +
histological O +
damage O +
6 O +
days O +
after O +
gentamicin O +
administration O -
. O +

These O +
in O +
vivo O +
markers O +
of O +
kidney B-Disease +
dysfunction I-Disease +
and O +
their O +
correction O +
by O +
metformin O +
were O +
complemented O +
by O +
in O +
vitro O +
studies O +
of O +
mitochondrial O +
function O -
. O +

We O +
found O +
that O +
gentamicin O +
treatment O +
depleted O +
respiratory O +
components O +
( O -
cytochrome O +
c O -
, O +
NADH O -
) O -
, O +
probably O +
due O +
to O +
the O +
opening O +
of O +
mitochondrial O +
transition O +
pores O -
. O +

These O +
injuries O -
, O +
partly O +
mediated O +
by O +
a O +
rise O +
in O +
reactive O +
oxygen O +
species O +
from O +
the O +
electron O +
transfer O +
chain O -
, O +
were O +
significantly O +
decreased O +
by O +
metformin O -
. O +

Thus O -
, O +
our O +
study O +
suggests O +
that O +
pleiotropic O +
effects O +
of O +
metformin O +
can O +
lessen O +
gentamicin O +
nephrotoxicity B-Disease +
and O +
improve O +
mitochondrial O +
homeostasis O -
. O +

Risk O +
of O +
nephropathy B-Disease +
after O +
consumption O +
of O +
nonionic O +
contrast O +
media O +
by O +
children O +
undergoing O +
cardiac O +
angiography O -
: O +
a O +
prospective O +
study O -
. O +

Despite O +
increasing O +
reports O +
on O +
nonionic O +
contrast O +
media O -
- O -
induced O +
nephropathy B-Disease +
( O -
CIN B-Disease -
) O +
in O +
hospitalized O +
adult O +
patients O +
during O +
cardiac O +
procedures O -
, O +
the O +
studies O +
in O +
pediatrics O +
are O +
limited O -
, O +
with O +
even O +
less O +
focus O +
on O +
possible O +
predisposing O +
factors O +
and O +
preventive O +
measures O +
for O +
patients O +
undergoing O +
cardiac O +
angiography O -
. O +

This O +
prospective O +
study O +
determined O +
the O +
incidence O +
of O +
CIN B-Disease +
for O +
two O +
nonionic O +
contrast O +
media O +
( O -
CM O -
) O -
, O +
iopromide O +
and O +
iohexol O -
, O +
among O +
80 O +
patients O +
younger O +
than O +
18 O +
years O +
and O +
compared O +
the O +
rates O +
for O +
this O +
complication O +
in O +
relation O +
to O +
the O +
type O +
and O +
dosage O +
of O +
CM O +
and O +
the O +
presence O +
of O +
cyanosis B-Disease -
. O +

The O +
80 O +
patients O +
in O +
the O +
study O +
consecutively O +
received O +
either O +
iopromide O +
( O -
group O +
A O -
, O +
n O +
= O +
40 O -
) O +
or O +
iohexol O +
( O -
group O +
B O -
, O +
n O +
= O +
40 O -
) O -
. O +

Serum O +
sodium O +
( O -
Na O -
) O -
, O +
potassium O +
( O -
K O -
) O -
, O +
and O +
creatinine O +
( O -
Cr O -
) O +
were O +
measured O +
24 O +
h O +
before O +
angiography O +
as O +
baseline O +
values O -
, O +
then O +
measured O +
again O +
at O +
12- O -
, O +
24- O -
, O +
and O +
48-h O +
intervals O +
after O +
CM O +
use O -
. O +

Urine O +
samples O +
for O +
Na O +
and O +
Cr O +
also O +
were O +
checked O +
at O +
the O +
same O +
intervals O -
. O +

Risk O +
of O +
renal B-Disease +
failure I-Disease -
, O +
Injury B-Disease +
to I-Disease +
the I-Disease +
kidney I-Disease -
, O +
Failure B-Disease +
of I-Disease +
kidney I-Disease +
function I-Disease -
, O +
Loss B-Disease +
of I-Disease +
kidney I-Disease +
function I-Disease -
, O +
and O +
End O -
- O -
stage O +
renal B-Disease +
damage I-Disease +
( O -
RIFLE O +
criteria O -
) O +
were O +
used O +
to O +
define O +
CIN B-Disease +
and O +
its O +
incidence O +
in O +
the O +
study O +
population O -
. O +

Accordingly O -
, O +
among O +
the O +
15 O +
CIN B-Disease +
patients O +
( O -
18.75 O -
% O -
) O -
, O +
7.5 O -
% O +
of O +
the O +
patients O +
in O +
group O +
A O +
had O +
increased O +
risk O +
and O +
3.75 O -
% O +
had O +
renal B-Disease +
injury I-Disease -
, O +
whereas O +
5 O -
% O +
of O +
group O +
B O +
had O +
increased O +
risk O +
and O +
2.5 O -
% O +
had O +
renal B-Disease +
injury I-Disease -
. O +

Whereas O +
33.3 O -
% O +
of O +
the O +
patients O +
with O +
CIN B-Disease +
were O +
among O +
those O +
who O +
received O +
the O +
proper O +
dosage O +
of O +
CM O -
, O +
the O +
percentage O +
increased O +
to O +
66.6 O -
% O +
among O +
those O +
who O +
received O +
larger O +
doses O -
, O +
with O +
a O +
significant O +
difference O +
in O +
the O +
incidence O +
of O +
CIN B-Disease +
related O +
to O +
the O +
different O +
dosages O +
of O +
CM O +
( O -
p O +
= O +
0.014 O -
) O -
. O +

Among O +
the O +
15 O +
patients O +
with O +
CIN B-Disease -
, O +
6 O +
had O +
cyanotic O +
congenital B-Disease +
heart I-Disease +
diseases I-Disease -
, O +
but O +
the O +
incidence O +
did O +
not O +
differ O +
significantly O +
from O +
that O +
for O +
the O +
noncyanotic O +
patients O +
( O -
p O +
= O +
0.243 O -
) O -
. O +

Although O +
clinically O +
silent O -
, O +
CIN B-Disease +
is O +
not O +
rare O +
in O +
pediatrics O -
. O +

The O +
incidence O +
depends O +
on O +
dosage O +
but O +
not O +
on O +
the O +
type O +
of O +
consumed O +
nonionic O +
CM O -
, O +
nor O +
on O +
the O +
presence O +
of O +
cyanosis B-Disease -
, O +
and O +
although O +
CIN B-Disease +
usually O +
is O +
reversible O -
, O +
more O +
concern O +
is O +
needed O +
for O +
the O +
prevention O +
of O +
such O +
a O +
complication O +
in O +
children O -
. O +

Antituberculosis O +
therapy O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure I-Disease -
: O +
magnitude O -
, O +
profile O -
, O +
prognosis O -
, O +
and O +
predictors O +
of O +
outcome O -
. O +

Antituberculosis O +
therapy O +
( O -
ATT O -
) O -
-associated O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
( O -
ATT O -
- O -
ALF B-Disease -
) O +
is O +
the O +
commonest O +
drug O -
- O -
induced O +
ALF B-Disease +
in O +
South O +
Asia O -
. O +

Prospective O +
studies O +
on O +
ATT O -
- O -
ALF B-Disease +
are O +
lacking O -
. O +

The O +
current O +
study O +
prospectively O +
evaluated O +
the O +
magnitude O -
, O +
clinical O +
course O -
, O +
outcome O -
, O +
and O +
prognostic O +
factors O +
in O +
ATT O -
- O -
ALF B-Disease -
. O +

From O +
January O +
1986 O +
to O +
January O +
2009 O -
, O +
1223 O +
consecutive O +
ALF B-Disease +
patients O +
were O +
evaluated O -
: O +
ATT O +
alone O +
was O +
the O +
cause O +
in O +
70 O +
( O -
5.7 O -
% O -
) O +
patients O -
. O +

Another O +
15 O +
( O -
1.2 O -
% O -
) O +
had O +
ATT O +
and O +
simultaneous O +
hepatitis B-Disease +
virus I-Disease +
infection I-Disease -
. O +

In O +
44 O +
( O -
62.8 O -
% O -
) O +
patients O -
, O +
ATT O +
was O +
prescribed O +
empirically O +
without O +
definitive O +
evidence O +
of O +
tuberculosis B-Disease -
. O +

ATT O -
- O -
ALF B-Disease +
patients O +
were O +
younger O +
( O -
32.87 O +
[ O -
+ O -
/-15.8 O -
] O +
years O -
) O -
, O +
and O +
49 O +
( O -
70 O -
% O -
) O +
of O +
them O +
were O +
women O -
. O +

Most O +
had O +
hyperacute O +
presentation O -
; O +
the O +
median O +
icterus B-Disease +
encephalopathy B-Disease +
interval O +
was O +
4.5 O +
( O -
0 O -
- O -
30 O -
) O +
days O -
. O +

The O +
median O +
duration O +
of O +
ATT O +
before O +
ALF B-Disease +
was O +
30 O +
( O -
7 O -
- O -
350 O -
) O +
days O -
. O +

At O +
presentation O -
, O +
advanced O +
encephalopathy B-Disease +
and O +
cerebral B-Disease +
edema I-Disease +
were O +
present O +
in O +
51 O +
( O -
76 O -
% O -
) O +
and O +
29 O +
( O -
41.4 O -
% O -
) O +
patients O -
, O +
respectively O -
. O +

Gastrointestinal B-Disease +
bleed I-Disease -
, O +
seizures B-Disease -
, O +
infection B-Disease -
, O +
and O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
were O +
documented O +
in O +
seven O +
( O -
10 O -
% O -
) O -
, O +
five O +
( O -
7.1 O -
% O -
) O -
, O +
26 O +
( O -
37.1 O -
% O -
) O -
, O +
and O +
seven O +
( O -
10 O -
% O -
) O +
patients O -
, O +
respectively O -
. O +

Compared O +
with O +
hepatitis B-Disease +
E I-Disease +
virus O +
( O -
HEV O -
) O +
and O +
non O -
- O -
A O +
non O -
- O -
E O -
- O -
induced O +
ALF B-Disease -
, O +
ATT O -
- O -
ALF B-Disease +
patients O +
had O +
nearly O +
similar O +
presentations O +
except O +
for O +
older O +
age O +
and O +
less O +
elevation O +
of O +
liver O +
enzymes O -
. O +

The O +
mortality O +
rate O +
among O +
patients O +
with O +
ATT O -
- O -
ALF B-Disease +
was O +
high O +
( O -
67.1 O -
% O -
, O +
n O +
= O +
47 O -
) O -
, O +
and O +
only O +
23 O +
( O -
32.9 O -
% O -
) O +
patients O +
recovered O +
with O +
medical O +
treatment O -
. O +

In O +
multivariate O +
analysis O -
, O +
three O +
factors O +
independently O +
predicted O +
mortality O -
: O +
serum O +
bilirubin O +
( O -
> O -
or=10.8 O +
mg O -
/ O -
dL O -
) O -
, O +
prothrombin O +
time O +
( O -
PT O -
) O +
prolongation O +
( O -
> O -
or=26 O +
seconds O -
) O -
, O +
and O +
grade O +
III O -
/ O -
IV O +
encephalopathy B-Disease +
at O +
presentation O -
. O +

CONCLUSION O -
: O +
ATT O -
- O -
ALF B-Disease +
constituted O +
5.7 O -
% O +
of O +
ALF B-Disease +
at O +
our O +
center O +
and O +
had O +
a O +
high O +
mortality O +
rate O -
. O +

Because O +
the O +
mortality O +
rate O +
is O +
so O +
high O -
, O +
determining O +
which O +
factors O +
are O +
predictors O +
is O +
less O +
important O -
. O +

A O +
high O +
proportion O +
of O +
patients O +
had O +
consumed O +
ATT O +
empirically O -
, O +
which O +
could O +
have O +
been O +
prevented O -
. O +

Renal O +
function O +
and O +
hemodynamics O +
during O +
prolonged O +
isoflurane O -
- O -
induced O +
hypotension B-Disease +
in O +
humans O -
. O +

The O +
effect O +
of O +
isoflurane O -
- O -
induced O +
hypotension B-Disease +
on O +
glomerular O +
function O +
and O +
renal O +
blood O +
flow O +
was O +
investigated O +
in O +
20 O +
human O +
subjects O -
. O +

Glomerular O +
filtration O +
rate O +
( O -
GFR O -
) O +
and O +
effective O +
renal O +
plasma O +
flow O +
( O -
ERPF O -
) O +
were O +
measured O +
by O +
inulin O +
and O +
para O -
- O -
aminohippurate O +
( O -
PAH O -
) O +
clearance O -
, O +
respectively O -
. O +

Anesthesia O +
was O +
maintained O +
with O +
fentanyl O -
, O +
nitrous O +
oxide O -
, O +
oxygen O -
, O +
and O +
isoflurane O -
. O +

Hypotension B-Disease +
was O +
induced O +
for O +
236.9 O +
+ O -
/- O +

15.1 O +
min O +
by O +
increasing O +
the O +
isoflurane O +
inspired O +
concentration O +
to O +
maintain O +
a O +
mean O +
arterial O +
pressure O +
of O +
59.8 O +
+ O -
/- O +

0.4 O +
mmHg O -
. O +

GFR O +
and O +
ERPF O +
decreased O +
with O +
the O +
induction O +
of O +
anesthesia O +
but O +
not O +
significantly O +
more O +
during O +
hypotension B-Disease -
. O +

Postoperatively O -
, O +
ERPF O +
returned O +
to O +
preoperative O +
values O -
, O +
whereas O +
GFR O +
was O +
higher O +
than O +
preoperative O +
values O -
. O +

Renal O +
vascular O +
resistance O +
increased O +
during O +
anesthesia O +
but O +
decreased O +
when O +
hypotension B-Disease +
was O +
induced O -
, O +
allowing O +
the O +
maintenance O +
of O +
renal O +
blood O +
flow O -
. O +

We O +
conclude O +
that O +
renal O +
compensatory O +
mechanisms O +
are O +
preserved O +
during O +
isoflurane O -
- O -
induced O +
hypotension B-Disease +
and O +
that O +
renal O +
function O +
and O +
hemodynamics O +
quickly O +
return O +
to O +
normal O +
when O +
normotension O +
is O +
resumed O -
. O +

Design O +
and O +
analysis O +
of O +
the O +
HYPREN O -
- O -
trial O -
: O +
safety O +
of O +
enalapril O +
and O +
prazosin O +
in O +
the O +
initial O +
treatment O +
phase O +
of O +
patients O +
with O +
congestive B-Disease +
heart I-Disease +
failure I-Disease -
. O +

Since O +
the O +
introduction O +
of O +
angiotensin O +
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitors O +
into O +
the O +
adjunctive O +
treatment O +
of O +
patients O +
with O +
congestive B-Disease +
heart I-Disease +
failure I-Disease -
, O +
cases O +
of O +
severe O +
hypotension B-Disease -
, O +
especially O +
on O +
the O +
first O +
day O +
of O +
treatment O -
, O +
have O +
occasionally O +
been O +
reported O -
. O +

To O +
assess O +
the O +
safety O +
of O +
the O +
ACE O +
inhibitor O +
enalapril O +
a O +
multicenter O -
, O +
randomized O -
, O +
prazosin O -
- O -
controlled O +
trial O +
was O +
designed O +
that O +
compared O +
the O +
incidence O +
and O +
severity O +
of O +
symptomatic O +
hypotension B-Disease +
on O +
the O +
first O +
day O +
of O +
treatment O -
. O +

Trial O +
medication O +
was O +
2.5 O +
mg O +
enalapril O +
or O +
0.5 O +
prazosin O -
. O +

Subjects O +
were O +
1210 O +
inpatients O +
with O +
New O +
York O +
Heart O +
Association O +
( O -
NYHA O -
) O +
functional O +
class O +
II O +
and O +
III O -
. O +

Patients O +
who O +
received O +
enalapril O +
experienced O +
clinically O +
and O +
statistically O +
significantly O +
less O +
symptomatic O +
hypotension B-Disease +
( O -
5.2 O -
% O -
) O +
than O +
the O +
patients O +
who O +
received O +
prazosin O +
( O -
12.9 O -
% O -
) O -
. O +

All O +
patients O +
recovered O -
. O +

It O +
was O +
concluded O +
that O +
treatment O +
with O +
enalapril O +
was O +
well O +
tolerated O +
and O +
it O +
is O -
, O +
therefore O -
, O +
unreasonable O +
to O +
restrict O +
the O +
initiation O +
of O +
treatment O +
with O +
enalapril O +
to O +
inpatients O -
. O +

Brainstem B-Disease +
dysgenesis I-Disease +
in O +
an O +
infant O +
prenatally O +
exposed O +
to O +
cocaine O -
. O +

Many O +
authors O +
described O +
the O +
effects O +
on O +
the O +
fetus O +
of O +
maternal O +
cocaine B-Disease +
abuse I-Disease +
during O +
pregnancy O -
. O +

Vasoconstriction O +
appears O +
to O +
be O +
the O +
common O +
mechanism O +
of O +
action O +
leading O +
to O +
a O +
wide O +
range O +
of O +
fetal B-Disease +
anomalies I-Disease -
. O +

We O +
report O +
on O +
an O +
infant O +
with O +
multiple B-Disease +
cranial I-Disease -
- I-Disease -
nerve I-Disease +
involvement I-Disease +
attributable O +
to O +
brainstem B-Disease +
dysgenesis I-Disease -
, O +
born O +
to O +
a O +
cocaine B-Disease -
- I-Disease -
addicted I-Disease +
mother O -
. O +

A O +
cross O -
- O -
sectional O +
evaluation O +
of O +
the O +
effect O +
of O +
risperidone O +
and O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
on O +
bone O +
mineral O +
density O +
in O +
boys O -
. O +

OBJECTIVE O -
: O +
The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
on O +
trabecular O +
bone O +
mineral O +
density O +
( O -
BMD O -
) O +
in O +
children O +
and O +
adolescents O -
. O +

METHOD O -
: O +
Medically O +
healthy O +
7- O +
to O +
17-year O -
- O -
old O +
males O +
chronically O +
treated O -
, O +
in O +
a O +
naturalistic O +
setting O -
, O +
with O +
risperidone O +
were O +
recruited O +
for O +
this O +
cross O -
- O -
sectional O +
study O +
through O +
child O +
psychiatry O +
outpatient O +
clinics O +
between O +
November O +
2005 O +
and O +
June O +
2007 O -
. O +

Anthropometric O +
measurements O +
and O +
laboratory O +
testing O +
were O +
conducted O -
. O +

The O +
clinical O +
diagnoses O +
were O +
based O +
on O +
chart O +
review O -
, O +
and O +
developmental O +
and O +
treatment O +
history O +
was O +
obtained O +
from O +
the O +
medical O +
record O -
. O +

Volumetric O +
BMD O +
of O +
the O +
ultradistal O +
radius O +
was O +
measured O +
using O +
peripheral O +
quantitative O +
computed O +
tomography O -
, O +
and O +
areal O +
BMD O +
of O +
the O +
lumbar O +
spine O +
was O +
estimated O +
using O +
dual O -
- O -
energy O +
x O -
- O -
ray O +
absorptiometry O -
. O +

RESULTS O -
: O +
Hyperprolactinemia B-Disease +
was O +
present O +
in O +
49 O -
% O +
of O +
83 O +
boys O +
( O -
n O +
= O +
41 O -
) O +
treated O +
with O +
risperidone O +
for O +
a O +
mean O +
of O +
2.9 O +
years O -
. O +

Serum O +
testosterone O +
concentration O +
increased O +
with O +
pubertal O +
status O +
but O +
was O +
not O +
affected O +
by O +
hyperprolactinemia B-Disease -
. O +

As O +
expected O -
, O +
bone O +
mineral O +
content O +
and O +
BMD O +
increased O +
with O +
sexual O +
maturity O -
. O +

After O +
adjusting O +
for O +
the O +
stage O +
of O +
sexual O +
development O +
and O +
height O +
and O +
BMI O +
z O +
scores O -
, O +
serum O +
prolactin O +
was O +
negatively O +
associated O +
with O +
trabecular O +
volumetric O +
BMD O +
at O +
the O +
ultradistal O +
radius O +
( O -
P O +
< O +
.03 O -
) O -
. O +

Controlling O +
for O +
relevant O +
covariates O -
, O +
we O +
also O +
found O +
treatment O +
with O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
to O +
be O +
associated O +
with O +
lower O +
trabecular O +
BMD O +
at O +
the O +
radius O +
( O -
P O +
= O +
.03 O -
) O +
and O +
BMD O +
z O +
score O +
at O +
the O +
lumbar O +
spine O +
( O -
P O +
< O +
.05 O -
) O -
. O +

These O +
findings O +
became O +
more O +
marked O +
when O +
the O +
analysis O +
was O +
restricted O +
to O +
non O -
- O -
Hispanic O +
white O +
patients O -
. O +

Of O +
13 O +
documented O +
fractures B-Disease -
, O +
3 O +
occurred O +
after O +
risperidone O +
and O +
SSRIs O +
were O +
started O -
, O +
and O +
none O +
occurred O +
in O +
patients O +
with O +
hyperprolactinemia B-Disease -
. O +

CONCLUSIONS O -
: O +
This O +
is O +
the O +
first O +
study O +
to O +
link O +
risperidone O -
- O -
induced O +
hyperprolactinemia B-Disease +
and O +
SSRI O +
treatment O +
to O +
lower O +
BMD O +
in O +
children O +
and O +
adolescents O -
. O +

Future O +
research O +
should O +
evaluate O +
the O +
longitudinal O +
course O +
of O +
this O +
adverse O +
event O +
to O +
determine O +
its O +
temporal O +
stability O +
and O +
whether O +
a O +
higher O +
fracture O +
rate O +
ensues O -
. O +

Rosaceiform O +
dermatitis B-Disease +
associated O +
with O +
topical O +
tacrolimus O +
treatment O -
. O +

We O +
describe O +
herein O +
3 O +
patients O +
who O +
developed O +
rosacea B-Disease -
- O -
like O +
dermatitis B-Disease +
eruptions B-Disease +
while O +
using O +
0.03 O -
% O +
or O +
0.1 O -
% O +
tacrolimus O +
ointment O +
for O +
facial B-Disease +
dermatitis I-Disease -
. O +

Skin O +
biopsy O +
specimens O +
showed O +
telangiectasia B-Disease +
and O +
noncaseating O +
epithelioid O +
granulomatous O +
tissue O +
formation O +
in O +
the O +
papillary O +
to O +
mid O +
dermis O -
. O +

Continuous O +
topical O +
use O +
of O +
immunomodulators O +
such O +
as O +
tacrolimus O +
or O +
pimecrolimus O +
should O +
be O +
regarded O +
as O +
a O +
potential O +
cause O +
of O +
rosaceiform O +
dermatitis B-Disease -
, O +
although O +
many O +
cases O +
have O +
not O +
been O +
reported O -
. O +

Central B-Disease +
nervous I-Disease +
system I-Disease +
complications I-Disease +
during O +
treatment O +
of O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia I-Disease +
in O +
a O +
single O +
pediatric O +
institution O -
. O +

Central B-Disease +
nervous I-Disease +
system I-Disease +
( I-Disease -
CNS I-Disease -
) I-Disease +
complications I-Disease +
during O +
treatment O +
of O +
childhood O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia I-Disease +
( O -
ALL B-Disease -
) O +
remain O +
a O +
challenging O +
clinical O +
problem O -
. O +

Outcome O +
improvement O +
with O +
more O +
intensive O +
chemotherapy O +
has O +
significantly O +
increased O +
the O +
incidence O +
and O +
severity O +
of O +
adverse O +
events O -
. O +

This O +
study O +
analyzed O +
the O +
incidence O +
of O +
neurological B-Disease +
complications I-Disease +
during O +
ALL B-Disease +
treatment O +
in O +
a O +
single O +
pediatric O +
institution O -
, O +
focusing O +
on O +
clinical O -
, O +
radiological O -
, O +
and O +
electrophysiological O +
findings O -
. O +

Exclusion O +
criteria O +
included O +
CNS O +
leukemic B-Disease +
infiltration I-Disease +
at O +
diagnosis O -
, O +
therapy O -
- O -
related O +
peripheral B-Disease +
neuropathy I-Disease -
, O +
late O -
- O -
onset O +
encephalopathy B-Disease -
, O +
or O +
long O -
- O -
term O +
neurocognitive B-Disease +
defects I-Disease -
. O +

During O +
a O +
9-year O +
period O -
, O +
we O +
retrospectively O +
collected O +
27 O +
neurological O +
events O +
( O -
11 O -
% O -
) O +
in O +
as O +
many O +
patients O -
, O +
from O +
253 O +
children O +
enrolled O +
in O +
the O +
ALL B-Disease +
front O -
- O -
line O +
protocol O -
. O +

CNS O +
complications O +
included O +
posterior O +
reversible O +
leukoencephalopathy B-Disease +
syndrome O +
( O -
n O +
= O +
10 O -
) O -
, O +
stroke B-Disease +
( O -
n O +
= O +
5 O -
) O -
, O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease +
( O -
n O +
= O +
2 O -
) O -
, O +
high O -
- O -
dose O +
methotrexate O +
toxicity B-Disease +
( O -
n O +
= O +
2 O -
) O -
, O +
syndrome O +
of O +
inappropriate B-Disease +
antidiuretic I-Disease +
hormone I-Disease +
secretion I-Disease +
( O -
n O +
= O +
1 O -
) O -
, O +
and O +
other O +
unclassified O +
events O +
( O -
n O +
= O +
7 O -
) O -
. O +

In O +
conclusion O -
, O +
CNS O +
complications O +
are O +
frequent O +
events O +
during O +
ALL B-Disease +
therapy O -
, O +
and O +
require O +
rapid O +
detection O +
and O +
prompt O +
treatment O +
to O +
limit O +
permanent O +
damage O -
. O +

Cocaine O +
causes O +
memory B-Disease +
and I-Disease +
learning I-Disease +
impairments I-Disease +
in O +
rats O -
: O +
involvement O +
of O +
nuclear O +
factor O +
kappa O +
B O +
and O +
oxidative O +
stress O -
, O +
and O +
prevention O +
by O +
topiramate O -
. O +

Different O +
mechanisms O +
have O +
been O +
suggested O +
for O +
cocaine O +
toxicity B-Disease +
including O +
an O +
increase O +
in O +
oxidative O +
stress O +
but O +
the O +
association O +
between O +
oxidative O +
status O +
in O +
the O +
brain O +
and O +
cocaine O +
induced O -
- O -
behaviour O +
is O +
poorly O +
understood O -
. O +

Nuclear O +
factor O +
kappa O +
B O +
( O -
NFkappaB O -
) O +
is O +
a O +
sensor O +
of O +
oxidative O +
stress O +
and O +
participates O +
in O +
memory O +
formation O +
that O +
could O +
be O +
involved O +
in O +
drug O +
toxicity B-Disease +
and O +
addiction O +
mechanisms O -
. O +

Therefore O +
NFkappaB O +
activity O -
, O +
oxidative O +
stress O -
, O +
neuronal O +
nitric O +
oxide O +
synthase O +
( O -
nNOS O -
) O +
activity O -
, O +
spatial O +
learning O +
and O +
memory O +
as O +
well O +
as O +
the O +
effect O +
of O +
topiramate O -
, O +
a O +
previously O +
proposed O +
therapy O +
for O +
cocaine B-Disease +
addiction I-Disease -
, O +
were O +
evaluated O +
in O +
an O +
experimental O +
model O +
of O +
cocaine O +
administration O +
in O +
rats O -
. O +

NFkappaB O +
activity O +
was O +
decreased O +
in O +
the O +
frontal O +
cortex O +
of O +
cocaine O +
treated O +
rats O -
, O +
as O +
well O +
as O +
GSH O +
concentration O +
and O +
glutathione O +
peroxidase O +
activity O +
in O +
the O +
hippocampus O -
, O +
whereas O +
nNOS O +
activity O +
in O +
the O +
hippocampus O +
was O +
increased O -
. O +

Memory O +
retrieval O +
of O +
experiences O +
acquired O +
prior O +
to O +
cocaine O +
administration O +
was O +
impaired O +
and O +
negatively O +
correlated O +
with O +
NFkappaB O +
activity O +
in O +
the O +
frontal O +
cortex O -
. O +

In O +
contrast O -
, O +
learning O +
of O +
new O +
tasks O +
was O +
enhanced O +
and O +
correlated O +
with O +
the O +
increase O +
of O +
nNOS O +
activity O +
and O +
the O +
decrease O +
of O +
glutathione O +
peroxidase O -
. O +

These O +
results O +
provide O +
evidence O +
for O +
a O +
possible O +
mechanistic O +
role O +
of O +
oxidative O +
and O +
nitrosative O +
stress O +
and O +
NFkappaB O +
in O +
the O +
alterations O +
induced O +
by O +
cocaine O -
. O +

Topiramate O +
prevented O +
all O +
the O +
alterations O +
observed O -
, O +
showing O +
novel O +
neuroprotective O +
properties O -
. O +

Coenzyme O +
Q10 O +
treatment O +
ameliorates O +
acute O +
cisplatin O +
nephrotoxicity B-Disease +
in O +
mice O -
. O +

The O +
nephroprotective O +
effect O +
of O +
coenzyme O +
Q10 O +
was O +
investigated O +
in O +
mice O +
with O +
acute B-Disease +
renal I-Disease +
injury I-Disease +
induced O +
by O +
a O +
single O +
i.p O -
. O +

injection O +
of O +
cisplatin O +
( O -
5 O +
mg O -
/ O -
kg O -
) O -
. O +

Coenzyme O +
Q10 O +
treatment O +
( O -
10 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
i.p O -
. O -
) O +
was O +
applied O +
for O +
6 O +
consecutive O +
days O -
, O +
starting O +
1 O +
day O +
before O +
cisplatin O +
administration O -
. O +

Coenzyme O +
Q10 O +
significantly O +
reduced O +
blood O +
urea O +
nitrogen O +
and O +
serum O +
creatinine O +
levels O +
which O +
were O +
increased O +
by O +
cisplatin O -
. O +

Coenzyme O +
Q10 O +
significantly O +
compensated O +
deficits O +
in O +
the O +
antioxidant O +
defense O +
mechanisms O +
( O -
reduced O +
glutathione O +
level O +
and O +
superoxide O +
dismutase O +
activity O -
) O -
, O +
suppressed O +
lipid O +
peroxidation O -
, O +
decreased O +
the O +
elevations O +
of O +
tumor B-Disease +
necrosis B-Disease +
factor O -
- O -
alpha O -
, O +
nitric O +
oxide O +
and O +
platinum O +
ion O +
concentration O -
, O +
and O +
attenuated O +
the O +
reductions O +
of O +
selenium O +
and O +
zinc O +
ions O +
in O +
renal O +
tissue O +
resulted O +
from O +
cisplatin O +
administration O -
. O +

Also O -
, O +
histopathological O +
renal B-Disease +
tissue I-Disease +
damage I-Disease +
mediated O +
by O +
cisplatin O +
was O +
ameliorated O +
by O +
coenzyme O +
Q10 O +
treatment O -
. O +

Immunohistochemical O +
analysis O +
revealed O +
that O +
coenzyme O +
Q10 O +
significantly O +
decreased O +
the O +
cisplatin O -
- O -
induced O +
overexpression O +
of O +
inducible O +
nitric O +
oxide O +
synthase O -
, O +
nuclear O +
factor O -
- O -
kappaB O -
, O +
caspase-3 O +
and O +
p53 O +
in O +
renal O +
tissue O -
. O +

It O +
was O +
concluded O +
that O +
coenzyme O +
Q10 O +
represents O +
a O +
potential O +
therapeutic O +
option O +
to O +
protect O +
against O +
acute O +
cisplatin O +
nephrotoxicity B-Disease +
commonly O +
encountered O +
in O +
clinical O +
practice O -
. O +

Reversible O +
cholestasis B-Disease +
with O +
bile B-Disease +
duct I-Disease +
injury I-Disease +
following O +
azathioprine O +
therapy O -
. O +

A O +
case O +
report O -
. O +

A O +
67-year O -
- O -
old O +
patient O -
, O +
with O +
primary O +
polymyositis B-Disease +
and O +
without O +
previous O +
evidence O +
of O +
liver B-Disease +
disease I-Disease -
, O +
developed O +
clinical O +
and O +
biochemical O +
features O +
of O +
severe O +
cholestasis B-Disease +
3 O +
months O +
after O +
initiation O +
of O +
azathioprine O +
therapy O -
. O +

Liver O +
biopsy O +
showed O +
cholestasis B-Disease +
with O +
both O +
cytological O +
and O +
architectural O +
alterations O +
of O +
interlobular O +
bile O +
ducts O -
. O +

Azathioprine O +
withdrawal O +
resulted O +
after O +
7 O +
weeks O +
in O +
the O +
resolution O +
of O +
clinical O +
and O +
biochemical O +
abnormalities O -
. O +

It O +
is O +
believed O +
that O +
this O +
is O +
the O +
first O +
reported O +
case O +
of O +
reversible O +
azathioprine O -
- O -
induced O +
cholestasis B-Disease +
associated O +
with O +
histological O +
evidence O +
of O +
bile B-Disease +
duct I-Disease +
injury I-Disease -
. O +

Efficacy O +
and O +
safety O +
of O +
asenapine O +
in O +
a O +
placebo- O +
and O +
haloperidol O -
- O -
controlled O +
trial O +
in O +
patients O +
with O +
acute O +
exacerbation O +
of O +
schizophrenia B-Disease -
. O +

Asenapine O +
is O +
approved O +
by O +
the O +
Food O +
and O +
Drugs O +
Administration O +
in O +
adults O +
for O +
acute O +
treatment O +
of O +
schizophrenia B-Disease +
or O +
of O +
manic B-Disease +
or O +
mixed O +
episodes O +
associated O +
with O +
bipolar B-Disease +
I I-Disease +
disorder I-Disease +
with O +
or O +
without O +
psychotic B-Disease +
features O -
. O +

In O +
a O +
double O -
- O -
blind O +
6-week O +
trial O -
, O +
458 O +
patients O +
with O +
acute O +
schizophrenia B-Disease +
were O +
randomly O +
assigned O +
to O +
fixed O -
- O -
dose O +
treatment O +
with O +
asenapine O +
at O +
5 O +
mg O +
twice O +
daily O +
( O -
BID O -
) O -
, O +
asenapine O +
at O +
10 O +
mg O +
BID O -
, O +
placebo O -
, O +
or O +
haloperidol O +
at O +
4 O +
mg O +
BID O +
( O -
to O +
verify O +
assay O +
sensitivity O -
) O -
. O +

With O +
last O +
observations O +
carried O +
forward O +
( O -
LOCF O -
) O -
, O +
mean O +
Positive O +
and O +
Negative O +
Syndrome O +
Scale O +
total O +
score O +
reductions O +
from O +
baseline O +
to O +
endpoint O +
were O +
significantly O +
greater O +
with O +
asenapine O +
at O +
5 O +
mg O +
BID O +
( O -
-16.2 O -
) O +
and O +
haloperidol O +
( O -
-15.4 O -
) O +
than O +
placebo O +
( O -
-10.7 O -
; O +
both O +
P O +
< O +
0.05 O -
) O -
; O +
using O +
mixed O +
model O +
for O +
repeated O +
measures O +
( O -
MMRM O -
) O -
, O +
changes O +
at O +
day O +
42 O +
were O +
significantly O +
greater O +
with O +
asenapine O +
at O +
5 O +
and O +
10 O +
mg O +
BID O +
( O -
-21.3 O +
and O +
-19.4 O -
, O +
respectively O -
) O +
and O +
haloperidol O +
( O -
-20.0 O -
) O +
than O +
placebo O +
( O -
-14.6 O -
; O +
all O +
P O +
< O +
0.05 O -
) O -
. O +

On O +
the O +
Positive O +
and O +
Negative O +
Syndrome O +
Scale O +
positive O +
subscale O -
, O +
all O +
treatments O +
were O +
superior O +
to O +
placebo O +
with O +
LOCF O +
and O +
MMRM O -
; O +
asenapine O +
at O +
5 O +
mg O +
BID O +
was O +
superior O +
to O +
placebo O +
on O +
the O +
negative O +
subscale O +
with O +
MMRM O +
and O +
on O +
the O +
general O +
psychopathology O +
subscale O +
with O +
LOCF O +
and O +
MMRM O -
. O +

Treatment O -
- O -
related O +
adverse O +
events O +
( O -
AEs O -
) O +
occurred O +
in O +
44 O -
% O +
and O +
52 O -
% O -
, O +
57 O -
% O -
, O +
and O +
41 O -
% O +
of O +
the O +
asenapine O +
at O +
5 O +
and O +
10 O +
mg O +
BID O -
, O +
haloperidol O -
, O +
and O +
placebo O +
groups O -
, O +
respectively O -
. O +

Extrapyramidal B-Disease +
symptoms I-Disease +
reported O +
as O +
AEs O +
occurred O +
in O +
15 O -
% O +
and O +
18 O -
% O -
, O +
34 O -
% O -
, O +
and O +
10 O -
% O +
of O +
the O +
asenapine O +
at O +
5 O +
and O +
10 O +
mg O +
BID O -
, O +
haloperidol O -
, O +
and O +
placebo O +
groups O -
, O +
respectively O -
. O +

Across O +
all O +
groups O -
, O +
no O +
more O +
than O +
5 O -
% O +
of O +
patients O +
had O +
clinically O +
significant O +
weight O +
change O -
. O +

Post O +
hoc O +
analyses O +
indicated O +
that O +
efficacy O +
was O +
similar O +
with O +
asenapine O +
and O +
haloperidol O -
; O +
greater O +
contrasts O +
were O +
seen O +
in O +
AEs O -
, O +
especially O +
extrapyramidal B-Disease +
symptoms I-Disease -
. O +

Salvage O +
therapy O +
with O +
nelarabine O -
, O +
etoposide O -
, O +
and O +
cyclophosphamide O +
in O +
relapsed O -
/ O -
refractory O +
paediatric O +
T B-Disease -
- I-Disease -
cell I-Disease +
lymphoblastic I-Disease +
leukaemia I-Disease +
and B-Disease +
lymphoma I-Disease -
. O +

A O +
combination O +
of O +
5 O +
d O +
of O +
nelarabine O +
( O -
AraG O -
) O +
with O +
5 O +
d O +
of O +
etoposide O +
( O -
VP O -
) O +
and O +
cyclophosphamide O +
( O -
CPM O -
) O +
and O +
prophylactic O +
intrathecal O +
chemotherapy O +
was O +
used O +
as O +
salvage O +
therapy O +
in O +
seven O +
children O +
with O +
refractory O +
or O +
relapsed O +
T B-Disease -
- I-Disease -
cell I-Disease +
leukaemia I-Disease +
or B-Disease +
lymphoma I-Disease -
. O +

The O +
most O +
common O +
side O +
effects O +
attributable O +
to O +
the O +
AraG O +
included O +
Grade O +
2 O +
and O +
3 O +
sensory O +
and O +
motor O +
neuropathy B-Disease +
and O +
musculoskeletal B-Disease +
pain I-Disease -
. O +

Haematological B-Disease +
toxicity I-Disease +
was O +
greater O +
for O +
the O +
combination O +
than O +
AraG O +
alone O -
, O +
although O +
median O +
time O +
to O +
neutrophil O +
and O +
platelet O +
recovery O +
was O +
consistent O +
with O +
other O +
salvage O +
therapies O -
. O +

All O +
patients O +
had O +
some O +
response O +
to O +
the O +
combined O +
therapy O +
and O +
five O +
of O +
the O +
seven O +
went O +
into O +
complete O +
remission O +
after O +
one O +
or O +
two O +
courses O +
of O +
AraG O -
/ O -
VP O -
/ O -
CPM O -
. O +

Our O +
experience O +
supports O +
the O +
safety O +
of O +
giving O +
AraG O +
as O +
salvage O +
therapy O +
in O +
synchrony O +
with O +
etoposide O +
and O +
cyclophosphamide O -
, O +
although O +
neurological B-Disease +
toxicity I-Disease +
must O +
be O +
closely O +
monitored O -
. O +

Dopamine O +
is O +
not O +
essential O +
for O +
the O +
development O +
of O +
methamphetamine O -
- O -
induced O +
neurotoxicity B-Disease -
. O +

It O +
is O +
widely O +
believed O +
that O +
dopamine O +
( O -
DA O -
) O +
mediates O +
methamphetamine O +
( O -
METH O -
) O -
-induced O +
toxicity B-Disease +
to O +
brain O +
dopaminergic O +
neurons O -
, O +
because O +
drugs O +
that O +
interfere O +
with O +
DA O +
neurotransmission O +
decrease O +
toxicity B-Disease -
, O +
whereas O +
drugs O +
that O +
increase O +
DA O +
neurotransmission O +
enhance O +
toxicity B-Disease -
. O +

However O -
, O +
temperature O +
effects O +
of O +
drugs O +
that O +
have O +
been O +
used O +
to O +
manipulate O +
brain O +
DA O +
neurotransmission O +
confound O +
interpretation O +
of O +
the O +
data O -
. O +

Here O +
we O +
show O +
that O +
the O +
recently O +
reported O +
ability O +
of O +
L O -
- O -
dihydroxyphenylalanine O +
to O +
reverse O +
the O +
protective O +
effect O +
of O +
alpha O -
- O -
methyl O -
- O -
para O -
- O -
tyrosine O +
on O +
METH O -
- O -
induced O +
DA O +
neurotoxicity B-Disease +
is O +
also O +
confounded O +
by O +
drug O +
effects O +
on O +
body O +
temperature O -
. O +

Further O -
, O +
we O +
show O +
that O +
mice O +
genetically O +
engineered O +
to O +
be O +
deficient O +
in O +
brain O +
DA O +
develop O +
METH O +
neurotoxicity B-Disease -
, O +
as O +
long O +
as O +
the O +
thermic O +
effects O +
of O +
METH O +
are O +
preserved O -
. O +

In O +
addition O -
, O +
we O +
demonstrate O +
that O +
mice O +
genetically O +
engineered O +
to O +
have O +
unilateral O +
brain O +
DA O +
deficits O +
develop O +
METH O -
- O -
induced O +
dopaminergic B-Disease +
deficits I-Disease +
that O +
are O +
of O +
comparable O +
magnitude O +
on O +
both O +
sides O +
of O +
the O +
brain O -
. O +

Taken O +
together O -
, O +
these O +
findings O +
demonstrate O +
that O +
DA O +
is O +
not O +
essential O +
for O +
the O +
development O +
of O +
METH O -
- O -
induced O +
dopaminergic O +
neurotoxicity B-Disease +
and O +
suggest O +
that O +
mechanisms O +
independent O +
of O +
DA O +
warrant O +
more O +
intense O +
investigation O -
. O +

Effect O +
of O +
adriamycin O +
combined O +
with O +
whole O +
body O +
hyperthermia B-Disease +
on O +
tumor B-Disease +
and O +
normal O +
tissues O -
. O +

Thermal O +
enhancement O +
of O +
Adriamycin O -
- O -
mediated O +
antitumor O +
activity O +
and O +
normal O +
tissue O +
toxicities B-Disease +
by O +
whole O +
body O +
hyperthermia B-Disease +
were O +
compared O +
using O +
a O +
F344 O +
rat O +
model O -
. O +

Antitumor O +
activity O +
was O +
studied O +
using O +
a O +
tumor B-Disease +
growth O +
delay O +
assay O -
. O +

Acute O +
normal O +
tissue O +
toxicities B-Disease +
( O -
i.e. O -
, O +
leukopenia B-Disease +
and O +
thrombocytopenia B-Disease -
) O +
and O +
late O +
normal O +
tissue O +
toxicities B-Disease +
( O -
i.e. O -
, O +
myocardial B-Disease +
and I-Disease +
kidney I-Disease +
injury I-Disease -
) O +
were O +
evaluated O +
by O +
functional O -
/ O -
physiological O +
assays O +
and O +
by O +
morphological O +
techniques O -
. O +

Whole O +
body O +
hyperthermia B-Disease +
( O -
120 O +
min O +
at O +
41.5 O +
degrees O +
C O -
) O +
enhanced O +
both O +
Adriamycin O -
- O -
mediated O +
antitumor O +
activity O +
and O +
toxic O +
side O +
effects O -
. O +

The O +
thermal O +
enhancement O +
ratio O +
calculated O +
for O +
antitumor O +
activity O +
was O +
1.6 O -
. O +

Thermal O +
enhancement O +
ratios O +
estimated O +
for O +
" O -
acute O -
" O +
hematological O +
changes O +
were O +
1.3 O -
, O +
whereas O +
those O +
estimated O +
for O +
" O -
late O -
" O +
damage O +
( O -
based O +
on O +
morphological O +
cardiac B-Disease +
and I-Disease +
renal I-Disease +
lesions I-Disease -
) O +
varied O +
between O +
2.4 O +
and O +
4.3 O -
. O +

Thus O -
, O +
while O +
whole O +
body O +
hyperthermia B-Disease +
enhances O +
Adriamycin O -
- O -
mediated O +
antitumor O +
effect O -
, O +
normal O +
tissue O +
toxicity B-Disease +
is O +
also O +
increased O -
, O +
and O +
the O +
potential O +
therapeutic O +
gain O +
of O +
the O +
combined O +
modality O +
treatment O +
is O +
eroded O -
. O +

Swallowing O -
- O -
induced O +
atrial B-Disease +
tachyarrhythmia I-Disease +
triggered O +
by O +
salbutamol O -
: O +
case O +
report O +
and O +
review O +
of O +
the O +
literature O -
. O +

CASE O -
: O +
A O +
49-year O -
- O -
old O +
patient O +
experienced O +
chest O +
discomfort O +
while O +
swallowing O -
. O +

On O +
electrocardiogram O -
, O +
episodes O +
of O +
atrial B-Disease +
tachyarrhythmia I-Disease +
were O +
recorded O +
immediately O +
after O +
swallowing O -
; O +
24-hour O +
Holter O +
monitoring O +
recorded O +
several O +
events O -
. O +

The O +
arrhythmia B-Disease +
resolved O +
after O +
therapy O +
with O +
atenolol O -
, O +
but O +
recurred O +
a O +
year O +
later O -
. O +

The O +
patient O +
noticed O +
that O +
before O +
these O +
episodes O +
he O +
had O +
been O +
using O +
an O +
inhalator O +
of O +
salbutamol O -
. O +

After O +
stopping O +
the O +
beta O -
- O -
agonist O -
, O +
and O +
after O +
a O +
week O +
with O +
the O +
atenolol O -
, O +
the O +
arrhythmia B-Disease +
disappeared O -
. O +

DISCUSSION O -
: O +
Swallowing O -
- O -
induced O +
atrial B-Disease +
tachyarrhythmia I-Disease +
( O -
SIAT B-Disease -
) O +
is O +
a O +
rare O +
phenomenon O -
. O +

Fewer O +
than O +
50 O +
cases O +
of O +
SIAT B-Disease +
have O +
been O +
described O +
in O +
the O +
literature O -
. O +

This O +
article O +
summarizes O +
all O +
the O +
cases O +
published O -
, O +
creating O +
a O +
comprehensive O +
review O +
of O +
the O +
current O +
knowledge O +
and O +
approach O +
to O +
SIAT B-Disease -
. O +

It O +
discusses O +
demographics O -
, O +
clinical O +
characteristics O +
and O +
types O +
of O +
arrhythmia B-Disease -
, O +
postulated O +
mechanisms O +
of O +
SIAT B-Disease -
, O +
and O +
different O +
treatment O +
possibilities O +
such O +
as O +
medications O -
, O +
surgery O -
, O +
and O +
radiofrequency O +
catheter O +
ablation O +
( O -
RFCA O -
) O -
. O +

CONCLUSION O -
: O +
Salbutamol O +
is O +
presented O +
here O +
as O +
a O +
possible O +
trigger O +
for O +
SIAT B-Disease -
. O +

Although O +
it O +
is O +
difficult O +
to O +
define O +
causality O +
in O +
a O +
case O +
report O -
, O +
it O +
is O +
logical O +
to O +
think O +
that O +
a O +
beta O -
- O -
agonist O +
like O +
salbutamol O +
( O -
known O +
to O +
induce O +
tachycardia B-Disease -
) O +
may O +
be O +
the O +
trigger O +
of O +
adrenergic O +
reflexes O +
originating O +
in O +
the O +
esophagus O +
while O +
swallowing O +
and O +
that O +
a O +
beta O -
- O -
blocker O +
such O +
as O +
atenolol O +
( O -
that O +
blocks O +
the O +
adrenergic O +
activity O -
) O +
may O +
relieve O +
it O -
. O +

Glutamatergic O +
neurotransmission O +
mediated O +
by O +
NMDA O +
receptors O +
in O +
the O +
inferior O +
colliculus O +
can O +
modulate O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease -
. O +

The O +
inferior O +
colliculus O +
( O -
IC O -
) O +
is O +
primarily O +
involved O +
in O +
the O +
processing O +
of O +
auditory O +
information O -
, O +
but O +
it O +
is O +
distinguished O +
from O +
other O +
auditory O +
nuclei O +
in O +
the O +
brainstem O +
by O +
its O +
connections O +
with O +
structures O +
of O +
the O +
motor O +
system O -
. O +

Functional O +
evidence O +
relating O +
the O +
IC O +
to O +
motor O +
behavior O +
derives O +
from O +
experiments O +
showing O +
that O +
activation O +
of O +
the O +
IC O +
by O +
electrical O +
stimulation O +
or O +
excitatory O +
amino O +
acid O +
microinjection O +
causes O +
freezing O -
, O +
escape O -
- O -
like O +
behavior O -
, O +
and O +
immobility O -
. O +

However O -
, O +
the O +
nature O +
of O +
this O +
immobility O +
is O +
still O +
unclear O -
. O +

The O +
present O +
study O +
examined O +
the O +
influence O +
of O +
excitatory O +
amino O +
acid O -
- O -
mediated O +
mechanisms O +
in O +
the O +
IC O +
on O +
the O +
catalepsy B-Disease +
induced O +
by O +
the O +
dopamine O +
receptor O +
blocker O +
haloperidol O +
administered O +
systemically O +
( O -
1 O +
or O +
0.5 O +
mg O -
/ O -
kg O -
) O +
in O +
rats O -
. O +

Haloperidol O -
- O -
induced O +
catalepsy B-Disease +
was O +
challenged O +
with O +
prior O +
intracollicular O +
microinjections O +
of O +
glutamate O +
NMDA O +
receptor O +
antagonists O -
, O +
MK-801 O +
( O -
15 O +
or O +
30 O +
mmol O -
/ O -
0.5 O +
microl O -
) O +
and O +
AP7 O +
( O -
10 O +
or O +
20 O +
nmol O -
/ O -
0.5 O +
microl O -
) O -
, O +
or O +
of O +
the O +
NMDA O +
receptor O +
agonist O +
N O -
- O -
methyl O -
- O -
d O -
- O -
aspartate O +
( O -
NMDA O -
, O +
20 O +
or O +
30 O +
nmol O -
/ O -
0.5 O +
microl O -
) O -
. O +

The O +
results O +
showed O +
that O +
intracollicular O +
microinjection O +
of O +
MK-801 O +
and O +
AP7 O +
previous O +
to O +
systemic O +
injections O +
of O +
haloperidol O +
significantly O +
attenuated O +
the O +
catalepsy B-Disease -
, O +
as O +
indicated O +
by O +
a O +
reduced O +
latency O +
to O +
step O +
down O +
from O +
a O +
horizontal O +
bar O -
. O +

Accordingly O -
, O +
intracollicular O +
microinjection O +
of O +
NMDA O +
increased O +
the O +
latency O +
to O +
step O +
down O +
the O +
bar O -
. O +

These O +
findings O +
suggest O +
that O +
glutamate O -
- O -
mediated O +
mechanisms O +
in O +
the O +
neural O +
circuits O +
at O +
the O +
IC O +
level O +
influence O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
and O +
participate O +
in O +
the O +
regulation O +
of O +
motor O +
activity O -
. O +

Permeability O -
, O +
ultrastructural O +
changes O -
, O +
and O +
distribution O +
of O +
novel O +
proteins O +
in O +
the O +
glomerular O +
barrier O +
in O +
early O +
puromycin O +
aminonucleoside O +
nephrosis B-Disease -
. O +

BACKGROUND O -
/ O -
AIMS O -
: O +
It O +
is O +
still O +
unclear O +
what O +
happens O +
in O +
the O +
glomerulus O +
when O +
proteinuria B-Disease +
starts O -
. O +

Using O +
puromycin O +
aminonucleoside O +
nephrosis B-Disease +
( O -
PAN O -
) O +
rats O -
, O +
we O +
studied O +
early O +
ultrastructural O +
and O +
permeability O +
changes O +
in O +
relation O +
to O +
the O +
expression O +
of O +
the O +
podocyte O -
- O -
associated O +
molecules O +
nephrin O -
, O +
a O -
- O -
actinin O -
, O +
dendrin O -
, O +
and O +
plekhh2 O -
, O +
the O +
last O +
two O +
of O +
which O +
were O +
only O +
recently O +
discovered O +
in O +
podocytes O -
. O +

METHODS O -
: O +
Using O +
immune O +
stainings O -
, O +
semiquantitative O +
measurement O +
was O +
performed O +
under O +
the O +
electron O +
microscope O -
. O +

Permeability O +
was O +
assessed O +
using O +
isolated O +
kidney O +
perfusion O +
with O +
tracers O -
. O +

Possible O +
effects O +
of O +
ACE O +
inhibition O +
were O +
tested O -
. O +

RESULTS O -
: O +
By O +
day O +
2 O -
, O +
some O +
patchy O +
foot O +
process O +
effacement O -
, O +
but O +
no O +
proteinuria B-Disease -
, O +
appeared O -
. O +

The O +
amount O +
of O +
nephrin O +
was O +
reduced O +
in O +
both O +
diseased O +
and O +
normal O +
areas O -
. O +

The O +
other O +
proteins O +
showed O +
few O +
changes O -
, O +
which O +
were O +
limited O +
to O +
diseased O +
areas O -
. O +

By O +
day O +
4 O -
, O +
foot O +
process O +
effacement O +
was O +
complete O +
and O +
proteinuria B-Disease +
appeared O +
in O +
parallel O +
with O +
signs O +
of O +
size O +
barrier O +
damage O -
. O +

Nephrin O +
decreased O +
further O -
, O +
while O +
dendrin O +
and O +
plekhh2 O +
also O +
decreased O +
but O +
a O -
- O -
actinin O +
remained O +
unchanged O -
. O +

ACE O +
inhibition O +
had O +
no O +
significant O +
protective O +
effect O -
. O +

CONCLUSIONS O -
: O +
PAN O +
glomeruli O +
already O +
showed O +
significant O +
pathology O +
by O +
day O +
4 O -
, O +
despite O +
relatively O +
mild O +
proteinuria B-Disease -
. O +

This O +
was O +
preceded O +
by O +
altered O +
nephrin O +
expression O -
, O +
supporting O +
its O +
pivotal O +
role O +
in O +
podocyte O +
morphology O -
. O +

The O +
novel O +
proteins O +
dendrin O +
and O +
plekhh2 O +
were O +
both O +
reduced O -
, O +
suggesting O +
roles O +
in O +
PAN O -
, O +
whereas O +
a O -
- O -
actinin O +
was O +
unchanged O -
. O +

A O +
novel O -
, O +
multiple O +
symptom O +
model O +
of O +
obsessive B-Disease -
- I-Disease -
compulsive I-Disease -
- I-Disease -
like I-Disease +
behaviors I-Disease +
in O +
animals O -
. O +

BACKGROUND O -
: O +
Current O +
animal O +
models O +
of O +
obsessive B-Disease -
- I-Disease -
compulsive I-Disease +
disorder I-Disease +
( O -
OCD B-Disease -
) O +
typically O +
involve O +
acute O -
, O +
drug O -
- O -
induced O +
symptom O +
provocation O +
or O +
a O +
genetic O +
association O +
with O +
stereotypies O +
or O +
anxiety B-Disease -
. O +

None O +
of O +
these O +
current O +
models O +
demonstrate O +
multiple O +
OCD B-Disease -
- O -
like O +
behaviors O -
. O +

METHODS O -
: O +
Neonatal O +
rats O +
were O +
treated O +
with O +
the O +
tricyclic O +
antidepressant O +
clomipramine O +
or O +
vehicle O +
between O +
days O +
9 O +
and O +
16 O +
twice O +
daily O +
and O +
behaviorally O +
tested O +
in O +
adulthood O -
. O +

RESULTS O -
: O +
Clomipramine O +
exposure O +
in O +
immature O +
rats O +
produced O +
significant O +
behavioral O +
and O +
biochemical O +
changes O +
that O +
include O +
enhanced O +
anxiety B-Disease +
( O -
elevated O +
plus O +
maze O +
and O +
marble O +
burying O -
) O -
, O +
behavioral B-Disease +
inflexibility I-Disease +
( O -
perseveration O +
in O +
the O +
spontaneous O +
alternation O +
task O +
and O +
impaired O +
reversal O +
learning O -
) O -
, O +
working O +
memory B-Disease +
impairment I-Disease +
( O -
e.g. O -
, O +
win O -
- O -
shift O +
paradigm O -
) O -
, O +
hoarding B-Disease -
, O +
and O +
corticostriatal B-Disease +
dysfunction I-Disease -
. O +

Dopamine O +
D2 O +
receptors O +
were O +
elevated O +
in O +
the O +
striatum O -
, O +
whereas O +
serotonin O +
2C O -
, O +
but O +
not O +
serotonin O +
1A O -
, O +
receptors O +
were O +
elevated O +
in O +
the O +
orbital O +
frontal O +
cortex O -
. O +

CONCLUSIONS O -
: O +
This O +
is O +
the O +
first O +
demonstration O +
of O +
multiple O +
symptoms O +
consistent O +
with O +
an O +
OCD B-Disease -
- O -
like O +
profile O +
in O +
animals O -
. O +

Moreover O -
, O +
these O +
behaviors O +
are O +
accompanied O +
by O +
biochemical O +
changes O +
in O +
brain O +
regions O +
previously O +
identified O +
as O +
relevant O +
to O +
OCD B-Disease -
. O +

This O +
novel O +
model O +
of O +
OCD B-Disease +
demonstrates O +
that O +
drug O +
exposure O +
during O +
a O +
sensitive O +
period O +
can O +
program O +
disease O -
- O -
like O +
systems O +
permanently O -
, O +
which O +
could O +
have O +
implications O +
for O +
current O +
and O +
future O +
therapeutic O +
strategies O +
for O +
this O +
and O +
other O +
psychiatric B-Disease +
disorders I-Disease -
. O +

Elevation O +
of O +
ADAM10 O -
, O +
ADAM17 O -
, O +
MMP-2 O +
and O +
MMP-9 O +
expression O +
with O +
media O +
degeneration O +
features O +
CaCl2-induced O +
thoracic B-Disease +
aortic I-Disease +
aneurysm I-Disease +
in O +
a O +
rat O +
model O -
. O +

PURPOSE O -
: O +
This O +
study O +
was O +
designed O +
to O +
establish O +
a O +
rat O +
model O +
of O +
thoracic B-Disease +
aortic I-Disease +
aneurysm I-Disease +
( O -
TAA B-Disease -
) O +
by O +
calcium O +
chloride O +
( O -
CaCl O -
( O -
2 O -
) O -
) O -
-induced O +
arterial B-Disease +
injury I-Disease +
and O +
to O +
explore O +
the O +
potential O +
role O +
of O +
a O +
disintegrin O +
and O +
metalloproteinase O +
( O -
ADAM O -
) O -
, O +
matrix O +
metalloproteinases O +
( O -
MMPs O -
) O +
and O +
their O +
endogenous O +
inhibitors O +
( O -
TIMPs O -
) O +
in O +
TAA B-Disease +
formation O -
. O +

METHODS O -
: O +
Thoracic O +
aorta O +
of O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
was O +
exposed O +
to O +
0.5 O -
M O +
CaCl O -
( O -
2 O -
) O +
or O +
normal O +
saline O +
( O -
NaCl O -
) O -
. O +

After O +
12weeks O -
, O +
animals O +
were O +
euthanized O -
, O +
and O +
CaCl O -
( O -
2 O -
) O -
-treated O -
, O +
CaCl O -
( O -
2 O -
) O -
-untreated O +
( O -
n=12 O -
) O +
and O +
NaCl O -
- O -
treated O +
aortic O +
segments O +
( O -
n=12 O -
) O +
were O +
collected O +
for O +
histological O +
and O +
molecular O +
assessments O -
. O +

MMP O -
- O -
TIMP O +
and O +
ADAM O +
mRNAs O +
were O +
semi O -
- O -
quantitatively O +
analyzed O +
and O +
protein O +
expressions O +
were O +
determined O +
by O +
immunohistochemistry O -
. O +

RESULTS O -
: O +
Despite O +
similar O +
external O +
diameters O +
among O +
CaCl O -
( O -
2 O -
) O -
-treated O -
, O +
non O -
- O -
CaCl O -
( O -
2 O -
) O -
-treated O +
and O +
NaCl O -
- O -
treated O +
segments O -
, O +
aneurymal O +
alteration O +
( O -
n=6 O -
, O +
50 O -
% O -
) O -
, O +
media O +
degeneration O +
with O +
regional O +
disruption O -
, O +
fragmentation O +
of O +
elastic O +
fiber O -
, O +
and O +
increased O +
collagen O +
deposition O +
( O -
n=12 O -
, O +
100 O -
% O -
) O +
were O +
demonstrated O +
in O +
CaCl O -
( O -
2 O -
) O -
-treated O +
segments O -
. O +

MMP-2 O -
, O +
MMP-9 O -
, O +
ADAM-10 O +
and O +
ADAM-17 O +
mRNA O +
levels O +
were O +
increased O +
in O +
CaCl O -
( O -
2 O -
) O -
-treated O +
segments O +
( O -
all O +
p<0.01 O -
) O -
, O +
with O +
trends O +
of O +
elevation O +
in O +
CaCl O -
( O -
2 O -
) O -
-untreated O +
segments O -
, O +
as O +
compared O +
with O +
NaCl O -
- O -
treated O +
segments O -
. O +

Immunohistochemistry O +
displayed O +
significantly O +
increased O +
expressions O +
of O +
MMP-2 O -
, O +
MMP-9 O -
, O +
ADAM-10 O +
and O +
ADAM-17 O +
( O -
all O +
p<0.01 O -
) O +
in O +
intima O +
and O +
media O +
for O +
CaCl O -
( O -
2 O -
) O -
-treated O +
segments O -
. O +

TIMP O +
mRNA O +
and O +
tissue O +
levels O +
did O +
not O +
differ O +
obviously O +
among O +
the O +
three O +
aortic O +
segments O -
. O +

CONCLUSION O -
: O +
This O +
study O +
establishes O +
a O +
TAA B-Disease +
model O +
by O +
periarterial O +
CaCl O -
( O -
2 O -
) O +
exposure O +
in O +
rats O -
, O +
and O +
demonstrates O +
a O +
significant O +
elevation O +
of O +
expression O +
of O +
MMP-2 O -
, O +
MMP-9 O -
, O +
ADAM10 O +
and O +
ADAM17 O +
in O +
the O +
pathogenesis O +
of O +
vascular O +
remodeling O -
. O +

Suxamethonium O +
induced O +
prolonged O +
apnea B-Disease +
in O +
a O +
patient O +
receiving O +
electroconvulsive O +
therapy O -
. O +

Suxamethonium O +
causes O +
prolonged O +
apnea B-Disease +
in O +
patients O +
in O +
whom O +
pseudocholinesterase O +
enzyme O +
gets O +
deactivated O +
by O +
organophosphorus O +
( O -
OP O -
) O +
poisons O -
. O +

Here O -
, O +
we O +
present O +
a O +
similar O +
incident O +
in O +
a O +
severely O +
depressed B-Disease +
patient O +
who O +
received O +
electroconvulsive O +
therapy O +
( O -
ECT O -
) O -
. O +

Prolonged O +
apnea B-Disease +
in O +
our O +
case O +
ensued O +
because O +
the O +
information O +
about O +
suicidal O +
attempt O +
by O +
OP O +
compound O +
was O +
concealed O +
from O +
the O +
treating O +
team O -
. O +

Curcumin O +
ameliorates O +
cognitive B-Disease +
dysfunction I-Disease +
and O +
oxidative O +
damage O +
in O +
phenobarbitone O +
and O +
carbamazepine O +
administered O +
rats O -
. O +

The O +
antiepileptic O +
drugs O -
, O +
phenobarbitone O +
and O +
carbamazepine O +
are O +
well O +
known O +
to O +
cause O +
cognitive B-Disease +
impairment I-Disease +
on O +
chronic O +
use O -
. O +

The O +
increase O +
in O +
free O +
radical O +
generation O +
has O +
been O +
implicated O +
as O +
one O +
of O +
the O +
important O +
mechanisms O +
of O +
cognitive B-Disease +
impairment I-Disease +
by O +
antiepileptic O +
drugs O -
. O +

Curcumin O +
has O +
shown O +
antioxidant O -
, O +
anti O -
- O -
inflammatory O +
and O +
neuro O -
- O -
protective O +
properties O -
. O +

Therefore O -
, O +
the O +
present O +
study O +
was O +
carried O +
out O +
to O +
investigate O +
the O +
effect O +
of O +
chronic O +
curcumin O +
administration O +
on O +
phenobarbitone- O +
and O +
carbamazepine O -
- O -
induced O +
cognitive B-Disease +
impairment I-Disease +
and O +
oxidative O +
stress O +
in O +
rats O -
. O +

Pharmacokinetic O +
interactions O +
of O +
curcumin O +
with O +
phenobarbitone O +
and O +
carbamazepine O +
were O +
also O +
studied O -
. O +

Vehicle O -
/ O -
drugs O +
were O +
administered O +
daily O +
for O +
21days O +
to O +
male O +
Wistar O +
rats O -
. O +

Passive O +
avoidance O +
paradigm O +
and O +
elevated O +
plus O +
maze O +
test O +
were O +
used O +
to O +
assess O +
cognitive O +
function O -
. O +

At O +
the O +
end O +
of O +
study O +
period O -
, O +
serum O +
phenobarbitone O +
and O +
carbamazepine O -
, O +
whole O +
brain O +
malondialdehyde O +
and O +
reduced O +
glutathione O +
levels O +
were O +
estimated O -
. O +

The O +
administration O +
of O +
phenobarbitone O +
and O +
carbamazepine O +
for O +
21days O +
caused O +
a O +
significant O +
impairment B-Disease +
of I-Disease +
learning I-Disease +
and I-Disease +
memory I-Disease +
as O +
well O +
as O +
an O +
increased O +
oxidative O +
stress O -
. O +

Concomitant O +
curcumin O +
administration O +
prevented O +
the O +
cognitive B-Disease +
impairment I-Disease +
and O +
decreased O +
the O +
increased O +
oxidative O +
stress O +
induced O +
by O +
these O +
antiepileptic O +
drugs O -
. O +

Curcumin O +
co O -
- O -
administration O +
did O +
not O +
cause O +
any O +
significant O +
alteration O +
in O +
the O +
serum O +
concentrations O +
of O +
both O +
phenobarbitone O +
as O +
well O +
as O +
carbamazepine O -
. O +

These O +
results O +
show O +
that O +
curcumin O +
has O +
beneficial O +
effect O +
in O +
mitigating O +
the O +
deterioration B-Disease +
of I-Disease +
cognitive I-Disease +
functions I-Disease +
and O +
oxidative O +
damage O +
in O +
rats O +
treated O +
with O +
phenobarbitone O +
and O +
carbamazepine O +
without O +
significantly O +
altering O +
their O +
serum O +
concentrations O -
. O +

The O +
findings O +
suggest O +
that O +
curcumin O +
can O +
be O +
considered O +
as O +
a O +
potential O +
safe O +
and O +
effective O +
adjuvant O +
to O +
phenobarbitone O +
and O +
carbamazepine O +
therapy O +
in O +
preventing O +
cognitive B-Disease +
impairment I-Disease +
associated O +
with O +
these O +
drugs O -
. O +

Effects O +
of O +
active O +
constituents O +
of O +
Crocus O +
sativus O +
L. O -
, O +
crocin O +
on O +
streptozocin O -
- O -
induced O +
model O +
of O +
sporadic O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
in O +
male O +
rats O -
. O +

BACKGROUND O -
: O +
The O +
involvement O +
of O +
water O -
- O -
soluble O +
carotenoids O -
, O +
crocins O -
, O +
as O +
the O +
main O +
and O +
active O +
components O +
of O +
Crocus O +
sativus O +
L. O +
extract O +
in O +
learning O +
and O +
memory O +
processes O +
has O +
been O +
proposed O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
effect O +
of O +
crocins O +
on O +
sporadic O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
induced O +
by O +
intracerebroventricular O +
( O -
icv O -
) O +
streptozocin O +
( O -
STZ O -
) O +
in O +
male O +
rats O +
was O +
investigated O -
. O +

METHODS O -
: O +
Male O +
adult O +
Wistar O +
rats O +
( O -
n O +
= O +
90 O +
and O +
260 O -
- O -
290 O +
g O -
) O +
were O +
divided O +
into O +
1 O -
, O +
control O -
; O +
2 O +
and O +
3 O -
, O +
crocins O +
( O -
15 O +
and O +
30 O +
mg O -
/ O -
kg O -
) O -
; O +
4 O -
, O +
STZ O -
; O +
5 O +
and O +
6 O -
, O +
STZ O +
+ O +
crocins O +
( O -
15 O +
and O +
30 O +
mg O -
/ O -
kg O -
) O +
groups O -
. O +

In O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
groups O -
, O +
rats O +
were O +
injected O +
with O +
STZ O -
- O -
icv O +
bilaterally O +
( O -
3 O +
mg O -
/ O -
kg O -
) O +
in O +
first O +
day O +
and O +
3 O +
days O +
later O -
, O +
a O +
similar O +
STZ O -
- O -
icv O +
application O +
was O +
repeated O -
. O +

In O +
STZ O +
+ O +
crocin O +
animal O +
groups O -
, O +
crocin O +
was O +
applied O +
in O +
doses O +
of O +
15 O +
and O +
30 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
, O +
one O +
day O +
pre O -
- O -
surgery O +
and O +
continued O +
for O +
three O +
weeks O -
. O +

Prescription O +
of O +
crocin O +
in O +
each O +
dose O +
was O +
repeated O +
once O +
for O +
two O +
days O -
. O +

However O -
, O +
the O +
learning O +
and O +
memory O +
performance O +
was O +
assessed O +
using O +
passive O +
avoidance O +
paradigm O -
, O +
and O +
for O +
spatial O +
cognition O +
evaluation O -
, O +
Y O -
- O -
maze O +
task O +
was O +
used O -
. O +

RESULTS O -
: O +
It O +
was O +
found O +
out O +
that O +
crocin O +
( O -
30 O +
mg O -
/ O -
kg O -
) O -
-treated O +
STZ O -
- O -
injected O +
rats O +
show O +
higher O +
correct O +
choices O +
and O +
lower O +
errors O +
in O +
Y O -
- O -
maze O +
than O +
vehicle O -
- O -
treated O +
STZ O -
- O -
injected O +
rats O -
. O +

In O +
addition O -
, O +
crocin O +
in O +
the O +
mentioned O +
dose O +
could O +
significantly O +
attenuated O +
learning B-Disease +
and I-Disease +
memory I-Disease +
impairment I-Disease +
in O +
treated O +
STZ O -
- O -
injected O +
group O +
in O +
passive O +
avoidance O +
test O -
. O +

CONCLUSION O -
: O +
Therefore O -
, O +
these O +
results O +
demonstrate O +
the O +
effectiveness O +
of O +
crocin O +
( O -
30 O +
mg O -
/ O -
kg O -
) O +
in O +
antagonizing O +
the O +
cognitive B-Disease +
deficits I-Disease +
caused O +
by O +
STZ O -
- O -
icv O +
in O +
rats O +
and O +
its O +
potential O +
in O +
the O +
treatment O +
of O +
neurodegenerative B-Disease +
diseases I-Disease +
such O +
as O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

Can O +
angiogenesis O +
be O +
a O +
target O +
of O +
treatment O +
for O +
ribavirin O +
associated O +
hemolytic B-Disease +
anemia I-Disease -
? O +

BACKGROUND O -
/ O -
AIMS O -
: O +
Recently O +
ribavirin O +
has O +
been O +
found O +
to O +
inhibit O +
angiogenesis O +
and O +
a O +
number O +
of O +
angiogenesis O +
inhibitors O +
such O +
as O +
sunitinib O +
and O +
sorafenib O +
have O +
been O +
found O +
to O +
cause O +
acute O +
hemolysis B-Disease -
. O +

We O +
aimed O +
to O +
investigate O +
whether O +
there O +
is O +
a O +
relation O +
between O +
hemoglobin O -
, O +
haptoglobin O +
and O +
angiogenesis O +
soluble O +
markers O +
which O +
are O +
modifiable O +
and O +
can O +
help O +
in O +
developing O +
strategies O +
against O +
anemia B-Disease -
. O +

METHODS O -
: O +
Fourteen O +
patients O +
chronically B-Disease +
infected I-Disease +
with I-Disease +
hepatitis I-Disease +
C I-Disease +
virus I-Disease +
were O +
treated O +
by O +
pegylated O +
interferon O +
alpha O +
2a O +
and O +
ribavirin O -
. O +

Serum O +
hemoglobin O -
, O +
haptoglobin O +
and O +
angiogenesis O +
markers O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
angiopoetin-2 O +
were O +
investigated O +
before O +
and O +
after O +
therapy O -
. O +

RESULTS O -
: O +
We O +
observed O +
a O +
significant O +
decrease O +
in O +
haptoglobin O +
levels O +
at O +
the O +
end O +
of O +
the O +
treatment O +
period O -
. O +

Hemoglobin O +
levels O +
also O +
decreased O +
but O +
insignificantly O +
by O +
treatment O -
. O +

In O +
contrast O +
with O +
the O +
literature O -
, O +
serum O +
levels O +
of O +
angiogenesis O +
factors O +
did O +
not O +
change O +
significantly O +
by O +
pegylated O +
interferon O +
and O +
ribavirin O +
therapy O -
. O +

We O +
found O +
no O +
correlation O +
of O +
angiogenesis O +
soluble O +
markers O +
with O +
either O +
hemoglobin O +
or O +
haptoglobin O -
. O +

CONCLUSION O -
: O +
This O +
is O +
the O +
first O +
study O +
in O +
the O +
literature O +
investigating O +
a O +
link O +
between O +
angiogenesis O +
soluble O +
markers O +
and O +
ribavirin O +
induced O +
anemia B-Disease +
in O +
patients O +
with O +
hepatitis B-Disease +
C I-Disease +
and O +
we O +
could O +
not O +
find O +
any O +
relation O -
. O +

Future O +
research O +
with O +
larger O +
number O +
of O +
patients O +
is O +
needed O +
to O +
find O +
out O +
modifiable O +
factors O +
that O +
will O +
improve O +
the O +
safety O +
of O +
ribavirin O +
therapy O -
. O +

Reduction O +
in O +
injection O +
pain B-Disease +
using O +
buffered O +
lidocaine O +
as O +
a O +
local O +
anesthetic O +
before O +
cardiac O +
catheterization O -
. O +

Previous O +
reports O +
have O +
suggested O +
that O +
pain B-Disease +
associated O +
with O +
the O +
injection O +
of O +
lidocaine O +
is O +
related O +
to O +
the O +
acidic O +
pH O +
of O +
the O +
solution O -
. O +

To O +
determine O +
if O +
the O +
addition O +
of O +
a O +
buffering O +
solution O +
to O +
adjust O +
the O +
pH O +
of O +
lidocaine O +
into O +
the O +
physiologic O +
range O +
would O +
reduce O +
pain B-Disease +
during O +
injection O -
, O +
we O +
performed O +
a O +
blinded O +
randomized O +
study O +
in O +
patients O +
undergoing O +
cardiac O +
catheterization O -
. O +

Twenty O +
patients O +
were O +
asked O +
to O +
quantify O +
the O +
severity O +
of O +
pain B-Disease +
after O +
receiving O +
standard O +
lidocaine O +
in O +
one O +
femoral O +
area O +
and O +
buffered O +
lidocaine O +
in O +
the O +
opposite O +
femoral O +
area O -
. O +

The O +
mean O +
pain B-Disease +
score O +
for O +
buffered O +
lidocaine O +
was O +
significantly O +
lower O +
than O +
the O +
mean O +
score O +
for O +
standard O +
lidocaine O +
( O -
2.7 O +
+ O -
/- O +

1.9 O +
vs. O +
3.8 O +
+ O -
/- O +

2.2 O -
, O +
P O +
= O +
0.03 O -
) O -
. O +

The O +
pH O +
adjustment O +
of O +
standard O +
lidocaine O +
can O +
be O +
accomplished O +
easily O +
in O +
the O +
catheterization O +
laboratory O +
before O +
injection O +
and O +
results O +
in O +
a O +
reduction O +
of O +
the O +
pain B-Disease +
occurring O +
during O +
the O +
infiltration O +
of O +
tissues O -
. O +

Serotonin O +
6 O +
receptor O +
gene O +
is O +
associated O +
with O +
methamphetamine O -
- O -
induced O +
psychosis B-Disease +
in O +
a O +
Japanese O +
population O -
. O +

BACKGROUND O -
: O +
Altered O +
serotonergic O +
neural O +
transmission O +
is O +
hypothesized O +
to O +
be O +
a O +
susceptibility O +
factor O +
for O +
psychotic B-Disease +
disorders I-Disease +
such O +
as O +
schizophrenia B-Disease -
. O +

The O +
serotonin O +
6 O +
( O -
5-HT6 O -
) O +
receptor O +
is O +
therapeutically O +
targeted O +
by O +
several O +
second O +
generation O +
antipsychotics O -
, O +
such O +
as O +
clozapine O +
and O +
olanzapine O -
, O +
and O +
d O -
- O -
amphetamine O -
- O -
induced O +
hyperactivity B-Disease +
in O +
rats O +
is O +
corrected O +
with O +
the O +
use O +
of O +
a O +
selective O +
5-HT6 O +
receptor O +
antagonist O -
. O +

In O +
addition O -
, O +
the O +
disrupted O +
prepulse O +
inhibition O +
induced O +
by O +
d O -
- O -
amphetamine O +
or O +
phencyclidine O +
was O +
restored O +
by O +
5-HT6 O +
receptor O +
antagonist O +
in O +
an O +
animal O +
study O +
using O +
rats O -
. O +

These O +
animal O +
models O +
were O +
considered O +
to O +
reflect O +
the O +
positive O +
symptoms O +
of O +
schizophrenia B-Disease -
, O +
and O +
the O +
above O +
evidence O +
suggests O +
that O +
altered O +
5-HT6 O +
receptors O +
are O +
involved O +
in O +
the O +
pathophysiology O +
of O +
psychotic B-Disease +
disorders I-Disease -
. O +

The O +
symptoms O +
of O +
methamphetamine O +
( O -
METH O -
) O -
-induced O +
psychosis B-Disease +
are O +
similar O +
to O +
those O +
of O +
paranoid B-Disease +
type I-Disease +
schizophrenia I-Disease -
. O +

Therefore O -
, O +
we O +
conducted O +
an O +
analysis O +
of O +
the O +
association O +
of O +
the O +
5-HT6 O +
gene O +
( O -
HTR6 O -
) O +
with O +
METH O -
- O -
induced O +
psychosis B-Disease -
. O +

METHOD O -
: O +
Using O +
five O +
tagging O +
SNPs O +
( O -
rs6693503 O -
, O +
rs1805054 O -
, O +
rs4912138 O -
, O +
rs3790757 O +
and O +
rs9659997 O -
) O -
, O +
we O +
conducted O +
a O +
genetic O +
association O +
analysis O +
of O +
case O -
- O -
control O +
samples O +
( O -
197 O +
METH O -
- O -
induced O +
psychosis B-Disease +
patients O +
and O +
337 O +
controls O -
) O +
in O +
the O +
Japanese O +
population O -
. O +

The O +
age O +
and O +
sex O +
of O +
the O +
control O +
subjects O +
did O +
not O +
differ O +
from O +
those O +
of O +
the O +
methamphetamine O +
dependence O +
patients O -
. O +

RESULTS O -
: O +
rs6693503 O +
was O +
associated O +
with O +
METH O -
- O -
induced O +
psychosis B-Disease +
patients O +
in O +
the O +
allele O -
/ O -
genotype O -
- O -
wise O +
analysis O -
. O +

Moreover O -
, O +
this O +
association O +
remained O +
significant O +
after O +
Bonferroni O +
correction O -
. O +

In O +
the O +
haplotype O -
- O -
wise O +
analysis O -
, O +
we O +
detected O +
an O +
association O +
between O +
two O +
markers O +
( O -
rs6693503 O +
and O +
rs1805054 O -
) O +
and O +
three O +
markers O +
( O -
rs6693503 O -
, O +
rs1805054 O +
and O +
rs4912138 O -
) O +
in O +
HTR6 O +
and O +
METH O -
- O -
induced O +
psychosis B-Disease +
patients O -
, O +
respectively O -
. O +

CONCLUSION O -
: O +
HTR6 O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
pathophysiology O +
of O +
METH O -
- O -
induced O +
psychosis B-Disease +
in O +
the O +
Japanese O +
population O -
. O +

Effect O +
of O +
L O -
- O -
alpha O -
- O -
glyceryl O -
- O -
phosphorylcholine O +
on O +
amnesia B-Disease +
caused O +
by O +
scopolamine O -
. O +

The O +
present O +
study O +
was O +
carried O +
out O +
to O +
test O +
the O +
effects O +
of O +
L O -
- O -
alpha O -
- O -
glycerylphosphorylcholine O +
( O -
L O -
- O -
alpha O -
- O -
GFC O -
) O +
on O +
memory B-Disease +
impairment I-Disease +
induced O +
by O +
scopolamine O +
in O +
man O -
. O +

Thirty O -
- O -
two O +
healthy O +
young O +
volunteers O +
were O +
randomly O +
allocated O +
to O +
four O +
different O +
groups O -
. O +

They O +
were O +
given O +
a O +
ten O +
day O +
pretreatment O +
with O +
either O +
L O -
- O -
alpha O -
- O -
GFC O +
or O +
placebo O -
, O +
p.o O -
. O -
, O +
and O +
on O +
the O +
eleventh O +
day O +
either O +
scopolamine O +
or O +
placebo O -
, O +
i.m O -
. O +

Before O +
and O +
0.5 O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
and O +
6 O +
h O +
after O +
injection O +
the O +
subjects O +
were O +
given O +
attention O +
and O +
mnemonic O +
tests O -
. O +

The O +
findings O +
of O +
this O +
study O +
indicate O +
that O +
the O +
drug O +
is O +
able O +
to O +
antagonize O +
impairment B-Disease +
of I-Disease +
attention I-Disease +
and I-Disease +
memory I-Disease +
induced O +
by O +
scopolamine O -
. O +

Safety O +
of O +
capecitabine O -
: O +
a O +
review O -
. O +

IMPORTANCE O +
OF O +
THE O +
FIELD O -
: O +
Fluoropyrimidines O -
, O +
in O +
particular O +
5-fluorouracil O +
( O -
5-FU O -
) O -
, O +
have O +
been O +
the O +
mainstay O +
of O +
treatment O +
for O +
several O +
solid O +
tumors B-Disease -
, O +
including O +
colorectal B-Disease -
, I-Disease +
breast I-Disease +
and I-Disease +
head I-Disease +
and I-Disease +
neck I-Disease +
cancers I-Disease -
, O +
for O +
> O +
40 O +
years O -
. O +

AREAS O +
COVERED O +
IN O +
THIS O +
REVIEW O +

: O +
This O +
article O +
reviews O +
the O +
pharmacology O +
and O +
efficacy O +
of O +
capecitabine O +
with O +
a O +
special O +
emphasis O +
on O +
its O +
safety O -
. O +

WHAT O +
THE O +
READER O +
WILL O +
GAIN O -
: O +
The O +
reader O +
will O +
gain O +
better O +
insight O +
into O +
the O +
safety O +
of O +
capecitabine O +
in O +
special O +
populations O +
such O +
as O +
patients O +
with O +
advanced O +
age O -
, O +
renal B-Disease +
and I-Disease +
kidney I-Disease +
disease I-Disease -
. O +

We O +
also O +
explore O +
different O +
dosing O +
and O +
schedules O +
of O +
capecitabine O +
administration O -
. O +

TAKE O +
HOME O +
MESSAGE O -
: O +
Capecitabine O +
is O +
an O +
oral O +
prodrug O +
of O +
5-FU O +
and O +
was O +
developed O +
to O +
fulfill O +
the O +
need O +
for O +
a O +
more O +
convenient O +
therapy O +
and O +
provide O +
an O +
improved O +
safety O -
/ O -
efficacy O +
profile O -
. O +

It O +
has O +
shown O +
promising O +
results O +
alone O +
or O +
in O +
combination O +
with O +
other O +
chemotherapeutic O +
agents O +
in O +
colorectal B-Disease -
, I-Disease +
breast I-Disease -
, I-Disease +
pancreaticobiliary I-Disease -
, I-Disease +
gastric I-Disease -
, I-Disease +
renal I-Disease +
cell I-Disease +
and I-Disease +
head I-Disease +
and I-Disease +
neck I-Disease +
cancers I-Disease -
. O +

The O +
most O +
commonly O +
reported O +
toxic O +
effects O +
of O +
capecitabine O +
are O +
diarrhea B-Disease -
, O +
nausea B-Disease -
, O +
vomiting B-Disease -
, O +
stomatitis B-Disease +
and O +
hand B-Disease -
- I-Disease -
foot I-Disease +
syndrome I-Disease -
. O +

Capecitabine O +
has O +
a O +
well O -
- O -
established O +
safety O +
profile O +
and O +
can O +
be O +
given O +
safely O +
to O +
patients O +
with O +
advanced O +
age O -
, O +
hepatic B-Disease +
and I-Disease +
renal I-Disease +
dysfunctions I-Disease -
. O +

Neural O +
correlates O +
of O +
S O -
- O -
ketamine O +
induced O +
psychosis B-Disease +
during O +
overt O +
continuous O +
verbal O +
fluency O -
. O +

The O +
glutamatergic O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O +
receptor O +
has O +
been O +
implicated O +
in O +
the O +
pathophysiology O +
of O +
schizophrenia B-Disease -
. O +

Administered O +
to O +
healthy O +
volunteers O -
, O +
a O +
subanesthetic O +
dose O +
of O +
the O +
non O -
- O -
competitive O +
NMDA O +
receptor O +
antagonist O +
ketamine O +
leads O +
to O +
psychopathological O +
symptoms O +
similar O +
to O +
those O +
observed O +
in O +
schizophrenia B-Disease -
. O +

In O +
patients O +
with O +
schizophrenia B-Disease -
, O +
ketamine O +
exacerbates O +
the O +
core O +
symptoms O +
of O +
illness O -
, O +
supporting O +
the O +
hypothesis O +
of O +
a O +
glutamatergic B-Disease +
dysfunction I-Disease -
. O +

In O +
a O +
counterbalanced O -
, O +
placebo O -
- O -
controlled O -
, O +
double O -
- O -
blind O +
study O +
design O -
, O +
healthy O +
subjects O +
were O +
administered O +
a O +
continuous O +
subanesthetic O +
S O -
- O -
ketamine O +
infusion O +
while O +
differences O +
in O +
BOLD O +
responses O +
measured O +
with O +
fMRI O +
were O +
detected O -
. O +

During O +
the O +
scanning O +
period O -
, O +
subjects O +
performed O +
continuous O +
overt O +
verbal O +
fluency O +
tasks O +
( O -
phonological O -
, O +
lexical O +
and O +
semantic O -
) O -
. O +

Ketamine O -
- O -
induced O +
psychopathological O +
symptoms O +
were O +
assessed O +
with O +
the O +
Positive O +
and O +
Negative O +
Syndrome O +
Scale O +
( O -
PANSS O -
) O -
. O +

Ketamine O +
elicited O +
psychosis B-Disease +
like O +
psychopathology O -
. O +

Post O -
- O -
hoc O +
t O -
- O -
tests O +
revealed O +
significant O +
differences O +
between O +
placebo O +
and O +
ketamine O +
for O +
the O +
amounts O +
of O +
words O +
generated O +
during O +
lexical O +
and O +
semantic O +
verbal O +
fluency O -
, O +
while O +
the O +
phonological O +
domain O +
remained O +
unaffected O -
. O +

Ketamine O +
led O +
to O +
enhanced O +
cortical O +
activations O +
in O +
supramarginal O +
and O +
frontal O +
brain O +
regions O +
for O +
phonological O +
and O +
lexical O +
verbal O +
fluency O -
, O +
but O +
not O +
for O +
semantic O +
verbal O +
fluency O -
. O +

Ketamine O +
induces O +
activation O +
changes O +
in O +
healthy O +
subjects O +
similar O +
to O +
those O +
observed O +
in O +
patients O +
with O +
schizophrenia B-Disease -
, O +
particularly O +
in O +
frontal O +
and O +
temporal O +
brain O +
regions O -
. O +

Our O +
results O +
provide O +
further O +
support O +
for O +
the O +
hypothesis O +
of O +
an O +
NMDA O +
receptor O +
dysfunction O +
in O +
the O +
pathophysiology O +
of O +
schizophrenia B-Disease -
. O +

Long O -
- O -
term O +
prognosis O +
for O +
transplant O -
- O -
free O +
survivors O +
of O +
paracetamol O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure I-Disease -
. O +

BACKGROUND O -
: O +
The O +
prognosis O +
for O +
transplant O -
- O -
free O +
survivors O +
of O +
paracetamol O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
remains O +
unknown O -
. O +

AIM O -
: O +
To O +
examine O +
whether O +
paracetamol O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
increases O +
long O -
- O -
term O +
mortality O -
. O +

METHODS O -
: O +
We O +
followed O +
up O +
all O +
transplant O -
- O -
free O +
survivors O +
of O +
paracetamol O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
injury I-Disease -
, O +
hospitalized O +
in O +
a O +
Danish O +
national O +
referral O +
centre O +
during O +
1984 O -
- O -
2004 O -
. O +

We O +
compared O +
age O -
- O -
specific O +
mortality O +
rates O +
from O +
1 O +
year O +
post O -
- O -
discharge O +
through O +
2008 O +
between O +
those O +
in O +
whom O +
the O +
liver B-Disease +
injury I-Disease +
led O +
to O +
an O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
and O +
those O +
in O +
whom O +
it O +
did O +
not O -
. O +

RESULTS O -
: O +
We O +
included O +
641 O +
patients O -
. O +

On O +
average O -
, O +
age O -
- O -
specific O +
mortality O +
rates O +
were O +
slightly O +
higher O +
for O +
the O +
101 O +
patients O +
whose O +
paracetamol O -
- O -
induced O +
liver B-Disease +
injury I-Disease +
had O +
caused O +
an O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
( O -
adjusted O +
mortality O +
rate O +
ratio O +
= O +
1.70 O -
, O +
95 O -
% O +
CI O +
1.02 O -
- O -
2.85 O -
) O -
, O +
but O +
the O +
association O +
was O +
age O -
- O -
dependent O -
, O +
and O +
no O +
survivors O +
of O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
died O +
of O +
liver B-Disease +
disease I-Disease -
, O +
whereas O +
suicides O +
were O +
frequent O +
in O +
both O +
groups O -
. O +

These O +
observations O +
speak O +
against O +
long O -
- O -
term O +
effects O +
of O +
acute B-Disease +
liver I-Disease +
failure I-Disease -
. O +

More O +
likely O -
, O +
the O +
elevated O +
mortality O +
rate O +
ratio O +
resulted O +
from O +
incomplete O +
adjustment O +
for O +
the O +
greater O +
prevalence O +
of O +
substance B-Disease +
abuse I-Disease +
among O +
survivors O +
of O +
acute B-Disease +
liver I-Disease +
failure I-Disease -
. O +

CONCLUSIONS O -
: O +
Paracetamol O -
- O -
induced O +
acute B-Disease +
liver I-Disease +
failure I-Disease +
did O +
not O +
affect O +
long O -
- O -
term O +
mortality O -
. O +

Clinical O +
follow O -
- O -
up O +
may O +
be O +
justified O +
by O +
the O +
cause O +
of O +
the O +
liver B-Disease +
failure I-Disease -
, O +
but O +
not O +
by O +
the O +
liver B-Disease +
failure I-Disease +
itself O -
. O +

Levodopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
: O +
filling O +
the O +
bench O -
- O -
to O -
- O -
bedside O +
gap O -
. O +

Levodopa O +
is O +
the O +
most O +
effective O +
drug O +
for O +
the O +
treatment O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

However O -
, O +
the O +
long O -
- O -
term O +
use O +
of O +
this O +
dopamine O +
precursor O +
is O +
complicated O +
by O +
highly O +
disabling O +
fluctuations O +
and O +
dyskinesias B-Disease -
. O +

Although O +
preclinical O +
and O +
clinical O +
findings O +
suggest O +
pulsatile O +
stimulation O +
of O +
striatal O +
postsynaptic O +
receptors O +
as O +
a O +
key O +
mechanism O +
underlying O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease -
, O +
their O +
pathogenesis O +
is O +
still O +
unclear O -
. O +

In O +
recent O +
years O -
, O +
evidence O +
from O +
animal O +
models O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
has O +
provided O +
important O +
information O +
to O +
understand O +
the O +
effect O +
of O +
specific O +
receptor O +
and O +
post O -
- O -
receptor O +
molecular O +
mechanisms O +
underlying O +
the O +
development O +
of O +
dyskinetic B-Disease +
movements I-Disease -
. O +

Recent O +
preclinical O +
and O +
clinical O +
data O +
from O +
promising O +
lines O +
of O +
research O +
focus O +
on O +
the O +
differential O +
role O +
of O +
presynaptic O +
versus O +
postsynaptic O +
mechanisms O -
, O +
dopamine O +
receptor O +
subtypes O -
, O +
ionotropic O +
and O +
metabotropic O +
glutamate O +
receptors O -
, O +
and O +
non O -
- O -
dopaminergic O +
neurotransmitter O +
systems O +
in O +
the O +
pathophysiology O +
of O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease -
. O +

Effects O +
of O +
pallidal O +
neurotensin O +
on O +
haloperidol O -
- O -
induced O +
parkinsonian B-Disease +
catalepsy I-Disease -
: O +
behavioral O +
and O +
electrophysiological O +
studies O -
. O +

OBJECTIVE O -
: O +
The O +
globus O +
pallidus O +
plays O +
a O +
critical O +
role O +
in O +
movement O +
regulation O -
. O +

Previous O +
studies O +
have O +
indicated O +
that O +
the O +
globus O +
pallidus O +
receives O +
neurotensinergic O +
innervation O +
from O +
the O +
striatum O -
, O +
and O +
systemic O +
administration O +
of O +
a O +
neurotensin O +
analog O +
could O +
produce O +
antiparkinsonian O +
effects O -
. O +

The O +
present O +
study O +
aimed O +
to O +
investigate O +
the O +
effects O +
of O +
pallidal O +
neurotensin O +
on O +
haloperidol O -
- O -
induced O +
parkinsonian B-Disease +
symptoms I-Disease -
. O +

METHODS O -
: O +
Behavioral O +
experiments O +
and O +
electrophysiological O +
recordings O +
were O +
performed O +
in O +
the O +
present O +
study O -
. O +

RESULTS O -
: O +
Bilateral O +
infusions O +
of O +
neurotensin O +
into O +
the O +
globus O +
pallidus O +
reversed O +
haloperidol O -
- O -
induced O +
parkinsonian B-Disease +
catalepsy I-Disease +
in O +
rats O -
. O +

Electrophysiological O +
recordings O +
showed O +
that O +
microinjection O +
of O +
neurotensin O +
induced O +
excitation O +
of O +
pallidal O +
neurons O +
in O +
the O +
presence O +
of O +
systemic O +
haloperidol O +
administration O -
. O +

The O +
neurotensin O +
type-1 O +
receptor O +
antagonist O +
SR48692 O +
blocked O +
both O +
the O +
behavioral O +
and O +
the O +
electrophysiological O +
effects O +
induced O +
by O +
neurotensin O -
. O +

CONCLUSION O -
: O +
Activation O +
of O +
pallidal O +
neurotensin O +
receptors O +
may O +
be O +
involved O +
in O +
neurotensin O -
- O -
induced O +
antiparkinsonian O +
effects O -
. O +

Carmofur O -
- O -
induced O +
organic B-Disease +
mental I-Disease +
disorders I-Disease -
. O +

Organic B-Disease +
mental I-Disease +
disorder I-Disease +
was O +
observed O +
in O +
a O +
29-year O -
- O -
old O +
female O +
in O +
the O +
prognostic O +
period O +
after O +
the O +
onset O +
of O +
carmofur O -
- O -
induced O +
leukoencephalopathy B-Disease -
. O +

Symptoms O +
such O +
as O +
euphoria O -
, O +
emotional O +
lability O +
and O +
puerile O +
attitude O +
noted O +
in O +
the O +
patient O +
were O +
diagnosed O +
as O +
organic B-Disease +
personality I-Disease +
syndrome I-Disease +
according O +
to O +
the O +
criteria O +
defined O +
in O +
the O +
DSM O -
- O -
III O -
- O -
R. O +
It O +
is O +
referred O +
to O +
as O +
a O +
frontal B-Disease +
lobe I-Disease +
syndrome I-Disease -
. O +

Brain O +
CT O +
revealed O +
a O +
periventricular O +
low O +
density O +
area O +
in O +
the O +
frontal O +
white O +
matter O +
and O +
moderate O +
dilatation O +
of O +
the O +
lateral O +
ventricles O +
especially O +
at O +
the O +
bilateral O +
anterior O +
horns O -
. O +

Consequently O -
, O +
carmofur O -
- O -
induced O +
leukoencephalopathy B-Disease +
may O +
uncommonly O +
result O +
in O +
organic B-Disease +
personality I-Disease +
syndrome I-Disease +
in O +
the O +
residual O +
state O -
. O +

It O +
may O +
be O +
attributed O +
to O +
the O +
structural B-Disease +
damage I-Disease +
to I-Disease +
the I-Disease +
frontal I-Disease +
lobe I-Disease -
. O +

In O +
vivo O +
characterization O +
of O +
a O +
dual O +
adenosine O +
A2A O -
/ O -
A1 O +
receptor O +
antagonist O +
in O +
animal O +
models O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

The O +
in O +
vivo O +
characterization O +
of O +
a O +
dual O +
adenosine O +
A O -
( O -
2A O -
) O -
/ O -
A O -
( O -
1 O -
) O +
receptor O +
antagonist O +
in O +
several O +
animal O +
models O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
is O +
described O -
. O +

Discovery O +
and O +
scale O -
- O -
up O +
syntheses O +
of O +
compound O +
1 O +
are O +
described O +
in O +
detail O -
, O +
highlighting O +
optimization O +
steps O +
that O +
increased O +
the O +
overall O +
yield O +
of O +
1 O +
from O +
10.0 O -
% O +
to O +
30.5 O -
% O -
. O +

Compound O +
1 O +
is O +
a O +
potent O +
A O -
( O -
2A O -
) O -
/ O -
A O -
( O -
1 O -
) O +
receptor O +
antagonist O +
in O +
vitro O +
( O -
A O -
( O -
2A O -
) O +
K O -
( O -
i O -
) O +
= O +
4.1 O +
nM O -
; O +
A O -
( O -
1 O -
) O +
K O -
( O -
i O -
) O +
= O +
17.0 O +
nM O -
) O +
that O +
has O +
excellent O +
activity O -
, O +
after O +
oral O +
administration O -
, O +
across O +
a O +
number O +
of O +
animal O +
models O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
including O +
mouse O +
and O +
rat O +
models O +
of O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease -
, O +
mouse O +
model O +
of O +
reserpine O -
- O -
induced O +
akinesia B-Disease -
, O +
rat O +
6-hydroxydopamine O +
( O -
6-OHDA O -
) O +
lesion O +
model O +
of O +
drug O -
- O -
induced O +
rotation O -
, O +
and O +
MPTP O -
- O -
treated O +
non O -
- O -
human O +
primate O +
model O -
. O +

Butyrylcholinesterase O +
gene O +
mutations O +
in O +
patients O +
with O +
prolonged O +
apnea B-Disease +
after O +
succinylcholine O +
for O +
electroconvulsive O +
therapy O -
. O +

BACKGROUND O -
: O +
patients O +
undergoing O +
electroconvulsive O +
therapy O +
( O -
ECT O -
) O +
often O +
receive O +
succinylcholine O +
as O +
part O +
of O +
the O +
anesthetic O +
procedure O -
. O +

The O +
duration O +
of O +
action O +
may O +
be O +
prolonged O +
in O +
patients O +
with O +
genetic O +
variants O +
of O +
the O +
butyrylcholinesterase O +
enzyme O +
( O -
BChE O -
) O -
, O +
the O +
most O +
common O +
being O +
the O +
K- O +
and O +
the O +
A O -
- O -
variants O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
assess O +
the O +
clinical O +
significance O +
of O +
genetic O +
variants O +
in O +
butyrylcholinesterase O +
gene O +
( O -
BCHE O -
) O +
in O +
patients O +
with O +
a O +
suspected O +
prolonged O +
duration O +
of O +
action O +
of O +
succinylcholine O +
after O +
ECT O -
. O +

METHODS O -
: O +
a O +
total O +
of O +
13 O +
patients O +
were O +
referred O +
to O +
the O +
Danish O +
Cholinesterase O +
Research O +
Unit O +
after O +
ECT O +
during O +
38 O +
months O -
. O +

We O +
determined O +
the O +
BChE O +
activity O +
and O +
the O +
BCHE O +
genotype O +
using O +
molecular O +
genetic O +
methods O -
, O +
the O +
duration O +
of O +
apnea B-Disease -
, O +
time O +
to O +
sufficient O +
spontaneous O +
ventilation O +
and O +
whether O +
neuromuscular O +
monitoring O +
was O +
used O -
. O +

The O +
duration O +
of O +
apnea B-Disease +
was O +
compared O +
with O +
published O +
data O +
on O +
normal O +
subjects O -
. O +

RESULTS O -
: O +
in O +
11 O +
patients O -
, O +
mutations O +
were O +
found O +
in O +
the O +
BCHE O +
gene O -
, O +
the O +
K O -
- O -
variant O +
being O +
the O +
most O +
frequent O -
. O +

The O +
duration O +
of O +
apnea B-Disease +
was O +
5 O -
- O -
15 O +
min O +
compared O +
with O +
3 O -
- O -
5.3 O +
min O +
from O +
the O +
literature O -
. O +

Severe O +
distress O +
was O +
noted O +
in O +
the O +
recovery O +
phase O +
in O +
two O +
patients O -
. O +

Neuromuscular O +
monitoring O +
was O +
used O +
in O +
two O +
patients O -
. O +

CONCLUSION O -
: O +
eleven O +
of O +
13 O +
patients O +
with O +
a O +
prolonged O +
duration O +
of O +
action O +
of O +
succinylcholine O +
had O +
mutations O +
in O +
BCHE O -
, O +
indicating O +
that O +
this O +
is O +
the O +
possible O +
reason O +
for O +
a O +
prolonged O +
period O +
of O +
apnea B-Disease -
. O +

We O +
recommend O +
objective O +
neuromuscular O +
monitoring O +
during O +
the O +
first O +
ECT O -
. O +

Effects O +
of O +
the O +
hippocampal O +
deep O +
brain O +
stimulation O +
on O +
cortical O +
epileptic B-Disease +
discharges O +
in O +
penicillin O +
- O +
induced O +
epilepsy B-Disease +
model O +
in O +
rats O -
. O +

AIM O -
: O +
Experimental O +
and O +
clinical O +
studies O +
have O +
revealed O +
that O +
hippocampal O +
DBS O +
can O +
control O +
epileptic B-Disease +
activity O -
, O +
but O +
the O +
mechanism O +
of O +
action O +
is O +
obscure O +
and O +
optimal O +
stimulation O +
parameters O +
are O +
not O +
clearly O +
defined O -
. O +

The O +
aim O +
was O +
to O +
evaluate O +
the O +
effects O +
of O +
high O +
frequency O +
hippocampal O +
stimulation O +
on O +
cortical O +
epileptic B-Disease +
activity O +
in O +
penicillin O -
- O -
induced O +
epilepsy B-Disease +
model O -
. O +

MATERIAL O +
AND O +
METHODS O -
: O +
Twenty O -
- O -
five O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
implanted O +
DBS O +
electrodes O -
. O +

In O +
group-1 O +
( O -
n=10 O -
) O +
hippocampal O +
DBS O +
was O +
off O +
and O +
in O +
the O +
group-2 O +
( O -
n=10 O -
) O +
hippocampal O +
DBS O +
was O +
on O +
( O -
185 O +
Hz O -
, O +
0.5V O -
, O +
1V O -
, O +
2V O -
, O +
and O +
5V O +
for O +
60 O +
sec O -
) O +
following O +
penicillin O +
G O +
injection O +
intracortically O -
. O +

In O +
the O +
control O +
group O +
hippocampal O +
DBS O +
was O +
on O +
following O +
8 O +
l O +
saline O +
injection O +
intracortically O -
. O +

EEG O +
recordings O +
were O +
obtained O +
before O +
and O +
15 O +
minutes O +
following O +
penicillin O -
- O -
G O +
injection O -
, O +
and O +
at O +
10th O +
minutes O +
following O +
each O +
stimulus O +
for O +
analysis O +
in O +
terms O +
of O +
frequency O -
, O +
amplitude O -
, O +
and O +
power O +
spectrum O -
. O +

RESULTS O -
: O +
High O +
frequency O +
hippocampal O +
DBS O +
suppressed O +
the O +
acute O +
penicillin O -
- O -
induced O +
cortical O +
epileptic B-Disease +
activity O +
independent O +
from O +
stimulus O +
intensity O -
. O +

In O +
the O +
control O +
group O -
, O +
hippocampal O +
stimulation O +
alone O +
lead O +
only O +
to O +
diffuse O +
slowing O +
of O +
cerebral O +
bioelectrical O +
activity O +
at O +
5V O +
stimulation O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
revealed O +
that O +
continuous O +
high O +
frequency O +
stimulation O +
of O +
the O +
hippocampus O +
suppressed O +
acute O +
cortical O +
epileptic B-Disease +
activity O +
effectively O +
without O +
causing O +
secondary O +
epileptic B-Disease +
discharges O -
. O +

These O +
results O +
are O +
important O +
in O +
terms O +
of O +
defining O +
the O +
optimal O +
parameters O +
of O +
hippocampal O +
DBS O +
in O +
patients O +
with O +
epilepsy B-Disease -
. O +

CCNU O +
( O -
lomustine O -
) O +
toxicity B-Disease +
in O +
dogs O -
: O +
a O +
retrospective O +
study O +
( O -
2002 O -
- O -
07 O -
) O -
. O +

OBJECTIVE O -
: O +
To O +
describe O +
the O +
incidence O +
of O +
haematological B-Disease -
, I-Disease +
renal I-Disease -
, I-Disease +
hepatic I-Disease +
and I-Disease +
gastrointestinal I-Disease +
toxicities I-Disease +
in O +
tumour O -
- O -
bearing O +
dogs O +
receiving O +
1- O -
( O -
2-chloroethyl O -
) O -
-3-cyclohexyl-1-nitrosourea O +
( O -
CCNU O -
) O -
. O +

DESIGN O -
: O +
The O +
medical O +
records O +
of O +
206 O +
dogs O +
that O +
were O +
treated O +
with O +
CCNU O +
at O +
the O +
Melbourne O +
Veterinary O +
Specialist O +
Centre O +
between O +
February O +
2002 O +
and O +
December O +
2007 O +
were O +
retrospectively O +
evaluated O -
. O +

RESULTS O -
: O +
Of O +
the O +
206 O +
dogs O +
treated O +
with O +
CCNU O -
, O +
185 O +
met O +
the O +
inclusion O +
criteria O +
for O +
at O +
least O +
one O +
class O +
of O +
toxicity B-Disease -
. O +

CCNU O +
was O +
used O +
most O +
commonly O +
in O +
the O +
treatment O +
of O +
lymphoma B-Disease -
, O +
mast B-Disease +
cell I-Disease +
tumour I-Disease -
, O +
brain B-Disease +
tumour I-Disease -
, O +
histiocytic B-Disease +
tumours I-Disease +
and O +
epitheliotropic B-Disease +
lymphoma I-Disease -
. O +

Throughout O +
treatment O -
, O +
56.9 O -
% O +
of O +
dogs O +
experienced O +
neutropenia B-Disease -
, O +
34.2 O -
% O +
experienced O +
anaemia B-Disease +
and O +
14.2 O -
% O +
experienced O +
thrombocytopenia B-Disease -
. O +

Gastrointestinal B-Disease +
toxicosis I-Disease +
was O +
detected O +
in O +
37.8 O -
% O +
of O +
dogs O -
, O +
the O +
most O +
common O +
sign O +
of O +
which O +
was O +
vomiting B-Disease +
( O -
24.3 O -
% O -
) O -
. O +

Potential O +
renal O +
toxicity B-Disease +
and O +
elevated O +
alanine O +
transaminase O +
( O -
ALT O -
) O +
concentration O +
were O +
reported O +
in O +
12.2 O -
% O +
and O +
48.8 O -
% O +
of O +
dogs O -
, O +
respectively O -
. O +

The O +
incidence O +
of O +
hepatic B-Disease +
failure I-Disease +
was O +
1.2 O -
% O -
. O +

CONCLUSIONS O -
: O +
CCNU O -
- O -
associated O +
toxicity B-Disease +
in O +
dogs O +
is O +
common O -
, O +
but O +
is O +
usually O +
not O +
life O +
threatening O -
. O +

Perhexiline O +
maleate O +
and O +
peripheral B-Disease +
neuropathy I-Disease -
. O +

Peripheral B-Disease +
neuropathy I-Disease +
has O +
been O +
noted O +
as O +
a O +
complication O +
of O +
therapy O +
with O +
perhexiline O +
maleate O -
, O +
a O +
drug O +
widely O +
used O +
in O +
France O +
( O -
and O +
in O +
clinical O +
trials O +
in O +
the O +
United O +
States O -
) O +
for O +
the O +
prophylactic O +
treatment O +
of O +
angina B-Disease +
pectoris I-Disease -
. O +

In O +
24 O +
patients O +
with O +
this O +
complication O -
, O +
the O +
marked O +
slowing O +
of O +
motor O +
nerve O +
conduction O +
velocity O +
and O +
the O +
electromyographic O +
changes O +
imply O +
mainly O +
a O +
demyelinating B-Disease +
disorder I-Disease -
. O +

Improvement O +
was O +
noted O +
with O +
cessation O +
of O +
therapy O -
. O +

In O +
a O +
few O +
cases O +
the O +
presence O +
of O +
active O +
denervation O +
signified O +
a O +
poor O +
prognosis O -
, O +
with O +
only O +
slight O +
improvement O -
. O +

The O +
underlying O +
mechanism O +
causing O +
the O +
neuropathy B-Disease +
is O +
not O +
yet O +
fully O +
known O -
, O +
although O +
some O +
evidence O +
indicates O +
that O +
it O +
may O +
be O +
a O +
lipid O +
storage O +
process O -
. O +

Central O +
vein B-Disease +
thrombosis I-Disease +
and O +
topical O +
dipivalyl O +
epinephrine O -
. O +

A O +
report O +
is O +
given O +
on O +
an O +
83-year O -
- O -
old O +
female O +
who O +
acquired O +
central O +
vein B-Disease +
thrombosis I-Disease +
in O +
her O +
seeing O +
eye O +
one O +
day O +
after O +
having O +
started O +
topical O +
medication O +
with O +
dipivalyl O +
epinephrine O +
for O +
advanced O +
glaucoma B-Disease +
discovered O +
in O +
the O +
other O +
eye O -
. O +

From O +
present O +
knowledge O +
about O +
the O +
effects O +
of O +
adrenergic O +
eye O +
drops O +
on O +
ocular O +
blood O +
circulation O -
, O +
it O +
is O +
difficult O +
to O +
suggest O +
an O +
association O +
between O +
the O +
two O +
events O -
, O +
which O +
may O +
be O +
coincidental O +
only O -
. O +

A O +
phase O +
I O +
study O +
of O +
4'-0-tetrahydropyranyladriamycin O -
. O +

Clinical O +
pharmacology O +
and O +
pharmacokinetics O -
. O +

A O +
Phase O +
I O +
study O +
of O +
intravenous O +
( O -
IV O -
) O +
bolus O +
4'-0-tetrahydropyranyladriamycin O +
( O -
Pirarubicin O -
) O +
was O +
done O +
in O +
55 O +
patients O +
in O +
good O +
performance O +
status O +
with O +
refractory O +
tumors B-Disease -
. O +

Twenty O -
- O -
six O +
had O +
minimal O +
prior O +
therapy O +
( O -
good O +
risk O -
) O -
, O +
23 O +
had O +
extensive O +
prior O +
therapy O +
( O -
poor O +
risk O -
) O -
, O +
and O +
six O +
had O +
renal B-Disease +
and/or I-Disease +
hepatic I-Disease +
dysfunction I-Disease -
. O +

A O +
total O +
of O +
167 O +
courses O +
at O +
doses O +
of O +
15 O +
to O +
70 O +
mg O -
/ O -
m2 O +
were O +
evaluable O -
. O +

Maximum O +
tolerated O +
dose O +
in O +
good O -
- O -
risk O +
patients O +
was O +
70 O +
mg O -
/ O -
m2 O -
, O +
and O +
in O +
poor O -
- O -
risk O +
patients O -
, O +
60 O +
mg O -
/ O -
m2 O -
. O +

The O +
dose O -
- O -
limiting O +
toxic O +
effect O +
was O +
transient O +
noncumulative O +
granulocytopenia B-Disease -
. O +

Granulocyte O +
nadir O +
was O +
on O +
day O +
14 O +
( O -
range O -
, O +
4 O -
- O -
22 O -
) O -
. O +

Less O +
frequent O +
toxic O +
effects O +
included O +
thrombocytopenia B-Disease -
, O +
anemia B-Disease -
, O +
nausea B-Disease -
, O +
mild O +
alopecia B-Disease -
, O +
phlebitis B-Disease -
, O +
and O +
mucositis B-Disease -
. O +

Myelosuppression B-Disease +
was O +
more O +
in O +
patients O +
with O +
hepatic B-Disease +
dysfunction I-Disease -
. O +

Pharmacokinetic O +
analyses O +
in O +
21 O +
patients O +
revealed O +
Pirarubicin O +
plasma O +
T O +
1 O -
/ O -
2 O +
alpha O +
( O -
+ O -
/- O +

SE O -
) O +
of O +
2.5 O +
+ O -
/- O +

0.85 O +
minutes O -
, O +
T O +
beta O +
1 O -
/ O -
2 O +
of O +
25.6 O +
+ O -
/- O +

6.5 O +
minutes O -
, O +
and O +
T O +
1 O -
/ O -
2 O +
gamma O +
of O +
23.6 O +
+ O -
/- O +

7.6 O +
hours O -
. O +

The O +
area O +
under O +
the O +
curve O +
was O +
537 O +
+ O -
/- O +

149 O +
ng O -
/ O -
ml O +
x O +
hours O -
, O +
volume O +
of O +
distribution O +
( O -
Vd O -
) O +
3504 O +
+ O -
/- O +

644 O +
l O -
/ O -
m2 O -
, O +
and O +
total O +
clearance O +
( O -
ClT O -
) O +
was O +
204 O +
+ O +
39.3 O +
l O -
/ O -
hour O -
/ O -
m2 O -
. O +

Adriamycinol O -
, O +
doxorubicin O -
, O +
adriamycinone O -
, O +
and O +
tetrahydropyranyladriamycinol O +
were O +
the O +
metabolites O +
detected O +
in O +
plasma O +
and O +
the O +
amount O +
of O +
doxorubicin O +
was O +
less O +
than O +
or O +
equal O +
to O +
10 O -
% O +
of O +
the O +
total O +
metabolites O -
. O +

Urinary O +
excretion O +
of O +
Pirarubicin O +
in O +
the O +
first O +
24 O +
hours O +
was O +
less O +
than O +
or O +
equal O +
to O +
10 O -
% O -
. O +

Activity O +
was O +
noted O +
in O +
mesothelioma B-Disease -
, O +
leiomyosarcoma B-Disease -
, O +
and O +
basal B-Disease +
cell I-Disease +
carcinoma I-Disease -
. O +

The O +
recommended O +
starting O +
dose O +
for O +
Phase O +
II O +
trials O +
is O +
60 O +
mg O -
/ O -
m2 O +
IV O +
bolus O +
every O +
3 O +
weeks O -
. O +

Ocular B-Disease +
and I-Disease +
auditory I-Disease +
toxicity I-Disease +
in O +
hemodialyzed O +
patients O +
receiving O +
desferrioxamine O -
. O +

During O +
an O +
18-month O +
period O +
of O +
study O +
41 O +
hemodialyzed O +
patients O +
receiving O +
desferrioxamine O +
( O -
10 O -
- O -
40 O +
mg O -
/ O -
kg O +
BW O -
/ O -
3 O +
times O +
weekly O -
) O +
for O +
the O +
first O +
time O +
were O +
monitored O +
for O +
detection O +
of O +
audiovisual B-Disease +
toxicity I-Disease -
. O +

6 O +
patients O +
presented O +
clinical O +
symptoms O +
of O +
visual B-Disease +
or I-Disease +
auditory I-Disease +
toxicity I-Disease -
. O +

Moreover O -
, O +
detailed O +
ophthalmologic O +
and O +
audiologic O +
studies O +
disclosed O +
abnormalities O +
in O +
7 O +
more O +
asymptomatic O +
patients O -
. O +

Visual B-Disease +
toxicity I-Disease +
was O +
of O +
retinal O +
origin O +
and O +
was O +
characterized O +
by O +
a O +
tritan O -
- O -
type O +
dyschromatopsy B-Disease -
, O +
sometimes O +
associated O +
with O +
a B-Disease +
loss I-Disease +
of I-Disease +
visual I-Disease +
acuity I-Disease +
and O +
pigmentary B-Disease +
retinal I-Disease +
deposits I-Disease -
. O +

Auditory B-Disease +
toxicity I-Disease +
was O +
characterized O +
by O +
a O +
mid- O +
to O +
high O -
- O -
frequency O +
neurosensorial B-Disease +
hearing I-Disease +
loss I-Disease +
and O +
the O +
lesion O +
was O +
of O +
the O +
cochlear O +
type O -
. O +

Desferrioxamine O +
withdrawal O +
resulted O +
in O +
a O +
complete O +
recovery O +
of O +
visual O +
function O +
in O +
1 O +
patient O +
and O +
partial O +
recovery O +
in O +
3 O -
, O +
and O +
a O +
complete O +
reversal O +
of O +
hearing B-Disease +
loss I-Disease +
in O +
3 O +
patients O +
and O +
partial O +
recovery O +
in O +
3 O -
. O +

This O +
toxicity B-Disease +
appeared O +
in O +
patients O +
receiving O +
the O +
higher O +
doses O +
of O +
desferrioxamine O +
or O +
coincided O +
with O +
the O +
normalization O +
of O +
ferritin O +
or O +
aluminium O +
serum O +
levels O -
. O +

The O +
data O +
indicate O +
that O +
audiovisual B-Disease +
toxicity I-Disease +
is O +
not O +
an O +
infrequent O +
complication O +
in O +
hemodialyzed O +
patients O +
receiving O +
desferrioxamine O -
. O +

Periodical O +
audiovisual O +
monitoring O +
should O +
be O +
performed O +
on O +
hemodialyzed O +
patients O +
receiving O +
the O +
drug O +
in O +
order O +
to O +
detect O +
adverse O +
effects O +
as O +
early O +
as O +
possible O -
. O +

Serial O +
epilepsy B-Disease +
caused O +
by O +
levodopa O -
/ O -
carbidopa O +
administration O +
in O +
two O +
patients O +
on O +
hemodialysis O -
. O +

Two O +
patients O +
with O +
similar O +
clinical O +
features O +
are O +
presented O -
: O +
both O +
patients O +
had O +
chronic B-Disease +
renal I-Disease +
failure I-Disease -
, O +
on O +
hemodialysis O +
for O +
many O +
years O +
but O +
recently O +
begun O +
on O +
a O +
high O -
- O -
flux O +
dialyzer O -
; O +
both O +
had O +
been O +
receiving O +
a O +
carbidopa O -
/ O -
levodopa O +
preparation O -
; O +
and O +
both O +
had O +
the O +
onset O +
of O +
hallucinosis B-Disease +
and O +
recurrent O +
seizures B-Disease -
, O +
which O +
were O +
refractory O +
to O +
anticonvulsants O -
. O +

The O +
first O +
patient O +
died O +
without O +
a O +
diagnosis O -
; O +
the O +
second O +
patient O +
had O +
a O +
dramatic O +
recovery O +
following O +
the O +
administration O +
of O +
vitamin O +
B6 O -
. O +

Neither O +
patient O +
was O +
considered O +
to O +
have O +
a O +
renal O +
state O +
sufficiently O +
severe O +
enough O +
to O +
explain O +
their O +
presentation O -
. O +

Randomized O -
, O +
double O -
- O -
blind O +
trial O +
of O +
mazindol O +
in O +
Duchenne B-Disease +
dystrophy I-Disease -
. O +

There O +
is O +
evidence O +
that O +
growth O +
hormone O +
may O +
be O +
related O +
to O +
the O +
progression O +
of O +
weakness B-Disease +
in O +
Duchenne B-Disease +
dystrophy I-Disease -
. O +

We O +
conducted O +
a O +
12-month O +
controlled O +
trial O +
of O +
mazindol O -
, O +
a O +
putative O +
growth O +
hormone O +
secretion O +
inhibitor O -
, O +
in O +
83 O +
boys O +
with O +
Duchenne B-Disease +
dystrophy I-Disease -
. O +

Muscle O +
strength O -
, O +
contractures O -
, O +
functional O +
ability O +
and O +
pulmonary O +
function O +
were O +
tested O +
at O +
baseline O -
, O +
and O +
6 O +
and O +
12 O +
months O +
after O +
treatment O +
with O +
mazindol O +
( O -
3 O +
mg O -
/ O -
d O -
) O +
or O +
placebo O -
. O +

The O +
study O +
was O +
designed O +
to O +
have O +
a O +
power O +
of O +
greater O +
than O +
0.90 O +
to O +
detect O +
a O +
slowing O +
to O +
25 O -
% O +
of O +
the O +
expected O +
rate O +
of O +
progression O +
of O +
weakness B-Disease +
at O +
P O +
less O +
than O +
0.05 O -
. O +

Mazindol O +
did O +
not O +
benefit O +
strength O +
at O +
any O +
point O +
in O +
the O +
study O -
. O +

Side O +
effects O +
attributable O +
to O +
mazindol O +
included O +
decreased B-Disease +
appetite I-Disease +
( O -
36 O -
% O -
) O -
, O +
dry B-Disease +
mouth I-Disease +
( O -
10 O -
% O -
) O -
, O +
behavioral O +
change O +
( O -
22 O -
% O -
) O -
, O +
and O +
gastrointestinal B-Disease +
symptoms I-Disease +
( O -
18 O -
% O -
) O -
; O +
mazindol O +
dosage O +
was O +
reduced O +
in O +
43 O -
% O +
of O +
patients O -
. O +

The O +
effect O +
of O +
mazindol O +
on O +
GH O +
secretion O +
was O +
estimated O +
indirectly O +
by O +
comparing O +
the O +
postabsorptive O +
IGF O -
- O -
I O +
levels O +
obtained O +
following O +
3 O -
, O +
6 O -
, O +
9 O -
, O +
and O +
12 O +
months O +
in O +
the O +
mazindol O +
treated O +
to O +
those O +
in O +
the O +
placebo O +
groups O -
. O +

Although O +
mazindol O -
- O -
treated O +
patients O +
gained O +
less O +
weight O +
and O +
height O +
than O +
placebo O -
- O -
treated O +
patients O -
, O +
no O +
significant O +
effect O +
on O +
IGF O -
- O -
I O +
levels O +
was O +
observed O -
. O +

Mazindol O +
doses O +
not O +
slow O +
the O +
progression O +
of O +
weakness B-Disease +
in O +
Duchenne B-Disease +
dystrophy I-Disease -
. O +

Facilitation O +
of O +
memory O +
retrieval O +
by O +
pre O -
- O -
test O +
morphine O +
and O +
its O +
state O +
dependency O +
in O +
the O +
step O -
- O -
through O +
type O +
passive O +
avoidance O +
learning O +
test O +
in O +
mice O -
. O +

Amnesia B-Disease +
produced O +
by O +
scopolamine O +
and O +
cycloheximide O +
were O +
reversed O +
by O +
morphine O +
given O +
30 O +
min O +
before O +
the O +
test O +
trial O +
( O -
pre O -
- O -
test O -
) O -
, O +
and O +
pre O -
- O -
test O +
morphine O +
also O +
facilitated O +
the O +
memory O +
retrieval O +
in O +
the O +
animals O +
administered O +
naloxone O +
during O +
the O +
training O +
trial O -
. O +

Similarly O -
, O +
pre O -
- O -
test O +
scopolamine O +
partially O +
reversed O +
the O +
scopolamine O -
- O -
induced O +
amnesia B-Disease -
, O +
but O +
not O +
significantly O -
; O +
and O +
pre O -
- O -
test O +
cycloheximide O +
failed O +
to O +
reverse O +
the O +
cycloheximide O -
- O -
induced O +
amnesia B-Disease -
. O +

These O +
results O +
suggest O +
that O +
the O +
facilitation O +
of O +
memory O +
retrieval O +
by O +
pre O -
- O -
test O +
morphine O +
might O +
be O +
the O +
direct O +
action O +
of O +
morphine O +
rather O +
than O +
a O +
state O +
dependent O +
effect O -
. O +

Naloxone O +
reverses O +
the O +
antihypertensive O +
effect O +
of O +
clonidine O -
. O +

In O +
unanesthetized O -
, O +
spontaneously O +
hypertensive B-Disease +
rats O +
the O +
decrease O +
in O +
blood O +
pressure O +
and O +
heart O +
rate O +
produced O +
by O +
intravenous O +
clonidine O -
, O +
5 O +
to O +
20 O +
micrograms O -
/ O -
kg O -
, O +
was O +
inhibited O +
or O +
reversed O +
by O +
nalozone O -
, O +
0.2 O +
to O +
2 O +
mg O -
/ O -
kg O -
. O +

The O +
hypotensive B-Disease +
effect O +
of O +
100 O +
mg O -
/ O -
kg O +
alpha O -
- O -
methyldopa O +
was O +
also O +
partially O +
reversed O +
by O +
naloxone O -
. O +

Naloxone O +
alone O +
did O +
not O +
affect O +
either O +
blood O +
pressure O +
or O +
heart O +
rate O -
. O +

In O +
brain O +
membranes O +
from O +
spontaneously O +
hypertensive B-Disease +
rats O +
clonidine O -
, O +
10 O -
( O -
-8 O -
) O +
to O +
10 O -
( O -
-5 O -
) O +
M O -
, O +
did O +
not O +
influence O +
stereoselective O +
binding O +
of O +
[ O -
3H O -
] O -
-naloxone O +
( O -
8 O +
nM O -
) O -
, O +
and O +
naloxone O -
, O +
10 O -
( O -
-8 O -
) O +
to O +
10 O -
( O -
-4 O -
) O +
M O -
, O +
did O +
not O +
influence O +
clonidine O -
- O -
suppressible O +
binding O +
of O +
[ O -
3H O -
] O -
-dihydroergocryptine O +
( O -
1 O +
nM O -
) O -
. O +

These O +
findings O +
indicate O +
that O +
in O +
spontaneously O +
hypertensive B-Disease +
rats O +
the O +
effects O +
of O +
central O +
alpha O -
- O -
adrenoceptor O +
stimulation O +
involve O +
activation O +
of O +
opiate O +
receptors O -
. O +

As O +
naloxone O +
and O +
clonidine O +
do O +
not O +
appear O +
to O +
interact O +
with O +
the O +
same O +
receptor O +
site O -
, O +
the O +
observed O +
functional O +
antagonism O +
suggests O +
the O +
release O +
of O +
an O +
endogenous O +
opiate O +
by O +
clonidine O +
or O +
alpha O -
- O -
methyldopa O +
and O +
the O +
possible O +
role O +
of O +
the O +
opiate O +
in O +
the O +
central O +
control O +
of O +
sympathetic O +
tone O -
. O +

Neurotoxicity B-Disease +
of O +
halogenated O +
hydroxyquinolines O -
: O +
clinical O +
analysis O +
of O +
cases O +
reported O +
outside O +
Japan O -
. O +

An O +
analysis O +
is O +
presented O +
of O +
220 O +
cases O +
of O +
possible O +
neurotoxic B-Disease +
reactions O +
to O +
halogenated O +
hydroxyquinolines O +
reported O +
from O +
outside O +
Japan O -
. O +

In O +
80 O +
cases O +
insufficient O +
information O +
was O +
available O +
for O +
adequate O +
comment O +
and O +
in O +
29 O +
a O +
relationship O +
to O +
the O +
administration O +
of O +
clioquinol O +
could O +
be O +
excluded O -
. O +

Of O +
the O +
remainder O -
, O +
a O +
relationship O +
to O +
clioquinol O +
was O +
considered O +
probable O +
in O +
42 O +
and O +
possible O +
in O +
69 O +
cases O -
. O +

In O +
six O +
of O +
the O +
probable O +
cases O +
the O +
neurological B-Disease +
disturbance I-Disease +
consisted O +
of O +
an O +
acute O +
reversible O +
encephalopathy B-Disease +
usually O +
related O +
to O +
the O +
ingestion O +
of O +
a O +
high O +
dose O +
of O +
clioquinol O +
over O +
a O +
short O +
period O -
. O +

The O +
most O +
common O +
manifestation O -
, O +
observed O +
in O +
15 O +
further O +
cases O -
, O +
was O +
isolated O +
optic B-Disease +
atrophy I-Disease -
. O +

This O +
was O +
most O +
frequently O +
found O +
in O +
children O -
, O +
many O +
of O +
whom O +
had O +
received O +
clioquinol O +
as O +
treatment O +
for O +
acrodermatitis B-Disease +
enteropathica I-Disease -
. O +

In O +
the O +
remaining O +
cases O -
, O +
a O +
combination O +
of O +
myelopathy B-Disease -
, O +
visual B-Disease +
disturbance I-Disease -
, O +
and O +
peripheral B-Disease +
neuropathy I-Disease +
was O +
the O +
most O +
common O +
manifestation O -
. O +

Isolated O +
myelopathy B-Disease +
or O +
peripheral B-Disease +
neuropathy I-Disease -
, O +
or O +
these O +
manifestations O +
occurring O +
together O -
, O +
were O +
infrequent O -
. O +

The O +
onset O +
of O +
all O +
manifestations O +
( O -
except O +
toxic O +
encephalopathy B-Disease -
) O +
was O +
usually O +
subacute O -
, O +
with O +
subsequent O +
partial O +
recovery O -
. O +

Older O +
subjects O +
tended O +
to O +
display O +
more O +
side O +
effects O -
. O +

The O +
full O +
syndrome O +
of O +
subacute O +
myelo B-Disease -
- I-Disease -
optic I-Disease +
neuropathy I-Disease +
was O +
more O +
frequent O +
in O +
women O -
, O +
but O +
they O +
tended O +
to O +
have O +
taken O +
greater O +
quantities O +
of O +
the O +
drug O -
. O +

Prazosin O -
- O -
induced O +
stress B-Disease +
incontinence I-Disease -
. O +

A O +
case O +
of O +
genuine O +
stress B-Disease +
incontinence I-Disease +
due O +
to O +
prazosin O -
, O +
a O +
common O +
antihypertensive O +
drug O -
, O +
is O +
presented O -
. O +

Prazosin O +
exerts O +
its O +
antihypertensive O +
effects O +
through O +
vasodilatation O +
caused O +
by O +
selective O +
blockade O +
of O +
postsynaptic O +
alpha-1 O +
adrenergic O +
receptors O -
. O +

As O +
an O +
alpha O -
- O -
blocker O -
, O +
it O +
also O +
exerts O +
a O +
significant O +
relaxant O +
effect O +
on O +
the O +
bladder O +
neck O +
and O +
urethra O -
. O +

The O +
patient O -
's O +
clinical O +
course O +
is O +
described O +
and O +
correlated O +
with O +
initial O +
urodynamic O +
studies O +
while O +
on O +
prazosin O +
and O +
subsequent O +
studies O +
while O +
taking O +
verapamil O -
. O +

Her O +
incontinence B-Disease +
resolved O +
with O +
the O +
change O +
of O +
medication O -
. O +

The O +
restoration O +
of O +
continence O +
was O +
accompanied O +
by O +
a O +
substantial O +
rise O +
in O +
maximum O +
urethral O +
pressure O -
, O +
maximum O +
urethral O +
closure O +
pressure O -
, O +
and O +
functional O +
urethral O +
length O -
. O +

Patients O +
who O +
present O +
with O +
stress B-Disease +
incontinence I-Disease +
while O +
taking O +
prazosin O +
should O +
change O +
their O +
antihypertensive O +
medication O +
before O +
considering O +
surgery O -
, O +
because O +
their O +
incontinence B-Disease +
may O +
resolve O +
spontaneously O +
with O +
a O +
change O +
in O +
drug O +
therapy O -
. O +

Myocardial B-Disease +
infarction I-Disease +
following O +
sublingual O +
administration O +
of O +
isosorbide O +
dinitrate O -
. O +

A O +
78-year O -
- O -
old O +
with O +
healed O +
septal O +
necrosis B-Disease +
suffered O +
a O +
recurrent O +
myocardial B-Disease +
infarction I-Disease +
of O +
the O +
anterior O +
wall O +
following O +
the O +
administration O +
of O +
isosorbide O +
dinitrate O +
5 O +
mg O +
sublingually O -
. O +

After O +
detailing O +
the O +
course O +
of O +
events O -
, O +
we O +
discuss O +
the O +
role O +
of O +
paradoxical O +
coronary O +
spasm B-Disease +
and O +
hypotension B-Disease -
- O -
mediated O +
myocardial B-Disease +
ischemia I-Disease +
occurring O +
downstream O +
to O +
significant O +
coronary B-Disease +
arterial I-Disease +
stenosis I-Disease +
in O +
the O +
pathophysiology O +
of O +
acute B-Disease +
coronary I-Disease +
insufficiency I-Disease -
. O +

Lethal O +
anuria B-Disease +
complicating O +
high O +
dose O +
ifosfamide O +
chemotherapy O +
in O +
a O +
breast B-Disease +
cancer I-Disease +
patient O +
with O +
an O +
impaired B-Disease +
renal I-Disease +
function I-Disease -
. O +

A O +
sixty O -
- O -
year O -
- O -
old O +
woman O +
with O +
advanced O +
breast B-Disease +
cancer I-Disease -
, O +
previously O +
treated O +
with O +
cisplatin O -
, O +
developed O +
an O +
irreversible O +
lethal O +
renal B-Disease +
failure I-Disease +
with O +
anuria B-Disease -
, O +
the O +
day O +
after O +
5 O +
g O -
/ O -
m2 O +
bolus O +
ifosfamide O -
. O +

Postrenal B-Disease +
failure I-Disease +
was O +
excluded O +
by O +
echography O -
. O +

A O +
prerenal O +
component O +
could O +
have O +
contributed O +
to O +
renal B-Disease +
failure I-Disease +
because O +
of O +
a O +
transient O +
hypotension B-Disease -
, O +
due O +
to O +
an O +
increasing O +
ascitis O -
, O +
occurring O +
just O +
before O +
anuria B-Disease -
. O +

However O -
, O +
correction O +
of O +
the O +
hemodynamic O +
parameters O +
did O +
not O +
improve O +
renal O +
function O -
. O +

Ifosfamide O +
is O +
a O +
known O +
nephrotoxic B-Disease +
drug O +
with O +
demonstrated O +
tubulopathies B-Disease -
. O +

We O +
strongly O +
suspect O +
that O +
this O +
lethal O +
anuria B-Disease +
was O +
mainly O +
due O +
to O +
ifosfamide O -
, O +
occurring O +
in O +
a O +
patient O +
having O +
received O +
previous O +
cisplatin O +
chemotherapy O +
and O +
with O +
poor O +
kidney O +
perfusion O +
due O +
to O +
transient O +
hypotension B-Disease -
. O +

We O +
recommend O +
careful O +
use O +
of O +
ifosfamide O +
in O +
patients O +
pretreated O +
with O +
nephrotoxic B-Disease +
chemotherapy O +
and O +
inadequate O +
renal O +
perfusion O -
. O +

Nociceptive O +
effects O +
induced O +
by O +
intrathecal O +
administration O +
of O +
prostaglandin O +
D2 O -
, O +
E2 O -
, O +
or O +
F2 O +
alpha O +
to O +
conscious O +
mice O -
. O +

The O +
effects O +
of O +
intrathecal O +
administration O +
of O +
prostaglandins O +
on O +
pain B-Disease +
responses O +
in O +
conscious O +
mice O +
were O +
evaluated O +
by O +
using O +
hot O +
plate O +
and O +
acetic O +
acid O +
writhing O +
tests O -
. O +

Prostaglandin O +
D2 O +
( O -
0.5 O -
- O -
3 O +
ng O -
/ O -
mouse O -
) O +
had O +
a O +
hyperalgesic B-Disease +
action O +
on O +
the O +
response O +
to O +
a O +
hot O +
plate O +
during O +
a O +
3 O -
- O -
60 O +
min O +
period O +
after O +
injection O -
. O +

Prostaglandin O +
E2 O +
showed O +
a O +
hyperalgesic B-Disease +
effect O +
at O +
doses O +
of O +
1 O +
pg O +
to O +
10 O +
ng O -
/ O -
mouse O -
, O +
but O +
the O +
effect O +
lasted O +
shorter O +
( O -
3 O -
- O -
30 O +
min O -
) O +
than O +
that O +
of O +
prostaglandin O +
D2 O -
. O +

Similar O +
results O +
were O +
obtained O +
by O +
acetic O +
acid O +
writhing O +
tests O -
. O +

The O +
hyperalgesic B-Disease +
effect O +
of O +
prostaglandin O +
D2 O +
was O +
blocked O +
by O +
simultaneous O +
injection O +
of O +
a O +
substance O +
P O +
antagonist O +
( O -
greater O +
than O +
or O +
equal O +
to O +
100 O +
ng O -
) O +
but O +
not O +
by O +
AH6809 O -
, O +
a O +
prostanoid O +
EP1-receptor O +
antagonist O -
. O +

Conversely O -
, O +
prostaglandin O +
E2-induced O +
hyperalgesia B-Disease +
was O +
blocked O +
by O +
AH6809 O +
( O -
greater O +
than O +
or O +
equal O +
to O +
500 O +
ng O -
) O +
but O +
not O +
by O +
the O +
substance O +
P O +
antagonist O -
. O +

Prostaglandin O +
F2 O +
alpha O +
had O +
little O +
effect O +
on O +
pain B-Disease +
responses O -
. O +

These O +
results O +
demonstrate O +
that O +
both O +
prostaglandin O +
D2 O +
and O +
prostaglandin O +
E2 O +
exert O +
hyperalgesia B-Disease +
in O +
the O +
spinal O +
cord O -
, O +
but O +
in O +
different O +
ways O -
. O +

D O -
- O -
penicillamine O +
in O +
the O +
treatment O +
of O +
localized B-Disease +
scleroderma I-Disease -
. O +

Localized B-Disease +
scleroderma I-Disease +
has O +
no O +
recognized O +
internal O +
organ O +
involvement O +
but O +
may O +
be O +
disfiguring O +
and O +
disabling O +
when O +
the O +
cutaneous O +
lesions O +
are O +
extensive O +
or O +
affect O +
children O -
. O +

There O +
is O +
no O +
accepted O +
or O +
proven O +
treatment O +
for O +
localized B-Disease +
scleroderma I-Disease -
. O +

Case O +
reports O +
of O +
11 O +
patients O +
with O +
severe O -
, O +
extensive O +
localized B-Disease +
scleroderma I-Disease +
who O +
were O +
treated O +
with O +
D O -
- O -
penicillamine O +
are O +
summarized O +
in O +
this O +
article O -
. O +

This O +
drug O +
was O +
judged O +
to O +
have O +
a O +
favorable O +
effect O +
on O +
the O +
disease O +
course O +
in O +
7 O +
( O -
64 O -
% O -
) O +
of O +
11 O +
patients O -
. O +

Improvement O +
began O +
within O +
3 O +
to O +
6 O +
months O +
and O +
consisted O +
of O +
cessation O +
of O +
active O +
cutaneous O +
lesions O +
in O +
all O +
7 O +
patients O -
, O +
skin O +
softening O +
in O +
5 O -
, O +
and O +
more O +
normal O +
growth O +
of O +
the O +
affected O +
limb O +
in O +
2 O +
of O +
3 O +
children O -
. O +

Joint O +
stiffness O +
and O +
contractures B-Disease +
also O +
improved O -
. O +

The O +
dose O +
of O +
D O -
- O -
penicillamine O +
associated O +
with O +
a O +
favorable O +
response O +
was O +
as O +
low O +
as O +
2 O +
to O +
5 O +
mg O -
/ O -
kg O +
per O +
day O +
given O +
over O +
a O +
period O +
ranging O +
from O +
15 O +
to O +
53 O +
months O -
. O +

D O -
- O -
Penicillamine O +
caused O +
nephrotic B-Disease +
syndrome I-Disease +
in O +
1 O +
patient O +
and O +
milder O +
reversible O +
proteinuria B-Disease +
in O +
3 O +
other O +
patients O -
; O +
none O +
developed O +
renal B-Disease +
insufficiency I-Disease -
. O +

These O +
data O +
suggest O +
that O +
D O -
- O -
penicillamine O +
may O +
be O +
effective O +
in O +
severe O +
cases O +
of O +
localized B-Disease +
scleroderma I-Disease -
. O +

Comparison O +
of O +
the O +
respiratory O +
effects O +
of O +
i.v O -
. O +

infusions O +
of O +
morphine O +
and O +
regional O +
analgesia O +
by O +
extradural O +
block O -
. O +

The O +
incidence O +
of O +
postoperative O +
respiratory O +
apnoea B-Disease +
was O +
compared O +
between O +
five O +
patients O +
receiving O +
a O +
continuous O +
i.v O -
. O +

infusion O +
of O +
morphine O +
( O -
mean O +
73.6 O +
mg O -
) O +
and O +
five O +
patients O +
receiving O +
a O +
continuous O +
extradural O +
infusion O +
of O +
0.25 O -
% O +
bupivacaine O +
( O -
mean O +
192 O +
mg O -
) O +
in O +
the O +
24-h O +
period O +
following O +
upper O +
abdominal O +
surgery O -
. O +

Monitoring O +
consisted O +
of O +
airflow O +
detection O +
by O +
a O +
carbon O +
dioxide O +
analyser O -
, O +
chest O +
wall O +
movement O +
detected O +
by O +
pneumatic O +
capsules O -
, O +
and O +
continuous O +
electrocardiograph O +
recorded O +
with O +
a O +
Holter O +
ambulatory O +
monitor O -
. O +

Both O +
obstructive B-Disease +
( I-Disease -
P I-Disease +
less I-Disease +
than I-Disease +
0.05 I-Disease -
) I-Disease +
and I-Disease +
central I-Disease +
apnoea I-Disease +
( O -
P O +
less O +
than O +
0.05 O -
) O +
occurred O +
more O +
frequently O +
in O +
patients O +
who O +
had O +
a O +
morphine O +
infusion O -
. O +

There O +
was O +
also O +
a O +
higher O +
incidence O +
of O +
tachyarrhythmias B-Disease +
( O -
P O +
less O +
than O +
0.05 O -
) O +
and O +
ventricular B-Disease +
ectopic I-Disease +
beats I-Disease +
( O -
P O +
less O +
than O +
0.05 O -
) O +
in O +
the O +
morphine O +
infusion O +
group O -
. O +

Cerebral B-Disease +
sinus I-Disease +
thrombosis I-Disease +
as O +
a O +
potential O +
hazard O +
of O +
antifibrinolytic O +
treatment O +
in O +
menorrhagia B-Disease -
. O +

We O +
describe O +
a O +
42-year O -
- O -
old O +
woman O +
who O +
developed O +
superior O +
sagittal B-Disease +
and I-Disease +
left I-Disease +
transverse I-Disease +
sinus I-Disease +
thrombosis I-Disease +
associated O +
with O +
prolonged O +
epsilon O -
- O -
aminocaproic O +
acid O +
therapy O +
for O +
menorrhagia B-Disease -
. O +

This O +
antifibrinolytic O +
agent O +
has O +
been O +
used O +
in O +
women O +
with O +
menorrhagia B-Disease +
to O +
promote O +
clotting O +
and O +
reduce O +
blood B-Disease +
loss I-Disease -
. O +

Although O +
increased O +
risk O +
of O +
thromboembolic B-Disease +
disease I-Disease +
has O +
been O +
reported O +
during O +
treatment O +
with O +
epsilon O -
- O -
aminocaproic O +
acid O -
, O +
cerebral B-Disease +
sinus I-Disease +
thrombosis I-Disease +
has O +
not O +
been O +
previously O +
described O -
. O +

Careful O +
use O +
of O +
epsilon O -
- O -
aminocaproic O +
acid O +
therapy O +
is O +
recommended O -
. O +

Effects O +
of O +
aminophylline O +
on O +
the O +
threshold O +
for O +
initiating O +
ventricular B-Disease +
fibrillation I-Disease +
during O +
respiratory B-Disease +
failure I-Disease -
. O +

Cardiac B-Disease +
arrhythmias I-Disease +
have O +
frequently O +
been O +
reported O +
in O +
association O +
with O +
respiratory B-Disease +
failure I-Disease -
. O +

The O +
possible O +
additive O +
role O +
of O +
pharmacologic O +
agents O +
in O +
precipitating O +
cardiac B-Disease +
disturbances I-Disease +
in O +
patients O +
with O +
respiratory B-Disease +
failure I-Disease +
has O +
only O +
recently O +
been O +
emphasized O -
. O +

The O +
effects O +
of O +
aminophylline O +
on O +
the O +
ventricular B-Disease +
fibrillation I-Disease +
threshold O +
during O +
normal O +
acid O -
- O -
base O +
conditions O +
and O +
during O +
respiratory B-Disease +
failure I-Disease +
were O +
studied O +
in O +
anesthetized O +
open O +
chest O +
dogs O -
. O +

The O +
ventricular B-Disease +
fibrillation I-Disease +
threshold O +
was O +
measured O +
by O +
passing O +
a O +
gated O +
train O +
of O +
12 O +
constant O +
current O +
pulses O +
through O +
the O +
ventricular O +
myocardium O +
during O +
the O +
vulnerable O +
period O +
of O +
the O +
cardiac O +
cycle O -
. O +

During O +
the O +
infusion O +
of O +
aminophylline O -
, O +
the O +
ventricular B-Disease +
fibrillation I-Disease +
threshold O +
was O +
reduced O +
by O +
30 O +
to O +
40 O +
percent O +
of O +
the O +
control O +
when O +
pH O +
and O +
partial O +
pressures O +
of O +
oxygen O +
( O -
PO2 O -
) O +
and O +
carbon O +
dioxide O +
( O -
CO2 O -
) O +
were O +
kept O +
within O +
normal O +
limits O -
. O +

When O +
respiratory B-Disease +
failure I-Disease +
was O +
produced O +
by O +
hypoventilation B-Disease +
( O -
pH O +
7.05 O +
to O +
7.25 O -
; O +
PC02 O +
70 O +
to O +
100 O +
mm O +
Hg O -
: O +
P02 O +
20 O +
to O +
40 O +
mm O +
Hg O -
) O -
, O +
infusion O +
of O +
aminophylline O +
resulted O +
in O +
an O +
even O +
greater O +
decrease O +
in O +
ventricular B-Disease +
fibrillation I-Disease +
threshold O +
to O +
60 O +
percent O +
of O +
the O +
control O +
level O -
. O +

These O +
experiments O +
suggest O +
that O +
although O +
many O +
factors O +
may O +
contribute O +
to O +
the O +
increased O +
incidence O +
of O +
ventricular B-Disease +
arrhythmias I-Disease +
in O +
respiratory B-Disease +
failure I-Disease -
, O +
pharmacologic O +
agents O -
, O +
particularly O +
aminophylline O -
, O +
may O +
play O +
a O +
significant O +
role O -
. O +

Pentoxifylline O +
( O -
Trental O -
) O +
does O +
not O +
inhibit O +
dipyridamole O -
- O -
induced O +
coronary O +
hyperemia B-Disease -
: O +
implications O +
for O +
dipyridamole O -
- O -
thallium-201 O +
myocardial O +
imaging O -
. O +

Dipyridamole O -
- O -
thallium-201 O +
imaging O +
is O +
often O +
performed O +
in O +
patients O +
unable O +
to O +
exercise O +
because O +
of O +
peripheral B-Disease +
vascular I-Disease +
disease I-Disease -
. O +

Many O +
of O +
these O +
patients O +
are O +
taking O +
pentoxifylline O +
( O -
Trental O -
) O -
, O +
a O +
methylxanthine O +
derivative O +
which O +
may O +
improve O +
intermittent B-Disease +
claudication I-Disease -
. O +

Whether O +
pentoxifylline O +
inhibits O +
dipyridamole O -
- O -
induced O +
coronary O +
hyperemia B-Disease +
like O +
other O +
methylxanthines O +
such O +
as O +
theophylline O +
and O +
should O +
be O +
stopped O +
prior O +
to O +
dipyridamole O -
- O -
thallium-201 O +
imaging O +
is O +
unknown O -
. O +

Therefore O -
, O +
we O +
studied O +
the O +
hyperemic O +
response O +
to O +
dipyridamole O +
in O +
seven O +
open O -
- O -
chest O +
anesthetized O +
dogs O +
after O +
pretreatment O +
with O +
either O +
pentoxifylline O +
( O -
0 O -
, O +
7.5 O -
, O +
or O +
15 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
or O +
theophylline O +
( O -
3 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O -
. O +

Baseline O +
circumflex O +
coronary O +
blood O +
flows O +
did O +
not O +
differ O +
significantly O +
among O +
treatment O +
groups O -
. O +

Dipyridamole O +
significantly O +
increased O +
coronary O +
blood O +
flow O +
before O +
and O +
after O +
7.5 O +
or O +
15 O +
mm O -
/ O -
kg O +
i.v O -
. O +

pentoxifylline O +
( O -
p O +
less O +
than O +
0.002 O -
) O -
. O +

Neither O +
dose O +
of O +
pentoxifylline O +
significantly O +
decreased O +
the O +
dipyridamole O -
- O -
induced O +
hyperemia B-Disease -
, O +
while O +
peak O +
coronary O +
blood O +
flow O +
was O +
significantly O +
lower O +
after O +
theophylline O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
. O +

We O +
conclude O +
that O +
pentoxyifylline O +
does O +
not O +
inhibit O +
dipyridamole O -
- O -
induced O +
coronary O +
hyperemia B-Disease +
even O +
at O +
high O +
doses O -
. O +

Cause O +
of O +
death B-Disease +
among O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
: O +
a O +
rare O +
mortality O +
due O +
to O +
cerebral B-Disease +
haemorrhage I-Disease -
. O +

Causes O +
of O +
death B-Disease -
, O +
with O +
special O +
reference O +
to O +
cerebral B-Disease +
haemorrhage I-Disease -
, O +
among O +
240 O +
patients O +
with O +
pathologically O +
verified O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
were O +
investigated O +
using O +
the O +
Annuals O +
of O +
the O +
Pathological O +
Autopsy O +
Cases O +
in O +
Japan O +
from O +
1981 O +
to O +
1985 O -
. O +

The O +
leading O +
causes O +
of O +
death B-Disease +
were O +
pneumonia B-Disease +
and O +
bronchitis B-Disease +
( O -
44.1 O -
% O -
) O -
, O +
malignant O +
neoplasms B-Disease +
( O -
11.6 O -
% O -
) O -
, O +
heart B-Disease +
diseases I-Disease +
( O -
4.1 O -
% O -
) O -
, O +
cerebral B-Disease +
infarction I-Disease +
( O -
3.7 O -
% O -
) O +
and O +
septicaemia B-Disease +
( O -
3.3 O -
% O -
) O -
. O +

Cerebral B-Disease +
haemorrhage I-Disease +
was O +
the O +
11th O +
most O +
frequent O +
cause O +
of O +
death B-Disease -
, O +
accounting O +
for O +
only O +
0.8 O -
% O +
of O +
deaths B-Disease +
among O +
the O +
patients O -
, O +
whereas O +
it O +
was O +
the O +
5th O +
most O +
common O +
cause O +
of O +
death B-Disease +
among O +
the O +
Japanese O +
general O +
population O +
in O +
1985 O -
. O +

The O +
low O +
incidence O +
of O +
cerebral B-Disease +
haemorrhage I-Disease +
as O +
a O +
cause O +
of O +
death B-Disease +
in O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
may O +
reflect O +
the O +
hypotensive B-Disease +
effect O +
of O +
levodopa O +
and O +
a O +
hypotensive B-Disease +
mechanism O +
due O +
to O +
reduced O +
noradrenaline O +
levels O +
in O +
the O +
parkinsonian B-Disease +
brain O -
. O +

Possible O +
intramuscular O +
midazolam O -
- O -
associated O +
cardiorespiratory B-Disease +
arrest I-Disease +
and O +
death B-Disease -
. O +

Midazolam O +
hydrochloride O +
is O +
commonly O +
used O +
for O +
dental O +
or O +
endoscopic O +
procedures O -
. O +

Although O +
generally O +
consisted O +
safe O +
when O +
given O +
intramuscularly O -
, O +
intravenous O +
administration O +
is O +
known O +
to O +
cause O +
respiratory B-Disease +
and I-Disease +
cardiovascular I-Disease +
depression I-Disease -
. O +

This O +
report O +
describes O +
the O +
first O +
published O +
case O +
of O +
cardiorespiratory B-Disease +
arrest I-Disease +
and O +
death B-Disease +
associated O +
with O +
intramuscular O +
administration O +
of O +
midazolam O -
. O +

Information O +
regarding O +
midazolam O +
use O +
is O +
reviewed O +
to O +
provide O +
recommendation O +
for O +
safe O +
administration O -
. O +

Myasthenia B-Disease +
gravis I-Disease +
presenting O +
as O +
weakness O +
after O +
magnesium O +
administration O -
. O +

We O +
studied O +
a O +
patient O +
with O +
no O +
prior O +
history O +
of O +
neuromuscular B-Disease +
disease I-Disease +
who O +
became O +
virtually O +
quadriplegic B-Disease +
after O +
parenteral O +
magnesium O +
administration O +
for O +
preeclampsia B-Disease -
. O +

The O +
serum O +
magnesium O +
concentration O +
was O +
3.0 O +
mEq O -
/ O -
L O -
, O +
which O +
is O +
usually O +
well O +
tolerated O -
. O +

The O +
magnesium O +
was O +
stopped O +
and O +
she O +
recovered O +
over O +
a O +
few O +
days O -
. O +

While O +
she O +
was O +
weak O -
, O +
2-Hz O +
repetitive O +
stimulation O +
revealed O +
a O +
decrement O +
without O +
significant O +
facilitation O +
at O +
rapid O +
rates O +
or O +
after O +
exercise O -
, O +
suggesting O +
postsynaptic B-Disease +
neuromuscular I-Disease +
blockade I-Disease -
. O +

After O +
her O +
strength O +
returned O -
, O +
repetitive O +
stimulation O +
was O +
normal O -
, O +
but O +
single O +
fiber O +
EMG O +
revealed O +
increased O +
jitter O +
and O +
blocking O -
. O +

Her O +
acetylcholine O +
receptor O +
antibody O +
level O +
was O +
markedly O +
elevated O -
. O +

Although O +
paralysis B-Disease +
after O +
magnesium O +
administration O +
has O +
been O +
described O +
in O +
patients O +
with O +
known O +
myasthenia B-Disease +
gravis I-Disease -
, O +
it O +
has O +
not O +
previously O +
been O +
reported O +
to O +
be O +
the O +
initial O +
or O +
only O +
manifestation O +
of O +
the O +
disease O -
. O +

Patients O +
who O +
are O +
unusually O +
sensitive O +
to O +
the O +
neuromuscular O +
effects O +
of O +
magnesium O +
should O +
be O +
suspected O +
of O +
having O +
an O +
underlying O +
disorder B-Disease +
of I-Disease +
neuromuscular I-Disease +
transmission I-Disease -
. O +

No O +
enhancement O +
by O +
phenobarbital O +
of O +
the O +
hepatocarcinogenicity O +
of O +
a O +
choline O -
- O -
devoid O +
diet O +
in O +
the O +
rat O -
. O +

An O +
experiment O +
was O +
performed O +
to O +
test O +
whether O +
inclusion O +
of O +
phenobarbital O +
in O +
a O +
choline O -
- O -
devoid O +
diet O +
would O +
increase O +
the O +
hepatocarcinogenicity O +
of O +
the O +
diet O -
. O +

Groups O +
of O +
5-week O +
old O +
male O +
Fischer-344 O +
rats O +
were O +
fed O +
for O +
7 O -
- O -
25 O +
months O +
semipurified O +
choline O -
- O -
devoid O +
or O +
choline O -
- O -
supplemented O +
diets O -
, O +
containing O +
or O +
not O +
0.06 O -
% O +
phenobarbital O -
. O +

No O +
hepatic O +
preneoplastic O +
nodules O +
or O +
hepatocellular B-Disease +
carcinomas I-Disease +
developed O +
in O +
rats O +
fed O +
the O +
plain O +
choline O -
- O -
supplemented O +
diet O -
, O +
while O +
one O +
preneoplastic O +
nodule O +
and O +
one O +
hepatocellular B-Disease +
carcinoma I-Disease +
developed O +
in O +
two O +
rats O +
fed O +
the O +
same O +
diet O +
containing O +
phenobarbital O -
. O +

The O +
incidence O +
of O +
preneoplastic O +
nodules O +
and O +
of O +
hepatocellular B-Disease +
carcinomas I-Disease +
was O +
10 O -
% O +
and O +
37 O -
% O -
, O +
respectively O -
, O +
in O +
rats O +
fed O +
the O +
plain O +
choline O -
- O -
devoid O +
diet O -
, O +
and O +
17 O -
% O +
and O +
30 O -
% O -
, O +
in O +
rats O +
fed O +
the O +
phenobarbital O -
- O -
containing O +
choline O -
- O -
devoid O +
diet O -
. O +

The O +
results O +
evinced O +
no O +
enhancement O +
of O +
the O +
hepatocarcinogenicity O +
of O +
the O +
choline O -
- O -
devoid O +
diet O +
by O +
phenobarbital O -
. O +

Sporadic O +
neoplastic O +
lesions O +
were O +
observed O +
in O +
organs O +
other O +
than O +
the O +
liver O +
of O +
some O +
of O +
the O +
animals O -
, O +
irrespective O +
of O +
the O +
diet O +
fed O -
. O +

Midline O +
B3 O +
serotonin O +
nerves O +
in O +
rat O +
medulla O +
are O +
involved O +
in O +
hypotensive B-Disease +
effect O +
of O +
methyldopa O -
. O +

Previous O +
experiments O +
in O +
this O +
laboratory O +
have O +
shown O +
that O +
microinjection O +
of O +
methyldopa O +
onto O +
the O +
ventrolateral O +
cells O +
of O +
the O +
B3 O +
serotonin O +
neurons O +
in O +
the O +
medulla O +
elicits O +
a O +
hypotensive B-Disease +
response O +
mediated O +
by O +
a O +
projection O +
descending O +
into O +
the O +
spinal O +
cord O -
. O +

The O +
present O +
experiments O +
were O +
designed O +
to O +
investigate O +
the O +
role O +
of O +
the O +
midline O +
cells O +
of O +
the O +
B3 O +
serotonin O +
neurons O +
in O +
the O +
medulla O -
, O +
coinciding O +
with O +
the O +
raphe O +
magnus O -
. O +

In O +
spontaneously O +
hypertensive B-Disease -
, O +
stroke B-Disease -
- O -
prone O +
rats O -
, O +
microinjection O +
of O +
methyldopa O +
into O +
the O +
area O +
of O +
the O +
midline O +
B3 O +
serotonin O +
cell O +
group O +
in O +
the O +
ventral O +
medulla O +
caused O +
a O +
potent O +
hypotension B-Disease +
of O +
30 O -
- O -
40 O +
mm O +
Hg O -
, O +
which O +
was O +
maximal O +
2 O -
- O -
3 O +
h O +
after O +
administration O +
and O +
was O +
abolished O +
by O +
the O +
serotonin O +
neurotoxin O +
5,7-dihydroxytryptamine O +
( O -
5,7-DHT O -
) O +
injected O +
intracerebroventricularly O -
. O +

However O -
, O +
intraspinal O +
injection O +
of O +
5,7-DHT O +
to O +
produce O +
a O +
more O +
selective O +
lesion O +
of O +
only O +
descending O +
serotonin O +
projections O +
in O +
the O +
spinal O +
cord O +
did O +
not O +
affect O +
this O +
hypotension B-Disease -
. O +

Further O -
, O +
5,7-DHT O +
lesion O +
of O +
serotonin O +
nerves O +
travelling O +
in O +
the O +
median O +
forebrain O +
bundle O -
, O +
one O +
of O +
the O +
main O +
ascending O +
pathways O +
from O +
the O +
B3 O +
serotonin O +
cells O -
, O +
did O +
not O +
affect O +
the O +
fall O +
in O +
blood O +
pressure O +
associated O +
with O +
a O +
midline O +
B3 O +
serotonin O +
methyldopa O +
injection O -
. O +

It O +
is O +
concluded O +
therefore O +
that O -
, O +
unlike O +
the O +
ventrolateral O +
B3 O +
cells O +
which O +
mediate O +
a O +
methyldopa O -
- O -
induced O +
hypotension B-Disease +
via O +
descending O +
projections O -
, O +
the O +
midline O +
serotonin O +
B3 O +
cells O +
in O +
the O +
medulla O +
contribute O +
to O +
the O +
hypotensive B-Disease +
action O +
of O +
methyldopa O -
, O +
either O +
by O +
way O +
of O +
an O +
ascending O +
projection O +
which O +
does O +
not O +
pass O +
through O +
the O +
median O +
forebrain O +
bundle O -
, O +
or O +
through O +
a O +
projection O +
restricted O +
to O +
the O +
caudal O +
brainstem O -
. O +

On O +
two O +
paradoxical O +
side O -
- O -
effects O +
of O +
prednisolone O +
in O +
rats O -
, O +
ribosomal O +
RNA O +
biosyntheses O -
, O +
and O +
a O +
mechanism O +
of O +
action O -
. O +

Liver B-Disease +
enlargement I-Disease +
and O +
muscle B-Disease +
wastage I-Disease +
occurred O +
in O +
Wistar O +
rats O +
following O +
the O +
subcutaneous O +
administration O +
of O +
prednisolone O -
. O +

In O +
the O +
liver O +
both O +
the O +
content O +
of O +
RNA O +
and O +
the O +
biosynthesis O +
of O +
ribosomal O +
RNA O +
increased O +
while O +
both O +
the O +
RNA O +
content O +
and O +
ribosomal O +
RNA O +
biosynthesis O +
were O +
reduced O +
in O +
the O +
gastrocnemius O +
muscle O -
. O +

It O +
is O +
suggested O +
that O +
the O +
drug O +
acted O +
in O +
a O +
selective O +
and O +
tissue O -
- O -
specific O +
manner O +
to O +
enhance O +
ribosomal O +
RNA O +
synthesis O +
in O +
the O +
liver O +
and O +
depress O +
such O +
synthesis O +
in O +
the O +
muscle O -
. O +

This O +
view O +
supports O +
the O +
contention O +
that O +
the O +
liver O +
and O +
muscle O +
are O +
independent O +
sites O +
of O +
prednisolone O +
action O -
. O +

Antiarrhythmic O +
plasma O +
concentrations O +
of O +
cibenzoline O +
on O +
canine O +
ventricular B-Disease +
arrhythmias I-Disease -
. O +

Using O +
two O -
- O -
stage O +
coronary O +
ligation- O -
, O +
digitalis- O -
, O +
and O +
adrenaline O -
- O -
induced O +
canine O +
ventricular B-Disease +
arrhythmias I-Disease -
, O +
antiarrhythmic O +
effects O +
of O +
cibenzoline O +
were O +
examined O +
and O +
the O +
minimum O +
effective O +
plasma O +
concentration O +
for O +
each O +
arrhythmia B-Disease +
model O +
was O +
determined O -
. O +

Cibenzoline O +
suppressed O +
all O +
the O +
arrhythmias B-Disease -
, O +
and O +
the O +
minimum O +
effective O +
plasma O +
concentrations O +
for O +
arrhythmias B-Disease +
induced O +
by O +
24-h O +
coronary O +
ligation O -
, O +
48-h O +
coronary O +
ligation O -
, O +
digitalis O -
, O +
and O +
adrenaline O +
were O +
1.9 O +
+ O -
/- O +

0.9 O +
( O -
by O +
8 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O -
, O +
1.6 O +
+ O -
/- O +

0.5 O +
( O -
by O +
8 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O -
, O +
0.6 O +
+ O -
/- O +

0.2 O +
( O -
by O +
2 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O -
, O +
and O +
3.5 O +
+ O -
/- O +

1.3 O +
( O -
by O +
5 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
micrograms O -
/ O -
ml O -
, O +
respectively O +
( O -
mean O +
+ O -
/- O +

SDM O -
, O +
n O +
= O +
6 O -
- O -
7 O -
) O -
. O +

The O +
concentration O +
for O +
adrenaline O -
- O -
induced O +
arrhythmia B-Disease +
was O +
significantly O +
higher O +
than O +
those O +
for O +
the O +
other O +
types O +
of O +
arrhythmias B-Disease -
. O +

This O +
pharmacological O +
profile O +
is O +
similar O +
to O +
those O +
of O +
mexiletine O +
and O +
tocainide O -
, O +
and O +
all O +
three O +
drugs O +
have O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
stimulant O +
action O -
. O +

Because O +
cibenzoline O +
had O +
only O +
weak O +
hypotensive B-Disease +
and O +
sinus O +
node O +
depressive B-Disease +
effects O +
and O +
was O +
found O +
to O +
be O +
orally O +
active O +
when O +
given O +
to O +
coronary O +
ligation O +
arrhythmia B-Disease +
dogs O -
, O +
its O +
clinical O +
usefulness O +
is O +
expected O -
. O +

Differential O +
effects O +
of O +
gamma O -
- O -
hexachlorocyclohexane O +
( O -
lindane O -
) O +
on O +
pharmacologically O -
- O -
induced O +
seizures B-Disease -
. O +

Gamma O -
- O -
hexachlorocyclohexane O +
( O -
gamma O -
- O -
HCH O -
) O -
, O +
the O +
active O +
ingredient O +
of O +
the O +
insecticide O +
lindane O -
, O +
has O +
been O +
shown O +
to O +
decrease O +
seizure B-Disease +
threshold O +
to O +
pentylenetrazol O +
( O -
PTZ O -
) O +
3 O +
h O +
after O +
exposure O +
to O +
gamma O -
- O -
HCH O +
and O +
conversely O +
increase O +
threshold O +
to O +
PTZ O -
- O -
induced O +
seizures B-Disease +
24 O +
h O +
after O +
exposure O +
to O +
gamma O -
- O -
HCH O +
( O -
Vohland O +
et O +
al. O +
1981 O -
) O -
. O +

In O +
this O +
study O -
, O +
the O +
severity O +
of O +
response O +
to O +
other O +
seizure B-Disease -
- O -
inducing O +
agents O +
was O +
tested O +
in O +
mice O +
1 O +
and O +
24 O +
h O +
after O +
intraperitoneal O +
administration O +
of O +
80 O +
mg O -
/ O -
kg O +
gamma O -
- O -
HCH O -
. O +

One O +
hour O +
after O +
the O +
administration O +
of O +
gamma O -
- O -
HCH O -
, O +
the O +
activity O +
of O +
seizure B-Disease -
- O -
inducing O +
agents O +
was O +
increased O -
, O +
regardless O +
of O +
their O +
mechanism O -
, O +
while O +
24 O +
h O +
after O +
gamma O -
- O -
HCH O +
a O +
differential O +
response O +
was O +
observed O -
. O +

Seizure B-Disease +
activity O +
due O +
to O +
PTZ O +
and O +
picrotoxin O +
( O -
PTX O -
) O +
was O +
significantly O +
decreased O -
; O +
however O -
, O +
seizure B-Disease +
activity O +
due O +
to O +
3-mercaptopropionic O +
acid O +
( O -
MPA O -
) O -
, O +
bicuculline O +
( O -
BCC O -
) O -
, O +
methyl O +
6,7-dimethoxy-4-ethyl O -
- O -
B O -
- O -
carboline-3-carboxylate O +
( O -
DMCM O -
) O -
, O +
or O +
strychnine O +
( O -
STR O -
) O +
was O +
not O +
different O +
from O +
control O -
. O +

In O +
vitro O -
, O +
gamma O -
- O -
HCH O -
, O +
pentylenetetrazol O +
and O +
picrotoxin O +
were O +
shown O +
to O +
inhibit O +
3H O -
- O -
TBOB O +
binding O +
in O +
mouse O +
whole O +
brain O -
, O +
with O +
IC50 O +
values O +
of O +
4.6 O -
, O +
404 O +
and O +
9.4 O +
microM O -
, O +
respectively O -
. O +

MPA O -
, O +
BCC O -
, O +
DMCM O -
, O +
and O +
STR O +
showed O +
no O +
inhibition O +
of O +
3H O -
- O -
TBOB O +
( O -
t O -
- O -
butyl O +
bicyclo O -
- O -
orthobenzoate O -
) O +
binding O +
at O +
concentrations O +
of O +
100 O +
micron O -
. O +

The O +
pharmacological O +
challenge O +
data O +
suggest O +
that O +
tolerance O +
may O +
occur O +
to O +
seizure B-Disease +
activity O +
induced O +
by O +
PTZ O +
and O +
PTX O +
24 O +
h O +
after O +
gamma O -
- O -
HCH O -
, O +
since O +
the O +
response O +
to O +
only O +
these O +
two O +
seizure B-Disease -
- O -
inducing O +
agents O +
is O +
decreased O -
. O +

The O +
in O +
vitro O +
data O +
suggest O +
that O +
the O +
site O +
responsible O +
for O +
the O +
decrease O +
in O +
seizure B-Disease +
activity O +
24 O +
h O +
after O +
gamma O -
- O -
HCH O +
may O +
be O +
the O +
GABA O -
- O -
A O +
receptor O -
- O -
linked O +
chloride O +
channel O -
. O +

Tolerance O +
and O +
antiviral O +
effect O +
of O +
ribavirin O +
in O +
patients O +
with O +
Argentine B-Disease +
hemorrhagic I-Disease +
fever I-Disease -
. O +

Tolerance O +
and O +
antiviral O +
effect O +
of O +
ribavirin O +
was O +
studied O +
in O +
6 O +
patients O +
with O +
Argentine B-Disease +
hemorrhagic I-Disease +
fever I-Disease +
( O -
AHF B-Disease -
) O +
of O +
more O +
than O +
8 O +
days O +
of O +
evolution O -
. O +

Administration O +
of O +
ribavirin O +
resulted O +
in O +
a O +
neutralization O +
of O +
viremia B-Disease +
and O +
a O +
drop O +
of O +
endogenous O +
interferon O +
titers O -
. O +

The O +
average O +
time O +
of O +
death B-Disease +
was O +
delayed O -
. O +

A O +
reversible O +
anemia B-Disease +
was O +
the O +
only O +
adverse O +
effect O +
observed O -
. O +

From O +
these O +
results O -
, O +
we O +
conclude O +
that O +
ribavirin O +
has O +
an O +
antiviral O +
effect O +
in O +
advanced O +
cases O +
of O +
AHF B-Disease -
, O +
and O +
that O +
anemia B-Disease -
, O +
the O +
only O +
secondary O +
reaction O +
observed O -
, O +
can O +
be O +
easily O +
managed O -
. O +

The O +
possible O +
beneficial O +
effect O +
of O +
ribavirin O +
during O +
the O +
initial O +
days O +
of O +
AHF B-Disease +
is O +
discussed O -
. O +

Continuous O +
ambulatory O +
ECG O +
monitoring O +
during O +
fluorouracil O +
therapy O -
: O +
a O +
prospective O +
study O -
. O +

Although O +
there O +
have O +
been O +
anecdotal O +
reports O +
of O +
cardiac B-Disease +
toxicity I-Disease +
associated O +
with O +
fluorouracil O +
( O -
5-FU O -
) O +
therapy O -
, O +
this O +
phenomenon O +
has O +
not O +
been O +
studied O +
in O +
a O +
systematic O +
fashion O -
. O +

We O +
prospectively O +
performed O +
continuous O +
ambulatory O +
ECG O +
monitoring O +
on O +
25 O +
patients O +
undergoing O +
5-FU O +
infusion O +
for O +
treatment O +
of O +
solid O +
tumors B-Disease +
in O +
order O +
to O +
assess O +
the O +
incidence O +
of O +
ischemic B-Disease +
ST O +
changes O -
. O +

Patients O +
were O +
monitored O +
for O +
23 O +
+ O -
/- O +

4 O +
hours O +
before O +
5-FU O +
infusion O -
, O +
and O +
98 O +
+ O -
/- O +

9 O +
hours O +
during O +
5-FU O +
infusion O -
. O +

Anginal B-Disease +
episodes O +
were O +
rare O -
: O +
only O +
one O +
patient O +
had O +
angina B-Disease +
( O -
during O +
5-FU O +
infusion O -
) O -
. O +

However O -
, O +
asymptomatic O +
ST O +
changes O +
( O -
greater O +
than O +
or O +
equal O +
to O +
1 O +
mm O +
ST O +
deviation O -
) O +
were O +
common O -
: O +
six O +
of O +
25 O +
patients O +
( O -
24 O -
% O -
) O +
had O +
ST O +
changes O +
before O +
5-FU O +
infusion O +
v O +
17 O +
( O -
68 O -
% O -
) O +
during O +
5-FU O +
infusion O +
( O -
P O +
less O +
than O +
.002 O -
) O -
. O +

The O +
incidence O +
of O +
ischemic B-Disease +
episodes O +
per O +
patient O +
per O +
hour O +
was O +
0.05 O +
+ O -
/- O +

0.02 O +
prior O +
to O +
5-FU O +
infusion O +
v O +
0.13 O +
+ O -
/- O +

0.03 O +
during O +
5-FU O +
infusion O +
( O -
P O +
less O +
than O +
.001 O -
) O -
; O +
the O +
duration O +
of O +
ECG O +
changes O +
was O +
0.6 O +
+ O -
/- O +

0.3 O +
minutes O +
per O +
patient O +
per O +
hour O +
before O +
5-FU O +
v O +
1.9 O +
+ O -
/- O +

0.5 O +
minutes O +
per O +
patient O +
per O +
hour O +
during O +
5-FU O +
( O -
P O +
less O +
than O +
.01 O -
) O -
. O +

ECG O +
changes O +
were O +
more O +
common O +
among O +
patients O +
with O +
known O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
. O +

There O +
were O +
two O +
cases O +
of O +
sudden B-Disease +
death I-Disease -
, O +
both O +
of O +
which O +
occurred O +
at O +
the O +
end O +
of O +
the O +
chemotherapy O +
course O -
. O +

We O +
conclude O +
that O +
5-FU O +
infusion O +
is O +
associated O +
with O +
a O +
significant O +
increase O +
in O +
silent O +
ST O +
segment O +
deviation O +
suggestive O +
of O +
ischemia B-Disease -
, O +
particularly O +
among O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
. O +

The O +
mechanism O +
and O +
clinical O +
significance O +
of O +
these O +
ECG O +
changes O +
remain O +
to O +
be O +
determined O -
. O +

Is O +
the O +
treatment O +
of O +
scabies B-Disease +
hazardous O -
? O +

Treatment O +
for O +
scabies B-Disease +
is O +
usually O +
initiated O +
by O +
general O +
practitioners O -
; O +
most O +
consider O +
lindane O +
( O -
gamma O +
benzene O +
hexachloride O -
) O +
the O +
treatment O +
of O +
choice O -
. O +

Lindane O +
is O +
also O +
widely O +
used O +
as O +
an O +
agricultural O +
and O +
industrial O +
pesticide O -
, O +
and O +
as O +
a O +
result O +
the O +
toxic O +
profile O +
of O +
this O +
insecticide O +
is O +
well O +
understood O -
. O +

Evidence O +
is O +
accumulating O +
that O +
lindane O +
can O +
be O +
toxic B-Disease +
to I-Disease +
the I-Disease +
central I-Disease +
nervous I-Disease +
system I-Disease +
and O +
may O +
be O +
associated O +
with O +
aplastic B-Disease +
anaemia I-Disease -
. O +

Preparations O +
containing O +
lindane O +
continue O +
to O +
be O +
sold O +
over O +
the O +
counter O +
and O +
may O +
represent O +
a O +
hazard O +
to O +
poorly O +
informed O +
patients O -
. O +

This O +
literature O +
review O +
suggests O +
that O +
general O +
practitioners O +
should O +
prescribe O +
scabicides O +
with O +
increased O +
caution O +
for O +
certain O +
at O -
- O -
risk O +
groups O -
, O +
and O +
give O +
adequate O +
warnings O +
regarding O +
potential O +
toxicity B-Disease -
. O +

Mouse O +
strain O -
- O -
dependent O +
effect O +
of O +
amantadine O +
on O +
motility O +
and O +
brain O +
biogenic O +
amines O -
. O +

The O +
effect O +
of O +
amantadine O +
hydrochloride O -
, O +
injected O +
i.p O -
. O +
in O +
6 O +
increments O +
of O +
100 O +
mg O -
/ O -
kg O +
each O +
over O +
30 O +
hr O -
, O +
on O +
mouse O +
motility O +
and O +
whole O +
brain O +
content O +
of O +
selected O +
biogenic O +
amines O +
and O +
major O +
metabolites O +
was O +
studied O +
in O +
4 O +
strains O +
of O +
mice O -
. O +

These O +
were O +
the O +
albino O +
Sprague O -
- O -
Dawley O +
ICR O +
and O +
BALB O -
/ O -
C O -
, O +
the O +
black O +
C57BL O -
/ O -
6 O +
and O +
the O +
brown O +
CDF O -
- O -
I O +
mouse O +
strains O -
. O +

Amantadine O +
treatment O +
produced O +
a O +
biphasic O +
effect O +
on O +
mouse O +
motility O -
. O +

The O +
initial O +
dose O +
of O +
amantadine O +
depressed B-Disease +
locomotor O +
activity O +
in O +
all O +
mouse O +
strains O +
studied O +
with O +
the O +
BALB O -
/ O -
C O +
mice O +
being O +
the O +
most O +
sensitive O -
. O +

Subsequent O +
amantadine O +
treatments O +
produced O +
enhancement O +
of O +
motility O +
from O +
corresponding O +
control O +
in O +
all O +
mouse O +
strains O +
with O +
the O +
BALB O -
/ O -
C O +
mice O +
being O +
the O +
least O +
sensitive O -
. O +

The O +
locomotor O +
activity O +
was O +
decreased O +
from O +
corresponding O +
controls O +
in O +
all O +
strains O +
studied O -
, O +
except O +
for O +
the O +
ICR O +
mice O -
, O +
during O +
an O +
overnight O +
drug O -
- O -
free O +
period O +
following O +
the O +
fourth O +
amantadine O +
treatment O -
. O +

Readministration O +
of O +
amantadine O -
, O +
after O +
a O +
drug O -
- O -
free O +
overnight O +
period O -
, O +
increased O +
motility O +
from O +
respective O +
saline O +
control O +
in O +
all O +
strains O +
with O +
exception O +
of O +
the O +
BALB O -
/ O -
C O +
mice O +
where O +
suppression B-Disease +
of I-Disease +
motility I-Disease +
occurred O -
. O +

Treatment O +
with O +
amantadine O +
did O +
not O +
alter O +
whole O +
brain O +
dopamine O +
levels O +
but O +
decreased O +
the O +
amounts O +
of O +
3,4-dihydroxyphenylacetic O +
acid O +
in O +
the O +
BALB O -
/ O -
C O +
mice O +
compared O +
to O +
saline O +
control O -
. O +

Conversely O -
, O +
brain O +
normetanephrine O +
concentration O +
was O +
increased O +
from O +
saline O +
control O +
by O +
amantadine O +
in O +
the O +
BALB O -
/ O -
C O +
mice O -
. O +

The O +
results O +
suggest O +
a O +
strain O -
- O -
dependent O +
effect O +
of O +
amantadine O +
on O +
motility O +
and O +
indicate O +
a O +
differential O +
response O +
to O +
the O +
acute O +
and O +
multiple O +
dose O +
regimens O +
used O -
. O +

The O +
BALB O -
/ O -
C O +
mouse O +
was O +
the O +
most O +
sensitive O +
strain O +
and O +
could O +
serve O +
as O +
the O +
strain O +
of O +
choice O +
for O +
evaluating O +
the O +
side O +
effects O +
of O +
amantadine O -
. O +

The O +
biochemical O +
results O +
of O +
brain O +
biogenic O +
amines O +
of O +
BALB O -
/ O -
C O +
mouse O +
strain O +
suggest O +
a O +
probable O +
decrease O +
of O +
catecholamine O +
turnover O +
rate O +
and/or O +
metabolism O +
by O +
monoamine O +
oxidase O +
and O +
a O +
resulting O +
increase O +
in O +
O O -
- O -
methylation O +
of O +
norepinephrine O +
which O +
may O +
account O +
for O +
a O +
behavioral B-Disease +
depression I-Disease +
caused O +
by O +
amantadine O +
in O +
the O +
BALB O -
/ O -
C O +
mice O -
. O +

Chloroacetaldehyde O +
and O +
its O +
contribution O +
to O +
urotoxicity O +
during O +
treatment O +
with O +
cyclophosphamide O +
or O +
ifosfamide O -
. O +

An O +
experimental O +
study O -
/ O -
short O +
communication O -
. O +

Based O +
on O +
clinical O +
data O -
, O +
indicating O +
that O +
chloroacetaldehyde O +
( O -
CAA O -
) O +
is O +
an O +
important O +
metabolite O +
of O +
oxazaphosphorine O +
cytostatics O -
, O +
an O +
experimental O +
study O +
was O +
carried O +
out O +
in O +
order O +
to O +
elucidate O +
the O +
role O +
of O +
CAA O +
in O +
the O +
development O +
of O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

The O +
data O +
demonstrate O +
that O +
CAA O +
after O +
i.v O -
. O +

administration O +
does O +
not O +
contribute O +
to O +
bladder B-Disease +
damage I-Disease -
. O +

When O +
instilled O +
directly O +
into O +
the O +
bladder O -
, O +
CAA O +
exerts O +
urotoxic O +
effects O -
, O +
it O +
is O -
, O +
however O -
, O +
susceptible O +
to O +
detoxification O +
with O +
mesna O -
. O +

Source O +
of O +
pain B-Disease +
and O +
primitive O +
dysfunction O +
in O +
migraine B-Disease -
: O +
an O +
identical O +
site O -
? O +

Twenty O +
common O +
migraine B-Disease +
patients O +
received O +
a O +
one O +
sided O +
frontotemporal O +
application O +
of O +
nitroglycerin O +
( O -
10 O +
patients O -
) O +
or O +
placebo O +
ointment O +
( O -
10 O +
patients O -
) O +
in O +
a O +
double O +
blind O +
study O -
. O +

Early O +
onset O +
migraine B-Disease +
attacks O +
were O +
induced O +
by O +
nitroglycerin O +
in O +
seven O +
out O +
of O +
10 O +
patients O +
versus O +
no O +
patient O +
in O +
the O +
placebo O +
group O -
. O +

Subsequently O +
20 O +
migraine B-Disease +
patients O -
, O +
who O +
developed O +
an O +
early O +
onset O +
attack O +
with O +
frontotemporal O +
nitroglycerin O -
, O +
received O +
the O +
drug O +
in O +
a O +
second O +
induction O +
test O +
at O +
other O +
body O +
areas O -
. O +

No O +
early O +
onset O +
migraine B-Disease +
was O +
observed O -
. O +

Thus O +
the O +
migraine B-Disease -
- O -
inducing O +
effect O +
of O +
nitroglycerin O +
seems O +
to O +
depend O +
on O +
direct O +
stimulation O +
of O +
the O +
habitual O +
site O +
of O +
pain B-Disease -
, O +
suggesting O +
that O +
the O +
frontotemporal O +
region O +
is O +
of O +
crucial O +
importance O +
in O +
the O +
development O +
of O +
a O +
migraine B-Disease +
crisis O -
. O +

This O +
is O +
not O +
consistent O +
with O +
a O +
CNS O +
origin O +
of O +
migraine B-Disease +
attack O -
. O +

Hypersensitivity B-Disease +
to O +
carbamazepine O +
presenting O +
with O +
a O +
leukemoid B-Disease +
reaction I-Disease -
, O +
eosinophilia B-Disease -
, O +
erythroderma B-Disease -
, O +
and O +
renal B-Disease +
failure I-Disease -
. O +

We O +
report O +
a O +
patient O +
in O +
whom O +
hypersensitivity B-Disease +
to O +
carbamazepine O +
presented O +
with O +
generalized O +
erythroderma B-Disease -
, O +
a O +
severe O +
leukemoid B-Disease +
reaction I-Disease -
, O +
eosinophilia B-Disease -
, O +
hyponatremia B-Disease -
, O +
and O +
renal B-Disease +
failure I-Disease -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
such O +
an O +
unusual O +
reaction O +
to O +
carbamazepine O -
. O +

Nature O -
, O +
time O +
course O +
and O +
dose O +
dependence O +
of O +
zidovudine O -
- O -
related O +
side O +
effects O -
: O +
results O +
from O +
the O +
Multicenter O +
Canadian O +
Azidothymidine O +
Trial O -
. O +

To O +
characterize O +
the O +
nature O -
, O +
time O +
course O +
and O +
dose O +
dependency O +
of O +
zidovudine O -
- O -
related O +
side O +
effects O -
, O +
we O +
undertook O +
a O +
multicenter O -
, O +
prospective O -
, O +
dose O -
- O -
range O +
finding O +
study O -
. O +

Our O +
study O +
group O +
consisted O +
of O +
74 O +
HIV O -
- O -
positive O +
homosexual O +
men O +
belonging O +
to O +
groups O +
II O +
B O -
, O +
III O +
and O +
IV O +
C2 O +
from O +
the O +
Centers O +
for O +
Disease O +
Control O +
( O -
CDC O -
) O +
classification O +
of O +
HIV B-Disease +
disease I-Disease -
. O +

Following O +
a O +
3-week O +
observation O +
period O -
, O +
volunteers O +
were O +
treated O +
with O +
zidovudine O +
600 O +
mg O -
/ O -
day O +
for O +
18 O +
weeks O -
, O +
900 O +
mg O -
/ O -
day O +
for O +
9 O +
weeks O +
and O +
1200 O +
mg O -
/ O -
day O +
for O +
9 O +
weeks O -
, O +
followed O +
by O +
a O +
washout O +
period O +
of O +
6 O +
weeks O +
after O +
which O +
they O +
were O +
re O -
- O -
started O +
on O +
1200 O +
mg O -
/ O -
day O +
or O +
the O +
highest O +
tolerated O +
dose O +
at O +
8-hourly O +
intervals O -
. O +

Subjects O +
were O +
randomly O +
assigned O +
to O +
4-hourly O +
or O +
8-hourly O +
regimens O +
within O +
CDC O +
groups O +
while O +
taking O +
600 O +
and O +
1200 O +
mg O -
/ O -
day O -
. O +

Clinical O +
and O +
laboratory O +
evaluations O +
were O +
performed O +
at O +
3-week O +
intervals O -
. O +

Symptomatic O +
adverse O +
effects O +
were O +
present O +
in O +
96 O -
% O +
of O +
subjects O -
, O +
most O +
commonly O +
nausea B-Disease +
( O -
64 O -
% O -
) O -
, O +
fatigue B-Disease +
( O -
55 O -
% O -
) O +
and O +
headache B-Disease +
( O -
49 O -
% O -
) O -
. O +

These O +
were O +
generally O +
self O -
- O -
limited O -
, O +
reappearing O +
briefly O +
at O +
each O +
dose O +
increment O -
. O +

A O +
decrease O +
in O +
hemoglobin O +
occurred O +
shortly O +
after O +
initiation O +
of O +
therapy O -
. O +

This O +
was O +
not O +
dose O +
dependent O +
and O +
reversed O +
rapidly O +
upon O +
discontinuation O +
of O +
treatment O -
. O +

A O +
red O +
blood O +
cell O +
count O +
decrease O -
, O +
a O +
mean O +
cell O +
volume O +
increase O +
and O +
a O +
granulocyte O +
count O +
decrease O +
developed O +
early O +
in O +
a O +
dose O -
- O -
independent O +
fashion O -
, O +
reverting O +
at O +
least O +
partially O +
during O +
the O +
washout O +
phase O -
. O +

The O +
decrease O +
in O +
reticulocyte O +
count O +
was O +
dose O +
related O +
between O +
600 O +
and O +
900 O +
mg O -
/ O -
day O +
with O +
no O +
further O +
change O +
when O +
the O +
dose O +
was O +
escalated O +
to O +
1200 O +
mg O -
/ O -
day O -
. O +

Bone O +
marrow O +
changes O +
occurred O +
rapidly O +
as O +
demonstrated O +
by O +
megaloblastosis B-Disease +
in O +
95 O -
% O +
of O +
65 O +
specimens O +
at O +
week O +
18. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

National O +
project O +
on O +
the O +
prevention O +
of O +
mother O -
- O -
to O -
- O -
infant O +
infection B-Disease +
by I-Disease +
hepatitis I-Disease +
B I-Disease +
virus I-Disease +
in O +
Japan O -
. O +

In O +
Japan O -
, O +
a O +
nationwide O +
prevention O +
program O +
against O +
mother O -
- O -
to O -
- O -
infant O +
infection B-Disease +
by I-Disease +
hepatitis I-Disease +
B I-Disease +
virus I-Disease +
( O -
HBV O -
) O +
started O +
in O +
1985 O -
. O +

This O +
program O +
consists O +
of O +
double O +
screenings O +
of O +
pregnant O +
women O +
and O +
prophylactic O +
treatment O +
to O +
the O +
infants O +
born O +
to O +
both O +
hepatitis O +
B O +
surface O +
antigen O +
( O -
HBsAg O -
) O +
and O +
hepatitis O +
B O +
e O +
antigen O +
( O -
HBeAg O -
) O +
positive O +
mothers O -
. O +

These O +
infants O +
are O +
treated O +
with O +
two O +
injections O +
of O +
hepatitis B-Disease +
B I-Disease +
immune O +
globulin O +
( O -
HBIG O -
) O +
and O +
at O +
least O +
three O +
injections O +
of O +
plasma O +
derived O +
hepatitis O +
B O +
vaccine O -
. O +

We O +
sent O +
questionnaires O +
about O +
the O +
numbers O +
of O +
each O +
procedure O +
or O +
examination O +
during O +
nine O +
months O +
of O +
investigation O +
period O +
to O +
each O +
local O +
government O +
in O +
1986 O +
and O +
1987 O -
. O +

93.4 O -
% O +
pregnant O +
women O +
had O +
the O +
chance O +
to O +
be O +
examined O +
for O +
HBsAg O -
, O +
and O +
the O +
positive O +
rate O +
was O +
1.4 O +
to O +
1.5 O -
% O -
. O +

The O +
HBeAg O +
positive O +
rate O +
in O +
HBsAg O +
positive O +
was O +
23 O +
to O +
26 O -
% O -
. O +

The O +
HBsAg O +
positive O +
rate O +
in O +
neonates O +
and O +
in O +
infants O +
before O +
two O +
months O +
were O +
3 O -
% O +
and O +
2 O -
% O +
respectively O -
. O +

Some O +
problems O +
may O +
arise O -
, O +
because O +
27 O +
to O +
30 O -
% O +
of O +
infants O +
need O +
the O +
fourth O +
vaccination O +
in O +
some O +
restricted O +
areas O -
. O +

Fluoxetine O -
- O -
induced O +
akathisia B-Disease -
: O +
clinical O +
and O +
theoretical O +
implications O -
. O +

Five O +
patients O +
receiving O +
fluoxetine O +
for O +
the O +
treatment O +
of O +
obsessive B-Disease +
compulsive I-Disease +
disorder I-Disease +
or O +
major B-Disease +
depression I-Disease +
developed O +
akathisia B-Disease -
. O +

The O +
typical O +
fluoxetine O -
- O -
induced O +
symptoms O +
of O +
restlessness O -
, O +
constant O +
pacing O -
, O +
purposeless O +
movements O +
of O +
the O +
feet O +
and O +
legs O -
, O +
and O +
marked O +
anxiety B-Disease +
were O +
indistinguishable O +
from O +
those O +
of O +
neuroleptic O -
- O -
induced O +
akathisia B-Disease -
. O +

Three O +
patients O +
who O +
had O +
experienced O +
neuroleptic O -
- O -
induced O +
akathisia B-Disease +
in O +
the O +
past O +
reported O +
that O +
the O +
symptoms O +
of O +
fluoxetine O -
- O -
induced O +
akathisia B-Disease +
were O +
identical O -
, O +
although O +
somewhat O +
milder O -
. O +

Akathisia B-Disease +
appeared O +
to O +
be O +
a O +
common O +
side O +
effect O +
of O +
fluoxetine O +
and O +
generally O +
responded O +
well O +
to O +
treatment O +
with O +
the O +
beta O -
- O -
adrenergic O +
antagonist O +
propranolol O -
, O +
dose O +
reduction O -
, O +
or O +
both O -
. O +

The O +
authors O +
suggest O +
that O +
fluoxetine O -
- O -
induced O +
akathisia B-Disease +
may O +
be O +
caused O +
by O +
serotonergically O +
mediated O +
inhibition O +
of O +
dopaminergic O +
neurotransmission O +
and O +
that O +
the O +
pathophysiology O +
of O +
fluoxetine O -
- O -
induced O +
akathisia B-Disease +
and O +
tricyclic O +
antidepressant O -
- O -
induced O +
" O -
jitteriness O -
" O +
may O +
be O +
identical O -
. O +

Involvement O +
of O +
the O +
mu O -
- O -
opiate O +
receptor O +
in O +
peripheral O +
analgesia B-Disease -
. O +

The O +
intradermal O +
injection O +
of O +
mu O +
( O -
morphine O -
, O +
Tyr O -
- O -
D O -
- O -
Ala O -
- O -
Gly O -
- O -
NMe O -
- O -
Phe O -
- O -
Gly O -
- O -
ol O +
and O +
morphiceptin O -
) O -
, O +
kappa O +
( O -
trans-3,4-dichloro O -
- O -
N O -
- O -
methyl O -
- O -
N O -
[ O -
2- O -
( O -
1-pyrrolidinyl O -
) O +
cyclohexyl O -
] O -
benzeneactemide O -
) O +
and O +
delta O +
( O -
[ O -
D O -
- O -
Pen2.5 O -
] O -
-enkephalin O +
and O +
[ O -
D O -
- O -
Ser2 O -
] O -
- O -
[ O -
Leu O -
] O -
enkephalin O -
- O -
Thr O -
) O +
selective O +
opioid O -
- O -
agonists O -
, O +
by O +
themselves O -
, O +
did O +
not O +
significantly O +
affect O +
the O +
mechanical O +
nociceptive O +
threshold O +
in O +
the O +
hindpaw O +
of O +
the O +
rat O -
. O +

Intradermal O +
injection O +
of O +
mu O -
, O +
but O +
not O +
delta O +
or O +
kappa O +
opioid O -
- O -
agonists O -
, O +
however O -
, O +
produced O +
dose O -
- O -
dependent O +
inhibition O +
of O +
prostaglandin O +
E2-induced O +
hyperalgesia B-Disease -
. O +

The O +
analgesic O +
effect O +
of O +
the O +
mu O -
- O -
agonist O +
morphine O +
was O +
dose O -
- O -
dependently O +
antagonized O +
by O +
naloxone O +
and O +
prevented O +
by O +
co O -
- O -
injection O +
of O +
pertussis O +
toxin O -
. O +

Morphine O +
did O +
not O -
, O +
however O -
, O +
alter O +
the O +
hyperalgesia B-Disease +
induced O +
by O +
8-bromo O +
cyclic O +
adenosine O +
monophosphate O -
. O +

We O +
conclude O +
that O +
the O +
analgesic O +
action O +
of O +
opioids O +
on O +
the O +
peripheral O +
terminals O +
of O +
primary O +
afferents O +
is O +
via O +
a O +
binding O +
site O +
with O +
characteristics O +
of O +
the O +
mu O -
- O -
opioid O +
receptor O +
and O +
that O +
this O +
action O +
is O +
mediated O +
by O +
inhibition O +
of O +
the O +
cyclic O +
adenosine O +
monophosphate O +
second O +
messenger O +
system O -
. O +

Effect O +
of O +
converting O +
enzyme O +
inhibition O +
on O +
the O +
course O +
of O +
adriamycin O -
- O -
induced O +
nephropathy B-Disease -
. O +

The O +
effect O +
of O +
the O +
converting O +
enzyme O +
inhibitor O +
( O -
CEI O -
) O +
enalapril O +
was O +
assessed O +
in O +
Munich O -
- O -
Wistar O +
rats O +
with O +
established O +
adriamycin O +
nephrosis B-Disease -
. O +

Rats O +
were O +
given O +
a O +
single O +
dose O +
of O +
adriamycin O +
and O +
one O +
month O +
later O +
divided O +
into O +
four O +
groups O +
matched O +
for O +
albuminuria B-Disease -
, O +
blood O +
pressure O -
, O +
and O +
plasma O +
albumin O +
concentration O -
. O +

Groups O +
1 O +
and O +
3 O +
remained O +
untreated O +
while O +
groups O +
2 O +
and O +
4 O +
received O +
enalapril O -
. O +

Groups O +
1 O +
and O +
2 O +
underwent O +
micropuncture O +
studies O +
after O +
10 O +
days O -
. O +

These O +
short O -
- O -
term O +
studies O +
showed O +
that O +
enalapril O +
reduced O +
arterial O +
blood O +
pressure O +
( O -
101 O +
+ O -
/- O +

2 O +
vs. O +
124 O +
+ O -
/- O +

3 O +
mm O +
Hg O -
, O +
group O +
2 O +
vs. O +
1 O -
, O +
P O +
less O +
than O +
0.05 O -
) O +
and O +
glomerular O +
capillary O +
pressure O +
( O -
54 O +
+ O -
/- O +

1 O +
vs. O +
61 O +
+ O -
/- O +

2 O +
mm O +
Hg O -
, O +
P O +
less O +
than O +
0.05 O -
) O +
without O +
reducing O +
albuminuria B-Disease +
( O -
617 O +
+ O -
/- O +
50 O +
vs. O +
570 O +
+ O -
/- O +

47 O +
mg O -
/ O -
day O -
) O +
or O +
GFR O +
( O -
1.03 O +
+ O -
/- O +

0.04 O +
vs. O +
1.04 O +
+ O -
/- O +

0.11 O +
ml O -
/ O -
min O -
) O -
. O +

Groups O +
3 O +
and O +
4 O +
were O +
studied O +
at O +
four O +
and O +
at O +
six O +
months O +
to O +
assess O +
the O +
effect O +
of O +
enalapril O +
on O +
progression O +
of O +
renal B-Disease +
injury I-Disease +
in O +
adriamycin O +
nephrosis B-Disease -
. O +

Chronic O +
enalapril O +
treatment O +
reduced O +
blood O +
pressure O +
without O +
reducing O +
albuminuria B-Disease +
in O +
group O +
4 O -
. O +

Untreated O +
group O +
3 O +
rats O +
exhibited O +
a O +
progressive O +
reduction O +
in O +
GFR O +
( O -
0.35 O +
+ O -
/- O +

0.08 O +
ml O -
/ O -
min O +
at O +
4 O +
months O -
, O +
0.27 O +
+ O -
/- O +

0.07 O +
ml O -
/ O -
min O +
at O +
6 O +
months O -
) O -
. O +

Enalapril O +
treatment O +
blunted O +
but O +
did O +
not O +
prevent O +
reduction O +
in O +
GFR O +
in O +
group O +
4 O +
( O -
0.86 O +
+ O -
/- O +

0.15 O +
ml O -
/ O -
min O +
at O +
4 O +
months O -
, O +
0.69 O +
+ O -
/- O +

0.13 O +
ml O -
/ O -
min O +
at O +
6 O +
months O -
, O +
both O +
P O +
less O +
than O +
0.05 O +
vs. O +
group O +
3 O -
) O -
. O +

Reduction O +
in O +
GFR O +
was O +
associated O +
with O +
the O +
development O +
of O +
glomerular B-Disease +
sclerosis I-Disease +
in O +
both O +
treated O +
and O +
untreated O +
rats. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Involvement O +
of O +
locus O +
coeruleus O +
and O +
noradrenergic O +
neurotransmission O +
in O +
fentanyl O -
- O -
induced O +
muscular B-Disease +
rigidity I-Disease +
in O +
the O +
rat O -
. O +

Whereas O +
muscular B-Disease +
rigidity I-Disease +
is O +
a O +
well O -
- O -
known O +
side O +
effect O +
that O +
is O +
associated O +
with O +
high O -
- O -
dose O +
fentanyl O +
anesthesia O -
, O +
a O +
paucity O +
of O +
information O +
exists O +
with O +
regard O +
to O +
its O +
underlying O +
mechanism O -
( O -
s O -
) O -
. O +

We O +
investigated O +
in O +
this O +
study O +
the O +
possible O +
engagement O +
of O +
locus O +
coeruleus O +
of O +
the O +
pons O +
in O +
this O +
phenomenon O -
, O +
using O +
male O +
Sprague O -
- O -
Dawley O +
rats O +
anesthetized O +
with O +
ketamine O -
. O +

Under O +
proper O +
control O +
of O +
respiration O -
, O +
body O +
temperature O +
and O +
end O -
- O -
tidal O +
CO2 O -
, O +
intravenous O +
administration O +
of O +
fentanyl O +
( O -
50 O +
or O +
100 O +
micrograms O -
/ O -
kg O -
) O +
consistently O +
promoted O +
an O +
increase O +
in O +
electromyographic O +
activity O +
recorded O +
from O +
the O +
gastrocnemius O +
and O +
abdominal O +
rectus O +
muscles O -
. O +

Such O +
an O +
induced O +
muscular B-Disease +
rigidity I-Disease +
by O +
the O +
narcotic O +
agent O +
was O +
significantly O +
antagonized O +
or O +
even O +
reduced O +
by O +
prior O +
electrolytic O +
lesions O +
of O +
the O +
locus O +
coeruleus O +
or O +
pretreatment O +
with O +
the O +
alpha O -
- O -
adrenoceptor O +
blocker O -
, O +
prazosin O -
. O +

Microinjection O +
of O +
fentanyl O +
( O -
2.5 O +
micrograms O -
/ O -
50 O +
nl O -
) O +
directly O +
into O +
this O +
pontine O +
nucleus O -
, O +
on O +
the O +
other O +
hand O -
, O +
elicited O +
discernible O +
electromyographic O +
excitation O -
. O +

It O +
is O +
speculated O +
that O +
the O +
induction O +
of O +
muscular B-Disease +
rigidity I-Disease +
by O +
fentanyl O +
may O +
involve O +
the O +
coerulospinal O +
noradrenergic O +
fibers O +
to O +
the O +
spinal O +
motoneurons O -
. O +

Clotiazepam O -
- O -
induced O +
acute O +
hepatitis B-Disease -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
patient O +
who O +
developed O +
acute O +
hepatitis B-Disease +
with O +
extensive B-Disease +
hepatocellular I-Disease +
necrosis I-Disease -
, O +
7 O +
months O +
after O +
the O +
onset O +
of O +
administration O +
of O +
clotiazepam O -
, O +
a O +
thienodiazepine O +
derivative O -
. O +

Clotiazepam O +
withdrawal O +
was O +
followed O +
by O +
prompt O +
recovery O -
. O +

The O +
administration O +
of O +
several O +
benzodiazepines O -
, O +
chemically O +
related O +
to O +
clotiazepam O -
, O +
did O +
not O +
interfere O +
with O +
recovery O +
and O +
did O +
not O +
induce O +
any O +
relapse O +
of O +
hepatitis B-Disease -
. O +

This O +
observation O +
shows O +
that O +
clotiazepam O +
can O +
induce O +
acute O +
hepatitis B-Disease +
and O +
suggests O +
that O +
there O +
is O +
no O +
cross O +
hepatotoxicity B-Disease +
between O +
clotiazepam O +
and O +
several O +
benzodiazepines O -
. O +

5-azacytidine O +
potentiates O +
initiation B-Disease +
induced I-Disease +
by I-Disease +
carcinogens I-Disease +
in O +
rat O +
liver O -
. O +

To O +
test O +
the O +
validity O +
of O +
the O +
hypothesis O +
that O +
hypomethylation O +
of O +
DNA O +
plays O +
an O +
important O +
role O +
in O +
the O +
initiation B-Disease +
of I-Disease +
carcinogenic I-Disease +
process I-Disease -
, O +
5-azacytidine O +
( O -
5-AzC O -
) O +
( O -
10 O +
mg O -
/ O -
kg O -
) O -
, O +
an O +
inhibitor O +
of O +
DNA O +
methylation O -
, O +
was O +
given O +
to O +
rats O +
during O +
the O +
phase O +
of O +
repair O +
synthesis O +
induced O +
by O +
the O +
three O +
carcinogens O -
, O +
benzo O -
[ O -
a O -
] O -
-pyrene O +
( O -
200 O +
mg O -
/ O -
kg O -
) O -
, O +
N O -
- O -
methyl O -
- O -
N O -
- O -
nitrosourea O +
( O -
60 O +
mg O -
/ O -
kg O -
) O +
and O +
1,2-dimethylhydrazine O +
( O -
1,2-DMH O -
) O +
( O -
100 O +
mg O -
/ O -
kg O -
) O -
. O +

The O +
initiated O +
hepatocytes O +
in O +
the O +
liver O +
were O +
assayed O +
as O +
the O +
gamma O -
- O -
glutamyltransferase O +
( O -
gamma O -
- O -
GT O -
) O +
positive O +
foci O +
formed O +
following O +
a O +
2-week O +
selection O +
regimen O +
consisting O +
of O +
dietary O +
0.02 O -
% O +
2-acetylaminofluorene O +
coupled O +
with O +
a O +
necrogenic O +
dose O +
of O +
CCl4 O -
. O +

The O +
results O +
obtained O +
indicate O +
that O +
with O +
all O +
three O +
carcinogens O -
, O +
administration O +
of O +
5-AzC O +
during O +
repair O +
synthesis O +
increased O +
the O +
incidence O +
of O +
initiated O +
hepatocytes O -
, O +
for O +
example O +
10 O -
- O -
20 O +
foci O -
/ O -
cm2 O +
in O +
5-AzC O +
and O +
carcinogen O -
- O -
treated O +
rats O +
compared O +
with O +
3 O -
- O -
5 O +
foci O -
/ O -
cm2 O +
in O +
rats O +
treated O +
with O +
carcinogen O +
only O -
. O +

Administration O +
of O +
[ O -
3H O -
] O -
-5-azadeoxycytidine O +
during O +
the O +
repair O +
synthesis O +
induced O +
by O +
1,2-DMH O +
further O +
showed O +
that O +
0.019 O +
mol O +
% O +
of O +
cytosine O +
residues O +
in O +
DNA O +
were O +
substituted O +
by O +
the O +
analogue O -
, O +
indicating O +
that O +
incorporation O +
of O +
5-AzC O +
occurs O +
during O +
repair O +
synthesis O -
. O +

In O +
the O +
absence O +
of O +
the O +
carcinogen O -
, O +
5-AzC O +
given O +
after O +
a O +
two O +
thirds O +
partial O +
hepatectomy O -
, O +
when O +
its O +
incorporation O +
should O +
be O +
maximum O -
, O +
failed O +
to O +
induce O +
any O +
gamma O -
- O -
GT O +
positive O +
foci O -
. O +

The O +
results O +
suggest O +
that O +
hypomethylation O +
of O +
DNA O +
per O +
se O +
may O +
not O +
be O +
sufficient O +
for O +
initiation O -
. O +

Perhaps O +
two O +
events O +
might O +
be O +
necessary O +
for O +
initiation O -
, O +
the O +
first O +
caused O +
by O +
the O +
carcinogen O +
and O +
a O +
second O +
involving O +
hypomethylation O +
of O +
DNA O -
. O +

Antihypertensive O +
drugs O +
and O +
depression B-Disease -
: O +
a O +
reappraisal O -
. O +

Eighty O -
- O -
nine O +
new O +
referral O +
hypertensive B-Disease +
out O -
- O -
patients O +
and O +
46 O +
new O +
referral O +
non O -
- O -
hypertensive B-Disease +
chronically O +
physically O +
ill O +
out O -
- O -
patients O +
completed O +
a O +
mood O +
rating O +
scale O +
at O +
regular O +
intervals O +
for O +
one O +
year O -
. O +

The O +
results O +
showed O +
a O +
high O +
prevalence O +
of O +
depression B-Disease +
in O +
both O +
groups O +
of O +
patients O -
, O +
with O +
no O +
preponderance O +
in O +
the O +
hypertensive B-Disease +
group O -
. O +

Hypertensive B-Disease +
patients O +
with O +
psychiatric B-Disease +
histories O +
had O +
a O +
higher O +
prevalence O +
of O +
depression B-Disease +
than O +
the O +
comparison O +
patients O -
. O +

This O +
was O +
accounted O +
for O +
by O +
a O +
significant O +
number O +
of O +
depressions B-Disease +
occurring O +
in O +
methyl O +
dopa O +
treated O +
patients O +
with O +
psychiatric B-Disease +
histories O -
. O +

Chronic B-Disease +
active I-Disease +
hepatitis I-Disease +
associated O +
with O +
diclofenac O +
sodium O +
therapy O -
. O +

Diclofenac O +
sodium O +
( O -
Voltarol O -
, O +
Geigy O +
Pharmaceuticals O -
) O +
is O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
derivative O +
of O +
phenylacetic O +
acid O -
. O +

Although O +
generally O +
well O -
- O -
tolerated O -
, O +
asymptomatic O +
abnormalities B-Disease +
of I-Disease +
liver I-Disease +
function I-Disease +
have O +
been O +
recorded O +
and O -
, O +
less O +
commonly O -
, O +
severe O +
hepatitis B-Disease +
induced O +
by O +
diclofenac O -
. O +

The O +
patient O +
described O +
developed O +
chronic B-Disease +
active I-Disease +
hepatitis I-Disease +
after O +
six O +
months O +
therapy O +
with O +
diclofenac O +
sodium O +
which O +
progressed O +
despite O +
the O +
withdrawal O +
of O +
the O +
drug O -
, O +
a O +
finding O +
not O +
previously O +
reported O -
. O +

Arterial O +
hypertension B-Disease +
as O +
a O +
complication O +
of O +
prolonged O +
ketoconazole O +
treatment O -
. O +

Two O +
of O +
14 O +
patients O +
with O +
Cushing B-Disease -
's I-Disease +
syndrome I-Disease +
treated O +
on O +
a O +
long O -
- O -
term O +
basis O +
with O +
ketoconazole O +
developed O +
sustained O +
hypertension B-Disease -
. O +

In O +
both O +
cases O +
normal O +
plasma O +
and O +
urinary O +
free O +
cortisol O +
levels O +
had O +
been O +
achieved O +
following O +
ketoconazole O +
therapy O -
, O +
yet O +
continuous O +
blood O +
pressure O +
monitoring O +
demonstrated O +
hypertension B-Disease +
31 O +
( O -
patient O +
1 O -
) O +
and O +
52 O +
weeks O +
( O -
patient O +
2 O -
) O +
after O +
treatment O -
. O +

In O +
patient O +
1 O -
, O +
plasma O +
levels O +
of O +
deoxycorticosterone O +
and O +
11-deoxycortisol O +
were O +
elevated O -
. O +

In O +
patient O +
2 O -
, O +
in O +
addition O +
to O +
an O +
increase O +
in O +
both O +
deoxycorticosterone O +
and O +
11-deoxycortisol O +
levels O -
, O +
plasma O +
aldosterone O +
values O +
were O +
raised O -
, O +
with O +
a O +
concomitant O +
suppression O +
of O +
renin O +
levels O -
. O +

Our O +
findings O +
show O +
that O +
long O -
- O -
term O +
treatment O +
with O +
high O +
doses O +
of O +
ketoconazole O +
may O +
induce O +
enzyme O +
blockade O +
leading O +
to O +
mineralocorticoid O -
- O -
related O +
hypertension B-Disease -
. O +

Effects O +
of O +
an O +
inhibitor O +
of O +
angiotensin O +
converting O +
enzyme O +
( O -
Captopril O -
) O +
on O +
pulmonary B-Disease +
and I-Disease +
renal I-Disease +
insufficiency I-Disease +
due O +
to O +
intravascular B-Disease +
coagulation I-Disease +
in O +
the O +
rat O -
. O +

Induction O +
of O +
intravascular B-Disease +
coagulation I-Disease +
and O +
inhibition O +
of O +
fibrinolysis O +
by O +
injection O +
of O +
thrombin O +
and O +
tranexamic O +
acid O +
( O -
AMCA O -
) O +
in O +
the O +
rat O +
gives O +
rise O +
to O +
pulmonary B-Disease +
and I-Disease +
renal I-Disease +
insufficiency I-Disease +
resembling O +
that O +
occurring O +
after O +
trauma B-Disease +
or O +
sepsis B-Disease +
in O +
man O -
. O +

Injection O +
of O +
Captopril O +
( O -
1 O +
mg O -
/ O -
kg O -
) O -
, O +
an O +
inhibitor O +
of O +
angiotensin O +
converting O +
enzyme O +
( O -
ACE O -
) O -
, O +
reduced O +
both O +
pulmonary B-Disease +
and I-Disease +
renal I-Disease +
insufficiency I-Disease +
in O +
this O +
rat O +
model O -
. O +

The O +
lung O +
weights O +
were O +
lower O +
and O +
PaO2 O +
was O +
improved O +
in O +
rats O +
given O +
this O +
enzyme O -
- O -
blocking O +
agent O -
. O +

The O +
contents O +
of O +
albumin O +
in O +
the O +
lungs O +
were O +
not O +
changed O -
, O +
indicating O +
that O +
Captopril O +
did O +
not O +
influence O +
the O +
extravasation O +
of O +
protein O -
. O +

Renal B-Disease +
damage I-Disease +
as O +
reflected O +
by O +
an O +
increase O +
in O +
serum O +
urea O +
and O +
in O +
kidney O +
weight O +
was O +
prevented O +
by O +
Captopril O -
. O +

The O +
amount O +
of O +
fibrin O +
in O +
the O +
kidneys O +
was O +
also O +
considerably O +
lower O +
than O +
in O +
animals O +
which O +
received O +
thrombin O +
and O +
AMCA O +
alone O -
. O +

It O +
is O +
suggested O +
that O +
the O +
effects O +
of O +
Captopril O +
on O +
the O +
lungs O +
may O +
be O +
attributable O +
to O +
a O +
vasodilatory O +
effect O +
due O +
to O +
a O +
reduction O +
in O +
the O +
circulating O +
level O +
of O +
Angiotension O +
II O +
and O +
an O +
increase O +
in O +
prostacyclin O +
( O -
secondary O +
to O +
an O +
increase O +
in O +
bradykinin O -
) O -
. O +

Captopril O +
may O -
, O +
by O +
the O +
same O +
mechanism O -
, O +
reduce O +
the O +
increase O +
in O +
glomerular O +
filtration O +
that O +
is O +
known O +
to O +
occur O +
after O +
an O +
injection O +
of O +
thrombin O -
, O +
thereby O +
diminishing O +
the O +
aggregation O +
of O +
fibrin O +
monomers O +
in O +
the O +
glomeruli O -
, O +
with O +
the O +
result O +
that O +
less O +
fibrin O +
will O +
be O +
deposited O +
and O +
thus O +
less O +
kidney B-Disease +
damage I-Disease +
will O +
be O +
produced O -
. O +

Stroke B-Disease +
associated O +
with O +
cocaine O +
use O -
. O +

We O +
describe O +
eight O +
patients O +
in O +
whom O +
cocaine O +
use O +
was O +
related O +
to O +
stroke B-Disease +
and O +
review O +
39 O +
cases O +
from O +
the O +
literature O -
. O +

Among O +
these O +
47 O +
patients O +
the O +
mean O +
( O -
+ O -
/- O +

SD O -
) O +
age O +
was O +
32.5 O +
+ O -
/- O +

12.1 O +
years O -
; O +
76 O -
% O +
( O -
34 O -
/ O -
45 O -
) O +
were O +
men O -
. O +

Stroke B-Disease +
followed O +
cocaine O +
use O +
by O +
inhalation O -
, O +
intranasal O -
, O +
intravenous O -
, O +
and O +
intramuscular O +
routes O -
. O +

Intracranial B-Disease +
aneurysms I-Disease +
or O +
arteriovenous B-Disease +
malformations I-Disease +
were O +
present O +
in O +
17 O +
of O +
32 O +
patients O +
studied O +
angiographically O +
or O +
at O +
autopsy O -
; O +
cerebral B-Disease +
vasculitis I-Disease +
was O +
present O +
in O +
two O +
patients O -
. O +

Cerebral B-Disease +
infarction I-Disease +
occurred O +
in O +
10 O +
patients O +
( O -
22 O -
% O -
) O -
, O +
intracerebral B-Disease +
hemorrhage I-Disease +
in O +
22 O +
( O -
49 O -
% O -
) O -
, O +
and O +
subarachnoid B-Disease +
hemorrhage I-Disease +
in O +
13 O +
( O -
29 O -
% O -
) O -
. O +

These O +
data O +
indicate O +
that O +
( O -
1 O -
) O +
the O +
apparent O +
incidence O +
of O +
stroke B-Disease +
related O +
to O +
cocaine O +
use O +
is O +
increasing O -
; O +
( O -
2 O -
) O +
cocaine O -
- O -
associated O +
stroke B-Disease +
occurs O +
primarily O +
in O +
young O +
adults O -
; O +
( O -
3 O -
) O +
stroke B-Disease +
may O +
follow O +
any O +
route O +
of O +
cocaine O +
administration O -
; O +
( O -
4 O -
) O +
stroke B-Disease +
after O +
cocaine O +
use O +
is O +
frequently O +
associated O +
with O +
intracranial B-Disease +
aneurysms I-Disease +
and O +
arteriovenous B-Disease +
malformations I-Disease -
; O +
and O +
( O -
5 O -
) O +
in O +
cocaine O -
- O -
associated O +
stroke B-Disease -
, O +
the O +
frequency O +
of O +
intracranial B-Disease +
hemorrhage I-Disease +
exceeds O +
that O +
of O +
cerebral B-Disease +
infarction I-Disease -
. O +

A O +
randomized O +
comparison O +
of O +
labetalol O +
and O +
nitroprusside O +
for O +
induced O +
hypotension B-Disease -
. O +

In O +
a O +
randomized O +
study O -
, O +
labetalol O -
- O -
induced O +
hypotension B-Disease +
and O +
nitroprusside O -
- O -
induced O +
hypotension B-Disease +
were O +
compared O +
in O +
20 O +
patients O +
( O -
10 O +
in O +
each O +
group O -
) O +
scheduled O +
for O +
major O +
orthopedic O +
procedures O -
. O +

Each O +
patient O +
was O +
subjected O +
to O +
an O +
identical O +
anesthetic O +
protocol O +
and O +
similar O +
drug O -
- O -
induced O +
reductions B-Disease +
in I-Disease +
mean I-Disease +
arterial I-Disease +
blood I-Disease +
pressure I-Disease +
( O -
BP O -
) O +
( O -
50 O +
to O +
55 O +
mmHg O -
) O -
. O +

Nitroprusside O +
infusion O +
was O +
associated O +
with O +
a O +
significant O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
increase B-Disease +
in I-Disease +
heart I-Disease +
rate I-Disease +
and I-Disease +
cardiac I-Disease +
output I-Disease -
; O +
rebound O +
hypertension B-Disease +
was O +
observed O +
in O +
three O +
patients O +
after O +
discontinuation O +
of O +
nitroprusside O -
. O +

Labetalol O +
administration O +
was O +
not O +
associated O +
with O +
any O +
of O +
these O +
findings O -
. O +

Arterial O +
PO2 O +
decreased O +
in O +
both O +
groups O -
. O +

It O +
was O +
concluded O +
that O +
labetalol O +
offers O +
advantages O +
over O +
nitroprusside O -
. O +

Phlorizin O -
- O -
induced O +
glycosuria B-Disease +
does O +
not O +
prevent O +
gentamicin O +
nephrotoxicity B-Disease +
in O +
rats O -
. O +

Because O +
rats O +
with O +
streptozotocin O -
- O -
induced O +
diabetes B-Disease +
mellitus I-Disease +
( O -
DM B-Disease -
) O +
have O +
a O +
high O +
solute O +
diuresis O +
( O -
glycosuria B-Disease +
of O +
10 O +
to O +
12 O +
g O -
/ O -
day O -
) O -
, O +
we O +
have O +
suggested O +
that O +
this O +
may O +
in O +
part O +
be O +
responsible O +
for O +
their O +
resistance O +
to O +
gentamicin O -
- O -
induced O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
( O -
ARF B-Disease -
) O -
. O +

The O +
protection O +
from O +
gentamicin O +
nephrotoxicity B-Disease +
was O +
studied O +
in O +
non O -
- O -
diabetic B-Disease +
rats O +
with O +
chronic O +
solute O +
diuresis O +
induced O +
by O +
blockage O +
of O +
tubular O +
glucose O +
reabsorption O +
with O +
phlorizin O +
( O -
P O -
) O -
. O +

DM B-Disease +
rats O +
with O +
mild O +
glycosuria B-Disease +
( O -
similar O +
in O +
degree O +
to O +
that O +
of O +
the O +
P O +
treated O +
animals O -
) O +
were O +
also O +
studied O -
. O +

Unanesthetized O +
adult O +
female O -
, O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
divided O +
in O +
four O +
groups O +
and O +
studied O +
for O +
15 O +
days O -
. O +

Group O +
1 O +
( O -
P O +
alone O -
) O +
received O +
P O -
, O +
360 O +
mg O -
/ O -
day O -
, O +
for O +
15 O +
days O -
; O +
Group O +
II O +
( O -
P O +
+ O +
gentamicin O -
) O -
; O +
Group O +
III O +
( O -
gentamicin O +
alone O -
) O +
and O +
Group O +
IV O +
( O -
mild O +
DM B-Disease +
+ O +
gentamicin O -
) O -
. O +

Nephrotoxic B-Disease +
doses O +
( O -
40 O +
mg O -
/ O -
kg O +
body O +
wt O -
/ O -
day O -
) O +
of O +
gentamicin O +
were O +
injected O +
during O +
the O +
last O +
nine O +
days O +
of O +
study O +
to O +
the O +
animals O +
of O +
groups O +
II O +
to O +
IV O -
. O +

In O +
Group O +
I O -
, O +
P O +
induced O +
a O +
moderate O +
and O +
stable O +
glycosuria B-Disease +
( O -
3.9 O +
+ O -
/- O +

0.1 O +
g O -
/ O -
day O -
, O +
SE O -
) O -
, O +
and O +
no O +
functional O +
or O +
morphologic O +
evidence O +
of O +
renal B-Disease +
dysfunction I-Disease +
( O -
baseline O +
CCr O +
2.1 O +
+ O -
/- O +

0.1 O +
ml O -
/ O -
min O -
, O +
undetectable O +
lysozymuria O -
) O +
or O +
damage O +
( O -
tubular B-Disease +
necrosis I-Disease +
score O +
[ O -
maximum O +
4 O -
] O -
, O +
zero O -
) O -
. O +

In O +
Group O +
II O -
, O +
P O +
did O +
not O +
prevent O +
gentamicin O -
- O -
ARF B-Disease +
( O -
maximal O +
decrease O +
in O +
CCr O +
at O +
day O +
9.89 O -
% O -
, O +
P O +
less O +
than O +
0.001 O -
; O +
peak O +
lysozymuria O -
, O +
1863 O +
+ O -
/- O +

321 O +
micrograms O -
/ O -
day O -
; O +
and O +
tubular B-Disease +
necrosis I-Disease +
score O -
, O +
3.9 O +
+ O -
/- O +

0.1 O -
) O -
. O +

These O +
values O +
were O +
not O +
different O +
from O +
those O +
of O +
Group O +
III O -
: O +
maximal O +
decrease O +
in O +
CCr O +
73 O -
% O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
; O +
lysozymuria O -
, O +
2147 O +
+ O -
/- O +

701 O +
micrograms O -
/ O -
day O -
; O +
tubular B-Disease +
necrosis I-Disease +
score O -
, O +
3.8 O +
+ O -
/- O +

0.1. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Catalepsy B-Disease +
induced O +
by O +
combinations O +
of O +
ketamine O +
and O +
morphine O -
: O +
potentiation O -
, O +
antagonism O -
, O +
tolerance O +
and O +
cross O -
- O -
tolerance O +
in O +
the O +
rat O -
. O +

Previous O +
studies O +
demonstrated O +
that O +
both O +
ketamine O +
and O +
morphine O +
induced O +
analgesia B-Disease +
and O +
catalepsy B-Disease +
in O +
the O +
rat O -
. O +

Pre O -
- O -
treatment O +
with O +
ketamine O +
produced O +
cross O -
- O -
tolerance O +
to O +
morphine O -
, O +
whereas O +
pretreatment O +
with O +
morphine O +
did O +
not O +
induce O +
cross O -
- O -
tolerance O +
to O +
ketamine O +
but O +
rather O +
augmented O +
the O +
cataleptic B-Disease +
response O -
; O +
this O +
augmentation O +
was O +
attributed O +
to O +
residual O +
morphine O +
in O +
the O +
brain O -
. O +

The O +
present O +
studies O +
explored O +
the O +
duration O +
of O +
the O +
loss O +
of O +
righting O +
reflex O +
induced O +
by O +
sub O -
- O -
effective O +
doses O +
of O +
ketamine O +
and O +
morphine O -
, O +
administered O +
simultaneously O -
. O +

There O +
was O +
mutual O +
potentiation O +
between O +
sub O -
- O -
effective O +
doses O +
of O +
ketamine O +
and O +
morphine O -
, O +
but O +
sub O -
- O -
effective O +
doses O +
of O +
ketamine O +
partly O +
antagonized O +
fully O -
- O -
effective O +
doses O +
of O +
morphine O -
. O +

Latency O +
to O +
the O +
loss O +
of O +
righting O +
reflex O -
, O +
rigidity B-Disease +
and O +
behavior O +
on O +
recovery O -
, O +
reflected O +
the O +
relative O +
predominance O +
of O +
ketamine O +
or O +
morphine O +
in O +
each O +
combination O -
. O +

Naloxone O +
inhibited O +
the O +
induced O +
cataleptic B-Disease +
effects O -
. O +

The O +
degree O +
and O +
time O +
course O +
of O +
development O +
of O +
tolerance O +
to O +
daily O +
administration O +
of O +
sub O -
- O -
effective O +
dose O +
combinations O +
of O +
ketamine O +
and O +
morphine O +
were O +
similar O -
. O +

Rats O -
, O +
tolerant O +
to O +
ketamine O -
- O -
dominant O +
combinations O -
, O +
were O +
cross O -
- O -
tolerant O +
to O +
both O +
drugs O -
, O +
while O +
those O +
tolerant O +
to O +
morphine O -
- O -
dominant O +
combinations O +
were O +
cross O -
- O -
tolerant O +
to O +
morphine O +
but O +
showed O +
either O +
no O +
cross O -
- O -
tolerance O +
or O +
an O +
augmented O +
response O +
to O +
ketamine O -
. O +

While O +
the O +
mutual O +
potentiation O -
, O +
antagonism O +
and O +
tolerance O +
suggest O +
common O +
mechanisms O +
for O +
the O +
induced O +
catalepsy B-Disease -
, O +
differences O +
in O +
latency O -
, O +
rigidity B-Disease +
and O +
behavior O -
, O +
asymmetry O +
of O +
cross O -
- O -
tolerance O +
and O +
a O +
widely O -
- O -
different O +
ID50 O +
for O +
naloxone O +
would O +
argue O +
against O +
an O +
action O +
at O +
a O +
single O +
opioid O +
site O -
. O +

Hydrocortisone O -
- O -
induced O +
hypertension B-Disease +
in O +
humans O -
: O +
pressor O +
responsiveness O +
and O +
sympathetic O +
function O -
. O +

Oral O +
hydrocortisone O +
increases O +
blood O +
pressure O +
and O +
enhances O +
pressor O +
responsiveness O +
in O +
normal O +
human O +
subjects O -
. O +

We O +
studied O +
the O +
effects O +
of O +
1 O +
week O +
of O +
oral O +
hydrocortisone O +
( O -
200 O +
mg O -
/ O -
day O -
) O +
on O +
blood O +
pressure O -
, O +
cardiac O +
output O -
, O +
total O +
peripheral O +
resistance O -
, O +
forearm O +
vascular O +
resistance O -
, O +
and O +
norepinephrine O +
spillover O +
to O +
plasma O +
in O +
eight O +
healthy O +
male O +
volunteers O -
. O +

Although O +
diastolic O +
blood O +
pressure O +
remained O +
unchanged O -
, O +
systolic O +
blood O +
pressure O +
increased O +
from O +
119 O +
to O +
135 O +
mm O +
Hg O +
( O -
SED O +
+ O -
/- O +

3.4 O -
, O +
p O +
less O +
than O +
0.01 O -
) O -
, O +
associated O +
with O +
an O +
increased B-Disease +
cardiac I-Disease +
output I-Disease +
( O -
5.85 O -
- O -
7.73 O +
l O -
/ O -
min O -
, O +
SED O +
+ O -
/- O +

0.46 O -
, O +
p O +
less O +
than O +
0.01 O -
) O -
. O +

Total O +
peripheral O +
vascular O +
resistance O +
fell O +
from O +
15.1 O +
to O +
12.2 O +
mm O +
Hg O -
/ O -
l O -
/ O -
min O +
( O -
SED O +
+ O -
/- O +

1.03 O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
. O +

Resting O +
forearm O +
vascular O +
resistance O +
remained O +
unchanged O -
, O +
but O +
the O +
reflex O +
response O +
to O +
the O +
cold O +
pressor O +
test O +
was O +
accentuated O -
, O +
the O +
rise O +
in O +
resistance O +
increasing O +
from O +
10.5 O +
mm O +
Hg O -
/ O -
ml O -
/ O -
100 O +
ml O -
/ O -
min O +
( O -
R O +
units O -
) O +
before O +
treatment O +
to O +
32.6 O +
R O +
units O +
after O +
treatment O +
( O -
SED O +
+ O -
/- O +

6.4 O -
, O +
p O +
less O +
than O +
0.025 O -
) O -
. O +

The O +
rise O +
in O +
forearm O +
vascular O +
resistance O +
accompanying O +
intra O -
- O -
arterial O +
norepinephrine O +
( O -
25 O -
, O +
50 O -
, O +
and O +
100 O +
ng O -
/ O -
min O -
) O +
was O +
also O +
significantly O +
greater O +
after O +
hydrocortisone O -
, O +
increasing O +
from O +
an O +
average O +
of O +
14.9 O +
+ O -
/- O +

2.4 O +
R O +
units O +
before O +
treatment O +
to O +
35.1 O +
+ O -
/- O +

5.5 O +
R O +
units O +
after O +
hydrocortisone O +
( O -
SED O +
+ O -
/- O +

6.0 O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
. O +

A O +
shift O +
to O +
the O +
left O +
in O +
the O +
dose O -
- O -
response O +
relation O +
and O +
fall O +
in O +
threshold O +
suggested O +
increased O +
sensitivity O +
to O +
norepinephrine O +
after O +
treatment O -
. O +

Measurement O +
of O +
resting O +
norepinephrine O +
spillover O +
rate O +
to O +
plasma O +
and O +
norepinephrine O +
uptake O +
indicated O +
that O +
overall O +
resting O +
sympathetic O +
nervous O +
system O +
activity O +
was O +
not O +
increased O -
. O +

The O +
rise B-Disease +
in I-Disease +
resting I-Disease +
blood I-Disease +
pressure I-Disease +
with O +
hydrocortisone O +
is O +
associated O +
with O +
an O +
increased B-Disease +
cardiac I-Disease +
output I-Disease +
( O -
presumably O +
due O +
to O +
increased O +
blood O +
volume O -
) O -
. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Neuromuscular B-Disease +
blockade I-Disease +
with O +
magnesium O +
sulfate O +
and O +
nifedipine O -
. O +

A O +
patient O +
who O +
received O +
tocolysis O +
with O +
nifedipine O +
developed O +
neuromuscular B-Disease +
blockade I-Disease +
after O +
500 O +
mg O +
of O +
magnesium O +
sulfate O +
was O +
administered O -
. O +

This O +
reaction O +
demonstrates O +
that O +
nifedipine O +
can O +
seriously O +
potentiate O +
the O +
toxicity B-Disease +
of O +
magnesium O -
. O +

Caution O +
should O +
be O +
exercised O +
when O +
these O +
two O +
tocolytics O +
are O +
combined O -
. O +

Chronic O +
carbamazepine O +
inhibits O +
the O +
development O +
of O +
local O +
anesthetic O +
seizures B-Disease +
kindled O +
by O +
cocaine O +
and O +
lidocaine O -
. O +

The O +
effects O +
of O +
carbamazepine O +
( O -
CBZ O -
) O +
treatment O +
on O +
local O +
anesthetic O -
- O -
kindled O +
seizures B-Disease +
and O +
lethality O +
were O +
evaluated O +
in O +
different O +
stages O +
of O +
the O +
kindling O +
process O +
and O +
under O +
different O +
methods O +
of O +
CBZ O +
administration O -
. O +

Chronic O +
oral O +
CBZ O +
inhibited O +
the O +
development O +
of O +
both O +
lidocaine- O +
and O +
cocaine O -
- O -
induced O +
seizures B-Disease -
, O +
but O +
had O +
little O +
effect O +
on O +
the O +
fully O +
developed O +
local O +
anesthetic O +
seizures B-Disease -
. O +

Chronic O +
CBZ O +
also O +
decreased O +
the O +
incidence O +
of O +
seizure B-Disease -
- O -
related O +
mortality O +
in O +
the O +
cocaine O -
- O -
injected O +
rats O -
. O +

Acute O +
CBZ O +
over O +
a O +
range O +
of O +
doses O +
( O -
15 O -
- O -
50 O +
mg O -
/ O -
kg O -
) O +
had O +
no O +
effect O +
on O +
completed O +
lidocaine O -
- O -
kindled O +
or O +
acute O +
cocaine O -
- O -
induced O +
seizures B-Disease -
. O +

Repeated O +
i.p O -
. O +

injection O +
of O +
CBZ O +
( O -
15 O +
mg O -
/ O -
kg O -
) O +
also O +
was O +
without O +
effect O +
on O +
the O +
development O +
of O +
lidocaine- O +
or O +
cocaine O -
- O -
kindled O +
seizures B-Disease -
. O +

The O +
differential O +
effects O +
of O +
CBZ O +
depending O +
upon O +
stage O +
of O +
seizure B-Disease +
development O +
suggest O +
that O +
distinct O +
mechanisms O +
underlie O +
the O +
development O +
versus O +
maintenance O +
of O +
local O +
anesthetic O -
- O -
kindled O +
seizures B-Disease -
. O +

The O +
effectiveness O +
of O +
chronic O +
but O +
not O +
repeated O -
, O +
intermittent O +
injections O +
of O +
CBZ O +
suggests O +
that O +
different O +
biochemical O +
consequences O +
result O +
from O +
the O +
different O +
treatment O +
regimens O -
. O +

The O +
possible O +
utility O +
of O +
chronic O +
CBZ O +
in O +
preventing O +
the O +
development O +
of O +
toxic O +
side O +
effects O +
in O +
human O +
cocaine O +
users O +
is O +
suggested O +
by O +
these O +
data O -
, O +
but O +
remains O +
to O +
be O +
directly O +
evaluated O -
. O +

Sodium O +
status O +
influences O +
chronic O +
amphotericin O +
B O +
nephrotoxicity B-Disease +
in O +
rats O -
. O +

The O +
nephrotoxic B-Disease +
potential O +
of O +
amphotericin O +
B O +
( O -
5 O +
mg O -
/ O -
kg O +
per O +
day O +
intraperitoneally O +
for O +
3 O +
weeks O -
) O +
has O +
been O +
investigated O +
in O +
salt O -
- O -
depleted O -
, O +
normal O -
- O -
salt O -
, O +
and O +
salt O -
- O -
loaded O +
rats O -
. O +

In O +
salt O -
- O -
depleted O +
rats O -
, O +
amphotericin O +
B O +
decreased O +
creatinine O +
clearance O +
linearly O +
with O +
time O -
, O +
with O +
an O +
85 O -
% O +
reduction O +
by O +
week O +
3 O -
. O +

In O +
contrast O -
, O +
in O +
normal O -
- O -
salt O +
rats O +
creatinine O +
clearance O +
was O +
decreased O +
but O +
to O +
a O +
lesser O +
extent O +
at O +
week O +
2 O +
and O +
3 O -
, O +
and O +
in O +
salt O -
- O -
loaded O +
rats O +
creatinine O +
clearance O +
did O +
not O +
change O +
for O +
2 O +
weeks O +
and O +
was O +
decreased O +
by O +
43 O -
% O +
at O +
week O +
3 O -
. O +

All O +
rats O +
in O +
the O +
sodium O -
- O -
depleted O +
group O +
had O +
histopathological O +
evidence O +
of O +
patchy O +
tubular O +
cytoplasmic O +
degeneration O +
in O +
tubules O +
that O +
was O +
not O +
observed O +
in O +
any O +
normal O -
- O -
salt O +
or O +
salt O -
- O -
loaded O +
rat O -
. O +

Concentrations O +
of O +
amphotericin O +
B O +
in O +
plasma O +
were O +
not O +
significantly O +
different O +
among O +
the O +
three O +
groups O +
at O +
any O +
time O +
during O +
the O +
study O -
. O +

However O -
, O +
at O +
the O +
end O +
of O +
3 O +
weeks O -
, O +
amphotericin O +
B O +
levels O +
in O +
the O +
kidneys O +
and O +
liver O +
were O +
significantly O +
higher O +
in O +
salt O -
- O -
depleted O +
and O +
normal O -
- O -
salt O +
rats O +
than O +
those O +
in O +
salt O -
- O -
loaded O +
rats O -
, O +
with O +
plasma O -
/ O -
kidney O +
ratios O +
of O +
21 O -
, O +
14 O -
, O +
and O +
8 O +
in O +
salt O -
- O -
depleted O -
, O +
normal O -
- O -
salt O -
, O +
and O +
salt O -
- O -
loaded O +
rats O -
, O +
respectively O -
. O +

In O +
conclusion O -
, O +
reductions O +
in O +
creatinine O +
clearance O +
and O +
renal O +
amphotericin O +
B O +
accumulation O +
after O +
chronic O +
amphotericin O +
B O +
administration O +
were O +
enhanced O +
by O +
salt O +
depletion O +
and O +
attenuated O +
by O +
sodium O +
loading O +
in O +
rats O -
. O +

Magnetic O +
resonance O +
imaging O +
of O +
cerebral O +
venous B-Disease +
thrombosis I-Disease +
secondary O +
to O +
" O -
low O -
- O -
dose O -
" O +
birth O +
control O +
pills O -
. O +

The O +
clinical O +
and O +
radiographic O +
features O +
of O +
cerebral O +
deep B-Disease +
venous I-Disease +
thrombosis I-Disease +
in O +
a O +
21-year O -
- O -
old O +
white O +
woman O +
are O +
presented O -
. O +

This O +
nulliparous O +
patient O +
presented O +
with O +
relatively O +
mild O +
clinical O +
symptoms O +
and O +
progressing O +
mental O +
status O +
changes O -
. O +

The O +
only O +
known O +
risk O +
factor O +
was O +
" O -
low O -
- O -
dose O -
" O +
oral O +
contraceptive O +
pills O -
. O +

The O +
magnetic O +
resonance O +
image O +
( O -
MRI O -
) O +
showed O +
increased O +
signal O +
intensity O +
from O +
the O +
internal O +
cerebral O +
veins O -
, O +
vein O +
of O +
Galen O -
, O +
and O +
straight O +
sinus O -
. O +

The O +
diagnosis O +
was O +
confirmed O +
by O +
arterial O +
angiography O -
. O +

Beta-2-adrenoceptor O -
- O -
mediated O +
hypokalemia B-Disease +
and O +
its O +
abolishment O +
by O +
oxprenolol O -
. O +

The O +
time O +
course O +
and O +
concentration O -
- O -
effect O +
relationship O +
of O +
terbutaline O -
- O -
induced O +
hypokalemia B-Disease +
was O +
studied O -
, O +
using O +
computer O -
- O -
aided O +
pharmacokinetic O -
- O -
dynamic O +
modeling O -
. O +

Subsequently O +
we O +
investigated O +
the O +
efficacy O +
of O +
oxprenolol O +
in O +
antagonizing O +
such O +
hypokalemia B-Disease -
, O +
together O +
with O +
the O +
pharmacokinetic O +
interaction O +
between O +
both O +
drugs O -
. O +

Six O +
healthy O +
subjects O +
were O +
given O +
a O +
0.5 O +
mg O +
subcutaneous O +
dose O +
of O +
terbutaline O +
on O +
two O +
occasions O -
: O +
1 O +
hour O +
after O +
oral O +
administration O +
of O +
a O +
placebo O +
and O +
1 O +
hour O +
after O +
80 O +
mg O +
oxprenolol O +
orally O -
. O +

In O +
the O +
7-hour O +
period O +
after O +
terbutaline O +
administration O -
, O +
plasma O +
samples O +
were O +
taken O +
for O +
determination O +
of O +
plasma O +
potassium O +
levels O +
and O +
drug O +
concentrations O -
. O +

The O +
sigmoid O +
Emax O +
model O +
offered O +
a O +
good O +
description O +
of O +
the O +
relation O +
between O +
terbutaline O +
concentrations O +
and O +
potassium O +
effects O -
. O +

Oxprenolol O +
caused O +
decreases O +
of O +
65 O -
% O +
and O +
56 O -
% O +
of O +
terbutaline O +
volume O +
of O +
distribution O +
and O +
clearance O -
, O +
respectively O -
, O +
and O +
an O +
increase O +
of O +
130 O -
% O +
of O +
its O +
AUC O -
. O +

In O +
spite O +
of O +
higher O +
terbutaline O +
concentrations O +
after O +
oxprenolol O +
pretreatment O -
, O +
the O +
hypokalemia B-Disease +
was O +
almost O +
completely O +
antagonized O +
by O +
the O +
beta O +
2-blocking O +
action O -
. O +

Flestolol O -
: O +
an O +
ultra O -
- O -
short O -
- O -
acting O +
beta O -
- O -
adrenergic O +
blocking O +
agent O -
. O +

Flestolol O +
( O -
ACC-9089 O -
) O +
is O +
a O +
nonselective O -
, O +
competitive O -
, O +
ultra O -
- O -
short O -
- O -
acting O +
beta O -
- O -
adrenergic O +
blocking O +
agent O -
, O +
without O +
any O +
intrinsic O +
sympathomimetic O +
activity O -
. O +

Flestolol O +
is O +
metabolized O +
by O +
plasma O +
esterases O +
and O +
has O +
an O +
elimination O +
half O -
- O -
life O +
of O +
approximately O +
6.5 O +
minutes O -
. O +

This O +
agent O +
was O +
well O +
tolerated O +
in O +
healthy O +
volunteers O +
at O +
doses O +
up O +
to O +
100 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
. O +

In O +
long O -
- O -
term O +
infusion O +
studies O -
, O +
flestolol O +
was O +
well O +
tolerated O +
at O +
the O +
effective O +
beta O -
- O -
blocking O +
dose O +
( O -
5 O +
micrograms O -
/ O -
kg O -
/ O -
min O -
) O +
for O +
up O +
to O +
seven O +
days O -
. O +

Flestolol O +
blood O +
concentrations O +
increased O +
linearly O +
with O +
increasing O +
dose O +
and O +
good O +
correlation O +
exists O +
between O +
blood O +
concentrations O +
of O +
flestolol O +
and O +
beta O -
- O -
adrenergic O +
blockade O -
. O +

Flestolol O +
produced O +
a O +
dose O -
- O -
dependent O +
attenuation O +
of O +
isoproterenol O -
- O -
induced O +
tachycardia B-Disease -
. O +

Electrophysiologic O +
and O +
hemodynamic O +
effects O +
of O +
flestolol O +
are O +
similar O +
to O +
those O +
of O +
other O +
beta O +
blockers O -
. O +

In O +
contrast O +
with O +
other O +
beta O +
blockers O -
, O +
flestolol O -
- O -
induced O +
effects O +
reverse O +
rapidly O +
( O -
within O +
30 O +
minutes O -
) O +
following O +
discontinuation O +
because O +
of O +
its O +
short O +
half O -
- O -
life O -
. O +

Flestolol O +
effectively O +
reduced O +
heart O +
rate O +
in O +
patients O +
with O +
supraventricular B-Disease +
tachyarrhythmia I-Disease -
. O +

In O +
patients O +
with O +
unstable B-Disease +
angina I-Disease -
, O +
flestolol O +
infusion O +
was O +
found O +
to O +
be O +
safe O +
and O +
effective O +
in O +
controlling O +
chest B-Disease +
pain I-Disease -
. O +

It O +
is O +
concluded O +
that O +
flestolol O +
is O +
a O +
potent O -
, O +
well O -
- O -
tolerated O -
, O +
ultra O -
- O -
short O -
- O -
acting O +
beta O -
- O -
adrenergic O +
blocking O +
agent O -
. O +

Use O +
of O +
flestolol O +
in O +
the O +
critical O +
care O +
setting O +
is O +
currently O +
undergoing O +
investigation O -
. O +

Immunohistochemical O -
, O +
electron O +
microscopic O +
and O +
morphometric O +
studies O +
of O +
estrogen O -
- O -
induced O +
rat O +
prolactinomas B-Disease +
after O +
bromocriptine O +
treatment O -
. O +

To O +
clarify O +
the O +
effects O +
of O +
bromocriptine O +
on O +
prolactinoma B-Disease +
cells O +
in O +
vivo O -
, O +
immunohistochemical O -
, O +
ultrastructural O +
and O +
morphometrical O +
analyses O +
were O +
applied O +
to O +
estrogen O -
- O -
induced O +
rat O +
prolactinoma B-Disease +
cells O +
1 O +
h O +
and O +
6 O +
h O +
after O +
injection O +
of O +
bromocriptine O +
( O -
3 O +
mg O -
/ O -
kg O +
of O +
body O +
weight O -
) O -
. O +

One O +
h O +
after O +
treatment O -
, O +
serum O +
prolactin O +
levels O +
decreased O +
markedly O -
. O +

Electron O +
microscopy O +
disclosed O +
many O +
secretory O +
granules O -
, O +
slightly O +
distorted O +
rough O +
endoplasmic O +
reticulum O -
, O +
and O +
partially O +
dilated O +
Golgi O +
cisternae O +
in O +
the O +
prolactinoma B-Disease +
cells O -
. O +

Morphometric O +
analysis O +
revealed O +
that O +
the O +
volume O +
density O +
of O +
secretory O +
granules O +
increased O -
, O +
while O +
the O +
volume O +
density O +
of O +
cytoplasmic O +
microtubules O +
decreased O -
. O +

These O +
findings O +
suggest O +
that O +
lowered O +
serum O +
prolactin O +
levels O +
in O +
the O +
early O +
phase O +
of O +
bromocriptine O +
treatment O +
may O +
result O +
from O +
an O +
impaired O +
secretion O +
of O +
prolactin O +
due O +
to O +
decreasing O +
numbers O +
of O +
cytoplasmic O +
microtubules O -
. O +

At O +
6 O +
h O +
after O +
injection O -
, O +
serum O +
prolactin O +
levels O +
were O +
still O +
considerably O +
lower O +
than O +
in O +
controls O -
. O +

The O +
prolactinoma B-Disease +
cells O +
at O +
this O +
time O +
were O +
well O +
granulated O -
, O +
with O +
vesiculated O +
rough O +
endoplasmic O +
reticulum O +
and O +
markedly O +
dilated O +
Golgi O +
cisternae O -
. O +

Electron O +
microscopical O +
immunohistochemistry O +
revealed O +
positive O +
reaction O +
products O +
noted O +
on O +
the O +
secretory O +
granules O -
, O +
Golgi O +
cisternae O -
, O +
and O +
endoplasmic O +
reticulum O +
of O +
the O +
untreated O +
rat O +
prolactinoma B-Disease +
cells O -
. O +

However O -
, O +
only O +
secretory O +
granules O +
showed O +
the O +
positive O +
reaction O +
products O +
for O +
prolactin O +
6 O +
h O +
after O +
bromocriptine O +
treatment O +
of O +
the O +
adenoma B-Disease +
cells O -
. O +

An O +
increase O +
in O +
the O +
volume O +
density O +
of O +
secretory O +
granules O +
and O +
a O +
decrease O +
in O +
the O +
volume O +
densities O +
of O +
rough O +
endoplasmic O +
reticulum O +
and O +
microtubules O +
was O +
determined O +
by O +
morphometric O +
analysis O -
, O +
suggesting O +
that O +
bromocriptine O +
inhibits O +
protein O +
synthesis O +
as O +
well O +
as O +
bringing O +
about O +
a O +
disturbance O +
of O +
the O +
prolactin O +
secretion O -
. O +

GABA O +
involvement O +
in O +
naloxone O +
induced O +
reversal O +
of O +
respiratory B-Disease +
paralysis I-Disease +
produced O +
by O +
thiopental O -
. O +

No O +
agent O +
is O +
yet O +
available O +
to O +
reverse O +
respiratory B-Disease +
paralysis I-Disease +
produced O +
by O +
CNS O +
depressants O -
, O +
such O +
as O +
general O +
anesthetics O -
. O +

In O +
this O +
study O +
naloxone O +
reversed O +
respiratory B-Disease +
paralysis I-Disease +
induced O +
by O +
thiopental O +
in O +
rats O -
. O +

25 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O +

thiopental O +
produced O +
anesthesia O +
without O +
altering O +
respiratory O +
rate O -
, O +
increased O +
GABA O -
, O +
decreased O +
glutamate O -
, O +
and O +
had O +
no O +
effect O +
on O +
aspartate O +
or O +
glycine O +
levels O +
compared O +
to O +
controls O +
in O +
rat O +
cortex O +
and O +
brain O +
stem O -
. O +

Pretreatment O +
of O +
rats O +
with O +
thiosemicarbazide O +
for O +
30 O +
minutes O +
abolished O +
the O +
anesthetic O +
action O +
as O +
well O +
as O +
the O +
respiratory O +
depressant O +
action O +
of O +
thiopental O -
. O +

50 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O +

thiopental O +
produced O +
respiratory B-Disease +
arrest I-Disease +
with O +
further O +
increase O +
in O +
GABA O +
and O +
decrease O +
in O +
glutamate O +
again O +
in O +
cortex O +
and O +
brain O +
stem O +
without O +
affecting O +
any O +
of O +
the O +
amino O +
acids O +
studied O +
in O +
four O +
regions O +
of O +
rat O +
brain O -
. O +

Naloxone O +
( O -
2.5 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
reversed O +
respiratory B-Disease +
paralysis I-Disease -
, O +
glutamate O +
and O +
GABA O +
levels O +
to O +
control O +
values O +
in O +
brain O +
stem O +
and O +
cortex O +
with O +
no O +
changes O +
in O +
caudate O +
or O +
cerebellum O -
. O +

These O +
data O +
suggest O +
naloxone O +
reverses O +
respiratory B-Disease +
paralysis I-Disease +
produced O +
by O +
thiopental O +
and O +
involves O +
GABA O +
in O +
its O +
action O -
. O +

Diazepam O +
facilitates O +
reflex O +
bradycardia B-Disease +
in O +
conscious O +
rats O -
. O +

The O +
effects O +
of O +
diazepam O +
on O +
cardiovascular O +
function O +
were O +
assessed O +
in O +
conscious O +
rats O -
. O +

Intravenous O +
administration O +
of O +
diazepam O +
( O -
1 O -
- O -
30 O +
mg O +
kg-1 O -
) O +
produced O +
a O +
dose O -
- O -
dependent O +
decrease O +
in O +
both O +
the O +
mean O +
arterial O +
pressure O +
and O +
the O +
heart O +
rate O -
. O +

Also O -
, O +
reflex O +
bradycardia B-Disease +
was O +
produced O +
in O +
rats O +
by O +
intravenous O +
infusion O +
of O +
adrenaline O +
( O -
1.25 O -
- O -
2.5 O +
micrograms O +
kg-1 O -
) O -
. O +

Intravenous O +
pretreatment O +
of O +
the O +
rats O +
with O +
diazepam O -
, O +
although O +
causing O +
no O +
change O +
in O +
the O +
adrenaline O -
- O -
induced O +
pressor O +
effect O -
, O +
did O +
enhance O +
the O +
adrenaline O -
- O -
induced O +
reflex O +
bradycardia B-Disease -
. O +

However O -
, O +
the O +
diazepam O +
enhancement O +
of O +
adrenaline O -
- O -
induced O +
reflex O +
bradycardia B-Disease +
was O +
antagonized O +
by O +
pretreatment O +
of O +
rats O +
with O +
an O +
intravenous O +
dose O +
of O +
picrotoxin O +
( O -
an O +
agent O +
blocks O +
chloride O +
channels O +
by O +
binding O +
to O +
sites O +
associated O +
with O +
the O +
benzodiazepine O -
- O -
GABA O -
- O -
chloride O +
channel O +
macromolecular O +
complex O -
) O -
. O +

The O +
data O +
indicate O +
that O +
diazepam O +
acts O +
through O +
the O +
benzodiazepine O -
- O -
GABA O -
- O -
chloride O +
channel O +
macromolecular O +
complex O +
within O +
the O +
central O +
nervous O +
system O +
to O +
facilitate O +
reflex O +
bradycardia B-Disease +
mediated O +
through O +
baroreceptor O +
reflexes O +
in O +
response O +
to O +
an O +
acute O +
increase O +
in O +
arterial O +
pressure O -
. O +

Sulfasalazine O -
- O -
induced O +
lupus B-Disease +
erythematosus I-Disease -
. O +

Pneumonitis B-Disease -
, O +
bilateral O +
pleural B-Disease +
effusions I-Disease -
, O +
echocardiographic O +
evidence O +
of O +
cardiac B-Disease +
tamponade I-Disease -
, O +
and O +
positive O +
autoantibodies O +
developed O +
in O +
a O +
43-year O -
- O -
old O +
man O -
, O +
who O +
was O +
receiving O +
long O -
- O -
term O +
sulfasalazine O +
therapy O +
for O +
chronic O +
ulcerative B-Disease +
colitis I-Disease -
. O +

After O +
cessation O +
of O +
the O +
sulfasalazine O +
and O +
completion O +
of O +
a O +
six O -
- O -
week O +
course O +
of O +
corticosteroids O -
, O +
these O +
problems O +
resolved O +
over O +
a O +
period O +
of O +
four O +
to O +
six O +
months O -
. O +

It O +
is O +
suggested O +
that O +
the O +
patient O +
had O +
sulfasalazine O -
- O -
induced O +
lupus B-Disease -
, O +
which O +
manifested O +
with O +
serositis B-Disease +
and O +
pulmonary O +
parenchymal O +
involvement O +
in O +
the O +
absence O +
of O +
joint O +
symptoms O -
. O +

Physicians O +
who O +
use O +
sulfasalazine O +
to O +
treat O +
patients O +
with O +
inflammatory B-Disease +
bowel I-Disease +
disease I-Disease +
should O +
be O +
aware O +
of O +
the O +
signs O +
of O +
sulfasalazine O -
- O -
induced O +
lupus B-Disease +
syndrome I-Disease -
. O +

Reversal O +
of O +
neuroleptic O -
- O -
induced O +
catalepsy B-Disease +
by O +
novel O +
aryl O -
- O -
piperazine O +
anxiolytic O +
drugs O -
. O +

The O +
novel O +
anxiolytic O +
drug O -
, O +
buspirone O -
, O +
reverses O +
catalepsy B-Disease +
induced O +
by O +
haloperidol O -
. O +

A O +
series O +
of O +
aryl O -
- O -
piperazine O +
analogues O +
of O +
buspirone O +
and O +
other O +
5-hydroxytryptaminergic O +
agonists O +
were O +
tested O +
for O +
their O +
ability O +
to O +
reverse O +
haloperidol O +
induced O +
catalepsy B-Disease -
. O +

Those O +
drugs O +
with O +
strong O +
affinity O +
for O +
5-hydroxytryptamine1a O +
receptors O +
were O +
able O +
to O +
reverse O +
catalepsy B-Disease -
. O +

Drugs O +
with O +
affinity O +
for O +
other O +
5-HT O +
receptors O +
or O +
weak O +
affinity O +
were O +
ineffective O -
. O +

However O -
, O +
inhibition O +
of O +
postsynaptic O +
5-HT O +
receptors O +
neither O +
inhibited O +
nor O +
potentiated O +
reversal O +
of O +
catalepsy B-Disease +
and O +
leaves O +
open O +
the O +
question O +
as O +
to O +
the O +
site O +
or O +
mechanism O +
for O +
this O +
effect O -
. O +

Glycopyrronium O +
requirements O +
for O +
antagonism O +
of O +
the O +
muscarinic O +
side O +
effects O +
of O +
edrophonium O -
. O +

We O +
have O +
compared O -
, O +
in O +
60 O +
adult O +
patients O -
, O +
the O +
cardiovascular O +
effects O +
of O +
glycopyrronium O +
5 O +
micrograms O +
kg-1 O +
and O +
10 O +
micrograms O +
kg-1 O +
given O +
either O +
simultaneously O +
or O +
1 O +
min O +
before O +
edrophonium O +
1 O +
mg O +
kg-1 O -
. O +

Significant O +
differences O +
between O +
the O +
four O +
groups O +
were O +
detected O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
. O +

Both O +
groups O +
receiving O +
10 O +
micrograms O +
kg-1 O +
showed O +
increases O +
in O +
heart O +
rate O +
of O +
up O +
to O +
30 O +
beat O +
min-1 O +
( O -
95 O -
% O +
confidence O +
limits O +
28 O -
- O -
32 O +
beat O +
min-1 O -
) O -
. O +

Use O +
of O +
glycopyrronium O +
5 O +
micrograms O +
kg-1 O +
provided O +
greater O +
cardiovascular O +
stability O +
and O -
, O +
given O +
1 O +
min O +
before O +
the O +
edrophonium O -
, O +
was O +
sufficient O +
to O +
minimize O +
early O -
, O +
edrophonium O -
- O -
induced O +
bradycardias B-Disease -
. O +

This O +
low O +
dose O +
of O +
glycopyrronium O +
provided O +
good O +
control O +
of O +
oropharyngeal O +
secretions O -
. O +

Chronic O +
carbamazepine O +
treatment O +
in O +
the O +
rat O -
: O +
efficacy O -
, O +
toxicity B-Disease -
, O +
and O +
effect O +
on O +
plasma O +
and O +
tissue O +
folate O +
concentrations O -
. O +

Folate O +
depletion O +
has O +
often O +
been O +
a O +
problem O +
in O +
chronic O +
antiepileptic O +
drug O +
( O -
AED O -
) O +
therapy O -
. O +

Carbamazepine O +
( O -
CBZ O -
) O -
, O +
a O +
commonly O +
used O +
AED O -
, O +
has O +
been O +
implicated O +
in O +
some O +
clinical O +
studies O -
. O +

A O +
rat O +
model O +
was O +
developed O +
to O +
examine O +
the O +
effects O +
of O +
chronic O +
CBZ O +
treatment O +
on O +
folate O +
concentrations O +
in O +
the O +
rat O -
. O +

In O +
the O +
course O +
of O +
developing O +
this O +
model O -
, O +
a O +
common O +
vehicle O -
, O +
propylene O +
glycol O -
, O +
by O +
itself O +
in O +
high O +
doses O -
, O +
was O +
found O +
to O +
exhibit O +
protective O +
properties O +
against O +
induced O +
seizures B-Disease +
and O +
inhibited O +
weight B-Disease +
gain I-Disease -
. O +

Seizures B-Disease +
induced O +
by O +
hexafluorodiethyl O +
ether O +
( O -
HFDE O -
) O +
were O +
also O +
found O +
to O +
be O +
a O +
more O +
sensitive O +
measure O +
of O +
protection O +
by O +
CBZ O +
than O +
seizures B-Disease +
induced O +
by O +
maximal O +
electroshock O +
( O -
MES O -
) O -
. O +

Oral O +
administration O +
of O +
CBZ O +
as O +
an O +
aqueous O +
suspension O +
every O +
8 O +
h O +
at O +
a O +
dose O +
of O +
250 O +
mg O -
/ O -
kg O +
was O +
continuously O +
protective O +
against O +
HFDE O -
- O -
induced O +
seizures B-Disease +
and O +
was O +
minimally O +
toxic O +
as O +
measured O +
by O +
weight B-Disease +
gain I-Disease +
over O +
8 O +
weeks O +
of O +
treatment O -
. O +

The O +
CBZ O +
levels O +
measured O +
in O +
plasma O +
and O +
brain O +
of O +
these O +
animals O -
, O +
however O -
, O +
were O +
below O +
those O +
normally O +
considered O +
protective O -
. O +

This O +
treatment O +
with O +
CBZ O +
had O +
no O +
apparent O +
adverse O +
effect O +
on O +
folate O +
concentrations O +
in O +
the O +
rat O -
, O +
and O -
, O +
indeed O -
, O +
the O +
folate O +
concentration O +
increased O +
in O +
liver O +
after O +
6 O +
weeks O +
of O +
treatment O +
and O +
in O +
plasma O +
at O +
8 O +
weeks O +
of O +
treatment O -
. O +

Dipyridamole O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease -
. O +

Angina B-Disease +
and O +
ischemic O +
electrocardiographic O +
changes O +
occurred O +
after O +
administration O +
of O +
oral O +
dipyridamole O +
in O +
four O +
patients O +
awaiting O +
urgent O +
myocardial O +
revascularization O +
procedures O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
has O +
not O +
previously O +
been O +
reported O +
as O +
a O +
side O +
effect O +
of O +
preoperative O +
dipyridamole O +
therapy O -
, O +
although O +
dipyridamole O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease +
has O +
been O +
demonstrated O +
to O +
occur O +
in O +
animals O +
and O +
humans O +
with O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
. O +

Epicardial O +
coronary O +
collateral O +
vessels O +
were O +
demonstrated O +
in O +
all O +
four O +
patients O -
; O +
a O +
coronary O +
" O -
steal O -
" O +
phenomenon O +
may O +
be O +
the O +
mechanism O +
of O +
the O +
dipyridamole O -
- O -
induced O +
ischemia B-Disease +
observed O -
. O +

Inhibition O +
of O +
sympathoadrenal O +
activity O +
by O +
atrial O +
natriuretic O +
factor O +
in O +
dogs O -
. O +

In O +
six O +
conscious O -
, O +
trained O +
dogs O -
, O +
maintained O +
on O +
a O +
normal O +
sodium O +
intake O +
of O +
2 O +
to O +
4 O +
mEq O -
/ O -
kg O -
/ O -
day O -
, O +
sympathetic O +
activity O +
was O +
assessed O +
as O +
the O +
release O +
rate O +
of O +
norepinephrine O +
and O +
epinephrine O +
during O +
15-minute O +
i.v O -
. O +

infusions O +
of O +
human O +
alpha O -
- O -
atrial O +
natriuretic O +
factor O -
. O +

Mean O +
arterial O +
pressure O +
( O -
as O +
a O +
percentage O +
of O +
control O +
+ O -
/- O +

SEM O -
) O +
during O +
randomized O +
infusions O +
of O +
0.03 O -
, O +
0.1 O -
, O +
0.3 O -
, O +
or O +
1.0 O +
microgram O -
/ O -
kg O -
/ O -
min O +
was O +
99 O +
+ O -
/- O +

1 O -
, O +
95 O +
+ O -
/- O +

1 O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
, O +
93 O +
+ O -
/- O +

1 O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
, O +
or O +
79 O +
+ O -
/- O +

6 O -
% O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
, O +
respectively O -
, O +
but O +
no O +
tachycardia B-Disease +
and O +
no O +
augmentation O +
of O +
the O +
norepinephrine O +
release O +
rate O +
( O -
up O +
to O +
0.3 O +
microgram O -
/ O -
kg O -
/ O -
min O -
) O +
were O +
observed O -
, O +
which O +
is O +
in O +
contrast O +
to O +
comparable O +
hypotension B-Disease +
induced O +
by O +
hydralazine O +
or O +
nitroglycerin O -
. O +

The O +
release O +
rate O +
of O +
epinephrine O +
( O -
control O -
, O +
6.7 O +
+ O -
/- O +

0.6 O +
ng O -
/ O -
kg O -
/ O -
min O -
) O +
declined O +
immediately O +
during O +
infusions O +
of O +
atrial O +
natriuretic O +
factor O +
to O +
a O +
minimum O +
of O +
49 O +
+ O -
/- O +

5 O -
% O +
of O +
control O +
( O -
p O +
less O +
than O +
0.001 O -
) O +
during O +
0.1 O +
microgram O -
/ O -
kg O -
/ O -
min O +
and O +
to O +
63 O +
+ O -
/- O +

5 O -
% O +
( O -
0.1 O +
greater O +
than O +
p O +
greater O +
than O +
0.05 O -
) O +
or O +
95 O +
+ O -
/- O +

13 O -
% O +
( O -
not O +
significant O -
) O +
during O +
0.3 O +
or O +
1.0 O +
microgram O -
/ O -
kg O -
/ O -
min O -
. O +

Steady O +
state O +
arterial O +
plasma O +
concentrations O +
of O +
atrial O +
natriuretic O +
factor O +
were O +
39 O +
+ O -
/- O +

10 O +
pg O -
/ O -
ml O +
( O -
n O +
= O +
6 O -
) O +
during O +
infusions O +
of O +
saline O +
and O +
284 O +
+ O -
/- O +

24 O +
pg O -
/ O -
ml O +
( O -
n O +
= O +
6 O -
) O +
and O +
1520 O +
+ O -
/- O +

300 O +
pg O -
/ O -
ml O +
( O -
n O +
= O +
9 O -
) O +
during O +
0.03 O +
and O +
0.1 O +
microgram O -
/ O -
kg O -
/ O -
min O +
infusions O +
of O +
the O +
factor. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Selective O +
injection O +
of O +
iopentol O -
, O +
iohexol O +
and O +
metrizoate O +
into O +
the O +
left O +
coronary O +
artery O +
of O +
the O +
dog O -
. O +

Induction O +
of O +
ventricular B-Disease +
fibrillation I-Disease +
and O +
decrease O +
of O +
aortic O +
pressure O -
. O +

In O +
twenty O +
beagle O +
dogs O +
selective O +
injections O +
were O +
made O +
into O +
the O +
left O +
coronary O +
artery O +
with O +
iopentol O -
, O +
iohexol O +
and O +
metrizoate O +
in O +
doses O +
of O +
4 O +
ml O -
, O +
8 O +
ml O +
and O +
16 O +
ml O -
. O +

Thirty O -
- O -
six O +
iopentol O +
injections O -
, O +
35 O +
iohexol O +
injections O +
and O +
37 O +
metrizoate O +
injections O +
were O +
made O -
. O +

Frequencies O +
of O +
ventricular B-Disease +
fibrillation I-Disease +
were O +
significantly O +
lower O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
after O +
iopentol O +
( O -
0 O -
% O -
) O +
and O +
iohexol O +
( O -
3 O -
% O -
) O +
than O +
after O +
metrizoate O +
( O -
22 O -
% O -
) O -
. O +

Iopentol O +
and O +
iohexol O +
also O +
produced O +
significantly O +
less O +
decrease O +
in O +
aortic O +
blood O +
pressure O +
than O +
metrizoate O +
at O +
the O +
different O +
doses O -
. O +

Thyroid O +
function O +
and O +
urine O -
- O -
concentrating O +
ability O +
during O +
lithium O +
treatment O -
. O +

It O +
has O +
been O +
suggested O +
that O +
adenylate O +
cyclase O +
inhibition O +
may O +
be O +
important O +
in O +
the O +
development O +
of O +
both O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease +
and O +
hypothyroidism B-Disease +
during O +
lithium O +
treatment O -
. O +

We O +
measured O +
serum O +
thyroxine O +
and O +
urine O -
- O -
concentrating O +
ability O +
( O -
Umax O -
) O +
in O +
response O +
to O +
desmopressin O +
( O -
DDAVP O -
) O +
in O +
85 O +
patients O +
receiving O +
lithium O -
. O +

Hypothyroidism B-Disease +
developed O +
in O +
eight O +
patients O +
while O +
they O +
were O +
taking O +
lithium O -
. O +

Impaired O +
Umax O +
was O +
found O +
in O +
both O +
euthyroid O +
and O +
hypothyroid B-Disease +
patients O +
while O +
some O +
hypothyroid B-Disease +
patients O +
concentrated O +
their O +
urine O +
well O -
. O +

It O +
is O +
concluded O +
that O +
the O +
dominant O +
mechanisms O +
by O +
which O +
lithium O +
exerts O +
these O +
two O +
effects O +
are O +
different O -
. O +

Remodelling O +
of O +
nerve O +
structure O +
in O +
experimental O +
isoniazid O +
neuropathy B-Disease +
in O +
the O +
rat O -
. O +

The O +
neuropathy B-Disease +
caused O +
by O +
a O +
single O +
dose O +
of O +
isoniazid O +
in O +
rats O +
was O +
studied O +
with O +
a O +
computer O -
- O -
assisted O +
morphometric O +
method O -
. O +

Scatter O +
diagrams O +
of O +
the O +
g O +
ratio O +
( O -
quotient O +
fibre O +
diameter O -
/ O -
axon O +
diameter O -
) O +
define O +
regenerating O +
fibres O +
as O +
a O +
distinct O +
population O -
, O +
distinguishable O +
from O +
the O +
surviving O +
fibres O +
by O +
reduced O +
sheath O +
thickness O +
and O +
reduced O +
axon O +
calibre O -
. O +

There O +
was O +
also O +
evidence O +
of O +
a O +
subtle O +
direct O +
toxic O +
effect O +
on O +
the O +
entire O +
fibre O +
population O -
, O +
causing O +
axon O +
shrinkage O +
masked O +
by O +
readjustment O +
of O +
the O +
myelin O +
sheath O -
. O +

Inhibition O +
of O +
immunoreactive O +
corticotropin O -
- O -
releasing O +
factor O +
secretion O +
into O +
the O +
hypophysial O -
- O -
portal O +
circulation O +
by O +
delayed O +
glucocorticoid O +
feedback O -
. O +

Nitroprusside O -
- O -
induced O +
hypotension B-Disease +
evokes O +
ACTH O +
secretion O +
which O +
is O +
primarily O +
mediated O +
by O +
enhanced O +
secretion O +
of O +
immunoreactive O +
corticotropin O -
- O -
releasing O +
factor O +
( O -
irCRF O -
) O +
into O +
the O +
hypophysial O -
- O -
portal O +
circulation O -
. O +

Portal O +
plasma O +
concentrations O +
of O +
neither O +
arginine O +
vasopressin O +
nor O +
oxytocin O +
are O +
significantly O +
altered O +
in O +
this O +
paradigm O -
. O +

Application O +
of O +
a O +
delayed O +
feedback O +
signal O -
, O +
in O +
the O +
form O +
of O +
a O +
2-h O +
systemic O +
corticosterone O +
infusion O +
in O +
urethane O -
- O -
anesthetized O +
rats O +
with O +
pharmacological O +
blockade O +
of O +
glucocorticoid O +
synthesis O -
, O +
is O +
without O +
effect O +
on O +
the O +
resting O +
secretion O +
of O +
arginine O +
vasopressin O +
and O +
oxytocin O +
at O +
any O +
corticosterone O +
feedback O +
dose O +
tested O -
. O +

Resting O +
irCRF O +
levels O +
are O +
suppressed O +
only O +
at O +
the O +
highest O +
corticosterone O +
infusion O +
rate O -
, O +
which O +
resulted O +
in O +
systemic O +
corticosterone O +
levels O +
of O +
40 O +
micrograms O -
/ O -
dl O -
. O +

Suppression O +
of O +
irCRF O +
secretion O +
in O +
response O +
to O +
nitroprusside O -
- O -
induced O +
hypotension B-Disease +
is O +
observed O +
and O +
occurs O +
at O +
a O +
plasma O +
corticosterone O +
level O +
between O +
8 O -
- O -
12 O +
micrograms O -
/ O -
dl O -
. O +

These O +
studies O +
provide O +
further O +
evidence O +
for O +
a O +
strong O +
central O +
component O +
of O +
the O +
delayed O +
feedback O +
process O +
which O +
is O +
mediated O +
by O +
modulation O +
of O +
irCRF O +
release O -
. O +

Noradrenergic O +
involvement O +
in O +
catalepsy B-Disease +
induced O +
by O +
delta O +
9-tetrahydrocannabinol O -
. O +

In O +
order O +
to O +
elucidate O +
the O +
role O +
of O +
the O +
catecholaminergic O +
system O +
in O +
the O +
cataleptogenic O +
effect O +
of O +
delta O +
9-tetrahydrocannabinol O +
( O -
THC O -
) O -
, O +
the O +
effect O +
of O +
pretreatment O +
with O +
6-hydroxydopamine O +
( O -
6-OHDA O -
) O +
or O +
with O +
desipramine O +
and O +
6-OHDA O +
and O +
lesions O +
of O +
the O +
locus O +
coeruleus O +
were O +
investigated O +
in O +
rats O -
. O +

The O +
cataleptogenic O +
effect O +
of O +
THC O +
was O +
significantly O +
reduced O +
in O +
rats O +
treated O +
with O +
6-OHDA O +
and O +
in O +
rats O +
with O +
lesions O +
of O +
the O +
locus O +
coeruleus O +
but O +
not O +
in O +
rats O +
treated O +
with O +
desipramine O +
and O +
6-OHDA O -
, O +
as O +
compared O +
with O +
control O +
rats O -
. O +

On O +
the O +
contrary O -
, O +
the O +
cataleptogenic O +
effect O +
of O +
haloperidol O +
was O +
significantly O +
reduced O +
in O +
rats O +
treated O +
with O +
desipramine O +
and O +
6-OHDA O +
but O +
not O +
in O +
rats O +
treated O +
with O +
6-OHDA O +
or O +
in O +
rats O +
with O +
lesions O +
of O +
the O +
locus O +
coeruleus O -
. O +

These O +
results O +
indicate O +
that O +
noradrenergic O +
neurons O +
have O +
an O +
important O +
role O +
in O +
the O +
manifestation O +
of O +
catalepsy B-Disease +
induced O +
by O +
THC O -
, O +
whereas O +
dopaminergic O +
neurons O +
are O +
important O +
in O +
catalepsy B-Disease +
induced O +
by O +
haloperidol O -
. O +

Multicenter O -
, O +
double O -
- O -
blind O -
, O +
multiple O -
- O -
dose O -
, O +
parallel O -
- O -
groups O +
efficacy O +
and O +
safety O +
trial O +
of O +
azelastine O -
, O +
chlorpheniramine O -
, O +
and O +
placebo O +
in O +
the O +
treatment O +
of O +
spring B-Disease +
allergic I-Disease +
rhinitis I-Disease -
. O +

Azelastine O -
, O +
a O +
novel O +
antiallergic O +
medication O -
, O +
was O +
compared O +
with O +
chlorpheniramine O +
maleate O +
and O +
placebo O +
for O +
efficacy O +
and O +
safety O +
in O +
the O +
treatment O +
of O +
spring B-Disease +
allergic I-Disease +
rhinitis I-Disease +
in O +
a O +
multicenter O -
, O +
double O -
- O -
blind O -
, O +
multiple O -
- O -
dose O -
, O +
parallel O -
- O -
groups O +
study O -
. O +

One O +
hundred O +
fifty O -
- O -
five O +
subjects O +
participated O -
. O +

Subjects O +
ranged O +
in O +
age O +
from O +
18 O +
to O +
60 O +
years O +
of O +
age O +
and O +
had O +
at O +
least O +
a O +
2-year O +
history O +
of O +
spring B-Disease +
allergic I-Disease +
rhinitis I-Disease -
, O +
confirmed O +
by O +
positive O +
skin O +
test O +
to O +
spring O +
aeroallergens O -
. O +

Medications O +
were O +
given O +
four O +
times O +
daily O -
; O +
the O +
azelastine O +
groups O +
received O +
0.5 O -
, O +
1.0 O -
, O +
or O +
2.0 O +
mg O +
in O +
the O +
morning O +
and O +
evening O +
with O +
placebo O +
in O +
the O +
early O +
and O +
late O +
afternoon O -
; O +
the O +
chlorpheniramine O +
group O +
received O +
4.0 O +
mg O +
four O +
times O +
daily O -
. O +

Daily O +
subject O +
symptom O +
cards O +
were O +
completed O +
during O +
a O +
screening O +
period O +
to O +
assess O +
pretreatment O +
symptoms O +
and O +
during O +
a O +
4-week O +
treatment O +
period O +
while O +
subjects O +
received O +
study O +
medications O -
. O +

Individual O +
symptoms O -
, O +
total O +
symptoms O -
, O +
and O +
major O +
symptoms O +
were O +
compared O +
to O +
determine O +
efficacy O +
of O +
medication O -
. O +

Elicited O -
, O +
volunteered O -
, O +
and O +
observed O +
adverse O +
experiences O +
were O +
recorded O +
for O +
each O +
subject O +
and O +
compared O +
among O +
groups O -
. O +

Vital O +
signs O -
, O +
body O +
weights O -
, O +
serum O +
chemistry O +
values O -
, O +
complete O +
blood O +
cell O +
counts O -
, O +
urine O +
studies O -
, O +
and O +
electrocardiograms O +
were O +
obtained O +
for O +
each O +
subject O +
and O +
compared O +
among O +
groups O -
. O +

Symptoms O +
relief O +
in O +
the O +
group O +
receiving O +
the O +
highest O +
concentration O +
of O +
azelastine O +
( O -
2.0 O +
mg O +
twice O +
daily O -
) O +
was O +
statistically O +
greater O +
than O +
in O +
the O +
placebo O +
group O +
during O +
all O +
weeks O +
of O +
the O +
study O -
. O +

Lower O +
doses O +
of O +
azelastine O +
were O +
statistically O +
more O +
effective O +
than O +
placebo O +
only O +
during O +
portions O +
of O +
the O +
first O +
3 O +
weeks O +
of O +
the O +
study O -
. O +

In O +
contrast O -
, O +
although O +
the O +
chlorpheniramine O +
group O +
did O +
have O +
fewer O +
symptoms O +
than O +
the O +
placebo O +
group O +
during O +
the O +
study O -
, O +
the O +
difference O +
never O +
reached O +
statistical O +
significance O +
during O +
any O +
week O +
of O +
the O +
study O -
. O +

There O +
were O +
no O +
serious O +
side O +
effects O +
in O +
any O +
of O +
the O +
treatment O +
groups O -
. O +

Drowsiness B-Disease +
and O +
altered B-Disease +
taste I-Disease +
perception I-Disease +
were O +
increased O +
significantly O +
over O +
placebo O +
only O +
in O +
the O +
high O -
- O -
dose O +
azelastine O +
group O -
. O +

Azelastine O +
appears O +
to O +
be O +
a O +
safe O -
, O +
efficacious O +
medication O +
for O +
seasonal B-Disease +
allergic I-Disease +
rhinitis I-Disease -
. O +

Reversibility O +
of O +
captopril O -
- O -
induced O +
renal B-Disease +
insufficiency I-Disease +
after O +
prolonged O +
use O +
in O +
an O +
unusual O +
case O +
of O +
renovascular B-Disease +
hypertension I-Disease -
. O +

We O +
report O +
a O +
case O +
of O +
severe O +
hypertension B-Disease +
with O +
an O +
occluded O +
renal O +
artery O +
to O +
a O +
solitary O +
kidney O -
, O +
who O +
developed O +
sudden B-Disease +
deterioration I-Disease +
of I-Disease +
renal I-Disease +
function I-Disease +
following O +
treatment O +
with O +
captopril O -
. O +

His O +
renal O +
function O +
remained O +
impaired O +
but O +
stable O +
during O +
2 O +
years O -
' O +
treatment O +
with O +
captopril O +
but O +
returned O +
to O +
pre O -
- O -
treatment O +
levels O +
soon O +
after O +
cessation O +
of O +
the O +
drug O -
. O +

This O +
indicates O +
reversibility O +
in O +
captopril O -
- O -
induced O +
renal B-Disease +
failure I-Disease +
even O +
after O +
its O +
prolonged O +
use O +
and O +
suggests O +
that O +
no O +
organic O +
damage O +
occurs O +
to O +
glomerular O +
arterioles O +
following O +
chronic O +
ACE O +
inhibition O -
. O +

HMG O +
CoA O +
reductase O +
inhibitors O -
. O +

Current O +
clinical O +
experience O -
. O +

Lovastatin O +
and O +
simvastatin O +
are O +
the O +
2 O +
best O -
- O -
known O +
members O +
of O +
the O +
class O +
of O +
hypolipidaemic O +
agents O +
known O +
as O +
HMG O +
CoA O +
reductase O +
inhibitors O -
. O +

Clinical O +
experience O +
with O +
lovastatin O +
includes O +
over O +
5000 O +
patients O -
, O +
700 O +
of O +
whom O +
have O +
been O +
treated O +
for O +
2 O +
years O +
or O +
more O -
, O +
and O +
experience O +
with O +
simvastatin O +
includes O +
over O +
3500 O +
patients O -
, O +
of O +
whom O +
350 O +
have O +
been O +
treated O +
for O +
18 O +
months O +
or O +
more O -
. O +

Lovastatin O +
has O +
been O +
marketed O +
in O +
the O +
United O +
States O +
for O +
over O +
6 O +
months O -
. O +

Both O +
agents O +
show O +
substantial O +
clinical O +
efficacy O -
, O +
with O +
reductions O +
in O +
total O +
cholesterol O +
of O +
over O +
30 O -
% O +
and O +
in O +
LDL O -
- O -
cholesterol O +
of O +
40 O -
% O +
in O +
clinical O +
studies O -
. O +

Modest O +
increases O +
in O +
HDL O -
- O -
cholesterol O +
levels O +
of O +
about O +
10 O -
% O +
are O +
also O +
reported O -
. O +

Clinical O +
tolerability O +
of O +
both O +
agents O +
has O +
been O +
good O -
, O +
with O +
fewer O +
than O +
3 O -
% O +
of O +
patients O +
withdrawn O +
from O +
treatment O +
because O +
of O +
clinical O +
adverse O +
experiences O -
. O +

Ophthalmological O +
examinations O +
in O +
over O +
1100 O +
patients O +
treated O +
with O +
one O +
or O +
the O +
other O +
agent O +
have O +
revealed O +
no O +
evidence O +
of O +
significant O +
short O +
term O +
( O -
up O +
to O +
2 O +
years O -
) O +
cataractogenic O +
potential O -
. O +

One O +
to O +
2 O -
% O +
of O +
patients O +
have O +
elevations O +
of O +
serum O +
transaminases O +
to O +
greater O +
than O +
3 O +
times O +
the O +
upper O +
limit O +
of O +
normal O -
. O +

These O +
episodes O +
are O +
asymptomatic O +
and O +
reversible O +
when O +
therapy O +
is O +
discontinued O -
. O +

Minor O +
elevations O +
of O +
creatine O +
kinase O +
levels O +
are O +
reported O +
in O +
about O +
5 O -
% O +
of O +
patients O -
. O +

Myopathy B-Disease -
, O +
associated O +
in O +
some O +
cases O +
with O +
myoglobinuria B-Disease -
, O +
and O +
in O +
2 O +
cases O +
with O +
transient O +
renal B-Disease +
failure I-Disease -
, O +
has O +
been O +
rarely O +
reported O +
with O +
lovastatin O -
, O +
especially O +
in O +
patients O +
concomitantly O +
treated O +
with O +
cyclosporin O -
, O +
gemfibrozil O +
or O +
niacin O -
. O +

Lovastatin O +
and O +
simvastatin O +
are O +
both O +
effective O +
and O +
well O -
- O -
tolerated O +
agents O +
for O +
lowering O +
elevated O +
levels O +
of O +
serum O +
cholesterol O -
. O +

As O +
wider O +
use O +
confirms O +
their O +
safety O +
profile O -
, O +
they O +
will O +
gain O +
increasing O +
importance O +
in O +
the O +
therapeutic O +
approach O +
to O +
hypercholesterolaemia B-Disease +
and O +
its O +
consequences O -
. O +

Transient O +
contralateral B-Disease +
rotation I-Disease +
following O +
unilateral O +
substantia B-Disease +
nigra I-Disease +
lesion I-Disease +
reflects O +
susceptibility O +
of O +
the O +
nigrostriatal O +
system O +
to O +
exhaustion O +
by O +
amphetamine O -
. O +

Following O +
unilateral O +
6-OHDA O +
induced O +
SN B-Disease +
lesion I-Disease -
, O +
a O +
transient O +
period O +
of O +
contralateral B-Disease +
rotation I-Disease +
has O +
been O +
reported O +
to O +
precede O +
the O +
predominant O +
ipsilateral B-Disease +
circling I-Disease -
. O +

In O +
order O +
to O +
clarify O +
the O +
nature O +
of O +
this O +
initial O +
contralateral B-Disease +
rotation I-Disease +
we O +
examined O +
the O +
effect O +
of O +
the O +
duration O +
of O +
recovery O +
period O +
after O +
the O +
lesion O -
, O +
on O +
amphetamine O -
- O -
induced O +
rotational B-Disease +
behavior I-Disease -
. O +

Three O +
days O +
post O +
lesion O -
, O +
most O +
rats O +
circled O +
predominantly O +
contralaterally O +
to O +
the O +
lesion O -
. O +

Such O +
contralateral B-Disease +
rotation I-Disease +
may O +
result O +
from O +
either O +
degeneration O -
- O -
induced O +
breakdown O +
of O +
the O +
DA O +
pool O -
, O +
or O +
lesion O -
- O -
induced O +
increase O +
of O +
DA O +
turnover O +
in O +
the O +
spared O +
neurons O -
. O +

A O +
substantial O +
degree O +
of O +
contralateral O +
preference O +
was O +
still O +
evident O +
when O +
amphetamine O +
was O +
administered O +
for O +
the O +
first O +
time O +
24 O +
days O +
after O +
lesioning O -
, O +
indicating O +
involvement O +
of O +
spared O +
cells O +
in O +
the O +
contralateral B-Disease +
rotation I-Disease -
. O +

However O -
, O +
regardless O +
of O +
the O +
duration O +
of O +
recovery O +
( O -
and O +
irrespective O +
of O +
either O +
lesion O +
volume O -
, O +
amphetamine O +
dose O -
, O +
or O +
post O -
- O -
lesion O +
motor O +
exercise O -
) O -
, O +
amphetamine O -
- O -
induced O +
rotation B-Disease +
tended O +
to O +
become O +
gradually O +
more O +
ipsilateral O +
as O +
the O +
observation O +
session O +
progressed O -
, O +
and O +
all O +
rats O +
circled O +
ipsilaterally O +
to O +
the O +
lesion O +
in O +
response O +
to O +
further O +
amphetamine O +
injections O -
. O +

These O +
findings O +
suggest O +
that O +
amphetamine O +
has O +
an O +
irreversible O +
effect O +
on O +
the O +
post O -
- O -
lesion O +
DA O +
pool O +
contributing O +
to O +
contralateral B-Disease +
rotation I-Disease -
. O +

Hepatic O +
reactions O +
associated O +
with O +
ketoconazole O +
in O +
the O +
United O +
Kingdom O -
. O +

Ketoconazole O +
was O +
introduced O +
in O +
the O +
United O +
Kingdom O +
in O +
1981 O -
. O +

By O +
November O +
1984 O +
the O +
Committee O +
on O +
Safety O +
of O +
Medicines O +
had O +
received O +
82 O +
reports O +
of O +
possible O +
hepatotoxicity B-Disease +
associated O +
with O +
the O +
drug O -
, O +
including O +
five O +
deaths B-Disease -
. O +

An O +
analysis O +
of O +
the O +
75 O +
cases O +
that O +
had O +
been O +
adequately O +
followed O +
up O +
suggested O +
that O +
16 O -
, O +
including O +
three O +
deaths B-Disease -
, O +
were O +
probably O +
related O +
to O +
treatment O +
with O +
the O +
drug O -
. O +

Of O +
the O +
remainder O -
, O +
48 O +
were O +
possibly O +
related O +
to O +
treatment O -
, O +
five O +
were O +
unlikely O +
to O +
be O +
so O -
, O +
and O +
six O +
were O +
unclassifiable O -
. O +

The O +
mean O +
age O +
of O +
patients O +
in O +
the O +
16 O +
probable O +
cases O +
was O +
57.9 O -
, O +
with O +
hepatotoxicity B-Disease +
being O +
more O +
common O +
in O +
women O -
. O +

The O +
average O +
duration O +
of O +
treatment O +
before O +
the O +
onset O +
of O +
jaundice B-Disease +
was O +
61 O +
days O -
. O +

None O +
of O +
these O +
well O +
validated O +
cases O +
occurred O +
within O +
the O +
first O +
10 O +
days O +
after O +
treatment O -
. O +

The O +
results O +
of O +
serum O +
liver O +
function O +
tests O +
suggested O +
hepatocellular B-Disease +
injury I-Disease +
in O +
10 O +
( O -
63 O -
% O -
) O -
; O +
the O +
rest O +
showed O +
a O +
mixed O +
pattern O -
. O +

In O +
contrast O -
, O +
the O +
results O +
of O +
histological O +
examination O +
of O +
the O +
liver O +
often O +
showed O +
evidence O +
of O +
cholestasis B-Disease -
. O +

The O +
characteristics O +
of O +
the O +
48 O +
patients O +
in O +
the O +
possible O +
cases O +
were O +
similar O -
. O +

Allergic O +
manifestations O +
such O +
as O +
rash B-Disease +
and O +
eosinophilia B-Disease +
were O +
rare O -
. O +

Hepatitis B-Disease +
was O +
usually O +
reversible O +
when O +
treatment O +
was O +
stopped O -
, O +
with O +
the O +
results O +
of O +
liver O +
function O +
tests O +
returning O +
to O +
normal O +
after O +
an O +
average O +
of O +
3.1 O +
months O -
. O +

In O +
two O +
of O +
the O +
three O +
deaths B-Disease +
probably O +
associated O +
with O +
ketoconazole O +
treatment O +
the O +
drug O +
had O +
been O +
continued O +
after O +
the O +
onset O +
of O +
jaundice B-Disease +
and O +
other O +
symptoms O +
of O +
hepatitis B-Disease -
. O +

Clinical O +
and O +
biochemical O +
monitoring O +
at O +
regular O +
intervals O +
for O +
evidence O +
of O +
hepatitis B-Disease +
is O +
advised O +
during O +
long O +
term O +
treatment O +
with O +
ketoconazole O +
to O +
prevent O +
possible O +
serious O +
hepatic B-Disease +
injury I-Disease -
. O +

Glyburide O -
- O -
induced O +
hepatitis B-Disease -
. O +

Drug O -
- O -
induced O +
hepatotoxicity B-Disease -
, O +
although O +
common O -
, O +
has O +
been O +
reported O +
only O +
infrequently O +
with O +
sulfonylureas O -
. O +

For O +
glyburide O -
, O +
a O +
second O -
- O -
generation O +
sulfonylurea O -
, O +
only O +
two O +
brief O +
reports O +
of O +
hepatotoxicity B-Disease +
exist O -
. O +

Two O +
patients O +
with O +
type B-Disease +
II I-Disease +
diabetes I-Disease +
mellitus I-Disease +
developed O +
an O +
acute B-Disease +
hepatitis I-Disease -
- I-Disease -
like I-Disease +
syndrome I-Disease +
soon O +
after O +
initiation O +
of O +
glyburide O +
therapy O -
. O +

There O +
was O +
no O +
serologic O +
evidence O +
of O +
viral B-Disease +
infection I-Disease -
, O +
and O +
a O +
liver O +
biopsy O +
sample O +
showed O +
a O +
histologic O +
pattern O +
consistent O +
with O +
drug B-Disease -
- I-Disease -
induced I-Disease +
hepatitis I-Disease -
. O +

Both O +
patients O +
recovered O +
quickly O +
after O +
stopping O +
glyburide O +
therapy O +
and O +
have O +
remained O +
well O +
for O +
a O +
follow O -
- O -
up O +
period O +
of O +
1 O +
year O -
. O +

Glyburide O +
can O +
produce O +
an O +
acute B-Disease +
hepatitis I-Disease -
- I-Disease -
like I-Disease +
illness I-Disease +
in O +
some O +
persons O -
. O +

Mitomycin O +
C O +
associated O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease -
. O +

Mitomycin O +
C O +
associated O +
Hemolytic B-Disease +
Uremic I-Disease +
Syndrome I-Disease +
( O -
HUS B-Disease -
) O +
is O +
a O +
potentially O +
fatal O +
but O +
uncommon O +
condition O +
that O +
is O +
not O +
yet O +
widely O +
recognised O -
. O +

It O +
consists O +
of O +
microangiopathic O +
hemolytic B-Disease +
anemia I-Disease -
, O +
thrombocytopenia B-Disease +
and O +
progressive O +
renal B-Disease +
failure I-Disease +
associated O +
with O +
mitomycin O +
C O +
treatment O +
and O +
affects O +
about O +
10 O -
% O +
of O +
patients O +
treated O +
with O +
this O +
agent O -
. O +

The O +
renal B-Disease +
failure I-Disease +
usually O +
develops O +
about O +
8 O -
- O -
10 O +
mth O +
after O +
start O +
of O +
mitomycin O +
C O +
treatment O +
and O +
the O +
mortality O +
is O +
approximately O +
60 O -
% O +
from O +
renal B-Disease +
failure I-Disease +
or O +
pulmonary B-Disease +
edema I-Disease -
. O +

Renal B-Disease +
lesions I-Disease +
are O +
similar O +
to O +
those O +
seen O +
in O +
idiopathic O +
HUS B-Disease +
and O +
include O +
arteriolar O +
fibrin O +
thrombi B-Disease -
, O +
expanded O +
subendothelial O +
zones O +
in O +
glomerular O +
capillary O +
walls O -
, O +
ischemic B-Disease +
wrinkling O +
of O +
glomerular O +
basement O +
membranes O +
and O +
mesangiolysis O -
. O +

The O +
mechanism O +
of O +
action O +
is O +
postulated O +
as O +
mitomycin O +
C O -
- O -
induced O +
endothelial O +
cell O +
damage O -
. O +

We O +
describe O +
the O +
clinical O +
course O +
and O +
pathological O +
findings O +
in O +
a O +
65 O +
yr O -
- O -
old O +
man O +
with O +
gastric B-Disease +
adenocarcinoma I-Disease +
who O +
developed O +
renal B-Disease +
failure I-Disease +
and O +
thrombocytopenia B-Disease +
while O +
on O +
treatment O +
with O +
mitomycin O +
C O +
and O +
died O +
in O +
pulmonary B-Disease +
edema I-Disease -
. O +

Ketanserin O +
pretreatment O +
reverses O +
alfentanil O -
- O -
induced O +
muscle B-Disease +
rigidity I-Disease -
. O +

Systemic O +
pretreatment O +
with O +
ketanserin O -
, O +
a O +
relatively O +
specific O +
type-2 O +
serotonin O +
receptor O +
antagonist O -
, O +
significantly O +
attenuated O +
the O +
muscle B-Disease +
rigidity I-Disease +
produced O +
in O +
rats O +
by O +
the O +
potent O +
short O -
- O -
acting O +
opiate O +
agonist O +
alfentanil O -
. O +

Following O +
placement O +
of O +
subcutaneous O +
electrodes O +
in O +
each O +
animal O -
's O +
left O +
gastrocnemius O +
muscle O -
, O +
rigidity B-Disease +
was O +
assessed O +
by O +
analyzing O +
root O -
- O -
mean O -
- O -
square O +
electromyographic O +
activity O -
. O +

Intraperitoneal O +
ketanserin O +
administration O +
at O +
doses O +
of O +
0.63 O +
and O +
2.5 O +
mg O -
/ O -
kg O +
prevented O +
the O +
alfentanil O -
- O -
induced O +
increase O +
in O +
electromyographic O +
activity O +
compared O +
with O +
animals O +
pretreated O +
with O +
saline O -
. O +

Chlordiazepoxide O +
at O +
doses O +
up O +
to O +
10 O +
mg O -
/ O -
kg O +
failed O +
to O +
significantly O +
influence O +
the O +
rigidity B-Disease +
produced O +
by O +
alfentanil O -
. O +

Despite O +
the O +
absence O +
of O +
rigidity B-Disease -
, O +
animals O +
that O +
received O +
ketanserin O +
( O -
greater O +
than O +
0.31 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
followed O +
by O +
alfentanil O +
were O +
motionless O -
, O +
flaccid O -
, O +
and O +
less O +
responsive O +
to O +
external O +
stimuli O +
than O +
were O +
animals O +
receiving O +
alfentanil O +
alone O -
. O +

Rats O +
that O +
received O +
ketanserin O +
and O +
alfentanil O +
exhibited O +
less O +
rearing O +
and O +
exploratory O +
behavior O +
at O +
the O +
end O +
of O +
the O +
60-min O +
recording O +
period O +
than O +
did O +
animals O +
that O +
received O +
ketanserin O +
alone O -
. O +

These O +
results O -
, O +
in O +
combination O +
with O +
previous O +
work O -
, O +
suggest O +
that O +
muscle B-Disease +
rigidity I-Disease -
, O +
a O +
clinically O +
relevant O +
side O -
- O -
effect O +
of O +
parenteral O +
narcotic O +
administration O -
, O +
may O +
be O +
partly O +
mediated O +
via O +
serotonergic O +
pathways O -
. O +

Pretreatment O +
with O +
type-2 O +
serotonin O +
antagonists O +
may O +
be O +
clinically O +
useful O +
in O +
attenuating O +
opiate O -
- O -
induced O +
rigidity B-Disease -
, O +
although O +
further O +
studies O +
will O +
be O +
necessary O +
to O +
assess O +
the O +
interaction O +
of O +
possibly O +
enhanced O +
CNS O -
, O +
cardiovascular B-Disease -
, I-Disease +
and I-Disease +
respiratory I-Disease +
depression I-Disease -
. O +

Chorea B-Disease +
associated O +
with O +
oral O +
contraception O -
. O +

Three O +
patients O +
developed O +
chorea B-Disease +
while O +
receiving O +
oral O +
contraceptives O -
. O +

Two O +
were O +
young O +
patients O +
whose O +
chorea B-Disease +
developed O +
long O +
after O +
treatment O +
had O +
been O +
started O +
and O +
disappeared O +
soon O +
after O +
it O +
had O +
been O +
discontinued O -
. O +

The O +
third O +
patient O +
had O +
acute O +
amphetamine O -
- O -
induced O +
chorea B-Disease +
after O +
prolonged O +
oral O +
contraception O -
. O +

Prolonged O +
administration O +
of O +
female O +
sex O +
hormones O +
is O +
a O +
possible O +
cause O +
of O +
chorea B-Disease +
in O +
women O +
who O +
have O +
not O +
previously O +
had O +
chorea B-Disease +
or O +
rheumatic B-Disease +
fever I-Disease -
. O +

Intracranial O +
pressure O +
increases O +
during O +
alfentanil O -
- O -
induced O +
rigidity B-Disease -
. O +

Intracranial O +
pressure O +
( O -
ICP O -
) O +
was O +
measured O +
during O +
alfentanil O -
- O -
induced O +
rigidity B-Disease +
in O +
rats O -
. O +

Ten O +
rats O +
had O +
arterial O -
, O +
central O +
venous O +
( O -
CVP O -
) O -
, O +
and O +
subdural O +
cannulae O +
inserted O +
under O +
halothane O +
anesthesia O -
. O +

The O +
animals O +
were O +
mechanically O +
ventilated O +
to O +
achieve O +
normocarbia O +
( O -
PCO2 O +
= O +
42 O +
+ O -
/- O +

1 O +
mmHg O -
, O +
mean O +
+ O -
/- O +

SE O -
) O -
. O +

Following O +
instrumentation O -
, O +
halothane O +
was O +
discontinued O +
and O +
alfentanil O +
( O -
125 O +
mu O -
/ O -
kg O -
) O +
administered O +
iv O +
during O +
emergence O +
from O +
halothane O +
anesthesia O -
. O +

In O +
the O +
five O +
rats O +
that O +
developed O +
somatic B-Disease +
rigidity I-Disease -
, O +
ICP O +
and O +
CVP O +
increased O +
significantly O +
above O +
baseline O +
( O -
delta O +
ICP O +
7.5 O +
+ O -
/- O +

1.0 O +
mmHg O -
, O +
delta O +
CVP O +
5.9 O +
+ O -
/- O +

1.3 O +
mmHg O -
) O -
. O +

These O +
variables O +
returned O +
to O +
baseline O +
when O +
rigidity B-Disease +
was O +
abolished O +
with O +
metocurine O -
. O +

In O +
five O +
rats O +
that O +
did O +
not O +
become O +
rigid O -
, O +
ICP O +
and O +
CVP O +
did O +
not O +
change O +
following O +
alfentanil O -
. O +

These O +
observations O +
suggest O +
that O +
rigidity B-Disease +
should O +
be O +
prevented O +
when O +
alfentanil O -
, O +
and O -
, O +
presumably O -
, O +
other O +
opiates O -
, O +
are O +
used O +
in O +
the O +
anesthetic O +
management O +
of O +
patients O +
with O +
ICP O +
problems O -
. O +

Co O -
- O -
carcinogenic B-Disease +
effect O +
of O +
retinyl O +
acetate O +
on O +
forestomach B-Disease +
carcinogenesis I-Disease +
of O +
male O +
F344 O +
rats O +
induced O +
with O +
butylated O +
hydroxyanisole O -
. O +

The O +
potential O +
modifying O +
effect O +
of O +
retinyl O +
acetate O +
( O -
RA O -
) O +
on O +
butylated O +
hydroxyanisole O +
( O -
BHA O -
) O -
-induced O +
rat O +
forestomach B-Disease +
tumorigenesis I-Disease +
was O +
examined O -
. O +

Male O +
F344 O +
rats O -
, O +
5 O +
weeks O +
of O +
age O -
, O +
were O +
maintained O +
on O +
diet O +
containing O +
1 O -
% O +
or O +
2 O -
% O +
BHA O +
by O +
weight O +
and O +
simultaneously O +
on O +
drinking O +
water O +
supplemented O +
with O +
RA O +
at O +
various O +
concentrations O +
( O -
w O -
/ O -
v O -
) O +
for O +
52 O +
weeks O -
. O +

In O +
groups O +
given O +
2 O -
% O +
BHA O -
, O +
although O +
marked O +
hyperplastic O +
changes O +
of O +
the O +
forestomach O +
epithelium O +
were O +
observed O +
in O +
all O +
animals O -
, O +
co O -
- O -
administration O +
of O +
0.25 O -
% O +
RA O +
significantly O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
increased O +
the O +
incidence O +
of O +
forestomach B-Disease +
tumors I-Disease +
( O -
squamous B-Disease +
cell I-Disease +
papilloma I-Disease +
and O +
carcinoma B-Disease -
) O +
to O +
60 O -
% O +
( O -
9 O -
/ O -
15 O -
, O +
2 O +
rats O +
with O +
carcinoma B-Disease -
) O +
from O +
15 O -
% O +
( O -
3 O -
/ O -
20 O -
, O +
one O +
rat O +
with O +
carcinoma B-Disease -
) O +
in O +
the O +
group O +
given O +
RA O -
- O -
free O +
water O -
. O +

In O +
rats O +
given O +
1 O -
% O +
BHA O -
, O +
RA O +
co O -
- O -
administered O +
at O +
a O +
dose O +
of O +
0.05 O -
, O +
0.1 O -
, O +
0.2 O +
or O +
0.25 O -
% O +
showed O +
a O +
dose O -
- O -
dependent O +
enhancing O +
effect O +
on O +
the O +
development O +
of O +
the O +
BHA O -
- O -
induced O +
epithelial B-Disease +
hyperplasia I-Disease -
. O +

Tumors B-Disease -
, O +
all O +
papillomas B-Disease -
, O +
were O +
induced O +
in O +
3 O +
rats O +
( O -
17 O -
% O -
) O +
with O +
0.25 O -
% O +
RA O +
and O +
in O +
one O +
rat O +
( O -
10 O -
% O -
) O +
with O +
0.05 O -
% O +
RA O +
co O -
- O -
administration O -
. O +

RA O +
alone O +
did O +
not O +
induce O +
hyperplastic O +
changes O +
in O +
the O +
forestomach O -
. O +

These O +
findings O +
indicate O +
that O +
RA O +
acted O +
as O +
a O +
co O -
- O -
carcinogen O +
in O +
the O +
BHA O +
forestomach B-Disease +
carcinogenesis I-Disease +
of O +
the O +
rat O -
. O +

A O +
prospective O +
study O +
on O +
the O +
dose O +
dependency O +
of O +
cardiotoxicity B-Disease +
induced O +
by O +
mitomycin O +
C. O +
Since O +
1975 O +
mitomycin O +
C O +
( O -
MMC O -
) O +
has O +
been O +
suggested O +
to O +
be O +
cardiotoxic B-Disease -
, O +
especially O +
when O +
combined O +
with O +
or O +
given O +
following O +
doxorubicin O -
. O +

Data O +
on O +
dose O +
dependency O +
or O +
incidence O +
concerning O +
this O +
side O +
effect O +
were O +
not O +
known O -
. O +

We O +
have O +
initiated O +
a O +
prospective O +
study O +
to O +
obtain O +
some O +
more O +
data O +
on O +
these O +
subjects O -
. O +

Forty O -
- O -
four O +
MMC O -
- O -
treated O +
patients O +
were O +
studied O -
, O +
37 O +
of O +
them O +
could O +
be O +
evaluated O -
. O +

All O +
patients O +
were O +
studied O +
by O +
repeated O +
physical O +
examinations O -
, O +
chest O +
X O -
- O -
rays O -
, O +
electro- O +
and O +
echocardiography O +
and O +
radionuclide O +
left O +
ventricular O +
ejection O +
fraction O +
( O -
EF O -
) O +
determinations O -
. O +

The O +
results O +
were O +
evaluated O +
per O +
cumulative O +
dose O +
level O -
. O +

One O +
of O +
the O +
patients O +
developed O +
cardiac B-Disease +
failure I-Disease +
after O +
30 O +
mg O +
m-2 O +
MMC O +
and O +
only O +
150 O +
mg O +
m-2 O +
doxorubicin O -
. O +

The O +
cardiac B-Disease +
failure I-Disease +
was O +
predicted O +
by O +
a O +
drop O +
in O +
EF O +
determined O +
during O +
a O +
cold O +
pressor O +
test O -
. O +

None O +
of O +
the O +
other O +
patients O +
developed O +
clinical O +
cardiotoxicity B-Disease -
, O +
nor O +
did O +
the O +
studied O +
parameters O +
change O -
. O +

The O +
literature O +
on O +
this O +
subject O +
was O +
also O +
reviewed O -
. O +

Based O +
on O +
the O +
combined O +
data O +
from O +
the O +
present O +
study O +
and O +
the O +
literature O -
, O +
we O +
suggest O +
that O +
MMC O -
- O -
related O +
cardiotoxicity B-Disease +
is O +
dose O +
dependent O -
, O +
occurring O +
at O +
cumulative O +
dose O +
levels O +
of O +
30 O +
mg O +
m-2 O +
or O +
more O -
, O +
mainly O +
in O +
patients O +
also O +
( O -
previously O +
or O +
simultaneously O -
) O +
treated O +
with O +
doxorubicin O -
. O +

The O +
incidence O +
is O +
likely O +
to O +
be O +
less O +
than O +
10 O -
% O +
even O +
for O +
this O +
risk O +
group O -
. O +

Verapamil O +
withdrawal O +
as O +
a O +
possible O +
cause O +
of O +
myocardial B-Disease +
infarction I-Disease +
in O +
a O +
hypertensive B-Disease +
woman O +
with O +
a O +
normal O +
coronary O +
angiogram O -
. O +

Verapamil O +
is O +
an O +
effective O +
and O +
relatively O -
- O -
safe O +
antihypertensive O +
drug O -
. O +

Serious O +
adverse O +
effects O +
are O +
uncommon O +
and O +
mainly O +
have O +
been O +
related O +
to O +
the O +
depression B-Disease +
of O +
cardiac O +
contractility O +
and O +
conduction O -
, O +
especially O +
when O +
the O +
drug O +
is O +
combined O +
with O +
beta O -
- O -
blocking O +
agents O -
. O +

We O +
report O +
a O +
case O +
in O +
which O +
myocardial B-Disease +
infarction I-Disease +
coincided O +
with O +
the O +
introduction O +
of O +
captopril O +
and O +
the O +
withdrawal O +
of O +
verapamil O +
in O +
a O +
previously O +
asymptomatic O +
woman O +
with O +
severe O +
hypertension B-Disease -
. O +

Possible O +
mechanisms O +
that O +
involve O +
a O +
verapamil O -
- O -
related O +
increase O +
in O +
platelet O +
and/or O +
vascular O +
alpha O +
2-adrenoreceptor O +
affinity O +
for O +
catecholamines O +
are O +
discussed O -
. O +

Haemolytic B-Disease -
- I-Disease -
uraemic I-Disease +
syndrome I-Disease +
after O +
treatment O +
with O +
metronidazole O -
. O +

This O +
paper O +
describes O +
the O +
clinical O +
features O +
of O +
six O +
children O +
who O +
developed O +
the O +
haemolytic B-Disease -
- I-Disease -
uraemic I-Disease +
syndrome I-Disease +
after O +
treatment O +
with O +
metronidazole O -
. O +

These O +
children O +
were O +
older O +
and O +
were O +
more O +
likely O +
to O +
have O +
undergone O +
recent O +
bowel O +
surgery O +
than O +
are O +
other O +
children O +
with O +
this O +
condition O -
. O +

While O +
the O +
involvement O +
of O +
metronidazole O +
in O +
the O +
aetiology O +
of O +
the O +
haemolytic B-Disease -
- I-Disease -
uraemic I-Disease +
syndrome I-Disease +
is O +
not O +
established O +
firmly O -
, O +
the O +
action O +
of O +
this O +
drug O +
in O +
sensitizing O +
tissues O +
to O +
oxidation O +
injury O +
and O +
the O +
reported O +
evidence O +
of O +
oxidation O +
changes O +
in O +
the O +
haemolytic B-Disease -
- I-Disease -
uraemic I-Disease +
syndrome I-Disease +
suggest O +
a O +
possible O +
link O +
between O +
metronidazole O +
treatment O +
and O +
some O +
cases O +
of O +
the O +
haemolytic B-Disease -
- I-Disease -
uraemic I-Disease +
syndrome I-Disease -
. O +

Adverse O +
cardiac O +
effects O +
during O +
induction O +
chemotherapy O +
treatment O +
with O +
cis O -
- O -
platin O +
and O +
5-fluorouracil O -
. O +

Survival O +
for O +
patients O +
with O +
advanced O +
head B-Disease +
and I-Disease +
neck I-Disease +
carcinoma I-Disease +
and O +
esophageal B-Disease +
carcinoma I-Disease +
is O +
poor O +
with O +
radiotherapy O +
and/or O +
surgery O -
. O +

Obviously O -
, O +
there O +
is O +
a O +
need O +
for O +
effective O +
chemotherapy O -
. O +

In O +
the O +
present O +
study O -
, O +
cis O -
- O -
platin O +
( O -
80 O -
- O -
120 O +
mg O -
/ O -
m2BSA O -
) O +
and O +
5-FU O +
( O -
1000 O +
mg O -
/ O -
m2BSA O +
daily O +
as O +
a O +
continuous O +
infusion O +
during O +
5 O +
days O -
) O +
were O +
given O +
to O +
76 O +
patients O +
before O +
radiotherapy O +
and O +
surgery O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
clarify O +
the O +
incidence O +
and O +
severity O +
of O +
adverse O +
cardiac O +
effects O +
to O +
this O +
treatment O -
. O +

Before O +
treatment O +
all O +
patients O +
had O +
a O +
cardiac O +
evaluation O +
and O +
during O +
treatment O +
serial O +
ECG O +
recordings O +
were O +
performed O -
. O +

In O +
the O +
pre O -
- O -
treatment O +
evaluation O -
, O +
signs O +
of O +
cardiovascular B-Disease +
disease I-Disease +
were O +
found O +
in O +
33 O +
patients O +
( O -
43 O -
% O -
) O -
. O +

During O +
treatment O -
, O +
adverse O +
cardiac O +
effects O +
were O +
observed O +
in O +
14 O +
patients O +
( O -
18 O -
% O -
) O -
. O +

The O +
mean O +
age O +
of O +
these O +
patients O +
was O +
the O +
same O +
as O +
for O +
the O +
entire O +
group O -
, O +
64 O +
years O -
. O +

The O +
incidence O +
of O +
cardiotoxicity B-Disease +
was O +
not O +
higher O +
in O +
patients O +
with O +
signs O +
of O +
cardiovascular B-Disease +
disease I-Disease +
than O +
in O +
those O +
without O +
in O +
the O +
pre O -
- O -
treatment O +
evaluation O -
. O +

The O +
most O +
common O +
signs O +
of O +
cardiotoxicity B-Disease +
were O +
chest B-Disease +
pain I-Disease -
, O +
ST O -
- O -
T O +
wave O +
changes O +
and O +
atrial B-Disease +
fibrillation I-Disease -
. O +

This O +
was O +
followed O +
by O +
ventricular B-Disease +
fibrillation I-Disease +
in O +
one O +
patient O +
and O +
sudden B-Disease +
death I-Disease +
in O +
another O -
. O +

It O +
is O +
concluded O +
that O +
patients O +
on O +
5-FU O +
treatment O +
should O +
be O +
under O +
close O +
supervision O +
and O +
that O +
the O +
treatment O +
should O +
be O +
discontinued O +
if O +
chest B-Disease +
pain I-Disease +
or O +
tachyarrhythmia B-Disease +
is O +
observed O -
. O +

Death B-Disease +
from O +
chemotherapy O +
in O +
gestational B-Disease +
trophoblastic I-Disease +
disease I-Disease -
. O +

Multiple O +
cytotoxic O +
drug O +
administration O +
is O +
the O +
generally O +
accepted O +
treatment O +
of O +
patients O +
with O +
a O +
high O -
- O -
risk O +
stage O +
of O +
choriocarcinoma B-Disease -
. O +

Based O +
on O +
this O +
principle O +
a O +
27-year O +
old O +
woman O -
, O +
classified O +
as O +
being O +
in O +
the O +
high O -
- O -
risk O +
group O +
( O -
Goldstein O +
and O +
Berkowitz O +
score O -
: O +
11 O -
) O -
, O +
was O +
treated O +
with O +
multiple O +
cytotoxic O +
drugs O -
. O +

The O +
multiple O +
drug O +
schema O +
consisted O +
of O -
: O +
Etoposide O +
16.213 O -
, O +
Methotrexate O -
, O +
Cyclophosphamide O -
, O +
Actomycin O -
- O -
D O -
, O +
and O +
Cisplatin O -
. O +

On O +
the O +
first O +
day O +
of O +
the O +
schedule O -
, O +
moderate O +
high O +
doses O +
of O +
Methotrexate O -
, O +
Etoposide O +
and O +
Cyclophosphamide O +
were O +
administered O -
. O +

Within O +
8 O +
hours O +
after O +
initiation O +
of O +
therapy O +
the O +
patient O +
died O +
with O +
a O +
clinical O +
picture O +
resembling O +
massive O +
pulmonary B-Disease +
obstruction I-Disease +
due O +
to O +
choriocarcinomic O +
tissue O +
plugs O -
, O +
probably O +
originating O +
from O +
the O +
uterus O -
. O +

Formation O +
of O +
these O +
plugs O +
was O +
probably O +
due O +
to O +
extensive O +
tumor B-Disease +
necrosis B-Disease +
at O +
the O +
level O +
of O +
the O +
walls O +
of O +
the O +
major O +
uterine O +
veins O -
, O +
which O +
resulted O +
in O +
an O +
open O +
exchange O +
of O +
tumor B-Disease +
plugs O +
to O +
the O +
vascular O +
spaces O -
; O +
decrease O +
in O +
tumor B-Disease +
tissue O +
coherence O +
secondary O +
to O +
chemotherapy O +
may O +
have O +
further O +
contributed O +
to O +
the O +
formation O +
of O +
tumor B-Disease +
emboli O -
. O +

In O +
view O +
of O +
the O +
close O +
time O +
association O +
between O +
the O +
start O +
of O +
chemotherapy O +
and O +
the O +
acute O +
onset O +
of O +
massive O +
embolism B-Disease +
other O +
explanations O -
, O +
such O +
as O +
spontaneous O +
necrosis B-Disease -
, O +
must O +
be O +
considered O +
less O +
likely O -
. O +

Patients O +
with O +
large O +
pelvic B-Disease +
tumor I-Disease +
loads O +
are O -
, O +
according O +
to O +
existing O +
classifications O -
, O +
at O +
high O +
risk O +
to O +
die O +
and O +
to O +
develop O +
drug O +
resistance O -
. O +

Notwithstanding O +
these O +
facts O +
our O +
findings O +
suggest O +
that O +
these O +
patients O +
might O +
benefit O +
from O +
relatively O +
mild O +
initial O +
treatment O -
, O +
especially O +
true O +
for O +
patients O +
not O +
previously O +
exposed O +
to O +
this O +
drug O -
. O +

Close O +
observation O +
of O +
the O +
response O +
status O +
both O +
clinically O +
and O +
with O +
beta O -
- O -
hCG O +
values O +
may O +
indicate O +
whether O +
and O +
when O +
more O +
agressive O +
combination O +
chemotherapy O +
should O +
be O +
started. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Receptor O +
mechanisms O +
of O +
nicotine O -
- O -
induced O +
locomotor B-Disease +
hyperactivity I-Disease +
in O +
chronic O +
nicotine O -
- O -
treated O +
rats O -
. O +

Rats O +
were O +
pretreated O +
with O +
saline O +
or O +
nicotine O +
( O -
1.5 O +
mg O -
/ O -
kg O +
per O +
day O -
) O +
by O +
subcutaneously O +
implanting O +
each O +
animal O +
with O +
an O +
Alzet O +
osmotic O +
mini O -
- O -
pump O +
which O +
continuously O +
released O +
saline O +
or O +
nicotine O +
for O +
1 O -
, O +
5 O +
and O +
14 O +
days O -
. O +

At O +
the O +
end O +
of O +
each O +
pretreatment O +
period O -
, O +
animals O +
were O +
used O +
for O +
( O -
i O -
) O +
determining O +
their O +
locomotor O +
response O +
to O +
acutely O +
injected O +
nicotine O +
( O -
0.2 O +
mg O -
/ O -
kg O -
, O +
s.c O -
. O -
) O +
and O +
( O -
ii O -
) O +
measuring O +
the O +
density O +
of O +
L- O -
[ O -
3H O -
] O -
nicotine O +
and O +
[ O -
3H O -
] O -
spiperone O +
binding O +
sites O +
in O +
the O +
striatum O -
. O +

We O +
observed O +
no O +
changes O +
in O +
nicotine O -
- O -
induced O +
locomotor O +
response O -
, O +
striatal O +
L- O -
[ O -
3H O -
] O -
nicotine O +
and O +
[ O -
3H O -
] O -
spiperone O +
binding O +
in O +
the O +
animals O +
pretreated O +
with O +
nicotine O +
for O +
1 O +
day O -
. O +

In O +
rats O +
which O +
were O +
pretreated O +
with O +
nicotine O +
for O +
5 O +
days O -
, O +
there O +
was O +
a O +
significant O +
increase O +
in O +
the O +
nicotine O -
- O -
stimulated O +
locomotor O +
response O +
which O +
was O +
associated O +
with O +
an O +
increase O +
in O +
the O +
number O +
of O +
L- O -
[ O -
3H O -
] O -
nicotine O +
binding O +
sites O +
and O +
also O +
with O +
an O +
elevated O +
dopamine O +
( O -
DA O -
) O +
level O +
in O +
the O +
striatum O -
. O +

The O +
number O +
of O +
striatal O +
[ O -
3H O -
] O -
spiperone O +
binding O +
sites O +
was O +
not O +
affected O -
. O +

In O +
animals O +
pretreated O +
with O +
nicotine O +
for O +
14 O +
days O -
, O +
the O +
nicotine O -
- O -
induced O +
locomotor O +
response O +
remained O +
to O +
be O +
potentiated O -
. O +

However O -
, O +
this O +
response O +
was O +
correlated O +
with O +
an O +
elevated O +
number O +
of O +
striatal O +
[ O -
3H O -
] O -
spiperone O +
binding O +
sites O -
, O +
whereas O +
the O +
number O +
of O +
striatal O +
L- O -
[ O -
3H O -
] O -
nicotine O +
binding O +
sites O +
and O +
the O +
striatal O +
DA O +
level O +
were O +
normal O -
. O +

These O +
results O +
suggest O +
that O +
chronic O +
nicotine O -
- O -
treated O +
rats O +
develop O +
locomotor B-Disease +
hyperactivity I-Disease +
in O +
response O +
to O +
nicotine O +
initially O +
due O +
to O +
increases O +
of O +
both O +
the O +
density O +
of O +
nicotinic O +
receptors O +
and O +
DA O +
concentration O -
, O +
followed O +
by O +
inducing O +
DA O +
receptor O +
supersensitivity O +
in O +
the O +
striatum O -
. O +

Pulmonary O +
shunt O +
and O +
cardiovascular O +
responses O +
to O +
CPAP O +
during O +
nitroprusside O -
- O -
induced O +
hypotension B-Disease -
. O +

The O +
effects O +
of O +
continuous O +
positive O +
airway O +
pressure O +
( O -
CPAP O -
) O +
on O +
cardiovascular O +
dynamics O +
and O +
pulmonary O +
shunt O +
( O -
QS O -
/ O -
QT O -
) O +
were O +
investigated O +
in O +
12 O +
dogs O +
before O +
and O +
during O +
sodium O +
nitroprusside O +
infusion O +
that O +
decreased O +
mean O +
arterial O +
blood O +
pressure O +
40 O -
- O -
50 O +
per O +
cent O -
. O +

Before O +
nitroprusside O +
infusion O -
, O +
5 O +
cm O +
H2O O +
CPAP O +
significantly O -
, O +
P O +
less O +
than O +
.05 O -
, O +
decreased O +
arterial O +
blood O +
pressure O -
, O +
but O +
did O +
not O +
significantly O +
alter O +
heart O +
rate O -
, O +
cardiac O +
output O -
, O +
systemic O +
vascular O +
resistance O -
, O +
or O +
QS O -
/ O -
QT O -
. O +

Ten O +
cm O +
H2O O +
CPAP O +
before O +
nitroprusside O +
infusion O +
produced O +
a O +
further O +
decrease B-Disease +
in I-Disease +
arterial I-Disease +
blood I-Disease +
pressure I-Disease +
and O +
significantly O +
increased O +
heart O +
rate O +
and O +
decreased B-Disease +
cardiac I-Disease +
output I-Disease +
and O +
QS O -
/ O -
QT O -
. O +

Nitroprusside O +
caused O +
significant O +
decreases B-Disease +
in I-Disease +
arterial I-Disease +
blood I-Disease +
pressure I-Disease +
and O +
systemic O +
vascular O +
resistance O +
and O +
increases O +
in O +
heart O +
rate O -
, O +
but O +
did O +
not O +
change O +
cardiac O +
output O +
or O +
QS O -
/ O -
QT O -
. O +

Five O +
cm O +
H2O O +
CPAP O +
during O +
nitroprusside O +
did O +
not O +
further O +
alter O +
any O +
of O +
the O +
above O -
- O -
mentioned O +
variables O -
. O +

However O -
, O +
10 O +
cm O +
H2O O +
CPAP O +
decreased O +
arterial O +
blood O +
pressure O -
, O +
cardiac O +
output O -
, O +
and O +
QS O -
/ O -
QT O -
. O +

These O +
data O +
indicate O +
that O +
nitroprusside O +
infusion O +
rates O +
that O +
decrease O +
mean O +
arterial O +
blood O +
pressure O +
by O +
40 O -
- O -
50 O +
per O +
cent O +
do O +
not O +
change O +
cardiac O +
output O +
or O +
QS O -
/ O -
QT O -
. O +

During O +
nitroprusside O +
infusion O +
low O +
levels O +
of O +
CPAP O +
do O +
not O +
markedly O +
alter O +
cardiovascular O +
dynamics O -
, O +
but O +
high O +
levels O +
of O +
CPAP O +
( O -
10 O +
cm O +
H2O O -
) O -
, O +
while O +
decreasing O +
QS O -
/ O -
QT O -
, O +
produce O +
marked O +
decreases B-Disease +
in I-Disease +
arterial I-Disease +
blood I-Disease +
pressure I-Disease +
and I-Disease +
cardiac I-Disease +
output I-Disease -
. O +

Amelioration O +
of O +
bendrofluazide O -
- O -
induced O +
hypokalemia B-Disease +
by O +
timolol O -
. O +

The O +
beta O +
adrenergic O +
blocking O +
drug O -
, O +
timolol O -
, O +
tended O +
to O +
correct O +
the O +
hypokalemia B-Disease +
of O +
short O -
- O -
term O +
bendrofluazide O +
treatment O +
in O +
6 O +
healthy O +
male O +
subjects O +
and O +
although O +
the O +
effect O +
was O +
small O +
it O +
was O +
significant O -
. O +

Timolol O +
also O +
reduced O +
the O +
rise O +
in O +
plasma O +
aldosterone O +
and O +
urine O +
potassium O +
excretion O +
following O +
bendrofluazide O +
and O +
increased O +
the O +
urine O +
sodium O -
/ O -
potassium O +
ratio O -
. O +

There O +
was O +
no O +
evidence O +
of O +
a O +
shift O +
of O +
potassium O +
from O +
the O +
intracellular O +
to O +
the O +
extracellular O +
space O -
. O +

St. B-Disease +
Anthony I-Disease -
's I-Disease +
fire I-Disease -
, O +
then O +
and O +
now O -
: O +
a O +
case O +
report O +
and O +
historical O +
review O -
. O +

A O +
rare O +
case O +
of O +
morbid O +
vasospasm B-Disease -
, O +
together O +
with O +
striking O +
angiographic O +
findings O -
, O +
is O +
described O +
secondary O +
to O +
the O +
ingestion O +
of O +
methysergide O +
by O +
a O +
48-year O -
- O -
old O +
woman O -
. O +

A O +
brief O +
review O +
of O +
the O +
literature O +
on O +
similar O +
cases O +
is O +
presented O -
. O +

A O +
discussion O +
of O +
the O +
history O +
of O +
ergot O +
includes O +
its O +
original O +
discovery O -
, O +
the O +
epidemics O +
of O +
gangrene B-Disease +
that O +
it O +
has O +
caused O +
through O +
the O +
ages O +
and O +
its O +
past O +
and O +
present O +
role O +
in O +
the O +
management O +
of O +
migraine B-Disease +
headache I-Disease -
. O +

Despite O +
the O +
advent O +
of O +
calcium O +
channel O +
blockers O +
and O +
beta O -
- O -
adrenergic O +
antagonists O -
, O +
ergot O +
preparations O +
continue O +
to O +
play O +
a O +
major O +
role O +
in O +
migraine B-Disease +
therapy O -
, O +
so O +
that O +
the O +
danger O +
of O +
St. B-Disease +
Anthony I-Disease -
's I-Disease +
fire I-Disease +
persists O -
. O +

Cardiac O +
transplantation O -
: O +
improved O +
quality O +
of O +
survival O +
with O +
a O +
modified O +
immunosuppressive O +
protocol O -
. O +

The O +
effects O +
on O +
renal O +
function O +
on O +
two O +
different O +
immunosuppressive O +
protocols O +
were O +
evaluated O +
retrospectively O +
in O +
two O +
subsequent O +
groups O +
of O +
heart O +
transplant O +
recipients O -
. O +

In O +
group O +
I O -
, O +
cyclosporine O +
was O +
given O +
before O +
the O +
procedure O +
at O +
a O +
loading O +
dose O +
of O +
17.5 O +
mg O -
/ O -
kg O +
and O +
then O +
continued O +
after O +
the O +
procedure O +
to O +
keep O +
a O +
whole O +
blood O +
level O +
about O +
1000 O +
ng O -
/ O -
ml O -
. O +

In O +
group O +
II O -
, O +
cyclosporine O +
was O +
started O +
only O +
after O +
the O +
procedure O +
at O +
a O +
lower O +
dosage O +
and O +
was O +
complemented O +
by O +
azathioprine O -
, O +
which O +
was O +
used O +
for O +
the O +
first O +
postoperative O +
week O -
. O +

Group O +
II O +
showed O +
a O +
better O +
perioperative O +
renal O +
function O +
as O +
determined O +
by O +
serum O +
blood O +
urea O +
nitrogen O +
and O +
serum O +
creatinine O +
levels O -
. O +

Group O +
II O +
also O +
showed O +
a O +
significant O +
decrease O +
of O +
chronic O +
nephrotoxicity B-Disease +
secondary O +
to O +
long O -
- O -
term O +
therapy O +
with O +
cyclosporine O -
. O +

Despite O +
this O +
improvement O +
in O +
late O +
renal O +
function O -
, O +
group O +
II O +
still O +
shows O +
a O +
slow O +
rise O +
in O +
serum O +
creatinine O -
. O +

We O +
think O +
that O +
even O +
these O +
lower O +
dosages O +
of O +
cyclosporine O +
can O +
cause O +
chronic O +
nephrotoxicity B-Disease +
and O +
that O +
further O +
modification O +
of O +
the O +
immunosuppressive O +
regimen O +
is O +
required O +
to O +
completely O +
abolish O +
this O +
toxic O +
side O +
effect O -
. O +

Systolic O +
pressure O +
variation O +
is O +
greater O +
during O +
hemorrhage B-Disease +
than O +
during O +
sodium O +
nitroprusside O -
- O -
induced O +
hypotension B-Disease +
in O +
ventilated O +
dogs O -
. O +

The O +
systolic O +
pressure O +
variation O +
( O -
SPV O -
) O -
, O +
which O +
is O +
the O +
difference O +
between O +
the O +
maximal O +
and O +
minimal O +
values O +
of O +
the O +
systolic O +
blood O +
pressure O +
( O -
SBP O -
) O +
after O +
one O +
positive O -
- O -
pressure O +
breath O -
, O +
was O +
studied O +
in O +
ventilated O +
dogs O +
subjected O +
to O +
hypotension B-Disease -
. O +

Mean O +
arterial O +
pressure O +
was O +
decreased O +
to O +
50 O +
mm O +
Hg O +
for O +
30 O +
minutes O +
either O +
by O +
hemorrhage B-Disease +
( O -
HEM B-Disease -
, O +
n O +
= O +
7 O -
) O +
or O +
by O +
continuous O +
infusion O +
of O +
sodium O +
nitroprusside O +
( O -
SNP O -
, O +
n O +
= O +
7 O -
) O -
. O +

During O +
HEM B-Disease -
- O -
induced O +
hypotension B-Disease +
the O +
cardiac O +
output O +
was O +
significantly O +
lower O +
and O +
systemic O +
vascular O +
resistance O +
higher O +
compared O +
with O +
that O +
in O +
the O +
SNP O +
group O -
. O +

The O +
systemic O -
, O +
central O +
venous O -
, O +
pulmonary O +
capillary O +
wedge O +
pressures O -
, O +
and O +
heart O +
rates O -
, O +
were O +
similar O +
in O +
the O +
two O +
groups O -
. O +

Analysis O +
of O +
the O +
respiratory O +
changes O +
in O +
the O +
arterial O +
pressure O +
waveform O +
enabled O +
differentiation O +
between O +
the O +
two O +
groups O -
. O +

The O +
SPV O +
during O +
hypotension B-Disease +
was O +
15.7 O +
+ O -
/- O +

6.7 O +
mm O +
Hg O +
in O +
the O +
HEM B-Disease +
group O -
, O +
compared O +
with O +
9.1 O +
+ O -
/- O +

2.0 O +
mm O +
Hg O +
in O +
the O +
SNP O +
group O +
( O -
P O +
less O +
than O +
0.02 O -
) O -
. O +

The O +
delta O +
down O -
, O +
which O +
is O +
the O +
measure O +
of O +
decrease O +
of O +
SBP O +
after O +
a O +
mechanical O +
breath O -
, O +
was O +
20.3 O +
+ O -
/- O +

8.4 O +
and O +
10.1 O +
+ O -
/- O +

3.8 O +
mm O +
Hg O +
in O +
the O +
HEM B-Disease +
and O +
SNP O +
groups O -
, O +
respectively O -
, O +
during O +
hypotension B-Disease +
( O -
P O +
less O +
than O +
0.02 O -
) O -
. O +

It O +
is O +
concluded O +
that O +
increases O +
in O +
the O +
SPV O +
and O +
the O +
delta O +
down O +
are O +
characteristic O +
of O +
a O +
hypotensive B-Disease +
state O +
due O +
to O +
a O +
predominant O +
decrease O +
in O +
preload O -
. O +

They O +
are O +
thus O +
more O +
important O +
during O +
absolute O +
hypovolemia B-Disease +
than O +
during O +
deliberate O +
hypotension B-Disease -
. O +

Ventricular B-Disease +
tachyarrhythmias I-Disease +
during O +
cesarean O +
section O +
after O +
ritodrine O +
therapy O -
: O +
interaction O +
with O +
anesthetics O -
. O +

This O +
case O +
illustrates O +
that O +
patients O +
receiving O +
ritodrine O +
for O +
preterm B-Disease +
labor I-Disease +
may O +
risk O +
interactions O +
between O +
the O +
residual O +
betamimetic O +
effects O +
of O +
ritodrine O +
and O +
the O +
effects O +
of O +
anesthetics O +
during O +
cesarean O +
section O -
. O +

Such O +
interactions O +
may O +
result O +
in O +
serious O +
cardiovascular B-Disease +
complications I-Disease +
even O +
after O +
cessation O +
of O +
an O +
infusion O +
of O +
ritodrine O -
. O +

Preoperative O +
assessment O +
should O +
focus O +
on O +
cardiovascular O +
status O +
and O +
serum O +
potassium O +
level O -
. O +

Delaying O +
induction O +
of O +
anesthesia O +
should O +
be O +
considered O +
whenever O +
possible O -
. O +

Careful O +
fluid O +
administration O +
and O +
cautious O +
use O +
of O +
titrated O +
doses O +
of O +
ephedrine O +
are O +
advised O -
. O +

After O +
delivery O +
of O +
the O +
infant O -
, O +
there O +
should O +
be O +
no O +
contraindication O +
to O +
the O +
use O +
of O +
an O +
alpha O -
- O -
adrenergic O +
vasopressor O +
such O +
as O +
phenylephrine O +
to O +
treat O +
hypotensive B-Disease +
patients O +
with O +
tachycardia B-Disease -
. O +

Verapamil O -
- O -
induced O +
carbamazepine O +
neurotoxicity B-Disease -
. O +

A O +
report O +
of O +
two O +
cases O -
. O +

Two O +
patients O +
with O +
signs O +
of O +
carbamazepine O +
neurotoxicity B-Disease +
after O +
combined O +
treatment O +
with O +
verapamil O +
showed O +
complete O +
recovery O +
after O +
discontinuation O +
of O +
the O +
calcium O +
entry O +
blocker O -
. O +

Use O +
of O +
verapamil O +
in O +
combination O +
with O +
carbamazepine O +
should O +
either O +
be O +
avoided O +
or O +
prescribed O +
only O +
with O +
appropriate O +
adjustment O +
of O +
the O +
carbamazepine O +
dose O +
( O -
usually O +
reduction O +
of O +
the O +
carbamazepine O +
dose O +
by O +
one O +
half O -
) O -
. O +

Ethopropazine O +
and O +
benztropine O +
in O +
neuroleptic O -
- O -
induced O +
parkinsonism B-Disease -
. O +

In O +
a O +
12-week O +
controlled O +
study O +
ethopropazine O +
was O +
compared O +
to O +
benztropine O +
in O +
the O +
treatment O +
of O +
parkinsonism B-Disease +
induced O +
by O +
fluphenazine O +
enanthate O +
in O +
60 O +
schizophrenic B-Disease +
outpatients O -
. O +

Ethopropazine O +
and O +
benztropine O +
were O +
found O +
to O +
be O +
equally O +
effective O +
in O +
controlling O +
parkinsonian B-Disease +
symptoms I-Disease +
and O +
were O +
as O +
efficacious O +
as O +
procyclidine O -
, O +
their O +
previous O +
antiparkinsonian O +
drug O -
. O +

However O -
, O +
benztropine O +
treated O +
patients O +
had O +
a O +
significant O +
increase O +
in O +
tardive B-Disease +
dyskinesia I-Disease +
compared O +
to O +
their O +
condition O +
during O +
procyclindine O +
treatment O -
, O +
and O +
significantly O +
more O +
anxiety B-Disease +
and O +
depression B-Disease +
than O +
ethopropazine O +
treated O +
patients O -
. O +

This O +
suggests O +
that O +
benztropine O +
is O +
not O +
the O +
anticholinergic O +
drug O +
of O +
choice O +
in O +
the O +
treatment O +
of O +
neuroleptic O -
- O -
induced O +
parkinsonian B-Disease +
symptoms I-Disease -
, O +
because O +
of O +
its O +
more O +
toxic O +
central O +
and O +
peripheral O +
atropinic O +
effect O -
. O +

Paracetamol O -
- O -
associated O +
coma B-Disease -
, O +
metabolic B-Disease +
acidosis I-Disease -
, O +
renal B-Disease +
and I-Disease +
hepatic I-Disease +
failure I-Disease -
. O +

A O +
case O +
of O +
metabolic B-Disease +
acidosis I-Disease -
, O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
and I-Disease +
hepatic I-Disease +
failure I-Disease +
following O +
paracetamol O +
ingestion O +
is O +
presented O -
. O +

The O +
diagnostic O +
difficulty O +
at O +
presentation O +
is O +
highlighted O -
. O +

Continuous O +
arteriovenous O +
haemofiltration O +
proved O +
a O +
valuable O +
means O +
of O +
maintaining O +
fluid O +
and O +
electrolyte O +
balance O -
. O +

The O +
patient O +
recovered O -
. O +

Sexual B-Disease +
dysfunction I-Disease +
among O +
patients O +
with O +
arthritis B-Disease -
. O +

The O +
relationship O +
of O +
arthritis B-Disease +
and O +
sexual B-Disease +
dysfunction I-Disease +
was O +
investigated O +
among O +
169 O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease -
, O +
osteoarthritis B-Disease +
and O +
spondyloarthropathy B-Disease -
, O +
130 O +
of O +
whom O +
were O +
pair O -
- O -
matched O +
to O +
controls O -
. O +

Assessments O +
of O +
marital O +
happiness O +
and O +
depressed B-Disease +
mood I-Disease +
were O +
also O +
made O +
using O +
the O +
CES O -
- O -
D O +
and O +
the O +
Azrin O +
Marital O +
Happiness O +
Scale O +
( O -
AMHS O -
) O -
. O +

Sexual B-Disease +
dysfunctions I-Disease +
were O +
found O +
to O +
be O +
common O +
among O +
patients O +
and O +
controls O -
, O +
the O +
majority O +
in O +
both O +
groups O +
reporting O +
one O +
or O +
more O +
dysfunctions O -
. O +

Impotence B-Disease +
was O +
more O +
common O +
among O +
male O +
patients O +
than O +
controls O +
and O +
was O +
found O +
to O +
be O +
associated O +
with O +
co O -
- O -
morbidity O +
and O +
the O +
taking O +
of O +
methotrexate O -
. O +

Depressed B-Disease +
mood I-Disease +
was O +
more O +
common O +
among O +
patients O +
and O +
was O +
associated O +
with O +
certain O +
sexual O +
difficulties O -
, O +
but O +
not O +
with O +
impotence B-Disease -
. O +

Marital O +
unhappiness O -
, O +
as O +
indicated O +
by O +
AMHS O +
scores O -
, O +
was O +
not O +
associated O +
with O +
arthritis B-Disease +
but O +
was O +
associated O +
with O +
sexual B-Disease +
dysfunction I-Disease -
, O +
sexual O +
dissatisfaction O +
and O +
being O +
female O -
. O +

Does O +
paracetamol O +
cause O +
urothelial B-Disease +
cancer I-Disease +
or O +
renal B-Disease +
papillary I-Disease +
necrosis I-Disease -
? O +

The O +
risk O +
of O +
developing O +
renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
or O +
cancer B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
pelvis I-Disease -
, B-Disease +
ureter I-Disease +
or B-Disease +
bladder I-Disease +
associated O +
with O +
consumption O +
of O +
either O +
phenacetin O +
or O +
paracetamol O +
was O +
calculated O +
from O +
data O +
acquired O +
by O +
questionnaire O +
from O +
381 O +
cases O +
and O +
808 O +
controls O -
. O +

The O +
risk O +
of O +
renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
was O +
increased O +
nearly O +
20-fold O +
by O +
consumption O +
of O +
phenacetin O -
, O +
which O +
also O +
increased O +
the O +
risk O +
for O +
cancer B-Disease +
of I-Disease +
the I-Disease +
renal I-Disease +
pelvis I-Disease +
and B-Disease +
bladder I-Disease +
but O +
not O +
for O +
ureteric B-Disease +
cancer I-Disease -
. O +

By O +
contrast O -
, O +
we O +
were O +
unable O +
to O +
substantiate O +
an O +
increased O +
risk O +
from O +
paracetamol O +
consumption O +
for O +
renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
or O +
any O +
of O +
these O +
cancers B-Disease +
although O +
there O +
was O +
a O +
suggestion O +
of O +
an O +
association O +
with O +
cancer B-Disease +
of I-Disease +
the I-Disease +
ureter I-Disease -
. O +

Mechanisms O +
of O +
myocardial B-Disease +
ischemia I-Disease +
induced O +
by O +
epinephrine O -
: O +
comparison O +
with O +
exercise O -
- O -
induced O +
ischemia B-Disease -
. O +

The O +
role O +
of O +
epinephrine O +
in O +
eliciting O +
myocardial B-Disease +
ischemia I-Disease +
was O +
examined O +
in O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
. O +

Objective O +
signs O +
of O +
ischemia B-Disease +
and O +
factors O +
increasing O +
myocardial O +
oxygen O +
consumption O +
were O +
compared O +
during O +
epinephrine O +
infusion O +
and O +
supine O +
bicycle O +
exercise O -
. O +

Both O +
epinephrine O +
and O +
exercise O +
produced O +
myocardial B-Disease +
ischemia I-Disease +
as O +
evidenced O +
by O +
ST O +
segment O +
depression B-Disease +
and O +
angina B-Disease -
. O +

However O -
, O +
the O +
mechanisms O +
of O +
myocardial B-Disease +
ischemia I-Disease +
induced O +
by O +
epinephrine O +
were O +
significantly O +
different O +
from O +
those O +
of O +
exercise O -
. O +

Exercise O -
- O -
induced O +
myocardial B-Disease +
ischemia I-Disease +
was O +
marked O +
predominantly O +
by O +
increased O +
heart O +
rate O +
and O +
rate O -
- O -
pressure O +
product O +
with O +
a O +
minor O +
contribution O +
of O +
end O -
- O -
diastolic O +
volume O -
, O +
while O +
epinephrine O -
- O -
induced O +
ischemia B-Disease +
was O +
characterized O +
by O +
a O +
marked O +
increase O +
in O +
contractility O +
and O +
a O +
less O +
pronounced O +
increase O +
in O +
heart O +
rate O +
and O +
rate O -
- O -
pressure O +
product O -
. O +

These O +
findings O +
indicate O +
that O +
ischemia B-Disease +
produced O +
by O +
epinephrine O -
, O +
as O +
may O +
occur O +
during O +
states O +
of O +
emotional O +
distress O -
, O +
has O +
a O +
mechanism O +
distinct O +
from O +
that O +
due O +
to O +
physical O +
exertion O -
. O +

Dapsone O -
- O -
associated O +
Heinz O +
body O +
hemolytic B-Disease +
anemia I-Disease +
in O +
a O +
Cambodian O +
woman O +
with O +
hemoglobin O +
E O +
trait O -
. O +

A O +
Cambodian O +
woman O +
with O +
hemoglobin O +
E O +
trait O +
( O -
AE O -
) O +
and O +
leprosy B-Disease +
developed O +
a O +
Heinz O +
body O +
hemolytic B-Disease +
anemia I-Disease +
while O +
taking O +
a O +
dose O +
of O +
dapsone O +
( O -
50 O +
mg O -
/ O -
day O -
) O +
not O +
usually O +
associated O +
with O +
clinical O +
hemolysis B-Disease -
. O +

Her O +
red O +
blood O +
cells O +
( O -
RBCs O -
) O +
had O +
increased O +
incubated O +
Heinz O +
body O +
formation O -
, O +
decreased O +
reduced O +
glutathione O +
( O -
GSH O -
) O -
, O +
and O +
decreased O +
GSH O +
stability O -
. O +

The O +
pentose O +
phosphate O +
shunt O +
activity O +
of O +
the O +
dapsone O -
- O -
exposed O +
AE O +
RBCs O +
was O +
increased O +
compared O +
to O +
normal O +
RBCs O -
. O +

Although O +
the O +
AE O +
RBCs O +
from O +
an O +
individual O +
not O +
taking O +
dapsone O +
had O +
increased O +
incubated O +
Heinz O +
body O +
formation O -
, O +
the O +
GSH O +
content O +
and O +
GSH O +
stability O +
were O +
normal O -
. O +

The O +
pentose O +
phosphate O +
shunt O +
activity O +
of O +
the O +
non O -
- O -
dapsone O -
- O -
exposed O +
AE O +
RBCs O +
was O +
decreased O +
compared O +
to O +
normal O +
RBCs O -
. O +

Thus O -
, O +
AE O +
RBCs O +
appear O +
to O +
have O +
an O +
increased O +
sensitivity O +
to O +
oxidant O +
stress O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
since O +
dapsone O +
does O +
not O +
cause O +
hemolytic B-Disease +
anemia I-Disease +
at O +
this O +
dose O +
in O +
hematologically O +
normal O +
individuals O -
. O +

Given O +
the O +
influx O +
of O +
Southeast O +
Asians O +
into O +
the O +
United O +
States O -
, O +
oxidant O +
medications O +
should O +
be O +
used O +
with O +
caution O -
, O +
especially O +
if O +
an O +
infection B-Disease +
is O +
present O -
, O +
in O +
individuals O +
of O +
ethnic O +
backgrounds O +
that O +
have O +
an O +
increased O +
prevalence O +
of O +
hemoglobin O +
E. O +

Recent O +
preclinical O +
and O +
clinical O +
studies O +
with O +
the O +
thymidylate O +
synthase O +
inhibitor O +
N10-propargyl-5,8-dideazafolic O +
acid O +
( O -
CB O +
3717 O -
) O -
. O +

CB O +
3717 O -
, O +
N10-propargyl-5,8-dideazafolic O +
acid O -
, O +
is O +
a O +
tight O -
- O -
binding O +
inhibitor O +
of O +
thymidylate O +
synthase O +
( O -
TS O -
) O +
whose O +
cytotoxicity B-Disease +
is O +
mediated O +
solely O +
through O +
the O +
inhibition O +
of O +
this O +
enzyme O -
. O +

Recent O +
preclinical O +
studies O +
have O +
focused O +
on O +
the O +
intracellular O +
formation O +
of O +
CB O +
3717 O +
polyglutamates O -
. O +

Following O +
a O +
12-hour O +
exposure O +
of O +
L1210 O +
cells O +
to O +
50 O +
microM O +
[ O -
3H O -
] O -
CB O +
3717 O -
, O +
30 O -
% O +
of O +
the O +
extractable O +
radioactivity O +
could O +
be O +
accounted O +
for O +
as O +
CB O +
3717 O +
tetra- O +
and O +
pentaglutamate O -
, O +
as O +
determined O +
by O +
high O -
- O -
pressure O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
analyses O -
. O +

As O +
inhibitors O +
of O +
isolated O +
L1210 O +
TS O -
, O +
CB O +
3717 O +
di- O -
, O +
tri- O -
, O +
tetra- O +
and O +
pentaglutamate O +
are O +
26- O -
, O +
87- O -
, O +
119- O +
and O +
114-fold O +
more O +
potent O +
than O +
CB O +
3717 O -
, O +
respectively O -
, O +
and O +
their O +
formation O +
may O -
, O +
therefore O -
, O +
be O +
an O +
important O +
determinant O +
of O +
CB O +
3717 O +
cytotoxicity B-Disease -
. O +

In O +
early O +
clinical O +
studies O +
with O +
CB O +
3717 O -
, O +
activity O +
has O +
been O +
seen O +
in O +
breast B-Disease +
cancer I-Disease -
, O +
ovarian B-Disease +
cancer I-Disease -
, O +
hepatoma B-Disease -
, O +
and O +
mesothelioma B-Disease -
. O +

Toxicities B-Disease +
included O +
hepatotoxicity B-Disease -
, O +
malaise B-Disease -
, O +
and O +
dose O -
- O -
limiting O +
nephrotoxicity B-Disease -
. O +

This O +
latter O +
effect O +
is O +
thought O +
to O +
be O +
due O +
to O +
drug O +
precipitation O +
within O +
the O +
renal O +
tubule O +
as O +
a O +
result O +
of O +
the O +
poor O +
solubility O +
of O +
CB O +
3717 O +
under O +
acidic O +
conditions O -
. O +

In O +
an O +
attempt O +
to O +
overcome O +
this O +
problem O -
, O +
a O +
clinical O +
trial O +
of O +
CB O +
3717 O +
administered O +
with O +
alkaline O +
diuresis O +
is O +
under O +
way O -
. O +

Preliminary O +
results O +
at O +
400 O +
and O +
500 O +
mg O -
/ O -
m2 O +
suggest O +
that O +
a O +
reduction O +
in O +
nephrotoxicity B-Disease +
may O +
have O +
been O +
achieved O +
with O +
only O +
1 O +
instance O +
of O +
renal B-Disease +
toxicity I-Disease +
in O +
10 O +
patients O -
. O +

Hepatotoxicity B-Disease +
and O +
malaise B-Disease +
are O +
again O +
the O +
most O +
frequent O +
side O +
effects O -
. O +

Evidence O +
of O +
antitumor O +
activity O +
has O +
been O +
seen O +
in O +
3 O +
patients O -
. O +

Pharmacokinetic O +
investigations O +
have O +
shown O +
that O +
alkaline O +
diuresis O +
does O +
not O +
alter O +
CB O +
3717 O +
plasma O +
levels O +
or O +
urinary O +
excretion O +
and O +
that O +
satisfactory O +
urinary O +
alkalinization O +
can O +
be O +
readily O +
achieved O -
. O +

Type B-Disease +
B I-Disease +
hepatitis I-Disease +
after O +
needle O -
- O -
stick O +
exposure O -
: O +
prevention O +
with O +
hepatitis B-Disease +
B I-Disease +
immune O +
globulin O -
. O +

Final O +
report O +
of O +
the O +
Veterans O +
Administration O +
Cooperative O +
Study O -
. O +

Hepatitis B-Disease +
B I-Disease +
immune O +
globulin O +
( O -
HBIG O -
) O +
and O +
immune O +
serum O +
globulin O +
( O -
ISG O -
) O +
were O +
examined O +
in O +
a O +
randomized O -
, O +
double O -
- O -
blind O +
trial O +
to O +
assess O +
their O +
relative O +
efficacies O +
in O +
preventing O +
type B-Disease +
B I-Disease +
hepatitis I-Disease +
after O +
needle O -
- O -
stick O +
exposure O +
to O +
hepatitis O +
B O +
surface O +
antigen O +
( O -
HBsAG O -
) O -
-positive O +
donors O -
. O +

Clinical O +
hepatitis B-Disease +
developed O +
in O +
1.4 O -
% O +
of O +
HBIG O +
and O +
in O +
5.9 O -
% O +
of O +
ISG O +
recipients O +
( O -
P O +
= O +
0.016 O -
) O -
, O +
and O +
seroconversion O +
( O -
anti O -
- O -
HBs O -
) O +
occurred O +
in O +
5.6 O -
% O +
and O +
20.7 O -
% O +
of O +
them O +
respectively O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
. O +

Mild O +
and O +
transient O +
side O -
- O -
effects O +
were O +
noted O +
in O +
3.0 O -
% O +
of O +
ISG O +
and O +
in O +
3.2 O -
% O +
of O +
HBIG O +
recipients O -
. O +

Available O +
donor O +
sera O +
were O +
examined O +
for O +
DNA O +
polymerase O +
( O -
DNAP O -
) O +
and O +
e O +
antigen O +
and O +
antibody O +
( O -
HBeAg O -
; O +
anti O -
- O -
HBE O -
) O -
. O +

Both O +
DNAP O +
and O +
HBeAg O +
showed O +
a O +
highly O +
statistically O +
significant O +
correlation O +
with O +
the O +
infectivity O +
of O +
HBsAg O -
- O -
positive O +
donors O -
. O +

Hepatitis B-Disease +
B I-Disease +
immune O +
globulin O +
remained O +
significantly O +
superior O +
to O +
ISG O +
in O +
preventing O +
type B-Disease +
B I-Disease +
hepatitis I-Disease +
even O +
when O +
the O +
analysis O +
was O +
confined O +
to O +
these O +
two O +
high O -
- O -
risk O +
subgroups O -
. O +

The O +
efficacy O +
of O +
ISG O +
in O +
preventing O +
type B-Disease +
B I-Disease +
hepatitis I-Disease +
can O -
not O +
be O +
ascertained O +
because O +
a O +
true O +
placebo O +
group O +
was O +
not O +
included O -
. O +

Severe O +
complications O +
of O +
antianginal O +
drug O +
therapy O +
in O +
a O +
patient O +
identified O +
as O +
a O +
poor O +
metabolizer O +
of O +
metoprolol O -
, O +
propafenone O -
, O +
diltiazem O -
, O +
and O +
sparteine O -
. O +

A O +
47-year O -
- O -
old O +
patient O +
suffering O +
from O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
was O +
admitted O +
to O +
the O +
CCU O +
in O +
shock B-Disease +
with O +
III O -
. O +

AV B-Disease +
block I-Disease -
, O +
severe O +
hypotension B-Disease -
, O +
and O +
impairment B-Disease +
of I-Disease +
ventricular I-Disease +
function I-Disease -
. O +

One O +
week O +
prior O +
to O +
admission O +
a O +
therapy O +
with O +
standard O +
doses O +
of O +
metoprolol O +
( O -
100 O +
mg O +
t.i.d O -
. O +

and O +
then O +
100 O +
mg O +
b.i.d O -
. O -
) O +
had O +
been O +
initiated O -
. O +

Two O +
days O +
before O +
admission O +
diltiazem O +
( O -
60 O +
mg O +
b.i.d O -
. O -
) O +
was O +
prescribed O +
in O +
addition O -
. O +

Analyses O +
of O +
a O +
blood O +
sample O +
revealed O +
unusually O +
high O +
plasma O +
concentrations O +
of O +
metoprolol O +
( O -
greater O +
than O +
3000 O +
ng O -
/ O -
ml O -
) O +
and O +
diltiazem O +
( O -
526 O +
ng O -
/ O -
ml O -
) O -
. O +

The O +
patient O +
recovered O +
within O +
1 O +
week O +
following O +
discontinuation O +
of O +
antianginal O +
therapy O -
. O +

Three O +
months O +
later O +
the O +
patient O +
was O +
exposed O +
to O +
a O +
single O +
dose O +
of O +
metoprolol O -
, O +
diltiazem O -
, O +
propafenone O +
( O -
since O +
he O +
had O +
received O +
this O +
drug O +
in O +
the O +
past O -
) O -
, O +
and O +
sparteine O +
( O -
as O +
a O +
probe O +
for O +
the O +
debrisoquine O -
/ O -
sparteine O +
type O +
polymorphism O +
of O +
oxidative O +
drug O +
metabolism O -
) O -
. O +

It O +
was O +
found O +
that O +
he O +
was O +
a O +
poor O +
metabolizer O +
of O +
all O +
four O +
drugs O -
, O +
indicating O +
that O +
their O +
metabolism O +
is O +
under O +
the O +
same O +
genetic O +
control O -
. O +

Therefore O -
, O +
patients O +
belonging O +
to O +
the O +
poor O -
- O -
metabolizer O +
phenotype O +
of O +
sparteine O -
/ O -
debrisoquine O +
polymorphism O +
in O +
drug O +
metabolism O -
, O +
which O +
constitutes O +
6.4 O -
% O +
of O +
the O +
German O +
population O -
, O +
may O +
experience O +
adverse B-Disease +
drug I-Disease +
reactions I-Disease +
when O +
treated O +
with O +
standard O +
doses O +
of O +
one O +
of O +
these O +
drugs O +
alone O -
. O +

Moreover O -
, O +
the O +
coadministration O +
of O +
these O +
frequently O +
used O +
drugs O +
is O +
expected O +
to O +
be O +
especially O +
harmful O +
in O +
this O +
subgroup O +
of O +
patients O -
. O +

Clinical O +
experiences O +
in O +
an O +
open O +
and O +
a O +
double O -
- O -
blind O +
trial O -
. O +

A O +
total O +
of O +
sixty O +
patients O +
were O +
trated O +
with O +
bromperidol O +
first O +
in O +
open O +
conditions O +
( O -
20 O +
patients O -
) O -
, O +
then O +
on O +
a O +
double O +
blind O +
basis O +
( O -
40 O +
patients O -
) O +
with O +
haloperidol O +
as O +
the O +
reference O +
substance O -
. O +

The O +
open O +
study O +
lasted O +
for O +
four O +
weeks O -
; O +
the O +
drug O +
was O +
administrated O +
in O +
the O +
form O +
of O +
1 O +
mg O +
tablets O -
. O +

The O +
daily O +
dose O +
( O -
initial O +
dose O -
: O +
1 O +
mg O -
; O +
mean O +
dose O +
at O +
the O +
end O +
of O +
the O +
trial O -
: O +
4.47 O +
mg O -
) O +
was O +
always O +
administered O +
in O +
one O +
single O +
dose O -
. O +

Nineteen O +
patients O +
finished O +
the O +
trial O -
, O +
and O +
in O +
18 O +
cases O +
the O +
therapeutic O +
result O +
was O +
considered O +
very O +
good O +
to O +
good O -
. O +

These O +
results O +
were O +
confirmed O +
by O +
statistical O +
analysis O -
. O +

Nine O +
patients O +
exhibited O +
mild O +
to O +
moderate O +
extrapyramidal B-Disease +
concomitant I-Disease +
symptoms I-Disease -
; O +
no O +
other O +
side O +
effects O +
were O +
observed O -
. O +

The O +
results O +
of O +
detailed O +
laboratory O +
tests O +
and O +
evaluations O +
of O +
various O +
quantitative O +
and O +
qualitative O +
tolerability O +
parameters O +
were O +
not O +
indicative O +
of O +
toxic O +
effects O -
. O +

In O +
the O +
double O +
blind O +
study O +
with O +
haloperidol O -
, O +
both O +
substances O +
were O +
found O +
to O +
be O +
highly O +
effective O +
in O +
the O +
treatment O +
of O +
psychotic B-Disease +
syndromes I-Disease +
belonging I-Disease +
predominantly I-Disease +
to I-Disease +
the I-Disease +
schizophrenia I-Disease +
group I-Disease -
. O +

Certain O +
clues O -
, O +
including O +
the O +
onset O +
of O +
action O -
, O +
seem O +
to O +
be O +
indicative O +
of O +
the O +
superiority O +
of O +
bromperidol O -
. O +

No O +
differences O +
were O +
observed O +
with O +
respect O +
to O +
side O +
effects O +
and O +
general O +
tolerability O -
. O +

Prolonged O +
cholestasis B-Disease +
after O +
troleandomycin O -
- O -
induced O +
acute O +
hepatitis B-Disease -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
patient O +
in O +
whom O +
troleandomycin O -
- O -
induced O +
hepatitis B-Disease +
was O +
followed O +
by O +
prolonged O +
anicteric O +
cholestasis B-Disease -
. O +

Jaundice B-Disease +
occurred O +
after O +
administration O +
of O +
troleandomycin O +
for O +
7 O +
days O +
and O +
was O +
associated O +
with O +
hypereosinophilia B-Disease -
. O +

Jaundice B-Disease +
disappeared O +
within O +
3 O +
months O +
but O +
was O +
followed O +
by O +
prolonged O +
anicteric O +
cholestasis B-Disease +
marked O +
by O +
pruritus B-Disease +
and O +
high O +
levels O +
of O +
alkaline O +
phosphatase O +
and O +
gammaglutamyltransferase O +
activities O -
. O +

Finally O -
, O +
pruritus B-Disease +
disappeared O +
within O +
19 O +
months O -
, O +
and O +
liver O +
tests O +
returned O +
to O +
normal O +
27 O +
months O +
after O +
the O +
onset O +
of O +
hepatitis B-Disease -
. O +

This O +
observation O +
demonstrates O +
that O +
prolonged O +
cholestasis B-Disease +
can O +
follow O +
troleandomycin O -
- O -
induced O +
acute O +
hepatitis B-Disease -
. O +

Serial O +
studies O +
of O +
auditory B-Disease +
neurotoxicity I-Disease +
in O +
patients O +
receiving O +
deferoxamine O +
therapy O -
. O +

Visual B-Disease +
and I-Disease +
auditory I-Disease +
neurotoxicity I-Disease +
was O +
previously O +
documented O +
in O +
42 O +
of O +
89 O +
patients O +
with O +
transfusion O -
- O -
dependent O +
anemia B-Disease +
who O +
were O +
receiving O +
iron O +
chelation O +
therapy O +
with O +
daily O +
subcutaneous O +
deferoxamine O -
. O +

Twenty O -
- O -
two O +
patients O +
in O +
the O +
affected O +
group O +
had O +
abnormal B-Disease +
audiograms I-Disease +
with I-Disease +
deficits I-Disease +
mostly I-Disease +
in I-Disease +
the I-Disease +
high I-Disease +
frequency I-Disease +
range I-Disease +
of I-Disease +
4,000 I-Disease +
to I-Disease +
8,000 I-Disease +
Hz I-Disease +
and O +
in O +
the O +
hearing O +
threshold O +
levels O +
of O +
30 O +
to O +
100 O +
decibels O -
. O +

When O +
deferoxamine O +
therapy O +
was O +
discontinued O +
and O +
serial O +
studies O +
were O +
performed O -
, O +
audiograms O +
in O +
seven O +
cases O +
reverted O +
to O +
normal O +
or O +
near O +
normal O +
within O +
two O +
to O +
three O +
weeks O -
, O +
and O +
nine O +
of O +
13 O +
patients O +
with O +
symptoms O +
became O +
asymptomatic O -
. O +

Audiograms O +
from O +
15 O +
patients O +
remained O +
abnormal O +
and O +
four O +
patients O +
required O +
hearing O +
aids O +
because O +
of O +
permanent B-Disease +
disability I-Disease -
. O +

Since O +
18 O +
of O +
the O +
22 O +
patients O +
were O +
initially O +
receiving O +
deferoxamine O +
doses O +
in O +
excess O +
of O +
the O +
commonly O +
recommended O +
50 O +
mg O -
/ O -
kg O +
per O +
dose O -
, O +
therapy O +
was O +
restarted O +
with O +
lower O +
doses O -
, O +
usually O +
50 O +
mg O -
/ O -
kg O +
per O +
dose O +
or O +
less O +
depending O +
on O +
the O +
degree O +
of O +
auditory B-Disease +
abnormality I-Disease -
, O +
and O +
with O +
the O +
exception O +
of O +
two O +
cases O +
no O +
further O +
toxicity B-Disease +
was O +
demonstrated O -
. O +

Auditory O +
deterioration O +
and O +
improvement O -
, O +
demonstrated O +
serially O +
in O +
individual O +
patients O +
receiving O +
and O +
not O +
receiving O +
deferoxamine O -
, O +
respectively O -
, O +
provided O +
convincing O +
evidence O +
for O +
a O +
cause O -
- O -
and O -
- O -
effect O +
relation O +
between O +
deferoxamine O +
administration O +
and O +
ototoxicity B-Disease -
. O +

Based O +
on O +
these O +
data O -
, O +
a O +
plan O +
of O +
management O +
was O +
developed O +
that O +
allows O +
effective O +
yet O +
safe O +
administration O +
of O +
deferoxamine O -
. O +

A O +
dose O +
of O +
50 O +
mg O -
/ O -
kg O +
is O +
recommended O +
in O +
those O +
without O +
audiogram O +
abnormalities O -
. O +

With O +
mild O +
toxicity B-Disease -
, O +
a O +
reduction O +
to O +
30 O +
or O +
40 O +
mg O -
/ O -
kg O +
per O +
dose O +
should O +
result O +
in O +
a O +
reversal O +
of O +
the O +
abnormal O +
results O +
to O +
normal O +
within O +
four O +
weeks O -
. O +

Moderate O +
abnormalities O +
require O +
a O +
reduction O +
of O +
deferoxamine O +
to O +
25 O +
mg O -
/ O -
kg O +
per O +
dose O +
with O +
careful O +
monitoring O -
. O +

In O +
those O +
with O +
symptoms O +
of O +
hearing B-Disease +
loss I-Disease -
, O +
the O +
drug O +
should O +
be O +
stopped O +
for O +
four O +
weeks O -
, O +
and O +
when O +
the O +
audiogram O +
is O +
stable O +
or O +
improved O -
, O +
therapy O +
should O +
be O +
restarted O +
at O +
10 O +
to O +
25 O +
mg O -
/ O -
kg O +
per O +
dose O -
. O +

Serial O +
audiograms O +
should O +
be O +
performed O +
every O +
six O +
months O +
in O +
those O +
without O +
problems O +
and O +
more O +
frequently O +
in O +
young O +
patients O +
with O +
normal O +
serum O +
ferritin O +
values O +
and O +
in O +
those O +
with O +
auditory B-Disease +
dysfunction I-Disease -
. O +

Relative O +
efficacy O +
and O +
toxicity B-Disease +
of O +
netilmicin O +
and O +
tobramycin O +
in O +
oncology O +
patients O -
. O +

We O +
prospectively O +
compared O +
the O +
efficacy O +
and O +
safety O +
of O +
netilmicin O +
sulfate O +
or O +
tobramycin O +
sulfate O +
in O +
conjunction O +
with O +
piperacillin O +
sodium O +
in O +
118 O +
immunocompromised O +
patients O +
with O +
presumed O +
severe O +
infections B-Disease -
. O +

The O +
two O +
treatment O +
regimens O +
were O +
equally O +
efficacious O -
. O +

Nephrotoxicity B-Disease +
occurred O +
in O +
a O +
similar O +
proportion O +
in O +
patients O +
treated O +
with O +
netilmicin O +
and O +
tobramycin O +
( O -
17 O -
% O +
vs O +
11 O -
% O -
) O -
. O +

Ototoxicity B-Disease +
occurred O +
in O +
four O +
( O -
9.5 O -
% O -
) O +
of O +
42 O +
netilmicin O +
and O +
piperacillin O +
and O +
in O +
12 O +
( O -
22 O -
% O -
) O +
of O +
54 O +
tobramycin O +
and O +
piperacillin O -
- O -
treated O +
patients O -
. O +

Of O +
those O +
evaluated O +
with O +
posttherapy O +
audiograms O -
, O +
three O +
of O +
four O +
netilmicin O +
and O +
piperacillin O -
- O -
treated O +
patients O +
had O +
auditory O +
thresholds O +
return O +
to O +
baseline O +
compared O +
with O +
one O +
of O +
nine O +
tobramycin O +
and O +
piperacillin O -
- O -
treated O +
patients O -
. O +

The O +
number O +
of O +
greater O +
than O +
or O +
equal O +
to O +
15-dB O +
increases O +
in O +
auditory O +
threshold O +
as O +
a O +
proportion O +
of O +
total O +
greater O +
than O +
or O +
equal O +
to O +
15-dB O +
changes O +
( O -
increases O +
and O +
decreases O -
) O +
was O +
significantly O +
lower O +
in O +
netilmicin O +
and O +
piperacillin- O +
vs O +
tobramycin O +
and O +
piperacillin O -
- O -
treated O +
patients O +
( O -
18 O +
of O +
78 O +
vs O +
67 O +
of O +
115 O -
) O -
. O +

We O +
conclude O +
that O +
aminoglycoside O -
- O -
associated O +
ototoxicity B-Disease +
was O +
less O +
severe O +
and O +
more O +
often O +
reversible O +
with O +
netilmicin O +
than O +
with O +
tobramycin O -
. O +

Lidocaine O -
- O -
induced O +
cardiac B-Disease +
asystole I-Disease -
. O +

Intravenous O +
administration O +
of O +
a O +
single O +
50-mg O +
bolus O +
of O +
lidocaine O +
in O +
a O +
67-year O -
- O -
old O +
man O +
resulted O +
in O +
profound O +
depression B-Disease +
of O +
the O +
activity O +
of O +
the O +
sinoatrial O +
and O +
atrioventricular O +
nodal O +
pacemakers O -
. O +

The O +
patient O +
had O +
no O +
apparent O +
associated O +
conditions O +
which O +
might O +
have O +
predisposed O +
him O +
to O +
the O +
development O +
of O +
bradyarrhythmias B-Disease -
; O +
and O -
, O +
thus O -
, O +
this O +
probably O +
represented O +
a O +
true O +
idiosyncrasy O +
to O +
lidocaine O -
. O +

Flurbiprofen O +
in O +
the O +
treatment O +
of O +
juvenile B-Disease +
rheumatoid I-Disease +
arthritis I-Disease -
. O +

Thirty O -
- O -
four O +
patients O +
with O +
juvenile B-Disease +
rheumatoid I-Disease +
arthritis I-Disease -
, O +
who O +
were O +
treated O +
with O +
flurbiprofen O +
at O +
a O +
maximum O +
dose O +
of O +
4 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
had O +
statistically O +
significant O +
decreases O +
from O +
baseline O +
in O +
6 O +
arthritis B-Disease +
indices O +
after O +
12 O +
weeks O +
of O +
treatment O -
. O +

Improvements O +
were O +
seen O +
in O +
the O +
number O +
of O +
tender B-Disease +
joints I-Disease -
, O +
the O +
severity O +
of O +
swelling B-Disease +
and O +
tenderness B-Disease -
, O +
the O +
time O +
of O +
walk O +
50 O +
feet O -
, O +
the O +
duration O +
of O +
morning B-Disease +
stiffness I-Disease +
and O +
the O +
circumference O +
of O +
the O +
left O +
knee O -
. O +

The O +
most O +
frequently O +
observed O +
side O +
effect O +
was O +
fecal B-Disease +
occult I-Disease +
blood I-Disease +
( O -
25 O -
% O +
of O +
patients O -
) O -
; O +
however O -
, O +
there O +
was O +
no O +
other O +
evidence O +
of O +
gastrointestinal B-Disease +
( I-Disease -
GI I-Disease -
) I-Disease +
bleeding I-Disease +
in O +
these O +
patients O -
. O +

One O +
patient O +
was O +
prematurely O +
discontinued O +
from O +
the O +
study O +
for O +
severe O +
headache B-Disease +
and O +
abdominal B-Disease +
pain I-Disease -
. O +

Most O +
side O +
effects O +
were O +
mild O +
and O +
related O +
to O +
the O +
GI O +
tract O -
. O +

Hyperkalemia B-Disease +
associated O +
with O +
sulindac O +
therapy O -
. O +

Hyperkalemia B-Disease +
has O +
recently O +
been O +
recognized O +
as O +
a O +
complication O +
of O +
nonsteroidal O +
antiinflammatory O +
agents O +
( O -
NSAID O -
) O +
such O +
as O +
indomethacin O -
. O +

Several O +
recent O +
studies O +
have O +
stressed O +
the O +
renal O +
sparing O +
features O +
of O +
sulindac O -
, O +
owing O +
to O +
its O +
lack O +
of O +
interference O +
with O +
renal O +
prostacyclin O +
synthesis O -
. O +

We O +
describe O +
4 O +
patients O +
in O +
whom O +
hyperkalemia B-Disease +
ranging O +
from O +
6.1 O +
to O +
6.9 O +
mEq O -
/ O -
l O +
developed O +
within O +
3 O +
to O +
8 O +
days O +
of O +
sulindac O +
administration O -
. O +

In O +
all O +
of O +
them O +
normal O +
serum O +
potassium O +
levels O +
reached O +
within O +
2 O +
to O +
4 O +
days O +
of O +
stopping O +
sulindac O -
. O +

As O +
no O +
other O +
medications O +
known O +
to O +
effect O +
serum O +
potassium O +
had O +
been O +
given O +
concomitantly O -
, O +
this O +
course O +
of O +
events O +
is O +
suggestive O +
of O +
a O +
cause O -
- O -
and O -
- O -
effect O +
relationship O +
between O +
sulindac O +
and O +
hyperkalemia B-Disease -
. O +

These O +
observations O +
indicate O +
that O +
initial O +
hopes O +
that O +
sulindac O +
may O +
not O +
be O +
associated O +
with O +
the O +
adverse O +
renal O +
effects O +
of O +
other O +
NSAID O +
are O +
probably O +
not O +
justified O -
. O +

Drug O -
- O -
induced O +
arterial O +
spasm B-Disease +
relieved O +
by O +
lidocaine O -
. O +

Case O +
report O -
. O +

Following O +
major O +
intracranial O +
surgery O +
in O +
a O +
35-year O -
- O -
old O +
man O -
, O +
sodium O +
pentothal O +
was O +
intravenously O +
infused O +
to O +
minimize O +
cerebral B-Disease +
ischaemia I-Disease -
. O +

Intense O +
vasospasm B-Disease +
with O +
threatened O +
gangrene B-Disease +
arose O +
in O +
the O +
arm O +
used O +
for O +
the O +
infusion O -
. O +

Since O +
the O +
cranial O +
condition O +
precluded O +
use O +
of O +
more O +
usual O +
methods O -
, O +
lidocaine O +
was O +
given O +
intra O -
- O -
arterially O -
, O +
with O +
careful O +
cardiovascular O +
monitoring O -
, O +
to O +
counteract O +
the O +
vasospasm B-Disease -
. O +

The O +
treatment O +
was O +
rapidly O +
successful O -
. O +

Regional O +
localization O +
of O +
the O +
antagonism O +
of O +
amphetamine O -
- O -
induced O +
hyperactivity B-Disease +
by O +
intracerebral O +
calcitonin O +
injections O -
. O +

Calcitonin O +
receptors O +
are O +
found O +
in O +
the O +
brain O -
, O +
and O +
intracerebral O +
infusions O +
of O +
calcitonin O +
can O +
produce O +
behavioral O +
effects O -
. O +

Among O +
these O +
behavioral O +
effects O +
are O +
decreases O +
in O +
food O +
intake O +
and O +
decreases O +
in O +
amphetamine O -
- O -
induced O +
locomotor O +
activity O -
. O +

In O +
previous O +
experiments O +
we O +
found O +
that O +
decreases O +
in O +
food O +
intake O +
were O +
induced O +
by O +
local O +
administration O +
of O +
calcitonin O +
into O +
several O +
hypothalamic O +
sites O +
and O +
into O +
the O +
nucleus O +
accumbens O -
. O +

In O +
the O +
present O +
experiment O +
calcitonin O +
decreased O +
locomotor O +
activity O +
when O +
locally O +
injected O +
into O +
the O +
same O +
sites O +
where O +
it O +
decreases O +
food O +
intake O -
. O +

The O +
areas O +
where O +
calcitonin O +
is O +
most O +
effective O +
in O +
decreasing O +
locomotor O +
activity O +
are O +
located O +
in O +
the O +
hypothalamus O +
and O +
nucleus O +
accumbens O -
, O +
suggesting O +
that O +
these O +
areas O +
are O +
the O +
major O +
sites O +
of O +
action O +
of O +
calcitonin O +
in O +
inhibiting O +
amphetamine O -
- O -
induced O +
locomotor O +
activity O -
. O +

The O +
hematologic O +
effects O +
of O +
cefonicid O +
and O +
cefazedone O +
in O +
the O +
dog O -
: O +
a O +
potential O +
model O +
of O +
cephalosporin O +
hematotoxicity B-Disease +
in O +
man O -
. O +

Cephalosporin O +
antibiotics O +
cause O +
a O +
variety O +
of O +
hematologic B-Disease +
disturbances I-Disease +
in O +
man O -
, O +
the O +
pathogeneses O +
and O +
hematopathology O +
of O +
which O +
remain O +
poorly O +
characterized O -
. O +

There O +
is O +
a O +
need O +
for O +
a O +
well O -
- O -
defined O +
animal O +
model O +
in O +
which O +
these O +
blood B-Disease +
dyscrasias I-Disease +
can O +
be O +
studied O -
. O +

In O +
four O +
subacute O +
toxicity B-Disease +
studies O -
, O +
the O +
intravenous O +
administration O +
of O +
cefonicid O +
or O +
cefazedone O +
to O +
beagle O +
dogs O +
caused O +
a O +
dose O -
- O -
dependent O +
incidence O +
of O +
anemia B-Disease -
, O +
neutropenia B-Disease -
, O +
and O +
thrombocytopenia B-Disease +
after O +
1 O -
- O -
3 O +
months O +
of O +
treatment O -
. O +

A O +
nonregenerative O +
anemia B-Disease +
was O +
the O +
most O +
compromising O +
of O +
the O +
cytopenias B-Disease +
and O +
occurred O +
in O +
approximately O +
50 O -
% O +
of O +
dogs O +
receiving O +
400 O -
- O -
500 O +
mg O -
/ O -
kg O +
cefonicid O +
or O +
540 O -
- O -
840 O +
mg O -
/ O -
kg O +
cefazedone O -
. O +

All O +
three O +
cytopenias B-Disease +
were O +
completely O +
reversible O +
following O +
cessation O +
of O +
treatment O -
; O +
the O +
time O +
required O +
for O +
recovery O +
of O +
the O +
erythron O +
( O -
approximately O +
1 O +
month O -
) O +
was O +
considerably O +
longer O +
than O +
that O +
of O +
the O +
granulocytes O +
and O +
platelets O +
( O -
hours O +
to O +
a O +
few O +
days O -
) O -
. O +

Upon O +
rechallenge O +
with O +
either O +
cephalosporin O -
, O +
the O +
hematologic B-Disease +
syndrome I-Disease +
was O +
reproduced O +
in O +
most O +
dogs O +
tested O -
; O +
cefonicid O +
( O -
but O +
not O +
cefazedone O -
) O -
-treated O +
dogs O +
showed O +
a O +
substantially O +
reduced O +
induction O +
period O +
( O -
15 O +
+ O -
/- O +

5 O +
days O -
) O +
compared O +
to O +
that O +
of O +
the O +
first O +
exposure O +
to O +
the O +
drug O +
( O -
61 O +
+ O -
/- O +

24 O +
days O -
) O -
. O +

This O +
observation O -
, O +
along O +
with O +
the O +
rapid O +
rate O +
of O +
decline O +
in O +
red O +
cell O +
mass O +
parameters O +
of O +
affected O +
dogs O -
, O +
suggests O +
that O +
a O +
hemolytic B-Disease +
component O +
complicated O +
the O +
red O +
cell O +
production O +
problem O +
and O +
that O +
multiple O +
toxicologic O +
mechanisms O +
contributed O +
to O +
the O +
cytopenia B-Disease -
. O +

We O +
conclude O +
that O +
the O +
administration O +
of O +
high O +
doses O +
of O +
cefonicid O +
or O +
cefazedone O +
to O +
dogs O +
can O +
induce O +
hematotoxicity B-Disease +
similar O +
to O +
the O +
cephalosporin O -
- O -
induced O +
blood B-Disease +
dyscrasias I-Disease +
described O +
in O +
man O +
and O +
thus O +
provides O +
a O +
useful O +
model O +
for O +
studying O +
the O +
mechanisms O +
of O +
these O +
disorders O -
. O +

Urinary O +
enzymes O +
and O +
protein O +
patterns O +
as O +
indicators O +
of O +
injury B-Disease +
to I-Disease +
different I-Disease +
regions I-Disease +
of I-Disease +
the I-Disease +
kidney I-Disease -
. O +

Acute B-Disease +
experimental I-Disease +
models I-Disease +
of I-Disease +
renal I-Disease +
damage I-Disease +
to O +
the O +
proximal O +
tubular O -
, O +
glomerular O -
, O +
and O +
papillary O +
regions O +
of O +
the O +
rat O +
were O +
produced O +
by O +
administration O +
of O +
hexachloro-1:3-butadiene O +
( O -
HCBD O -
) O -
, O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O -
, O +
and O +
2-bromoethylamine O +
( O -
BEA O -
) O -
, O +
respectively O -
. O +

Several O +
routine O +
indicators O +
of O +
nephrotoxicity B-Disease -
, O +
the O +
enzymes O +
alkaline O +
phosphatase O +
and O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
glucosaminidase O -
, O +
and O +
the O +
molecular O +
weight O +
of O +
protein B-Disease +
excretion I-Disease +
were O +
determined O +
on O +
urine O +
samples O -
. O +

Tubular O +
damage O +
produced O +
by O +
HCBD O +
or O +
BEA O +
was O +
discriminated O +
both O +
quantitatively O +
and O +
qualitatively O +
from O +
glomerular B-Disease +
damage I-Disease +
produced O +
by O +
PAN O -
. O +

The O +
latter O +
was O +
characterized O +
by O +
a O +
pronounced O +
increase O +
in O +
protein B-Disease +
excretion I-Disease -
, O +
especially O +
proteins O +
with O +
molecular O +
weight O +
greater O +
than O +
40,000 O +
Da O -
. O +

In O +
contrast O -
, O +
protein B-Disease +
excretion I-Disease +
in O +
tubular O +
damage O +
was O +
raised O +
only O +
slightly O +
and O +
characterized O +
by O +
excretion B-Disease +
of I-Disease +
proteins I-Disease +
of O +
a O +
wide O +
range O +
of O +
molecular O +
weights O -
. O +

Proximal O +
tubular O +
damage O +
caused O +
by O +
HCBD O +
and O +
papillary O +
damage O +
caused O +
by O +
BEA O +
were O +
distinguished O +
both O +
by O +
conventional O +
urinalysis O +
( O -
volume O +
and O +
specific O +
gravity O -
) O +
and O +
by O +
measurement O +
of O +
the O +
two O +
urinary O +
enzymes O -
. O +

Alkaline O +
phosphatase O +
and O +
glucose O +
were O +
markedly O +
and O +
transiently O +
elevated O +
in O +
proximal O +
tubular O +
damage O +
and O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
glucosaminidase O +
showed O +
a O +
sustained O +
elevation O +
in O +
papillary O +
damage O -
. O +

It O +
is O +
concluded O +
that O +
both O +
selective O +
urinary O +
enzymes O +
and O +
the O +
molecular O +
weight O +
pattern O +
of O +
urinary O +
proteins O +
can O +
be O +
used O +
to O +
provide O +
diagnostic O +
information O +
about O +
the O +
possible O +
site O +
of O +
renal B-Disease +
damage I-Disease -
. O +

A O +
catch O +
in O +
the O +
Reye B-Disease -
. O +

Twenty O -
- O -
six O +
cases O +
of O +
Reye B-Disease +
syndrome I-Disease +
from O +
The O +
Children O -
's O +
Hospital O -
, O +
Camperdown O -
, O +
Australia O -
, O +
occurring O +
between O +
1973 O +
and O +
1982 O +
were O +
reviewed O -
. O +

Of O +
these O -
, O +
20 O +
cases O +
met O +
the O +
US O +
Public O +
Health O +
Service O +
Centers O +
for O +
Disease O +
Control O +
criteria O +
for O +
the O +
diagnosis O +
of O +
Reye B-Disease +
syndrome I-Disease -
. O +

Aspirin O +
or O +
salicylate O +
ingestion O +
had O +
occurred O +
in O +
only O +
one O +
of O +
the O +
20 O +
cases O +
( O -
5 O -
% O -
) O -
, O +
and O +
paracetamol O +
( O -
acetaminophen O -
) O +
had O +
been O +
administered O +
in O +
only O +
six O +
of O +
the O +
cases O +
( O -
30 O -
% O -
) O -
. O +

Pathologic O +
confirmation O +
of O +
the O +
diagnosis O +
of O +
Reye B-Disease +
syndrome I-Disease +
was O +
accomplished O +
in O +
90 O -
% O +
of O +
the O +
cases O -
. O +

The O +
incidence O +
of O +
Reye B-Disease +
syndrome I-Disease +
in O +
New O +
South O +
Wales O -
, O +
Australia O -
, O +
is O +
estimated O +
from O +
this O +
study O +
to O +
be O +
approximately O +
nine O +
cases O +
per O +
1 O +
million O +
children O +
compared O +
with O +
recent O +
US O +
data O +
of O +
ten O +
to O +
20 O +
cases O +
per O +
1 O +
million O +
children O +
and O +
three O +
to O +
seven O +
cases O +
per O +
1 O +
million O +
children O +
in O +
Great O +
Britain O -
. O +

The O +
mortality O +
for O +
these O +
Reye B-Disease +
syndrome I-Disease +
cases O +
in O +
Australia O +
was O +
45 O -
% O +
as O +
compared O +
with O +
a O +
32 O -
% O +
case O -
- O -
fatality O +
rate O +
in O +
the O +
United O +
States O -
. O +

In O +
Australia O -
, O +
the O +
pediatric O +
usage O +
of O +
aspirin O +
has O +
been O +
extremely O +
low O +
for O +
the O +
past O +
25 O +
years O +
( O -
less O +
than O +
1 O -
% O +
of O +
total O +
dosage O +
units O +
sold O -
) O -
, O +
with O +
paracetamol O +
( O -
acetaminophen O -
) O +
dominating O +
the O +
pediatric O +
analgesic O +
and O +
antipyretic O +
market O -
. O +

Reye B-Disease +
syndrome I-Disease +
may O +
be O +
disappearing O +
from O +
Australia O +
despite O +
a O +
total O +
lack O +
of O +
association O +
with O +
salicylates O +
or O +
aspirin O +
ingestion O -
, O +
since O +
there O +
were O +
no O +
cases O +
found O +
at O +
The O +
Children O -
's O +
Hospital O +
in O +
1983 O -
, O +
1984 O -
, O +
or O +
1985 O -
. O +

Cerebral O +
blood O +
flow O +
and O +
metabolism O +
during O +
isoflurane O -
- O -
induced O +
hypotension B-Disease +
in O +
patients O +
subjected O +
to O +
surgery O +
for O +
cerebral B-Disease +
aneurysms I-Disease -
. O +

Cerebral O +
blood O +
flow O +
and O +
cerebral O +
metabolic O +
rate O +
for O +
oxygen O +
were O +
measured O +
during O +
isoflurane O -
- O -
induced O +
hypotension B-Disease +
in O +
10 O +
patients O +
subjected O +
to O +
craniotomy O +
for O +
clipping O +
of O +
a O +
cerebral B-Disease +
aneurysm I-Disease -
. O +

Flow O +
and O +
metabolism O +
were O +
measured O +
5 O -
- O -
13 O +
days O +
after O +
the O +
subarachnoid B-Disease +
haemorrhage I-Disease +
by O +
a O +
modification O +
of O +
the O +
classical O +
Kety O -
- O -
Schmidt O +
technique O +
using O +
xenon-133 O +
i.v O -
. O +

Anaesthesia O +
was O +
maintained O +
with O +
an O +
inspired O +
isoflurane O +
concentration O +
of O +
0.75 O -
% O +
( O -
plus O +
67 O -
% O +
nitrous O +
oxide O +
in O +
oxygen O -
) O -
, O +
during O +
which O +
CBF O +
and O +
CMRO2 O +
were O +
34.3 O +
+ O -
/- O +

2.1 O +
ml O -
/ O -
100 O +
g O +
min-1 O +
and O +
2.32 O +
+ O -
/- O +

0.16 O +
ml O -
/ O -
100 O +
g O +
min-1 O +
at O +
PaCO2 O +
4.1 O +
+ O -
/- O +

0.1 O +
kPa O +
( O -
mean O +
+ O -
/- O +
SEM O -
) O -
. O +

Controlled O +
hypotension B-Disease +
to O +
an O +
average O +
MAP O +
of O +
50 O -
- O -
55 O +
mm O +
Hg O +
was O +
induced O +
by O +
increasing O +
the O +
dose O +
of O +
isoflurane O -
, O +
and O +
maintained O +
at O +
an O +
inspired O +
concentration O +
of O +
2.2 O +
+ O -
/- O +

0.2 O -
% O -
. O +

This O +
resulted O +
in O +
a O +
significant O +
decrease O +
in O +
CMRO2 O +
( O -
to O +
1.73 O +
+ O -
/- O +

0.16 O +
ml O -
/ O -
100 O +
g O +
min-1 O -
) O -
, O +
while O +
CBF O +
was O +
unchanged O -
. O +

After O +
the O +
clipping O +
of O +
the O +
aneurysm B-Disease +
the O +
isoflurane O +
concentration O +
was O +
reduced O +
to O +
0.75 O -
% O -
. O +

There O +
was O +
a O +
significant O +
increase O +
in O +
CBF O -
, O +
although O +
CMRO2 O +
was O +
unchanged O -
, O +
compared O +
with O +
pre O -
- O -
hypotensive B-Disease +
values O -
. O +

These O +
changes O +
might O +
offer O +
protection O +
to O +
brain O +
tissue O +
during O +
periods O +
of O +
induced O +
hypotension B-Disease -
. O +

Postpartum O +
psychosis B-Disease +
induced O +
by O +
bromocriptine O -
. O +

Two O +
multigravida O +
patients O +
with O +
no O +
prior O +
psychiatric B-Disease +
history O +
were O +
seen O +
with O +
postpartum O +
psychosis B-Disease -
, O +
having O +
received O +
bromocriptine O +
for O +
inhibition B-Disease +
of I-Disease +
lactation I-Disease -
. O +

Bromocriptine O +
given O +
in O +
high O +
doses O +
has O +
been O +
associated O +
with O +
psychosis B-Disease +
in O +
patients O +
receiving O +
the O +
drug O +
for O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

These O +
cases O +
demonstrate O +
that O +
bromocriptine O +
may O +
cause O +
psychosis B-Disease +
even O +
when O +
given O +
in O +
low O +
doses O -
. O +

Triazolam O -
- O -
induced O +
brief O +
episodes O +
of O +
secondary O +
mania B-Disease +
in O +
a O +
depressed B-Disease +
patient O -
. O +

Large O +
doses O +
of O +
triazolam O +
repeatedly O +
induced O +
brief O +
episodes O +
of O +
mania B-Disease +
in O +
a O +
depressed B-Disease +
elderly O +
woman O -
. O +

Features O +
of O +
organic B-Disease +
mental I-Disease +
disorder I-Disease +
( O -
delirium B-Disease -
) O +
were O +
not O +
present O -
. O +

Manic B-Disease +
excitement O +
was O +
coincident O +
with O +
the O +
duration O +
of O +
action O +
of O +
triazolam O -
. O +

The O +
possible O +
contribution O +
of O +
the O +
triazolo O +
group O +
to O +
changes O +
in O +
affective O +
status O +
is O +
discussed O -
. O +

Hyperglycemic B-Disease +
acidotic B-Disease +
coma B-Disease +
and O +
death O +
in O +
Kearns B-Disease -
- I-Disease -
Sayre I-Disease +
syndrome I-Disease -
. O +

This O +
paper O +
presents O +
the O +
clinical O +
and O +
metabolic O +
findings O +
in O +
two O +
young O +
boys O +
with O +
long O -
- O -
standing O +
Kearns B-Disease -
- I-Disease -
Sayre I-Disease +
syndrome I-Disease -
. O +

Following O +
short O +
exposure O +
to O +
oral O +
prednisone O -
, O +
both O +
boys O +
developed O +
lethargy B-Disease -
, O +
increasing O +
somnolence B-Disease -
, O +
polydipsia B-Disease -
, O +
polyphagia B-Disease -
, O +
and O +
polyuria B-Disease -
. O +

Both O +
presented O +
in O +
the O +
emergency O +
room O +
with O +
profound O +
coma B-Disease -
, O +
hypotension B-Disease -
, O +
severe O +
hyperglycemia B-Disease -
, O +
and O +
acidosis B-Disease -
. O +

Nonketotic O +
lactic B-Disease +
acidosis I-Disease +
was O +
present O +
in O +
one O +
and O +
ketosis B-Disease +
without O +
a O +
known O +
serum O +
lactate O +
level O +
was O +
present O +
in O +
the O +
other O -
. O +

Respiratory B-Disease +
failure I-Disease +
rapidly O +
ensued O +
and O +
both O +
patients O +
expired O +
in O +
spite O +
of O +
efforts O +
at O +
resuscitation O -
. O +

We O +
believe O +
these O +
two O +
cases O +
represent O +
a O +
newly O +
described O +
and O +
catastrophic O +
metabolic B-Disease -
- I-Disease -
endocrine I-Disease +
failure I-Disease +
in O +
the O +
Kearns B-Disease -
- I-Disease -
Sayre I-Disease +
syndrome I-Disease -
. O +

Experimental O +
cyclosporine O +
nephrotoxicity B-Disease -
: O +
risk O +
of O +
concomitant O +
chemotherapy O -
. O +

The O +
role O +
of O +
cyclosporine O +
( O -
CSA O -
) O +
alone O +
or O +
in O +
combination O +
with O +
various O +
chemotherapeutics O +
in O +
the O +
development O +
of O +
renal B-Disease +
toxicity I-Disease +
was O +
evaluated O +
in O +
rats O -
. O +

Administration O +
of O +
20 O +
mg O -
/ O -
kg O -
/ O -
day O +
CSA O +
for O +
4 O +
weeks O +
caused O +
renal O +
functional O +
and O +
structural O +
changes O +
similar O +
to O +
those O +
reported O +
in O +
man O -
. O +

The O +
combined O +
administration O +
of O +
CSA O +
and O +
various O +
chemotherapeutic O +
drugs O +
with O +
a O +
nephrotoxic B-Disease +
potential O -
, O +
such O +
as O +
gentamicin O +
( O -
at O +
therapeutic O +
doses O -
) O -
, O +
amphothericin O +
B O +
and O +
ketoconazole O -
, O +
which O +
are O +
frequently O +
used O +
in O +
immunosuppressed O +
patients O -
, O +
did O +
not O +
aggravate O +
the O +
CSA O +
induced O +
toxicity B-Disease +
in O +
the O +
rat O +
model O -
. O +

Gentamicin O +
at O +
toxic O +
doses O -
, O +
however O -
, O +
increased O +
CSA O +
nephrotoxicity B-Disease -
. O +

Thus O -
, O +
the O +
nephrotoxicity B-Disease +
induced O +
by O +
CSA O +
has O +
a O +
different O +
pathogenetic O +
mechanism O -
. O +

The O +
correlation O +
between O +
neurotoxic B-Disease +
esterase O +
inhibition O +
and O +
mipafox O -
- O -
induced O +
neuropathic B-Disease +
damage I-Disease +
in O +
rats O -
. O +

The O +
correlation O +
between O +
neuropathic B-Disease +
damage I-Disease +
and O +
inhibition O +
of O +
neurotoxic B-Disease +
esterase O +
or O +
neuropathy B-Disease +
target O +
enzyme O +
( O -
NTE O -
) O +
was O +
examined O +
in O +
rats O +
acutely O +
exposed O +
to O +
Mipafox O +
( O -
N O -
, O +
N'-diisopropylphosphorodiamidofluoridate O -
) O -
, O +
a O +
neurotoxic B-Disease +
organophosphate O -
. O +

Brain O +
and O +
spinal O +
cord O +
NTE O +
activities O +
were O +
measured O +
in O +
Long O -
- O -
Evans O +
male O +
rats O +
1 O +
hr O +
post O -
- O -
exposure O +
to O +
various O +
dosages O +
of O +
Mipafox O +
( O -
ip O -
, O +
1 O -
- O -
15 O +
mg O -
/ O -
kg O -
) O -
. O +

These O +
data O +
were O +
correlated O +
with O +
histologically O +
scored O +
cervical O +
cord B-Disease +
damage I-Disease +
in O +
a O +
separate O +
group O +
of O +
similarly O +
dosed O +
rats O +
sampled O +
14 O -
- O -
21 O +
days O +
post O -
- O -
exposure O -
. O +

Those O +
dosages O +
( O -
greater O +
than O +
or O +
equal O +
to O +
10 O +
mg O -
/ O -
kg O -
) O +
that O +
inhibited O +
mean O +
NTE O +
activity O +
in O +
the O +
spinal O +
cord O +
greater O +
than O +
or O +
equal O +
to O +
73 O -
% O +
and O +
brain O +
greater O +
than O +
or O +
equal O +
to O +
67 O -
% O +
of O +
control O +
values O +
produced O +
severe O +
( O -
greater O +
than O +
or O +
equal O +
to O +
3 O -
) O +
cervical O +
cord O +
pathology O +
in O +
85 O -
% O +
of O +
the O +
rats O -
. O +

In O +
contrast O -
, O +
dosages O +
of O +
Mipafox O +
( O -
less O +
than O +
or O +
equal O +
to O +
5 O +
mg O -
/ O -
kg O -
) O +
which O +
inhibited O +
mean O +
NTE O +
activity O +
in O +
spinal O +
cord O +
less O +
than O +
or O +
equal O +
to O +
61 O -
% O +
and O +
brain O +
less O +
than O +
or O +
equal O +
to O +
60 O -
% O +
produced O +
this O +
degree O +
of O +
cord B-Disease +
damage I-Disease +
in O +
only O +
9 O -
% O +
of O +
the O +
animals O -
. O +

These O +
data O +
indicate O +
that O +
a O +
critical O +
percentage O +
of O +
NTE O +
inhibition O +
in O +
brain O +
and O +
spinal O +
cord O +
sampled O +
shortly O +
after O +
Mipafox O +
exposure O +
can O +
predict O +
neuropathic B-Disease +
damage I-Disease +
in O +
rats O +
several O +
weeks O +
later O -
. O +

Allergic B-Disease +
reaction I-Disease +
to O +
5-fluorouracil O +
infusion O -
. O +

An O +
allergic B-Disease +
reaction I-Disease +
consisting O +
of O +
angioneurotic B-Disease +
edema I-Disease +
secondary O +
to O +
continuous O +
infusion O +
5-fluorouracil O +
occurred O +
in O +
a O +
patient O +
with O +
recurrent O +
carcinoma B-Disease +
of I-Disease +
the I-Disease +
oral I-Disease +
cavity I-Disease -
, O +
cirrhosis B-Disease -
, O +
and O +
cisplatin O -
- O -
induced O +
impaired B-Disease +
renal I-Disease +
function I-Disease -
. O +

This O +
reaction O +
occurred O +
during O +
the O +
sixth O +
and O +
seventh O +
courses O +
of O +
infusional O +
chemotherapy O -
. O +

Oral O +
diphenhydramine O +
and O +
prednisone O +
were O +
ineffective O +
in O +
preventing O +
the O +
recurrence O +
of O +
the O +
allergic B-Disease +
reaction I-Disease -
. O +

Discontinuance O +
of O +
effective O +
chemotherapy O +
in O +
this O +
patient O +
during O +
partial O +
remission O +
resulted O +
in O +
fatal O +
disease O +
progression O -
. O +

Diuretics O -
, O +
potassium O +
and O +
arrhythmias B-Disease +
in O +
hypertensive B-Disease +
coronary B-Disease +
disease I-Disease -
. O +

It O +
has O +
been O +
proposed O +
that O +
modest O +
changes O +
in O +
plasma O +
potassium O +
can O +
alter O +
the O +
tendency O +
towards O +
cardiac B-Disease +
arrhythmias I-Disease -
. O +

If O +
this O +
were O +
so O -
, O +
patients O +
with O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
might O +
be O +
especially O +
susceptible O -
. O +

Thus O -
, O +
myocardial O +
electrical O +
excitability O +
was O +
measured O +
in O +
patients O +
with O +
mild O +
essential O +
hypertension B-Disease +
and O +
known O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
after O +
8 O +
weeks O +
of O +
treatment O +
with O +
a O +
potassium O -
- O -
conserving O +
diuretic O +
( O -
amiloride O -
) O +
and O +
a O +
similar O +
period O +
on O +
a O +
potassium O -
- O -
losing O +
diuretic O +
( O -
chlorthalidone O -
) O +
in O +
a O +
randomised O +
study O -
. O +

Plasma O +
potassium O +
concentrations O +
were O +
on O +
average O +
1 O +
mmol O -
/ O -
L O +
lower O +
during O +
the O +
chlorthalidone O +
phase O +
compared O +
to O +
amiloride O +
therapy O -
. O +

Blood O +
pressure O +
and O +
volume O +
states O +
as O +
assessed O +
by O +
bodyweight O -
, O +
plasma O +
renin O +
and O +
noradrenaline O +
( O -
norepinephrine O -
) O +
concentrations O +
were O +
similar O +
on O +
the O +
2 O +
regimens O -
. O +

Compared O +
to O +
amiloride O +
treatment O -
, O +
the O +
chlorthalidone O +
phase O +
was O +
associated O +
with O +
an O +
increased O +
frequency O +
of O +
ventricular B-Disease +
ectopic I-Disease +
beats I-Disease +
( O -
24-hour O +
Holter O +
monitoring O -
) O +
and O +
a O +
higher O +
Lown O +
grading O -
, O +
increased O +
upslope O +
and O +
duration O +
of O +
the O +
monophasic O +
action O +
potential O -
, O +
prolonged O +
ventricular O +
effective O +
refractory O +
period O -
, O +
and O +
increased O +
electrical O +
instability O +
during O +
programmed O +
ventricular O +
stimulation O -
. O +

The O +
above O +
results O +
indicate O +
that O +
because O +
potassium O -
- O -
losing O +
diuretic O +
therapy O +
can O +
increase O +
myocardial O +
electrical O +
excitability O +
in O +
patients O +
with O +
ischaemic B-Disease +
heart I-Disease +
disease I-Disease -
, O +
even O +
minor O +
falls O +
in O +
plasma O +
potassium O +
concentrations O +
are O +
probably O +
best O +
avoided O +
in O +
such O +
patients O -
. O +

Myasthenia B-Disease +
gravis I-Disease +
caused O +
by O +
penicillamine O +
and O +
chloroquine O +
therapy O +
for O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

We O +
have O +
described O +
a O +
unique O +
patient O +
who O +
had O +
reversible O +
and O +
dose O -
- O -
related O +
myasthenia B-Disease +
gravis I-Disease +
after O +
penicillamine O +
and O +
chloroquine O +
therapy O +
for O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

Although O +
acetylcholine O +
receptor O +
antibodies O +
were O +
not O +
detectable O -
, O +
the O +
time O +
course O +
was O +
consistent O +
with O +
an O +
autoimmune O +
process O -
. O +

Transketolase O +
abnormality O +
in O +
tolazamide O -
- O -
induced O +
Wernicke B-Disease -
's I-Disease +
encephalopathy I-Disease -
. O +

We O +
studied O +
a O +
thiamine O -
- O -
dependent O +
enzyme O -
, O +
transketolase O -
, O +
from O +
fibroblasts O +
of O +
a O +
diabetic B-Disease +
patient O +
who O +
developed O +
Wernicke B-Disease -
's I-Disease +
encephalopathy I-Disease +
when O +
treated O +
with O +
tolazamide O -
, O +
in O +
order O +
to O +
delineate O +
if O +
this O +
patient O +
also O +
had O +
transketolase O +
abnormality O +
[ O -
high O +
Km O +
for O +
thiamine O +
pyrophosphate O +
( O -
TPP O -
) O -
] O -
, O +
as O +
previously O +
reported O +
in O +
postalcoholic O +
Wernicke B-Disease -
- I-Disease -
Korsakoff I-Disease +
syndrome I-Disease -
. O +

In O +
addition O +
to O +
this O +
patient O -
, O +
we O +
also O +
studied O +
this O +
enzyme O +
from O +
three O +
diabetic B-Disease +
kindreds O +
without O +
any O +
history O +
of O +
Wernicke B-Disease -
's I-Disease +
encephalopathy I-Disease +
and O +
from O +
four O +
normal O +
controls O -
. O +

We O +
found O +
that O +
the O +
above O -
- O -
mentioned O +
patient O +
and O +
one O +
of O +
the O +
diabetic B-Disease +
kindreds O +
with O +
no O +
history O +
of O +
Wernicke B-Disease -
's I-Disease +
encephalopathy I-Disease +
had O +
abnormal O +
transketolase O +
as O +
determined O +
by O +
its O +
Km O +
for O +
TPP O -
. O +

These O +
data O +
suggest O +
a O +
similarity O +
between O +
postalcoholic O +
Wernicke B-Disease -
- I-Disease -
Korsakoff I-Disease +
syndrome I-Disease +
and O +
the O +
patient O +
with O +
tolazamide O -
- O -
induced O +
Wernicke B-Disease -
's I-Disease +
encephalopathy I-Disease +
from O +
the O +
standpoint O +
of O +
transketolase O +
abnormality O -
. O +

Bradycardia B-Disease +
due O +
to O +
trihexyphenidyl O +
hydrochloride O -
. O +

A O +
chronic O +
schizophrenic B-Disease +
patient O +
was O +
treated O +
with O +
an O +
anticholinergic O +
drug O -
, O +
trihexyphenidyl O +
hydrochloride O -
. O +

The O +
patient O +
developed O -
, O +
paradoxically O -
, O +
sinus O +
bradycardia B-Disease -
. O +

The O +
reaction O +
was O +
specific O +
to O +
trihexyphenidyl O +
and O +
not O +
to O +
other O +
anticholinergic O +
drugs O -
. O +

This O +
antidyskinetic O +
drug O +
is O +
widely O +
used O +
in O +
clinical O +
psychiatric B-Disease +
practice O +
and O +
physicians O +
should O +
be O +
aware O +
of O +
this O +
side O +
effect O -
. O +

Post O -
- O -
operative O +
rigidity B-Disease +
after O +
fentanyl O +
administration O -
. O +

A O +
case O +
of O +
thoraco O -
- O -
abdominal O +
rigidity B-Disease +
leading O +
to O +
respiratory B-Disease +
failure I-Disease +
is O +
described O +
in O +
the O +
post O -
- O -
operative O +
period O +
in O +
an O +
elderly O +
patient O +
who O +
received O +
a O +
moderate O +
dose O +
of O +
fentanyl O -
. O +

This O +
was O +
successfully O +
reversed O +
by O +
naloxone O -
. O +

The O +
mechanisms O +
possibly O +
implicated O +
in O +
this O +
accident O +
are O +
discussed O -
. O +

Anti O -
- O -
carcinogenic B-Disease +
action O +
of O +
phenobarbital O +
given O +
simultaneously O +
with O +
diethylnitrosamine O +
in O +
the O +
rat O -
. O +

The O +
present O +
work O +
has O +
been O +
planned O +
in O +
order O +
to O +
elucidate O +
the O +
effect O +
of O +
phenobarbital O +
( O -
PB O -
: O +
15 O +
mg O +
per O +
rat O +
of O +
ingested O +
dose O -
) O +
on O +
carcinogenesis B-Disease +
when O +
it O +
is O +
administered O +
simultaneously O +
with O +
diethylnitrosamine O +
( O -
DEN O -
: O +
10 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O -
. O +

Wistar O +
rats O +
( O -
180 O +
g O -
) O +
were O +
treated O +
by O +
DEN O +
alone O +
or O +
by O +
DEN O +
+ O +
PB O +
during O +
2 O -
, O +
4 O +
and O +
6 O +
weeks O +
according O +
to O +
our O +
schedule O +
for O +
hepatocarcinogenesis B-Disease -
. O +

After O +
the O +
end O +
of O +
the O +
treatment O -
, O +
the O +
number O +
and O +
the O +
size O +
of O +
induced O +
PAS O +
positive O +
preneoplastic B-Disease +
foci I-Disease +
was O +
significantly O +
reduced O +
when O +
PB O +
was O +
given O +
simultaneously O +
with O +
DEN O +
for O +
4 O +
and O +
6 O +
weeks O -
. O +

The O +
mitotic O +
inhibition O +
and O +
the O +
production O +
of O +
micronuclei O +
normally O +
observed O +
after O +
partial O +
hepatectomy O +
in O +
DEN O +
treated O +
rats O +
were O +
also O +
significantly O +
decreased O +
in O +
DEN O +
+ O +
PB O +
treated O +
rats O -
. O +

When O +
the O +
treatment O +
last O +
only O +
2 O +
weeks O -
, O +
the O +
presence O +
of O +
PB O +
did O +
not O +
change O +
significantly O +
the O +
last O +
parameters O -
. O +

In O +
DEN O +
+ O +
PB O +
treated O +
rats O -
, O +
the O +
survival O +
was O +
prolonged O +
and O +
the O +
tumor B-Disease +
incidence O +
decreased O +
as O +
compared O +
with O +
the O +
results O +
obtained O +
by O +
DEN O +
alone O -
. O +

It O +
is O +
concluded O +
that O +
PB O -
, O +
which O +
promotes O +
carcinogenesis B-Disease +
when O +
administered O +
after O +
the O +
DEN O +
treatment O -
, O +
reduces O +
the O +
carcinogen O +
effect O +
when O +
given O +
simultaneously O +
with O +
DEN O -
. O +

This O +
' O -
anti O -
- O -
carcinogen O -
' O +
effect O +
acts O +
on O +
the O +
initiation O +
as O +
well O +
as O +
on O +
the O +
promotion O +
of O +
the O +
precancerous B-Disease +
lesions I-Disease -
. O +

Biochemical O +
investigations O +
are O +
in O +
progress O +
to O +
obtain O +
more O +
information O +
about O +
this O +
' O -
paradoxical O -
' O +
PB O +
effect O -
. O +

On O +
the O +
mechanisms O +
of O +
the O +
development O +
of O +
tolerance O +
to O +
the O +
muscular B-Disease +
rigidity I-Disease +
produced O +
by O +
morphine O +
in O +
rats O -
. O +

The O +
development O +
of O +
tolerance O +
to O +
the O +
muscular B-Disease +
rigidity I-Disease +
produced O +
by O +
morphine O +
was O +
studied O +
in O +
rats O -
. O +

Saline O -
- O -
pretreated O +
controls O +
given O +
a O +
test O +
dose O +
of O +
morphine O +
( O -
20 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
showed O +
a O +
pronounced O +
rigidity B-Disease +
recorded O +
as O +
tonic O +
activity O +
in O +
the O +
electromyogram O -
. O +

Rats O +
treated O +
for O +
11 O +
days O +
with O +
morphine O +
and O +
withdrawn O +
for O +
36 O -
- O -
40 O +
h O +
showed O +
differences O +
in O +
the O +
development O +
of O +
tolerance O -
: O +
about O +
half O +
of O +
the O +
animals O +
showed O +
a O +
rigidity B-Disease +
after O +
the O +
test O +
dose O +
of O +
morphine O +
that O +
was O +
not O +
significantly O +
less O +
than O +
in O +
the O +
controls O +
and O +
were O +
akinetic B-Disease +
( O -
A O +
group O -
) O -
. O +

The O +
other O +
rats O +
showed O +
a O +
strong O +
decrease O +
in O +
the O +
rigidity B-Disease +
and O +
the O +
occurrence O +
of O +
stereotyped O +
( O -
S O -
) O +
licking O +
and/or O +
gnawing O +
in O +
presence O +
of O +
akinetic B-Disease +
or O +
hyperkinetic B-Disease +
( O -
K O -
) O +
behaviour O +
( O -
AS O -
/ O -
KS O +
group O -
) O -
, O +
suggesting O +
signs O +
of O +
dopaminergic O +
activation O -
. O +

The O +
rigidity B-Disease +
was O +
considerably O +
decreased O +
in O +
both O +
groups O +
after O +
20 O +
days O -
' O +
treatment O -
. O +

In O +
a O +
further O +
series O +
of O +
experiments O -
, O +
haloperidol O +
( O -
0.2 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
was O +
used O +
in O +
order O +
to O +
block O +
the O +
dopaminergic O +
activation O +
and O +
to O +
estimate O +
the O +
real O +
degree O +
of O +
the O +
tolerance O +
to O +
the O +
rigidity B-Disease +
without O +
any O +
dopaminergic O +
interference O -
. O +

Haloperidol O +
enhanced O +
the O +
rigidity B-Disease +
in O +
the O +
A O +
group O -
. O +

However O -
, O +
the O +
level O +
in O +
the O +
AS O -
/ O -
KS O +
group O +
remained O +
considerably O +
lower O +
than O +
in O +
the O +
A O +
group O -
. O +

The O +
results O +
suggest O +
that O +
rigidity B-Disease -
, O +
which O +
is O +
assumed O +
to O +
be O +
due O +
to O +
an O +
action O +
of O +
morphine O +
in O +
the O +
striatum O -
, O +
can O +
be O +
antagonized O +
by O +
another O +
process O +
leading O +
to O +
dopaminergic O +
activation O +
in O +
the O +
striatum O -
. O +

Nevertheless O -
, O +
there O +
occurs O +
some O +
real O +
tolerance O +
to O +
this O +
effect O -
. O +

The O +
rapid O +
alternations O +
of O +
rigidity B-Disease +
and O +
the O +
signs O +
of O +
dopaminergic O +
activation O +
observed O +
in O +
the O +
animals O +
of O +
the O +
AS O -
/ O -
KS O +
group O +
might O +
be O +
due O +
to O +
rapid O +
shifts O +
in O +
the O +
predominance O +
of O +
various O +
DA O -
- O -
innervated O +
structures O -
. O +

A O +
case O +
of O +
massive O +
rhabdomyolysis B-Disease +
following O +
molindone O +
administration O -
. O +

Rhabdomyolysis B-Disease +
is O +
a O +
potentially O +
lethal O +
syndrome O +
that O +
psychiatric B-Disease +
patients O +
seem O +
predisposed O +
to O +
develop O -
. O +

The O +
clinical O +
signs O +
and O +
symptoms O -
, O +
typical O +
laboratory O +
features O -
, O +
and O +
complications O +
of O +
rhabdomyolysis B-Disease +
are O +
presented O -
. O +

The O +
case O +
of O +
a O +
schizophrenic B-Disease +
patient O +
is O +
reported O +
to O +
illustrate O +
massive O +
rhabdomyolysis B-Disease +
and O +
subsequent O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
following O +
molindone O +
administration O -
. O +

Physicians O +
who O +
prescribe O +
molindone O +
should O +
be O +
aware O +
of O +
this O +
reaction O -
. O +

Compression B-Disease +
neuropathy I-Disease +
of B-Disease +
the I-Disease +
radial I-Disease +
nerve I-Disease +
due O +
to O +
pentazocine O -
- O -
induced O +
fibrous B-Disease +
myopathy I-Disease -
. O +

Fibrous B-Disease +
myopathy I-Disease +
is O +
a O +
common O -
, O +
well O -
- O -
known O +
side O +
effect O +
of O +
repeated O +
pentazocine O +
injection O -
. O +

However O -
, O +
compression B-Disease +
neuropathy I-Disease +
due O +
to O +
fibrotic O +
muscle O +
affected O +
by O +
pentazocine O -
- O -
induced O +
myopathy B-Disease +
has O +
not O +
previously O +
been O +
reported O -
. O +

In O +
a O +
37-year O -
- O -
old O +
woman O +
with O +
documented O +
pentazocine O -
- O -
induced O +
fibrous B-Disease +
myopathy I-Disease +
of O +
triceps O +
and O +
deltoid O +
muscles O +
bilaterally O +
and O +
a O +
three O -
- O -
week O +
history O +
of O +
right O +
wrist O +
drop O -
, O +
electrodiagnostic O +
examination O +
showed O +
a O +
severe O +
but O +
partial O +
lesion O +
of O +
the O +
right O +
radial O +
nerve O +
distal O +
to O +
the O +
branches O +
to O +
the O +
triceps O -
, O +
in O +
addition O +
to O +
the O +
fibrous B-Disease +
myopathy I-Disease -
. O +

Surgery O +
revealed O +
the O +
right O +
radial O +
nerve O +
to O +
be O +
severely O +
compressed O +
by O +
the O +
densely O +
fibrotic O +
lateral O +
head O +
of O +
the O +
triceps O -
. O +

Decompression O +
and O +
neurolysis O +
were O +
performed O +
with O +
good O +
subsequent O +
recovery O +
of O +
function O -
. O +

Recurrent O +
reversible O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
from O +
amphotericin O -
. O +

A O +
patient O +
with O +
cryptogenic O +
cirrhosis B-Disease +
and O +
disseminated O +
sporotrichosis B-Disease +
developed O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
immediately O +
following O +
the O +
administration O +
of O +
amphotericin O +
B O +
on O +
four O +
separate O +
occasions O -
. O +

The O +
abruptness O +
of O +
the O +
renal B-Disease +
failure I-Disease +
and O +
its O +
reversibility O +
within O +
days O +
suggests O +
that O +
there O +
was O +
a O +
functional O +
component O +
to O +
the O +
renal B-Disease +
dysfunction I-Disease -
. O +

We O +
propose O +
that O +
amphotericin O -
, O +
in O +
the O +
setting O +
of O +
reduced O +
effective O +
arterial O +
volume O -
, O +
may O +
activate O +
tubuloglomerular O +
feedback O -
, O +
thereby O +
contributing O +
to O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
. O +

Cerebral B-Disease +
infarction I-Disease +
with O +
a O +
single O +
oral O +
dose O +
of O +
phenylpropanolamine O -
. O +

Phenylpropanolamine O +
( O -
PPA O -
) O -
, O +
a O +
synthetic O +
sympathomimetic O +
that O +
is O +
structurally O +
similar O +
to O +
amphetamine O -
, O +
is O +
available O +
over O +
the O +
counter O +
in O +
anorectics O -
, O +
nasal O +
congestants O -
, O +
and O +
cold O +
preparations O -
. O +

Its O +
prolonged O +
use O +
or O +
overuse O +
has O +
been O +
associated O +
with O +
seizures B-Disease -
, O +
intracerebral B-Disease +
hemorrhage I-Disease -
, O +
neuropsychiatric B-Disease +
symptoms I-Disease -
, O +
and O +
nonhemorrhagic O +
cerebral B-Disease +
infarction I-Disease -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
young O +
woman O +
who O +
suffered O +
a O +
cerebral B-Disease +
infarction I-Disease +
after O +
taking O +
a O +
single O +
oral O +
dose O +
of O +
PPA O -
. O +

Bilateral B-Disease +
optic I-Disease +
neuropathy I-Disease +
due O +
to O +
combined O +
ethambutol O +
and O +
isoniazid O +
treatment O -
. O +

The O +
case O +
of O +
a O +
40-year O -
- O -
old O +
patient O +
who O +
underwent O +
an O +
unsuccessful O +
cadaver O +
kidney O +
transplantation O +
and O +
was O +
treated O +
with O +
ethambutol O +
and O +
isoniazid O +
is O +
reported O -
. O +

A O +
bilateral B-Disease +
retrobulbar I-Disease +
neuropathy I-Disease +
with O +
an O +
unusual O +
central O +
bitemporal O +
hemianopic O +
scotoma B-Disease +
was O +
found O -
. O +

Ethambutol O +
was O +
stopped O +
and O +
only O +
small O +
improvement O +
of O +
the O +
visual O +
acuity O +
followed O -
. O +

Isoniazid O +
was O +
discontinued O +
later O -
, O +
followed O +
by O +
a O +
dramatic O +
improvement O +
in O +
the O +
visual O +
acuity O -
. O +

The O +
hazards O +
of O +
optic O +
nerve O +
toxicity B-Disease +
due O +
to O +
ethambutol O +
are O +
known O -
. O +

We O +
emphasize O +
the O +
potential O +
danger O +
in O +
the O +
use O +
of O +
ethambutol O +
and O +
isoniazid O -
. O +

Remission O +
induction O +
of O +
meningeal B-Disease +
leukemia I-Disease +
with O +
high O -
- O -
dose O +
intravenous O +
methotrexate O -
. O +

Twenty O +
children O +
with O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia I-Disease +
who O +
developed O +
meningeal B-Disease +
disease I-Disease +
were O +
treated O +
with O +
a O +
high O -
- O -
dose O +
intravenous O +
methotrexate O +
regimen O +
that O +
was O +
designed O +
to O +
achieve O +
and O +
maintain O +
CSF O +
methotrexate O +
concentrations O +
of O +
10 O -
( O -
-5 O -
) O +
mol O -
/ O -
L O +
without O +
the O +
need O +
for O +
concomitant O +
intrathecal O +
dosing O -
. O +

The O +
methotrexate O +
was O +
administered O +
as O +
a O +
loading O +
dose O +
of O +
6,000 O +
mg O -
/ O -
m2 O +
for O +
a O +
period O +
of O +
one O +
hour O +
followed O +
by O +
an O +
infusion O +
of O +
1,200 O +
mg O -
/ O -
m2 O -
/ O -
h O +
for O +
23 O +
hours O -
. O +

Leucovorin O +
rescue O +
was O +
initiated O +
12 O +
hours O +
after O +
the O +
end O +
of O +
the O +
infusion O +
with O +
a O +
loading O +
dose O +
of O +
200 O +
mg O -
/ O -
m2 O +
followed O +
by O +
12 O +
mg O -
/ O -
m2 O +
every O +
three O +
hours O +
for O +
six O +
doses O +
and O +
then O +
every O +
six O +
hours O +
until O +
the O +
plasma O +
methotrexate O +
level O +
decreased O +
to O +
less O +
than O +
1 O +
X O +
10 O -
( O -
-7 O -
) O +
mol O -
/ O -
L. O +
The O +
mean O +
steady O -
- O -
state O +
plasma O +
and O +
CSF O +
methotrexate O +
concentrations O +
achieved O +
were O +
1.1 O +
X O +
10 O -
( O -
-3 O -
) O +
mol O -
/ O -
L O +
and O +
3.6 O +
X O +
10 O -
( O -
-5 O -
) O +
mol O -
/ O -
L O -
, O +
respectively O -
. O +

All O +
20 O +
patients O +
responded O +
to O +
this O +
regimen O -
, O +
16 O -
/ O -
20 O +
( O -
80 O -
% O -
) O +
achieved O +
a O +
complete O +
remission O -
, O +
and O +
20 O -
% O +
obtained O +
a O +
partial O +
remission O -
. O +

The O +
most O +
common O +
toxicities B-Disease +
encountered O +
were O +
transient O +
serum O +
transaminase O +
and O +
bilirubin O +
elevations O -
, O +
neutropenia B-Disease -
, O +
and O +
mucositis B-Disease -
. O +

One O +
patient O +
had O +
focal O +
seizures B-Disease +
and O +
transient B-Disease +
hemiparesis I-Disease +
but O +
recovered O +
completely O -
. O +

High O -
- O -
dose O +
intravenous O +
methotrexate O +
is O +
an O +
effective O +
treatment O +
for O +
the O +
induction O +
of O +
remission O +
after O +
meningeal O +
relapse O +
in O +
acute B-Disease +
lymphoblastic I-Disease +
leukemia I-Disease -
. O +

Interaction O +
of O +
cyclosporin O +
A O +
with O +
antineoplastic O +
agents O -
. O +

A O +
synergistic O +
effect O +
of O +
etoposide O +
and O +
cyclosporin O +
A O +
was O +
observed O +
in O +
a O +
patient O +
with O +
acute B-Disease +
T I-Disease -
- I-Disease -
lymphocytic I-Disease +
leukemia I-Disease +
in O +
relapse O -
. O +

The O +
concomitant O +
administration O +
of O +
etoposide O +
and O +
cyclosporin O +
A O +
resulted O +
in O +
eradication O +
of O +
hitherto O +
refractory O +
leukemic B-Disease +
infiltration I-Disease +
of O +
bone O +
marrow O -
. O +

Severe O +
side O +
effects O +
in O +
terms O +
of O +
mental O +
confusion B-Disease +
and O +
progressive O +
hyperbilirubinemia B-Disease -
, O +
however O -
, O +
point O +
to O +
an O +
enhancement O +
not O +
only O +
of O +
antineoplastic O +
effects O +
but O +
also O +
of O +
toxicity B-Disease +
in O +
normal O +
tissues O -
. O +

This O +
report O +
demonstrates O +
for O +
the O +
first O +
time O +
that O +
the O +
pharmacodynamic O +
properties O +
of O +
cyclosporin O +
A O +
may O +
not O +
be O +
confined O +
strictly O +
to O +
suppression O +
of O +
normal O +
T O -
- O -
cell O +
functions O -
. O +

Factors O +
associated O +
with O +
nephrotoxicity B-Disease +
and O +
clinical O +
outcome O +
in O +
patients O +
receiving O +
amikacin O -
. O +

Data O +
from O +
60 O +
patients O +
treated O +
with O +
amikacin O +
were O +
analyzed O +
for O +
factors O +
associated O +
with O +
nephrotoxicity B-Disease -
. O +

In O +
42 O +
of O +
these O +
patients O -
, O +
data O +
were O +
examined O +
for O +
factors O +
associated O +
with O +
clinical O +
outcome O -
. O +

Variables O +
evaluated O +
included O +
patient O +
weight O -
, O +
age O -
, O +
sex O -
, O +
serum O +
creatinine O +
level O -
, O +
creatinine O +
clearance O -
, O +
duration O +
of O +
therapy O -
, O +
total O +
dose O -
, O +
mean O +
daily O +
dose O -
, O +
organism O +
minimum O +
inhibitory O +
concentration O +
( O -
MIC O -
) O -
, O +
mean O +
peak O +
levels O -
, O +
mean O +
trough O +
levels O -
, O +
mean O +
area O +
under O +
the O +
serum O +
concentration O -
- O -
time O +
curve O +
( O -
AUC O -
) O -
, O +
total O +
AUC O -
, O +
mean O +
AUC O +
greater O +
than O +
MIC O -
, O +
total O +
AUC O +
greater O +
than O +
MIC O -
, O +
mean O +
Schumacher O -
's O +
intensity O +
factor O +
( O -
IF O -
) O -
, O +
total O +
IF O -
, O +
In O +
( O -
mean O +
maximum O +
concentration O +
[ O -
Cmax O -
] O -
/ O -
MIC O -
) O -
. O +

Model O -
- O -
dependent O +
pharmacokinetic O +
parameters O +
were O +
calculated O +
by O +
computer O +
based O +
on O +
a O +
one O -
- O -
compartment O +
model O -
. O +

When O +
the O +
parameters O +
were O +
examined O +
individually O -
, O +
duration O +
of O +
therapy O +
and O +
total O +
AUC O +
correlated O +
significantly O +
( O -
P O +
less O +
than O +
.05 O -
) O +
with O +
nephrotoxicity B-Disease -
. O +

In O +
contrast O -
, O +
a O +
stepwise O +
discriminant O +
function O +
analysis O +
identified O +
only O +
duration O +
of O +
therapy O +
( O -
P O +
less O +
than O +
.001 O -
) O +
as O +
an O +
important O +
factor O -
. O +

Based O +
on O +
this O +
model O +
and O +
on O +
Bayes O -
' O +
theorem O -
, O +
the O +
predictive O +
accuracy O +
of O +
identifying O +
" O -
nephrotoxic B-Disease -
" O +
patients O +
increased O +
from O +
0.17 O +
to O +
0.39 O -
. O +

When O +
examined O +
individually O -
, O +
mean O +
IF O -
, O +
MIC O -
, O +
total O +
dose O -
, O +
mean O +
daily O +
dose O -
, O +
and O +
ln O +
( O -
mean O +
Cmax O -
/ O -
MIC O -
) O +
correlated O +
significantly O +
( O -
P O +
less O +
than O +
.05 O -
) O +
with O +
cure O -
. O +

In O +
contrast O -
, O +
a O +
simultaneous O +
multivariable O +
analysis O +
identified O +
IF O -
, O +
MIC O -
, O +
and O +
total O +
dose O +
according O +
to O +
one O +
model O +
and O +
ln O +
( O -
mean O +
Cmax O -
/ O -
MIC O -
) O +
according O +
to O +
a O +
second O +
statistical O +
model O +
of O +
parameters O +
selected O +
to O +
have O +
the O +
greatest O +
prospective O +
value O -
. O +

Based O +
on O +
Bayes O -
' O +
theorem O +
and O +
the O +
first O +
model O -
, O +
the O +
predictive O +
accuracy O +
of O +
identifying O +
patients O +
not O +
cured O +
increased O +
from O +
0.19 O +
to O +
0.83 O -
. O +

For O +
the O +
second O +
model O -
, O +
the O +
predictive O +
accuracy O +
increased O +
from O +
0.19 O +
to O +
0.50. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Dose O -
- O -
related O +
beneficial O +
and O +
adverse O +
effects O +
of O +
dietary O +
corticosterone O +
on O +
organophosphorus O -
- O -
induced O +
delayed O +
neuropathy B-Disease +
in O +
chickens O -
. O +

Tri O -
- O -
ortho O -
- O -
tolyl O +
phosphate O +
( O -
TOTP O -
) O -
, O +
360 O +
mg O -
/ O -
kg O -
, O +
po O -
, O +
and O +
0,0'-diisopropyl O +
phosphorofluoridate O +
( O -
DFP O -
) O -
, O +
1 O +
mg O -
/ O -
kg O +
sc O -
, O +
were O +
administered O +
to O +
adult O +
White O +
Leghorn O +
chickens O +
24 O +
hr O +
after O +
they O +
were O +
placed O +
on O +
diets O +
containing O +
0 O +
to O +
300 O +
ppm O +
corticosterone O -
. O +

Supplemented O +
diets O +
were O +
continued O +
until O +
clinical O +
signs O +
and O +
lesions O +
of O +
delayed O +
neuropathy B-Disease +
appeared O -
. O +

Although O +
low O +
concentrations O +
( O -
less O +
than O +
or O +
equal O +
to O +
50 O +
ppm O -
) O +
of O +
corticosterone O +
had O +
beneficial O +
effects O +
on O +
TOTP O -
- O -
induced O +
neuropathy B-Disease -
, O +
greater O +
than O +
or O +
equal O +
to O +
200 O +
ppm O +
exacerbated O +
clinical O +
signs O +
in O +
chickens O +
given O +
either O +
TOTP O +
or O +
DFP O -
. O +

Neurotoxic B-Disease +
esterase O +
activities O +
24 O +
hr O +
after O +
TOTP O +
or O +
DFP O +
were O +
less O +
than O +
20 O -
% O +
of O +
values O +
measured O +
in O +
chickens O +
not O +
given O +
organophosphorous O +
compounds O -
. O +

Chickens O +
given O +
200 O +
ppm O +
corticosterone O +
without O +
TOTP O +
or O +
DFP O +
had O +
significantly O +
elevated O +
activity O +
of O +
plasma O +
cholinesterase O +
and O +
significantly O +
inhibited O +
activity O +
of O +
liver O +
carboxylesterase O -
. O +

Degenerating B-Disease +
myelinated I-Disease +
fibers I-Disease +
were O +
also O +
evident O +
in O +
distal O +
levels O +
of O +
the O +
peripheral O +
nerves O +
of O +
chickens O +
given O +
TOTP O +
or O +
DFP O -
. O +

Hepatotoxicity B-Disease +
of O +
amiodarone O -
. O +

Amiodarone O +
has O +
proved O +
very O +
effective O +
in O +
the O +
treatment O +
of O +
otherwise O +
resistant O +
cardiac O +
tachyarrhythmias B-Disease -
. O +

The O +
use O +
of O +
amiodarone O +
has O -
, O +
however O -
, O +
been O +
limited O +
due O +
to O +
its O +
serious O +
side O -
- O -
effects O -
. O +

A O +
patient O +
with O +
cholestatic B-Disease +
hepatitis B-Disease +
due O +
to O +
amiodarone O +
treatment O +
is O +
presented O +
below O +
and O +
a O +
review O +
of O +
the O +
hepatotoxicity B-Disease +
of O +
amiodarone O +
is O +
given O -
. O +

It O +
is O +
concluded O +
that O +
solid O +
evidence O +
exists O +
of O +
hepatic B-Disease +
injury I-Disease +
due O +
to O +
amiodarone O +
treatment O -
, O +
including O +
steatosis B-Disease -
, O +
alterations O +
resembling O +
alcoholic B-Disease +
hepatitis I-Disease -
, O +
cholestatic B-Disease +
hepatitis B-Disease +
and O +
micronodular O +
cirrhosis B-Disease +
of I-Disease +
the I-Disease +
liver I-Disease -
. O +

Patients O +
receiving O +
amiodarone O +
should O +
be O +
regularly O +
screened O +
with O +
respect O +
to O +
hepatic O +
enzyme O +
levels O -
. O +

Therapy O +
should O +
be O +
discontinued O +
on O +
the O +
suspicion O +
of O +
cholestatic B-Disease +
injury I-Disease +
or O +
hepatomegaly B-Disease -
. O +

Promotional O +
effects O +
of O +
testosterone O +
and O +
dietary O +
fat O +
on O +
prostate O +
carcinogenesis B-Disease +
in O +
genetically O +
susceptible O +
rats O -
. O +

Germfree O +
( O -
GF O -
) O +
Lobund O +
strain O +
Wistar O +
( O -
LW O -
) O +
rats O -
, O +
fed O +
vegetable O +
diet O +
L-485 O -
, O +
have O +
developed O +
prostate B-Disease +
adenocarcinomas I-Disease +
spontaneously O +
( O -
10 O -
% O +
incidence O -
) O +
at O +
average O +
age O +
34 O +
months O -
. O +

Conventional O +
LW O +
rats O -
, O +
implanted O +
with O +
testosterone O +
at O +
age O +
4 O +
months O -
, O +
developed O +
a O +
higher O +
incidence O +
of O +
prostate B-Disease +
cancer I-Disease +
after O +
an O +
average O +
interval O +
of O +
14 O +
months O -
: O +
24 O -
% O +
had O +
developed O +
gross O +
tumors B-Disease -
, O +
and O +
40 O -
% O +
when O +
it O +
included O +
microscopic O +
tumors B-Disease -
. O +

Preliminary O +
results O +
indicate O +
that O +
testosterone O -
- O -
treated O +
LW O +
rats O +
that O +
were O +
fed O +
the O +
same O +
diet O -
, O +
which O +
was O +
supplemented O +
with O +
corn O +
oil O +
up O +
to O +
20 O -
% O +
fat O -
, O +
developed O +
prostate B-Disease +
cancer I-Disease +
after O +
intervals O +
of O +
6 O -
- O -
12 O +
months O -
. O +

Aged O +
GF O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O +
have O +
not O +
developed O +
prostate B-Disease +
cancer I-Disease +
spontaneously O -
. O +

Conventional O +
SD O +
rats O +
fed O +
diet O +
L-485 O +
and O +
treated O +
with O +
testosterone O +
developed O +
only O +
prostatitis B-Disease -
. O +

Experimental O +
designs O +
should O +
consider O +
genetic O +
susceptibility O +
as O +
a O +
basic O +
prerequisite O +
for O +
studies O +
on O +
experimental O +
prostate B-Disease +
cancer I-Disease -
. O +

Incidence O +
of O +
neoplasms B-Disease +
in O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
exposed O +
to O +
different O +
treatment O +
regimens O -
. O +

Immunosuppressive O +
drugs O +
have O +
been O +
used O +
during O +
the O +
last O +
30 O +
years O +
in O +
treatment O +
of O +
patients O +
with O +
severe O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

The O +
drugs O +
commonly O +
used O +
are O +
cyclophosphamide O +
and O +
chlorambucil O +
( O -
alkylating O +
agents O -
) O -
, O +
azathioprine O +
( O -
purine O +
analogue O -
) O -
, O +
and O +
methotrexate O +
( O -
folic O +
acid O +
analogue O -
) O -
. O +

There O +
is O +
evidence O +
that O +
all O +
four O +
immunosuppressive O +
drugs O +
can O +
reduce O +
synovitis B-Disease -
, O +
but O +
disease O +
activity O +
almost O +
always O +
recurs O +
after O +
therapy O +
is O +
stopped O -
. O +

Since O +
adverse O +
reactions O +
are O +
frequent O -
, O +
less O +
than O +
50 O +
percent O +
of O +
patients O +
are O +
able O +
to O +
continue O +
a O +
particular O +
drug O +
for O +
more O +
than O +
one O +
year O -
. O +

Since O +
it O +
takes O +
three O +
to O +
12 O +
months O +
to O +
achieve O +
maximal O +
effects O -
, O +
those O +
patients O +
who O +
are O +
unable O +
to O +
continue O +
the O +
drug O +
receive O +
little O +
benefit O +
from O +
it O -
. O +

Patients O +
treated O +
with O +
alkylating O +
agents O +
have O +
an O +
increased O +
risk O +
of O +
development O +
of O +
acute B-Disease +
nonlymphocytic I-Disease +
leukemia I-Disease -
, O +
and O +
both O +
alkylating O +
agents O +
and O +
azathioprine O +
are O +
associated O +
with O +
the O +
development O +
of O +
non B-Disease -
- I-Disease -
Hodgkin I-Disease -
's I-Disease +
lymphoma I-Disease -
. O +

Cyclophosphamide O +
therapy O +
increases O +
the O +
risk O +
of O +
carcinoma B-Disease +
of B-Disease +
the I-Disease +
bladder I-Disease -
. O +

There O +
have O +
been O +
several O +
long O -
- O -
term O +
studies O +
of O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
treated O +
with O +
azathioprine O +
and O +
cyclophosphamide O +
and O +
the O +
incidence O +
of O +
most O +
of O +
the O +
common O +
cancers B-Disease +
is O +
not O +
increased O -
. O +

Data O +
on O +
the O +
possible O +
increased O +
risk O +
of O +
malignancy B-Disease +
in O +
rheumatoid B-Disease +
arthritis I-Disease +
are O +
still O +
being O +
collected O -
, O +
and O +
until O +
further O +
information O +
is O +
available O -
, O +
the O +
use O +
of O +
immunosuppressive O +
drugs O -
, O +
particularly O +
alkylating O +
agents O -
, O +
in O +
the O +
treatment O +
of O +
rheumatoid B-Disease +
arthritis I-Disease +
should O +
be O +
reserved O +
for O +
patients O +
with O +
severe O +
progressive O +
disease O +
or O +
life O -
- O -
threatening O +
complications O -
. O +

Warfarin O -
- O -
induced O +
iliopsoas O +
hemorrhage B-Disease +
with O +
subsequent O +
femoral B-Disease +
nerve I-Disease +
palsy I-Disease -
. O +

We O +
present O +
the O +
case O +
of O +
a O +
28-year O -
- O -
old O +
man O +
on O +
chronic O +
warfarin O +
therapy O +
who O +
sustained O +
a O +
minor O +
muscle B-Disease +
tear I-Disease +
and O +
developed O +
increasing O +
pain B-Disease +
and O +
a O +
flexure O +
contracture B-Disease +
of O +
the O +
right O +
hip O -
. O +

Surgical O +
exploration O +
revealed O +
an O +
iliopsoas O +
hematoma B-Disease +
and O +
femoral O +
nerve B-Disease +
entrapment I-Disease -
, O +
resulting O +
in O +
a O +
femoral B-Disease +
nerve I-Disease +
palsy I-Disease +
and O +
partial B-Disease +
loss I-Disease +
of I-Disease +
quadriceps I-Disease +
functions I-Disease -
. O +

Anticoagulant O -
- O -
induced O +
femoral B-Disease +
nerve I-Disease +
palsy I-Disease +
represents O +
the O +
most O +
common O +
form O +
of O +
warfarin O -
- O -
induced O +
peripheral B-Disease +
neuropathy I-Disease -
; O +
it O +
is O +
characterized O +
by O +
severe O +
pain B-Disease +
in O +
the O +
inguinal O +
region O -
, O +
varying O +
degrees O +
of O +
motor B-Disease +
and I-Disease +
sensory I-Disease +
impairment I-Disease -
, O +
and O +
flexure O +
contracture B-Disease +
of O +
the O +
involved O +
extremity O -
. O +

Pneumonitis O +
with O +
pleural B-Disease +
and I-Disease +
pericardial I-Disease +
effusion I-Disease +
and O +
neuropathy B-Disease +
during O +
amiodarone O +
therapy O -
. O +

A O +
patient O +
with O +
sinuatrial B-Disease +
disease I-Disease +
and O +
implanted O +
pacemaker O +
was O +
treated O +
with O +
amiodarone O +
( O -
maximum O +
dose O +
1000 O +
mg O -
, O +
maintenance O +
dose O +
800 O +
mg O +
daily O -
) O +
for O +
10 O +
months O -
, O +
for O +
control O +
of O +
supraventricular B-Disease +
tachyarrhythmias I-Disease -
. O +

He O +
developed O +
pneumonitis B-Disease -
, O +
pleural B-Disease +
and I-Disease +
pericardial I-Disease +
effusions I-Disease -
, O +
and O +
a O +
predominantly O +
proximal B-Disease +
motor I-Disease +
neuropathy I-Disease -
. O +

Immediate O +
but O +
gradual O +
improvement O +
followed O +
withdrawal O +
of O +
amiodarone O +
and O +
treatment O +
with O +
prednisolone O -
. O +

Review O +
of O +
this O +
and O +
previously O +
reported O +
cases O +
indicates O +
the O +
need O +
for O +
early O +
diagnosis O +
of O +
amiodarone O +
pneumonitis B-Disease -
, O +
immediate O +
withdrawal O +
of O +
amiodarone O -
, O +
and O +
prompt O +
but O +
continued O +
steroid O +
therapy O +
to O +
ensure O +
full O +
recovery O -
. O +

Amiodarone O -
- O -
induced O +
sinoatrial B-Disease +
block I-Disease -
. O +

We O +
observed O +
sinoatrial B-Disease +
block I-Disease +
due O +
to O +
chronic O +
amiodarone O +
administration O +
in O +
a O +
5-year O -
- O -
old O +
boy O +
with O +
primary B-Disease +
cardiomyopathy I-Disease -
, O +
Wolff B-Disease -
- I-Disease -
Parkinson I-Disease -
- I-Disease -
White I-Disease +
syndrome I-Disease +
and O +
supraventricular B-Disease +
tachycardia I-Disease -
. O +

Reduction O +
in O +
the O +
dosage O +
of O +
amiodarone O +
resulted O +
in O +
the O +
disappearance O +
of O +
the O +
sinoatrial B-Disease +
block I-Disease +
and O +
the O +
persistence O +
of O +
asymptomatic O +
sinus B-Disease +
bradycardia I-Disease -
. O +

Desipramine O -
- O -
induced O +
delirium B-Disease +
at O +
" O -
subtherapeutic O -
" O +
concentrations O -
: O +
a O +
case O +
report O -
. O +

An O +
elderly O +
patient O +
treated O +
with O +
low O +
dose O +
Desipramine O +
developed O +
a O +
delirium B-Disease +
while O +
her O +
plasma O +
level O +
was O +
in O +
the O +
" O -
subtherapeutic O -
" O +
range O -
. O +

Delirium B-Disease -
, O +
which O +
may O +
be O +
induced O +
by O +
tricyclic O +
drug O +
therapy O +
in O +
the O +
elderly O -
, O +
can O +
be O +
caused O +
by O +
tricyclics O +
with O +
low O +
anticholinergic O +
potency O -
. O +

Therapeutic O +
ranges O +
for O +
antidepressants O +
that O +
have O +
been O +
derived O +
from O +
general O +
adult O +
population O +
studies O +
may O +
not O +
be O +
appropriate O +
for O +
the O +
elderly O -
. O +

Further O +
studies O +
of O +
specifically O +
elderly O +
patients O +
are O +
now O +
required O +
to O +
establish O +
safer O +
and O +
more O +
appropriate O +
guidelines O +
for O +
drug O +
therapy O -
. O +

Rat O +
extraocular O +
muscle O +
regeneration O -
. O +

Repair O +
of O +
local O +
anesthetic O -
- O -
induced O +
damage O -
. O +

Local O +
anesthetics O +
that O +
are O +
commonly O +
used O +
in O +
ophthalmic O +
surgery O +
( O -
0.75 O -
% O +
bupivacaine O +
hydrochloride O -
, O +
2.0 O -
% O +
mepivacaine O +
hydrochloride O -
, O +
and O +
2.0 O -
% O +
lidocaine O +
hydrochloride O +
plus O +
1:100,000 O +
epinephrine O -
) O +
were O +
injected O +
into O +
the O +
retrobulbar O +
area O +
of O +
rat O +
eyes O -
. O +

Controls O +
were O +
injected O +
with O +
physiological O +
saline O -
. O +

All O +
three O +
anesthetics O +
produced O +
massive O +
degeneration O +
of O +
the O +
extraocular O +
muscles O -
. O +

Muscle B-Disease +
degeneration I-Disease +
is O +
followed O +
by O +
regeneration O +
of O +
the O +
damaged O +
muscle O +
fibers O -
. O +

In O +
addition O +
to O +
muscle B-Disease +
damage I-Disease -
, O +
severe O +
damage O +
was O +
also O +
seen O +
in O +
harderian O +
glands O -
, O +
especially O +
after O +
exposure O +
to O +
mepivacaine O +
and O +
lidocaine O +
plus O +
epinephrine O -
. O +

With O +
these O +
findings O +
in O +
rats O -
, O +
it O +
is O +
hypothesized O +
that O +
the O +
temporary O +
diplopia B-Disease +
sometimes O +
seen O +
in O +
patients O +
after O +
ophthalmic O +
surgery O +
might O +
be O +
due O +
to O +
anesthetic O -
- O -
induced O +
damage O +
to O +
the O +
extraocular O +
muscles O -
. O +

Gentamicin O +
nephropathy B-Disease +
in O +
a O +
neonate O -
. O +

The O +
clinical O +
and O +
autopsy O +
findings O +
in O +
a O +
premature O +
baby O +
who O +
died O +
of O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
after O +
therapy O +
with O +
gentamicin O +
( O -
5 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
and O +
penicillin O +
are O +
presented O -
. O +

The O +
serum O +
gentamicin O +
concentration O +
had O +
reached O +
toxic O +
levels O +
when O +
anuria B-Disease +
developed O -
. O +

Numerous O +
periodic O +
acid O +
Schiff O +
( O -
PAS O -
) O +
positive O -
, O +
diastase O +
resistant O +
cytoplasmic O +
inclusion O +
bodies O +
which O +
appeared O +
as O +
myelin O +
figures O +
in O +
cytosegresomes O +
under O +
the O +
electron O +
microscope O +
were O +
identified O +
in O +
the O +
proximal O +
convoluted O +
tubules O -
. O +

The O +
pathological O +
changes O +
induced O +
by O +
gentamicin O +
in O +
the O +
human O +
neonatal O +
kidneys O +
have O +
not O +
been O +
previously O +
reported O -
. O +

Indomethacin O -
- O -
induced O +
renal B-Disease +
insufficiency I-Disease -
: O +
recurrence O +
on O +
rechallenge O -
. O +

We O +
have O +
reported O +
a O +
case O +
of O +
acute O +
oliguric O +
renal B-Disease +
failure I-Disease +
with O +
hyperkalemia B-Disease +
in O +
a O +
patient O +
with O +
cirrhosis B-Disease -
, O +
ascites B-Disease -
, O +
and O +
cor B-Disease +
pulmonale I-Disease +
after O +
indomethacin O +
therapy O -
. O +

Prompt O +
restoration O +
of O +
renal O +
function O +
followed O +
drug O +
withdrawal O -
, O +
while O +
re O -
- O -
exposure O +
to O +
a O +
single O +
dose O +
of O +
indomethacin O +
caused O +
recurrence O +
of O +
acute O +
reversible O +
oliguria B-Disease -
. O +

Our O +
case O +
supports O +
the O +
hypothesis O +
that O +
endogenous O +
renal O +
prostaglandins O +
play O +
a O +
role O +
in O +
the O +
maintenance O +
of O +
renal O +
blood O +
flow O +
when O +
circulating O +
plasma O +
volume O +
is O +
diminished O -
. O +

Since O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
agents O +
interfere O +
with O +
this O +
compensatory O +
mechanism O +
and O +
may O +
cause O +
acute B-Disease +
renal I-Disease +
failure I-Disease -
, O +
they O +
should O +
be O +
used O +
with O +
caution O +
in O +
such O +
patients O -
. O +

Induction O +
by O +
paracetamol O +
of O +
bladder B-Disease +
and I-Disease +
liver I-Disease +
tumours I-Disease +
in O +
the O +
rat O -
. O +

Effects O +
on O +
hepatocyte O +
fine O +
structure O -
. O +

Groups O +
of O +
male O +
and O +
female O +
inbred O +
Leeds O +
strain O +
rats O +
were O +
fed O +
diets O +
containing O +
either O +
0.5 O -
% O +
or O +
1.0 O -
% O +
paracetamol O +
by O +
weight O +
for O +
up O +
to O +
18 O +
months O -
. O +

At O +
the O +
1.0 O -
% O +
dosage O +
level O -
, O +
20 O -
% O +
of O +
rats O +
of O +
both O +
sexes O +
developed O +
neoplastic O +
nodules O +
of O +
the O +
liver O -
, O +
a O +
statistically O +
significant O +
incidence O -
. O +

These O +
rats O +
also O +
showed O +
gross O +
enlargement O +
of O +
their O +
livers O +
and O +
an O +
increase O +
in O +
foci O +
of O +
cellular O +
alteration O -
, O +
the O +
latter O +
also O +
being O +
observed O +
in O +
the O +
low O +
dosage O +
male O +
rats O -
. O +

Papillomas B-Disease +
of O +
the O +
transitional O +
epithelium O +
of O +
the O +
bladder O +
developed O +
in O +
all O +
paracetamol O -
- O -
treated O +
groups O -
, O +
and O +
three O +
rats O +
bore O +
bladder B-Disease +
carcinomas I-Disease -
. O +

However O -
, O +
significant O +
yields O +
of O +
bladder B-Disease +
tumours I-Disease +
were O +
only O +
obtained O +
from O +
low O +
dosage O +
females O +
and O +
high O +
dosage O +
males O -
. O +

Additionally O -
, O +
20 O +
to O +
25 O -
% O +
of O +
paracetamol O -
- O -
treated O +
rats O +
developed O +
hyperplasia B-Disease +
of O +
the O +
bladder O +
epithelium O -
, O +
which O +
was O +
not O +
coincident O +
with O +
the O +
presence O +
of O +
bladder B-Disease +
calculi I-Disease -
. O +

A O +
low O +
yield O +
of O +
tumours B-Disease +
at O +
various O +
other O +
sites O +
also O +
arose O +
following O +
paracetamol O +
feeding O -
. O +

An O +
electron O +
microscope O +
study O +
of O +
the O +
livers O +
of O +
paracetamol O -
- O -
treated O +
rats O +
revealed O +
ultrastructural O +
changes O +
in O +
the O +
hepatocytes O +
that O +
resemble O +
those O +
that O +
result O +
from O +
exposure O +
to O +
a O +
variety O +
of O +
known O +
hepatocarcinogens B-Disease -
. O +

Patterns O +
of O +
hepatic B-Disease +
injury I-Disease +
induced O +
by O +
methyldopa O -
. O +

Twelve O +
patients O +
with O +
liver B-Disease +
disease I-Disease +
related O +
to O +
methyldopa O +
were O +
seen O +
between O +
1967 O +
and O +
1977 O -
. O +

Illness O +
occurred O +
within O +
1 O -
- O -
-9 O +
weeks O +
of O +
commencement O +
of O +
therapy O +
in O +
9 O +
patients O -
, O +
the O +
remaining O +
3 O +
patients O +
having O +
received O +
the O +
drug O +
for O +
13 O +
months O -
, O +
15 O +
months O +
and O +
7 O +
years O +
before O +
experiencing O +
symptoms O -
. O +

Jaundice B-Disease +
with O +
tender O +
hepatomegaly B-Disease -
, O +
usually O +
preceded O +
by O +
symptoms O +
of O +
malaise O -
, O +
anorexia B-Disease -
, O +
nausea B-Disease +
and O +
vomiting B-Disease -
, O +
and O +
associated O +
with O +
upper O +
abdominal B-Disease +
pain I-Disease -
, O +
was O +
an O +
invariable O +
finding O +
in O +
all O +
patients O -
. O +

Biochemical O +
liver O +
function O +
tests O +
indicated O +
hepatocellular O +
necrosis B-Disease +
and O +
correlated O +
with O +
histopathological O +
evidence O +
of O +
hepatic B-Disease +
injury I-Disease -
, O +
the O +
spectrum O +
of O +
which O +
ranged O +
from O +
fatty B-Disease +
change I-Disease +
and O +
focal O +
hepatocellular O +
necrosis B-Disease +
to O +
massive B-Disease +
hepatic I-Disease +
necrosis I-Disease -
. O +

Most O +
patients O +
showed O +
moderate O +
to O +
severe O +
acute B-Disease +
hepatitis I-Disease +
or O +
chronic B-Disease +
active I-Disease +
hepatitis I-Disease +
with O +
associated O +
cholestasis B-Disease -
. O +

The O +
drug O +
was O +
withdrawn O +
on O +
presentation O +
to O +
hospital O +
in O +
11 O +
patients O -
, O +
with O +
rapid O +
clinical O +
improvement O +
in O +
9 O -
. O +

One O +
patient O +
died O -
, O +
having O +
presented O +
in O +
hepatic B-Disease +
failure I-Disease -
, O +
and O +
another O -
, O +
who O +
had O +
been O +
taking O +
methyldopa O +
for O +
7 O +
years O -
, O +
showed O +
slower O +
clinical O +
and O +
biochemical O +
resolution O +
over O +
a O +
period O +
of O +
several O +
months O -
. O +

The O +
remaining O +
patient O +
in O +
the O +
series O +
developed O +
fulminant B-Disease +
hepatitis I-Disease +
when O +
the O +
drug O +
was O +
accidentally O +
recommenced O +
1 O +
year O +
after O +
a O +
prior O +
episode O +
of O +
methyldopa O -
- O -
induced O +
hepatitis B-Disease -
. O +

In O +
this O +
latter O +
patient O -
, O +
and O +
in O +
2 O +
others O -
, O +
the O +
causal O +
relationship O +
between O +
methyldopa O +
and O +
hepatic B-Disease +
dysfunction I-Disease +
was O +
proved O +
with O +
the O +
recurrence O +
of O +
hepatitis B-Disease +
within O +
2 O +
weeks O +
of O +
re O -
- O -
exposure O +
to O +
the O +
drug O -
. O +

Suxamethonium O +
infusion O +
rate O +
and O +
observed O +
fasciculations B-Disease -
. O +

A O +
dose O -
- O -
response O +
study O -
. O +

Suxamethonium O +
chloride O +
( O -
Sch O -
) O +
was O +
administered O +
i.v O -
. O +

to O +
36 O +
adult O +
males O +
at O +
six O +
rates O -
: O +
0.25 O +
mg O +
s-1 O +
to O +
20 O +
mg O +
s-1 O -
. O +

The O +
infusion O +
was O +
discontinued O +
either O +
when O +
there O +
was O +
no O +
muscular O +
response O +
to O +
tetanic B-Disease +
stimulation O +
of O +
the O +
ulnar O +
nerve O +
or O +
when O +
Sch O +
120 O +
mg O +
was O +
exceeded O -
. O +

Six O +
additional O +
patients O +
received O +
a O +
30-mg O +
i.v O -
. O +

bolus O +
dose O -
. O +

Fasciculations B-Disease +
in O +
six O +
areas O +
of O +
the O +
body O +
were O +
scored O +
from O +
0 O +
to O +
3 O +
and O +
summated O +
as O +
a O +
total O +
fasciculation B-Disease +
score O -
. O +

The O +
times O +
to O +
first O +
fasciculation B-Disease -
, O +
twitch B-Disease +
suppression O +
and O +
tetanus B-Disease +
suppression O +
were O +
inversely O +
related O +
to O +
the O +
infusion O +
rates O -
. O +

Fasciculations B-Disease +
in O +
the O +
six O +
areas O +
and O +
the O +
total O +
fasciculation B-Disease +
score O +
were O +
related O +
directly O +
to O +
the O +
rate O +
of O +
infusion O -
. O +

Total O +
fasciculation B-Disease +
scores O +
in O +
the O +
30-mg O +
bolus O +
group O +
and O +
the O +
5-mg O +
s-1 O +
and O +
20-mg O +
s-1 O +
infusion O +
groups O +
were O +
not O +
significantly O +
different O -
. O +

Tiapride O +
in O +
levodopa O -
- O -
induced O +
involuntary B-Disease +
movements I-Disease -
. O +

Tiapride O -
, O +
a O +
substituted O +
benzamide O +
derivative O +
closely O +
related O +
to O +
metoclopramide O -
, O +
reduced O +
levodopa O -
- O -
induced O +
peak O +
dose O +
involuntary B-Disease +
movements I-Disease +
in O +
16 O +
patients O +
with O +
idiopathic B-Disease +
Parkinson I-Disease -
's I-Disease +
disease I-Disease -
. O +

However O -
, O +
an O +
unacceptable O +
increase O +
in O +
disability O +
from O +
Parkinsonism B-Disease +
with O +
aggravation O +
of O +
end O -
- O -
of O -
- O -
dose O +
akinesia B-Disease +
led O +
to O +
its O +
cessation O +
in O +
14 O +
patients O -
. O +

Tiapride O +
had O +
no O +
effect O +
on O +
levodopa O -
- O -
induced O +
early O +
morning O +
of O +
" O -
off O -
- O -
period O -
" O +
segmental O +
dystonia B-Disease -
. O +

These O +
results O +
fail O +
to O +
support O +
the O +
notion O +
that O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
are O +
caused O +
by O +
overstimulation O +
of O +
a O +
separate O +
group O +
of O +
dopamine O +
receptors O -
. O +

Treatment O +
of O +
psoriasis B-Disease +
with O +
azathioprine O -
. O +

Azathioprine O +
treatment O +
benefited O +
19 O +
( O -
66 O -
% O -
) O +
out O +
of O +
29 O +
patients O +
suffering O +
from O +
severe O +
psoriasis B-Disease -
. O +

Haematological O +
complications O +
were O +
not O +
troublesome O +
and O +
results O +
of O +
biochemical O +
liver O +
function O +
tests O +
remained O +
normal O -
. O +

Minimal O +
cholestasis B-Disease +
was O +
seen O +
in O +
two O +
cases O +
and O +
portal O +
fibrosis B-Disease +
of O +
a O +
reversible O +
degree O +
in O +
eight O -
. O +

Liver O +
biopsies O +
should O +
be O +
undertaken O +
at O +
regular O +
intervals O +
if O +
azathioprine O +
therapy O +
is O +
continued O +
so O +
that O +
structural O +
liver B-Disease +
damage I-Disease +
may O +
be O +
detected O +
at O +
an O +
early O +
and O +
reversible O +
stage O -
. O +

Angiosarcoma B-Disease +
of B-Disease +
the I-Disease +
liver I-Disease +
associated O +
with O +
diethylstilbestrol O -
. O +

Angiosarcoma B-Disease +
of B-Disease +
the I-Disease +
liver I-Disease +
occurred O +
in O +
a O +
76-year O -
- O -
old O +
man O +
who O +
had O +
been O +
treated O +
for O +
a O +
well O -
- O -
differentiated O +
adenocarcinoma B-Disease +
of B-Disease +
the I-Disease +
liver I-Disease +
with O +
diethylstilbestrol O +
for O +
13 O +
years O -
. O +

Angiosarcoma B-Disease +
was O +
also O +
present O +
within O +
pulmonary O +
and O +
renal O +
arteries O -
. O +

The O +
possibility O +
that O +
the O +
intraarterial B-Disease +
lesions I-Disease +
might O +
represent O +
independent O +
primary O +
tumors B-Disease +
is O +
considered O -
. O +

Arterial O +
thromboembolism B-Disease +
in O +
patients O +
receiving O +
systemic O +
heparin O +
therapy O -
: O +
a O +
complication O +
associated O +
with O +
heparin O -
- O -
induced O +
thrombocytopenia B-Disease -
. O +

Arterial O +
thromboembolism B-Disease +
is O +
a O +
recognized O +
complication O +
of O +
systemic O +
heparin O +
therapy O -
. O +

Characteristic O +
of O +
the O +
entity O +
is O +
arterial B-Disease +
occlusion I-Disease +
by O +
platelet O -
- O -
fibrin O +
thrombi B-Disease +
with O +
distal O +
ischemia B-Disease +
occurring O +
four O +
to O +
twenty O +
days O +
after O +
the O +
initiation O +
of O +
heparin O +
therapy O -
, O +
preceded O +
by O +
profound O +
thrombocytopenia B-Disease +
with O +
platelet O +
counts O +
in O +
the O +
range O +
of O +
30,000 O +
to O +
40,000 O +
per O +
cubic O +
millimeter O -
. O +

The O +
clinically O +
apparent O +
occlusion O +
may O +
be O +
preceded O +
by O +
gastrointestinal B-Disease +
and I-Disease +
musculoskeletal I-Disease +
symptoms I-Disease +
that O +
appear O +
to O +
be O +
ischemic B-Disease +
in O +
origin O -
, O +
and O +
might O +
serve O +
to O +
warn O +
the O +
clinician O +
of O +
these O +
complications O -
. O +

Previous O +
reports O +
of O +
these O +
phenomena O +
as O +
well O +
as O +
recent O +
studies O +
of O +
the O +
effect O +
of O +
heparin O +
are O +
reviewed O -
. O +

The O +
common O +
factor O +
relating O +
thromboembolism B-Disease +
and O +
thrombocytopenia B-Disease +
is O +
heparin O -
- O -
induced O +
platelet B-Disease +
aggregation I-Disease -
. O +

Appropriate O +
treatment O +
consists O +
of O +
discontinuation O +
of O +
heparin O -
, O +
and O +
anticoagulation O +
with O +
sodium O +
warfarin O +
if O +
necessary O -
. O +

Vascular O +
procedures O +
are O +
performed O +
as O +
indicated O -
. O +

Galanthamine O +
hydrobromide O -
, O +
a O +
longer O +
acting O +
anticholinesterase O +
drug O -
, O +
in O +
the O +
treatment O +
of O +
the O +
central O +
effects O +
of O +
scopolamine O +
( O -
Hyoscine O -
) O -
. O +

Galanthamine O +
hydrobromide O -
, O +
an O +
anticholinesterase O +
drug O +
capable O +
of O +
penetrating O +
the O +
blood O -
- O -
brain O +
barrier O -
, O +
was O +
used O +
in O +
a O +
patient O +
demonstrating O +
central O +
effects O +
of O +
scopolamine O +
( O -
hyoscine O -
) O +
overdosage B-Disease -
. O +

It O +
is O +
longer O +
acting O +
than O +
physostigmine O +
and O +
is O +
used O +
in O +
anaesthesia O +
to O +
reverse O +
the O +
non O -
- O -
depolarizing O +
neuromuscular O +
block O -
. O +

However O -
, O +
studies O +
into O +
the O +
dose O +
necessary O +
to O +
combating O +
scopolamine O +
intoxication O +
are O +
indicated O -
. O +

Comparison O +
of O +
the O +
subjective O +
effects O +
and O +
plasma O +
concentrations O +
following O +
oral O +
and O +
i.m O -
. O +

administration O +
of O +
flunitrazepam O +
in O +
volunteers O -
. O +

Flunitrazepam O +
0.5 O -
, O +
1.0 O +
or O +
2.0 O +
mg O +
was O +
given O +
by O +
the O +
oral O +
or O +
i.m O -
. O +

routes O +
to O +
groups O +
of O +
volunteers O +
and O +
its O +
effects O +
compared O -
. O +

Plasma O +
concentrations O +
of O +
the O +
drug O +
were O +
estimated O +
by O +
gas O -
- O -
liquid O +
chromatography O -
, O +
in O +
a O +
smaller O +
number O +
of O +
the O +
subjects O -
. O +

The O +
most O +
striking O +
effect O +
was O +
sedation O +
which O +
increased O +
with O +
the O +
dose O -
, O +
2 O +
mg O +
producing O +
deep O +
sleep O +
although O +
the O +
subjects O +
could O +
still O +
be O +
aroused O -
. O +

The O +
effects O +
of O +
i.m O -
. O +

administration O +
were O +
apparent O +
earlier O +
and O +
sometimes O +
lasted O +
longer O +
than O +
those O +
following O +
oral O +
administration O -
. O +

Dizziness B-Disease +
was O +
less O +
marked O +
than O +
sedation O -
, O +
but O +
increased O +
with O +
the O +
dose O -
. O +

There O +
was O +
pain B-Disease +
on O +
i.m O -
. O +

injection O +
of O +
flunitrazepam O +
significantly O +
more O +
often O +
than O +
with O +
isotonic O +
saline O -
. O +

Plasma O +
concentrations O +
varied O +
with O +
dose O +
and O +
route O +
and O +
corresponded O +
qualitatively O +
with O +
the O +
subjective O +
effects O -
. O +

The O +
drug O +
was O +
still O +
present O +
in O +
measurable O +
quantities O +
after O +
24 O +
h O +
even O +
with O +
the O +
smallest O +
dose O -
. O +

Pharmacology O +
of O +
GYKI-41 O +
099 O +
( O -
chlorpropanol O -
, O +
Tobanum O -
) O +
a O +
new O +
potent O +
beta O -
- O -
adrenergic O +
antagonist O -
. O +

The O +
compound O +
GYKI-41 O +
099 O -
, O +
as O +
a O +
beta O -
- O -
adrenergic O +
antagonist O -
, O +
is O +
3 O -
- O -
8 O +
times O +
more O +
potent O +
than O +
propranolol O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Its O +
antiarrhythmic O +
effectiveness O +
surpasses O +
that O +
of O +
propranolol O +
and O +
pindolol O +
inhibiting O +
the O +
ouabain O +
arrhythmia B-Disease +
in O +
dogs O +
and O +
cats O -
. O +

GYKI-41 O +
900 O +
has O +
a O +
negligible O +
cardiodepressant O +
activity O -
; O +
it O +
is O +
not O +
cardioselective O -
. O +

The O +
compound O +
shows O +
a O +
rapid O +
and O +
long O +
lasting O +
effect O -
. O +

There O +
was O +
a O +
prolonged O +
elimination O +
of O +
the O +
radioactivity O +
after O +
the O +
injection O +
of O +
14C-41 O +
099 O +
to O +
rats O +
and O +
dogs O -
. O +

The O +
half O +
life O +
of O +
the O +
unlabeled O +
substance O +
in O +
humans O +
was O +
more O +
than O +
10 O +
hours O -
. O +

Adverse O +
reactions O +
to O +
bendrofluazide O +
and O +
propranolol O +
for O +
the O +
treatment O +
of O +
mild O +
hypertension B-Disease -
. O +

Report O +
of O +
Medical O +
Research O +
Council O +
Working O +
Party O +
on O +
Mild O +
to O +
Moderate O +
Hypertension B-Disease -
. O +

Participants O +
in O +
the O +
Medical O +
Research O +
Council O +
treatment O +
trial O +
for O +
mild O +
hypertension B-Disease +
are O +
randomly O +
allocated O +
to O +
one O +
of O +
four O +
treatment O +
groups O -
: O +
bendrofluazide O -
, O +
propranolol O -
, O +
or O +
a O +
placebo O +
for O +
either O +
of O +
these O +
drugs O -
. O +

The O +
trial O +
is O +
single O -
- O -
blind O -
. O +

23 O +
582 O +
patient O -
- O -
years O +
of O +
observation O +
have O +
been O +
completed O +
so O +
far O -
, O +
10 O +
684 O +
on O +
active O +
drugs O +
and O +
12 O +
898 O +
on O +
placebos O -
. O +

The O +
results O +
show O +
an O +
association O +
between O +
bendrofluazide O +
treatment O +
and O +
impotence B-Disease -
, O +
and O +
impotence B-Disease +
also O +
occurred O +
more O +
frequently O +
in O +
patients O +
taking O +
propranolol O +
than O +
in O +
those O +
taking O +
placebos O -
. O +

Other O +
adverse O +
reactions O +
significantly O +
linked O +
with O +
active O +
drugs O +
include O +
impaired B-Disease +
glucose I-Disease +
tolerance I-Disease +
in O +
men O +
and O +
women O +
and O +
gout B-Disease +
in O +
men O -
, O +
associated O +
with O +
bendrofluazide O +
treatment O -
, O +
and O +
Raynaud B-Disease -
's I-Disease +
phenomenon I-Disease +
and O +
dyspnoea B-Disease +
in O +
men O +
and O +
women O +
taking O +
propranolol O -
. O +

No O +
corneal B-Disease +
disease I-Disease +
is O +
known O +
to O +
have O +
occurred O +
in O +
the O +
propranolol O +
group O -
. O +

Mean O +
serum O +
potassium O +
level O +
fell O -
, O +
and O +
urea O +
and O +
uric O +
acid O +
levels O +
rose O -
, O +
in O +
men O +
and O +
women O +
taking O +
bendrofluazide O -
. O +

In O +
the O +
propranolol O +
group O -
, O +
serum O +
potassium O +
and O +
uric O +
acid O +
levels O +
rose O +
in O +
both O +
sexes O -
, O +
but O +
the O +
urea O +
level O +
rose O +
significantly O +
in O +
women O +
only O -
. O +

Serotonergic O +
drugs O -
, O +
benzodiazepines O +
and O +
baclofen O +
block O +
muscimol O -
- O -
induced O +
myoclonic B-Disease +
jerks I-Disease +
in O +
a O +
strain O +
of O +
mice O -
. O +

In O +
male O +
Swiss O +
mice O -
, O +
muscimol O +
produced O +
myoclonic B-Disease +
jerks I-Disease -
. O +

A O +
3 O +
mg O -
/ O -
kg O +
( O -
i.p O -
. O -
) O +
dose O +
induced O +
this O +
response O +
in O +
all O +
of O +
the O +
mice O +
tested O +
and O +
the O +
peak O +
response O +
of O +
73 O +
jerks O +
per O +
min O +
was O +
observed O +
between O +
27 O +
and O +
45 O +
min O -
. O +

Increasing O +
the O +
brain O +
serotonin O +
levels O +
by O +
the O +
administration O +
of O +
5-hydroxytryptophan O +
( O -
80 O -
- O -
160 O +
mg O -
/ O -
kg O -
) O +
in O +
combination O +
with O +
a O +
peripheral O +
decarboxylase O +
inhibitor O +
resulted O +
in O +
an O +
inhibition O +
of O +
the O +
muscimol O +
effect O -
. O +

However O -
, O +
in O +
a O +
similar O +
experiment O +
l O -
- O -
dopa O +
( O -
80 O -
- O -
160 O +
mg O -
/ O -
kg O -
) O +
was O +
without O +
effect O -
. O +

In O +
doses O +
of O +
3 O -
- O -
10 O +
mg O -
/ O -
kg O -
, O +
the O +
serotonin O +
receptor O +
agonist O +
MK-212 O +
caused O +
a O +
dose O -
- O -
dependent O +
blockade O +
of O +
the O +
response O +
of O +
muscimol O -
. O +

Of O +
the O +
benzodiazepines O -
, O +
clonazepam O +
( O -
0.1 O -
- O -
0.3 O +
mg O -
/ O -
kg O -
) O +
was O +
found O +
to O +
be O +
several O +
fold O +
more O +
potent O +
than O +
diazepam O +
( O -
0.3 O -
- O -
3 O +
mg O -
/ O -
kg O -
) O +
in O +
blocking O +
the O +
myoclonic B-Disease +
jerks I-Disease -
. O +

While O +
( O -
- O -
) O -
-baclofen O +
( O -
1 O -
- O -
3 O +
mg O -
/ O -
kg O -
) O +
proved O +
to O +
be O +
an O +
effective O +
antagonist O +
of O +
muscimol O -
, O +
its O +
( O -
+ O -
) O -
-isomer O +
( O -
5 O -
- O -
20 O +
mg O -
/ O -
kg O -
) O +
lacked O +
this O +
property O -
. O +

Considering O +
the O +
fact O +
that O +
5-HTP O +
and O +
the O +
benzodiazepines O +
have O +
been O +
found O +
to O +
be O +
beneficial O +
in O +
the O +
management O +
of O +
clinical O +
myoclonus B-Disease -
, O +
the O +
muscimol O -
- O -
induced O +
myoclonus B-Disease +
seems O +
to O +
be O +
a O +
satisfactory O +
animal O +
model O +
that O +
may O +
prove O +
useful O +
for O +
the O +
development O +
of O +
new O +
drug O +
treatments O +
for O +
this O +
condition O -
. O +

Our O +
present O +
study O +
indicated O +
the O +
possible O +
value O +
of O +
MK-212 O +
and O +
( O -
- O -
) O -
-baclofen O +
in O +
the O +
management O +
of O +
clinical O +
myoclonus B-Disease -
. O +

Adverse O +
interaction O +
between O +
beta O -
- O -
adrenergic O +
blocking O +
drugs O +
and O +
verapamil O -
-- O -
report O +
of O +
three O +
cases O -
. O +

Three O +
patients O +
with O +
ischaemic B-Disease +
heart I-Disease +
disease I-Disease +
developed O +
profound O +
cardiac B-Disease +
failure I-Disease -
, O +
hypotension B-Disease +
and O +
bradycardia B-Disease +
during O +
combined O +
therapy O +
with O +
verapamil O +
and O +
beta O -
- O -
adrenergic O +
blocking O +
drugs O -
. O +

This O +
clinical O +
picture O +
resolved O +
completely O +
with O +
cessation O +
of O +
the O +
combined O +
therapy O -
. O +

Baseline O +
left O +
ventricular O +
function O -
, O +
assessed O +
by O +
cardiac O +
catheterisation O +
or O +
nuclear O +
angiography O -
, O +
was O +
normal O +
in O +
two O +
patients O +
and O +
only O +
mildly O +
reduced O +
in O +
the O +
other O -
. O +

Simultaneously O +
administration O +
of O +
beta O -
- O -
adrenergic O +
blocking O +
drugs O +
and O +
verapamil O +
may O +
result O +
in O +
profound O +
adverse O +
interactions O +
and O +
should O +
only O +
be O +
administered O +
with O +
great O +
caution O -
. O +

Possible O +
teratogenicity O +
of O +
sulphasalazine O -
. O +

Three O +
infants O -
, O +
born O +
of O +
two O +
mothers O +
with O +
inflammatory B-Disease +
bowel I-Disease +
disease I-Disease +
who O +
received O +
treatment O +
with O +
sulphasalazine O +
throughout O +
pregnancy O -
, O +
were O +
found O +
to O +
have O +
major O +
congenital B-Disease +
anomalies I-Disease -
. O +

In O +
the O +
singleton O +
pregnancy O -
, O +
the O +
mother O +
had O +
ulcerative B-Disease +
colitis I-Disease -
, O +
and O +
the O +
infant O -
, O +
a O +
male O -
, O +
had O +
coarctation B-Disease +
of I-Disease +
the I-Disease +
aorta I-Disease +
and O +
a O +
ventricular B-Disease +
septal I-Disease +
defect I-Disease -
. O +

In O +
the O +
twin O +
pregnancy O -
, O +
the O +
mother O +
had O +
Crohn B-Disease -
's I-Disease +
disease I-Disease -
. O +

The O +
first O +
twin O -
, O +
a O +
female O -
, O +
had O +
a O +
left O +
Potter B-Disease -
- I-Disease -
type I-Disease +
IIa I-Disease +
polycystic I-Disease +
kidney I-Disease +
and O +
a O +
rudimentary B-Disease +
left I-Disease +
uterine I-Disease +
cornu I-Disease -
. O +

The O +
second O +
twin O -
, O +
a O +
male O -
, O +
had O +
some O +
features O +
of O +
Potter B-Disease -
's I-Disease +
facies I-Disease -
, O +
hypoplastic B-Disease +
lungs I-Disease -
, O +
absent B-Disease +
kidneys I-Disease +
and I-Disease +
ureters I-Disease -
, O +
and O +
talipes B-Disease +
equinovarus I-Disease -
. O +

Despite O +
reports O +
to O +
the O +
contrary O -
, O +
it O +
is O +
suggested O +
that O +
sulphasalazine O +
may O +
be O +
teratogenic O -
. O +

Comparison O +
of O +
the O +
effectiveness O +
of O +
ranitidine O +
and O +
cimetidine O +
in O +
inhibiting O +
acid O +
secretion O +
in O +
patients O +
with O +
gastric O +
hypersecretory O +
states O -
. O +

The O +
H2-histamine O +
receptor O +
antagonists O +
ranitidine O +
and O +
cimetidine O +
were O +
compared O +
for O +
their O +
abilities O +
to O +
control O +
gastric O +
acid O +
hypersecretion O +
on O +
a O +
short- O +
and O +
long O -
- O -
term O +
basis O +
in O +
22 O +
patients O +
with O +
gastric O +
acid O +
hypersecretory O +
states O -
. O +

Nineteen O +
patients O +
had O +
Zollinger B-Disease -
- I-Disease -
Ellison I-Disease +
syndrome I-Disease -
, O +
one O +
patient O +
had O +
systemic B-Disease +
mastocytosis I-Disease -
, O +
and O +
two O +
patients O +
had O +
idiopathic O +
hypersecretion O -
. O +

The O +
rates O +
of O +
onset O +
of O +
the O +
action O +
of O +
cimetidine O +
and O +
ranitidine O +
were O +
the O +
same O -
. O +

The O +
actions O +
of O +
both O +
drugs O +
were O +
increased O +
by O +
anticholinergic O +
agents O -
, O +
and O +
there O +
was O +
a O +
close O +
correlation O +
between O +
the O +
daily O +
maintenance O +
dose O +
of O +
each O +
drug O +
needed O +
to O +
control O +
acid O +
secretion O -
. O +

However O -
, O +
ranitidine O +
was O +
threefold O +
more O +
potent O +
than O +
cimetidine O +
both O +
in O +
acute O +
inhibition O +
studies O +
and O +
in O +
the O +
median O +
maintenance O +
dose O +
needed O +
( O -
1.2 O +
g O +
per O +
day O +
for O +
ranitidine O +
and O +
3.6 O +
g O +
per O +
day O +
for O +
cimetidine O -
) O -
. O +

Sixty O +
percent O +
of O +
the O +
males O +
developed O +
breast O +
changes O +
or O +
impotence B-Disease +
while O +
taking O +
cimetidine O +
and O +
in O +
all O +
cases O +
these O +
changes O +
disappeared O +
when O +
cimetidine O +
was O +
replaced O +
by O +
ranitidine O -
. O +

Treatment O +
with O +
high O +
doses O +
of O +
cimetidine O +
( O -
one O +
to O +
60 O +
months O -
; O +
median O -
, O +
11 O +
months O -
) O +
or O +
ranitidine O +
( O -
two O +
to O +
31 O +
months O -
; O +
median O -
, O +
14 O +
months O -
) O +
was O +
not O +
associated O +
with O +
hepatic B-Disease +
or I-Disease +
hematologic I-Disease +
toxicity I-Disease +
or O +
alterations O +
of O +
serum O +
gastrin O +
concentrations O -
, O +
but O +
ranitidine O +
therapy O +
was O +
associated O +
with O +
a O +
significantly O +
lower O +
serum O +
creatinine O +
level O +
than O +
seen O +
with O +
cimetidine O +
therapy O -
. O +

The O +
results O +
show O +
that O +
both O +
drugs O +
can O +
adequately O +
inhibit O +
acid O +
secretion O +
in O +
patients O +
with O +
gastric O +
hypersecretory O +
states O -
. O +

Both O +
are O +
safe O +
at O +
high O +
doses O -
, O +
but O +
ranitidine O +
is O +
threefold O +
more O +
potent O +
and O +
does O +
not O +
cause O +
the O +
antiandrogen O +
side O +
effects O +
frequently O +
seen O +
with O +
high O +
doses O +
of O +
cimetidine O -
. O +

Thrombotic B-Disease +
microangiopathy I-Disease +
and O +
renal B-Disease +
failure I-Disease +
associated O +
with O +
antineoplastic O +
chemotherapy O -
. O +

Five O +
patients O +
with O +
carcinoma B-Disease +
developed O +
thrombotic B-Disease +
microangiopathy I-Disease +
( O -
characterized O +
by O +
renal B-Disease +
insufficiency I-Disease -
, O +
microangiopathic B-Disease +
hemolytic I-Disease +
anemia I-Disease -
, O +
and O +
usually O +
thrombocytopenia B-Disease -
) O +
after O +
treatment O +
with O +
cisplatin O -
, O +
bleomycin O -
, O +
and O +
a O +
vinca O +
alkaloid O -
. O +

One O +
patient O +
had O +
thrombotic B-Disease +
thrombocytopenic I-Disease +
purpura I-Disease -
, O +
three O +
the O +
hemolytic B-Disease -
- I-Disease -
uremic I-Disease +
syndrome I-Disease -
, O +
and O +
one O +
an O +
apparent O +
forme O +
fruste O +
of O +
one O +
of O +
these O +
disorders O -
. O +

Histologic O +
examination O +
of O +
the O +
renal O +
tissue O +
showed O +
evidence O +
of O +
intravascular B-Disease +
coagulation I-Disease -
, O +
primarily O +
affecting O +
the O +
small O +
arteries O -
, O +
arterioles O -
, O +
and O +
glomeruli O -
. O +

Because O +
each O +
patient O +
was O +
tumor B-Disease -
- O -
free O +
or O +
had O +
only O +
a O +
small O +
tumor B-Disease +
at O +
the O +
onset O +
of O +
this O +
syndrome O -
, O +
the O +
thrombotic B-Disease +
microangiopathy I-Disease +
may O +
have O +
been O +
induced O +
by O +
chemotherapy O -
. O +

Diagnosis O +
of O +
this O +
potentially O +
fatal O +
complication O +
may O +
be O +
delayed O +
or O +
missed O +
if O +
renal O +
tissue O +
or O +
the O +
peripheral O +
blood O +
smear O +
is O +
not O +
examined O -
, O +
because O +
renal B-Disease +
failure I-Disease +
may O +
be O +
ascribed O +
to O +
cisplatin O +
nephrotoxicity B-Disease +
and O +
the O +
anemia B-Disease +
and O +
thrombocytopenia B-Disease +
to O +
drug O -
- O -
induced O +
bone B-Disease +
marrow I-Disease +
suppression I-Disease -
. O +

Development O +
of O +
isoproterenol O -
- O -
induced O +
cardiac B-Disease +
hypertrophy I-Disease -
. O +

The O +
development O +
of O +
cardiac B-Disease +
hypertrophy I-Disease +
was O +
studied O +
in O +
adult O +
female O +
Wistar O +
rats O +
following O +
daily O +
subcutaneous O +
injections O +
of O +
isoproterenol O +
( O -
ISO O -
) O +
( O -
0.3 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O -
. O +

A O +
time O +
course O +
was O +
established O +
for O +
the O +
change O +
in O +
tissue O +
mass O -
, O +
RNA O +
and O +
DNA O +
content O -
, O +
as O +
well O +
as O +
hydroxyproline O +
content O -
. O +

Heart O +
weight O +
increased O +
44 O -
% O +
after O +
8 O +
days O +
of O +
treatment O +
with O +
a O +
half O +
time O +
of O +
3.4 O +
days O -
. O +

Ventricular O +
RNA O +
content O +
was O +
elevated O +
26 O -
% O +
after O +
24 O +
h O +
of O +
a O +
single O +
injection O +
and O +
reached O +
a O +
maximal O +
level O +
following O +
8 O +
days O +
of O +
therapy O -
. O +

The O +
half O +
time O +
for O +
RNA O +
accumulation O +
was O +
2.0 O +
days O -
. O +

The O +
total O +
content O +
of O +
hydroxyproline O +
remained O +
stable O +
during O +
the O +
first O +
2 O +
days O +
of O +
treatment O +
but O +
increased O +
46 O -
% O +
after O +
4 O +
days O +
of O +
therapy O -
. O +

Ventricular O +
DNA O +
content O +
was O +
unchanged O +
during O +
the O +
early O +
stage O +
( O -
1 O -
- O -
4 O +
days O -
) O +
of O +
hypertrophic B-Disease +
growth O +
but O +
increased O +
to O +
a O +
new O +
steady O -
- O -
state O +
level O +
19 O -
% O +
above O +
the O +
controls O +
after O +
8 O +
days O +
of O +
treatment O -
. O +

Intraventricular O +
pressures O +
and O +
coronary O +
flow O +
measures O +
were O +
similar O +
for O +
control O +
and O +
experimental O +
animals O +
following O +
4 O +
days O +
of O +
developed O +
hypertrophy B-Disease -
. O +

However O -
, O +
dP O -
/ O -
dt O +
in O +
the O +
ISO O -
- O -
treated O +
hearts O +
was O +
slightly O +
but O +
significantly O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
elevated O -
. O +

These O +
data O +
indicate O +
that O +
the O +
adaptive O +
response O +
to O +
ISO O +
shows O +
an O +
early O +
hypertrophic B-Disease +
phase O +
( O -
1 O -
- O -
4 O +
days O -
) O +
characterized O +
by O +
a O +
substantial O +
increase O +
in O +
RNA O +
content O +
and O +
cardiac O +
mass O +
in O +
the O +
absence O +
of O +
changes O +
in O +
DNA O -
. O +

However O -
, O +
prolonged O +
stimulation O +
( O -
8 O -
- O -
12 O +
days O -
) O +
appears O +
to O +
represent O +
a O +
complex O +
integration O +
of O +
both O +
cellular O +
hypertrophy B-Disease +
and O +
hyperplasia B-Disease +
within O +
the O +
heart O -
. O +

International O +
mexiletine O +
and O +
placebo O +
antiarrhythmic O +
coronary O +
trial O -
: O +
I. O +
Report O +
on O +
arrhythmia B-Disease +
and O +
other O +
findings O -
. O +

Impact O +
Research O +
Group O -
. O +

The O +
antiarrhythmic O +
effects O +
of O +
the O +
sustained O +
release O +
form O +
of O +
mexiletine O +
( O -
Mexitil O -
- O -
Perlongets O -
) O +
were O +
evaluated O +
in O +
a O +
double O -
- O -
blind O +
placebo O +
trial O +
in O +
630 O +
patients O +
with O +
recent O +
documented O +
myocardial B-Disease +
infarction I-Disease -
. O +

The O +
primary O +
response O +
variable O +
was O +
based O +
on O +
central O +
reading O +
of O +
24 O +
hour O +
ambulatory O +
electrocardiographic O +
recordings O +
and O +
was O +
defined O +
as O +
the O +
occurrence O +
of O +
30 O +
or O +
more O +
single O +
premature O +
ventricular O +
complexes O +
in O +
any O +
two O +
consecutive O +
30 O +
minute O +
blocks O +
or O +
one O +
or O +
more O +
runs O +
of O +
two O +
or O +
more O +
premature O +
ventricular O +
complexes O +
in O +
the O +
entire O +
24 O +
hour O +
electrocardiographic O +
recording O -
. O +

Large O +
differences O -
, O +
regarded O +
as O +
statistically O +
significant O -
, O +
between O +
the O +
mexiletine O +
and O +
placebo O +
groups O +
were O +
noted O +
in O +
that O +
end O +
point O +
at O +
months O +
1 O +
and O +
4 O -
, O +
but O +
only O +
trends O +
were O +
observed O +
at O +
month O +
12 O -
. O +

These O +
differences O +
were O +
observed O +
even O +
though O +
the O +
serum O +
mexiletine O +
levels O +
obtained O +
in O +
this O +
study O +
were O +
generally O +
lower O +
than O +
those O +
observed O +
in O +
studies O +
that O +
have O +
used O +
the O +
regular O +
form O +
of O +
the O +
drug O -
. O +

There O +
were O +
more O +
deaths B-Disease +
in O +
the O +
mexiletine O +
group O +
( O -
7.6 O -
% O -
) O +
than O +
in O +
the O +
placebo O +
group O +
( O -
4.8 O -
% O -
) O -
; O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
. O +

The O +
incidence O +
of O +
coronary O +
events O +
was O +
similar O +
in O +
both O +
groups O -
. O +

Previously O +
recognized O +
side O +
effects O -
, O +
particularly O +
tremor B-Disease +
and O +
gastrointestinal B-Disease +
problems I-Disease -
, O +
were O +
more O +
frequent O +
in O +
the O +
mexiletine O +
group O +
than O +
in O +
the O +
placebo O +
group O -
. O +

Multiple O +
side O +
effects O +
of O +
penicillamine O +
therapy O +
in O +
one O +
patient O +
with O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

Skin B-Disease +
rashes I-Disease -
, O +
proteinuria B-Disease -
, O +
systemic B-Disease +
lupus I-Disease +
erythematosus I-Disease -
, O +
polymyositis B-Disease +
and O +
myasthenia B-Disease +
gravis I-Disease +
have O +
all O +
been O +
recorded O +
as O +
complications O +
of O +
penicillamine O +
therapy O +
in O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

A O +
patient O +
who O +
had O +
developed O +
all O +
5 O +
is O +
now O +
described O -
. O +

The O +
skin B-Disease +
lesion I-Disease +
resembled O +
elastosis B-Disease +
perforans I-Disease +
serpiginosa I-Disease -
, O +
which O +
has O +
been O +
reported O +
as O +
a O +
rare O +
side O +
effect O +
in O +
patients O +
with O +
Wilson B-Disease -
's I-Disease +
disease I-Disease +
but O +
not O +
in O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
treated O +
with O +
penicillamine O -
. O +

Changes O +
in O +
heart O +
size O +
during O +
long O -
- O -
term O +
timolol O +
treatment O +
after O +
myocardial B-Disease +
infarction I-Disease -
. O +

The O +
effect O +
of O +
long O -
- O -
term O +
timolol O +
treatment O +
on O +
heart O +
size O +
after O +
myocardial B-Disease +
infarction I-Disease +
was O +
evaluated O +
by O +
X O -
- O -
ray O +
in O +
a O +
double O -
- O -
blind O +
study O +
including O +
241 O +
patients O +
( O -
placebo O +
126 O -
, O +
timolol O +
115 O -
) O -
. O +

The O +
follow O -
- O -
up O +
period O +
was O +
12 O +
months O -
. O +

The O +
timolol O -
- O -
treated O +
patients O +
showed O +
a O +
small O +
but O +
significant O +
increase O +
in O +
heart O +
size O +
from O +
baseline O +
in O +
contrast O +
to O +
a O +
decrease O +
in O +
the O +
placebo O +
group O -
. O +

These O +
differences O +
may O +
be O +
caused O +
by O +
timolol O -
- O -
induced O +
bradycardia B-Disease +
and O +
a O +
compensatory O +
increase O +
in O +
end O -
- O -
diastolic O +
volume O -
. O +

The O +
timolol O -
- O -
related O +
increase O +
in O +
heart O +
size O +
was O +
observed O +
only O +
in O +
patients O +
with O +
normal O +
and O +
borderline O +
heart O +
size O -
. O +

In O +
patients O +
with O +
cardiomegaly B-Disease -
, O +
the O +
increase O +
in O +
heart O +
size O +
was O +
similar O +
in O +
both O +
groups O -
. O +

After O +
re O -
- O -
infarction B-Disease -
, O +
heart O +
size O +
increased O +
in O +
the O +
placebo O +
group O +
and O +
remained O +
unchanged O +
in O +
the O +
timolol O +
group O -
. O +

Obsolete O +
but O +
dangerous O +
antacid O +
preparations O -
. O +

One O +
case O +
of O +
acute O +
hypercalcaemia B-Disease +
and O +
two O +
of O +
recurrent O +
nephrolithiasis B-Disease +
are O +
reported O +
in O +
patients O +
who O +
had O +
regularly O +
consumed O +
large O +
amounts O +
of O +
calcium O +
carbon O -
- O -
ate O -
- O -
sodium O +
bicarbonate O +
powders O +
for O +
more O +
than O +
20 O +
years O -
. O +

The O +
powders O +
had O +
been O +
obtained O +
from O +
pharmacists O +
unknown O +
to O +
the O +
patients O -
' O +
medical O +
practitioners O -
. O +

It O +
is O +
suggested O +
that O +
these O +
preparations O +
were O +
responsible O +
for O +
the O +
patient O -
's O +
problems O -
, O +
and O +
that O +
such O +
powders O +
should O +
no O +
longer O +
be O +
freely O +
obtainable O -
. O +

Vitamin O +
D3 O +
toxicity B-Disease +
in O +
dairy O +
cows O -
. O +

Large O +
parenteral O +
doses O +
of O +
vitamin O +
D3 O +
( O -
15 O +
to O +
17.5 O +
x O +
10 O -
( O -
6 O -
) O +
IU O +
vitamin O +
D3 O -
) O +
were O +
associated O +
with O +
prolonged O +
hypercalcemia B-Disease -
, O +
hyperphosphatemia B-Disease -
, O +
and O +
large O +
increases O +
of O +
vitamin O +
D3 O +
and O +
its O +
metabolites O +
in O +
the O +
blood O +
plasma O +
of O +
nonlactating O +
nonpregnant O +
and O +
pregnant O +
Jersey O +
cows O -
. O +

Calcium O +
concentrations O +
1 O +
day O +
postpartum O +
were O +
higher O +
in O +
cows O +
treated O +
with O +
vitamin O +
D3 O +
about O +
32 O +
days O +
prepartum O +
( O -
8.8 O +
mg O -
/ O -
100 O +
ml O -
) O +
than O +
in O +
control O +
cows O +
( O -
5.5 O +
mg O -
/ O -
100 O +
ml O -
) O -
. O +

None O +
of O +
the O +
cows O +
treated O +
with O +
vitamin O +
D3 O +
showed O +
signs O +
of O +
milk B-Disease +
fever I-Disease +
during O +
the O +
peripartal O +
period O -
; O +
however O -
, O +
22 O -
% O +
of O +
the O +
control O +
cows O +
developed O +
clinical O +
signs O +
of O +
milk B-Disease +
fever I-Disease +
during O +
this O +
period O -
. O +

Signs O +
of O +
vitamin O +
D3 O +
toxicity B-Disease +
were O +
not O +
observed O +
in O +
nonlactating O +
nonpregnant O +
cows O -
; O +
however O -
, O +
pregnant O +
cows O +
commonly O +
developed O +
severe O +
signs O +
of O +
vitamin O +
D3 O +
toxicity B-Disease +
and O +
10 O +
of O +
17 O +
cows O +
died O -
. O +

There O +
was O +
widespread O +
metastatic O +
calcification O +
in O +
the O +
cows O +
that O +
died O -
. O +

Because O +
of O +
the O +
extreme O +
toxicity B-Disease +
of O +
vitamin O +
D3 O +
in O +
pregnant O +
Jersey O +
cows O +
and O +
the O +
low O +
margin O +
of O +
safety O +
between O +
doses O +
of O +
vitamin O +
D3 O +
that O +
prevent O +
milk B-Disease +
fever I-Disease +
and O +
doses O +
that O +
induce O +
milk B-Disease +
fever I-Disease -
, O +
we O +
concluded O +
that O +
vitamin O +
D3 O +
can O -
not O +
be O +
used O +
practically O +
to O +
prevent O +
milk B-Disease +
fever I-Disease +
when O +
injected O +
several O +
weeks O +
prepartum O -
. O +

Diseases B-Disease +
of I-Disease +
peripheral I-Disease +
nerves I-Disease +
as O +
seen O +
in O +
the O +
Nigerian O +
African O -
. O +

The O +
anatomical O +
and O +
aetiological O +
diagnoses O +
of O +
peripheral B-Disease +
nerve I-Disease +
disease I-Disease +
excluding O +
its O +
primary O +
benign O +
and O +
malignant O +
disorders O -
, O +
as O +
seen O +
in O +
358 O +
Nigerians O +
are O +
presented O -
. O +

There O +
is O +
a O +
male O +
preponderance O +
and O +
the O +
peak O +
incidence O +
is O +
in O +
the O +
fourth O +
decade O -
. O +

Sensori B-Disease -
- I-Disease -
motor I-Disease +
neuropathy I-Disease +
was O +
the O +
commonest O +
presentation O +
( O -
50 O -
% O -
) O -
. O +

Guillain B-Disease -
- I-Disease -
Barr I-Disease +
syndrome I-Disease +
was O +
the O +
commonest O +
identifiable O +
cause O +
( O -
15.6 O -
% O -
) O -
, O +
accounting O +
for O +
half O +
of O +
the O +
cases O +
with O +
motor B-Disease +
neuropathy I-Disease -
. O +

Peripheral B-Disease +
neuropathy I-Disease +
due O +
to O +
nutritional B-Disease +
deficiency I-Disease +
of O +
thiamine O +
and O +
riboflavin O +
was O +
common O +
( O -
10.1 O -
% O -
) O +
and O +
presented O +
mainly O +
as O +
sensory O +
and O +
sensori B-Disease -
- I-Disease -
motor I-Disease +
neuropathy I-Disease -
. O +

Diabetes B-Disease +
mellitus I-Disease +
was O +
the O +
major O +
cause O +
of O +
autonomic B-Disease +
neuropathy I-Disease -
. O +

Isoniazid O +
was O +
the O +
most O +
frequent O +
agent O +
in O +
drug O -
- O -
induced O +
neuropathy B-Disease -
. O +

Migraine B-Disease +
( O -
20 O -
% O -
) O +
was O +
not O +
an O +
uncommon O +
cause O +
of O +
cranial B-Disease +
neuropathy I-Disease +
although O +
malignancies B-Disease +
arising O +
from O +
the O +
reticuloendothelial O +
system O +
or O +
related O +
structures O +
of O +
the O +
head O +
and O +
neck O +
were O +
more O +
frequent O +
( O -
26 O -
% O -
) O -
. O +

In O +
26.5 O -
% O +
of O +
all O +
the O +
cases O -
, O +
the O +
aetiology O +
of O +
the O +
neuropathy B-Disease +
was O +
undetermined O -
. O +

Heredofamilial O +
and O +
connective B-Disease +
tissue I-Disease +
disorders I-Disease +
were O +
rare O -
. O +

Some O +
of O +
the O +
factors O +
related O +
to O +
the O +
clinical O +
presentation O +
and O +
pathogenesis O +
of O +
the O +
neuropathies B-Disease +
are O +
briefly O +
discussed O -
. O +

Doxorubicin O +
cardiomyopathy B-Disease +
in O +
children O +
with O +
left O -
- O -
sided O +
Wilms B-Disease +
tumor I-Disease -
. O +

Two O +
children O +
with O +
Wilms B-Disease +
tumor I-Disease +
of O +
the O +
left O +
kidney O +
experienced O +
severe O +
anthracycline O +
cardiomyopathy B-Disease +
after O +
irradiation O +
to O +
the O +
tumor B-Disease +
bed O +
and O +
conventional O +
dosage O +
of O +
doxorubicin O -
. O +

The O +
cardiomyopathy B-Disease +
is O +
attributed O +
1 O -
) O +
to O +
the O +
fact O +
that O +
radiation O +
fields O +
for O +
left O +
Wilms B-Disease +
tumor I-Disease +
include O +
the O +
lower O +
portion O +
of O +
the O +
heart O +
and O +
2 O -
) O +
to O +
the O +
interaction O +
of O +
doxorubicin O +
and O +
irradiation O +
on O +
cardiac O +
muscle O -
. O +

It O +
is O +
recommended O +
that O +
doxorubicin O +
dosage O +
be O +
sharply O +
restricted O +
in O +
children O +
with O +
Wilms B-Disease +
tumor I-Disease +
of O +
the O +
left O +
kidney O +
who O +
receive O +
postoperative O +
irradiation O -
. O +

Effects O +
of O +
calcitonin O +
on O +
rat O +
extrapyramidal O +
motor O +
system O -
: O +
behavioral O +
and O +
biochemical O +
data O -
. O +

The O +
effects O +
of O +
i.v.c O -
. O +

injection O +
of O +
human O +
and O +
salmon O +
calcitonin O +
on O +
biochemical O +
and O +
behavioral O +
parameters O +
related O +
to O +
the O +
extrapyramidal O +
motor O +
system O -
, O +
were O +
investigated O +
in O +
male O +
rats O -
. O +

Calcitonin O +
injection O +
resulted O +
in O +
a O +
potentiation O +
of O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
and O +
a O +
partial O +
prevention O +
of O +
apomorphine O -
- O -
induced O +
hyperactivity B-Disease -
. O +

Moreover O +
calcitonin O +
induced O +
a O +
significant O +
decrease O +
in O +
nigral O +
GAD O +
activity O +
but O +
no O +
change O +
in O +
striatal O +
DA O +
and O +
DOPAC O +
concentration O +
or O +
GAD O +
activity O -
. O +

The O +
results O +
are O +
discussed O +
in O +
view O +
of O +
a O +
primary O +
action O +
of O +
calcitonin O +
on O +
the O +
striatonigral O +
GABAergic O +
pathway O +
mediating O +
the O +
DA O -
- O -
related O +
behavioral O +
messages O +
of O +
striatal O +
origin O -
. O +

Reduction O +
in O +
caffeine O +
toxicity B-Disease +
by O +
acetaminophen O -
. O +

A O +
patient O +
who O +
allegedly O +
consumed O +
100 O +
tablets O +
of O +
an O +
over O -
- O -
the O -
- O -
counter O +
analgesic O +
containing O +
sodium O +
acetylsalicylate O -
, O +
caffeine O -
, O +
and O +
acetaminophen O +
displayed O +
no O +
significant O +
CNS O +
stimulation O +
despite O +
the O +
presence O +
of O +
175 O +
micrograms O +
of O +
caffeine O +
per O +
mL O +
of O +
serum O -
. O +

Because O +
salicylates O +
have O +
been O +
reported O +
to O +
augment O +
the O +
stimulatory O +
effects O +
of O +
caffeine O +
on O +
the O +
CNS O -
, O +
attention O +
was O +
focused O +
on O +
the O +
possibility O +
that O +
the O +
presence O +
of O +
acetaminophen O +
( O -
52 O +
micrograms O -
/ O -
mL O -
) O +
reduced O +
the O +
CNS O +
toxicity B-Disease +
of O +
caffeine O -
. O +

Studies O +
in O +
DBA O -
/ O -
2J O +
mice O +
showed O +
that O -
: O +
1 O -
) O +
pretreatment O +
with O +
acetaminophen O +
( O -
100 O +
mg O -
/ O -
kg O -
) O +
increased O +
the O +
interval O +
between O +
the O +
administration O +
of O +
caffeine O +
( O -
300 O +
to O +
450 O +
mg O -
/ O -
kg O +
IP O -
) O +
and O +
the O +
onset O +
of O +
fatal O +
convulsions B-Disease +
by O +
a O +
factor O +
of O +
about O +
two O -
; O +
and O +
2 O -
) O +
pretreatment O +
with O +
acetaminophen O +
( O -
75 O +
mg O -
/ O -
kg O -
) O +
reduced O +
the O +
incidence O +
of O +
audiogenic O +
seizures B-Disease +
produced O +
in O +
the O +
presence O +
of O +
caffeine O +
( O -
12.5 O +
to O +
75 O +
mg O -
/ O -
kg O +
IP O -
) O -
. O +

The O +
frequency O +
of O +
sound O -
- O -
induced O +
seizures B-Disease +
after O +
12.5 O +
or O +
25 O +
mg O -
/ O -
kg O +
caffeine O +
was O +
reduced O +
from O +
50 O +
to O +
5 O -
% O +
by O +
acetaminophen O -
. O +

In O +
the O +
absence O +
of O +
caffeine O -
, O +
acetaminophen O +
( O -
up O +
to O +
300 O +
mg O -
/ O -
kg O -
) O +
did O +
not O +
modify O +
the O +
seizures B-Disease +
induced O +
by O +
maximal O +
electroshock O +
and O +
did O +
not O +
alter O +
the O +
convulsant O +
dose O +
of O +
pentylenetetrezol O +
in O +
mice O +
( O -
tests O +
performed O +
by O +
the O +
Anticonvulsant O +
Screening O +
Project O +
of O +
NINCDS O -
) O -
. O +

Acetaminophen O +
( O -
up O +
to O +
150 O +
micrograms O -
/ O -
mL O -
) O +
did O +
not O +
retard O +
the O +
incorporation O +
of O +
radioactive O +
adenosine O +
into O +
ATP O +
in O +
slices O +
of O +
rat O +
cerebral O +
cortex O -
. O +

Thus O +
the O +
mechanism O +
by O +
which O +
acetaminophen O +
antagonizes O +
the O +
actions O +
of O +
caffeine O +
in O +
the O +
CNS O +
remains O +
unknown O -
. O +

Modification O +
of O +
drug O +
action O +
by O +
hyperammonemia B-Disease -
. O +

Pretreatment O +
with O +
ammonium O +
acetate O +
( O -
NH4Ac O -
) O +
( O -
6 O +
mmol O -
/ O -
kg O +
s.c O -
. O -
) O +
approximately O +
doubled O +
the O +
time O +
morphine O -
- O -
treated O +
mice O +
remained O +
on O +
a O +
hot O +
surface O +
and O +
similarly O +
increased O +
muscular O +
incoordination B-Disease +
by O +
diazepam O -
, O +
but O +
NH4Ac O +
treatment O +
alone O +
had O +
no O +
effect O -
. O +

Thus O -
, O +
hyperammonemia B-Disease +
is O +
capable O +
of O +
altering O +
drug O +
action O +
and O +
must O +
be O +
considered O +
along O +
with O +
impaired O +
drug O +
metabolism O +
in O +
enhanced O +
drug O +
responses O +
associated O +
with O +
liver B-Disease +
disease I-Disease -
. O +

Experiments O +
in O +
vitro O +
showed O +
that O +
acetylcholine O -
- O -
induced O +
catecholamine O +
release O +
from O +
bovine O +
adrenal O +
medulla O +
is O +
depressed O +
as O +
much O +
as O +
50 O -
% O +
by O +
0.3 O +
mM O +
NH4Ac O +
and O +
KCl O -
- O -
induced O +
contractions O +
of O +
guinea O -
- O -
pig O +
ileum O +
were O +
inhibited O +
20 O -
% O +
by O +
5 O +
mM O +
NH4Ac O -
. O +

Addition O +
of O +
excess O +
calcium O +
reversed O +
the O +
depression B-Disease +
in O +
both O +
tissues O -
, O +
but O +
calcium O -
- O -
independent O +
catecholamine O +
release O +
by O +
acetaldehyde O +
was O +
not O +
blocked O +
by O +
NH4Ac O -
. O +

These O +
results O +
suggested O +
that O +
ammonia O +
blocks O +
calcium O +
channels O -
. O +

Parallels O +
in O +
the O +
actions O +
of O +
NH4Ac O +
and O +
the O +
calcium O +
channel O +
blocker O +
verapamil O +
support O +
this O +
concept O -
. O +

Both O +
verapamil O +
( O -
10 O +
mg O -
/ O -
kg O +
i.p O -
. O -
) O +
and O +
NH4Ac O +
pretreatment O +
enhanced O +
morphine O +
analgesia- B-Disease +
and O +
diazepam O -
- O -
induced O +
muscular O +
incoordination B-Disease +
and O +
antagonized O +
amphetamine O -
- O -
induced O +
motor O +
activity O -
, O +
and O +
neither O +
verapamil O +
nor O +
NH4Ac O +
affected O +
the O +
convulsant O +
action O +
of O +
metrazol O -
. O +

The O +
data O +
suggest O +
that O +
hyperammonemia B-Disease +
exerts O +
a O +
calcium O +
channel O +
blocking O +
action O +
which O +
enhances O +
the O +
effects O +
of O +
central O +
nervous O +
system O +
depressants O +
and O +
certain O +
opioid O +
analgesics O -
. O +

Levodopa O -
- O -
induced O +
dyskinesia B-Disease +
and O +
thalamotomy O -
. O +

Levodopa O -
- O -
induced O +
dyskinesia B-Disease +
of O +
the O +
limbs O +
in O +
thirteen O +
cases O +
of O +
Parkinsonism B-Disease -
, O +
which O +
was O +
choreic O -
, O +
ballistic O +
or O +
dystonic B-Disease +
in O +
type O -
, O +
was O +
alleviated O +
almost O +
completely O +
by O +
stereotaxic O +
surgery O +
using O +
a O +
microelectrode O +
technique O +
for O +
the O +
ventralis O +
oralis O +
anterior O +
and O +
posterior O +
nuclei O +
of O +
the O +
thalamus O -
, O +
but O +
much O +
less O +
by O +
the O +
ventralis O +
intermedius O +
nucleus O -
. O +

Control O +
of O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
by O +
thalamic B-Disease +
lesions I-Disease +
in O +
the O +
course O +
of O +
routine O +
treatment O +
of O +
Parkinsonism B-Disease +
is O +
discussed O -
. O +

A O +
double O -
- O -
blind O +
study O +
of O +
the O +
efficacy O +
and O +
safety O +
of O +
dothiepin O +
hydrochloride O +
in O +
the O +
treatment O +
of O +
major O +
depressive B-Disease +
disorder I-Disease -
. O +

In O +
a O +
6-week O +
double O -
- O -
blind O +
parallel O +
treatment O +
study O -
, O +
dothiepin O +
and O +
amitriptyline O +
were O +
compared O +
to O +
placebo O +
in O +
the O +
treatment O +
of O +
33 O +
depressed B-Disease +
outpatients O -
. O +

Dothiepin O +
and O +
amitriptyline O +
were O +
equally O +
effective O +
in O +
alleviating O +
the O +
symptoms O +
of O +
depressive B-Disease +
illness I-Disease -
, O +
and O +
both O +
were O +
significantly O +
superior O +
to O +
placebo O -
. O +

The O +
overall O +
incidence O +
of O +
side O +
effects O +
and O +
the O +
frequency O +
and O +
severity O +
of O +
blurred B-Disease +
vision I-Disease -
, O +
dry B-Disease +
mouth I-Disease -
, O +
and O +
drowsiness O +
were O +
significantly O +
less O +
with O +
dothiepin O +
than O +
with O +
amitriptyline O -
. O +

Dothiepin O +
also O +
produced O +
fewer O +
CNS O +
and O +
cardiovascular O +
effects O -
. O +

There O +
were O +
no O +
clinically O +
important O +
changes O +
in O +
laboratory O +
parameters O -
. O +

Dothiepin O +
thus O +
was O +
found O +
to O +
be O +
an O +
effective O +
antidepressant O +
drug O +
associated O +
with O +
fewer O +
side O +
effects O +
than O +
amitriptyline O +
in O +
the O +
treatment O +
of O +
depressed B-Disease +
outpatients O -
. O +

Behavioral O +
effects O +
of O +
diazepam O +
and O +
propranolol O +
in O +
patients O +
with O +
panic B-Disease +
disorder I-Disease +
and O +
agoraphobia B-Disease -
. O +

The O +
effects O +
of O +
oral O +
doses O +
of O +
diazepam O +
( O -
single O +
dose O +
of O +
10 O +
mg O +
and O +
a O +
median O +
dose O +
of O +
30 O +
mg O -
/ O -
day O +
for O +
2 O +
weeks O -
) O +
and O +
propranolol O +
( O -
single O +
dose O +
of O +
80 O +
mg O +
and O +
a O +
median O +
dose O +
of O +
240 O +
mg O -
/ O -
day O +
for O +
2 O +
weeks O -
) O +
on O +
psychological O +
performance O +
of O +
patients O +
with O +
panic B-Disease +
disorders I-Disease +
and O +
agoraphobia B-Disease +
were O +
investigated O +
in O +
a O +
double O -
- O -
blind O -
, O +
randomized O +
and O +
crossover O +
design O -
. O +

Both O +
drugs O +
impaired B-Disease +
immediate I-Disease +
free I-Disease +
recall I-Disease +
but O +
the O +
decrease O +
was O +
greater O +
for O +
diazepam O +
than O +
propranolol O -
. O +

Delayed B-Disease +
free I-Disease +
recall I-Disease +
was I-Disease +
also I-Disease +
impaired I-Disease +
but O +
the O +
two O +
drugs O +
did O +
not O +
differ O -
. O +

Patients O +
tapped O +
faster O +
after O +
propranolol O +
than O +
diazepam O +
and O +
they O +
were O +
more O +
sedated O +
after O +
diazepam O +
than O +
propranolol O -
. O +

After O +
2 O +
weeks O +
of O +
treatment O -
, O +
patients O +
tested O +
5 O -
- O -
8 O +
h O +
after O +
the O +
last O +
dose O +
of O +
medication O +
did O +
not O +
show O +
any O +
decrement O +
of O +
performance O -
. O +

These O +
results O +
are O +
similar O +
to O +
those O +
previously O +
found O +
in O +
healthy O +
subjects O -
. O +

Accumulation O +
of O +
drugs O +
was O +
not O +
reflected O +
in O +
prolonged O +
behavioral B-Disease +
impairment I-Disease -
. O +

Myoclonic B-Disease -
, I-Disease +
atonic I-Disease -
, I-Disease +
and I-Disease +
absence I-Disease +
seizures I-Disease +
following O +
institution O +
of O +
carbamazepine O +
therapy O +
in O +
children O -
. O +

Five O +
children O -
, O +
aged O +
3 O +
to O +
11 O +
years O -
, O +
treated O +
with O +
carbamazepine O +
for O +
epilepsy B-Disease -
, O +
had O +
an O +
acute O +
aberrant O +
reaction O +
characterized O +
by O +
the O +
onset O +
of O +
myoclonic B-Disease -
, I-Disease +
atypical I-Disease +
absence I-Disease +
and/or I-Disease +
atonic I-Disease +
( I-Disease -
minor I-Disease +
motor I-Disease -
) I-Disease +
seizures I-Disease +
within O +
a O +
few O +
days O -
. O +

When O +
the O +
carbamazepine O +
was O +
discontinued O -
, O +
two O +
of O +
the O +
children O +
returned O +
to O +
their O +
former O +
state O +
very O +
quickly O -
, O +
two O +
had O +
the O +
minor O +
motor O +
seizures B-Disease +
resolve O +
in O +
3 O +
and O +
6 O +
months O -
, O +
and O +
one O +
had O +
the O +
seizures B-Disease +
persist O -
. O +

The O +
child O +
in O +
whom O +
the O +
seizures B-Disease +
persisted O +
was O +
later O +
found O +
to O +
have O +
ceroid B-Disease +
lipofuscinosis I-Disease -
. O +

The O +
other O +
children O +
are O +
doing O +
well O +
on O +
other O +
anticonvulsants O -
. O +

Effect O +
of O +
prostaglandin O +
synthetase O +
inhibitors O +
on O +
experimentally O +
induced O +
convulsions B-Disease +
in O +
rats O -
. O +

To O +
investigate O +
the O +
relationship O +
of O +
prostaglandins O +
( O -
PGs O -
) O +
to O +
seizure B-Disease +
induction O -
, O +
the O +
effects O +
of O +
six O +
PG O +
synthetase O +
inhibitors O +
on O +
convulsions B-Disease +
induced O +
by O +
flurothyl O -
, O +
picrotoxin O -
, O +
pentetrazol O +
( O -
PTZ O -
) O -
, O +
electroshock O +
or O +
bicuculline O +
were O +
evaluated O -
. O +

Ibuprofen O -
, O +
sulindac O -
, O +
mefenamic O +
acid O -
, O +
and O +
low O +
dose O +
meclofenamic O +
acid O +
increased O +
the O +
latency O -
- O -
to O -
- O -
onset O +
in O +
the O +
flurothyl O +
and/or O +
PTZ O +
models O -
; O +
the O +
electroshock O -
, O +
picrotoxin O +
and O +
bicuculline O +
models O +
were O +
not O +
significantly O +
affected O +
by O +
any O +
of O +
the O +
pretreatment O +
agents O -
. O +

These O +
results O +
suggest O +
that O +
PGs O +
are O +
involved O +
in O +
the O +
mechanism O -
( O -
s O -
) O +
underlying O +
fluorthyl- O +
and O +
PTZ O -
- O -
induced O +
convulsions B-Disease -
, O +
but O +
not O +
picrotoxin- O -
, O +
electroshock- O -
, O +
or O +
bicuculline O -
- O -
induced O +
convulsions B-Disease -
. O +

Acute O +
changes O +
of O +
blood O +
ammonia O +
may O +
predict O +
short O -
- O -
term O +
adverse O +
effects O +
of O +
valproic O +
acid O -
. O +

Valproic O +
acid O +
( O -
VPA O -
) O +
was O +
given O +
to O +
24 O +
epileptic B-Disease +
patients O +
who O +
were O +
already O +
being O +
treated O +
with O +
other O +
antiepileptic O +
drugs O -
. O +

A O +
standardized O +
loading O +
dose O +
of O +
VPA O +
was O +
administered O -
, O +
and O +
venous O +
blood O +
was O +
sampled O +
at O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
and O +
4 O +
hours O -
. O +

Ammonia O +
( O -
NH3 O -
) O +
was O +
higher O +
in O +
patients O +
who O -
, O +
during O +
continuous O +
therapy O -
, O +
complained O +
of O +
drowsiness B-Disease +
( O -
7 O +
patients O -
) O +
than O +
in O +
those O +
who O +
were O +
symptom O -
- O -
free O +
( O -
17 O +
patients O -
) O -
, O +
although O +
VPA O +
plasma O +
levels O +
were O +
similar O +
in O +
both O +
groups O -
. O +

By O +
measuring O +
VPA O -
- O -
induced O +
changes O +
of O +
blood O +
NH3 O +
content O -
, O +
it O +
may O +
be O +
possible O +
to O +
identify O +
patients O +
at O +
higher O +
risk O +
of O +
obtundation O +
when O +
VPA O +
is O +
given O +
chronically O -
. O +

Comparison O +
of O +
i.v O -
. O +

glycopyrrolate O +
and O +
atropine O +
in O +
the O +
prevention O +
of O +
bradycardia B-Disease +
and O +
arrhythmias B-Disease +
following O +
repeated O +
doses O +
of O +
suxamethonium O +
in O +
children O -
. O +

The O +
effectiveness O +
of O +
administration O +
of O +
glycopyrrolate O +
5 O +
and O +
10 O +
micrograms O +
kg-1 O +
and O +
atropine O +
10 O +
and O +
20 O +
micrograms O +
kg-1 O +
i.v O -
. O +
immediately O +
before O +
the O +
induction O +
of O +
anaesthesia O -
, O +
to O +
prevent O +
arrhythmia B-Disease +
and O +
bradycardia B-Disease +
following O +
repeated O +
doses O +
of O +
suxamethonium O +
in O +
children O -
, O +
was O +
studied O -
. O +

A O +
control O +
group O +
was O +
included O +
for O +
comparison O +
with O +
the O +
lower O +
dose O +
range O +
of O +
glycopyrrolate O +
and O +
atropine O -
. O +

A O +
frequency O +
of O +
bradycardia B-Disease +
of O +
50 O -
% O +
was O +
noted O +
in O +
the O +
control O +
group O -
, O +
but O +
this O +
was O +
not O +
significantly O +
different O +
from O +
the O +
frequency O +
with O +
the O +
active O +
drugs O -
. O +

Bradycardia B-Disease +
( O -
defined O +
as O +
a O +
decrease O +
in O +
heart O +
rate O +
to O +
less O +
than O +
50 O +
beat O +
min-1 O -
) O +
was O +
prevented O +
when O +
the O +
larger O +
dose O +
of O +
either O +
active O +
drug O +
was O +
used O -
. O +

It O +
is O +
recommended O +
that O +
either O +
glycopyrrolate O +
10 O +
micrograms O +
kg-1 O +
or O +
atropine O +
20 O +
micrograms O +
kg-1 O +
i.v O -
. O +
should O +
immediately O +
precede O +
induction O +
of O +
anaesthesia O -
, O +
in O +
children O -
, O +
if O +
the O +
repeated O +
administration O +
of O +
suxamethonium O +
is O +
anticipated O -
. O +

Veno B-Disease -
- I-Disease -
occlusive I-Disease +
liver I-Disease +
disease I-Disease +
after O +
dacarbazine O +
therapy O +
( O -
DTIC O -
) O +
for O +
melanoma B-Disease -
. O +

A O +
case O +
of O +
veno B-Disease -
- I-Disease -
occlusive I-Disease +
disease I-Disease +
of I-Disease +
the I-Disease +
liver I-Disease +
with O +
fatal O +
outcome O +
after O +
dacarbazine O +
( O -
DTIC O -
) O +
therapy O +
for O +
melanoma B-Disease +
is O +
reported O -
. O +

There O +
was O +
a O +
fulminant O +
clinical O +
course O +
from O +
start O +
of O +
symptoms O +
until O +
death B-Disease -
. O +

At O +
autopsy O +
the O +
liver O +
was O +
enlarged O +
and O +
firm O +
with O +
signs O +
of O +
venous B-Disease +
congestion I-Disease -
. O +

Small- O +
and O +
medium O -
- O -
sized O +
hepatic O +
veins O +
were O +
blocked O +
by O +
thrombosis B-Disease -
. O +

Eosinophilic O +
infiltrations O +
were O +
found O +
around O +
the O +
vessels O -
. O +

Published O +
cases O +
from O +
the O +
literature O +
are O +
reviewed O +
and O +
pertinent O +
features O +
discussed O -
. O +

Phenobarbital O -
- O -
induced O +
dyskinesia B-Disease +
in O +
a O +
neurologically B-Disease -
- I-Disease -
impaired I-Disease +
child O -
. O +

A O +
2-year O -
- O -
old O +
child O +
with O +
known O +
neurologic B-Disease +
impairment I-Disease +
developed O +
a O +
dyskinesia B-Disease +
soon O +
after O +
starting O +
phenobarbital O +
therapy O +
for O +
seizures B-Disease -
. O +

Known O +
causes O +
of O +
movement B-Disease +
disorders I-Disease +
were O +
eliminated O +
after O +
evaluation O -
. O +

On O +
repeat O +
challenge O +
with O +
phenobarbital O -
, O +
the O +
dyskinesia B-Disease +
recurred O -
. O +

Phenobarbital O +
should O +
be O +
added O +
to O +
the O +
list O +
of O +
anticonvulsant O +
drugs O +
that O +
can O +
cause O +
movement B-Disease +
disorders I-Disease -
. O +

Maternal O +
lithium O +
and O +
neonatal O +
Ebstein B-Disease -
's I-Disease +
anomaly I-Disease -
: O +
evaluation O +
with O +
cross O -
- O -
sectional O +
echocardiography O -
. O +

Cross O -
- O -
sectional O +
echocardiography O +
was O +
used O +
to O +
evaluate O +
two O +
neonates O +
whose O +
mothers O +
ingested O +
lithium O +
during O +
pregnancy O -
. O +

In O +
one O +
infant O -
, O +
Ebstein B-Disease -
's I-Disease +
anomaly I-Disease +
of O +
the O +
tricuspid O +
valve O +
was O +
identified O -
. O +

In O +
the O +
other O +
infant O +
cross O -
- O -
sectional O +
echocardiography O +
provided O +
reassurance O +
that O +
the O +
infant O +
did O +
not O +
have O +
Ebstein B-Disease -
's I-Disease +
anomaly I-Disease -
. O +

Cross O -
- O -
sectional O +
echocardiographic O +
screening O +
of O +
newborns O +
exposed O +
to O +
lithium O +
during O +
gestation O +
can O +
provide O +
highly O +
accurate O -
, O +
noninvasive O +
assessment O +
of O +
the O +
presence O +
or O +
absence O +
of O +
lithium O -
- O -
induced O +
cardiac B-Disease +
malformations I-Disease -
. O +

Effects O +
of O +
training O +
on O +
the O +
extent O +
of O +
experimental O +
myocardial B-Disease +
infarction I-Disease +
in O +
aging O +
rats O -
. O +

The O +
effects O +
of O +
exercise O +
on O +
the O +
severity O +
of O +
isoproterenol O -
- O -
induced O +
myocardial B-Disease +
infarction I-Disease +
were O +
studied O +
in O +
female O +
albino O +
rats O +
of O +
20,40,60 O +
and O +
80 O +
weeks O +
of O +
age O -
. O +

The O +
rats O +
were O +
trained O +
to O +
swim O +
for O +
a O +
specific O +
duration O +
and O +
for O +
a O +
particular O +
period O -
. O +

The O +
occurrence O +
of O +
infarcts B-Disease +
were O +
confirmed O +
by O +
histological O +
methods O -
. O +

Elevations O +
in O +
the O +
serum O +
GOT O +
and O +
GPT O +
were O +
maximum O +
in O +
the O +
sedentary O -
- O -
isoproterenols O +
and O +
minimum O +
in O +
the O +
exercise O -
- O -
controls O -
. O +

These O +
changes O +
in O +
the O +
serum O +
transaminases O +
were O +
associated O +
with O +
corresponding O +
depletions O +
in O +
the O +
cardiac O +
GOT O +
and O +
GPT O -
. O +

However O -
, O +
age O +
was O +
seen O +
to O +
interfere O +
with O +
the O +
responses O +
exhibited O +
by O +
the O +
young O +
and O +
old O +
rats O -
. O +

Studies O +
dealing O +
with O +
myocardial B-Disease +
infarction I-Disease +
are O +
more O +
informative O +
when O +
dealt O +
with O +
age O -
. O +

Effect O +
of O +
polyethylene O +
glycol O +
400 O +
on O +
adriamycin O +
toxicity B-Disease +
in O +
mice O -
. O +

The O +
effect O +
of O +
a O +
widely O +
used O +
organic O +
solvent O -
, O +
polyethylene O +
glycol O +
400 O +
( O -
PEG O +
400 O -
) O -
, O +
on O +
the O +
toxic O +
action O +
of O +
an O +
acute O +
or O +
chronic O +
treatment O +
with O +
adriamycin O +
( O -
ADR O -
) O +
was O +
evaluated O +
in O +
mice O -
. O +

PEG O +
400 O +
impressively O +
decreased O +
both O +
acute O +
high O -
- O -
dose O +
and O +
chronic O +
low O -
- O -
dose O -
- O -
ADR O -
- O -
associated O +
lethality O -
. O +

Light O +
microscopic O +
analysis O +
showed O +
a O +
significant O +
protection O +
against O +
ADR O -
- O -
induced O +
cardiac B-Disease +
morphological I-Disease +
alterations I-Disease -
. O +

Such O +
treatment O +
did O +
not O +
diminish O +
the O +
ADR O +
antitumor O +
activity O +
in O +
L1210 B-Disease +
leukemia I-Disease +
and O +
in O +
Ehrlich B-Disease +
ascites I-Disease +
tumor I-Disease -
. O +

Effects O +
of O +
amine O +
pretreatment O +
on O +
ketamine O +
catatonia B-Disease +
in O +
pinealectomized O +
or O +
hypophysectomized O +
animals O -
. O +

The O +
present O +
studies O +
were O +
designed O +
to O +
clarify O +
the O +
role O +
of O +
catecholamines O +
and O +
pineal O +
idolamines O +
on O +
ketamine O -
- O -
induced O +
catatonia B-Disease +
in O +
the O +
intact O -
, O +
pinealectomized O +
or O +
hypophysectomized O +
chick O +
and O +
rat O -
. O +

In O +
the O +
pinealectomized O +
chick O -
, O +
pretreatment O +
with O +
dopamine O +
increased O +
the O +
duration O +
of O +
catatonia B-Disease +
( O -
DOC O -
) O +
after O +
ketamine O -
, O +
but O +
pretreatment O +
with O +
norepinephrine O +
did O +
not O -
. O +

The O +
pineal O +
indolamines O +
exhibited O +
mixed O +
actions O -
. O +

Serotonin O +
and O +
N O -
- O -
acetyl O +
serotonin O +
which O +
augmented O +
ketamine O +
DOC O -
, O +
did O +
not O +
do O +
so O +
in O +
the O +
absence O +
of O +
the O +
pineal O +
gland O -
, O +
whereas O +
melatonin O +
potentiated O +
the O +
ketamine O +
DOC O +
in O +
both O +
the O +
intact O +
and O +
pinealectomized O +
chick O -
. O +

Ketamine O +
was O +
more O +
potent O +
in O +
the O +
hypophysectomized O +
chick O +
and O +
the O +
circadian O +
rhythm O +
noted O +
in O +
the O +
intact O +
chick O +
was O +
absent O -
; O +
furthermore O -
, O +
melatonin O +
did O +
not O +
augment O +
the O +
ketamine O +
DOC O +
whereas O +
dopamine O +
continued O +
to O +
do O +
so O -
. O +

This O +
study O +
did O +
not O +
demonstrate O +
a O +
species O +
difference O +
regarding O +
the O +
role O +
of O +
the O +
amines O +
on O +
the O +
pineal O +
in O +
spite O +
of O +
the O +
immature O +
blood O -
- O -
brain O +
barrier O +
in O +
the O +
young O +
chick O +
and O +
the O +
intact O +
barrier O +
in O +
the O +
rat O -
. O +

In O +
addition O -
, O +
these O +
data O +
indicate O +
a O +
direct O +
role O +
of O +
the O +
pituitary O +
in O +
the O +
augmentation O +
of O +
ketamine O +
DOC O +
induced O +
by O +
melatonin O -
. O +

Furthermore O -
, O +
dopamine O +
appeared O +
to O +
act O +
on O +
systems O +
more O +
closely O +
involved O +
with O +
the O +
induction O +
of O +
ketamine O +
catatonia B-Disease +
rather O +
than O +
directly O +
on O +
the O +
pituitary O -
. O +

Ventricular B-Disease +
fibrillation I-Disease +
from O +
diatrizoate O +
with O +
and O +
without O +
chelating O +
agents O -
. O +

The O +
toxicity B-Disease +
of O +
Renografin O +
76 O -
% O +
was O +
compared O +
with O +
that O +
of O +
Hypaque O +
76 O -
% O +
by O +
selective O +
injection O +
of O +
each O +
into O +
the O +
right O +
coronary O +
artery O +
of O +
dogs O -
. O +

Renografin O +
contains O +
the O +
chelating O +
agents O +
sodium O +
citrate O +
and O +
disodium O +
edetate O -
, O +
while O +
Hypaque O +
contains O +
calcium O +
disodium O +
edetate O +
and O +
no O +
sodium O +
citrate O -
. O +

Ventricular B-Disease +
fibrillation I-Disease +
occurred O +
significantly O +
more O +
often O +
with O +
Renografin O -
, O +
suggesting O +
that O +
chelating O +
agents O +
contribute O +
to O +
toxicity B-Disease +
in O +
coronary O +
angiography O -
. O +

Sublingual O +
absorption O +
of O +
the O +
quaternary O +
ammonium O +
antiarrhythmic O +
agent O -
, O +
UM-272 O -
. O +

UM-272 O +
( O -
N O -
, O -
N O -
- O -
dimethylpropranolol O -
) O -
, O +
a O +
quaternary O +
antiarrhythmic O +
agent O -
, O +
was O +
administered O +
sublingually O +
to O +
dogs O +
with O +
ouabain O -
- O -
induced O +
ventricular B-Disease +
tachycardias I-Disease -
. O +

Both O +
anti O -
- O -
arrhythmic O +
efficacy O +
and O +
bioavailability O +
were O +
compared O +
to O +
oral O +
drug O -
. O +

Sublingual O +
UM-272 O +
converted O +
ventricular B-Disease +
tachycardia I-Disease +
to O +
sinus O +
rhythm O +
in O +
all O +
5 O +
dogs O -
. O +

The O +
area O +
under O +
the O +
plasma O +
concentration O +
time O +
curve O +
at O +
90 O +
min O +
was O +
4 O -
- O -
12 O +
times O +
greater O +
than O +
for O +
oral O +
drug O -
, O +
suggesting O +
the O +
existence O +
of O +
an O +
absorption O -
- O -
limiting O +
process O +
in O +
the O +
intestine O -
, O +
and O +
providing O +
an O +
alternate O +
form O +
of O +
administration O +
for O +
quaternary O +
drugs O -
. O +

Long O -
- O -
term O +
efficacy O +
and O +
toxicity B-Disease +
of O +
high O -
- O -
dose O +
amiodarone O +
therapy O +
for O +
ventricular B-Disease +
tachycardia I-Disease +
or O +
ventricular B-Disease +
fibrillation I-Disease -
. O +

Amiodarone O +
was O +
administered O +
to O +
154 O +
patients O +
who O +
had O +
sustained O -
, O +
symptomatic O +
ventricular B-Disease +
tachycardia I-Disease +
( O -
VT B-Disease -
) O +
( O -
n O +
= O +
118 O -
) O +
or O +
a O +
cardiac B-Disease +
arrest I-Disease +
( O -
n O +
= O +
36 O -
) O +
and O +
who O +
were O +
refractory O +
to O +
conventional O +
antiarrhythmic O +
drugs O -
. O +

The O +
loading O +
dose O +
was O +
800 O +
mg O -
/ O -
day O +
for O +
6 O +
weeks O +
and O +
the O +
maintenance O +
dose O +
was O +
600 O +
mg O -
/ O -
day O -
. O +

Sixty O -
- O -
nine O +
percent O +
of O +
patients O +
continued O +
treatment O +
with O +
amiodarone O +
and O +
had O +
no O +
recurrence O +
of O +
symptomatic O +
VT B-Disease +
or O +
ventricular B-Disease +
fibrillation I-Disease +
( O -
VF B-Disease -
) O +
over O +
a O +
follow O -
- O -
up O +
of O +
6 O +
to O +
52 O +
months O +
( O -
mean O +
+ O -
/- O +

standard O +
deviation O +
14.2 O +
+ O -
/- O +

8.2 O -
) O -
. O +

Six O +
percent O +
of O +
the O +
patients O +
had O +
a O +
nonfatal O +
recurrence O +
of O +
VT B-Disease +
and O +
were O +
successfully O +
managed O +
by O +
continuing O +
amiodarone O +
at O +
a O +
higher O +
dose O +
or O +
by O +
the O +
addition O +
of O +
a O +
conventional O +
antiarrhythmic O +
drug O -
. O +

One O +
or O +
more O +
adverse O +
drug O +
reactions O +
occurred O +
in O +
51 O -
% O +
of O +
patients O -
. O +

Adverse O +
effects O +
forced O +
a O +
reduction O +
in O +
the O +
dose O +
of O +
amiodarone O +
in O +
41 O -
% O +
and O +
discontinuation O +
of O +
amiodarone O +
in O +
10 O -
% O +
of O +
patients O -
. O +

The O +
most O +
common O +
symptomatic O +
adverse O +
reactions O +
were O +
tremor B-Disease +
or O +
ataxia B-Disease +
( O -
35 O -
% O -
) O -
, O +
nausea B-Disease +
and O +
anorexia B-Disease +
( O -
8 O -
% O -
) O -
, O +
visual B-Disease +
halos I-Disease +
or I-Disease +
blurring I-Disease +
( O -
6 O -
% O -
) O -
, O +
thyroid B-Disease +
function I-Disease +
abnormalities I-Disease +
( O -
6 O -
% O -
) O +
and O +
pulmonary B-Disease +
interstitial I-Disease +
infiltrates I-Disease +
( O -
5 O -
% O -
) O -
. O +

Although O +
large O -
- O -
dose O +
amiodarone O +
is O +
highly O +
effective O +
in O +
the O +
long O -
- O -
term O +
treatment O +
of O +
VT B-Disease +
or O +
VF B-Disease +
refractory O +
to O +
conventional O +
antiarrhythmic O +
drugs O -
, O +
it O +
causes O +
significant O +
toxicity B-Disease +
in O +
approximately O +
50 O -
% O +
of O +
patients O -
. O +

However O -
, O +
when O +
the O +
dose O +
is O +
adjusted O +
based O +
on O +
clinical O +
response O +
or O +
the O +
development O +
of O +
adverse O +
effects O -
, O +
75 O -
% O +
of O +
patients O +
with O +
VT B-Disease +
or O +
VF B-Disease +
can O +
be O +
successfully O +
managed O +
with O +
amiodarone O -
. O +

Early O +
adjuvant O +
adriamycin O +
in O +
superficial O +
bladder B-Disease +
carcinoma I-Disease -
. O +

A O +
multicenter O +
study O +
was O +
performed O +
in O +
110 O +
patients O +
with O +
superficial O +
transitional O +
cell O +
carcinoma B-Disease +
of B-Disease +
the I-Disease +
bladder I-Disease -
. O +

Adriamycin O +
( O -
50 O +
mg O -
/ O -
50 O +
ml O -
) O +
was O +
administered O +
intravesically O +
within O +
24 O +
h O +
after O +
transurethral O +
resection O +
of O +
TA O -
- O -
T1 O +
( O -
O O -
- O -
A O -
) O +
bladder B-Disease +
tumors I-Disease -
. O +

Instillation O +
was O +
repeated O +
twice O +
during O +
the O +
first O +
week O -
, O +
then O +
weekly O +
during O +
the O +
first O +
month O +
and O +
afterwards O +
monthly O +
for O +
1 O +
year O -
. O +

The O +
tolerance O +
was O +
evaluated O +
in O +
these O +
110 O +
patients O -
, O +
and O +
29 O +
patients O +
presented O +
with O +
local O +
side O -
- O -
effects O -
. O +

In O +
24 O +
of O +
these O +
patients O +
chemical O +
cystitis B-Disease +
was O +
severe O +
enough O +
for O +
them O +
to O +
drop O +
out O +
of O +
the O +
study O -
. O +

No O +
systemic O +
side O -
- O -
effects O +
were O +
observed O -
. O +

Recurrence O +
was O +
studied O +
in O +
82 O +
evaluable O +
patients O +
after O +
1 O +
year O +
of O +
follow O -
- O -
up O +
and O +
in O +
72 O +
patients O +
followed O +
for O +
2 O -
- O -
3 O +
years O +
( O -
mean O +
32 O +
months O -
) O -
. O +

Of O +
the O +
82 O +
patients O +
studied O +
after O +
1 O +
year O -
, O +
23 O +
had O +
primary O +
and O +
59 O +
recurrent O +
disease O -
. O +

Of O +
the O +
82 O +
evaluable O +
patients O -
, O +
50 O +
did O +
not O +
show O +
any O +
recurrence O +
after O +
1 O +
year O +
( O -
61 O -
% O -
) O -
, O +
while O +
32 O +
presented O +
with O +
one O +
or O +
more O +
recurrences O +
( O -
39 O -
% O -
) O -
. O +

Of O +
these O +
recurrences O -
, O +
27 O +
were O +
T1 O +
tumors B-Disease +
while O +
five O +
progressed O +
to O +
more O +
highly O +
invasive O +
lesions O -
. O +

In O +
patients O +
that O +
were O +
free O +
of O +
recurrence O +
during O +
the O +
first O +
year O -
, O +
80 O -
% O +
remained O +
tumor B-Disease -
- O -
free O +
during O +
the O +
2- O +
to O +
3-year O +
follow O -
- O -
up O +
period O -
. O +

Of O +
the O +
patients O +
developing O +
one O +
or O +
more O +
recurrences O +
during O +
the O +
first O +
year O -
, O +
only O +
50 O -
% O +
presented O +
with O +
further O +
recurrence O +
once O +
the O +
instillations O +
were O +
stopped O -
. O +

The O +
beneficial O +
effect O +
of O +
Adriamycin O +
appears O +
obvious O +
and O +
might O +
be O +
related O +
to O +
the O +
drug O +
itself O -
, O +
the O +
early O +
and O +
repeated O +
instillations O +
after O +
TUR O -
, O +
or O +
both O -
. O +

D O -
- O -
penicillamine O -
- O -
induced O +
angiopathy B-Disease +
in O +
rats O -
. O +

The O +
effect O +
of O +
high O +
dose O +
D O -
- O -
penicillamine O +
treatment O +
on O +
aortic O +
permeability O +
to O +
albumin O +
and O +
on O +
the O +
ultrastructure O +
of O +
the O +
vessel O -
. O +

Male O +
Sprague O -
- O -
Dawley O +
rats O +
were O +
treated O +
with O +
D O -
- O -
penicillamine O +
( O -
D O -
- O -
pen O -
) O +
500 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
10 O +
or O +
42 O +
days O -
. O +

Pair O +
fed O +
rats O +
served O +
as O +
controls O -
. O +

Changes O +
in O +
aortic O +
morphology O +
were O +
examined O +
by O +
light- O +
and O +
transmission O -
- O -
electron O +
microscopy O +
( O -
TEM O -
) O -
. O +

In O +
addition O -
, O +
the O +
endothelial O +
permeability O +
and O +
the O +
penetration O +
through O +
the O +
aortic O +
wall O +
of O +
albumin O +
were O +
studied O +
10 O +
minutes O -
, O +
24 O +
and O +
48 O +
hours O +
after O +
i. O +
v. O +
injection O +
of O +
human O +
serum O +
131I O -
- O -
albumin O +
( O -
131I O -
- O -
HSA O -
) O -
. O +

TEM O +
revealed O +
extensive O +
elastolysis O +
in O +
the O +
arterial O +
wall O +
of O +
D O -
- O -
pen O -
- O -
treated O +
rats O -
, O +
consistent O +
with O +
an O +
inhibitory O +
effect O +
on O +
crosslink O +
formation O -
. O +

In O +
experimental O +
animals O +
excess O +
deposition O +
of O +
collagen O +
and O +
glycoaminoglycans O +
was O +
observed O +
in O +
the O +
subendothelial O +
and O +
medial O +
layer O +
of O +
the O +
aortic O +
wall O -
, O +
together O +
with O +
prominent O +
basal O +
membrane O +
substance O +
around O +
aortic O +
smooth O +
muscle O +
cells O -
. O +

The O +
aorta O -
/ O -
serum O -
- O -
ratio O +
and O +
the O +
radioactive O +
build O -
- O -
up O +
24 O +
and O +
48 O +
hours O +
after O +
injection O +
of O +
131I O -
- O -
HSA O +
was O +
reduced O +
in O +
animals O +
treated O +
with O +
D O -
- O -
pen O +
for O +
42 O +
days O -
, O +
indicating O +
an O +
impeded O +
transmural O +
transport O +
of O +
tracer O +
which O +
may O +
be O +
caused O +
by O +
a O +
steric O +
exclusion O +
effect O +
of O +
abundant O +
hyaluronate O -
. O +

The O +
endothelial O +
ultrastructure O +
was O +
unaffected O +
by O +
D O -
- O -
pen O -
, O +
and O +
no O +
differences O +
in O +
aortic O +
131I O -
- O -
HSA O +
radioactivity O +
or O +
aorta O -
/ O -
serum O -
- O -
ratio O +
were O +
recorded O +
between O +
experimental O +
and O +
control O +
groups O +
10 O +
minutes O +
after O +
tracer O +
injection O -
, O +
indicating O +
that O +
the O +
permeability O +
of O +
the O +
endothelial O +
barrier O +
to O +
albumin O +
remained O +
unaffected O +
by O +
D O -
- O -
pen O +
treatment O -
. O +

These O +
observations O +
support O +
the O +
hypothesis O +
that O +
treatment O +
with O +
high O +
doses O +
of O +
D O -
- O -
pen O +
may O +
induce O +
a O +
fibroproliferative O +
response O +
in O +
rat O +
aorta O -
, O +
possibly O +
by O +
an O +
inhibitory O +
effect O +
on O +
the O +
cross O -
- O -
linking O +
of O +
collagen O +
and O +
elastin O -
. O +

Why O +
may O +
epsilon O -
- O -
aminocaproic O +
acid O +
( O -
EACA O -
) O +
induce O +
myopathy B-Disease +
in O +
man O -
? O +

Report O +
of O +
a O +
case O +
and O +
literature O +
review O -
. O +

A O +
case O +
of O +
necrotizing B-Disease +
myopathy B-Disease +
due O +
to O +
a O +
short O +
epsilon O -
- O -
aminocaproic O +
acid O +
( O -
EACA O -
) O +
treatment O +
in O +
a O +
72 O +
year O -
- O -
old O +
patient O +
with O +
subarachnoid B-Disease +
haemorrhage I-Disease +
( O -
SAH B-Disease -
) O +
is O +
described O -
. O +

Pathogenetic O +
hypotheses O +
are O +
discussed O -
. O +

Effect O +
of O +
aspirin O +
on O +
N- O -
[ O -
4- O -
( O -
5-nitro-2-furyl O -
) O -
-2-thiazolyl O -
] O -
-formamide O -
- O -
induced O +
epithelial O +
proliferation O +
in O +
the O +
urinary O +
bladder O +
and O +
forestomach O +
of O +
the O +
rat O -
. O +

The O +
co O -
- O -
administration O +
of O +
aspirin O +
with O +
N- O -
[ O -
4- O -
( O -
5-nitro-2-furyl O -
) O -
-2-thiazolyl O -
] O -
-formamide O +
( O -
FANFT O -
) O +
to O +
rats O +
resulted O +
in O +
a O +
reduced O +
incidence O +
of O +
FANFT O -
- O -
induced O +
bladder B-Disease +
carcinomas I-Disease +
but O +
a O +
concomitant O +
induction O +
of O +
forestomach B-Disease +
tumors I-Disease -
. O +

An O +
autoradiographic O +
study O +
was O +
performed O +
on O +
male O +
F-344 O +
rats O +
fed O +
diet O +
containing O +
FANFT O +
at O +
a O +
level O +
of O +
0.2 O -
% O +
and/or O +
aspirin O +
at O +
a O +
level O +
of O +
0.5 O -
% O +
to O +
evaluate O +
the O +
effect O +
of O +
aspirin O +
on O +
the O +
increased O +
cell O +
proliferation O +
induced O +
by O +
FANFT O +
in O +
the O +
forestomach O +
and O +
bladder O -
. O +

FANFT O -
- O -
induced O +
cell O +
proliferation O +
in O +
the O +
bladder O +
was O +
significantly O +
suppressed O +
by O +
aspirin O +
co O -
- O -
administration O +
after O +
4 O +
weeks O +
but O +
not O +
after O +
12 O +
weeks O -
. O +

In O +
the O +
forestomach O -
, O +
and O +
also O +
in O +
the O +
liver O -
, O +
aspirin O +
did O +
not O +
affect O +
the O +
FANFT O -
- O -
induced O +
increase O +
in O +
labeling O +
index O -
. O +

The O +
present O +
results O +
are O +
consistent O +
with O +
the O +
carcinogenicity O +
experiment O +
suggesting O +
that O +
different O +
mechanisms O +
are O +
involved O +
in O +
FANFT O +
carcinogenesis B-Disease +
in O +
the O +
bladder O +
and O +
forestomach O -
, O +
and O +
that O +
aspirin O -
's O +
effect O +
on O +
FANFT O +
in O +
the O +
forestomach O +
is O +
not O +
due O +
to O +
an O +
irritant O +
effect O +
associated O +
with O +
increased O +
cell O +
proliferation O -
. O +

Also O -
, O +
there O +
appears O +
to O +
be O +
an O +
adaptation O +
by O +
the O +
rats O +
to O +
the O +
chronic O +
ingestion O +
of O +
aspirin O -
. O +

Cerebral B-Disease +
hemorrhage I-Disease +
associated O +
with O +
phenylpropanolamine O +
in O +
combination O +
with O +
caffeine O -
. O +

Phenylpropanolamine O +
( O -
PPA O -
) O +
is O +
a O +
drug O +
that O +
has O +
been O +
associated O +
with O +
serious O +
side O +
effects O +
including O +
stroke B-Disease -
. O +

It O +
is O +
often O +
combined O +
with O +
caffeine O +
in O +
diet O +
preparations O +
and O +
" O -
look O -
- O -
alike O -
" O +
pills O -
. O +

In O +
order O +
to O +
determine O +
if O +
PPA O -
/ O -
caffeine O +
can O +
lead O +
to O +
stroke B-Disease +
in O +
normotensive O +
and/or O +
hypertensive B-Disease +
rats O -
, O +
we O +
administered O +
the O +
combination O +
in O +
six O +
times O +
the O +
allowed O +
human O +
dose O +
calculated O +
on O +
a O +
per O +
weight O +
basis O +
for O +
the O +
rats O +
two O +
times O +
per O +
day O +
for O +
five O +
days O -
. O +

Subarachnoid B-Disease +
and I-Disease +
cerebral I-Disease +
hemorrhage I-Disease +
was O +
noted O +
in O +
18 O -
% O +
of O +
the O +
hypertensive B-Disease +
rats O -
. O +

A O +
single O +
PPA O -
/ O -
caffeine O +
administration O +
( O -
same O +
dose O -
) O +
lead O +
to O +
acute O +
hypertension B-Disease +
in O +
both O +
the O +
normotensive O +
and O +
hypertensive B-Disease +
animals O -
. O +

These O +
results O +
suggest O +
that O +
PPA O -
/ O -
caffeine O +
can O +
lead O +
to O +
cerebral B-Disease +
hemorrhage I-Disease +
in O +
previously O +
hypertensive B-Disease +
animals O +
when O +
administered O +
in O +
greater O +
than O +
the O +
allowed O +
dosage O -
. O +

An O +
acute O +
elevation O +
in O +
blood O +
pressure O +
may O +
be O +
a O +
contributing O +
factor O -
. O +

Renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
due O +
to O +
naproxen O -
. O +

A O +
31-year O -
- O -
old O +
man O +
with O +
rheumatoid B-Disease +
arthritis I-Disease -
, O +
who O +
had O +
previously O +
been O +
treated O +
with O +
sulindac O -
, O +
fenoprofen O +
calcium O -
, O +
high O +
dose O +
salicylates O +
and O +
gold O +
salts O -
, O +
developed O +
renal B-Disease +
papillary I-Disease +
necrosis I-Disease +
( O -
RPN B-Disease -
) O +
4 O +
months O +
after O +
institution O +
of O +
naproxen O +
therapy O -
. O +

No O +
other O +
factor O +
predisposing O +
to O +
RPN B-Disease +
could O +
be O +
discovered O -
. O +

Sulindac O +
was O +
substituted O +
for O +
naproxen O +
and O +
no O +
further O +
adverse O +
renal O +
effects O +
occurred O +
over O +
the O +
next O +
12 O +
months O -
. O +

We O +
review O +
previous O +
reports O +
linking O +
RPN B-Disease +
to O +
antiinflammatory O +
drug O +
use O +
and O +
discuss O +
possible O +
advantages O +
of O +
sulindac O +
in O +
patients O +
who O +
have O +
experienced O +
renal B-Disease +
toxicity I-Disease +
from O +
other O +
antiinflammatory O +
agents O -
. O +

A O +
case O +
of O +
tardive B-Disease +
dyskinesia I-Disease +
caused O +
by O +
metoclopramide O -
. O +

Abnormal B-Disease +
involuntary I-Disease +
movements I-Disease +
appeared O +
in O +
the O +
mouth O -
, O +
tongue O -
, O +
neck O +
and O +
abdomen O +
of O +
a O +
64-year O -
- O -
old O +
male O +
patient O +
after O +
he O +
took O +
metoclopramide O +
for O +
gastrointestinal B-Disease +
disorder I-Disease +
in O +
a O +
regimen O +
of O +
30 O +
mg O +
per O +
day O +
for O +
a O +
total O +
of O +
about O +
260 O +
days O -
. O +

The O +
symptoms O +
exacerbated O +
to O +
a O +
maximum O +
in O +
a O +
month O -
. O +

When O +
the O +
metoclopramide O +
administration O +
was O +
discontinued O -
, O +
the O +
abnormal B-Disease +
movements I-Disease +
gradually O +
improved O +
to O +
a O +
considerable O +
extent O -
. O +

Attention O +
to O +
the O +
possible O +
induction O +
of O +
specific O +
tardive B-Disease +
dyskinesia I-Disease +
is O +
called O +
for O +
in O +
the O +
use O +
of O +
this O +
drug O -
. O +

Nephrotoxic B-Disease +
effects O +
of O +
aminoglycoside O +
treatment O +
on O +
renal O +
protein O +
reabsorption O +
and O +
accumulation O -
. O +

To O +
quantify O +
the O +
effects O +
of O +
gentamicin O -
, O +
kanamycin O +
and O +
netilmicin O +
on O +
renal O +
protein O +
reabsorption O +
and O +
accumulation O -
, O +
these O +
drugs O +
were O +
administered O +
to O +
rats O +
intraperitoneally O +
( O -
30 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
for O +
7 O -
, O +
14 O +
or O +
21 O +
days O -
. O +

Scanning O +
electron O +
microscopy O +
of O +
the O +
glomerular O +
endothelia O -
, O +
urinary O +
measurements O +
of O +
sodium O -
, O +
potassium O -
, O +
endogenous O +
lysozyme O -
, O +
N O -
- O -
acetyl O -
- O -
beta O -
- O -
D O -
- O -
glucosaminidase O +
( O -
NAG O -
) O +
as O +
well O +
as O +
clearance O +
and O +
accumulation O +
experiments O +
after O +
i.v O -
. O +

administration O +
of O +
egg O -
- O -
white O +
lysozyme O +
and O +
measurements O +
of O +
inulin O +
clearance O +
( O -
GFR O -
) O +
were O +
done O +
in O +
each O +
treatment O +
group O -
. O +

Gentamicin O +
administration O +
decreased O +
diameter O -
, O +
density O +
and O +
shape O +
of O +
endothelial O +
fenestrae O -
. O +

Kanamycin O +
and O +
netilmicin O +
appeared O +
to O +
have O +
no O +
effect O +
at O +
the O +
dose O +
used O -
. O +

All O +
three O +
aminoglycosides O +
decreased O +
GFR O +
and O +
increased O +
urinary O +
excretion O +
of O +
sodium O +
and O +
potassium O -
. O +

While O +
gentamicin O +
and O +
kanamycin O +
decreased O +
the O +
percentage O +
reabsorption O +
and O +
accumulation O +
of O +
lysozyme O +
after O +
i.v O -
. O +

administration O +
of O +
egg O -
- O -
white O +
lysozyme O +
netilmicin O +
had O +
no O +
effect O -
. O +

Daily O +
excretion O +
of O +
total O +
protein O -
, O +
endogenous O +
lysozyme O +
and O +
NAG O +
increased O +
only O +
after O +
treatment O +
with O +
kanamycin O +
and O +
gentamicin O -
. O +

Thus O -
, O +
aminoglycosides O +
may O +
act O +
as O +
nephrotoxicants O +
at O +
glomerular O +
and/or O +
tubular O +
level O +
inducing O +
impairment B-Disease +
of I-Disease +
renal I-Disease +
reabsorption I-Disease +
and O +
accumulation O +
of O +
proteins O -
. O +

Intra O -
- O -
arterial O +
BCNU O +
chemotherapy O +
for O +
treatment O +
of O +
malignant B-Disease +
gliomas I-Disease +
of O +
the O +
central O +
nervous O +
system O -
. O +

Because O +
of O +
the O +
rapid O +
systemic O +
clearance O +
of O +
BCNU O +
( O -
1,3-bis- O -
( O -
2-chloroethyl O -
) O -
-1-nitrosourea O -
) O -
, O +
intra O -
- O -
arterial O +
administration O +
should O +
provide O +
a O +
substantial O +
advantage O +
over O +
intravenous O +
administration O +
for O +
the O +
treatment O +
of O +
malignant B-Disease +
gliomas I-Disease -
. O +

Thirty O -
- O -
six O +
patients O +
were O +
treated O +
with O +
BCNU O +
every O +
6 O +
to O +
8 O +
weeks O -
, O +
either O +
by O +
transfemoral O +
catheterization O +
of O +
the O +
internal O +
carotid O +
or O +
vertebral O +
artery O +
or O +
through O +
a O +
fully O +
implantable O +
intracarotid O +
drug O +
delivery O +
system O -
, O +
beginning O +
with O +
a O +
dose O +
of O +
200 O +
mg O -
/ O -
sq O +
m O +
body O +
surface O +
area O -
. O +

Twelve O +
patients O +
with O +
Grade O +
III O +
or O +
IV O +
astrocytomas B-Disease +
were O +
treated O +
after O +
partial O +
resection O +
of O +
the O +
tumor B-Disease +
without O +
prior O +
radiation O +
therapy O -
. O +

After O +
two O +
to O +
seven O +
cycles O +
of O +
chemotherapy O -
, O +
nine O +
patients O +
showed O +
a O +
decrease O +
in O +
tumor B-Disease +
size O +
and O +
surrounding O +
edema B-Disease +
on O +
contrast O -
- O -
enhanced O +
computerized O +
tomography O +
scans O -
. O +

In O +
the O +
nine O +
responders O -
, O +
median O +
duration O +
of O +
chemotherapy O +
response O +
from O +
the O +
time O +
of O +
operation O +
was O +
25 O +
weeks O +
( O -
range O +
12 O +
to O +
more O +
than O +
91 O +
weeks O -
) O -
. O +

The O +
median O +
duration O +
of O +
survival O +
in O +
the O +
12 O +
patients O +
was O +
54 O +
weeks O +
( O -
range O +
21 O +
to O +
more O +
than O +
156 O +
weeks O -
) O -
, O +
with O +
an O +
18-month O +
survival O +
rate O +
of O +
42 O -
% O -
. O +

Twenty O -
- O -
four O +
patients O +
with O +
recurrent O +
Grade O +
I O +
to O +
IV O +
astrocytomas B-Disease -
, O +
whose O +
resection O +
and O +
irradiation O +
therapy O +
had O +
failed O -
, O +
received O +
two O +
to O +
eight O +
courses O +
of O +
intra O -
- O -
arterial O +
BCNU O +
therapy O -
. O +

Seventeen O +
of O +
these O +
had O +
a O +
response O +
or O +
were O +
stable O +
for O +
a O +
median O +
of O +
20 O +
weeks O +
( O -
range O +
6 O +
to O +
more O +
than O +
66 O +
weeks O -
) O -
. O +

The O +
catheterization O +
procedure O +
is O +
safe O -
, O +
with O +
no O +
immediate O +
complication O +
in O +
111 O +
infusions O +
of O +
BCNU O -
. O +

A O +
delayed O +
complication O +
in O +
nine O +
patients O +
has O +
been O +
unilateral O +
loss B-Disease +
of I-Disease +
vision I-Disease +
secondary O +
to O +
a O +
retinal B-Disease +
vasculitis I-Disease -
. O +

The O +
frequency O +
of O +
visual B-Disease +
loss I-Disease +
decreased O +
after O +
the O +
concentration O +
of O +
the O +
ethanol O +
diluent O +
was O +
lowered O -
. O +

Cardiotoxic B-Disease +
and O +
possible O +
leukemogenic O +
effects O +
of O +
adriamycin O +
in O +
nonhuman O +
primates O -
. O +

10 O +
monkeys O +
( O -
macaques O -
) O +
received O +
adriamycin O +
by O +
monthly O +
intravenous O +
injections O +
at O +
12 O +
mg O -
/ O -
m2 O +
( O -
1 O +
mg O -
/ O -
kg O -
) O -
. O +

8 O +
of O +
the O +
10 O +
monkeys O +
developed O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
at O +
an O +
average O +
cumulative O +
adriamycin O +
dose O +
( O -
310 O +
mg O -
/ O -
m2 O -
) O +
well O +
below O +
that O +
considered O +
the O +
safe O +
upper O +
limit O +
( O -
550 O +
mg O -
/ O -
m2 O -
) O +
in O +
man O -
. O +

Histologically O -
, O +
the O +
myocardial B-Disease +
lesions I-Disease +
resembled O +
those O +
found O +
in O +
human O +
anthracycline O -
- O -
induced O +
cardiomyopathy B-Disease -
. O +

1 O +
of O +
the O +
10 O +
monkeys O +
developed O +
acute B-Disease +
myeloblastic I-Disease +
leukemia I-Disease +
after O +
receiving O +
324 O +
mg O -
/ O -
m2 O +
of O +
adriamycin O -
; O +
the O +
10th O +
monkey O +
is O +
alive O +
and O +
well O +
26 O +
months O +
after O +
the O +
last O +
dose O +
of O +
drug O -
. O +

Our O +
results O +
suggest O +
that O +
adriamycin O +
is O +
a O +
more O +
potent O +
cardiotoxin O +
in O +
monkeys O +
than O +
in O +
man O -
, O +
and O +
that O +
leukemia B-Disease +
may O +
be O +
a O +
consequence O +
of O +
prolonged O +
treatment O +
with O +
this O +
drug O -
. O +

Provocation O +
of O +
postural O +
hypotension B-Disease +
by O +
nitroglycerin O +
in O +
diabetic B-Disease +
autonomic I-Disease +
neuropathy I-Disease -
? O +

The O +
effect O +
of O +
nitroglycerin O +
on O +
heart O +
rate O +
and O +
systolic O +
blood O +
pressure O +
was O +
compared O +
in O +
5 O +
normal O +
subjects O -
, O +
12 O +
diabetic B-Disease +
subjects O +
without O +
autonomic B-Disease +
neuropathy I-Disease -
, O +
and O +
5 O +
diabetic B-Disease +
subjects O +
with O +
autonomic B-Disease +
neuropathy I-Disease -
. O +

The O +
magnitude O +
and O +
time O +
course O +
of O +
the O +
increase O +
in O +
heart O +
rate O +
and O +
the O +
decrease O +
in O +
systolic O +
blood O +
pressure O +
after O +
nitroglycerin O +
were O +
similar O +
in O +
the O +
normal O +
and O +
diabetic B-Disease +
subjects O +
without O +
autonomic B-Disease +
neuropathy I-Disease -
, O +
whereas O +
a O +
lesser O +
increase O +
in O +
heart O +
rate O +
and O +
a O +
greater O +
decrease O +
in O +
systolic O +
blood O +
pressure O +
occurred O +
in O +
the O +
diabetic B-Disease +
subjects O +
with O +
autonomic B-Disease +
neuropathy I-Disease -
. O +

It O +
is O +
therefore O +
suggested O +
that O +
caution O +
should O +
be O +
exercised O +
when O +
prescribing O +
vasodilator O +
drugs O +
in O +
diabetic B-Disease +
patients O -
, O +
particularly O +
those O +
with O +
autonomic B-Disease +
neuropathy I-Disease -
. O +

Tricuspid B-Disease +
valve I-Disease +
regurgitation I-Disease +
and O +
lithium O +
carbonate O +
toxicity B-Disease +
in O +
a O +
newborn O +
infant O -
. O +

A O +
newborn O +
with O +
massive O +
tricuspid B-Disease +
regurgitation I-Disease -
, O +
atrial B-Disease +
flutter I-Disease -
, O +
congestive B-Disease +
heart I-Disease +
failure I-Disease -
, O +
and O +
a O +
high O +
serum O +
lithium O +
level O +
is O +
described O -
. O +

This O +
is O +
the O +
first O +
patient O +
to O +
initially O +
manifest O +
tricuspid B-Disease +
regurgitation I-Disease +
and O +
atrial B-Disease +
flutter I-Disease -
, O +
and O +
the O +
11th O +
described O +
patient O +
with O +
cardiac B-Disease +
disease I-Disease +
among O +
infants O +
exposed O +
to O +
lithium O +
compounds O +
in O +
the O +
first O +
trimester O +
of O +
pregnancy O -
. O +

Sixty O -
- O -
three O +
percent O +
of O +
these O +
infants O +
had O +
tricuspid O +
valve O +
involvement O -
. O +

Lithium O +
carbonate O +
may O +
be O +
a O +
factor O +
in O +
the O +
increasing O +
incidence O +
of O +
congenital B-Disease +
heart I-Disease +
disease I-Disease +
when O +
taken O +
during O +
early O +
pregnancy O -
. O +

It O +
also O +
causes O +
neurologic B-Disease +
depression I-Disease -
, O +
cyanosis B-Disease -
, O +
and O +
cardiac B-Disease +
arrhythmia I-Disease +
when O +
consumed O +
prior O +
to O +
delivery O -
. O +

Blood O +
pressure O +
response O +
to O +
chronic O +
low O -
- O -
dose O +
intrarenal O +
noradrenaline O +
infusion O +
in O +
conscious O +
rats O -
. O +

Sodium O +
chloride O +
solution O +
( O -
0.9 O -
% O -
) O +
or O +
noradrenaline O +
in O +
doses O +
of O +
4 O -
, O +
12 O +
and O +
36 O +
micrograms O +
h-1 O +
kg-1 O +
was O +
infused O +
for O +
five O +
consecutive O +
days O -
, O +
either O +
intrarenally O +
( O -
by O +
a O +
new O +
technique O -
) O +
or O +
intravenously O +
into O +
rats O +
with O +
one O +
kidney O +
removed O -
. O +

Intrarenal O +
infusion O +
of O +
noradrenaline O +
caused O +
hypertension B-Disease +
at O +
doses O +
which O +
did O +
not O +
do O +
so O +
when O +
infused O +
intravenously O -
. O +

Intrarenal O +
compared O +
with O +
intravenous O +
infusion O +
of O +
noradrenaline O +
caused O +
higher O +
plasma O +
noradrenaline O +
concentrations O +
and O +
a O +
shift O +
of O +
the O +
plasma O +
noradrenaline O +
concentration O -
- O -
blood O +
pressure O +
effect O +
curve O +
towards O +
lower O +
plasma O +
noradrenaline O +
levels O -
. O +

These O +
results O +
suggest O +
that O +
hypertension B-Disease +
after O +
chronic O +
intrarenal O +
noradrenaline O +
infusion O +
is O +
produced O +
by O +
relatively O +
higher O +
levels O +
of O +
circulating O +
noradrenaline O +
and O +
by O +
triggering O +
of O +
an O +
additional O +
intrarenal O +
pressor O +
mechanism O -
. O +

Characterization O +
of O +
estrogen O -
- O -
induced O +
adenohypophyseal B-Disease +
tumors I-Disease +
in O +
the O +
Fischer O +
344 O +
rat O -
. O +

Pituitary B-Disease +
tumors I-Disease +
were O +
induced O +
in O +
F344 O +
female O +
rats O +
by O +
chronic O +
treatment O +
with O +
diethylstilbestrol O +
( O -
DES O -
, O +
8 O -
- O -
10 O +
mg O -
) O +
implanted O +
subcutaneously O +
in O +
silastic O +
capsules O -
. O +

Over O +
a O +
range O +
of O +
1 O -
- O -
150 O +
days O +
of O +
DES O +
treatment O -
, O +
pairs O +
of O +
control O +
and O +
DES O -
- O -
treated O +
rats O +
were O +
sacrificed O -
, O +
and O +
their O +
pituitaries O +
dissociated O +
enzymatically O +
into O +
single O -
- O -
cell O +
preparations O -
. O +

The O +
cell O +
populations O +
were O +
examined O +
regarding O +
total O +
cell O +
recovery O +
correlated O +
with O +
gland O +
weight O -
, O +
intracellular O +
prolactin O +
( O -
PRL O -
) O +
content O +
and O +
subsequent O +
release O +
in O +
primary O +
culture O -
, O +
immunocytochemical O +
PRL O +
staining O -
, O +
density O +
and/or O +
size O +
alterations O +
via O +
separation O +
on O +
Ficoll O -
- O -
Hypaque O +
and O +
by O +
unit O +
gravity O +
sedimentation O -
, O +
and O +
cell O +
cycle O +
analysis O -
, O +
after O +
acriflavine O +
DNA O +
staining O -
, O +
by O +
laser O +
flow O +
cytometry O -
. O +

Total O +
cell O +
yields O +
from O +
DES O -
- O -
treated O +
pituitaries O +
increased O +
from O +
1.3 O +
times O +
control O +
yields O +
at O +
8 O +
days O +
of O +
treatment O +
to O +
58.9 O +
times O +
control O +
values O +
by O +
day O +
150 O -
. O +

Intracellular O +
PRL O +
content O +
ranged O +
from O +
1.9 O +
to O +
9.4 O +
times O +
control O +
levels O -
, O +
and O +
PRL O +
release O +
in O +
vitro O +
was O +
significantly O +
and O +
consistently O +
higher O +
than O +
controls O -
, O +
after O +
at O +
least O +
8 O +
days O +
of O +
DES O +
exposure O -
. O +

Beyond O +
8 O +
days O +
of O +
DES O +
exposure O -
, O +
the O +
immunochemically O +
PRL O -
- O -
positive O +
proportion O +
of O +
cells O +
increased O +
to O +
over O +
50 O -
% O +
of O +
the O +
total O +
population O -
. O +

Increased O +
density O +
and/or O +
size O +
and O +
PRL O +
content O +
were O +
indicated O +
for O +
the O +
majority O +
of O +
the O +
PRL O +
cell O +
population O +
in O +
both O +
types O +
of O +
separation O +
protocols O -
. O +

All O +
these O +
effects O +
of O +
DES O +
were O +
more O +
pronounced O +
among O +
previously O +
ovariectomized O +
animals O -
. O +

The O +
data O +
extend O +
the O +
findings O +
of O +
other O +
investigators O -
, O +
further O +
establishing O +
the O +
DES O -
- O -
induced O +
tumor B-Disease +
as O +
a O +
model O +
for O +
study O +
of O +
PRL O +
cellular O +
control O +
mechanisms O -
. O +

Effect O +
of O +
calcium O +
chloride O +
on O +
gross O +
behavioural O +
changes O +
produced O +
by O +
carbachol O +
and O +
eserine O +
in O +
cats O -
. O +

The O +
effect O +
of O +
calcium O +
chloride O +
injected O +
into O +
the O +
cerebral O +
ventricles O +
of O +
group O -
- O -
housed O +
unanaesthetized O +
cats O +
upon O +
vocalization O +
( O -
rage O -
, O +
hissing O +
and O +
snarling O -
) O -
, O +
fighting O +
( O -
attack O +
with O +
paws O +
and O +
claws O -
, O +
defense O +
with O +
paws O +
and O +
claws O +
and O +
biting O -
) O -
, O +
mydriasis B-Disease -
, O +
tremor B-Disease +
and O +
clonic B-Disease -
- I-Disease -
tonic I-Disease +
convulsions I-Disease +
produced O +
by O +
carbachol O +
and O +
eserine O +
injected O +
similarly O +
was O +
investigated O -
. O +

Calcium O +
chloride O +
depressed O +
or O +
almost O +
completely O +
abolished O +
the O +
vocalization O +
and O +
fighting O +
due O +
to O +
carbachol O +
and O +
eserine O -
. O +

On O +
the O +
other O +
hand O -
, O +
mydriasis B-Disease -
, O +
tremor B-Disease +
and O +
clonic B-Disease -
- I-Disease -
tonic I-Disease +
convulsions I-Disease +
evoked O +
by O +
carbachol O +
and O +
eserine O +
were O +
not O +
significantly O +
changed O +
by O +
calcium O +
chloride O -
. O +

It O +
is O +
apparent O +
that O +
calcium O +
chloride O +
can O +
" O -
dissociate O -
" O +
vocalization O +
and O +
fighting O +
from O +
autonomic O +
and O +
motor O +
phenomena O +
such O +
as O +
mydriasis B-Disease -
, O +
tremor B-Disease +
and O +
clonic B-Disease -
- I-Disease -
tonic I-Disease +
convulsions I-Disease +
caused O +
by O +
carbachol O +
and O +
eserine O -
. O +

Calcium O +
chloride O +
inhibited O +
the O +
vocalization O +
and O +
fighting O +
produced O +
by O +
carbachol O +
and O +
eserine O +
most O +
probably O +
by O +
a O +
nonspecific O +
stabilizing O +
action O +
on O +
central O +
muscarinic O +
cholinoceptive O +
sites O -
. O +

These O +
results O +
further O +
support O +
the O +
view O +
that O +
calcium O +
ions O +
in O +
excess O +
have O +
an O +
atropine O -
- O -
like O +
action O +
also O +
in O +
the O +
central O +
nervous O +
system O -
. O +

Thiazide O +
diuretics O -
, O +
hypokalemia B-Disease +
and O +
cardiac B-Disease +
arrhythmias I-Disease -
. O +

Thiazide O +
diuretics O +
are O +
widely O +
accepted O +
as O +
the O +
cornerstone O +
of O +
antihypertensive O +
treatment O +
programs O -
. O +

Hypokalemia B-Disease +
is O +
a O +
commonly O +
encountered O +
metabolic O +
consequence O +
of O +
chronic O +
thiazide O +
therapy O -
. O +

We O +
treated O +
38 O +
patients O +
( O -
22 O +
low O +
renin O -
, O +
16 O +
normal O +
renin O -
) O +
with O +
moderate O +
diastolic B-Disease +
hypertension I-Disease +
with O +
hydrochlorothiazide O +
( O -
HCTC O -
) O +
administered O +
on O +
a O +
twice O +
daily O +
schedule O -
. O +

Initial O +
dose O +
was O +
50 O +
mg O +
and O +
the O +
dose O +
was O +
increased O +
at O +
monthly O +
intervals O +
to O +
100 O +
mg O -
, O +
150 O +
mg O +
and O +
200 O +
mg O +
daily O +
until O +
blood O +
pressure O +
normalized O -
. O +

The O +
serum O +
K O +
during O +
the O +
control O +
period O +
was O +
4.5 O +
+ O -
/- O +

0.2 O +
mEq O -
/ O -
l O +
an O +
on O +
50 O -
, O +
100 O -
, O +
150 O +
and O +
200 O +
mg O +
HCTZ O +
daily O +
3.9 O +
+ O -
/- O +

0.3 O -
, O +
3.4 O +
+ O -
/- O +

0.2 O -
, O +
2.9 O +
+ O -
/- O +

0.2 O -
, O +
and O +
2.4 O +
+ O -
/- O +

0.3 O +
mEq O -
/ O -
l O -
, O +
respectively O -
. O +

Corresponding O +
figures O +
for O +
whole O +
body O +
K O +
were O +
4107 O +
+ O -
/- O +

208 O -
, O +
3722 O +
+ O -
/- O +

319 O -
, O +
3628 O +
+ O -
/- O +

257 O -
, O +
3551 O +
+ O -
/- O +

336 O -
, O +
and O +
3269 O +
+ O -
/- O +

380 O +
mEq O -
, O +
respectively O -
. O +

In O +
13 O +
patients O +
we O +
observed O +
the O +
effects O +
of O +
HCTZ O +
therapy O +
( O -
100 O +
mg O +
daily O -
) O +
on O +
the O +
occurrence O +
of O +
PVC O -
's O +
during O +
rest O +
as O +
well O +
as O +
during O +
static O +
and O +
dynamic O +
exercise O -
. O +

During O +
rest O +
we O +
observed O +
0.6 O +
+ O -
/- O +

0.08 O +
PVC O +
beats O -
/ O -
min O +
+ O -
/- O +

SEM O +
and O +
during O +
static O +
and O +
dynamic O +
exercise O +
0.6 O +
+ O -
/- O +

0.06 O +
and O +
0.8 O +
+ O -
/- O +

0.15 O -
, O +
respectively O -
. O +

Corresponding O +
figures O +
during O +
HCTZ O +
therapy O +
100 O +
mg O +
daily O +
were O +
1.4 O +
+ O -
/- O +

0.1 O -
, O +
3.6 O +
+ O -
/- O +

0.7 O +
and O +
5.7 O +
4 O -
/ O -
- O +
0.8 O -
, O +
respectively O -
. O +

The O +
occurrence O +
of O +
PVC O -
's O +
correlated O +
significantly O +
with O +
the O +
fall O +
in O +
serum O +
K+ O +
observed O +
r O +
= O +
0.72 O -
, O +
p O +
less O +
than O +
0.001 O -
. O +

In O +
conclusion O +
we O +
found O +
that O +
thiazide O +
diuretics O +
cause O +
hypokalemia B-Disease +
and O +
depletion O +
of O +
body O +
potassium O -
. O +

The O +
more O +
profound O +
hypokalemia B-Disease -
, O +
the O +
greater O +
the O +
propensity O +
for O +
the O +
occurrence O +
of O +
PVC O -
's O -
. O +

Circulating O +
lysosomal O +
enzymes O +
and O +
acute B-Disease +
hepatic I-Disease +
necrosis I-Disease -
. O +

The O +
activities O +
of O +
the O +
lysosomal O +
enzymes O +
acid O +
and O +
neutral O +
protease O -
, O +
N O -
- O -
acetylglucosaminidase O -
, O +
and O +
acid O +
phosphatase O +
were O +
measured O +
in O +
the O +
serum O +
of O +
patients O +
with O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease -
. O +

Acid O +
protease O +
( O -
cathepsin O +
D O -
) O +
activity O +
was O +
increased O +
about O +
tenfold O +
in O +
patients O +
who O +
died O +
and O +
nearly O +
fourfold O +
in O +
those O +
who O +
survived O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease +
after O +
paracetamol O +
overdose B-Disease -
, O +
whereas O +
activities O +
were O +
increased O +
equally O +
in O +
patients O +
with O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease +
due O +
to O +
viral B-Disease +
hepatitis I-Disease +
whether O +
or O +
not O +
they O +
survived O -
. O +

A O +
correlation O +
was O +
found O +
between O +
serum O +
acid O +
protease O +
activity O +
and O +
prothrombin O +
time O -
, O +
and O +
the O +
increase O +
in O +
cathepsin O +
D O +
activity O +
was O +
sustained O +
over O +
several O +
days O +
compared O +
with O +
aspartate O +
aminotransferase O -
, O +
which O +
showed O +
a O +
sharp O +
early O +
peak O +
and O +
then O +
a O +
fall O -
. O +

Circulating O +
lysosomal O +
proteases O +
can O +
damage O +
other O +
organs O -
, O +
and O +
measurement O +
of O +
their O +
activity O +
may O +
therefore O +
be O +
of O +
added O +
value O +
in O +
assessing O +
prognosis O +
in O +
this O +
condition O -
. O +

Age O +
and O +
renal O +
clearance O +
of O +
cimetidine O -
. O +

In O +
35 O +
patients O +
( O -
ages O +
20 O +
to O +
86 O +
yr O -
) O +
receiving O +
cimetidine O +
therapeutically O +
two O +
serum O +
samples O +
and O +
all O +
urine O +
formed O +
in O +
the O +
interim O +
were O +
collected O +
for O +
analysis O +
of O +
cimetidine O +
by O +
high O -
- O -
pressure O +
liquid O +
chromatography O +
and O +
for O +
creatinine O -
. O +

Cimetidine O +
clearance O +
decreased O +
with O +
age O -
. O +

The O +
extrapolated O +
6-hr O +
serum O +
concentration O +
of O +
cimetidine O +
per O +
unit O +
dose O -
, O +
after O +
intravenous O +
cimetidine O -
, O +
increased O +
with O +
age O +
of O +
the O +
patients O -
. O +

The O +
ratio O +
of O +
cimetidine O +
clearance O +
to O +
creatinine O +
clearance O +
( O -
Rc O -
) O +
averaged O +
4.8 O +
+ O -
/- O +

2.0 O -
, O +
indicating O +
net O +
tubular O +
secretion O +
for O +
cimetidine O -
. O +

Rc O +
seemed O +
to O +
be O +
independent O +
of O +
age O +
and O +
decreased O +
with O +
increasing O +
serum O +
concentration O +
of O +
cimetidine O -
, O +
suggesting O +
that O +
secretion O +
of O +
cimetidine O +
is O +
a O +
saturable O +
process O -
. O +

There O +
was O +
only O +
one O +
case O +
of O +
dementia B-Disease +
possibly O +
due O +
to O +
cimetidine O +
( O -
with O +
a O +
drug O +
level O +
of O +
1.9 O +
microgram O -
/ O -
ml O +
6 O +
hr O +
after O +
a O +
dose O -
) O +
in O +
a O +
group O +
of O +
13 O +
patients O +
without O +
liver B-Disease +
or I-Disease +
kidney I-Disease +
disease I-Disease +
who O +
had O +
cimetidine O +
levels O +
above O +
1.25 O +
microgram O -
/ O -
ml O -
. O +

Thus O -
, O +
high O +
cimetidine O +
levels O +
alone O +
do O +
not O +
always O +
induce O +
dementia B-Disease -
. O +

Chlorpropamide O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease -
. O +

A O +
65-year O -
- O -
old O +
woman O +
with O +
adult B-Disease -
- I-Disease -
onset I-Disease +
diabetes I-Disease +
treated O +
with O +
chlorpropamide O +
( O -
Diabenese O -
) O +
had O +
a O +
toxic B-Disease +
optic I-Disease +
neuropathy I-Disease +
that O +
resolved O +
with O +
discontinuation O +
of O +
chlorpropamide O +
therapy O -
. O +

Visual B-Disease +
loss I-Disease +
occurs O +
in O +
diabetics B-Disease +
for O +
a O +
variety O +
of O +
reasons O -
, O +
and O +
accurate O +
diagnosis O +
is O +
necessary O +
to O +
institute O +
appropriate O +
therapy O -
. O +

The O +
possibility O +
of O +
a O +
drug O -
- O -
induced O +
optic B-Disease +
neuropathy I-Disease +
should O +
be O +
considered O +
in O +
the O +
differential O +
diagnosis O +
of O +
visual B-Disease +
loss I-Disease +
in O +
diabetics B-Disease -
. O +

Plasma O +
and O +
urinary O +
lipids O +
and O +
lipoproteins O +
during O +
the O +
development O +
of O +
nephrotic B-Disease +
syndrome I-Disease +
induced O +
in O +
the O +
rat O +
by O +
puromycin O +
aminonucleoside O -
. O +

This O +
study O +
was O +
undertaken O +
to O +
ascertain O +
whether O +
the O +
alterations O +
of O +
plasma O +
lipoproteins O +
found O +
in O +
nephrotic B-Disease +
syndrome I-Disease +
induced O +
by O +
puromycin O +
aminonucleoside O +
were O +
due O +
to O +
nephrotic B-Disease +
syndrome I-Disease +
per O +
se O -
, O +
or O -
, O +
at O +
least O +
in O +
part O -
, O +
to O +
the O +
aminonucleoside O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
changes O +
in O +
plasma O +
and O +
urinary O +
lipoproteins O +
during O +
the O +
administration O +
of O +
puromycin O +
aminonucleoside O +
( O -
20 O +
mg O -
/ O -
kg O +
for O +
7 O +
days O -
) O +
and O +
the O +
subsequent O +
development O +
of O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Since O +
massive O +
albuminuria B-Disease +
occurred O +
after O +
6 O +
days O +
of O +
treatment O -
, O +
the O +
time O -
- O -
course O +
study O +
was O +
divided O +
into O +
two O +
stages O -
: O +
pre O -
- O -
nephrotic B-Disease +
stage O +
( O -
day O +
1 O -
- O -
5 O -
) O +
and O +
nephrotic B-Disease +
stage O +
( O -
day O +
6 O -
- O -
11 O -
) O -
. O +

In O +
pre O -
- O -
nephrotic B-Disease +
stage O +
the O +
plasma O +
level O +
of O +
fatty O +
acids O -
, O +
triacylglycerol O +
and O +
VLDL O +
decreased O +
while O +
that O +
of O +
phospholipid O -
, O +
cholesteryl O +
esters O +
and O +
HDL O +
remained O +
constant O -
. O +

Plasma O +
apolipoprotein O +
A O -
- O -
I O +
tended O +
to O +
increase O +
( O -
40 O -
% O +
increase O +
at O +
day O +
5 O -
) O -
. O +

At O +
the O +
beginning O +
of O +
nephrotic B-Disease +
stage O +
( O -
day O +
6 O -
) O +
the O +
concentration O +
of O +
plasma O +
albumin O +
dropped O +
to O +
a O +
very O +
low O +
level O -
, O +
while O +
that O +
of O +
apolipoprotein O +
A O -
- O -
I O +
increased O +
abruptly O +
( O -
4-fold O +
increase O -
) O +
and O +
continued O +
to O +
rise O -
, O +
although O +
less O +
steeply O -
, O +
in O +
the O +
following O +
days O -
. O +

The O +
plasma O +
concentration O +
of O +
HDL O +
followed O +
the O +
same O +
pattern O -
. O +

Plasma O +
VLDL O +
and O +
LDL O +
increased O +
at O +
a O +
later O +
stage O +
( O -
day O +
9 O -
) O -
. O +

Plasma O +
apolipoprotein O +
A O -
- O -
I O +
was O +
found O +
not O +
only O +
in O +
HDL O +
( O -
1.063 O -
- O -
1.210 O +
g O -
/ O -
ml O -
) O +
but O +
also O +
in O +
the O +
LDL O +
density O +
class O +
( O -
1.025 O -
- O -
1.050 O +
g O -
/ O -
ml O -
) O -
. O +

In O +
the O +
pre O -
- O -
nephrotic B-Disease +
stage O +
lipoproteinuria O +
was O +
negligible O -
, O +
while O +
in O +
the O +
early O +
nephrotic B-Disease +
stage O +
the O +
urinary O +
loss O +
of O +
plasma O +
lipoproteins O +
consisted O +
mainly O +
of O +
HDL O -
. O +

These O +
observations O +
indicate O +
that O +
puromycin O +
aminonucleoside O +
alters O +
plasma O +
lipoproteins O +
by O +
lowering O +
VLDL O +
and O +
increasing O +
HDL O -
. O +

It O +
is O +
likely O +
that O +
the O +
early O +
and O +
striking O +
increase O +
of O +
plasma O +
HDL O +
found O +
in O +
nephrotic B-Disease +
rats O +
is O +
related O +
to O +
a O +
direct O +
effect O +
of O +
the O +
drug O +
on O +
HDL O +
metabolism O -
. O +

Fatal O +
aplastic B-Disease +
anemia I-Disease +
following O +
topical O +
administration O +
of O +
ophthalmic O +
chloramphenicol O -
. O +

A O +
73-year O -
- O -
old O +
woman O +
died O +
of O +
aplastic B-Disease +
anemia I-Disease +
less O +
than O +
two O +
months O +
after O +
undergoing O +
cataract B-Disease +
extraction O +
and O +
beginning O +
topical O +
therapy O +
with O +
chloramphenicol O -
. O +

The O +
first O +
signs O +
of O +
pancytopenia B-Disease +
began O +
within O +
one O +
month O +
of O +
the O +
surgery O -
. O +

The O +
pattern O +
of O +
the O +
aplastic B-Disease +
anemia I-Disease +
was O +
associated O +
with O +
an O +
idiosyncratic O +
response O +
to O +
chloramphenicol O -
. O +

This O +
was O +
the O +
second O +
report O +
of O +
fatal O +
aplastic B-Disease +
anemia I-Disease +
after O +
topical O +
treatment O +
with O +
chloramphenicol O +
for O +
ocular O +
conditions O -
, O +
although O +
two O +
cases O +
of O +
reversible O +
bone B-Disease +
marrow I-Disease +
hypoplasia I-Disease +
have O +
also O +
been O +
reported O -
. O +

Any O +
other O +
suspected O +
cases O +
of O +
ocular B-Disease +
toxicity I-Disease +
associated O +
with O +
topically O +
applied O +
chloramphenicol O +
should O +
be O +
reported O +
to O +
the O +
National O +
Registry O +
of O +
Drug O -
- O -
Induced O +
Ocular O +
Side O +
Effects O -
, O +
Oregon O +
Health O +
Sciences O +
University O -
, O +
Portland O -
, O +
OR O +
97201 O -
. O +

Further O +
observations O +
on O +
the O +
electrophysiologic O +
effects O +
of O +
oral O +
amiodarone O +
therapy O -
. O +

A O +
case O +
is O +
presented O +
of O +
a O +
reversible O +
intra B-Disease -
- I-Disease -
Hisian I-Disease +
block I-Disease +
occurring O +
under O +
amiodarone O +
treatment O +
for O +
atrial B-Disease +
tachycardia I-Disease +
in O +
a O +
patient O +
without O +
clear O +
intraventricular B-Disease +
conduction I-Disease +
abnormalities I-Disease -
. O +

His O +
bundle O +
recordings O +
showed O +
an O +
atrial B-Disease +
tachycardia I-Disease +
with O +
intermittent O +
exit O +
block O +
and O +
greatly O +
prolonged O +
BH O +
and O +
HV O +
intervals O +
( O -
40 O +
and O +
100 O +
msec O -
, O +
respectively O -
) O -
. O +

Thirty O +
days O +
after O +
amiodarone O +
discontinuation O -
, O +
His O +
bundle O +
electrograms O +
showed O +
atrial B-Disease +
flutter I-Disease +
without O +
intra O -
- O -
Hisian O +
or O +
infra O -
- O -
Hisian O +
delay O -
. O +

Amiodarone O +
should O +
be O +
used O +
with O +
caution O +
during O +
long O -
- O -
term O +
oral O +
therapy O +
in O +
patients O +
with O +
or O +
without O +
clear O +
intraventricular O +
conduction O +
defects O -
. O +

Development O +
of O +
clear B-Disease +
cell I-Disease +
adenocarcinoma I-Disease +
in O +
DES O -
- O -
exposed O +
offspring O +
under O +
observation O -
. O +

Two O +
cases O +
of O +
clear B-Disease +
cell I-Disease +
adenocarcinoma I-Disease +
of B-Disease +
the I-Disease +
vagina I-Disease +
detected O +
at O +
follow O -
- O -
up O +
in O +
young O +
women O +
exposed O +
in O +
utero O +
to O +
diethylstilbestrol O +
are O +
reported O -
. O +

One O +
patient O -
, O +
aged O +
23 O -
, O +
had O +
been O +
followed O +
for O +
2 O +
years O +
before O +
carcinoma B-Disease +
was O +
diagnosed O -
; O +
the O +
second O +
patient O -
, O +
aged O +
22 O -
, O +
had O +
been O +
seen O +
on O +
a O +
regular O +
basis O +
for O +
5 O +
years O -
, O +
8 O +
months O -
. O +

In O +
both O +
instances O -
, O +
suspicion O +
of O +
the O +
presence O +
of O +
carcinoma B-Disease +
was O +
aroused O +
by O +
the O +
palpation O +
of O +
a O +
small O +
nodule O +
in O +
the O +
vaginal O +
fornix O -
. O +

Hysterosalpingography O +
was O +
performed O +
on O +
both O +
patients O +
and O -
, O +
in O +
1 O +
instance O -
, O +
an O +
abnormal O +
x O -
- O -
ray O +
film O +
was O +
reflected O +
by O +
the O +
gross O +
appearance O +
of O +
the O +
uterine O +
cavity O +
found O +
in O +
the O +
surgical O +
specimen O -
. O +

Midazolam O +
compared O +
with O +
thiopentone O +
as O +
an O +
induction O +
agent O -
. O +

In O +
patients O +
premedicated O +
with O +
scopolamine O +
+ O +
morphine O +
( O -
+ O -
5 O +
mg O +
nitrazepam O +
the O +
evening O +
before O +
surgery O -
) O -
, O +
the O +
sleep O -
- O -
inducing O +
effect O +
of O +
midazolam O +
0.15 O +
mg O -
/ O -
kg O +
i.v O -
. O +
was O +
clearly O +
slower O +
in O +
onset O +
than O +
that O +
of O +
thiopentone O +
4.67 O +
mg O -
/ O -
kg O +
i.v O -
. O +

Somewhat O +
fewer O +
cardiovascular O +
and O +
local O +
sequelae O +
were O +
found O +
in O +
the O +
midazolam O +
group O -
, O +
but O -
, O +
although O +
apnoea B-Disease +
occurred O +
less O +
often O +
in O +
the O +
midazolam O +
group O +
it O +
lasted O +
longer O -
. O +

On O +
the O +
whole O -
, O +
the O +
differences O +
between O +
midazolam O +
and O +
thiopentone O +
had O +
no O +
apparent O +
clinical O +
consequences O -
. O +

Midazolam O +
is O +
a O +
new O +
alternative O +
agent O +
for O +
induction O +
in O +
combination O +
anaesthesia O -
. O +

Deaths O +
from O +
local O +
anesthetic O -
- O -
induced O +
convulsions B-Disease +
in O +
mice O -
. O +

Median O +
convulsant O +
( O -
CD50 O -
) O +
and O +
median O +
lethal O +
( O -
LD50 O -
) O +
doses O +
of O +
three O +
representative O +
local O +
anesthetics O +
were O +
determined O +
in O +
adult O +
mice O +
to O +
evaluate O +
the O +
threat O +
to O +
life O +
of O +
local O +
anesthetic O -
- O -
induced O +
convulsions B-Disease -
. O +

The O +
CD50 O +
and O +
LD50 O -
, O +
respectively O -
, O +
were O +
57.7 O +
and O +
58.7 O +
mg O -
/ O -
kg O +
for O +
bupivacaine O -
, O +
111.0 O +
and O +
133.1 O +
mg O -
/ O -
kg O +
for O +
lidocaine O -
, O +
and O +
243.4 O +
and O +
266.5 O +
mg O -
/ O -
kg O +
for O +
chloroprocaine O -
. O +

When O +
given O +
intraperitoneally O -
, O +
bupivacaine O +
thus O +
was O +
only O +
about O +
twice O +
as O +
toxic O +
as O +
lidocaine O +
and O +
four O +
times O +
as O +
toxic O +
as O +
chloroprocaine O -
. O +

Convulsions B-Disease +
always O +
preceded O +
death O -
, O +
except O +
after O +
precipitous O +
cardiopulmonary B-Disease +
arrest I-Disease +
from O +
extreme O +
doses O -
. O +

A O +
CD50 O +
dose O +
of O +
local O +
anesthetic O +
( O -
causing O +
convulsions B-Disease +
in O +
50 O -
% O +
of O +
mice O -
) O +
was O +
fatal O +
in O +
90 O -
% O +
of O +
bupivacaine O -
- O -
induced O +
seizures B-Disease -
, O +
in O +
57 O -
% O +
of O +
the O +
chloroprocaine O +
group O -
, O +
and O +
in O +
6 O -
% O +
of O +
the O +
lidocaine O +
group O -
. O +

The O +
narrow O +
gap O +
between O +
convulsant O +
and O +
lethal O +
doses O +
of O +
local O +
anesthetics O +
indicates O +
that O +
untreated O +
convulsions B-Disease +
present O +
much O +
more O +
of O +
a O +
threat O +
to O +
life O +
than O +
heretofore O +
appreciated O -
. O +

Neurologic O +
effects O +
of O +
subarachnoid O +
administration O +
of O +
2-chloroprocaine O -
- O -
CE O -
, O +
bupivacaine O -
, O +
and O +
low O +
pH O +
normal O +
saline O +
in O +
dogs O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
neurologic O +
consequences O +
of O +
deliberate O +
subarachnoid O +
injection O +
of O +
large O +
volumes O +
of O +
2-chloroprocaine O -
- O -
CE O +
in O +
experimental O +
animals O -
. O +

The O +
possible O +
role O +
of O +
low O +
pH O +
as O +
well O +
as O +
total O +
volume O +
as O +
potential O +
factors O +
in O +
causing O +
neurotoxicity B-Disease +
was O +
evaluated O -
. O +

The O +
65 O +
dogs O +
in O +
the O +
study O +
received O +
injections O +
in O +
the O +
subarachnoid O +
space O +
as O +
follows O -
: O +
6 O +
to O +
8 O +
ml O +
of O +
bupivacaine O +
( O -
N O +
= O +
15 O -
) O -
, O +
2-chloroprocaine O -
- O -
CE O +
( O -
N O +
= O +
20 O -
) O -
, O +
low O +
pH O +
normal O +
saline O +
( O -
pH O +
3.0 O -
) O +
( O -
N O +
= O +
20 O -
) O -
, O +
or O +
normal O +
saline O +
( O -
N O +
= O +
10 O -
) O -
. O +

Of O +
the O +
20 O +
animals O +
that O +
received O +
subarachnoid O +
injection O +
of O +
2-chloroprocaine O -
- O -
CE O +
seven O +
( O -
35 O -
% O -
) O +
developed O +
hind O -
- O -
limb O +
paralysis B-Disease -
. O +

None O +
of O +
the O +
animals O +
that O +
received O +
bupivacaine O -
, O +
normal O +
saline O -
, O +
or O +
normal O +
saline O +
titrated O +
to O +
a O +
pH O +
3.0 O +
developed O +
hind O -
- O -
limb O +
paralysis B-Disease -
. O +

Of O +
the O +
15 O +
spinal O +
cords O +
of O +
the O +
animals O +
that O +
received O +
2-chloroprocaine O -
- O -
CE O -
, O +
13 O +
showed O +
subpial B-Disease +
necrosis I-Disease -
; O +
the O +
nerve O +
roots O +
and O +
subarachnoid O +
vessels O +
were O +
normal O -
. O +

The O +
spinal O +
cords O +
of O +
the O +
animals O +
that O +
received O +
bupivacaine O -
, O +
low O +
pH O +
normal O +
saline O +
( O -
pH O +
3.0 O -
) O -
, O +
or O +
normal O +
saline O +
did O +
not O +
show O +
abnormal O +
findings O -
. O +

Procainamide O -
- O -
induced O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

Seven O +
cases O +
of O +
procainamide O -
- O -
induced O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease +
are O +
presented O -
. O +

In O +
four O +
patients O -
, O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease +
appeared O +
after O +
intravenous O +
administration O +
of O +
200 O +
to O +
400 O +
mg O +
of O +
procainamide O +
for O +
the O +
treatment O +
of O +
sustained O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

In O +
the O +
remaining O +
three O +
patients O -
, O +
procainamide O +
was O +
administered O +
orally O +
for O +
treatment O +
of O +
chronic O +
premature B-Disease +
ventricular I-Disease +
contractions I-Disease +
or O +
atrial B-Disease +
flutter I-Disease -
. O +

These O +
patients O +
had O +
Q B-Disease -
- I-Disease -
T I-Disease +
prolongation I-Disease +
and O +
recurrent O +
syncope B-Disease +
due O +
to O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

In O +
four O +
patients O -
, O +
the O +
arrhythmia B-Disease +
was O +
rapidly O +
diagnosed O +
and O +
treated O +
with O +
disappearance O +
of O +
further O +
episodes O +
of O +
the O +
arrhythmia B-Disease -
. O +

In O +
two O +
patients O -
, O +
the O +
arrhythmia B-Disease +
degenerated O +
into O +
irreversible O +
ventricular B-Disease +
fibrillation I-Disease +
and O +
both O +
patients O +
died O -
. O +

In O +
the O +
seventh O +
patient O -
, O +
a O +
permanent O +
ventricular O +
pacemaker O +
was O +
inserted O +
and O -
, O +
despite O +
continuation O +
of O +
procainamide O +
therapy O -
, O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease +
did O +
not O +
reoccur O -
. O +

These O +
seven O +
cases O +
demonstrate O +
that O +
procainamide O +
can O +
produce O +
an O +
acquired O +
prolonged B-Disease +
Q I-Disease -
- I-Disease -
T I-Disease +
syndrome I-Disease +
with O +
polymorphous O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

Phenobarbitone O -
- O -
induced O +
enlargement B-Disease +
of I-Disease +
the I-Disease +
liver I-Disease +
in O +
the O +
rat O -
: O +
its O +
relationship O +
to O +
carbon O +
tetrachloride O -
- O -
induced O +
cirrhosis B-Disease -
. O +

The O +
yield O +
of O +
severe O +
cirrhosis B-Disease +
of I-Disease +
the I-Disease +
liver I-Disease +
( O -
defined O +
as O +
a O +
shrunken O +
finely O +
nodular O +
liver O +
with O +
micronodular O +
histology O -
, O +
ascites B-Disease +
greater O +
than O +
30 O +
ml O -
, O +
plasma O +
albumin O +
less O +
than O +
2.2 O +
g O -
/ O -
dl O -
, O +
splenomegaly B-Disease +
2 O -
- O -
3 O +
times O +
normal O -
, O +
and O +
testicular O +
atrophy B-Disease +
approximately O +
half O +
normal O +
weight O -
) O +
after O +
12 O +
doses O +
of O +
carbon O +
tetrachloride O +
given O +
intragastrically O +
in O +
the O +
phenobarbitone O -
- O -
primed O +
rat O +
was O +
increased O +
from O +
25 O -
% O +
to O +
56 O -
% O +
by O +
giving O +
the O +
initial O +
" O -
calibrating O -
" O +
dose O +
of O +
carbon O +
tetrachloride O +
at O +
the O +
peak O +
of O +
the O +
phenobarbitone O -
- O -
induced O +
enlargement B-Disease +
of I-Disease +
the I-Disease +
liver I-Disease -
. O +

At O +
this O +
point O +
it O +
was O +
assumed O +
that O +
the O +
cytochrome O +
P450 O -
/ O -
CCl4 O +
toxic O +
state O +
was O +
both O +
maximal O +
and O +
stable O -
. O +

The O +
optimal O +
rat O +
size O +
to O +
begin O +
phenobarbitone O +
was O +
determined O +
as O +
100 O +
g O -
, O +
and O +
this O +
size O +
as O +
a O +
group O +
had O +
a O +
mean O +
maximum O +
relative O +
liver O +
weight O +
increase O +
47 O -
% O +
greater O +
than O +
normal O +
rats O +
of O +
the O +
same O +
body O +
weight O -
. O +

The O +
optimal O +
time O +
for O +
the O +
initial O +
dose O +
of O +
carbon O +
tetrachloride O +
was O +
after O +
14 O +
days O +
on O +
phenobarbitone O -
. O +

Fatal O +
aplastic B-Disease +
anemia I-Disease +
due O +
to O +
indomethacin O -
-- O -
lymphocyte O +
transformation O +
tests O +
in O +
vitro O -
. O +

Although O +
indomethacin O +
has O +
been O +
implicated O +
as O +
a O +
possible O +
cause O +
of O +
aplastic B-Disease +
anemia I-Disease +
on O +
the O +
basis O +
of O +
a O +
few O +
clinical O +
observations O -
, O +
its O +
role O +
has O +
not O +
been O +
definitely O +
established O -
. O +

A O +
case O +
of O +
fatal O +
aplastic B-Disease +
anemia I-Disease +
is O +
described O +
in O +
which O +
no O +
drugs O +
other O +
than O +
allopurinol O +
and O +
indomethacin O +
were O +
given O -
. O +

Indomethacin O +
was O +
first O +
given O +
four O +
weeks O +
prior O +
to O +
the O +
onset O +
of O +
symptoms O -
. O +

A O +
positive O +
lymphocyte O +
transformation O +
test O +
with O +
indomethacin O +
in O +
vitro O +
further O +
substantiates O +
the O +
potential O +
role O +
of O +
this O +
drug O +
in O +
causing O +
aplastic B-Disease +
anemia I-Disease +
in O +
a O +
susceptible O +
patient O -
. O +

Fortunately O -
, O +
this O +
seems O +
to O +
be O +
a O +
very O +
rare O +
complication O -
. O +

Triamterene O +
nephrolithiasis B-Disease +
complicating O +
dyazide O +
therapy O -
. O +

A O +
case O +
of O +
triamterene O +
nephrolithiasis B-Disease +
is O +
reported O +
in O +
a O +
man O +
after O +
4 O +
years O +
of O +
hydrochlorothiazide O -
- O -
triamterene O +
therapy O +
for O +
hypertension B-Disease -
. O +

The O +
stone O +
passed O +
spontaneously O +
and O +
was O +
found O +
to O +
contain O +
a O +
triamterene O +
metabolite O +
admixed O +
with O +
uric O +
acid O +
salts O -
. O +

Factors O +
affecting O +
triamterene O +
nephrolithiasis B-Disease +
are O +
discussed O +
and O +
2 O +
previously O +
reported O +
cases O +
are O +
reviewed O -
. O +

Busulfan O -
- O -
induced O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

A O +
case O +
of O +
a O +
busulfan O -
- O -
induced O +
hemorrhage B-Disease +
cystitis B-Disease +
is O +
reported O -
. O +

Spontaneous O +
resolution O +
occurred O +
following O +
cessation O +
of O +
the O +
drug O -
. O +

The O +
similarity O +
between O +
the O +
histologic O +
appearances O +
of O +
busulfan O +
cystitis B-Disease +
and O +
both O +
radiation O +
and O +
cyclophosphamide O -
- O -
induced O +
cystitis B-Disease +
is O +
discussed O +
and O +
the O +
world O +
literature O +
reviewed O -
. O +

In O +
view O +
of O +
the O +
known O +
tendency O +
of O +
busulfan O +
to O +
induce O +
cellular O +
atypia O +
and O +
carcinoma B-Disease +
in O +
other O +
sites O -
, O +
periodic O +
urinary O +
cytology O +
is O +
suggested O +
in O +
patients O +
on O +
long O -
- O -
term O +
therapy O -
. O +

Dose O -
- O -
effect O +
and O +
structure O -
- O -
function O +
relationships O +
in O +
doxorubicin O +
cardiomyopathy B-Disease -
. O +

The O +
cardiomyopathy B-Disease +
( O -
CM B-Disease -
) O +
produced O +
by O +
the O +
anticancer O +
drug O +
doxorubicin O +
( O -
DXR O -
) O +
( O -
Adriamycin O -
) O +
provides O +
a O +
unique O +
opportunity O +
to O +
analyze O +
dose O -
- O -
effect O +
and O +
structure O -
- O -
function O +
relationships O +
during O +
development O +
of O +
myocardial B-Disease +
disease I-Disease -
. O +

We O +
measured O +
the O +
degree O +
of O +
morphologic O +
damage O +
by O +
ultrastructural O +
examination O +
of O +
endomyocardial O +
biopsy O +
and O +
the O +
degree O +
of O +
performance O +
abnormally O +
by O +
right O +
heart O +
catheterization O +
in O +
patients O +
receiving O +
DXR O -
. O +

Morphologic O +
damage O +
was O +
variable O +
but O +
was O +
proportional O +
to O +
the O +
total O +
cumulative O +
DXR O +
dose O +
between O +
100 O +
and O +
600 O +
mg O -
/ O -
m2 O -
. O +

Performance O +
abnormalities O +
correlated O +
weakly O +
with O +
dose O -
, O +
exhibited O +
a O +
curvilinear O +
relationship O -
, O +
and O +
had O +
a O +
" O -
threshold O -
" O +
for O +
expression O -
. O +

Catheterization O +
abnormalities O +
correlated O +
well O +
with O +
morphologic O +
damage O +
( O -
r O +
= O +
0.57 O +
to O +
0.78 O -
) O +
in O +
a O +
subgroup O +
of O +
patients O +
in O +
whom O +
exercise O +
hemodynamics O +
were O +
measured O -
, O +
and O +
this O +
relationship O +
also O +
exhibited O +
a O +
curvilinear O -
, O +
threshold O +
configuration O -
. O +

In O +
DXR O -
- O -
CM B-Disease +
myocardial B-Disease +
damage I-Disease +
is O +
proportional O +
to O +
the O +
degree O +
of O +
cytotoxic O +
insult O +
( O -
DXR O +
dose O -
) O +
while O +
myocardial O +
function O +
is O +
preserved O +
until O +
a O +
critical O +
dose O +
or O +
degree O +
of O +
damage O +
is O +
reached O -
, O +
after O +
which O +
myocardial O +
performance O +
deteriorates O +
rapidly O -
. O +

Variant O +
ventricular B-Disease +
tachycardia I-Disease +
in O +
desipramine O +
toxicity B-Disease -
. O +

We O +
report O +
a O +
case O +
of O +
variant O +
ventricular B-Disease +
tachycardia I-Disease +
induced O +
by O +
desipramine O +
toxicity B-Disease -
. O +

Unusual O +
features O +
of O +
the O +
arrhythmia B-Disease +
are O +
repetitive O +
group O +
beating O -
, O +
progressive O +
shortening O +
of O +
the O +
R O -
- O -
R O +
interval O -
, O +
progressive O +
widening O +
of O +
the O +
QRS O +
complex O +
with O +
eventual O +
failure O +
of O +
intraventricular O +
conduction O -
, O +
and O +
changes O +
in O +
direction O +
of O +
the O +
QRS O +
axis O -
. O +

Recognition O +
of O +
variant O +
ventricular B-Disease +
tachycardia I-Disease +
is O +
important O +
because O +
therapy O +
differs O +
from O +
that O +
of O +
classic O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

Massive O +
cerebral B-Disease +
edema I-Disease +
associated O +
with O +
fulminant O +
hepatic B-Disease +
failure I-Disease +
in O +
acetaminophen O +
overdose B-Disease -
: O +
possible O +
role O +
of O +
cranial O +
decompression O -
. O +

Cerebral B-Disease +
edema I-Disease +
may O +
complicate O +
the O +
course O +
of O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease -
. O +

Response O +
to O +
conventional O +
therapy O +
has O +
been O +
disappointing O -
. O +

We O +
present O +
a O +
patient O +
with O +
fatal O +
acetaminophen O -
- O -
induced O +
fulminant B-Disease +
hepatic I-Disease +
failure I-Disease -
, O +
with O +
signs O +
and O +
symptoms O +
of O +
cerebral B-Disease +
edema I-Disease -
, O +
unresponsive O +
to O +
conventional O +
medical O +
therapy O -
. O +

Cranial O +
decompression O +
was O +
carried O +
out O -
. O +

A O +
justification O +
of O +
the O +
need O +
for O +
further O +
evaluation O +
of O +
cranial O +
decompression O +
in O +
such O +
patients O +
is O +
presented O -
. O +

Rebound O +
hypertensive B-Disease +
after O +
sodium O +
nitroprusside O +
prevented O +
by O +
saralasin O +
in O +
rats O -
. O +

The O +
role O +
of O +
the O +
renin O -
-- O -
angiotensin O +
system O +
in O +
the O +
maintenance O +
of O +
blood O +
pressure O +
during O +
halothane O +
anesthesia O +
and O +
sodium O +
nitroprusside O +
( O -
SNP O -
) O -
-induced O +
hypotension B-Disease +
was O +
evaluated O -
. O +

Control O +
rats O +
received O +
halothane O +
anesthesia O +
( O -
1 O +
MAC O -
) O +
for O +
one O +
hour O -
, O +
followed O +
by O +
SNP O +
infusion O -
, O +
40 O +
microgram O -
/ O -
kg O -
/ O -
min O -
, O +
for O +
30 O +
min O -
, O +
followed O +
by O +
a O +
30-min O +
recovery O +
period O -
. O +

A O +
second O +
group O +
of O +
rats O +
was O +
treated O +
identically O +
and O -
, O +
in O +
addition O -
, O +
received O +
an O +
infusion O +
of O +
saralasin O +
( O -
a O +
competitive O +
inhibitor O +
of O +
angiotensin O +
II O -
) O +
throughout O +
the O +
experimental O +
period O -
. O +

In O +
each O +
group O -
, O +
SNP O +
infusion O +
resulted O +
in O +
an O +
initial O +
decrease O +
in O +
blood O +
pressure O +
from O +
86 O +
torr O +
and O +
83 O +
torr O -
, O +
respectively O -
, O +
to O +
48 O +
torr O -
. O +

During O +
the O +
SNP O +
infusion O +
the O +
control O +
animals O +
demonstrated O +
a O +
progressive O +
increase B-Disease +
in I-Disease +
blood I-Disease +
pressure I-Disease +
to O +
61 O +
torr O -
, O +
whereas O +
the O +
saralasin O -
- O -
treated O +
animals O +
showed O +
no O +
change O -
. O +

Following O +
discontinuation O +
of O +
SNP O -
, O +
blood O +
pressure O +
in O +
the O +
control O +
animals O +
rebounded O +
to O +
94 O +
torr O -
, O +
as O +
compared O +
with O +
78 O +
torr O +
in O +
the O +
saralasin O -
- O -
treated O +
rats O -
. O +

This O +
study O +
indicates O +
that O +
with O +
stable O +
halothane O +
anesthesia O -
, O +
the O +
partial O +
recovery O +
of O +
blood O +
pressure O +
during O +
SNP O +
infusion O +
and O +
the O +
post O -
- O -
SNP O +
rebound O +
of O +
blood O +
pressure O +
can O +
be O +
completely O +
blocked O +
by O +
saralasin O -
. O +

This O +
demonstrates O +
the O +
participation O +
of O +
the O +
renin O -
-- O -
angiotensin O +
system O +
in O +
antagonizing O +
the O +
combined O +
hypotensive B-Disease +
effects O +
of O +
halothane O +
and O +
SNP O -
. O +

Subjective O +
assessment O +
of O +
sexual B-Disease +
dysfunction I-Disease +
of O +
patients O +
on O +
long O -
- O -
term O +
administration O +
of O +
digoxin O -
. O +

Various O +
data O +
suggest O +
that O +
male O +
patients O +
who O +
have O +
received O +
digoxin O +
on O +
a O +
longterm O +
basis O +
have O +
increased O +
levels O +
of O +
serum O +
estrogen O +
and O +
decreased O +
levels O +
of O +
plasma O +
testosterone O +
and O +
luteinizing O +
hormone O +
( O -
LH O -
) O -
. O +

This O +
study O +
was O +
undertaken O +
to O +
investigate O +
the O +
links O +
between O +
the O +
long O -
- O -
term O +
administration O +
of O +
digoxin O +
therapy O +
and O +
sexual O +
behavior O -
, O +
and O +
the O +
effect O +
of O +
digoxin O +
on O +
plasma O +
levels O +
of O +
estradiol O -
, O +
testosterone O -
, O +
and O +
LH O -
. O +

The O +
patients O +
of O +
the O +
study O +
and O +
control O +
group O +
( O -
without O +
digoxin O -
) O +
were O +
of O +
similar O +
cardiac O +
functional O +
capacity O +
and O +
age O +
( O -
25 O -
- O -
40 O +
years O -
) O +
and O +
were O +
randomly O +
selected O +
from O +
the O +
rheumatic B-Disease +
heart I-Disease +
disease I-Disease +
patients O -
. O +

A O +
subjective O +
assessment O +
of O +
sexual O +
behavior O +
in O +
the O +
study O +
and O +
control O +
groups O +
was O +
carried O +
out O -
, O +
using O +
parameters O +
such O +
as O +
sexual O +
desire O -
, O +
sexual O +
excitement O -
, O +
and O +
frequency O +
of O +
sexual O +
relations O -
. O +

Personal O +
interviews O +
and O +
a O +
questionnaire O +
were O +
also O +
used O +
for O +
the O +
evaluation O +
of O +
sexual O +
behavior O -
. O +

The O +
findings O +
support O +
the O +
reports O +
concerning O +
digoxin O +
effect O +
on O +
plasma O +
estradiol O -
, O +
testosterone O -
, O +
and O +
LH O -
. O +

The O +
differences O +
in O +
the O +
means O +
were O +
significant O -
. O +

Tests O +
used O +
to O +
evaluate O +
the O +
changes O +
in O +
sexual O +
behavior O +
showed O +
a O +
significant O +
decrease B-Disease +
in I-Disease +
sexual I-Disease +
desire I-Disease -
, O +
sexual O +
excitement O +
phase O +
( O -
erection O -
) O -
, O +
and O +
frequency O +
of O +
sexual O +
relations O +
in O +
the O +
study O +
group O -
. O +

Clinical O +
nephrotoxicity B-Disease +
of O +
tobramycin O +
and O +
gentamicin O -
. O +

A O +
prospective O +
study O -
. O +

Nearly O +
3.2 O +
million O +
people O +
in O +
this O +
country O +
receive O +
aminoglycoside O +
antibiotics O +
annually O -
. O +

Gentamicin O +
sulfate O +
and O +
tobramycin O +
sulfate O +
continue O +
to O +
demonstrate O +
ototoxicity B-Disease +
and O +
nephrotoxicity B-Disease +
in O +
both O +
animal O +
and O +
clinical O +
studies O -
. O +

In O +
this O +
study O -
, O +
62 O +
patients O +
with O +
confirmed O +
initial O +
normal O +
renal O +
function O +
and O +
treated O +
with O +
2 O +
to O +
5 O +
mg O -
/ O -
kg O -
/ O -
day O +
of O +
gentamicin O +
sulfate O +
or O +
tobramycin O +
sulfate O +
for O +
a O +
minimum O +
of O +
seven O +
days O +
were O +
followed O +
up O +
prospectively O +
for O +
the O +
development O +
of O +
aminoglycoside O -
- O -
related O +
renal B-Disease +
failure I-Disease -
, O +
defined O +
as O +
at O +
least O +
a O +
one O -
- O -
third O +
reduction O +
in O +
renal O +
function O -
. O +

In O +
these O +
62 O +
patients O -
, O +
no O +
other O +
causes O +
for O +
renal B-Disease +
failure I-Disease +
could O +
be O +
identified O -
. O +

Five O +
of O +
33 O +
( O -
15 O -
% O -
) O +
of O +
the O +
tobramycin O -
- O -
treated O +
patients O +
and O +
16 O +
of O +
29 O +
( O -
55.2 O -
% O -
) O +
of O +
the O +
gentamicin O -
- O -
treated O +
patients O +
had O +
renal B-Disease +
failure I-Disease -
. O +

Thus O -
, O +
gentamicin O +
was O +
associated O +
with O +
renal B-Disease +
failure I-Disease +
more O +
than O +
three O +
times O +
as O +
often O +
as O +
was O +
tobramycin O -
. O +

Metabolic O +
involvement O +
in O +
adriamycin O +
cardiotoxicity B-Disease -
. O +

The O +
cardiotoxic B-Disease +
effects O +
of O +
adriamycin O +
were O +
studied O +
in O +
mammalian O +
myocardial O +
cells O +
in O +
culture O +
as O +
a O +
model O +
system O -
. O +

Adriamycin O +
inhibited O +
cell O +
growth O +
and O +
the O +
rhythmic O +
contractions O +
characteristic O +
of O +
myocardial O +
cells O +
in O +
culture O -
. O +

A O +
possible O +
involvement O +
of O +
energy O +
metabolism O +
was O +
suggested O +
previously O -
, O +
and O +
in O +
this O +
study O +
the O +
adenylate O +
energy O +
charge O +
and O +
phosphorylcreatine O +
mole O +
fraction O +
were O +
determined O +
in O +
the O +
adriamycin O -
- O -
treated O +
cells O -
. O +

The O +
adenylate O +
energy O +
charge O +
was O +
found O +
to O +
be O +
significantly O +
decreased O -
, O +
while O +
the O +
phophorylcreatine O +
mole O +
fraction O +
was O +
unchanged O -
. O +

Such O +
disparity O +
suggests O +
an O +
inhibition O +
of O +
creatine O +
phosphokinase O -
. O +

The O +
addition O +
of O +
1 O +
mM O +
adenosine O +
to O +
the O +
myocardial O +
cell O +
cultures O +
markedly O +
increases O +
the O +
ATP O +
concentration O +
through O +
a O +
pathway O +
reportedly O +
leading O +
to O +
a O +
compartmentalized O +
ATP O +
pool O -
. O +

In O +
the O +
adriamycin O -
- O -
treated O +
cells O -
, O +
the O +
addition O +
of O +
adenosine O +
increased O +
the O +
adenylate O +
charge O +
and O -
, O +
concomitant O +
with O +
this O +
inrcease O -
, O +
the O +
cells O -
' O +
functional O +
integrity O -
, O +
in O +
terms O +
of O +
percentage O +
of O +
beating O +
cells O +
and O +
rate O +
of O +
contractions O -
, O +
was O +
maintained O -
. O +

Age O -
- O -
dependent O +
sensitivity O +
of O +
the O +
rat O +
to O +
neurotoxic B-Disease +
effects O +
of O +
streptomycin O -
. O +

Streptomycin O +
sulfate O +
( O -
300 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
was O +
injected O +
for O +
various O +
periods O +
into O +
preweanling O +
rats O +
and O +
for O +
3 O +
weeks O +
into O +
weanling O +
rats O -
. O +

Beginning O +
at O +
8 O +
days O +
of O +
age O -
, O +
body O +
movement O +
and O +
hearing O +
were O +
examined O +
for O +
6 O +
and O +
up O +
to O +
17 O +
weeks O -
, O +
respectively O -
. O +

Abnormal B-Disease +
movements I-Disease +
and O +
deafness B-Disease +
occurred O +
only O +
in O +
rats O +
treated O +
during O +
the O +
preweaning O +
period O -
; O +
within O +
this O +
period O +
the O +
greatest O +
sensitivities O +
for O +
these O +
abnormalities O +
occurred O +
from O +
2 O +
to O +
11 O -
- O -
17 O +
and O +
5 O +
to O +
11 O +
days O +
of O +
age O -
, O +
respectively O -
, O +
indicating O +
that O +
the O +
cochlea O +
is O +
more O +
sensitive O +
to O +
streptomycin O +
than O +
the O +
site O +
( O -
vestibular O +
or O +
central O -
) O +
responsible O +
for O +
the O +
dyskinesias B-Disease -
. O +

Late O -
, O +
late O +
doxorubicin O +
cardiotoxicity B-Disease -
. O +

Cardiac B-Disease +
toxicity I-Disease +
is O +
a O +
major O +
complication O +
which O +
limits O +
the O +
use O +
of O +
adriamycin O +
as O +
a O +
chemotherapeutic O +
agent O -
. O +

Cardiomyopathy B-Disease +
is O +
frequent O +
when O +
the O +
total O +
dose O +
exceeds O +
600 O +
mg O -
/ O -
m2 O +
and O +
occurs O +
within O +
one O +
to O +
six O +
months O +
after O +
cessation O +
of O +
therapy O -
. O +

A O +
patient O +
is O +
reported O +
who O +
developed O +
progressive O +
cardiomyopathy B-Disease +
two O +
and O +
one O -
- O -
half O +
years O +
after O +
receiving O +
580 O +
mg O -
/ O -
m2 O +
which O +
apparently O +
represents O +
late O -
, O +
late O +
cardiotoxicity B-Disease -
. O +

Attenuation O +
of O +
the O +
lithium O -
- O -
induced O +
diabetes B-Disease -
- I-Disease -
insipidus I-Disease -
- I-Disease -
like I-Disease +
syndrome I-Disease +
by O +
amiloride O +
in O +
rats O -
. O +

The O +
effect O +
of O +
amiloride O +
on O +
lithium O -
- O -
induced O +
polydipsia B-Disease +
and O +
polyuria B-Disease +
and O +
on O +
the O +
lithium O +
concentration O +
in O +
the O +
plasma O -
, O +
brain O -
, O +
kidney O -
, O +
thyroid O +
and O +
red O +
blood O +
cells O +
was O +
investigated O +
in O +
rats O -
, O +
chronically O +
treated O +
with O +
LiCl O -
. O +

Amiloride O +
reduced O +
the O +
drinking O +
and O +
urine O +
volume O +
of O +
rats O +
in O +
an O +
acute O +
( O -
6 O +
or O +
12 O +
h O -
) O +
and O +
a O +
subacute O +
( O -
3 O +
days O -
) O +
experiment O -
. O +

6 O +
h O +
after O +
the O +
administration O +
of O +
amiloride O -
, O +
a O +
reduction O +
was O +
observed O +
in O +
the O +
lithium O +
content O +
of O +
the O +
renal O +
medulla O +
but O +
not O +
in O +
the O +
other O +
organs O +
studied O -
. O +

At O +
12 O +
h O -
, O +
all O +
the O +
tissues O +
showed O +
a O +
slight O +
increase O +
in O +
lithium O +
levels O -
. O +

After O +
3 O +
days O +
of O +
combined O +
treatment O -
, O +
a O +
marked O +
elevation O +
in O +
plasma O +
and O +
tissue O +
lithium O +
levels O +
accompanied O +
a O +
reduction O +
in O +
water O +
intake O -
. O +

In O +
all O +
the O +
experiments O -
, O +
the O +
attenuation O +
of O +
the O +
lithium O -
- O -
induced O +
diabetes B-Disease -
- I-Disease -
insipidus I-Disease -
- I-Disease -
like I-Disease +
syndrome I-Disease +
by O +
amiloride O +
was O +
accompanied O +
by O +
a O +
reduction O +
of O +
the O +
ratio O +
between O +
the O +
lithium O +
concentration O +
in O +
the O +
renal O +
medulla O +
and O +
its O +
levels O +
in O +
the O +
blood O +
and O +
an O +
elevation O +
in O +
the O +
plasma O +
potassium O +
level O -
. O +

It O +
is O +
concluded O +
that O +
acute O +
amiloride O +
administration O +
to O +
lithium O -
- O -
treated O +
patients O +
suffering O +
from O +
polydipsia B-Disease +
and O +
polyuria B-Disease +
might O +
relieve O +
these O +
patients O +
but O +
prolonged O +
amiloride O +
supplementation O +
would O +
result O +
in O +
elevated O +
lithium O +
levels O +
and O +
might O +
be O +
hazardous O -
. O +

Cardiovascular B-Disease +
complications I-Disease +
associated O +
with O +
terbutaline O +
treatment O +
for O +
preterm B-Disease +
labor I-Disease -
. O +

Severe O +
cardiovascular B-Disease +
complications I-Disease +
occurred O +
in O +
eight O +
of O +
160 O +
patients O +
treated O +
with O +
terbutaline O +
for O +
preterm B-Disease +
labor I-Disease -
. O +

Associated O +
corticosteroid O +
therapy O +
and O +
twin O +
gestations O +
appear O +
to O +
be O +
predisposing O +
factors O -
. O +

Potential O +
mechanisms O +
of O +
the O +
pathophysiology O +
are O +
briefly O +
discussed O -
. O +

Toxic B-Disease +
hepatitis I-Disease +
induced O +
by O +
antithyroid O +
drugs O -
: O +
four O +
cases O +
including O +
one O +
with O +
cross O -
- O -
reactivity O +
between O +
carbimazole O +
and O +
benzylthiouracil O -
. O +

OBJECTIVE O -
: O +
This O +
study O +
was O +
conducted O +
to O +
assess O +
the O +
occurrence O +
of O +
hepatic B-Disease +
adverse I-Disease +
effects I-Disease +
encountered O +
with O +
antithyroid O +
drugs O -
. O +

METHODS O -
: O +
Retrospective O +
review O +
of O +
medical O +
records O +
of O +
236 O +
patients O +
with O +
hyperthyroidism B-Disease +
admitted O +
in O +
our O +
department O +
( O -
in- O +
or O +
out O -
- O -
patients O -
) O +
from O +
1986 O +
to O +
1992 O -
. O +

RESULTS O -
: O +
Four O +
patients O +
( O -
1.7 O -
% O -
) O +
were O +
identified O +
with O +
toxic B-Disease +
hepatitis I-Disease +
which O +
could O +
reasonably O +
be O +
attributed O +
to O +
the O +
use O +
of O +
antithyroid O +
agent O -
. O +

Two O +
patients O +
had O +
a O +
cholestatic B-Disease +
hepatitis B-Disease +
induced O +
by O +
carbimazole O +
( O -
N O +
omercazole O -
) O -
. O +

Two O +
others O +
had O +
a O +
mixed O +
( O -
cholestatic B-Disease +
and O +
cytolytic O -
) O +
hepatitis B-Disease +
following O +
carbimazole O -
. O +

One O +
of O +
the O +
latter O +
two O +
patients O +
further O +
experienced O +
a O +
cytolytic O +
hepatitis B-Disease +
which O +
appeared O +
after O +
Benzylthiouracil O +
( O -
Basd O +
ne O -
) O +
had O +
replaced O +
carbimazole O -
. O +

Biological O +
features O +
of O +
hepatitis B-Disease +
disappeared O +
in O +
all O +
cases O +
after O +
cessation O +
of O +
the O +
incriminated O +
drug O -
, O +
while O +
biliary O -
, O +
viral O +
and O +
immunological O +
searches O +
were O +
negative O -
. O +

Only O +
2 O +
patients O +
of O +
our O +
retrospective O +
study O +
experienced O +
a O +
mild O +
or O +
severe O +
neutropenia B-Disease -
. O +

CONCLUSION O -
: O +
Toxic B-Disease +
hepatitis I-Disease +
is O +
a O +
potential O +
adverse O +
effect O +
of O +
antithyroid O +
drugs O +
which O +
warrants O -
, O +
as O +
for O +
haematological O +
disturbances O -
, O +
a O +
pre O -
- O -
therapeutic O +
determination O +
and O +
a O +
careful O +
follow O -
- O -
up O +
of O +
relevant O +
biological O +
markers O -
. O +

Moreover O -
, O +
hepatotoxicity B-Disease +
may O +
not O +
be O +
restricted O +
to O +
one O +
class O +
of O +
antithyroid O +
agents O -
. O +

Interactive O +
effects O +
of O +
variations O +
in O +
[ O -
Na O -
] O -
o O +
and O +
[ O -
Ca O -
] O -
o O +
on O +
rat O +
atrial O +
spontaneous O +
frequency O -
. O +

The O +
effects O +
of O +
varying O +
the O +
extracellular O +
concentrations O +
of O +
Na O +
and O +
Ca O +
( O -
[ O -
Na O -
] O -
o O +
and O +
[ O -
Ca O -
] O -
o O -
) O +
on O +
both O -
, O +
the O +
spontaneous O +
beating O +
and O +
the O +
negative O +
chronotropic O +
action O +
of O +
verapamil O -
, O +
were O +
studied O +
in O +
the O +
isolated O +
rat O +
atria O -
. O +

Basal O +
frequency O +
( O -
BF O -
) O +
evaluated O +
by O +
surface O +
electrogram O +
was O +
223 O +
+ O -
/- O +

4 O +
beats O -
/ O -
min O -
. O +

in O +
control O +
Krebs O -
- O -
Ringer O +
containing O +
137 O +
mM O +
Na O +
and O +
1.35 O +
mM O +
Ca O +
( O -
N O -
) O -
. O +

It O +
decreased O +
by O +
16 O +
+ O -
/- O +

3 O -
% O +
by O +
lowering O +
[ O -
Na O -
] O -
o O +
to O +
78 O +
mM O +
( O -
LNa O -
) O -
, O +
23 O +
+ O -
/- O +

2 O -
% O +
by O +
lowering O +
simultaneously O +
[ O -
Na O -
] O -
o O +
to O +
78 O +
mM O +
and O +
[ O -
Ca O -
] O -
o O +
to O +
0.675 O +
mM O +
( O -
LNa+LCa O -
) O +
and O +
31 O +
+ O -
/- O +

5 O -
% O +
by O +
lowering O +
[ O -
Na O -
] O -
o O +
to O +
78 O +
mM O +
plus O +
increasing O +
[ O -
Ca O -
] O -
o O +
to O +
3.6 O +
mM O +
( O -
LNa+HCa O -
) O -
. O +

At O +
normal O +
[ O -
Na O -
] O -
o O -
, O +
decrease O +
( O -
0.675 O +
mM O -
) O +
or O +
increase O +
( O -
3.6 O +
mM O -
) O +
of O +
[ O -
Ca O -
] O -
o O +
did O +
not O +
modify O +
BF O -
; O +
a O +
reduction O +
of O +
ten O +
times O +
( O -
0.135 O +
mM O +
of O +
normal O +
[ O -
Ca O -
] O -
o O +
was O +
effective O +
to O +
reduce O +
BF O +
by O +
40 O +
+ O -
/- O +

13 O -
% O -
. O +

All O +
negative O +
chronotropic O +
effects O +
were O +
BF O -
- O -
dependent O -
. O +

Dose O -
- O -
dependent O +
bradycardia B-Disease +
induced O +
by O +
verapamil O +
was O +
potentiated O +
by O +
LNa O -
, O +
LCa O -
, O +
and O +
HCa O -
. O +

Independent O +
but O +
not O +
additive O +
effects O +
of O +
Na O +
and O +
Ca O +
are O +
shown O +
by O +
decreases O +
in O +
the O +
values O +
of O +
[ O -
verapamil O -
] O -
o O +
needed O +
to O +
reduce O +
BF O +
by O +
30 O -
% O +
( O -
IC30 O -
) O +
with O +
the O +
following O +
order O +
of O +
inhibitory O +
potency O -
: O +
LNa O +
> O +
LCa O +
> O +
HCa O +
> O +
N O -
, O +
resulting O +
LNa+HCa O +
similar O +
to O +
LNa O -
. O +

The O +
[ O -
verapamil O -
] O -
o O +
that O +
arrested O +
atrial O +
beating O +
( O -
AC O -
) O +
was O +
also O +
potentiated O +
with O +
the O +
order O +
LNa O +
= O +
LNa+LCa O +
= O +
LNa+HCa O +
= O +
LCa O +
> O +
HCa O +
= O +
N. O +
The O +
results O +
indicate O +
that O +
rat O +
atrial O +
spontaneous O +
beating O +
is O +
more O +
dependent O +
on O +
[ O -
Na O -
] O -
o O +
than O +
on O +
[ O -
Ca O -
] O -
o O +
in O +
a O +
range O +
of O +
+ O -
/- O +

50 O -
% O +
of O +
their O +
normal O +
concentration O -
. O +

Also O +
the O +
enhancement O +
of O +
verapamil O +
effects O +
on O +
atrial O +
beating O +
was O +
more O +
pronounced O +
at O +
LNa O +
than O +
at O +
LCa. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Nephrotoxicity B-Disease +
of O +
cyclosporin O +
A O +
and O +
FK506 O -
: O +
inhibition O +
of O +
calcineurin O +
phosphatase O -
. O +

Cyclosporin O +
A O +
( O -
CsA O -
; O +
50 O +
mg O -
/ O -
kg O -
) O +
and O +
Fujimycine O +
( O -
FK506 O -
; O +
5 O +
mg O -
/ O -
kg O -
) O -
, O +
but O +
not O +
the O +
related O +
macrolide O +
immunosuppressant O +
rapamycin O +
( O -
5 O +
mg O -
/ O -
kg O -
) O -
, O +
caused O +
a O +
reduction O +
of O +
glomerular O +
filtration O +
rate O -
, O +
degenerative O +
changes O +
of O +
proximal O +
tubular O +
epithelium O -
, O +
and O +
hypertrophy B-Disease +
of O +
the O +
juxtaglomerular O +
apparatus O +
in O +
male O +
Wistar O +
rats O +
when O +
given O +
for O +
10 O +
days O -
. O +

The O +
molecular O +
mechanisms O +
of O +
CsA O +
and O +
FK506 O +
toxicity B-Disease +
were O +
investigated O -
. O +

Cyclophilin O +
A O +
and O +
FK506-binding O +
protein O -
, O +
the O +
main O +
intracytoplasmic O +
receptors O +
for O +
CsA O +
and O +
FK506 O -
, O +
respectively O -
, O +
were O +
each O +
detected O +
in O +
renal O +
tissue O +
extract O -
. O +

In O +
the O +
kidney O -
, O +
high O +
levels O +
of O +
immunoreactive O +
and O +
enzymatically O +
active O +
calcineurin O +
were O +
found O +
which O +
were O +
inhibited O +
by O +
the O +
immunosuppressants O +
CsA O +
and O +
FK506 O -
, O +
but O +
not O +
by O +
rapamycin O -
. O +

Finally O -
, O +
specific O +
immunophilin O -
- O -
drug O -
- O -
calcineurin O +
complexes O +
formed O +
only O +
in O +
the O +
presence O +
of O +
CsA O +
and O +
FK506 O -
, O +
but O +
not O +
rapamycin O -
. O +

These O +
results O +
suggest O +
that O +
the O +
nephrotoxic B-Disease +
effects O +
of O +
CsA O +
and O +
FK506 O +
is O +
likely O +
mediated O +
through O +
binding O +
to O +
renal O +
immunophilin O +
and O +
inhibiting O +
calcineurin O +
phosphatase O -
. O +

Pseudo O -
- O -
allergic B-Disease +
reactions I-Disease +
to O +
corticosteroids O -
: O +
diagnosis O +
and O +
alternatives O -
. O +

Two O +
patients O +
treated O +
with O +
parenteral O +
paramethasone O +
( O -
Triniol O -
) O +
and O +
dexamethasone O +
( O -
Sedionbel O -
) O +
are O +
described O -
. O +

A O +
few O +
minutes O +
after O +
administration O +
of O +
the O +
drugs O -
, O +
they O +
presented O +
urticaria B-Disease +
( O -
patients O +
1 O +
and O +
2 O -
) O +
and O +
conjunctivitis B-Disease +
( O -
patient O +
1 O -
) O -
. O +

The O +
purpose O +
of O +
our O +
study O +
was O +
to O +
determine O +
the O +
cause O +
of O +
the O +
patients O -
' O +
reactions O -
, O +
the O +
immunological O +
mechanisms O +
involved O +
and O +
whether O +
these O +
patients O +
would O +
be O +
able O +
to O +
tolerate O +
any O +
kind O +
of O +
corticoid O -
. O +

Clinical O +
examinations O +
and O +
skin O -
, O +
oral O +
and O +
parenteral O +
challenges O +
with O +
different O +
corticosteroids O +
and O +
ELISA O +
tests O +
were O +
performed O -
. O +

In O +
the O +
two O +
patients O -
, O +
skin O +
and O +
ELISA O +
tests O +
with O +
paramethasone O +
were O +
negative O -
, O +
as O +
was O +
the O +
prick O +
test O +
with O +
each O +
of O +
its O +
excipients O -
. O +

A O +
single O -
- O -
blind O +
parenteral O +
challenge O +
with O +
Triniol O +
was O +
positive O +
in O +
both O +
patients O +
after O +
the O +
administration O +
of O +
1 O +
ml O +
of O +
the O +
drug O -
, O +
and O +
negative O +
with O +
its O +
excipients O -
. O +

We O +
also O +
carried O +
out O +
oral O +
and O +
parenteral O +
challenges O +
with O +
other O +
corticosteroids O +
and O +
found O +
intolerance O +
to O +
some O +
of O +
them O -
. O +

These O +
results O +
suggest O +
that O +
paramethasone O +
caused O +
pseudoallergic O +
reactions O +
in O +
our O +
patients O -
. O +

Corticosteroids O +
different O +
from O +
paramethasone O +
also O +
produced O +
hypersensitivity B-Disease +
reactions O +
in O +
these O +
patients O -
; O +
however O -
, O +
a O +
few O +
of O +
them O +
were O +
tolerated O -
. O +

The O +
basic O +
mechanisms O +
of O +
those O +
reactions O +
are O +
not O +
yet O +
fully O +
understood O -
. O +

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
of O +
a O +
pseudo O -
- O -
allergy B-Disease +
caused O +
by O +
paramethasone O -
. O +

Clinical O +
evaluation O +
on O +
combined O +
administration O +
of O +
oral O +
prostacyclin O +
analogue O +
beraprost O +
and O +
phosphodiesterase O +
inhibitor O +
cilostazol O -
. O +

Among O +
various O +
oral O +
antiplatelets O -
, O +
a O +
combination O +
of O +
a O +
novel O +
prostacyclin O +
analogue O +
beraprost O +
( O -
BPT O -
) O +
and O +
a O +
potent O +
phosphodiesterase O +
inhibitor O +
cilostazol O +
( O -
CLZ O -
) O +
may O +
result O +
in O +
untoward O +
clinical O +
effects O +
due O +
to O +
possible O +
synergistic O +
elevation O +
of O +
intracellular O +
cAMP O +
( O -
cyclic O +
adenosine O +
3',5'-monophosphate O -
) O -
. O +

Thereby O -
, O +
a O +
clinical O +
study O +
of O +
the O +
combined O +
administration O +
of O +
the O +
two O +
agents O +
was O +
attempted O -
. O +

Twelve O +
healthy O +
volunteers O +
were O +
assigned O +
to O +
take O +
BPT O -
/ O -
CLZ O +
in O +
the O +
following O +
schedule O -
; O +
BPT O -
: O +
40 O +
micrograms O +
at O +
day O +
1 O +
and O +
120 O +
micrograms O +
t.i.d O -
. O +

from O +
day O +
7 O +
to O +
14 O -
, O +
CLZ O -
: O +
200 O +
mg O +
t.i.d O -
. O +

from O +
day O +
3 O +
to O +
14 O -
. O +

At O +
various O +
time O +
intervals O -
, O +
physical O +
examination O +
and O +
blood O +
collection O +
for O +
ex O +
vivo O +
platelet B-Disease +
aggregation I-Disease +
and O +
determination O +
of O +
intraplatelet O +
cAMP O +
were O +
performed O -
. O +

Throughout O +
the O +
observation O +
period O -
, O +
no O +
significant O +
alteration O +
in O +
vital O +
signs O +
was O +
observed O -
. O +

Seven O +
out O +
of O +
12 O +
subjects O +
experienced O +
headache B-Disease +
of O +
a O +
short O +
duration O +
accompanying O +
facial B-Disease +
flush I-Disease +
in O +
one O +
and O +
nausea B-Disease +
in O +
one O -
, O +
especially O +
after O +
ingestion O +
of O +
CLZ O -
. O +

All O +
of O +
these O +
symptoms O -
, O +
probably O +
caused O +
by O +
the O +
vasodilating O +
effect O +
of O +
the O +
two O +
agents O -
, O +
were O +
of O +
mild O +
degree O +
and O +
no O +
special O +
treatment O +
was O +
required O -
. O +

Intraplatelet O +
cAMP O +
content O +
was O +
gradually O +
but O +
significantly O +
increased O +
to O +
9.84 O +
+ O -
/- O +

4.59 O +
pmol O +
per O +
10 O -
( O -
9 O -
) O +
platelets O +
at O +
day O +
14 O +
in O +
comparison O +
with O +
the O +
initial O +
value O +
( O -
6.87 O +
+ O -
/- O +

2.25 O +
pmol O -
) O -
. O +

The O +
platelet O +
aggregability O +
was O +
significantly O +
suppressed O +
at O +
various O +
time O +
intervals O +
but O +
no O +
additive O +
or O +
synergistic O +
inhibitory O +
effect O +
by O +
the O +
combined O +
administration O +
was O +
noted O -
. O +

In O +
conclusion O -
, O +
the O +
combined O +
administration O +
of O +
BPT O -
/ O -
CLZ O +
is O +
safe O +
at O +
doses O +
used O +
in O +
the O +
study O -
, O +
though O +
the O +
beneficial O +
clinical O +
effect O +
of O +
the O +
combined O +
administration O +
has O +
yet O +
to O +
be O +
elucidated O -
. O +

Pravastatin O -
- O -
associated O +
myopathy B-Disease -
. O +

Report O +
of O +
a O +
case O -
. O +

A O +
case O +
of O +
acute O +
inflammatory B-Disease +
myopathy I-Disease +
associated O +
with O +
the O +
use O +
of O +
pravastatin O -
, O +
a O +
new O +
hydrophilic O +
3-hydroxy-3 O +
methylglutaril O +
coenzyme O +
A O +
reductase O +
inhibitor O -
, O +
is O +
reported O -
. O +

The O +
patient O -
, O +
a O +
69-year O -
- O -
old O +
man O +
was O +
affected O +
by O +
non B-Disease -
- I-Disease -
insulin I-Disease -
- I-Disease -
dependent I-Disease +
diabetes I-Disease +
mellitus I-Disease +
and O +
hypertension B-Disease -
. O +

He O +
assumed O +
pravastatin O +
( O -
20 O +
mg O -
/ O -
day O -
) O +
because O +
of O +
hypercholesterolemia B-Disease -
. O +

He O +
was O +
admitted O +
with O +
acute O +
myopathy B-Disease +
of O +
the O +
lower O +
limbs O +
which O +
resolved O +
in O +
a O +
few O +
days O +
after O +
pravastatin O +
discontinuation O -
. O +

A O +
previously O +
unknown O +
hypothyroidism B-Disease -
, O +
probably O +
due O +
to O +
chronic O +
autoimmune B-Disease +
thyroiditis I-Disease -
, O +
was O +
evidenced O -
. O +

Muscle O +
biopsy O +
( O -
left O +
gastrocnemius O -
) O +
revealed O +
a O +
perimysial O +
and O +
endomysial O +
inflammatory O +
infiltrate O +
with O +
a O +
prevalence O +
of O +
CD4 O -
+ O +
lymphocytes O -
. O +

While O +
lovastatin O +
and O +
simvastatin O +
have O +
been O +
associated O +
with O +
toxic O +
myopathy B-Disease -
, O +
pravastatin O -
- O -
associated O +
myopathy B-Disease +
could O +
represent O +
a O +
distinct O -
, O +
inflammatory O +
entity O -
. O +

Reversal O +
of O +
ammonia O +
coma B-Disease +
in O +
rats O +
by O +
L O -
- O -
dopa O -
: O +
a O +
peripheral O +
effect O -
. O +

Ammonia O +
coma B-Disease +
was O +
produced O +
in O +
rats O +
within O +
10 O +
to O +
15 O +
minutes O +
of O +
an O +
intraperitonealinjection O +
of O +
1.7 O +
mmol O +
NH4CL O -
. O +

This O +
coma B-Disease +
was O +
prevented O +
with O +
1.68 O +
mmol O +
L O -
- O -
dopa O +
given O +
by O +
gastric O +
intubation O +
15 O +
minutes O +
before O +
the O +
ammonium O +
salt O +
injection O -
. O +

The O +
effect O +
of O +
L O -
- O -
dopa O +
was O +
correlated O +
with O +
a O +
decrease O +
in O +
blood O +
and O +
brain O +
ammonia O -
, O +
an O +
increase O +
in O +
brain O +
dopamine O -
, O +
and O +
an O +
increase O +
in O +
renal O +
excretion O +
of O +
ammonia O +
and O +
urea O -
. O +

Intraventricular O +
infusion O +
of O +
dopamine O +
sufficient O +
to O +
raise O +
the O +
brain O +
dopamine O +
to O +
the O +
same O +
extent O +
did O +
not O +
prevent O +
the O +
ammonia O +
coma B-Disease +
nor O +
affect O +
the O +
blood O +
and O +
brain O +
ammonia O +
concentrations O -
. O +

Bilateral O +
nephrectomy O +
eliminated O +
the O +
beneficial O +
effect O +
of O +
L O -
- O -
dopa O +
on O +
blood O +
and O +
brain O +
ammonia O +
and O +
the O +
ammonia O +
coma B-Disease +
was O +
not O +
prevented O -
. O +

Thus O -
, O +
the O +
reduction O +
in O +
blood O +
and O +
brain O +
ammonia O +
and O +
the O +
prevention O +
of O +
ammonia O +
coma B-Disease +
after O +
L O -
- O -
dopa O -
, O +
can O +
be O +
accounted O +
for O +
by O +
the O +
peripheral O +
effect O +
of O +
dopamine O +
on O +
renal O +
function O +
rather O +
than O +
its O +
central O +
action O -
. O +

These O +
results O +
provide O +
a O +
reasonable O +
explanation O +
for O +
the O +
beneficial O +
effects O +
observed O +
in O +
some O +
encephalopathic B-Disease +
patients O +
receiving O +
L O -
- O -
dopa O -
. O +

Etoposide O -
- O -
related O +
myocardial B-Disease +
infarction I-Disease -
. O +

The O +
occurrence O +
of O +
a O +
myocardial B-Disease +
infarction I-Disease +
is O +
reported O +
after O +
chemotherapy O +
containing O +
etoposide O -
, O +
in O +
a O +
man O +
with O +
no O +
risk O +
factors O +
for O +
coronary B-Disease +
heart I-Disease +
disease I-Disease -
. O +

Possible O +
causal O +
mechanisms O +
are O +
discussed O -
. O +

Study O +
of O +
the O +
role O +
of O +
vitamin O +
B12 O +
and O +
folinic O +
acid O +
supplementation O +
in O +
preventing O +
hematologic O +
toxicity B-Disease +
of O +
zidovudine O -
. O +

A O +
prospective O -
, O +
randomized O +
study O +
was O +
conducted O +
to O +
evaluate O +
the O +
role O +
of O +
vitamin O +
B12 O +
and O +
folinic O +
acid O +
supplementation O +
in O +
preventing O +
zidovudine O +
( O -
ZDV O -
) O -
-induced O +
bone B-Disease +
marrow I-Disease +
suppression I-Disease -
. O +

Seventy O -
- O -
five O +
human B-Disease +
immunodeficiency I-Disease +
virus I-Disease +
( I-Disease -
HIV I-Disease -
) I-Disease -
-infected I-Disease +
patients O +
with O +
CD4 O -
+ O +
cell O +
counts O +
< O +
500 O -
/ O -
mm3 O +
were O +
randomized O +
to O +
receive O +
either O +
ZDV O +
( O -
500 O +
mg O +
daily O -
) O +
alone O +
( O -
group O +
I O -
, O +
n O +
= O +
38 O -
) O +
or O +
in O +
combination O +
with O +
folinic O +
acid O +
( O -
15 O +
mg O +
daily O -
) O +
and O +
intramascular O +
vitamin O +
B12 O +
( O -
1000 O +
micrograms O +
monthly O -
) O +
( O -
group O +
II O -
, O +
n O +
= O +
37 O -
) O -
. O +

Finally O -
, O +
15 O +
patients O +
were O +
excluded O +
from O +
the O +
study O +
( O -
noncompliance O +
14 O -
, O +
death B-Disease +
1 O -
) O -
; O +
thus O -
, O +
60 O +
patients O +
( O -
31 O +
in O +
group O +
I O +
and O +
29 O +
in O +
group O +
II O -
) O +
were O +
eligible O +
for O +
analysis O -
. O +

No O +
significant O +
differences O +
between O +
groups O +
were O +
found O +
at O +
enrollment O -
. O +

During O +
the O +
study O -
, O +
vitamin O +
B12 O +
and O +
folate O +
levels O +
were O +
significantly O +
higher O +
in O +
group O +
II O +
patients O -
; O +
however O -
, O +
no O +
differences O +
in O +
hemoglobin O -
, O +
hematocrit O -
, O +
mean O +
corpuscular O +
volume O -
, O +
and O +
white O -
- O -
cell O -
, O +
neutrophil O +
and O +
platelet O +
counts O +
were O +
observed O +
between O +
groups O +
at O +
3 O -
, O +
6 O -
, O +
9 O +
and O +
12 O +
months O -
. O +

Severe O +
hematologic O +
toxicity B-Disease +
( O -
neutrophil O +
count O +
< O +
1000 O -
/ O -
mm3 O +
and/or O +
hemoglobin O +
< O +
8 O +
g O -
/ O -
dl O -
) O +
occurred O +
in O +
4 O +
patients O +
assigned O +
to O +
group O +
I O +
and O +
7 O +
assigned O +
to O +
group O +
II O -
. O +

There O +
was O +
no O +
correlation O +
between O +
vitamin O +
B12 O +
or O +
folate O +
levels O +
and O +
development O +
of O +
myelosuppression B-Disease -
. O +

Vitamin O +
B12 O +
and O +
folinic O +
acid O +
supplementation O +
of O +
ZDV O +
therapy O +
does O +
not O +
seem O +
useful O +
in O +
preventing O +
or O +
reducing O +
ZDV O -
- O -
induced O +
myelotoxicity B-Disease +
in O +
the O +
overall O +
treated O +
population O -
, O +
although O +
a O +
beneficial O +
effect O +
in O +
certain O +
subgroups O +
of O +
patients O +
can O -
not O +
be O +
excluded O -
. O +

Halogenated O +
anesthetics O +
form O +
liver O +
adducts O +
and O +
antigens O +
that O +
cross O -
- O -
react O +
with O +
halothane O -
- O -
induced O +
antibodies O -
. O +

Two O +
halogenated O +
anesthetics O -
, O +
enflurane O +
and O +
isoflurane O -
, O +
have O +
been O +
associated O +
with O +
an O +
allergic O -
- O -
type O +
hepatic B-Disease +
injury I-Disease +
both O +
alone O +
and O +
following O +
previous O +
exposure O +
to O +
halothane O -
. O +

Halothane O +
hepatitis B-Disease +
appears O +
to O +
involve O +
an O +
aberrant O +
immune O +
response O -
. O +

An O +
antibody O +
response O +
to O +
a O +
protein O -
- O -
bound O +
biotransformation O +
product O +
( O -
trifluoroacetyl O +
adduct O -
) O +
has O +
been O +
detected O +
on O +
halothane O +
hepatitis B-Disease +
patients O -
. O +

This O +
study O +
was O +
performed O +
to O +
determine O +
cross O -
- O -
reactivity O +
between O +
enflurane O +
and O +
isoflurane O +
with O +
the O +
hypersensitivity B-Disease +
induced O +
by O +
halothane O -
. O +

The O +
subcellular O +
and O +
lobular O +
production O +
of O +
hepatic O +
neoantigens O +
recognized O +
by O +
halothane O -
- O -
induced O +
antibodies O +
following O +
enflurane O +
and O +
isoflurane O -
, O +
and O +
the O +
biochemical O +
nature O +
of O +
these O +
neoantigens O +
was O +
investigated O +
in O +
two O +
animal O +
models O -
. O +

Enflurane O +
administration O +
resulted O +
in O +
neoantigens O +
detected O +
in O +
both O +
the O +
microsomal O +
and O +
cytosolic O +
fraction O +
of O +
liver O +
homogenates O +
and O +
in O +
the O +
centrilobular O +
region O +
of O +
the O +
liver O -
. O +

In O +
the O +
same O +
liver O -
, O +
biochemical O +
analysis O +
detected O +
fluorinated O +
liver O +
adducts O +
that O +
were O +
up O +
to O +
20-fold O +
greater O +
in O +
guinea O +
pigs O +
than O +
in O +
rats O -
. O +

This O +
supports O +
and O +
extends O +
previous O +
evidence O +
for O +
a O +
mechanism O +
by O +
which O +
enflurane O +
and/or O +
isoflurane O +
could O +
produce O +
a O +
hypersensitivity B-Disease +
condition O +
similar O +
to O +
that O +
of O +
halothane O +
hepatitis B-Disease +
either O +
alone O +
or O +
subsequent O +
to O +
halothane O +
administration O -
. O +

The O +
guinea O +
pig O +
would O +
appear O +
to O +
be O +
a O +
useful O +
model O +
for O +
further O +
investigations O +
of O +
the O +
immunological O +
response O +
to O +
these O +
antigens O -
. O +

Seizure B-Disease +
after O +
flumazenil O +
administration O +
in O +
a O +
pediatric O +
patient O -
. O +

Flumazenil O +
is O +
a O +
benzodiazepine O +
receptor O +
antagonist O +
used O +
to O +
reverse O +
sedation O +
and O +
respiratory B-Disease +
depression I-Disease +
induced O +
by O +
benzodiazepines O -
. O +

Seizures B-Disease +
and O +
cardiac B-Disease +
arrhythmias I-Disease +
have O +
complicated O +
its O +
use O +
in O +
adult O +
patients O -
. O +

Overdose B-Disease +
patients O +
who O +
have O +
coingested O +
tricyclic O +
antidepressants O +
have O +
a O +
higher O +
risk O +
of O +
these O +
complications O -
. O +

Little O +
information O +
exists O +
concerning O +
adverse O +
effects O +
of O +
flumazenil O +
in O +
children O -
. O +

We O +
report O +
the O +
occurrence O +
of O +
a O +
generalized O +
tonic B-Disease -
- I-Disease -
clonic I-Disease +
seizure I-Disease +
in O +
a O +
pediatric O +
patient O +
following O +
the O +
administration O +
of O +
flumazenil O -
. O +

Phase O +
I O +
trial O +
of O +
13-cis O -
- O -
retinoic O +
acid O +
in O +
children O +
with O +
neuroblastoma B-Disease +
following O +
bone O +
marrow O +
transplantation O -
. O +

PURPOSE O -
: O +
Treatment O +
of O +
neuroblastoma B-Disease +
cell O +
lines O +
with O +
13-cis O -
- O -
retinoic O +
acid O +
( O -
cis O -
- O -
RA O -
) O +
can O +
cause O +
sustained O +
inhibition O +
of O +
proliferation O -
. O +

Since O +
cis O -
- O -
RA O +
has O +
demonstrated O +
clinical O +
responses O +
in O +
neuroblastoma B-Disease +
patients O -
, O +
it O +
may O +
be O +
effective O +
in O +
preventing O +
relapse O +
after O +
cytotoxic O +
therapy O -
. O +

This O +
phase O +
I O +
trial O +
was O +
designed O +
to O +
determine O +
the O +
maximal O -
- O -
tolerated O +
dosage O +
( O -
MTD O -
) O -
, O +
toxicities B-Disease -
, O +
and O +
pharmacokinetics O +
of O +
cis O -
- O -
RA O +
administered O +
on O +
an O +
intermittent O +
schedule O +
in O +
children O +
with O +
neuroblastoma B-Disease +
following O +
bone O +
marrow O +
transplantation O +
( O -
BMT O -
) O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Fifty O -
- O -
one O +
assessable O +
patients O -
, O +
2 O +
to O +
12 O +
years O +
of O +
age O -
, O +
were O +
treated O +
with O +
oral O +
cis O -
- O -
RA O +
administered O +
in O +
two O +
equally O +
divided O +
doses O +
daily O +
for O +
2 O +
weeks O -
, O +
followed O +
by O +
a O +
2-week O +
rest O +
period O -
, O +
for O +
up O +
to O +
12 O +
courses O -
. O +

The O +
dose O +
was O +
escalated O +
from O +
100 O +
to O +
200 O +
mg O -
/ O -
m2 O -
/ O -
d O +
until O +
dose O -
- O -
limiting O +
toxicity B-Disease +
( O -
DLT O -
) O +
was O +
observed O -
. O +

A O +
single O +
intrapatient O +
dose O +
escalation O +
was O +
permitted O -
. O +

RESULTS O -
: O +
The O +
MTD O +
of O +
cis O -
- O -
RA O +
was O +
160 O +
mg O -
/ O -
m2 O -
/ O -
d O -
. O +

Dose O -
- O -
limiting O +
toxicities B-Disease +
in O +
six O +
of O +
nine O +
patients O +
at O +
200 O +
mg O -
/ O -
m2 O -
/ O -
d O +
included O +
hypercalcemia B-Disease +
( O -
n O +
= O +
3 O -
) O -
, O +
rash B-Disease +
( O -
n O +
= O +
2 O -
) O -
, O +
and O +
anemia B-Disease -
/ O -
thrombocytopenia B-Disease -
/ O -
emesis B-Disease -
/ O -
rash B-Disease +
( O -
n O +
= O +
1 O -
) O -
. O +

All O +
toxicities B-Disease +
resolved O +
after O +
cis O -
- O -
RA O +
was O +
discontinued O -
. O +

Three O +
complete O +
responses O +
were O +
observed O +
in O +
marrow O +
metastases B-Disease -
. O +

Serum O +
levels O +
of O +
7.4 O +
+ O -
/- O +

3.0 O +
mumol O -
/ O -
L O +
( O -
peak O -
) O +
and O +
4.0 O +
+ O -
/- O +

2.8 O +
mumol O -
/ O -
L O +
( O -
trough O -
) O +
at O +
the O +
MTD O +
were O +
maintained O +
during O +
14 O +
days O +
of O +
therapy O -
. O +

The O +
DLT O +
correlated O +
with O +
serum O +
levels O +
> O +
or O +
= O +
10 O +
mumol O -
/ O -
L. O +
CONCLUSION O -
: O +
The O +
MTD O +
of O +
cis O -
- O -
RA O +
given O +
on O +
this O +
intermittent O +
schedule O +
was O +
160 O +
mg O -
/ O -
m2 O -
/ O -
d O -
. O +

Serum O +
levels O +
known O +
to O +
be O +
effective O +
against O +
neuroblastoma B-Disease +
in O +
vitro O +
were O +
achieved O +
at O +
this O +
dose O -
. O +

The O +
DLT O +
included O +
hypercalcemia B-Disease -
, O +
and O +
may O +
be O +
predicted O +
by O +
serum O +
cis O -
- O -
RA O +
levels O -
. O +

Monitoring O +
of O +
serum O +
calcium O +
and O +
cis O -
- O -
RA O +
levels O +
is O +
indicated O +
in O +
future O +
trials O -
. O +

Acute O +
renal B-Disease +
toxicity I-Disease +
of O +
doxorubicin O +
( O -
adriamycin O -
) O -
-loaded O +
cyanoacrylate O +
nanoparticles O -
. O +

Acute O +
doxorubicin O -
- O -
loaded O +
nanoparticle O +
( O -
DXNP O -
) O +
renal B-Disease +
toxicity I-Disease +
was O +
explored O +
in O +
both O +
normal O +
rats O +
and O +
rats O +
with O +
experimental O +
glomerulonephritis B-Disease -
. O +

In O +
normal O +
rats O -
, O +
2 O -
/ O -
6 O +
rats O +
given O +
free O +
doxorubicin O +
( O -
DX O -
) O +
( O -
5 O +
mg O -
/ O -
kg O -
) O +
died O +
within O +
one O +
week O -
, O +
whereas O +
all O +
control O +
animals O +
and O +
all O +
rats O +
having O +
received O +
free O +
NP O +
or O +
DXNP O +
survived O -
. O +

A O +
3 O +
times O +
higher O +
proteinuria B-Disease +
appeared O +
in O +
animals O +
treated O +
with O +
DXNP O +
than O +
in O +
those O +
treated O +
with O +
DX O -
. O +

Free O +
NP O +
did O +
not O +
provoke O +
any O +
proteinuria B-Disease -
. O +

Two O +
hr O +
post O -
- O -
injection O -
, O +
DXNP O +
was O +
2.7 O +
times O +
more O +
concentrated O +
in O +
kidneys O +
than O +
free O +
DX O +
( O -
p O +
< O +
0.025 O -
) O -
. O +

In O +
rats O +
with O +
immune O +
experimental O +
glomerulonephritis B-Disease -
, O +
5 O -
/ O -
6 O +
rats O +
given O +
DX O +
died O +
within O +
7 O +
days O -
, O +
in O +
contrast O +
to O +
animals O +
treated O +
by O +
DXNP O -
, O +
NP O -
, O +
or O +
untreated O -
, O +
which O +
all O +
survived O -
. O +

Proteinuria B-Disease +
appeared O +
in O +
all O +
series O -
, O +
but O +
was O +
2 O -
- O -
5 O +
times O +
more O +
intense O +
( O -
p O +
> O +
0.001 O -
) O +
and O +
prolonged O +
after O +
doxorubicin O +
treatment O +
( O -
400 O -
- O -
700 O +
mg O -
/ O -
day O -
) O -
, O +
without O +
significant O +
difference O +
between O +
DXNP O +
and O +
DX O -
. O +

Rats O +
treated O +
by O +
unloaded O +
NP O +
behaved O +
as O +
controls O -
. O +

These O +
results O +
demonstrate O +
that O -
, O +
in O +
these O +
experimental O +
conditions O -
, O +
DXNP O +
killed O +
less O +
animals O +
than O +
free O +
DX O -
, O +
despite O +
of O +
an O +
enhanced O +
renal B-Disease +
toxicity I-Disease +
of O +
the O +
former O -
. O +

Both O +
effects O +
( O -
better O +
survival O +
and O +
nephrosis B-Disease -
) O +
are O +
most O +
probably O +
related O +
to O +
an O +
enhanced O +
capture O +
of O +
DXNP O +
by O +
cells O +
of O +
the O +
mononuclear O +
phagocyte O +
system O -
, O +
including O +
mesangial O +
cells O -
. O +

Prostaglandin O +
E2-induced O +
bladder B-Disease +
hyperactivity I-Disease +
in O +
normal O -
, O +
conscious O +
rats O -
: O +
involvement O +
of O +
tachykinins O -
? O +

In O +
normal O +
conscious O +
rats O +
investigated O +
by O +
continuous O +
cystometry O -
, O +
intravesically O +
instilled O +
prostaglandin O +
( O -
PG O -
) O +
E2 O +
facilitated O +
micturition O +
and O +
increased O +
basal O +
intravesical O +
pressure O -
. O +

The O +
effect O +
was O +
attenuated O +
by O +
both O +
the O +
NK1 O +
receptor O +
selective O +
antagonist O +
RP O +
67,580 O +
and O +
the O +
NK2 O +
receptor O +
selective O +
antagonist O +
SR O +
48,968 O -
, O +
given O +
intra O -
- O -
arterially O -
, O +
suggesting O +
that O +
it O +
was O +
mediated O +
by O +
stimulation O +
of O +
both O +
NK1 O +
and O +
NK2 O +
receptors O -
. O +

Intra O -
- O -
arterially O +
given O +
PGE2 O +
produced O +
a O +
distinct O +
increase O +
in O +
bladder O +
pressure O +
before O +
initiating O +
a O +
micturition O +
reflex O -
, O +
indicating O +
that O +
the O +
PG O +
had O +
a O +
direct O +
contractant O +
effect O +
on O +
the O +
detrusor O +
smooth O +
muscle O -
. O +

The O +
effect O +
of O +
intra O -
- O -
arterial O +
PGE2 O +
could O +
not O +
be O +
blocked O +
by O +
intra O -
- O -
arterial O +
RP O +
67,580 O +
or O +
SR O +
48,968 O -
, O +
which O +
opens O +
the O +
possibility O +
that O +
the O +
micturition O +
reflex O +
elicited O +
by O +
intra O -
- O -
arterial O +
PGE2 O +
was O +
mediated O +
by O +
pathways O +
other O +
than O +
the O +
reflex O +
initiated O +
when O +
the O +
PG O +
was O +
given O +
intravesically O -
. O +

The O +
present O +
results O +
thus O +
suggest O +
that O +
intra O -
- O -
arterial O +
PGE2 O -
, O +
given O +
near O +
the O +
bladder O -
, O +
may O +
initiate O +
micturition O +
in O +
the O +
normal O +
rat O +
chiefly O +
by O +
directly O +
contracting O +
the O +
smooth O +
muscle O +
of O +
the O +
detrusor O -
. O +

However O -
, O +
when O +
given O +
intravesically O -
, O +
PGE2 O +
may O +
stimulate O +
micturition O +
by O +
releasing O +
tachykinins O +
from O +
nerves O +
in O +
and/or O +
immediately O +
below O +
the O +
urothelium O -
. O +

These O +
tachykinins O -
, O +
in O +
turn O -
, O +
initiate O +
a O +
micturition O +
reflex O +
by O +
stimulating O +
NK1 O +
and O +
NK2 O +
receptors O -
. O +

Prostanoids O +
may O -
, O +
via O +
release O +
of O +
tachykinins O -
, O +
contribute O +
to O +
both O +
urge O +
and O +
bladder B-Disease +
hyperactivity I-Disease +
seen O +
in O +
inflammatory O +
conditions O +
of O +
the O +
lower O +
urinary O +
tract O -
. O +

Refractory O +
cardiogenic B-Disease +
shock I-Disease +
and O +
complete O +
heart B-Disease +
block I-Disease +
after O +
verapamil O +
SR O +
and O +
metoprolol O +
treatment O -
. O +

A O +
case O +
report O -
. O +

A O +
seventy O -
- O -
eight O -
- O -
year O -
- O -
old O +
woman O +
presented O +
with O +
complete O +
heart B-Disease +
block I-Disease +
and O +
refractory O +
hypotension B-Disease +
two O +
days O +
after O +
a O +
therapeutic O +
dose O +
of O +
sustained O -
- O -
release O +
verapamil O +
with O +
concomitant O +
use O +
of O +
metoprolol O -
. O +

The O +
patient O +
continued O +
to O +
remain O +
hypotensive B-Disease +
with O +
complete O +
heart B-Disease +
block I-Disease -
, O +
even O +
with O +
multiple O +
uses O +
of O +
intravenous O +
atropine O +
as O +
well O +
as O +
high O +
doses O +
of O +
pressor O +
agents O +
such O +
as O +
dopamine O +
and O +
dobutamine O -
. O +

However O -
, O +
shortly O +
after O +
the O +
use O +
of O +
intravenous O +
calcium O +
chloride O -
, O +
the O +
refractory O +
hypotension B-Disease +
and O +
complete O +
heart B-Disease +
block I-Disease +
resolved O -
. O +

Protective O +
effect O +
of O +
misoprostol O +
on O +
indomethacin O +
induced O +
renal B-Disease +
dysfunction I-Disease +
in O +
elderly O +
patients O -
. O +

OBJECTIVE O -
: O +
To O +
evaluate O +
the O +
possible O +
protective O +
effects O +
of O +
misoprostol O +
on O +
renal O +
function O +
in O +
hospitalized O +
elderly O +
patients O +
treated O +
with O +
indomethacin O -
. O +

METHODS O -
: O +
Forty O -
- O -
five O +
hospitalized O +
elderly O +
patients O +
( O -
> O +
65 O +
years O +
old O -
) O +
who O +
required O +
therapy O +
with O +
nonsteroidal O +
antiinflammatory O +
drugs O +
( O -
NSAID O -
) O +
were O +
randomly O +
assigned O +
to O +
receive O +
either O +
indomethacin O -
, O +
150 O +
mg O -
/ O -
day O +
( O -
Group O +
A O -
) O -
, O +
or O +
indomethacin O +
150 O +
mg O -
/ O -
day O +
plus O +
misoprostol O +
at O +
0.6 O +
mg O -
/ O -
day O +
( O -
Group O +
B O -
) O -
. O +

Laboratory O +
variables O +
of O +
renal O +
function O +
[ O -
serum O +
creatinine O -
, O +
blood O +
urea O +
nitrogen O +
( O -
BUN O -
) O +
and O +
electrolytes O -
] O +
were O +
evaluated O +
before O +
initiation O +
of O +
therapy O +
and O +
every O +
2 O +
days O -
, O +
until O +
termination O +
of O +
the O +
study O +
( O -
a O +
period O +
of O +
at O +
least O +
6 O +
days O -
) O -
. O +

Response O +
to O +
treatment O +
was O +
estimated O +
by O +
the O +
visual O +
analog O +
scale O +
for O +
severity O +
of O +
pain B-Disease -
. O +

RESULTS O -
: O +
Forty O -
- O -
two O +
patients O +
completed O +
the O +
study O -
, O +
22 O +
in O +
Group O +
A O +
and O +
20 O +
in O +
Group O +
B. O +
BUN O +
and O +
creatinine O +
increased O +
by O +
> O +
50 O -
% O +
of O +
baseline O +
levels O +
in O +
54 O +
and O +
45 O -
% O +
of O +
Group O +
A O +
patients O -
, O +
respectively O -
, O +
compared O +
to O +
only O +
20 O +
and O +
10 O -
% O +
of O +
Group O +
B O +
patients O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Potassium O +
( O -
K O -
) O +
increment O +
of O +
0.6 O +
mEq O -
/ O -
l O +
or O +
more O +
was O +
observed O +
in O +
50 O -
% O +
of O +
Group O +
A O -
, O +
but O +
in O +
only O +
15 O -
% O +
of O +
Group O +
B O +
patients O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

The O +
mean O +
increments O +
in O +
BUN O -
, O +
creatinine O -
, O +
and O +
K O +
were O +
reduced O +
by O +
63 O -
, O +
80 O -
, O +
and O +
42 O -
% O -
, O +
respectively O -
, O +
in O +
Group O +
B O +
patients O +
compared O +
to O +
Group O +
A. O +
Response O +
to O +
treatment O +
did O +
not O +
differ O +
significantly O +
between O +
the O +
2 O +
groups O -
. O +

CONCLUSION O -
: O +
Hospitalized O +
elderly O +
patients O +
are O +
at O +
risk O +
for O +
developing O +
indomethacin O +
related O +
renal B-Disease +
dysfunction I-Disease -
. O +

Addition O +
of O +
misoprostol O +
can O +
minimize O +
this O +
renal B-Disease +
impairment I-Disease +
without O +
affecting O +
pain B-Disease +
control O -
. O +

Safety O +
and O +
side O -
- O -
effects O +
of O +
alprazolam O -
. O +

Controlled O +
study O +
in O +
agoraphobia B-Disease +
with O +
panic B-Disease +
disorder I-Disease -
. O +

BACKGROUND O -
: O +
The O +
widespread O +
use O +
of O +
benzodiazepines O +
has O +
led O +
to O +
increasing O +
recognition O +
of O +
their O +
unwanted O +
effects O -
. O +

The O +
efficacy O +
of O +
alprazolam O +
and O +
placebo O +
in O +
panic B-Disease +
disorder I-Disease +
with O +
agoraphobia B-Disease -
, O +
and O +
the O +
side O -
- O -
effect O +
and O +
adverse O +
effect O +
profiles O +
of O +
both O +
drug O +
groups O +
were O +
measured O -
. O +

METHOD O -
: O +
In O +
London O +
and O +
Toronto O +
154 O +
patients O +
who O +
met O +
DSM O -
- O -
III O +
criteria O +
for O +
panic B-Disease +
disorder I-Disease +
with O +
agoraphobia B-Disease +
were O +
randomised O +
to O +
alprazolam O +
or O +
placebo O -
. O +

Subjects O +
in O +
each O +
drug O +
group O +
also O +
received O +
either O +
exposure O +
or O +
relaxation O -
. O +

Treatment O +
was O +
from O +
weeks O +
0 O +
to O +
8 O +
and O +
was O +
then O +
tapered O +
from O +
weeks O +
8 O +
to O +
16 O -
. O +

RESULTS O -
: O +
Mean O +
alprazolam O +
dose O +
was O +
5 O +
mg O +
daily O -
. O +

Compared O +
with O +
placebo O +
subjects O -
, O +
alprazolam O +
patients O +
developed O +
more O +
adverse O +
reactions O +
( O -
21 O -
% O +
v. O +
0 O -
% O -
) O +
of O +
depression B-Disease -
, O +
enuresis B-Disease -
, O +
disinhibition O +
and O +
aggression B-Disease -
; O +
and O +
more O +
side O -
- O -
effects O -
, O +
particularly O +
sedation O -
, O +
irritability B-Disease -
, O +
impaired B-Disease +
memory I-Disease -
, O +
weight B-Disease +
loss I-Disease +
and O +
ataxia B-Disease -
. O +

Side O -
- O -
effects O +
tended O +
to O +
diminish O +
during O +
treatment O +
but O +
remained O +
significant O +
at O +
week O +
8 O -
. O +

Despite O +
this O -
, O +
the O +
drop O -
- O -
out O +
rate O +
was O +
low O -
. O +

CONCLUSIONS O -
: O +
Alprazolam O +
caused O +
side O -
- O -
effects O +
and O +
adverse O +
effects O +
during O +
treatment O +
but O +
many O +
patients O +
were O +
willing O +
to O +
accept O +
these O -
. O +

Effects O +
of O +
ouabain O +
on O +
myocardial O +
oxygen O +
supply O +
and O +
demand O +
in O +
patients O +
with O +
chronic O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
. O +

A O +
hemodynamic O -
, O +
volumetric O -
, O +
and O +
metabolic O +
study O +
in O +
patients O +
without O +
heart B-Disease +
failure I-Disease -
. O +

The O +
effects O +
of O +
digitalis O +
glycosides O +
on O +
myocardial O +
oxygen O +
supply O +
and O +
demand O +
are O +
of O +
particular O +
interest O +
in O +
the O +
presence O +
of O +
obstructive O +
coronary B-Disease +
artery I-Disease +
disease I-Disease -
, O +
but O +
have O +
not O +
been O +
measured O +
previously O +
in O +
man O -
. O +

We O +
assessed O +
the O +
effects O +
of O +
ouabain O +
( O -
0.015 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
on O +
hemodynamic O -
, O +
volumetric O -
, O +
and O +
metabolic O +
parameters O +
in O +
11 O +
patients O +
with O +
severe O +
chronic O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
without O +
clinical O +
congestive B-Disease +
heart I-Disease +
failure I-Disease -
. O +

Because O +
the O +
protocol O +
was O +
long O +
and O +
involved O +
interventions O +
which O +
might O +
affect O +
the O +
determinations O -
, O +
we O +
also O +
studied O +
in O +
nine O +
patients O +
using O +
an O +
identical O +
protocol O +
except O +
that O +
ouabain O +
administration O +
was O +
omitted O -
. O +

Left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
volume O +
fell O +
in O +
each O +
patient O +
given O +
ouabain O -
, O +
even O +
though O +
they O +
were O +
initially O +
elevated O +
in O +
only O +
two O +
patients O -
. O +

Left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
fell O +
from O +
11.5+ O -
/ O -
-1.4 O +
( O -
mean+ O -
/ O -
-SE O -
) O +
to O +
5.6+ O -
/ O -
-0.9 O +
mm O +
Hg O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
volume O +
fell O +
from O +
100+ O -
/ O -
-17 O +
to O +
82+ O -
/ O -
-12 O +
ml O -
/ O -
m2 O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
1 O +
h O +
after O +
ouabain O +
infusion O +
was O +
completed O -
. O +

The O +
maximum O +
velocity O +
of O +
contractile O +
element O +
shortening O +
increased O +
from O +
1.68+ O -
/ O -
-0.11 O +
ml O -
/ O -
s O +
to O +
2.18+ O -
/ O -
-0.21 O +
muscle O -
- O -
lengths O -
/ O -
s O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
and O +
is O +
consistent O +
with O +
an O +
increase O +
in O +
contractility O -
. O +

No O +
significant O +
change O +
in O +
these O +
parameters O +
occurred O +
in O +
the O +
control O +
patients O -
. O +

No O +
significant O +
change O +
in O +
myocardial O +
oxygen O +
consumption O +
occurred O +
after O +
ouabain O +
administration O +
but O +
this O +
may O +
be O +
related O +
to O +
a O +
greater O +
decrease O +
in O +
mean O +
arterial O +
pressure O +
in O +
the O +
ouabain O +
patients O +
than O +
in O +
the O +
control O +
patients O -
. O +

We O +
conclude O +
that O +
in O +
patients O +
with O +
chronic O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
who O +
are O +
not O +
in O +
clinical O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
left B-Disease +
ventricular I-Disease +
end I-Disease -
- I-Disease -
diastolic I-Disease +
volume I-Disease +
falls I-Disease +
after O +
ouabain O +
administration O +
even O +
when O +
it O +
is O +
initially O +
normal O -
. O +

Though O +
this O +
fall O +
would O +
be O +
associated O +
with O +
a O +
decrease O +
in O +
wall O +
tension O -
, O +
and O -
, O +
therefore O -
, O +
of O +
myocardial O +
oxygen O +
consumption O -
, O +
it O +
may O +
not O +
be O +
of O +
sufficient O +
magnitude O +
to O +
prevent O +
a O +
net O +
increase O +
in O +
myocardial O +
oxygen O +
consumption O -
. O +

Nevertheless O -
, O +
compensatory O +
mechanisms O +
prevent O +
a O +
deterioration O +
of O +
resting O +
myocardial O +
metabolism O -
. O +

Crescentic O +
fibrillary O +
glomerulonephritis B-Disease +
associated O +
with O +
intermittent O +
rifampin O +
therapy O +
for O +
pulmonary B-Disease +
tuberculosis I-Disease -
. O +

This O +
case O +
study O +
reveals O +
an O +
unusual O +
finding O +
of O +
rapidly O +
proliferative O +
crescentic O +
glomerulonephritis B-Disease +
in O +
a O +
patient O +
treated O +
with O +
rifampin O +
who O +
had O +
no O +
other O +
identifiable O +
causes O +
for O +
developing O +
this O +
disease O -
. O +

This O +
patient O +
underwent O +
a O +
10-month O +
regimen O +
of O +
rifampin O +
and O +
isoniazid O +
for O +
pulmonary B-Disease +
tuberculosis I-Disease +
and O +
was O +
discovered O +
to O +
have O +
developed O +
signs O +
of O +
severe O +
renal B-Disease +
failure I-Disease +
five O +
weeks O +
after O +
completion O +
of O +
therapy O -
. O +

Renal O +
biopsy O +
revealed O +
severe O +
glomerulonephritis B-Disease +
with O +
crescents O -
, O +
electron O +
dense O +
fibrillar O +
deposits O +
and O +
moderate O +
lymphocytic O +
interstitial O +
infiltrate O -
. O +

Other O +
possible O +
causes O +
of O +
rapidly O +
progressive O +
glomerulonephritis B-Disease +
were O +
investigated O +
and O +
ruled O +
out O -
. O +

This O +
report O +
documents O +
the O +
unusual O +
occurrence O +
of O +
rapidly O +
progressive O +
glomerulonephritis B-Disease +
with O +
crescents O +
and O +
fibrillar O +
glomerulonephritis B-Disease +
in O +
a O +
patient O +
treated O +
with O +
rifampin O -
. O +

Acute O +
confusion B-Disease +
induced O +
by O +
a O +
high O -
- O -
dose O +
infusion O +
of O +
5-fluorouracil O +
and O +
folinic O +
acid O -
. O +

A O +
61-year O -
- O -
old O +
man O +
was O +
treated O +
with O +
combination O +
chemotherapy O +
incorporating O +
cisplatinum O -
, O +
etoposide O -
, O +
high O -
- O -
dose O +
5-fluorouracil O +
( O -
2,250 O +
mg O -
/ O -
m2 O -
/ O -
24 O +
hours O -
) O +
and O +
folinic O +
acid O +
for O +
an O +
inoperable O +
gastric B-Disease +
adenocarcinoma I-Disease -
. O +

He O +
developed O +
acute O +
neurologic O +
symptoms O +
of O +
mental O +
confusion B-Disease -
, O +
disorientation B-Disease +
and O +
irritability B-Disease -
, O +
and O +
then O +
lapsed O +
into O +
a O +
deep O +
coma B-Disease -
, O +
lasting O +
for O +
approximately O +
40 O +
hours O +
during O +
the O +
first O +
dose O +
( O -
day O +
2 O -
) O +
of O +
5-fluorouracil O +
and O +
folinic O +
acid O +
infusion O -
. O +

This O +
complication O +
reappeared O +
on O +
day O +
25 O +
during O +
the O +
second O +
dose O +
of O +
5-fluorouracil O +
and O +
folinic O +
acid O -
, O +
which O +
were O +
then O +
the O +
only O +
drugs O +
given O -
. O +

Because O +
folinic O +
acid O +
was O +
unlikely O +
to O +
be O +
associated O +
with O +
this O +
condition O -
, O +
neurotoxicity B-Disease +
due O +
to O +
high O -
- O -
dose O +
5-fluorouracil O +
was O +
highly O +
suspected O -
. O +

The O +
pathogenesis O +
of O +
5-fluorouracil O +
neurotoxicity B-Disease +
may O +
be O +
due O +
to O +
a O +
Krebs O +
cycle O +
blockade O +
by O +
fluoroacetate O +
and O +
fluorocitrate O -
, O +
thiamine O +
deficiency O -
, O +
or O +
dihydrouracil O +
dehydrogenase O +
deficiency O -
. O +

High O -
- O -
dose O +
5-fluorouracil O -
/ O -
folinic O +
acid O +
infusion O +
therapy O +
has O +
recently O +
become O +
a O +
popular O +
regimen O +
for O +
various O +
cancers B-Disease -
. O +

It O +
is O +
necessary O +
that O +
both O +
oncologists O +
and O +
neurologists O +
be O +
fully O +
aware O +
of O +
this O +
unusual O +
complication O -
. O +

Effect O +
of O +
switching O +
carbamazepine O +
to O +
oxcarbazepine O +
on O +
the O +
plasma O +
levels O +
of O +
neuroleptics O -
. O +

A O +
case O +
report O -
. O +

Carbamazepine O +
was O +
switched O +
to O +
its O +
10-keto O +
analogue O +
oxcarbazepine O +
among O +
six O +
difficult O -
- O -
to O -
- O -
treat O +
schizophrenic B-Disease +
or O +
organic B-Disease +
psychotic I-Disease +
patients O +
using O +
concomitantly O +
haloperidol O -
, O +
chlorpromazine O +
or O +
clozapine O -
. O +

This O +
change O +
resulted O +
within O +
2 O -
- O -
4 O +
weeks O +
in O +
the O +
50 O -
- O -
200 O -
% O +
increase O +
in O +
the O +
plasma O +
levels O +
of O +
these O +
neuroleptics O +
and O +
the O +
appearance O +
of O +
extrapyramidal B-Disease +
symptoms I-Disease -
. O +

None O +
of O +
the O +
patients O +
showed O +
any O +
clinical O +
deteriotation O +
during O +
the O +
following O +
3 O -
- O -
6 O +
months O -
. O +

The O +
results O +
of O +
this O +
case O +
report O +
support O +
the O +
idea O +
that O +
in O +
contrast O +
with O +
carbamazepine O +
oxcarbazepine O +
does O +
not O +
induce O +
the O +
hepatic O +
microsomal O +
enzyme O +
systems O +
regulating O +
the O +
inactivation O +
of O +
antipsychotic O +
drugs O -
. O +

Auditory O +
disturbance O +
associated O +
with O +
interscalene O +
brachial O +
plexus O +
block O -
. O +

We O +
performed O +
an O +
audiometric O +
study O +
in O +
20 O +
patients O +
who O +
underwent O +
surgery O +
of O +
the O +
shoulder O +
region O +
under O +
an O +
interscalene O +
brachial O +
plexus O +
block O +
( O -
IBPB O -
) O -
. O +

Bupivacaine O +
0.75 O -
% O +
with O +
adrenaline O +
was O +
given O +
followed O +
by O +
a O +
24-hr O +
continuous O +
infusion O +
of O +
0.25 O -
% O +
bupivacaine O -
. O +

Three O +
audiometric O +
threshold O +
measurements O +
( O -
0.25 O -
- O -
18 O +
kHz O -
) O +
were O +
made O -
: O +
the O +
first O +
before O +
IBPB O -
, O +
the O +
second O +
2 O -
- O -
6 O +
h O +
after O +
surgery O +
and O +
the O +
third O +
on O +
the O +
first O +
day O +
after O +
operation O -
. O +

In O +
four O +
patients O +
hearing B-Disease +
impairment I-Disease +
on O +
the O +
side O +
of O +
the O +
block O +
was O +
demonstrated O +
after O +
operation O -
, O +
in O +
three O +
measurements O +
on O +
the O +
day O +
of O +
surgery O +
and O +
in O +
one O +
on O +
the O +
following O +
day O -
. O +

The O +
frequencies O +
at O +
which O +
the O +
impairment O +
occurred O +
varied O +
between O +
patients O -
; O +
in O +
one O +
only O +
low O +
frequencies O +
( O -
0.25 O -
- O -
0.5 O +
kHz O -
) O +
were O +
involved O -
. O +

The O +
maximum O +
change O +
in O +
threshold O +
was O +
35 O +
dB O +
at O +
6 O +
kHz O +
measured O +
at O +
the O +
end O +
of O +
the O +
continuous O +
infusion O +
of O +
bupivacaine O -
. O +

This O +
patient O +
had O +
hearing O +
threshold O +
changes O +
( O -
15 O -
- O -
20 O +
dB O -
) O +
at O +
6 O -
- O -
10 O +
kHz O +
on O +
the O +
opposite O +
side O +
also O -
. O +

IBPB O +
may O +
cause O +
transient O +
auditory B-Disease +
dysfunction I-Disease +
in O +
the O +
ipsilateral O +
ear O -
, O +
possibly O +
via O +
an O +
effect O +
on O +
sympathetic O +
innervation O -
. O +

Time O +
course O +
of O +
lipid O +
peroxidation O +
in O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephropathy B-Disease -
. O +

Reactive O +
oxygen O +
species O +
have O +
been O +
implicated O +
in O +
the O +
pathogenesis O +
of O +
acute O +
puromycin O +
aminonucleoside O +
( O -
PAN O -
) O -
-induced O +
nephropathy B-Disease -
, O +
with O +
antioxidants O +
significantly O +
reducing O +
the O +
proteinuria B-Disease -
. O +

The O +
temporal O +
relationship O +
between O +
lipid O +
peroxidation O +
in O +
the O +
kidney O +
and O +
proteinuria B-Disease +
was O +
examined O +
in O +
this O +
study O -
. O +

Rats O +
were O +
treated O +
with O +
a O +
single O +
IV O +
injection O +
of O +
puromycin O +
aminonucleoside O -
, O +
( O -
PAN O -
, O +
7.5 O +
mg O -
/ O -
kg O -
) O +
and O +
24 O +
hour O +
urine O +
samples O +
were O +
obtained O +
prior O +
to O +
sacrifice O +
on O +
days O +
3,5,7,10,17,27,41 O +
( O -
N O +
= O +
5 O -
- O -
10 O +
per O +
group O -
) O -
. O +

The O +
kidneys O +
were O +
removed O -
, O +
flushed O +
with O +
ice O +
cold O +
TRIS O +
buffer O -
. O +

Kidney O +
cortices O +
from O +
each O +
animal O +
were O +
used O +
to O +
prepare O +
homogenates O -
. O +

Tissue O +
lipid O +
peroxidation O +
was O +
measured O +
in O +
whole O +
homogenates O +
as O +
well O +
as O +
in O +
lipid O +
extracts O +
from O +
homogenates O +
as O +
thiobarbituric O +
acid O +
reactive O +
substances O -
. O +

Proteinuria B-Disease +
was O +
evident O +
at O +
day O +
5 O -
, O +
peaked O +
at O +
day O +
7 O +
and O +
persisted O +
to O +
day O +
27 O -
. O +

Lipid O +
peroxidation O +
in O +
homogenates O +
was O +
maximal O +
at O +
day O +
3 O +
and O +
declined O +
rapidly O +
to O +
control O +
levels O +
by O +
day O +
17 O -
. O +

This O +
study O +
supports O +
the O +
role O +
of O +
lipid O +
peroxidation O +
in O +
mediating O +
the O +
proteinuric B-Disease +
injury I-Disease +
in O +
PAN O +
nephropathy B-Disease -
. O +

Composition O +
of O +
gall B-Disease +
bladder I-Disease +
stones I-Disease +
associated O +
with O +
octreotide O -
: O +
response O +
to O +
oral O +
ursodeoxycholic O +
acid O -
. O +

Octreotide O -
, O +
an O +
effective O +
treatment O +
for O +
acromegaly B-Disease -
, O +
induces O +
gall B-Disease +
bladder I-Disease +
stones I-Disease +
in O +
13 O -
- O -
60 O -
% O +
of O +
patients O -
. O +

Because O +
knowledge O +
of O +
stone O +
composition O +
is O +
essential O +
for O +
studies O +
of O +
their O +
pathogenesis O -
, O +
treatment O -
, O +
and O +
prevention O -
, O +
this O +
was O +
investigated O +
by O +
direct O +
and O +
indirect O +
methods O +
in O +
14 O +
octreotide O +
treated O +
acromegalic B-Disease +
patients O +
with O +
gall B-Disease +
stones I-Disease -
. O +

Chemical O +
analysis O +
of O +
gall B-Disease +
stones I-Disease +
retrieved O +
at O +
cholecystectomy O +
from O +
two O +
patients O -
, O +
showed O +
that O +
they O +
contained O +
71 O -
% O +
and O +
87 O -
% O +
cholesterol O +
by O +
weight O -
. O +

In O +
the O +
remaining O +
12 O +
patients O -
, O +
localised O +
computed O +
tomography O +
of O +
the O +
gall O +
bladder O +
showed O +
that O +
eight O +
had O +
stones O +
with O +
maximum O +
attenuation O +
scores O +
of O +
< O +
100 O +
Hounsfield O +
units O +
( O -
values O +
of O +
< O +
100 O +
HU O +
predict O +
cholesterol O +
rich O -
, O +
dissolvable O +
stones O -
) O -
. O +

Gall O +
bladder O +
bile O +
was O +
obtained O +
by O +
ultrasound O +
guided O -
, O +
fine O +
needle O +
puncture O +
from O +
six O +
patients O -
. O +

All O +
six O +
patients O +
had O +
supersaturated O +
bile O +
( O -
mean O +
( O -
SEM O -
) O +
cholesterol O +
saturation O +
index O +
of O +
1.19 O +
( O -
0.08 O -
) O +
( O -
range O +
1.01 O -
- O -
1.53 O -
) O -
) O +
and O +
all O +
had O +
abnormally O +
rapid O +
cholesterol O +
microcrystal O +
nucleation O +
times O +
( O -
< O +
4 O +
days O +
( O -
range O +
1 O -
- O -
4 O -
) O -
) O -
, O +
whilst O +
in O +
four O -
, O +
the O +
bile O +
contained O +
cholesterol O +
microcrystals O +
immediately O +
after O +
sampling O -
. O +

Of O +
the O +
12 O +
patients O +
considered O +
for O +
oral O +
ursodeoxycholic O +
acid O +
( O -
UDCA O -
) O +
treatment O -
, O +
two O +
had O +
a O +
blocked O +
cystic O +
duct O +
and O +
were O +
not O +
started O +
on O +
UDCA O +
while O +
one O +
was O +
lost O +
to O +
follow O +
up O -
. O +

After O +
one O +
year O +
of O +
treatment O -
, O +
five O +
of O +
the O +
remaining O +
nine O +
patients O +
showed O +
either O +
partial O +
( O -
n O +
= O +
3 O -
) O +
or O +
complete O +
( O -
n O +
= O +
2 O -
) O +
gall B-Disease +
stone I-Disease +
dissolution O -
, O +
suggesting O +
that O +
their O +
stones O +
were O +
cholesterol O +
rich O -
. O +

This O +
corresponds O -
, O +
by O +
actuarial O +
( O -
life O +
table O -
) O +
analysis O -
, O +
to O +
a O +
combined O +
gall B-Disease +
stone I-Disease +
dissolution O +
rate O +
of O +
58.3 O +
( O -
15.9 O -
% O -
) O -
. O +

In O +
conclusion O -
, O +
octreotide O +
induced O +
gall B-Disease +
stones I-Disease +
are O +
generally O +
small O -
, O +
multiple O -
, O +
and O +
cholesterol O +
rich O +
although O -
, O +
in O +
common O +
with O +
spontaneous O +
gall B-Disease +
stone I-Disease +
disease I-Disease -
, O +
at O +
presentation O +
some O +
patients O +
will O +
have O +
a O +
blocked O +
cystic O +
duct O +
and O +
some O +
gall B-Disease +
stones I-Disease +
containing O +
calcium O -
. O +

The O +
safety O +
and O +
efficacy O +
of O +
combination O +
N O -
- O -
butyl O -
- O -
deoxynojirimycin O +
( O -
SC-48334 O -
) O +
and O +
zidovudine O +
in O +
patients O +
with O +
HIV-1 B-Disease +
infection I-Disease +
and O +
200 O -
- O -
500 O +
CD4 O +
cells O -
/ O -
mm3 O -
. O +

We O +
conducted O +
a O +
double O -
- O -
blind O -
, O +
randomized O +
phase O +
II O +
study O +
to O +
evaluate O +
the O +
safety O +
and O +
activity O +
of O +
combination O +
therapy O +
with O +
N O -
- O -
butyl O -
- O -
deoxynojirimycin O +
( O -
SC-48334 O -
) O +
( O -
an O +
alpha O -
- O -
glucosidase O +
I O +
inhibitor O -
) O +
and O +
zidovudine O +
versus O +
zidovudine O +
alone O -
. O +

Patients O +
with O +
200 O +
to O +
500 O +
CD4 O +
cells O -
/ O -
mm3 O +
who O +
tolerated O +
< O +
or O +
= O +
12 O +
weeks O +
of O +
prior O +
zidovudine O +
therapy O +
received O +
SC-48334 O +
( O -
1000 O +
mg O +
every O +
8 O +
h O -
) O +
and O +
zidovudine O +
( O -
100 O +
mg O +
every O +
8 O +
h O -
) O +
or O +
zidovudine O +
and O +
placebo O -
. O +

Sixty O +
patients O +
received O +
combination O +
therapy O +
and O +
58 O -
, O +
zidovudine O +
and O +
placebo O -
. O +

Twenty O -
- O -
three O +
patients O +
( O -
38 O -
% O -
) O +
and O +
15 O +
( O -
26 O -
% O -
) O -
, O +
in O +
the O +
combination O +
and O +
zidovudine O +
groups O -
, O +
respectively O -
, O +
discontinued O +
therapy O +
( O -
p O +
= O +
0.15 O -
) O -
. O +

The O +
mean O +
SC-48334 O +
steady O -
- O -
state O +
trough O +
level O +
( O -
4.04 O +
+ O -
/- O +

0.99 O +
micrograms O -
/ O -
ml O -
) O +
was O +
below O +
the O +
in O +
vitro O +
inhibitory O +
concentration O +
for O +
human O +
immunodeficiency B-Disease +
virus O +
( O -
HIV O -
) O -
. O +

The O +
mean O +
increase O +
in O +
CD4 O +
cells O +
at O +
week O +
4 O +
was O +
73.8 O +
cells O -
/ O -
mm3 O +
and O +
52.4 O +
cells O -
/ O -
mm3 O +
for O +
the O +
combination O +
and O +
zidovudine O +
groups O -
, O +
respectively O +
( O -
p O +
> O +
0.36 O -
) O -
. O +

For O +
patients O +
with O +
prior O +
zidovudine O +
therapy O -
, O +
the O +
mean O +
change O +
in O +
CD4 O +
cells O +
in O +
the O +
combination O +
and O +
zidovudine O +
groups O +
was O +
63.7 O +
cells O -
/ O -
mm3 O +
and O +
4.9 O +
cells O -
/ O -
mm3 O +
at O +
week O +
8 O +
and O +
6.8 O +
cells O -
/ O -
mm3 O +
and O +
-45.1 O +
cells O -
/ O -
mm3 O +
at O +
week O +
16 O -
, O +
respectively O -
. O +

The O +
number O +
of O +
patients O +
with O +
suppression O +
of O +
HIV O +
p24 O +
antigenemia O +
in O +
the O +
combination O +
and O +
zidovudine O +
groups O +
was O +
six O +
( O -
40 O -
% O -
) O +
and O +
two O +
( O -
11 O -
% O -
) O +
at O +
week O +
4 O +
( O -
p O +
= O +
0.10 O -
) O +
and O +
five O +
( O -
45 O -
% O -
) O +
and O +
two O +
( O -
14 O -
% O -
) O +
at O +
week O +
24 O +
( O -
p O +
= O +
0.08 O -
) O -
, O +
respectively O -
. O +

Diarrhea B-Disease -
, O +
flatulence B-Disease -
, O +
abdominal B-Disease +
pain I-Disease -
, O +
and O +
weight B-Disease +
loss I-Disease +
were O +
common O +
for O +
combination O +
recipients. O -
( O -
ABSTRACT O +
TRUNCATED O +
AT O +
250 O +
WORDS O -
) O +

Prolonged O +
paralysis B-Disease +
due O +
to O +
nondepolarizing O +
neuromuscular O +
blocking O +
agents O +
and O +
corticosteroids O -
. O +

The O +
long O -
- O -
term O +
use O +
of O +
nondepolarizing O +
neuromuscular O +
blocking O +
agents O +
( O -
ND O -
- O -
NMBA O -
) O +
has O +
recently O +
been O +
implicated O +
as O +
a O +
cause O +
of O +
prolonged O +
muscle B-Disease +
weakness I-Disease -
, O +
although O +
the O +
site O +
of O +
the O +
lesion O +
and O +
the O +
predisposing O +
factors O +
have O +
been O +
unclear O -
. O +

We O +
report O +
3 O +
patients O +
( O -
age O +
37 O -
- O -
52 O +
years O -
) O +
with O +
acute O +
respiratory B-Disease +
insufficiency I-Disease +
who O +
developed O +
prolonged O +
weakness B-Disease +
following O +
the O +
discontinuation O +
of O +
ND O -
- O -
NMBAs O -
. O +

Two O +
patients O +
also O +
received O +
intravenous O +
corticosteroids O -
. O +

Renal O +
function O +
was O +
normal O +
but O +
hepatic O +
function O +
was O +
impaired O +
in O +
all O +
patients O -
, O +
and O +
all O +
had O +
acidosis B-Disease -
. O +

Electrophysiologic O +
studies O +
revealed O +
low O +
amplitude O +
compound O +
motor O +
action O +
potentials O -
, O +
normal O +
sensory O +
studies O -
, O +
and O +
fibrillations O -
. O +

Repetitive O +
stimulation O +
at O +
2 O +
Hz O +
showed O +
a O +
decremental O +
response O +
in O +
2 O +
patients O -
. O +

The O +
serum O +
vecuronium O +
level O +
measured O +
in O +
1 O +
patient O +
14 O +
days O +
after O +
the O +
drug O +
had O +
been O +
discontinued O +
was O +
172 O +
ng O -
/ O -
mL. O +
A O +
muscle O +
biopsy O +
in O +
this O +
patient O +
showed O +
loss B-Disease +
of I-Disease +
thick I-Disease -
, I-Disease +
myosin I-Disease +
filaments I-Disease -
. O +

The O +
weakness B-Disease +
in O +
these O +
patients O +
is O +
due O +
to O +
pathology B-Disease +
at I-Disease +
both I-Disease +
the I-Disease +
neuromuscular I-Disease +
junction I-Disease +
( O -
most O +
likely O +
due O +
to O +
ND O -
- O -
NMBA O -
) O +
and O +
muscle O +
( O -
most O +
likely O +
due O +
to O +
corticosteroids O -
) O -
. O +

Hepatic B-Disease +
dysfunction I-Disease +
and O +
acidosis B-Disease +
are O +
contributing O +
risk O +
factors O -
. O +

Erythema B-Disease +
multiforme I-Disease +
and O +
hypersensitivity B-Disease +
myocarditis I-Disease +
caused O +
by O +
ampicillin O -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
erythema B-Disease +
multiforme I-Disease +
and O +
hypersensitivity B-Disease +
myocarditis I-Disease +
caused O +
by O +
ampicillin O -
. O +

CASE O +
SUMMARY O -
: O +
A O +
13-year O -
- O -
old O +
boy O +
was O +
treated O +
with O +
ampicillin O +
and O +
gentamicin O +
because O +
of O +
suspected O +
septicemia B-Disease -
. O +

Medications O +
were O +
discontinued O +
when O +
erythema B-Disease +
multiforme I-Disease +
and O +
congestive B-Disease +
heart I-Disease +
failure I-Disease +
caused O +
by O +
myocarditis B-Disease +
occurred O -
. O +

The O +
patient O +
was O +
treated O +
with O +
methylprednisolone O +
and O +
gradually O +
improved O -
. O +

Macrophage O -
- O -
migration O +
inhibition O +
( O -
MIF O -
) O +
test O +
with O +
ampicillin O +
was O +
positive O -
. O +

DISCUSSION O -
: O +
After O +
most O +
infections B-Disease +
causing O +
erythema B-Disease +
multiforme I-Disease +
and O +
myocarditis B-Disease +
were O +
ruled O +
out O -
, O +
a O +
drug B-Disease -
- I-Disease -
induced I-Disease +
allergic I-Disease +
reaction I-Disease +
was O +
suspected O -
. O +

Positive O +
MIF O +
test O +
for O +
ampicillin O +
showed O +
sensitization O +
of O +
the O +
patient O -
's O +
lymphocytes O +
to O +
ampicillin O -
. O +

CONCLUSIONS O -
: O +
Hypersensitivity B-Disease +
myocarditis I-Disease +
is O +
a O +
rare O +
and O +
dangerous O +
manifestation O +
of O +
allergy B-Disease +
to O +
penicillins O -
. O +

Clomipramine O -
- O -
induced O +
sleep B-Disease +
disturbance I-Disease +
does O +
not O +
impair O +
its O +
prolactin O -
- O -
releasing O +
action O -
. O +

The O +
present O +
study O +
was O +
undertaken O +
to O +
examine O +
the O +
role O +
of O +
sleep B-Disease +
disturbance I-Disease -
, O +
induced O +
by O +
clomipramine O +
administration O -
, O +
on O +
the O +
secretory O +
rate O +
of O +
prolactin O +
( O -
PRL O -
) O +
in O +
addition O +
to O +
the O +
direct O +
drug O +
effect O -
. O +

Two O +
groups O +
of O +
supine O +
subjects O +
were O +
studied O +
under O +
placebo O -
- O -
controlled O +
conditions O -
, O +
one O +
during O +
the O +
night O -
, O +
when O +
sleeping O +
( O -
n O +
= O +
7 O -
) O +
and O +
the O +
other O +
at O +
daytime O -
, O +
when O +
awake O +
( O -
n O +
= O +
6 O -
) O -
. O +

Each O +
subject O +
received O +
a O +
single O +
50 O +
mg O +
dose O +
of O +
clomipramine O +
given O +
orally O +
2 O +
hours O +
before O +
blood O +
collection O -
. O +

Plasma O +
PRL O +
concentrations O +
were O +
analysed O +
at O +
10 O +
min O +
intervals O +
and O +
underlying O +
secretory O +
rates O +
calculated O +
by O +
a O +
deconvolution O +
procedure O -
. O +

For O +
both O +
experiments O +
the O +
drug O +
intake O +
led O +
to O +
significant O +
increases O +
in O +
PRL O +
secretion O -
, O +
acting O +
preferentially O +
on O +
tonic O +
secretion O +
as O +
pulse O +
amplitude O +
and O +
frequency O +
did O +
not O +
differ O +
significantly O +
from O +
corresponding O +
control O +
values O -
. O +

During O +
the O +
night O +
clomipramine O +
ingestion O +
altered O +
the O +
complete O +
sleep O +
architecture O +
in O +
that O +
it O +
suppressed O +
REM O +
sleep O +
and O +
the O +
sleep O +
cycles O +
and O +
induced O +
increased O +
wakefulness O -
. O +

As O +
the O +
relative O +
increase O +
in O +
PRL O +
secretion O +
expressed O +
as O +
a O +
percentage O +
of O +
the O +
mean O +
did O +
not O +
significantly O +
differ O +
between O +
the O +
night O +
and O +
day O +
time O +
studies O +
( O -
46 O +
+ O -
/- O +

19 O -
% O +
vs O +
34 O +
+ O -
/- O +

10 O -
% O -
) O -
, O +
it O +
can O +
be O +
concluded O +
that O +
the O +
observed O +
sleep B-Disease +
disturbance I-Disease +
did O +
not O +
interfere O +
with O +
the O +
drug O +
action O +
per O +
se O -
. O +

The O +
presence O +
of O +
REM O +
sleep O +
was O +
shown O +
not O +
to O +
be O +
a O +
determining O +
factor O +
either O +
for O +
secretory O +
pulse O +
amplitude O +
and O +
frequency O -
, O +
as O -
, O +
for O +
both O -
, O +
mean O +
nocturnal O +
values O +
were O +
similar O +
with O +
and O +
without O +
prior O +
clomipramine O +
ingestion O -
. O +

Survey O +
of O +
complications O +
of O +
indocyanine O +
green O +
angiography O +
in O +
Japan O -
. O +

PURPOSE O -
: O +
We O +
evaluated O +
the O +
safety O +
of O +
indocyanine O +
green O +
for O +
use O +
in O +
fundus O +
angiography O -
. O +

METHODS O -
: O +
We O +
sent O +
a O +
questionnaire O +
concerning O +
complications O +
of O +
indocyanine O +
green O +
to O +
32 O +
institutions O +
in O +
Japan O -
, O +
which O +
were O +
selected O +
on O +
the O +
basis O +
of O +
the O +
client O +
list O +
from O +
the O +
Topcon O +
Company O -
, O +
which O +
manufactures O +
the O +
indocyanine O +
green O +
fundus O +
camera O -
. O +

RESULTS O -
: O +
Ophthalmologists O +
at O +
15 O +
institutions O +
responded O -
, O +
reporting O +
a O +
total O +
of O +
3,774 O +
indocyanine O +
green O +
angiograms O +
performed O +
on O +
2,820 O +
patients O +
between O +
June O +
1984 O +
and O +
September O +
1992 O -
. O +

Before O +
angiography O -
, O +
intradermal O +
or O +
intravenous O +
indocyanine O +
green O +
testing O -
, O +
or O +
both O +
was O +
performed O +
at O +
13 O +
of O +
15 O +
institutions O -
. O +

For O +
three O +
patients O -
, O +
the O +
decision O +
was O +
made O +
not O +
to O +
proceed O +
with O +
angiography O +
after O +
positive O +
preangiographic O +
testing O -
. O +

The O +
dosage O +
of O +
indocyanine O +
green O +
used O +
for O +
angiography O +
varied O +
from O +
25 O +
to O +
75 O +
mg O -
, O +
depending O +
upon O +
the O +
institution O -
. O +

There O +
were O +
13 O +
cases O +
of O +
adverse O +
reactions O +
( O -
0.34 O -
% O -
) O -
, O +
ten O +
of O +
which O +
were O +
mild O +
reactions O +
such O +
as O +
nausea B-Disease -
, O +
exanthema B-Disease -
, O +
urtication B-Disease -
, O +
itchiness B-Disease -
, O +
and O +
urgency O +
to O +
defecate O -
, O +
and O +
did O +
not O +
require O +
treatment O -
. O +

Also O +
recorded O +
were O +
one O +
case O +
of O +
pain B-Disease +
of O +
the O +
vein O -
, O +
which O +
required O +
treatment O -
, O +
and O +
two O +
cases O +
of O +
hypotension B-Disease -
. O +

The O +
two O +
hypotensive B-Disease +
patients O +
required O +
treatment O +
for O +
shock B-Disease -
. O +

CONCLUSIONS O -
: O +
A O +
comparison O +
of O +
frequency O +
of O +
adverse O +
reactions O +
to O +
indocyanine O +
green O +
with O +
the O +
previously O +
reported O +
frequency O +
of O +
such O +
reactions O +
to O +
fluorescein O +
sodium O +
indicated O +
that O +
indocyanine O +
green O +
is O +
a O +
safe O +
as O +
fluorescein O +
for O +
use O +
in O +
angiography O -
. O +

Angioedema B-Disease +
following O +
the O +
intravenous O +
administration O +
of O +
metoprolol O -
. O +

A O +
72-year O -
- O -
old O +
woman O +
was O +
admitted O +
to O +
the O +
hospital O +
with O +
" O -
flash O -
" O +
pulmonary B-Disease +
edema I-Disease -
, O +
preceded O +
by O +
chest B-Disease +
pain I-Disease -
, O +
requiring O +
intubation O -
. O +

Her O +
medical O +
history O +
included O +
coronary B-Disease +
artery I-Disease +
disease I-Disease +
with O +
previous O +
myocardial B-Disease +
infarctions I-Disease -
, O +
hypertension B-Disease -
, O +
and O +
diabetes B-Disease +
mellitus I-Disease -
. O +

A O +
history O +
of O +
angioedema B-Disease +
secondary O +
to O +
lisinopril O +
therapy O +
was O +
elicited O -
. O +

Current O +
medications O +
did O +
not O +
include O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitors O +
or O +
beta O -
- O -
blockers O -
. O +

She O +
had O +
no O +
previous O +
beta O -
- O -
blocking O +
drug O +
exposure O -
. O +

During O +
the O +
first O +
day O +
of O +
hospitalization O +
( O -
while O +
intubated O -
) O -
, O +
intravenous O +
metoprolol O +
was O +
given O -
, O +
resulting O +
in O +
severe O +
angioedema B-Disease -
. O +

The O +
angioedema B-Disease +
resolved O +
after O +
therapy O +
with O +
intravenous O +
steroids O +
and O +
diphenhydramine O +
hydrochloride O -
. O +

Failure O +
of O +
ancrod O +
in O +
the O +
treatment O +
of O +
heparin O -
- O -
induced O +
arterial O +
thrombosis B-Disease -
. O +

The O +
morbidity O +
and O +
mortality O +
associated O +
with O +
heparin O -
- O -
induced O +
thrombosis B-Disease +
remain O +
high O +
despite O +
numerous O +
empirical O +
therapies O -
. O +

Ancrod O +
has O +
been O +
used O +
successfully O +
for O +
prophylaxis O +
against O +
development O +
of O +
thrombosis B-Disease +
in O +
patients O +
with O +
heparin O +
induced O +
platelet B-Disease +
aggregation I-Disease +
who O +
require O +
brief O +
reexposure O +
to O +
heparin O -
, O +
but O +
its O +
success O +
in O +
patients O +
who O +
have O +
developed O +
the O +
thrombosis B-Disease +
syndrome O +
is O +
not O +
well O +
defined O -
. O +

The O +
authors O +
present O +
a O +
case O +
of O +
failure O +
of O +
ancrod O +
treatment O +
in O +
a O +
patient O +
with O +
heparin O -
- O -
induced O +
thrombosis B-Disease -
. O +

Effect O +
of O +
coniine O +
on O +
the O +
developing O +
chick O +
embryo O -
. O +

Coniine O -
, O +
an O +
alkaloid O +
from O +
Conium O +
maculatum O +
( O -
poison O +
hemlock O -
) O -
, O +
has O +
been O +
shown O +
to O +
be O +
teratogenic O +
in O +
livestock O -
. O +

The O +
major O +
teratogenic O +
outcome O +
is O +
arthrogryposis B-Disease -
, O +
presumably O +
due O +
to O +
nicotinic O +
receptor O +
blockade O -
. O +

However O -
, O +
coniine O +
has O +
failed O +
to O +
produce O +
arthrogryposis B-Disease +
in O +
rats O +
or O +
mice O +
and O +
is O +
only O +
weakly O +
teratogenic O +
in O +
rabbits O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
and O +
compare O +
the O +
effects O +
of O +
coniine O +
and O +
nicotine O +
in O +
the O +
developing O +
chick O -
. O +

Concentrations O +
of O +
coniine O +
and O +
nicotine O +
sulfate O +
were O +
0.015 O -
% O -
, O +
0.03 O -
% O -
, O +
0.075 O -
% O -
, O +
0.15 O -
% O -
, O +
0.75 O -
% O -
, O +
1.5 O -
% O -
, O +
3 O -
% O -
, O +
and O +
6 O -
% O +
and O +
1 O -
% O -
, O +
5 O -
% O -
, O +
and O +
10 O -
% O -
, O +
respectively O -
. O +

Both O +
compounds O +
caused O +
deformations B-Disease +
and O +
lethality O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

All O +
concentrations O +
of O +
nicotine O +
sulfate O +
caused O +
some O +
lethality O +
but O +
a O +
no O +
effect O +
level O +
for O +
coniine O +
lethality O +
was O +
0.75 O -
% O -
. O +

The O +
deformations B-Disease +
caused O +
by O +
both O +
coniine O +
and O +
nicotine O +
sulfate O +
were O +
excessive B-Disease +
flexion I-Disease +
or I-Disease +
extension I-Disease +
of I-Disease +
one I-Disease +
or I-Disease +
more I-Disease +
toes I-Disease -
. O +

No O +
histopathological O +
alterations O +
or O +
differences O +
in O +
bone O +
formation O +
were O +
seen O +
in O +
the O +
limbs O +
or O +
toes O +
of O +
any O +
chicks O +
from O +
any O +
group O -
; O +
however O -
, O +
extensive O +
cranial B-Disease +
hemorrhage I-Disease +
occurred O +
in O +
all O +
nicotine O +
sulfate O -
- O -
treated O +
chicks O -
. O +

There O +
was O +
a O +
statistically O +
significant O +
( O -
P O +
< O +
or O +
= O +
0.01 O -
) O +
decrease O +
in O +
movement O +
in O +
coniine O +
and O +
nicotine O +
sulfate O +
treated O +
chicks O +
as O +
determined O +
by O +
ultrasound O -
. O +

Control O +
chicks O +
were O +
in O +
motion O +
an O +
average O +
of O +
33.67 O -
% O +
of O +
the O +
time O -
, O +
while O +
coniine O -
- O -
treated O +
chicks O +
were O +
only O +
moving O +
8.95 O -
% O +
of O +
a O +
5-min O +
interval O -
, O +
and O +
no O +
movement O +
was O +
observed O +
for O +
nicotine O +
sulfate O +
treated O +
chicks O -
. O +

In O +
summary O -
, O +
the O +
chick O +
embryo O +
provides O +
a O +
reliable O +
and O +
simple O +
experimental O +
animal O +
model O +
of O +
coniine O -
- O -
induced O +
arthrogryposis B-Disease -
. O +

Data O +
from O +
this O +
model O +
support O +
a O +
mechanism O +
involving O +
nicotinic O +
receptor O +
blockade O +
with O +
subsequent O +
decreased O +
fetal O +
movement O -
. O +

Immediate O +
allergic B-Disease +
reactions I-Disease +
to O +
amoxicillin O -
. O +

A O +
large O +
group O +
of O +
patients O +
with O +
suspected O +
allergic B-Disease +
reactions I-Disease +
to O +
beta O -
- O -
lactam O +
antibiotics O +
was O +
evaluated O -
. O +

A O +
detailed O +
clinical O +
history O -
, O +
together O +
with O +
skin O +
tests O -
, O +
RAST O +
( O -
radioallergosorbent O +
test O -
) O -
, O +
and O +
controlled O +
challenge O +
tests O -
, O +
was O +
used O +
to O +
establish O +
whether O +
patients O +
allergic B-Disease +
to O +
beta O -
- O -
lactam O +
antibiotics O +
had O +
selective O +
immediate O +
allergic B-Disease +
responses O +
to O +
amoxicillin O +
( O -
AX O -
) O +
or O +
were O +
cross O -
- O -
reacting O +
with O +
other O +
penicillin O +
derivatives O -
. O +

Skin O +
tests O +
were O +
performed O +
with O +
benzylpenicilloyl O -
- O -
poly O -
- O -
L O -
- O -
lysine O +
( O -
BPO O -
- O -
PLL O -
) O -
, O +
benzylpenicilloate O -
, O +
benzylpenicillin O +
( O -
PG O -
) O -
, O +
ampicillin O +
( O -
AMP O -
) O -
, O +
and O +
AX O -
. O +

RAST O +
for O +
BPO O -
- O -
PLL O +
and O +
AX O -
- O -
PLL O +
was O +
done O -
. O +

When O +
both O +
skin O +
test O +
and O +
RAST O +
for O +
BPO O +
were O +
negative O -
, O +
single O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
challenge O +
tests O +
were O +
done O +
to O +
ensure O +
tolerance O +
of O +
PG O +
or O +
sensitivity O +
to O +
AX O -
. O +

A O +
total O +
of O +
177 O +
patients O +
were O +
diagnosed O +
as O +
allergic B-Disease +
to O +
beta O -
- O -
lactam O +
antibiotics O -
. O +

We O +
selected O +
the O +
54 O +
( O -
30.5 O -
% O -
) O +
cases O +
of O +
immediate O +
AX O +
allergy B-Disease +
with O +
good O +
tolerance O +
of O +
PG O -
. O +

Anaphylaxis B-Disease +
was O +
seen O +
in O +
37 O +
patients O +
( O -
69 O -
% O -
) O -
, O +
the O +
other O +
17 O +
( O -
31 O -
% O -
) O +
having O +
urticaria B-Disease +
and/or O +
angioedema B-Disease -
. O +

All O +
the O +
patients O +
were O +
skin O +
test O +
negative O +
to O +
BPO O -
; O +
49 O +
of O +
51 O +
( O -
96 O -
% O -
) O +
were O +
also O +
negative O +
to O +
MDM B-Disease -
, O +
and O +
44 O +
of O +
46 O +
( O -
96 O -
% O -
) O +
to O +
PG O -
. O +

Skin O +
tests O +
with O +
AX O +
were O +
positive O +
in O +
34 O +
( O -
63 O -
% O -
) O +
patients O -
. O +

RAST O +
was O +
positive O +
for O +
AX O +
in O +
22 O +
patients O +
( O -
41 O -
% O -
) O +
and O +
to O +
BPO O +
in O +
just O +
5 O +
( O -
9 O -
% O -
) O -
. O +

None O +
of O +
the O +
sera O +
with O +
negative O +
RAST O +
for O +
AX O +
were O +
positive O +
to O +
BPO O -
. O +

Challenge O +
tests O +
with O +
AX O +
were O +
performed O +
in O +
23 O +
subjects O +
( O -
43 O -
% O -
) O +
to O +
establish O +
the O +
diagnosis O +
of O +
immediate O +
allergic B-Disease +
reaction I-Disease +
to O +
AX O -
, O +
and O +
in O +
15 O +
cases O +
( O -
28 O -
% O -
) O +
both O +
skin O +
test O +
and O +
RAST O +
for O +
AX O +
were O +
negative O -
. O +

PG O +
was O +
well O +
tolerated O +
by O +
all O +
54 O +
patients O -
. O +

We O +
describe O +
the O +
largest O +
group O +
of O +
AX O -
- O -
allergic B-Disease +
patients O +
who O +
have O +
tolerated O +
PG O +
reported O +
so O +
far O -
. O +

Diagnosis O +
of O +
these O +
patients O +
can O +
be O +
achieved O +
only O +
if O +
specific O +
AX O -
- O -
related O +
reagents O +
are O +
employed O -
. O +

Further O +
studies O +
are O +
necessary O +
to O +
determine O +
the O +
exact O +
extent O +
of O +
this O +
problem O +
and O +
to O +
improve O +
the O +
efficacy O +
of O +
diagnostic O +
methods O -
. O +

Reversal O +
by O +
phenylephrine O +
of O +
the O +
beneficial O +
effects O +
of O +
intravenous O +
nitroglycerin O +
in O +
patients O +
with O +
acute B-Disease +
myocardial I-Disease +
infarction I-Disease -
. O +

Nitroglycerin O +
has O +
been O +
shown O +
to O +
reduce O +
ST O -
- O -
segment O +
elevation O +
during O +
acute B-Disease +
myocardial I-Disease +
infarction I-Disease -
, O +
an O +
effect O +
potentiated O +
in O +
the O +
dog O +
by O +
agents O +
that O +
reverse O +
nitroglycerin O -
- O -
induced O +
hypotension B-Disease -
. O +

Our O +
study O +
was O +
designed O +
to O +
determine O +
the O +
effects O +
of O +
combined O +
nitroglycerin O +
and O +
phenylephrine O +
therapy O -
. O +

Ten O +
patients O +
with O +
acute O +
transmural O +
myocardial B-Disease +
infarctions I-Disease +
received O +
intravenous O +
nitroglycerin O -
, O +
sufficient O +
to O +
reduce O +
mean O +
arterial O +
pressure O +
from O +
107 O +
+ O -
/- O +

6 O +
to O +
85 O +
+ O -
/- O +

6 O +
mm O +
Hg O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
, O +
for O +
60 O +
minutes O -
. O +

Left O +
ventricular O +
filling O +
pressure O +
decreased O +
from O +
19 O +
+ O -
/- O +

2 O +
to O +
11 O +
+ O -
/- O +

2 O +
mm O +
Hg O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
. O +

SigmaST O -
, O +
the O +
sum O +
of O +
ST O -
- O -
segment O +
elevations O +
in O +
16 O +
precordial O +
leads O -
, O +
decreased O +
( O -
P O +
less O +
than O +
0.02 O -
) O +
with O +
intravenous O +
nitroglycerin O -
. O +

Subsequent O +
addition O +
of O +
phenylephrine O +
infusion O -
, O +
sufficient O +
to O +
re O -
- O -
elevate O +
mean O +
arterial O +
pressure O +
to O +
106 O +
+ O -
/- O +

4 O +
mm O +
Hg O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
for O +
30 O +
minutes O -
, O +
increased O +
left O +
ventricular O +
filling O +
pressure O +
to O +
17 O +
+ O -
/- O +

2 O +
mm O +
Hg O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
and O +
also O +
significantly O +
increased O +
sigmaST O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

Our O +
results O +
suggest O +
that O +
addition O +
of O +
phenylephrine O +
to O +
nitroglycerin O +
is O +
not O +
beneficial O +
in O +
the O +
treatment O +
of O +
patients O +
with O +
acute B-Disease +
myocardial I-Disease +
infarction I-Disease -
. O +

Effect O +
of O +
nondopaminergic O +
drugs O +
on O +
L O -
- O -
dopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
MPTP O -
- O -
treated O +
monkeys O -
. O +

A O +
group O +
of O +
four O +
monkeys O +
was O +
rendered O +
parkinsonian B-Disease +
with O +
the O +
toxin O +
MPTP O -
. O +

They O +
were O +
then O +
treated O +
chronically O +
with O +
L O -
- O -
DOPA O -
/ O -
benserazide O +
50 O -
/ O -
12.5 O +
mg O -
/ O -
kg O +
given O +
orally O +
daily O +
for O +
2 O +
months O -
. O +

This O +
dose O +
produced O +
a O +
striking O +
antiparkinsonian O +
effect O -
, O +
but O +
all O +
animals O +
manifested O +
dyskinesia B-Disease -
. O +

A O +
series O +
of O +
agents O +
acting O +
primarily O +
on O +
neurotransmitters O +
other O +
than O +
dopamine O +
were O +
then O +
tested O +
in O +
combination O +
with O +
L O -
- O -
DOPA O +
to O +
see O +
if O +
the O +
dyskinetic B-Disease +
movements O +
would O +
be O +
modified O -
. O +

Several O +
drugs O -
, O +
including O +
clonidine O -
, O +
physostigmine O -
, O +
methysergide O -
, O +
5-MDOT O -
, O +
propranolol O -
, O +
and O +
MK-801 O -
, O +
markedly O +
reduced O +
the O +
dyskinetic B-Disease +
movements O +
but O +
at O +
the O +
cost O +
of O +
a O +
return O +
of O +
parkinsonian B-Disease +
symptomatology O -
. O +

However O -
, O +
yohimbine O +
and O +
meperidine O +
reduced O +
predominantly O +
the O +
dyskinetic B-Disease +
movements O -
. O +

Baclofen O +
was O +
also O +
useful O +
in O +
one O +
monkey O +
against O +
a O +
more O +
dystonic B-Disease +
form O +
of O +
dyskinesia B-Disease -
. O +

Atropine O +
converted O +
the O +
dystonic B-Disease +
movements O +
into O +
chorea B-Disease -
. O +

Hallucinations B-Disease +
and O +
ifosfamide O -
- O -
induced O +
neurotoxicity B-Disease -
. O +

BACKGROUND O -
: O +
Hallucinations B-Disease +
as O +
a O +
symptom O +
of O +
central O +
neurotoxicity B-Disease +
are O +
a O +
known O +
but O +
poorly O +
described O +
side O +
effect O +
of O +
ifosfamide O -
. O +

Most O +
cases O +
of O +
ifosfamide O -
- O -
induced O +
hallucinations B-Disease +
have O +
been O +
reported O +
with O +
other O +
mental O +
status O +
changes O -
. O +

METHODS O -
: O +
The O +
authors O +
interviewed O +
six O +
persons O +
with O +
ifosfamide O -
- O -
induced O +
hallucinations B-Disease +
in O +
the O +
presence O +
of O +
a O +
clear O +
sensorium O -
. O +

All O +
patients O +
were O +
receiving O +
high O -
- O -
dose O +
ifosfamide O +
as O +
part O +
of O +
their O +
bone O +
marrow O +
transplant O +
procedure O -
. O +

RESULTS O -
: O +
Hallucinations B-Disease +
occurred O +
only O +
when O +
the O +
patient O -
's O +
eyes O +
were O +
closed O +
and O -
, O +
in O +
all O +
but O +
one O +
case O -
, O +
were O +
reported O +
as O +
disturbing O +
or O +
frightening O -
. O +

Underreporting O +
of O +
these O +
hallucinations B-Disease +
by O +
patients O +
is O +
likely O -
. O +

CONCLUSIONS O -
: O +
Hallucinations B-Disease +
may O +
be O +
the O +
sole O +
or O +
first O +
manifestation O +
of O +
neurotoxicity B-Disease -
. O +

The O +
incidence O +
may O +
be O +
dose O +
and O +
infusion O -
- O -
time O +
related O -
. O +

The O +
clinician O +
should O +
be O +
alerted O +
for O +
possible O +
ifosfamide O -
- O -
induced O +
hallucinations B-Disease -
, O +
which O +
may O +
occur O +
without O +
other O +
signs O +
of O +
neurotoxicity B-Disease -
. O +

" O -
Eyes O -
- O -
closed O -
" O +
hallucinatory B-Disease +
experiences O +
appear O +
to O +
be O +
an O +
unusual O +
feature O +
of O +
this O +
presentation O -
. O +

Patients O +
anxious O +
about O +
this O +
experience O +
respond O +
well O +
to O +
support O +
and O +
education O +
about O +
this O +
occurrence O -
. O +

Optimal O +
pharmacologic O +
management O +
of O +
disturbed O +
patients O +
is O +
unclear O -
. O +

If O +
agitation B-Disease +
becomes O +
marked O -
, O +
high O -
- O -
potency O +
neuroleptics O +
( O -
i.e. O -
, O +
haloperidol O -
) O +
may O +
be O +
effective O -
. O +

Acetazolamide O -
- O -
induced O +
nephrolithiasis B-Disease -
: O +
implications O +
for O +
treatment O +
of O +
neuromuscular B-Disease +
disorders I-Disease -
. O +

Carbonic O +
anhydrase O +
inhibitors O +
can O +
cause O +
nephrolithiasis B-Disease -
. O +

We O +
studied O +
20 O +
patients O +
receiving O +
long O -
- O -
term O +
carbonic O +
anhydrase O +
inhibitor O +
treatment O +
for O +
periodic O +
paralysis B-Disease +
and O +
myotonia B-Disease -
. O +

Three O +
patients O +
on O +
acetazolamide O +
( O -
15 O -
% O -
) O +
developed O +
renal B-Disease +
calculi I-Disease -
. O +

Extracorporeal O +
lithotripsy O +
successfully O +
removed O +
a O +
renal B-Disease +
calculus I-Disease +
in O +
one O +
patient O +
and O +
surgery O +
removed O +
a O +
staghorn O +
calculus B-Disease +
in O +
another O -
, O +
permitting O +
continued O +
treatment O -
. O +

Renal O +
function O +
remained O +
normal O +
in O +
all O +
patients O -
. O +

Nephrolithiasis B-Disease +
is O +
a O +
complication O +
of O +
acetazolamide O +
but O +
does O +
not O +
preclude O +
its O +
use O -
. O +

Effects O +
of O +
calcium O +
channel O +
blockers O +
on O +
bupivacaine O -
- O -
induced O +
toxicity B-Disease -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
influence O +
of O +
calcium O +
channel O +
blockers O +
on O +
bupivacaine O -
- O -
induced O +
acute O +
toxicity B-Disease -
. O +

For O +
each O +
of O +
the O +
three O +
tested O +
calcium O +
channel O +
blockers O +
( O -
diltiazem O -
, O +
verapamil O +
and O +
bepridil O -
) O +
6 O +
groups O +
of O +
mice O +
were O +
treated O +
by O +
two O +
different O +
doses O -
, O +
i.e. O +
2 O +
and O +
10 O +
mg O -
/ O -
kg O -
/ O -
i.p O -
. O -
, O +
or O +
an O +
equal O +
volume O +
of O +
saline O +
for O +
the O +
control O +
group O +
( O -
n O +
= O +
20 O -
) O -
; O +
15 O +
minutes O +
later O -
, O +
all O +
the O +
animals O +
were O +
injected O +
with O +
a O +
single O +
50 O +
mg O -
/ O -
kg O -
/ O -
i.p O -
. O +

dose O +
of O +
bupivacaine O -
. O +

The O +
convulsant O +
activity O -
, O +
the O +
time O +
of O +
latency O +
to O +
convulse O +
and O +
the O +
mortality O +
rate O +
were O +
assessed O +
in O +
each O +
group O -
. O +

The O +
local O +
anesthetic O -
- O -
induced O +
mortality O +
was O +
significantly O +
increased O +
by O +
the O +
three O +
different O +
calcium O +
channel O +
blockers O -
. O +

The O +
convulsant O +
activity O +
of O +
bupivacaine O +
was O +
not O +
significantly O +
modified O +
but O +
calcium O +
channel O +
blockers O +
decreased O +
the O +
time O +
of O +
latency O +
to O +
obtain O +
bupivacaine O -
- O -
induced O +
convulsions B-Disease -
; O +
this O +
effect O +
was O +
less O +
pronounced O +
with O +
bepridil O -
. O +

Photodistributed O +
nifedipine O -
- O -
induced O +
facial O +
telangiectasia B-Disease -
. O +

Five O +
months O +
after O +
starting O +
nifedipine O +
( O -
Adalat O -
) O -
, O +
two O +
patients O +
developed O +
photodistributed O +
facial O +
telangiectasia B-Disease -
, O +
which O +
became O +
more O +
noticeable O +
with O +
time O -
. O +

Neither O +
patient O +
complained O +
of O +
photosensitivity O +
or O +
flushing B-Disease -
. O +

Both O +
patients O +
reported O +
a O +
significant O +
cosmetic O +
improvement O +
after O +
discontinuing O +
the O +
drug O -
. O +

One O +
commenced O +
the O +
closely O +
related O +
drug O +
amlodipine O +
3 O +
years O +
later O -
, O +
with O +
recurrence O +
of O +
telangiectasia B-Disease -
. O +

The O +
photodistribution O +
of O +
the O +
telangiectasia B-Disease +
suggests O +
a O +
significant O +
drug O -
/ O -
light O +
interaction O -
. O +

Penicillamine O -
- O -
induced O +
rapidly O +
progressive O +
glomerulonephritis B-Disease +
in O +
a O +
patient O +
with O +
rheumatoid B-Disease +
arthritis I-Disease -
. O +

A O +
67-year O -
- O -
old O +
woman O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
presented O +
rapidly O +
progressive O +
glomerulonephritis B-Disease +
( O -
RPGN B-Disease -
) O +
after O +
5 O +
months O +
of O +
D O -
- O -
penicillamine O +
( O -
250 O +
mg O -
/ O -
day O -
) O +
treatment O -
. O +

Light O +
microscopy O +
study O +
showed O +
severe O +
glomerulonephritis B-Disease +
with O +
crescent O +
formation O +
in O +
60 O -
% O +
of O +
the O +
glomeruli O +
and O +
infiltration O +
of O +
inflammatory O +
cells O +
in O +
the O +
wall O +
of O +
an O +
arteriole O -
. O +

Immunofluorescence O +
revealed O +
scanty O +
granular O +
IgG O -
, O +
IgA O +
and O +
C3 O +
deposits O +
along O +
the O +
capillary O +
walls O +
and O +
mesangium O -
. O +

The O +
patient O +
was O +
treated O +
with O +
steroid O +
pulse O -
, O +
plasmapheresis O -
, O +
cyclophosphamide O +
and O +
antiplatelet O +
agents O -
. O +

A O +
complete O +
recovery O +
of O +
renal O +
function O +
was O +
achieved O +
in O +
a O +
few O +
weeks O -
. O +

This O +
new O +
case O +
of O +
RPGN B-Disease +
in O +
the O +
course O +
of O +
D O -
- O -
penicillamine O +
treatment O +
emphasizes O +
the O +
need O +
for O +
frequent O +
monitoring O +
of O +
renal O +
function O +
and O +
evaluation O +
of O +
urinary O +
sediment O +
and O +
proteinuria B-Disease +
in O +
these O +
patients O -
. O +

The O +
prompt O +
discontinuation O +
of O +
D O -
- O -
penicillamine O +
and O +
vigorous O +
treatment O +
measures O +
could O +
allow O +
for O +
a O +
good O +
prognosis O +
as O +
in O +
this O +
case O -
. O +

A O +
case O +
of O +
polymyositis B-Disease +
in O +
a O +
patient O +
with O +
primary B-Disease +
biliary I-Disease +
cirrhosis I-Disease +
treated O +
with O +
D O -
- O -
penicillamine O -
. O +

Although O +
D O -
- O -
penicillamine O +
has O +
been O +
used O +
for O +
many O +
rheumatologic B-Disease +
diseases I-Disease -
, O +
toxicity B-Disease +
limits O +
its O +
usefulness O +
in O +
many O +
patients O -
. O +

Polymyositis B-Disease -
/ O -
dermatomyositis B-Disease +
can O +
develop O +
as O +
one O +
of O +
the O +
autoimmune O +
complications O +
of O +
D O -
- O -
penicillamine O +
treatment O -
, O +
but O +
its O +
exact O +
pathogenesis O +
remains O +
unclear O -
. O +

We O +
report O +
a O +
patient O +
with O +
primary B-Disease +
biliary I-Disease +
cirrhosis I-Disease -
, O +
who O +
developed O +
polymyositis B-Disease +
while O +
receiving O +
D O -
- O -
penicillamine O +
therapy O -
. O +

We O +
described O +
the O +
special O +
clinical O +
course O +
of O +
the O +
patient O -
. O +

Patients O +
receiving O +
D O -
- O -
penicillamine O +
therapy O +
should O +
be O +
followed O +
carefully O +
for O +
the O +
development O +
of O +
autoimmune O +
complications O +
like O +
polymyositis B-Disease -
/ O -
dermatomyositis B-Disease -
. O +

Epidural O +
blood O +
flow O +
during O +
prostaglandin O +
E1 O +
or O +
trimethaphan O +
induced O +
hypotension B-Disease -
. O +

To O +
evaluate O +
the O +
effect O +
of O +
prostaglandin O +
E1 O +
( O -
PGE1 O -
) O +
or O +
trimethaphan O +
( O -
TMP O -
) O +
induced O +
hypotension B-Disease +
on O +
epidural O +
blood O +
flow O +
( O -
EBF O -
) O +
during O +
spinal O +
surgery O -
, O +
EBF O +
was O +
measured O +
using O +
the O +
heat O +
clearance O +
method O +
in O +
30 O +
patients O +
who O +
underwent O +
postero O -
- O -
lateral O +
interbody O +
fusion O +
under O +
isoflurane O +
anaesthesia O -
. O +

An O +
initial O +
dose O +
of O +
0.1 O +
microgram.kg-1.min-1 O +
of O +
PGE1 O +
( O -
15 O +
patients O -
) O -
, O +
or O +
10 O +
micrograms.kg-1.min-1 O +
of O +
TMP O +
( O -
15 O +
patients O -
) O +
was O +
administered O +
intravenously O +
after O +
the O +
dural O +
opening O +
and O +
the O +
dose O +
was O +
adjusted O +
to O +
maintain O +
the O +
mean O +
arterial O +
blood O +
pressure O +
( O -
MAP O -
) O +
at O +
about O +
60 O +
mmHg O -
. O +

The O +
hypotensive B-Disease +
drug O +
was O +
discontinued O +
at O +
the O +
completion O +
of O +
the O +
operative O +
procedure O -
. O +

After O +
starting O +
PGE1 O +
or O +
TMP O -
, O +
MAP O +
and O +
rate O +
pressure O +
product O +
( O -
RPP O -
) O +
decreased O +
significantly O +
compared O +
with O +
preinfusion O +
values O +
( O -
P O +
< O +
0.01 O -
) O -
, O +
and O +
the O +
degree O +
of O +
hypotension B-Disease +
due O +
to O +
PGE1 O +
remained O +
constant O +
until O +
60 O +
min O +
after O +
its O +
discontinuation O -
. O +

Heart O +
rate O +
( O -
HR O -
) O +
did O +
not O +
change O +
in O +
either O +
group O -
. O +

EBFF O +
did O +
not O +
change O +
during O +
PGE1 O +
infusion O +
whereas O +
in O +
the O +
TMP O +
group O -
, O +
EBF O +
decreased O +
significantly O +
at O +
30 O +
and O +
60 O +
min O +
after O +
the O +
start O +
of O +
TMP O +
( O -
preinfusion O -
: O +
45.9 O +
+ O -
/- O +

13.9 O +
ml O -
/ O -
100g O -
/ O -
min O -
. O +

30 O +
min O -
: O +
32.3 O +
+ O -
/- O +

9.9 O +
ml O -
/ O -
100 O +
g O -
/ O -
min O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

60 O +
min O -
: O +
30 O +
+ O -
/- O +

7.5 O +
ml O -
/ O -
100 O +
g O -
/ O -
min O +
( O -
P O +
< O +
0.05 O -
) O -
) O -
. O +

These O +
results O +
suggest O +
that O +
PGE1 O +
may O +
be O +
preferable O +
to O +
TMP O +
for O +
hypotensive B-Disease +
anaesthesia O +
in O +
spinal O +
surgery O +
because O +
TMP O +
decreased O +
EBF O -
. O +

Liposomal O +
daunorubicin O +
in O +
advanced O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease -
: O +
a O +
phase O +
II O +
study O -
. O +

We O +
report O +
a O +
non O -
- O -
randomized O +
Phase O +
II O +
clinical O +
trial O +
to O +
assess O +
the O +
efficacy O +
and O +
safety O +
of O +
liposomal O +
daunorubicin O +
( O -
DaunoXome O -
) O +
in O +
the O +
treatment O +
of O +
AIDS B-Disease +
related O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease -
. O +

Eleven O +
homosexual O +
men O +
with O +
advanced O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease +
were O +
entered O +
in O +
the O +
trial O -
. O +

Changes O +
in O +
size O -
, O +
colour O +
and O +
associated O +
oedema B-Disease +
of O +
selected O +
' O -
target O -
' O +
lesions O +
were O +
measured O -
. O +

Clinical O -
, O +
biochemical O +
and O +
haematological O +
toxicities B-Disease +
were O +
assessed O -
. O +

Ten O +
subjects O +
were O +
evaluated O -
. O +

A O +
partial O +
response O +
was O +
achieved O +
in O +
four O -
, O +
of O +
whom O +
two O +
subsequently O +
relapsed O -
. O +

Stabilization O +
of O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease +
occurred O +
in O +
the O +
remaining O +
six O -
, O +
maintained O +
until O +
the O +
end O +
of O +
the O +
trial O +
period O +
in O +
four O -
. O +

The O +
drug O +
was O +
generally O +
well O +
tolerated O -
, O +
with O +
few O +
mild O +
symptoms O +
of O +
toxicity B-Disease -
. O +

The O +
main O +
problem O +
encountered O +
was O +
haematological O +
toxicity B-Disease -
, O +
with O +
three O +
subjects O +
experiencing O +
severe O +
neutropenia B-Disease +
( O -
neutrophil O +
count O +
< O +
0.5 O +
x O +
10 O -
( O -
9 O -
) O -
/ O -
l O -
) O -
. O +

There O +
was O +
no O +
evidence O +
of O +
cardiotoxicity B-Disease -
. O +

In O +
this O +
small O +
patient O +
sample O -
, O +
liposomal O +
daunorubicin O +
was O +
an O +
effective O +
and O +
well O +
tolerated O +
agent O +
in O +
the O +
treatment O +
of O +
Kaposi B-Disease -
's I-Disease +
sarcoma I-Disease -
. O +

Dup O +
753 O +
prevents O +
the O +
development O +
of O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrosis B-Disease -
. O +

The O +
appearance O +
of O +
nephrotic B-Disease +
syndromes I-Disease +
such O +
as O +
proteinuria B-Disease -
, O +
hypoalbuminemia B-Disease -
, O +
hypercholesterolemia B-Disease +
and O +
increase O +
in O +
blood O +
nitrogen O +
urea O -
, O +
induced O +
in O +
rats O +
by O +
injection O +
of O +
puromycin O +
aminonucleoside O +
was O +
markedly O +
inhibited O +
by O +
oral O +
administration O +
of O +
Dup O +
753 O +
( O -
losartan O -
) O -
, O +
a O +
novel O +
angiotensin O +
II O +
receptor O +
antagonist O -
, O +
at O +
a O +
dose O +
of O +
1 O +
or O +
2 O +
mg O -
/ O -
kg O +
per O +
day O -
. O +

The O +
results O +
suggest O +
a O +
possible O +
involvement O +
of O +
the O +
renin O -
- O -
angiotensin O +
system O +
in O +
the O +
development O +
of O +
puromycin O +
aminonucleoside O -
- O -
induced O +
nephrosis B-Disease -
. O +

Neuroplasticity O +
of O +
the O +
adult O +
primate O +
auditory O +
cortex O +
following O +
cochlear O +
hearing B-Disease +
loss I-Disease -
. O +

Tonotopic O +
organization O +
is O +
an O +
essential O +
feature O +
of O +
the O +
primary O +
auditory O +
area O +
( O -
A1 O -
) O +
of O +
primate O +
cortex O -
. O +

In O +
A1 O +
of O +
macaque O +
monkeys O -
, O +
low O +
frequencies O +
are O +
represented O +
rostrolaterally O +
and O +
high O +
frequencies O +
are O +
represented O +
caudomedially O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
if O +
changes O +
occur O +
in O +
this O +
tonotopic O +
organization O +
following O +
cochlear O +
hearing B-Disease +
loss I-Disease -
. O +

Under O +
anesthesia O -
, O +
the O +
superior O +
temporal O +
gyrus O +
of O +
adult O +
macaque O +
monkeys O +
was O +
exposed O -
, O +
and O +
the O +
tonotopic O +
organization O +
of O +
A1 O +
was O +
mapped O +
using O +
conventional O +
microelectrode O +
recording O +
techniques O -
. O +

Following O +
recovery O -
, O +
the O +
monkeys O +
were O +
selectively O +
deafened O +
for O +
high O +
frequencies O +
using O +
kanamycin O +
and O +
furosemide O -
. O +

The O +
actual O +
frequencies O +
deafened O +
were O +
determined O +
by O +
the O +
loss O +
of O +
tone O -
- O -
burst O +
elicited O +
auditory O +
brainstem O +
responses O -
. O +

Three O +
months O +
after O +
deafening O -
, O +
A1 O +
was O +
remapped O -
. O +

Postmortem O +
cytoarchitectural O +
features O +
identifying O +
A1 O +
were O +
correlated O +
with O +
the O +
electrophysiologic O +
data O -
. O +

The O +
results O +
indicate O +
that O +
the O +
deprived O +
area O +
of O +
A1 O +
undergoes O +
extensive O +
reorganization O +
and O +
becomes O +
responsive O +
to O +
intact O +
cochlear O +
frequencies O -
. O +

The O +
region O +
of O +
cortex O +
that O +
represents O +
the O +
low O +
frequencies O +
was O +
not O +
obviously O +
affected O +
by O +
the O +
cochlear O +
hearing B-Disease +
loss I-Disease -
. O +

Long O -
- O -
term O +
effects O +
of O +
vincristine O +
on O +
the O +
peripheral O +
nervous O +
system O -
. O +

Forty O +
patients O +
with O +
Non B-Disease -
- I-Disease -
Hodgkin I-Disease -
's I-Disease +
Lymphoma I-Disease +
treated O +
with O +
vincristine O +
between O +
1984 O +
and O +
1990 O +
( O -
cumulative O +
dose O +
12 O +
mg O +
in O +
18 O -
- O -
24 O +
weeks O -
) O +
were O +
investigated O +
in O +
order O +
to O +
evaluate O +
the O +
long O +
term O +
effects O +
of O +
vincristine O +
on O +
the O +
peripheral O +
nervous O +
system O -
. O +

The O +
patients O +
were O +
interviewed O +
with O +
emphasis O +
on O +
neuropathic B-Disease +
symptoms I-Disease -
. O +

Physical O +
and O +
quantitative O +
sensory O +
examination O +
with O +
determination O +
of O +
vibratory O +
perception O +
and O +
thermal O +
discrimination O +
thresholds O +
were O +
performed O -
, O +
four O +
to O +
77 O +
months O +
( O -
median O +
34 O +
months O -
) O +
after O +
vincristine O +
treatment O -
. O +

Twenty O -
- O -
seven O +
patients O +
reported O +
neuropathic B-Disease +
symptoms I-Disease -
. O +

In O +
13 O +
of O +
these O +
27 O +
patients O +
symptoms O +
were O +
still O +
present O +
at O +
the O +
time O +
of O +
examination O -
. O +

In O +
these O +
patients O +
sensory O +
signs O +
and O +
symptoms O +
predominated O -
. O +

In O +
the O +
other O +
14 O +
patients O +
symptoms O +
had O +
been O +
present O +
in O +
the O +
past O -
. O +

Symptoms O +
persisted O +
maximally O +
40 O +
months O +
since O +
cessation O +
of O +
therapy O -
. O +

There O +
was O +
no O +
age O +
difference O +
between O +
patients O +
with O +
and O +
without O +
complaints O +
at O +
the O +
time O +
of O +
examination O -
. O +

Normal O +
reflexes O +
were O +
found O +
in O +
two O +
third O +
of O +
patients O -
. O +

Neuropathic O +
complaints O +
were O +
not O +
very O +
troublesome O +
on O +
the O +
long O +
term O -
. O +

It O +
is O +
concluded O +
that O +
with O +
the O +
above O +
mentioned O +
vincristine O +
dose O +
schedule O +
signs O +
and O +
symptoms O +
of O +
vincristine O +
neuropathy B-Disease +
are O +
reversible O +
for O +
a O +
great O +
deal O +
and O +
prognosis O +
is O +
fairly O +
good O -
. O +

Sodium O +
bicarbonate O +
alleviates O +
penile B-Disease +
pain I-Disease +
induced O +
by O +
intracavernous O +
injections O +
for O +
erectile B-Disease +
dysfunction I-Disease -
. O +

In O +
an O +
attempt O +
to O +
determine O +
whether O +
penile B-Disease +
pain I-Disease +
associated O +
with O +
intracorporeal O +
injections O +
could O +
be O +
due O +
to O +
the O +
acidity O +
of O +
the O +
medication O -
, O +
we O +
performed O +
a O +
randomized O +
study O +
comparing O +
the O +
incidence O +
of O +
penile B-Disease +
pain I-Disease +
following O +
intracorporeal O +
injections O +
with O +
or O +
without O +
the O +
addition O +
of O +
sodium O +
bicarbonate O +
to O +
the O +
intracorporeal O +
medications O -
. O +

A O +
total O +
of O +
38 O +
consecutive O +
patients O +
who O +
presented O +
to O +
our O +
clinic O +
with O +
impotence B-Disease +
received O +
0.2 O +
ml O -
. O +

of O +
a O +
combination O +
of O +
3 O +
drugs O -
: O +
6 O +
mg O -
. O +

papaverine O -
, O +
100 O +
micrograms O -
. O +

phentolamine O +
and O +
10 O +
micrograms O -
. O +

prostaglandin O +
E1 O +
with O +
( O -
pH O +
7.05 O -
) O +
or O +
without O +
( O -
pH O +
4.17 O -
) O +
the O +
addition O +
of O +
sodium O +
bicarbonate O +
( O -
0.03 O +
mEq O -
. O -
) O -
. O +

Of O +
the O +
19 O +
patients O +
without O +
sodium O +
bicarbonate O +
added O +
to O +
the O +
medication O +
11 O +
( O -
58 O -
% O -
) O +
complained O +
of O +
penile B-Disease +
pain I-Disease +
due O +
to O +
the O +
medication O -
, O +
while O +
only O +
1 O +
of O +
the O +
19 O +
men O +
( O -
5 O -
% O -
) O +
who O +
received O +
sodium O +
bicarbonate O +
complained O +
of O +
penile B-Disease +
pain I-Disease -
. O +

From O +
these O +
data O +
we O +
conclude O +
that O +
the O +
penile B-Disease +
pain I-Disease +
following O +
intracorporeal O +
injections O +
is O +
most O +
likely O +
due O +
to O +
the O +
acidity O +
of O +
the O +
medication O -
, O +
which O +
can O +
be O +
overcome O +
by O +
elevating O +
the O +
pH O +
to O +
a O +
neutral O +
level O -
. O +

The O +
use O +
and O +
toxicity B-Disease +
of O +
didanosine O +
( O -
ddI O -
) O +
in O +
HIV B-Disease +
antibody I-Disease -
- I-Disease -
positive I-Disease +
individuals O +
intolerant O +
to O +
zidovudine O +
( O -
AZT O -
) O +
One O +
hundred O +
and O +
fifty O -
- O -
one O +
patients O +
intolerant O +
to O +
zidovudine O +
( O -
AZT O -
) O +
received O +
didanosine O +
( O -
ddI O -
) O +
to O +
a O +
maximum O +
dose O +
of O +
12.5 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Patient O +
response O +
was O +
assessed O +
using O +
changes O +
in O +
CD4 O -
+ O +
lymphocyte O +
subset O +
count O -
, O +
HIV O +
p24 O +
antigen O -
, O +
weight O -
, O +
and O +
quality O +
of O +
life O -
. O +

Seventy O +
patients O +
developed O +
major O +
opportunistic B-Disease +
infections I-Disease +
whilst O +
on O +
therapy O -
; O +
this O +
was O +
the O +
first O +
AIDS B-Disease +
diagnosis O +
in O +
17 O -
. O +

Only O +
minor O +
changes O +
in O +
CD4 O -
+ O +
lymphocyte O +
subset O +
count O +
were O +
observed O +
in O +
AIDS B-Disease +
patients O -
, O +
although O +
a O +
more O +
significant O +
rise O +
occurred O +
in O +
those O +
with O +
earlier O +
stages O +
of O +
disease O -
. O +

Of O +
those O +
positive O +
for O +
p24 O +
antigen O +
at O +
the O +
commencement O +
of O +
the O +
study O +
67 O -
% O +
showed O +
a O +
positive O +
response O -
, O +
and O +
this O +
was O +
most O +
likely O +
in O +
those O +
with O +
CD4 O -
+ O +
lymphocyte O +
subset O +
counts O +
above O +
100 O +
mm3 O -
. O +

A O +
positive O +
weight O +
response O +
was O +
seen O +
in O +
16 O -
% O +
of O +
patients O -
. O +

Most O +
patients O +
showed O +
improvement O +
in O +
individual O +
parameters O +
and O +
global O +
score O +
of O +
quality O +
of O +
life O -
. O +

Adverse O +
reactions O +
possibly O +
attributable O +
to O +
didanosine O +
were O +
common O -
. O +

The O +
most O +
common O +
side O -
- O -
effect O +
was O +
diarrhoea B-Disease -
, O +
which O +
resulted O +
in O +
cessation O +
of O +
therapy O +
in O +
19 O +
individuals O -
. O +

Peripheral B-Disease +
neuropathy I-Disease +
occurred O +
in O +
12 O +
patients O +
and O +
pancreatitis B-Disease +
in O +
six O -
. O +

Thirteen O +
patients O +
developed O +
a O +
raised O +
serum O +
amylase O +
without O +
abdominal B-Disease +
pain I-Disease -
. O +

Seven O +
patients O +
developed O +
glucose B-Disease +
tolerance I-Disease +
curves I-Disease +
characteristic O +
of O +
diabetes B-Disease +
but O +
these O +
were O +
mild O -
, O +
did O +
not O +
require O +
treatment O +
and O +
returned O +
to O +
normal O +
on O +
ceasing O +
didanosine O -
. O +

Hepatic O +
adenomas B-Disease +
and O +
focal B-Disease +
nodular I-Disease +
hyperplasia I-Disease +
of O +
the O +
liver O +
in O +
young O +
women O +
on O +
oral O +
contraceptives O -
: O +
case O +
reports O -
. O +

Two O +
cases O +
of O +
hepatic O +
adenoma B-Disease +
and O +
one O +
of O +
focal B-Disease +
nodular I-Disease +
hyperplasia I-Disease +
presumably O +
associated O +
with O +
the O +
use O +
of O +
oral O +
contraceptives O -
, O +
are O +
reported O -
. O +

Special O +
reference O +
is O +
made O +
to O +
their O +
clinical O +
presentation O -
, O +
which O +
may O +
be O +
totally O +
asymptomatic O -
. O +

Liver O -
- O -
function O +
tests O +
are O +
of O +
little O +
diagnostic O +
value O -
, O +
but O +
valuable O +
information O +
may O +
be O +
obtained O +
from O +
both O +
liver O +
scanning O +
and O +
hepatic O +
angiography O -
. O +

Histologic O +
differences O +
and O +
clinical O +
similarities O +
between O +
hepatic O +
adenoma B-Disease +
and O +
focal B-Disease +
nodular I-Disease +
hyperplasia I-Disease +
of O +
the O +
liver O +
are O +
discussed O -
. O +

Immunohistochemical O +
studies O +
with O +
antibodies O +
to O +
neurofilament O +
proteins O +
on O +
axonal B-Disease +
damage I-Disease +
in O +
experimental O +
focal O +
lesions O +
in O +
rat O -
. O +

Immunohistochemistry O +
with O +
monoclonal O +
antibodies O +
against O +
neurofilament O +
( O -
NF O -
) O +
proteins O +
of O +
middle O +
and O +
high O +
molecular O +
weight O +
class O -
, O +
NF O -
- O -
M O +
and O +
NF O -
- O -
H O -
, O +
was O +
used O +
to O +
study O +
axonal B-Disease +
injury I-Disease +
in O +
the O +
borderzone O +
of O +
focal O +
lesions O +
in O +
rats O -
. O +

Focal O +
injury B-Disease +
in I-Disease +
the I-Disease +
cortex I-Disease +
was O +
produced O +
by O +
infusion O +
of O +
lactate O +
at O +
acid O +
pH O +
or O +
by O +
stab O +
caused O +
by O +
needle O +
insertion O -
. O +

Infarcts B-Disease +
in I-Disease +
substantia I-Disease +
nigra I-Disease +
pars I-Disease +
reticulata I-Disease +
were O +
evoked O +
by O +
prolonged O +
pilocarpine O -
- O -
induced O +
status B-Disease +
epilepticus I-Disease -
. O +

Immunohistochemical O +
staining O +
for O +
NFs O +
showed O +
characteristic O +
terminal O +
clubs O +
of O +
axons O +
in O +
the O +
borderzone O +
of O +
lesions O -
. O +

Differences O +
in O +
the O +
labelling O +
pattern O +
occurred O +
with O +
different O +
antibodies O +
which O +
apparently O +
depended O +
on O +
molecular O +
weight O +
class O +
of O +
NFs O +
and O +
phosphorylation O +
state O -
. O +

These O +
immunohistochemical O +
changes O +
of O +
NFs O +
can O +
serve O +
as O +
a O +
marker O +
for O +
axonal B-Disease +
damage I-Disease +
in O +
various O +
experimental O +
traumatic B-Disease +
or O +
ischemic O +
lesions O -
. O +

Loss O +
of O +
glutamate O +
decarboxylase O +
mRNA O -
- O -
containing O +
neurons O +
in O +
the O +
rat O +
dentate O +
gyrus O +
following O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
. O +

In O +
situ O +
hybridization O +
methods O +
were O +
used O +
to O +
determine O +
if O +
glutamic O +
acid O +
decarboxylase O +
( O -
GAD O -
) O +
mRNA O -
- O -
containing O +
neurons O +
within O +
the O +
hilus O +
of O +
the O +
dentate O +
gyrus O +
are O +
vulnerable O +
to O +
seizure B-Disease -
- O -
induced O +
damage O +
in O +
a O +
model O +
of O +
chronic O +
seizures B-Disease -
. O +

Sprague O -
- O -
Dawley O +
rats O +
were O +
injected O +
intraperitoneally O +
with O +
pilocarpine O -
, O +
and O +
the O +
hippocampal O +
formation O +
was O +
studied O +
histologically O +
at O +
1 O -
, O +
2 O -
, O +
4 O -
, O +
and O +
8 O +
week O +
intervals O +
after O +
pilocarpine O -
- O -
induced O +
seizures B-Disease -
. O +

In O +
situ O +
hybridization O +
histochemistry O -
, O +
using O +
a O +
digoxigenin O -
- O -
labeled O +
GAD O +
cRNA O +
probe O -
, O +
demonstrated O +
a O +
substantial O +
decrease O +
in O +
the O +
number O +
of O +
GAD O +
mRNA O -
- O -
containing O +
neurons O +
in O +
the O +
hilus O +
of O +
the O +
dentate O +
gyrus O +
in O +
the O +
pilocarpine O -
- O -
treated O +
rats O +
as O +
compared O +
to O +
controls O +
at O +
all O +
time O +
intervals O -
. O +

Additional O +
neuronanatomical O +
studies O -
, O +
including O +
cresyl O +
violet O +
staining O -
, O +
neuronal B-Disease +
degeneration I-Disease +
methods O -
, O +
and O +
histochemical O +
localization O +
of O +
glial O +
fibrillary O +
acidic O +
protein O -
, O +
suggested O +
that O +
the O +
decrease O +
in O +
the O +
number O +
of O +
GAD O +
mRNA O -
- O -
containing O +
neurons O +
was O +
related O +
to O +
neuronal B-Disease +
loss I-Disease +
rather O +
than O +
to O +
a O +
decrease O +
in O +
GAD O +
mRNA O +
levels O -
. O +

The O +
loss O +
of O +
GAD O +
mRNA O -
- O -
containing O +
neurons O +
in O +
the O +
hilus O +
contrasted O +
with O +
the O +
relative O +
preservation O +
of O +
labeled O +
putative O +
basket O +
cells O +
along O +
the O +
inner O +
margin O +
of O +
the O +
granule O +
cell O +
layer O -
. O +

Quantitative O +
analyses O +
of O +
labeled O +
neurons O +
in O +
three O +
regions O +
of O +
the O +
dentate O +
gyrus O +
in O +
the O +
1 O +
and O +
2 O +
week O +
groups O +
showed O +
statistically O +
significant O +
decreases O +
in O +
the O +
mean O +
number O +
of O +
GAD O +
mRNA O -
- O -
containing O +
neurons O +
in O +
the O +
hilus O +
of O +
both O +
groups O +
of O +
experimental O +
animals O -
. O +

No O +
significant O +
differences O +
were O +
found O +
in O +
the O +
molecular O +
layer O +
or O +
the O +
granule O +
cell O +
layer O -
, O +
which O +
included O +
labeled O +
neurons O +
along O +
the O +
lower O +
margin O +
of O +
the O +
granule O +
cell O +
layer O -
. O +

The O +
results O +
indicate O +
that O -
, O +
in O +
this O +
model O -
, O +
a O +
subpopulation O +
of O +
GAD O +
mRNA O -
- O -
containing O +
neurons O +
within O +
the O +
dentate O +
gyrus O +
is O +
selectively O +
vulnerable O +
to O +
seizure B-Disease -
- O -
induced O +
damage O -
. O +

Such O +
differential O +
vulnerability O +
appears O +
to O +
be O +
another O +
indication O +
of O +
the O +
heterogeneity O +
of O +
GABA O +
neurons O -
. O +

Pharmacokinetic O +
and O +
clinical O +
studies O +
in O +
patients O +
with O +
cimetidine O -
- O -
associated O +
mental O +
confusion B-Disease -
. O +

15 O +
cases O +
of O +
cimetidine O -
- O -
associated O +
mental O +
confusion B-Disease +
have O +
been O +
reported O -
. O +

In O +
order O +
that O +
this O +
syndrome O +
might O +
be O +
investigated O +
changes O +
in O +
mental O +
status O +
( O -
M.S. O -
) O +
were O +
correlated O +
with O +
serum O +
concentrations O +
and O +
renal O +
and O +
hepatic O +
function O +
in O +
36 O +
patients O -
, O +
30 O +
patients O +
had O +
no O +
M.S. O +
change O +
on O +
cimetidine O +
and O +
6 O +
had O +
moderate O +
to O +
severe O +
changes O -
. O +

These O +
6 O +
patients O +
had O +
both O +
renal B-Disease +
and I-Disease +
liver I-Disease +
dysfunction I-Disease +
( O -
P O +
less O +
than O +
0.05 O -
) O -
, O +
as O +
well O +
as O +
cimetidine O +
trough O -
- O -
concentrations O +
of O +
more O +
than O +
1.25 O +
microgram O -
/ O -
ml O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

The O +
severity O +
of O +
M.S. O +
changes O +
increased O +
as O +
trough O -
- O -
concentrations O +
rose O -
, O +
5 O +
patients O +
had O +
lumbar O +
puncture O -
. O +

The O +
cerebrospinal O +
fluid O -
: O +
serum O +
ratio O +
of O +
cimetidine O +
concentrations O +
was O +
0.24:1 O +
and O +
indicates O +
that O +
cimetidine O +
passes O +
the O +
blood O -
- O -
brain O +
barrier O -
; O +
it O +
also O +
raises O +
the O +
possibility O +
that O +
M.S. O +
changes O +
are O +
due O +
to O +
blockade O +
of O +
histamine O +
H2-receptors O +
in O +
the O +
central O +
nervous O +
system O -
. O +

Patients O +
likely O +
to O +
have O +
both O +
raised O +
trough O -
- O -
concentrations O +
and O +
mental O +
confusion B-Disease +
are O +
those O +
with O +
both O +
severe O +
renal B-Disease +
and I-Disease +
hepatic I-Disease +
dysfunction I-Disease -
. O +

They O +
should O +
be O +
closely O +
observed O +
and O +
should O +
be O +
given O +
reduced O +
doses O +
of O +
cimetidine O -
. O +

Prospective O +
study O +
of O +
the O +
long O -
- O -
term O +
effects O +
of O +
somatostatin O +
analog O +
( O -
octreotide O -
) O +
on O +
gallbladder O +
function O +
and O +
gallstone B-Disease +
formation O +
in O +
Chinese O +
acromegalic B-Disease +
patients O -
. O +

This O +
article O +
reports O +
the O +
changes O +
in O +
gallbladder O +
function O +
examined O +
by O +
ultrasonography O +
in O +
20 O +
Chinese O +
patients O +
with O +
active O +
acromegaly B-Disease +
treated O +
with O +
sc O +
injection O +
of O +
the O +
somatostatin O +
analog O +
octreotide O +
in O +
dosages O +
of O +
300 O -
- O -
1500 O +
micrograms O -
/ O -
day O +
for O +
a O +
mean O +
of O +
24.2 O +
+ O -
/- O +

13.9 O +
months O -
. O +

During O +
treatment O +
with O +
octreotide O -
, O +
17 O +
patients O +
developed O +
sludge O -
, O +
10 O +
had O +
gallstones B-Disease -
, O +
and O +
1 O +
developed O +
acute B-Disease +
cholecystitis I-Disease +
requiring O +
surgery O -
. O +

In O +
all O +
of O +
7 O +
patients O +
examined O +
acutely O -
, O +
gallbladder O +
contractility O +
was O +
inhibited O +
after O +
a O +
single O +
100-micrograms O +
injection O -
. O +

In O +
8 O +
patients O +
followed O +
for O +
24 O +
weeks O -
, O +
gallbladder O +
contractility O +
remained O +
depressed B-Disease +
throughout O +
therapy O -
. O +

After O +
withdrawal O +
of O +
octreotide O +
in O +
10 O +
patients O +
without O +
gallstones B-Disease -
, O +
8 O +
patients O +
assessed O +
had O +
return O +
of O +
normal O +
gallbladder O +
contractility O +
within O +
1 O +
month O -
. O +

In O +
8 O +
of O +
the O +
remaining O +
10 O +
patients O +
who O +
developed O +
gallstones B-Disease +
during O +
treatment O -
, O +
gallbladder O +
contractility O +
normalized O +
in O +
5 O +
patients O +
( O -
3 O +
of O +
whom O +
has O +
disappearance O +
of O +
their O +
stones O +
within O +
3 O +
weeks O -
) O -
, O +
and O +
remained O +
depressed B-Disease +
in O +
3 O +
( O -
2 O +
of O +
whom O +
had O +
stones O +
present O +
at O +
6 O +
months O -
) O -
. O +

Our O +
results O +
suggest O +
that O +
the O +
suppression O +
of O +
gallbladder O +
contractility O +
is O +
the O +
cause O +
of O +
the O +
successive O +
formation O +
of O +
bile O +
sludge O -
, O +
gallstones B-Disease -
, O +
and O +
cholecystitis B-Disease +
during O +
octreotide O +
therapy O +
in O +
Chinese O +
acromegalic B-Disease +
patients O -
. O +

It O +
is O +
therefore O +
very O +
important O +
to O +
follow O +
the O +
changes O +
of O +
gallbladder O +
function O +
during O +
long O -
- O -
term O +
octreotide O +
therapy O +
of O +
acromegalic B-Disease +
patients O -
. O +

Increase O +
of O +
Parkinson B-Disease +
disability I-Disease +
after O +
fluoxetine O +
medication O -
. O +

Depression B-Disease +
is O +
a O +
major O +
clinical O +
feature O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

We O +
report O +
the O +
increased O +
amount O +
of O +
motor B-Disease +
disability I-Disease +
in O +
four O +
patients O +
with O +
idiopathic B-Disease +
Parkinson I-Disease -
's I-Disease +
disease I-Disease +
after O +
exposure O +
to O +
the O +
antidepressant O +
fluoxetine O -
. O +

The O +
possibility O +
of O +
a O +
clinically O +
relevant O +
dopamine O -
- O -
antagonistic O +
capacity O +
of O +
fluoxetine O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
patients O +
must O +
be O +
considered O -
. O +

Effects O +
of O +
deliberate O +
hypotension B-Disease +
induced O +
by O +
labetalol O +
with O +
isoflurane O +
on O +
neuropsychological O +
function O -
. O +

The O +
effect O +
of O +
deliberate O +
hypotension B-Disease +
on O +
brain O +
function O +
measured O +
by O +
neuropsychological O +
tests O +
was O +
studied O +
in O +
41 O +
adult O +
patients O -
. O +

Twenty O -
- O -
four O +
patients O +
were O +
anaesthetized O +
for O +
middle O -
- O -
ear O +
surgery O +
with O +
deliberate O +
hypotension B-Disease +
induced O +
by O +
labetalol O +
with O +
isoflurane O +
( O -
hypotensive B-Disease +
group O -
) O -
. O +

Seventeen O +
patients O +
without O +
hypotension B-Disease +
served O +
as O +
a O +
control O +
group O -
. O +

The O +
mean O +
arterial O +
pressure O +
was O +
77 O +
+ O -
/- O +

2 O +
mmHg O +
( O -
10.3 O +
+ O -
/- O +

0.3 O +
kPa O -
) O +
before O +
hypotension B-Disease +
and O +
50 O +
+ O -
/- O +

0 O +
mmHg O +
( O -
6.7 O +
+ O -
/- O +

0.0 O +
kPa O -
) O +
during O +
hypotension B-Disease +
in O +
the O +
hypotensive B-Disease +
group O -
, O +
and O +
86 O +
+ O -
/- O +

2 O +
mmHg O +
( O -
11.5 O +
+ O -
/- O +

0.3 O +
kPa O -
) O +
during O +
anaesthesia O +
in O +
the O +
control O +
group O -
. O +

The O +
following O +
psychological O +
tests O +
were O +
performed O -
: O +
four O +
subtests O +
of O +
the O +
Wechsler O +
Adult O +
Intelligence O +
Scale O +
( O -
similarities O -
, O +
digit O +
span O -
, O +
vocabulary O +
and O +
digit O +
symbol O -
) O -
, O +
Trail O -
- O -
Making O +
tests O +
A O +
and O +
B O -
, O +
Zung O +
tests O +
( O -
self O -
- O -
rating O +
anxiety B-Disease +
scale O +
and O +
self O -
- O -
rating O +
depression B-Disease +
scale O -
) O +
and O +
two O -
- O -
part O +
memory O +
test O +
battery O +
with O +
immediate O +
and O +
delayed O +
recall O -
. O +

The O +
tests O +
were O +
performed O +
preoperatively O +
and O +
2 O +
days O +
postoperatively O -
. O +

There O +
were O +
no O +
statistically O +
significant O +
differences O +
between O +
the O +
groups O +
in O +
any O +
of O +
the O +
tests O +
in O +
the O +
changes O +
from O +
preoperative O +
value O +
to O +
postoperative O +
value O -
. O +

The O +
results O +
indicate O +
that O +
hypotension B-Disease +
induced O +
by O +
labetalol O +
with O +
isoflurane O +
has O +
no O +
significant O +
harmful O +
effects O +
on O +
mental O +
functions O +
compared O +
to O +
normotensive O +
anaesthesia O -
. O +

Sinus B-Disease +
arrest I-Disease +
associated O +
with O +
continuous O -
- O -
infusion O +
cimetidine O -
. O +

The O +
administration O +
of O +
intermittent O +
intravenous O +
infusions O +
of O +
cimetidine O +
is O +
infrequently O +
associated O +
with O +
the O +
development O +
of O +
bradyarrhythmias B-Disease -
. O +

A O +
40-year O -
- O -
old O +
man O +
with O +
leukemia B-Disease +
and O +
no O +
history O +
of O +
cardiac B-Disease +
disease I-Disease +
developed O +
recurrent O -
, O +
brief O +
episodes O +
of O +
apparent O +
sinus B-Disease +
arrest I-Disease +
while O +
receiving O +
continuous O -
- O -
infusion O +
cimetidine O +
50 O +
mg O -
/ O -
hour O -
. O +

The O +
arrhythmias B-Disease +
were O +
temporally O +
related O +
to O +
cimetidine O +
administration O -
, O +
disappeared O +
after O +
dechallenge O -
, O +
and O +
did O +
not O +
recur O +
during O +
ranitidine O +
treatment O -
. O +

This O +
is O +
the O +
first O +
reported O +
case O +
of O +
sinus B-Disease +
arrest I-Disease +
associated O +
with O +
continuous O -
- O -
infusion O +
cimetidine O -
. O +

Apparent O +
cure O +
of O +
rheumatoid B-Disease +
arthritis I-Disease +
by O +
bone O +
marrow O +
transplantation O -
. O +

We O +
describe O +
the O +
induction O +
of O +
sustained O +
remissions O +
and O +
possible O +
cure O +
of O +
severe O +
erosive O +
rheumatoid B-Disease +
arthritis I-Disease +
( O -
RA B-Disease -
) O +
by O +
bone O +
marrow O +
transplantation O +
( O -
BMT O -
) O +
in O +
2 O +
patients O -
. O +

BMT O +
was O +
used O +
to O +
treat O +
severe O +
aplastic B-Disease +
anemia I-Disease +
which O +
was O +
caused O +
by O +
gold O +
in O +
one O +
case O +
and O +
D O -
- O -
penicillamine O +
in O +
the O +
other O -
. O +

In O +
the O +
8 O +
and O +
6 O +
years O +
since O +
the O +
transplants O +
( O -
representing O +
8 O +
and O +
4 O +
years O +
since O +
cessation O +
of O +
all O +
immunosuppressive O +
therapy O -
, O +
respectively O -
) O -
, O +
the O +
RA B-Disease +
in O +
each O +
case O +
has O +
been O +
completely O +
quiescent O -
. O +

Although O +
short O +
term O +
remission O +
of O +
severe O +
RA B-Disease +
following O +
BMT O +
has O +
been O +
reported O -
, O +
these O +
are O +
the O +
first O +
cases O +
for O +
which O +
prolonged O +
followup O +
has O +
been O +
available O -
. O +

This O +
experience O +
raises O +
the O +
question O +
of O +
the O +
role O +
of O +
BMT O +
itself O +
as O +
a O +
therapeutic O +
option O +
for O +
patients O +
with O +
uncontrolled O +
destructive O +
synovitis B-Disease -
. O +

Seizures B-Disease +
induced O +
by O +
combined O +
levomepromazine O -
- O -
fluvoxamine O +
treatment O -
. O +

We O +
report O +
a O +
case O +
of O +
combined O +
levomepromazine O -
- O -
fluvoxamine O +
treatment O -
- O -
induced O +
seizures B-Disease -
. O +

It O +
seems O +
that O +
combined O +
treatment O +
of O +
fluvoxamine O +
with O +
phenothiazines O +
may O +
possess O +
proconvulsive O +
activity O -
. O +

Tetany B-Disease +
and O +
rhabdomyolysis B-Disease +
due O +
to O +
surreptitious O +
furosemide O -
-- O -
importance O +
of O +
magnesium O +
supplementation O -
. O +

Diuretics O +
may O +
induce O +
hypokalemia B-Disease -
, O +
hypocalcemia B-Disease +
and O +
hypomagnesemia B-Disease -
. O +

While O +
severe O +
hypokalemia B-Disease +
may O +
cause O +
muscle B-Disease +
weakness I-Disease -
, O +
severe O +
hypomagnesemia B-Disease +
is O +
associated O +
with O +
muscle B-Disease +
spasms I-Disease +
and O +
tetany B-Disease +
which O +
can O -
not O +
be O +
corrected O +
by O +
potassium O +
and O +
calcium O +
supplementation O +
alone O +
( O -
1,2 O -
) O -
. O +

Surreptitious O +
diuretic O +
ingestion O +
has O +
been O +
described O -
, O +
mainly O +
in O +
women O +
who O +
are O +
concerned O +
that O +
they O +
are O +
obese B-Disease +
or O +
edematous B-Disease -
. O +

Symptomatic O +
hypokalemia B-Disease +
has O +
been O +
reported O +
in O +
such O +
patients O +
( O -
3 O -
- O -
7 O -
) O +
and O +
in O +
one O +
case O +
hypocalcemia B-Disease +
was O +
observed O +
( O -
8) O -
, O +
but O +
the O +
effects O +
of O +
magnesium O +
depletion O +
were O +
not O +
noted O +
in O +
these O +
patients O -
. O +

Venous B-Disease +
complications I-Disease +
of O +
midazolam O +
versus O +
diazepam O -
. O +

Although O +
some O +
studies O +
have O +
suggested O +
fewer O +
venous B-Disease +
complications I-Disease +
are O +
associated O +
with O +
midazolam O +
than O +
with O +
diazepam O +
for O +
endoscopic O +
procedures O -
, O +
this O +
variable O +
has O +
not O +
been O +
well O +
documented O -
. O +

We O +
prospectively O +
evaluated O +
the O +
incidence O +
of O +
venous B-Disease +
complications I-Disease +
after O +
intravenous O +
injection O +
of O +
diazepam O +
or O +
midazolam O +
in O +
122 O +
consecutive O +
patients O +
undergoing O +
colonoscopy O +
and O +
esophagogastroduodenoscopy O -
. O +

Overall O -
, O +
venous B-Disease +
complications I-Disease +
were O +
more O +
frequent O +
with O +
diazepam O +
( O -
22 O +
of O +
62 O +
patients O -
) O +
than O +
with O +
midazolam O +
( O -
4 O +
of O +
60 O +
patients O -
) O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

A O +
palpable O +
venous O +
cord O +
was O +
present O +
in O +
23 O -
% O +
( O -
14 O +
of O +
62 O -
) O +
of O +
patients O +
in O +
the O +
diazepam O +
group O -
, O +
compared O +
with O +
2 O -
% O +
( O -
1 O +
of O +
60 O +
patients O -
) O +
in O +
the O +
midazolam O +
group O +
( O -
p O +
< O +
0.002 O -
) O -
. O +

Pain B-Disease +
at O +
the O +
injection O +
site O +
occurred O +
in O +
35 O -
% O +
( O -
22 O +
of O +
62 O -
) O +
of O +
patients O +
in O +
the O +
diazepam O +
group O +
compared O +
with O +
7 O -
% O +
( O -
4 O +
of O +
60 O +
patients O -
) O +
in O +
the O +
midazolam O +
group O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Swelling B-Disease +
and O +
warmth O +
at O +
the O +
injection O +
site O +
were O +
not O +
significantly O +
different O +
between O +
the O +
two O +
groups O -
. O +

Smoking O -
, O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
use O -
, O +
intravenous O +
catheter O +
site O -
, O +
dwell O +
time O +
of O +
the O +
needle O -
, O +
alcohol O +
use O -
, O +
and O +
pain B-Disease +
during O +
the O +
injection O +
had O +
no O +
effect O +
on O +
the O +
incidence O +
of O +
venous B-Disease +
complications I-Disease -
. O +

Clarithromycin O -
- O -
associated O +
visual B-Disease +
hallucinations I-Disease +
in O +
a O +
patient O +
with O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
on O +
continuous O +
ambulatory O +
peritoneal O +
dialysis O -
. O +

Visual B-Disease +
hallucinations I-Disease +
are O +
a O +
rare O +
event O +
in O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
and O +
not O +
related O +
to O +
uremia B-Disease +
per O +
se O -
. O +

Unreported O +
in O +
the O +
literature O +
is O +
visual B-Disease +
hallucinations I-Disease +
occurring O +
in O +
association O +
with O +
the O +
new O +
macrolide O +
antibiotic O -
, O +
clarithromycin O -
. O +

We O +
describe O +
such O +
a O +
case O +
in O +
a O +
patient O +
with O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease I-Disease +
( O -
ESRD B-Disease -
) O +
maintained O +
on O +
continuous O +
ambulatory O +
peritoneal O +
dialysis O +
( O -
CAPD O -
) O -
. O +

The O +
combination O +
of O +
a O +
relatively O +
high O +
dose O +
of O +
clarithromycin O +
in O +
face O +
of O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
in O +
a O +
functionally O +
anephric O +
patient O -
, O +
with O +
underlying O +
aluminum O +
intoxication O -
, O +
may O +
have O +
facilitated O +
the O +
appearance O +
of O +
this O +
neurotoxic B-Disease +
side O +
effect O -
. O +

It O +
is O +
important O +
to O +
understand O +
the O +
pharmacokinetics O +
of O +
medications O +
in O +
face O +
of O +
chronic B-Disease +
renal I-Disease +
failure I-Disease -
, O +
the O +
possibility O +
of O +
drug O +
interactions O -
, O +
and O +
how O +
these O +
factors O +
should O +
help O +
guide O +
medication O +
therapy O +
in O +
the O +
ESRD B-Disease +
patient O -
. O +

Phase O +
II O +
trial O +
of O +
vinorelbine O +
in O +
metastatic O +
squamous B-Disease +
cell I-Disease +
esophageal I-Disease +
carcinoma I-Disease -
. O +

European O +
Organization O +
for O +
Research O +
and O +
Treatment O +
of O +
Cancer B-Disease +
Gastrointestinal O +
Treat O +
Cancer B-Disease +
Cooperative O +
Group O -
. O +

PURPOSE O -
: O +
To O +
evaluate O +
the O +
response O +
rate O +
and O +
toxic O +
effects O +
of O +
vinorelbine O +
( O -
VNB O -
) O +
administered O +
as O +
a O +
single O +
agent O +
in O +
metastatic O +
squamous B-Disease +
cell I-Disease +
esophageal I-Disease +
carcinoma I-Disease -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Forty O -
- O -
six O +
eligible O +
patients O +
with O +
measurable O +
lesions O +
were O +
included O +
and O +
were O +
stratified O +
according O +
to O +
previous O +
chemotherapy O -
. O +

Thirty O +
patients O +
without O +
prior O +
chemotherapy O +
and O +
16 O +
pretreated O +
with O +
cisplatin O -
- O -
based O +
chemotherapy O +
were O +
assessable O +
for O +
toxicity B-Disease +
and O +
response O -
. O +

VNB O +
was O +
administered O +
weekly O +
as O +
a O +
25-mg O -
/ O -
m2 O +
short O +
intravenous O +
( O -
i.v O -
. O -
) O +
infusion O -
. O +

RESULTS O -
: O +
Six O +
of O +
30 O +
patients O +
( O -
20 O -
% O -
) O +
without O +
prior O +
chemotherapy O +
achieved O +
a O +
partial O +
response O +
( O -
PR O -
) O +
( O -
95 O -
% O +
confidence O +
interval O +
[ O -
CI O -
] O -
, O +
8 O -
% O +
to O +
39 O -
% O -
) O -
. O +

The O +
median O +
duration O +
of O +
response O +
was O +
21 O +
weeks O +
( O -
range O -
, O +
17 O +
to O +
28 O -
) O -
. O +

One O +
of O +
16 O +
patients O +
( O -
6 O -
% O -
) O +
with O +
prior O +
chemotherapy O +
had O +
a O +
complete O +
response O +
( O -
CR O -
) O +
of O +
31 O +
weeks O -
' O +
duration O +
( O -
95 O -
% O +
CI O -
, O +
0 O -
% O +
to O +
30 O -
% O -
) O -
. O +

The O +
overall O +
response O +
rate O +
( O -
World O +
Health O +
Organization O +
[ O -
WHO O -
] O +
criteria O -
) O +
was O +
15 O -
% O +
( O -
CR O -
, O +
2 O -
% O -
; O +
PR O +
13 O -
% O -
; O +
95 O -
% O +
CI O -
, O +
6 O -
% O +
to O +
29 O -
% O -
) O -
. O +

The O +
median O +
dose O -
- O -
intensity O +
( O -
DI O -
) O +
was O +
20 O +
mg O -
/ O -
m2 O -
/ O -
wk O -
. O +

VNB O +
was O +
well O +
tolerated O +
and O +
zero O +
instances O +
of O +
WHO O +
grade O +
4 O +
nonhematologic O +
toxicity B-Disease +
occurred O -
. O +

At O +
least O +
one O +
episode O +
of O +
grade O +
3 O +
or O +
4 O +
granulocytopenia B-Disease +
was O +
seen O +
in O +
59 O -
% O +
of O +
patients O -
. O +

A O +
grade O +
2 O +
or O +
3 O +
infection B-Disease +
occurred O +
in O +
16 O -
% O +
of O +
patients O -
, O +
but O +
no O +
toxic O +
deaths B-Disease +
occurred O -
. O +

Other O +
side O +
effects O +
were O +
rare O -
, O +
and O +
peripheral B-Disease +
neurotoxicity I-Disease +
has O +
been O +
minor O +
( O -
26 O -
% O +
grade O +
1 O -
) O -
. O +

CONCLUSION O -
: O +
These O +
data O +
indicate O +
that O +
VNB O +
is O +
an O +
active O +
agent O +
in O +
metastatic O +
esophageal B-Disease +
squamous I-Disease +
cell I-Disease +
carcinoma I-Disease -
. O +

Given O +
its O +
excellent O +
tolerance O +
profile O +
and O +
low O +
toxicity B-Disease -
, O +
further O +
evaluation O +
of O +
VNB O +
in O +
combination O +
therapy O +
is O +
warranted O -
. O +

Contribution O +
of O +
the O +
sympathetic O +
nervous O +
system O +
to O +
salt O -
- O -
sensitivity O +
in O +
lifetime O +
captopril O -
- O -
treated O +
spontaneously O +
hypertensive B-Disease +
rats O -
. O +

OBJECTIVE O -
: O +
To O +
test O +
the O +
hypothesis O +
that O -
, O +
in O +
lifetime O +
captopril O -
- O -
treated O +
spontaneously O +
hypertensive B-Disease +
rats O +
( O -
SHR O -
) O -
, O +
the O +
sympathetic O +
nervous O +
system O +
contributes O +
importantly O +
to O +
the O +
hypertensive B-Disease +
effect O +
of O +
dietary O +
sodium O +
chloride O +
supplementation O -
. O +

METHODS O -
: O +
Male O +
SHR O +
( O -
aged O +
6 O +
weeks O -
) O +
that O +
had O +
been O +
treated O +
from O +
conception O +
onward O +
with O +
either O +
captopril O +
or O +
vehicle O +
remained O +
on O +
a O +
basal O +
sodium O +
chloride O +
diet O +
or O +
were O +
fed O +
a O +
high O +
sodium O +
chloride O +
diet O -
. O +

After O +
2 O +
weeks O -
, O +
the O +
rats O +
were O +
subjected O +
to O +
ganglionic O +
blockade O +
and O +
2 O +
days O +
later O -
, O +
an O +
infusion O +
of O +
clonidine O -
. O +

RESULTS O -
: O +
Lifetime O +
captopril O +
treatment O +
significantly O +
lowered O +
mean O +
arterial O +
pressure O +
in O +
both O +
groups O -
. O +

Intravenous O +
infusion O +
of O +
the O +
ganglionic O +
blocker O +
hexamethonium O +
resulted O +
in O +
a O +
rapid O +
decline O +
in O +
MAP O +
that O +
eliminated O +
the O +
dietary O +
sodium O +
chloride O -
- O -
induced O +
increase B-Disease +
in I-Disease +
MAP I-Disease +
in O +
both O +
groups O -
. O +

Infusion O +
of O +
the O +
central O +
nervous O +
system O +
alpha2-adrenergic O +
receptor O +
agonist O +
clonidine O +
also O +
resulted O +
in O +
a O +
greater O +
reduction O +
in O +
MAP O +
in O +
both O +
groups O +
of O +
SHR O +
that O +
were O +
fed O +
the O +
high O +
( O -
compared O +
with O +
the O +
basal O -
) O +
sodium O +
chloride O +
diet O -
. O +

CONCLUSIONS O -
: O +
In O +
both O +
lifetime O +
captopril O -
- O -
treated O +
and O +
control O +
SHR O -
, O +
the O +
sympathetic O +
nervous O +
system O +
contributes O +
to O +
the O +
pressor O +
effects O +
of O +
a O +
high O +
sodium O +
chloride O +
diet O -
. O +

Evaluation O +
of O +
adverse O +
reactions O +
of O +
aponidine O +
hydrochloride O +
ophthalmic O +
solution O -
. O +

We O +
prospectively O +
evaluated O +
the O +
adverse O +
reactions O +
of O +
apraclonidine O +
in O +
20 O +
normal O +
volunteers O +
by O +
instilling O +
a O +
single O +
drop O +
of O +
1 O -
% O +
apraclonidine O +
in O +
their O +
right O +
eyes O -
. O +

Examinations O -
, O +
including O +
blood O +
pressure O -
, O +
pulse O +
rate O -
, O +
conjunctiva O +
and O +
cornea O -
, O +
intraocular O +
pressure O +
( O -
IOP O -
) O -
, O +
pupil O +
diameter O -
, O +
basal O +
tear O +
secretion O +
and O +
margin O +
reflex O +
distance O +
of O +
both O +
upper O +
and O +
lower O +
eyelids O -
, O +
were O +
performed O +
prior O +
to O +
entry O +
and O +
at O +
1 O -
, O +
3 O -
, O +
5 O +
and O +
7 O +
hours O +
after O +
instillation O -
. O +

The O +
ocular B-Disease +
hypotensive I-Disease +
effects O +
were O +
statistically O +
significant O +
for O +
apraclonidine O -
- O -
treated O +
eyes O +
throughout O +
the O +
study O +
and O +
also O +
statistically O +
significant O +
for O +
contralateral O +
eyes O +
from O +
three O +
hours O +
after O +
topical O +
administration O +
of O +
1 O -
% O +
apraclonidine O -
. O +

Decreases B-Disease +
in I-Disease +
systolic I-Disease +
blood I-Disease +
pressure I-Disease +
were O +
statistically O -
, O +
but O +
not O +
clinically O -
, O +
significant O -
. O +

No O +
significant O +
changes O +
in O +
diastolic O +
blood O +
pressure O -
, O +
pulse O +
rate O +
and O +
basal O +
tear O +
secretion O +
were O +
noted O -
. O +

Conjunctival B-Disease +
blanching I-Disease +
and O +
mydriasis B-Disease +
were O +
commonly O +
found O -
. O +

Upper O +
lid O +
retraction O +
was O +
frequently O +
noted O -
. O +

While O +
the O +
elevations O +
of O +
the O +
upper O +
lid O +
margin O +
in O +
most O +
subjects O +
were O +
not O +
more O +
than O +
2 O +
mm O +
and O +
did O +
not O +
cause O +
noticeable O +
change O +
in O +
appearance O -
, O +
one O +
subject O +
suffered O +
from O +
mechanical O +
entropion B-Disease +
and O +
marked O +
corneal B-Disease +
abrasion I-Disease +
3 O +
hours O +
after O +
instillation O +
of O +
the O +
medication O -
. O +

This O +
may O +
well O +
be O +
a O +
particularly O +
notable O +
finding O +
in O +
Asian O +
people O -
. O +

Thiopentone O +
pretreatment O +
for O +
propofol O +
injection O +
pain B-Disease +
in O +
ambulatory O +
patients O -
. O +

This O +
study O +
investigated O +
propofol O +
injection O +
pain B-Disease +
in O +
patients O +
undergoing O +
ambulatory O +
anaesthesia O -
. O +

In O +
a O +
randomized O -
, O +
double O -
- O -
blind O +
trial O -
, O +
90 O +
women O +
were O +
allocated O +
to O +
receive O +
one O +
of O +
three O +
treatments O +
prior O +
to O +
induction O +
of O +
anaesthesia O +
with O +
propofol O -
. O +

Patients O +
in O +
Group O +
C O +
received O +
2 O +
ml O +
normal O +
saline O -
, O +
Group O +
L O -
, O +
2 O +
ml O -
, O +
lidocaine O +
2 O -
% O +
( O -
40 O +
mg O -
) O +
and O +
Group O +
T O -
, O +
2 O +
ml O +
thiopentone O +
2.5 O -
% O +
( O -
50 O +
mg O -
) O -
. O +

Venous O +
discomfort O +
was O +
assessed O +
with O +
a O +
visual O +
analogue O +
scale O +
( O -
VAS O -
) O +
5 O -
- O -
15 O +
sec O +
after O +
commencing O +
propofol O +
administration O +
using O +
an O +
infusion O +
pump O +
( O -
rate O +
1000 O +
micrograms.kg-1.min-1 O -
) O -
. O +

Loss B-Disease +
of I-Disease +
consciousness I-Disease +
occurred O +
in O +
60 O -
- O -
90 O +
sec. O +
Visual O +
analogue O +
scores O +
( O -
mean O +
+ O -
/- O +

SD O -
) O +
during O +
induction O +
were O +
lower O +
in O +
Groups O +
L O +
( O -
3.3 O +
+ O -
/- O +

2.5 O -
) O +
and O +
T O +
( O -
4.1 O +
+ O -
/- O +

2.7 O -
) O +
than O +
in O +
Group O +
C O +
( O -
5.6 O +
+ O -
/- O +

2.3 O -
) O -
; O +
P O +
= O +
0.0031 O -
. O +

The O +
incidence O +
of O +
venous O +
discomfort O +
was O +
lower O +
in O +
Group O +
L O +
( O -
76.6 O -
% O -
; O +
P O +
< O +
0.05 O -
) O +
than O +
in O +
Group O +
C O +
( O -
100 O -
% O -
) O +
but O +
not O +
different O +
from O +
Group O +
T O +
( O -
90 O -
% O -
) O -
. O +

The O +
VAS O +
scores O +
for O +
recall O +
of O +
pain B-Disease +
in O +
the O +
recovery O +
room O +
were O +
correlated O +
with O +
the O +
VAS O +
scores O +
during O +
induction O +
( O -
r O +
= O +
0.7045 O -
; O +
P O +
< O +
0.0001 O -
) O -
. O +

Recovery O +
room O +
discharge O +
times O +
were O +
similar O -
: O +
C O +
( O -
75.9 O +
+ O -
/- O +

19.4 O +
min O -
) O -
; O +
L O +
73.6 O +
+ O -
/- O +

21.6 O +
min O -
) O -
; O +
T O +
( O -
77.1 O +
+ O -
/- O +

18.9 O +
min O -
) O -
. O +

Assessing O +
their O +
overall O +
satisfaction O -
, O +
89.7 O -
% O +
would O +
choose O +
propofol O +
anaesthesia O +
again O -
. O +

We O +
conclude O +
that O +
lidocaine O +
reduces O +
the O +
incidence O +
and O +
severity O +
of O +
propofol O +
injection O +
pain B-Disease +
in O +
ambulatory O +
patients O +
whereas O +
thiopentone O +
only O +
reduces O +
its O +
severity O -
. O +

Angioedema B-Disease +
associated O +
with O +
droperidol O +
administration O -
. O +

Angioedema B-Disease -
, O +
also O +
known O +
as O +
angioneurotic B-Disease +
edema I-Disease +
or O +
Quincke B-Disease -
's I-Disease +
disease I-Disease -
, O +
is O +
a O +
well O -
- O -
demarcated O -
, O +
localized O +
edema B-Disease +
involving O +
the O +
subcutaneous O +
tissues O +
that O +
may O +
cause O +
upper B-Disease -
- I-Disease -
airway I-Disease +
obstruction I-Disease -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
previously O +
healthy O +
19-year O -
- O -
old O +
man O +
with O +
no O +
known O +
drug B-Disease +
allergies I-Disease +
in O +
whom O +
angioedema B-Disease +
with O +
significant O +
tongue B-Disease +
swelling I-Disease +
and O +
protrusion O +
developed O +
within O +
10 O +
minutes O +
of O +
the O +
administration O +
of O +
a O +
single O +
IV O +
dose O +
of O +
droperidol O -
. O +

Late O +
cardiotoxicity B-Disease +
after O +
treatment O +
for O +
a O +
malignant O +
bone B-Disease +
tumor I-Disease -
. O +

Cardiac O +
function O +
was O +
assessed O +
in O +
long O -
- O -
term O +
survivors O +
of O +
malignant O +
bone B-Disease +
tumors I-Disease +
who O +
were O +
treated O +
according O +
to O +
Rosen O -
's O +
T5 O +
or O +
T10 O +
protocol O -
, O +
both O +
including O +
doxorubicin O -
. O +

Thirty O -
- O -
one O +
patients O -
, O +
age O +
10 O -
- O -
45 O +
years O +
( O -
median O +
age O +
17.8 O +
years O -
) O +
were O +
evaluated O +
2.3 O -
- O -
14.1 O +
years O +
( O -
median O +
8.9 O +
years O -
) O +
following O +
completion O +
of O +
treatment O -
. O +

Cumulative O +
doses O +
of O +
doxorubicin O +
were O +
225 O -
- O -
550 O +
mg O -
/ O -
m2 O +
( O -
median O +
dose O +
360 O -
) O -
. O +

The O +
evaluation O +
consisted O +
of O +
a O +
history O -
, O +
physical O +
examination O -
, O +
electrocardiogram O +
( O -
ECG O -
) O -
, O +
signal O +
averaged O +
ECG O -
, O +
24-hour O +
ambulatory O +
ECG O -
, O +
echocardiography O +
and O +
radionuclide O +
angiography O -
. O +

Eighteen O +
of O +
31 O +
( O -
58 O -
% O -
) O +
patients O +
showed O +
cardiac B-Disease +
toxicity I-Disease -
, O +
defined O +
as O +
having O +
one O +
or O +
more O +
of O +
the O +
following O +
abnormalities O -
: O +
late O +
potentials O -
, O +
complex O +
ventricular B-Disease +
arrhythmias I-Disease -
, O +
left O +
ventricular B-Disease +
dilation I-Disease -
, O +
decreased O +
shortening O +
fraction O -
, O +
or O +
decreased O +
ejection O +
fraction O -
. O +

The O +
incidence O +
of O +
cardiac B-Disease +
abnormalities I-Disease +
increased O +
with O +
length O +
of O +
follow O -
- O -
up O +
( O -
P O -
< O +
or O +
= O +
.05 O -
) O -
. O +

No O +
correlation O +
could O +
be O +
demonstrated O +
between O +
cumulative O +
dose O +
of O +
doxorubicin O +
and O +
cardiac O +
status O -
, O +
except O +
for O +
heart O +
rate O +
variability O -
. O +

When O +
adjusted O +
to O +
body O +
surface O +
area O -
, O +
the O +
left O +
ventricular O +
posterior O +
wall O +
thickness O +
( O -
LVPW O +
index O -
) O +
was O +
decreased O +
in O +
all O +
patients O -
. O +

The O +
incidence O +
of O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease +
is O +
high O +
and O +
increases O +
with O +
follow O -
- O -
up O -
, O +
irrespective O +
of O +
cumulative O +
dose O -
. O +

Life O -
- O -
long O +
cardiac O +
follow O -
- O -
up O +
in O +
these O +
patients O +
is O +
warranted O -
. O +

The O +
results O +
of O +
our O +
study O +
suggest O +
that O +
heart O +
rate O +
variability O +
and O +
LVPW O +
index O +
could O +
be O +
sensitive O +
indicators O +
for O +
cardiotoxicity B-Disease -
. O +

Acute O +
blood O +
pressure O +
elevations O +
with O +
caffeine O +
in O +
men O +
with O +
borderline O +
systemic O +
hypertension B-Disease -
. O +

Whether O +
the O +
vasoconstrictive O +
actions O +
of O +
caffeine O +
are O +
enhanced O +
in O +
hypertensive B-Disease +
persons O +
has O +
not O +
been O +
demonstrated O -
. O +

Thus O -
, O +
caffeine O +
( O -
3.3 O +
mg O -
/ O -
kg O -
) O +
versus O +
placebo O +
was O +
tested O +
in O +
48 O +
healthy O +
men O +
( O -
aged O +
20 O +
to O +
35 O +
years O -
) O +
selected O +
after O +
screening O +
on O +
2 O +
separate O +
occasions O -
. O +

Borderline O +
hypertensive B-Disease +
men O +
( O -
n O +
= O +
24 O -
) O +
were O +
selected O +
with O +
screening O +
systolic O +
blood O +
pressure O +
( O -
BP O -
) O +
of O +
140 O +
to O +
160 O +
mm O +
Hg O +
and/or O +
diastolic O +
BP O +
90 O +
to O +
99 O +
mm O +
Hg O -
. O +

Low O -
- O -
risk O +
controls O +
( O -
n O +
= O +
24 O -
) O +
reported O +
no O +
parental O +
history O +
of O +
hypertension B-Disease +
and O +
had O +
screening O +
BP O +
< O +
130 O -
/ O -
85 O +
mm O +
Hg O -
. O +

Participants O +
were O +
then O +
tested O +
on O +
2 O +
occasions O +
after O +
12-hour O +
abstinence O +
from O +
caffeine O +
in O +
each O +
of O +
2 O +
protocols O -
; O +
this O +
required O +
a O +
total O +
of O +
4 O +
laboratory O +
visits O -
. O +

Caffeine O -
- O -
induced O +
changes O +
in O +
diastolic O +
BP O +
were O +
2 O +
to O +
3 O +
times O +
larger O +
in O +
borderline O +
subjects O +
than O +
in O +
controls O +
( O -
+ O -
8.4 O +
vs O +
+ O -
3.8 O +
mm O +
Hg O -
, O +
p O +
< O +
0.0001 O -
) O -
, O +
and O +
were O +
attributable O +
to O +
larger O +
changes O +
in O +
impedance O -
- O -
derived O +
measures O +
of O +
systemic O +
vascular O +
resistance O +
( O -
+ O -
135 O +
vs O +
+ O -
45 O +
dynes.s.cm-5 O -
, O +
p O +
< O +
0.004 O -
) O -
. O +

These O +
findings O +
were O +
consistent O +
and O +
reached O +
significance O +
in O +
both O +
protocols O -
. O +

The O +
percentage O +
of O +
borderline O +
subjects O +
in O +
whom O +
diastolic O +
BP O +
changes O +
exceeded O +
the O +
median O +
control O +
response O +
was O +
96 O -
% O -
. O +

Consequently O -
, O +
whereas O +
all O +
participants O +
exhibited O +
normotensive O +
levels O +
during O +
the O +
resting O +
predrug O +
baseline O -
, O +
33 O -
% O +
of O +
borderline O +
subjects O +
achieved O +
hypertensive B-Disease +
BP O +
levels O +
after O +
caffeine O +
ingestion O -
. O +

Thus O -
, O +
in O +
borderline O +
hypertensive B-Disease +
men O -
, O +
exaggerated O +
responses O +
to O +
caffeine O +
were O -
: O +
selective O +
for O +
diastolic O +
BP O -
, O +
consistent O +
with O +
greater O +
vasoconstriction O -
, O +
replicated O +
in O +
2 O +
protocols O -
, O +
and O +
representative O +
of O +
nearly O +
all O +
borderline O +
hypertensives B-Disease -
. O +

We O +
suspect O +
that O +
the O +
potential O +
for O +
caffeine O +
to O +
stabilize O +
high O +
resistance O +
states O +
in O +
susceptible O +
persons O +
suggests O +
that O +
its O +
use O +
may O +
facilitate O +
their O +
disease O +
progression O -
, O +
as O +
well O +
as O +
hinder O +
accurate O +
diagnosis O +
and O +
treatment O -
. O +

Persistent O +
paralysis B-Disease +
after O +
prolonged O +
use O +
of O +
atracurium O +
in O +
the O +
absence O +
of O +
corticosteroids O -
. O +

Neuromuscular O +
blocking O +
agents O +
( O -
NMBAs O -
) O +
are O +
often O +
used O +
for O +
patients O +
requiring O +
prolonged O +
mechanical O +
ventilation O -
. O +

Reports O +
of O +
persistent O +
paralysis B-Disease +
after O +
the O +
discontinuance O +
of O +
these O +
drugs O +
have O +
most O +
often O +
involved O +
aminosteroid O -
- O -
based O +
NMBAs O +
such O +
as O +
vecuronium O +
bromide O -
, O +
especially O +
when O +
used O +
in O +
conjunction O +
with O +
corticosteroids O -
. O +

Atracurium O +
besylate O -
, O +
a O +
short O -
- O -
acting O +
benzylisoquinolinium O +
NMBA O +
that O +
is O +
eliminated O +
independently O +
of O +
renal O +
or O +
hepatic O +
function O -
, O +
has O +
also O +
been O +
associated O +
with O +
persistent O +
paralysis B-Disease -
, O +
but O +
only O +
when O +
used O +
with O +
corticosteroids O -
. O +

We O +
report O +
a O +
case O +
of O +
atracurium O -
- O -
related O +
paralysis B-Disease +
persisting O +
for O +
approximately O +
50 O +
hours O +
in O +
a O +
patient O +
who O +
was O +
not O +
treated O +
with O +
corticosteroids O -
. O +

Coexistence O +
of O +
cerebral B-Disease +
venous I-Disease +
sinus I-Disease +
and I-Disease +
internal I-Disease +
carotid I-Disease +
artery I-Disease +
thrombosis I-Disease +
associated O +
with O +
exogenous O +
sex O +
hormones O -
. O +

A O +
case O +
report O -
. O +

A O +
forty O -
- O -
six O +
year O -
- O -
old O +
premenopausal O +
woman O +
developed O +
headache B-Disease -
, O +
nausea B-Disease +
and O +
vomiting B-Disease -
, O +
left O +
hemiparesis B-Disease +
and O +
seizure B-Disease +
two O +
days O +
after O +
parenteral O +
use O +
of O +
progesterone O +
and O +
estradiol O -
. O +

Diabetes B-Disease +
mellitus I-Disease +
( O -
DM B-Disease -
) O +
was O +
found O +
during O +
admission O -
. O +

Computed O +
tomography O +
showed O +
a O +
hemorrhagic B-Disease +
infarct B-Disease +
in O +
the O +
right O +
frontal O +
lobe O +
and O +
increased O +
density O +
in O +
the O +
superior O +
sagittal O +
sinus O +
( O -
SSS O -
) O -
. O +

Left O +
carotid O +
angiography O +
found O +
occlusion B-Disease +
of I-Disease +
the I-Disease +
left I-Disease +
internal I-Disease +
carotid I-Disease +
artery I-Disease +
( O -
ICA O -
) O -
. O +

Right O +
carotid O +
angiograms O +
failed O +
to O +
show O +
the O +
SSS O +
and O +
inferior O +
sagittal O +
sinus O -
, O +
suggestive O +
of O +
venous B-Disease +
sinus I-Disease +
thrombosis I-Disease -
. O +

Coexistence O +
of O +
the O +
cerebral B-Disease +
artery I-Disease +
and I-Disease +
the I-Disease +
venous I-Disease +
sinus I-Disease +
occlusion I-Disease +
has O +
been O +
described O +
infrequently O -
. O +

In O +
this O +
case O -
, O +
the O +
authors O +
postulate O +
that O +
the O +
use O +
of O +
estradiol O +
and O +
progesterone O +
and O +
the O +
underlying O +
DM B-Disease +
increased O +
vascular O +
thrombogenicity O -
, O +
which O +
provided O +
a O +
common O +
denominator O +
for O +
thrombosis B-Disease +
of I-Disease +
both I-Disease +
the I-Disease +
ICA I-Disease +
and I-Disease +
the I-Disease +
venous I-Disease +
sinus I-Disease -
. O +

Chemotherapy O +
of O +
advanced O +
inoperable O +
non B-Disease -
- I-Disease -
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer I-Disease +
with O +
paclitaxel O -
: O +
a O +
phase O +
II O +
trial O -
. O +

Paclitaxel O +
( O -
Taxol O -
; O +
Bristol O -
- O -
Myers O +
Squibb O +
Company O -
, O +
Princeton O -
, O +
NJ O -
) O +
has O +
demonstrated O +
significant O +
antineoplastic O +
activity O +
against O +
different O +
tumor B-Disease +
types O -
, O +
notably O +
ovarian B-Disease +
and I-Disease +
breast I-Disease +
carcinoma I-Disease -
. O +

Two O +
phase O +
II O +
trials O +
of O +
24-hour O +
paclitaxel O +
infusions O +
in O +
chemotherapy O -
- O -
naive O +
patients O +
with O +
stage O +
IIIB O +
or O +
IV O +
non B-Disease -
- I-Disease -
small I-Disease +
cell I-Disease +
lung I-Disease +
cancer I-Disease +
( O -
NSCLC B-Disease -
) O +
reported O +
response O +
rates O +
of O +
21 O -
% O +
and O +
24 O -
% O -
. O +

Leukopenia B-Disease +
was O +
dose O +
limiting O -
: O +
as O +
many O +
as O +
62.5 O -
% O +
of O +
patients O +
experienced O +
grade O +
4 O +
leukopenia B-Disease -
. O +

We O +
investigated O +
the O +
efficacy O +
and O +
toxicity B-Disease +
of O +
a O +
3-hour O +
paclitaxel O +
infusion O +
in O +
a O +
phase O +
II O +
trial O +
in O +
patients O +
with O +
inoperable O +
stage O +
IIIB O +
or O +
IV O +
NSCLC B-Disease -
. O +

The O +
58 O +
patients O +
treated O +
( O -
41 O +
men O +
and O +
17 O +
women O -
) O +
had O +
a O +
median O +
age O +
of O +
59 O +
years O +
( O -
age O +
range O -
, O +
25 O +
to O +
75 O -
) O +
and O +
a O +
performance O +
status O +
of O +
0 O +
through O +
2 O -
. O +

Most O +
patients O +
( O -
72.4 O -
% O -
) O +
had O +
stage O +
IV O +
NSCLC B-Disease -
. O +

Paclitaxel O +
225 O +
mg O -
/ O -
m2 O +
was O +
infused O +
over O +
3 O +
hours O +
every O +
3 O +
weeks O +
with O +
standard O +
prophylactic O +
premedication O -
. O +

Of O +
50 O +
patients O +
evaluable O +
for O +
response O -
, O +
12 O +
( O -
24 O -
% O -
) O +
had O +
partial O +
remission O -
, O +
26 O +
( O -
52 O -
% O -
) O +
had O +
no O +
change O -
, O +
and O +
12 O +
had O +
disease O +
progression O +
( O -
24 O -
% O -
) O -
. O +

Hematologic O +
toxicities B-Disease +
were O +
mild O -
: O +
only O +
one O +
patient O +
( O -
2 O -
% O -
) O +
developed O +
grade O +
3 O +
or O +
4 O +
neutropenia B-Disease -
, O +
while O +
29 O -
% O +
had O +
grade O +
1 O +
or O +
2 O -
. O +

Grade O +
1 O +
or O +
2 O +
polyneuropathy B-Disease +
affected O +
56 O -
% O +
of O +
patients O +
while O +
only O +
one O +
( O -
2 O -
% O -
) O +
experienced O +
severe O +
polyneuropathy B-Disease -
. O +

Similarly O -
, O +
grade O +
1 O +
or O +
2 O +
myalgia B-Disease -
/ O -
arthralgia B-Disease +
was O +
observed O +
in O +
63.2 O -
% O +
of O +
patients O -
, O +
but O +
only O +
14.3 O -
% O +
experienced O +
grade O +
3 O +
or O +
4 O -
. O +

Nausea B-Disease +
and O +
vomiting B-Disease +
were O +
infrequent O -
, O +
with O +
14 O -
% O +
of O +
patients O +
experiencing O +
grade O +
1 O +
or O +
2 O +
and O +
only O +
2 O -
% O +
experiencing O +
grade O +
3 O +
or O +
4 O -
. O +

Paclitaxel O +
is O +
thus O +
an O +
active O +
single O +
agent O +
in O +
this O +
patient O +
population O -
, O +
with O +
a O +
3-hour O +
infusion O +
proving O +
comparably O +
effective O +
to O +
a O +
24-hour O +
infusion O +
and O +
superior O +
in O +
terms O +
of O +
the O +
incidence O +
of O +
hematologic O +
and O +
nonhematologic O +
toxicity B-Disease -
. O +

Further O +
phase O +
II O +
studies O +
with O +
paclitaxel O +
combined O +
with O +
other O +
drugs O +
active O +
against O +
NSCLC B-Disease +
are O +
indicated O -
, O +
and O +
phase O +
III O +
studies O +
comparing O +
paclitaxel O +
with O +
standard O +
chemotherapy O +
remain O +
to O +
be O +
completed O -
. O +

A O +
phase O +
I O -
/ O -
II O +
study O +
of O +
paclitaxel O +
plus O +
cisplatin O +
as O +
first O -
- O -
line O +
therapy O +
for O +
head B-Disease +
and I-Disease +
neck I-Disease +
cancers I-Disease -
: O +
preliminary O +
results O -
. O +

Improved O +
outcomes O +
among O +
patients O +
with O +
head B-Disease +
and I-Disease +
neck I-Disease +
carcinomas I-Disease +
require O +
investigations O +
of O +
new O +
drugs O +
for O +
induction O +
therapy O -
. O +

Preliminary O +
results O +
of O +
an O +
Eastern O +
Cooperative O +
Oncology O +
Group O +
study O +
of O +
single O -
- O -
agent O +
paclitaxel O +
( O -
Taxol O -
; O +
Bristol O -
- O -
Myers O +
Squibb O +
Company O -
, O +
Princeton O -
, O +
NJ O -
) O +
reported O +
a O +
37 O -
% O +
response O +
rate O +
in O +
patients O +
with O +
head B-Disease +
and I-Disease +
neck I-Disease +
cancer I-Disease -
, O +
and O +
the O +
paclitaxel O -
/ O -
cisplatin O +
combination O +
has O +
been O +
used O +
successfully O +
and O +
has O +
significantly O +
improved O +
median O +
response O +
duration O +
in O +
ovarian B-Disease +
cancer I-Disease +
patients O -
. O +

We O +
initiated O +
a O +
phase O +
I O -
/ O -
II O +
trial O +
to O +
determine O +
the O +
response O +
and O +
toxicity B-Disease +
of O +
escalating O +
paclitaxel O +
doses O +
combined O +
with O +
fixed O -
- O -
dose O +
cisplatin O +
with O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
support O +
in O +
patients O +
with O +
untreated O +
locally O +
advanced O +
inoperable O +
head B-Disease +
and I-Disease +
neck I-Disease +
carcinoma I-Disease -
. O +

To O +
date O -
, O +
23 O +
men O +
with O +
a O +
median O +
age O +
of O +
50 O +
years O +
and O +
good O +
performance O +
status O +
have O +
entered O +
the O +
trial O -
. O +

Primary O +
tumor B-Disease +
sites O +
were O +
oropharynx O -
, O +
10 O +
patients O -
; O +
hypopharynx O -
, O +
four O -
; O +
larynx O -
, O +
two O -
; O +
oral O +
cavity O -
, O +
three O -
; O +
unknown O +
primary O -
, O +
two O -
; O +
and O +
nasal O +
cavity O +
and O +
parotid O +
gland O -
, O +
one O +
each O -
. O +

Of O +
20 O +
patients O +
evaluable O +
for O +
toxicity B-Disease -
, O +
four O +
had O +
stage O +
III O +
and O +
16 O +
had O +
stage O +
IV O +
disease O -
. O +

Treatment O -
, O +
given O +
every O +
21 O +
days O +
for O +
a O +
maximum O +
of O +
three O +
cycles O -
, O +
consisted O +
of O +
paclitaxel O +
by O +
3-hour O +
infusion O +
followed O +
the O +
next O +
day O +
by O +
a O +
fixed O +
dose O +
of O +
cisplatin O +
( O -
75 O +
mg O -
/ O -
m2 O -
) O -
. O +

The O +
dose O +
levels O +
incorporate O +
escalating O +
paclitaxel O +
doses O -
, O +
and O +
intrapatient O +
escalations O +
within O +
a O +
given O +
dose O +
level O +
are O +
permitted O +
if O +
toxicity B-Disease +
permits O -
. O +

At O +
the O +
time O +
of O +
this O +
writing O -
, O +
dose O +
level O +
4 O +
( O -
260 O -
, O +
270 O -
, O +
and O +
280 O +
mg O -
/ O -
m2 O -
) O +
is O +
being O +
evaluated O -
; O +
three O +
patients O +
from O +
this O +
level O +
are O +
evaluable O -
. O +

With O +
paclitaxel O +
doses O +
of O +
200 O +
mg O -
/ O -
m2 O +
and O +
higher O -
, O +
granulocyte O +
colony O -
- O -
stimulating O +
factor O +
5 O +
micrograms O -
/ O -
kg O -
/ O -
d O +
is O +
given O +
( O -
days O +
4 O +
through O +
12 O -
) O -
. O +

Of O +
18 O +
patients O +
evaluable O +
for O +
response O -
, O +
seven O +
( O -
39 O -
% O -
) O +
achieved O +
a O +
complete O +
response O +
and O +
six O +
( O -
33 O -
% O -
) O +
achieved O +
a O +
partial O +
response O -
. O +

Three O +
patients O +
had O +
no O +
change O +
and O +
disease O +
progressed O +
in O +
two O -
. O +

The O +
overall O +
response O +
rate O +
is O +
72 O -
% O -
. O +

Eleven O +
responding O +
patients O +
had O +
subsequent O +
surgery O -
/ O -
radiotherapy O +
or O +
radical O +
radiotherapy O -
. O +

Two O +
pathologic O +
complete O +
responses O +
were O +
observed O +
in O +
patients O +
who O +
had O +
achieved O +
clinical O +
complete O +
responses O -
. O +

Alopecia B-Disease -
, O +
paresthesias B-Disease -
, O +
and O +
arthralgias B-Disease -
/ O -
myalgias B-Disease +
have O +
occurred O +
frequently O -
, O +
but O +
with O +
one O +
exception O +
( O -
a O +
grade O +
3 O +
myalgia B-Disease -
) O +
they O +
have O +
been O +
grade O +
1 O +
or O +
2 O -
. O +

No O +
dose O -
- O -
limiting O +
hematologic O +
toxicity B-Disease +
has O +
been O +
seen O -
. O +

Paclitaxel O -
/ O -
cisplatin O +
is O +
an O +
effective O +
first O -
- O -
line O +
regimen O +
for O +
locoregionally O +
advanced O +
head B-Disease +
and I-Disease +
neck I-Disease +
cancer I-Disease +
and O +
continued O +
study O +
is O +
warranted O -
. O +

Results O +
thus O +
far O +
suggest O +
no O +
dose O -
- O -
response O +
effect O +
for O +
paclitaxel O +
doses O +
above O +
200 O +
mg O -
/ O -
m2 O -
. O +

Paclitaxel O +
combined O +
with O +
carboplatin O +
in O +
the O +
first O -
- O -
line O +
treatment O +
of O +
advanced O +
ovarian B-Disease +
cancer I-Disease -
. O +

In O +
a O +
phase O +
I O +
study O +
to O +
determine O +
the O +
maximum O +
tolerated O +
dose O +
of O +
paclitaxel O +
( O -
Taxol O -
; O +
Bristol O -
- O -
Myers O +
Squibb O +
Company O -
, O +
Princeton O -
, O +
NJ O -
) O +
given O +
as O +
a O +
3-hour O +
infusion O +
in O +
combination O +
with O +
carboplatin O +
administered O +
every O +
21 O +
days O +
to O +
women O +
with O +
advanced O +
ovarian B-Disease +
cancer I-Disease -
, O +
paclitaxel O +
doses O +
were O +
escalated O +
as O +
follows O -
: O +
level O +
1 O -
, O +
135 O +
mg O -
/ O -
m2 O -
; O +
level O +
2 O -
, O +
160 O +
mg O -
/ O -
m2 O -
; O +
level O +
3 O -
, O +
185 O +
mg O -
/ O -
m2 O -
; O +
and O +
level O +
4,210 O +
mg O -
/ O -
m2 O -
. O +

The O +
fixed O +
dose O +
of O +
carboplatin O +
at O +
levels O +
1 O +
through O +
4 O +
was O +
given O +
to O +
achieve O +
an O +
area O +
under O +
the O +
concentration O -
- O -
time O +
curve O +
( O -
AUC O -
) O +
of O +
5 O +
using O +
the O +
Calvert O +
formula O -
. O +

In O +
levels O +
5 O +
and O +
6 O +
the O +
carboplatin O +
dose O +
was O +
targeted O +
at O +
AUCs O +
of O +
6 O +
and O +
7.5 O -
, O +
respectively O -
, O +
combined O +
with O +
a O +
fixed O +
paclitaxel O +
dose O +
of O +
185 O +
mg O -
/ O -
m2 O -
. O +

To O +
date O -
, O +
30 O +
previously O +
untreated O +
patients O -
, O +
all O +
with O +
a O +
good O +
performance O +
status O +
( O -
Eastern O +
Cooperative O +
Oncology O +
Group O +
0 O +
to O +
2 O -
) O +
have O +
been O +
entered O +
into O +
this O +
ongoing O +
study O -
. O +

The O +
dose O -
- O -
limiting O +
toxicity B-Disease +
of O +
the O +
combination O +
was O +
myelosuppression B-Disease +
( O -
leukopenia B-Disease -
, O +
granulocytopenia B-Disease -
, O +
and O +
thrombocytopenia B-Disease -
) O -
. O +

Neurotoxicity B-Disease +
was O +
largely O +
moderate O -
. O +

So O +
far O -
, O +
14 O +
patients O +
are O +
evaluable O +
for O +
response O -
; O +
of O +
these O -
, O +
eight O +
( O -
57 O -
% O -
) O +
showed O +
objective O +
( O -
complete O +
or O +
partial O -
) O +
response O +
and O +
disease O +
stabilized O +
in O +
six O +
patients O -
. O +

No O +
patient O +
had O +
disease O +
progression O -
. O +

We O +
conclude O +
that O +
the O +
combination O +
of O +
paclitaxel O +
185 O +
mg O -
/ O -
m2 O +
administered O +
as O +
a O +
3-hour O +
infusion O +
followed O +
immediately O +
by O +
a O +
1-hour O +
infusion O +
of O +
carboplatin O +
at O +
an O +
AUC O +
of O +
6 O +
can O +
be O +
administered O +
safely O +
in O +
a O +
21-day O +
schedule O +
in O +
the O +
outpatient O +
setting O -
. O +

The O +
recommended O +
dose O +
for O +
phase O +
III O +
studies O +
is O +
paclitaxel O +
185 O +
mg O -
/ O -
m2 O +
and O +
carboplatin O +
AUC O +
6 O -
. O +

Improvement O +
of O +
levodopa O -
- O -
induced O +
dyskinesia B-Disease +
by O +
propranolol O +
in O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

Seven O +
patients O +
suffering O +
from O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
with O +
severely O +
disabling O +
dyskinesia B-Disease +
received O +
low O -
- O -
dose O +
propranolol O +
as O +
an O +
adjunct O +
to O +
the O +
currently O +
used O +
medical O +
treatment O -
. O +

There O +
was O +
a O +
significant O +
40 O -
% O +
improvement O +
in O +
the O +
dyskinesia B-Disease +
score O +
without O +
increase O +
of O +
parkinsonian B-Disease +
motor B-Disease +
disability I-Disease -
. O +

Ballistic O +
and O +
choreic O +
dyskinesia B-Disease +
were O +
markedly O +
ameliorated O -
, O +
whereas O +
dystonia B-Disease +
was O +
not O -
. O +

This O +
study O +
suggests O +
that O +
administration O +
of O +
low O +
doses O +
of O +
beta O -
- O -
blockers O +
may O +
improve O +
levodopa O -
- O -
induced O +
ballistic O +
and O +
choreic O +
dyskinesia B-Disease +
in O +
PD B-Disease -
. O +

Effects O +
of O +
acute O +
steroid O +
administration O +
on O +
ventilatory O +
and O +
peripheral O +
muscles O +
in O +
rats O -
. O +

Occasional O +
case O +
reports O +
have O +
shown O +
that O +
acute O +
myopathy B-Disease +
may O +
occur O +
in O +
patients O +
treated O +
with O +
massive O +
doses O +
of O +
corticosteroids O -
. O +

The O +
mechanism O +
of O +
this O +
myopathy B-Disease +
is O +
poorly O +
understood O -
. O +

Therefore O -
, O +
60 O +
male O +
rats O +
were O +
randomly O +
assigned O +
to O +
receive O +
daily O +
injection O +
of O +
saline O +
( O -
C O -
) O -
, O +
methylprednisolone O +
( O -
M O -
) O -
, O +
or O +
triamcinolone O +
( O -
T O -
) O +
80 O +
mg O -
/ O -
kg O -
/ O -
d O +
for O +
5 O +
d. O +
Nutritional O +
intake O -
, O +
measured O +
daily O +
in O +
15 O +
animals O -
, O +
showed O +
a O +
significant O +
reduction B-Disease +
of I-Disease +
food I-Disease +
intake I-Disease +
in O +
the O +
steroid O -
- O -
treated O +
groups O +
( O -
-50 O +
and O +
-79 O -
% O +
in O +
M O +
and O +
T O -
, O +
respectively O -
) O -
. O +

This O +
was O +
associated O +
with O +
a O +
similar O +
loss B-Disease +
in I-Disease +
body I-Disease +
weight I-Disease -
. O +

In O +
the O +
45 O +
remaining O +
animals O -
, O +
diaphragm O +
contractility O +
and O +
histopathologic O +
features O +
of O +
several O +
muscles O +
were O +
studied O -
. O +

Weights O +
of O +
respiratory O +
and O +
peripheral O +
muscles O +
were O +
similarly O +
decreased O +
after O +
steroid O +
treatment O -
. O +

Maximal O +
twitches O +
of O +
the O +
diaphragm O +
were O +
lower O +
in O +
the O +
C O +
group O +
( O -
653 O +
+ O -
/- O +

174 O +
g O -
/ O -
cm O -
( O -
2 O -
) O -
) O +
than O +
in O +
the O +
M O +
group O +
( O -
837 O +
+ O -
/- O +

171 O +
g O -
/ O -
cm O -
( O -
2 O -
) O -
; O +
p O +
< O +
0.05 O -
) O +
and O +
the O +
T O +
group O +
( O -
765 O +
+ O -
/- O +

145 O +
g O -
/ O -
cm O -
( O -
2 O -
) O -
, O +
NS O -
) O -
. O +

Half O -
- O -
relaxation O +
time O +
was O +
prolonged O +
in O +
both O +
steroid O +
groups O -
, O +
and O +
time O +
to O +
peak O +
tension O +
was O +
longer O +
with O +
M O -
, O +
whereas O +
tetanic B-Disease +
tensions O +
were O +
similar O -
. O +

Steroid O +
treatment O +
also O +
induced O +
a O +
leftward O +
shift O +
of O +
the O +
force O -
- O -
frequency O +
curve O +
at O +
25 O +
and O +
50 O +
Hz O +
when O +
compared O +
with O +
saline O +
treatment O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

ATPase O +
staining O +
of O +
the O +
diaphragm O -
, O +
scalenus O +
medius O -
, O +
and O +
gastrocnemius O +
showed O +
type O +
IIb O +
fiber O +
atrophy B-Disease +
in O +
the O +
steroid O +
groups O +
and O +
also O +
diaphragmatic O +
type O +
IIa O +
atrophy B-Disease +
with O +
T O -
, O +
whereas O +
histologic O +
examinations O +
revealed O +
a O +
normal O +
muscular O +
pattern O +
with O +
absence O +
of O +
necrosis B-Disease -
. O +

Finally O -
, O +
a O +
pair O -
- O -
fed O +
( O -
PF O -
) O +
study O -
, O +
performed O +
in O +
18 O +
rats O +
( O -
C O -
, O +
T O -
, O +
and O +
PF O -
) O -
, O +
showed O +
that O +
muscle B-Disease +
atrophy I-Disease +
was O +
considerably O +
less O +
pronounced O +
in O +
PF O +
animals O +
than O +
in O +
T O -
- O -
treated O +
animals O -
. O +

We O +
conclude O +
that O +
( O -
1 O -
) O +
short O -
- O -
term O +
treatment O +
with O +
massive O +
doses O +
of O +
steroids O +
induced O +
severe O +
respiratory O +
and O +
limb O +
muscle O +
wasting O -
; O +
( O -
2 O -
) O +
both O +
types O +
of O +
steroids O +
induced O +
predominantly O +
type O +
IIb O +
atrophy B-Disease -
, O +
resulting O +
in O +
the O +
expected O +
alterations O +
in O +
diaphragm O +
contractile O +
properties O -
; O +
( O -
3 O -
) O +
neither O +
steroid O +
caused O +
muscle O +
necrosis B-Disease -
; O +
( O -
4 O -
) O +
type O +
IIb O +
atrophy B-Disease +
was O +
not O +
caused O +
by O +
acute O +
nutritional O +
deprivation O +
alone O -
. O +

Habitual O +
use O +
of O +
acetaminophen O +
as O +
a O +
risk O +
factor O +
for O +
chronic B-Disease +
renal I-Disease +
failure I-Disease -
: O +
a O +
comparison O +
with O +
phenacetin O -
. O +

Six O +
epidemiologic O +
studies O +
in O +
the O +
United O +
States O +
and O +
Europe O +
indicate O +
that O +
habitual O +
use O +
of O +
phenacetin O +
is O +
associated O +
with O +
the O +
development O +
of O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
and O +
end B-Disease -
- I-Disease -
stage I-Disease +
renal I-Disease +
disease I-Disease +
( O -
ESRD B-Disease -
) O -
, O +
with O +
a O +
relative O +
risk O +
in O +
the O +
range O +
of O +
4 O +
to O +
19 O -
. O +

As O +
a O +
result O +
of O +
these O +
and O +
other O +
studies O -
, O +
phenacetin O +
has O +
now O +
been O +
withdrawn O +
from O +
the O +
market O +
in O +
most O +
countries O -
. O +

However O -
, O +
three O +
case O +
control O +
studies O -
, O +
one O +
each O +
in O +
North O +
Carolina O -
, O +
northern O +
Maryland O -
, O +
and O +
West O +
Berlin O -
, O +
Germany O -
, O +
showed O +
that O +
habitual O +
use O +
of O +
acetaminophen O +
is O +
also O +
associated O +
with O +
chronic B-Disease +
renal I-Disease +
failure I-Disease +
and O +
ESRD B-Disease -
, O +
with O +
a O +
relative O +
risk O +
in O +
the O +
range O +
of O +
2 O +
to O +
4 O -
. O +

These O +
studies O +
suggest O +
that O +
both O +
phenacetin O +
and O +
acetaminophen O +
may O +
contribute O +
to O +
the O +
burden O +
of O +
ESRD B-Disease -
, O +
with O +
the O +
risk O +
of O +
the O +
latter O +
being O +
somewhat O +
less O +
than O +
that O +
of O +
the O +
former O -
. O +

This O +
apparent O +
difference O +
in O +
risk O +
may O +
not O +
be O +
due O +
to O +
differences O +
in O +
nephrotoxic B-Disease +
potential O +
of O +
the O +
drugs O +
themselves O -
. O +

A O +
lower O +
relative O +
risk O +
would O +
be O +
expected O +
for O +
acetaminophen O +
if O +
the O +
risk O +
of O +
both O +
drugs O +
in O +
combination O +
with O +
other O +
analgesics O +
was O +
higher O +
than O +
the O +
risk O +
of O +
either O +
agent O +
alone O -
. O +

Thus O -
, O +
acetaminophen O +
has O +
been O +
used O +
both O +
as O +
a O +
single O +
agent O +
and O +
in O +
combination O +
with O +
other O +
analgesics O -
, O +
whereas O +
phenacetin O +
was O +
available O +
only O +
in O +
combinations O -
. O +

The O +
possibility O +
that O +
habitual O +
use O +
of O +
acetaminophen O +
alone O +
increases O +
the O +
risk O +
of O +
ESRD B-Disease +
has O +
not O +
been O +
clearly O +
demonstrated O -
, O +
but O +
can O -
not O +
be O +
dismissed O -
. O +

Continuous O +
subcutaneous O +
administration O +
of O +
mesna O +
to O +
prevent O +
ifosfamide O -
- O -
induced O +
hemorrhagic B-Disease +
cystitis B-Disease -
. O +

Hemorrhagic B-Disease +
cystitis B-Disease +
is O +
a O +
major O +
potential O +
toxicity B-Disease +
of O +
ifosfamide O +
that O +
can O +
be O +
prevented O +
by O +
administering O +
mesna O +
along O +
with O +
the O +
cytotoxic O +
agent O -
. O +

Mesna O +
is O +
generally O +
administered O +
by O +
the O +
intravenous O +
route O -
, O +
although O +
experience O +
with O +
oral O +
delivery O +
of O +
the O +
drug O +
has O +
increased O -
. O +

The O +
continuous O +
subcutaneous O +
administration O +
of O +
mesna O +
has O +
the O +
advantage O +
of O +
not O +
requiring O +
intravenous O +
access O -
. O +

In O +
addition O -
, O +
subcutaneous O +
delivery O +
of O +
the O +
neutralizing O +
agent O +
will O +
not O +
be O +
associated O +
with O +
the O +
risk O +
of O +
inadequate O +
urinary O +
mesna O +
concentrations O -
, O +
such O +
as O +
in O +
a O +
patient O +
taking O +
oral O +
mesna O +
who O +
experiences O +
severe O +
ifosfamide O -
- O -
induced O +
emesis B-Disease +
and O +
is O +
unable O +
to O +
absorb O +
the O +
drug O -
. O +

Limited O +
clinical O +
experience O +
with O +
continuous O +
subcutaneous O +
mesna O +
administration O +
suggests O +
it O +
is O +
a O +
safe O -
, O +
practical O -
, O +
and O +
economic O +
method O +
of O +
drug O +
delivery O +
that O +
permits O +
ifosfamide O +
to O +
be O +
administered O +
successfully O +
in O +
the O +
outpatient O +
setting O -
. O +

Acetaminophen O -
- O -
induced O +
hypotension B-Disease -
. O +

Through O +
30 O +
years O +
of O +
widespread O +
use O -
, O +
acetaminophen O +
has O +
been O +
shown O +
to O +
be O +
a O +
remarkably O +
safe O +
medication O +
in O +
therapeutic O +
dosages O -
. O +

The O +
potential O +
for O +
acetaminophen O +
to O +
produce O +
cardiovascular B-Disease +
toxicities I-Disease +
is O +
very O +
low O -
. O +

However O -
, O +
acetaminophen O +
has O +
been O +
demonstrated O +
to O +
produce O +
symptoms O +
of O +
anaphylaxis B-Disease -
, O +
including O +
hypotension B-Disease -
, O +
in O +
sensitive O +
individuals O -
. O +

This O +
article O +
describes O +
two O +
critically B-Disease +
ill I-Disease +
patients O +
in O +
whom O +
transient O +
episodes O +
of O +
hypotension B-Disease +
reproducibly O +
developed O +
after O +
administration O +
of O +
acetaminophen O -
. O +

Other O +
symptoms O +
of O +
allergic B-Disease +
reactions I-Disease +
were O +
not O +
clinically O +
detectable O -
. O +

The O +
hypotensive B-Disease +
episodes O +
were O +
severe O +
enough O +
to O +
require O +
vasopressor O +
administration O -
. O +

The O +
reports O +
illustrate O +
the O +
need O +
for O +
clinicians O +
to O +
consider O +
acetaminophen O +
in O +
patients O +
with O +
hypotension B-Disease +
of O +
unknown O +
origin O -
. O +

Leg B-Disease +
and I-Disease +
back I-Disease +
pain I-Disease +
after O +
spinal O +
anaesthesia O +
involving O +
hyperbaric O +
5 O -
% O +
lignocaine O -
. O +

Fifty O -
- O -
four O +
patients O -
, O +
aged O +
27 O -
- O -
90 O +
years O -
, O +
who O +
were O +
given O +
lignocaine O +
5 O -
% O +
in O +
6.8 O -
% O +
glucose O +
solution O +
for O +
spinal O +
anaesthesia O +
were O +
studied O -
. O +

Thirteen O +
of O +
these O +
patients O +
experienced O +
pain B-Disease +
in I-Disease +
the I-Disease +
legs I-Disease +
and/or I-Disease +
back I-Disease +
after O +
recovery O +
from O +
anaesthesia O -
. O +

The O +
patients O +
affected O +
were O +
younger O +
( O -
p O +
< O +
0.05 O -
) O +
and O +
the O +
site O +
of O +
the O +
dural O +
puncture O +
was O +
higher O +
( O -
p O +
< O +
0.01 O -
) O +
than O +
those O +
individuals O +
without O +
pain B-Disease -
. O +

Five O +
of O +
the O +
13 O +
patients O +
( O -
38 O -
% O -
) O +
with O +
pain B-Disease +
and O +
seven O +
of O +
the O +
41 O +
patients O +
( O -
17 O -
% O -
) O +
without O +
pain B-Disease +
admitted O +
to O +
a O +
high O +
alcohol O +
intake O -
, O +
which O +
might O +
be O +
a O +
contributing O +
factor O -
. O +

Leg B-Disease +
and/or I-Disease +
back I-Disease +
pain I-Disease +
is O +
associated O +
with O +
the O +
intrathecal O +
use O +
of O +
hyperbaric O +
5 O -
% O +
lignocaine O -
. O +

Reduction O +
of O +
heparan O +
sulphate O -
- O -
associated O +
anionic O +
sites O +
in O +
the O +
glomerular O +
basement O +
membrane O +
of O +
rats O +
with O +
streptozotocin O -
- O -
induced O +
diabetic B-Disease +
nephropathy I-Disease -
. O +

Heparan O +
sulphate O -
- O -
associated O +
anionic O +
sites O +
in O +
the O +
glomerular O +
basement O +
membrane O +
were O +
studied O +
in O +
rats O +
8 O +
months O +
after O +
induction O +
of O +
diabetes B-Disease +
by O +
streptozotocin O +
and O +
in O +
age- O +
adn O +
sex O -
- O -
matched O +
control O +
rats O -
, O +
employing O +
the O +
cationic O +
dye O +
cuprolinic O +
blue O -
. O +

Morphometric O +
analysis O +
at O +
the O +
ultrastructural O +
level O +
was O +
performed O +
using O +
a O +
computerized O +
image O +
processor O -
. O +

The O +
heparan O +
sulphate O +
specificity O +
of O +
the O +
cuprolinic O +
blue O +
staining O +
was O +
demonstrated O +
by O +
glycosaminoglycan O -
- O -
degrading O +
enzymes O -
, O +
showing O +
that O +
pretreatment O +
of O +
the O +
sections O +
with O +
heparitinase O +
abolished O +
all O +
staining O -
, O +
whereas O +
chondroitinase O +
ABC O +
had O +
no O +
effect O -
. O +

The O +
majority O +
of O +
anionic O +
sites O +
( O -
74 O -
% O +
in O +
diabetic B-Disease +
and O +
81 O -
% O +
in O +
control O +
rats O -
) O +
were O +
found O +
within O +
the O +
lamina O +
rara O +
externa O +
of O +
the O +
glomerular O +
basement O +
membrane O -
. O +

A O +
minority O +
of O +
anionic O +
sites O +
were O +
scattered O +
throughout O +
the O +
lamina O +
densa O +
and O +
lamina O +
rara O +
interna O -
, O +
and O +
were O +
significantly O +
smaller O +
than O +
those O +
in O +
the O +
lamina O +
rara O +
externa O +
of O +
the O +
glomerular O +
basement O +
membrane O +
( O -
p<0.001 O +
and O +
p<0.01 O +
for O +
diabetic B-Disease +
and O +
control O +
rats O -
, O +
respectively O -
) O -
. O +

Diabetic B-Disease +
rats O +
progressively O +
developed O +
albuminuria B-Disease +
reaching O +
40.3 O +
( O -
32.2 O -
- O -
62.0 O -
) O +
mg O -
/ O -
24 O +
h O +
after O +
8 O +
months O +
in O +
contrast O +
to O +
the O +
control O +
animals O +
( O -
0.8 O +
( O -
0.2 O -
- O -
0.9 O -
) O +
mg O -
/ O -
24 O +
h O -
, O +
p<0.002 O -
) O -
. O +

At O +
the O +
same O +
time O -
, O +
the O +
number O +
of O +
heparan O +
sulphate O +
anionic O +
sites O +
and O +
the O +
total O +
anionic O +
site O +
surface O +
( O -
number O +
of O +
anionic O +
sites O +
x O +
mean O +
anionic O +
site O +
surface O -
) O +
in O +
the O +
lamina O +
rara O +
externa O +
of O +
the O +
glomerular O +
basement O +
membrane O +
was O +
reduced O +
by O +
19 O -
% O +
( O -
p<0.021 O -
) O +
and O +
by O +
26 O -
% O +
( O -
p<0.02 O -
) O -
, O +
respectively O -
. O +

Number O +
and O +
total O +
anionic O +
site O +
surface O +
in O +
the O +
remaining O +
part O +
of O +
the O +
glomerular O +
basement O +
membrane O +
( O -
lamina O +
densa O +
and O +
lamina O +
rara O +
interna O -
) O +
were O +
not O +
significantly O +
changed O -
. O +

We O +
conclude O +
that O +
in O +
streptozotocin O -
- O -
diabetic B-Disease +
rats O +
with O +
an O +
increased O +
urinary O +
albumin O +
excretion O -
, O +
a O +
reduced O +
heparan O +
sulphate O +
charge O +
barrier O -
/ O -
density O +
is O +
found O +
at O +
the O +
lamina O +
rara O +
externa O +
of O +
the O +
glomerular O +
basement O +
membrane O -
. O +

Mediation O +
of O +
enhanced O +
reflex O +
vagal O +
bradycardia B-Disease +
by O +
L O -
- O -
dopa O +
via O +
central O +
dopamine O +
formation O +
in O +
dogs O -
. O +

L O -
- O -
Dopa O +
( O -
5 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
decreased O +
blood O +
pressure O +
and O +
heart O +
rate O +
after O +
extracerebral O +
decarboxylase O +
inhibition O +
with O +
MK-486 O +
( O -
25 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
in O +
anesthetize O +
MAO O -
- O -
inhibited O +
dogs O -
. O +

In O +
addition O -
, O +
reflex O +
bradycardia B-Disease +
caused O +
by O +
injected O +
norepinephrine O +
was O +
significantly O +
enhanced O +
by O +
L O -
- O -
dopa O -
, O +
DL O -
- O -
Threo O -
- O -
dihydroxyphenylserine O +
had O +
no O +
effect O +
on O +
blood O +
pressure O -
, O +
heart O +
rate O +
or O +
reflex O +
responses O +
to O +
norepinephrine O -
. O +

FLA-63 O -
, O +
a O +
dopamine O -
- O -
beta O -
- O -
oxidase O +
inhibitor O -
, O +
did O +
not O +
have O +
any O +
effect O +
on O +
the O +
hypotension B-Disease -
, O +
bradycardia B-Disease +
or O +
reflex O -
- O -
enhancing O +
effect O +
of O +
L O -
- O -
dopa O -
. O +

Pimozide O +
did O +
not O +
affect O +
the O +
actions O +
of O +
L O -
- O -
dopa O +
on O +
blood O +
pressure O +
and O +
heart O +
rate O +
but O +
completely O +
blocked O +
the O +
enhancement O +
of O +
reflexes O -
. O +

Removal O +
of O +
the O +
carotid O +
sinuses O +
caused O +
an O +
elevation O +
blood O +
pressure O +
and O +
heart O +
rate O +
and O +
abolished O +
the O +
negative O +
chronotropic O +
effect O +
of O +
norepinephrine O -
. O +

However O -
, O +
L O -
- O -
dopa O +
restored O +
the O +
bradycardia B-Disease +
caused O +
by O +
norepinephrine O +
in O +
addition O +
to O +
decreasing O +
blood O +
pressure O +
and O +
heart O +
rate O -
. O +

5-HTP O +
( O -
5 O +
mg O -
/ O -
kg O +
i.v O -
. O -
) O +
decreased O +
blood O +
pressure O +
and O +
heart O +
rate O +
and O +
decreased O +
the O +
reflex O +
bradycardia B-Disease +
to O +
norepinephrine O -
. O +

It O +
is O +
concluded O +
that O +
L O -
- O -
dopa O +
enhances O +
reflex O +
bradycardia B-Disease +
through O +
central O +
alpha O -
- O -
receptor O +
stimulation O -
. O +

Furthermore O -
, O +
the O +
effects O +
are O +
mediated O +
through O +
dopamine O +
rather O +
than O +
norepinephrine O +
and O +
do O +
not O +
require O +
the O +
carotid O +
sinus O +
baroreceptors O -
. O +

Microangiopathic B-Disease +
hemolytic I-Disease +
anemia I-Disease +
complicating O +
FK506 O +
( O -
tacrolimus O -
) O +
therapy O -
. O +

We O +
describe O +
3 O +
episodes O +
of O +
microangiopathic B-Disease +
hemolytic I-Disease +
anemia I-Disease +
( O -
MAHA B-Disease -
) O +
in O +
2 O +
solid O +
organ O +
recipients O +
under O +
FK506 O +
( O -
tacrolimus O -
) O +
therapy O -
. O +

In O +
both O +
cases O -
, O +
discontinuation O +
of O +
FK506 O +
and O +
treatment O +
with O +
plasma O +
exchange O -
, O +
fresh O +
frozen O +
plasma O +
replacement O -
, O +
corticosteroids O -
, O +
aspirin O -
, O +
and O +
dipyridamole O +
led O +
to O +
resolution O +
of O +
MAHA B-Disease -
. O +

In O +
one O +
patient O -
, O +
reintroduction O +
of O +
FK506 O +
led O +
to O +
rapid O +
recurrence O +
of O +
MAHA B-Disease -
. O +

FK506-associated O +
MAHA B-Disease +
is O +
probably O +
rare O +
but O +
physicians O +
must O +
be O +
aware O +
of O +
this O +
severe O +
complication O -
. O +

In O +
our O +
experience O +
and O +
according O +
to O +
the O +
literature O -
, O +
FK506 O +
does O +
not O +
seem O +
to O +
cross O -
- O -
react O +
with O +
cyclosporin O +
A O +
( O -
CyA O -
) O -
, O +
an O +
immuno O -
- O -
suppressive O +
drug O +
already O +
known O +
to O +
induce O +
MAHA B-Disease -
. O +

The O +
use O +
of O +
serum O +
cholinesterase O +
in O +
succinylcholine O +
apnoea B-Disease -
. O +

Fifteen O +
patients O +
demonstrating O +
unexpected O +
prolonged O +
apnoea B-Disease +
lasting O +
several O +
hours O +
after O +
succinylcholine O +
have O +
been O +
treated O +
by O +
a O +
new O +
preparation O +
of O +
human O +
serum O +
cholinesterase O -
. O +

Adequate O +
spontaneous O +
respiration O +
was O +
re O -
- O -
established O +
in O +
an O +
average O +
period O +
of O +
ten O +
minutes O +
after O +
the O +
injection O -
. O +

In O +
12 O +
patients O +
biochemical O +
genetic O +
examinations O +
confirmed O +
the O +
presence O +
of O +
an O +
atypical O +
serum O +
cholinesterase O -
. O +

In O +
three O +
patients O +
none O +
of O +
the O +
usual O +
variants O +
were O +
found O -
. O +

It O +
is O +
therefore O +
supposed O +
that O +
other O +
unknown O +
variants O +
of O +
serum O +
cholinesterase O +
exist O +
which O +
can O -
not O +
hydrolyze O +
succinylcholine O -
. O +

The O +
use O +
of O +
serum O +
cholinesterase O +
in O +
succinylcholine O +
apnoea B-Disease +
provided O +
considerable O +
relief O +
to O +
both O +
patient O +
and O +
anaesthetist O -
. O +

Increased O +
sulfation O +
and O +
decreased O +
7alpha O -
- O -
hydroxylation O +
of O +
deoxycholic O +
acid O +
in O +
ethinyl O +
estradiol O -
- O -
induced O +
cholestasis B-Disease +
in O +
rats O -
. O +

Deoxycholic O +
acid O +
conjugation O -
, O +
transport O +
capacity O -
, O +
and O +
metabolism O +
were O +
compared O +
in O +
control O +
and O +
ethinyl O +
estradiol O -
- O -
treated O +
rats O -
. O +

Control O +
rats O +
were O +
found O +
to O +
have O +
a O +
lower O +
capacity O +
to O +
transport O +
deoxycholic O +
acid O +
than O +
taurodeoxycholic O +
acid O -
, O +
and O +
both O +
were O +
decreased O +
by O +
ethinyl O +
estradiol O +
treatment O -
. O +

During O +
[ O -
24 O -
- O -
14C O -
] O -
sodium O +
deoxycholate O +
infusion O -
, O +
[ O -
14C O -
] O -
biliary O +
bile O +
acid O +
secretion O +
increased O -
, O +
but O +
bile O +
flow O +
did O +
not O +
change O +
significantly O +
in O +
either O +
control O +
or O +
ethinyl O +
estradiol O -
- O -
treated O +
rats O -
. O +

Ethinyl O +
estradiol O -
- O -
treated O +
animals O +
excreted O +
significantly O +
less O +
14C O +
as O +
taurocholic O +
acid O +
than O +
did O +
control O +
animals O -
, O +
consistent O +
with O +
an O +
impairment O +
of O +
7alpha O -
- O -
hydroxylation O +
of O +
taurodeoxycholic O +
acid O -
. O +

Ethinyl O +
estradiol O +
treatment O +
did O +
not O +
impair O +
conjugation O +
of O +
deoxycholic O +
acid O -
, O +
but O +
did O +
result O +
in O +
an O +
increase O +
in O +
sulfation O +
of O +
taurodeoxycholic O +
acid O +
from O +
1.5 O -
% O +
in O +
controls O +
to O +
nearly O +
4.0 O -
% O +
( O -
P O +
less O +
than O +
0.01 O -
) O -
. O +

These O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
the O +
rat O +
has O +
a O +
poorer O +
tolerance O +
for O +
deoxycholic O +
acid O +
than O +
do O +
certain O +
other O +
species O -
. O +

Furthermore O -
, O +
the O +
rat O +
converts O +
deoxycholic O +
acid O -
, O +
a O +
poor O +
choleretic O -
, O +
to O +
taurocholic O +
acid O -
, O +
a O +
good O +
choleretic O -
. O +

When O +
this O +
conversion O +
is O +
impaired O +
with O +
ethinyl O +
estradiol O +
treatment O -
, O +
sulfation O +
may O +
be O +
an O +
important O +
alternate O +
pathway O +
for O +
excretion O +
of O +
this O +
potentially O +
harmful O +
bile O +
acid O -
. O +

Effect O +
of O +
some O +
anticancer O +
drugs O +
and O +
combined O +
chemotherapy O +
on O +
renal B-Disease +
toxicity I-Disease -
. O +

The O +
nephrotoxic B-Disease +
action O +
of O +
anticancer O +
drugs O +
such O +
as O +
nitrogranulogen O +
( O -
NG O -
) O -
, O +
methotrexate O +
( O -
MTX O -
) O -
, O +
5-fluorouracil O +
( O -
5-FU O -
) O +
and O +
cyclophosphamide O +
( O -
CY O -
) O +
administered O +
alone O +
or O +
in O +
combination O +
[ O -
MTX O +
+ O +
5-FU O +
+ O +
CY O +
( O -
CMF O -
) O -
] O +
was O +
evaluated O +
in O +
experiments O +
on O +
Wistar O +
rats O -
. O +

After O +
drug O +
administration O -
, O +
creatinine O +
concentrations O +
in O +
the O +
plasma O +
and O +
in O +
the O +
urine O +
of O +
the O +
rats O +
were O +
determined O -
, O +
as O +
well O +
as O +
creatinine O +
clearance O -
. O +

Histopathologic O +
evaluation O +
of O +
the O +
kidneys O +
was O +
also O +
performed O -
. O +

After O +
MTX O +
administration O +
a O +
significant O +
increase O +
( O -
p O +
= O +
0.0228 O -
) O +
in O +
the O +
plasma O +
creatinine O +
concentration O +
and O +
a O +
significant O +
( O -
p O +
= O +
0.0001 O -
) O +
decrease O +
in O +
creatinine O +
clearance O +
was O +
noted O +
compared O +
to O +
controls O -
. O +

After O +
the O +
administration O +
of O +
NG O -
, O +
5-FU O +
and O +
CY O +
neither O +
a O +
statistically O +
significant O +
increase O +
in O +
creatinine O +
concentration O +
nor O +
an O +
increase O +
in O +
creatinine O +
clearance O +
was O +
observed O +
compared O +
to O +
the O +
group O +
receiving O +
no O +
cytostatics O -
. O +

Following O +
polytherapy O +
according O +
to O +
the O +
CMF O +
regimen O -
, O +
a O +
statistically O +
significant O +
decrease O +
( O -
p O +
= O +
0.0343 O -
) O +
in O +
creatinine O +
clearance O +
was O +
found O -
, O +
but O +
creatinine O +
concentration O +
did O +
not O +
increase O +
significantly O +
compared O +
to O +
controls O -
. O +

CY O +
caused O +
hemorrhagic B-Disease +
cystitis B-Disease +
in O +
40 O -
% O +
of O +
rats O -
, O +
but O +
it O +
did O +
not O +
cause O +
this O +
complication O +
when O +
combined O +
with O +
5-FU O +
and O +
MTX O -
. O +

Histologic O +
changes O +
were O +
found O +
in O +
rat O +
kidneys O +
after O +
administration O +
of O +
MTX O -
, O +
CY O +
and O +
NG O -
, O +
while O +
no O +
such O +
change O +
was O +
observed O +
after O +
5-FU O +
and O +
joint O +
administration O +
of O +
MTX O +
+ O +
5-FU O +
+ O +
CY O +
compared O +
to O +
controls O -
. O +

Our O +
studies O +
indicate O +
that O +
nephrotoxicity B-Disease +
of O +
MTX O +
+ O +
5-FU O +
+ O +
CY O +
administered O +
jointly O +
is O +
lower O +
than O +
in O +
monotherapy O -
. O +

The O +
interpeduncular O +
nucleus O +
regulates O +
nicotine O -
's O +
effects O +
on O +
free O -
- O -
field O +
activity O -
. O +

Partial O +
lesions O +
were O +
made O +
with O +
kainic O +
acid O +
in O +
the O +
interpeduncular O +
nucleus O +
of O +
the O +
ventral O +
midbrain O +
of O +
the O +
rat O -
. O +

Compared O +
with O +
sham O -
- O -
operated O +
controls O -
, O +
lesions O +
significantly O +
( O -
p O +
< O +
0.25 O -
) O +
blunted O +
the O +
early O +
( O -
< O -
60 O +
min O -
) O +
free O -
- O -
field O +
locomotor B-Disease +
hypoactivity I-Disease +
caused O +
by O +
nicotine O +
( O -
0.5 O +
mg O +
kg O -
( O -
-1 O -
) O -
, O +
i.m O -
. O -
) O -
, O +
enhanced O +
the O +
later O +
( O -
60 O -
- O -
120 O +
min O -
) O +
nicotine O -
- O -
induced O +
hyperactivity B-Disease -
, O +
and O +
raised O +
spontaneous O +
nocturnal O +
activity O -
. O +

Lesions O +
reduced O +
the O +
extent O +
of O +
immunohistological O +
staining O +
for O +
choline O +
acetyltransferase O +
in O +
the O +
interpeduncular O +
nucleus O +
( O -
p O +
< O -
0.025 O -
) O -
, O +
but O +
not O +
for O +
tyrosine O +
hydroxylase O +
in O +
the O +
surrounding O +
catecholaminergic O +
A10 O +
region O -
. O +

We O +
conclude O +
that O +
the O +
interpeduncular O +
nucleus O +
mediates O +
nicotinic O +
depression B-Disease +
of O +
locomotor O +
activity O +
and O +
dampens O +
nicotinic O +
arousal O +
mechanisms O +
located O +
elsewhere O +
in O +
the O +
brain O -
. O +

Influence O +
of O +
diet O +
free O +
of O +
NAD O -
- O -
precursors O +
on O +
acetaminophen O +
hepatotoxicity B-Disease +
in O +
mice O -
. O +

Recently O -
, O +
we O +
demonstrated O +
the O +
hepatoprotective O +
effects O +
of O +
nicotinic O +
acid O +
amide O -
, O +
a O +
selective O +
inhibitor O +
of O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
( O -
PARP O -
; O +
EC O +
2.4.2.30 O -
) O +
on O +
mice O +
suffering O +
from O +
acetaminophen O +
( O -
AAP O -
) O -
-hepatitis O -
, O +
suggesting O +
that O +
the O +
AAP O -
- O -
induced O +
liver B-Disease +
injury I-Disease +
involves O +
a O +
step O +
which O +
depends O +
on O +
adenoribosylation O -
. O +

The O +
present O +
study O +
investigates O +
the O +
effects O +
of O +
a O +
diet O +
free O +
of O +
precursors O +
of O +
NAD O -
, O +
the O +
substrate O +
on O +
which O +
PARP O +
acts O -
, O +
in O +
female O +
NMRI O +
mice O +
with O +
AAP O +
hepatitis B-Disease +
and O +
evaluates O +
the O +
influence O +
of O +
simultaneous O +
ethanol O +
consumption O +
in O +
these O +
animals O -
. O +

Liver B-Disease +
injuries I-Disease +
were O +
quantified O +
as O +
serum O +
activities O +
of O +
glutamate O -
- O -
oxaloacetate O +
transaminase O +
( O -
GOT O -
) O +
and O +
glutamate O -
- O -
pyruvate O +
transaminase O +
( O -
GPT O -
) O -
. O +

While O +
AAP O +
caused O +
a O +
117-fold O +
elevation O +
of O +
serum O +
transaminase O +
activities O +
in O +
mice O +
kept O +
on O +
a O +
standard O +
laboratory O +
diet O -
, O +
which O +
was O +
significantly O +
exacerbated O +
by O +
ethanol O +
and O +
inhibited O +
by O +
nicotinic O +
acid O +
amide O +
( O -
NAA O -
) O -
, O +
adverse O +
effects O +
were O +
noted O +
in O +
animals O +
fed O +
a O +
diet O +
free O +
of O +
precursors O +
of O +
NAD O -
. O +

In O +
these O +
animals O -
, O +
only O +
minor O +
increases O +
of O +
serum O +
transaminase O +
activities O +
were O +
measured O +
in O +
the O +
presence O +
of O +
AAP O -
, O +
and O +
unlike O +
the O +
exacerbation O +
caused O +
by O +
ethanol O +
in O +
mice O +
on O +
a O +
standard O +
diet O -
, O +
the O +
liver B-Disease +
damage I-Disease +
was O +
inhibited O +
by O +
50 O -
% O +
by O +
ethanol O -
. O +

A O +
further O +
64 O -
% O +
reduction O +
of O +
hepatitis B-Disease +
was O +
observed O -
, O +
when O +
NAA O +
was O +
given O +
to O +
ethanol O -
/ O -
AAP O -
- O -
mice O -
. O +

Our O +
results O +
provide O +
evidence O +
that O +
the O +
AAP O -
- O -
induced O +
hepatitis B-Disease +
and O +
its O +
exacerbation O +
by O +
ethanol O +
can O +
either O +
be O +
reduced O +
by O +
end O -
- O -
product O +
inhibition O +
of O +
PARP O +
by O +
NAA O +
or O +
by O +
dietary O +
depletion O +
of O +
the O +
enzyme O -
's O +
substrate O +
NAD O -
. O +

We O +
see O +
the O +
main O +
application O +
of O +
NAA O +
as O +
for O +
the O +
combinational O +
use O +
in O +
pharmaceutical O +
preparations O +
of O +
acetaminophen O +
in O +
order O +
to O +
avoid O +
hepatic B-Disease +
damage I-Disease +
in O +
patients O +
treated O +
with O +
this O +
widely O +
used O +
analgesic O -
. O +

Lithium O -
- O -
associated O +
cognitive B-Disease +
and I-Disease +
functional I-Disease +
deficits I-Disease +
reduced O +
by O +
a O +
switch O +
to O +
divalproex O +
sodium O -
: O +
a O +
case O +
series O -
. O +

BACKGROUND O -
: O +
Lithium O +
remains O +
a O +
first O -
- O -
line O +
treatment O +
for O +
the O +
acute O +
and O +
maintenance O +
treatment O +
of O +
bipolar B-Disease +
disorder I-Disease -
. O +

Although O +
much O +
has O +
been O +
written O +
about O +
the O +
management O +
of O +
the O +
more O +
common O +
adverse O +
effects O +
of O +
lithium O -
, O +
such O +
as O +
polyuria B-Disease +
and O +
tremor B-Disease -
, O +
more O +
subtle O +
lithium O +
side O +
effects O +
such O +
as O +
cognitive B-Disease +
deficits I-Disease -
, O +
loss B-Disease +
of I-Disease +
creativity I-Disease -
, O +
and O +
functional B-Disease +
impairments I-Disease +
remain O +
understudied O -
. O +

This O +
report O +
summarizes O +
our O +
experience O +
in O +
switching O +
bipolar B-Disease +
patients O +
from O +
lithium O +
to O +
divalproex O +
sodium O +
to O +
alleviate O +
such O +
cognitive B-Disease +
and I-Disease +
functional I-Disease +
impairments I-Disease -
. O +

METHOD O -
: O +
Open O -
, O +
case O +
series O +
design O -
. O +

RESULTS O -
: O +
We O +
report O +
seven O +
cases O +
where O +
substitution O +
of O +
lithium O -
, O +
either O +
fully O +
or O +
partially O -
, O +
with O +
divalproex O +
sodium O +
was O +
extremely O +
helpful O +
in O +
reducing O +
the O +
cognitive B-Disease -
, I-Disease +
motivational I-Disease -
, I-Disease +
or I-Disease +
creative I-Disease +
deficits I-Disease +
attributed O +
to O +
lithium O +
in O +
our O +
bipolar B-Disease +
patients O -
. O +

CONCLUSION O -
: O +
In O +
this O +
preliminary O +
report O -
, O +
divalproex O +
sodium O +
was O +
a O +
superior O +
alternative O +
to O +
lithium O +
in O +
bipolar B-Disease +
patients O +
experiencing O +
cognitive B-Disease +
deficits I-Disease -
, O +
loss B-Disease +
of I-Disease +
creativity I-Disease -
, O +
and O +
functional B-Disease +
impairments I-Disease -
. O +

Nightmares O +
and O +
hallucinations B-Disease +
after O +
long O -
- O -
term O +
intake O +
of O +
tramadol O +
combined O +
with O +
antidepressants O -
. O +

Tramadol O +
is O +
a O +
weak O +
opioid O +
with O +
effects O +
on O +
adrenergic O +
and O +
serotonergic O +
neurotransmission O +
that O +
is O +
used O +
to O +
treat O +
cancer B-Disease +
pain B-Disease +
and O +
chronic O +
non O +
malignant O +
pain B-Disease -
. O +

This O +
drug O +
was O +
initiated O +
in O +
association O +
with O +
paroxetine O +
and O +
dosulepine O +
hydrochloride O +
in O +
a O +
tetraparetic B-Disease +
patient O +
with O +
chronic B-Disease +
pain I-Disease -
. O +

Fifty O -
- O -
six O +
days O +
after O +
initiation O +
of O +
the O +
treatment O +
the O +
patient O +
presented O +
hallucinations B-Disease +
that O +
only O +
stopped O +
after O +
the O +
withdrawal O +
of O +
psycho O -
- O -
active O +
drugs O +
and O +
tramadol O -
. O +

The O +
case O +
report O +
questions O +
the O +
long O +
term O +
use O +
of O +
pain B-Disease +
killers O +
combined O +
with O +
psycho O -
- O -
active O +
drugs O +
in O +
chronic O +
non O +
malignant O +
pain B-Disease -
, O +
especially O +
if O +
pain B-Disease +
is O +
under O +
control O -
. O +

Effect O +
of O +
calcium O +
chloride O +
and O +
4-aminopyridine O +
therapy O +
on O +
desipramine O +
toxicity B-Disease +
in O +
rats O -
. O +

BACKGROUND O -
: O +
Hypotension B-Disease +
is O +
a O +
major O +
contributor O +
to O +
mortality O +
in O +
tricyclic O +
antidepressant O +
overdose B-Disease -
. O +

Recent O +
data O +
suggest O +
that O +
tricyclic O +
antidepressants O +
inhibit O +
calcium O +
influx O +
in O +
some O +
tissues O -
. O +

This O +
study O +
addressed O +
the O +
potential O +
role O +
of O +
calcium O +
channel O +
blockade O +
in O +
tricyclic O +
antidepressant O -
- O -
induced O +
hypotension B-Disease -
. O +

METHODS O -
: O +
Two O +
interventions O +
were O +
studied O +
that O +
have O +
been O +
shown O +
previously O +
to O +
improve O +
blood O +
pressure O +
with O +
calcium O +
channel O +
blocker O +
overdose B-Disease -
. O +

CaCl2 O +
and O +
4-aminopyridine O -
. O +

Anesthetized O +
rats O +
received O +
the O +
tricyclic O +
antidepressant O +
desipramine O +
IP O +
to O +
produce O +
hypotension B-Disease -
, O +
QRS O +
prolongation O -
, O +
and O +
bradycardia B-Disease -
. O +

Fifteen O +
min O +
later O -
, O +
animals O +
received O +
CaCl2 O -
, O +
NaHCO3 O -
, O +
or O +
saline O -
. O +

In O +
a O +
second O +
experiment O -
, O +
rats O +
received O +
tricyclic O +
antidepressant O +
desipramine O +
IP O +
followed O +
in O +
15 O +
min O +
by O +
4-aminopyridine O +
or O +
saline O -
. O +

RESULTS O -
: O +
NaHCO3 O +
briefly O +
( O -
5 O +
min O -
) O +
reversed O +
hypotension B-Disease +
and O +
QRS O +
prolongation O -
. O +

CaCl2 O +
and O +
4-aminopyridine O +
failed O +
to O +
improve O +
blood O +
pressure O -
. O +

The O +
incidence O +
of O +
ventricular B-Disease +
arrhythmias I-Disease +
( O -
p O +
= O +
0.004 O -
) O +
and O +
seizures B-Disease +
( O -
p O +
= O +
0.03 O -
) O +
in O +
the O +
CaCl2 O +
group O +
was O +
higher O +
than O +
the O +
other O +
groups O -
. O +

CONCLUSION O -
: O +
The O +
administration O +
of O +
CaCl2 O +
or O +
4-aminopyridine O +
did O +
not O +
reverse O +
tricyclic O +
antidepressant O -
- O -
induced O +
hypotension B-Disease +
in O +
rats O -
. O +

CaCl2 O +
therapy O +
may O +
possibly O +
worsen O +
both O +
cardiovascular B-Disease +
and I-Disease +
central I-Disease +
nervous I-Disease +
system I-Disease +
toxicity I-Disease -
. O +

These O +
findings O +
do O +
not O +
support O +
a O +
role O +
for O +
calcium O +
channel O +
inhibition O +
in O +
the O +
pathogenesis O +
of O +
tricyclic O +
antidepressant O -
- O -
induced O +
hypotension B-Disease -
. O +

Effect O +
of O +
nifedipine O +
on O +
renal O +
function O +
in O +
liver O +
transplant O +
recipients O +
receiving O +
tacrolimus O -
. O +

The O +
effect O +
of O +
nifedipine O +
on O +
renal O +
function O +
in O +
liver O +
transplant O +
recipients O +
who O +
were O +
receiving O +
tacrolimus O +
was O +
evaluated O +
between O +
January O +
1992 O +
and O +
January O +
1996 O -
. O +

Two O +
groups O +
of O +
patients O +
receiving O +
tacrolimus O +
were O +
compared O +
over O +
a O +
period O +
of O +
1 O +
year O -
, O +
one O +
group O +
comprising O +
hypertensive B-Disease +
patients O +
who O +
were O +
receiving O +
nifedipine O -
, O +
and O +
the O +
other O +
comprising O +
nonhypertensive O +
patients O +
not O +
receiving O +
nifedipine O -
. O +

The O +
time O +
from O +
transplant O +
to O +
baseline O +
was O +
similar O +
in O +
all O +
patients O -
. O +

Nifedipine O +
significantly O +
improved O +
kidney O +
function O +
as O +
indicated O +
by O +
a O +
significant O +
lowering O +
of O +
serum O +
creatinine O +
levels O +
at O +
6 O +
and O +
12 O +
months O -
. O +

The O +
observed O +
positive O +
impact O +
of O +
nifedipine O +
on O +
reducing O +
the O +
nephrotoxicity B-Disease +
associated O +
with O +
tacrolimus O +
in O +
liver O +
transplant O +
recipients O +
should O +
be O +
an O +
important O +
factor O +
in O +
selecting O +
an O +
agent O +
to O +
treat O +
hypertension B-Disease +
in O +
this O +
population O -
. O +

Alpha O +
and O +
beta O +
coma B-Disease +
in O +
drug O +
intoxication O +
uncomplicated O +
by O +
cerebral B-Disease +
hypoxia I-Disease -
. O +

Four O +
patients O +
who O +
were O +
rendered O +
comatose B-Disease +
or O +
stuporous B-Disease +
by O +
drug O +
intoxication O -
, O +
but O +
who O +
were O +
not O +
hypoxic O -
, O +
are O +
described O -
. O +

Three O +
patients O +
received O +
high O +
doses O +
of O +
chlormethiazole O +
for O +
alcohol O +
withdrawal B-Disease +
symptoms I-Disease -
, O +
and O +
one O +
took O +
a O +
suicidal O +
overdose B-Disease +
of O +
nitrazepam O -
. O +

The O +
patient O +
with O +
nitrazepam O +
overdose B-Disease +
and O +
two O +
of O +
those O +
with O +
chlormethiazole O +
intoxication O +
conformed O +
to O +
the O +
criteria O +
of O +
' O -
alpha O +
coma B-Disease -
' O -
, O +
showing O +
non O -
- O -
reactive O +
generalized O +
or O +
frontally O +
predominant O +
alpha O +
activity O +
in O +
the O +
EEG O -
. O +

The O +
fourth O +
patient O +
who O +
was O +
unconscious O +
after O +
chlormethiazole O +
administration O +
exhibite O +
generalized O +
non O -
- O -
reactive O +
activity O +
in O +
the O +
slow O +
beta O +
range O -
. O +

All O +
four O +
recovered O +
completely O +
without O +
neurological B-Disease +
sequelae I-Disease +
following O +
the O +
withdrawal O +
of O +
the O +
offending O +
agents O -
. O +

The O +
similarities O +
between O +
the O +
effects O +
of O +
structural O +
lesions O +
and O +
pharmacological O +
depression B-Disease +
of O +
the O +
brain O +
stem O +
reticular O +
formation O +
are O +
discussed O -
. O +

It O +
is O +
suggested O +
that O +
in O +
both O +
situations O +
disturbed O +
reticulo O -
- O -
thalamic O +
interactions O +
are O +
important O +
in O +
the O +
pathogenesis O +
of O +
alpha O +
coma B-Disease -
. O +

It O +
is O +
concluded O +
that O +
when O +
this O +
electroencephalographic O +
and O +
behavioural O +
picture O +
is O +
seen O +
in O +
drug O +
intoxication O -
, O +
in O +
the O +
absence O +
of O +
significant O +
hypoxaemia B-Disease -
, O +
a O +
favourable O +
outcome O +
may O +
be O +
anticipated O -
. O +

A O +
measure O +
of O +
pupillary B-Disease +
oscillation I-Disease +
as O +
a O +
marker O +
of O +
cocaine O -
- O -
induced O +
paranoia B-Disease -
. O +

Cocaine O -
- O -
induced O +
paranoia B-Disease +
( O -
CIP B-Disease -
) O +
remains O +
an O +
important O +
drug O -
- O -
induced O +
model O +
of O +
idiopathic O +
paranoia B-Disease +
for O +
which O +
no O +
psychophysiologic O +
marker O +
has O +
yet O +
emerged O -
. O +

Measures O +
of O +
pupillary B-Disease +
oscillation I-Disease +
were O +
able O +
to O +
significantly O +
distinguish O +
a O +
group O +
of O +
abstinent O +
crack O +
cocaine O +
abusers O +
endorsing O +
past O +
CIP B-Disease +
( O -
n O +
= O +
32 O -
) O +
from O +
another O +
group O +
of O +
crack O +
addicts O +
who O +
denied O +
past O +
CIP B-Disease +
( O -
n O +
= O +
29 O -
) O -
. O +

Magnetic O +
resonance O +
volumetry O +
of O +
the O +
cerebellum O +
in O +
epileptic B-Disease +
patients O +
after O +
phenytoin O +
overdosages B-Disease -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
relationship O +
between O +
phenytoin O +
medication O +
and O +
cerebellar B-Disease +
atrophy I-Disease +
in O +
patients O +
who O +
had O +
experienced O +
clinical O +
intoxication O -
. O +

Five O +
females O +
and O +
6 O +
males O -
, O +
21 O -
- O -
59 O +
years O +
of O +
age O -
, O +
were O +
examined O +
with O +
a O +
1.5-T O +
whole O -
- O -
body O +
system O +
using O +
a O +
circular O +
polarized O +
head O +
coil O -
. O +

Conventional O +
spin O +
echo O +
images O +
were O +
acquired O +
in O +
the O +
sagittal O +
and O +
transverse O +
orientation O -
. O +

In O +
addition O -
, O +
we O +
performed O +
a O +
high O -
- O -
resolution O +
3D O +
gradient O +
echo O -
, O +
T1-weighted O +
sequences O +
at O +
a O +
1-mm O +
slice O +
thickness O -
. O +

The O +
images O +
were O +
subsequently O +
processed O +
to O +
obtain O +
volumetric O +
data O +
for O +
the O +
cerebellum O -
. O +

Cerebellar O +
volume O +
for O +
the O +
patient O +
group O +
ranged O +
between O +
67.66 O +
and O +
131.08 O +
ml O +
( O -
mean O +
108.9 O +
ml O -
) O -
. O +

In O +
addition O +
3D O +
gradient O +
echo O +
data O +
sets O +
from O +
10 O +
healthy O +
male O +
and O +
10 O +
healthy O +
female O +
age O -
- O -
matched O +
volunteers O +
were O +
used O +
to O +
compare O +
cerebellar O +
volumes O -
. O +

Using O +
linear O +
regression O +
we O +
found O +
that O +
no O +
correlation O +
exists O +
between O +
seizure B-Disease +
duration O -
, O +
elevation O +
of O +
phenytoin O +
serum O +
levels O +
and O +
cerebellar O +
volume O -
. O +

However O -
, O +
multiple O +
regression O +
for O +
the O +
daily O +
dosage O -
, O +
duration O +
of O +
phenytoin O +
treatment O +
and O +
cerebellar O +
volume O +
revealed O +
a O +
correlation O +
of O +
these O +
parameters O -
. O +

We O +
conclude O +
that O +
phenytoin O +
overdosage B-Disease +
does O +
not O +
necessarily O +
result O +
in O +
cerebellar B-Disease +
atrophy I-Disease +
and O +
it O +
is O +
unlikely O +
that O +
phenytoin O +
medication O +
was O +
the O +
only O +
cause O +
of O +
cerebellar B-Disease +
atrophy I-Disease +
in O +
the O +
remaining O +
patients O -
. O +

Quantitative O +
morphometric O +
studies O +
of O +
the O +
cerebellum O +
provide O +
valuable O +
insights O +
into O +
the O +
pathogenesis O +
of O +
cerebellar B-Disease +
disorders I-Disease -
. O +

Serotonin B-Disease +
syndrome I-Disease +
from O +
venlafaxine O -
- O -
tranylcypromine O +
interaction O -
. O +

Excessive O +
stimulation O +
of O +
serotonin O +
5HT1A O +
receptors O +
causes O +
a O +
syndrome O +
of O +
serotonin O +
excess O +
that O +
consists O +
of O +
shivering O -
, O +
muscle B-Disease +
rigidity I-Disease -
, O +
salivation B-Disease -
, O +
confusion B-Disease -
, O +
agitation B-Disease +
and O +
hyperthermia B-Disease -
. O +

The O +
most O +
common O +
cause O +
of O +
this O +
syndrome O +
is O +
an O +
interaction O +
between O +
a O +
monoamine O +
oxidase O +
inhibitor O +
( O -
MAOI O -
) O +
and O +
a O +
specific O +
serotonin O +
reuptake O +
inhibitor O -
. O +

Venlafaxine O +
is O +
a O +
new O +
antidepressant O +
agent O +
that O +
inhibits O +
the O +
reuptake O +
of O +
serotonin O +
and O +
norepinephrine O -
. O +

We O +
report O +
a O +
venlafaxine O -
- O -
MAOI O +
interaction O +
that O +
resulted O +
in O +
the O +
serotonin B-Disease +
syndrome I-Disease +
in O +
a O +
23-y O -
- O -
old O +
male O +
who O +
was O +
taking O +
tranylcypromine O +
for O +
depression B-Disease -
. O +

He O +
had O +
been O +
well O +
until O +
the O +
morning O +
of O +
presentation O +
when O +
he O +
took O +
1 O -
/ O -
2 O +
tab O +
of O +
venlafaxine O -
. O +

Within O +
2 O +
h O +
he O +
became O +
confused O +
with O +
jerking O +
movements O +
of O +
his O +
extremities O -
, O +
tremors B-Disease +
and O +
rigidity B-Disease -
. O +

He O +
was O +
brought O +
directly O +
to O +
a O +
hospital O +
where O +
he O +
was O +
found O +
to O +
be O +
agitated O +
and O +
confused O +
with O +
shivering O -
, O +
myoclonic B-Disease +
jerks I-Disease -
, O +
rigidity B-Disease -
, O +
salivation B-Disease +
and O +
diaphoresis O -
. O +

His O +
pupils O +
were O +
7 O +
mm O +
and O +
sluggishly O +
reactive O +
to O +
light O -
. O +

Vital O +
signs O +
were O -
: O +
blood O +
pressure O +
120 O -
/ O -
67 O +
mm O +
Hg O -
, O +
heart O +
rate O +
127 O -
/ O -
min O -
, O +
respiratory O +
rate O +
28 O -
/ O -
min O -
, O +
and O +
temperature O +
97 O +
F. O +
After O +
180 O +
mg O +
of O +
diazepam O +
i.v O -
. O +

he O +
remained O +
tremulous O +
with O +
muscle B-Disease +
rigidity I-Disease +
and O +
clenched O +
jaws O -
. O +

He O +
was O +
intubated O +
for O +
airway O +
protection O +
and O +
because O +
of O +
hypoventilation B-Disease -
, O +
and O +
was O +
paralyzed B-Disease +
to O +
control O +
muscle B-Disease +
rigidity I-Disease -
. O +

His O +
subsequent O +
course O +
was O +
remarkable O +
for O +
non O -
- O -
immune O +
thrombocytopenia B-Disease +
which O +
resolved O -
. O +

The O +
patient O -
's O +
maximal O +
temperature O +
was O +
101.2 O +
F O +
and O +
his O +
CPK O +
remained O +
< O +
500 O +
units O -
/ O -
L O +
with O +
no O +
other O +
evidence O +
of O +
rhabdomyolysis B-Disease -
. O +

His O +
mental O +
status O +
normalized O +
and O +
he O +
was O +
transferred O +
to O +
a O +
psychiatry O +
ward O -
. O +

This O +
patient O +
survived O +
without O +
sequelae O +
due O +
to O +
the O +
aggressive O +
sedation O +
and O +
neuromuscular O +
paralysis B-Disease -
. O +

Late O +
recovery O +
of O +
renal O +
function O +
in O +
a O +
woman O +
with O +
the O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease -
. O +

A O +
case O +
is O +
reported O +
of O +
the O +
hemolytic B-Disease +
uremic I-Disease +
syndrome I-Disease +
( O -
HUS B-Disease -
) O +
in O +
a O +
woman O +
taking O +
oral O +
contraceptives O -
. O +

She O +
was O +
treated O +
with O +
heparin O -
, O +
dipyridamole O +
and O +
hemodialysis O -
; O +
and O +
after O +
more O +
than O +
three O +
months O -
, O +
her O +
urinary O +
output O +
rose O +
above O +
500 O +
ml O -
; O +
and O +
six O +
months O +
after O +
the O +
onset O +
of O +
anuria B-Disease -
, O +
dialysis O +
treatment O +
was O +
stopped O -
. O +

This O +
case O +
emphasizes O +
the O +
possibility O +
that O +
HUS B-Disease +
in O +
adults O +
is O +
not O +
invariably O +
irreversible O +
and O +
that O -
, O +
despite O +
prolonged O +
oliguria B-Disease -
, O +
recovery O +
of O +
renal O +
function O +
can O +
be O +
obtained O -
. O +

Therefore O -
, O +
in O +
adult O +
patients O +
affected O +
by O +
HUS B-Disease -
, O +
dialysis O +
should O +
not O +
be O +
discontinued O +
prematurely O -
; O +
moreover O -
, O +
bilateral O +
nephrectomy O -
, O +
for O +
treatment O +
of O +
severe O +
hypertension B-Disease +
and O +
microangiopathic B-Disease +
hemolytic I-Disease +
anemia I-Disease -
, O +
should O +
be O +
performed O +
with O +
caution O -
. O +

Cyclophosphamide O +
associated O +
bladder B-Disease +
cancer I-Disease -
-- O -
a O +
highly O +
aggressive O +
disease O -
: O +
analysis O +
of O +
12 O +
cases O -
. O +

PURPOSE O -
: O +
We O +
gained O +
knowledge O +
of O +
the O +
etiology O -
, O +
treatment O +
and O +
prevention O +
of O +
cyclophosphamide O +
associated O +
urothelial B-Disease +
cancer I-Disease -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
The O +
medical O +
records O +
of O +
6 O +
men O +
and O +
6 O +
women O +
( O -
mean O +
age O +
55 O +
years O -
) O +
with O +
cyclophosphamide O +
associated O +
bladder B-Disease +
cancer I-Disease +
were O +
reviewed O -
. O +

RESULTS O -
: O +
All O +
tumors B-Disease +
were O +
grade O +
3 O +
or O +
4 O +
transitional O +
cell O +
carcinoma B-Disease -
. O +

Of O +
the O +
5 O +
patients O +
initially O +
treated O +
with O +
endoscopic O +
resection O +
alone O +
only O +
1 O +
is O +
alive O +
without O +
disease O -
. O +

Of O +
the O +
6 O +
patients O +
who O +
underwent O +
early O +
cystectomy O +
4 O +
were O +
alive O +
at O +
24 O +
to O +
111 O +
months O -
. O +

The O +
remaining O +
patient O +
with O +
extensive O +
cancer B-Disease +
underwent O +
partial O +
cystectomy O +
for O +
palliation O +
and O +
died O +
3 O +
months O +
later O -
. O +

CONCLUSIONS O -
: O +
Cyclophosphamide O +
associated O +
bladder B-Disease +
tumor I-Disease +
is O +
an O +
aggressive O +
disease O -
. O +

However O -
, O +
long O -
- O -
term O +
survival O +
is O +
possible O +
when O +
radical O +
cystectomy O +
is O +
performed O +
for O +
bladder B-Disease +
tumors I-Disease +
with O +
any O +
sign O +
of O +
invasion O +
and O +
for O +
recurrent O +
high O +
grade O +
disease O -
, O +
even O +
when O +
noninvasive O -
. O +

Morphological O +
features O +
of O +
encephalopathy B-Disease +
after O +
chronic O +
administration O +
of O +
the O +
antiepileptic O +
drug O +
valproate O +
to O +
rats O -
. O +

A O +
transmission O +
electron O +
microscopic O +
study O +
of O +
capillaries O +
in O +
the O +
cerebellar O +
cortex O -
. O +

Long O -
- O -
term O +
intragastric O +
application O +
of O +
the O +
antiepileptic O +
drug O +
sodium O +
valproate O +
( O -
Vupral O +
" O -
Polfa O -
" O -
) O +
at O +
the O +
effective O +
dose O +
of O +
200 O +
mg O -
/ O -
kg O +
b. O +
w. O +
once O +
daily O +
to O +
rats O +
for O +
1 O -
, O +
3 O -
, O +
6 O -
, O +
9 O +
and O +
12 O +
months O +
revealed O +
neurological B-Disease +
disorders I-Disease +
indicating O +
cerebellum B-Disease +
damage I-Disease +
( O -
" O -
valproate O +
encephalopathy B-Disease -
" O -
) O -
. O +

The O +
first O +
ultrastructural O +
changes O +
in O +
structural O +
elements O +
of O +
the O +
blood O -
- O -
brain O -
- O -
barrier O +
( O -
BBB O -
) O +
in O +
the O +
cerebellar O +
cortex O +
were O +
detectable O +
after O +
3 O +
months O +
of O +
the O +
experiment O -
. O +

They O +
became O +
more O +
severe O +
in O +
the O +
later O +
months O +
of O +
the O +
experiment O -
, O +
and O +
were O +
most O +
severe O +
after O +
12 O +
months O -
, O +
located O +
mainly O +
in O +
the O +
molecular O +
layer O +
of O +
the O +
cerebellar O +
cortex O -
. O +

Lesions O +
of O +
the O +
capillary O +
included O +
necrosis B-Disease +
of O +
endothelial O +
cells O -
. O +

Organelles O +
of O +
these O +
cells O -
, O +
in O +
particular O +
the O +
mitochondria O +
( O -
increased O +
number O +
and O +
size O -
, O +
distinct O +
degeneration O +
of O +
their O +
matrix O +
and O +
cristae O -
) O +
and O +
Golgi O +
apparatus O +
were O +
altered O -
. O +

Reduced O +
size O +
of O +
capillary O +
lumen O +
and O +
occlusion O +
were O +
caused O +
by O +
swollen O +
endothelial O +
cells O +
which O +
had O +
luminal O +
protrusions O +
and O +
swollen O +
microvilli O -
. O +

Pressure O +
on O +
the O +
vessel O +
wall O +
was O +
produced O +
by O +
enlarged O +
perivascular O +
astrocytic O +
processes O -
. O +

Fragments O +
of O +
necrotic B-Disease +
endothelial O +
cells O +
were O +
in O +
the O +
vascular O +
lumens O +
and O +
in O +
these O +
there O +
was O +
loosening O +
and O +
breaking O +
of O +
tight O +
cellular O +
junctions O -
. O +

Damage O +
to O +
the O +
vascular O +
basement O +
lamina O +
was O +
also O +
observed O -
. O +

Damage O +
to O +
the O +
capillary O +
was O +
accompanied O +
by O +
marked O +
damage O +
to O +
neuroglial O +
cells O -
, O +
mainly O +
to O +
perivascular O +
processes O +
of O +
astrocytes O -
. O +

The O +
proliferation O +
of O +
astrocytes O +
( O -
Bergmann O -
's O +
in O +
particular O -
) O +
and O +
occasionally O +
of O +
oligodendrocytes O +
was O +
found O -
. O +

Alterations O +
in O +
the O +
structural O +
elements O +
of O +
the O +
BBB O +
coexisted O +
with O +
marked O +
lesions O +
of O +
neurons O +
of O +
the O +
cerebellum O +
( O -
Purkinje O +
cells O +
are O +
earliest O -
) O -
. O +

In O +
electron O +
micrographs O +
both O +
luminal O +
and O +
antiluminal O +
sides O +
of O +
the O +
BBB O +
of O +
the O +
cerebellar O +
cortex O +
had O +
similar O +
lesions O -
. O +

The O +
possible O +
influence O +
of O +
the O +
hepatic B-Disease +
damage I-Disease -
, O +
mainly O +
hyperammonemia B-Disease -
, O +
upon O +
the O +
development O +
of O +
valproate O +
encephalopathy B-Disease +
is O +
discussed O -
. O +

Fatal O +
intracranial B-Disease +
bleeding I-Disease +
associated O +
with O +
prehospital O +
use O +
of O +
epinephrine O -
. O +

We O +
present O +
a O +
case O +
of O +
paramedic O +
misjudgment O +
in O +
the O +
execution O +
of O +
a O +
protocol O +
for O +
the O +
treatment O +
of O +
allergic B-Disease +
reaction I-Disease +
in O +
a O +
case O +
of O +
pulmonary B-Disease +
edema I-Disease +
with O +
wheezing B-Disease -
. O +

The O +
sudden O +
onset O +
of O +
respiratory B-Disease +
distress I-Disease -
, O +
rash B-Disease -
, O +
and O +
a O +
history O +
of O +
a O +
new O +
medicine O +
led O +
the O +
two O +
paramedics O +
on O +
the O +
scene O +
to O +
administer O +
subcutaneous O +
epinephrine O -
. O +

Subsequently O -
, O +
acute O +
cardiac B-Disease +
arrest I-Disease +
and O +
fatal O +
subarachnoid B-Disease +
hemorrhage I-Disease +
occurred O -
. O +

Epinephrine O +
has O +
a O +
proven O +
role O +
in O +
cardiac B-Disease +
arrest I-Disease +
in O +
prehospital O +
care O -
; O +
however O -
, O +
use O +
by O +
paramedics O +
in O +
patients O +
with O +
suspected O +
allergic B-Disease +
reaction I-Disease +
and O +
severe O +
hypertension B-Disease +
should O +
be O +
viewed O +
with O +
caution O -
. O +

Role O +
of O +
activation O +
of O +
bradykinin O +
B2 O +
receptors O +
in O +
disruption O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
during O +
acute O +
hypertension B-Disease -
. O +

Cellular O +
mechanisms O +
which O +
account O +
for O +
disruption O +
the O +
blood O -
- O -
brain O +
barrier O +
during O +
acute O +
hypertension B-Disease +
are O +
not O +
clear O -
. O +

The O +
goal O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
role O +
of O +
synthesis O -
/ O -
release O +
of O +
bradykinin O +
to O +
activate O +
B2 O +
receptors O +
in O +
disruption O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
during O +
acute O +
hypertension B-Disease -
. O +

Permeability O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
was O +
quantitated O +
by O +
clearance O +
of O +
fluorescent O -
- O -
labeled O +
dextran O +
before O +
and O +
during O +
phenylephrine O -
- O -
induced O +
acute O +
hypertension B-Disease +
in O +
rats O +
treated O +
with O +
vehicle O +
and O +
Hoe-140 O +
( O -
0.1 O +
microM O -
) O -
. O +

Phenylephrine O +
infusion O +
increased O +
arterial O +
pressure O -
, O +
arteriolar O +
diameter O +
and O +
clearance O +
of O +
fluorescent O +
dextran O +
by O +
a O +
similar O +
magnitude O +
in O +
both O +
groups O -
. O +

These O +
findings O +
suggest O +
that O +
disruption O +
of O +
the O +
blood O -
- O -
brain O +
barrier O +
during O +
acute O +
hypertension B-Disease +
is O +
not O +
related O +
to O +
the O +
synthesis O -
/ O -
release O +
of O +
bradykinin O +
to O +
activate O +
B2 O +
receptors O -
. O +

A O +
phase O +
I O +
clinical O +
study O +
of O +
the O +
antipurine O +
antifolate O +
lometrexol O +
( O -
DDATHF O -
) O +
given O +
with O +
oral O +
folic O +
acid O -
. O +

Lometrexol O +
is O +
an O +
antifolate O +
which O +
inhibits O +
glycinamide O +
ribonucleotide O +
formyltransferase O +
( O -
GARFT O -
) O -
, O +
an O +
enzyme O +
essential O +
for O +
de O +
novo O +
purine O +
synthesis O -
. O +

Extensive O +
experimental O +
and O +
limited O +
clinical O +
data O +
have O +
shown O +
that O +
lometrexol O +
has O +
activity O +
against O +
tumours B-Disease +
which O +
are O +
refractory O +
to O +
other O +
drugs O -
, O +
notably O +
methotrexate O -
. O +

However O -
, O +
the O +
initial O +
clinical O +
development O +
of O +
lometrexol O +
was O +
curtailed O +
because O +
of O +
severe O +
and O +
cumulative O +
antiproliferative O +
toxicities B-Disease -
. O +

Preclinical O +
murine O +
studies O +
demonstrated O +
that O +
the O +
toxicity B-Disease +
of O +
lometrexol O +
can O +
be O +
prevented O +
by O +
low O +
dose O +
folic O +
acid O +
administration O -
, O +
i.e. O +
for O +
7 O +
days O +
prior O +
to O +
and O +
7 O +
days O +
following O +
a O +
single O +
bolus O +
dose O -
. O +

This O +
observation O +
prompted O +
a O +
Phase O +
I O +
clinical O +
study O +
of O +
lometrexol O +
given O +
with O +
folic O +
acid O +
supplementation O +
which O +
has O +
confirmed O +
that O +
the O +
toxicity B-Disease +
of O +
lometrexol O +
can O +
be O +
markedly O +
reduced O +
by O +
folic O +
acid O +
supplementation O -
. O +

Thrombocytopenia B-Disease +
and O +
mucositis B-Disease +
were O +
the O +
major O +
toxicities B-Disease -
. O +

There O +
was O +
no O +
clear O +
relationship O +
between O +
clinical O +
toxicity B-Disease +
and O +
the O +
extent O +
of O +
plasma O +
folate O +
elevation O -
. O +

Associated O +
studies O +
demonstrated O +
that O +
lometrexol O +
plasma O +
pharmacokinetics O +
were O +
not O +
altered O +
by O +
folic O +
acid O +
administration O +
indicating O +
that O +
supplementation O +
is O +
unlikely O +
to O +
reduce O +
toxicity B-Disease +
by O +
enhancing O +
lometrexol O +
plasma O +
clearance O -
. O +

The O +
work O +
described O +
in O +
this O +
report O +
has O +
identified O +
for O +
the O +
first O +
time O +
a O +
clinically O +
acceptable O +
schedule O +
for O +
the O +
administration O +
of O +
a O +
GARFT O +
inhibitor O -
. O +

This O +
information O +
will O +
facilitate O +
the O +
future O +
evaluation O +
of O +
this O +
class O +
of O +
compounds O +
in O +
cancer B-Disease +
therapy O -
. O +

Risk O +
factors O +
of O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease +
in O +
preterm O +
infants O -
. O +

Among O +
547 O +
preterm O +
infants O +
of O +
< O +
or O +
= O +
34 O +
weeks O +
gestation O +
born O +
between O +
1987 O +
and O +
1991 O -
, O +
8 O +
children O +
( O -
1.46 O -
% O -
) O +
developed O +
severe O +
progressive O +
and O +
bilateral O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease -
. O +

Perinatal O +
risk O +
factors O +
of O +
infants O +
with O +
hearing B-Disease +
loss I-Disease +
were O +
compared O +
with O +
those O +
of O +
two O +
control O +
groups O +
matched O +
for O +
gestation O +
and O +
birth O +
weight O +
and O +
for O +
perinatal O +
complications O -
. O +

Our O +
observations O +
demonstrated O +
an O +
association O +
of O +
hearing B-Disease +
loss I-Disease +
with O +
a O +
higher O +
incidence O +
of O +
perinatal O +
complications O -
. O +

Ototoxicity B-Disease +
appeared O +
closely O +
related O +
to O +
a O +
prolonged O +
administration O +
and O +
higher O +
total O +
dose O +
of O +
ototoxic B-Disease +
drugs O -
, O +
particularly O +
aminoglycosides O +
and O +
furosemide O -
. O +

Finally O -
, O +
we O +
strongly O +
recommend O +
to O +
prospectively O +
and O +
regularly O +
perform O +
audiologic O +
assessment O +
in O +
sick O +
preterm O +
children O +
as O +
hearing B-Disease +
loss I-Disease +
is O +
of O +
delayed O +
onset O +
and O +
in O +
most O +
cases O +
bilateral O +
and O +
severe O -
. O +

Pemoline O +
induced O +
acute O +
choreoathetosis B-Disease -
: O +
case O +
report O +
and O +
review O +
of O +
the O +
literature O -
. O +

BACKGROUND O -
: O +
Pemoline O +
is O +
an O +
oxazolidine O +
derivative O +
that O +
is O +
structurally O +
different O +
from O +
amphetamines O +
and O +
used O +
in O +
the O +
treatment O +
of O +
attention B-Disease +
deficit I-Disease +
disorder I-Disease -
. O +

Pemoline O +
has O +
not O +
been O +
commonly O +
associated O +
in O +
the O +
literature O +
as O +
a O +
cause O +
of O +
acute O +
movement B-Disease +
disorders I-Disease -
. O +

The O +
following O +
case O +
describes O +
two O +
children O +
acutely O +
poisoned O +
with O +
pemoline O +
who O +
experienced O +
profound O +
choreoathetosis B-Disease -
. O +

CASE O +
REPORT O -
: O +
Two O -
, O +
3-year O -
- O -
old O +
male O -
, O +
identical O +
twin O +
siblings O +
presented O +
to O +
the O +
emergency O +
department O +
after O +
found O +
playing O +
with O +
a O +
an O +
empty O +
bottle O +
of O +
pemoline O +
originally O +
containing O +
59 O +
tablets O -
. O +

The O +
children O +
had O +
a O +
medical O +
history O +
significant O +
for O +
attention B-Disease +
deficit I-Disease +
disorder I-Disease +
previously O +
treated O +
with O +
methylphenidate O +
without O +
success O -
. O +

This O +
was O +
their O +
first O +
day O +
of O +
pemoline O +
therapy O -
. O +

The O +
choreoathetoid B-Disease +
movements O +
began O +
45 O +
min O +
to O +
1 O +
h O +
after O +
ingestion O -
. O +

The O +
children O +
gave O +
no O +
history O +
of O +
prior O +
movement B-Disease +
disorders I-Disease +
and O +
there O +
was O +
no O +
family O +
history O +
of O +
movement B-Disease +
disorders I-Disease -
. O +

The O +
children O +
received O +
gastrointestinal O +
decontamination O +
and O +
high O +
doses O +
of O +
intravenous O +
benzodiazepines O +
in O +
an O +
attempt O +
to O +
control O +
the O +
choreoathetoid B-Disease +
movements O -
. O +

Despite O +
treatment O -
, O +
the O +
children O +
continued O +
to O +
have O +
choreoathetosis B-Disease +
for O +
approximately O +
24 O +
hours O -
. O +

Forty O -
- O -
eight O +
hours O +
after O +
admission O -
, O +
the O +
children O +
appeared O +
to O +
be O +
at O +
their O +
baseline O +
and O +
were O +
discharged O +
home O -
. O +

CONCLUSION O -
: O +
Pemoline O +
associated O +
movement B-Disease +
disorder I-Disease +
has O +
been O +
rarely O +
reported O +
in O +
the O +
acute O +
toxicology O +
literature O -
. O +

The O +
possibility O +
of O +
choreoathetoid B-Disease +
movements O +
should O +
be O +
considered O +
in O +
patients O +
presenting O +
after O +
pemoline O +
overdose B-Disease -
. O +

Seizure B-Disease +
resulting O +
from O +
a O +
venlafaxine O +
overdose B-Disease -
. O +

OBJECTIVE O -
: O +
To O +
report O +
a O +
case O +
of O +
venlafaxine O +
overdose B-Disease -
. O +

CASE O +
SUMMARY O -
: O +
A O +
40-year O -
- O -
old O +
woman O +
with O +
major B-Disease +
depression I-Disease +
took O +
an O +
overdose B-Disease +
of O +
venlafaxine O +
in O +
an O +
apparent O +
suicide O +
attempt O -
. O +

After O +
the O +
ingestion O +
of O +
26 O +
venlafaxine O +
50-mg O +
tablets O -
, O +
the O +
patient O +
experienced O +
a O +
witnessed O +
generalized O +
seizure B-Disease -
. O +

She O +
was O +
admitted O +
to O +
the O +
medical O +
intensive O +
care O +
unit O -
, O +
venlafaxine O +
was O +
discontinued O -
, O +
and O +
no O +
further O +
sequelae O +
were O +
seen O -
. O +

DISCUSSION O -
: O +
To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
reported O +
case O +
of O +
venlafaxine O +
overdose B-Disease +
that O +
resulted O +
in O +
a O +
generalized O +
seizure B-Disease -
. O +

Based O +
on O +
nonoverdose O +
pharmacokinetics O +
and O +
pharmacodynamics O +
of O +
venlafaxine O +
and O +
the O +
potential O +
risks O +
of O +
available O +
interventions O -
, O +
no O +
emergent O +
therapy O +
was O +
instituted O -
. O +

CONCLUSIONS O -
: O +
The O +
venlafaxine O +
overdose B-Disease +
in O +
our O +
patient O +
resulted O +
in O +
a O +
single O +
episode O +
of O +
generalized O +
seizure B-Disease +
but O +
elicited O +
no O +
further O +
sequelae O -
. O +

Effect O +
of O +
myopic O +
excimer O +
laser O +
photorefractive O +
keratectomy O +
on O +
the O +
electrophysiologic O +
function O +
of O +
the O +
retina O +
and O +
optic O +
nerve O -
. O +

PURPOSE O -
: O +
To O +
assess O +
by O +
electrophysiologic O +
testing O +
the O +
effect O +
of O +
photorefractive O +
keratectomy O +
( O -
PRK O -
) O +
on O +
the O +
retina O +
and O +
optic O +
nerve O -
. O +

SETTING O -
: O +
Eye O +
Clinic O -
, O +
S. O +
Salvatore O +
Hospital O -
, O +
L'Aquila O +
University O -
, O +
Italy O -
. O +

METHODS O -
: O +
Standard O +
pattern O +
electroretinograms O +
( O -
P O -
- O -
ERGs O -
) O +
and O +
standard O +
pattern O +
visual O +
evoked O +
potentials O +
( O -
P O -
- O -
VEPs O -
) O +
were O +
done O +
in O +
25 O +
eyes O +
of O +
25 O +
patients O +
who O +
had O +
myopic O +
PRK O +
for O +
an O +
attempted O +
correction O +
between O +
5.00 O +
and O +
15.00 O +
diopters O +
( O -
D O -
) O +
( O -
mean O +
8.00 O +
D O -
) O -
. O +

Testing O +
was O +
done O +
preoperatively O +
and O +
3 O -
, O +
6 O -
, O +
12 O -
, O +
and O +
18 O +
months O +
postoperatively O -
. O +

The O +
contralateral O +
eyes O +
served O +
as O +
controls O -
. O +

During O +
the O +
follow O -
- O -
up O -
, O +
3 O +
patients O +
( O -
12 O -
% O -
) O +
developed O +
steroid O -
- O -
induced O +
elevated B-Disease +
intraocular I-Disease +
pressure I-Disease +
( O -
IOP O -
) O +
that O +
resolved O +
after O +
corticosteroid O +
therapy O +
was O +
discontinued O -
. O +

RESULTS O -
: O +
No O +
statistically O +
significant O +
differences O +
were O +
seen O +
between O +
treated O +
and O +
control O +
eyes O +
nor O +
between O +
treated O +
eyes O +
preoperatively O +
and O +
postoperatively O -
. O +

CONCLUSION O -
: O +
Myopic O +
excimer O +
laser O +
PRK O +
did O +
not O +
seem O +
to O +
affect O +
the O +
posterior O +
segment O -
. O +

The O +
transient O +
steroid O -
- O -
induced O +
IOP B-Disease +
rise I-Disease +
did O +
not O +
seem O +
to O +
cause O +
functional O +
impairment O -
. O +

Combined O +
effects O +
of O +
prolonged O +
prostaglandin O +
E1-induced O +
hypotension B-Disease +
and O +
haemodilution B-Disease +
on O +
human O +
hepatic O +
function O -
. O +

Combined O +
effects O +
of O +
prolonged O +
prostaglandin O +
E1 O +
( O -
PGE1 O -
) O -
-induced O +
hypotension B-Disease +
and O +
haemodilution B-Disease +
on O +
hepatic O +
function O +
were O +
studied O +
in O +
30 O +
patients O +
undergoing O +
hip O +
surgery O -
. O +

The O +
patients O +
were O +
randomly O +
allocated O +
to O +
one O +
of O +
three O +
groups O -
; O +
those O +
in O +
group O +
A O +
( O -
n O +
= O +
10 O -
) O +
were O +
subjected O +
to O +
controlled O +
hypotension B-Disease +
alone O -
, O +
those O +
in O +
group O +
B O +
( O -
n O +
= O +
10 O -
) O +
to O +
haemodilution B-Disease +
alone O +
and O +
those O +
in O +
group O +
C O +
( O -
n O +
= O +
10 O -
) O +
to O +
both O +
controlled O +
hypotension B-Disease +
and O +
haemodilution B-Disease -
. O +

Haemodilution B-Disease +
in O +
groups O +
B O +
and O +
C O +
was O +
produced O +
by O +
withdrawing O +
approximately O +
1000 O +
mL O +
of O +
blood O +
and O +
replacing O +
it O +
with O +
the O +
same O +
amount O +
of O +
dextran O +
solution O -
, O +
and O +
final O +
haematocrit O +
values O +
were O +
21 O +
or O +
22 O -
% O -
. O +

Controlled O +
hypotension B-Disease +
in O +
groups O +
A O +
and O +
C O +
was O +
induced O +
with O +
PGE1 O +
to O +
maintain O +
mean O +
arterial O +
blood O +
pressure O +
at O +
55 O +
mmHg O +
for O +
180 O +
min O -
. O +

Measurements O +
included O +
arterial O +
ketone O +
body O +
ratio O +
( O -
AKBR O -
, O +
aceto O -
- O -
acetate O -
/ O -
3-hydroxybutyrate O -
) O +
and O +
clinical O +
hepatic O +
function O +
parameters O -
. O +

AKBR O +
and O +
biological O +
hepatic O +
function O +
tests O +
showed O +
no O +
change O +
throughout O +
the O +
time O +
course O +
in O +
groups O +
A O +
and O +
B. O +
In O +
group O +
C O -
, O +
AKBR O +
showed O +
a O +
significant O +
decrease O +
at O +
120 O +
min O +
( O -
-40 O -
% O -
) O +
and O +
at O +
180 O +
min O +
( O -
-49 O -
% O -
) O +
after O +
the O +
start O +
of O +
hypotension B-Disease +
and O +
at O +
60 O +
min O +
( O -
-32 O -
% O -
) O +
after O +
recovery O +
of O +
normotension O -
, O +
and O +
SGOT O -
, O +
SGPT O -
, O +
LDH O +
and O +
total O +
bilirubin O +
showed O +
significant O +
increases O +
after O +
operation O -
. O +

The O +
results O +
suggest O +
that O +
a O +
prolonged O +
combination O +
of O +
more O +
than O +
120 O +
min O +
of O +
PGE1-induced O +
hypotension B-Disease +
and O +
moderate O +
haemodilution B-Disease +
would O +
cause O +
impairment B-Disease +
of I-Disease +
hepatic I-Disease +
function I-Disease -
. O +

A O +
murine O +
model O +
of O +
adenomyosis B-Disease -
: O +
the O +
effects O +
of O +
hyperprolactinemia B-Disease +
induced O +
by O +
fluoxetine O +
hydrochloride O -
, O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O -
, O +
on O +
adenomyosis B-Disease +
induction O +
in O +
Wistar O +
albino O +
rats O -
. O +

OBJECTIVE O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
whether O +
fluoxetine O +
given O +
to O +
castrated O +
and O +
noncastrated O +
rats O +
caused O +
hyperprolactinemia B-Disease +
and O +
its O +
effects O +
with O +
respect O +
to O +
adenomyosis B-Disease -
. O +

DESIGN O -
: O +
Fluoxetine O -
, O +
a O +
serotonin O +
reuptake O +
inhibitor O -
, O +
was O +
given O +
to O +
Wistar O +
Albino O +
rats O +
for O +
98 O +
days O +
to O +
produce O +
hyperprolactinemia B-Disease -
. O +

The O +
drug O +
was O +
given O +
to O +
two O +
groups O +
consisting O +
of O +
castrated O +
and O +
noncastrated O +
rats O +
and O +
compared O +
to O +
two O +
groups O +
of O +
castrated O +
and O +
noncastrated O +
controls O -
. O +

Prolactin O +
levels O +
were O +
measured O +
and O +
the O +
uteri O +
of O +
the O +
rats O +
were O +
removed O +
for O +
histopathological O +
analysis O +
at O +
the O +
end O +
of O +
98 O +
days O -
. O +

SETTING O -
: O +
Marmara O +
University O +
School O +
of O +
Medicine O -
, O +
Department O +
of O +
Histology O +
and O +
Embryology O -
, O +
Zeynep O +
Kamil O +
Women O +
and O +
Children O -
's O +
Hospital O -
. O +

MAIN O +
OUTCOME O +
MEASURES O -
: O +
Serum O +
prolactin O +
levels O -
, O +
uterine O +
histopathology O -
. O +

RESULTS O -
: O +
The O +
prolactin O +
levels O +
of O +
castrated O +
and O +
noncastrated O +
groups O +
treated O +
with O +
fluoxetine O +
were O +
statistically O +
significantly O +
higher O +
when O +
compared O +
to O +
their O +
respective O +
control O +
groups O -
. O +

Histological O +
studies O +
revealed O +
11 O +
cases O +
of O +
adenomyosis B-Disease -
, O +
all O +
within O +
the O +
noncastrated O +
group O +
receiving O +
fluoxetine O -
. O +

CONCLUSION O -
: O +
It O +
was O +
suggested O +
that O +
high O +
serum O +
prolactin O +
levels O +
cause O +
degeneration O +
of O +
myometrial O +
cells O +
in O +
the O +
presence O +
of O +
ovarian O +
steroids O +
that O +
results O +
in O +
a O +
myometrial O +
invasion O +
by O +
endometrial O +
stroma O -
. O +

This O +
invasion O +
eventually O +
progresses O +
to O +
adenomyosis B-Disease -
. O +

Cardiovascular B-Disease +
alterations I-Disease +
in O +
rat O +
fetuses O +
exposed O +
to O +
calcium O +
channel O +
blockers O -
. O +

Preclinical O +
toxicologic O +
investigation O +
suggested O +
that O +
a O +
new O +
calcium O +
channel O +
blocker O -
, O +
Ro O +
40 O -
- O -
5967 O -
, O +
induced O +
cardiovascular B-Disease +
alterations I-Disease +
in O +
rat O +
fetuses O +
exposed O +
to O +
this O +
agent O +
during O +
organogenesis O -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
hypothesis O +
that O +
calcium O +
channel O +
blockers O +
in O +
general O +
induce O +
cardiovascular B-Disease +
malformations I-Disease +
indicating O +
a O +
pharmacologic O +
class O +
effect O -
. O +

We O +
studied O +
three O +
calcium O +
channel O +
blockers O +
of O +
different O +
structure O -
, O +
nifedipine O -
, O +
diltiazem O -
, O +
and O +
verapamil O -
, O +
along O +
with O +
the O +
new O +
agent O -
. O +

Pregnant O +
rats O +
were O +
administered O +
one O +
of O +
these O +
calcium O +
channel O +
blockers O +
during O +
the O +
period O +
of O +
cardiac O +
morphogenesis O +
and O +
the O +
offspring O +
examined O +
on O +
day O +
20 O +
of O +
gestation O +
for O +
cardiovascular B-Disease +
malformations I-Disease -
. O +

A O +
low O +
incidence O +
of O +
cardiovascular B-Disease +
malformations I-Disease +
was O +
observed O +
after O +
exposure O +
to O +
each O +
of O +
the O +
four O +
calcium O +
channel O +
blockers O -
, O +
but O +
this O +
incidence O +
was O +
statistically O +
significant O +
only O +
for O +
verapamil O +
and O +
nifedipine O -
. O +

All O +
four O +
agents O +
were O +
associated O +
with O +
aortic O +
arch O +
branching O +
variants O -
, O +
although O +
significantly O +
increased O +
only O +
for O +
Ro O +
40 O -
- O -
5967 O +
and O +
verapamil O -
. O +

Postinfarction O +
ventricular B-Disease +
septal I-Disease +
defect I-Disease +
associated O +
with O +
long O -
- O -
term O +
steroid O +
therapy O -
. O +

Two O +
cases O +
of O +
postinfarction O +
ventricular B-Disease +
septal I-Disease +
rupture I-Disease +
in O +
patients O +
on O +
long O -
- O -
term O +
steroid O +
therapy O +
are O +
presented O +
and O +
the O +
favourable O +
outcome O +
in O +
both O +
cases O +
described O -
. O +

A O +
possible O +
association O +
between O +
steroid O +
therapy O +
and O +
subsequent O +
postinfarction O +
septal B-Disease +
rupture I-Disease +
is O +
discussed O -
. O +

Neuroactive O +
steroids O +
protect O +
against O +
pilocarpine- O +
and O +
kainic O +
acid O -
- O -
induced O +
limbic O +
seizures B-Disease +
and O +
status B-Disease +
epilepticus I-Disease +
in O +
mice O -
. O +

Several O +
structurally O +
related O +
metabolites O +
of O +
progesterone O +
( O -
3 O +
alpha O -
- O -
hydroxy O +
pregnane-20-ones O -
) O +
and O +
deoxycorticosterone O +
( O -
3 O +
alpha O -
- O -
hydroxy O +
pregnane-21-diol-20-ones O -
) O +
and O +
their O +
3 O +
beta O -
- O -
epimers O +
were O +
evaluated O +
for O +
protective O +
activity O +
against O +
pilocarpine- O -
, O +
kainic O +
acid- O +
and O +
N O -
- O -
methyl O -
- O -
D O -
- O -
aspartate O +
( O -
NMDA O -
) O -
-induced O +
seizures B-Disease +
in O +
mice O -
. O +

Steroids O +
with O +
the O +
3-hydroxy O +
group O +
in O +
the O +
alpha O -
- O -
position O +
and O +
5-H O +
in O +
the O +
alpha- O +
or O +
beta O -
- O -
configurations O +
were O +
highly O +
effective O +
in O +
protecting O +
against O +
pilocarpine O +
( O -
416 O +
mg O -
/ O -
kg O -
, O +
s.c. O -
) O -
-induced O +
limbic O +
motor O +
seizures B-Disease +
and O +
status B-Disease +
epilepticus I-Disease +
( O -
ED50 O +
values O -
, O +
7.0 O -
- O -
18.7 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O +

The O +
corresponding O +
epimers O +
with O +
the O +
3-hydroxy O +
group O +
in O +
the O +
beta O -
- O -
position O +
were O +
also O +
effective O +
but O +
less O +
potent O +
( O -
ED50 O +
values O -
, O +
33.8 O -
- O -
63.5 O -
, O +
i.p O -
. O -
) O -
. O +

Although O +
the O +
neuroactive O +
steroids O +
were O +
considerably O +
less O +
potent O +
than O +
the O +
benzodiazepine O +
clonazepam O +
in O +
protecting O +
against O +
pilocarpine O +
seizures B-Disease -
, O +
steroids O +
with O +
the O +
5 O +
alpha,3 O +
alpha O -
- O -
configuration O +
had O +
comparable O +
or O +
higher O +
protective O +
index O +
values O +
( O -
TD50 O +
for O +
motor O +
impairment O +
divided O +
by O +
ED50 O +
for O +
seizure B-Disease +
protection O -
) O +
than O +
clonazepam O -
, O +
indicating O +
that O +
some O +
neuroactive O +
steroids O +
may O +
have O +
lower O +
relative O +
toxicity B-Disease -
. O +

Steroids O +
with O +
the O +
5 O +
alpha,3 O +
alpha- O +
or O +
5 O +
beta,3 O +
alpha O -
- O -
configurations O +
also O +
produced O +
a O +
dose O -
- O -
dependent O +
delay O +
in O +
the O +
onset O +
of O +
limbic O +
seizures B-Disease +
induced O +
by O +
kainic O +
acid O +
( O -
32 O +
mg O -
/ O -
kg O -
, O +
s.c O -
. O -
) O -
, O +
but O +
did O +
not O +
completely O +
protect O +
against O +
the O +
seizures B-Disease -
. O +

However O -
, O +
when O +
a O +
second O +
dose O +
of O +
the O +
steroid O +
was O +
administered O +
1 O +
hr O +
after O +
the O +
first O +
dose O -
, O +
complete O +
protection O +
from O +
the O +
kainic O +
acid O -
- O -
induced O +
limbic O +
seizures B-Disease +
and O +
status B-Disease +
epilepticus I-Disease +
was O +
obtained O -
. O +

The O +
steroids O +
also O +
caused O +
a O +
dose O -
- O -
dependent O +
delay O +
in O +
NMDA O +
( O -
257 O +
mg O -
/ O -
kg O -
, O +
s.c. O -
) O -
-induced O +
lethality O -
, O +
but O +
did O +
not O +
completely O +
protect O +
against O +
NMDA O +
seizures B-Disease +
or O +
lethality O -
. O +

We O +
conclude O +
that O +
neuroactive O +
steroids O +
are O +
highly O +
effective O +
in O +
protecting O +
against O +
pilocarpine- O +
and O +
kainic O +
acid O -
- O -
induced O +
seizures B-Disease +
and O +
status B-Disease +
epilepticus I-Disease +
in O +
mice O -
, O +
and O +
may O +
be O +
of O +
utility O +
in O +
the O +
treatment O +
of O +
some O +
forms O +
of O +
status B-Disease +
epilepticus I-Disease +
in O +
humans O -
. O +

Hepatic O +
and O +
extrahepatic O +
angiotensinogen O +
gene O +
expression O +
in O +
rats O +
with O +
acute O +
nephrotic B-Disease +
syndrome I-Disease -
. O +

Plasma O +
concentration O +
and O +
urine O +
excretion O +
of O +
the O +
renin O -
- O -
angiotensin O +
system O +
proteins O +
are O +
altered O +
in O +
rats O +
with O +
nephrotic B-Disease +
syndrome I-Disease +
( O -
NS B-Disease -
) O -
. O +

In O +
this O +
work O +
the O +
messenger O +
ribonucleic O +
acid O +
( O -
mRNA O -
) O +
levels O +
of O +
angiotensinogen O +
( O -
Ao O -
) O +
were O +
analyzed O +
with O +
the O +
slot O -
- O -
blot O +
hybridization O +
technique O +
in O +
liver O +
and O +
other O +
extrahepatic O +
tissues O -
: O +
kidney O -
, O +
heart O -
, O +
brain O -
, O +
and O +
adrenal O +
gland O +
from O +
control O -
, O +
nephrotic B-Disease -
, O +
and O +
pair O -
- O -
fed O +
( O -
PF O -
) O +
rats O -
. O +

NS B-Disease +
was O +
induced O +
by O +
a O +
single O +
injection O +
of O +
puromycin O +
amino O -
- O -
nucleoside O +
( O -
PAN O -
) O -
. O +

Although O +
a O +
great O +
urinary O +
excretion O +
and O +
half O -
- O -
normal O +
plasma O +
levels O +
of O +
Ao O +
were O +
observed O +
on O +
day O +
6 O +
after O +
PAN O +
injection O -
, O +
when O +
NS B-Disease +
was O +
clearly O +
established O -
, O +
hepatic O +
Ao O +
mRNA O +
levels O +
did O +
not O +
change O -
. O +

Furthermore O -
, O +
the O +
Ao O +
mRNA O +
levels O +
did O +
not O +
change O +
in O +
any O +
of O +
the O +
extrahepatic O +
tissues O +
studied O +
on O +
day O +
6 O -
, O +
nor O +
did O +
its O +
hepatic O +
levels O +
at O +
days O +
1 O -
, O +
3 O -
, O +
5 O -
, O +
or O +
7 O +
after O +
PAN O +
injection O -
. O +

These O +
data O +
suggest O +
that O +
the O +
hepatic O +
and O +
extrahepatic O +
Ao O +
mRNA O +
levels O +
are O +
unaltered O +
during O +
the O +
development O +
of O +
the O +
acute O +
NS B-Disease +
induced O +
by O +
PAN O -
. O +

Neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
with O +
risperidone O -
. O +

Neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
is O +
thought O +
to O +
be O +
a O +
result O +
of O +
dopamine O +
D2 O +
receptor O +
blockade O +
in O +
the O +
striatum O +
of O +
the O +
basal O +
ganglia O -
. O +

Risperidone O -
, O +
a O +
benzisoxazole O +
derivative O +
antipsychotic O -
, O +
has O +
high O +
serotonin O +
5-HT2 O +
receptor O +
blockade O +
and O +
dose O -
- O -
related O +
D2 O +
receptor O +
blockade O -
. O +

The O +
high O +
ratio O +
is O +
believed O +
to O +
impart O +
the O +
low O +
frequency O +
of O +
extrapyramidal B-Disease +
symptoms I-Disease +
with O +
risperidone O +
at O +
low O +
dosages O -
. O +

With O +
this O +
low O +
frequency O +
of O +
extrapyramidal B-Disease +
symptoms I-Disease -
, O +
it O +
was O +
thought O +
the O +
frequency O +
of O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
might O +
also O +
be O +
lowered O -
. O +

A O +
73-year O -
- O -
old O +
woman O +
developed O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease +
after O +
monotherapy O +
with O +
risperidone O -
. O +

The O +
syndrome O +
reversed O +
after O +
discontinuing O +
risperidone O +
and O +
starting O +
treatment O +
with O +
dantrolene O +
and O +
bromocriptine O -
. O +

It O +
appears O +
that O +
the O +
protection O +
from O +
extrapyramidal O +
side O +
effects O +
observed O +
with O +
risperidone O +
does O +
not O +
ensure O +
protection O +
from O +
neuroleptic B-Disease +
malignant I-Disease +
syndrome I-Disease -
. O +

The O +
site O +
of O +
common O +
side O +
effects O +
of O +
sumatriptan O -
. O +

Atypical B-Disease +
sensations I-Disease +
following O +
the O +
use O +
of O +
subcutaneous O +
sumatriptan O +
are O +
common O -
, O +
but O +
of O +
uncertain O +
origin O -
. O +

They O +
are O +
almost O +
always O +
benign O -
, O +
but O +
can O +
be O +
mistaken O +
for O +
a O +
serious O +
adverse O +
event O +
by O +
the O +
patient O -
. O +

Two O +
patients O +
are O +
presented O +
with O +
tingling B-Disease +
or I-Disease +
burning I-Disease +
sensations I-Disease +
limited O +
to O +
areas O +
of O +
heat O +
exposure O +
or O +
sunburn B-Disease -
. O +

In O +
these O +
individuals O -
, O +
side O +
effects O +
are O +
most O +
likely O +
generated O +
superficially O +
in O +
the O +
skin O -
. O +

Macula O +
toxicity B-Disease +
after O +
intravitreal O +
amikacin O -
. O +

BACKGROUND O -
: O +
Although O +
intravitreal O +
aminoglycosides O +
have O +
substantially O +
improved O +
visual O +
prognosis O +
in O +
endophthalmitis B-Disease -
, O +
macular O +
infarction B-Disease +
may O +
impair O +
full O +
visual O +
recovery O -
. O +

METHODS O -
: O +
We O +
present O +
a O +
case O +
of O +
presumed O +
amikacin O +
retinal B-Disease +
toxicity I-Disease +
following O +
treatment O +
with O +
amikacin O +
and O +
vancomycin O +
for O +
alpha O -
- O -
haemolytic O +
streptococcal B-Disease +
endophthalmitis I-Disease -
. O +

RESULTS O -
: O +
Endophthalmitis B-Disease +
resolved O +
with O +
improvement O +
in O +
visual O +
acuity O +
to O +
6 O -
/ O -
24 O +
at O +
three O +
months O -
. O +

Fundus O +
fluorescein O +
angiography O +
confirmed O +
macular O +
capillary O +
closure O +
and O +
telangiectasis B-Disease -
. O +

CONCLUSIONS O -
: O +
Currently O +
accepted O +
intravitreal O +
antibiotic O +
regimens O +
may O +
cause O +
retinal B-Disease +
toxicity I-Disease +
and O +
macular O +
ischaemia B-Disease -
. O +

Treatment O +
strategies O +
aimed O +
at O +
avoiding O +
retinal B-Disease +
toxicity I-Disease +
are O +
discussed O -
. O +

The O +
attenuating O +
effect O +
of O +
carteolol O +
hydrochloride O -
, O +
a O +
beta O -
- O -
adrenoceptor O +
antagonist O -
, O +
on O +
neuroleptic O -
- O -
induced O +
catalepsy B-Disease +
in O +
rats O -
. O +

It O +
is O +
known O +
that O +
beta O -
- O -
adrenoceptor O +
antagonists O +
are O +
effective O +
in O +
the O +
treatment O +
of O +
akathisia B-Disease -
, O +
one O +
of O +
the O +
extrapyramidal O +
side O +
effects O +
that O +
occur O +
during O +
neuroleptic O +
treatment O -
. O +

Neuroleptic O -
- O -
induced O +
catalepsy B-Disease -
, O +
a O +
model O +
of O +
neuroleptic O -
- O -
induced O +
extrapyramidal O +
side O +
effects O -
, O +
was O +
considered O +
suitable O +
as O +
a O +
model O +
for O +
predicting O +
neuroleptic O -
- O -
induced O +
akathisia B-Disease +
in O +
humans O -
, O +
although O +
neuroleptic O -
- O -
induced O +
catalepsy B-Disease +
was O +
not O +
considered O +
a O +
specific O +
test O +
for O +
neuroleptic O -
- O -
induced O +
akathisia B-Disease -
. O +

Therefore O -
, O +
the O +
effects O +
of O +
carteolol O -
, O +
a O +
beta O -
- O -
adrenoceptor O +
antagonist O -
, O +
on O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
in O +
rats O +
were O +
behaviorally O +
studied O +
and O +
compared O +
with O +
those O +
of O +
propranolol O +
and O +
biperiden O -
, O +
a O +
muscarinic O +
receptor O +
antagonist O -
. O +

Carteolol O -
, O +
as O +
well O +
as O +
propranolol O +
and O +
biperiden O -
, O +
inhibited O +
the O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease -
. O +

The O +
inhibitory O +
effect O +
of O +
carteolol O +
was O +
almost O +
comparable O +
to O +
that O +
of O +
propranolol O -
, O +
but O +
was O +
weaker O +
than O +
that O +
of O +
biperiden O -
. O +

Carteolol O +
did O +
not O +
evoke O +
postsynaptic O +
dopamine O +
receptor O -
- O -
stimulating O +
behavioral O +
signs O +
such O +
as O +
stereotypy O +
and O +
hyperlocomotion B-Disease +
in O +
rats O -
. O +

Carteolol O +
did O +
not O +
antagonize O +
the O +
inhibitory O +
effects O +
of O +
haloperidol O +
on O +
apomorphine O -
- O -
induced O +
stereotypy O +
and O +
locomotor O +
activity O +
in O +
rats O -
. O +

In O +
addition O -
, O +
carteolol O +
did O +
not O +
evoke O +
5-HT1A O +
receptor O -
- O -
stimulating O +
behavioral O +
signs O +
such O +
as O +
flat O +
body O +
posture O +
and O +
forepaw O +
treading O +
and O +
did O +
not O +
inhibit O +
5-hydroxytryptophan O -
- O -
induced O +
head O +
twitch O +
in O +
rats O -
. O +

Finally O -
, O +
carteolol O +
did O +
not O +
inhibit O +
physostigmine O -
- O -
induced O +
lethality O +
in O +
rats O -
. O +

These O +
results O +
strongly O +
suggest O +
that O +
carteolol O +
improves O +
haloperidol O -
- O -
induced O +
catalepsy B-Disease +
via O +
its O +
beta O -
- O -
adrenoceptor O +
antagonistic O +
activity O +
and O +
is O +
expected O +
to O +
be O +
effective O +
in O +
the O +
treatment O +
of O +
akathisia B-Disease +
without O +
attenuating O +
neuroleptic O -
- O -
induced O +
antipsychotic O +
effects O +
due O +
to O +
its O +
postsynaptic O +
dopamine O +
receptor O +
antagonistic O +
activity O -
. O +

Granulosa B-Disease +
cell I-Disease +
tumor I-Disease +
of I-Disease +
the I-Disease +
ovary I-Disease +
associated O +
with O +
antecedent O +
tamoxifen O +
use O -
. O +

BACKGROUND O -
: O +
Increased O +
attention O +
has O +
been O +
focused O +
recently O +
on O +
the O +
estrogenic O +
effects O +
of O +
tamoxifen O -
. O +

Review O +
of O +
the O +
literature O +
reveals O +
an O +
association O +
between O +
tamoxifen O +
use O +
and O +
gynecologic O +
tumors B-Disease -
. O +

CASE O -
: O +
A O +
52-year O -
- O -
old O +
postmenopausal O +
woman O +
was O +
treated O +
with O +
tamoxifen O +
for O +
stage O +
II O +
estrogen O +
receptor O -
- O -
positive O +
breast B-Disease +
carcinoma I-Disease -
. O +

Her O +
aspartate O +
transaminase O +
and O +
alanine O +
transaminase O +
levels O +
increase O +
markedly O +
after O +
6 O +
months O +
of O +
tamoxifen O +
use O -
. O +

After O +
an O +
additional O +
17 O +
months O +
of O +
elevated O +
serum O +
transaminases O -
, O +
the O +
patient O +
was O +
found O +
to O +
have O +
a O +
stage O +
Ic O +
granulosa B-Disease +
cell I-Disease +
tumor I-Disease +
of I-Disease +
the I-Disease +
ovary I-Disease -
. O +

CONCLUSION O -
: O +
Patients O +
with O +
tamoxifen O -
- O -
induced O +
liver B-Disease +
dysfunction I-Disease +
may O +
be O +
at O +
increased O +
risk O +
for O +
granulosa B-Disease +
cell I-Disease +
tumors I-Disease +
because O +
of O +
alterations O +
in O +
tamoxifen O +
metabolism O -
. O +

Lifetime O +
treatment O +
of O +
mice O +
with O +
azidothymidine O +
( O -
AZT O -
) O +
produces O +
myelodysplasia B-Disease -
. O +

AZT O +
has O +
induced O +
a O +
macrocytic B-Disease +
anemia I-Disease +
in O +
AIDS B-Disease +
patients O +
on O +
long O +
term O +
AZT O +
therapy O -
. O +

It O +
is O +
generally O +
assumed O +
that O +
DNA O +
elongation O +
is O +
stopped O +
by O +
the O +
insertion O +
of O +
AZT O +
into O +
the O +
chain O +
in O +
place O +
of O +
thymidine O +
thus O +
preventing O +
the O +
phosphate O +
hydroxyl O +
linkages O +
and O +
therefore O +
suppresses O +
hemopoietic O +
progenitor O +
cell O +
proliferation O +
in O +
an O +
early O +
stage O +
of O +
differentiation O -
. O +

CBA O -
/ O -
Ca O +
male O +
mice O +
started O +
on O +
AZT O +
0.75 O +
mg O -
/ O -
ml O +
H2O O +
at O +
84 O +
days O +
of O +
age O +
and O +
kept O +
on O +
it O +
for O +
687 O +
days O +
when O +
dosage O +
reduced O +
to O +
0.5 O +
mg O -
/ O -
ml O +
H2O O +
for O +
a O +
group O -
, O +
another O +
group O +
removed O +
from O +
AZT O +
to O +
see O +
recovery O -
, O +
and O +
third O +
group O +
remained O +
on O +
0.75 O +
mg O -
. O +

At O +
687 O +
days O +
mice O +
that O +
had O +
been O +
on O +
0.75 O +
mg O +
had O +
average O +
platelet O +
counts O +
of O +
2.5 O +
x O +
10 O -
( O -
6 O -
) O -
. O +

Histological O +
examination O +
on O +
9 O +
of O +
10 O +
mice O +
with O +
such O +
thrombocytopenia B-Disease +
showed O +
changes O +
compatible O +
with O +
myelodysplastic B-Disease +
syndrome I-Disease +
( O -
MDS B-Disease -
) O -
. O +

A O +
variety O +
of O +
histological O +
patterns O +
was O +
observed O -
. O +

There O +
were O +
two O +
cases O +
of O +
hypocellular O +
myelodysplasia B-Disease -
, O +
two O +
cases O +
of O +
hypersegmented O +
myelodysplastic B-Disease +
granulocytosis O -
, O +
two O +
cases O +
of O +
hypercellular O +
marrow O +
with O +
abnormal O +
megakaryocytes O +
with O +
bizarre O +
nuclei O -
, O +
one O +
case O +
of O +
megakaryocytic O +
myelosis O +
associated O +
with O +
a O +
hyperplastic B-Disease +
marrow I-Disease -
, O +
dysmyelopoiesis B-Disease +
and O +
a O +
hypocellular B-Disease +
marrow I-Disease +
and O +
two O +
cases O +
of O +
myelodysplasia B-Disease +
with O +
dyserythropoiesis B-Disease -
, O +
hemosiderosis B-Disease +
and O +
a O +
hypocellular B-Disease +
marrow I-Disease -
. O +

Above O +
mentioned O +
AZT O +
incorporation O +
may O +
have O +
induced O +
an O +
ineffective O +
hemopoiesis O +
in O +
the O +
primitive O +
hemopoietic O +
progenitor O +
cells O -
, O +
which O +
is O +
known O +
to O +
be O +
seen O +
commonly O +
in O +
the O +
myelodysplastic B-Disease +
syndrome I-Disease -
. O +

Biphasic O +
response O +
of O +
the O +
SA O +
node O +
of O +
the O +
dog O +
heart O +
in O +
vivo O +
to O +
selective O +
administration O +
of O +
ketamine O -
. O +

Effect O +
of O +
ketamine O +
on O +
the O +
SA O +
node O +
of O +
the O +
dog O +
heart O +
was O +
studied O +
in O +
vivo O +
using O +
a O +
selective O +
perfusion O +
technique O +
of O +
the O +
SA O +
node O +
artery O -
. O +

Injections O +
of O +
ketamine O +
in O +
doses O +
from O +
100 O +
microgram O +
to O +
3 O +
mg O +
into O +
the O +
artery O +
produced O +
a O +
depression B-Disease +
of O +
the O +
SA O +
nodal O +
activity O +
by O +
a O +
direct O +
action O -
. O +

This O +
depression B-Disease +
was O +
followed O +
by O +
the O +
sudden O +
appearance O +
of O +
a O +
stimulatory O +
phase O -
. O +

Bilateral O +
vagotomy O +
and O +
sympathectomy O +
or O +
prior O +
administration O +
of O +
a O +
ganglion O +
blocker O +
failed O +
to O +
inhibit O +
the O +
occurrence O +
of O +
the O +
ketamine O -
- O -
induced O +
tachycardia B-Disease -
, O +
while O +
it O +
was O +
completely O +
abolished O +
in O +
the O +
reserpinized O +
dogs O +
or O +
by O +
a O +
prior O +
injection O +
of O +
a O +
beta O -
- O -
blocking O +
agent O +
into O +
the O +
SA O +
node O +
artery O -
. O +

This O +
may O +
indicate O +
that O +
an O +
activation O +
of O +
the O +
peripheral O +
adrenergic O +
mechanism O +
plays O +
an O +
important O +
role O +
in O +
the O +
induction O +
of O +
the O +
excitatory O +
effect O +
of O +
ketamine O +
injected O +
in O +
the O +
SA O +
node O +
artery O -
. O +

Over O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
its O +
receptor O +
during O +
the O +
development O +
of O +
estrogen O -
- O -
induced O +
rat O +
pituitary B-Disease +
tumors I-Disease +
may O +
mediate O +
estrogen O -
- O -
initiated O +
tumor B-Disease +
angiogenesis O -
. O +

Estrogens O -
, O +
which O +
have O +
been O +
associated O +
with O +
several O +
types O +
of O +
human O +
and O +
animal O +
cancers B-Disease -
, O +
can O +
induce O +
tumor B-Disease +
angiogenesis O +
in O +
the O +
pituitary O +
of O +
Fischer O +
344 O +
rats O -
. O +

The O +
mechanistic O +
details O +
of O +
tumor B-Disease +
angiogenesis O +
induction O -
, O +
during O +
estrogen O +
carcinogenesis B-Disease -
, O +
are O +
still O +
unknown O -
. O +

To O +
elucidate O +
the O +
role O +
of O +
estrogen O +
in O +
the O +
regulation O +
of O +
tumor B-Disease +
angiogenesis O +
in O +
the O +
pituitary O +
of O +
female O +
rats O -
, O +
the O +
density O +
of O +
blood O +
vessels O +
was O +
analysed O +
using O +
factor O +
VIII O +
related O +
antigen O +
( O -
FVIIIRAg O -
) O +
immunohistochemistry O +
and O +
the O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O -
/ O -
vascular O +
permeability O +
factor O +
( O -
VEGF O -
/ O -
VPF O -
) O +
was O +
examined O +
by O +
Western O +
blot O +
and O +
immunohistochemical O +
analysis O -
. O +

The O +
expression O +
of O +
VEGF O +
receptor O +
( O -
VEGFR-2 O -
/ O -
Flk-1 O -
/ O -
KDR O -
) O +
was O +
also O +
examined O +
by O +
immunohistochemistry O -
. O +

The O +
results O +
demonstrated O +
that O +
17beta O -
- O -
estradiol O +
( O -
E2 O -
) O +
induces O +
neovascularization O -
, O +
as O +
well O +
as O +
the O +
growth O +
and O +
enlargement O +
of O +
blood O +
vessels O +
after O +
7 O +
days O +
of O +
exposure O -
. O +

The O +
high O +
tumor B-Disease +
angiogenic O +
potential O +
was O +
associated O +
with O +
an O +
elevated O +
VEGF O -
/ O -
VPF O +
protein O +
expression O +
in O +
the O +
E2 O +
exposed O +
pituitary O +
of O +
ovariectomized O +
( O -
OVEX O -
) O +
rats O -
. O +

VEGF O -
/ O -
VPF O +
and O +
FVIIIRAg O +
immunohistochemistry O +
and O +
endothelial O +
specific O +
lectin O +
( O -
UEA1 O -
) O +
binding O +
studies O -
, O +
indicate O +
that O +
the O +
elevation O +
of O +
VEGF O +
protein O +
expression O +
initially O +
occurred O +
in O +
both O +
blood O +
vessels O +
and O +
non O -
- O -
endothelial O +
cells O -
. O +

After O +
15 O +
days O +
of O +
E2 O +
exposure O -
, O +
VEGF O -
/ O -
VPF O +
protein O +
expression O -
, O +
in O +
the O +
non O -
- O -
endothelial O +
cell O +
population O -
, O +
sharply O +
declined O +
and O +
was O +
restricted O +
to O +
the O +
blood O +
vessels O -
. O +

The O +
function O +
of O +
non O -
- O -
endothelial O -
- O -
derived O +
VEGF O +
is O +
not O +
clear O -
. O +

Furthermore O -
, O +
immunohistochemical O +
studies O +
demonstrated O +
that O +
VEGFR-2 O +
( O -
flk-1 O -
/ O -
KDR O -
) O -
, O +
expression O +
was O +
elevated O +
significantly O +
in O +
the O +
endothelial O +
cells O +
of O +
microblood O +
vessels O +
after O +
7 O +
days O +
of O +
E2 O +
exposure O -
. O +

These O +
findings O +
suggest O +
that O +
over O +
expression O +
of O +
VEGF O +
and O +
its O +
receptor O +
( O -
VEGFR-2 O -
) O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
initial O +
step O +
of O +
the O +
regulation O +
of O +
estrogen O +
induced O +
tumor B-Disease +
angiogenesis O +
in O +
the O +
rat O +
pituitary O -
. O +

Persistent O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease +
following O +
lithium O +
therapy O -
. O +

We O +
report O +
the O +
case O +
of O +
a O +
patient O +
who O +
developed O +
severe O +
hypernatraemic O +
dehydration B-Disease +
following O +
a O +
head B-Disease +
injury I-Disease -
. O +

Ten O +
years O +
previously O +
he O +
had O +
been O +
diagnosed O +
to O +
have O +
lithium O -
- O -
induced O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease -
, O +
and O +
lithium O +
therapy O +
had O +
been O +
discontinued O -
. O +

He O +
remained O +
thirsty O +
and O +
polyuric B-Disease +
despite O +
cessation O +
of O +
lithium O +
and O +
investigations O +
on O +
admission O +
showed O +
him O +
to O +
have O +
normal O +
osmoregulated O +
thirst O +
and O +
vasopressin O +
secretion O -
, O +
with O +
clear O +
evidence O +
of O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease -
. O +

Lithium O +
induced O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease +
is O +
considered O +
to O +
be O +
reversible O +
on O +
cessation O +
of O +
therapy O +
but O +
polyuria B-Disease +
persisted O +
in O +
this O +
patient O +
for O +
ten O +
years O +
after O +
lithium O +
was O +
stopped O -
. O +

We O +
discuss O +
the O +
possible O +
renal O +
mechanisms O +
and O +
the O +
implications O +
for O +
management O +
of O +
patients O +
with O +
lithium O -
- O -
induced O +
nephrogenic B-Disease +
diabetes I-Disease +
insipidus I-Disease -
. O +

Effects O +
of O +
NIK-247 O +
on O +
cholinesterase O +
and O +
scopolamine O -
- O -
induced O +
amnesia B-Disease -
. O +

The O +
effects O +
of O +
NIK-247 O +
on O +
cholinesterase O -
, O +
scopolamine O -
- O -
induced O +
amnesia B-Disease +
and O +
spontaneous O +
movement O +
were O +
examined O +
and O +
compared O +
with O +
those O +
of O +
the O +
well O -
- O -
known O +
cholinesterase O +
inhibitors O +
tacrine O +
and O +
E-2020 O -
. O +

NIK-247 O -
, O +
tacrine O +
and O +
E-2020 O +
all O +
strongly O +
inhibited O +
acetylcholinesterase O +
( O -
AChE O -
) O +
in O +
human O +
red O +
blood O +
cells O +
( O -
IC50s O +
= O +
1.0 O +
x O +
10 O -
( O -
-6 O -
) O -
, O +
2.9 O +
x O +
10 O -
( O -
-7 O -
) O +
and O +
3.7 O +
x O +
10 O -
( O -
-8 O -
) O +
M O -
, O +
respectively O -
) O -
. O +

In O +
addition O -
, O +
NIK-247 O +
and O +
tacrine O -
, O +
but O +
not O +
E-2020 O -
, O +
strongly O +
inhibited O +
butyrylcholinestrase O +
( O -
BuChE O -
) O +
in O +
human O +
serum O -
. O +

All O +
three O +
drugs O +
produced O +
mixed O +
inhibition O +
of O +
AChE O +
activity O -
. O +

Moreover O -
, O +
the O +
inhibitory O +
effect O +
of O +
NIK-247 O +
on O +
AChE O +
was O +
reversible O -
. O +

All O +
compounds O +
at O +
0.1 O -
- O -
1 O +
mg O -
/ O -
kg O +
p.o O -
. O +

significantly O +
improved O +
the O +
amnesia B-Disease +
induced O +
by O +
scopolamine O +
( O -
0.5 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
in O +
rats O +
performing O +
a O +
passive O +
avoidance O +
task O -
. O +

The O +
three O +
compounds O +
at O +
1 O +
and O +
3 O +
mg O -
/ O -
kg O +
p.o O -
. O +
did O +
not O +
significantly O +
decrease O +
spontaneous O +
movement O +
by O +
rats O -
. O +

These O +
findings O +
suggest O +
that O +
NIK-247 O +
at O +
a O +
low O +
dose O +
( O -
0.1 O -
- O -
1 O +
mg O -
/ O -
kg O +
p.o O -
. O -
) O +
improves O +
scopolamine O -
- O -
induced O +
amnesia B-Disease +
but O +
does O +
not O +
affect O +
spontaneous O +
movement O -
. O +

The O +
findings O +
suggest O +
that O +
NIK-247 O +
may O +
be O +
a O +
useful O +
drug O +
for O +
the O +
treatment O +
of O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

The O +
role O +
of O +
nicotine O +
in O +
smoking O -
- O -
related O +
cardiovascular B-Disease +
disease I-Disease -
. O +

Nicotine O +
activates O +
the O +
sympathetic O +
nervous O +
system O +
and O +
in O +
this O +
way O +
could O +
contribute O +
to O +
cardiovascular B-Disease +
disease I-Disease -
. O +

Animal O +
studies O +
and O +
mechanistic O +
studies O +
indicate O +
that O +
nicotine O +
could O +
play O +
a O +
role O +
in O +
accelerating O +
atherosclerosis B-Disease -
, O +
but O +
evidence O +
among O +
humans O +
is O +
too O +
inadequate O +
to O +
be O +
definitive O +
about O +
such O +
an O +
effect O -
. O +

Almost O +
certainly O -
, O +
nicotine O +
via O +
its O +
hemodynamic O +
effects O +
contributes O +
to O +
acute O +
cardiovascular O +
events O -
, O +
although O +
current O +
evidence O +
suggests O +
that O +
the O +
effects O +
of O +
nicotine O +
are O +
much O +
less O +
important O +
than O +
are O +
the O +
prothrombotic O +
effects O +
of O +
cigarette O +
smoking O +
or O +
the O +
effects O +
of O +
carbon O +
monoxide O -
. O +

Nicotine O +
does O +
not O +
appear O +
to O +
enhance O +
thrombosis B-Disease +
among O +
humans O -
. O +

Clinical O +
studies O +
of O +
pipe O +
smokers O +
and O +
people O +
using O +
transdermal O +
nicotine O +
support O +
the O +
idea O +
that O +
toxins O +
other O +
than O +
nicotine O +
are O +
the O +
most O +
important O +
causes O +
of O +
acute O +
cardiovascular O +
events O -
. O +

Finally O -
, O +
the O +
dose O +
response O +
for O +
cardiovascular O +
events O +
of O +
nicotine O +
appears O +
to O +
be O +
flat O -
, O +
suggesting O +
that O +
if O +
nicotine O +
is O +
involved O -
, O +
adverse O +
effects O +
might O +
be O +
seen O +
with O +
relatively O +
low O -
- O -
level O +
cigarette O +
exposures O -
. O +

Iatrogenically O +
induced O +
intractable O +
atrioventricular B-Disease +
reentrant I-Disease +
tachycardia I-Disease +
after O +
verapamil O +
and O +
catheter O +
ablation O +
in O +
a O +
patient O +
with O +
Wolff B-Disease -
- I-Disease -
Parkinson I-Disease -
- I-Disease -
White I-Disease +
syndrome I-Disease +
and O +
idiopathic B-Disease +
dilated I-Disease +
cardiomyopathy I-Disease -
. O +

In O +
a O +
patient O +
with O +
WPW B-Disease +
syndrome I-Disease +
and O +
idiopathic B-Disease +
dilated I-Disease +
cardiomyopathy I-Disease -
, O +
intractable O +
atrioventricular B-Disease +
reentrant I-Disease +
tachycardia I-Disease +
( O -
AVRT B-Disease -
) O +
was O +
iatrogenically O +
induced O -
. O +

QRS O +
without O +
preexcitation O -
, O +
caused O +
by O +
junctional O +
escape O +
beats O +
after O +
verapamil O +
or O +
unidirectional O +
antegrade O +
block O +
of O +
accessory O +
pathway O +
after O +
catheter O +
ablation O -
, O +
established O +
frequent O +
AVRT B-Disease +
attack O -
. O +

Potential O +
therapeutic O +
use O +
of O +
the O +
selective O +
dopamine O +
D1 O +
receptor O +
agonist O -
, O +
A-86929 O -
: O +
an O +
acute O +
study O +
in O +
parkinsonian B-Disease +
levodopa O -
- O -
primed O +
monkeys O -
. O +

The O +
clinical O +
utility O +
of O +
dopamine O +
( O -
DA O -
) O +
D1 O +
receptor O +
agonists O +
in O +
the O +
treatment O +
of O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
( O -
PD B-Disease -
) O +
is O +
still O +
unclear O -
. O +

The O +
therapeutic O +
use O +
of O +
selective O +
DA O +
D1 O +
receptor O +
agonists O +
such O +
as O +
SKF-82958 O +
( O -
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze O +
pine O +
hydrobromide O -
) O +
and O +
A-77636 O +
( O -
[ O -
1R O -
, O +
3S O -
] O +
3- O -
[ O -
1'-admantyl O -
] O -
-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo O +
pyran O +
hydrochloride O -
) O +
seems O +
limited O +
because O +
of O +
their O +
duration O +
of O +
action O -
, O +
which O +
is O +
too O +
short O +
for O +
SKF-82958 O +
( O -
< O +
1 O +
hr O -
) O +
and O +
too O +
long O +
for O +
A-77636 O +
( O -
> O +
20 O +
hr O -
, O +
leading O +
to O +
behavioral O +
tolerance O -
) O -
. O +

We O +
therefore O +
conducted O +
the O +
present O +
acute O +
dose O -
- O -
response O +
study O +
in O +
four O +
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O +
( O -
MPTP O -
) O -
-exposed O +
cynomolgus O +
monkeys O +
primed O +
to O +
exhibit O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
to O +
evaluate O +
the O +
locomotor O +
and O +
dyskinetic B-Disease +
effects O +
on O +
challenge O +
with O +
four O +
doses O +
( O -
from O +
0.03 O +
to O +
1.0 O +
mg O -
/ O -
kg O -
) O +
of O +
A-86929 O +
( O -
[ O -
- O -
] O -
- O -
[ O -
5aR,11bS O -
] O -
-4,5,5a,6,7,11b O -
- O -
hexahydro-2-propyl-3-thia-5-+ O +
+ O -
+ O -
azacyclopent-1- O +
ena O -
[ O -
c O -
] O -
phenathrene-9 O -
- O -
10-diol O -
) O -
, O +
a O +
selective O +
and O +
full O +
DA O +
D1-like O +
receptor O +
agonist O +
with O +
an O +
intermediate O +
duration O +
of O +
action O -
. O +

Levodopa O +
and O +
the O +
DA O +
D2-like O +
receptor O +
agonist O -
, O +
LY-171555 O +
( O -
[ O -
4aR O -
- O -
trans O -
] O -
-4,4a,5,6,7,8,8a,9-o O -
- O -
dihydro-5n O -
- O -
propyl-2H O -
- O -
pyrazo O +
lo-3 O -
- O -
4-quinoline O +
hydrochloride O -
) O +
were O +
also O +
used O +
for O +
comparison O -
. O +

Acute O +
administration O +
of O +
A-86929 O +
was O +
as O +
efficacious O +
in O +
alleviating O +
MPTP O -
- O -
induced O +
parkinsonism B-Disease +
as O +
levodopa O +
and O +
LY-171555 O -
, O +
but O +
was O +
less O +
likely O +
to O +
reproduce O +
the O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
in O +
these O +
animals O +
than O +
with O +
either O +
LY-171555 O +
or O +
subsequent O +
challenge O +
of O +
levodopa O -
. O +

Selective O +
stimulation O +
of O +
the O +
DA O +
D1 O +
receptor O +
may O +
provide O +
better O +
integration O +
of O +
neural O +
inputs O +
transmitted O +
to O +
the O +
internal O +
segment O +
of O +
the O +
globus O +
pallidus O +
( O -
referred O +
to O +
as O +
the O +
basal O +
ganglia O +
output O -
) O +
compared O +
with O +
levodopa O +
and O +
selective O +
DA O +
D2 O +
receptor O +
agonist O -
. O +

Potent O +
DA O +
D1 O +
receptor O +
agents O +
with O +
an O +
intermediate O +
duration O +
of O +
efficacy O +
such O +
as O +
A-86929 O +
( O -
approximately O +
4 O +
hr O +
at O +
higher O +
doses O +
tested O -
) O +
are O +
potential O +
therapeutic O +
tools O +
in O +
PD B-Disease +
and O +
merit O +
further O +
attention O -
. O +

Epidemic O +
of O +
liver B-Disease +
disease I-Disease +
caused O +
by O +
hydrochlorofluorocarbons O +
used O +
as O +
ozone O -
- O -
sparing O +
substitutes O +
of O +
chlorofluorocarbons O -
. O +

BACKGROUND O -
: O +
Hydrochlorofluorocarbons O +
( O -
HCFCs O -
) O +
are O +
used O +
increasingly O +
in O +
industry O +
as O +
substitutes O +
for O +
ozone O -
- O -
depleting O +
chlorofluorocarbons O +
( O -
CFCs O -
) O -
. O +

Limited O +
studies O +
in O +
animals O +
indicate O +
potential O +
hepatotoxicity B-Disease +
of O +
some O +
of O +
these O +
compounds O -
. O +

We O +
investigated O +
an O +
epidemic O +
of O +
liver B-Disease +
disease I-Disease +
in O +
nine O +
industrial O +
workers O +
who O +
had O +
had O +
repeated O +
accidental O +
exposure O +
to O +
a O +
mixture O +
of O +
1,1-dichloro-2,2,2-trifluoroethane O +
( O -
HCFC O +
123 O -
) O +
and O +
1-chloro-1,2,2,2-tetrafluoroethane O +
( O -
HCFC O +
124 O -
) O -
. O +

All O +
nine O +
exposed O +
workers O +
were O +
affected O +
to O +
various O +
degrees O -
. O +

Both O +
compounds O +
are O +
metabolised O +
in O +
the O +
same O +
way O +
as O +
1-bromo-1-chloro-2,2,2-trifluoroethane O +
( O -
halothane O -
) O +
to O +
form O +
reactive O +
trifluoroacetyl O +
halide O +
intermediates O -
, O +
which O +
have O +
been O +
implicated O +
in O +
the O +
hepatotoxicity B-Disease +
of O +
halothane O -
. O +

We O +
aimed O +
to O +
test O +
whether O +
HCFCs O +
123 O +
and O +
124 O +
can O +
result O +
in O +
serious O +
liver B-Disease +
disease I-Disease -
. O +

METHODS O -
: O +
For O +
one O +
severely O +
affected O +
worker O +
liver O +
biopsy O +
and O +
immunohistochemical O +
stainings O +
for O +
the O +
presence O +
of O +
trifluoroacetyl O +
protein O +
adducts O +
were O +
done O -
. O +

The O +
serum O +
of O +
six O +
affected O +
workers O +
and O +
five O +
controls O +
was O +
tested O +
for O +
autoantibodies O +
that O +
react O +
with O +
human O +
liver O +
cytochrome O -
- O -
P450 O +
2E1 O +
( O -
P450 O +
2E1 O -
) O +
and O +
P58 O +
protein O +
disulphide O +
isomerase O +
isoform O +
( O -
P58 O -
) O -
. O +

FINDINGS O -
: O +
The O +
liver O +
biopsy O +
sample O +
showed O +
hepatocellular O +
necrosis B-Disease +
which O +
was O +
prominent O +
in O +
perivenular O +
zone O +
three O +
and O +
extended O +
focally O +
from O +
portal O +
tracts O +
to O +
portal O +
tracts O +
and O +
centrilobular O +
areas O +
( O -
bridging O +
necrosis B-Disease -
) O -
. O +

Trifluoroacetyl O -
- O -
adducted O +
proteins O +
were O +
detected O +
in O +
surviving O +
hepatocytes O -
. O +

Autoantibodies O +
against O +
P450 O +
2E1 O +
or O +
P58 O -
, O +
previously O +
associated O +
with O +
halothane B-Disease +
hepatitis I-Disease -
, O +
were O +
detected O +
in O +
the O +
serum O +
of O +
five O +
affected O +
workers O -
. O +

INTERPRETATION O -
: O +
Repeated O +
exposure O +
of O +
human O +
beings O +
to O +
HCFCs O +
123 O +
and O +
124 O +
can O +
result O +
in O +
serious O +
liver B-Disease +
injury I-Disease +
in O +
a O +
large O +
proportion O +
of O +
the O +
exposed O +
population O -
. O +

Although O +
the O +
exact O +
mechanism O +
of O +
hepatotoxicity B-Disease +
of O +
these O +
agents O +
is O +
not O +
known O -
, O +
the O +
results O +
suggest O +
that O +
trifluoroacetyl O -
- O -
altered O +
liver O +
proteins O +
are O +
involved O -
. O +

In O +
view O +
of O +
the O +
potentially O +
widespread O +
use O +
of O +
these O +
compounds O -
, O +
there O +
is O +
an O +
urgent O +
need O +
to O +
develop O +
safer O +
alternatives O -
. O +

Bile B-Disease +
duct I-Disease +
hamartoma I-Disease +
occurring O +
in O +
association O +
with O +
long O -
- O -
term O +
treatment O +
with O +
danazol O -
. O +

We O +
report O +
a O +
case O +
of O +
bile B-Disease +
duct I-Disease +
hamartoma I-Disease +
which O +
developed O +
in O +
a O +
patient O +
who O +
had O +
been O +
on O +
long O -
- O -
term O +
danazol O +
treatment O -
. O +

Such O +
patients O +
should O +
be O +
under O +
close O +
follow O -
- O -
up O -
, O +
preferably O +
with O +
periodic O +
ultrasound O +
examination O +
of O +
the O +
liver O -
. O +

If O +
the O +
patient O +
develops O +
a O +
liver B-Disease +
mass I-Disease -
, O +
because O +
of O +
non O -
- O -
specific O +
clinical O +
features O +
and O +
imaging O +
appearances O -
, O +
biopsy O +
may O +
be O +
the O +
only O +
way O +
to O +
achieve O +
a O +
definitive O +
diagnosis O -
. O +

Neuropeptide O -
- O -
Y O +
immunoreactivity O +
in O +
the O +
pilocarpine O +
model O +
of O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease -
. O +

Neuropeptide O -
- O -
Y O +
( O -
NPY O -
) O +
is O +
expressed O +
by O +
granule O +
cells O +
and O +
mossy O +
fibres O +
of O +
the O +
hippocampal O +
dentate O +
gyrus O +
during O +
experimental O +
temporal B-Disease +
lobe I-Disease +
epilepsy I-Disease +
( O -
TLE B-Disease -
) O -
. O +

This O +
expression O +
may O +
represent O +
an O +
endogenous O +
damping O +
mechanism O +
since O +
NPY O +
has O +
been O +
shown O +
to O +
block O +
seizure B-Disease -
- O -
like O +
events O +
following O +
high O -
- O -
frequency O +
stimulation O +
in O +
hippocampal O +
slices O -
. O +

The O +
pilocarpine O +
( O -
PILO O -
) O +
model O +
of O +
epilepsy B-Disease +
is O +
characterized O +
by O +
an O +
acute O +
period O +
of O +
status B-Disease +
epilepticus I-Disease +
followed O +
by O +
spontaneous O +
recurrent O +
seizures B-Disease +
and O +
related O +
brain B-Disease +
damage I-Disease -
. O +

We O +
report O +
peroxidase O -
- O -
antiperoxidase O +
immunostaining O +
for O +
NPY O +
in O +
several O +
brain O +
regions O +
in O +
this O +
model O -
. O +

PILO O -
- O -
injected O +
animals O +
exhibited O +
NPY O +
immunoreactivity O +
in O +
the O +
region O +
of O +
the O +
mossy O +
fibre O +
terminals O -
, O +
in O +
the O +
dentate O +
gyrus O +
inner O +
molecular O +
layer O +
and O -
, O +
in O +
a O +
few O +
cases O -
, O +
within O +
presumed O +
granule O +
cells O -
. O +

NPY O +
immunoreactivity O +
was O +
also O +
dramatically O +
changed O +
in O +
the O +
entorhinal O +
cortex O -
, O +
amygdala O +
and O +
sensorimotor O +
areas O -
. O +

In O +
addition O -
, O +
PILO O +
injected O +
animals O +
exhibited O +
a O +
reduction O +
in O +
the O +
number O +
of O +
NPY O -
- O -
immunoreactive O +
interneurons O +
compared O +
with O +
controls O -
. O +

The O +
results O +
demonstrate O +
that O +
changes O +
in O +
NPY O +
expression O -
, O +
including O +
expression O +
in O +
the O +
granule O +
cells O +
and O +
mossy O +
fibres O +
and O +
the O +
loss O +
of O +
vulnerable O +
NPY O +
neurons O -
, O +
are O +
present O +
in O +
the O +
PILO O +
model O +
of O +
TLE B-Disease -
. O +

However O -
, O +
the O +
significance O +
of O +
this O +
changed O +
synthesis O +
of O +
NPY O +
remains O +
to O +
be O +
determined O -
. O +

Posteroventral O +
medial O +
pallidotomy O +
in O +
advanced O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
. O +

BACKGROUND O -
: O +
Posteroventral O +
medial O +
pallidotomy O +
sometimes O +
produces O +
striking O +
improvement O +
in O +
patients O +
with O +
advanced O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
, O +
but O +
the O +
studies O +
to O +
date O +
have O +
involved O +
small O +
numbers O +
of O +
patients O +
and O +
short O -
- O -
term O +
follow O -
- O -
up O -
. O +

METHODS O -
: O +
Forty O +
patients O +
with O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease +
underwent O +
serial O -
, O +
detailed O +
assessments O +
both O +
after O +
drug O +
withdrawal O +
( O -
" O -
off O -
" O +
period O -
) O +
and O +
while O +
taking O +
their O +
optimal O +
medical O +
regimens O +
( O -
" O -
on O -
" O +
period O -
) O -
. O +

All O +
patients O +
were O +
examined O +
preoperatively O +
and O +
39 O +
were O +
examined O +
at O +
six O +
months O -
; O +
27 O +
of O +
the O +
patients O +
were O +
also O +
examined O +
at O +
one O +
year O -
, O +
and O +
11 O +
at O +
two O +
years O -
. O +

RESULTS O -
: O +
The O +
percent O +
improvements O +
at O +
six O +
months O +
were O +
as O +
follows O -
: O +
off O -
- O -
period O +
score O +
for O +
overall O +
motor O +
function O -
, O +
28 O +
percent O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
19 O +
to O +
38 O +
percent O -
) O -
, O +
with O +
most O +
of O +
the O +
improvement O +
in O +
the O +
contralateral O +
limbs O -
; O +
off O -
- O -
period O +
score O +
for O +
activities O +
of O +
daily O +
living O -
, O +
29 O +
percent O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
19 O +
to O +
39 O +
percent O -
) O -
; O +
on O -
- O -
period O +
score O +
for O +
contralateral O +
dyskinesias B-Disease -
, O +
82 O +
percent O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
72 O +
to O +
91 O +
percent O -
) O -
; O +
and O +
on O -
- O -
period O +
score O +
for O +
ipsilateral O +
dyskinesias B-Disease -
, O +
44 O +
percent O +
( O -
95 O +
percent O +
confidence O +
interval O -
, O +
29 O +
to O +
59 O +
percent O -
) O -
. O +

The O +
improvements O +
in O +
dyskinesias B-Disease +
and O +
the O +
total O +
scores O +
for O +
off O -
- O -
period O +
parkinsonism B-Disease -
, O +
contralateral O +
bradykinesia B-Disease -
, O +
and O +
rigidity B-Disease +
were O +
sustained O +
in O +
the O +
11 O +
patients O +
examined O +
at O +
two O +
years O -
. O +

The O +
improvement O +
in O +
ipsilateral O +
dyskinesias B-Disease +
was O +
lost O +
after O +
one O +
year O -
, O +
and O +
the O +
improvements O +
in O +
postural O +
stability O +
and O +
gait O +
lasted O +
only O +
three O +
to O +
six O +
months O -
. O +

Approximately O +
half O +
the O +
patients O +
who O +
had O +
been O +
dependent O +
on O +
assistance O +
in O +
activities O +
of O +
daily O +
living O +
in O +
the O +
off O +
period O +
before O +
surgery O +
became O +
independent O +
after O +
surgery O -
. O +

The O +
complications O +
of O +
surgery O +
were O +
generally O +
well O +
tolerated O -
, O +
and O +
there O +
were O +
no O +
significant O +
changes O +
in O +
the O +
use O +
of O +
medication O -
. O +

CONCLUSIONS O -
: O +
In O +
late O -
- O -
stage O +
Parkinson B-Disease -
's I-Disease +
disease I-Disease -
, O +
pallidotomy O +
significantly O +
reduces O +
levodopa O -
- O -
induced O +
dyskinesias B-Disease +
and O +
off O -
- O -
period O +
disability O -
. O +

Much O +
of O +
the O +
benefit O +
is O +
sustained O +
at O +
two O +
years O -
, O +
although O +
some O +
improvements O -
, O +
such O +
as O +
those O +
on O +
the O +
ipsilateral O +
side O +
and O +
in O +
axial O +
symptoms O -
, O +
wane O +
within O +
the O +
first O +
year O -
. O +

The O +
on O -
- O -
period O +
symptoms O +
that O +
are O +
resistant O +
to O +
dopaminergic O +
therapy O +
do O +
not O +
respond O +
to O +
pallidotomy O -
. O +

Clarithromycin O -
- O -
induced O +
ventricular B-Disease +
tachycardia I-Disease -
. O +

Clarithromycin O +
is O +
a O +
relatively O +
new O +
macrolide O +
antibiotic O +
that O +
offers O +
twice O -
- O -
daily O +
dosing O -
. O +

It O +
differs O +
from O +
erythromycin O +
only O +
in O +
the O +
methylation O +
of O +
the O +
hydroxyl O +
group O +
at O +
position O +
6 O -
. O +

Although O +
the O +
side O -
- O -
effect O +
profile O +
of O +
erythromycin O +
is O +
established O -
, O +
including O +
gastroenteritis B-Disease +
and O +
interactions O +
with O +
other O +
drugs O +
subject O +
to O +
hepatic O +
mixed O -
- O -
function O +
oxidase O +
metabolism O -
, O +
experience O +
with O +
the O +
newer O +
macrolides O +
is O +
still O +
being O +
recorded O -
. O +

Cardiotoxicity B-Disease +
has O +
been O +
demonstrated O +
after O +
both O +
intravenous O +
and O +
oral O +
administration O +
of O +
erythromycin O +
but O +
has O +
never O +
been O +
reported O +
with O +
the O +
newer O +
macrolides O -
. O +

We O +
report O +
a O +
case O +
of O +
ventricular B-Disease +
dysrhythmias I-Disease +
that O +
occurred O +
after O +
six O +
therapeutic O +
doses O +
of O +
clarithromycin O -
. O +

The O +
dysrhythmias B-Disease +
resolved O +
after O +
discontinuation O +
of O +
the O +
drug O -
. O +

Endocrine O +
screening O +
in O +
1,022 O +
men O +
with O +
erectile B-Disease +
dysfunction I-Disease -
: O +
clinical O +
significance O +
and O +
cost O -
- O -
effective O +
strategy O -
. O +

PURPOSE O -
: O +
We O +
reviewed O +
the O +
results O +
of O +
serum O +
testosterone O +
and O +
prolactin O +
determination O +
in O +
1,022 O +
patients O +
referred O +
because O +
of O +
erectile B-Disease +
dysfunction I-Disease +
and O +
compared O +
the O +
data O +
with O +
history O -
, O +
results O +
of O +
physical O +
examination O -
, O +
other O +
etiological O +
investigations O +
and O +
effects O +
of O +
endocrine O +
therapy O +
to O +
refine O +
the O +
rules O +
of O +
cost O -
- O -
effective O +
endocrine O +
screening O +
and O +
to O +
pinpoint O +
actual O +
responsibility O +
for O +
hormonal O +
abnormalities O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Testosterone O +
and O +
prolactin O +
were O +
determined O +
by O +
radioimmunoassay O -
. O +

Every O +
patient O +
was O +
screened O +
for O +
testosterone O +
and O +
451 O +
were O +
screened O +
for O +
prolactin O +
on O +
the O +
basis O +
of O +
low B-Disease +
sexual I-Disease +
desire I-Disease -
, O +
gynecomastia B-Disease +
or O +
testosterone O +
less O +
than O +
4 O +
ng. O -
/ O -
ml O -
. O +

Determination O +
was O +
repeated O +
in O +
case O +
of O +
abnormal O +
first O +
results O -
. O +

Prolactin O +
results O +
were O +
compared O +
with O +
those O +
of O +
a O +
previous O +
personal O +
cohort O +
of O +
1,340 O +
patients O +
with O +
erectile B-Disease +
dysfunction I-Disease +
and O +
systematic O +
prolactin O +
determination O -
. O +

Main O +
clinical O +
criteria O +
tested O +
regarding O +
efficiency O +
in O +
hormone O +
determination O +
were O +
low B-Disease +
sexual I-Disease +
desire I-Disease -
, O +
small O +
testes O +
and O +
gynecomastia B-Disease -
. O +

Endocrine O +
therapy O +
consisted O +
of O +
testosterone O +
heptylate O +
or O +
human O +
chorionic O +
gonadotropin O +
for O +
hypogonadism B-Disease +
and O +
bromocriptine O +
for O +
hyperprolactinemia B-Disease -
. O +

RESULTS O -
: O +
Testosterone O +
was O +
less O +
than O +
3 O +
ng. O -
/ O -
ml O -
. O +

in O +
107 O +
patients O +
but O +
normal O +
in O +
40 O -
% O +
at O +
repeat O +
determination O -
. O +

The O +
prevalence O +
of O +
repeatedly O +
low O +
testosterone O +
increased O +
with O +
age O +
( O -
4 O -
% O +
before O +
age O +
50 O +
years O +
and O +
9 O -
% O +
50 O +
years O +
or O +
older O -
) O -
. O +

Two O +
pituitary B-Disease +
tumors I-Disease +
were O +
discovered O +
after O +
testosterone O +
determination O -
. O +

Most O +
of O +
the O +
other O +
low O +
testosterone O +
levels O +
seemed O +
to O +
result O +
from O +
nonorganic O +
hypothalamic B-Disease +
dysfunction I-Disease +
because O +
of O +
normal O +
serum O +
luteinizing O +
hormone O +
and O +
prolactin O +
and O +
to O +
have O +
only O +
a O +
small O +
role O +
in O +
erectile B-Disease +
dysfunction I-Disease +
( O -
definite O +
improvement O +
in O +
only O +
16 O +
of O +
44 O +
[ O -
36 O -
% O -
] O +
after O +
androgen O +
therapy O -
, O +
normal O +
morning O +
or O +
nocturnal O +
erections O +
in O +
30 O -
% O +
and O +
definite O +
vasculogenic O +
contributions O +
in O +
42 O -
% O -
) O -
. O +

Determining O +
testosterone O +
only O +
in O +
cases O +
of O +
low B-Disease +
sexual I-Disease +
desire I-Disease +
or O +
abnormal O +
physical O +
examination O +
would O +
have O +
missed O +
40 O -
% O +
of O +
the O +
cases O +
with O +
low O +
testosterone O -
, O +
including O +
37 O -
% O +
of O +
those O +
subsequently O +
improved O +
by O +
androgen O +
therapy O -
. O +

Prolactin O +
exceeded O +
20 O +
ng. O -
/ O -
ml O -
. O +

in O +
5 O +
men O +
and O +
was O +
normal O +
in O +
2 O +
at O +
repeat O +
determination O -
. O +

Only O +
1 O +
prolactinoma B-Disease +
was O +
discovered O -
. O +

These O +
data O +
are O +
lower O +
than O +
those O +
we O +
found O +
during O +
the O +
last O +
2 O +
decades O +
( O -
overall O +
prolactin O +
greater O +
than O +
20 O +
ng. O -
/ O -
ml O -
. O +

in O +
1.86 O -
% O +
of O +
1,821 O +
patients O -
, O +
prolactinomas B-Disease +
in O +
7 O -
, O +
0.38 O -
% O -
) O -
. O +

Bromocriptine O +
was O +
definitely O +
effective O +
in O +
cases O +
with O +
prolactin O +
greater O +
than O +
35 O +
ng. O -
/ O -
ml O -
. O +

( O -
8 O +
of O +
12 O +
compared O +
to O +
only O +
9 O +
of O +
22 O +
cases O +
with O +
prolactin O +
between O +
20 O +
and O +
35 O +
ng. O -
/ O -
ml O -
. O -
) O -
. O +

Testosterone O +
was O +
low O +
in O +
less O +
than O +
50 O -
% O +
of O +
cases O +
with O +
prolactin O +
greater O +
than O +
35 O +
ng. O -
/ O -
ml O -
. O +

CONCLUSIONS O -
: O +
Low O +
prevalences O +
and O +
effects O +
of O +
low O +
testosterone O +
and O +
high O +
prolactin O +
in O +
erectile B-Disease +
dysfunction I-Disease +
can O -
not O +
justify O +
their O +
routine O +
determination O -
. O +

However O -
, O +
cost O -
- O -
effective O +
screening O +
strategies O +
recommended O +
so O +
far O +
missed O +
40 O +
to O +
50 O -
% O +
of O +
cases O +
improved O +
with O +
endocrine O +
therapy O +
and O +
the O +
pituitary B-Disease +
tumors I-Disease -
. O +

We O +
now O +
advocate O +
that O +
before O +
age O +
50 O +
years O +
testosterone O +
be O +
determined O +
only O +
in O +
cases O +
of O +
low B-Disease +
sexual I-Disease +
desire I-Disease +
and O +
abnormal O +
physical O +
examination O +
but O +
that O +
it O +
be O +
measured O +
in O +
all O +
men O +
older O +
than O +
50 O +
years O -
. O +

Prolactin O +
should O +
be O +
determined O +
only O +
in O +
cases O +
of O +
low B-Disease +
sexual I-Disease +
desire I-Disease -
, O +
gynecomastia B-Disease +
and/or O +
testosterone O +
less O +
than O +
4 O +
ng. O -
/ O -
ml O -
. O +

Extrapyramidal O +
side O +
effects O +
with O +
risperidone O +
and O +
haloperidol O +
at O +
comparable O +
D2 O +
receptor O +
occupancy O +
levels O -
. O +

Risperidone O +
is O +
an O +
antipsychotic O +
drug O +
with O +
high O +
affinity O +
at O +
dopamine O +
D2 O +
and O +
serotonin O +
5-HT2 O +
receptors O -
. O +

Previous O +
clinical O +
studies O +
have O +
proposed O +
that O +
risperidone O -
's O +
pharmacologic O +
profile O +
may O +
produce O +
improved O +
efficacy O +
for O +
negative O +
psychotic B-Disease +
symptoms I-Disease +
and O +
decreased O +
propensity O +
for O +
extrapyramidal O +
side O +
effects O -
; O +
features O +
shared O +
by O +
so O -
- O -
called O +
' O -
atypical O -
' O +
neuroleptics O -
. O +

To O +
determine O +
if O +
routine O +
risperidone O +
treatment O +
is O +
associated O +
with O +
a O +
unique O +
degree O +
of O +
D2 O +
receptor O +
occupancy O +
and O +
pattern O +
of O +
clinical O +
effects O -
, O +
we O +
used O +
[ O -
123I O -
] O -
IBZM O +
SPECT O +
to O +
determine O +
D2 O +
occupancy O +
in O +
subjects O +
treated O +
with O +
routine O +
clinical O +
doses O +
of O +
risperidone O +
( O -
n O +
= O +
12 O -
) O +
or O +
haloperidol O +
( O -
n O +
= O +
7 O -
) O -
. O +

Both O +
risperidone O +
and O +
haloperidol O +
produced O +
D2 O +
occupancy O +
levels O +
between O +
approximately O +
60 O +
and O +
90 O -
% O +
at O +
standard O +
clinical O +
doses O -
. O +

There O +
was O +
no O +
significant O +
difference O +
between O +
occupancy O +
levels O +
obtained O +
with O +
haloperidol O +
or O +
risperidone O -
. O +

Drug B-Disease -
- I-Disease -
induced I-Disease +
parkinsonism I-Disease +
was O +
observed O +
in O +
subjects O +
treated O +
with O +
risperidone O +
( O -
42 O -
% O -
) O +
and O +
haloperidol O +
( O -
29 O -
% O -
) O +
and O +
was O +
observed O +
at O +
occupancy O +
levels O +
above O +
60 O -
% O -
. O +

Based O +
on O +
these O +
observations O -
, O +
it O +
is O +
concluded O +
that O +
5-HT2 O +
blockade O +
obtained O +
with O +
risperidone O +
at O +
D2 O +
occupancy O +
rates O +
of O +
60 O -
% O +
and O +
above O +
does O +
not O +
appear O +
to O +
protect O +
against O +
the O +
risk O +
for O +
extrapyramidal O +
side O +
effects O -
. O +

Treatment O +
of O +
previously O +
treated O +
metastatic O +
breast B-Disease +
cancer I-Disease +
by O +
mitoxantrone O +
and O +
48-hour O +
continuous O +
infusion O +
of O +
high O -
- O -
dose O +
5-FU O +
and O +
leucovorin O +
( O -
MFL O -
) O -
: O +
low O +
palliative O +
benefit O +
and O +
high O +
treatment O -
- O -
related O +
toxicity B-Disease -
. O +

For O +
previously O +
treated O +
advanced O +
breast B-Disease +
cancer I-Disease -
, O +
there O +
is O +
no O +
standard O +
second O -
- O -
line O +
therapy O -
. O +

Combination O +
chemotherapy O +
with O +
mitoxantrone O -
, O +
high O -
- O -
dose O +
5-fluorouracil O +
( O -
5-FU O -
) O +
and O +
leucovorin O +
( O -
MFL O +
regimen O -
) O +
had O +
been O +
reported O +
as O +
an O +
effective O +
and O +
well O +
tolerated O +
regimen O -
. O +

From O +
October O +
1993 O +
to O +
November O +
1995 O -
, O +
we O +
treated O +
13 O +
patients O +
with O +
previously O +
chemotherapy O -
- O -
treated O +
metastatic O +
breast B-Disease +
cancer I-Disease +
by O +
mitoxantrone O -
, O +
12 O +
mg O -
/ O -
m2 O -
, O +
on O +
day O +
1 O +
and O +
continuous O +
infusion O +
of O +
5-FU O -
, O +
3000 O +
mg O -
/ O -
m2 O -
, O +
together O +
with O +
leucovorin O -
, O +
300 O +
mg O -
/ O -
m2 O -
, O +
for O +
48 O +
h O +
from O +
day O +
1 O +
to O +
2 O -
. O +

Each O +
course O +
of O +
chemotherapy O +
was O +
given O +
every O +
4 O +
weeks O -
. O +

Most O +
of O +
these O +
patients O +
had O +
more O +
than O +
two O +
metastatic O +
sites O -
, O +
with O +
lung O +
metastasis O +
predominant O -
. O +

Seven O +
patients O +
had O +
been O +
treated O +
with O +
anthracycline O -
. O +

Seven O +
patients O +
had O +
previously O +
received O +
radiotherapy O +
and O +
seven O +
had O +
received O +
hormone O +
therapy O -
. O +

Median O +
number O +
of O +
courses O +
of O +
MFL O +
regimen O +
given O +
was O +
six O +
and O +
the O +
median O +
cumulative O +
dose O +
of O +
mitoxantrone O +
was O +
68.35 O +
mg O -
/ O -
m2 O -
. O +

One O +
patient O +
had O +
complete O +
response O -
, O +
seven O +
had O +
stable O +
disease O -
, O +
none O +
had O +
partial O +
response O +
and O +
five O +
had O +
progressive O +
disease O -
. O +

The O +
overall O +
objective O +
response O +
rate O +
was O +
7.6 O -
% O -
. O +

The O +
median O +
follow O -
- O -
up O +
period O +
was O +
14 O +
months O -
. O +

Median O +
survival O +
was O +
16 O +
months O -
. O +

Median O +
progression O -
- O -
free O +
survival O +
was O +
5 O +
months O -
. O +

A O +
complete O +
responder O +
had O +
relapse O -
- O -
free O +
survival O +
up O +
to O +
17 O +
months O -
. O +

Major O +
toxicities B-Disease +
were O +
cardiotoxicity B-Disease +
and O +
leukopenia B-Disease -
. O +

Eight O +
patients O +
were O +
dead O +
in O +
the O +
last O +
follow O -
- O -
up O -
; O +
two O +
of O +
them O +
died O +
of O +
treatment O -
- O -
related O +
toxicity B-Disease -
. O +

The O +
MFL O +
regimen O +
achieves O +
little O +
palliative O +
benefit O +
and O +
induces O +
severe O +
toxicity B-Disease +
at O +
a O +
fairly O +
high O +
rate O -
. O +

Administration O +
of O +
this O +
regimen O +
to O +
breast B-Disease +
cancer I-Disease +
patients O +
who O +
have O +
been O +
treated O +
by O +
chemotherapy O +
and O +
those O +
with O +
impaired B-Disease +
heart I-Disease +
function I-Disease +
requires O +
careful O +
attention O -
. O +

Ticlopidine O -
- O -
induced O +
aplastic B-Disease +
anemia I-Disease -
: O +
report O +
of O +
three O +
Chinese O +
patients O +
and O +
review O +
of O +
the O +
literature O -
. O +

In O +
this O +
study O -
, O +
three O +
Chinese O +
patients O +
with O +
ticlopidine O -
- O -
induced O +
aplastic B-Disease +
anemia I-Disease +
were O +
reported O +
and O +
another O +
13 O +
patients O +
in O +
the O +
English O +
literature O +
were O +
reviewed O -
. O +

We O +
attempted O +
to O +
find O +
underlying O +
similarities O -
, O +
evaluate O +
the O +
risk O +
factors O -
, O +
and O +
identify O +
appropriate O +
treatment O +
for O +
this O +
complication O -
. O +

All O +
but O +
one O +
of O +
the O +
patients O +
were O +
over O +
60 O +
years O +
old O -
, O +
and O +
the O +
6 O +
who O +
died O +
were O +
all O +
older O +
than O +
65 O -
. O +

Therefore O -
, O +
old O +
age O +
may O +
be O +
a O +
risk O +
factor O +
for O +
developing O +
this O +
complication O -
. O +

Agranulocytosis B-Disease +
occurred O +
3 O -
- O -
20 O +
weeks O +
after O +
initiation O +
of O +
ticlopidine O -
, O +
so O +
frequent O +
examination O +
of O +
white O +
cell O +
count O +
during O +
treatment O +
is O +
recommended O -
. O +

There O +
seemed O +
to O +
be O +
no O +
direct O +
correlation O +
between O +
the O +
dose O +
or O +
duration O +
used O +
and O +
the O +
severity O +
of O +
bone B-Disease +
marrow I-Disease +
suppression I-Disease -
. O +

Treatment O +
for O +
ticlopidine O -
- O -
induced O +
aplastic B-Disease +
anemia I-Disease +
with O +
colony O -
- O -
stimulating O +
factors O +
seemed O +
to O +
have O +
little O +
effect O -
. O +

The O +
fact O +
that O +
5 O +
of O +
the O +
6 O +
patients O +
who O +
received O +
concurrent O +
calcium O +
channel O +
blockers O +
died O -
, O +
should O +
alert O +
clinicians O +
to O +
be O +
more O +
cautious O +
when O +
using O +
these O +
two O +
drugs O +
simultaneously O -
. O +

Upregulation O +
of O +
the O +
expression O +
of O +
vasopressin O +
gene O +
in O +
the O +
paraventricular O +
and O +
supraoptic O +
nuclei O +
of O +
the O +
lithium O -
- O -
induced O +
diabetes B-Disease +
insipidus I-Disease +
rat O -
. O +

The O +
expression O +
of O +
arginine O +
vasopressin O +
( O -
AVP O -
) O +
gene O +
in O +
the O +
paraventricular O +
( O -
PVN O -
) O +
and O +
supraoptic O +
nuclei O +
( O -
SON O -
) O +
was O +
investigated O +
in O +
rats O +
with O +
lithium O +
( O -
Li O -
) O -
-induced O +
polyuria B-Disease -
, O +
using O +
in O +
situ O +
hybridization O +
histochemistry O +
and O +
radioimmunoassay O -
. O +

The O +
male O +
Wistar O +
rats O +
consuming O +
a O +
diet O +
that O +
contained O +
LiCl O +
( O -
60 O +
mmol O -
/ O -
kg O -
) O +
for O +
4 O +
weeks O +
developed O +
marked O +
polyuria B-Disease -
. O +

The O +
Li O -
- O -
treated O +
rats O +
produced O +
a O +
large O +
volume O +
of O +
hypotonic O +
urine O +
with O +
low O +
ionic O +
concentrations O -
. O +

Plasma O +
sodium O +
concentrations O +
were O +
found O +
to O +
be O +
slightly O +
increased O +
in O +
the O +
Li O -
- O -
treated O +
rats O +
compared O +
with O +
those O +
in O +
controls O -
. O +

Plasma O +
concentration O +
of O +
AVP O +
and O +
transcripts O +
of O +
AVP O +
gene O +
in O +
the O +
PVN O +
and O +
SON O +
were O +
significantly O +
increased O +
in O +
the O +
Li O -
- O -
treated O +
rats O +
compared O +
with O +
controls O -
. O +

These O +
results O +
suggest O +
that O +
dehydration B-Disease +
and/or O +
the O +
activation O +
of O +
visceral O +
afferent O +
inputs O +
may O +
contribute O +
to O +
the O +
elevation O +
of O +
plasma O +
AVP O +
and O +
the O +
upregulation O +
of O +
AVP O +
gene O +
expression O +
in O +
the O +
PVN O +
and O +
the O +
SON O +
of O +
the O +
Li O -
- O -
induced O +
diabetes B-Disease +
insipidus I-Disease +
rat O -
. O +

Effect O +
of O +
glyceryl O +
trinitrate O +
on O +
the O +
sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
spasm I-Disease +
evoked O +
by O +
prostigmine O -
- O -
morphine O +
administration O -
. O +

OBJECTIVE O -
: O +
In O +
this O +
study O +
the O +
effect O +
of O +
glyceryl O +
trinitrate O +
on O +
the O +
prostigmine O -
- O -
morphine O -
- O -
induced O +
sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
spasm I-Disease +
was O +
evaluated O +
in O +
nine O +
female O +
patients O +
with O +
sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
dyskinesia I-Disease -
. O +

METHOD O -
: O +
Sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
spasm I-Disease +
was O +
induced O +
by O +
prostigmine O -
- O -
morphine O +
administration O +
( O -
0.5 O +
mg O +
prostigmine O +
intramuscularly O +
and O +
10 O +
mg O +
morphine O +
subcutaneously O -
) O +
and O +
visualized O +
by O +
quantitative O +
hepatobiliary O +
scintigraphy O -
. O +

The O +
entire O +
procedure O +
was O +
repeated O +
during O +
glyceryl O +
trinitrate O +
infusion O +
( O -
Nitrolingual O +
1 O +
microg O -
/ O -
kg O -
/ O -
min O +
for O +
120 O +
min O -
) O -
. O +

RESULTS O -
: O +
Prostigmine O -
- O -
morphine O +
provocation O +
caused O +
significant O +
increases O +
in O +
the O +
time O +
to O +
peak O +
activity O +
( O -
Tmax O -
) O +
over O +
the O +
hepatic O +
hilum O +
( O -
HH O -
: O +
34.33 O +
+ O -
/- O +

5.05 O +
vs. O +
22.77 O +
+ O -
/- O +

3.26 O -
) O +
and O +
the O +
common O +
bile O +
duct O +
( O -
CBD O -
: O +
60.44 O +
+ O -
/- O +

5.99 O +
vs. O +
40.0 O +
+ O -
/- O +

2.88 O -
) O +
and O +
in O +
the O +
half O -
- O -
time O +
of O +
excretion O +
( O -
T1 O -
/ O -
2 O -
) O +
over O +
the O +
liver O +
parenchyma O +
( O -
LP O -
: O +
120.04 O +
+ O -
/- O +

16.01 O +
vs. O +
27.37 O +
+ O -
/- O +

2.19 O -
) O -
, O +
HH O +
( O -
117.61 O +
+ O -
/- O +

14.71 O +
vs. O +
31.85 O +
+ O -
/- O +

3.99 O -
) O +
and O +
CBD O +
( O -
158.11 O +
+ O -
/- O +

9.18 O +
vs. O +
40.1 O +
+ O -
/- O +

6.24 O -
) O -
, O +
indicating O +
a O +
complete O +
spasm B-Disease +
at O +
the O +
level O +
of O +
the O +
sphincter O +
of O +
Oddi O -
. O +

Glyceryl O +
trinitrate O +
infusion O +
completely O +
normalized O +
the O +
prostigmine O -
- O -
morphine O -
- O -
induced O +
alterations O +
in O +
these O +
quantitative O +
parameters O +
( O -
TmaX O +
over O +
the O +
LP O -
: O +
11.33 O +
+ O -
/- O +

1.13 O -
; O +
over O +
the O +
HH O -
: O +
18.88 O +
+ O -
/- O +
1.48 O -
; O +
and O +
over O +
the O +
CBD O -
: O +
36.22 O +
+ O -
/- O +

1.92 O -
; O +
and O +
T1 O -
/ O -
2 O +
over O +
the O +
LP O -
: O +
28.21 O +
+ O -
/- O +

1.83 O -
; O +
over O +
the O +
HH O -
: O +
33.42 O +
+ O -
/- O +

3.10 O -
; O +
and O +
over O +
the O +
CBD O -
: O +
41.66 O +
+ O -
/- O +

6.33 O -
) O -
, O +
suggesting O +
an O +
effective O +
sphincter O -
- O -
relaxing O +
effect O +
of O +
glyceryl O +
trinitrate O -
. O +

CONCLUSION O -
: O +
These O +
results O +
provide O +
the O +
first O +
evidence O +
of O +
the O +
effectiveness O +
of O +
glyceryl O +
trinitrate O +
on O +
the O +
morphine O -
- O -
induced O +
sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
spasm I-Disease +
in O +
humans O -
. O +

Since O +
glyceryl O +
trinitrate O +
is O +
able O +
to O +
overcome O +
even O +
the O +
drastic O +
effect O +
of O +
morphine O -
, O +
it O +
might O +
be O +
of O +
relevance O +
in O +
the O +
treatment O +
of O +
sphincter B-Disease +
of I-Disease +
Oddi I-Disease +
dyskinesia I-Disease -
. O +

Antinociceptive O +
and O +
antiamnesic O +
properties O +
of O +
the O +
presynaptic O +
cholinergic O +
amplifier O +
PG-9 O -
. O +

The O +
antinociceptive O +
effect O +
of O +
3 O +
alpha O -
- O -
tropyl O +
2- O -
( O -
p O -
- O -
bromophenyl O -
) O -
propionate O +
[ O -
( O -
+ O -
/- O -
) O -
-PG-9 O -
] O +
( O -
10 O -
- O -
40 O +
mg O +
kg-1 O +
s.c O -
. O -
; O +
30 O -
- O -
60 O +
mg O +
kg-1 O +
p.o O -
. O -
; O +
10 O -
- O -
30 O +
mg O +
kg-1 O +
i.v O -
. O -
; O +
10 O -
- O -
30 O +
micrograms O -
/ O -
mouse O +
i.c.v O -
. O -
) O +
was O +
examined O +
in O +
mice O -
, O +
rats O +
and O +
guinea O +
pigs O +
by O +
use O +
of O +
the O +
hot O -
- O -
plate O -
, O +
abdominal O -
- O -
constriction O -
, O +
tail O -
- O -
flick O +
and O +
paw O -
- O -
pressure O +
tests O -
. O +

( O -
+ O -
/- O -
) O -
-PG-9 O +
antinociception O +
peaked O +
15 O +
min O +
after O +
injection O +
and O +
then O +
slowly O +
diminished O -
. O +

The O +
antinociception O +
produced O +
by O +
( O -
+ O -
/- O -
) O -
-PG-9 O +
was O +
prevented O +
by O +
the O +
unselective O +
muscarinic O +
antagonist O +
atropine O -
, O +
the O +
M1-selective O +
antagonists O +
pirenzepine O +
and O +
dicyclomine O +
and O +
the O +
acetylcholine O +
depletor O +
hemicholinium-3 O -
, O +
but O +
not O +
by O +
the O +
opioid O +
antagonist O +
naloxone O -
, O +
the O +
gamma O -
- O -
aminobutyric O +
acidB O +
antagonist O +
3-aminopropyl O -
- O -
diethoxy O -
- O -
methyl O -
- O -
phosphinic O +
acid O -
, O +
the O +
H3 O +
agonist O +
R- O -
( O -
alpha O -
) O -
-methylhistamine O -
, O +
the O +
D2 O +
antagonist O +
quinpirole O -
, O +
the O +
5-hydroxytryptamine4 O +
antagonist O +
2-methoxy-4-amino-5-chlorobenzoic O +
acid O +
2- O -
( O -
diethylamino O -
) O -
ethyl O +
ester O +
hydrochloride O -
, O +
the O +
5-hydroxytryptamin1A O +
antagonist O +
1- O -
( O -
2-methoxyphenyl O -
) O -
-4- O -
[ O -
4- O -
( O -
2-phthalimido O -
) O -
butyl O -
] O -
piperazine O +
hydrobromide O +
and O +
the O +
polyamines O +
depletor O +
reserpine O -
. O +

Based O +
on O +
these O +
data O -
, O +
it O +
can O +
be O +
postulated O +
that O +
( O -
+ O -
/- O -
) O -
-PG-9 O +
exerted O +
an O +
antinociceptive O +
effect O +
mediated O +
by O +
a O +
central O +
potentiation O +
of O +
cholinergic O +
transmission O -
. O +

( O -
+ O -
/- O -
) O -
-PG-9 O +
( O -
10 O -
- O -
40 O +
mg O +
kg-1 O +
i.p O -
. O -
) O +
was O +
able O +
to O +
prevent O +
amnesia B-Disease +
induced O +
by O +
scopolamine O +
( O -
1 O +
mg O +
kg-1 O +
i.p O -
. O -
) O +
and O +
dicyclomine O +
( O -
2 O +
mg O +
kg-1 O +
i.p O -
. O -
) O +
in O +
the O +
mouse O +
passive O -
- O -
avoidance O +
test O -
. O +

Affinity O +
profiles O +
of O +
( O -
+ O -
/- O -
) O -
-PG-9 O +
for O +
muscarinic O +
receptor O +
subtypes O -
, O +
determined O +
by O +
functional O +
studies O +
( O -
rabbit O +
vas O +
deferens O +
for O +
M1 O -
, O +
guinea O +
pig O +
atrium O +
for O +
M2 O -
, O +
guinea O +
pig O +
ileum O +
for O +
M3 O +
and O +
immature O +
guinea O +
pig O +
uterus O +
for O +
putative O +
M4 O -
) O -
, O +
have O +
shown O +
an O +
M4 O -
/ O -
M1 O +
selectivity O +
ratio O +
of O +
10.2 O +
that O +
might O +
be O +
responsible O +
for O +
the O +
antinociception O +
and O +
the O +
anti O -
- O -
amnesic B-Disease +
effect O +
induced O +
by O +
( O -
+ O -
/- O -
) O -
-PG-9 O +
through O +
an O +
increase O +
in O +
acetylcholine O +
extracellular O +
levels O -
. O +

In O +
the O +
antinociceptive O +
and O +
antiamnesic O +
dose O +
range O -
, O +
( O -
+ O -
/- O -
) O -
-PG-9 O +
did O +
not O +
impair O +
mouse O +
performance O +
evaluated O +
by O +
the O +
rota O -
- O -
rod O +
test O +
and O +
Animex O +
apparatus O -
. O +

Immunopathology O +
of O +
penicillamine O -
- O -
induced O +
glomerular B-Disease +
disease I-Disease -
. O +

Four O +
patients O +
with O +
rheumatoid B-Disease +
arthritis I-Disease +
developed O +
heavy O +
proteinuria B-Disease +
after O +
five O +
to O +
12 O +
months O +
of O +
treatment O +
with O +
D O -
- O -
penicillamine O -
. O +

Light O +
microscopy O +
of O +
renal O +
biopsy O +
samples O +
showed O +
minimal O +
glomerular O +
capillary O +
wall O +
thickening O +
and O +
mesangial O +
matrix O +
increase O -
, O +
or O +
no O +
departure O +
from O +
normal O -
. O +

Electron O +
microscopy O -
, O +
however O -
, O +
revealed O +
subepithelial O +
electron O -
- O -
dense O +
deposits O -
, O +
fusion O +
of O +
epithelial O +
cell O +
foot O +
processes O -
, O +
and O +
evidence O +
of O +
mesangial O +
cell O +
hyperactivity O -
. O +

Immunofluorescence O +
microscopy O +
demonstrated O +
granular O +
capillary O +
wall O +
deposits O +
of O +
IgG O +
and O +
C3 O -
. O +

The O +
findings O +
were O +
similar O +
to O +
those O +
in O +
early O +
membranous B-Disease +
glomerulonephritis I-Disease -
, O +
differences O +
being O +
observed O +
however O +
in O +
the O +
results O +
of O +
staining O +
for O +
the O +
early O -
- O -
acting O +
complement O +
components O +
C1q O +
and O +
C4 O -
. O +

It O +
is O +
tentatively O +
concluded O +
that O +
complement O +
was O +
activated O +
by O +
the O +
classical O +
pathway O -
. O +

Experimental O +
cranial O +
pain B-Disease +
elicited O +
by O +
capsaicin O -
: O +
a O +
PET O +
study O -
. O +

Using O +
a O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
study O +
it O +
was O +
shown O +
recently O +
that O +
in O +
migraine B-Disease +
without O +
aura O +
certain O +
areas O +
in O +
the O +
brain O +
stem O +
were O +
activated O +
during O +
the O +
headache B-Disease +
state O -
, O +
but O +
not O +
in O +
the O +
headache B-Disease +
free O +
interval O -
. O +

It O +
was O +
suggested O +
that O +
this O +
brain O +
stem O +
activation O +
is O +
inherent O +
to O +
the O +
migraine B-Disease +
attack O +
itself O +
and O +
represents O +
the O +
so O +
called O +
' O -
migraine B-Disease +
generator O -
' O -
. O +

To O +
test O +
this O +
hypothesis O +
we O +
performed O +
an O +
experimental O +
pain B-Disease +
study O +
in O +
seven O +
healthy O +
volunteers O -
, O +
using O +
the O +
same O +
positioning O +
in O +
the O +
PET O +
scanner O +
as O +
in O +
the O +
migraine B-Disease +
patients O -
. O +

A O +
small O +
amount O +
of O +
capsaicin O +
was O +
administered O +
subcutaneously O +
in O +
the O +
right O +
forehead O +
to O +
evoke O +
a O +
burning O +
painful B-Disease +
sensation O +
in O +
the O +
first O +
division O +
of O +
the O +
trigeminal O +
nerve O -
. O +

Increases O +
of O +
regional O +
cerebral O +
blood O +
flow O +
( O -
rCBF O -
) O +
were O +
found O +
bilaterally O +
in O +
the O +
insula O -
, O +
in O +
the O +
anterior O +
cingulate O +
cortex O -
, O +
the O +
cavernous O +
sinus O +
and O +
the O +
cerebellum O -
. O +

Using O +
the O +
same O +
stereotactic O +
space O +
limits O +
as O +
in O +
the O +
above O +
mentioned O +
migraine B-Disease +
study O +
no O +
brain O +
stem O +
activation O +
was O +
found O +
in O +
the O +
acute O +
pain B-Disease +
state O +
compared O +
to O +
the O +
pain B-Disease +
free O +
state O -
. O +

The O +
increase O +
of O +
activation O +
in O +
the O +
region O +
of O +
the O +
cavernous O +
sinus O +
however O -
, O +
suggests O +
that O +
this O +
structure O +
is O +
more O +
likely O +
to O +
be O +
involved O +
in O +
trigeminal O +
transmitted O +
pain B-Disease +
as O +
such O -
, O +
rather O +
than O +
in O +
a O +
specific O +
type O +
of O +
headache B-Disease +
as O +
was O +
suggested O +
for O +
cluster B-Disease +
headache I-Disease -
. O +

The O +
effect O +
of O +
different O +
anaesthetic O +
agents O +
in O +
hearing B-Disease +
loss I-Disease +
following O +
spinal O +
anaesthesia O -
. O +

The O +
cause O +
of O +
hearing B-Disease +
loss I-Disease +
after O +
spinal O +
anaesthesia O +
is O +
unknown O -
. O +

Up O +
until O +
now O -
, O +
the O +
only O +
factor O +
studied O +
has O +
been O +
the O +
effect O +
of O +
the O +
diameter O +
of O +
the O +
spinal O +
needle O +
on O +
post O -
- O -
operative O +
sensorineural B-Disease +
hearing I-Disease +
loss I-Disease -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
describe O +
this O +
hearing B-Disease +
loss I-Disease +
and O +
to O +
investigate O +
other O +
factors O +
influencing O +
the O +
degree O +
of O +
hearing B-Disease +
loss I-Disease -
. O +

Two O +
groups O +
of O +
22 O +
similar O +
patients O +
were O +
studied O -
: O +
one O +
group O +
received O +
6 O +
mL O +
prilocaine O +
2 O -
% O -
; O +
and O +
the O +
other O +
received O +
3 O +
mL O +
bupivacaine O +
0.5 O -
% O -
. O +

Patients O +
given O +
prilocaine O +
were O +
more O +
likely O +
to O +
develop O +
hearing B-Disease +
loss I-Disease +
( O -
10 O +
out O +
of O +
22 O -
) O +
than O +
those O +
given O +
bupivacaine O +
( O -
4 O +
out O +
of O +
22 O -
) O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

The O +
average O +
hearing B-Disease +
loss I-Disease +
for O +
speech O +
frequencies O +
was O +
about O +
10 O +
dB O +
after O +
prilocaine O +
and O +
15 O +
dB O +
after O +
bupivacaine O -
. O +

None O +
of O +
the O +
patients O +
complained O +
of O +
subjective O +
hearing B-Disease +
loss I-Disease -
. O +

Long O -
- O -
term O +
follow O -
- O -
up O +
of O +
the O +
patients O +
was O +
not O +
possible O -
. O +

A O +
transient O +
neurological B-Disease +
deficit I-Disease +
following O +
intrathecal O +
injection O +
of O +
1 O -
% O +
hyperbaric O +
bupivacaine O +
for O +
unilateral O +
spinal O +
anaesthesia O -
. O +

We O +
describe O +
a O +
case O +
of O +
transient O +
neurological B-Disease +
deficit I-Disease +
that O +
occurred O +
after O +
unilateral O +
spinal O +
anaesthesia O +
with O +
8 O +
mg O +
of O +
1 O -
% O +
hyperbaric O +
bupivacaine O +
slowly O +
injected O +
through O +
a O +
25-gauge O +
pencil O -
- O -
point O +
spinal O +
needle O -
. O +

The O +
surgery O +
and O +
anaesthesia O +
were O +
uneventful O -
, O +
but O +
3 O +
days O +
after O +
surgery O -
, O +
the O +
patient O +
reported O +
an O +
area O +
of O +
hypoaesthesia O +
over O +
L3-L4 O +
dermatomes O +
of O +
the O +
leg O +
which O +
had O +
been O +
operated O +
on O +
( O -
loss B-Disease +
of I-Disease +
pinprick I-Disease +
sensation I-Disease -
) O +
without O +
reduction O +
in O +
muscular O +
strength O -
. O +

Sensation O +
in O +
this O +
area O +
returned O +
to O +
normal O +
over O +
the O +
following O +
2 O +
weeks O -
. O +

Prospective O +
multicentre O +
studies O +
with O +
a O +
large O +
population O +
and O +
a O +
long O +
follow O -
- O -
up O +
should O +
be O +
performed O +
in O +
order O +
to O +
evaluate O +
the O +
incidence O +
of O +
this O +
unusual O +
side O +
effect O -
. O +

However O -
, O +
we O +
suggest O +
that O +
a O +
low O +
solution O +
concentration O +
should O +
be O +
preferred O +
for O +
unilateral O +
spinal O +
anaesthesia O +
with O +
a O +
hyperbaric O +
anaesthetic O +
solution O +
( O -
if O +
pencil O -
- O -
point O +
needle O +
and O +
slow O +
injection O +
rate O +
are O +
employed O -
) O -
, O +
in O +
order O +
to O +
minimize O +
the O +
risk O +
of O +
a O +
localized O +
high O +
peak O +
anaesthetic O +
concentration O -
, O +
which O +
might O +
lead O +
to O +
a O +
transient O +
neurological B-Disease +
deficit I-Disease -
. O +

Transient B-Disease +
neurologic I-Disease +
symptoms I-Disease +
after O +
spinal O +
anesthesia O -
: O +
a O +
lower O +
incidence O +
with O +
prilocaine O +
and O +
bupivacaine O +
than O +
with O +
lidocaine O -
. O +

BACKGROUND O -
: O +
Recent O +
evidence O +
suggests O +
that O +
transient B-Disease +
neurologic I-Disease +
symptoms I-Disease +
( O -
TNSs B-Disease -
) O +
frequently O +
follow O +
lidocaine O +
spinal O +
anesthesia O +
but O +
are O +
infrequent O +
with O +
bupivacaine O -
. O +

However O -
, O +
identification O +
of O +
a O +
short O -
- O -
acting O +
local O +
anesthetic O +
to O +
substitute O +
for O +
lidocaine O +
for O +
brief O +
surgical O +
procedures O +
remains O +
an O +
important O +
goal O -
. O +

Prilocaine O +
is O +
an O +
amide O +
local O +
anesthetic O +
with O +
a O +
duration O +
of O +
action O +
similar O +
to O +
that O +
of O +
lidocaine O -
. O +

Accordingly O -
, O +
the O +
present O -
, O +
prospective O +
double O -
- O -
blind O +
study O +
compares O +
prilocaine O +
with O +
lidocaine O +
and O +
bupivacaine O +
with O +
respect O +
to O +
duration O +
of O +
action O +
and O +
relative O +
risk O +
of O +
TNSs B-Disease -
. O +

METHODS O -
: O +
Ninety O +
patients O +
classified O +
as O +
American O +
Society O +
of O +
Anesthesiologists O +
physical O +
status O +
I O +
or O +
II O +
who O +
were O +
scheduled O +
for O +
short O +
gynecologic O +
procedures O +
under O +
spinal O +
anesthesia O +
were O +
randomly O +
allocated O +
to O +
receive O +
2.5 O +
ml O +
2 O -
% O +
lidocaine O +
in O +
7.5 O -
% O +
glucose O -
, O +
2 O -
% O +
prilocaine O +
in O +
7.5 O -
% O +
glucose O -
, O +
or O +
0.5 O -
% O +
bupivacaine O +
in O +
7.5 O -
% O +
glucose O -
. O +

All O +
solutions O +
were O +
provided O +
in O +
blinded O +
vials O +
by O +
the O +
hospital O +
pharmacy O -
. O +

Details O +
of O +
spinal O +
puncture O -
, O +
extension O +
and O +
regression O +
of O +
spinal O +
block O -
, O +
and O +
the O +
times O +
to O +
reach O +
discharge O +
criteria O +
were O +
noted O -
. O +

In O +
the O +
evening O +
of O +
postoperative O +
day O +
1 O -
, O +
patients O +
were O +
evaluated O +
for O +
TNSs B-Disease +
by O +
a O +
physician O +
unaware O +
of O +
the O +
drug O +
administered O +
and O +
the O +
details O +
of O +
the O +
anesthetic O +
procedure O -
. O +

RESULTS O -
: O +
Nine O +
of O +
30 O +
patients O +
receiving O +
lidocaine O +
experienced O +
TNSs B-Disease -
, O +
1 O +
of O +
30 O +
patients O +
receiving O +
prilocaine O +
( O -
P O +
= O +
0.03 O -
) O +
had O +
them O -
, O +
and O +
none O +
of O +
30 O +
patients O +
receiving O +
bupivacaine O +
had O +
TNSs B-Disease -
. O +

Times O +
to O +
ambulate O +
and O +
to O +
void O +
were O +
similar O +
after O +
lidocaine O +
and O +
prilocaine O +
( O -
150 O +
vs. O +
165 O +
min O +
and O +
238 O +
vs. O +
253 O +
min O -
, O +
respectively O -
) O +
but O +
prolonged O +
after O +
bupivacaine O +
( O -
200 O +
and O +
299 O +
min O -
, O +
respectively O -
; O +
P O +
< O +
0.05 O -
) O -
. O +

CONCLUSIONS O -
: O +
Prilocaine O +
may O +
be O +
preferable O +
to O +
lidocaine O +
for O +
short O +
surgical O +
procedures O +
because O +
it O +
has O +
a O +
similar O +
duration O +
of O +
action O +
but O +
a O +
lower O +
incidence O +
of O +
TNSs B-Disease -
. O +

Value O +
of O +
methylprednisolone O +
in O +
prevention O +
of O +
the O +
arthralgia B-Disease -
- O -
myalgia B-Disease +
syndrome O +
associated O +
with O +
the O +
total O +
dose O +
infusion O +
of O +
iron O +
dextran O -
: O +
a O +
double O +
blind O +
randomized O +
trial O -
. O +

The O +
safety O +
and O +
efficacy O +
of O +
total O +
dose O +
infusion O +
( O -
TDI O -
) O +
of O +
iron O +
dextran O +
has O +
been O +
well O +
documented O -
. O +

In O +
40 O -
% O +
of O +
treated O +
patients O -
, O +
an O +
arthralgia B-Disease -
- O -
myalgia B-Disease +
syndrome O +
develops O -
. O +

The O +
purpose O +
of O +
this O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
prospective O +
study O +
was O +
to O +
investigate O +
whether O +
intravenous O +
( O -
i.v O -
. O -
) O +
administration O +
of O +
methylprednisolone O +
( O -
MP O -
) O +
prevents O +
this O +
complication O -
. O +

Sixty O -
- O -
five O +
patients O -
, O +
34 O +
women O +
and O +
31 O +
men O -
, O +
ages O +
36 O +
to O +
80 O +
years O -
, O +
received O +
either O +
normal O +
saline O +
before O +
and O +
after O +
TDI O +
( O -
group O +
1 O -
) O -
, O +
125 O +
mg O +
i.v O -
. O +

MP O +
before O +
and O +
saline O +
after O +
TDI O +
( O -
group O +
2 O -
) O -
, O +
or O +
125 O +
mg O +
i.v O -
. O +

MP O +
before O +
and O +
after O +
TDI O +
( O -
group O +
3 O -
) O -
. O +

Patients O +
were O +
observed O +
for O +
72 O +
hours O +
and O +
reactions O +
were O +
recorded O +
and O +
graded O +
according O +
to O +
severity O -
. O +

Fifty O -
- O -
eight O +
percent O +
of O +
group O +
1 O +
patients O -
, O +
33 O -
% O +
of O +
group O +
2 O -
, O +
and O +
26 O -
% O +
of O +
group O +
3 O +
had O +
reactions O +
to O +
TDI O -
. O +

The O +
severity O +
of O +
reactions O +
( O -
minimal O -
, O +
mild O -
, O +
and O +
moderate O -
, O +
respectively O -
) O +
was O +
as O +
follows O -
: O +
group O +
1 O -
- O -
-6 O -
, O +
6 O -
, O +
and O +
2 O -
; O +
group O +
2 O -
- O -
-1 O -
, O +
5 O -
, O +
and O +
0 O -
; O +
group O +
3 O -
- O -
-5 O -
, O +
1 O -
, O +
and O +
0 O -
. O +

Data O +
were O +
analyzed O +
by O +
the O +
two O -
- O -
sided O +
Fisher O -
's O +
exact O +
test O +
using O +
95 O -
% O +
confidence O +
intervals O +
with O +
the O +
approximation O +
of O +
Woolf O -
. O +

These O +
data O +
demonstrate O +
that O +
administration O +
of O +
MP O +
before O +
and O +
after O +
TDI O +
reduces O +
the O +
frequency O +
and O +
severity O +
of O +
the O +
arthralgia B-Disease -
- O -
myalgia B-Disease +
syndrome O -
. O +

We O +
conclude O +
that O +
125 O +
mg O +
i.v O -
. O +

MP O +
should O +
be O +
given O +
routinely O +
before O +
and O +
after O +
TDI O +
of O +
iron O +
dextran O -
. O +

Prolongation B-Disease +
of I-Disease +
the I-Disease +
QT I-Disease +
interval I-Disease +
related O +
to O +
cisapride O -
- O -
diltiazem O +
interaction O -
. O +

Cisapride O -
, O +
a O +
cytochrome O +
P450 O +
3A4 O +
( O -
CYP3A4 O -
) O +
substrate O -
, O +
is O +
widely O +
prescribed O +
for O +
the O +
treatment O +
of O +
gastrointestinal B-Disease +
motility I-Disease +
disorders I-Disease -
. O +

Prolongation B-Disease +
of I-Disease +
QT I-Disease +
interval I-Disease -
, O +
torsades B-Disease +
de I-Disease +
pointes I-Disease -
, O +
and O +
sudden B-Disease +
cardiac I-Disease +
death I-Disease +
have O +
been O +
reported O +
after O +
concomitant O +
administration O +
with O +
erythromycin O +
or O +
azole O +
antifungal O +
agents O -
, O +
but O +
not O +
with O +
other O +
CYP3A4 O +
inhibitors O -
. O +

A O +
possible O +
drug O +
interaction O +
occurred O +
in O +
a O +
45-year O -
- O -
old O +
woman O +
who O +
was O +
taking O +
cisapride O +
for O +
gastroesophageal B-Disease +
reflux I-Disease +
disorder I-Disease +
and O +
diltiazem O -
, O +
an O +
agent O +
that O +
has O +
inhibitory O +
effect O +
on O +
CYP3A4 O -
, O +
for O +
hypertension B-Disease -
. O +

The O +
patient O +
was O +
in O +
near O +
syncope B-Disease +
and O +
had O +
QT B-Disease -
- I-Disease -
interval I-Disease +
prolongation I-Disease -
. O +

After O +
discontinuing O +
cisapride O -
, O +
the O +
QT O +
interval O +
returned O +
to O +
normal O +
and O +
symptoms O +
did O +
not O +
recur O -
. O +

We O +
suggest O +
that O +
caution O +
be O +
taken O +
when O +
cisapride O +
is O +
prescribed O +
with O +
any O +
potent O +
inhibitor O +
of O +
CYP3A4 O -
, O +
including O +
diltiazem O -
. O +

Open O -
- O -
label O +
assessment O +
of O +
levofloxacin O +
for O +
the O +
treatment O +
of O +
acute O +
bacterial O +
sinusitis B-Disease +
in O +
adults O -
. O +

PURPOSE O -
: O +
To O +
evaluate O +
the O +
efficacy O +
and O +
safety O +
of O +
levofloxacin O +
( O -
500 O +
mg O +
orally O +
once O +
daily O +
for O +
10 O +
to O +
14 O +
days O -
) O +
in O +
treating O +
adult O +
outpatients O +
with O +
acute O +
bacterial O +
sinusitis B-Disease -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
A O +
total O +
of O +
329 O +
patients O +
enrolled O +
in O +
the O +
study O +
at O +
24 O +
centers O -
. O +

All O +
patients O +
had O +
a O +
pre O -
- O -
therapy O +
Gram O -
's O +
stain O +
and O +
culture O +
of O +
sinus O +
exudate O +
obtained O +
by O +
antral O +
puncture O +
or O +
nasal O +
endoscopy O -
. O +

Clinical O +
response O +
was O +
assessed O +
on O +
the O +
basis O +
of O +
signs O +
and O +
symptoms O +
and O +
sinus O +
radiograph O +
or O +
computed O +
tomography O +
results O -
. O +

Microbiologic O +
cure O +
rates O +
were O +
determined O +
on O +
the O +
basis O +
of O +
presumed O +
plus O +
documented O +
eradication O +
of O +
the O +
pre O -
- O -
therapy O +
pathogen O -
( O -
s O -
) O -
. O +

RESULTS O -
: O +
The O +
most O +
common O +
pathogens O +
were O +
Haemophilus O +
influenzae O -
, O +
Streptococcus O +
pneumoniae O -
, O +
Staphylococcus O +
aureus O -
, O +
and O +
Moraxella O +
catarrhalis O -
. O +

Of O +
300 O +
clinically O +
evaluable O +
patients O -
, O +
175 O +
( O -
58 O -
% O -
) O +
were O +
cured O +
and O +
90 O +
( O -
30 O -
% O -
) O +
were O +
improved O +
at O +
the O +
post O -
- O -
therapy O +
evaluation O -
, O +
resulting O +
in O +
a O +
clinical O +
success O +
rate O +
of O +
88 O -
% O -
. O +

Thirty O -
- O -
five O +
patients O +
( O -
12 O -
% O -
) O +
clinically O +
failed O +
treatment O -
. O +

The O +
microbiologic O +
eradication O +
rate O +
( O -
presumed O +
plus O +
documented O -
) O +
among O +
138 O +
microbiologically O +
evaluable O +
patients O +
was O +
92 O -
% O -
. O +

Microbiologic O +
eradication O +
rates O +
( O -
presumed O +
plus O +
documented O -
) O +
of O +
the O +
most O +
common O +
pathogens O +
ranged O +
from O +
93 O -
% O +
( O -
M. O +
catarrhalis O -
) O +
to O +
100 O -
% O +
( O -
S. O +
pneumoniae O -
) O +
at O +
the O +
post O -
- O -
therapy O +
visit O -
. O +

All O +
but O +
one O +
of O +
the O +
265 O +
patients O +
who O +
were O +
cured O +
or O +
improved O +
at O +
post O -
- O -
therapy O +
returned O +
for O +
a O +
long O -
- O -
term O +
follow O -
- O -
up O +
visit O -
; O +
243 O +
( O -
92 O -
% O -
) O +
remained O +
well O +
4 O +
to O +
6 O +
weeks O +
after O +
therapy O -
; O +
and O +
21 O +
( O -
8 O -
% O -
) O +
had O +
a O +
relapse O +
of O +
symptoms O -
. O +

Adverse O +
events O +
considered O +
to O +
be O +
related O +
to O +
levofloxacin O +
administration O +
were O +
reported O +
by O +
29 O +
patients O +
( O -
9 O -
% O -
) O -
. O +

The O +
most O +
common O +
drug O -
- O -
related O +
adverse O +
events O +
were O +
diarrhea B-Disease -
, O +
flatulence B-Disease -
, O +
and O +
nausea B-Disease -
; O +
most O +
adverse O +
events O +
were O +
mild O +
to O +
moderate O +
in O +
severity O -
. O +

CONCLUSION O -
: O +
The O +
results O +
of O +
this O +
study O +
indicate O +
that O +
levofloxacin O +
500 O +
mg O +
once O +
daily O +
is O +
an O +
effective O +
and O +
safe O +
treatment O +
for O +
acute O +
bacterial O +
sinusitis B-Disease -
. O +

Iatrogenic O +
risks O +
of O +
endometrial B-Disease +
carcinoma I-Disease +
after O +
treatment O +
for O +
breast B-Disease +
cancer I-Disease +
in O +
a O +
large O +
French O +
case O -
- O -
control O +
study O -
. O +

F O +
d O +
ration O +
Nationale O +
des O +
Centres O +
de O +
Lutte O +
Contre O +
le O +
Cancer O +
( O -
FNCLCC O -
) O -
. O +

Since O +
tamoxifen O +
is O +
widely O +
used O +
in O +
breast B-Disease +
cancer I-Disease +
treatment O +
and O +
has O +
been O +
proposed O +
for O +
the O +
prevention O +
of O +
breast B-Disease +
cancer I-Disease -
, O +
its O +
endometrial O +
iatrogenic O +
effects O +
must O +
be O +
carefully O +
examined O -
. O +

We O +
have O +
investigated O +
the O +
association O +
between O +
endometrial B-Disease +
cancer I-Disease +
and O +
tamoxifen O +
use O +
or O +
other O +
treatments O +
in O +
women O +
treated O +
for O +
breast B-Disease +
cancer I-Disease +
in O +
a O +
case O -
- O -
control O +
study O -
. O +

Cases O +
of O +
endometrial B-Disease +
cancer I-Disease +
diagnosed O +
after O +
breast B-Disease +
cancer I-Disease +
( O -
n O +
= O +
135 O -
) O +
and O +
467 O +
controls O +
matched O +
for O +
age O -
, O +
year O +
of O +
diagnosis O +
of O +
breast B-Disease +
cancer I-Disease +
and O +
hospital O +
and O +
survival O +
time O +
with O +
an O +
intact O +
uterus O +
were O +
included O -
. O +

Women O +
who O +
had O +
received O +
tamoxifen O +
were O +
significantly O +
more O +
likely O +
to O +
have O +
endometrial B-Disease +
cancer I-Disease +
diagnosed O +
than O +
those O +
who O +
had O +
not O +
( O -
crude O +
relative O +
risk O +
= O +
4.9 O -
, O +
p O +
= O +
0.0001 O -
) O -
. O +

Univariate O +
and O +
adjusted O +
analyses O +
showed O +
that O +
the O +
risk O +
increased O +
with O +
the O +
length O +
of O +
treatment O +
( O -
p O +
= O +
0.0001 O -
) O +
or O +
the O +
cumulative O +
dose O +
of O +
tamoxifen O +
received O +
( O -
p O +
= O +
0.0001 O -
) O -
, O +
irrespective O +
of O +
the O +
daily O +
dose O -
. O +

Women O +
who O +
had O +
undergone O +
pelvic O +
radiotherapy O +
also O +
had O +
a O +
higher O +
risk O +
( O -
crude O +
relative O +
risk O +
= O +
7.8 O -
, O +
p O +
= O +
0.0001 O -
) O -
. O +

After O +
adjusting O +
for O +
confounding O +
factors O -
, O +
the O +
risk O +
was O +
higher O +
for O +
tamoxifen O +
users O +
( O -
p O +
= O +
0.0012 O -
) O -
, O +
treatment O +
for O +
more O +
than O +
3 O +
years O +
( O -
all O +
p O +
< O +
0.03 O -
) O +
and O +
pelvic O +
radiotherapy O +
( O -
p O +
= O +
0.012 O -
) O -
. O +

Women O +
who O +
had O +
endometrial B-Disease +
cancer I-Disease +
and O +
had O +
received O +
tamoxifen O +
had O +
more O +
advanced B-Disease +
disease I-Disease +
and O +
poorer O +
prognosis O +
than O +
those O +
with O +
endometrial B-Disease +
cancer I-Disease +
who O +
had O +
not O +
received O +
this O +
treatment O -
. O +

Our O +
results O +
suggest O +
a O +
causal O +
role O +
of O +
tamoxifen O +
in O +
endometrial B-Disease +
cancer I-Disease -
, O +
particularly O +
when O +
used O +
as O +
currently O +
proposed O +
for O +
breast B-Disease +
cancer I-Disease +
prevention O -
. O +

Pelvic O +
radiotherapy O +
may O +
be O +
an O +
additional O +
iatrogenic O +
factor O +
for O +
women O +
with O +
breast B-Disease +
cancer I-Disease -
. O +

Endometrial B-Disease +
cancers I-Disease +
diagnosed O +
in O +
women O +
treated O +
with O +
tamoxifen O +
have O +
poorer O +
prognosis O -
. O +

Women O +
who O +
receive O +
tamoxifen O +
for O +
breast B-Disease +
cancer I-Disease +
should O +
be O +
offered O +
gynaecological O +
surveillance O +
during O +
and O +
after O +
treatment O -
. O +

A O +
long O -
- O -
term O +
evaluation O +
of O +
the O +
risk O -
- O -
benefit O +
ratio O +
of O +
tamoxifen O +
as O +
a O +
preventive O +
treatment O +
for O +
breast B-Disease +
cancer I-Disease +
is O +
clearly O +
warranted O -
. O +

Suxamethonium O -
- O -
induced O +
cardiac B-Disease +
arrest I-Disease +
and O +
death B-Disease +
following O +
5 O +
days O +
of O +
immobilization O -
. O +

The O +
present O +
report O +
describes O +
a O +
case O +
of O +
cardiac B-Disease +
arrest I-Disease +
and O +
subsequent O +
death B-Disease +
as O +
a O +
result O +
of O +
hyperkalaemia B-Disease +
following O +
the O +
use O +
of O +
suxamethonium O +
in O +
a O +
23-year O -
- O -
old O +
Malawian O +
woman O -
. O +

Five O +
days O +
after O +
the O +
onset O +
of O +
the O +
symptoms O +
of O +
meningitis B-Disease -
, O +
the O +
patient O +
aspirated O +
stomach O +
contents O +
and O +
needed O +
endotracheal O +
intubation O -
. O +

Forty O +
seconds O +
after O +
injection O +
of O +
suxamethonium O -
, O +
bradycardia B-Disease +
and O +
cardiac B-Disease +
arrest I-Disease +
occurred O -
. O +

Attempts O +
to O +
resuscitate O +
the O +
patient O +
were O +
not O +
successful O -
. O +

The O +
serum O +
level O +
of O +
potassium O +
was O +
observed O +
to O +
be O +
8.4 O +
mequiv O +
L-1 O -
. O +

Apart O +
from O +
the O +
reduction O +
in O +
the O +
patient O -
's O +
level O +
of O +
consciousness O -
, O +
there O +
were O +
no O +
signs O +
of O +
motor O +
neurone O +
damage O +
or O +
of O +
any O +
of O +
the O +
other O +
known O +
predisposing O +
conditions O +
for O +
hyperkalaemia B-Disease +
following O +
the O +
administration O +
of O +
suxamethonium O -
. O +

It O +
is O +
postulated O +
that O +
her O +
death B-Disease +
was O +
caused O +
by O +
hypersensitivity B-Disease +
to O +
suxamethonium O -
, O +
associated O +
with O +
her O +
5-day O +
immobilization O -
. O +

Acute O +
hepatitis B-Disease -
, O +
autoimmune B-Disease +
hemolytic I-Disease +
anemia I-Disease -
, O +
and O +
erythroblastocytopenia B-Disease +
induced O +
by O +
ceftriaxone O -
. O +

An O +
80-yr O -
- O -
old O +
man O +
developed O +
acute O +
hepatitis B-Disease +
shortly O +
after O +
ingesting O +
oral O +
ceftriaxone O -
. O +

Although O +
the O +
transaminases O +
gradually O +
returned O +
to O +
baseline O +
after O +
withholding O +
the O +
beta O +
lactam O +
antibiotic O -
, O +
there O +
was O +
a O +
gradual O +
increase O +
in O +
serum O +
bilirubin O +
and O +
a O +
decrease O +
in O +
hemoglobin O +
concentration O +
caused O +
by O +
an O +
autoimmune B-Disease +
hemolytic I-Disease +
anemia I-Disease +
and O +
erythroblastocytopenia B-Disease -
. O +

These O +
responded O +
to O +
systemic O +
steroids O +
and O +
immunoglobulins O -
. O +

Despite O +
the O +
widespread O +
use O +
of O +
these O +
agents O +
this O +
triad O +
of O +
side O +
effects O +
has O +
not O +
previously O +
been O +
reported O +
in O +
connection O +
with O +
beta O +
lactam O +
antibiotics O -
. O +

Carboplatin O +
toxic O +
effects O +
on O +
the O +
peripheral O +
nervous O +
system O +
of O +
the O +
rat O -
. O +

BACKGROUND O -
: O +
The O +
most O +
striking O +
of O +
carboplatin O -
's O +
advantages O +
( O -
CBDCA O -
) O +
over O +
cisplatin O +
( O -
CDDP O -
) O +
is O +
its O +
markedly O +
reduced O +
rate O +
of O +
neurotoxic B-Disease +
effects O -
. O +

However O -
, O +
the O +
use O +
of O +
CBDCA O +
higher O -
- O -
intensity O +
schedules O +
and O +
the O +
association O +
with O +
other O +
neurotoxic B-Disease +
drugs O +
in O +
polychemotherapy O +
may O +
cause O +
some O +
concern O +
about O +
its O +
safety O +
with O +
respect O +
to O +
peripheral B-Disease +
nervous I-Disease +
system I-Disease +
damage I-Disease -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Two O +
different O +
schedules O +
of O +
CBDCA O +
administration O +
( O -
10 O +
mg O -
/ O -
kg O +
and O +
15 O +
mg O -
/ O -
kg O +
i.p O -
. O +

twice O +
a O +
week O +
for O +
nine O +
times O -
) O +
were O +
evaluated O +
in O +
Wistar O +
rats O -
. O +

Neurotoxicity B-Disease +
was O +
assessed O +
for O +
behavioral O +
( O -
tail O -
- O -
flick O +
test O -
) O -
, O +
neurophysiological O +
( O -
nerve O +
conduction O +
velocity O +
in O +
the O +
tail O +
nerve O -
) O -
, O +
morphological O -
, O +
morphometrical O +
and O +
analytical O +
effects O -
. O +

RESULTS O -
: O +
CBDCA O +
administration O +
induced O +
dose O -
- O -
dependent O +
peripheral B-Disease +
neurotoxicity I-Disease -
. O +

Pain B-Disease +
perception O +
and O +
nerve O +
conduction O +
velocity O +
in O +
the O +
tail O +
were O +
significantly O +
impaired O -
, O +
particularly O +
after O +
the O +
high O -
- O -
dose O +
treatment O -
. O +

The O +
dorsal O +
root O +
ganglia O +
sensory O +
neurons O +
and O -
, O +
to O +
a O +
lesser O +
extent O -
, O +
satellite O +
cells O +
showed O +
the O +
same O +
changes O +
as O +
those O +
induced O +
by O +
CDDP O -
, O +
mainly O +
affecting O +
the O +
nucleus O +
and O +
nucleolus O +
of O +
ganglionic O +
sensory O +
neurons O -
. O +

Moreover O -
, O +
significant O +
amounts O +
of O +
platinum O +
were O +
detected O +
in O +
the O +
dorsal O +
root O +
ganglia O +
and O +
kidney O +
after O +
CBDCA O +
treatment O -
. O +

CONCLUSIONS O -
: O +
CBDCA O +
is O +
neurotoxic B-Disease +
in O +
our O +
model O -
, O +
and O +
the O +
type O +
of O +
pathological O +
changes O +
it O +
induces O +
are O +
so O +
closely O +
similar O +
to O +
those O +
caused O +
by O +
CDDP O +
that O +
it O +
is O +
probable O +
that O +
neurotoxicity B-Disease +
is O +
induced O +
in O +
the O +
two O +
drugs O +
by O +
the O +
same O +
mechanism O -
. O +

This O +
model O +
can O +
be O +
used O +
alone O +
or O +
in O +
combination O +
with O +
other O +
drugs O +
to O +
explore O +
the O +
effect O +
of O +
CBDCA O +
on O +
the O +
peripheral O +
nervous O +
system O -
. O +

Thyroxine O +
abuse O -
: O +
an O +
unusual O +
case O +
of O +
thyrotoxicosis B-Disease +
in O +
pregnancy O -
. O +

Eating B-Disease +
disorders I-Disease +
and O +
the O +
associated O +
behavioural O +
problems O +
and O +
drug B-Disease +
abuse I-Disease +
are O +
uncommon O +
in O +
pregnancy O -
. O +

When O +
they O +
do O +
occur O +
they O +
are O +
often O +
unrecognized O +
because O +
of O +
denial O +
but O +
when O +
significant O +
may O +
pose O +
a O +
risk O +
to O +
both O +
the O +
mother O +
and O +
her O +
fetus O -
. O +

This O +
case O +
illustrates O +
a O +
number O +
of O +
problems O +
that O +
may O +
be O +
encountered O +
in O +
women O +
with O +
eating B-Disease +
disorders I-Disease +
in O +
pregnancy O -
, O +
including O +
prolonged O +
and O +
recurrent O +
metabolic O +
disturbances O +
and O +
diuretic O +
abuse O -
. O +

In O +
particular O +
it O +
illustrates O +
the O +
derangements O +
of O +
thyroid O +
function O +
seen O +
in O +
pregnant O +
women O +
with O +
eating B-Disease +
disorders I-Disease +
and O +
reminds O +
us O +
that O +
when O +
a O +
cause O +
for O +
thyrotoxicosis B-Disease +
remains O +
obscure O -
, O +
thyroxine O +
abuse O +
should O +
be O +
considered O +
and O +
explored O -
. O +

Repeated O +
trimipramine O +
induces O +
dopamine O +
D2 O -
/ O -
D3 O +
and O +
alpha1-adrenergic O +
up O -
- O -
regulation O -
. O +

Trimipramine O +
( O -
TRI O -
) O -
, O +
which O +
shows O +
a O +
clinical O +
antidepressant O +
activity O -
, O +
is O +
chemically O +
related O +
to O +
imipramine O +
but O +
does O +
not O +
inhibit O +
the O +
reuptake O +
of O +
noradrenaline O +
and O +
5-hydroxytryptamine O -
, O +
nor O +
does O +
it O +
induce O +
beta O -
- O -
adrenergic O +
down O -
- O -
regulation O -
. O +

The O +
mechanism O +
of O +
its O +
antidepressant O +
activity O +
is O +
still O +
unknown O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
find O +
out O +
whether O +
TRI O +
given O +
repeatedly O +
was O +
able O +
to O +
induce O +
adaptive O +
changes O +
in O +
the O +
dopaminergic O +
and O +
alpha1-adrenergic O +
systems O -
, O +
demonstrated O +
by O +
us O +
previously O +
for O +
various O +
antidepressants O -
. O +

TRI O +
was O +
given O +
to O +
male O +
Wistar O +
rats O +
and O +
male O +
Albino O +
Swiss O +
mice O +
perorally O +
twice O +
daily O +
for O +
14 O +
days O -
. O +

In O +
the O +
acute O +
experiment O +
TRI O +
( O -
given O +
i.p O -
. O -
) O +
does O +
not O +
antagonize O +
the O +
reserpine O +
hypothermia B-Disease +
in O +
mice O +
and O +
does O +
not O +
potentiate O +
the O +
5-hydroxytryptophan O +
head O +
twitches O +
in O +
rats O -
. O +

TRI O +
given O +
repeatedly O +
to O +
rats O +
increases O +
the O +
locomotor O +
hyperactivity B-Disease +
induced O +
by O +
d O -
- O -
amphetamine O -
, O +
quinpirole O +
and O +
( O -
+ O -
) O -
-7-hydroxy O -
- O -
dipropyloaminotetralin O +
( O -
dopamine O +
D2 O +
and O +
D3 O +
effects O -
) O -
. O +

The O +
stereotypies O +
induced O +
by O +
d O -
- O -
amphetamine O +
or O +
apomorphine O +
are O +
not O +
potentiated O +
by O +
TRI O -
. O +

It O +
increases O +
the O +
behaviour O +
stimulation O +
evoked O +
by O +
phenylephrine O +
( O -
given O +
intraventricularly O -
) O +
in O +
rats O -
, O +
evaluated O +
in O +
the O +
open O +
field O +
test O +
as O +
well O +
as O +
the O +
aggressiveness B-Disease +
evoked O +
by O +
clonidine O +
in O +
mice O -
, O +
both O +
these O +
effects O +
being O +
mediated O +
by O +
an O +
alpha1-adrenergic O +
receptor O -
. O +

It O +
may O +
be O +
concluded O +
that O -
, O +
like O +
other O +
tricyclic O +
antidepressants O +
studied O +
previously O -
, O +
TRI O +
given O +
repeatedly O +
increases O +
the O +
responsiveness O +
of O +
brain O +
dopamine O +
D2 O +
and O +
D3 O +
( O -
locomotor O +
activity O +
but O +
not O +
stereotypy O -
) O +
as O +
well O +
as O +
alpha1-adrenergic O +
receptors O +
to O +
their O +
agonists O -
. O +

A O +
question O +
arises O +
whether O +
the O +
reuptake O +
inhibition O +
is O +
of O +
any O +
importance O +
to O +
the O +
adaptive O +
changes O +
induced O +
by O +
repeated O +
antidepressants O -
, O +
suggested O +
to O +
be O +
responsible O +
for O +
the O +
antidepressant O +
activity O -
. O +

Effects O +
of O +
cisapride O +
on O +
symptoms O +
and O +
postcibal O +
small O -
- O -
bowel O +
motor O +
function O +
in O +
patients O +
with O +
irritable B-Disease +
bowel I-Disease +
syndrome I-Disease -
. O +

BACKGROUND O -
: O +
Irritable B-Disease +
bowel I-Disease +
syndrome I-Disease +
is O +
a O +
common O +
cause O +
of O +
abdominal B-Disease +
pain I-Disease +
and O +
discomfort O +
and O +
may O +
be O +
related O +
to O +
disordered B-Disease +
gastrointestinal I-Disease +
motility I-Disease -
. O +

Our O +
aim O +
was O +
to O +
assess O +
the O +
effects O +
of O +
long O -
- O -
term O +
treatment O +
with O +
a O +
prokinetic O +
agent O -
, O +
cisapride O -
, O +
on O +
postprandial O +
jejunal O +
motility O +
and O +
symptoms O +
in O +
the O +
irritable B-Disease +
bowel I-Disease +
syndrome I-Disease +
( O -
IBS B-Disease -
) O -
. O +

METHODS O -
: O +
Thirty O -
- O -
eight O +
patients O +
with O +
IBS B-Disease +
( O -
constipation B-Disease -
- O -
predominant O -
, O +
n O +
= O +
17 O -
; O +
diarrhoea B-Disease -
- O -
predominant O -
, O +
n O +
= O +
21 O -
) O +
underwent O +
24-h O +
ambulatory O +
jejunal O +
manometry O +
before O +
and O +
after O +
12 O +
week O -
's O +
treatment O +
[ O -
cisapride O -
, O +
5 O +
mg O +
three O +
times O +
daily O +
( O -
n O +
= O +
19 O -
) O +
or O +
placebo O +
( O -
n O +
= O +
19 O -
) O -
] O -
. O +

RESULTS O -
: O +
In O +
diarrhoea B-Disease -
- O -
predominant O +
patients O +
significant O +
differences O +
in O +
contraction O +
characteristics O +
were O +
observed O +
between O +
the O +
cisapride O +
and O +
placebo O +
groups O -
. O +

In O +
cisapride O -
- O -
treated O +
diarrhoea B-Disease -
- O -
predominant O +
patients O +
the O +
mean O +
contraction O +
amplitude O +
was O +
higher O +
( O -
29.3 O +
+ O -
/- O +

3.2 O +
versus O +
24.9 O +
+ O -
/- O +

2.6 O +
mm O +
Hg O -
, O +
cisapride O +
versus O +
placebo O +
( O -
P O +
< O +
0.001 O -
) O -
; O +
pretreatment O -
, O +
25.7 O +
+ O -
/- O +

6.0 O +
mm O +
Hg O -
) O -
, O +
the O +
mean O +
contraction O +
duration O +
longer O +
( O -
3.4 O +
+ O -
/- O +

0.2 O +
versus O +
3.0 O +
+ O -
/- O +

0.2 O +
sec O -
, O +
cisapride O +
versus O +
placebo O +
( O -
P O +
< O +
0.001 O -
) O -
; O +
pretreatment O -
, O +
3.1 O +
+ O -
/- O +

0.5 O +
sec O -
) O -
, O +
and O +
the O +
mean O +
contraction O +
frequency O +
lower O +
( O -
2.0 O +
+ O -
/- O +

0.2 O +
versus O +
2.5 O +
+ O -
/- O +

0.4 O +
cont. O -
/ O -
min O -
, O +
cisapride O +
versus O +
placebo O +
( O -
P O +
< O +
0.001 O -
) O -
; O +
pretreatment O -
, O +
2.5 O +
+ O -
/- O +

1.1 O +
cont. O -
/ O -
min O -
] O +
than O +
patients O +
treated O +
with O +
placebo O -
. O +

No O +
significant O +
differences O +
in O +
jejunal O +
motility O +
were O +
found O +
in O +
the O +
constipation B-Disease -
- O -
predominant O +
IBS B-Disease +
group O -
. O +

Symptoms O +
were O +
assessed O +
by O +
using O +
a O +
visual O +
analogue O +
scale O +
before O +
and O +
after O +
treatment O -
. O +

Symptom O +
scores O +
relating O +
to O +
the O +
severity O +
of O +
constipation B-Disease +
were O +
lower O +
in O +
cisapride O -
- O -
treated O +
constipation B-Disease -
- O -
predominant O +
IBS B-Disease +
patients O +
[ O -
score O -
, O +
54 O +
+ O -
/- O +

5 O +
versus O +
67 O +
+ O -
/- O +

14 O +
mm O -
, O +
cisapride O +
versus O +
placebo O +
( O -
P O +
< O +
0.05 O -
) O -
; O +
pretreatment O -
, O +
62 O +
+ O -
/- O +

19 O +
mm O -
] O -
. O +

Diarrhoea B-Disease -
- O -
predominant O +
IBS B-Disease +
patients O +
had O +
a O +
higher O +
pain B-Disease +
score O +
after O +
cisapride O +
therapy O +
[ O -
score O -
, O +
55 O +
+ O -
/- O +

15 O +
versus O +
34 O +
+ O -
/- O +

12 O +
mm O -
, O +
cisapride O +
versus O +
placebo O +
( O -
P O +
< O +
0.05 O -
) O -
; O +
pretreatment O -
, O +
67 O +
+ O -
/- O +

19 O +
mm O -
] O -
. O +

CONCLUSION O -
: O +
Cisapride O +
affects O +
jejunal O +
contraction O +
characteristics O +
and O +
some O +
symptoms O +
in O +
IBS B-Disease -
. O +

Prevention O +
of O +
breast B-Disease +
cancer I-Disease +
with O +
tamoxifen O -
: O +
preliminary O +
findings O +
from O +
the O +
Italian O +
randomised O +
trial O +
among O +
hysterectomised O +
women O -
. O +

Italian O +
Tamoxifen O +
Prevention O +
Study O -
. O +

BACKGROUND O -
: O +
Tamoxifen O +
is O +
a O +
candidate O +
chemopreventive O +
agent O +
in O +
breast B-Disease +
cancer I-Disease -
, O +
although O +
the O +
drug O +
may O +
be O +
associated O +
with O +
the O +
development O +
of O +
endometrial B-Disease +
cancer I-Disease -
. O +

Therefore O +
we O +
did O +
a O +
trial O +
in O +
hysterectomised O +
women O +
of O +
tamoxifen O +
as O +
a O +
chemopreventive O -
. O +

METHODS O -
: O +
In O +
October O -
, O +
1992 O -
, O +
we O +
started O +
a O +
double O -
- O -
blind O +
placebo O -
- O -
controlled O -
, O +
randomised O +
trial O +
of O +
tamoxifen O +
in O +
women O +
( O -
mainly O +
in O +
Italy O -
) O +
who O +
did O +
not O +
have O +
breast B-Disease +
cancer I-Disease +
and O +
who O +
had O +
had O +
a O +
hysterectomy O -
. O +

Women O +
were O +
randomised O +
to O +
receive O +
tamoxifen O +
20 O +
mg O +
per O +
day O +
or O +
placebo O -
, O +
both O +
orally O +
for O +
5 O +
years O -
. O +

The O +
original O +
plan O +
was O +
to O +
follow O +
the O +
intervention O +
phase O +
by O +
5 O +
years O -
' O +
follow O -
- O -
up O -
. O +

In O +
June O -
, O +
1997 O -
, O +
the O +
trialists O +
and O +
the O +
data O -
- O -
monitoring O +
committee O +
decided O +
to O +
end O +
recruitment O +
primarily O +
because O +
of O +
the O +
number O +
of O +
women O +
dropping O +
out O +
of O +
the O +
study O -
. O +

Recruitment O +
ended O +
on O +
July O +
11 O -
, O +
1997 O -
, O +
and O +
the O +
study O +
will O +
continue O +
as O +
planned O -
. O +

The O +
primary O +
endpoints O +
are O +
the O +
occurrence O +
of O +
and O +
deaths O +
from O +
breast B-Disease +
cancer I-Disease -
. O +

This O +
preliminary O +
interim O +
analysis O +
is O +
based O +
on O +
intention O -
- O -
to O -
- O -
treat O -
. O +

FINDINGS O -
: O +
5408 O +
women O +
were O +
randomised O -
; O +
participating O +
women O +
have O +
a O +
median O +
follow O -
- O -
up O +
of O +
46 O +
months O +
for O +
major O +
endpoints O -
. O +

41 O +
cases O +
of O +
breast B-Disease +
cancer I-Disease +
occurred O +
so O +
far O -
; O +
there O +
have O +
been O +
no O +
deaths O +
from O +
breast B-Disease +
cancer I-Disease -
. O +

There O +
is O +
no O +
difference O +
in O +
breast B-Disease -
- I-Disease -
cancer I-Disease +
frequency O +
between O +
the O +
placebo O +
( O -
22 O +
cases O -
) O +
and O +
tamoxifen O +
( O -
19 O -
) O +
arms O -
. O +

There O +
is O +
a O +
statistically O +
significant O +
reduction O +
of O +
breast B-Disease +
cancer I-Disease +
among O +
women O +
receiving O +
tamoxifen O +
who O +
also O +
used O +
hormone O -
- O -
replacement O +
therapy O +
during O +
the O +
trial O -
: O +
among O +
390 O +
women O +
on O +
such O +
therapy O +
and O +
allocated O +
to O +
placebo O -
, O +
we O +
found O +
eight O +
cases O +
of O +
breast B-Disease +
cancer I-Disease +
compared O +
with O +
one O +
case O +
among O +
362 O +
women O +
allocated O +
to O +
tamoxifen O -
. O +

Compared O +
with O +
the O +
placebo O +
group O -
, O +
there O +
was O +
a O +
significantly O +
increased O +
risk O +
of O +
vascular B-Disease +
events I-Disease +
and O +
hypertriglyceridaemia B-Disease +
among O +
women O +
on O +
tamoxifen O -
. O +

INTERPRETATION O -
: O +
Although O +
this O +
preliminary O +
analysis O +
has O +
low O +
power O -
, O +
in O +
this O +
cohort O +
of O +
women O +
at O +
low O -
- O -
to O -
- O -
normal O +
risk O +
of O +
breast B-Disease +
cancer I-Disease -
, O +
the O +
postulated O +
protective O +
effects O +
of O +
tamoxifen O +
are O +
not O +
yet O +
apparent O -
. O +

Women O +
using O +
hormone O -
- O -
replacement O +
therapy O +
appear O +
to O +
have O +
benefited O +
from O +
use O +
of O +
tamoxifen O -
. O +

There O +
were O +
no O +
deaths O +
from O +
breast B-Disease +
cancer I-Disease +
recorded O +
in O +
women O +
in O +
the O +
study O -
. O +

It O +
is O +
essential O +
to O +
continue O +
follow O -
- O -
up O +
to O +
quantify O +
the O +
long O -
- O -
term O +
risks O +
and O +
benefits O +
of O +
tamoxifen O +
therapy O -
. O +

Pethidine O -
- O -
associated O +
seizure B-Disease +
in O +
a O +
healthy O +
adolescent O +
receiving O +
pethidine O +
for O +
postoperative B-Disease +
pain I-Disease +
control O -
. O +

A O +
healthy O +
17-year O -
- O -
old O +
male O +
received O +
standard O +
intermittent O +
doses O +
of O +
pethidine O +
via O +
a O +
patient O -
- O -
controlled O +
analgesia O +
( O -
PCA O -
) O +
pump O +
for O +
management O +
of O +
postoperative B-Disease +
pain I-Disease +
control O -
. O +

Twenty O -
- O -
three O +
h O +
postoperatively O +
he O +
developed O +
a O +
brief O +
self O -
- O -
limited O +
seizure B-Disease -
. O +

Both O +
plasma O +
pethidine O +
and O +
norpethidine O +
were O +
elevated O +
in O +
the O +
range O +
associated O +
with O +
clinical O +
manifestations O +
of O +
central O +
nervous O +
system O +
excitation O -
. O +

No O +
other O +
risk O +
factors O +
for O +
CNS O +
toxicity B-Disease +
were O +
identified O -
. O +

This O +
method O +
allowed O +
frequent O +
self O -
- O -
dosing O +
of O +
pethidine O +
at O +
short O +
time O +
intervals O +
and O +
rapid O +
accumulation O +
of O +
pethidine O +
and O +
norpethidine O -
. O +

The O +
routine O +
use O +
of O +
pethidine O +
via O +
PCA O +
even O +
for O +
a O +
brief O +
postoperative O +
analgesia O +
should O +
be O +
reconsidered O -
. O +

An O +
unusual O +
toxic O +
reaction O +
to O +
axillary O +
block O +
by O +
mepivacaine O +
with O +
adrenaline O -
. O +

An O +
increase B-Disease +
in I-Disease +
blood I-Disease +
pressure I-Disease -
, O +
accompanied O +
by O +
atrial B-Disease +
fibrillation I-Disease -
, O +
agitation B-Disease -
, O +
incomprehensible B-Disease +
shouts I-Disease +
and O +
loss B-Disease +
of I-Disease +
consciousness I-Disease -
, O +
was O +
observed O +
in O +
an O +
elderly O -
, O +
ASA O +
classification O +
group O +
II O -
, O +
cardiovascularly O +
medicated O +
male O -
, O +
12 O +
min O +
after O +
performance O +
of O +
axillary O +
block O +
with O +
mepivacaine O +
850 O +
mg O +
containing O +
adrenaline O +
0.225 O +
mg O -
, O +
for O +
correction O +
of O +
Dupuytren B-Disease -
's I-Disease +
contracture I-Disease -
. O +

After O +
intravenous O +
administration O +
of O +
labetalol O -
, O +
metoprolol O +
and O +
midazolam O +
the O +
patient O -
's O +
condition O +
improved O -
, O +
and O +
15 O +
min O +
later O +
he O +
woke O +
up O -
. O +

The O +
block O +
was O +
successful O +
and O +
surgery O +
was O +
conducted O +
as O +
scheduled O +
despite O +
persisting O +
atrial B-Disease +
fibrillation I-Disease -
. O +

Postoperatively O -
, O +
the O +
patient O +
refused O +
DC O +
cardioversion O +
and O +
was O +
treated O +
medically O -
. O +

Both O +
the O +
temporal O +
relationship O +
of O +
events O +
and O +
the O +
response O +
to O +
treatment O +
suggest O +
that O +
a O +
rapid O +
systemic O +
absorption O +
of O +
mepivacaine O +
with O +
adrenaline O +
and/or O +
interaction O +
of O +
these O +
drugs O +
with O +
the O +
patient O -
's O +
cardiovascular O +
medications O +
were O +
responsible O +
for O +
the O +
perioperative O +
complications O -
. O +

Drug O -
- O -
associated O +
acute O -
- O -
onset O +
vanishing B-Disease +
bile I-Disease +
duct I-Disease +
and O +
Stevens B-Disease -
- I-Disease -
Johnson I-Disease +
syndromes I-Disease +
in O +
a O +
child O -
. O +

Acute O +
vanishing B-Disease +
bile I-Disease +
duct I-Disease +
syndrome O +
is O +
a O +
rare O +
but O +
established O +
cause O +
of O +
progressive O +
cholestasis B-Disease +
in O +
adults O -
, O +
is O +
most O +
often O +
drug O +
or O +
toxin O +
related O -
, O +
and O +
is O +
of O +
unknown O +
pathogenesis O -
. O +

It O +
has O +
not O +
been O +
reported O +
previously O +
in O +
children O -
. O +

Stevens B-Disease -
- I-Disease -
Johnson I-Disease +
syndrome I-Disease +
is O +
a O +
well O -
- O -
recognized O +
immune O +
complex O -
- O -
mediated O +
hypersensitivity B-Disease +
reaction O +
that O +
affects O +
all O +
age O +
groups O -
, O +
is O +
drug O +
or O +
infection B-Disease +
induced O -
, O +
and O +
has O +
classic O +
systemic O -
, O +
mucosal O -
, O +
and O +
dermatologic O +
manifestations O -
. O +

A O +
previously O +
healthy O +
child O +
who O +
developed O +
acute O -
, O +
severe O -
, O +
rapidly O +
progressive O +
vanishing B-Disease +
bile I-Disease +
duct I-Disease +
syndrome I-Disease +
shortly O +
after O +
Stevens B-Disease -
- I-Disease -
Johnson I-Disease +
syndrome I-Disease +
is O +
described O -
; O +
this O +
was O +
temporally O +
associated O +
with O +
ibuprofen O +
use O -
. O +

Despite O +
therapy O +
with O +
ursodeoxycholic O +
acid O -
, O +
prednisone O -
, O +
and O +
then O +
tacrolimus O -
, O +
her O +
cholestatic B-Disease +
disease I-Disease +
was O +
unrelenting O -
, O +
with O +
cirrhosis B-Disease +
shown O +
by O +
biopsy O +
6 O +
months O +
after O +
presentation O -
. O +

This O +
case O +
documents O +
acute O +
drug O -
- O -
related O +
vanishing B-Disease +
bile I-Disease +
duct I-Disease +
syndrome I-Disease +
in O +
the O +
pediatric O +
age O +
group O +
and O +
suggests O +
shared O +
immune O +
mechanisms O +
in O +
the O +
pathogenesis O +
of O +
both O +
Stevens B-Disease -
- I-Disease -
Johnson I-Disease +
syndrome I-Disease +
and O +
vanishing B-Disease +
bile I-Disease +
duct I-Disease +
syndrome I-Disease -
. O +

High O +
incidence O +
of O +
primary B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
associated O +
with O +
appetite O +
suppressants O +
in O +
Belgium O -
. O +

Primary B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
is O +
a O +
rare O -
, O +
progressive O +
and O +
incurable O +
disease O -
, O +
which O +
has O +
been O +
associated O +
with O +
the O +
intake O +
of O +
appetite O +
suppressant O +
drugs O -
. O +

The O +
importance O +
of O +
this O +
association O +
was O +
evaluated O +
in O +
Belgium O +
while O +
this O +
country O +
still O +
had O +
no O +
restriction O +
on O +
the O +
prescription O +
of O +
appetite O +
suppressants O -
. O +

Thirty O -
- O -
five O +
patients O +
with O +
primary B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
and O +
85 O +
matched O +
controls O +
were O +
recruited O +
over O +
32 O +
months O +
( O -
1992 O -
- O -
1994 O -
) O +
in O +
Belgium O -
. O +

Exposure O +
to O +
appetite O -
- O -
suppressants O +
was O +
assessed O +
on O +
the O +
basis O +
of O +
hospital O +
records O +
and O +
standardized O +
interview O -
. O +

Twenty O -
- O -
three O +
of O +
the O +
patients O +
had O +
previously O +
taken O +
appetite O +
suppressants O -
, O +
mainly O +
fenfluramines O -
, O +
as O +
compared O +
with O +
only O +
5 O +
of O +
the O +
controls O +
( O -
66 O +
versus O +
6 O -
% O -
, O +
p<0.0001 O -
) O -
. O +

Five O +
patients O +
died O +
before O +
the O +
interview O -
, O +
all O +
of O +
them O +
had O +
taken O +
appetite O +
suppressants O -
. O +

In O +
8 O +
patients O +
the O +
diagnosis O +
of O +
primary B-Disease +
pulmonary I-Disease +
hypertension I-Disease +
was O +
uncertain O -
, O +
5 O +
of O +
them O +
had O +
taken O +
appetite O +
suppressants O -
. O +

The O +
patients O +
who O +
had O +
been O +
exposed O +
to O +
appetite O +
suppressants O +
tended O +
to O +
be O +
on O +
average O +
more O +
severely O +
ill O -
, O +
and O +
to O +
have O +
a O +
shorter O +
median O +
delay O +
between O +
onset O +
of O +
symptoms O +
and O +
diagnosis O -
. O +

A O +
policy O +
of O +
unrestricted O +
prescription O +
of O +
appetite O +
suppressants O +
may O +
lead O +
to O +
a O +
high O +
incidence O +
of O +
associated O +
primary B-Disease +
pulmonary I-Disease +
hypertension I-Disease -
. O +

Intake O +
of O +
appetite O +
suppressants O +
may O +
accelerate O +
the O +
progression O +
of O +
the O +
disease O -
. O +

Inappropriate O +
use O +
of O +
carbamazepine O +
and O +
vigabatrin O +
in O +
typical O +
absence B-Disease +
seizures I-Disease -
. O +

Carbamazepine O +
and O +
vigabatrin O +
are O +
contraindicated O +
in O +
typical O +
absence B-Disease +
seizures I-Disease -
. O +

Of O +
18 O +
consecutive O +
referrals O +
of O +
children O +
with O +
resistant O +
typical O +
absences O +
only O -
, O +
eight O +
were O +
erroneously O +
treated O +
with O +
carbamazepine O +
either O +
as O +
monotherapy O +
or O +
as O +
an O +
add O -
- O -
on O -
. O +

Vigabatrin O +
was O +
also O +
used O +
in O +
the O +
treatment O +
of O +
two O +
children O -
. O +

Frequency O +
of O +
absences O +
increased O +
in O +
four O +
children O +
treated O +
with O +
carbamazepine O +
and O +
two O +
of O +
these O +
developed O +
myoclonic B-Disease +
jerks I-Disease -
, O +
which O +
resolved O +
on O +
withdrawal O +
of O +
carbamazepine O -
. O +

Absences O +
were O +
aggravated O +
in O +
both O +
cases O +
where O +
vigabatrin O +
was O +
added O +
on O +
to O +
concurrent O +
treatment O -
. O +

Optimal O +
control O +
of O +
the O +
absences O +
was O +
achieved O +
with O +
sodium O +
valproate O -
, O +
lamotrigine O -
, O +
or O +
ethosuximide O +
alone O +
or O +
in O +
combination O -
. O +

Choreoathetoid B-Disease +
movements I-Disease +
associated O +
with O +
rapid O +
adjustment O +
to O +
methadone O -
. O +

Choreatiform B-Disease +
hyperkinesias B-Disease +
are O +
known O +
to O +
be O +
occasional O +
movement B-Disease +
abnormalities I-Disease +
during O +
intoxications O +
with O +
cocaine O +
but O +
not O +
opiates O -
. O +

This O +
is O +
a O +
case O +
report O +
of O +
euphoria O +
and O +
choreoathetoid B-Disease +
movements I-Disease +
both O +
transiently O +
induced O +
by O +
rapid O +
adjustment O +
to O +
the O +
selective O +
mu O -
- O -
opioid O +
receptor O +
agonist O +
methadone O +
in O +
an O +
inpatient O +
previously O +
abusing O +
heroine O +
and O +
cocaine O -
. O +

In O +
addition O -
, O +
minor O +
EEG O +
abnormalities O +
occurred O -
. O +

Possible O +
underlying O +
neurobiological O +
phenomena O +
are O +
discussed O -
. O +

Epileptogenic O +
activity O +
of O +
folic O +
acid O +
after O +
drug O +
induces O +
SLE B-Disease +
( O -
folic O +
acid O +
and O +
epilepsy B-Disease -
) O +
OBJECTIVE O -
: O +
To O +
study O +
the O +
effect O +
of O +
folic O +
acid O -
- O -
containing O +
multivitamin O +
supplementation O +
in O +
epileptic B-Disease +
women O +
before O +
and O +
during O +
pregnancy O +
in O +
order O +
to O +
determine O +
the O +
rate O +
of O +
structural O +
birth B-Disease +
defects I-Disease +
and O +
epilepsy B-Disease -
- O -
related O +
side O +
effects O -
. O +

STUDY O +
DESIGN O -
: O +
First O +
a O +
randomised O +
trial O -
, O +
later O +
periconception O +
care O +
including O +
in O +
total O +
12225 O +
females O -
. O +

RESULTS O -
: O +
Of O +
60 O +
epileptic B-Disease +
women O +
with O +
periconceptional O +
folic O +
acid O +
( O -
0.8 O +
mg O -
) O -
-containing O +
multivitamin O +
supplementation O -
, O +
no O +
one O +
developed O +
epilepsy B-Disease -
- O -
related O +
side O +
effects O +
during O +
the O +
periconception O +
period O -
. O +

One O +
epileptic B-Disease +
woman O +
delivered O +
a O +
newborn O +
with O +
cleft B-Disease +
lip I-Disease +
and B-Disease +
palate I-Disease -
. O +

Another O +
patient O +
exhibited O +
with O +
a O +
cluster O +
of O +
seizures B-Disease +
after O +
the O +
periconception O +
period O +
using O +
another O +
multivitamin O -
. O +

This O +
22-year O -
- O -
old O +
epileptic B-Disease +
woman O +
was O +
treated O +
continuously O +
by O +
carbamazepine O +
and O +
a O +
folic O +
acid O +
( O -
1 O +
mg O -
) O -
-containing O +
multivitamin O +
from O +
the O +
20th O +
week O +
of O +
gestation O -
. O +

She O +
developed O +
status B-Disease +
epilepticus I-Disease +
and O +
later O +
symptoms O +
of O +
systemic B-Disease +
lupus I-Disease +
erythematodes I-Disease -
. O +

Her O +
pregnancy O +
ended O +
with O +
stillbirth B-Disease -
. O +

CONCLUSIONS O -
: O +
The O +
epileptic B-Disease +
pregnant O +
patient O -
's O +
autoimmune B-Disease +
disease I-Disease +
( O -
probably O +
drug O -
- O -
induced O +
lupus B-Disease -
) O +
could O +
damage O +
the O +
blood O -
- O -
brain O +
barrier O -
, O +
therefore O +
the O +
therapeutic O +
dose O +
( O -
> O +
or O +
= O -
1 O +
mg O -
) O +
of O +
folic O +
acid O +
triggered O +
a O +
cluster O +
of O +
seizures B-Disease -
. O +

Physiological O +
dose O +
( O -
< O -
1 O +
mg O -
) O +
of O +
folic O +
acid O +
both O +
in O +
healthy O +
and O +
60 O +
epileptic B-Disease +
women O -
, O +
all O +
without O +
any O +
autoimmune B-Disease +
disease I-Disease -
, O +
did O +
not O +
increase O +
the O +
risk O +
for O +
epileptic B-Disease +
seizures I-Disease -
. O +

Adverse O +
effects O +
of O +
the O +
atypical O +
antipsychotics O -
. O +

Collaborative O +
Working O +
Group O +
on O +
Clinical O +
Trial O +
Evaluations O -
. O +

Adverse O +
effects O +
of O +
antipsychotics O +
often O +
lead O +
to O +
noncompliance O -
. O +

Thus O -
, O +
clinicians O +
should O +
address O +
patients O -
' O +
concerns O +
about O +
adverse O +
effects O +
and O +
attempt O +
to O +
choose O +
medications O +
that O +
will O +
improve O +
their O +
patients O -
' O +
quality O +
of O +
life O +
as O +
well O +
as O +
overall O +
health O -
. O +

The O +
side O +
effect O +
profiles O +
of O +
the O +
atypical O +
antipsychotics O +
are O +
more O +
advantageous O +
than O +
those O +
of O +
the O +
conventional O +
neuroleptics O -
. O +

Conventional O +
agents O +
are O +
associated O +
with O +
unwanted O +
central O +
nervous O +
system O +
effects O -
, O +
including O +
extrapyramidal B-Disease +
symptoms I-Disease +
( O -
EPS B-Disease -
) O -
, O +
tardive B-Disease +
dyskinesia I-Disease -
, O +
sedation O -
, O +
and O +
possible O +
impairment O +
of O +
some O +
cognitive O +
measures O -
, O +
as O +
well O +
as O +
cardiac O +
effects O -
, O +
orthostatic B-Disease +
hypotension I-Disease -
, O +
hepatic O +
changes O -
, O +
anticholinergic O +
side O +
effects O -
, O +
sexual B-Disease +
dysfunction I-Disease -
, O +
and O +
weight B-Disease +
gain I-Disease -
. O +

The O +
newer O +
atypical O +
agents O +
have O +
a O +
lower O +
risk O +
of O +
EPS B-Disease -
, O +
but O +
are O +
associated O +
in O +
varying O +
degrees O +
with O +
sedation O -
, O +
cardiovascular O +
effects O -
, O +
anticholinergic O +
effects O -
, O +
weight B-Disease +
gain I-Disease -
, O +
sexual B-Disease +
dysfunction I-Disease -
, O +
hepatic O +
effects O -
, O +
lowered O +
seizure B-Disease +
threshold O +
( O -
primarily O +
clozapine O -
) O -
, O +
and O +
agranulocytosis B-Disease +
( O -
clozapine O +
only O -
) O -
. O +

Since O +
the O +
incidence O +
and O +
severity O +
of O +
specific O +
adverse O +
effects O +
differ O +
among O +
the O +
various O +
atypicals O -
, O +
the O +
clinician O +
should O +
carefully O +
consider O +
which O +
side O +
effects O +
are O +
most O +
likely O +
to O +
lead O +
to O +
the O +
individual O -
's O +
dissatisfaction O +
and O +
noncompliance O +
before O +
choosing O +
an O +
antipsychotic O +
for O +
a O +
particular O +
patient O -
. O +

Stroke B-Disease +
and O +
cocaine O +
or O +
amphetamine O +
use O -
. O +

The O +
association O +
of O +
cocaine O +
and O +
amphetamine O +
use O +
with O +
hemorrhagic O +
and O +
ischemic B-Disease +
stroke B-Disease +
is O +
based O +
almost O +
solely O +
on O +
data O +
from O +
case O +
series O -
. O +

The O +
limited O +
number O +
of O +
epidemiologic O +
studies O +
of O +
stroke B-Disease +
and O +
use O +
of O +
cocaine O +
and/or O +
amphetamine O +
have O +
been O +
done O +
in O +
settings O +
that O +
serve O +
mostly O +
the O +
poor O +
and/or O +
minorities O -
. O +

This O +
case O -
- O -
control O +
study O +
was O +
conducted O +
in O +
the O +
defined O +
population O +
comprising O +
members O +
of O +
Kaiser O +
Permanente O +
of O +
Northern O +
and O +
Southern O +
California O -
. O +

We O +
attempted O +
to O +
identify O +
all O +
incident O +
strokes B-Disease +
in O +
women O +
ages O +
15 O -
- O -
44 O +
years O +
during O +
a O +
3-year O +
period O +
using O +
hospital O +
admission O +
and O +
discharge O +
records O -
, O +
emergency O +
department O +
logs O -
, O +
and O +
payment O +
requests O +
for O +
out O -
- O -
of O -
- O -
plan O +
hospitalizations O -
. O +

We O +
selected O +
controls O -
, O +
matched O +
on O +
age O +
and O +
facility O +
of O +
usual O +
care O -
, O +
at O +
random O +
from O +
healthy O +
members O +
of O +
the O +
health O +
plan O -
. O +

We O +
obtained O +
information O +
in O +
face O -
- O -
to O -
- O -
face O +
interviews O -
. O +

There O +
were O +
347 O +
confirmed O +
stroke B-Disease +
cases O +
and O +
1,021 O +
controls O -
. O +

The O +
univariate O +
matched O +
odds O +
ratio O +
for O +
stroke B-Disease +
in O +
women O +
who O +
admitted O +
to O +
using O +
cocaine O +
and/or O +
amphetamine O +
was O +
8.5 O +
( O -
95 O -
% O +
confidence O +
interval O +
= O +
3.6 O -
- O -
20.0 O -
) O -
. O +

After O +
further O +
adjustment O +
for O +
potential O +
confounders O -
, O +
the O +
odds O +
ratio O +
in O +
women O +
who O +
reported O +
using O +
cocaine O +
and/or O +
amphetamine O +
was O +
7.0 O +
( O -
95 O -
% O +
confidence O +
interval O +
= O +
2.8 O -
- O -
17.9 O -
) O -
. O +

The O +
use O +
of O +
cocaine O +
and/or O +
amphetamine O +
is O +
a O +
strong O +
risk O +
factor O +
for O +
stroke B-Disease +
in O +
this O +
socioeconomically O +
heterogeneous O -
, O +
insured O +
urban O +
population O -
. O +

A O +
randomized O -
, O +
placebo O -
- O -
controlled O +
dose O -
- O -
comparison O +
trial O +
of O +
haloperidol O +
for O +
psychosis B-Disease +
and O +
disruptive B-Disease +
behaviors I-Disease +
in O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

OBJECTIVE O -
: O +
The O +
goal O +
of O +
this O +
study O +
was O +
to O +
compare O +
the O +
efficacy O +
and O +
side O +
effects O +
of O +
two O +
doses O +
of O +
haloperidol O +
and O +
placebo O +
in O +
the O +
treatment O +
of O +
psychosis B-Disease +
and O +
disruptive B-Disease +
behaviors I-Disease +
in O +
patients O +
with O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

METHOD O -
: O +
In O +
a O +
6-week O +
random O -
- O -
assignment O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
trial O +
( O -
phase O +
A O -
) O -
, O +
haloperidol O -
, O +
2 O -
- O -
3 O +
mg O -
/ O -
day O +
( O -
standard O +
dose O -
) O -
, O +
and O +
haloperidol O -
, O +
0.50 O -
- O -
0.75 O +
mg O -
/ O -
day O +
( O -
low O +
dose O -
) O -
, O +
were O +
compared O +
in O +
71 O +
outpatients O +
with O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease -
. O +

For O +
the O +
subsequent O +
6-week O +
double O -
- O -
blind O +
crossover O +
phase O +
( O -
phase O +
B O -
) O -
, O +
patients O +
taking O +
standard- O +
or O +
low O -
- O -
dose O +
haloperidol O +
were O +
switched O +
to O +
placebo O -
, O +
and O +
patients O +
taking O +
placebo O +
were O +
randomly O +
assigned O +
to O +
standard- O +
or O +
low O -
- O -
dose O +
haloperidol O -
. O +

RESULTS O -
: O +
For O +
the O +
60 O +
patients O +
who O +
completed O +
phase O +
A O -
, O +
standard O -
- O -
dose O +
haloperidol O +
was O +
efficacious O +
and O +
superior O +
to O +
both O +
low O -
- O -
dose O +
haloperidol O +
and O +
placebo O +
for O +
scores O +
on O +
the O +
Brief O +
Psychiatric O +
Rating O +
Scale O +
psychosis B-Disease +
factor O +
and O +
on O +
psychomotor B-Disease +
agitation I-Disease -
. O +

Response O +
rates O +
according O +
to O +
three O +
sets O +
of O +
criteria O +
were O +
greater O +
with O +
the O +
standard O +
dose O +
( O -
55%-60 O -
% O -
) O +
than O +
the O +
low O +
dose O +
( O -
25%-35 O -
% O -
) O +
and O +
placebo O +
( O -
25%-30 O -
% O -
) O -
. O +

The O +
advantage O +
of O +
standard O +
dose O +
over O +
low O +
dose O +
was O +
replicated O +
in O +
phase O +
B. O +
In O +
phase O +
A O -
, O +
extrapyramidal B-Disease +
signs I-Disease +
tended O +
to O +
be O +
greater O +
with O +
the O +
standard O +
dose O +
than O +
in O +
the O +
other O +
two O +
conditions O -
, O +
primarily O +
because O +
of O +
a O +
subgroup O +
( O -
20 O -
% O -
) O +
who O +
developed O +
moderate O +
to O +
severe O +
signs O -
. O +

Low O -
- O -
dose O +
haloperidol O +
did O +
not O +
differ O +
from O +
placebo O +
on O +
any O +
measure O +
of O +
efficacy O +
or O +
side O +
effects O -
. O +

CONCLUSIONS O -
: O +
The O +
results O +
indicated O +
a O +
favorable O +
therapeutic O +
profile O +
for O +
haloperidol O +
in O +
doses O +
of O +
2 O -
- O -
3 O +
mg O -
/ O -
day O -
, O +
although O +
a O +
subgroup O +
developed O +
moderate O +
to O +
severe O +
extrapyramidal B-Disease +
signs I-Disease -
. O +

A O +
starting O +
dose O +
of O +
1 O +
mg O -
/ O -
day O +
with O +
gradual O -
, O +
upward O +
dose O +
titration O +
is O +
recommended O -
. O +

The O +
narrow O +
therapeutic O +
window O +
observed O +
with O +
haloperidol O +
may O +
also O +
apply O +
to O +
other O +
neuroleptics O +
used O +
in O +
Alzheimer B-Disease -
's I-Disease +
disease I-Disease +
patients O +
with O +
psychosis B-Disease +
and O +
disruptive B-Disease +
behaviors I-Disease -
. O +

Acute B-Disease +
renal I-Disease +
failure I-Disease +
subsequent O +
to O +
the O +
administration O +
of O +
rifampicin O -
. O +

A O +
follow O -
- O -
up O +
study O +
of O +
cases O +
reported O +
earlier O -
. O +

A O +
clinical O +
presentation O +
is O +
made O +
of O +
a O +
2 O -
- O -
3 O +
year O +
follow O -
- O -
up O +
of O +
six O +
cases O +
of O +
acute B-Disease +
renal I-Disease +
failure I-Disease +
that O +
have O +
been O +
reported O +
earlier O -
. O +

The O +
patients O +
had O +
developed O +
transient O +
renal B-Disease +
failure I-Disease +
after O +
the O +
intermittent O +
administration O +
of O +
rifampicin O -
. O +

The O +
stage O +
of O +
olig O -
- O -
anuria B-Disease +
lasted O +
for O +
1 O -
- O -
3 O +
weeks O -
, O +
and O +
five O +
of O +
the O +
patients O +
were O +
treated O +
by O +
hemodialysis O -
. O +

Two O +
of O +
the O +
patients O +
died O +
due O +
to O +
unrelated O +
causes O +
during O +
the O +
follow O -
- O -
up O +
period O -
. O +

The O +
four O +
patients O +
re O -
- O -
examined O +
were O +
clinically O +
cured O -
. O +

Pathologic O +
findings O +
by O +
light O +
microscopy O +
and O +
immunofluorescence O +
at O +
biopsy O +
were O +
scarce O -
. O +

Nothing O +
abnormal O +
was O +
seen O +
by O +
electron O +
microscopy O +
in O +
two O +
of O +
the O +
cases O +
studied O -
. O +

Renal O +
function O +
was O +
normal O -
. O +

In O +
three O +
cases O +
the O +
excretion O +
at O +
131I O -
- O -
hippuran O +
renography O +
was O +
slightly O +
slowed O -
. O +

Although O +
in O +
the O +
acute O +
stage O +
the O +
renal B-Disease +
lesions I-Disease +
histologically O +
appeared O +
toxic O -
, O +
evidence O +
suggestive O +
of O +
an O +
immunological O +
mechanism O +
can O -
not O +
be O +
excluded O -
. O +

Effects O +
of O +
acetylsalicylic O +
acid O -
, O +
dipyridamole O -
, O +
and O +
hydrocortisone O +
on O +
epinephrine O -
- O -
induced O +
myocardial B-Disease +
injury I-Disease +
in O +
dogs O -
. O +

A O +
reproducible O +
model O +
for O +
producing O +
diffuse O +
myocardial B-Disease +
injury I-Disease +
( O -
epinephrine O +
infusion O -
) O +
has O +
been O +
developed O +
to O +
study O +
the O +
cardioprotective O +
effects O +
of O +
agents O +
or O +
maneuvers O +
which O +
might O +
alter O +
the O +
evolution O +
of O +
acute O +
myocardial B-Disease +
infarction I-Disease -
. O +

Infusions O +
of O +
epinephrine O +
( O -
4 O +
mug O +
per O +
kilogram O +
per O +
minute O +
for O +
6 O +
hours O -
) O +
increased O +
radiocalcium O +
uptakes O +
into O +
intact O +
myocardium O +
and O +
each O +
of O +
its O +
subcellular O +
components O +
with O +
the O +
mitochondrial O +
fraction O +
showing O +
the O +
most O +
consistent O +
changes O +
when O +
compared O +
to O +
saline O -
- O -
infused O +
control O +
animals O +
( O -
4,957 O +
vs. O +
827 O +
counts O +
per O +
minute O +
per O +
gram O +
of O +
dried O +
tissue O +
or O +
fraction O -
) O -
. O +

Myocardial O +
concentrations O +
of O +
calcium O +
also O +
increased O +
significantly O +
( O -
12.0 O +
vs. O +
5.0 O +
mg.per O +
100 O +
Gm O -
. O +

of O +
fat O -
- O -
free O +
dry O +
weight O -
) O -
. O +

Infusions O +
of O +
calcium O +
chloride O +
sufficient O +
to O +
raise O +
serum O +
calcium O +
concentrations O +
2 O +
mEq O -
. O +

per O +
liter O +
failed O +
to O +
increase O +
calcium O +
influx O +
into O +
the O +
myocardial O +
cell O -
. O +

Mitochondrial O +
radiocalcium O +
uptakes O +
were O +
significantly O +
decreased O +
in O +
animals O +
pretreated O +
with O +
acetylsalicylic O +
acid O +
or O +
dipyridamole O +
or O +
when O +
hydrocortisone O +
was O +
added O +
to O +
the O +
epinephrine O +
infusion O +
( O -
2,682,2,803 O -
, O +
and O +
3,424 O +
counts O +
per O +
minute O +
per O +
gram O +
of O +
dried O +
fraction O -
, O +
respectively O -
) O -
. O +

Myocardial O +
calcium O +
concentrations O +
also O +
were O +
decreased O +
( O -
11.2 O -
, O +
8.3 O -
, O +
and O +
8.9 O +
mg O -
. O +

per O +
100 O +
Gm O -
. O +

of O +
fat O -
- O -
free O +
dry O +
weight O -
, O +
respectively O -
) O +
in O +
the O +
three O +
treatment O +
groups O -
, O +
being O +
significantly O +
decreased O +
only O +
in O +
the O +
last O +
two O -
. O +

Evidence O +
of O +
microscopic O +
damage O +
was O +
graded O +
as O +
less O +
severe O +
in O +
the O +
three O +
treatment O +
groups O -
. O +

Acetylsalicylic O +
acid O -
, O +
dipyridamole O -
, O +
and O +
hydrocortisone O +
all O +
appear O +
to O +
have O +
cardioprotective O +
effects O +
when O +
tested O +
in O +
this O +
model O -
. O +

Chronic O +
effects O +
of O +
a O +
novel O +
synthetic O +
anthracycline O +
derivative O +
( O -
SM-5887 O -
) O +
on O +
normal O +
heart O +
and O +
doxorubicin O -
- O -
induced O +
cardiomyopathy B-Disease +
in O +
beagle O +
dogs O -
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
chronic O +
cardiotoxic B-Disease +
potential O +
of O +
SM-5887 O +
and O +
a O +
possible O +
deteriorating O +
effect O +
of O +
SM-5887 O +
on O +
low O -
- O -
grade O +
cardiotoxicity B-Disease +
pre O -
- O -
induced O +
by O +
doxorubicin O +
in O +
beagle O +
dogs O -
. O +

In O +
the O +
chronic O +
treatment O -
, O +
beagle O +
dogs O +
of O +
each O +
sex O +
were O +
given O +
intravenously O +
once O +
every O +
3 O +
weeks O -
, O +
either O +
a O +
sublethal O +
dose O +
of O +
doxorubicin O +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O +
or O +
SM-5887 O +
( O -
2.5 O +
mg O -
/ O -
kg O -
) O -
. O +

The O +
experiment O +
was O +
terminated O +
3 O +
weeks O +
after O +
the O +
ninth O +
dosing O -
. O +

Animals O +
which O +
received O +
over O +
six O +
courses O +
of O +
doxorubicin O +
demonstrated O +
the O +
electrocardiogram O +
( O -
ECG O -
) O +
changes O -
, O +
decrease O +
of O +
blood O +
pressure O +
and O +
high O -
- O -
grade O +
histopathological O +
cardiomyopathy B-Disease -
, O +
while O +
animals O +
which O +
were O +
terminally O +
sacrificed O +
after O +
the O +
SM-5887 O +
administration O +
did O +
not O +
show O +
any O +
changes O +
in O +
ECG O -
, O +
blood O +
pressure O +
and O +
histopathological O +
examinations O -
. O +

To O +
examine O +
a O +
possibly O +
deteriorating O +
cardiotoxic B-Disease +
effect O +
of O +
SM-5887 O -
, O +
low O -
- O -
grade O +
cardiomyopathy B-Disease +
was O +
induced O +
in O +
dogs O +
by O +
four O +
courses O +
of O +
doxorubicin O +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O -
. O +

Nine O +
weeks O +
after O +
pre O -
- O -
treatment O -
, O +
dogs O +
were O +
given O +
four O +
courses O +
of O +
either O +
doxorubicin O +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O +
or O +
SM-5887 O +
( O -
2.5 O +
mg O -
/ O -
kg O -
) O +
once O +
every O +
3 O +
weeks O -
. O +

The O +
low O -
- O -
grade O +
cardiotoxic B-Disease +
changes O +
were O +
enhanced O +
by O +
the O +
additional O +
doxorubicin O +
treatment O -
. O +

On O +
the O +
contrary O -
, O +
the O +
SM-5887 O +
treatment O +
did O +
not O +
progress O +
the O +
grade O +
of O +
cardiomyopathy B-Disease -
. O +

In O +
conclusion O -
, O +
SM-5887 O +
does O +
not O +
have O +
any O +
potential O +
of O +
chronic O +
cardiotoxicity B-Disease +
and O +
deteriorating O +
effect O +
on O +
doxorubicin O -
- O -
induced O +
cardiotoxicity B-Disease +
in O +
dogs O -
. O +

Clinical O +
and O +
histopathologic O +
examination O +
of O +
renal O +
allografts O +
treated O +
with O +
tacrolimus O +
( O -
FK506 O -
) O +
for O +
at O +
least O +
one O +
year O -
. O +

BACKGROUND O -
: O +
We O +
clinically O +
and O +
pathologically O +
analyzed O +
renal O +
allografts O +
from O +
1 O +
9 O +
renal O +
transplant O +
patients O +
treated O +
with O +
tacrolimus O +
( O -
FK506 O -
) O +
for O +
more O +
than O +
1 O +
year O -
. O +

METHODS O -
: O +
Twenty O -
- O -
six O +
renal O +
allograft O +
biopsy O +
specimens O +
from O +
1 O +
9 O +
renal O +
transplant O +
patients O +
who O +
underwent O +
transplantations O +
between O +
1991 O +
and O +
1993 O +
were O +
evaluated O -
. O +

Thirteen O +
biopsies O +
were O +
performed O +
from O +
stable O +
functioning O +
renal O +
allografts O +
with O +
informed O +
consent O +
( O -
nonepisode O +
biopsy O -
) O +
and O +
the O +
other O +
13 O +
were O +
from O +
dysfunctional O +
renal O +
allografts O +
with O +
a O +
clinical O +
indication O +
for O +
biopsy O +
( O -
episode O +
biopsy O -
) O -
. O +

RESULTS O -
: O +
The O +
main O +
pathologic O +
diagnoses O +
( O -
some O +
overlap O -
) O +
were O +
acute O +
rejection O +
( O -
AR O -
; O +
n O +
= O +
4 O -
) O -
, O +
chronic O +
rejection O +
( O -
CR O -
; O +
n=5 O -
) O -
, O +
AR+CR O +
( O -
n O +
= O -
4 O -
) O -
, O +
recurrent O +
IgA B-Disease +
nephropathy I-Disease +
( O -
n O +
= O -
5 O -
) O -
, O +
normal O +
findings O +
( O -
n O +
= O -
2 O -
) O -
, O +
minimal O -
- O -
type O +
chronic O +
FK506 O +
nephropathy B-Disease +
( O -
n O +
= O +
9 O -
) O -
, O +
and O +
mild O -
- O -
type O +
FK506 O +
nephropathy B-Disease +
( O -
n O +
= O +
11 O -
) O -
. O +

Of O +
the O +
nonepisode O +
biopsies O -
, O +
7 O +
and O +
4 O +
biopsies O +
showed O +
minimal O -
- O -
type O +
and O +
mild O -
- O -
type O +
chronic O +
FK506 O +
nephropathy B-Disease -
, O +
respectively O -
. O +

Chronic O +
FK506 O +
nephropathy B-Disease +
consisted O +
of O +
rough O +
and O +
foamy O +
tubular O +
vacuolization O +
( O -
5 O +
biopsies O -
) O -
, O +
arteriolopathy O +
( O -
angiodegeneration O +
of O +
the O +
arteriolar O +
wall O -
; O +
20 O +
biopsies O -
) O -
, O +
focal B-Disease +
segmental I-Disease +
glomerulosclerosis I-Disease +
( O -
4 O +
biopsies O -
) O +
and O +
the O +
striped O +
form O +
of O +
interstitial B-Disease +
fibrosis I-Disease +
( O -
11 O +
biopsies O -
) O -
. O +

The O +
serum O +
creatinine O +
levels O +
of O +
patients O +
in O +
the O +
mild O -
- O -
type O +
chronic O +
FK506 O +
nephropathy B-Disease +
group O -
, O +
which O +
included O +
7 O +
episode O +
biopsies O -
, O +
were O +
statistically O +
higher O +
than O +
those O +
in O +
the O +
minimum O -
- O -
type O +
chronic O +
FK506-nephropathy O +
group O +
( O -
P O -
< O +
0.001 O -
) O -
. O +

CONCLUSIONS O -
: O +
This O +
study O +
demonstrates O +
that O +
chronic O +
FK506 O +
nephropathy B-Disease +
consists O +
primarily O +
of O +
arteriolopathy O +
manifesting O +
as O +
insudative O +
hyalinosis O +
of O +
the O +
arteriolar O +
wall O -
, O +
and O +
suggests O +
that O +
mild O -
- O -
type O +
chronic O +
FK506 O +
nephropathy B-Disease +
is O +
a O +
condition O +
which O +
may O +
lead O +
to O +
deterioration O +
of O +
renal O +
allograft O +
function O -
. O +

Different O +
lobular O +
distributions O +
of O +
altered O +
hepatocyte O +
tight O +
junctions O +
in O +
rat O +
models O +
of O +
intrahepatic B-Disease +
and I-Disease +
extrahepatic I-Disease +
cholestasis I-Disease -
. O +

Hepatocyte O +
tight O +
junctions O +
( O -
TJs O -
) O -
, O +
the O +
only O +
intercellular O +
barrier O +
between O +
the O +
sinusoidal O +
and O +
the O +
canalicular O +
spaces O -
, O +
play O +
a O +
key O +
role O +
in O +
bile O +
formation O -
. O +

Although O +
hepatocyte O +
TJs O +
are O +
impaired O +
in O +
cholestasis B-Disease -
, O +
attempts O +
to O +
localize O +
the O +
precise O +
site O +
of O +
hepatocyte O +
TJ O +
damage O +
by O +
freeze O -
- O -
fracture O +
electron O +
microscopy O +
have O +
produced O +
limited O +
information O -
. O +

Recently O -
, O +
several O +
TJ O -
- O -
associated O +
proteins O +
like O +
ZO-1 O +
and O +
7H6 O +
have O +
been O +
identified O +
and O +
characterized O -
. O +

Immunolocalization O +
of O +
7H6 O +
appears O +
to O +
closely O +
correlate O +
with O +
paracellular O +
permeability O -
. O +

We O +
used O +
rat O +
models O +
of O +
intrahepatic B-Disease +
cholestasis I-Disease +
by O +
ethinyl O +
estradiol O +
( O -
EE O -
) O +
treatment O +
and O +
extrahepatic B-Disease +
cholestasis I-Disease +
by O +
bile O +
duct O +
ligation O +
( O -
BDL O -
) O +
to O +
precisely O +
determine O +
the O +
site O +
of O +
TJ O +
damage O -
. O +

Alterations O +
in O +
hepatocyte O +
TJs O +
were O +
assessed O +
by O +
double O -
- O -
immunolabeling O +
for O +
7H6 O +
and O +
ZO-1 O +
using O +
a O +
confocal O +
laser O +
scanning O +
microscope O -
. O +

In O +
control O +
rats O -
, O +
immunostaining O +
for O +
7H6 O +
and O +
ZO-1 O +
colocalized O +
to O +
outline O +
bile O +
canaliculi O +
in O +
a O +
continuous O +
fashion O -
. O +

In O +
contrast O -
, O +
7H6 O +
and O +
ZO-1 O +
immunostaining O +
was O +
more O +
discontinuous O -
, O +
outlining O +
the O +
bile O +
canaliculi O +
after O +
BDL O -
. O +

Immunostaining O +
for O +
7H6 O -
, O +
not O +
ZO-1 O -
, O +
decreased O +
and O +
predominantly O +
appeared O +
as O +
discrete O +
signals O +
in O +
the O +
submembranous O +
cytoplasm O +
of O +
periportal O +
hepatocytes O +
after O +
BDL O -
. O +

After O +
EE O +
treatment O -
, O +
changes O +
in O +
immunostaining O +
for O +
7H6 O +
and O +
ZO-1 O +
were O +
similar O +
to O +
those O +
seen O +
in O +
periportal O +
hepatocytes O +
after O +
BDL O -
, O +
but O +
distributed O +
more O +
diffusely O +
throughout O +
the O +
lobule O -
. O +

This O +
study O +
is O +
the O +
first O +
to O +
demonstrate O +
that O +
impairment O +
of O +
hepatocyte O +
TJs O +
occurs O +
heterogenously O +
in O +
the O +
liver O +
lobule O +
after O +
BDL O +
and O +
suggests O +
that O +
BDL O +
and O +
EE O +
treatments O +
produce O +
different O +
lobular O +
distributions O +
of O +
increased O +
paracellular O +
permeability O -
. O +

Risk O +
for O +
valvular B-Disease +
heart I-Disease +
disease I-Disease +
among O +
users O +
of O +
fenfluramine O +
and O +
dexfenfluramine O +
who O +
underwent O +
echocardiography O +
before O +
use O +
of O +
medication O -
. O +

BACKGROUND O -
: O +
Because O +
uncontrolled O +
echocardiographic O +
surveys O +
suggested O +
that O +
up O +
to O +
30 O -
% O +
to O +
38 O -
% O +
of O +
users O +
of O +
fenfluramine O +
and O +
dexfenfluramine O +
had O +
valvular B-Disease +
disease I-Disease -
, O +
these O +
drugs O +
were O +
withdrawn O +
from O +
the O +
market O -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
the O +
risk O +
for O +
new O +
or O +
worsening O +
valvular B-Disease +
abnormalities I-Disease +
among O +
users O +
of O +
fenfluramine O +
or O +
dexfenfluramine O +
who O +
underwent O +
echocardiography O +
before O +
they O +
began O +
to O +
take O +
these O +
medications O -
. O +

DESIGN O -
: O +
Cohort O +
study O -
. O +

SETTING O -
: O +
Academic O +
primary O +
care O +
practices O -
. O +

PATIENTS O -
: O +
46 O +
patients O +
who O +
used O +
fenfluramine O +
or O +
dexfenfluramine O +
for O +
14 O +
days O +
or O +
more O +
and O +
had O +
echocardiograms O +
obtained O +
before O +
therapy O -
. O +

MEASUREMENTS O -
: O +
Follow O -
- O -
up O +
echocardiography O -
. O +

The O +
primary O +
outcome O +
was O +
new O +
or O +
worsening O +
valvulopathy B-Disease -
, O +
defined O +
as O +
progression O +
of O +
either O +
aortic B-Disease +
or I-Disease +
mitral I-Disease +
regurgitation I-Disease +
by O +
at O +
least O +
one O +
degree O +
of O +
severity O +
and O +
disease O +
that O +
met O +
U.S. O +
Food O +
and O +
Drug O +
Administration O +
criteria O +
( O -
at O +
least O +
mild O +
aortic B-Disease +
regurgitation I-Disease +
or O +
moderate O +
mitral B-Disease +
regurgitation I-Disease -
) O -
. O +

RESULTS O -
: O +
Two O +
patients O +
( O -
4.3 O -
% O +
[ O -
95 O -
% O +
CI O -
, O +
0.6 O -
% O +
to O +
14.8 O -
% O -
] O -
) O +
receiving O +
fenfluramine O -
- O -
phentermine O +
developed O +
valvular B-Disease +
heart I-Disease +
disease I-Disease -
. O +

One O +
had O +
baseline O +
bicuspid B-Disease +
aortic I-Disease +
valve I-Disease +
and O +
mild O +
aortic B-Disease +
regurgitation I-Disease +
that O +
progressed O +
to O +
moderate O +
regurgitation O -
. O +

The O +
second O +
patient O +
developed O +
new O +
moderate O +
aortic B-Disease +
insufficiency I-Disease -
. O +

CONCLUSION O -
: O +
Users O +
of O +
diet O +
medications O +
are O +
at O +
risk O +
for O +
valvular B-Disease +
heart I-Disease +
disease I-Disease -
. O +

However O -
, O +
the O +
incidence O +
may O +
be O +
lower O +
than O +
that O +
reported O +
previously O -
. O +

Memory O +
facilitation O +
and O +
stimulation O +
of O +
endogenous O +
nerve O +
growth O +
factor O +
synthesis O +
by O +
the O +
acetylcholine O +
releaser O +
PG-9 O -
. O +

The O +
effects O +
of O +
PG-9 O +
( O -
3alpha O -
- O -
tropyl O +
2- O -
( O -
p O -
- O -
bromophenyl O -
) O -
propionate O -
) O -
, O +
the O +
acetylcholine O +
releaser O -
, O +
on O +
memory O +
processes O +
and O +
nerve O +
growth O +
factor O +
( O -
NGF O -
) O +
synthesis O +
were O +
evaluated O -
. O +

In O +
the O +
mouse O +
passive O -
- O -
avoidance O +
test O -
, O +
PG-9 O +
( O -
10 O -
- O -
30 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
, O +
administered O +
20 O +
min O +
before O +
the O +
training O +
session O -
, O +
prevented O +
amnesia B-Disease +
induced O +
by O +
both O +
the O +
non O +
selective O +
antimuscarinic O +
drug O +
scopolamine O +
and O +
the O +
M1-selective O +
antagonist O +
S- O -
( O -
- O -
) O -
-ET-126 O -
. O +

In O +
the O +
same O +
experimental O +
conditions O -
, O +
PG-9 O +
( O -
5 O -
- O -
20 O +
microg O +
per O +
mouse O -
, O +
i.c.v O -
. O -
) O +
was O +
also O +
able O +
to O +
prevent O +
antimuscarine O -
- O -
induced O +
amnesia B-Disease -
, O +
demonstrating O +
a O +
central O +
localization O +
of O +
the O +
activity O -
. O +

At O +
the O +
highest O +
effective O +
doses O -
, O +
PG-9 O +
did O +
not O +
produce O +
any O +
collateral O +
symptoms O +
as O +
revealed O +
by O +
the O +
Irwin O +
test O -
, O +
and O +
it O +
did O +
not O +
modify O +
spontaneous O +
motility O +
and O +
inspection O +
activity O -
, O +
as O +
revealed O +
by O +
the O +
hole O -
- O -
board O +
test O -
. O +

PG-9 O +
was O +
also O +
able O +
to O +
increase O +
the O +
amount O +
of O +
NGF O +
secreted O +
in O +
vitro O +
by O +
astrocytes O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

The O +
maximal O +
NGF O +
contents O +
obtained O +
by O +
PG-9 O +
were O +
17.6-fold O +
of O +
the O +
control O +
value O -
. O +

During O +
culture O -
, O +
no O +
morphological O +
changes O +
were O +
found O +
at O +
effective O +
concentrations O +
of O +
PG-9 O -
. O +

The O +
current O +
work O +
indicates O +
the O +
ability O +
of O +
PG-9 O +
to O +
induce O +
beneficial O +
effects O +
on O +
cognitive O +
processes O +
and O +
stimulate O +
activity O +
of O +
NGF O +
synthesis O +
in O +
astroglial O +
cells O -
. O +

Therefore O -
, O +
PG-9 O +
could O +
represent O +
a O +
potential O +
useful O +
drug O +
able O +
to O +
improve O +
the O +
function O +
of O +
impaired O +
cognitive O +
processes O -
. O +

Therapeutic O +
drug O +
monitoring O +
of O +
tobramycin O -
: O +
once O -
- O -
daily O +
versus O +
twice O -
- O -
daily O +
dosage O +
schedules O -
. O +

OBJECTIVE O -
: O +
To O +
evaluate O +
the O +
effect O +
of O +
dosage O +
regimen O +
( O -
once O -
- O -
daily O +
vs. O +
twice O -
- O -
daily O -
) O +
of O +
tobramicyn O +
on O +
steady O -
- O -
state O +
serum O +
concentrations O +
and O +
toxicity B-Disease -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Patients O +
undergoing O +
treatment O +
with O +
i.v O -
. O +

tobramycin O +
( O -
4 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
were O +
randomised O +
to O +
two O +
groups O -
. O +

Group O +
OD O +
( O -
n O +
= O +
22 O -
) O +
received O +
a O +
once O -
- O -
daily O +
dose O +
of O +
tobramycin O +
and O +
group O +
TD O +
( O -
n O +
= O +
21 O -
) O +
received O +
the O +
same O +
dose O +
divided O +
into O +
two O +
doses O +
daily O -
. O +

Tobramycin O +
serum O +
concentrations O +
( O -
peak O +
and O +
trough O -
) O +
were O +
measured O +
by O +
enzyme O +
multiplied O +
immunoassay O -
. O +

The O +
renal O +
and O +
auditory O +
functions O +
of O +
the O +
patients O +
were O +
monitored O +
before O -
, O +
during O +
and O +
immediately O +
after O +
treatment O -
. O +

RESULTS O -
: O +
The O +
two O +
groups O +
were O +
comparable O +
with O +
respect O +
to O +
sex O -
, O +
age O -
, O +
body O +
weight O +
and O +
renal O +
function O -
. O +

No O +
statistically O +
significant O +
differences O +
were O +
found O +
in O +
mean O +
daily O +
dose O -
, O +
duration O +
of O +
treatment O -
, O +
or O +
cumulative O +
dose O -
. O +

Trough O +
concentrations O +
were O +
< O +
2 O +
g O -
/ O -
ml O +
in O +
the O +
two O +
groups O +
( O -
100 O -
% O -
) O -
. O +

Peak O +
concentrations O +
were O +
> O +
6 O +
microg O -
/ O -
ml O +
in O +
100 O -
% O +
of O +
the O +
OD O +
group O +
and O +
in O +
67 O -
% O +
of O +
the O +
TD O +
group O +
( O -
P O -
< O +
0.01 O -
) O -
. O +

Mean O +
peak O +
concentrations O +
were O +
markedly O +
different O -
: O +
11.00+ O -
/ O -
-2.89 O +
microg O -
/ O -
ml O +
in O +
OD O +
vs. O +
6.53+ O -
/ O -
-1.45 O +
microg O -
/ O -
ml O +
in O +
TD O +
( O -
P O -
< O +
0.01 O -
) O -
. O +

The O +
pharmacokinetics O +
parameters O +
were O -
: O +
Ke O -
, O +
( O -
0.15+ O -
/ O -
-0.03 O -
/ O -
h O +
in O +
OD O +
vs. O +
0.24+ O -
/ O -
-0.06 O -
/ O -
h O +
in O +
TD O -
) O -
, O +
t1 O -
/ O -
2 O -
, O +
( O -
4.95+ O -
/ O -
-1.41 O +
h O +
in O +
OD O +
vs. O +
3.07+ O -
/ O -
-0.71 O +
h O +
in O +
TD O -
) O -
, O +
Vd O +
( O -
0.35+ O -
/ O -
-0.11 O +
l O -
/ O -
kg O +
in O +
OD O +
vs. O +
0.33+ O -
/ O -
-0.09 O +
l O -
/ O -
kg O +
in O +
TD O -
) O -
, O +
Cl O +
( O -
0.86+ O -
/ O -
-0.29 O +
ml O -
/ O -
min O -
/ O -
kg O +
in O +
OD O +
vs. O +
1.28+ O -
/ O -
-0.33 O +
ml O -
/ O -
min O -
/ O -
kg O +
in O +
TD O -
) O -
. O +

Increased O +
serum O +
creatinine O +
was O +
observed O +
in O +
73 O -
% O +
of O +
patients O +
in O +
OD O +
versus O +
57 O -
% O +
of O +
patients O +
in O +
TD O -
, O +
without O +
evidence O +
of O +
nephrotoxicity B-Disease -
. O +

In O +
TD O +
group O -
, O +
three O +
patients O +
developed O +
decreased B-Disease +
auditory I-Disease +
function I-Disease -
, O +
of O +
which O +
one O +
presented O +
with O +
an O +
auditory B-Disease +
loss I-Disease +
of O +
-30 O +
dB O -
, O +
whereas O +
in O +
the O +
OD O +
group O +
only O +
one O +
patient O +
presented O +
decreased B-Disease +
auditory I-Disease +
function I-Disease -
. O +

CONCLUSION O -
: O +
This O +
small O +
study O +
suggests O +
that O +
a O +
once O -
- O -
daily O +
dosing O +
regimen O +
of O +
tobramycin O +
is O +
at O +
least O +
as O +
effective O +
as O +
and O +
is O +
no O +
more O +
and O +
possibly O +
less O +
toxic O +
than O +
the O +
twice O -
- O -
daily O +
regimen O -
. O +

Using O +
a O +
single O -
- O -
dose O +
therapy O -
, O +
peak O +
concentration O +
determination O +
is O +
not O +
necessary O -
, O +
only O +
trough O +
samples O +
should O +
be O +
monitored O +
to O +
ensure O +
levels O +
below O +
2 O +
microg O -
/ O -
ml O -
. O +

Enhanced O +
bradycardia B-Disease +
induced O +
by O +
beta O -
- O -
adrenoceptor O +
antagonists O +
in O +
rats O +
pretreated O +
with O +
isoniazid O -
. O +

High O +
doses O +
of O +
isoniazid O +
increase O +
hypotension B-Disease +
induced O +
by O +
vasodilators O +
and O +
change O +
the O +
accompanying O +
reflex O +
tachycardia B-Disease +
to O +
bradycardia B-Disease -
, O +
an O +
interaction O +
attributed O +
to O +
decreased O +
synthesis O +
of O +
brain O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
possible O +
enhancement O +
by O +
isoniazid O +
of O +
bradycardia B-Disease +
induced O +
by O +
beta O -
- O -
adrenoceptor O +
antagonists O +
was O +
determined O +
in O +
rats O +
anaesthetised O +
with O +
chloralose O -
- O -
urethane O -
. O +

Isoniazid O +
significantly O +
increased O +
bradycardia B-Disease +
after O +
propranolol O -
, O +
pindolol O -
, O +
labetalol O +
and O +
atenolol O -
, O +
as O +
well O +
as O +
after O +
clonidine O -
, O +
but O +
not O +
after O +
hexamethonium O +
or O +
carbachol O -
. O +

Enhancement O +
was O +
not O +
observed O +
in O +
rats O +
pretreated O +
with O +
methylatropine O +
or O +
previously O +
vagotomised O -
. O +

These O +
results O +
are O +
compatible O +
with O +
interference O +
by O +
isoniazid O +
with O +
GABAergic O +
inhibition O +
of O +
cardiac O +
parasympathetic O +
tone O -
. O +

Such O +
interference O +
could O +
be O +
exerted O +
centrally O -
, O +
possibly O +
at O +
the O +
nucleus O +
ambiguus O -
, O +
or O +
peripherally O +
at O +
the O +
sinus O +
node O -
. O +

Mechanisms O +
of O +
FK O +
506-induced O +
hypertension B-Disease +
in O +
the O +
rat O -
. O +

-Tacrolimus O +
( O -
FK O +
506 O -
) O +
is O +
a O +
powerful O -
, O +
widely O +
used O +
immunosuppressant O -
. O +

The O +
clinical O +
utility O +
of O +
FK O +
506 O +
is O +
complicated O +
by O +
substantial O +
hypertension B-Disease +
and O +
nephrotoxicity B-Disease -
. O +

To O +
clarify O +
the O +
mechanisms O +
of O +
FK O +
506-induced O +
hypertension B-Disease -
, O +
we O +
studied O +
the O +
chronic O +
effects O +
of O +
FK O +
506 O +
on O +
the O +
synthesis O +
of O +
endothelin-1 O +
( O -
ET-1 O -
) O -
, O +
the O +
expression O +
of O +
mRNA O +
of O +
ET-1 O +
and O +
endothelin O -
- O -
converting O +
enzyme-1 O +
( O -
ECE-1 O -
) O -
, O +
the O +
endothelial O +
nitric O +
oxide O +
synthase O +
( O -
eNOS O -
) O +
activity O -
, O +
and O +
the O +
expression O +
of O +
mRNA O +
of O +
eNOS O +
and O +
C O -
- O -
type O +
natriuretic O +
peptide O +
( O -
CNP O -
) O +
in O +
rat O +
blood O +
vessels O -
. O +

In O +
addition O -
, O +
the O +
effect O +
of O +
the O +
specific O +
endothelin O +
type O +
A O +
receptor O +
antagonist O +
FR O +
139317 O +
on O +
FK O +
506-induced O +
hypertension B-Disease +
in O +
rats O +
was O +
studied O -
. O +

FK O +
506 O -
, O +
5 O +
mg O -
. O +

kg-1 O -
. O +

d-1 O +
given O +
for O +
4 O +
weeks O -
, O +
elevated O +
blood O +
pressure O +
from O +
102+ O -
/ O -
-13 O +
to O +
152+ O -
/ O -
-15 O +
mm O +
Hg O +
and O +
increased O +
the O +
synthesis O +
of O +
ET-1 O +
and O +
the O +
levels O +
of O +
ET-1 O +
mRNA O +
in O +
the O +
mesenteric O +
artery O +
( O -
240 O -
% O +
and O +
230 O -
% O -
, O +
respectively O -
) O -
. O +

Little O +
change O +
was O +
observed O +
in O +
the O +
expression O +
of O +
ECE-1 O +
mRNA O +
and O +
CNP O +
mRNA O -
. O +

FK O +
506 O +
decreased O +
eNOS O +
activity O +
and O +
the O +
levels O +
of O +
eNOS O +
mRNA O +
in O +
the O +
aorta O +
( O -
48 O -
% O +
and O +
55 O -
% O -
, O +
respectively O -
) O -
. O +

The O +
administration O +
of O +
FR O +
139317 O +
( O -
10 O +
mg O -
. O +

kg-1 O -
. O +

d-1 O -
) O +
prevented O +
FK O +
506-induced O +
hypertension B-Disease +
in O +
rats O -
. O +

These O +
results O +
indicate O +
that O +
FK O +
506 O +
may O +
increase O +
blood O +
pressure O +
not O +
only O +
by O +
increasing O +
ET-1 O +
production O +
but O +
also O +
by O +
decreasing O +
NO O +
synthesis O +
in O +
the O +
vasculature O -
. O +

Structural B-Disease +
and I-Disease +
functional I-Disease +
impairment I-Disease +
of I-Disease +
mitochondria I-Disease +
in O +
adriamycin O -
- O -
induced O +
cardiomyopathy B-Disease +
in O +
mice O -
: O +
suppression O +
of O +
cytochrome O +
c O +
oxidase O +
II O +
gene O +
expression O -
. O +

The O +
use O +
of O +
adriamycin O +
( O -
ADR O -
) O +
in O +
cancer B-Disease +
chemotherapy O +
has O +
been O +
limited O +
due O +
to O +
its O +
cumulative O +
cardiovascular B-Disease +
toxicity I-Disease -
. O +

Earlier O +
observations O +
that O +
ADR O +
interacts O +
with O +
mitochondrial O +
cytochrome O +
c O +
oxidase O +
( O -
COX O -
) O +
and O +
suppresses O +
its O +
enzyme O +
activity O +
led O +
us O +
to O +
investigate O +
ADR O -
's O +
action O +
on O +
the O +
cardiovascular O +
functions O +
and O +
heart O +
mitochondrial O +
morphology O +
in O +
Balb O -
- O -
c O +
mice O +
i.p O -
. O +

treated O +
with O +
ADR O +
for O +
several O +
weeks O -
. O +

At O +
various O +
times O +
during O +
treatment O -
, O +
the O +
animals O +
were O +
assessed O +
for O +
cardiovascular O +
functions O +
by O +
electrocardiography O +
and O +
for O +
heart O +
tissue O +
damage O +
by O +
electron O +
microscopy O -
. O +

In O +
parallel O -
, O +
total O +
RNA O +
was O +
extracted O +
from O +
samples O +
of O +
dissected O +
heart O +
and O +
analyzed O +
by O +
Northern O +
blot O +
hybridization O +
to O +
determine O +
the O +
steady O -
- O -
state O +
level O +
of O +
three O +
RNA O +
transcripts O +
encoded O +
by O +
the O +
COXII O -
, O +
COXIII O -
, O +
and O +
COXIV O +
genes O -
. O +

Similarly O -
, O +
samples O +
obtained O +
from O +
the O +
liver O +
of O +
the O +
same O +
animals O +
were O +
analyzed O +
for O +
comparative O +
studies O -
. O +

Our O +
results O +
indicated O +
that O +
1 O -
) O +
treatment O +
of O +
mice O +
with O +
ADR O +
caused O +
cardiovascular B-Disease +
arrhythmias I-Disease +
characterized O +
by O +
bradycardia B-Disease -
, O +
extension O +
of O +
ventricular O +
depolarization O +
time O +
( O -
tQRS O -
) O -
, O +
and O +
failure O +
of O +
QRS O +
at O +
high O +
concentrations O +
( O -
10 O -
- O -
14 O +
mg O -
/ O -
kg O +
body O +
weight O +
cumulative O +
dose O -
) O -
; O +
2 O -
) O +
the O +
heart O +
mitochondria O +
underwent O +
swelling B-Disease -
, O +
fusion O -
, O +
dissolution O -
, O +
and/or O +
disruption O +
of O +
mitochondrial O +
cristae O +
after O +
several O +
weeks O +
of O +
treatment O -
. O +

Such O +
abnormalities O +
were O +
not O +
observed O +
in O +
the O +
mitochondria O +
of O +
liver O +
tissue O -
; O +
and O +
3 O -
) O +
among O +
the O +
three O +
genes O +
of O +
COX O +
enzyme O +
examined O -
, O +
only O +
COXII O +
gene O +
expression O +
was O +
suppressed O +
by O +
ADR O +
treatment O -
, O +
mainly O +
after O +
8 O +
weeks O +
in O +
both O +
heart O +
and O +
liver O -
. O +

Knowing O +
that O +
heart O +
mitochondria O +
represent O +
almost O +
40 O -
% O +
of O +
heart O +
muscle O +
by O +
weight O -
, O +
we O +
conclude O +
that O +
the O +
deteriorating O +
effects O +
of O +
ADR O +
on O +
cardiovascular O +
function O +
involve O +
mitochondrial B-Disease +
structural I-Disease +
and I-Disease +
functional I-Disease +
impairment I-Disease -
. O +

